PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Salto-Tellez, M; Peh, BK; Ito, K; Tan, SH; Chong, PY; Han, HC; Tada, K; Ong, WY; Soong, R; Voon, DC; Ito, Y				Salto-Tellez, M.; Peh, B. K.; Ito, K.; Tan, S. H.; Chong, P. Y.; Han, H. C.; Tada, K.; Ong, W. Y.; Soong, R.; Voon, D. C.; Ito, Y.			RUNX3 protein is overexpressed in human basal cell carcinomas	ONCOGENE			English	Article						basal cell carcinoma; RUNX3; beta-catenin; Sonic Hedgehog	TRANSCRIPTION FACTOR LEF-1; WNT SIGNALING PATHWAY; NUCLEAR BETA-CATENIN; SONIC HEDGEHOG; COLORECTAL-CANCER; TUMOR-SUPPRESSOR; GENE-EXPRESSION; GASTRIC-CANCER; LINES; INACTIVATION	Basal cell carcinomas (BCC), which are the most common form of skin malignancy, are invariably associated with the deregulation of the Sonic Hedgehog (Shh) signalling pathway. As such, BCC represent a unique model for the study of interactions of the Shh pathway with other genes and pathways. We constructed a tissue microarray (TMA) of 75 paired BCC and normal skin and analysed the expression of beta-catenin and RUNX3, nuclear effectors of the wingless-Int (Wnt) and bone morphogenetic protein/transforming growth factor-beta pathways, respectively. In line with previous reports, we observed varying subcellular expression pattern of beta-catenin in BCC, with 31 cases (41%) showing nuclear accumulation. In contrast, all the BCC cases tested by the TMA showed RUNX3 protein uniformly overexpressed in the nuclei of the cancer cells. Analysis by Western blotting and DNA sequencing indicates that the overexpressed protein is normal and full-length, containing no mutation in the coding region, implicating RUNX3 as an oncogene in certain human cancers. Our results indicate that although the deregulation of Wnt signalling could contribute to the pathogenesis of a subset of BCC, RUNX3 appears to be a universal downstream mediator of a constitutively active Shh pathway in BCC.	Inst Mol & Cell Biol, Singapore 138673, Singapore; Natl Univ Singapore Hosp, Yong Loo Lin Med Sch, Dept Pathol, Singapore 117548, Singapore; Natl Univ Singapore, Oncol Res Inst, Singapore 117548, Singapore; Natl Skin Ctr, Singapore, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore; National Skin Centre	Ito, Y (corresponding author), Inst Mol & Cell Biol, 61 Biopolis Dr Proteos, Singapore 138673, Singapore.	itoy@imcb.a-star.edu.sg		Voon, Dominic Chih-Cheng/0000-0002-2963-9305; Soong, Richie/0000-0002-0152-1225; Salto-Tellez, Manuel/0000-0001-8586-282X				Andl T, 2002, DEV CELL, V2, P643, DOI 10.1016/S1534-5807(02)00167-3; Bae SC, 2004, ONCOGENE, V23, P4336, DOI 10.1038/sj.onc.1207286; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Boonchai W, 2000, ARCH DERMATOL, V136, P937, DOI 10.1001/archderm.136.7.937; Cameron ER, 2004, ONCOGENE, V23, P4308, DOI 10.1038/sj.onc.1207130; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Chen YG, 2004, CELL RES, V14, P441, DOI 10.1038/sj.cr.7290246; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Daya-Grosjean L, 2005, CANCER LETT, V225, P181, DOI 10.1016/j.canlet.2004.10.003; El-Bahrawy M, 2003, BRIT J DERMATOL, V148, P964, DOI 10.1046/j.1365-2133.2003.05240.x; Gianakopoulos PJ, 2005, J BIOL CHEM, V280, P21022, DOI 10.1074/jbc.M502977200; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Kawai S, 2001, BONE, V29, P54, DOI 10.1016/S8756-3282(01)00470-7; Kim WJ, 2005, CANCER RES, V65, P9347, DOI 10.1158/0008-5472.CAN-05-1647; Ku JL, 2004, ONCOGENE, V23, P6736, DOI 10.1038/sj.onc.1207731; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Marigo V, 1996, P NATL ACAD SCI USA, V93, P9346, DOI 10.1073/pnas.93.18.9346; Mori T, 2005, LIVER INT, V25, P380, DOI 10.1111/j.1478-3231.2005.1059.x; Reddy S, 2001, MECH DEVELOP, V107, P69, DOI 10.1016/S0925-4773(01)00452-X; Rubin AI, 2005, NEW ENGL J MED, V353, P2262, DOI 10.1056/NEJMra044151; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Saldanha G, 2004, BRIT J DERMATOL, V151, P157, DOI 10.1111/j.1365-2133.2004.06048.x; Salto-Tellez M, 2004, CLIN CHEM, V50, P1082, DOI 10.1373/clinchem.2003.030700; Unden AB, 1997, CANCER RES, V57, P2336; van Wijnen AJ, 2004, ONCOGENE, V23, P4209, DOI 10.1038/sj.onc.1207758; Weeraratna AT, 2005, CANCER METAST REV, V24, P237, DOI 10.1007/s10555-005-1574-z; Yamazaki F, 2001, BRIT J DERMATOL, V145, P771, DOI 10.1046/j.1365-2133.2001.04468.x; Yanada M, 2005, ONCOL REP, V14, P817; Yanagida M, 2005, ONCOGENE, V24, P4477, DOI 10.1038/sj.onc.1208675; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	36	67	69	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2006	25	58					7646	7649		10.1038/sj.onc.1209739	http://dx.doi.org/10.1038/sj.onc.1209739			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	16767156				2022-12-28	WOS:000242655500009
J	Takeuchi, T; Adachi, Y; Sonobe, H; Furihata, M; Ohtsuki, Y				Takeuchi, T.; Adachi, Y.; Sonobe, H.; Furihata, M.; Ohtsuki, Y.			A ubiquitin ligase, skeletrophin, is a negative regulator of melanoma invasion	ONCOGENE			English	Article						melanoma; invasion; ubiquitin; skeletrophin; Notch	METHYLATION-SPECIFIC PCR; T-CADHERIN CDH13; MALIGNANT-MELANOMA; TUMOR PROGRESSION; DYSPLASTIC NEVUS; NOTCH LIGAND; H-CADHERIN; STEM-CELL; MIND BOMB; EXPRESSION	Skeletrophin (mindbomb homolog 2 (MIB2)) is a RING (Really Interesting New Gene) finger-dependent ubiquitin ligase, which targets the intracellular region of Notch ligands. A previous immunohistochemical study demonstrated that skeletrophin was downregulated in many melanomas. In the present study, we have identified a promoter region of skeletrophin on a CpG island and detected aberrant methylation of this region in six of 31 invasive melanomas, but in none of 25 benign nevi or five non-invasive superficial spreading melanomas. Subsequently, we found that a zinc-finger transcriptional factor Snail, which is overexpressed in many melanoma cells, repressed the skeletrophin promoter activity via an E-box-related element and was involved in downregulation of skeletrophin. An activator protein-2, which has a tumor suppressor-like role in melanoma, increased skeletrophin expression. Interestingly, exogenously expressed skeletrophin reduced melanoma cell invasion in vitro and in vivo. Colony formation in soft agar was also reduced in a RING motif-dependent manner, without affecting cell growth. We also found that skeletrophin downregulated transcription of the Met oncogene, which encodes the hepatocyte growth factor receptor and plays a role in the determination of the invasive phenotype of many malignant tumors. Finally, exogenously expressed skeletrophin, but not its RING mutant, increased transcription of Hes1 gene, a downstream effector of Notch pathway in melanoma cells. The present findings indicate that skeletrophin might be a novel suppressor factor for melanoma invasion.	Kochi Med Sch, Dept Pathol, Nankoku, Kochi 7838505, Japan; Natl Hosp Org, Fukuyama Med Ctr, Dept Lab Med & Pathol, Hiroshima, Japan	Kochi University	Takeuchi, T (corresponding author), Kochi Med Sch, Dept Pathol, Nankoku, Kochi 7838505, Japan.	takeutit@med.kochi-ms.ac.jp						BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; Balint K, 2005, J CLIN INVEST, V115, P3166, DOI 10.1172/JCI25001; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Fan X, 2002, ONCOL REP, V9, P181; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; GOLDSTEIN AM, 1993, AM J HUM GENET, V52, P537; Grichnik JM, 2006, J INVEST DERMATOL, V126, P142, DOI 10.1038/sj.jid.5700017; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hewett PW, 1998, BIOCHEM BIOPH RES CO, V252, P546, DOI 10.1006/bbrc.1998.9690; Hoek K, 2004, CANCER RES, V64, P5270, DOI 10.1158/0008-5472.CAN-04-0731; ISHIHARA T, IN PRESS VIRCHOW ARC; Itoh M, 2003, DEV CELL, V4, P67, DOI 10.1016/S1534-5807(02)00409-4; Jin YJ, 2002, J BIOL CHEM, V277, P46980, DOI 10.1074/jbc.M208585200; Koo BK, 2005, DEVELOPMENT, V132, P3459, DOI 10.1242/dev.01922; Koo BK, 2005, J BIOL CHEM, V280, P22335, DOI 10.1074/jbc.M501631200; LEONGKG, 2006, BLOOD, V107, P2223; MAUHIN V, 1993, NUCLEIC ACIDS RES, V21, P3951, DOI 10.1093/nar/21.17.3951; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; Nickoloff BJ, 2003, ONCOGENE, V22, P6598, DOI 10.1038/sj.onc.1206758; Nijjar SS, 2002, AM J PATHOL, V160, P1695, DOI 10.1016/S0002-9440(10)61116-9; Parr C, 2004, INT J MOL MED, V14, P779; Pitsouli C, 2005, DEVELOPMENT, V132, P4041, DOI 10.1242/dev.01979; Poetsch M, 2003, MELANOMA RES, V13, P29, DOI 10.1097/00008390-200302000-00006; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Stella MC, 2005, MOL CELL BIOL, V25, P3982, DOI 10.1128/MCB.25.10.3982-3996.2005; Takeuchi T, 2005, AM J PATHOL, V166, P1817, DOI 10.1016/S0002-9440(10)62491-1; Takeuchi T, 2000, J NEUROCHEM, V74, P1489, DOI 10.1046/j.1471-4159.2000.0741489.x; Takeuchi T, 2003, AM J PATHOL, V163, P1395, DOI 10.1016/S0002-9440(10)63497-9; Takeuchi T, 2002, LAB INVEST, V82, P1023, DOI 10.1097/01.LAB.0000025391.35798.F1; Takeuchi T, 1997, J IMMUNOL, V159, P726; Tellez C, 2003, ONCOGENE, V22, P3130, DOI 10.1038/sj.onc.1206453; Wang WD, 2005, DEVELOPMENT, V132, P2883, DOI 10.1242/dev.01860; Zweidler-McKay PA, 2005, BLOOD, V106, P3898, DOI 10.1182/blood-2005-01-0355	35	29	31	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2006	25	53					7059	7069		10.1038/sj.onc.1209688	http://dx.doi.org/10.1038/sj.onc.1209688			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16715130				2022-12-28	WOS:000241910500005
J	Cerone, MA; Londono-Vallejo, JA; Autexier, C				Cerone, M. A.; Londono-Vallejo, J. A.; Autexier, C.			Mutated telomeres sensitize tumor cells to anticancer drugs independently of telomere shortening and mechanisms of telomere maintenance	ONCOGENE			English	Article						telomeres; telomerase; anticancer drugs; telomere uncapping; mutant template hTR	IMMORTAL HUMAN-CELLS; CANCER-CELLS; REVERSE-TRANSCRIPTASE; MUTANT TELOMERASE; CHROMOSOME SEPARATION; HUMAN FIBROBLASTS; MELANOMA-CELLS; DNA-REPAIR; INHIBITION; RNA	Telomerase is a ribonucleoprotein complex that maintains the stability of chromosome ends and regulates replicative potential. Telomerase is upregulated in over 85% of human tumors, but not in adjacent normal tissues and represents a promising target for anticancer therapy. Most telomerase-based therapies rely on the inhibition of telomerase activity and require extensive telomere shortening before inducing any antiproliferative effect. Disturbances of telomere structure rather than length may be more effective in inducing cell death. Telomerase RNA subunits (hTRs) with mutations in the template region reconstitute active holoenzymes that incorporate mutated telomeric sequences. Here, we analysed the feasibility of an anticancer approach based on the combination of telomere destabilization and conventional chemotherapeutic drugs. We show that a mutant template hTR dictates the synthesis of mutated telomeric repeats in telomerase-positive cancer cells, without significantly affecting their viability and proliferative ability. Nevertheless, the mutant hTR increased sensitivity to anticancer drugs in cells with different initial telomere lengths and mechanisms of telomere maintenance and without requiring overall telomere shortening. This report is the first to show that interfering with telomere structure maintenance in a telomerase-dependent manner may be used to increase the susceptibility of tumor cells to anticancer drugs and may lead to the development of a general therapy for the treatment of human cancers.	McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Anat & Cell Biol,Bloomfield Ctr Res Aging, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3T 1E2, Canada; Inst Curie, UPMC, IC,CNRS, Telomeres & Canc Lab, F-75231 Paris, France	Lady Davis Institute; McGill University; McGill University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Autexier, C (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Anat & Cell Biol,Bloomfield Ctr Res Aging, 3755 Cote St Catherine, Montreal, PQ H3T 1E2, Canada.	chantal.autexier@mcgill.ca	Londono-Vallejo, Arturo/ABH-5555-2020	Londono-Vallejo, Arturo/0000-0003-3535-7563				Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Cerone MA, 2001, HUM MOL GENET, V10, P1945, DOI 10.1093/hmg/10.18.1945; Chen Z, 2003, CANCER RES, V63, P5917; Christodoulopoulos G, 1999, CLIN CANCER RES, V5, P2178; Chung HK, 2005, CURR MOL MED, V5, P233, DOI 10.2174/1566524053586635; Cimino-Reale G, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.7.e35; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Folini M, 2000, EUR J CANCER, V36, P2137, DOI 10.1016/S0959-8049(00)00295-1; Guiducci C, 2001, ONCOGENE, V20, P714, DOI 10.1038/sj.onc.1204145; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Kelland LR, 2005, EUR J CANCER, V41, P971, DOI 10.1016/j.ejca.2004.11.024; Kim MM, 2001, P NATL ACAD SCI USA, V98, P7982, DOI 10.1073/pnas.131211098; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478; Kondo Y, 1998, ONCOGENE, V16, P2243, DOI 10.1038/sj.onc.1201754; Lee KH, 2001, P NATL ACAD SCI USA, V98, P3381, DOI 10.1073/pnas.051629198; Li S, 2004, CANCER RES, V64, P4833, DOI 10.1158/0008-5472.CAN-04-0953; Lin J, 2004, MOL BIOL CELL, V15, P1623, DOI 10.1091/mbc.E03-10-0740; Ludwig A, 2001, CANCER RES, V61, P3053; Marusic L, 1997, MOL CELL BIOL, V17, P6394, DOI 10.1128/MCB.17.11.6394; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Misawa M, 2002, INT J ONCOL, V21, P1087; Nakamura M, 2005, HUM GENE THER, V16, P859, DOI 10.1089/hum.2005.16.859; Park KH, 1998, INT J ONCOL, V13, P489; Sharma GG, 2003, ONCOGENE, V22, P131, DOI 10.1038/sj.onc.1206063; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shin KH, 2004, CLIN CANCER RES, V10, P2551, DOI 10.1158/1078-0432.CCR-0669-3; Smith CD, 1999, J CELL BIOL, V145, P203, DOI 10.1083/jcb.145.2.203; Stewart SA, 2003, NAT GENET, V33, P492, DOI 10.1038/ng1127; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tentori L, 2003, MOL PHARMACOL, V63, P192, DOI 10.1124/mol.63.1.192; Ward RJ, 2005, MOL PHARMACOL, V68, P779, DOI 10.1124/mol.105.011494; Wen JP, 1998, HUM MOL GENET, V7, P1137, DOI 10.1093/hmg/7.7.1137; Xu LF, 2004, J CELL BIOL, V167, P819, DOI 10.1083/jcb.200408181; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	46	24	26	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	56					7411	7420		10.1038/sj.onc.1209727	http://dx.doi.org/10.1038/sj.onc.1209727			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16767163				2022-12-28	WOS:000242419100010
J	Franci, C; Takkunen, M; Dave, N; Alameda, F; Gomez, S; Rodriguez, R; Escriva, M; Montserrat-Sentis, B; Baro, T; Garrido, M; Bonilla, F; Virtanen, I; de Herreros, AG				Franci, C.; Takkunen, M.; Dave, N.; Alameda, F.; Gomez, S.; Rodriguez, R.; Escriva, M.; Montserrat-Sentis, B.; Baro, T.; Garrido, M.; Bonilla, F.; Virtanen, I.; Garcia de Herreros, A.			Expression of Snail protein in tumor-stroma interface	ONCOGENE			English	Article						Snail transcriptional factor; fibroblast; epithelial-mesenchymal transition	TRANSCRIPTION FACTOR SNAIL; EPITHELIAL-MESENCHYMAL TRANSITION; E-CADHERIN EXPRESSION; MAMMARY-CARCINOMA; REPRESSOR SNAIL; BREAST-CANCER; GROWTH; PHOSPHORYLATION; FIBROBLASTS; CELLS	The product of Snail gene is a repressor of E-cadherin transcription and an inductor of the epithelial-to-mesenchymal transition in several epithelial tumor cell lines. In order to examine Snail expression in animal and human tissues, we have raised a monoclonal antibody(MAb) that reacts with the regulatory domain of this protein. Analysis of murine embryos shows that Snail is expressed in extraembryonic tissues and embryonic mesoderm, in mesenchymal cells of lungs and dermis as well as in cartilage. Little reactivity was detected in adult tissues as Snail was not constitutively expressed in most mesenchymal cells. However, Snail expression was observed in activated fibroblasts involved in wound healing in mice skin. Moreover, Snail was detected in pathological conditions causing hyperstimulation of fibroblasts, such as fibromatosis. Analysis of Snail expression in tumors revealed that it was highly expressed in sarcomas and. brosarcomas. In epithelial tumors, it presented a more limited distribution, restricted to stromal cells placed in the vicinity of the tumor and to tumoral cells in the same areas. These results demonstrate that Snail is present in activated mesenchymal cells, indicate its relevance in the communication between tumor and stroma and suggest that it can promote the conversion of carcinoma cells to stromal cells.	Univ Helsinki, Inst Biomed Anat, Biomedicum, FIN-00014 Helsinki, Finland; Univ Pompea Fabra, Inst Municipal Invest Med, Unitat Biol Cellular & Mol, Barcelona, Spain; Hosp Mar, Serv Anat Patol, E-08003 Barcelona, Spain; Univ Autonoma Barcelona, Fac Med, E-08193 Barcelona, Spain; Univ Pompau Fabra, Inst Municipal Invest Med, Serv Estab, Barcelona, Spain; Hosp Virgen Salud, Dept Patol, Toledo, Spain; Hosp Univ Puerta Hierro, Med Oncol Serv, Madrid, Spain	University of Helsinki; Pompeu Fabra University; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Autonomous University of Barcelona; University of Barcelona; Complejo Hospitalario de Toledo; Hospital Puerta de Hierro-Majadahonda	Virtanen, I (corresponding author), Univ Helsinki, Inst Biomed Anat, Biomedicum, POB 63,Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	ismo.virtanen@helsinki.fi; agarcia@imim.es	de Herreros, A Garcia/H-3104-2014	de Herreros, A Garcia/0000-0001-5270-0808				Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; De Craene B, 2005, CELL SIGNAL, V17, P535, DOI 10.1016/j.cellsig.2004.10.011; Dominguez D, 2003, MOL CELL BIOL, V23, P5078, DOI 10.1128/MCB.23.14.5078-5089.2003; Elloul S, 2005, CANCER-AM CANCER SOC, V103, P1631, DOI 10.1002/cncr.20946; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Galie M, 2005, CARCINOGENESIS, V26, P1868, DOI 10.1093/carcin/bgi158; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; JAHODA CAB, 1984, NATURE, V311, P560, DOI 10.1038/311560a0; Jamora C, 2005, PLOS BIOL, V3, P131, DOI 10.1371/journal.pbio.0030011; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Moinfar F, 2000, CANCER RES, V60, P2562; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; NIETO MA, 1992, DEVELOPMENT, V116, P227; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Olumi AF, 1999, CANCER RES, V59, P5002; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Palmer HG, 2004, NAT MED, V10, P917, DOI 10.1038/nm1095; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Peinado H, 2005, EMBO J, V24, P3446, DOI 10.1038/sj.emboj.7600781; Pena C, 2005, HUM MOL GENET, V14, P3361, DOI 10.1093/hmg/ddi366; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Petersen OW, 2003, AM J PATHOL, V162, P391, DOI 10.1016/S0002-9440(10)63834-5; Rosivatz E, 2006, VIRCHOWS ARCH, V448, P277, DOI 10.1007/s00428-005-0118-9; Rosivatz E, 2004, INT J CANCER, V111, P711, DOI 10.1002/ijc.20317; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Shekhar MPV, 2001, CANCER RES, V61, P1320; Stuelten CH, 2005, J CELL SCI, V118, P2143, DOI 10.1242/jcs.02334; Sugimachi K, 2003, CLIN CANCER RES, V9, P2657; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Yang ZB, 2005, CANCER RES, V65, P3179, DOI 10.1158/0008-5472.CAN-04-3480; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	43	186	188	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2006	25	37					5134	5144		10.1038/sj.onc.1209519	http://dx.doi.org/10.1038/sj.onc.1209519			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16568079				2022-12-28	WOS:000240063700006
J	Mochizuki, T; Furuta, S; Mitsushita, J; Shang, W; Ito, M; Yokoo, Y; Yamaura, M; Ishizone, S; Nakayama, J; Konagai, A; Hirose, K; Kiyosawa, K; Kamata, T				Mochizuki, T.; Furuta, S.; Mitsushita, J.; Shang, W. H.; Ito, M.; Yokoo, Y.; Yamaura, M.; Ishizone, S.; Nakayama, J.; Konagai, A.; Hirose, K.; Kiyosawa, K.; Kamata, T.			Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic cancer PANC-1 cells	ONCOGENE			English	Article						Nox4; apoptosis; AKT; ASK1	PROTEIN-KINASE B; NAD(P)H OXIDASE; ANGIOTENSIN-II; NADPH OXIDASE; SUPEROXIDE; INSULIN; PHOSPHORYLATES; EXPRESSION; MECHANISM; HOMOLOGS	Pancreatic adenocarcinoma is an aggressive human malignancy and is characterized by resistance to apoptosis. Recently, NADPH oxidase ( Nox) 4-mediated generation of intracellular reactive oxygen species ( ROS) was proposed to confer antiapoptotic activity and thus a growth advantage to pancreatic cancer cells. The signaling mechanism by which Nox4 transmits cell survival signals remains unclear. Here, we show that both a flavoprotein inhibitor, diphenylene iodonium ( DPI), and small interfering RNAs designed to target Nox4 mRNA ( siNox4R-NAs) inhibited superoxide production in PANC-1 pancreatic cancer cells, and depletion of ROS by DPI or siNox4RNAs induced apoptosis. Parallely, DPI treatment and siNox4RNA transfection blocked activation of the cell survival kinase AKT by attenuating phosphorylation of AKT. Furthermore, AKT phosphorylation of apoptosis signal-regulating kinase 1 ( ASK1) on Ser-83 was reduced by DPI and siNox4RNAs. When ASK1Ser83Ala ( an AKT phosphorylation-defective ASK1 mutant) was introduced into PANC-1 cells, this mutant alone induced apoptosis. But, addition of DPI or co-transfection of siNox4RNA had no additive effect, indicating that the mutant can substitute for these reagents in apoptosis induction. Taken together, these findings suggest that ROS generated by Nox4, at least in part, transmit cell survival signals through the AKT ASK1 pathway in pancreatic cancer cells and their depletion leads to apoptosis.	Shinshu Univ, Sch Med, Dept Mol Biol & Biochem, Matsumoto, Nagano 3908621, Japan; Shinshu Univ, Grad Sch Med, Dept Internal Med 2, Nagano, Japan; Shinshu Univ, Grad Sch Med, Dept Dermatol, Matsumoto, Nagano, Japan; Shinshu Univ, Grad Sch Med, Dept Surg, Matsumoto, Nagano, Japan; Shinshu Univ, Grad Sch Med, Inst Organ Transplants Reconstruct Med & Tissue E, Nagano, Japan; Kureha Chem Ind Co Ltd, Biomed Res Inst, Tokyo, Japan	Shinshu University; Shinshu University; Shinshu University; Shinshu University; Shinshu University	Kamata, T (corresponding author), Shinshu Univ, Sch Med, Dept Mol Biol & Biochem, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	kamatat@sch.md.shinshu-u.ac.jp	Mitsushita, Junji/D-7688-2016	Mitsushita, Junji/0000-0001-9402-4318				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; Brar SS, 2003, AM J PHYSIOL-CELL PH, V285, pC353, DOI 10.1152/ajpcell.00525.2002; Brar SS, 2002, AM J PHYSIOL-CELL PH, V282, pC1212, DOI 10.1152/ajpcell.00496.2001; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; Djordjevic T, 2005, ARTERIOSCL THROM VAS, V25, P519, DOI 10.1161/01.ATV.0000154279.98244.eb; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Gorin Y, 2004, BIOCHEM J, V381, P231, DOI 10.1042/BJ20031614; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299; Lawlor MA, 2001, J CELL SCI, V114, P2903; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Lin KI, 1999, J BIOL CHEM, V274, P13650, DOI 10.1074/jbc.274.19.13650; Mabuchi S, 2004, ENDOCRINOLOGY, V145, P49, DOI 10.1210/en.2003-0792; Mahadev K, 2004, MOL CELL BIOL, V24, P1844, DOI 10.1128/MCB.24.5.1844-1854.2004; Mitsushita J, 2004, CANCER RES, V64, P3580, DOI 10.1158/0008-5472.CAN-03-3909; Miura K, 2001, J BIOL CHEM, V276, P46276, DOI 10.1074/jbc.M102387200; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Park HS, 2004, J IMMUNOL, V173, P3589, DOI 10.4049/jimmunol.173.6.3589; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Shiose A, 2001, J BIOL CHEM, V276, P1417, DOI 10.1074/jbc.M007597200; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Vaquero EC, 2004, J BIOL CHEM, V279, P34643, DOI 10.1074/jbc.M400078200; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Yu WP, 2003, CANCER RES, V63, P2483	37	187	196	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3699	3707		10.1038/sj.onc.1209406	http://dx.doi.org/10.1038/sj.onc.1209406			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16532036				2022-12-28	WOS:000238448300009
J	Fei, JW; Angel, P; Wei, QX; de Villiers, EM				Fei, J-W; Angel, P.; Wei, Q-X; de Villiers, E-M			TAp63 alpha indirectly regulates a cutaneous HPV promoter through complex formation with Jun family members	ONCOGENE			English	Article						TAp63 alpha; Jun; HPV 20; mtp53 R248W	C-JUN; HUMAN PAPILLOMAVIRUSES; AP-1 SUBUNITS; P53 HOMOLOG; P63; CELL; PROTEINS; DELTA-NP63-ALPHA; FOS; P73	The p63 alpha isoforms of the p53 family have been demonstrated to play a crucial role in the development and differentiation of the skin. We show that expression of the TAp63 alpha isoform leads to an upregulation of the cutaneous papillomavirus HPV 20 promoter, which is increased at least three-fold when c-Jun is co-expressed, in contrast to a minimal increase in activity in the presence of c-Jun alone. Co-expression of TAp63 alpha with JunB or JunD, respectively, and in combination, leads to a reduction in the viral promoter activation measured by the expression of TAp63 alpha alone. JunB and JunD also inhibits the additive effect exerted on the TAp63a activation by c-Jun. Co-immunoprecipitation assays demonstrate a complex formation of c-Jun, JunB and JunD with TAp 63 alpha through the SAM domain mediating protein-protein interactions, which is characteristic for p63 alpha. Co-expression of p53 mutant R248W not only downregulates the differential modulation of the viral promoter by TAp63 alpha alone and in the presence of the Jun family members, but leads to a reduction in the protein levels of the overexpressed c-Jun, JunB, JunD, as well as TAp63 alpha. This model system provides insight into yet unknown pathways through which TAp63 alpha and Jun may cooperate in the pathogenesis of HPV associated cutaneous lesions.	Deutsch Krebsforschungszentrum, Div Characterizat Tumorviruses, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	de Villiers, EM (corresponding author), Deutsch Krebsforschungszentrum, Div Characterizat Tumorviruses, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	e.devilliers@dkfz.de	Piris, Miguel A/AAP-1445-2020	Piris, Miguel A/0000-0001-5839-3634				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Angel P, 2002, BIOCHEM PHARMACOL, V64, P949, DOI 10.1016/S0006-2952(02)01158-9; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; BOSSYWETZEL E, 1992, GENE DEV, V6, P2340, DOI 10.1101/gad.6.12a.2340; Caldeira S, 2003, J VIROL, V77, P2195, DOI 10.1128/JVI.77.3.2195-2206.2003; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; de Villiers EM, 1999, SEMIN CANCER BIOL, V9, P413, DOI 10.1006/scbi.1999.0145; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Duijf PHG, 2002, HUM MOL GENET, V11, P799, DOI 10.1093/hmg/11.7.799; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Fehrmann F, 2003, ONCOGENE, V22, P5201, DOI 10.1038/sj.onc.1206554; Fei JW, 2005, CELL CYCLE, V4, P689, DOI 10.4161/cc.4.5.1653; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Ghioni P, 2002, MOL CELL BIOL, V22, P8659, DOI 10.1128/MCB.22.24.8659-8668.2002; Green H, 2003, P NATL ACAD SCI USA, V100, P15625, DOI 10.1073/pnas.0307226100; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Irwin MS, 2001, APOPTOSIS, V6, P17, DOI 10.1023/A:1009663809458; Jackson S, 2000, ONCOGENE, V19, P592, DOI 10.1038/sj.onc.1203339; Kim CA, 2003, TRENDS BIOCHEM SCI, V28, P625, DOI 10.1016/j.tibs.2003.11.001; King KE, 2003, ONCOGENE, V22, P3635, DOI 10.1038/sj.onc.1206536; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Koster MI, 2004, CELL CYCLE, V3, P411; Leaner VD, 2003, ONCOGENE, V22, P5619, DOI 10.1038/sj.onc.1206644; Lee H, 2002, DEV CELL, V2, P607, DOI 10.1016/S1534-5807(02)00166-1; Longworth MS, 2004, MICROBIOL MOL BIOL R, V68, P362, DOI 10.1128/MMBR.68.2.362-372.2004; MAJEWSKI S, 1995, ARCH DERMATOL, V131, P1312, DOI 10.1001/archderm.131.11.1312; McKeon F, 2004, GENE DEV, V18, P465, DOI 10.1101/gad.1190504; Mehic D, 2005, J INVEST DERMATOL, V124, P212, DOI 10.1111/j.0022-202X.2004.23558.x; Meixner A, 2004, EMBO J, V23, P1325, DOI 10.1038/sj.emboj.7600133; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Passegue E, 2002, NAT GENET, V30, P158, DOI 10.1038/ng790; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Ruhland A, 2001, INT J CANCER, V91, P828, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1129&gt;3.0.CO;2-B; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Vinciguerra M, 2004, J BIOL CHEM, V279, P9634, DOI 10.1074/jbc.M308721200; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Vogt PK, 2002, NAT REV CANCER, V2, P465, DOI 10.1038/nrc818; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Westfall MD, 2004, CARCINOGENESIS, V25, P857, DOI 10.1093/carcin/bgh148; Wu GJ, 2003, CANCER RES, V63, P2351; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	60	4	4	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3914	3923		10.1038/sj.onc.1209420	http://dx.doi.org/10.1038/sj.onc.1209420			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16474846				2022-12-28	WOS:000238668800004
J	Sun, C; Shi, Y; Xu, LL; Nageswararao, C; Davis, LD; Segawa, T; Dobi, A; McLeod, DG; Srivastava, S				Sun, C.; Shi, Y.; Xu, L. L.; Nageswararao, C.; Davis, L. D.; Segawa, T.; Dobi, A.; McLeod, D. G.; Srivastava, S.			Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival	ONCOGENE			English	Article						prostate cancer; androgen receptor; mutation; p53; cell proliferation; cell apoptosis	WILD-TYPE P53; DOWN-REGULATION; BINDING DOMAIN; EXPRESSION; GENE; APOPTOSIS; PROGRESSION; CARCINOMA; LEADS	Alteration of the AR functions due to amplication, overexpression and somatic mutation of the AR itself or altered interaction of AR with other cell growth regulatory proteins, may contribute to a significant subset of advanced prostate cancer (CaP). Very little is known about the pathways impacted by AR dysfunctions, although CaP associated AR alterations suggest the biological role of the AR dysfunction in disease progression. Comparative evaluations of wild type (wt) AR and mutant (mt) ARs in appropriate experimental models should provide a better understanding of the functional impact of AR alterations in CaP. Here, we provide direct evidence showing cell growth/cell survival promoting effects of the widely studied CaP associated AR mutation (T877A). In contrast to Ad-wtAR or Ad-control infected LNCaP or LAPC4 cells, Ad-mtAR (T877A) infected LNCaP or LAPC4 cells continued to grow in the androgen-deprived medium and exhibited an androgen independent AR-transcription factor activity. Further, Ad-mtAR (T877A) infected LNCaP or LAPC4 cells exhibited enhanced cell growth in the presence of lower concentrations of the synthetic androgen, R1881. Of note, Ad-mtAR (T877A) infected LNCaP cells showed striking resistance to cell growth inhibition/apoptosis mediated by the wt p53. Taken together, these findings provide novel insights into the AR dysfunctions resulting from the T877A mutation and functionally similar AR alterations may provide selective cell growth/survival advantage for CaP progression. These observations have important implications for developing biology-based prognostic biomarkers and therapeutic strategies for CaP showing such AR dysfunctions.	Uniformed Serv Univ Hlth Sci, Dept Surg, Ctr Prostate Dis Res, Rockville, MD 20852 USA; Walter Reed Army Med Ctr, Serv Urol, Washington, DC 20307 USA	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Srivastava, S (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Surg, Ctr Prostate Dis Res, 1530 E Jefferson St, Rockville, MD 20852 USA.	ssrivastava@cpdr.org						Arrowsmith CH, 1999, CELL DEATH DIFFER, V6, P1169, DOI 10.1038/sj.cdd.4400619; Bauer JJ, 1995, CLIN CANCER RES, V1, P1295; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Culig Z, 1999, BRIT J CANCER, V81, P242, DOI 10.1038/sj.bjc.6690684; Culig Z, 2000, UROL RES, V28, P211, DOI 10.1007/s002400000111; GADDIPATI JP, 1994, CANCER RES, V54, P2861; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Haag P, 2005, J STEROID BIOCHEM, V96, P251, DOI 10.1016/j.jsbmb.2005.04.029; Han GZ, 2005, P NATL ACAD SCI USA, V102, P1151, DOI 10.1073/pnas.0408925102; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HEIDENBERG HB, 1995, J UROLOGY, V154, P414, DOI 10.1016/S0022-5347(01)67065-4; Huggins C, 1941, CANCER RES, V1, P293; Ioffe ML, 2004, PROSTATE, V61, P243, DOI 10.1002/pros.20108; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Liao XB, 2005, MOL CANCER THER, V4, P505, DOI 10.1158/1535-7163.MCT-04-0313; NAKAO R, 1992, J CLIN ENDOCR METAB, V74, P1152, DOI 10.1210/jc.74.5.1152; RAFFO AJ, 1995, CANCER RES, V55, P4438; Rokhlin OW, 2005, ONCOGENE, V24, P6773, DOI 10.1038/sj.onc.1208833; SCHUURMANS ALG, 1990, J STEROID BIOCHEM, V37, P849, DOI 10.1016/0960-0760(90)90431-J; Segawa T, 1998, CANCER RES, V58, P2282; Shi XB, 2002, CANCER RES, V62, P1496; Small Eric J., 1998, Current Opinion in Oncology, V10, P244, DOI 10.1097/00001622-199805000-00012; Sobel RE, 2005, J UROLOGY, V173, P342, DOI 10.1097/01.ju.0000141580.30910.57; SRIVASTAVA S, 1995, UROLOGY, V46, P843, DOI 10.1016/S0090-4295(99)80355-0; Taplin ME, 1999, CANCER RES, V59, P2511; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; Tsui KH, 2004, J UROLOGY, V172, P2035, DOI 10.1097/01.ju.0000138053.78518.b2; van Bokhoven A, 2003, PROSTATE, V57, P205, DOI 10.1002/pros.10290; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; Wen Y, 2000, CANCER RES, V60, P6841; Xu LL, 2000, J UROLOGY, V163, P972, DOI 10.1016/S0022-5347(05)67867-6; YANG CL, 1995, CANCER RES, V55, P4210; Yap DBS, 1999, ONCOGENE, V18, P7681, DOI 10.1038/sj.onc.1202954; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008	35	59	59	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3905	3913		10.1038/sj.onc.1209424	http://dx.doi.org/10.1038/sj.onc.1209424			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16636679				2022-12-28	WOS:000238668800003
J	Coleman, ML; Densham, RM; Croft, DR; Olson, MF				Coleman, ML; Densham, RM; Croft, DR; Olson, MF			Stability of p21(Waf1)/(Cip1) CDK inhibitor protein is responsive to RhoA- mediated regulation of the actin cytoskeleton	ONCOGENE			English	Article						signal transduction; cellular; molecular and tumour biology; guanine nucleotide binding proteins and effectors	CELL-CYCLE PROGRESSION; HMG-COA REDUCTASE; SIGNALING PATHWAYS; C-JUN; MORPHOGENESIS CHECKPOINT; RETINOBLASTOMA PROTEIN; INDUCED PROLIFERATION; KINASE-ACTIVITY; GROWTH-FACTORS; G1 PHASE	The proto-oncogene Ras GTPase stimulates transcription of p21(Waf1/Cip1) (p21), which is repressed by the RhoA GTPase. We previously showed that Ras also elevates p21 protein levels by reducing its proteasome-mediated degradation. Therefore, we investigated whether RhoA also influenced p21 protein degradation. Pulse-chase analysis of p21 protein stability revealed that inhibitors of Rho function, which disrupt filamentous actin (F-actin), drastically slowed p21 degradation. Direct F-actin disruption mimicked Rho inhibition to stabilize p21. We found that Rho inhibition, or F-actin disruption, activated the JNK stress-activated protein kinase, and that interfering with JNK signalling, but not p38, abrogated p21 stabilization by Rho inhibition or F-actin-disrupting drugs. In addition, Ras-transformation led to increased constitutive JNK activity that contributed to the elevated p21 protein levels. These data suggest that p21 stability is influenced by a mechanism that monitors F-actin downstream of Rho, and which acts through a pathway involving activation of JNK. These results may have significant implications for therapies that target Rho-signalling pathways to induce p21-mediated cell-cycle arrest.	Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; Wellcome Trust Ctr Human Genet, Oxford, England	Beatson Institute; University of Oxford; Wellcome Centre for Human Genetics	Olson, MF (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	m.olson@beatson.gla.ac.uk	Coleman, Mathew L/C-1676-2014; Olson, Michael/ABA-4240-2021; Olson, Michael F/A-3240-2011; Densham, Ruth/AAO-1971-2020	Coleman, Mathew L/0000-0001-6020-9023; Olson, Michael/0000-0003-3428-3507; Densham, Ruth/0000-0003-4490-2842	NCI NIH HHS [R01 CA030721] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA030721] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Beltman J, 1999, J BIOL CHEM, V274, P3772, DOI 10.1074/jbc.274.6.3772; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bergo MO, 2004, J CLIN INVEST, V113, P539, DOI 10.1172/JCI200418829; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Coleman ML, 2003, EMBO J, V22, P2036, DOI 10.1093/emboj/cdg189; Danesh FR, 2002, P NATL ACAD SCI USA, V99, P8301, DOI 10.1073/pnas.122228799; Denoyelle C, 2003, CELL SIGNAL, V15, P327, DOI 10.1016/S0898-6568(02)00124-9; Denoyelle C, 2001, CARCINOGENESIS, V22, P1139, DOI 10.1093/carcin/22.8.1139; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Escote X, 2004, NAT CELL BIOL, V6, P997, DOI 10.1038/ncb1174; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Han SW, 2005, CANCER LETT, V219, P71, DOI 10.1016/j.canlet.2004.07.040; Harrison JC, 2001, NAT CELL BIOL, V3, P417, DOI 10.1038/35070104; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Huang S, 2002, EXP CELL RES, V275, P255, DOI 10.1006/excr.2002.5504; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; Lee S, 2004, J BIOL CHEM, V279, P1885, DOI 10.1074/jbc.M306968200; Lew DJ, 2003, CURR OPIN CELL BIOL, V15, P648, DOI 10.1016/j.ceb.2003.09.001; Liberto M, 2002, ONCOGENE, V21, P1590, DOI 10.1038/sj.onc.1205242; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Reshetnikova G, 2000, EXP CELL RES, V259, P35, DOI 10.1006/excr.2000.4966; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; Tanaka H, 2002, J CELL BIOL, V158, P321, DOI 10.1083/jcb.200202071; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Walker K, 2005, CURR OPIN GENET DEV, V15, P62, DOI 10.1016/j.gde.2004.11.001; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yokoo T, 2003, J BIOL CHEM, V278, P52919, DOI 10.1074/jbc.M309334200; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	56	31	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2708	2716		10.1038/sj.onc.1209322	http://dx.doi.org/10.1038/sj.onc.1209322			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16407839				2022-12-28	WOS:000237272900002
J	De Oliveira, F; Chauvin, C; Ronot, X; Mousseau, M; Leverve, X; Fontaine, E				De Oliveira, F; Chauvin, C; Ronot, X; Mousseau, M; Leverve, X; Fontaine, E			Effects of permeability transition inhibition and decrease in cytochrome c content on doxorubicin toxicity in K562 cells	ONCOGENE			English	Article						chemoresistance; PTP; mitochondria; cytochrome c	INDUCED MITOCHONDRIAL DYSFUNCTION; CYCLOPHILIN-D; P-GLYCOPROTEIN; INDUCED APOPTOSIS; TUMOR-CELLS; DEATH; BCL-2; PORE; ANTHRACYCLINES; CHEMORESISTANCE	As mitochondria play a key role in the commitment to cell death, we have investigated the mitochondrial consequences of resistance to doxorubicin ( DOX) in K562 cells. We found that the permeability transition pore ( PTP) inhibitor cyclosporine A ( CsA) failed to inhibit PTP opening in the resistant clone. Moreover, the Ca2+ loading capacity in the resistant clone was identical to that observed in the parent cells in the presence of CsA, suggesting that the PTP was already inhibited in a CsA-like manner in the resistant cells. In agreement with this proposal, the mitochondrial target of CsA cyclophilin D ( CyD) decreased by half in the resistant cells. The levels of adenine nucleotide translocator, voltage anion-dependent channel, Bax, Bcl-2, Bcl-x(L), AIF and Smac/Diablo, were similar in both cell lines, whereas cytochrome c content was divided by three in the resistant cells. Since P-glycoprotein inhibition did not restore DOX toxicity in the resistant cells, while DOX-induced cell death in the parent cells was prevented by either PTP inhibition or siRNA-induced decrease in cytochrome c content, we conclude that the inhibition of PTP opening and the decrease in cytochrome c content participate in the mechanism that makes K562 cells resistant to DOX.	Univ Grenoble 1, INSERM E0221, Lab Bioenerget Fontamentale & Appl, F-38041 Grenoble, France; EPHE, CNRS, UMR, Lab Dynam Cellulaire,Inst Albert Bonniot, La Tronche, France; Hop Albert Michallon, Dept Cancerol & Hematol, Grenoble, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); CHU Grenoble Alpes	Fontaine, E (corresponding author), Univ Grenoble 1, INSERM E0221, Lab Bioenerget Fontamentale & Appl, BP 53, F-38041 Grenoble, France.	eric.fontaine@ujf-grenoble.fr	Mousseau, Mireille/M-5942-2014; RONOT, Xavier/B-8412-2014; Fontaine, Eric/ABA-8853-2020	Fontaine, Eric/0000-0002-5204-9477				Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; Campone M, 2001, LEUKEMIA, V15, P1377, DOI 10.1038/sj.leu.2402222; Chauvin C, 2001, J BIOL CHEM, V276, P41394, DOI 10.1074/jbc.M106417200; Childs AC, 2002, CANCER RES, V62, P4592; Connern CP, 1996, BIOCHEMISTRY-US, V35, P8172, DOI 10.1021/bi9525177; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Crompton Martin, 1998, Biochemical Society Transactions, V26, pS330; Decaudin D, 1997, CANCER RES, V57, P62; Denis-Gay M, 1998, BIOCHEM PHARMACOL, V56, P451, DOI 10.1016/S0006-2952(98)00084-7; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Fukushima T, 2000, LEUKEMIA RES, V24, P249, DOI 10.1016/S0145-2126(99)00177-0; GALAT A, 1995, PROG BIOPHYS MOL BIO, V63, P67, DOI 10.1016/0079-6107(94)00009-X; Gamen S, 2000, EXP CELL RES, V258, P223, DOI 10.1006/excr.2000.4924; Gauchez AS, 2001, IN VIVO, V15, P101; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Grandjean F, 2002, BIOCHEM PHARMACOL, V63, P823, DOI 10.1016/S0006-2952(01)00865-6; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Green PS, 2002, BBA-MOL BASIS DIS, V1588, P94, DOI 10.1016/S0925-4439(02)00144-8; Huigsloot M, 2002, J BIOL CHEM, V277, P35869, DOI 10.1074/jbc.M200378200; Jung K, 2001, ADV DRUG DELIVER REV, V49, P87, DOI 10.1016/S0169-409X(01)00128-4; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Kowaltowski A, 2000, CELL DEATH DIFFER, V7, P903, DOI 10.1038/sj.cdd.4400722; Li YM, 2004, BIOCHEM J, V383, P101, DOI 10.1042/BJ20040669; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mankhetkorn S, 1998, EUR J PHARMACOL, V343, P313, DOI 10.1016/S0014-2999(97)01548-3; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Nielsen D, 1996, GEN PHARMACOL-VASC S, V27, P251, DOI 10.1016/0306-3623(95)02013-6; Nogueira V, 2005, J BIOENERG BIOMEMBR, V37, P25, DOI 10.1007/s10863-005-4120-3; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; Seelig A, 1998, EUR J BIOCHEM, V251, P252, DOI 10.1046/j.1432-1327.1998.2510252.x; Serafino A, 2000, ANTICANCER RES, V20, P3383; Smyth MJ, 1998, P NATL ACAD SCI USA, V95, P7024, DOI 10.1073/pnas.95.12.7024; Solem LE, 1996, J MOL CELL CARDIOL, V28, P1023, DOI 10.1006/jmcc.1996.0095; Trindade GS, 1999, PHOTOCHEM PHOTOBIOL, V69, P694, DOI 10.1562/0031-8655(1999)069<0694:DISTUU>2.3.CO;2; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287	41	23	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2646	2655		10.1038/sj.onc.1209293	http://dx.doi.org/10.1038/sj.onc.1209293			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16331251				2022-12-28	WOS:000237099400008
J	Wendt, MK; Johanesen, PA; Kang-Decker, N; Binion, DG; Shah, V; Dwinell, MB				Wendt, M. K.; Johanesen, P. A.; Kang-Decker, N.; Binion, D. G.; Shah, V.; Dwinell, M. B.			Silencing of epithelial CXCL12 expression by DNA hypermethylation promotes colonic carcinoma metastasis	ONCOGENE			English	Article						chemokine; intestinal mucosa; epithelial cell; epigenetic	CHEMOKINE RECEPTOR CXCR4; FACTOR-I; CPG METHYLATION; BREAST-CANCER; CELLS; SDF-1; METHYLTRANSFERASES; LOCALIZATION; LACKING; GROWTH	Cellular metastasis is the most detrimental step in carcinoma disease progression, yet the mechanisms that regulate this process are poorly understood. CXCL12 and its receptor CXCR4 are co-expressed in several tissues and cell types throughout the body and play essential roles in development. Disruption of either gene causes embryonic lethality due to similar defects. Post-natally, CXCL12 signaling has a wide range of effects on CXCR4-expressing cells, including the directed migration of leukocytes, lymphocytes and hematopoietic stem cells. Recently, this signaling axis has also been described as an important regulator of directed carcinoma cell metastasis. We show herein that while CXCR4 expression remains consistent, constitutive colonic epithelial expression of CXCL12 is silenced by DNA hypermethylation in primary colorectal carcinomas as well as colorectal carcinoma-derived cell lines. Inhibition of DNA methyltransferase (Dnmt) enzymes with 5-aza-2'-deoxycytidine or genetic ablation of both Dnmt1 and Dnmt3b prevented promoter methylation and restored CXCL12 expression. Re-expression of functional, endogenous CXCL12 in colorectal carcinoma cells dramatically reduced metastatic tumor formation in mice, as well as foci formation in soft agar. Decreased metastasis was correlated with increased caspase activity in cells re-expressing CXCL12. These data constitute the unique observation that silencing CXCL12 within colonic carcinoma cells greatly enhances their metastatic potential.	Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA; Mayo Clin Fdn, GI Res Unit, Dept Med, Rochester, MN USA; Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Mayo Clinic; Medical College of Wisconsin	Dwinell, MB (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	mdwinell@mcw.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062066, R56DK062066, K01DK002808] Funding Source: NIH RePORTER; NIDDK NIH HHS [R56 DK062066, DK002808, DK062066, R01 DK062066] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agace WW, 2000, CURR BIOL, V10, P325, DOI 10.1016/S0960-9822(00)00380-8; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Arya M, 2003, CURR MED RES OPIN, V19, P557, DOI 10.1185/030079903125002216; Begum NA, 1996, BIOCHEM BIOPH RES CO, V229, P864, DOI 10.1006/bbrc.1996.1893; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Binion DG, 1997, GASTROENTEROLOGY, V112, P1895, DOI 10.1053/gast.1997.v112.pm9178682; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Christopherson KW, 2004, SCIENCE, V305, P1000, DOI 10.1126/science.1097071; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Derdeyn CA, 1999, AIDS RES HUM RETROV, V15, P1063, DOI 10.1089/088922299310359; Dwinell MB, 1999, GASTROENTEROLOGY, V117, P359, DOI 10.1053/gast.1999.0029900359; Dwinell MB, 2001, GASTROENTEROLOGY, V120, P49, DOI 10.1053/gast.2001.20914; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Garcia-Moruja C, 2005, J MOL BIOL, V348, P43, DOI 10.1016/j.jmb.2005.02.016; Gazitt Y, 2004, LEUKEMIA, V18, P1, DOI 10.1038/sj.leu.2403173; Haviv YS, 2004, MOL CANCER THER, V3, P687; Heidemann J, 2004, AM J PHYSIOL-GASTR L, V286, pG1059, DOI 10.1152/ajpgi.00417.2003; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Izadpanah A, 2001, AM J PHYSIOL-GASTR L, V280, pG710, DOI 10.1152/ajpgi.2001.280.4.G710; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jordan NJ, 1999, J CLIN INVEST, V104, P1061, DOI 10.1172/JCI6685; Jubb AM, 2003, ANN NY ACAD SCI, V983, P251, DOI 10.1111/j.1749-6632.2003.tb05980.x; Kang H, 2005, BREAST CANCER RES, V7, pR402, DOI 10.1186/bcr1022; Kimura R, 2003, GENES IMMUN, V4, P356, DOI 10.1038/sj.gene.6363978; Lenhard K, 2005, CLIN GASTROENTEROL H, V3, P142, DOI 10.1016/S1542-3565(04)00624-X; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; PANIS Y, 1990, J HEPATOL, V11, P53, DOI 10.1016/0168-8278(90)90271-R; Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC; Ponomaryov T, 2000, J CLIN INVEST, V106, P1331, DOI 10.1172/JCI10329; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Scherf M, 2000, J MOL BIOL, V297, P599, DOI 10.1006/jmbi.2000.3589; Schrader AJ, 2002, BRIT J CANCER, V86, P1250, DOI 10.1038/sj.bjc.6600221; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Smith JM, 2005, AM J PHYSIOL-GASTR L, V288, pG316, DOI 10.1152/ajpgi.00208.2004; Sun YX, 2003, J CELL BIOCHEM, V89, P462, DOI 10.1002/jcb.10522; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Whitehead RH, 1999, GASTROENTEROLOGY, V117, P858, DOI 10.1016/S0016-5085(99)70344-6; Zeelenberg IS, 2003, CANCER RES, V63, P3833; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	45	119	123	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					4986	4997		10.1038/sj.onc.1209505	http://dx.doi.org/10.1038/sj.onc.1209505			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568088	Green Accepted			2022-12-28	WOS:000239921300004
J	Furukawa, T; Kanai, N; Shiwaku, HO; Soga, N; Uehara, A; Horii, A				Furukawa, T.; Kanai, N.; Shiwaku, H. O.; Soga, N.; Uehara, A.; Horii, A.			AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer	ONCOGENE			English	Article						aurora; gene expression; kinase; microarray; phosphatase; signal transduction	COMMON ALLELIC LOSS; CHROMOSOME ARM 12Q; AURORA-A; RNA INTERFERENCE; DNA-POLYMERASE; KINASE; PROTEIN; GENE; OVEREXPRESSION; CELLS	DUSP6/MKP-3, a specific inhibitor of MAPK1/ERK2, frequently loses its expression in primary pancreatic cancer tissues. This evidence suggests that constitutive activation of MAPK1 synergistically induced by frequent mutation of KRAS2 and the loss of function of DUSP6 plays key roles in pancreatic carcinogenesis and progression. By pro. ling of gene expressions associated with downregulation of MAPK1 induced by exogenous overexpression of DUSP6 in pancreatic cancer cells, we found that AURKA/STK15, the gene encoding Aurora-A kinase, which plays key roles in cellular mitosis, was among the downregulated genes along with its related genes, which included AURKB, TPX2 and CENPA. An association of expression and promoter activity of AURKA with MAPK activity was verified. Knockdown of ETS2 resulted in a reduction of AURKA expression. These results indicate that AURKA is a direct target of the MAPK pathway and that its overexpression in pancreatic cancer is induced by hyperactivation of the pathway, at least via ETS2.	Tokyo Womens Med Univ, Int Res & Educ Inst Integrated Med Sci, Shinjuku Ku, Tokyo 1628666, Japan; Tohoku Univ, Sch Med, Dept Mol Pathol, Sendai, Miyagi 980, Japan	Tokyo Women's Medical University; Tohoku University	Furukawa, T (corresponding author), Tokyo Womens Med Univ, Int Res & Educ Inst Integrated Med Sci, Shinjuku Ku, 8-1 Kawado Cho, Tokyo 1628666, Japan.	furukawa@imcir.twmu.ac.jp	Horii, Akira/AAW-2839-2021; Furukawa, Toru/AAF-5596-2021	Horii, Akira/0000-0002-3967-3291; Furukawa, Toru/0000-0002-1083-2324				Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; CALDAS C, 1995, INT J PANCREATOL, V18, P1; Calhoun ES, 2003, AM J PATHOL, V163, P1255, DOI 10.1016/S0002-9440(10)63485-2; DEMARTIN R, 1987, EMBO J, V6, P3673, DOI 10.1002/j.1460-2075.1987.tb02700.x; DiSepio D, 1998, P NATL ACAD SCI USA, V95, P14811, DOI 10.1073/pnas.95.25.14811; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Foulds CE, 2004, MOL CELL BIOL, V24, P10954, DOI 10.1128/MCB.24.24.10954-10964.2004; Fukushige S, 1997, GENE CHROMOSOME CANC, V19, P161, DOI 10.1002/(SICI)1098-2264(199707)19:3<161::AID-GCC5>3.0.CO;2-W; Furukawa T, 2005, MODERN PATHOL, V18, P1034, DOI 10.1038/modpathol.3800383; Furukawa T, 2004, PANCREAS, V28, P253, DOI 10.1097/00006676-200404000-00007; Furukawa T, 1998, CYTOGENET CELL GENET, V82, P156, DOI 10.1159/000015091; Furukawa T, 2003, AM J PATHOL, V162, P1807, DOI 10.1016/S0002-9440(10)64315-5; Hata T, 2005, CANCER RES, V65, P2899, DOI 10.1158/0008-5472.CAN-04-3981; Hoshi M, 2000, BRIT J CANCER, V82, P1801, DOI 10.1054/bjoc.2000.1108; Hunter AW, 2003, MOL CELL, V11, P445, DOI 10.1016/S1097-2765(03)00049-2; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; Hussein D, 2002, J CELL SCI, V115, P3403; Jeng YM, 2004, CLIN CANCER RES, V10, P2065, DOI 10.1158/1078-0432.CCR-1057-03; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kimura M, 1996, GENE CHROMOSOME CANC, V17, P88, DOI 10.1002/(SICI)1098-2264(199610)17:2<88::AID-GCC3>3.0.CO;2-X; Kimura M, 1998, CANCER RES, V58, P2456; Kinch MS, 2003, CLIN EXP METASTAS, V20, P59, DOI 10.1023/A:1022546620495; Kita K, 2003, RADIAT RES, V160, P302, DOI 10.1667/RR3039; Kondo E, 1999, J BIOCHEM-TOKYO, V125, P818; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Kunitoku N, 2003, DEV CELL, V5, P853, DOI 10.1016/S1534-5807(03)00364-2; Li DH, 2003, CLIN CANCER RES, V9, P991; Liu Q, 2004, J BIOL CHEM, V279, P18210, DOI 10.1074/jbc.M400678200; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; Matsuno S, 2004, PANCREAS, V28, P219, DOI 10.1097/00006676-200404000-00002; Miyoshi Y, 2001, INT J CANCER, V92, P370, DOI 10.1002/ijc.1200; Mori Y, 1997, HUM GENET, V99, P590, DOI 10.1007/s004390050411; MUSAHL C, 1995, EUR J BIOCHEM, V230, P1096, DOI 10.1111/j.1432-1033.1995.tb20660.x; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; PARKER NJ, 1995, GENOMICS, V27, P280, DOI 10.1006/geno.1995.1043; Rojanala S, 2004, MOL CANCER THER, V3, P451; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Seiki M, 2003, CANCER SCI, V94, P569, DOI 10.1111/j.1349-7006.2003.tb01484.x; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Sharief FS, 1999, GENOMICS, V59, P90, DOI 10.1006/geno.1999.5843; STADLBAUER F, 1994, EUR J BIOCHEM, V222, P781, DOI 10.1111/j.1432-1033.1994.tb18925.x; Tanaka M, 2002, J BIOL CHEM, V277, P10719, DOI 10.1074/jbc.M108252200; Tanner MM, 2000, CLIN CANCER RES, V6, P1833; Tong T, 2004, CLIN CANCER RES, V10, P7304, DOI 10.1158/1078-0432.CCR-04-0806; Wang Y, 2000, GENE DEV, V14, P927; Xu SH, 2005, J HUM GENET, V50, P159, DOI 10.1007/s10038-005-0235-y; Yamanaka S, 2004, LAB INVEST, V84, P1339, DOI 10.1038/labinvest.3700160; Yatsuoka T, 2004, ONCOL REP, V12, P1263; Zhang DW, 2004, ONCOGENE, V23, P8720, DOI 10.1038/sj.onc.1208153; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	54	89	96	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2006	25	35					4831	4839		10.1038/sj.onc.1209494	http://dx.doi.org/10.1038/sj.onc.1209494			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16532023				2022-12-28	WOS:000239687100001
J	Han, SW; Roman, J				Han, S. W.; Roman, J.			Fibronectin induces cell proliferation and inhibits apoptosis in human bronchial epithelial cells: pro-oncogenic effects mediated by PI3-kinase and NF-kappa B	ONCOGENE			English	Article						fibronectin; PI3-K; NF-kappa B; cell cycle; tumor suppressor gene; human bronchial epithelial cells	TUMOR-SUPPRESSOR PTEN; SMOOTH-MUSCLE-CELLS; C-MYC; EXTRACELLULAR-MATRIX; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAY; CYCLE PROGRESSION; GENE-EXPRESSION; GROWTH-FACTORS; CANCER CELLS	The extracellular matrix glycoprotein, fibronectin, influences a variety of cellular functions including adhesion, migration, survival, differentiation, and growth. Fibronectin has also been shown to increase the migration and proliferation of human lung carcinoma cells. However, the role of fibronectin in controlling lung airway epithelial cell phenotype remains unknown. Here, we demonstrate that fibronectin stimulates the proliferation of human bronchial epithelial cells (BEAS-2B and 16-HBE). Of note, fibronectin induced the mRNA and protein expression of c-Myc and cyclin D1, while it decreased the expressions of cyclin-dependent kinase inhibitor p21 (WAF-1/CIP1/MDA-6) (p21) and the tumor suppressor gene phosphatase and tensin homolog deleted on chromosome ten ( PTEN). Fibronectin also stimulated the phosphorylation of the phosphatidylinositol 3 kinase (PI3-K) downstream signal Akt. The inhibitor of PI3-K, Wortmannin, and anti-alpha 5 beta 1 integrin antibodies abrogated the effect of fibronectin on c-Myc, cyclin D1, p21, and PTEN expression. The stimulatory effect of. bronectin was mediated by nuclear factor kappaB (NF-kappa B) since. bronectin induced the expression of the p65 component of NF-kappa B and enhanced NF-kappa B DNA binding. Furthermore, we found that p65 small interfering RNA inhibited the effect of. bronectin on c-Myc, cyclin D1, p21, PTEN expression, and on fibronectin-induced cell proliferation. Finally, we found that. bronectin inhibits apoptosis by reducing DNA fragmentation and inhibiting the activities of caspases 3/7. Taken together, our findings demonstrate that fibronectin stimulates human bronchial epithelial cell growth and inhibits apoptosis through activation of NF-kappa B, which, in turn, increases the expression of c-Myc and cyclin D1 and decreases p21 and PTEN via alpha 5 beta 1 integrin-dependent signals that include PI3-K/Akt. Therefore, alternations in the extracellular matrix composition of the lung, with increased. bronectin, might promote epithelial cell growth and thereby contribute to oncogenesis in certain settings.	Emory Univ, Sch Med, Div Pulm Allergy & Crit Care Med, Dept Med, Atlanta, GA 30322 USA; Atlanta Vet Affairs Med Ctr, Atlanta, GA USA	Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System	Han, SW (corresponding author), Emory Univ, Sch Med, Div Pulm Allergy & Crit Care Med, Dept Med, Whitehead Biomed Res Bldg,615 Michael St,Suite 20, Atlanta, GA 30322 USA.	shan2@emory.edu						AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; Alexandrova A, 2000, ONCOGENE, V19, P5826, DOI 10.1038/sj.onc.1203944; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; Aoshiba K, 1997, AM J PHYSIOL-LUNG C, V273, pL684, DOI 10.1152/ajplung.1997.273.3.L684; Arcuri C, 2005, J BIOL CHEM, V280, P4402, DOI 10.1074/jbc.M406440200; Asano T, 2004, ONCOGENE, V23, P8571, DOI 10.1038/sj.onc.1207902; Benaud CM, 2001, ONCOGENE, V20, P759, DOI 10.1038/sj.onc.1204152; Braun-Dullaeus RC, 2001, ARTERIOSCL THROM VAS, V21, P1152, DOI 10.1161/hq0701.092104; Chen F, 2001, J BIOL CHEM, V276, P11414, DOI 10.1074/jbc.M011682200; Cordes N, 2004, INT J RADIAT ONCOL, V58, P453, DOI 10.1016/j.ijrobp.2003.09.069; Cordes N, 2004, CANCER BIOL THER, V3, P47, DOI 10.4161/cbt.3.1.570; Cordes N, 2003, BRIT J CANCER, V88, P1470, DOI 10.1038/sj.bjc.6600912; Dai R, 2005, APOPTOSIS, V10, P503, DOI 10.1007/s10495-005-1880-5; Danen EHJ, 2000, J CELL BIOL, V151, P1413, DOI 10.1083/jcb.151.7.1413; de Jong-Hesse Y, 2005, GRAEF ARCH CLIN EXP, V243, P695, DOI 10.1007/s00417-004-1116-3; de la Fuente MT, 1999, LEUKEMIA, V13, P266, DOI 10.1038/sj.leu.2401275; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Galmozzi E, 2004, J CELL PHYSIOL, V200, P82, DOI 10.1002/jcp.20012; Gao N, 2004, AM J PHYSIOL-CELL PH, V287, pC281, DOI 10.1152/ajpcell.00422.2003; Garl PJ, 2004, CIRC RES, V94, P175, DOI 10.1161/01.RES.0000109791.69181.B6; Gordon AH, 2005, CANCER RES, V65, P3209, DOI 10.1158/0008-5472.CAN-04-4017; Halder SK, 2005, EXP CELL RES, V307, P231, DOI 10.1016/j.yexcr.2005.03.009; Han SW, 2005, CANCER LETT, V219, P71, DOI 10.1016/j.canlet.2004.07.040; Han SW, 2004, INT J CANCER, V111, P322, DOI 10.1002/ijc.20281; Han SW, 2003, J CLIN ENDOCR METAB, V88, P713, DOI 10.1210/jc.2002-020876; Han SW, 1996, ENDOCRINOLOGY, V137, P1791, DOI 10.1210/en.137.5.1791; Illario M, 2005, J CLIN ENDOCR METAB, V90, P2865, DOI 10.1210/jc.2004-1520; Jin ZH, 2004, J BIOL CHEM, V279, P40209, DOI 10.1074/jbc.M404056200; Kijima T, 2003, J CELL MOL MED, V7, P157; Landowski TH, 2003, ONCOGENE, V22, P2417, DOI 10.1038/sj.onc.1206315; Liu B, 2004, J SURG RES, V120, P256, DOI 10.1016/j.jss.2003.12.015; Loeser RF, 2002, BIORHEOLOGY, V39, P119; Moon SK, 2004, ARCH BIOCHEM BIOPHYS, V421, P267, DOI 10.1016/j.abb.2003.11.007; Nasu-Tada K, 2005, GLIA, V52, P98, DOI 10.1002/glia.20224; Orend G, 2003, ONCOGENE, V22, P3917, DOI 10.1038/sj.onc.1206618; Pulai JI, 2005, J IMMUNOL, V174, P5781, DOI 10.4049/jimmunol.174.9.5781; Rajabi HN, 2005, J BIOL CHEM, V280, P361, DOI 10.1074/jbc.M408633200; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; TAKIZAWA H, 1991, AM J RESP CELL MOL, V5, P548, DOI 10.1165/ajrcmb/5.6.548; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tang CH, 2004, MOL PHARMACOL, V66, P440; Tell G, 2004, ENDOCRINOLOGY, V145, P4660, DOI 10.1210/en.2004-0282; Vignola AM, 2001, J ALLERGY CLIN IMMUN, V108, P738, DOI 10.1067/mai.2001.119160; Wadsworth SJ, 2004, AM J PHYSIOL-LUNG C, V286, pL596, DOI 10.1152/ajplung.00217.2003; Wang A, 1996, AM J RESP CELL MOL, V15, P664, DOI 10.1165/ajrcmb.15.5.8918373; Wu JT, 2005, J SURG RES, V123, P158, DOI 10.1016/j.jss.2004.06.006; Zhang F, 2003, ONCOGENE, V22, P894, DOI 10.1038/sj.onc.1206158; Zhao YL, 2002, BRIT J CANCER, V86, P1923, DOI 10.1038/sj.bjc.6600304	49	79	82	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2006	25	31					4341	4349		10.1038/sj.onc.1209460	http://dx.doi.org/10.1038/sj.onc.1209460			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16518410				2022-12-28	WOS:000239240100009
J	He, YY; Pi, J; Huang, JL; Diwan, BA; Waalkes, MP; Chignell, CF				He, YY; Pi, J; Huang, JL; Diwan, BA; Waalkes, MP; Chignell, CF			Chronic UVA irradiation of human HaCaT keratinocytes induces malignant transformation associated with acquired apoptotic resistance	ONCOGENE			English	Article						UVA; transformation; carcinogenesis; AKT; keratinocyte; PTEN	SOLAR ULTRAVIOLET-RADIATION; SQUAMOUS-CELL-CARCINOMA; SKIN-CANCER; IV COLLAGENASE; SUN EXPOSURE; MOUSE SKIN; INDUCTION; PTEN; EXPRESSION; CARCINOGENESIS	Ultraviolet A ( UVA, 315 - 400 nm), constituting about 95% of ultraviolet irradiation in natural sunlight, represents a major environmental challenge to the skin and is clearly associated with human skin cancer. It has proven difficult to show direct actions of UVA as a carcinogen in human cells. Here, we demonstrate that chronic UVA exposures at environmentally relevant doses in vitro can induce malignant transformation of human keratinocytes associated with acquired apoptotic resistance. As evidence of carcinogenic transformation, UVA-long-treated ( 24 J/cm(2) once/week for 18 weeks) HaCaT ( ULTH) cells showed increased secretion of matrix metalloproteinase ( MMP-9), overexpression of keratin 13, altered morphology and anchorage-independent growth. Malignant transformation was established by the production of aggressive squamous cell carcinomas after inoculation of ULTH cells into nude mice ( NCr-nu). ULTH cells were resistant to apoptosis induced not only by UVA but also by UVB and arsenite, two other human skin carcinogens. ULTH cells also became resistant to apoptosis induced by etoposide, staurosporine and doxorubicin hydrochloride. Elevated phosphorylation of protein kinase B ( PKB, also called AKT) and reduced expression of phosphatase and tensin homologue deleted on chromosome 10 ( PTEN) were detected in ULTH cells. The resistance of ULTH cells to UVA-induced apoptosis was reversed by either inhibition of phosphatidylinositol 3-kinase ( PI-3K) or adenovirus expression of PTEN or dominant negative AKT. These data indicate that UVA has carcinogenic potential in human keratinocytes and that the increased AKT signaling and decreased PTEN expression may contribute to this malignant transformation. Further comparisons between the transformed ULTH and control cells should lead to a better understanding of the mechanism of UVA carcinogenesis and may help identify biomarkers for UVA-induced skin malignancies.	NIEHS, Lab Comparat Carcinogenesis, Inorgan Carcinogenesis Sect, Res Triangle Pk, NC USA; Sci Applicat Int Corp, Basic Res Program, NCI, Frederick, MA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	He, YY (corresponding author), NIEHS, Lab Pharmacol & Chem, NIH, 111 TW Alexander Dr,POB 12233,MD F0-06, Res Triangle Pk, NC 27709 USA.	he3@niehs.nih.gov	PI, JINGBO/GWC-2514-2022	PI, JINGBO/0000-0003-0227-8041	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050046] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achanzar WE, 2001, CANCER RES, V61, P455; Agar NS, 2004, P NATL ACAD SCI USA, V101, P4954, DOI 10.1073/pnas.0401141101; Autier P, 1999, JNCI-J NATL CANCER I, V91, P1304, DOI 10.1093/jnci/91.15.1304; Backman SA, 2004, P NATL ACAD SCI USA, V101, P1725, DOI 10.1073/pnas.0308217100; BERNHARD EJ, 1990, CANCER RES, V50, P3872; Borchers AH, 1997, MOL CARCINOGEN, V19, P258, DOI 10.1002/(SICI)1098-2744(199708)19:4<258::AID-MC7>3.0.CO;2-8; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRULS WAG, 1984, PHOTOCHEM PHOTOBIOL, V40, P485, DOI 10.1111/j.1751-1097.1984.tb04622.x; Catani MV, 2001, BIOCHEM J, V356, P77, DOI 10.1042/0264-6021:3560077; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Cokkinides VE, 2001, PREV MED, V33, P141, DOI 10.1006/pmed.2001.0877; COX AD, 1994, METHOD ENZYMOL, V238, P277; Dahle J, 2003, CANCER RES, V63, P1464; Davies MA, 2002, CLIN CANCER RES, V8, P1904; DEGRUIJL FR, 1993, CANCER RES, V53, P53; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Gasparro FP, 2000, ENVIRON HEALTH PERSP, V108, P71, DOI 10.2307/3454633; Geller AC, 2002, PEDIATRICS, V109, P1009, DOI 10.1542/peds.109.6.1009; He YY, 2004, J BIOL CHEM, V279, P53867, DOI 10.1074/jbc.M405781200; He YY, 2003, J BIOL CHEM, V278, P42457, DOI 10.1074/jbc.M303376200; He YY, 2003, J BIOL CHEM, V278, P8058, DOI 10.1074/jbc.M207781200; Huang JH, 2002, J BIOL CHEM, V277, P10760, DOI 10.1074/jbc.M110219200; JEANMOUGIN M, 1987, ANN DERMATOL VENER, V114, P671; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; JUAREZ J, 1993, INT J CANCER, V55, P10, DOI 10.1002/ijc.2910550104; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Minaguchi T, 1999, CANCER RES, V59, P6063; Noonan FP, 2001, NATURE, V413, P271, DOI 10.1038/35095108; Phillipson RP, 2002, FREE RADICAL BIO MED, V32, P474, DOI 10.1016/S0891-5849(01)00829-2; Pi JB, 2005, INT J CANCER, V116, P20, DOI 10.1002/ijc.20990; Rossman TG, 2001, TOXICOL APPL PHARM, V176, P64, DOI 10.1006/taap.2001.9277; Segrelles C, 2002, ONCOGENE, V21, P53, DOI 10.1038/sj.onc.1205032; SETLOW RB, 1993, P NATL ACAD SCI USA, V90, P6666, DOI 10.1073/pnas.90.14.6666; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; Slaga T J, 1995, Prog Clin Biol Res, V391, P1; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Suzuki A, 2003, CANCER RES, V63, P674; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WARREN BS, 1993, P SOC EXP BIOL MED, V202, P9; Wyllie A H, 1980, Int Rev Cytol, V68, P251	40	75	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 22	2006	25	26					3680	3688		10.1038/sj.onc.1209384	http://dx.doi.org/10.1038/sj.onc.1209384			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16682958				2022-12-28	WOS:000238448300007
J	Ren, Y; Chan, HM; Fan, J; Xie, Y; Chen, YX; Li, W; Jiang, GP; Liu, Q; Meinhardt, A; Tam, PKH				Ren, Y.; Chan, H. M.; Fan, J.; Xie, Y.; Chen, Y. X.; Li, W.; Jiang, G. P.; Liu, Q.; Meinhardt, A.; Tam, P. K. H.			Inhibition of tumor growth and metastasis in vitro and in vivo by targeting macrophage migration inhibitory factor in human neuroblastoma	ONCOGENE			English	Article						MIF; neuroblastoma; antisense; tumor growth and metastasis	SQUAMOUS-CELL CARCINOMA; FACTOR MIF; HEPATOCELLULAR-CARCINOMA; PROSTATIC ADENOCARCINOMA; UP-REGULATION; CANCER CELLS; EXPRESSION; ANGIOGENESIS; INTERLEUKIN-8; MET	Macrophage migration inhibitory factor (MIF) has been defined as a novel oncogene. Our previous results have shown that MIF may contribute to the progression of neuroblastoma by (a) inducing N-Myc expression and (b) upregulating the expression of angiogenic factors. The aim of this study was to test whether tumor growth could be inhibited by reduction of endogenous MIF expression in neuroblastoma and clarify the molecular mechanisms underlying MIF reduction on the control of neuroblastoma growth. We established human neuroblastoma cell lines stably expressing antisense MIF (AS-MIF) cDNA. These stable transfectants were characterized by cell proliferation, gene expression pro. le, tumorigenicity and metastasis in vitro and in vivo. Decreased MIF expression was observed after transfection with AS-MIF in neuroblastoma cells and downregulation of MIF expression significantly correlated with decreased expression of N-Myc, Ras, c-Met and TrkB at protein level. Affymetrix microarray analysis revealed that expression of IL-8 and c-met was inhibited and neuroblastoma-favorable genes such as EPHB6 and BLU were upregulated in MIF reduced cells. Neuroblastoma cell growth exhibited a nearly 80% reduction in AS-MIF transfectants in vitro. Furthermore, mice in which tumors formed after subcutaneous injection of AS-MIF transfectants showed a 90% reduction in tumor growth compared to control. Metastasis in mice was also suppressed dramatically. Our data demonstrate that targeting MIF expression is a promising therapeutic strategy in human neuroblastoma therapy, and also identifies the MIF target genes for further study.	Cleveland Clin Fdn, Ctr Hematol & Oncol Mol Therapeut R40, Taussig Canc Ctr, Cleveland, OH 44195 USA; Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Princeton Univ, Stat Lab, ORFE, Princeton, NJ 08544 USA; Univ Giessen, Dept Anat & Cell Biol, Giessen, Germany	Cleveland Clinic Foundation; University of Hong Kong; Princeton University; Justus Liebig University Giessen	Ren, Y (corresponding author), Cleveland Clin Fdn, Ctr Hematol & Oncol Mol Therapeut R40, Taussig Canc Ctr, 9500 Euclid Ave, Cleveland, OH 44195 USA.	reny@ccf.org; paultam@hkucc.hku.hk	Meinhardt, Andreas/B-3688-2009; /C-4405-2009	/0000-0001-6231-3035	NIGMS NIH HHS [R01-GM072611] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072611] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agathanggelou A, 2003, ONCOGENE, V22, P1580, DOI 10.1038/sj.onc.1206243; Akbar SMF, 2001, CANCER LETT, V171, P125, DOI 10.1016/S0304-3835(01)00606-1; Bini L, 1997, ELECTROPHORESIS, V18, P2832, DOI 10.1002/elps.1150181519; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Bown N, 2001, J CLIN PATHOL, V54, P897, DOI 10.1136/jcp.54.12.897; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Chambery D, 1999, CANCER RES, V59, P2898; Chesney J, 1999, MOL MED, V5, P181, DOI 10.1007/BF03402061; del Vecchio MT, 2000, PROSTATE, V45, P51, DOI 10.1002/1097-0045(20000915)45:1<51::AID-PROS6>3.0.CO;2-9; Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201; Edsjo A, 2003, LAB INVEST, V83, P813, DOI 10.1097/01.LAB.0000074895.48776.D8; Fan JQ, 2004, P NATL ACAD SCI USA, V101, P1135, DOI 10.1073/pnas.0307557100; Fox BP, 2004, BIOCHEM BIOPH RES CO, V318, P882, DOI 10.1016/j.bbrc.2004.04.102; Hafner C, 2003, INT J ONCOL, V23, P1553; Hecht M, 2005, CARCINOGENESIS, V26, P2105, DOI 10.1093/carcin/bgi192; Hecht M, 2004, CANCER RES, V64, P6109, DOI 10.1158/0008-5472.CAN-04-1014; Kamimura A, 2000, CANCER, V89, P334, DOI 10.1002/1097-0142(20000715)89:2<334::AID-CNCR18>3.0.CO;2-N; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mahloogi H, 2003, CANCER RES, V63, P4997; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Meitar D, 1996, J CLIN ONCOL, V14, P405, DOI 10.1200/JCO.1996.14.2.405; Meyer-Siegler K, 2000, J INTERF CYTOK RES, V20, P769, DOI 10.1089/10799900050151030; Meyer-Siegler KL, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-34; MeyerSiegler K, 1996, UROLOGY, V48, P448, DOI 10.1016/S0090-4295(96)00207-5; Mitchell RA, 2000, SEMIN CANCER BIOL, V10, P359, DOI 10.1006/scbi.2000.0328; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Nishihira J, 2003, ANN NY ACAD SCI, V995, P171, DOI 10.1111/j.1749-6632.2003.tb03220.x; Ogawa H, 2000, CYTOKINE, V12, P309, DOI 10.1006/cyto.1999.0562; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PRITCHARD J, 1994, LANCET, V344, P869, DOI 10.1016/S0140-6736(94)92834-7; Ren Y, 2005, ANN SURG, V242, P55, DOI 10.1097/01.sla.0000168555.97710.bb; Ren Y, 2004, ONCOGENE, V23, P4146, DOI 10.1038/sj.onc.1207490; Ren Y, 2003, CLIN CANCER RES, V9, P5996; Ren Y, 2003, INT J CANCER, V107, P22, DOI 10.1002/ijc.11287; Sasaki Y, 2002, INT J MOL MED, V10, P579; Seeger R C, 1988, Prog Clin Biol Res, V271, P41; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Shimizu T, 1999, BIOCHEM BIOPH RES CO, V264, P751, DOI 10.1006/bbrc.1999.1584; Tang XX, 2004, CLIN CANCER RES, V10, P5837, DOI 10.1158/1078-0432.CCR-04-0395; Tang XX, 2000, P NATL ACAD SCI USA, V97, P10936, DOI 10.1073/pnas.190123297; TOMIYASU M, 2000, CLIN CANCER RES, V8, P3755; Xie KP, 2001, CYTOKINE GROWTH F R, V12, P375, DOI 10.1016/S1359-6101(01)00016-8; Yang YB, 2000, J CLIN ENDOCR METAB, V85, P4721, DOI 10.1210/jc.85.12.4721	44	56	62	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3501	3508		10.1038/sj.onc.1209395	http://dx.doi.org/10.1038/sj.onc.1209395			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16449971				2022-12-28	WOS:000238448200002
J	Leiblich, A; Cross, SS; Catto, JWF; Phillips, JT; Leung, HY; Hamdy, FC; Rehman, I				Leiblich, A.; Cross, S. S.; Catto, J. W. F.; Phillips, J. T.; Leung, H. Y.; Hamdy, F. C.; Rehman, I.			Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer	ONCOGENE			English	Article						prostate cancer; hypermethylation; proteomic; benign prostatic hyperplasia; metastatic	PROTEOMIC ANALYSIS; EXPRESSION; HYPOXIA; GROWTH; TISSUE; SITES; LDH	In order to identify novel candidates associated with prostate cancer metastasis, we compared the proteomic pro. le of the poorly metastatic human prostate cancer cell line LNCaP, with its highly metastatic variant LNCaP-LN3, by two- dimensional gel electrophoresis. A major protein spot ( pI of 5.9 and molecular weight of 37 kDa) was seen in LNCaP cells, but not in LNCaP- LN3 cells and was identified as lactate dehydrogenase- B ( LDHB), by tandem mass spectrometry. Furthermore, enzyme kinetic assays and zymography showed a higher LDH enzyme activity in LNCaP cells compared with LNCaP-LN3. Bisulphite- modified DNA sequencing showed promoter hypermethylation in LNCaP- LN3 cells but not in LNCaP, Du145, PC3, CWR22 or BPH45 cells. Treatment of LNCaP- LN3 cells with 5'- azacytidine caused re-expression of LDHB transcripts. In tissues, LDHB promoter hypermethylation occurred at a higher frequency in prostate cancer, 14/ 31 ( 45%), compared to adjacent nonmalignant or benign tissue, 2/ 19 ( 11%) ( P < 0.025). Immunohistochemistry showed a higher frequency of LDHB expression in benign or nonmalignant tissues, 59/ 73 ( 81%), compared to cancer cases, 3/ 53 ( 6%) ( P < 0.001). Absent LDHB expression was also seen in 7/ 7 ( 100%) cases of metastatic cancer in bone. Our data are the first to show loss of LDHB expression in prostate cancer, the mechanism of which appears to involve promoter hypermethylation.	Univ Sheffield, Div Clin Sci S, Acad Urol Unit, Sheffield S10 2JF, S Yorkshire, England; Univ Sheffield, Div Genom Med, Acad Unit Pathol, Sheffield S10 2JF, S Yorkshire, England; Univ Newcastle, No Inst Canc Res, Urol Res Grp, Newcastle Upon Tyne, Tyne & Wear, England	University of Sheffield; University of Sheffield; Newcastle University - UK	Rehman, I (corresponding author), Univ Sheffield, Royal Hallamshire Hosp, Acad Urol Unit, Glossop Rd,Floor K, Sheffield S10 2JF, S Yorkshire, England.	i.rehman@sheffield.ac.uk		Cross, Simon/0000-0003-2044-1754; catto, james/0000-0003-2787-8828; Leung, Hing Y./0000-0002-3933-3975; Hamdy, Freddie/0000-0003-2627-2154	Medical Research Council [G0100444] Funding Source: Medline; MRC [G0100444] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ahram M, 2002, MOL CARCINOGEN, V33, P9, DOI 10.1002/mc.10019; Allen S, 2003, J BIOL CHEM, V278, P6371, DOI 10.1074/jbc.M209915200; Banks RE, 2000, LANCET, V356, P1749, DOI 10.1016/S0140-6736(00)03214-1; BERGMEYER HU, 1974, METHOD ENZYMAT AN, P574; Bhandari MS, 2005, EUR J CANCER, V41, P941, DOI 10.1016/j.ejca.2005.02.008; Brizel DM, 2001, INT J RADIAT ONCOL, V51, P349, DOI 10.1016/S0360-3016(01)01630-3; Cheung PK, 2004, CANCER RES, V64, P5929, DOI 10.1158/0008-5472.CAN-04-1216; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; Chu LW, 2001, CANCER GENET CYTOGEN, V127, P161, DOI 10.1016/S0165-4608(01)00389-2; Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151; Ding SJ, 2004, PROTEOMICS, V4, P982, DOI 10.1002/pmic.200300653; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; Graves PR, 2002, MICROBIOL MOL BIOL R, V66, P39, DOI 10.1128/MMBR.66.1.39-63.2002; Grayhack J T, 1980, Prostate, V1, P227, DOI 10.1002/pros.2990010208; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Gronberg H, 2003, LANCET, V361, P859, DOI 10.1016/S0140-6736(03)12713-4; Hamdy FC, 2001, CANCER TREAT REV, V27, P143, DOI 10.1053/ctrv.2000.0208; Himpel S, 2001, BIOCHEM J, V359, P497, DOI 10.1042/0264-6021:3590497; HOLBROOK JJ, 1975, LACTATE DEHYDROGENAS, P191; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; Klingler HC, 1999, PROSTATE, V41, P110; Koukourakis MI, 2005, NEOPLASIA, V7, P1, DOI 10.1593/neo.04373; Li LC, 2005, JNCI-J NATL CANCER I, V97, P103, DOI 10.1093/jnci/dji010; Liu XH, 2003, ELECTROPHORESIS, V24, P3445, DOI 10.1002/elps.200305574; Maekawa M, 2003, CLIN CHEM, V49, P1518, DOI 10.1373/49.9.1518; MARKERT CL, 1975, SCIENCE, V189, P102, DOI 10.1126/science.1138367; MartinezZaguilan R, 1996, CLIN EXP METASTAS, V14, P176, DOI 10.1007/BF00121214; Meehan KL, 2002, PROSTATE, V50, P54, DOI 10.1002/pros.10032; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Rehman I, 2005, PROSTATE, V65, P322, DOI 10.1002/pros.20302; Rehman I, 2004, UROLOGY, V64, P1238, DOI 10.1016/j.urology.2004.06.063; Rehman I, 2004, HUM PATHOL, V35, P1385, DOI 10.1016/j.humpath.2004.07.015; Rehman I, 1996, ONCOGENE, V12, P2483; RETHORE MO, 1976, ANN GENET-PARIS, V19, P140; Salplachta J, 2000, ACTA VET BRNO, V69, P267, DOI 10.2754/avb200069040267; Schulz WA, 2003, MOL HUM REPROD, V9, P437, DOI 10.1093/molehr/gag064; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Shi Q, 2001, ONCOGENE, V20, P3751, DOI 10.1038/sj.onc.1204500; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Stern R, 2002, EXP CELL RES, V276, P24, DOI 10.1006/excr.2002.5508; TAKENO T, 1989, BIOCHEM J, V257, P921, DOI 10.1042/bj2570921; Tsoi SCM, 2001, PLACENTA, V22, P317, DOI 10.1053/plac.2000.0620; Vaupel P, 2004, ONCOLOGIST, V9, P4, DOI 10.1634/theoncologist.9-90005-4; Walenta S, 2004, SEMIN RADIAT ONCOL, V14, P267, DOI 10.1016/j.semradonc.2004.04.004; Walenta S, 2004, CURR MED CHEM, V11, P2195, DOI 10.2174/0929867043364711	45	95	102	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2953	2960		10.1038/sj.onc.1209262	http://dx.doi.org/10.1038/sj.onc.1209262			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16547507				2022-12-28	WOS:000237448200015
J	Gong, J; Zhu, J; Goodman, OB; Pestell, RG; Schlegel, PN; Nanus, DM; Shen, R				Gong, J; Zhu, J; Goodman, OB; Pestell, RG; Schlegel, PN; Nanus, DM; Shen, R			Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells	ONCOGENE			English	Article						bombesin; neuropeptides; p300; androgen receptor; acetylation; androgen-independent prostate cancer	FOCAL ADHESION KINASE; CREB-BINDING PROTEIN; GROWTH-FACTOR; PHOSPHORYLATION; EXPRESSION; TRANSACTIVATION; DIFFERENTIATION; IDENTIFICATION; COREGULATORS; RECRUITMENT	Androgen receptor signaling in prostate cancer cells is augmented by the androgen receptor (AR) coactivator p300, which transactivates and acetylates the AR in the presence of dihydrotestosterone (DHT). As prostate cancer (PC) cells progress to androgen independence, AR signaling remains intact, indicating that other factors stimulate AR activities in the absence of androgen. We previously reported that neuropeptide growth factors could transactivate the AR in the presence of very low concentrations of DHT. Here, we examine the involvement of p300 in neuropeptide activation of AR signaling. Transfection of increasing concentrations of p300 in the presence of bombesin into PC-3 cells resulted in a linear increase in AR transactivation, suggesting that p300 acts as a coactivator in neuropeptide-mediated AR transactivation. P300 is endowed with histone acetyltransferase ( HAT) activity. Therefore, we examine the effect of bombesin on p300 HAT activity. At 4 h after the addition of bombesin, p300 HAT activity increased 2.0-fold (P < 0.01). Incubation with neutral endopeptidase, which degrades bombesin, or bombesin receptor antagonists blocked bombesin-induced p300 HAT activity. To explore the potential signaling pathways involved in bombesin-induced p300 HAT activity, we examined Src and PKC delta pathways that mediate bombesin signaling. Inhibitors of Src kinase activity or Src kinase siRNA blocked bombesin-induced p300 HAT activity, whereas PKCd inhibitors or PKCd siRNA significantly increased bombesin-induced p300 HAT activity suggesting that Src kinase and PKCd kinase are involved in the regulation of p300 HAT activity. As AR is acetylated in the presence of 100 nM DHT, we next examined whether bombesin-induced p300 HAT activity would result in enhanced AR acetylation. Bombesin-induced AR acetylation at the same motif KLKK observed in DHT-induced acetylation. Elimination of p300 using p300 siRNA reduced AR acetylation, demonstrating that AR acetylation was mediated by p300. AR acetylation results in AR transactivation and the expression of the AR-regulated gene prostate-specific antigen (PSA). Therefore, we examined bombesin-induced AR transactivation and PSA expression in the presence and absence of p300 siRNA and found inhibition of p300 expression reduced bombesin-induced AR transactivation and PSA expression. Together these results demonstrate that bombesin, via Src and PKCd signaling pathways, activates p300 HAT activity which leads to enhanced acetylation of AR resulting in increased expression of AR-regulated genes.	Cornell Univ, Weill Med Coll, Dept Urol, New York, NY 10021 USA; New York Presbyterian Hosp, New York, NY USA; Cornell Univ, Weill Med Coll, Dept Med, New York, NY USA; Georgetown Univ, Med Ctr, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC USA	Cornell University; NewYork-Presbyterian Hospital; Cornell University; Georgetown University	Shen, R (corresponding author), Cornell Univ, Weill Med Coll, Dept Urol, Rm E-300,Box 23,1300 York Ave, New York, NY 10021 USA.	rshen@med.cornell.edu		Goodman, Oscar/0000-0002-0882-3621	NCI NIH HHS [R01 CA80240, R01CA93596-01, P30CA51008-14, R01CA107382, R01CA86072] Funding Source: Medline; NIDDK NIH HHS [R01 DK060908-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA051008, R01CA080240, R01CA107382, R01CA093596, R01CA086072] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060908] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aprikian AG, 1998, PROSTATE, P52; Aprikian AG, 1997, INT J CANCER, V72, P498, DOI 10.1002/(SICI)1097-0215(19970729)72:3<498::AID-IJC19>3.3.CO;2-P; BOLOGNA M, 1989, CANCER, V63, P1714; Borre M, 2000, CLIN CANCER RES, V6, P1882; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; Bubendorf L, 1999, J NATL CANCER I, V91, P1758, DOI 10.1093/jnci/91.20.1758; Chan HM, 2001, J CELL SCI, V114, P2363; Chim CS, 2004, CANCER GENET CYTOGEN, V150, P164, DOI 10.1016/j.cancergencyto.2003.09.006; Cui Y, 2004, CANCER RES, V64, P9199, DOI 10.1158/0008-5472.CAN-04-2126; Culig Z, 2000, MICROSC RES TECHNIQ, V51, P447; Culig Z, 2002, ENDOCR-RELAT CANCER, V9, P155, DOI 10.1677/erc.0.0090155; CULIG Z, 1994, CANCER RES, V54, P5474; Dai J, 2002, CLIN CANCER RES, V8, P2399; Darne C, 1998, EUR J BIOCHEM, V256, P541, DOI 10.1046/j.1432-1327.1998.2560541.x; Debes JD, 2005, CANCER RES, V65, P5965, DOI 10.1158/0008-5472.CAN-04-2837; Debes JD, 2002, CANCER RES, V62, P5632; Debes JD, 2003, CANCER RES, V63, P7638; Fu MF, 2004, BIOCHEM PHARMACOL, V68, P1199, DOI 10.1016/j.bcp.2004.05.037; Fu MF, 2005, J BIOL CHEM, V280, P29728, DOI 10.1074/jbc.M503188200; Fu MF, 2004, J BIOL CHEM, V279, P29436, DOI 10.1074/jbc.M313466200; Fu MF, 2003, MOL CELL BIOL, V23, P8563, DOI 10.1128/MCB.23.23.8563-8575.2003; Fu MF, 2002, MOL CELL BIOL, V22, P3373, DOI 10.1128/MCB.22.10.3373-3388.2002; Fu MF, 2002, CYTOKINE GROWTH F R, V13, P259, DOI 10.1016/S1359-6101(02)00003-5; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Kang ZG, 2004, MOL ENDOCRINOL, V18, P2633, DOI 10.1210/me.2004-0245; Kasper S, 1999, J MOL ENDOCRINOL, V22, P313, DOI 10.1677/jme.0.0220313; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Levine L, 2003, CANCER RES, V63, P3495; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Papandreou CN, 1998, NAT MED, V4, P50, DOI 10.1038/nm0198-050; Sadar MD, 1999, ENDOCR-RELAT CANCER, V6, P487, DOI 10.1677/erc.0.0060487; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; Shen RQ, 2000, MOL CELL ENDOCRINOL, V170, P131, DOI 10.1016/S0303-7207(00)00326-9; Shigeno K, 2004, CANCER LETT, V213, P11, DOI 10.1016/S0304-3835(03)00442-7; Sumitomo M, 2000, J CLIN INVEST, V106, P1399, DOI 10.1172/JCI10536; Sumitomo M, 2000, CANCER RES, V60, P6590; Sumitomo M, 2001, CANCER RES, V61, P3294; Vashchenko N, 2005, EUR UROL, V47, P147, DOI 10.1016/j.eururo.2004.09.007; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Wang C, 2004, METH MOL B, V241, P207; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; Yuan LW, 2002, BBA-MOL CELL RES, V1592, P205, DOI 10.1016/S0167-4889(02)00327-0; Yuan LW, 2000, J BIOL CHEM, V275, P40946, DOI 10.1074/jbc.M007832200	49	58	61	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2011	2021		10.1038/sj.onc.1209231	http://dx.doi.org/10.1038/sj.onc.1209231			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16434977				2022-12-28	WOS:000236359700004
J	Nowell, S; Falany, CN				Nowell, S; Falany, CN			Pharmacogenetics of human cytosolic sulfotransferases	ONCOGENE			English	Review						sulfotransferase; tamoxifen; minoxidil	THERMOSTABLE PHENOL SULFOTRANSFERASE; BREAST-CANCER PATIENTS; HUMAN-PLATELET; SULT1A1 GENE; ORAL DEHYDROEPIANDROSTERONE; SULFATION PHARMACOGENETICS; BIOCHEMICAL-PROPERTIES; POSTMENOPAUSAL WOMEN; PARTIAL-PURIFICATION; HUMAN MEGAKARYOCYTES	Cytosolic sulfotransferases (SULTs) are phase II detoxification enzymes that are involved in the biotransformation of a wide variety of structurally diverse endo- and xenobiotics, including many therapeutic agents and endogenous steroids. Single-nucleotide polymorphisms (SNPs) in SULTs have functional consequences on the translated protein. For the most part, these SNPs are fairly uncommon in the population, but some, most notably for SULT isoform 1A1, are commonly found and have been associated with cancer risk for a variety of tumor sites and also with response to therapeutic agents. SNPs in the hydroxysteroid sulfotransferase, SULT2A1, have been identified in African-American subjects and influence the ratio of plasma DHEA: DHEA-S. This modi. cation could potentially influence cancer risk in steroidogenic tissues. SNPs in many SULTs are ethnically distributed, another factor that could influence SULT pharmacogenetics. Finally, genetic variation has also been identified in 3'-phosphoadenoside 5'-phosphosulfate synthetase (PAPPS), the enzymes responsible for producing the obligatory cosubstrate for all sulfotransferases. Taken together, this variability could substantially influence the disposition of drugs metabolized by SULTs. Elucidation of the basis and effect of variability in sulfation could greatly impact individualized therapy in the future.	Univ Arkansas Med Sci, Coll Publ Hlth, Little Rock, AR 72205 USA; Univ Alabama, Birmingham, AL USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Alabama System; University of Alabama Birmingham	Nowell, S (corresponding author), Univ Arkansas Med Sci, Coll Publ Hlth, 820 Little Rock,4301 W Markham St, Little Rock, AR 72205 USA.	sanowell@uams.edu; cfalany@uab.edu						ANDERSON RJ, 1988, J LAB CLIN MED, V112, P773; [Anonymous], 1985, JAMA, V254, P3461; Arlt W, 1999, J CLIN ENDOCR METAB, V84, P2170, DOI 10.1210/jc.84.6.2170; Besset S, 2000, FASEB J, V14, P345, DOI 10.1096/fasebj.14.2.345; Brittelli A, 1999, EUR J CLIN PHARMACOL, V55, P691, DOI 10.1007/s002280050695; CAMPBELL NRC, 1987, BIOCHEM PHARMACOL, V36, P1435, DOI 10.1016/0006-2952(87)90108-0; CAPPIELLO M, 1989, EUR J CLIN PHARMACOL, V37, P317, DOI 10.1007/BF00679793; Duanmu Z, 2001, DRUG METAB DISPOS, V29, P1130; Falany CN, 1995, ANN NY ACAD SCI, V774, P59, DOI 10.1111/j.1749-6632.1995.tb17372.x; FALANY CN, 1994, J STEROID BIOCHEM, V48, P369, DOI 10.1016/0960-0760(94)90077-9; Falany JL, 1996, CANCER RES, V56, P1551; Falany JL, 1998, CHEM-BIOL INTERACT, V109, P329, DOI 10.1016/S0009-2797(97)00143-9; Fang HL, 2003, DRUG METAB DISPOS, V31, P1378, DOI 10.1124/dmd.31.11.1378; Glatt H, 2000, CHEM-BIOL INTERACT, V129, P141, DOI 10.1016/S0009-2797(00)00202-7; Glatt H, 2004, N-S ARCH PHARMACOL, V369, P55, DOI 10.1007/s00210-003-0826-0; Hashimoto Y, 1992, Tanpakushitsu Kakusan Koso, V37, P1701; Hempel N, 2004, MOL PHARMACOL, V66, P1690, DOI 10.1124/mol.104.003350; Hume R, 1996, HISTOCHEM CELL BIOL, V105, P147, DOI 10.1007/BF01696154; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; Kester MHA, 1999, J CLIN ENDOCR METAB, V84, P1357, DOI 10.1210/jc.84.4.1357; Khetawat G, 2000, BLOOD, V95, P2289, DOI 10.1182/blood.V95.7.2289.007k03_2289_2296; Kotov A, 1999, J STEROID BIOCHEM, V68, P137, DOI 10.1016/S0960-0760(99)00022-9; KUDLACEK PE, 1995, BIOCHEM BIOPH RES CO, V210, P363, DOI 10.1006/bbrc.1995.1670; Li X, 2001, J ENDOCRINOL, V171, P525, DOI 10.1677/joe.0.1710525; Liyou NE, 2003, J HISTOCHEM CYTOCHEM, V51, P1655, DOI 10.1177/002215540305101209; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; MARAZZITI D, 1995, CHRONOBIOL INT, V12, P100, DOI 10.3109/07420529509064505; Marazziti D, 1998, NEUROPSYCHOBIOLOGY, V38, P1, DOI 10.1159/000026509; Mariotto A, 2002, CANCER CAUSE CONTROL, V13, P101, DOI 10.1023/A:1014380323037; MORTOLA JF, 1990, J CLIN ENDOCR METAB, V71, P696, DOI 10.1210/jcem-71-3-696; Nagata K, 2000, ANNU REV PHARMACOL, V40, P159, DOI 10.1146/annurev.pharmtox.40.1.159; Ning BT, 2005, PHARMACOGENET GENOM, V15, P465, DOI 10.1097/01.fpc.0000166823.74378.79; Nishiyama T, 2002, BIOCHEM PHARMACOL, V63, P1817, DOI 10.1016/S0006-2952(02)00994-2; Nowell S, 2002, J NATL CANCER I, V94, P1635; Nowell S, 2000, PHARMACOGENETICS, V10, P789, DOI 10.1097/00008571-200012000-00004; Ozawa S, 1998, CHEM-BIOL INTERACT, V109, P237, DOI 10.1016/S0009-2797(97)00135-X; Parker CR, 1999, STEROIDS, V64, P640, DOI 10.1016/S0039-128X(99)00046-X; Raftogianis RB, 1997, BIOCHEM BIOPH RES CO, V239, P298, DOI 10.1006/bbrc.1997.7466; Spink BC, 2000, CARCINOGENESIS, V21, P1947, DOI 10.1093/carcin/21.11.1947; SUNDARAM RS, 1989, CLIN PHARMACOL THER, V46, P501, DOI 10.1038/clpt.1989.178; SUNDARAM RS, 1989, DRUG METAB DISPOS, V17, P255; TARANTINO MD, 1994, ANN NY ACAD SCI, V714, P293, DOI 10.1111/j.1749-6632.1994.tb12059.x; Thomae B. A., 2002, Pharmacogenomics Journal, V2, P48, DOI 10.1038/sj.tpj.6500089; VANLOON J, 1984, BIOCHEM GENET, V22, P997, DOI 10.1007/BF00499627; Visser TJ, 1998, CHEM-BIOL INTERACT, V109, P279, DOI 10.1016/S0009-2797(97)00139-7; Wegman P, 2005, BREAST CANCER RES, V7, pR284, DOI 10.1186/bcr993; WEINSHILBOUM R, 1990, PHARMACOL THERAPEUT, V45, P93, DOI 10.1016/0163-7258(90)90010-Y; WEINSHILBOUM R, 1994, CHEM-BIOL INTERACT, V92, P233, DOI 10.1016/0009-2797(94)90066-3; WILBORN T, 2005, IN PRESS J STEROID B; Xu ZH, 2000, BIOCHEM BIOPH RES CO, V268, P437, DOI 10.1006/bbrc.2000.2123; Xu ZH, 2003, BIOCHEM PHARMACOL, V65, P1787, DOI 10.1016/S0006-2952(03)00104-7; Xu ZH, 2002, PHARMACOGENETICS, V12, P11, DOI 10.1097/00008571-200201000-00003; YOUNG WF, 1985, J NEUROCHEM, V44, P1131, DOI 10.1111/j.1471-4159.1985.tb08734.x; ZOU JY, 1990, J NEUROCHEM, V55, P1154, DOI 10.1111/j.1471-4159.1990.tb03119.x; 1986, CA CANC J CLIN, V36, P42	55	105	110	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2006	25	11					1673	1678		10.1038/sj.onc.1209376	http://dx.doi.org/10.1038/sj.onc.1209376			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020JL	16550167				2022-12-28	WOS:000235904700009
J	Tang, S; Tao, M; McCoy, J; Zheng, ZM				Tang, S; Tao, M; McCoy, J; Zheng, ZM			Short-term induction and long-term suppression of HPV16 oncogene silencing by RNA interference in cervical cancer cells	ONCOGENE			English	Article						HPV16; E6; E7; oncogene; siRNA; cervical cancer	HUMAN-PAPILLOMAVIRUS TYPE-16; VIRAL SUPPRESSOR; MESSENGER-RNA; IN-VITRO; EXPRESSION; E6; GENE; E7; ONCOPROTEIN; NUCLEAR	RNA interference-mediated gene silencing has the potential to block gene expression. A synthetic double-stranded small interfering RNA (siRNA) based on a sequence motif of 21 nucleotides from human papillomavirus 16 (HPV16) E6E7 bicistronic RNA was found to be a potent siRNA that suppresses expression of both the E6 and E7 oncogenes in HPV16(+) CaSki and SiHa cells. When stably expressed as a short hairpin RNA in these cells, however, siRNA silencing of E6 and E7 expression was efficient only at early cell passages, but became inefficient with increased cell passages despite the continued expression of the siRNA at the same level. The loss of the siRNA function was duplicable in stable p53 siRNA cells, but not in stable lamin A/C siRNA cells, suggesting that it is gene selective. The cells resistant to siRNA function retained normal siRNA processing, duplex unwinding and degradation of the unwound sense strand and RNA-induced silencing complex formation, suggesting that loss of the siRNA function occurred at a later step. Surprisingly, the siRNA-resistant cells were found to express notably a cytoplasmic protein of similar to 50 kDa that specifically and characteristically interacted with the unwound, antisense strand E7 siRNA. Altogether, our data indicate that a potent siRNA targeting to an essential or regulatory gene might induce a cell to develop siRNA-suppressive function.	NCI, HIV & AIDS Malignancy Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NHLBI, Flow Cytometry Core Facil, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Zheng, ZM (corresponding author), NCI, HIV & AIDS Malignancy Branch, Ctr Canc Res, NIH, Bldg 10,Room10S255,MSC 1868,10 Ctr Dr, Bethesda, MD 20892 USA.	zhengt@exchange.nih.gov	Tang, Shuang/F-9115-2014	Tang, Shuang/0000-0002-3084-0903; Zheng, Zhi-Ming/0000-0001-5547-7912	NATIONAL CANCER INSTITUTE [Z01SC010357] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [Z01 SC010357-06] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; Boyer SN, 1996, CANCER RES, V56, P4620; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Butz K, 2003, ONCOGENE, V22, P5938, DOI 10.1038/sj.onc.1206894; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P10978, DOI 10.1073/pnas.97.20.10978; Haley B, 2004, NAT STRUCT MOL BIOL, V11, P599, DOI 10.1038/nsmb780; Hall AHS, 2003, J VIROL, V77, P6066, DOI 10.1128/JVI.77.10.6066-6069.2003; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Howley P. M., 2001, FIELDS VIROLOGY, V2, P2197; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Kasschau KD, 2003, DEV CELL, V4, P205, DOI 10.1016/S1534-5807(03)00025-X; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Knight SW, 2002, MOL CELL, V10, P809, DOI 10.1016/S1097-2765(02)00649-4; Lecellier CH, 2005, SCIENCE, V308, P557, DOI 10.1126/science.1108784; Li HW, 2002, SCIENCE, V296, P1319, DOI 10.1126/science.1070948; Li WX, 2004, P NATL ACAD SCI USA, V101, P1350, DOI 10.1073/pnas.0308308100; Lu SH, 2004, J VIROL, V78, P12868, DOI 10.1128/JVI.78.23.12868-12876.2004; Mallory AC, 2002, P NATL ACAD SCI USA, V99, P15228, DOI 10.1073/pnas.232434999; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Mayeda A, 1999, METH MOL B, V118, P309; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; PFEFFER S, 2003, CURRETN PROTOCOLS MO; Pham JW, 2004, CELL, V117, P83, DOI 10.1016/S0092-8674(04)00258-2; Provost P, 2002, EMBO J, V21, P5864, DOI 10.1093/emboj/cdf578; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Scadden ADJ, 2001, EMBO REP, V2, P1107, DOI 10.1093/embo-reports/kve244; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schulze A, 1998, J VIROL, V72, P2323, DOI 10.1128/JVI.72.3.2323-2334.1998; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; Soldan SS, 2005, J VIROL, V79, P234, DOI 10.1128/JVI.79.1.234-244.2005; Tang S, 2002, J BIOL CHEM, V277, P14547, DOI 10.1074/jbc.M111308200; Tao MF, 2003, J VIROL, V77, P13232, DOI 10.1128/JVI.77.24.13232-13247.2003; Tomari Y, 2004, CELL, V116, P831, DOI 10.1016/S0092-8674(04)00218-1; VINDELOV LL, 1977, VIRCHOWS ARCH B, V24, P227; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; YAGINUMA Y, 1991, CANCER RES, V51, P6506; Yang WD, 2005, J BIOL CHEM, V280, P3946, DOI 10.1074/jbc.M407876200; Yoshinouchi M, 2003, MOL THER, V8, P762, DOI 10.1016/j.ymthe.2003.08.004; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100; Zhang HD, 2002, EMBO J, V21, P5875, DOI 10.1093/emboj/cdf582; Zheng ZM, 2004, J MOL BIOL, V337, P1091, DOI 10.1016/j.jmb.2004.02.023; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	51	43	48	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2094	2104		10.1038/sj.onc.1209244	http://dx.doi.org/10.1038/sj.onc.1209244			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16369495	Green Accepted			2022-12-28	WOS:000236359700012
J	Patterson, SG; Wei, S; Chen, X; Sallman, DA; Gilvary, DL; Zhong, B; Pow-Sang, J; Yeatman, T; Djeu, JY				Patterson, S. G.; Wei, S.; Chen, X.; Sallman, D. A.; Gilvary, D. L.; Zhong, B.; Pow-Sang, J.; Yeatman, T.; Djeu, J. Y.			Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells	ONCOGENE			English	Article						stat1; clusterin; chemoresistance; prostate cancer; siRNA	CHEMOTHERAPY-INDUCED APOPTOSIS; CANCER-CELLS; IN-VITRO; CLUSTERIN/APOLIPOPROTEIN-J; ANDROGEN INDEPENDENCE; UP-REGULATION; NOBLE RAT; CLUSTERIN; EXPRESSION; PROTEINS	A major obstacle for clinicians in the treatment of advanced prostate cancer is the inevitable progression to chemoresistance, especially to docetaxel. It is essential to understand the molecular events that lead to docetaxel resistance in order to identify means to prevent or interfere with chemoresistance. In initial attempts to detect these events, we analysed genomic differences between non-resistant and docetaxel-resistant prostate tumor cells and, of the genes modulated by docetaxel treatment, we observed Stat1 and clusterin gene expression heightened in the resistant phenotype. In this study, we provide biochemical and biological evidence that these two gene products are related. Stat1 and clusterin protein expression was induced upon docetaxel treatment of DU145 cells and highly overexpressed in the docetaxel-resistant DU145 cells (DU145-DR). The increase in total Stat1 corresponded to an increase in phosphorylated Stat1. Interestingly, there was no detectable difference between DU145 and DU145-DR cells expression of total Stat3 and phosphorylated Stat3. Treatment of DU145-DR cells with small interfering RNA targeted for Stat1 not only resulted in the knockdown of Stat1 expression, but it also caused the inhibition of clusterin expression. Thus, Stat1 appears to play a key role in the regulation of clusterin. Remarkably, inhibition of Stat1 or clusterin expression resulted in the re-sensitization of DU145-DR cells to docetaxel. These results offer the first evidence that Stat1, and its subsequent regulation of clusterin, are essential for docetaxel resistance in prostate cancer. Targeting this pathway could be a potential therapeutic means for intervention of docetaxel resistance.	H Lee Moffitt Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL USA; Genitourinary Oncol Program, Tampa, FL USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Djeu, JY (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Program Immunol, MRC-4 E,12902 Magnolia Dr, Tampa, FL 33612 USA.	djeu@moffitt.usf.edu			NCI NIH HHS [CA98080] Funding Source: Medline; NIAID NIH HHS [AI056213] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056213] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Assikis VJ, 2004, CLIN CANCER RES, V10, P6770, DOI 10.1158/1078-0432.CCR-04-0275; Barton BE, 2004, MOL CANCER THER, V3, P1183; Bettuzzi S, 2000, CANCER RES, V60, P1472; Cochet O, 2006, CELL SIGNAL, V18, P449, DOI 10.1016/j.cellsig.2005.05.010; Culine S, 2000, ANN ONCOL, V11, P1523, DOI 10.1023/A:1008394823889; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; De Marzo AM, 2004, J CELL BIOCHEM, V91, P459, DOI 10.1002/jcb.10747; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; DeMiguel F, 2002, PROSTATE, V52, P123, DOI 10.1002/pros.10110; Dhir R, 2002, PROSTATE, V51, P241, DOI 10.1002/pros.10079; El-Hashemite N, 2004, CANCER RES, V64, P3436, DOI 10.1158/0008-5472.CAN-03-3609; Geney R, 2002, CLIN CHEM LAB MED, V40, P918, DOI 10.1515/CCLM.2002.161; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Ho SM, 1998, AM J PATHOL, V153, P131, DOI 10.1016/S0002-9440(10)65553-8; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Humphreys DT, 1999, J BIOL CHEM, V274, P6875, DOI 10.1074/jbc.274.11.6875; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; July LV, 2004, MOL CANCER THER, V3, P223; Kominsky SL, 2000, CANCER RES, V60, P3904; Lacroix H, 1998, Expert Opin Investig Drugs, V7, P273, DOI 10.1517/13543784.7.2.273; Lee SO, 2004, PROSTATE, V60, P178, DOI 10.1002/pros.20045; Legrand A, 2004, LIVER INT, V24, P149, DOI 10.1111/j.1478-3231.2004.00899.x; Liu KB, 2005, CANCER RES, V65, P1045; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Makarovskiy AN, 2002, CELL MOL LIFE SCI, V59, P1198, DOI 10.1007/s00018-002-8498-3; Milbank AJ, 2002, UROLOGY, V60, P738, DOI 10.1016/S0090-4295(02)01867-8; Miller ML, 2001, CHEM REC, V1, P195, DOI 10.1002/tcr.1008; Miyake H, 2000, CLIN CANCER RES, V6, P1655; Miyake H, 2000, CANCER RES, V60, P170; Miyake H, 2003, ONCOL REP, V10, P469; Miyake H, 2000, CANCER RES, V60, P3058; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Nickerson T, 1999, CANCER RES, V59, P3392; O'Sullivan J, 2003, CELL DEATH DIFFER, V10, P914, DOI 10.1038/sj.cdd.4401254; Ouyang XS, 2001, CARCINOGENESIS, V22, P965, DOI 10.1093/carcin/22.6.965; Peto J, 2001, NATURE, V411, P390, DOI 10.1038/35077256; Petrylak DP, 2005, UROLOGY, V65, P3, DOI 10.1016/j.urology.2005.03.053; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Pucci S, 2004, ONCOGENE, V23, P2298, DOI 10.1038/sj.onc.1207404; Stephanou A, 2003, INT J EXP PATHOL, V84, P239, DOI 10.1111/j.0959-9673.2003.00363.x; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Thomas M, 2004, CANCER RES, V64, P8357, DOI 10.1158/0008-5472.CAN-04-1864; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; Trougakos IP, 2004, CANCER RES, V64, P1834, DOI 10.1158/0008-5472.CAN-03-2664; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Zellweger T, 2003, BJU INT, V92, P463, DOI 10.1046/j.1464-410X.2003.04349.x; Zellweger T, 2001, J PHARMACOL EXP THER, V298, P934	48	97	105	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6113	6122		10.1038/sj.onc.1209632	http://dx.doi.org/10.1038/sj.onc.1209632			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16652143				2022-12-28	WOS:000241101200008
J	Yoshida, T; Hisamoto, T; Akiba, J; Koga, H; Nakamura, K; Tokunaga, Y; Hanada, S; Kumemura, H; Maeyama, M; Harada, M; Ogata, H; Yano, H; Kojiro, M; Ueno, T; Yoshimura, A; Sata, M				Yoshida, T.; Hisamoto, T.; Akiba, J.; Koga, H.; Nakamura, K.; Tokunaga, Y.; Hanada, S.; Kumemura, H.; Maeyama, M.; Harada, M.; Ogata, H.; Yano, H.; Kojiro, M.; Ueno, T.; Yoshimura, A.; Sata, M.			Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors	ONCOGENE			English	Article						Ras; Raf-1; ERK; spred; sprouty; HCC	CELL-CYCLE ARREST; PROTEIN-KINASE; MICE LACKING; MAP KINASE; ACTIVATION; EXPRESSION; ERK; PATHWAYS; BINDING; RAS	Aberrant activation of the Ras/Raf-1/extracellular-regulated kinase (ERK) pathway has been shown to be involved in the progression of human hepatocellular carcinoma (HCC). However, the mechanism of dysregulation of ERK activation is poorly understood. Recently, we identified Sprouty-related protein with Ena/vasodilator stimulated phosphoprotein homology-1 domain (Spred) as a physiological inhibitor of the Ras/Raf-1/ERK pathway. In this study, we found that the expression levels of Spred-1 and -2 in human HCC tissue were frequently decreased, comparing with those in adjacent non-tumorous tissue. Moreover, Spred expression levels in HCC tissue were inversely correlated with the incidence of tumor invasion and metastasis. Forced expression of Spred-1 inhibited HCC cell proliferation in vitro and in vivo, which was associated with reduced ERK activation. Spred-1 overexpression also reduced the secretion of matrix metalloproteinase-9 (MMP-9) and MMP-2, which play important roles in tumor invasion and metastasis. In addition, Spred-1 inhibited growth factor-mediated HCC cell motility. These data indicate that the reduction of Spred expression in HCC is one of the causes of the acquisition of malignant features. Thus, Spred could be not only a novel prognostic factor but also a new therapeutic target for human HCC.	Kurume Univ, Dept Med, Sch Med, Liver Canc Div,Res Ctr Innovat Canc Therapy, Kurume, Fukuoka, Japan; Ctr 21st Century Program Med Sci, Kurume, Fukuoka, Japan; Kurume Univ, Dept Pathol, Sch Med, Liver Canc Div,Res Ctr Innovat Canc Therapy, Kurume, Fukuoka, Japan; Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 812, Japan	Kurume University; Kurume University; Kyushu University	Yoshida, T (corresponding author), Kurume Univ, Dept Med, Sch Med, Liver Canc Div,Res Ctr Innovat Canc Therapy, 67 Asahi Machi, Kurume, Fukuoka, Japan.	tayoshi@med.kurume-u.ac.jp	Yoshimura, Akihiko/K-5515-2013					Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; Chen LX, 2004, FASEB J, V18, P914, DOI 10.1096/fj.03-1204fje; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Ehrenreiter K, 2005, J CELL BIOL, V168, P955, DOI 10.1083/jcb.200409162; Inoue H, 2005, J EXP MED, V201, P73, DOI 10.1084/jem.20040616; Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kato R, 2003, BIOCHEM BIOPH RES CO, V302, P767, DOI 10.1016/S0006-291X(03)00259-6; Koga H, 2001, HEPATOLOGY, V33, P1087, DOI 10.1053/jhep.2001.24024; Liu JF, 2002, BIOCHEM BIOPH RES CO, V293, P1174, DOI 10.1016/S0006-291X(02)00350-9; Marrero JA, 2004, GASTROENTEROLOGY, V127, pS113, DOI 10.1053/j.gastro.2004.09.024; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Masson V, 2004, FASEB J, V18, P234, DOI 10.1096/fj.04-2140fje; McAllister SS, 2003, MOL CELL BIOL, V23, P216, DOI 10.1128/MCB.23.1.216-228.2003; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Miyoshi K, 2004, ONCOGENE, V23, P5567, DOI 10.1038/sj.onc.1207759; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Nonami A, 2004, J BIOL CHEM, V279, P52543, DOI 10.1074/jbc.M405189200; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Prehoda KE, 1999, CELL, V97, P471, DOI 10.1016/S0092-8674(00)80757-6; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Schmidt CM, 1997, BIOCHEM BIOPH RES CO, V236, P54, DOI 10.1006/bbrc.1997.6840; Stahl S, 2005, HEPATOLOGY, V42, P353, DOI 10.1002/hep.20768; Tsuboi Y, 2004, LIVER INT, V24, P432, DOI 10.1111/j.1478-3231.2004.0940.x; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Volkman BF, 2002, CELL, V111, P565, DOI 10.1016/S0092-8674(02)01076-0; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; YANO H, 1988, ACTA PATHOL JAPON, V38, P953; Yoshida T, 2004, J EXP MED, V199, P1701, DOI 10.1084/jem.20031675; Zaragoza C, 2002, MOL PHARMACOL, V62, P927, DOI 10.1124/mol.62.4.927; Zhang DL, 2004, J BIOL CHEM, V279, P19683, DOI 10.1074/jbc.M313145200	34	128	140	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6056	6066		10.1038/sj.onc.1209635	http://dx.doi.org/10.1038/sj.onc.1209635			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16652141				2022-12-28	WOS:000241101200003
J	Zheng, R; Iwase, A; Shen, R; Goodman, OB; Sugimoto, N; Takuwa, Y; Lerner, DJ; Nanus, DM				Zheng, R.; Iwase, A.; Shen, R.; Goodman, O. B., Jr.; Sugimoto, N.; Takuwa, Y.; Lerner, D. J.; Nanus, D. M.			Neuropeptide-stimulated cell migration in prostate cancer cells is mediated by RhoA kinase signaling and inhibited by neutral endopeptidase	ONCOGENE			English	Article						neutral endopeptidase; neuropetide; Rho kinase; RhoGEF; G-protein	NUCLEOTIDE EXCHANGE FACTORS; GTP-BINDING PROTEIN; FOCAL ADHESION KINASE; HETEROTRIMERIC G-PROTEINS; LEUKEMIA-ASSOCIATED RHO; G-BETA-GAMMA; CARCINOMA-CELLS; TYROSINE PHOSPHORYLATION; GROWTH-FACTORS; ALPHA-SUBUNIT	The neuropeptides bombesin and endothelin-1 stimulate prostate cancer (PC) cell migration and invasion (J Clin Invest, 2000; 106: 1399-1407). The intracellular signaling pathways that direct this cell movement are not well delineated. The monomeric GTPase RhoA is required for migration in several cell types including neutrophils, monocytes and. broblasts. We demonstrate that bombesin-stimulated PC cell migration occurs via the heterotrimeric G-protein-coupled receptors (G-protein) G alpha 13 subunit leading to activation of RhoA, and Rho-associated coiled-coil forming protein kinase (ROCK). Using siRNA to suppress expression of the three known G-protein asubunitassociated RhoA guanine nucleotide exchange factors (GEFs), we also show that two of these RhoA GEFs, PDZ-RhoGEF and leukemia-associated RhoGEF (LARG), link bombesin receptors to RhoA in a non-redundant manner in PC cells. We next show that focal adhesion kinase, which activates PDZ-RhoGEF and LARG, is required for bombesin-stimulated RhoA activation. Neutral endopeptidase (NEP) is expressed on normal prostate epithelium whereas loss of NEP expression contributes to PC progression. We also demonstrate that NEP inhibits neuropeptide activation of RhoA. Together, these results establish a contiguous signaling pathway from the bombesin receptor to ROCK in PC cells, and they implicate NEP as a major regulator of neuropeptide-stimulated RhoA in these cells. This work also identifies members of this signaling pathway as potential targets for rational pharmacologic manipulation of neuropeptide-stimulated migration of PC cells.	Cornell Univ, Weill Med Coll, Div Hematol & Med Oncol, Dept Med,Gerintourinary Oncol Res Lab, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Urol, Urol Oncol Res Lab, New York, NY 10021 USA; New York Presbyterian Hosp, New York, NY USA; Kanazawa Univ, Sch Med, Dept Physiol, Kanazawa, Ishikawa 920, Japan; Cornell Univ, Weill Med Coll, Div Cardiol, Dept Med, New York, NY 10021 USA	Cornell University; Cornell University; NewYork-Presbyterian Hospital; Kanazawa University; Cornell University	Nanus, DM (corresponding author), Cornell Univ, Weill Med Coll, Div Hematol & Med Oncol, Dept Med,Gerintourinary Oncol Res Lab, 525 E 68th St,ST-359, New York, NY 10021 USA.	dnanus@med.cornell.edu	Sugimoto, Naotoshi/C-4739-2015	Sugimoto, Naotoshi/0000-0003-1995-5002; Goodman, Oscar/0000-0002-0882-3621	NCI NIH HHS [CA80240] Funding Source: Medline; NHLBI NIH HHS [HL04080] Funding Source: Medline; NIDDK NIH HHS [DK60908] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080240] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060908] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aprikian AG, 1997, INT J CANCER, V72, P498, DOI 10.1002/(SICI)1097-0215(19970729)72:3<498::AID-IJC19>3.3.CO;2-P; Arai K, 2003, MOL PHARMACOL, V63, P478, DOI 10.1124/mol.63.3.478; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Braga V, 2000, NAT CELL BIOL, V2, pE182, DOI 10.1038/35036433; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Dai J, 2001, CLIN CANCER RES, V7, P1370; DELOMBAERT S, 1994, J MED CHEM, V37, P498, DOI 10.1021/jm00030a009; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fukuhara S, 2001, ONCOGENE, V20, P1661, DOI 10.1038/sj.onc.1204182; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Grant K, 2003, BRIT J CANCER, V88, P163, DOI 10.1038/sj.bjc.6700750; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hersch E, 2004, AM J PHYSIOL-CELL PH, V287, pC1209, DOI 10.1152/ajpcell.00198.2004; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Iwase A, 2004, J BIOL CHEM, V279, P11898, DOI 10.1074/jbc.M212737200; Jiang YD, 2003, MOL CANCER RES, V1, P453; Kajiyama H, 2005, CLIN CANCER RES, V11, P1798, DOI 10.1158/1078-0432.CCR-04-2395; Karnoub AE, 2004, BREAST CANCER RES TR, V84, P61, DOI 10.1023/B:BREA.0000018427.84929.5c; Kassis J, 2001, SEMIN CANCER BIOL, V11, P105, DOI 10.1006/scbi.2000.0362; Kitamura K, 1999, AM J PHYSIOL-CELL PH, V276, pC930, DOI 10.1152/ajpcell.1999.276.4.C930; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kurose H, 2003, LIFE SCI, V74, P155, DOI 10.1016/j.lfs.2003.09.003; Leung T, 1996, MOL CELL BIOL, V16, P5313; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Liu B, 2003, J BIOL CHEM, V278, P2384, DOI 10.1074/jbc.M208683200; Lummen G, 1997, N-S ARCH PHARMACOL, V356, P769, DOI 10.1007/PL00005117; LYONS LS, 2005, MOL ENDOCRINOL  1229; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Nagakawa O, 2001, INT J UROL, V8, P65, DOI 10.1046/j.1442-2042.2001.00250.x; Nagakawa O, 1998, CANCER LETT, V133, P27, DOI 10.1016/S0304-3835(98)00186-4; Nakagawa T, 2005, BIOCHEM PHARMACOL, V69, P579, DOI 10.1016/j.bcp.2004.11.003; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Papandreou CN, 1998, NAT MED, V4, P50, DOI 10.1038/nm0198-050; Radhika V, 2004, J BIOL CHEM, V279, P49406, DOI 10.1074/jbc.M408836200; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; Reuther GW, 2001, J BIOL CHEM, V276, P27145, DOI 10.1074/jbc.M103565200; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rosano L, 2001, CANCER RES, V61, P8340; Rozengurt E, 2002, TRENDS ENDOCRIN MET, V13, P128, DOI 10.1016/S1043-2760(01)00544-6; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Saurin JC, 2002, CANCER RES, V62, P4829; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Shen RQ, 2000, ENDOCRINOLOGY, V141, P1699, DOI 10.1210/en.141.5.1699; SHIPP MA, 1993, BLOOD, V82, P1052, DOI 10.1182/blood.V82.4.1052.bloodjournal8241052; Somlyo AV, 2000, BIOCHEM BIOPH RES CO, V269, P652, DOI 10.1006/bbrc.2000.2343; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; Sugden PH, 2003, J MOL CELL CARDIOL, V35, P871, DOI 10.1016/S0022-2828(03)00153-6; Sugimoto N, 2003, MOL CELL BIOL, V23, P1534, DOI 10.1128/MCB.23.5.1534-1545.2003; Sumitomo M, 2000, J CLIN INVEST, V106, P1399, DOI 10.1172/JCI10536; Sumitomo M, 2005, BBA-PROTEINS PROTEOM, V1751, P52, DOI 10.1016/j.bbapap.2004.11.001; Sumitomo M, 2001, CANCER RES, V61, P3294; Suzuki N, 2003, P NATL ACAD SCI USA, V100, P733, DOI 10.1073/pnas.0234057100; Tangkijvanich P, 2001, HEPATOLOGY, V33, P74, DOI 10.1053/jhep.2001.20677; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VAN AL, 1997, GENE DEV, V11, P2295; Wang Q, 2004, METHOD ENZYMOL, V389, P244; Wang Q, 2004, J BIOL CHEM, V279, P28831, DOI 10.1074/jbc.C400105200; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; Worthylake RA, 2001, J CELL BIOL, V154, P147, DOI 10.1083/jcb.200103048; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5; Yuan JZ, 2001, J BIOL CHEM, V276, P38619, DOI 10.1074/jbc.M105530200; Zhao RB, 1997, J BIOL CHEM, V272, P21207, DOI 10.1074/jbc.272.34.21207; Zhou KM, 1998, J BIOL CHEM, V273, P16782, DOI 10.1074/jbc.273.27.16782	76	42	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2006	25	44					5942	5952		10.1038/sj.onc.1209586	http://dx.doi.org/10.1038/sj.onc.1209586			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16652149	Bronze			2022-12-28	WOS:000240826300003
J	Zhang, J; Lahti, JM; Bruce, A; He, L; Parihar, K; Fan, C; Grenet, J; Liu, L; Kidd, VJ; Cormier, S; Tang, D				Zhang, J.; Lahti, J. M.; Bruce, A.; He, L.; Parihar, K.; Fan, C.; Grenet, J.; Liu, L.; Kidd, V. J.; Cormier, S.; Tang, D.			Identification of an ataxia telangiectasia-mutated protein mediated surveillance system to regulate Bcl-2 overexpression	ONCOGENE			English	Article						Bcl-2; ATM; p53; oncogene surveillance system	CELL-CYCLE ENTRY; NEGATIVE BREAST-CANCER; DNA-DAMAGE; TUMOR-SUPPRESSOR; PARADOXICAL INHIBITION; PROGNOSTIC MARKERS; TRANSGENIC MICE; CYTOCHROME-C; P53; APOPTOSIS	Bcl-2 can both promote and attenuate tumorigenesis. Although the former function is relatively well characterized, the mechanism of the latter remains elusive. We report here that enforced Bcl-2 expression in MCF7 cells stabilizes p53, induces phosphorylation of p53 serine 15 (p53pSer15) and inhibits MCF7 cell growth. Consistent with p53 Ser15 being a target of ataxia telangiectasia mutated protein(ATM)/ATR (ATM- and rad3-related) in the DNA damage response, Bcl-2 activates ATM by inducing ATM Ser1981 phosphorylation, which is accompanied with the phosphorylaton of two additional ATM substrates, Chk2 Thr68 and H2AX Ser139. Downregulation of ATM using a specific small interference RNA fragment (ATMRNAi) abolished Bcl-2-induced p53pSer15 and Bcl-2-mediated growth inhibition of MCF7 cells. Ectopic expression of a dominant-negative p53 mutant, p53175H, partially rescued this growth inhibition. Taken together, these observations demonstrate the contribution of ATM-p53 function to Bcl-2-mediated inhibition of MCF7 cell growth, indicating an ATM- mediated surveillance system for regulating Bcl-2 overexpression. Consistent with this concept, we found that MCF7 cells express Bcl-2 heterogeneously with 34.5% of cells being Bcl-2 negative. In general, Bcl-2-positive MCF7 cells proliferate slower than those of Bcl-2 negative. Thus, we provide evidence suggesting that activation of ATM suppresses Bcl-2-induced tumorigenesis, and that attenuation of ATM function may be an important event in breast cancer progression.	St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA; McMaster Univ, Dept Med, Div Nephrol, Hamilton, ON, Canada; McMaster Univ, St Josephs Hosp, Father Sean OSullivan Res Inst, Hamilton, ON, Canada	St Jude Children's Research Hospital; McMaster University; McGill University; McMaster University	Lahti, JM (corresponding author), St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, 332 N Lauderdale, Memphis, TN 38105 USA.	jill.lahti@stjude.org.or; damut@mcmaster.ca	Tang, Damu/AAQ-1786-2021; Lahti, Jari/P-7987-2018	Tang, Damu/0000-0002-3282-9521; Lahti, Jari/0000-0002-4310-5297	NATIONAL CANCER INSTITUTE [R56CA067938, R01CA067938] Funding Source: NIH RePORTER; NCI NIH HHS [CA67938] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; Chang J, 2003, CANCER-AM CANCER SOC, V97, P545, DOI 10.1002/cncr.11083; Charpin C, 1998, J CLIN ONCOL, V16, P2025, DOI 10.1200/JCO.1998.16.6.2025; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Cong F, 1999, ONCOGENE, V18, P7731, DOI 10.1038/sj.onc.1203290; Daidone MG, 1999, ENDOCR-RELAT CANCER, V6, P61, DOI 10.1677/erc.0.0060061; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; de la Coste A, 1999, CANCER RES, V59, P5017; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; GEE JMW, 1994, INT J CANCER, V59, P619, DOI 10.1002/ijc.2910590508; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; HELLEMANS P, 1995, BRIT J CANCER, V72, P354, DOI 10.1038/bjc.1995.338; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Jager JJ, 2002, APOPTOSIS, V7, P361, DOI 10.1023/A:1016179530785; JOENSUU H, 1994, AM J PATHOL, V145, P1191; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kirkin V, 2004, BBA-MOL CELL RES, V1644, P229, DOI 10.1016/j.bbamcr.2003.08.009; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Le MG, 1999, INT J CANCER, V84, P562, DOI 10.1002/(SICI)1097-0215(19991222)84:6<562::AID-IJC4>3.0.CO;2-0; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Li YX, 2004, ONCOGENE, V23, P7355, DOI 10.1038/sj.onc.1207957; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; LIPPONEN P, 1995, J PATHOL, V177, P49, DOI 10.1002/path.1711770109; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; Murphy KL, 1999, ONCOGENE, V18, P6597, DOI 10.1038/sj.onc.1203099; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; PIETENPOL JA, 1994, CANCER RES, V54, P3714; Saintigny Y, 2001, EMBO J, V20, P2596, DOI 10.1093/emboj/20.10.2596; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; TSUIMOTO Y, 1984, SCIENCE, V266, P1097; Vairo G, 1996, ONCOGENE, V13, P1511; vanSlooten HJ, 1996, BRIT J CANCER, V74, P78, DOI 10.1038/bjc.1996.319; YANG J, 1997, SCIENCE, V275, P1132; Youn CK, 2005, NAT CELL BIOL, V7, P137, DOI 10.1038/ncb1215; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	48	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2006	25	41					5601	5611		10.1038/sj.onc.1209565	http://dx.doi.org/10.1038/sj.onc.1209565			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16636671				2022-12-28	WOS:000240599100002
J	Andrews, P; He, YJ; Xiong, Y				Andrews, P.; He, Y. J.; Xiong, Y.			Cytoplasmic localized ubiquitin ligase cullin 7 binds to p53 and promotes cell growth by antagonizing p53 function	ONCOGENE			English	Article						cullin 7; p53; ROC1; cytoplasmic localization	LARGE T-ANTIGEN; PROTEIN UBIQUITINATION; NUCLEAR EXPORT; RING FINGER; F-BOX; COMPLEX; FAMILY; DOMAIN; SCF; DEGRADATION	Cullins are a family of evolutionarily conserved proteins that bind to the small RING finger protein, ROC1, to constitute potentially a large number of distinct E3 ubiquitin ligases. CUL7 mediates an essential function for mouse embryo development and has been linked with cell transformation by its physical association with the SV40 large T antigen. We report here that, like its closely related homolog PARC, CUL7 is localized predominantly in the cytoplasm and binds directly to p53. In contrast to PARC, however, CUL7, even when overexpressed, did not sequester p53 in the cytoplasm. We have identified a sequence in the N-terminal region of CUL7 that is highly conserved in PARC and a sequence spanning the tetramerization domain in p53 that are required for CUL7-p53 binding. CUL7 and MDM2 did not form a detectable tertiary complex with p53. In vitro, CUL7 caused only mono- or di-ubiquitination of p53 under the conditions MDM2 polyubiquitinated p53. Co-expression of CUL7 reduced the transactivating activity of p53. Constitutive ectopic expression of CUL7 increased the rate of cell proliferation and delayed UV-induced G2 accumulation in U2OS cells expressing functional p53, but had no detectable effect in p53-deficient H1299 cells. Deletion of the N-terminal domain of CUL7 or a mutation disrupting p53 binding abolished the ability of CUL7 to increase the rate of U2OS cell proliferation. Our results suggest that CUL7 functions to promote cell growth through, in part, antagonizing the function of p53.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27514 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Xiong, Y (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27514 USA.	yxiong@email.unc.edu		He, Yizhou/0000-0002-1396-7275	NCI NIH HHS [CA65572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065572] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ali SH, 2004, J VIROL, V78, P2749, DOI 10.1128/JVI.78.6.2749-2757.2004; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Arai T, 2003, P NATL ACAD SCI USA, V100, P9855, DOI 10.1073/pnas.1733908100; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Baptiste N, 2004, CELL, V116, P487, DOI 10.1016/S0092-8674(04)00164-3; Chipuk JE, 2004, CELL CYCLE, V3, P429; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dias DC, 2002, P NATL ACAD SCI USA, V99, P16601, DOI 10.1073/pnas.252646399; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Furukawa M, 2002, J BIOL CHEM, V277, P15758, DOI 10.1074/jbc.M108565200; Furukawa M, 2000, MOL CELL BIOL, V20, P8185, DOI 10.1128/MCB.20.21.8185-8197.2000; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; JENKINS CW, 1995, CELL CYCLE MAT METHO, P250; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Marin I, 2004, PHYSIOL GENOMICS, V17, P253, DOI 10.1152/physiolgenomics.00226.2003; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; O'Keefe K, 2003, MOL CELL BIOL, V23, P6396, DOI 10.1128/MCB.23.18.6396-6405.2003; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tang ZY, 2001, MOL BIOL CELL, V12, P3839, DOI 10.1091/mbc.12.12.3839; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Tsai SC, 2000, J BIOL CHEM, V275, P3239, DOI 10.1074/jbc.275.5.3239; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	43	75	82	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2006	25	33					4534	4548		10.1038/sj.onc.1209490	http://dx.doi.org/10.1038/sj.onc.1209490			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16547496				2022-12-28	WOS:000239457500004
J	Caslini, C; D Capo-Chichi, C; Roland, IH; Nicolas, E; T Yeung, A; Xu, XX				Caslini, C.; D Capo-Chichi, C.; Roland, I. H.; Nicolas, E.; T Yeung, A.; Xu, X-X			Histone modifications silence the GATA transcription factor genes in ovarian cancer	ONCOGENE			English	Article						ovarian epithelial cells; ovarian carcinomas; chromatin; transcription repression; GATA transcription factors; Disabled-2 (DAB2)	TUMOR-SUPPRESSOR GENE; H3 LYSINE 9; METHYLATION PATTERNS; HYPERSENSITIVE SITE; GASTRIC-CANCER; ALLELIC LOSS; ACETYLATION; EXPRESSION; DNA; CARCINOMAS	Altered expression of GATA factors was found and proposed as the underlying mechanism for dedifferentiation in ovarian carcinogenesis. In particular, GATA6 is lost or excluded from the nucleus in 85% of ovarian tumors and GATA4 expression is absent in majority of ovarian cancer cell lines. Here, we evaluated their DNA and histone epigenetic modi. cations in five ovarian epithelial and carcinoma cell lines (human 'immortalized' ovarian surface epithelium (HIO)-117, HIO-114, A2780, SKOV3 and ES2). GATA4 and GATA6 gene silencing was found to correlate with hypoacetylation of histones H3 and H4 and loss of histone H3/lysine K4 trimethylation at their promoters in all lines. Conversely, histone H3/lysine K9 di-methylation and HP1 gamma association were not observed, excluding reorganization of GATA genes into heterochromatic structures. The histone deacetylase inhibitor trichostatin A, but not the DNA methylation inhibitor 5'-aza-2'-deoxycytidine, re-established the expression of GATA4 and/or GATA6 in A2780 and HIO-114 cells, correlating with increased histone H3 and H4 acetylation, histone H3 lysine K4 methylation and DNase I sensitivity at the promoters. Therefore, altered histone modi. cation of the promoter loci is one mechanism responsible for the silencing of GATA transcription factors and the subsequent loss of a target gene, the tumor suppressor Disabled-2, in ovarian carcinogenesis.	Fox Chase Canc Ctr, Ovarian Canc Program, Dept Med Oncol, Philadelphia, PA 19111 USA; Fox Chase Canc Ctr, Tumor Cell Biol Program, Dept Med Oncol, Philadelphia, PA 19111 USA; Fox Chase Canc Ctr, Basic Sci & Fannie E Rippel Biochem & Biotechnol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center; Fox Chase Cancer Center; Fox Chase Cancer Center	Xu, XX (corresponding author), Fox Chase Canc Ctr, Ovarian Canc Program, Dept Med Oncol, 333 Cottman Ave, Philadelphia, PA 19111 USA.	xiangxi.xu@fccc.edu	Caslini, Corrado/A-1689-2012; Caslini, Corrado/W-6123-2019	Caslini, Corrado/0000-0001-8326-8368; Caslini, Corrado/0000-0001-8326-8368; CAPO-CHICHI, D. Callinice/0000-0003-4941-7301	NATIONAL CANCER INSTITUTE [P30CA006927, R01CA075389, R01CA079716, P50CA083638] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA79716, P50 CA083638, R01 CA75389, P30 CA006927, CA006927, P50 CA83638, R01 CA079716] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bai YQ, 2000, MOL CARCINOGEN, V28, P184, DOI 10.1002/1098-2744(200007)28:3<184::AID-MC7>3.0.CO;2-6; Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BOVA GS, 1993, CANCER RES, V53, P3869; Capo-Chichi CD, 2003, CANCER RES, V63, P4967; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; FUJIWARA Y, 1993, CANCER RES, V53, P1172; Gong QH, 1996, MOL CELL BIOL, V16, P6055; Gregory PD, 2001, EXP CELL RES, V265, P195, DOI 10.1006/excr.2001.5187; Guo MZ, 2004, CLIN CANCER RES, V10, P7917, DOI 10.1158/1078-0432.CCR-04-1140; Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Ho CL, 2004, CANCER RES, V64, P6915, DOI 10.1158/0008-5472.CAN-04-2067; JACKSON PD, 1985, P NATL ACAD SCI USA, V82, P2296, DOI 10.1073/pnas.82.8.2296; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lassus H, 2001, LAB INVEST, V81, P517, DOI 10.1038/labinvest.3780260; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Morrisey EE, 2000, J BIOL CHEM, V275, P19949, DOI 10.1074/jbc.M001331200; Mutskov V, 2004, EMBO J, V23, P138, DOI 10.1038/sj.emboj.7600013; Nemer G, 1999, MAMM GENOME, V10, P993, DOI 10.1007/s003359901146; Park IK, 2004, J CLIN INVEST, V113, P175, DOI 10.1172/JCI200420800; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Sheng ZJ, 2000, ONCOGENE, V19, P4847, DOI 10.1038/sj.onc.1203853; Spencer VA, 2003, METHODS, V31, P67, DOI 10.1016/S1046-2023(03)00089-6; Umlauf David, 2004, Methods Mol Biol, V287, P99; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; WAKANA K, 2005, CANC LETT; Yang DH, 2002, DEV BIOL, V251, P27, DOI 10.1006/dbio.2002.0810; Yang DH, 2002, CANCER-AM CANCER SOC, V94, P2380, DOI 10.1002/cncr.10497; ZHENG JP, 1995, J NATL CANCER I, V87, P1146, DOI 10.1093/jnci/87.15.1146; ZHENG JP, 1993, CANCER RES, V53, P4138	44	81	84	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	39					5446	5461		10.1038/sj.onc.1209533	http://dx.doi.org/10.1038/sj.onc.1209533			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16607277	Green Accepted			2022-12-28	WOS:000240144900009
J	Stevens, TA; Meech, R				Stevens, T. A.; Meech, R.			BARX2 and estrogen receptor-alpha (ESR1) coordinatelyregulate the production of alternatively spliced ESR1 isoforms and control breast cancer cell growth and invasion	ONCOGENE			English	Article						homeobox; estrogen; breast cancer; invasion; splicing	ANCHORAGE INDEPENDENT GROWTH; HOMEODOMAIN PROTEIN BARX2; SERUM RESPONSE FACTOR; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR; BRANCHING MORPHOGENESIS; NUCLEAR RECEPTOR; TRANSCRIPTION FACTOR; EPITHELIAL-CELLS; GENE-EXPRESSION	The estrogen receptor-alpha gene (ESR1) was previously identified as a direct target of the homeobox transcription factor BARX2 in MCF7 cells. Here, we show that BARX2 and ESR1 proteins bind to different ESR1 gene promoters and regulate the expression of alternatively spliced mRNAs that encode 66 and 46 kDa ESR1 protein isoforms. BARX2 increases the expression of both ESR1 isoforms; however, it has a greater effect on the 46 kDa isoform, leading to an increased ratio between the 46 and 66 kDa proteins. BARX2 also influences estrogen-dependent processes such as anchorage-independent growth and modulates the expression of the estrogen-responsive genes SOX5, RBM15, Dynein and Mortalin. In addition, BARX2 expression promotes cellular invasion and increases the expression of active matrix metalloproteinase-9 (MMP9). BARX2 also increases the expression of the tissue inhibitor of metalloproteinase (TIMP) genes, TIMP1 and TIMP3, in cooperation with estrogen signaling. Overall, these data indicate that BARX2 and ESR1 may coordinately regulate cell growth, survival and invasion pathways that are critical to breast cancer progression.	Scripps Res Inst, Dept Neurobiol, La Jolla, CA 92037 USA	Scripps Research Institute	Meech, R (corresponding author), Scripps Res Inst, Dept Neurobiol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rmeech@scripps.edu		Meech, Robyn/0000-0002-6831-0801				Auboeuf D, 2005, MOL CELL BIOL, V25, P5307, DOI 10.1128/MCB.25.13.5307-5316.2005; Auboeuf D, 2004, MOL CELL BIOL, V24, P442, DOI 10.1128/MCB.24.1.442-453.2004; Auboeuf D, 2002, SCIENCE, V298, P416, DOI 10.1126/science.1073734; Balduyck M, 2000, CLIN EXP METASTAS, V18, P171, DOI 10.1023/A:1006762425323; Care A, 2001, CANCER RES, V61, P6532; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Cramer P, 1999, MOL CELL, V4, P251, DOI 10.1016/S1097-2765(00)80372-X; Cramer P, 1997, P NATL ACAD SCI USA, V94, P11456, DOI 10.1073/pnas.94.21.11456; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Denger S, 2001, MOL ENDOCRINOL, V15, P2064, DOI 10.1210/me.15.12.2064; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fasco MJ, 2000, MOL CELL ENDOCRINOL, V162, P167, DOI 10.1016/S0303-7207(00)00194-5; Fata JE, 1999, DEV BIOL, V211, P238, DOI 10.1006/dbio.1999.9313; FIENBERG AA, 1987, CURR TOP DEV BIOL, V23, P23; Flouriot G, 2000, EMBO J, V19, P4688, DOI 10.1093/emboj/19.17.4688; Flouriot G, 1998, MOL ENDOCRINOL, V12, P1939, DOI 10.1210/me.12.12.1939; Gill SE, 2003, DEV BIOL, V261, P313, DOI 10.1016/S0012-1606(03)00318-X; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Herring BP, 2001, J BIOL CHEM, V276, P14482, DOI 10.1074/jbc.M011585200; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Jones FS, 1997, P NATL ACAD SCI USA, V94, P2632, DOI 10.1073/pnas.94.6.2632; Krasner A, 2000, GENE, V250, P171, DOI 10.1016/S0378-1119(00)00169-4; Lambertini E, 2003, BIOCHEM J, V372, P831, DOI 10.1042/BJ20021633; Lelongt B, 1997, J CELL BIOL, V136, P1363, DOI 10.1083/jcb.136.6.1363; Li GY, 1999, CANCER RES, V59, P6267; Liu D, 2001, EUR J CANCER, V37, P268, DOI 10.1016/S0959-8049(00)00392-0; Liu XW, 2003, J BIOL CHEM, V278, P40364, DOI 10.1074/jbc.M302999200; Mark M, 1997, PEDIATR RES, V42, P421, DOI 10.1203/00006450-199710000-00001; McDowell N, 1999, SEMIN CELL DEV BIOL, V10, P311, DOI 10.1006/scdb.1999.0307; Meech R, 2003, J BIOL CHEM, V278, P8269, DOI 10.1074/jbc.M207617200; Meech R, 2005, DEVELOPMENT, V132, P2135, DOI 10.1242/dev.01811; Metivier R, 2004, EMBO J, V23, P3653, DOI 10.1038/sj.emboj.7600377; Nguyen M, 1998, J BIOL CHEM, V273, P5400, DOI 10.1074/jbc.273.9.5400; Nothnick WB, 2004, BIOL REPROD, V70, P500, DOI 10.1095/biolreprod.103.020834; O'Doherty A, 2002, BRIT J CANCER, V86, P282, DOI 10.1038/sj.bjc.6600028; PENOT G, 2005, ENDOCRINOLOGY, V8, P8; Rayala SK, 2005, EMBO REP, V6, P538, DOI 10.1038/sj.embor.7400417; Samady L, 2004, CANCER BIOL THER, V3, P317, DOI 10.4161/cbt.3.3.698; Satoh K, 2004, J MAMMARY GLAND BIOL, V9, P195, DOI 10.1023/B:JOMG.0000037162.84758.b5; Schratt G, 2002, J CELL BIOL, V156, P737, DOI 10.1083/jcb.200106008; Sellar GC, 2001, CANCER RES, V61, P6977; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; Sivak JM, 2004, MOL CELL BIOL, V24, P245, DOI 10.1128/MCB.24.1.245-257.2004; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STETLERSTEVENSON WG, 1990, CANCER METAST REV, V9, P289, DOI 10.1007/BF00049520; Stevens TA, 2004, J BIOL CHEM, V279, P14520, DOI 10.1074/jbc.M310259200; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Yoshiji H, 1996, INT J CANCER, V69, P131, DOI 10.1002/(SICI)1097-0215(19960422)69:2<131::AID-IJC11>3.0.CO;2-C; Zhao YG, 2004, CANCER RES, V64, P590, DOI 10.1158/0008-5472.CAN-03-1932; ZUGMAIER G, 1991, J STEROID BIOCHEM, V39, P681, DOI 10.1016/0960-0760(91)90367-E	52	46	47	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2006	25	39					5426	5435		10.1038/sj.onc.1209529	http://dx.doi.org/10.1038/sj.onc.1209529			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16636675				2022-12-28	WOS:000240144900007
J	Koturbash, I; Rugo, RE; Hendricks, CA; Loree, J; Thibault, B; Kutanzi, K; Pogribny, I; Yanch, JC; Engelward, BP; Kovalchuk, O				Koturbash, I.; Rugo, R. E.; Hendricks, C. A.; Loree, J.; Thibault, B.; Kutanzi, K.; Pogribny, I.; Yanch, J. C.; Engelward, B. P.; Kovalchuk, O.			Irradiation induces DNA damage and modulates epigenetic effectors in distant bystander tissue in vivo	ONCOGENE			English	Article						radiation; bystander effect; DNA damage; epigenetics	INDUCED GENOMIC INSTABILITY; DOUBLE-STRAND BREAKS; HUMAN RAD51 PROTEIN; IONIZING-RADIATION; MAMMALIAN-CELLS; ALPHA-PARTICLES; HOMOLOGOUS RECOMBINATION; HUMAN FIBROBLASTS; HISTONE H2AX; GLOBAL DNA	Irradiated cells induce chromosomal instability in unirradiated bystander cells in vitro. Although bystander effects are thought to be linked to radiation-induced secondary cancers, almost no studies have evaluated bystander effects in vivo. Furthermore, it has been proposed that epigenetic changes mediate bystander effects, but few studies have evaluated epigenetic factors in bystander tissues in vivo. Here, we describe studies in which mice were unilaterally exposed to X-irradiation and the levels of DNA damage, DNA methylation and protein expression were evaluated in irradiated and bystander cutaneous tissue. The data show that X-ray exposure to one side of the animal body induces DNA strand breaks and causes an increase in the levels of Rad51 in unexposed bystander tissue. In terms of epigenetic changes, unilateral radiation suppresses global methylation in directly irradiated tissue, but not in bystander tissue at given time-points studied. Intriguingly, however, we observed a significant reduction in the levels of the de novo DNA methyltransferases DNMT3a and 3b and a concurrent increase in the levels of the maintenance DNA methyltransferase DNMT1 in bystander tissues. Further more, the levels of two methyl-binding proteins known to be involved in transcriptional silencing, MeCP2 and MBD2, were also increased in bystander tissue. Together, these results show that irradiation induces DNA damage in bystander tissue more than a centimeter away from directly irradiated tissues, and suggests that epigenetic transcriptional regulation may be involved in the etiology of radiation-induced bystander effects.	Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 3M4, Canada; MIT, Div Biol Engn, Cambridge, MA 02139 USA; Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA; MIT, Dept Nucl Sci & Engn, Cambridge, MA 02139 USA	University of Lethbridge; Massachusetts Institute of Technology (MIT); US Food & Drug Administration (FDA); Massachusetts Institute of Technology (MIT)	Kovalchuk, O (corresponding author), Univ Lethbridge, Dept Biol Sci, 4401 Univ Dr,HH127, Lethbridge, AB T1K 3M4, Canada.	olga.kovalchuk@uleth.ca		Loree, Jonathan/0000-0001-8189-2132	NCI NIH HHS [R01CA79827, R01 CA079827, R21 CA084740, P01-CA26731] Funding Source: Medline; NIEHS NIH HHS [P30-ES02109, P30 ES001209-26A1, P30 ES002109] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA084740, R01CA079827, P01CA026731] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		[Anonymous], 2003, MCNP GEN MONT CARL N; Balmain A, 2000, CARCINOGENESIS, V21, P371, DOI 10.1093/carcin/21.3.371; Basnakian AG, 1996, DNA CELL BIOL, V15, P255, DOI 10.1089/dna.1996.15.255; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bowen NJ, 2004, CELL MOL LIFE SCI, V61, P2163, DOI 10.1007/s00018-004-4177-x; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Goldberg Z, 2003, ONCOGENE, V22, P7011, DOI 10.1038/sj.onc.1206990; Goldberg Z, 2002, INT J ONCOL, V21, P337; Gonzalgo ML, 1997, MUTAT RES-REV MUTAT, V386, P107, DOI 10.1016/S1383-5742(96)00047-6; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Hall EJ, 2003, HEALTH PHYS, V85, P31, DOI 10.1097/00004032-200307000-00008; Helleday T, 2003, MUTAT RES-FUND MOL M, V532, P103, DOI 10.1016/j.mrfmmm.2003.08.013; Hendrich B, 2003, TRENDS GENET, V19, P269, DOI 10.1016/S0168-9525(03)00080-5; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Huang L, 2003, ONCOGENE, V22, P5848, DOI 10.1038/sj.onc.1206697; Huo LH, 2001, RADIAT RES, V156, P521, DOI 10.1667/0033-7587(2001)156[0521:HMIIBC]2.0.CO;2; Ichijima Y, 2005, BIOCHEM BIOPH RES CO, V336, P807, DOI 10.1016/j.bbrc.2005.08.164; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; KALINICH JF, 1989, RADIAT RES, V117, P185, DOI 10.2307/3577319; Kashino G, 2004, MUTAT RES-FUND MOL M, V556, P209, DOI 10.1016/j.mrfmmm.2004.08.009; Koturbash I, 2005, BIOCHEM BIOPH RES CO, V337, P526, DOI 10.1016/j.bbrc.2005.09.084; Kovalchuk O, 2004, MOL CANCER RES, V2, P567; Little JB, 1999, CR ACAD SCI III-VIE, V322, P127, DOI 10.1016/S0764-4469(99)80034-1; Little JB, 1998, INT J RADIAT BIOL, V74, P663, DOI 10.1080/095530098140925; Lundin C, 2003, J MOL BIOL, V328, P521, DOI 10.1016/S0022-2836(03)00313-9; Maguire P, 2005, RADIAT RES, V163, P384, DOI 10.1667/RR3325; McGlynn P, 2002, NAT REV MOL CELL BIO, V3, P859, DOI 10.1038/nrm951; Minamoto T, 1999, CARCINOGENESIS, V20, P519, DOI 10.1093/carcin/20.4.519; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Morgan WF, 2002, MUTAT RES-FUND MOL M, V504, P91, DOI 10.1016/S0027-5107(02)00083-0; Mothersill C, 2005, RADIAT RES, V163, P391, DOI 10.1667/RR3320; Mothersill C, 2004, NAT REV CANCER, V4, P158, DOI 10.1038/nrc1277; Mothersill C, 2002, RADIAT RES, V158, P626, DOI 10.1667/0033-7587(2002)158[0626:BADEAF]2.0.CO;2; Mothersill CE, 2004, INT J RADIAT ONCOL, V58, P575, DOI 10.1016/j.ijrobp.2003.09.038; Nagar S, 2003, CANCER RES, V63, P324; NAGASAWA H, 1992, CANCER RES, V52, P6394; Panayiotidis MI, 2004, ANTIOXID REDOX SIGN, V6, P129, DOI 10.1089/152308604771978435; Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187; Pogribny I, 2004, BIOCHEM BIOPH RES CO, V320, P1253, DOI 10.1016/j.bbrc.2004.06.081; Pogrlbny I, 2005, MOL CANCER RES, V3, P553, DOI 10.1158/1541-7786.MCR-05-0074; Ponnaiya B, 2004, MUTAT RES-FUND MOL M, V568, P41, DOI 10.1016/j.mrfmmm.2004.06.045; Raiche J, 2004, BIOCHEM BIOPH RES CO, V325, P39, DOI 10.1016/j.bbrc.2004.10.002; Richardson C, 2004, ONCOGENE, V23, P546, DOI 10.1038/sj.onc.1207098; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Rothkamm K, 2002, INT J ONCOL, V21, P433; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Rugo RE, 2005, ONCOGENE, V24, P5016, DOI 10.1038/sj.onc.1208690; Sawant SG, 2001, RADIAT RES, V155, P397, DOI 10.1667/0033-7587(2001)155[0397:TBEIRO]2.0.CO;2; Sigurdson AJ, 2003, ONCOGENE, V22, P7018, DOI 10.1038/sj.onc.1206989; Sokolov MV, 2005, ONCOGENE, V24, P7257, DOI 10.1038/sj.onc.1208886; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Tawa R, 1998, J RADIAT RES, V39, P271, DOI 10.1269/jrr.39.271; TURK PW, 1995, CARCINOGENESIS, V16, P1253, DOI 10.1093/carcin/16.5.1253; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Ward JF, 2002, MUTAT RES-FUND MOL M, V499, P151, DOI 10.1016/S0027-5107(01)00286-X; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Xue LY, 2002, P NATL ACAD SCI USA, V99, P13765, DOI 10.1073/pnas.182209699; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797; Zhou HN, 2002, MUTAT RES-FUND MOL M, V499, P135, DOI 10.1016/S0027-5107(01)00285-8	68	165	185	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2006	25	31					4267	4275		10.1038/sj.onc.1209467	http://dx.doi.org/10.1038/sj.onc.1209467			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16532033				2022-12-28	WOS:000239240100002
J	Chevalier, SA; Meertens, L; Pise-Masison, C; Calattini, S; Park, H; Alhaj, AA; Zhou, M; Gessain, A; Kashanchi, F; Brady, JN; Mahieux, R				Chevalier, S. A.; Meertens, L.; Pise-Masison, C.; Calattini, S.; Park, H.; Alhaj, A. A.; Zhou, M.; Gessain, A.; Kashanchi, F.; Brady, J. N.; Mahieux, R.			The tax protein from the primate T-cell lymphotropic virus type 3 is expressed in vivo and is functionally related to HTLV-1 tax rather than HTLV-2 Tax	ONCOGENE			English	Article						HTLV-3; tax; PDZ; CREB; NF-kappa B	LONG TERMINAL REPEAT; LEUKEMIA-VIRUS; CENTRAL-AFRICA; MOLECULAR EPIDEMIOLOGY; 21-BASE-PAIR REPEATS; CERCOCEBUS-TORQUATUS; VIRAL REPLICATION; ESCHERICHIA-COLI; COACTIVATOR CBP; PAPIO-HAMADRYAS	Human T-cell leukemia virus and simian T-cell leukemia virus ( STLV) form the primate T-cell lymphotropic viruses group. Human T-cell leukemia virus type 1 and type 2 (HTLV-1 and HTLV-2) encode the Tax viral transactivator ( Tax1 and Tax2, respectively). Tax1 possesses an oncogenic potential and is responsible for cell transformation both in vivo and in vitro. We and others have recently discovered the existence of human T-cell lymphotropic virus type 3. However, there is currently no evidence for the presence of a Tax protein in HTLV-3-infected individuals. We show that the serum of an HTLV-3 asymptomatic carrier and the sera of two STLV-3-infected monkeys contain specific anti-Tax3 antibodies. We also show that tax3 mRNA is present in the PBMCs obtained from an STLV-3-infected monkey, demonstrating that Tax3 is expressed in vivo. We further demonstrate that Tax3 intracellular localization is very similar to that of Tax1 and that Tax3 binds to both CBP and p300 coactivators. Using purified Tax3, we show that the protein increases transcription from a 4TxRE G-free cassette plasmid in an in vitro transcription assay. In all cell types tested, including transiently transfected lymphocytes, Tax3 activates its own promoter STLV-3 long terminal repeat (LTR), which contains only two Tax Responsive Elements (TREs), and activates also HTLV-1 and HTLV-2 LTRs. In addition, Tax3 also activates the NF-kappa B pathway. We also show that Tax3 possesses a PDZ-binding sequence at its C-terminal end. Our results demonstrate that Tax3 is a transactivator, and that its properties are more similar to that of Tax1, rather than of Tax2. This suggests the possible occurrence of lymphoproliferative disorders among HTLV-3-infected populations.	Inst Pasteur, Unite Epidemiol & Physiopathol Virus Oncogenes, F-75724 Paris 15, France; NCI, Virus Tumor Biol Sect, NIH, Bethesda, MD USA; George Washington Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); George Washington University	Mahieux, R (corresponding author), Inst Pasteur, Unite Epidemiol & Physiopathol Virus Oncogenes, 28 Rue Dr Roux, F-75724 Paris 15, France.	rmahieux@pasteur.fr	Meertens, Laurent/E-8043-2017	Meertens, Laurent/0000-0003-2811-3675; mahieux, renaud/0000-0002-5129-6804	NATIONAL CANCER INSTITUTE [Z01BC005691, ZIABC005691, ZIABC005254, Z01BC005254] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI044357, R01AI043894] Funding Source: NIH RePORTER; NIAID NIH HHS [AI44357, AI43894, AI13969] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alefantis T, 2003, J BIOL CHEM, V278, P21814, DOI 10.1074/jbc.M211576200; Barnhart MK, 1997, J VIROL, V71, P337, DOI 10.1128/JVI.71.1.337-344.1997; BLAKESLEE JR, 1987, CANCER LETT, V37, P1, DOI 10.1016/0304-3835(87)90139-X; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; Calattini S, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-30; Casoli C, 2004, BLOOD, V103, P995, DOI 10.1182/blood-2003-07-2503; Chen YMA, 1997, INT J CANCER, V71, P196, DOI 10.1002/(SICI)1097-0215(19970410)71:2&lt;196::AID-IJC12&gt;3.0.CO;2-G; COATES SR, 1990, J CLIN MICROBIOL, V28, P1139, DOI 10.1128/JCM.28.6.1139-1142.1990; Courgnaud V, 2004, J VIROL, V78, P4700, DOI 10.1128/JVI.78.9.4700-4709.2004; Deng LW, 2000, VIROLOGY, V277, P278, DOI 10.1006/viro.2000.0593; DUVALL JF, 1995, J VIROL, V69, P5077, DOI 10.1128/JVI.69.8.5077-5086.1995; Endo K, 2002, J VIROL, V76, P2648, DOI 10.1128/JVI.76.6.2648-2653.2002; FROMENT A, 1993, AIDS RES HUM RETROV, V9, P707, DOI 10.1089/aid.1993.9.707; GESSAIN A, 1995, P NATL ACAD SCI USA, V92, P4041, DOI 10.1073/pnas.92.9.4041; GIRI A, 1994, J VIROL, V68, P8392, DOI 10.1128/JVI.68.12.8392-8395.1994; GITLIN SD, 1991, J VIROL, V65, P2612, DOI 10.1128/JVI.65.5.2612-2621.1991; GOUBAU P, 1994, P NATL ACAD SCI USA, V91, P2848, DOI 10.1073/pnas.91.7.2848; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; GUO HG, 1984, SCIENCE, V223, P1195, DOI 10.1126/science.6322297; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Hirata A, 2004, VIROLOGY, V318, P327, DOI 10.1016/j.virol.2003.10.006; Hisada M, 1998, BLOOD, V92, P3557, DOI 10.1182/blood.V92.10.3557.422k09_3557_3561; Hunsmann G, 1984, Princess Takamatsu Symp, V15, P109; Iwanaga Y, 1999, J VIROL, V73, P1271, DOI 10.1128/JVI.73.2.1271-1277.1999; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; Kashanchi F, 1998, J BIOL CHEM, V273, P34646, DOI 10.1074/jbc.273.51.34646; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lemasson I, 2001, J BIOL CHEM, V276, P15720, DOI 10.1074/jbc.M100131200; LINDHOLM PF, 1991, J BIOCHEM BIOPH METH, V22, P233, DOI 10.1016/0165-022X(91)90071-4; LIU HF, 1994, LANCET, V344, P265, DOI 10.1016/S0140-6736(94)93032-5; Lu HX, 2002, MOL CELL BIOL, V22, P4450, DOI 10.1128/MCB.22.13.4450-4462.2002; Mahieux R, 1997, J VIROL, V71, P1317, DOI 10.1128/JVI.71.2.1317-1333.1997; Mahieux Renaud, 2003, Rev Clin Exp Hematol, V7, P336; MAUCLERE P, 1993, AIDS, V7, P1394, DOI 10.1097/00002030-199310000-00019; Mauclere P, 1997, J INFECT DIS, V176, P505, DOI 10.1086/514071; Mboudjeka I, 1997, JPN J CANCER RES, V88, P619, DOI 10.1111/j.1349-7006.1997.tb00427.x; Meertens L, 2004, J BIOL CHEM, V279, P43307, DOI 10.1074/jbc.M400497200; Meertens L, 2004, ONCOGENE, V23, P5447, DOI 10.1038/sj.onc.1207719; Meertens L, 2003, J GEN VIROL, V84, P2723, DOI 10.1099/vir.0.19253-0; Meertens L, 2003, J VIROL, V77, P782, DOI 10.1128/JVI.77.1.782-789.2003; Meertens L, 2002, J VIROL, V76, P259, DOI 10.1128/JVI.76.1.259-268.2002; MIYOSHI I, 1982, LANCET, V2, P658; Nerrienet E, 2004, J GEN VIROL, V85, P25, DOI 10.1099/vir.0.19314-0; Nerrienet E, 2001, J GEN VIROL, V82, P2973, DOI 10.1099/0022-1317-82-12-2973; Nicot C, 2004, NAT MED, V10, P197, DOI 10.1038/nm984; Pise-Masison CA, 2005, FRONT BIOSCI-LANDMRK, V10, P919, DOI 10.2741/1586; Pise-Masison CA, 2000, AIDS RES HUM RETROV, V16, P1669, DOI 10.1089/08892220050193128; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; Ross TM, 1996, J VIROL, V70, P5194, DOI 10.1128/JVI.70.8.5194-5202.1996; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; Scoggin KES, 2001, MOL CELL BIOL, V21, P5520, DOI 10.1128/MCB.21.16.5520-5530.2001; Slattery JP, 1999, GENOME RES, V9, P525; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Takemura T, 2002, J VIROL, V76, P1642, DOI 10.1128/JVI.76.4.1642-1648.2002; Van Brussel M, 1999, REV MED VIROL, V9, P155, DOI 10.1002/(SICI)1099-1654(199907/09)9:3&lt;155::AID-RMV242&gt;3.0.CO;2-3; Van Dooren S, 2004, J GEN VIROL, V85, P507, DOI 10.1099/vir.0.19630-0; Van Dooren S, 2001, J VIROL, V75, P11939, DOI 10.1128/JVI.75.23.11939-11941.2001; VanBrussel M, 1997, J VIROL, V71, P5464; VanBrussel M, 1996, J GEN VIROL, V77, P347, DOI 10.1099/0022-1317-77-2-347; Watanabe M, 2005, BLOOD, V106, P2462, DOI 10.1182/blood-2004-09-3646; Wolfe ND, 2005, P NATL ACAD SCI USA, V102, P7994, DOI 10.1073/pnas.0501734102; Younis I, 2004, J VIROL, V78, P11077, DOI 10.1128/JVI.78.20.11077-11083.2004	63	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	32					4470	4482		10.1038/sj.onc.1209472	http://dx.doi.org/10.1038/sj.onc.1209472			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16532031				2022-12-28	WOS:000239326000010
J	Nakamura, N; Kobayashi, K; Nakamoto, M; Kohno, T; Sasaki, H; Matsuno, Y; Yokota, J				Nakamura, N.; Kobayashi, K.; Nakamoto, M.; Kohno, T.; Sasaki, H.; Matsuno, Y.; Yokota, J.			Identification of tumor markers and differentiation markers for molecular diagnosis of lung adenocarcinoma	ONCOGENE			English	Article						lung adenocarcinoma; lung epithelial cells; expression pro. le; microdissection; micrometastasis; differential diagnosis	LASER CAPTURE MICRODISSECTION; POLYMERASE-CHAIN-REACTION; CELL 10-KDA PROTEIN; MESSENGER-RNA; PERIPHERAL-BLOOD; EPITHELIAL-CELLS; GENE-EXPRESSION; CANCER; CARCINOMAS; CLASSIFICATION	To identify tumor markers and differentiation markers for lung adenocarcinoma (AdC), we analysed expression profiles of 14 500 genes against three cases of type II alveolar epithelial cells, bronchiolar epithelial cells, and bronchial epithelial cells, respectively, and 10 cases of AdC cells isolated by laser capture microdissection. Hierarchical clustering analysis indicated that AdC cells and noncancerous lung epithelial cells are significantly different in their expression profiles, and that different sets of differentiation markers are expressed among alveolar, bronchiolar and bronchial epithelial cells. Nine genes were identified as being highly expressed in AdC cells, but not expressed in noncancerous lung epithelial cells. Sixteen genes were identified as differentiation markers for lung epithelial cells. Real-time RT-PCR analysis of 45 lung AdC cases further revealed that expression of four tumor markers in AdC cells was significantly higher than that in noncancerous lung cells and that expression of ten differentiation markers was retained in a considerable fraction of lung AdC cases. Five tumor markers and seven differentiation markers were not expressed in peripheral blood cells. Similarities and differences in expression profiles between normal epithelial cells from different lung respiratory compartments and AdC cells demonstrated in this study will be informative for the molecular diagnosis of lung AdC.	Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Div Genet, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo 1040045, Japan	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan	Yokota, J (corresponding author), Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan.	jyokota@gan2.ncc.go.jp						Aoyagi K, 2003, BIOCHEM BIOPH RES CO, V300, P915, DOI 10.1016/S0006-291X(02)02967-4; Barth PJ, 2000, VIRCHOWS ARCH, V437, P648, DOI 10.1007/s004280000316; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; Borczuk AC, 2003, AM J PATHOL, V163, P1949, DOI 10.1016/S0002-9440(10)63553-5; BROERS JLV, 1992, LAB INVEST, V66, P337; Chhieng DC, 2001, CANCER CYTOPATHOL, V93, P330, DOI 10.1002/cncr.9048; D'Cunha J, 2002, J THORAC CARDIOV SUR, V123, P484, DOI 10.1067/mtc.2002.119883; Egland KA, 2002, MOL CANCER THER, V1, P441; Fischer H, 2001, CARCINOGENESIS, V22, P875, DOI 10.1093/carcin/22.6.875; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Hanaoka J, 2001, CANCER-AM CANCER SOC, V92, P2148, DOI 10.1002/1097-0142(20011015)92:8<2148::AID-CNCR1557>3.0.CO;2-6; Hosch SB, 2001, SEMIN SURG ONCOL, V20, P278, DOI 10.1002/ssu.1045; Kobayashi K, 2004, ONCOGENE, V23, P3089, DOI 10.1038/sj.onc.1207433; Kufer P, 2002, CANCER RES, V62, P251; Matsunaga H, 2002, INT J CANCER, V100, P592, DOI 10.1002/ijc.10534; Mbikay M, 2001, BIOCHEM J, V357, P329, DOI 10.1042/0264-6021:3570329; Mitas M, 2003, J MOL DIAGN, V5, P237, DOI 10.1016/S1525-1578(10)60480-1; Miura K, 2002, CANCER RES, V62, P3244; Moniaux N, 2004, BRIT J CANCER, V91, P1633, DOI 10.1038/sj.bjc.6602163; Naruke T, 2001, ANN THORAC SURG, V71, P1759, DOI 10.1016/S0003-4975(00)02609-6; Otto WR, 2002, J PATHOL, V197, P527, DOI 10.1002/path.1160; Player A, 2004, EXPERT REV MOL DIAGN, V4, P831, DOI 10.1586/14737159.4.6.831; Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434; SOBIN C, 2002, TNM CLASSIFICATION M, P97; Takamochi K, 2004, EUR J CARDIO-THORAC, V25, P877, DOI 10.1016/j.ejcts.2004.01.049; TenHaveOpbroek AAW, 1997, HISTOL HISTOPATHOL, V12, P319; Tomida S, 2004, ONCOGENE, V23, P5360, DOI 10.1038/sj.onc.1207697; Travis WD, 1999, HISTOLOGICAL TYPING; VIEAU D, 1991, CLIN ENDOCRINOL, V35, P319, DOI 10.1111/j.1365-2265.1991.tb03543.x; Virtanen C, 2002, P NATL ACAD SCI USA, V99, P12357, DOI 10.1073/pnas.192240599; Wang K, 2002, ONCOGENE, V21, P7598, DOI 10.1038/sj.onc.1205953; Xu P, 1998, VIRCHOWS ARCH, V432, P17, DOI 10.1007/s004280050129; Zamecnik J, 2002, VIRCHOWS ARCH, V440, P353, DOI 10.1007/s00428-001-0552-2	34	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	30					4245	4255		10.1038/sj.onc.1209442	http://dx.doi.org/10.1038/sj.onc.1209442			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16491115				2022-12-28	WOS:000239004800013
J	Adams, KE; Medhurst, AL; Dart, DA; Lakin, ND				Adams, KE; Medhurst, AL; Dart, DA; Lakin, ND			Recruitment of ATR to sites of ionising radiation-induced DNA damage requires ATM and components of the MRN protein complex	ONCOGENE			English	Article						ataxia telangiectasia mutated and rad3-related (ATR); cell cycle checkpoints; DNA damage and repair	DOUBLE-STRAND BREAKS; EARLY EMBRYONIC LETHALITY; CHECKPOINT KINASE ATR; ATAXIA-TELANGIECTASIA; MRE11 COMPLEX; S-PHASE; DEPENDENT PHOSPHORYLATION; REPLICATION CHECKPOINT; GENOTOXIC STRESS; DEFICIENT CELLS	ATM and ATR are two related kinases essential for signalling DNA damage. Although ATM is thought to be the principle kinase responsible for signalling ionising radiation (IR)-induced DNA damage, ATR also contributes to signalling this form of genotoxic stress. However, the molecular basis of differential ATM and ATR activation in response to IR remains unclear. Here, we report that ATR is recruited to sites of IR-induced DNA damage significantly later than activation of ATM. We show that ATR is recruited to IR-induced nuclear foci in G(1) and S phase of the cell cycle, supporting a role for ATR in detecting DNA damage outside of S phase. In addition, we report that recruitment of ATR to sites of IR-induced DNA damage is concomitant with appearance of large tracts of single-stranded DNA (ssDNA) and that this event is dependent on ATM and components of the Mre11/Rad50/Nbs1 (MRN) protein complex.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford	Lakin, ND (corresponding author), Univ Oxford, Dept Biochem, S Pks Rd, Oxford OX1 3QU, England.	nicholas.lakin@bioch.ox.ac.uk			Cancer Research UK [A5207] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Brown EJ, 2000, GENE DEV, V14, P397; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Brumbaugh KM, 2004, MOL CELL, V14, P585, DOI 10.1016/j.molcel.2004.05.005; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; CELIS JE, 1985, P NATL ACAD SCI USA, V82, P3262, DOI 10.1073/pnas.82.10.3262; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Davies SL, 2004, MOL CELL BIOL, V24, P1279, DOI 10.1128/MCB.24.3.1279-1291.2004; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; Dodson GE, 2004, J BIOL CHEM, V279, P34010, DOI 10.1074/jbc.C400242200; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; Downs JA, 2003, NATURE, V424, P732, DOI 10.1038/424732a; Garcia-Muse T, 2005, EMBO J, V24, P4345, DOI 10.1038/sj.emboj.7600896; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Helt CE, 2005, J BIOL CHEM, V280, P1186, DOI 10.1074/jbc.M410873200; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; IVANOV EL, 1994, MOL CELL BIOL, V14, P3414, DOI 10.1128/MCB.14.5.3414; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Lavin MF, 2004, DNA REPAIR, V3, P1515, DOI 10.1016/j.dnarep.2004.07.001; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lisby M, 2004, CELL, V118, P699, DOI 10.1016/j.cell.2004.08.015; Llorente B, 2004, MOL CELL BIOL, V24, P9682, DOI 10.1128/MCB.24.21.9682-9694.2004; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Moreau S, 1999, MOL CELL BIOL, V19, P556; Nakada D, 2004, MOL CELL BIOL, V24, P10016, DOI 10.1128/MCB.24.22.10016-10025.2004; Nghiem P, 2001, P NATL ACAD SCI USA, V98, P9092, DOI 10.1073/pnas.161281798; Nghiem P, 2002, J BIOL CHEM, V277, P4428, DOI 10.1074/jbc.M106113200; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Stiff T, 2005, EMBO J, V24, P199, DOI 10.1038/sj.emboj.7600504; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Tsubouchi H, 1998, MOL CELL BIOL, V18, P260, DOI 10.1128/MCB.18.1.260; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Ward IM, 2004, J BIOL CHEM, V279, P9677, DOI 10.1074/jbc.C300554200; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; Yuan SSF, 2002, TOXICOLOGY, V177, P123, DOI 10.1016/S0300-483X(02)00220-2; Zhong H, 2005, HUM MOL GENET, V14, P2685, DOI 10.1093/hmg/ddi302; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	61	117	124	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2006	25	28					3894	3904		10.1038/sj.onc.1209426	http://dx.doi.org/10.1038/sj.onc.1209426			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16474843	Green Accepted			2022-12-28	WOS:000238668800002
J	Li, Y; Xie, M; Yang, J; Yang, D; Deng, R; Wan, Y; Yan, B				Li, Y.; Xie, M.; Yang, J.; Yang, D.; Deng, R.; Wan, Y.; Yan, B.			The expression of antiapoptotic protein survivin is transcriptionally upregulated by DEC1 primarily through multiple sp1 binding sites in the proximal promoter	ONCOGENE			English	Article						DEC1; survivin; Sp1 element; transcription activation	WILD-TYPE P53; GENE-EXPRESSION; RESPONSE ELEMENTS; CANCER CELLS; E-BOX; HYPOXIA; STRA13; ACTIVATION; APOPTOSIS; PATHWAY	Human differentially expressed in chondrocytes (DEC), mouse stimulated with retinoic acid and rat split and hairy related proteins constitute a structurally distinct class of the basic helix-loop-helix proteins. DEC1 is abundantly expressed in tumors and protects against apoptosis induced by serum starvation. In this study, we report that DEC1 antiapoptosis is achieved by inducing survivin, an antiapoptotic protein. In paired tumor-normal tissues, survivin and DEC1 exhibited a paralleled expression pattern. Tetracycline-induced expression of DEC1 in stable lines proportionally increased the expression of survivin. In reporter assays, DEC1 trans activated the survivin promoter but repressed the DEC2 promoter. In contrast to the repression, the activation was delayed and varied depending on serum concentrations and cycle blockers. Studies with reporter mutants located, in the survivin promoter, two Sp1 sites that supported DEC1 transactivation. Electrophoretic mobility shift assay and chromatin immunoprecipitation detected the presence of DEC1 in the survivin promoter. These findings establish that the survivin gene is a transcription target of DEC1, and induction of survivin is at least in part responsible for DEC1 antiapoptosis.	Univ Rhode Isl, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA; Providence Coll, Dept Biol, Providence, RI 02908 USA	University of Rhode Island; Providence College	Yan, B (corresponding author), Univ Rhode Isl, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA.	byan@uri.edu	Yan, Bingfang/C-7706-2012		NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [F05AT003019] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007965] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061988] Funding Source: NIH RePORTER; NCCIH NIH HHS [F05AT003019, F05 AT003019] Funding Source: Medline; NIEHS NIH HHS [R01 ES007965, R01ES07965] Funding Source: Medline; NIGMS NIH HHS [R01 GM061988, R01GM61988] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Azmi S, 2003, J BIOL CHEM, V278, P20098, DOI 10.1074/jbc.M210427200; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chakrabarti J, 2004, BRIT J CANCER, V91, P954, DOI 10.1038/sj.bjc.6602059; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Currie MJ, 2004, J CLIN PATHOL, V57, P829, DOI 10.1136/jcp.2003.015644; Fujimoto K, 2001, BIOCHEM BIOPH RES CO, V280, P164, DOI 10.1006/bbrc.2000.4133; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Halaban R, 2005, CANCER METAST REV, V24, P339, DOI 10.1007/s10555-005-1582-z; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Honma S, 2002, NATURE, V419, P841, DOI 10.1038/nature01123; Inuzuka H, 1999, BIOCHEM BIOPH RES CO, V265, P664, DOI 10.1006/bbrc.1999.1734; Ivanova AV, 2001, J BIOL CHEM, V276, P15306, DOI 10.1074/jbc.M010516200; Jiang YY, 2004, J BIOL CHEM, V279, P40511, DOI 10.1074/jbc.M404496200; Kanda N, 2004, ONCOGENE, V23, P4921, DOI 10.1038/sj.onc.1207606; Kavurma MM, 2002, J BIOL CHEM, V277, P36244, DOI 10.1074/jbc.M200463200; Kawakami H, 2005, INT J CANCER, V115, P967, DOI 10.1002/ijc.20954; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li YX, 2004, BIOCHEM J, V382, P895, DOI 10.1042/BJ20040592; Li YX, 2003, J BIOL CHEM, V278, P16899, DOI 10.1074/jbc.M300596200; Li YX, 2002, BIOCHEM J, V367, P413, DOI 10.1042/BJ20020514; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Ma H, 2005, ONCOGENE, V24, P3619, DOI 10.1038/sj.onc.1208433; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Miyazaki K, 2002, J BIOL CHEM, V277, P47014, DOI 10.1074/jbc.M204938200; Reed JC, 2001, J CLIN INVEST, V108, P965, DOI 10.1172/JCI14123; Rossner MJ, 1997, MOL CELL NEUROSCI, V9, P460, DOI 10.1006/mcne.1997.0640; Shen M, 1997, BIOCHEM BIOPH RES CO, V236, P294, DOI 10.1006/bbrc.1997.6960; Shen M, 2002, J BIOL CHEM, V277, P50112, DOI 10.1074/jbc.M206771200; Shen M, 2001, EUR J CELL BIOL, V80, P329, DOI 10.1078/0171-9335-00167; Song XL, 2004, DRUG METAB DISPOS, V32, P35, DOI 10.1124/dmd.32.1.35; Sun H, 2001, NAT IMMUNOL, V2, P1040, DOI 10.1038/ni721; Turley H, 2004, J PATHOL, V203, P808, DOI 10.1002/path.1585; Vaupel P, 2001, SEMIN ONCOL, V28, P29, DOI 10.1016/S0093-7754(01)90210-6; Xie MX, 2003, DRUG METAB DISPOS, V31, P21, DOI 10.1124/dmd.31.1.21; Xie MX, 2002, DRUG METAB DISPOS, V30, P541, DOI 10.1124/dmd.30.5.541; Yang YL, 2000, CELL RES, V10, P169, DOI 10.1038/sj.cr.7290046; Yoon DY, 2001, BIOCHEM BIOPH RES CO, V288, P882, DOI 10.1006/bbrc.2001.5867; Yun Z, 2002, DEV CELL, V2, P331, DOI 10.1016/S1534-5807(02)00131-4; Zawel L, 2002, P NATL ACAD SCI USA, V99, P2848, DOI 10.1073/pnas.261714999	43	91	99	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3296	3306		10.1038/sj.onc.1209363	http://dx.doi.org/10.1038/sj.onc.1209363			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16462771	Green Accepted			2022-12-28	WOS:000237951200008
J	De Toni, F; Racaud-Sultan, C; Chicanne, G; Mansat-De Mas, V; Cariven, C; Mesange, F; Salles, JP; Demur, C; Allouche, M; Payrastre, B; Manenti, S; Ysebaert, L				De Toni, F.; Racaud-Sultan, C.; Chicanne, G.; Mansat-De Mas, V.; Cariven, C.; Mesange, F.; Salles, J-P; Demur, C.; Allouche, M.; Payrastre, B.; Manenti, S.; Ysebaert, L.			A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia	ONCOGENE			English	Article						leukemia; chemoresistance; adhesion; Wnt; GSK3 beta	GLYCOGEN-SYNTHASE KINASE-3-BETA; NF-KAPPA-B; FRIZZLED-RELATED PROTEIN-1; ACUTE MYELOGENOUS LEUKEMIA; TUMOR-NECROSIS-FACTOR; BETA-CATENIN; STEM-CELLS; DRUG-RESISTANCE; CANCER CELLS; ACTIVATION	Relapses following chemotherapy are a major hindrance to patients' survival in acute myeloid leukemia (AML). To investigate the role of the hematopoietic niche in the chemoresistance of leukemic cells, we examined two pathways: one mediated by adhesion molecules/integrins, and the other by soluble factors of the morphogen Wnt pathway. In our study, both the adhesion of leukemic blasts to fibronectin and the addition of Wnt antagonists induced, independently, resistance of AML cells to daunorubicin in a cell survival assay. Using pharmacological inhibitors and siRNA, we showed that both resistance pathways required the activity of the glycogen synthase kinase 3 beta (GSK3 beta). Moreover, the AML cell protection downstream of GSK3 beta was mediated by NF-kappa B. A link between the adhesion and the Wnt pathway was found, as adhesion of U937 on human osteoblasts, a component of the hematopoietic niche, triggered the secretion of the Wnt antagonist sFRP-1 and supported resistance to daunorubicin. The osteoblast-conditioned medium could also confer chemoresistance to U937 cells cultured in suspension, and this cell protective effect was abrogated after depletion of sFRP-1. In the context of this potential double in vivo resistance, modulators of the common signal GSK3 beta and of its target NF-kappa B could represent important novel therapeutic tools.	CHU Purpan, INSERM, U563,CPTP, Dept Oncogenesis & Hematopoiet Cells,Hosp Purpan, F-31024 Toulouse 3, France; CHU Purpan, INSERM, Hematol Lab, Unite 563, F-31024 Toulouse 3, France; CHU Purpan, INSERM, IFR 30, Unite 563,Dept Lipoprot & Mediateurs Lipid, F-31024 Toulouse 3, France; CHU Purpan, INSERM, Serv Hematol Clin, Unite 563, F-31024 Toulouse 3, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Racaud-Sultan, C (corresponding author), CHU Purpan, INSERM, U563,CPTP, Dept Oncogenesis & Hematopoiet Cells,Hosp Purpan, Pl Baylac, F-31024 Toulouse 3, France.	claire.racaud@toulouse.inserm.fr	manenti, stephane/P-1518-2014; Ysebaert, Loic/H-1554-2016; SALLES, Jean Pierre/K-2998-2014; De Mas, Véronique/P-2414-2014	manenti, stephane/0000-0002-4793-3196; Ysebaert, Loic/0000-0001-8478-5623; Chicanne, Gaetan/0000-0002-7081-2595; Racaud-Sultan, Claire/0000-0002-6549-1088; , Bernard/0000-0002-8693-0190				Bendall LJ, 1998, LEUKEMIA, V12, P1375, DOI 10.1038/sj.leu.2401136; Bournat JC, 2000, J NEUROSCI RES, V61, P21, DOI 10.1002/1097-4547(20000701)61:1<21::AID-JNR3>3.0.CO;2-7; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Chung EJ, 2002, BLOOD, V100, P982, DOI 10.1182/blood.V100.3.982; Czyz J, 2001, DIFFERENTIATION, V68, P167, DOI 10.1046/j.1432-0436.2001.680404.x; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Demarchi F, 2003, J BIOL CHEM, V278, P39583, DOI 10.1074/jbc.M305676200; Deng J, 2004, MOL CARCINOGEN, V39, P139, DOI 10.1002/mc.10169; Fukuhara K, 2002, J CLIN ENDOCR METAB, V87, P1729, DOI 10.1210/jc.87.4.1729; Ghosh JC, 2005, CLIN CANCER RES, V11, P4580, DOI 10.1158/1078-0432.CCR-04-2624; Gradl D, 1999, MOL CELL BIOL, V19, P5576; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Guzman ML, 2002, P NATL ACAD SCI USA, V99, P16220, DOI 10.1073/pnas.252462599; Han XZ, 2004, J BIOL CHEM, V279, P2832, DOI 10.1074/jbc.M308102200; Hazlehurst LA, 2003, ONCOGENE, V22, P7396, DOI 10.1038/sj.onc.1206943; Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008-5472.CAN-03-1952; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hwang SG, 2002, LEUKEMIA RES, V26, P863, DOI 10.1016/S0145-2126(02)00018-8; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Kenny PA, 2003, INT J CANCER, V107, P688, DOI 10.1002/ijc.11491; Landowski TH, 2003, ONCOGENE, V22, P2417, DOI 10.1038/sj.onc.1206315; Lee JL, 2004, J BIOL CHEM, V279, P14602, DOI 10.1074/jbc.M309008200; Liao XB, 2003, MOL CANCER THER, V2, P1215; Matsunaga T, 2003, NAT MED, V9, P1158, DOI 10.1038/nm909; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Ougolkov AV, 2005, CANCER RES, V65, P2076, DOI 10.1158/0008-5472.CAN-04-3642; Prindull G, 2004, BLOOD, V103, P2892, DOI 10.1182/blood-2003-08-2807; Recher C, 2004, CANCER RES, V64, P3191, DOI 10.1158/0008-5472.CAN-03-3005; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; Shou J, 2002, ONCOGENE, V21, P878, DOI 10.1038/sj.onc.1205138; Siggelkow H, 1999, J CELL BIOCHEM, V75, P22, DOI 10.1002/(SICI)1097-4644(19991001)75:1<22::AID-JCB3>3.0.CO;2-6; Simon M, 2005, ONCOGENE, V24, P2410, DOI 10.1038/sj.onc.1208431; Takada Y, 2004, J BIOL CHEM, V279, P39541, DOI 10.1074/jbc.M403449200; Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044; Yoganathan N, 2002, PHARMACOL THERAPEUT, V93, P233, DOI 10.1016/S0163-7258(02)00192-4	39	107	115	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3113	3122		10.1038/sj.onc.1209346	http://dx.doi.org/10.1038/sj.onc.1209346			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16407823				2022-12-28	WOS:000237951000003
J	Grande, SM; Katz, E; Crowley, JE; Bernardini, MS; Ross, SR; Monroe, JG				Grande, SM; Katz, E; Crowley, JE; Bernardini, MS; Ross, SR; Monroe, JG			Cellular ITAM-containing proteins are oncoproteins in nonhematopoietic cells	ONCOGENE			English	Article						oncogene proteins; cell transformation; neoplastic; mammary glands; animal; fibroblasts; signal transduction	EPSTEIN-BARR-VIRUS; SARCOMA-ASSOCIATED HERPESVIRUS; LYMPHOCYTE ANTIGEN RECEPTOR; EPITHELIAL-CELLS; K1 GENE; LATENT MEMBRANE-PROTEIN-2A; 3-DIMENSIONAL CULTURE; CD22-DEFICIENT MICE; SIGNAL-TRANSDUCTION; NEGATIVE REGULATOR	Immunoreceptor tyrosine-based activation motifs (ITAMs) are involved in the transduction of signals necessary for activation, differentiation, and survival in hematopoietic cells. Several viruses have been shown to encode ITAM-containing transmembrane proteins. Although expression of these viral proteins has in some cases been shown to transform nonhematopoietic cells, a causal role for a functional ITAM in this process has not been elucidated. To examine the potential transforming properties of ITAM-containing proteins, a recombinant protein consisting of ITAM-containing cytoplasmic regions of the B-cell antigen receptor was expressed in immortalized murine mammary epithelial and fibroblast cells. Mammary epithelial cells expressing this construct exhibited depolarized morphology in three-dimensional cultures. This transformed phenotype was characterized by a loss of anchorage dependence and hallmarks of epithelial to mesenchymal transition. Fibroblasts expressing this ITAM construct also lost contact inhibition and anchorage dependence. The transformed phenotype seen in both cell types was abrogated upon tyrosine to phenylalanine substitutions of the ITAMs. Inhibition of Syk tyrosine kinase, which associates with the ITAM, also prevented cell transformation. Our results indicate that expression of a nonviral ITAM-containing protein is sufficient for cell transformation. Despite lacking intrinsic enzymatic activity, ITAM-containing proteins can function as potent oncoproteins by scaffolding downstream mediators.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Monroe, JG (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Room 311 BRBII,421 Curie Blvd, Philadelphia, PA 19104 USA.	monroej@mail.med.upenn.edu		Ross, Susan R/0000-0002-3094-3769	NATIONAL CANCER INSTITUTE [T32CA009140, P01CA093615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032592] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA093615, CA09140] Funding Source: Medline; NIAID NIH HHS [R01-AI43620, R01-AI32592] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bannish G, 2001, J EXP MED, V194, P1583, DOI 10.1084/jem.194.11.1583; Caldwell RG, 1998, IMMUNITY, V9, P405, DOI 10.1016/S1074-7613(00)80623-8; Callahan R, 2000, ONCOGENE, V19, P992, DOI 10.1038/sj.onc.1203276; Cannons JL, 2004, CURR OPIN IMMUNOL, V16, P296, DOI 10.1016/j.coi.2004.03.011; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Harder T, 2004, TRAFFIC, V5, P265, DOI 10.1111/j.1600-0854.2003.00163.x; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; Ikeda M, 2000, VIROLOGY, V268, P178, DOI 10.1006/viro.1999.0166; Ikeda M, 2001, J VIROL, V75, P5711, DOI 10.1128/JVI.75.12.5711-5718.2001; Jacks T, 2002, CELL, V111, P923, DOI 10.1016/S0092-8674(02)01229-1; Katz E, 2005, J EXP MED, V201, P431, DOI 10.1084/jem.20041471; Keshvara LM, 1997, J BIOL CHEM, V272, P10377; Lagunoff M, 1999, P NATL ACAD SCI USA, V96, P5704, DOI 10.1073/pnas.96.10.5704; Lai JYQ, 2003, BIOORG MED CHEM LETT, V13, P3111, DOI 10.1016/S0960-894X(03)00658-9; Lee H, 1998, NAT MED, V4, P435, DOI 10.1038/nm0498-435; Lee H, 1998, MOL CELL BIOL, V18, P5219, DOI 10.1128/MCB.18.9.5219; LONGNECKER R, 1991, J VIROL, V65, P3681, DOI 10.1128/JVI.65.7.3681-3692.1991; Mainiero F, 1996, J CELL BIOL, V134, P241, DOI 10.1083/jcb.134.1.241; Mina-Osorio P, 2004, TRENDS IMMUNOL, V25, P529, DOI 10.1016/j.it.2004.08.008; MONROE JG, 2006, IN PRESS NAT REV IMM; Morrison JA, 2005, J VIROL, V79, P2375, DOI 10.1128/JVI.79.4.2375-2382.2005; Morrison JA, 2003, J VIROL, V77, P12276, DOI 10.1128/JVI.77.22.12276-12284.2003; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Niiro H, 2002, NAT REV IMMUNOL, V2, P945, DOI 10.1038/nri955; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; Portis T, 2004, ONCOGENE, V23, P8619, DOI 10.1038/sj.onc.1207905; Prakash O, 2002, JNCI-J NATL CANCER I, V94, P926; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Roose JP, 2003, PLOS BIOL, V1, P271, DOI 10.1371/journal.pbio.0000053; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Scholle F, 1999, J VIROL, V73, P4767, DOI 10.1128/JVI.73.6.4767-4775.1999; Staub E, 2004, CELL SIGNAL, V16, P435, DOI 10.1016/j.cellsig.2003.08.013; Swart R, 2000, J VIROL, V74, P10838, DOI 10.1128/JVI.74.22.10838-10845.2000; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; Veillette A, 2002, ANNU REV IMMUNOL, V20, P669, DOI 10.1146/annurev.immunol.20.081501.130710; Vivier E, 2004, SCIENCE, V306, P1517, DOI 10.1126/science.1103478; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; Zahir N, 2003, J CELL BIOL, V163, P1397, DOI 10.1083/jcb.200302023	44	17	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2006	25	19					2748	2757		10.1038/sj.onc.1209296	http://dx.doi.org/10.1038/sj.onc.1209296			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16369490				2022-12-28	WOS:000237272900006
J	Murakami, Y; Yasuda, T; Saigo, K; Urashima, T; Toyoda, H; Okanoue, T; Shimotohno, K				Murakami, Y; Yasuda, T; Saigo, K; Urashima, T; Toyoda, H; Okanoue, T; Shimotohno, K			Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues	ONCOGENE			English	Article						hepatocellular carcinoma; micro-RNA; support vector machine	MICROARRAY; RNA; CANCERS	MicroRNAs (miRNAs) are a non-coding family of genes involved in post-transcriptional gene regulation. These transcripts are associated with cell proliferation, cell differentiation, cell death and carcinogenesis. We analysed the miRNA expression profiles in 25 pairs of hepatocellular carcinoma (HCC) and adjacent non-tumorous tissue (NT) and nine additional chronic hepatitis (CH) specimens using a human miRNA microarray. Targets and references samples were co-hybridized to a microarray containing whole human mature and precursor miRNA sequences. Whereas three miRNAs exhibited higher expression in the HCC samples than that in the NT samples, five miRNAs demonstrated lower expression in the HCC samples than in the NT samples (P < 0.0001). Classification of samples as HCC or NT by using support vector machine algorithms based on these data provided an overall prediction accuracy of 97.8% (45/46). In addition, the expression levels of four miRNAs were inversely correlated with the degree of HCC differentiation (P < 0.01). A comparison of CH and liver cirrhosis samples revealed significantly different pattern of miRNA expression ( P < 0.01). There were no differences, however, between hepatitis B-positive and hepatitis C-positive samples. This information may help clarify the molecular mechanisms involved in the progression of liver disease, potentially serving as a diagnostic tool of HCC.	Kyoto Univ, Inst Viral Res, Lab Human Tumor Virus, Sakyo Ku, Kyoto 6068507, Japan; Chiba Higashi Natl Hosp, Dept Surg, Chiba, Japan; Chiba Univ, Dept Surg, Chiba, Japan; Ogaki Municipal Hosp, Dept Gastroenterol, Ogaki, Japan; Kyoto Prefectural Univ Med, Dept Gastroenterol, Kyoto, Japan	Kyoto University; Chiba University; Ogaki Municipal Hospital; Kyoto Prefectural University of Medicine	Shimotohno, K (corresponding author), Kyoto Univ, Inst Viral Res, Lab Human Tumor Virus, Sakyo Ku, Kyoto 6068507, Japan.	kshimoto@virus.kyoto-u.ac.jp						Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Brown MPS, 2000, P NATL ACAD SCI USA, V97, P262, DOI 10.1073/pnas.97.1.262; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Esau C, 2004, J BIOL CHEM, V279, P52361, DOI 10.1074/jbc.C400438200; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Ke XS, 2003, CURR OPIN CHEM BIOL, V7, P516, DOI 10.1016/S1367-5931(03)00075-9; Kiriakidou M, 2004, GENE DEV, V18, P1165, DOI 10.1101/gad.1184704; Liang RQ, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni019; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Michael MZ, 2003, MOL CANCER RES, V1, P882; Moss EG, 2003, TRENDS BIOTECHNOL, V21, P185, DOI 10.1016/S0167-7799(03)00088-X; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Tsangaris GT, 2002, TOXICOLOGY, V178, P135, DOI 10.1016/S0300-483X(02)00236-6; van den Berg A, 2003, GENE CHROMOSOME CANC, V37, P20, DOI 10.1002/gcc.10186; Xu PZ, 2003, CURR BIOL, V13, P790, DOI 10.1016/S0960-9822(03)00250-1	23	947	1096	1	113	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2537	2545		10.1038/sj.onc.1209283	http://dx.doi.org/10.1038/sj.onc.1209283			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16331254				2022-12-28	WOS:000236948000012
J	Teal, HE; Ni, S; Xu, J; Finkelstein, LD; Cheng, AM; Paulson, RF; Feng, GS; Correll, PH				Teal, HE; Ni, S; Xu, J; Finkelstein, LD; Cheng, AM; Paulson, RF; Feng, GS; Correll, PH			GRB2-mediated recruitment of GAB2, but not GAB1, to SF-STK supports the expansion of Friend virus-infected erythroid progenitor cells	ONCOGENE			English	Article						Friend virus; erythroleukemia; Fv2; Sf-Stk	RECEPTOR TYROSINE KINASE; PLECKSTRIN HOMOLOGY DOMAIN; TERMINAL SH3 DOMAIN; EPITHELIAL MORPHOGENESIS DOWNSTREAM; GRB2 BINDING-SITE; C-MET RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTER PROTEIN; IN-VIVO	Friend virus induces the development of erythroleukemia in mice through the interaction of a viral glycoprotein, gp55, with a truncated form of the Stk receptor tyrosine kinase, short form-Stk (Sf-Stk), and the EpoR. We have shown previously that the ability of Sf-Stk to participate in the transformation of Friend virus-infected cells requires the kinase activity and Grb2-binding site of Sf-Stk. Here we show that Grb2 heterozygous mice exhibit decreased susceptibility to Friend erythroleukemia and that expansion of erythroid progenitors in response to infection requires the C-terminal SH3 domain of Grb2. A fusion protein in which the Grb2-binding site in Sf-Stk is replaced by Gab2, supports the growth of progenitors from mice lacking Sf-Stk, whereas a Sf-Stk/Gab1 fusion protein does not. Gab2 is expressed in spleens from Friend virus-infected mice, co-immunoprecipitates with Sf-Stk and is tyrosine phosphorylated in the presence of Sf-Stk. Mice with a targeted deletion in Gab2 are less susceptible to Friend erythroleukemia and the expansion of erythroid progenitor cells in response to infection can be rescued by expression of Gab2, but not Gab1. Taken together, these data indicate that a Sf-Stk/Grb2/Gab2 complex mediates the growth of primary erythroid progenitor cells in response to Friend virus.	Penn State Univ, Dept Vet & Biomed Sci, Ctr Mol Immunol & Infect Dis, University Pk, PA USA; NHGRI, NIH, Bethesda, MD USA; Washington Univ, St Louis, MO USA; Burnham Inst, San Diego, CA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Washington University (WUSTL)	Correll, PH (corresponding author), Dept Vet Sci, 115 Henning Bldg, University Pk, PA 16802 USA.	phc7@psu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066208, R01HL066471] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL066471, R01-HL66208] Funding Source: Medline; PHS HHS [R01-L66471] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AXELRAD A, 1969, CAN CANC C, V8, P313; Bausenwein BS, 2000, MECH DEVELOP, V90, P205, DOI 10.1016/S0925-4773(99)00252-X; BEHRINGER RR, 1985, CELL, V40, P441, DOI 10.1016/0092-8674(85)90158-8; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; Cunnick JM, 2001, J BIOL CHEM, V276, P24380, DOI 10.1074/jbc.M010275200; DANDREA AD, 1992, CANCER SURV, V15, P19; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; Finkelstein LD, 2002, ONCOGENE, V21, P3562, DOI 10.1038/sj.onc.1205442; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Gong K, 2001, NAT IMMUNOL, V2, P29, DOI 10.1038/83134; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; HAYMAN MJ, 1985, P NATL ACAD SCI USA, V82, P8237, DOI 10.1073/pnas.82.23.8237; Herbst R, 1999, EMBO J, V18, P6950, DOI 10.1093/emboj/18.24.6950; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; Hibi M, 2000, LEUKEMIA LYMPHOMA, V37, P299, DOI 10.3109/10428190009089430; HOROSZEWICZ JS, 1975, J NATL CANCER I, V54, P265, DOI 10.1093/jnci/54.1.265; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Ischenko I, 2003, ONCOGENE, V22, P6311, DOI 10.1038/sj.onc.1206742; KOHDA D, 1994, STRUCTURE, V2, P1029, DOI 10.1016/S0969-2126(94)00106-5; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Lewitzky M, 2001, ONCOGENE, V20, P1052, DOI 10.1038/sj.onc.1204202; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIAO SK, 1975, INT J CANCER, V15, P467, DOI 10.1002/ijc.2910150313; LILLY F, 1970, J NATL CANCER I, V45, P163; Liu Y, 2002, FEBS LETT, V515, P1, DOI 10.1016/S0014-5793(02)02425-0; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Maroun CR, 1999, J BIOL CHEM, V274, P31719, DOI 10.1074/jbc.274.44.31719; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; MIRAND EA, 1968, P SOC EXP BIOL MED, V128, P844; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Nishigaki K, 2001, J VIROL, V75, P7893, DOI 10.1128/JVI.75.17.7893-7903.2001; Nishigaki K, 2000, J VIROL, V74, P3037, DOI 10.1128/JVI.74.7.3037-3045.2000; Park CY, 1999, J BIOL CHEM, V274, P7583, DOI 10.1074/jbc.274.11.7583; Persons DA, 1999, NAT GENET, V23, P159, DOI 10.1038/13787; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Saxton TM, 2001, CURR BIOL, V11, P662, DOI 10.1016/S0960-9822(01)00198-1; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Schutzman JL, 2001, MOL CELL BIOL, V21, P8104, DOI 10.1128/MCB.21.23.8104-8116.2001; Seiffert M, 2003, MOL CELL BIOL, V23, P2415, DOI 10.1128/MCB.23.7.2415-2424.2003; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; TAMBOURIN P, 1971, NATURE-NEW BIOL, V234, P230, DOI 10.1038/newbio234230a0; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; VANDERAKKER E, 2005, BLOOD, V103, P4457; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; Wolf I, 2002, MOL CELL BIOL, V22, P231, DOI 10.1128/MCB.22.1.231-244.2002; Zhang SS, 2003, ARTERIOSCL THROM VAS, V23, P1788, DOI 10.1161/01.ATV.0000085015.49110.85; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	60	23	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2433	2443		10.1038/sj.onc.1209288	http://dx.doi.org/10.1038/sj.onc.1209288			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16314834				2022-12-28	WOS:000236948000002
J	Alarcon-Vargas, D; Zhang, Z; Agarwal, B; Challagulla, K; Mani, S; Kalpana, GV				Alarcon-Vargas, D; Zhang, Z; Agarwal, B; Challagulla, K; Mani, S; Kalpana, GV			Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors	ONCOGENE			English	Article						rhabdoid; cyclin D1; 4-HPR; tamoxifen; cell cycle and apoptosis	BREAST-CANCER CELLS; ATYPICAL TERATOID/RHABDOID TUMOR; CENTRAL-NERVOUS-SYSTEM; IN-VITRO; TAMOXIFEN; EXPRESSION; N-(4-HYDROXYPHENYL)RETINAMIDE; FENRETINIDE; APOPTOSIS; RECEPTOR	Rhabdoid tumors (RTs) are aggressive and currently incurable pediatric malignancies. INI1/hSNF5 is a tumor suppressor biallelically inactivated in RTs. Our previous studies have indicated that cyclin D1 is a key downstream target of INI1/hSNF5 and genesis and/or survival of RTs in vivo is critically dependent on the presence of cyclin D1. In this report, we have tested the hypothesis that therapeutic targeting of cyclin D1 is an effective means of treating RTs. We found that RNA interference of cyclin D1 in rhabdoid cells was sufficient to induce G1 arrest and apoptosis. Furthermore, we found that pharmacological intervention with low micromolar concentrations of N-(4-hydroxyphenyl) retinamide (4-HPR), which downmodulates cyclin D1, induced G1 arrest and apoptosis in rhabdoid cell lines. 4-HPR in combination with 4-hydroxy-tamoxifen (4OH-Tam), synergistically inhibited survival as well as anchorage-dependent and -independent growth of rhabdoid cells and caused synergistic induction of cell cycle arrest and apoptosis. 4-HPR and tamoxifen exhibited synergistic growth inhibition of RTs in xenograft models in vivo. The effects of combination of drugs were correlated to the depletion of cyclin D1 levels both in in vitro and in vivo tumor models. These results demonstrate that 4-HPR and tamoxifen are effective chemotherapeutic agents for RTs. We propose that downmodulation of cyclin D1 is a novel and effective therapeutic strategy for RTs.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Mani, S (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, 1300 Morris Pk Ave,Ullman 821, Bronx, NY 10461 USA.	smani@montefiore.org; kalpana@aecom.yu.edu		Kalpana, Ganjam/0000-0003-4111-0604	NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA13330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ae K, 2002, ONCOGENE, V21, P3112, DOI 10.1038/sj.onc.1205414; Aoyama Yuko, 2002, Kurume Medical Journal, V49, P27; Appierto V, 2001, BRIT J CANCER, V84, P1528, DOI 10.1054/bjoc.2001.1826; Argiris A, 2004, CLIN CANCER RES, V10, P1409, DOI 10.1158/1078-0432.CCR-1060-02; Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706; Biegel JA, 1999, CANCER RES, V59, P74; Biegel Jaclyn A., 2002, Cancer Research, V62, P323; Brockdorff BL, 2003, ENDOCR-RELAT CANCER, V10, P579, DOI 10.1677/erc.0.0100579; DiPietrantonio AM, 1998, INT J CANCER, V78, P53, DOI 10.1002/(SICI)1097-0215(19980925)78:1<53::AID-IJC10>3.0.CO;2-6; Dragnev KH, 2004, CLIN CANCER RES, V10, P2570, DOI 10.1158/1078-0432.CCR-03-0271; Erdreich-Epstein A, 2002, J BIOL CHEM, V277, P49531, DOI 10.1074/jbc.M209962200; Favoni RE, 1998, BRIT J CANCER, V77, P2138, DOI 10.1038/bjc.1998.358; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Hilden JM, 2004, J CLIN ONCOL, V22, P2877, DOI 10.1200/jco.2004.07.073; Jang TJ, 2001, CANCER LETT, V170, P109, DOI 10.1016/S0304-3835(01)00593-6; Koshida S, 2002, JPN J CANCER RES, V93, P1351, DOI 10.1111/j.1349-7006.2002.tb01244.x; Le Marchand L, 2003, JAMA-J AM MED ASSOC, V290, P2843, DOI 10.1001/jama.290.21.2843; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; Lee TH, 1999, ONCOGENE, V18, P4269, DOI 10.1038/sj.onc.1202755; Li WW, 2001, CLIN CANCER RES, V7, P2908; Maurer BJ, 2000, JNCI-J NATL CANCER I, V92, P1897, DOI 10.1093/jnci/92.23.1897; Mitsiades CS, 2003, J ENDOCRINOL, V178, P205, DOI 10.1677/joe.0.1780205; Packer RJ, 2002, J PEDIAT HEMATOL ONC, V24, P337, DOI 10.1097/00043426-200206000-00004; Panigone S, 2000, ONCOGENE, V19, P4035, DOI 10.1038/sj.onc.1203743; Pirkmaier A, 2003, CLIN CANCER RES, V9, P1877; Pollack IF, 1997, CLIN CANCER RES, V3, P1109; Reynolds C P, 2000, Curr Oncol Rep, V2, P511, DOI 10.1007/s11912-000-0104-y; Reynolds CP, 2001, HEMATOL ONCOL CLIN N, V15, P867, DOI 10.1016/S0889-8588(05)70256-2; Riedeout D, 1991, ENCY HUMAN BIOL, V2, P371; Rousseau C, 2003, J STEROID BIOCHEM, V86, P1, DOI 10.1016/S0960-0760(03)00255-3; Simeone AM, 2002, MOL CANCER THER, V1, P1009; Singletary SE, 2002, CLIN CANCER RES, V8, P2835; Tsikitis M, 2005, P NATL ACAD SCI USA, V102, P12129, DOI 10.1073/pnas.0505300102; Versteege I, 2002, ONCOGENE, V21, P6403, DOI 10.1038/sj.onc.1205841; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vries RGJ, 2005, GENE DEV, V19, P665, DOI 10.1101/gad.335805; Wang HT, 2003, UROLOGY, V61, P1047, DOI 10.1016/S0090-4295(02)02511-6; Wu KM, 2002, MOL CANCER THER, V1, P695; Zeisig R, 2004, BREAST CANCER RES TR, V87, P245, DOI 10.1007/s10549-004-8699-6; Zhang ZK, 2002, MOL CELL BIOL, V22, P5975, DOI 10.1128/MCB.22.16.5975-5988.2002	40	57	58	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					722	734		10.1038/sj.onc.1209112	http://dx.doi.org/10.1038/sj.onc.1209112			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16302003				2022-12-28	WOS:000235068800008
J	Chirakkal, H; Leech, SH; Brookes, KE; Prais, AL; Waby, JS; Corfe, BM				Chirakkal, H.; Leech, S. H.; Brookes, K. E.; Prais, A. L.; Waby, J. S.; Corfe, B. M.			Upregulation of BAK by butyrate in the colon is associated with increased Sp3 binding	ONCOGENE			English	Article						butyrate; colon; BAK; apoptosis; Sp1; Sp3	GENOTOXIN-INDUCED APOPTOSIS; CHAIN FATTY-ACIDS; COLORECTAL-CANCER; DIETARY FIBER; TRANSCRIPTION FACTORS; RESISTANT STARCH; PROMOTER; EXPRESSION; INDUCTION; TRICHOSTATIN	Butyrate is a key bioactive product of dietary fibre fermentation thought to play a key role in cancer prevention. One contributory mechanism in this role is the regulation of apoptosis by butyrate. As butyrate shows lowlevels of toxicity, the mechanisms by which it triggers or regulates apoptosis are of great interest. We and others have shown that the proapoptotic protein BAK is upregulated by butyrate. We show ere that this observation is conserved across multiple cell lines, that it occurs in all cells in a population and is at the transcriptional level. We have used a promoter-reporter construct to identify the regulatory regions of the BAK promoter and found that much of the transcriptional activity occurs via a single Sp1/Sp3 binding site. We have shown that both Sp1 and Sp3 bind, but upon butyrate treatment Sp1 binding decreases in favour of Sp3 binding. We speculate that this may be an acetylation- mediated event.	Univ Sheffield, No Gen Hosp, Human Nutr Unit, Div Clin Sci N, Sheffield S5 7AU, S Yorkshire, England; Univ Manchester, Sch Biol Sci, Manchester, Lancs, England	Northern General Hospital; University of Sheffield; University of Manchester	Corfe, BM (corresponding author), Univ Sheffield, No Gen Hosp, Human Nutr Unit, Div Clin Sci N, Sheffield S5 7AU, S Yorkshire, England.	b.m.corfe@sheffield.ac.uk		Waby, Jennifer/0000-0003-4729-6657; Corfe, Bernard/0000-0003-0449-2228				Arasaradnam RP, 2004, GUT, V53, P155, DOI 10.1136/gut.53.1.155-a; Bingham SA, 2003, LANCET, V361, P1496, DOI 10.1016/S0140-6736(03)13174-1; Blottiere HM, 2003, P NUTR SOC, V62, P101, DOI 10.1079/PNS2002215; Bonithon-Kopp C, 2000, LANCET, V356, P1300, DOI 10.1016/S0140-6736(00)02813-0; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Camarero N, 2003, NUCLEIC ACIDS RES, V31, P1693, DOI 10.1093/nar/gkg262; Chen ZY, 2004, J NUTR, V134, P792, DOI 10.1093/jn/134.4.792; CORFE BM, 1994, MICROBIOL-UK, V140, P3079, DOI 10.1099/13500872-140-11-3079; Della Ragione F, 2001, FEBS LETT, V499, P199, DOI 10.1016/S0014-5793(01)02539-X; Griffiths GJ, 2001, ONCOGENE, V20, P7668, DOI 10.1038/sj.onc.1204995; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; Hass R, 1997, GASTROENTEROLOGY, V112, P875, DOI 10.1053/gast.1997.v112.pm9041249; Hill MJ, 1997, EUR J CANCER PREV, V6, P219, DOI 10.1097/00008469-199706000-00002; Hill MJ, 2002, EUR J CANCER PREV, V11, P1, DOI 10.1097/00008469-200202000-00001; Hirose T, 2003, ONCOGENE, V22, P7762, DOI 10.1038/sj.onc.1207091; Le Leu RK, 2003, CARCINOGENESIS, V24, P1347, DOI 10.1093/carcin/bgg098; Le Leu RK, 2002, CARCINOGENESIS, V23, P713, DOI 10.1093/carcin/23.5.713; MacCarthy-Morrogh L, 2000, ONCOGENE, V19, P5534, DOI 10.1038/sj.onc.1203949; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Mariadason JM, 2000, CANCER RES, V60, P4561; MCINTYRE A, 1993, GUT, V34, P386, DOI 10.1136/gut.34.3.386; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Perrin P, 2001, GUT, V48, P53, DOI 10.1136/gut.48.1.53; Potten CS, 1997, STEM CELLS, V15, P82, DOI 10.1002/stem.150082; Ruemmele FM, 1999, CELL DEATH DIFFER, V6, P729, DOI 10.1038/sj.cdd.4400545; Schatzkin A, 2000, NEW ENGL J MED, V342, P1149, DOI 10.1056/NEJM200004203421601; Siavoshian S, 2000, GUT, V46, P507, DOI 10.1136/gut.46.4.507; Sowa Y, 1999, CANCER RES, V59, P4266; Steiner E, 2004, BIOCHEM BIOPH RES CO, V317, P235, DOI 10.1016/j.bbrc.2004.03.029; WELTER C, 1991, J EXP CLIN CANC RES, V10, P75; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	34	56	57	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	54					7192	7200		10.1038/sj.onc.1209702	http://dx.doi.org/10.1038/sj.onc.1209702			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16732318				2022-12-28	WOS:000242046900008
J	Lund, P; Weisshaupt, K; Mikeska, T; Jammas, D; Chen, X; Kuban, RJ; Ungethum, U; Krapfenbauer, U; Herzel, HP; Schafer, R; Walter, J; Sers, C				Lund, P.; Weisshaupt, K.; Mikeska, T.; Jammas, D.; Chen, X.; Kuban, R-J; Ungethum, U.; Krapfenbauer, U.; Herzel, H-P; Schafer, R.; Walter, J.; Sers, C.			Oncogenic HRAS suppresses clusterin expression through promoter hypermethylation	ONCOGENE			English	Article						HRAS(G12V); MEK/ERK signalling; gene expression; CpG methylation; clusterin; Mmp2	PROGRAMMED CELL-DEATH; DNA-METHYLTRANSFERASE; HA-RAS; TRANSFORMED PHENOTYPE; GENE-EXPRESSION; METHYLATION; CANCER; TIMP-2; ACTIVATION; TRANSCRIPTION	Silencing of gene expression by methylation of CpG islands in regulatory elements is frequently observed in cancer. However, an influence of the most common oncogenic signalling pathways onto DNA methylation has not yet been investigated thoroughly. To address this issue, we identified genes suppressed in HRAS-transformed rat fibroblasts but upregulated after treatment with the demethylating agent 5-Aza-2-deoxycytidine and with the MEK1,2 inhibitor U0126. Analysis of gene expression by microarray and Northern blot analysis revealed the MEK/ERK target genes clusterin, matrix metalloproteinase 2 (Mmp2), peptidylpropyl isomerase C-associated protein, syndecan 4, Timp2 and Thbs1 to be repressed in the HRAS-transformed FE-8 cells in a MEK/ERK- and methylation-dependent manner. Hypermethylation of putative regulatory elements in HRAS-transformed cells as compared to immortalized fibroblasts was detected within a CpG island 14.5 kb upstream of clusterin, within the clusterin promoter and within a CpG island of the Mmp2 promoter by bisulphite sequencing. Furthermore, hypermethylation of the clusterin promoter was observed 10 days after induction of HRAS in immortalized rat fibroblasts and a clear correlation between reduced clusterin expression and hypermethlyation could also be observed in distinct rat tissues. These results suggest that silencing of individual genes by DNA methylation is controlled by oncogenic signalling pathways, yet the mechanisms responsible for initial target gene suppression are variable.	Inst Pathol, Lab Mol Tumorpathol, Charite, D-10117 Berlin, Germany; Univ Saarland, Dept Nat Sci, Tech Fac Biol Sci 3 FR 8 3, Inst Genet Epigenet, D-6600 Saarbrucken, Germany; Lab Funct Genome Res, Charite, Berlin, Germany; Humboldt Univ, Inst Theoret Biol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Saarland University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin	Sers, C (corresponding author), Inst Pathol, Lab Mol Tumorpathol, Charite, Schumannstr 20-21, D-10117 Berlin, Germany.	christine.sers@charite.de	Schäfer, Reinhold/AAB-5110-2021; Mikeska, Thomas/B-4876-2008; Sers, Christine/B-5438-2010; Lund, Per G/M-9019-2017; Lund, Per/Q-6737-2017	Mikeska, Thomas/0000-0003-1318-0859; Lund, Per/0000-0002-7457-4360; Sers, christine/0000-0002-6219-1514				Avner P, 2001, NAT REV GENET, V2, P59, DOI 10.1038/35047580; Baker KM, 2003, J BIOL CHEM, V278, P17876, DOI 10.1074/jbc.M209480200; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Behrens P, 2001, PATHOBIOLOGY, V69, P19, DOI 10.1159/000048753; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; BOS JL, 1989, CANCER RES, V49, P4682; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Brem R, 2001, ONCOGENE, V20, P2854, DOI 10.1038/sj.onc.1204403; Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cappabianca L, 2003, EXP CELL RES, V286, P209, DOI 10.1016/S0014-4827(03)00072-7; Chen TG, 2004, CANCER RES, V64, P7412, DOI 10.1158/0008-5472.CAN-04-2077; Criswell T, 2005, J BIOL CHEM, V280, P14212, DOI 10.1074/jbc.M412569200; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Deryugina EI, 1997, ANTICANCER RES, V17, P3201; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Esteller M, 2001, CANCER RES, V61, P3225; Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X; Fensterer H, 2004, GENE CHROMOSOME CANC, V39, P224, DOI 10.1002/gcc.20000; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Gadal F, 2003, NUCLEIC ACIDS RES, V31, P5789, DOI 10.1093/nar/gkg762; GRIEGEL S, 1986, INT J CANCER, V38, P697, DOI 10.1002/ijc.2910380513; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Itoh T, 1998, CANCER RES, V58, P1048; Ivanova T, 2004, INT J CANCER, V108, P882, DOI 10.1002/ijc.11652; Jones SE, 2002, INT J BIOCHEM CELL B, V34, P427, DOI 10.1016/S1357-2725(01)00155-8; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; Klock G, 1998, J CELL PHYSIOL, V177, P593, DOI 10.1002/(SICI)1097-4652(199812)177:4<593::AID-JCP10>3.3.CO;2-6; KYPRIANOU N, 1991, CANCER RES, V51, P162; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Laduron S, 2004, NUCLEIC ACIDS RES, V32, P4340, DOI 10.1093/nar/gkh735; Leskov KS, 2003, J BIOL CHEM, V278, P11590, DOI 10.1074/jbc.M209233200; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Li Q, 1999, ONCOGENE, V18, P3284, DOI 10.1038/sj.onc.1202663; LIU HS, 1992, CANCER RES, V52, P983; Lopes S, 2003, HUM MOL GENET, V12, P295, DOI 10.1093/hmg/ddg022; Lymar ES, 2000, BIOL REPROD, V63, P1341, DOI 10.1095/biolreprod63.5.1341; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; Ordway JM, 2004, ONCOGENE, V23, P3737, DOI 10.1038/sj.onc.1207483; Pucci S, 2004, ONCOGENE, V23, P2298, DOI 10.1038/sj.onc.1207404; Raudies O, 2005, ADV ENZYME REGUL, V45, P63, DOI 10.1016/j.advenzreg.2005.02.004; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; ROSEMBLIT N, 1994, J MOL ENDOCRINOL, V13, P69, DOI 10.1677/jme.0.0130069; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; Scaltriti M, 2004, INT J CANCER, V108, P23, DOI 10.1002/ijc.11496; Scaltriti M, 2004, CANCER RES, V64, P6174, DOI 10.1158/0008-5472.CAN-04-0920; SCHAEFER R, 1988, P NATL ACAD SCI USA, V85, P1590, DOI 10.1073/pnas.85.5.1590; Schneider-Stock R, 2005, J PHARMACOL EXP THER, V312, P525, DOI 10.1124/jpet.104.074195; SCHWARTEWALDHOFF I, 1994, ONCOGENE, V9, P899; Sers C, 2002, ADV ENZYME REGUL, V42, P63, DOI 10.1016/S0065-2571(01)00024-3; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Taraboletti G, 2000, FASEB J, V14, P1674; Tchernitsa OI, 2004, ONCOGENE, V23, P4536, DOI 10.1038/sj.onc.1207585; Villar-Garea A, 2004, INT J CANCER, V112, P171, DOI 10.1002/ijc.20372; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Wei G, 2003, ANTICANCER RES, V23, P2173; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P14329, DOI 10.1073/pnas.250494697; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	68	49	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2006	25	35					4890	4903		10.1038/sj.onc.1209502	http://dx.doi.org/10.1038/sj.onc.1209502			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16568090				2022-12-28	WOS:000239687100007
J	Durkin, SG; Arlt, MF; Howlett, NG; Glover, TW				Durkin, S. G.; Arlt, M. F.; Howlett, N. G.; Glover, T. W.			Depletion of CHK1, but not CHK2, induces chromosomal instability and breaks at common fragile sites	ONCOGENE			English	Article						fragile sites; checkpoints; CHK1; CHK2	S-PHASE CHECKPOINT; DNA-DAMAGE; ATR; REPLICATION; BRCA1; PHOSPHATIDYLSERINE; PHOSPHORYLATION; RECOGNITION; INVOLVEMENT; INHIBITION	Common fragile sites are specific regions of the genome that form gaps and breaks on metaphase chromosomes when DNA synthesis is partially inhibited. Fragile sites and their associated genes show frequent deletions and other rearrangements in cancer cells, and may be indicators of DNA replication stress early in tumorigenesis. We have previously shown that the DNA damage response proteins ATR, BRCA1 and FANCD2 play critical roles in maintaining the stability of fragile site regions. To further elucidate the pathways regulating fragile site stability, we have investigated the effects of depletion of the cell cycle checkpoint kinases, CHK1 and CHK2 on common fragile site stability in human cells. We demonstrate that both CHK1 and CHK2 are activated following treatment of cells with low doses of aphidicolin that induce fragile site breakage. Furthermore, we show that depletion of CHK1, but not CHK2, using short-interfering RNA (siRNA) leads to highly destabilized chromosomes and specific common fragile site breakage. In many cells, CHK1 depletion resulted in extensive chromosome fragmentation, which was distinct from endonucleolytic cleavage commonly associated with apoptosis. These findings demonstrate a critical role for the CHK1 kinase in regulating chromosome stability, and in particular, common fragile site stability.	Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Glover, TW (corresponding author), Univ Michigan, Dept Human Genet, 4909 Buhl,Box 0618,1241 E Catherine St, Ann Arbor, MI 48109 USA.	glover@umich.edu			NCI NIH HHS [CA 43222] Funding Source: Medline; NIGMS NIH HHS [5T32 GM07544] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007544] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Alderton GK, 2004, HUM MOL GENET, V13, P3127, DOI 10.1093/hmg/ddh335; Arlt MF, 2004, MOL CELL BIOL, V24, P6701, DOI 10.1128/mcb.24.15.6701-6709.2004; Arlt MF, 2002, GENE CHROMOSOME CANC, V33, P82, DOI 10.1002/gcc.10000; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; BARTKOVA J, 2005, AM J HUM GENET, V75, P654; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; CASPER AM, 2004, AM J HUM GENET, V4, P456; FADOK VA, 1992, J IMMUNOL, V148, P2207; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Glover TW, 2005, HUM MOL GENET, V14, pR197, DOI 10.1093/hmg/ddi265; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Howlett NG, 2005, HUM MOL GENET, V14, P693, DOI 10.1093/hmg/ddi065; Huang HJ, 1999, GENE CHROMOSOME CANC, V24, P48, DOI 10.1002/(SICI)1098-2264(199901)24:1<48::AID-GCC7>3.0.CO;2-V; Le Beau MM, 1998, HUM MOL GENET, V7, P755, DOI 10.1093/hmg/7.4.755; Lee SB, 2001, CANCER RES, V61, P8062; Liu QH, 2000, GENE DEV, V14, P1448; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; Mangelsdorf M, 2000, CANCER RES, V60, P1683; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Musio A, 2005, HUM MOL GENET, V14, P525, DOI 10.1093/hmg/ddi049; Niida H, 2005, J BIOL CHEM, V280, P39246, DOI 10.1074/jbc.M505009200; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; RODRIGUEZ R, 2005, MOLL CELL BIOL; Schwartz M, 2005, GENE DEV, V19, P2715, DOI 10.1101/gad.340905; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; TAIT JF, 1992, ARCH BIOCHEM BIOPHYS, V298, P187, DOI 10.1016/0003-9861(92)90111-9; Takai H, 2000, GENE DEV, V14, P1439; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Zachos G, 2005, MOL CELL BIOL, V25, P563, DOI 10.1128/MCB.25.2.563-574.2005; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhang YW, 2005, MOL CELL, V19, P607, DOI 10.1016/j.molcel.2005.07.019; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	41	101	102	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	32					4381	4388		10.1038/sj.onc.1209466	http://dx.doi.org/10.1038/sj.onc.1209466			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16732333				2022-12-28	WOS:000239326000001
J	Longworth, MS; Laimins, LA				Longworth, M. S.; Laimins, L. A.			Histone deacetylase 3 localizes to the plasma membrane and is a substrate of Src	ONCOGENE			English	Article						HDAC3; c-Src; plasma membrane; tyrosine; phosphorylation	HUMAN-PAPILLOMAVIRUS TYPE-31; PP60C-SRC PROTEIN-KINASE; TYROSINE KINASE; C-SRC; ACTIVATION; EXPRESSION; HDAC3; DIFFERENTIATION; TRANSCRIPTION; PROGRESSION	Histone deacetylases (HDACs) negatively regulate gene expression by removing acetyl groups from lysine residues present in histones and other proteins. Histone deacetylase 3 is unique among the Class I family of HDACs, as it is able to shuttle between the nucleus and the cytoplasm, whereas the other family members remain in the nucleus. Histone deacetylase 3 often forms complexes with corepressor proteins that do not associate with the other Class I HDACs, and its phosphorylation correlates with increased enzymatic activity. Here we show that HDAC3 also localizes to the plasma membrane in multiple cell types. Furthermore, c-Src is shown to form a complex with HDAC3 at the plasma membrane and to use HDAC3 as a substrate for phosphorylation. Our results describe a novel localization and binding partner for the HDAC3 protein, as well as implicate c-Src in HDAC3 regulation.	Northwestern Univ, Dept Microbiol & Immunol, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Laimins, LA (corresponding author), Northwestern Univ, Dept Microbiol & Immunol, Feinberg Sch Med, 303 E Chicago Ave, Chicago, IL 60611 USA.	l-laimins@northwestern.edu	longworth, michelle/S-8456-2019		NATIONAL CANCER INSTITUTE [R01CA059655, T32CA009560] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA059655-12, T32CA09560, R01 CA059655] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brunton VG, 1997, ONCOGENE, V14, P283, DOI 10.1038/sj.onc.1200827; Dib K, 2003, J BIOL CHEM, V278, P24181, DOI 10.1074/jbc.M302300200; Ellerbroek SM, 2001, J BIOL CHEM, V276, P24833, DOI 10.1074/jbc.M005631200; FANNING P, 1992, CANCER RES, V52, P1457; Fehrmann F, 2003, J VIROL, V77, P2819, DOI 10.1128/JVI.77.5.2819-2831.2003; FEHRMANN F, 2004, METHOD MOL BIOL, V292, P317; Fleming RYD, 1997, SURGERY, V122, P501, DOI 10.1016/S0039-6060(97)90044-1; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Guenther MG, 2000, GENE DEV, V14, P1048; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; JACOBS C, 1983, CANCER RES, V43, P1696; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Longworth MS, 2005, EMBO J, V24, P1821, DOI 10.1038/sj.emboj.7600651; Longworth MS, 2004, J VIROL, V78, P3533, DOI 10.1128/JVI.78.7.3533-3541.2004; MacMillan-Crow LA, 2000, ARCH BIOCHEM BIOPHYS, V377, P350, DOI 10.1006/abbi.2000.1799; Olszewska-Pazdrak B, 2004, J BIOL CHEM, V279, P40400, DOI 10.1074/jbc.C400208200; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; ROSEN N, 1986, J BIOL CHEM, V261, P3754; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171; Schroeder TM, 2004, J BIOL CHEM, V279, P41998, DOI 10.1074/jbc.M403702200; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Wrobel CN, 2004, J CELL BIOL, V165, P263, DOI 10.1083/jcb.200309102; Yang WM, 2002, J BIOL CHEM, V277, P9447, DOI 10.1074/jbc.M105993200; Zaidi SK, 2004, EMBO J, V23, P790, DOI 10.1038/sj.emboj.7600073; Zhang XH, 2005, GENE DEV, V19, P827, DOI 10.1101/gad.1286005; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964	27	87	93	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	32					4495	4500		10.1038/sj.onc.1209473	http://dx.doi.org/10.1038/sj.onc.1209473			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16532030				2022-12-28	WOS:000239326000013
J	Semba, S; Trapasso, F; Fabbri, M; McCorkell, KA; Volinia, S; Druck, T; Iliopoulos, D; Pekarsky, Y; Ishii, H; Garrison, PN; Barnes, LD; Croce, CM; Huebner, K				Semba, S.; Trapasso, F.; Fabbri, M.; McCorkell, K. A.; Volinia, S.; Druck, T.; Iliopoulos, D.; Pekarsky, Y.; Ishii, H.; Garrison, P. N.; Barnes, L. D.; Croce, C. M.; Huebner, K.			Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential	ONCOGENE			English	Article						Fhit; tyrosine 114 (Y114); Akt; survivin; lung cancer; apoptosis	FRAGILE HISTIDINE-TRIAD; EXPRESSION INDUCES APOPTOSIS; TUMOR-SUPPRESSOR; GENE; TUMORIGENICITY; CARCINOMA; KINASE; HYPERMETHYLATION; RESTORATION; COMPLEXES	The Fhit tumor suppressor binds and hydrolyses diadenosine polyphosphates and the Fhit - substrate complex has been proposed as a proapoptotic effector, as determined by infection of susceptible cancer cells with adenoviruses carrying wild- type fragile histidine triad ( FHIT) or catalytic site mutants. The highly conserved Fhit tyrosine 114 ( Y114), within the unstructured loop C- terminal of the catalytic site, can be phosphorylated by Src family tyrosine kinases, although endogenous phospho- Fhit is rarely detected. To explore the importance of Y114 and identify Fhit- mediated signaling events, wild- type and Y114 mutant FHIT- expressing adenoviruses were introduced into two human lung cancer cell lines. Caspase-dependent apoptosis was effectively induced only by wildtype but not Y114 mutant Fhit proteins. By expression proling of FHIT versus mutant FHIT- infected cells, we found that survivin, an Inhibitor of Apoptosis Protein ( IAP) family member, was significantly decreased by wildtype Fhit. In addition, Fhit inhibited activity of Akt, a key effector in the phosphatidylinositol 3- OH kinase ( PI3K) pathway; loss of endogenous Fhit expression caused increased Akt activity in vitro and in vivo, and overexpression of constitutively active Akt inhibited Fhit-induced apoptosis. The results indicate that the Fhit Y114 residue plays a critical role in Fhit- induced apoptosis, occurring through inactivation of the PI3K- Akt- survivin signal pathway.	Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Magna Graecia Univ Catanzaro, Med Sch Catanzaro, Dept Expt & Clin Med, Catanzaro, Italy; Univ Ferrara, Telethon Facil, Data Min Anal DNA Microarrays, I-44100 Ferrara, Italy; Jichi Med Sch, Ctr Mol Med, Div Stem Cell Regulat Mol Hematopoiesis, Minami Kawachi, Tochigi 32904, Japan; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78285 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Magna Graecia University of Catanzaro; University of Ferrara; Jichi Medical University; University of Texas System; University of Texas Health San Antonio	Huebner, K (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Room 455C Wiseman Hall,410 W 12th Ave, Columbus, OH 43210 USA.	kay.huebner@osumc.edu	Young, Richard A/F-6495-2012; Volinia, Stefano/A-3029-2010; Iliopoulos, Dimitrios/AAE-9106-2019; Volinia, Stefano/AAA-9264-2019	Young, Richard A/0000-0001-8855-8647; Volinia, Stefano/0000-0003-0910-3893; Volinia, Stefano/0000-0003-0910-3893	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007780] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL07780] Funding Source: Medline; Telethon [GTF03012] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Telethon(Fondazione Telethon)		Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; Brenner C, 1997, PROTEIN ENG, V10, P1461, DOI 10.1093/protein/10.12.1461; Croce CM, 1999, J CLIN ONCOL, V17, P1618, DOI 10.1200/JCO.1999.17.5.1618; Dan HC, 2004, ONCOGENE, V23, P706, DOI 10.1038/sj.onc.1207171; Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098; Dumon KR, 2001, CANCER RES, V61, P4827; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; Fornaro M, 2003, J BIOL CHEM, V278, P50402, DOI 10.1074/jbc.M307627200; Fujishita T, 2004, BRIT J CANCER, V91, P1571, DOI 10.1038/sj.bjc.6602182; Garrison PN, 2005, BIOCHEMISTRY-US, V44, P6286, DOI 10.1021/bi047670s; Hao XP, 2000, CANCER RES, V60, P18; Hu BC, 2005, J CELL PHYSIOL, V202, P518, DOI 10.1002/jcp.20139; Huebner K, 2003, BRIT J CANCER, V88, P1501, DOI 10.1038/sj.bjc.6600937; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; Iliopoulos D, 2005, ONCOGENE, V24, P1625, DOI 10.1038/sj.onc.1208398; Ishii H, 2001, CANCER RES, V61, P1578; Ji L, 1999, CANCER RES, V59, P3333; Junttila TT, 2003, CLIN CANCER RES, V9, P5346; Kato H, 2004, CLIN CANCER RES, V10, P7318, DOI 10.1158/1078-0432.CCR-04-0485; Kuroki T, 2003, CANCER RES, V63, P3724; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; Mao L, 1997, J NATL CANCER I, V89, P857, DOI 10.1093/jnci/89.12.857; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Mori M, 2000, CANCER RES, V60, P1177; Nishizaki M, 2004, CANCER RES, V64, P5745, DOI 10.1158/0008-5472.CAN-04-0195; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Ottey M, 2004, BRIT J CANCER, V91, P1669, DOI 10.1038/sj.bjc.6602058; Pace HC, 1998, P NATL ACAD SCI USA, V95, P5484, DOI 10.1073/pnas.95.10.5484; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Pekarsky Y, 2004, P NATL ACAD SCI USA, V101, P3775, DOI 10.1073/pnas.0400481101; Roz L, 2002, P NATL ACAD SCI USA, V99, P3615, DOI 10.1073/pnas.062030799; Semba S, 2002, CLIN CANCER RES, V8, P3824; Sevignani C, 2003, CANCER RES, V63, P1183; Shi YF, 2000, BIOCHEM J, V352, P443, DOI 10.1042/0264-6021:3520443; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Trapasso F, 2003, P NATL ACAD SCI USA, V100, P1592, DOI 10.1073/pnas.0437915100; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898	44	54	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2860	2872		10.1038/sj.onc.1209323	http://dx.doi.org/10.1038/sj.onc.1209323			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16407838				2022-12-28	WOS:000237448200004
J	Brummer, T; Martin, P; Herzog, S; Misawa, Y; Daly, RJ; Reth, M				Brummer, T.; Martin, P.; Herzog, S.; Misawa, Y.; Daly, R. J.; Reth, M.			Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein	ONCOGENE			English	Article						Ras; 14-3-3 proteins; beta-Catenin; E-cadherin; mammary epithelial cells	ACTIVATED PROTEIN-KINASE; WILD-TYPE BRAF; C-RAF; ONCOGENIC MUTATIONS; SIGNALING PATHWAY; COLORECTAL TUMORS; TYROSINE KINASES; HUMAN CANCER; IN-VITRO; PHOSPHORYLATION	The BRAF(V600E) mutation is found in approximately 6% of human cancers and mimics the phosphorylation of the kinase domain activation segment. In wild-type B-Raf (B-Raf(wt)), activation segment phosphorylation is thought to cooperate with negative charges within the N-region for full activation. In contrast to Raf-1, the N-region of B-Raf is constitutively negatively charged owing to the presence of residues D447/D448 and the phosphorylation of S446. Therefore, it has been suggested that this hallmark predisposes B-Raf for oncogenic activation. In this study, we demonstrate that neutralizing mutations of these residues (in particular S446 and S447), or uncoupling of B-Raf from Ras-guanine 5'-triphosphate (GTP), strongly reduce the biological activity of B-Raf in a PC12 cell differentiation assay. We also confirm that S365 is a 14-3-3 binding site, and determine that mutation of this residue rescues the impaired biological activity of B-Raf proteins with a neutralized N-region, suggesting that the N-region opposes a 14-3-3-mediated transition into an inactive conformation. However, in the case of B-Raf(V600E), although complete N-region neutralization resulted in a 2.5-fold reduction in kinase activity in vitro, this oncoprotein strongly induced PC12 differentiation or transformation and epithelial - mesenchymal transition of MCF-10A cells regardless of its N-region charge. Furthermore, the biological activity of B-RafV600E was independent of its ability to bind Ras-GTP. Our analysis identifies important regulatory differences between B-Raf(wt) and B-Raf(V600E) and suggests that B-Raf(V600E) cannot be inhibited by strategies aimed at blocking S446 phosphorylation or Ras activation.	Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; Univ Freiburg, Inst Biol 3, Dept Mol Immunol, D-7800 Freiburg, Germany; Max Planck Inst Immunbiol, D-7800 Freiburg, Germany; Univ Virginia, Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA USA	Garvan Institute of Medical Research; University of Freiburg; Max Planck Society; University of Virginia	Brummer, T (corresponding author), Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.	t.brummer@garvan.org.au	Brummer, Tilman/AAA-9428-2020; Brummer, Tilman/B-6218-2016; Daly, Roger J/C-8179-2009	Brummer, Tilman/0000-0003-4387-7905; Brummer, Tilman/0000-0003-4387-7905; Daly, Roger/0000-0002-5739-8027; Herzog, Sebastian/0000-0001-7167-3489				ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; Bergo MO, 2004, J CLIN INVEST, V113, P539, DOI 10.1172/JCI200418829; Brummer T, 2006, J BIOL CHEM, V281, P626, DOI 10.1074/jbc.M509567200; Brummer T, 2003, ONCOGENE, V22, P8823, DOI 10.1038/sj.onc.1207185; Brummer T, 2002, EMBO J, V21, P5611, DOI 10.1093/emboj/cdf588; Brummer Tilman, 2004, Methods Mol Biol, V271, P189; Carey KD, 2003, J BIOL CHEM, V278, P3185, DOI 10.1074/jbc.M207014200; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Chong HR, 2003, J BIOL CHEM, V278, P36269, DOI 10.1074/jbc.M212803200; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Dhillon AS, 2003, MOL CELL BIOL, V23, P1983, DOI 10.1128/MCB.23.6.1983-1993.2003; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Emuss V, 2005, CANCER RES, V65, P9719, DOI 10.1158/0008-5472.CAN-05-1683; Garnett MJ, 2005, MOL CELL, V20, P963, DOI 10.1016/j.molcel.2005.10.022; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; Gilles C, 2003, CANCER RES, V63, P2658; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Grbovic OM, 2006, P NATL ACAD SCI USA, V103, P57, DOI 10.1073/pnas.0609973103; Harding A, 2003, J BIOL CHEM, V278, P45519, DOI 10.1074/jbc.M303106200; Hekman M, 2004, J BIOL CHEM, V279, P14074, DOI 10.1074/jbc.M309620200; Hingorani SR, 2003, CANCER RES, V63, P5198; HOU XS, 1995, CELL, V81, P63, DOI 10.1016/0092-8674(95)90371-2; Hubbard SR, 2004, CELL, V116, P764, DOI 10.1016/S0092-8674(04)00256-9; Ikenoue T, 2004, CANCER RES, V64, P3428, DOI 10.1158/0008-5472.CAN-03-3591; Ikenoue T, 2003, CANCER RES, V63, P8132; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Light Y, 2002, MOL CELL BIOL, V22, P4984, DOI 10.1128/MCB.22.14.4984-4996.2002; MacNicol MC, 2000, J BIOL CHEM, V275, P3803, DOI 10.1074/jbc.275.6.3803; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Mercer K, 2005, CANCER RES, V65, P11493, DOI 10.1158/0008-5472.CAN-05-2211; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Morrison DK, 2004, NATURE, V428, P813, DOI 10.1038/428813a; O'Neill E, 2004, BRIT J CANCER, V90, P283, DOI 10.1038/sj.bjc.6601488; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Tanami H, 2004, ONCOGENE, V23, P8796, DOI 10.1038/sj.onc.1208152; Terai K, 2005, EMBO REP, V6, P251, DOI 10.1038/sj.embor.7400349; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tran NH, 2005, J BIOL CHEM, V280, P16244, DOI 10.1074/jbc.M501185200; Tran NH, 2003, J BIOL CHEM, V278, P11221, DOI 10.1074/jbc.M210318200; Tsavachidou D, 2004, CANCER RES, V64, P5556, DOI 10.1158/0008-5472.CAN-04-1669; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Xiang XQ, 2002, J BIOL CHEM, V277, P44996, DOI 10.1074/jbc.M203953200; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yamaguchi T, 2004, J BIOL CHEM, V279, P40419, DOI 10.1074/jbc.M405079200; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429; Zhang BH, 2001, J BIOL CHEM, V276, P31620, DOI 10.1074/jbc.M102808200; Zhu J, 2005, MOL BIOL CELL, V16, P4733, DOI 10.1091/mbc.E05-02-0090; Ziogas A, 2005, J BIOL CHEM, V280, P24205, DOI 10.1074/jbc.M413327200	58	49	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2006	25	47					6262	6276		10.1038/sj.onc.1209640	http://dx.doi.org/10.1038/sj.onc.1209640			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	094CY	16702958				2022-12-28	WOS:000241218200004
J	Sprangers, M; Feldhahn, N; Liedtke, S; Jumaa, H; Siebert, R; Muschen, M				Sprangers, M.; Feldhahn, N.; Liedtke, S.; Jumaa, H.; Siebert, R.; Mueschen, M.			SLP65 deficiency results in perpetual V(D)J recombinase activity in pre-B-lymphoblastic leukemia and B-cell lymphoma cells	ONCOGENE			English	Article						V(D)J recombination; pre-B cell receptor; leukemia; SH2-domain; DNA rearrangement	EXPRESSION; REARRANGEMENT; TRANSITION; SELECTION; RECEPTOR	Perpetual V(D)J recombinase activity involving multiple DNA double-strand break events in B-cell lineage leukemia and lymphoma cells may introduce secondary genetic aberrations leading towards malignant progression. Here, we investigated defective negative feedback signaling through the (pre-)B-cell receptor as a possible reason for deregulated V(D)J recombinase activity in B-cell malignancy. On studying 28 cases of pre-B-lymphoblastic leukemia and 27 B-cell lymphomas, expression of the (pre-) B-cell receptor-related linker molecule SLP65 (SH2 domain-containing lymphocyte protein of 65 kDa) was found to be defective in seven and five cases, respectively. SLP65 deficiency correlates with RAG1/2 expression and unremitting V-H gene rearrangement activity. Reconstitution of SLP65 expression in SLP65-deficient leukemia and lymphoma cells results in downregulation of RAG1/2 expression and prevents both de novo V-H-DJ(H) rearrangements and secondary V-H replacement. We conclude that iterative V-H gene rearrangement represents a frequent feature in B-lymphoid malignancy, which can be attributed to SLP65 deficiency in many cases.	Univ Dusseldorf, Lab Mol Stem Cell Biol, D-40225 Dusseldorf, Germany; Max Planck Inst Immunbiol, D-7800 Freiburg, Germany; Univ Hosp Schleswig, Inst Human Genet, Kiel, Germany	Heinrich Heine University Dusseldorf; Max Planck Society; University of Kiel; Schleswig Holstein University Hospital	Muschen, M (corresponding author), Univ Dusseldorf, Lab Mol Stem Cell Biol, Moorenstr 5, D-40225 Dusseldorf, Germany.	markus.mueschen@uni-duesseldorf.de	Siebert, Reiner/A-8049-2010					Feldhahn N, 2005, J EXP MED, V201, P1837, DOI 10.1084/jem.20042101; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; Hayashi K, 2003, IMMUNITY, V18, P825, DOI 10.1016/S1074-7613(03)00142-0; Height SE, 1996, BLOOD, V87, P5242, DOI 10.1182/blood.V87.12.5242.bloodjournal87125242; Imai C, 2004, LEUKEMIA, V18, P922, DOI 10.1038/sj.leu.2403349; Jumaa H, 2003, NATURE, V423, P452, DOI 10.1038/nature01608; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Klein F, 2005, J IMMUNOL, V174, P367, DOI 10.4049/jimmunol.174.1.367; Klein F, 2004, J EXP MED, V199, P673, DOI 10.1084/jem.20031637; Zhang ZX, 2003, IMMUNITY, V19, P21, DOI 10.1016/S1074-7613(03)00170-5	10	12	13	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2006	25	37					5180	5186		10.1038/sj.onc.1209520	http://dx.doi.org/10.1038/sj.onc.1209520			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16636677				2022-12-28	WOS:000240063700011
J	Castro, P; Soares, P; Gusmao, L; Seruca, R; Sobrinho-Simoes, M				Castro, P.; Soares, P.; Gusmao, L.; Seruca, R.; Sobrinho-Simoes, M.			H-RAS 81 polymorphism is significantly associated with aneuploidy in follicular tumors of the thyroid	ONCOGENE			English	Article						aneuploidy; RAS mutations; H-RAS polymorphism; H-RAS splicing	SPORADIC COLORECTAL ADENOMAS; GENOMIC INSTABILITY; PROTO-ONCOGENE; DNA ANEUPLOIDY; BRAF MUTATIONS; P21 PROTEIN; CELL-CYCLE; CANCER; CARCINOMA; ACTIVATION	Follicular thyroid tumors are often aneuploid. It was advanced that chromosomal instability is closely associated to RAS mutations, but such association remains unproven. H-RAS can be alternatively spliced in two different proteins, p21 and p19, the former being the active protein. In order to investigate the relationship between RAS mutational status and ploidy in thyroid tumors, we analysed RAS genes in a series of 99 follicular lesions (14 nodular goiters, 70 follicular adenomas and 15 follicular carcinomas), eight thyroid carcinoma cell lines and a control group of 102 blood donors, correlating the presence of RAS mutations with the ploidy of the tumors and evaluating the two spliced forms of H-RAS. Overall, 20% of the follicular tumors harbored RAS mutations and 62% of the patients with follicular tumors (and 51% of blood donors) harbored the H-RA S 81T -> C polymorphism. The presence of RAS mutations was not associated with aneuploidy. The H-RAS polymorphism did not seem to confer a higher propensity for neoplastic transformation as it was also found in hyperplastic lesions, but was strongly associated with aneuploidy (P < 0.0001). The presence of the H-RAS 81T -> C polymorphism was associated with significantly higher amounts of total H-RAS mRNA expression, higher amounts of p21 isoform and a higher fraction of neoplastic cells in S phase. Our results suggest that the H-RAS 81T -> C polymorphism may induce aneuploidy through overexpression of the active p21 isoform of H-RAS.	IPATIMUP, P-4200465 Oporto, Portugal; Fac Med Porto, Dept Pathol, Oporto, Portugal	Universidade do Porto	Sobrinho-Simoes, M (corresponding author), IPATIMUP, Rua Dr Roberto Frias S-N, P-4200465 Oporto, Portugal.	ssimoes@ipatimup.pt	Castro, Patricia/J-8537-2013; Sobrinho-Simões, Manuel/J-8290-2013; Gusmão, Leonor/L-8931-2019; Gusmao, Leonor/B-3122-2013; seruca, raquel/F-8187-2011; Soares, Paula/B-6054-2008	Gusmão, Leonor/0000-0003-0432-6481; Gusmao, Leonor/0000-0003-0432-6481; Soares, Paula/0000-0001-9607-6998; Castro, Patricia/0000-0001-9588-9065; Sobrinho-Simoes, Manuel/0000-0003-1613-1235; Seruca, Raquel/0000-0002-8851-4166				[Anonymous], 2013, INS PESTS POT GLOB, DOI DOI 10.1016/B978-0-12-386895-4.00005-3; BOS JL, 1989, CANCER RES, V49, P4682; Castro P, 2005, J PATHOL, V206, P305, DOI 10.1002/path.1772; Castro P, 2001, VIRCHOWS ARCH, V438, P336, DOI 10.1007/s004280000354; Codony C, 2001, ONCOGENE, V20, P3683, DOI 10.1038/sj.onc.1204473; COHEN JB, 1993, MOL CELL BIOL, V13, P2666, DOI 10.1128/MCB.13.5.2666; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; CUSICK EL, 1991, BRIT J SURG, V78, P94, DOI 10.1002/bjs.1800780129; DEITCH AD, 1982, J HISTOCHEM CYTOCHEM, V30, P967, DOI 10.1177/30.9.6182188; DeLellis R, 2004, PATHOLOGY GENETICS T; DENKO N, 1995, SOMAT CELL MOLEC GEN, V21, P241, DOI 10.1007/BF02255779; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; Esapa CT, 1999, CLIN ENDOCRINOL, V50, P529, DOI 10.1046/j.1365-2265.1999.00704.x; Fagin JA, 2002, MOL ENDOCRINOL, V16, P903, DOI 10.1210/me.16.5.903; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; Giaretti W, 2004, CELL ONCOL, V26, P301; GIARETTI W, 1995, GASTROENTEROLOGY, V108, P1040, DOI 10.1016/0016-5085(95)90201-5; Giaretti W, 1998, AM J PATHOL, V153, P1201, DOI 10.1016/S0002-9440(10)65664-7; Guil S, 2003, CANCER RES, V63, P5178; Guil S, 2003, MOL CELL BIOL, V23, P2927, DOI 10.1128/MCB.23.8.2927-2941.2003; HARA H, 1994, SURGERY, V116, P1010; HOSTETTER AL, 1988, AM J CLIN PATHOL, V89, P760, DOI 10.1093/ajcp/89.6.760; Huang MY, 1997, ONCOL RES, V9, P611; Illmer T, 2005, CLIN CANCER RES, V11, P3217, DOI 10.1158/1078-0432.CCR-04-2232; JOENSUU H, 1988, AM J CLIN PATHOL, V89, P35, DOI 10.1093/ajcp/89.1.35; JOHANNESSEN JV, 1982, AM J CLIN PATHOL, V77, P20; Johne A, 2003, CANCER EPIDEM BIOMAR, V12, P68; Kimura ET, 2003, CANCER RES, V63, P1454; KRONTIRIS TG, 1993, NEW ENGL J MED, V329, P517, DOI 10.1056/NEJM199308193290801; LIWO A, 1994, J PROTEIN CHEM, V13, P237, DOI 10.1007/BF01891982; Mammas IN, 2004, GYNECOL ONCOL, V92, P941, DOI 10.1016/j.ygyno.2003.11.040; Mascaux C, 2005, BRIT J CANCER, V92, P131, DOI 10.1038/sj.bjc.6602258; MONACO R, 1995, J PROTEIN CHEM, V14, P457, DOI 10.1007/BF01888140; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P2318, DOI 10.1210/jc.2002-021907; NOONAN T, 1991, J MED CHEM, V34, P1302, DOI 10.1021/jm00108a010; Pastinen T, 2004, SCIENCE, V306, P647, DOI 10.1126/science.1101659; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; Rosai J, 1993, TUMORS THYROID GLAND; Saavedra HI, 2000, ONCOGENE, V19, P3948, DOI 10.1038/sj.onc.1203723; SCHELFHOUT LJDM, 1990, INT J CANCER, V45, P16, DOI 10.1002/ijc.2910450105; Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706; Sugg SL, 1999, SURGERY, V125, P46, DOI 10.1067/msy.2099.92118; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; Wang B, 1997, ANTICANCER RES, V17, P4387	46	25	27	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2006	25	33					4620	4627		10.1038/sj.onc.1209491	http://dx.doi.org/10.1038/sj.onc.1209491			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16532025				2022-12-28	WOS:000239457500012
J	Cuilliere-Dartigues, P; El-Bchiri, J; Krimi, A; Buhard, O; Fontanges, P; Flejou, JF; Hamelin, R; Duval, A				Cuilliere-Dartigues, P.; El-Bchiri, J.; Krimi, A.; Buhard, O.; Fontanges, P.; Flejou, J-F; Hamelin, R.; Duval, A.			TCF-4 isoforms absent in TCF-4 mutated MSI-H colorectal cancer cells colocalize with nuclear CtBP and repress TCF-4-mediated transcription	ONCOGENE			English	Article						TCF-4 isoforms; CtBP; corepressor; alternative splicing; MSI-H cancer; Wnt/Wingless signalling	NONSENSE-MEDIATED DECAY; BETA-CATENIN; MICROSATELLITE INSTABILITY; FRAMESHIFT MUTATIONS; SEQUENCES; GENE	TCF-4 is the main effector of the Wnt/Wingless signalling pathway. As with other TCF/LEF factors, numerous alternative splicings at its 30 end affect its expression. Such a mechanism leads to the synthesis of numerous TCF-4 isoforms among which some contain binding domains for CtBP, an ubiquitous transcriptional corepressor. Of interest, we described a frequent TCF-4 frameshift mutation in mismatch-repair deficient colorectal cancers (MSI-H cancers) that leads to the selective loss of TCF-4 isoforms with CtBP binding abilities. We provide here data that argue for a partial colocalization of CtBP with TCF-4 isoforms containing CtBP binding domains in cellulo, and for a functional role of CtBP in repressing TCF-4 mediated transcription. We also demonstrate that such a colocalization is not observed in MSI-H colorectal cancer cells that harbour the TCF-4 frameshift mutation, and that CtBP is not able to repress TCF-4-mediated transcription in this context. Taken together, our results strongly suggest that CtBP would play a role in regulating TCF-4 mediated transcription upon its binding with some TCF-4 isoforms encoded by alternatively spliced mRNA. They also suggest a role for TCF-4 frameshift mutation during MSI-H colorectal tumour progression, by regulating the relative proportion of the different TCF-4 isoforms.	INSERM, U762, F-75010 Paris, France; Univ Paris 06, F-75005 Paris, France; Hop Tenon, IFR65, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite	Duval, A (corresponding author), INSERM, U762, 27 Rue Juliette Dodu, F-75010 Paris, France.	alex.duval@cephb.fr						AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brannon M, 1999, DEVELOPMENT, V126, P3159; Brantjes H, 2001, NUCLEIC ACIDS RES, V29, P1410, DOI 10.1093/nar/29.7.1410; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; Duval A, 1999, CANCER RES, V59, P4213; Duval A, 2002, CANCER RES, V62, P2447; Duval A, 2000, CANCER RES, V60, P3872; El-Bchiri J, 2005, HUM MOL GENET, V14, P2435, DOI 10.1093/hmg/ddi245; Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611; Hamada F, 2004, DEV CELL, V7, P677, DOI 10.1016/j.devcel.2004.08.022; Holbrook JA, 2004, NAT GENET, V36, P801, DOI 10.1038/ng1403; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jourdan F, 2003, VIRCHOWS ARCH, V443, P115, DOI 10.1007/s00428-003-0833-z; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Ruckert S, 2002, CANCER RES, V62, P3009; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Valenta T, 2003, NUCLEIC ACIDS RES, V31, P2369, DOI 10.1093/nar/gkg346	19	49	50	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	32					4441	4448		10.1038/sj.onc.1209471	http://dx.doi.org/10.1038/sj.onc.1209471			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16547505				2022-12-28	WOS:000239326000007
J	Guo, X; Stratton, L; Schrader, JW				Guo, X.; Stratton, L.; Schrader, J. W.			Expression of activated M-Ras in hemopoietic stem cells initiates leukemogenic transformation, immortalization and preferential generation of mast cells	ONCOGENE			English	Article						M-Ras; hematopoietic stem cells; leukemia; immortalization; mast cell	GROWTH; M-RAS/R-RAS3; INDUCTION; DISTINCT; KINASE; FAMILY; MUTANT; LINE	Cultures of purified hemopoietic stem cells transduced with an activated mutant of M-Ras contained abnormal cells that, despite the presence of only low levels of growth factors, generated large, dense colonies of macrophages and blast cells. Cells from these colonies survived and grew continuously in the absence of growth factors and generated clonal cell-lines that were mainly composed of well-differentiated mast cells, with a low frequency of undifferentiated cells. When transplanted into sublethally irradiated syngeneic mice, four out of four such clones gave rise to a systemic mastocytosis and mast-cell leukemia. However, the donor clones also generated low percentages of cells with the morphological and cell-surface characteristics of erythrocytes, granulocytes, monocytes and T- and B-lymphocytes. These data indicate that signals downstream of activated M-Ras are sufficient to transform hemopoietic stem cells, and while preserving their capacity to generate other cell-lineages in vivo, result in preferential generation of mast cells.	Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Schrader, JW (corresponding author), Univ British Columbia, Biomed Res Ctr, 2222 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	john@brc.ubc.ca						Akin C, 2000, EXP HEMATOL, V28, P140, DOI 10.1016/S0301-472X(99)00145-9; Christensen JL, 2001, P NATL ACAD SCI USA, V98, P14541, DOI 10.1073/pnas.261562798; Cortez D, 1996, ONCOGENE, V13, P2589; Drachman JG, 2000, CURR OPIN HEMATOL, V7, P183, DOI 10.1097/00062752-200005000-00010; Ehrhardt A, 2004, MOL CELL BIOL, V24, P6311, DOI 10.1128/MCB.24.14.6311-6323.2004; Ehrhardt A, 2002, EXP HEMATOL, V30, P1089, DOI 10.1016/S0301-472X(02)00904-9; Ehrhardt GRA, 1999, BLOOD, V94, P2433, DOI 10.1182/blood.V94.7.2433.419k31_2433_2444; Guo XC, 2005, ONCOGENE, V24, P2330, DOI 10.1038/sj.onc.1208441; Guo XC, 2003, J BIOL CHEM, V278, P22237, DOI 10.1074/jbc.M300847200; Hu ZQ, 1997, BLOOD, V89, P526, DOI 10.1182/blood.V89.2.526; Jiang XY, 2002, BLOOD, V100, P3731, DOI 10.1182/blood-2002-05-1324; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; KITAMURA Y, 1979, BLOOD, V53, P492; Louahed J, 1999, BLOOD, V94, P1701, DOI 10.1182/blood.V94.5.1701.417k29_1701_1710; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Wang DZ, 2000, ONCOGENE, V19, P4647, DOI 10.1038/sj.onc.1203820; Ward KR, 2004, ONCOGENE, V23, P1187, DOI 10.1038/sj.onc.1207226; Yang J, 2005, CANCER RES, V65, P939; Zhang KX, 2004, MOL CANCER RES, V2, P242	20	12	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	30					4241	4244		10.1038/sj.onc.1209452	http://dx.doi.org/10.1038/sj.onc.1209452			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16501601				2022-12-28	WOS:000239004800012
J	Pantic, M; Zimmermann, S; El Daly, H; Opitz, OG; Popp, S; Boukamp, P; Martens, UM				Pantic, M.; Zimmermann, S.; El Daly, H.; Opitz, O. G.; Popp, S.; Boukamp, P.; Martens, U. M.			Telomere dysfunction and loss of p53 cooperate in defective mitotic segregation of chromosomes in cancer cells	ONCOGENE			English	Article						telomere dysfunction; Q-FISH; telomerase inhibition; chromosomal instability; hyperdiploidy	SPINDLE CHECKPOINT; INSTABILITY; ANEUPLOIDY; INACTIVATION; PROGRESSION; CARCINOMA; DAMAGE; REQUIREMENT; CENTROSOME; MUTATIONS	Aneuploidy is a fundamental principle of many cancer cells and is mostly related to defects in mitotic segregation of chromosomes. Many solid tumors as well as some preneoplastic lesions have been shown to contain polyploid chromosome numbers. The exact mechanisms behind whole-genome duplications are not known but have been linked to compromised mitotic checkpoint genes. We now report that the telomere checkpoint plays a key role for polyploidy in colon cancer cells. Telomerase suppression by a dominant-negative mutant of hTERT and consecutive telomere dysfunction in wild-type HCT116 colon cancer cells resulted in only minor stable chromosomal alterations. However, higher ploidy levels with up to 350 chromosomes were found when the cell-cycle checkpoint proteins p53 or p21 were absent. These findings indicate that telomere dysfunction in the absence of cell-cycle control may explain the high frequency of alterations in chromosome numbers found in many solid tumors.	Univ Freiburg, Med Ctr, Dept Hematol Oncol, D-79106 Freiburg, Germany; Univ Freiburg, Med Ctr, Dept Gastroenterol, Freiburg, Germany; German Canc Res Ctr, D-6900 Heidelberg, Germany	University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ)	Martens, UM (corresponding author), Univ Freiburg, Med Ctr, Dept Hematol Oncol, Hugstetterstr 55, D-79106 Freiburg, Germany.	uwe.martens@uniklinik-freiburg.de						Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bunz F, 2002, CANCER RES, V62, P1129; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; DELANGE T, 1995, TELOMERES, P265; Edgar BA, 2001, CELL, V105, P297, DOI 10.1016/S0092-8674(01)00334-8; El-Daly H, 2005, BLOOD, V105, P1742, DOI 10.1182/blood-2003-12-4322; Feldser DM, 2003, NAT REV CANCER, V3, P623, DOI 10.1038/nrc1142; Fernandez-Capetillo O, 2004, NAT GENET, V36, P672, DOI 10.1038/ng0704-672; Filatov L, 1998, ONCOGENE, V16, P1825, DOI 10.1038/sj.onc.1201711; Fukasawa K, 2002, ONCOGENE, V21, P6140, DOI 10.1038/sj.onc.1205771; Gisselsson D, 2005, SEMIN CANCER BIOL, V15, P13, DOI 10.1016/j.semcancer.2004.09.002; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; Gordon KE, 2003, CANCER RES, V63, P458; Hanks S, 2004, NAT GENET, V36, P1159, DOI 10.1038/ng1449; Hansemann D., 1890, ARCH PATHOL ANAT PH, V119, P299, DOI DOI 10.1007/BF01882039; Hede K, 2005, J NATL CANCER I, V97, P87, DOI 10.1093/jnci/97.2.87; Herbig U, 2004, MOL CELL, V14, P501, DOI 10.1016/S1097-2765(04)00256-4; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; Murnane JP, 2004, BIOESSAYS, V26, P1164, DOI 10.1002/bies.20125; O'Sullivan JN, 2002, NAT GENET, V32, P280, DOI 10.1038/ng989; Pantic M, 2005, INT J ONCOL, V26, P1227; Popp S, 2000, J INVEST DERMATOL, V115, P1095, DOI 10.1046/j.1523-1747.2000.00173.x; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Saunders WS, 2000, P NATL ACAD SCI USA, V97, P303, DOI 10.1073/pnas.97.1.303; Sen S, 2000, CURR OPIN ONCOL, V12, P82, DOI 10.1097/00001622-200001000-00014; Shichiri M, 2002, CANCER RES, V62, P13; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Stewenius Y, 2005, P NATL ACAD SCI USA, V102, P5541, DOI 10.1073/pnas.0408454102; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang RH, 2004, P NATL ACAD SCI USA, V101, P17108, DOI 10.1073/pnas.0407585101; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592; Zimmermann S, 2004, STEM CELLS, V22, P741, DOI 10.1634/stemcells.22-5-741	40	25	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	32					4413	4420		10.1038/sj.onc.1209486	http://dx.doi.org/10.1038/sj.onc.1209486			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16547498				2022-12-28	WOS:000239326000004
J	Fukuda, N; Saitoh, M; Kobayashi, N; Miyazono, K				Fukuda, N.; Saitoh, M.; Kobayashi, N.; Miyazono, K.			Execution of BMP-4-induced apoptosis by p53-dependent ER dysfunction in myeloma and B-cell hybridoma cells	ONCOGENE			English	Article						bMP; apoptosis; p53; ER stress; signal transduction	ENDOPLASMIC-RETICULUM STRESS; BONE MORPHOGENETIC PROTEIN-2; MULTIPLE-MYELOMA; CARCINOMA-CELLS; ACTIVIN-A; ACTIVATION; GROWTH; P53; IDENTIFICATION; INVOLVEMENT	Bone morphogenic protein (BMP)-4 inhibits proliferation and induces the apoptosis of myeloma cells. However, little is known about the molecular mechanisms of how BMP-4 executes this apoptosis. In this report, we investigated the roles of p53 and the endoplasmic reticulum (ER) in BMP-4-induced apoptosis of mouse hybridoma HS-72 cells. We found that 3ng/ml of BMP-4 is sufficient to induce the expression of proapoptotic proteins, puma and bax, in a p53-dependent mechanism, and facilitate Ca2+ release from the ER to the cytosol, resulting in the activation of caspase-12 and ER dysfunction. Similarly to HS-72 cells, multiple myeloma cells with wild-type p53 genes show much higher sensitivity to BMP-4-induced apoptosis than cells without wild-type p53 genes, suggesting that wild-type p53 status is required for dysfunction of the ER during BMP-4-induced apoptosis in ER-enriched cells, such as hybridoma and myeloma cells. These. findings demonstrate that the presence of wild-type p53 genes and enrichment of the ER determines the sensitivity to effective apoptosis by BMP-4, and suggest that ER stress-inducing agents would be valuable in the treatment of multiple myeloma.	Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Miyazono, K (corresponding author), Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono-ind@umin.ac.jp		Fukuda, Noboru/0000-0003-0098-054X				BROSH N, 1995, J BIOL CHEM, V270, P29594, DOI 10.1074/jbc.270.49.29594; Bruno B, 2004, LANCET ONCOL, V5, P430, DOI 10.1016/S1470-2045(04)01511-6; Buckley S, 2004, AM J PHYSIOL-LUNG C, V286, pL81, DOI 10.1152/ajplung.00160.2003; CHO HJ, 2005, IN PRESS CANC LETT; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Franzen A, 2001, BIOCHEM BIOPH RES CO, V285, P773; Glozak MA, 2001, EXP CELL RES, V268, P128, DOI 10.1006/excr.2001.5281; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guo Q, 1998, J BIOL CHEM, V273, P12341, DOI 10.1074/jbc.273.20.12341; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Hjertner O, 2001, BLOOD, V97, P516, DOI 10.1182/blood.V97.2.516; Huang GC, 2002, BRIT J CANCER, V86, P1104, DOI 10.1038/sj/bjc/6600219; Kawamura C, 2000, BLOOD, V96, P2005, DOI 10.1182/blood.V96.6.2005.h8002005a_2005_2011; Kawamura C, 2002, LEUKEMIA LYMPHOMA, V43, P635, DOI 10.1080/10428190290012182; Kiyono M, 2003, MOL CELL BIOL, V23, P4627, DOI 10.1128/MCB.23.13.4627-4636.2003; Nagata S, 2003, CELL DEATH DIFFER, V10, P108, DOI 10.1038/sj.cdd.4401161; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Oh SJ, 2000, MOL CELLS, V10, P275; Pan Z, 2001, J BIOL CHEM, V276, P32257, DOI 10.1074/jbc.M100178200; Phillips DJ, 1999, J ENDOCRINOL, V162, P111, DOI 10.1677/joe.0.1620111; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Ro TB, 2004, ONCOGENE, V23, P3024, DOI 10.1038/sj.onc.1207386; Shapiro-Shelef M, 2004, CURR OPIN IMMUNOL, V16, P226, DOI 10.1016/j.coi.2004.02.001; Sun YP, 2005, J BIOL CHEM, V280, P15561, DOI 10.1074/jbc.m412630200; Takebayashi-Suzuki K, 2003, DEVELOPMENT, V130, P3929, DOI 10.1242/dev.00615; Takuma K, 2005, J PHARMACOL SCI, V97, P312, DOI 10.1254/jphs.CPJ04006X; Wach S, 2001, ONCOGENE, V20, P7761, DOI 10.1038/sj.onc.1204962; Yamato K, 2000, EXP CELL RES, V257, P198, DOI 10.1006/excr.2000.4876; Yamato K, 2001, ONCOGENE, V20, P4383, DOI 10.1038/sj.onc.1204572; Zipori D, 2001, J LEUKOCYTE BIOL, V69, P867	31	29	30	3	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3509	3517		10.1038/sj.onc.1209393	http://dx.doi.org/10.1038/sj.onc.1209393			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16449972				2022-12-28	WOS:000238448200003
J	Liu, Y; Chen, L; Ko, TC; Fields, AP; Thompson, EA				Liu, Y.; Chen, L.; Ko, T. C.; Fields, A. P.; Thompson, E. A.			Evi1 is a survival factor which conveys resistance to both TGFb-beta and taxol-mediated cell death via PI3K/AKT	ONCOGENE			English	Article						apoptosis; carcinogenesis; colon cancer; cell signaling; chemotherapy	KINASE-C-IOTA; INDUCED APOPTOSIS; PROTEIN; GROWTH; GENE; TRANSCRIPTION; AMPLIFICATION; EXPRESSION; ACTIVATION; INHIBITION	In hematopoietic cells the transforming potential of the ecotropic viral integration site 1 (Evi1) oncogene is thought to be dependent upon the ability to inhibit TGF beta signaling. Although Evi1 has recently been implicated in certain epithelial cancers, the effects of Evi1 on transformation and TGF beta signaling in epithelial cells are not completely understood. Herein, we have determined the effects of Evi1 on TGF beta signaling in intestinal epithelial cells. Stable expression of Evi1 in non-transformed intestinal epithelial cells inhibited induction of some Smad3-dependent TGF beta target genes, such as PAI1. However, TGF beta-mediated induction of cellular adhesion signaling components such as integrin1 and paxillin was not inhibited by Evi1; nor did Evi1 inhibit TGF beta-mediated epithelial to mesenchymal transition. Likewise, Evi1 did not inhibit TGF beta-mediated downregulation of cyclin D1 or block TGF beta-mediated growth inhibition. However, Evi1 did inhibit TGF beta-mediated apoptosis by a process that involves phosphoinositide-3-kinase (PI3K) and its downstream effector AKT. The ability of Evi1 to suppress apoptosis is not restricted to TGF beta-mediated cell death, since Evi1 also protects intestinal epithelial cells from taxol-mediated apoptosis. Evi1 is overexpressed in some human colon cancer cell lines, and overexpression is associated with amplification of the Evi1 gene. Knockdown of Evi1 by siRNA inhibited AKT phosphorylation in HT-29 human colon cancer cells and increased their sensitivity to taxol-mediated apoptosis. These data indicate that Evi1 functions as a survival gene in intestinal epithelial cells and colon cancer cells, activating PI3K/AKT and conveying resistance to both physiological and therapeutic apoptotic stimuli.	Mayo Clin, Dept Canc Biol, Ctr Comprehens Canc, Jacksonville, FL 32224 USA; Univ Texas, Med Branch, Dept Surg, Galveston, TX 77550 USA	Mayo Clinic; University of Texas System; University of Texas Medical Branch Galveston	Fields, AP (corresponding author), Mayo Clin, Dept Canc Biol, Ctr Comprehens Canc, 4500 San Pablo Rd,Griffin Canc Res Bldg,RM310, Jacksonville, FL 32224 USA.	fields.alan@mayo.edu; thompson.aubrey@mayo.edu			NCI NIH HHS [R01CA64701] Funding Source: Medline; NIDDK NIH HHS [R01DK060105, P01DK35608] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064701] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060105, P01DK035608] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Alliston T, 2005, J BIOL CHEM, V280, P24227, DOI 10.1074/jbc.M414305200; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; Bergamo NA, 2000, CANCER GENET CYTOGEN, V119, P48, DOI 10.1016/S0165-4608(99)00213-7; Brass N, 1996, EUR J CANCER, V32A, P1205, DOI 10.1016/0959-8049(96)00016-0; Brooks DJ, 1996, BRIT J CANCER, V74, P1518, DOI 10.1038/bjc.1996.583; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hay ED, 1995, ACTA ANAT, V154, P8; Higashidani Y, 2003, DIS COLON RECTUM, V46, P327, DOI 10.1007/s10350-004-6551-z; Hirai H, 1999, INT J BIOCHEM CELL B, V31, P1367, DOI 10.1016/S1357-2725(99)00064-3; Imoto I, 2001, BIOCHEM BIOPH RES CO, V286, P559, DOI 10.1006/bbrc.2001.5428; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; KO TC, 1995, ONCOGENE, V10, P177; KO TC, 1994, AM J SURG, V167, P14, DOI 10.1016/0002-9610(94)90048-5; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kurokawa M, 2000, EMBO J, V19, P2958, DOI 10.1093/emboj/19.12.2958; MARKOWITZ S, 1995, CLIN CANCER RES, V1, P441; Mochizuki N, 2000, BLOOD, V96, P3209, DOI 10.1182/blood.V96.9.3209.h8003209_3209_3214; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; Murray NR, 2002, J CELL BIOL, V157, P915, DOI 10.1083/jcb.200201127; Ogawa S, 1996, ONCOGENE, V13, P183; Palmer S, 2001, J BIOL CHEM, V276, P25834, DOI 10.1074/jbc.M102343200; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; PARSONS R, 1995, CANCER RES, V55, P5548; Racz A, 1999, EUR J CANCER, V35, P641, DOI 10.1016/S0959-8049(98)00419-5; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; Riggins GJ, 1997, CANCER RES, V57, P2578; Roman C, 2001, MICROSC RES TECHNIQ, V52, P450, DOI 10.1002/1097-0029(20010215)52:4<450::AID-JEMT1030>3.0.CO;2-O; Sattler HP, 2000, PROSTATE, V45, P207, DOI 10.1002/1097-0045(20001101)45:3<207::AID-PROS2>3.0.CO;2-H; Shih WL, 2000, J BIOL CHEM, V275, P25858, DOI 10.1074/jbc.M003578200; Sonoda G, 1997, GENE CHROMOSOME CANC, V20, P320; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; Sugita M, 2000, CANCER GENET CYTOGEN, V117, P9, DOI 10.1016/S0165-4608(99)00135-1; TANAKA T, 1994, J BIOL CHEM, V269, P24020; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Winesett MP, 1996, CARCINOGENESIS, V17, P989, DOI 10.1093/carcin/17.5.989; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zhang J, 2004, J BIOL CHEM, V279, P22118, DOI 10.1074/jbc.M400774200	46	81	87	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3565	3575		10.1038/sj.onc.1209403	http://dx.doi.org/10.1038/sj.onc.1209403			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16462766				2022-12-28	WOS:000238448200009
J	Leszczyniecka, M; Bhatia, U; Cueto, M; Nirmala, NR; Towbin, H; Vattay, A; Wang, B; Zabludoff, S; Phillips, PE				Leszczyniecka, M; Bhatia, U; Cueto, M; Nirmala, NR; Towbin, H; Vattay, A; Wang, B; Zabludoff, S; Phillips, PE			MAP1D, a novel methionine aminopeptidase family member is overexpressed in colon cancer	ONCOGENE			English	Article						methionine aminopeptidase; MAP1D; colon cancer; shRNA	EUKARYOTIC PEPTIDE DEFORMYLASES; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; CELL-GROWTH; PROTEIN; IDENTIFICATION; UNIVERSALITY; EXPRESSION; INITIATION; EXCISION	N-terminal methionine removal is an important cellular process required for proper biological activity, subcellular localization, and eventual degradation of many proteins. The enzymes that catalyze this reaction are called Methionine Aminopeptidases (MAPs). To date, only two MAP family members, MAP1A and MAP2, have been well characterized and studied in mammals. In our studies, we have cloned a full length MAP1D gene. Expression and purification of full length recombinant protein shows that the sequence encodes an enzyme with MAP activity. MAP1D is overexpressed in colon cancer cell lines and in colon tumors as compared to matched normal tissue samples. Downregulation of MAP1D expression by shRNA in HCT-116 colon carcinoma cells reduces anchorage-independant growth in soft agar. These data suggest that MAP1D is a potentially oncogenic, novel member of the MAP gene family that may play an important role in colon tumorigenesis.	Novartis Inst Biomed Res, Cambridge, MA 02139 USA; Novartis Pharma AG, Basel, Switzerland	Novartis; Novartis	Leszczyniecka, M (corresponding author), Novartis Inst Biomed Res, Cambridge, MA 02139 USA.	magdalena.leszczyniecka@novartis.com		Nirmala, Nanguneri/0000-0003-0267-9793				Addlagatta A, 2005, BIOCHEMISTRY-US, V44, P7166, DOI 10.1021/bi0501176; ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; ARFIN SM, 1995, P NATL ACAD SCI USA, V92, P7714, DOI 10.1073/pnas.92.17.7714; BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; Bradshaw RA, 2002, ESSAYS BIOCHEM, V38, P65, DOI 10.1042/bse0380065; Catalano A, 2001, AM J PATHOL, V159, P721, DOI 10.1016/S0002-9440(10)61743-9; CHANG SYP, 1989, J BACTERIOL, V171, P4071, DOI 10.1128/jb.171.7.4071-4072.1989; CHANG YH, 1990, J BIOL CHEM, V265, P19892; Chen SP, 2002, ARCH BIOCHEM BIOPHYS, V398, P87, DOI 10.1006/abbi.2001.2675; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cutforth T, 1999, MECH DEVELOP, V82, P23, DOI 10.1016/S0925-4773(99)00006-4; Endo H, 2002, J BIOL CHEM, V277, P26396, DOI 10.1074/jbc.M202244200; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; Garrabrant Thomas, 2004, Angiogenesis, V7, P91, DOI 10.1007/s10456-004-6089-7; Giglione C, 2003, EMBO J, V22, P13, DOI 10.1093/emboj/cdg007; Giglione C, 2001, TRENDS PLANT SCI, V6, P566, DOI 10.1016/S1360-1385(01)02151-3; Giglione C, 2000, EMBO J, V19, P5916, DOI 10.1093/emboj/19.21.5916; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; Kanno T, 2002, LAB INVEST, V82, P893, DOI 10.1097/01.LAB.0000020419.25365.C4; Kinder FR, 2001, J MED CHEM, V44, P3692; Li X, 1995, P NATL ACAD SCI USA, V92, P12357, DOI 10.1073/pnas.92.26.12357; Lowther WT, 2000, BBA-PROTEIN STRUCT M, V1477, P157, DOI 10.1016/S0167-4838(99)00271-X; MEINNEL T, 1993, BIOCHIMIE, V75, P1061, DOI 10.1016/0300-9084(93)90005-D; MILLER CG, 1987, P NATL ACAD SCI USA, V84, P2718, DOI 10.1073/pnas.84.9.2718; Serero A, 2003, J BIOL CHEM, V278, P52953, DOI 10.1074/jbc.M309770200; Serero A, 2001, J MOL BIOL, V314, P695, DOI 10.1006/jmbi.2001.5175; SING N, 1997, P NATL ACAD SCI USA, V94, P6099; Towbin H, 2003, J BIOL CHEM, V278, P52964, DOI 10.1074/jbc.M309039200; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142	30	21	24	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 8	2006	25	24					3471	3478		10.1038/sj.onc.1209383	http://dx.doi.org/10.1038/sj.onc.1209383			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16568094				2022-12-28	WOS:000238448100012
J	Nowis, D; Legat, M; Grzela, T; Niderla, J; Wilczek, E; Wilczynski, GM; Glodkowska, E; Mrowka, P; Issat, T; Dulak, J; Jozkowicz, A; Was, H; Adamek, M; Wrzosek, A; Nazarewski, S; Makowski, M; Stoklosa, T; Jakobisiak, M; Golab, J				Nowis, D.; Legat, M.; Grzela, T.; Niderla, J.; Wilczek, E.; Wilczynski, G. M.; Glodkowska, E.; Mrowka, P.; Issat, T.; Dulak, J.; Jozkowicz, A.; Was, H.; Adamek, M.; Wrzosek, A.; Nazarewski, S.; Makowski, M.; Stoklosa, T.; Jakobisiak, M.; Golab, J.			Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity	ONCOGENE			English	Article						photodynamic therapy; Photofrin; heme oxygenase; cancer	MANGANESE SUPEROXIDE-DISMUTASE; UP-REGULATION; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; GENE-EXPRESSION; CARBON-MONOXIDE; SINGLET OXYGEN; NITRIC-OXIDE; CANCER CELLS; APOPTOSIS	Photodynamic therapy is a promising antitumor treatment modality approved for the management of both early and advanced tumors. The mechanisms of its antitumor action include generation of singlet oxygen and reactive oxygen species that directly damage tumor cells and tumor vasculature. A number of mechanisms seem to be involved in the protective responses to PDT that include activation of transcription factors, heat shock proteins, antioxidant enzymes and antiapoptotic pathways. Elucidation of these mechanisms might result in the design of more effective combination strategies to improve the antitumor efficacy of PDT. Using DNA microarray analysis to identify stress-related genes induced by Photofrin-mediated PDT in colon adenocarcinoma C-26 cells, we observed a marked induction of heme oxygenase-1 (HO-1). Induction of HO-1 with hemin or stable transfection of C-26 with a plasmid vector encoding HO-1 increased resistance of tumor cells to PDT-mediated cytotoxicity. On the other hand, zinc (II) protoporphyrin IX, an HO-1 inhibitor, markedly augmented PDT-mediated cytotoxicity towards C-26 and human ovarian carcinoma MDAH2774 cells. Neither bilirubin, biliverdin nor carbon monoxide, direct products of HO-1 catalysed heme degradation, was responsible for cytoprotection. Importantly, desferrioxamine, a potent iron chelator significantly potentiated cytotoxic effects of PDT. Altogether our results indicate that HO-1 is involved in an important protective mechanism against PDT-mediated phototoxicity and administration of HO-1 inhibitors might be an effective way to potentiate antitumor effectiveness of PDT.	Warsaw Univ, Ctr Biostruct Res, Dept Immunol, PL-02097 Warsaw, Poland; Warsaw Univ, Ctr Biostruct Res, Dept Histol & Embryol, PL-02097 Warsaw, Poland; Warsaw Univ, Ctr Biostruct Res, Dept Pathol, PL-02097 Warsaw, Poland; Warsaw Univ, Dept Gen & Vasc Surg & Transplantat, PL-02097 Warsaw, Poland; Jagiellonian Univ, Fac Biotechnol, Dept Med Biotechnol, Krakow, Poland; Silesian Univ, Ctr Laser Diagnost & Therapy, Chair & Clin Internal Dis & Phys Med, Bytom, Poland; M Nencki Inst Expt Biol, Dept Muscle Biochem, PL-02093 Warsaw, Poland	University of Warsaw; University of Warsaw; University of Warsaw; University of Warsaw; Jagiellonian University; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences	Golab, J (corresponding author), Warsaw Univ, Ctr Biostruct Res, Dept Immunol, 1A Banacha Str,F Bldg, PL-02097 Warsaw, Poland.	jgolab@ib.amwaw.edu.pl	Glodkowska-Mrowka, Eliza/AAC-7294-2020; Golab, Jakub/K-6974-2013; Nowis, Dominika/P-6866-2019; Nazarewski, Sławomir D./T-3998-2018; Issat, Tadeusz/AAE-4176-2019; Wrzosek, Antoni/AAE-8070-2021; Nowis, Dominika/P-1213-2017; Glodkowska-Mrowka, Eliza/AAR-8503-2021; Wolinska, Ewa/AAE-4628-2021	Glodkowska-Mrowka, Eliza/0000-0002-5865-8425; Golab, Jakub/0000-0002-2830-5100; Nowis, Dominika/0000-0003-2748-9523; Nazarewski, Sławomir D./0000-0003-1195-9252; Issat, Tadeusz/0000-0002-3647-3550; Nowis, Dominika/0000-0003-2748-9523; Glodkowska-Mrowka, Eliza/0000-0002-5865-8425; Wilczynski, Grzegorz/0000-0001-6667-0291; Wolinska, Ewa/0000-0001-9592-1301; Wrzosek, Antoni/0000-0001-6376-8816; Stoklosa, Tomasz/0000-0001-6918-5056; Was, Halina/0000-0003-2743-0337				Abels C, 2004, PHOTOCH PHOTOBIO SCI, V3, P765, DOI 10.1039/b314241h; Almeida RD, 2004, BBA-REV CANCER, V1704, P59, DOI 10.1016/j.bbcan.2004.05.003; BACHOWSKI GJ, 1994, LIPIDS, V29, P449, DOI 10.1007/BF02578241; BALLA G, 1992, J BIOL CHEM, V267, P18148; Berberat PO, 2005, CLIN CANCER RES, V11, P3790, DOI 10.1158/1078-0432.CCR-04-2159; BRESSOUD D, 1992, J PHOTOCH PHOTOBIO B, V14, P311, DOI 10.1016/1011-1344(92)85110-G; Castano AP, 2004, PHOTODIAGN PHOTODYN, V1, P279, DOI 10.1016/S1572-1000(05)00007-4; Cisowski J, 2005, BIOCHEM BIOPH RES CO, V326, P670, DOI 10.1016/j.bbrc.2004.11.083; Deshane J, 2005, ACTA BIOCHIM POL, V52, P273; Dolgachev V, 2005, BIOCHEM BIOPH RES CO, V332, P411, DOI 10.1016/j.bbrc.2005.04.141; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Dulak J, 2002, ANTIOXID REDOX SIGN, V4, P229, DOI 10.1089/152308602753666280; Dulak J, 2003, ACTA BIOCHIM POL, V50, P31; Fang J, 2004, INT J CANCER, V109, P1, DOI 10.1002/ijc.11644; Ferrario A, 2000, CANCER RES, V60, P4066; Ferrario A, 2002, CANCER RES, V62, P3956; Frankel D, 2000, J CELL PHYSIOL, V185, P80, DOI 10.1002/1097-4652(200010)185:1<80::AID-JCP7>3.0.CO;2-W; Golab J, 2000, BRIT J CANCER, V82, P1485; Golab J, 2003, J BIOL CHEM, V278, P407, DOI 10.1074/jbc.M209125200; Golab J, 2002, CLIN CANCER RES, V8, P1265; Gomer CJ, 1996, CANCER RES, V56, P2355; GOMER CJ, 1991, PHOTOCHEM PHOTOBIOL, V53, P275, DOI 10.1111/j.1751-1097.1991.tb03934.x; Granville DJ, 2000, BLOOD, V95, P256; Granville DJ, 1999, BRIT J CANCER, V79, P95, DOI 10.1038/sj.bjc.6690017; Grune T, 2001, FREE RADICAL BIO MED, V30, P1243, DOI 10.1016/S0891-5849(01)00515-9; Hendrickx N, 2003, J BIOL CHEM, V278, P52231, DOI 10.1074/jbc.M307591200; Jalili A, 2004, CLIN CANCER RES, V10, P4498, DOI 10.1158/1078-0432.CCR-04-0367; Kapitulnik J, 2004, MOL PHARMACOL, V66, P773, DOI 10.1124/mol.104.002832; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Kick G, 1996, BRIT J CANCER, V74, P30, DOI 10.1038/bjc.1996.311; Kliukiene R, 1997, BIOCHEM MOL BIOL INT, V41, P707; Koukourakis MI, 2001, CANCER RES, V61, P1830; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Lin FB, 1996, CANCER RES, V56, P4636; LUNA MC, 1994, CANCER RES, V54, P1374; Makowski M, 2003, CLIN CANCER RES, V9, P5417; Mcbride G, 2002, J NATL CANCER I, V94, P1740; Minetti M, 1998, ARCH BIOCHEM BIOPHYS, V352, P165, DOI 10.1006/abbi.1998.0584; Motterlini R, 2000, J BIOL CHEM, V275, P13613, DOI 10.1074/jbc.275.18.13613; Nowis D, 2005, ACTA BIOCHIM POL, V52, P339; Oberdanner CB, 2005, PHOTOCHEM PHOTOBIOL, V81, P609, DOI 10.1562/2004-08-23-RN-284.1; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Rasch MH, 1997, PHOTOCHEM PHOTOBIOL, V66, P209, DOI 10.1111/j.1751-1097.1997.tb08645.x; Ryter SW, 2004, BIOESSAYS, V26, P270, DOI 10.1002/bies.20005; Sahoo SK, 2002, BIOCONJUGATE CHEM, V13, P1031, DOI 10.1021/bc020010k; Sharman WM, 2000, METHOD ENZYMOL, V319, P376; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; Shiraishi F, 2001, ANAL BIOCHEM, V289, P303, DOI 10.1006/abio.2000.4965; Srivastava M, 2001, J BIOL CHEM, V276, P15481, DOI 10.1074/jbc.M006920200; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Tanaka S, 2003, BRIT J CANCER, V88, P902, DOI 10.1038/sj.bjc.6600830; Turkseven S, 2005, AM J PHYSIOL-HEART C, V289, pH701, DOI 10.1152/ajpheart.00024.2005; Verwanger T, 2002, INT J ONCOL, V21, P1353; Wagener FADTG, 2003, PHARMACOL REV, V55, P551, DOI 10.1124/pr.55.3.5; Wang HP, 2002, PHOTOCHEM PHOTOBIOL, V76, P98, DOI 10.1562/0031-8655(2002)076<0098:UROHPA>2.0.CO;2; Wild PJ, 2005, MOL CANCER THER, V4, P516, DOI 10.1158/1535-7163.MCT-04-0141; Woods JA, 2004, PHOTOCHEM PHOTOBIOL, V79, P105, DOI 10.1111/j.1751-1097.2004.tb09864.x; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687; Zhuang SG, 2003, PHOTOCHEM PHOTOBIOL, V78, P361, DOI 10.1562/0031-8655(2003)078<0361:SOAOPK>2.0.CO;2	61	152	155	2	33	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3365	3374		10.1038/sj.onc.1209378	http://dx.doi.org/10.1038/sj.onc.1209378			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16462769	Green Accepted			2022-12-28	WOS:000238448100002
J	Frame, FM; Rogoff, HA; Pickering, MT; Cress, WD; Kowalik, TF				Frame, F. M.; Rogoff, H. A.; Pickering, M. T.; Cress, W. D.; Kowalik, T. F.			E2F1 induces MRN foci formation and a cell cycle checkpoint response in human fibroblasts	ONCOGENE			English	Article						E2F1; DNA damage; cell cycle checkpoint; apoptosis	NIJMEGEN BREAKAGE SYNDROME; DNA-DAMAGE CHECKPOINT; TRANSCRIPTION FACTOR; MRE11 COMPLEX; NUCLEAR FOCI; HISTONE H2AX; S-PHASE; ATAXIA-TELANGIECTASIA; TUMOR SUPPRESSION; GROWTH CONTROL	Deregulation of the Rb/E2F pathway in human fibroblasts results in an E2F1-mediated apoptosis dependent on Atm, Nbs1, Chk2 and p53. Here, we show that E2F1 expression results in MRN foci formation, which is independent of the Nbs1 interacting region and the DNA-binding domain of E2F1. E2F1-induced MRN foci are similar to irradiation-induced foci (IRIF) that result from double-strand DNA breaks because they correlate with 53BP1 and gamma H2AX foci, do not form in NBS cells, do form in AT cells and do not correlate with cell cycle entry. In fact, we find that in human fibroblasts deregulated E2F1 causes a G1 arrest, blocking serum-induced cell cycle progression, in part through an Nbs1/53BP1/p53/p21(WAF1/CIP1) checkpoint pathway. This checkpoint protects against apoptosis because depletion of 53BP1 or p21(WAF1/CIP1) increases both the rate and extent of apoptosis. Nbs1 and p53 contribute to both checkpoint and apoptosis pathways. These results suggest that E2F1-induced foci generate a cell cycle checkpoint that, with sustained E2F1 activity, eventually yields to apoptosis. Uncontrolled proliferation due to Rb/E2F deregulation as well as inactivation of both checkpoint and apoptosis programs would then be required for transformation of normal cells to tumor cells.	Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01655 USA; Univ Massachusetts, Program Immunol & Virol, Worcester, MA USA; H Lee Moffitt Comprehens Canc Ctr, Mol Oncol Program, Tampa, FL USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; H Lee Moffitt Cancer Center & Research Institute	Kowalik, TF (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, 55 Lake Ave N, Worcester, MA 01655 USA.	timothy.kowalik@umassmed.edu		Frame, Fiona/0000-0002-2377-1110	NCI NIH HHS [CA90489, CA86038] Funding Source: Medline; NIAID NIH HHS [5T32 AI09749] Funding Source: Medline; NIDDK NIH HHS [DK32520] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090489, R01CA086038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI009749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Castillo JP, 2000, J VIROL, V74, P8028, DOI 10.1128/JVI.74.17.8028-8037.2000; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; CRESS WD, 1994, J VIROL, V68, P4212, DOI 10.1128/JVI.68.7.4213-4219.1994; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kobayashi J, 2002, CURR BIOL, V12, P1846, DOI 10.1016/S0960-9822(02)01259-9; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Lindstrom MS, 2003, ONCOGENE, V22, P4993, DOI 10.1038/sj.onc.1206659; Lomazzi M, 2002, NAT GENET, V31, P190, DOI 10.1038/ng891; Lombard DB, 2000, CANCER RES, V60, P2331; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; PICKERING MT, 2005, ONOCOGENE; Powers JT, 2004, MOL CANCER RES, V2, P203; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; TAALMAN RDFM, 1983, MUTAT RES, V112, P23, DOI 10.1016/0167-8817(83)90021-4; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Tsai KY, 2002, CURR BIOL, V12, P159, DOI 10.1016/S0960-9822(01)00659-5; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Wim JM, 1997, MOL CELL BIOL, V17, P5016, DOI 10.1128/MCB.17.9.5016; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200	49	39	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3258	3266		10.1038/sj.onc.1209352	http://dx.doi.org/10.1038/sj.onc.1209352			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16434972				2022-12-28	WOS:000237951200004
J	Karagiannis, TC; El-Osta, A				Karagiannis, T. C.; El-Osta, A.			Modulation of cellular radiation responses by histone deacetylase inhibitors	ONCOGENE			English	Review						chromatin remodeling; histone acetylation; histone deacetylase; HDAC inhibitor; radiosensitivity; radiation response	DOUBLE-STRAND BREAKS; SUBEROYLANILIDE HYDROXAMIC ACID; DEPENDENT PROTEIN-KINASE; SODIUM-BUTYRATE; DNA-DAMAGE; TRICHOSTATIN-A; VALPROIC ACID; IN-VIVO; H2AX PHOSPHORYLATION; CANCER-THERAPY	Histone deacetylase ( HDAC) inhibitors are emerging as a new class of targeted cancer chemotherapeutics. Several HDAC inhibitors are currently in clinical trials and promising anticancer effects at well-tolerated doses have been observed for both hematologic and solid cancers. HDAC inhibitors have been shown to induce cell-cycle and growth arrest, differentiation and in certain cases apoptosis in cell cultures and in vivo. However, it is known that these compounds induce varying responses in different cells and biological settings, and identifying their precise mechanisms of action is an area of great interest. Important findings are continually expanding our understanding of the cellular effects of HDAC inhibitors and recent studies will be briefly outlined in this review. In addition to their intrinsic anticancer properties, numerous studies have demonstrated that HDAC inhibitors can modulate cellular responses to other cytotoxic modalities including ionizing radiation, ultraviolet radiation and chemotherapeutic drugs. Hence, there is a growing interest in potential clinical use of HDAC inhibitors in combination with conventional cancer therapies. In this review, the interaction of HDAC inhibitors with other anticancer agents is discussed. The focus of the article is on the different mechanisms by which HDAC inhibitors enhance the sensitivity of cells to the effects of ionizing radiation.	Alfred Med Res & Educ Precinct, Baker Med Res Inst, Epigenet Human Hlth & Dis Lab, Melbourne, Vic 3181, Australia; Peter MacCallum Canc Ctr, Trescowthick Res Labs, Melbourne, Vic, Australia	Baker Heart and Diabetes Institute; Peter Maccallum Cancer Center	El-Osta, A (corresponding author), Alfred Med Res & Educ Precinct, Baker Med Res Inst, Epigenet Human Hlth & Dis Lab, 2nd Floor,Commercial Rd, Melbourne, Vic 3181, Australia.	assam.el-osta@baker.edu.au		Karagiannis, Tom/0000-0002-9967-1546; El-Osta, Assam/0000-0003-2969-9137				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ARUNDEL CM, 1987, INT J RADIAT ONCOL, V13, P593, DOI 10.1016/0360-3016(87)90077-0; ARUNDEL CM, 1985, RADIAT RES, V104, P443, DOI 10.2307/3576603; Biade S, 2001, INT J RADIAT BIOL, V77, P1033, DOI 10.1080/09553000110066068; Blaheta RA, 2005, MED RES REV, V25, P383, DOI 10.1002/med.20027; Boivin AJ, 2002, ANTI-CANCER DRUG, V13, P869, DOI 10.1097/00001813-200209000-00013; Bowden CL, 2005, ACTA PSYCHIAT SCAND, V111, P13, DOI 10.1111/j.1600-0447.2005.00522.x; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; Camphausen K, 2005, INT J CANCER, V114, P380, DOI 10.1002/ijc.20774; Camphausen K, 2004, CLIN CANCER RES, V10, P6066, DOI 10.1158/1078-0432.CCR-04-0537; Camphausen K, 2004, CANCER RES, V64, P316, DOI 10.1158/0008-5472.CAN-03-2630; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Chang SM, 1999, J CLIN ONCOL, V17, P984, DOI 10.1200/JCO.1999.17.3.984; Chinnaiyan P, 2005, INT J RADIAT ONCOL, V62, P223, DOI 10.1016/j.ijrobp.2004.12.088; Chiu CY, 1998, J MOL BIOL, V284, P1075, DOI 10.1006/jmbi.1998.2212; Chung YL, 2000, CLIN CANCER RES, V6, P1452; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; Di Gennaro E, 2004, AMINO ACIDS, V26, P435, DOI 10.1007/s00726-004-0087-3; Dokmanovic M, 2005, J CELL BIOCHEM, V96, P293, DOI 10.1002/jcb.20532; Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; FALZON M, 1993, J BIOL CHEM, V268, P10546; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Frey RR, 2002, BIOORG MED CHEM LETT, V12, P3443, DOI 10.1016/S0960-894X(02)00754-0; Furumai R, 2002, CANCER RES, V62, P4916; Furumai R, 2001, P NATL ACAD SCI USA, V98, P87, DOI 10.1073/pnas.011405598; Gregoretti IV, 2004, J MOL BIOL, V338, P17, DOI 10.1016/j.jmb.2004.02.006; Gregory PD, 2001, EXP CELL RES, V265, P195, DOI 10.1006/excr.2001.5187; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gurvich N, 2004, CANCER RES, V64, P1079, DOI 10.1158/0008-5472.CAN-03-0799; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; Hess-Stumpp H, 2005, EUR J CELL BIOL, V84, P109, DOI 10.1016/j.ejcb.2004.12.010; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Jackson SP, 2001, BIOCHEM SOC T, V29, P655, DOI 10.1042/BST0290655; Jeggo P, 2002, DNA REPAIR, V1, P771, DOI 10.1016/S1568-7864(02)00096-4; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Johnstone RW, 2003, CANCER CELL, V4, P13, DOI 10.1016/S1535-6108(03)00165-X; Ju R, 2003, CANCER RES, V63, P2891; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Jung M, 2005, RADIAT RES, V163, P488, DOI 10.1667/RR3345; Jung M, 2001, CURR MED CHEM, V8, P1505, DOI 10.2174/0929867013372058; Kao GD, 2003, J CELL BIOL, V160, P1017, DOI 10.1083/jcb.200209065; Karagiannis TC, 2005, CANCER BIOL THER, V4, P787, DOI 10.4161/cbt.4.7.1922; Kastan MB, 2000, COLD SPRING HARB SYM, V65, P521, DOI 10.1101/sqb.2000.65.521; Kelly WK, 2005, NAT CLIN PRACT ONCOL, V2, P150, DOI 10.1038/ncponc0106; Kelly WK, 2002, EXPERT OPIN INV DRUG, V11, P1695, DOI 10.1517/13543784.11.12.1695; Kelly WK, 2005, J CLIN ONCOL, V23, P3923, DOI 10.1200/JCO.2005.14.167; Kelly WK, 2003, CLIN CANCER RES, V9, P3578; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Khanna KK, 2000, JNCI-J NATL CANCER I, V92, P795, DOI 10.1093/jnci/92.10.795; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kim GD, 1999, J BIOL CHEM, V274, P31127, DOI 10.1074/jbc.274.44.31127; Kim JH, 2004, INT J RADIAT ONCOL, V59, P1174, DOI 10.1016/j.ijrobp.2004.03.001; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kim MS, 2005, EXP CELL RES, V306, P94, DOI 10.1016/j.yexcr.2005.02.013; Kim MS, 2003, CANCER RES, V63, P7291; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; LEITH JT, 1988, RADIAT RES, V114, P186, DOI 10.2307/3577154; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Loscher W, 1999, PROG NEUROBIOL, V58, P31, DOI 10.1016/S0301-0082(98)00075-6; Louis M, 2005, INT J ONCOL, V26, P1569; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Marks PA, 2005, CELL CYCLE, V4, P549, DOI 10.4161/cc.4.4.1564; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4; MILLER AA, 1987, EUR J CANCER CLIN ON, V23, P1283, DOI 10.1016/0277-5379(87)90109-X; MIMORI T, 1986, J BIOL CHEM, V261, P375; Mitsiades CS, 2004, P NATL ACAD SCI USA, V101, P540, DOI 10.1073/pnas.2536759100; Munshi A, 2005, CLIN CANCER RES, V11, P4912, DOI 10.1158/1078-0432.CCR-04-2088; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nome RV, 2005, MOL CANCER THER, V4, P1231, DOI 10.1158/1535-7163.MCT-04-0304; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Olive PL, 2004, INT J RADIAT ONCOL, V58, P331, DOI 10.1016/j.ijrobp.2003.09.028; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; PERRINE SP, 1993, NEW ENGL J MED, V328, P81, DOI 10.1056/NEJM199301143280202; Perucca E, 2002, CNS DRUGS, V16, P695, DOI 10.2165/00023210-200216100-00004; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Piekarz R, 2004, CURR PHARM DESIGN, V10, P2289, DOI 10.2174/1381612043383980; Piekarz RL, 2004, BLOOD, V103, P4636, DOI 10.1182/blood-2003-09-3068; Prakash S, 2001, INVEST NEW DRUG, V19, P1, DOI 10.1023/A:1006489328324; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rooney S, 2003, J EXP MED, V197, P553, DOI 10.1084/jem.20021891; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Singh SB, 2002, J ORG CHEM, V67, P815, DOI 10.1021/jo016088w; SNEAD OC, 1985, J PEDIATR-US, V106, P323; Spotswood HT, 2002, J CLIN INVEST, V110, P577, DOI 10.1172/JCI200216547; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Taddei A, 2005, EMBO REP, V6, P520, DOI 10.1038/sj.embor.7400441; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; West RB, 1998, MOL CELL BIOL, V18, P5908, DOI 10.1128/MCB.18.10.5908; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Yoshida M, 2003, CURR MED CHEM, V10, P2351, DOI 10.2174/0929867033456602; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zgheib O, 2005, RADIOTHER ONCOL, V76, P119, DOI 10.1016/j.radonc.2005.06.026; Zhang Y, 2004, RADIAT RES, V161, P667, DOI 10.1667/RR3192; Zhang Y, 2004, INT J CANCER, V110, P301, DOI 10.1002/ijc.20117; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	120	74	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3885	3893		10.1038/sj.onc.1209417	http://dx.doi.org/10.1038/sj.onc.1209417			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16462761				2022-12-28	WOS:000238668800001
J	Gandhi, M; Medvedovic, M; Stringer, JR; Nikiforov, YE				Gandhi, M; Medvedovic, M; Stringer, JR; Nikiforov, YE			Interphase chromosome folding determines spatial proximity of genes participating in carcinogenic RET/PTC rearrangements	ONCOGENE			English	Article						chromosomal rearrangements; thyroid cancer; RET/ PTC; nuclear architecture	PAPILLARY THYROID CARCINOMAS; NUCLEAR ARCHITECTURE; RET PROTOONCOGENE; HUMAN-CELLS; CANCER; RADIATION; MODEL; ACTIVATION; FUSION; LOOPS	Recurrent chromosomal rearrangements are common in cancer cells and may be influenced by nonrandom positioning of recombination-prone genetic loci in the nucleus. However, the mechanism responsible for spatial proximity of specific loci is unknown. In this study, we use an 18Mb region on 10q11.2-21 containing the RET gene and its recombination partners, the H4 and NCOA4 (ELE1) genes, as a model chromosomal region frequently involved in RET/PTC rearrangements in thyroid cancer. RET/PTC is particularly common in tumors from children exposed to ionizing radiation. Using fluorescence in situ hybridization and three-dimensional microscopy, the locations of. five different loci in this region were mapped in interphase nuclei of normal human thyroid cells. We show that RET and NCOA4 are much closer to each other than expected based on their genomic separation. Modeling of chromosome folding in this region suggests the presence of chromosome coiling with coils of similar to 8Mb in length, which positions the RET gene close to both, the NCOA4 and H4, loci. There was no significant variation in gene proximity between adult and pediatric thyroid cells. This study provides evidence for large-scale chromosome folding of the 10q11.2-21 region that offers a structural basis for nonrandom positioning and spatial proximity of potentially recombinogenic intrachromosomal loci.	Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Ctr Biostat Serv, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45267 USA; Childrens Hosp Res Fdn, Div Biomed Informat, Cincinnati, OH 45229 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Nikiforov, YE (corresponding author), Univ Cincinnati, Dept Pathol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	Yuri.Nikiforov@uc.edu			NCI NIH HHS [CA88041] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088041] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELMONT AS, 1994, J CELL BIOL, V127, P287, DOI 10.1083/jcb.127.2.287; BONGARZONE I, 1994, CANCER RES, V54, P2979; Ciampi R, 2005, J CLIN INVEST, V115, P94, DOI 10.1172/JCI200523237; Cornforth MN, 2002, J CELL BIOL, V159, P237, DOI 10.1083/jcb.200206009; Cremer C, 1996, MUTAT RES-REV GENET, V366, P97, DOI 10.1016/S0165-1110(96)90031-7; Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Kozubek S, 1997, BLOOD, V89, P4537, DOI 10.1182/blood.V89.12.4537; MANTON I, 1950, BIOL REV, V25, P486, DOI 10.1111/j.1469-185X.1950.tb00770.x; MANUELIDIS L, 1990, CYTOMETRY, V11, P8, DOI 10.1002/cyto.990110104; MANUELIDIS L, 1990, SCIENCE, V250, P1533, DOI 10.1126/science.2274784; Munkel C, 1999, J MOL BIOL, V285, P1053, DOI 10.1006/jmbi.1998.2361; Nikiforov YE, 2002, ENDOCR PATHOL, V13, P3, DOI 10.1385/EP:13:1:03; Nikiforova MN, 2000, SCIENCE, V290, P138, DOI 10.1126/science.290.5489.138; ONHUKI Y, 1965, NATURE, V208, P916; Parada LA, 2002, CURR BIOL, V12, P1692, DOI 10.1016/S0960-9822(02)01166-1; Rabes HM, 2000, CLIN CANCER RES, V6, P1093; RATTNER JB, 1985, CELL, V42, P291, DOI 10.1016/S0092-8674(85)80124-0; Roccato E, 2005, CANCER RES, V65, P2572, DOI 10.1158/0008-5472.CAN-04-4294; Roix JJ, 2003, NAT GENET, V34, P287, DOI 10.1038/ng1177; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; SACHS RK, 1995, P NATL ACAD SCI USA, V92, P2710, DOI 10.1073/pnas.92.7.2710; SANTORO M, 1994, ONCOGENE, V9, P509; SHORE RE, 1992, RADIAT RES, V131, P98, DOI 10.2307/3578322; SUMNER AT, 1991, CHROMOSOMA, V100, P410, DOI 10.1007/BF00337519; YOKOTA H, 1995, J CELL BIOL, V130, P1239, DOI 10.1083/jcb.130.6.1239	27	55	57	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2360	2366		10.1038/sj.onc.1209268	http://dx.doi.org/10.1038/sj.onc.1209268			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16331264				2022-12-28	WOS:000236764300008
J	Lahne, HU; Kloster, MM; Lefdal, S; Blomhoff, HK; Naderi, S				Lahne, HU; Kloster, MM; Lefdal, S; Blomhoff, HK; Naderi, S			Degradation of cyclin D3 independent of Thr-283 phosphorylation	ONCOGENE			English	Article						okadaic acid; cyclin D3; degradation; phosphorylation	PHOSPHATIDYLINOSITOL 3-KINASE; RETINOBLASTOMA PROTEIN; DEPENDENT DEGRADATION; DOWN-REGULATION; CDK INHIBITORS; D1 EXPRESSION; OKADAIC ACID; PROGRESSION; PATHWAY; ARREST	Cyclin D3 has been shown to play a major role in the regulation of cell cycle progression in lymphocytes. It is therefore important to understand the mechanisms involved in the regulation of this protein. We have previously shown that both basal and cAMP-induced degradation of cyclin D3 in Reh cells is dependent on Thr-283 phosphorylation by glycogen synthase kinase-3 beta (GSK-3 beta). We now provide evidence of an alternative mechanism being involved in the regulation of cyclin D3 degradation. Treatment of lymphoid cells with okadaic acid (OA), an inhibitor of protein phosphatases 1 and 2A (PP1 and PP2A), induces rapid phosphorylation and proteasomal degradation of cyclin D3. This degradation is not inhibited by the GSK-3 beta inhibitors lithium or Kenpaullone, or by substitution of Thr-283 with Ala on cyclin D3, indicating that cyclin D3 can be degraded independently of Thr-283 phosphorylation and GSK-3 beta activity. Interestingly, in vitro experiments revealed that PP1, but not PP2A, was able to dephosphorylate cyclin D3 efficiently, and PP1 was found to associate with His-tagged cyclin D3. These results support the hypothesis that PP1 constitutively keeps cyclin D3 in a stable, dephosphorylated state, and that treatment of cells with OA leads to phosphorylation and degradation of cyclin D3 through inhibition of PP1.	Univ Oslo, Inst Basic Med Sci, Dept Biochem, N-0317 Oslo, Norway	University of Oslo	Naderi, S (corresponding author), Univ Oslo, Inst Basic Med Sci, Dept Biochem, POB 1112, N-0317 Oslo, Norway.	soheil.naderi@basalmed.uio.no						Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Bergsagel PL, 2005, BLOOD, V106, P296, DOI 10.1182/blood-2005-01-0034; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Bollen M, 2002, TRENDS CELL BIOL, V12, P138, DOI 10.1016/S0962-8924(01)02247-4; Boonen GJJC, 1999, J BIOL CHEM, V274, P34676, DOI 10.1074/jbc.274.49.34676; Brown K, 1997, MOL CELL BIOL, V17, P3021, DOI 10.1128/MCB.17.6.3021; Casanovas O, 2004, ONCOGENE, V23, P7537, DOI 10.1038/sj.onc.1208040; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; Deng XB, 2003, J BIOL CHEM, V278, P41347, DOI 10.1074/jbc.M306780200; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; Filipits M, 2002, CLIN CANCER RES, V8, P729; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; Gutzkow KB, 2003, CELL SIGNAL, V15, P871, DOI 10.1016/S0898-6568(03)00038-X; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hu XT, 2002, J BIOL CHEM, V277, P16528, DOI 10.1074/jbc.M109929200; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; Ma Y, 2005, CANCER RES, V65, P6476, DOI 10.1158/0008-5472.CAN-05-0370; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MIYATAKE S, 1995, J EXP MED, V182, P401, DOI 10.1084/jem.182.2.401; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Naderi S, 2000, EUR J IMMUNOL, V30, P1757, DOI 10.1002/1521-4141(200006)30:6<1757::AID-IMMU1757>3.0.CO;2-N; Naderi S, 2004, J CELL SCI, V117, P3769, DOI 10.1242/jcs.01210; Oliver C.J., 1998, FRONT BIOSCI, V3, P961; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; Tao GZ, 2002, J BIOL CHEM, V277, P19295, DOI 10.1074/jbc.M109654200; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Zou YL, 2004, J BIOL CHEM, V279, P27790, DOI 10.1074/jbc.M403042200	42	8	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2468	2476		10.1038/sj.onc.1209278	http://dx.doi.org/10.1038/sj.onc.1209278			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16331257				2022-12-28	WOS:000236948000005
J	Bernard, D; Gil, J; Dumont, P; Rizzo, S; Monte, D; Quatannens, B; Hudson, D; Visakorpi, T; Fuks, F; de Launoit, Y				Bernard, D; Gil, J; Dumont, P; Rizzo, S; Monte, D; Quatannens, B; Hudson, D; Visakorpi, T; Fuks, F; de Launoit, Y			The methyl-CpG- binding protein MECP2 is required for prostate cancer cell growth	ONCOGENE			English	Article						methyl-CpG-binding protein; epigenetic; cancer; prostate; growth	ANDROGEN DEPRIVATION THERAPY; HISTONE DEACETYLASE COMPLEX; DNA METHYLATION; NEUROENDOCRINE DIFFERENTIATION; MOLECULAR-GENETICS; C-MYC; EXPRESSION; CARCINOMA; RECEPTOR; METHYLTRANSFERASE	The incidence of prostate cancer is increasing in western countries because of population aging. Prostate cancer begins as an androgen-dependent disease, but it can become androgen independent at a later stage or in tumors recurring after an antihormonal treatment. Although many genetic events have been described to be involved in androgen-dependent and/or -independent prostate cancer growth, little is known about the contribution of epigenetic events. Here we have examined the possibility that the methyl-CpG-binding protein MECP2 might play a role in controlling the growth of prostate cancer cells. Inhibition of MECP2 expression by stable short hairpin RNA stopped the growth of both normal and cancer human prostate cells. In addition, ectopic expression of the MECP2 conferred a growth advantage to human prostate cancer cells. More importantly, this expression allowed androgen-dependent cells to grow independently of androgen stimulation and to retain tumorigenic properties in androgen-depleted conditions. Analysis of signaling pathways showed that this effect is independent of androgen receptor signaling. Instead, MECP2 appears to act by maintaining a constant c-myc level during antihormonal treatment. We further show that MECP2-expressing cells possess a functional p53 pathway and are still responsive to chemotherapeutic drugs.	ULB, Fac Med, Lab Virol Mol, B-1070 Brussels, Belgium; Imperial Coll Sch Med, MRC Clin Sci Ctr, London, England; Univ Sci & Technol, CNRS, UMR 8117, Inst Pasteur Lille,Inst Biol, Lille, France; Inst Canc Res, Prostate Stem Cell Lab, Sutton, Surrey, England; Tampere Univ Hosp, Tampere, Finland	Universite Libre de Bruxelles; Imperial College London; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; University of London; Institute of Cancer Research - UK; Tampere University; Tampere University Hospital	Bernard, D (corresponding author), ULB, Fac Med, Lab Virol Mol, CP 614,808 Route Lennik, B-1070 Brussels, Belgium.	dbernard@ulb.ac.be	Gil, Jesus/C-7739-2012; Bernard, David/D-6265-2018	Gil, Jesus/0000-0002-4303-6260; Bernard, David/0000-0002-1557-2074; monte, didier/0000-0002-0613-6203; Visakorpi, Tapio/0000-0002-5004-0364	Medical Research Council [MC_U120085810] Funding Source: Medline; MRC [MC_U120085810] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; ABRAHAMSSON PA, 1989, PATHOL RES PRACT, V185, P373, DOI 10.1016/S0344-0338(89)80016-0; Ahlgren G, 2000, PROSTATE, V42, P274, DOI 10.1002/(SICI)1097-0045(20000301)42:4<274::AID-PROS4>3.0.CO;2-R; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bernard D, 2003, J CLIN INVEST, V112, P1724; Bernard D, 2001, CANCER RES, V61, P2656; Burgers WA, 2002, TRENDS GENET, V18, P275, DOI 10.1016/S0168-9525(02)02667-7; Carlson CA, 2000, RADIAT RES, V154, P590, DOI 10.1667/0033-7587(2000)154[0590:LORPCW]2.0.CO;2; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Cheng JC, 2004, CANCER CELL, V6, P151, DOI 10.1016/j.ccr.2004.06.023; COHEN RJ, 1990, BRIT J UROL, V66, P405, DOI 10.1111/j.1464-410X.1990.tb14963.x; Denmeade SR, 2002, NAT REV CANCER, V2, P389, DOI 10.1038/nrc801; Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Fojo T, 2003, ONCOGENE, V22, P7512, DOI 10.1038/sj.onc.1206951; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Goffin J, 2002, ANN ONCOL, V13, P1699, DOI 10.1093/annonc/mdf314; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hirano D, 2004, EUR UROL, V45, P586, DOI 10.1016/j.eururo.2003.11.032; Hudson David L, 2003, Methods Mol Med, V81, P59; Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KELLEN JA, 1994, ANTICANCER RES, V14, P433; Kimura H, 2003, J BIOL CHEM, V278, P4806, DOI 10.1074/jbc.M209923200; Kongkanuntn R, 1999, ONCOGENE, V18, P7219, DOI 10.1038/sj.onc.1203181; Kudo S, 2001, BRAIN DEV-JPN, V23, pS165, DOI 10.1016/S0387-7604(01)00345-X; Li LC, 2004, BBA-REV CANCER, V1704, P87, DOI 10.1016/j.bbcan.2004.06.001; Lund AH, 2004, CURR OPIN CELL BIOL, V16, P239, DOI 10.1016/j.ceb.2004.03.010; Miyoshi Y, 2001, BJU INT, V88, P982, DOI 10.1046/j.1464-4096.2001.00936.x; Nan X., 1998, NOVART FDN SYMP, V214, P16, DOI DOI 10.1002/9780470515501.CH2; Nan XS, 1998, CIBA F SYMP, V214, P6; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Porkka KP, 2004, EUR UROL, V45, P683, DOI 10.1016/j.eururo.2004.01.012; Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; TETU B, 1987, CANCER, V59, P1803, DOI 10.1002/1097-0142(19870515)59:10<1803::AID-CNCR2820591019>3.0.CO;2-X; Valkov NI, 2003, DRUG RESIST UPDATE, V6, P27, DOI 10.1016/S1368-7646(02)00143-7; Visakorpi T, 2003, UROLOGY, V62, P3, DOI 10.1016/S0090-4295(03)00776-3; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; WOLF DA, 1992, MOL ENDOCRINOL, V6, P753, DOI 10.1210/me.6.5.753; Wright ME, 2003, MOL ENDOCRINOL, V17, P1726, DOI 10.1210/me.2003-0031; Yeap BB, 1999, ENDOCRINOLOGY, V140, P3282, DOI 10.1210/en.140.7.3282; Yoshida M, 2001, CANCER CHEMOTH PHARM, V48, pS20, DOI 10.1007/s002800100300; Zhu Wei-Guo, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P187, DOI 10.2174/1568011033482440	51	44	55	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1358	1366		10.1038/sj.onc.1209179	http://dx.doi.org/10.1038/sj.onc.1209179			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16331274				2022-12-28	WOS:000235708200009
J	McIlwain, CC; Townsend, DM; Tew, KD				McIlwain, CC; Townsend, DM; Tew, KD			Glutathione S-transferase polymorphisms: cancer incidence and therapy	ONCOGENE			English	Review						GST; polymorphism; resistance; MAP kinase pathway	GENETIC-POLYMORPHISM; COLORECTAL-CANCER; MALEYLACETOACETATE ISOMERASE; FUNCTIONAL POLYMORPHISM; CATALYTIC-ACTIVITY; MOLECULAR-CLONING; MYELOID-LEUKEMIA; ENZYME-ACTIVITY; CELL CARCINOMA; OVARIAN-CANCER	The super family of glutathione S-transferases (GSTs) is composed of multiple isozymes with significant evidence of functional polymorphic variation. Over the last three decades, data from cancer studies have linked aberrant expression of GST isozymes with the development and expression of resistance to a variety of chemicals, including cancer drugs. This review addresses how differences in the human GST isozyme expression patterns influence cancer susceptibility, prognosis and treatment. In addition to the well-characterized catalytic activity, recent evidence has shown that certain GST isozymes can regulate mitogen-activated protein kinases or can facilitate the addition of glutathione to cysteine residues in target proteins (S-glutathionylation). These multiple functionalities have contributed to the recent efforts to target GSTs with novel small molecule therapeutics. Presently, at least two drugs are in late-stage clinical testing. The evolving functions of GST and their divergent expression patterns in individuals make them an attractive target for drug discovery.	Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA	Medical University of South Carolina	Tew, KD (corresponding author), Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, 173 Ashley Ave,POB 250505, Charleston, SC 29425 USA.	tewk@musc.edu			NATIONAL CANCER INSTITUTE [R01CA053783, R01CA085660] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES012878] Funding Source: NIH RePORTER; NCI NIH HHS [CA53783, R01 CA085660] Funding Source: Medline; NIEHS NIH HHS [T32 ES012878] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Alexandrie AK, 2002, PHARMACOGENETICS, V12, P613, DOI 10.1097/00008571-200211000-00005; AliOsman F, 1997, J BIOL CHEM, V272, P10004; Ambrosone CB, 2001, CANCER RES, V61, P7130; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Baez S, 1997, BIOCHEM J, V324, P25, DOI 10.1042/bj3240025; Bakker J, 2002, J BIOL CHEM, V277, P22573, DOI 10.1074/jbc.M203009200; Beuckmann CT, 2000, NEUROCHEM RES, V25, P733, DOI 10.1023/A:1007579507804; Blackburn AC, 2001, PHARMACOGENETICS, V11, P671, DOI 10.1097/00008571-200111000-00005; Blackburn AC, 1998, CYTOGENET CELL GENET, V83, P109, DOI 10.1159/000015145; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; Cacciatore I, 2005, AMINO ACIDS, V29, P255, DOI 10.1007/s00726-005-0232-7; Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200; Chuang ST, 2005, AM J CLIN PATHOL, V123, P421, DOI 10.1309/AQXR6B2QPUGD638C; Coggan M, 1998, BIOCHEM J, V334, P617, DOI 10.1042/bj3340617; Coles B, 2001, MUTAT RES-FUND MOL M, V482, P3, DOI 10.1016/S0027-5107(01)00187-7; COWELL IG, 1988, BIOCHEM J, V255, P79, DOI 10.1042/bj2550079; Dang DT, 2005, CANCER RES, V65, P9485, DOI 10.1158/0008-5472.CAN-05-1930; Davies SM, 2001, J CLIN ONCOL, V19, P1279, DOI 10.1200/JCO.2001.19.5.1279; Davis W, 2001, J PHARMACOL EXP THER, V296, P1; DEJONG JL, 1991, BIOCHEM BIOPH RES CO, V180, P15, DOI 10.1016/S0006-291X(05)81248-3; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; Dorion S, 2002, J BIOL CHEM, V277, P30792, DOI 10.1074/jbc.M203642200; Fernandez-Canon JM, 2002, MOL CELL BIOL, V22, P4943, DOI 10.1128/MCB.22.13.4943-4951.2002; Findlay VJ, 2004, MOL PHARMACOL, V65, P1070, DOI 10.1124/mol.65.5.1070; Gate L, 2004, J BIOL CHEM, V279, P8608, DOI 10.1074/jbc.M308613200; Goto S, 1999, FREE RADICAL RES, V31, P549, DOI 10.1080/10715769900301121; GUO X, 2005, DRUG METAB DISPOS; Hand PA, 1996, CARCINOGENESIS, V17, P1919, DOI 10.1093/carcin/17.9.1919; Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857; Howells REJ, 1998, CLIN CANCER RES, V4, P2439; Howells REJ, 2001, INT J GYNECOL CANCER, V11, P107, DOI 10.1046/j.1525-1438.2001.00091.x; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Inskip A, 1995, BIOCHEM J, V312, P713, DOI 10.1042/bj3120713; Johansson AS, 2001, J BIOL CHEM, V276, P33061, DOI 10.1074/jbc.M104539200; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; Lin XH, 2001, AM J PATHOL, V159, P1815, DOI 10.1016/S0002-9440(10)63028-3; Liu J, 2004, MOL CANCER THER, V3, P709; Lo HW, 1998, CHEM-BIOL INTERACT, V112, P91, DOI 10.1016/S0009-2797(97)00153-1; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; LYTTLE MH, 1994, J MED CHEM, V37, P1501, DOI 10.1021/jm00036a016; Manevich Y, 2005, FREE RADICAL BIO MED, V38, P1422, DOI 10.1016/j.freeradbiomed.2005.02.011; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Matthias C, 1998, PHARMACOGENETICS, V8, P91; Maugard CM, 2001, INT J CANCER, V91, P334, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1057>3.0.CO;2-H; McLellan RA, 1997, MOL PHARMACOL, V52, P958, DOI 10.1124/mol.52.6.958; Mondal BC, 2005, EUR J CANCER PREV, V14, P281, DOI 10.1097/00008469-200506000-00014; Morgan AS, 1998, CANCER RES, V58, P2568; Morgan AS, 1996, CANCER CHEMOTH PHARM, V37, P363, DOI 10.1007/s002800050398; Nelson WG, 2001, ANN NY ACAD SCI, V952, P135, DOI 10.1111/j.1749-6632.2001.tb02734.x; Ning BT, 2004, PHARMACOGENETICS, V14, P35, DOI 10.1097/00008571-200401000-00004; O'Brien ML, 1999, J PHARMACOL EXP THER, V291, P1348; PEARSON WR, 1993, AM J HUM GENET, V53, P220; PEMBLE S, 1994, BIOCHEM J, V300, P271, DOI 10.1042/bj3000271; PLOEMEN JHTM, 1994, CANCER RES, V54, P915; Ricci G, 2005, J BIOL CHEM, V280, P26397, DOI 10.1074/jbc.M503295200; Rosario LA, 2000, MOL PHARMACOL, V58, P167, DOI 10.1124/mol.58.1.167; Ruscoe JE, 2001, J PHARMACOL EXP THER, V298, P339; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Seow HA, 2005, P NATL ACAD SCI USA, V102, P9282, DOI 10.1073/pnas.0409013102; SMITH CM, 1994, CANCER EPIDEM BIOMAR, V3, P471; Smith G, 1995, CANCER SURV, V25, P27; Stanulla M, 2000, BLOOD, V95, P1222, DOI 10.1182/blood.V95.4.1222.004k20_1222_1228; Stoehlmacher J, 2002, J NATL CANCER I, V94, P936; Strange R C, 1999, IARC Sci Publ, P231; TAN KL, 1995, GENOMICS, V25, P381, DOI 10.1016/0888-7543(95)80037-M; Tanaka-Kagawa T, 2003, BIOCHEM BIOPH RES CO, V301, P516, DOI 10.1016/S0006-291X(02)03066-8; Tetlow N, 2004, PHARMACOGENETICS, V14, P657, DOI 10.1097/00008571-200410000-00003; Tetlow N, 2004, PHARMACOGENETICS, V14, P359, DOI 10.1097/00008571-200406000-00005; Tew KD, 1998, CHEM-BIOL INTERACT, V112, P199, DOI 10.1016/S0009-2797(97)00162-2; TEW KD, 1994, CANCER RES, V54, P4313; Tiltman AJ, 2001, HISTOPATHOLOGY, V39, P266, DOI 10.1046/j.1365-2559.2001.01202.x; Townsend Danyelle, 2003, Am J Pharmacogenomics, V3, P157, DOI 10.2165/00129785-200303030-00002; Townsend DM, 2005, MOL PHARM; Turella P, 2005, CANCER RES, V65, P3751, DOI 10.1158/0008-5472.CAN-04-3903; van der Logt EMJ, 2004, CARCINOGENESIS, V25, P2407, DOI 10.1093/carcin/bgh251; Wang L, 2005, INT J MOL MED, V16, P19; Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200; Watson MA, 1998, CARCINOGENESIS, V19, P275, DOI 10.1093/carcin/19.2.275; Whitbread AK, 2003, PHARMACOGENETICS, V13, P131, DOI 10.1097/00008571-200303000-00003; Xu SJ, 1998, J BIOL CHEM, V273, P3517, DOI 10.1074/jbc.273.6.3517; Ye Z, 2005, EUR J CANCER, V41, P980, DOI 10.1016/j.ejca.2005.01.014; Yengi L, 1996, CANCER RES, V56, P1974; Yin ZL, 2001, J HISTOCHEM CYTOCHEM, V49, P983, DOI 10.1177/002215540104900806; Yin ZM, 2000, CANCER RES, V60, P4053; Zakharyan RA, 2001, CHEM RES TOXICOL, V14, P1051, DOI 10.1021/tx010052h	86	396	415	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	11					1639	1648		10.1038/sj.onc.1209373	http://dx.doi.org/10.1038/sj.onc.1209373			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020JL	16550164	Green Accepted			2022-12-28	WOS:000235904700006
J	Ohtsuka, T; Liu, XF; Koga, Y; Kitajima, Y; Nakafusa, Y; Ha, CW; Lee, SW; Miyazaki, K				Ohtsuka, T; Liu, XF; Koga, Y; Kitajima, Y; Nakafusa, Y; Ha, CW; Lee, SW; Miyazaki, K			Methylation-induced silencing of ASC and the effect of expressed ASC on p53-mediated chemosensitivity in colorectal cancer	ONCOGENE			English	Article						ASC; p53; methylation; chemosensitivity; colorectal cancer	RECRUITMENT DOMAIN PROTEIN; APOPTOTIC RESPONSE; HUMAN BREAST; P53; GENE; CELLS; BAX; ACTIVATION; MUTATIONS; ASC/TMS1	Tumor suppressor p53 is known to play a crucial role in chemosensitivity in colorectal cancer. We previously demonstrated that an apoptosis-associated speck-like protein, ASC, is a p53-target gene which regulates p53-Bax mitochondrial apoptotic pathway. ASC is also known to be a target of methylation-induced gene silencing. An inactivation of ASC might thus cause resistance to chemotherapy, and if this is the case, then the expression of ASC would restore the chemosensitivity. The aim of this study was to clarify this hypothesis. ASC was methylated in 25% of all resected specimens in patients with colorectal cancer; however, ASC methylation did not always correspond to a lack of ASC protein. When expressed in colon cancer cells, in which ASC is absent due to methylation, ASC was found to enhance the chemosensitivity in a p53-dependent manner. In p53-null cells, ASC increased the p53-mediated cell death induced by p53-expressing adenovirus infection. Our data suggest that the methylation-induced silencing of ASC might cause resistance to p53-mediated chemosensitivity in colorectal cancer. The gene introduction of ASC may thus restore such chemosensitivity, and this modality may therefore be a useful new treatment strategy for colorectal cancer.	Saga Univ, Fac Med, Dept Surg, Saga 8498501, Japan; Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Orthoped Surg, Seoul, South Korea; Massachusetts Gen Hosp, Cutaneuos Biol Res Ctr, Charlestown, MA USA; Harvard Univ, Sch Med, Charlestown, MA USA	Saga University; Sungkyunkwan University (SKKU); Samsung Medical Center; Harvard University; Massachusetts General Hospital; Harvard University	Ohtsuka, T (corresponding author), Saga Univ, Fac Med, Dept Surg, Saga 8498501, Japan.	ootsuka4@cc.saga-u.ac.jp	Ha, C/GZL-9046-2022	HA, Chul-Won/0000-0001-5123-6513	NCI NIH HHS [CA80058-06, CA078356-05] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Conway KE, 2000, CANCER RES, V60, P6236; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guan X, 2003, INT J CANCER, V107, P202, DOI 10.1002/ijc.11376; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; MIYASHITA T, 1995, CELL, V80, P293; Moriai R, 2002, ANTICANCER RES, V22, P4163; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Ohtsuka T, 2004, NAT CELL BIOL, V6, P121, DOI 10.1038/ncb1087; SCARPA A, 1993, AM J PATHOL, V142, P1534; Stehlik C, 2002, J EXP MED, V196, P1605, DOI 10.1084/jem.20021552; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yokoyama T, 2003, CANCER LETT, V202, P101, DOI 10.1016/j.canlet.2003.08.027; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	21	25	30	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2006	25	12					1807	1811		10.1038/sj.onc.1209204	http://dx.doi.org/10.1038/sj.onc.1209204			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16331272				2022-12-28	WOS:000236013700012
J	Patrawala, L; Calhoun, T; Schneider-Broussard, R; Li, H; Bhatia, B; Tang, S; Reilly, JG; Chandra, D; Zhou, J; Claypool, K; Coghlan, L; Tang, DG				Patrawala, L; Calhoun, T; Schneider-Broussard, R; Li, H; Bhatia, B; Tang, S; Reilly, JG; Chandra, D; Zhou, J; Claypool, K; Coghlan, L; Tang, DG			Highly purified CD44(+) prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells	ONCOGENE			English	Article						CD44; prostate cancer; progenitor cells; cancer stem cells; tumor progenitor cells; stemness genes	15-LIPOXYGENASE-2 15-LOX2; STEM-CELLS; IN-VITRO; EXPRESSION; CARCINOMA; MARKER; IDENTIFICATION; ASSOCIATION; ISOFORM; RENEWAL	CD44 is a multifunctional protein involved in cell adhesion and signaling. The role of CD44 in prostate cancer (PCa) development and progression is controversial with studies showing both tumor-promoting and tumor-inhibiting effects. Most of these studies have used bulk-cultured PCa cells or PCa tissues to carry out correlative or overexpression experiments. The key experiment using prospectively purified cells has not been carried out. Here we use FACS to obtain homogeneous CD44(+) and CD44(-) tumor cell populations from multiple PCa cell cultures as well as four xenograft tumors to compare their in vitro and in vivo tumor-associated properties. Our results reveal that the CD44(+) PCa cells are more proliferative, clonogenic, tumorigenic, and metastatic than the isogenic CD44(-) PCa cells. Subsequent molecular studies demonstrate that the CD44(+) PCa cells possess certain intrinsic properties of progenitor cells. First, BrdU pulse-chase experiments reveal that CD44(+) cells colocalize with a population of intermediate label-retaining cells. Second, CD44(+) PCa cells express higher mRNA levels of several 'stemness' genes including Oct- 3/4, Bmi, beta-catenin, and SMO. Third, CD44(+) PCa cells can generate CD44(-) cells in vitro and in vivo. Fourth, CD44(+) PCa cells, which are AR(-), can differentiate into AR(+) tumor cells. Finally, a very small percentage of CD44(+) PCa cells appear to undergo asymmetric cell division in clonal analyses. Altogether, our results suggest that the CD44(+) PCa cell population is enriched in tumorigenic and metastatic progenitor cells.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA; Grad Sch Biomed Sci, Program Environm & Mol Carcinogenesis, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center	Tang, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, 1808 Pk Rd 1C, Smithville, TX 78957 USA.	dtang@mdanderson.org	Tang, Dean/AAI-3457-2020	Tang, Dean/0000-0001-5029-1174; Chandra, Dhyan/0000-0001-7272-9384	NCI NIH HHS [P30 CA 166672, CA90297] Funding Source: Medline; NIA NIH HHS [AG023374] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090297, R01CA166672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG023374] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Bhatia B, 2005, ONCOGENE, V24, P3583, DOI 10.1038/sj.onc.1208406; Bhatia B, 2003, J BIOL CHEM, V278, P25091, DOI 10.1074/jbc.M301920200; Bhatt RI, 2003, CYTOM PART A, V54A, P89, DOI 10.1002/cyto.a.10058; BONKHOFF H, 1994, PROSTATE, V24, P114, DOI 10.1002/pros.2990240303; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Collins AT, 2001, J CELL SCI, V114, P3865; De Marzo AM, 1998, PROSTATE, V34, P162; Draffin JE, 2004, CANCER RES, V64, P5702, DOI 10.1158/0008-5472.CAN-04-0389; Gao AC, 1998, CANCER RES, V58, P2350; Gao AC, 1997, CANCER RES, V57, P846; Garraway LA, 2003, PROSTATE, V55, P206, DOI 10.1002/pros.10244; Hudson DL, 2000, LAB INVEST, V80, P1243, DOI 10.1038/labinvest.3780132; Kallakury BVS, 1996, CANCER, V78, P1461, DOI 10.1002/(SICI)1097-0142(19961001)78:7<1461::AID-CNCR13>3.0.CO;2-Y; LATZA U, 1990, J CLIN PATHOL, V43, P213, DOI 10.1136/jcp.43.3.213; Liu AY, 1999, PROSTATE, V40, P192; Liu AY, 1997, P NATL ACAD SCI USA, V94, P10705, DOI 10.1073/pnas.94.20.10705; LOKESHWAR BL, 1995, ANTICANCER RES, V15, P1191; MAITLAND NJ, 2005, P AM ASSOC CANC RES, pA2518; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; Nagabhushan M, 1996, AM J CLIN PATHOL, V106, P647; Noordzij MA, 1999, INT J CANCER, V84, P478, DOI 10.1002/(SICI)1097-0215(19991022)84:5<478::AID-IJC5>3.0.CO;2-N; Omara-Opyene AL, 2004, LAB INVEST, V84, P894, DOI 10.1038/labinvest.3700112; Paradis V, 1998, J CLIN PATHOL, V51, P798, DOI 10.1136/jcp.51.11.798; Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Reiter RE, 2001, CONT CANC RES, P163; Richardson GD, 2004, J CELL SCI, V117, P3539, DOI 10.1242/jcs.01222; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; Tai MH, 2005, CARCINOGENESIS, V26, P495, DOI 10.1093/carcin/bgh321; Tang SH, 2002, J BIOL CHEM, V277, P16189, DOI 10.1074/jbc.M111936200; Tran CP, 2002, MOL CANCER RES, V1, P113; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; van Bokhoven A, 2003, PROSTATE, V57, P205, DOI 10.1002/pros.10290; van Leenders G, 2000, LAB INVEST, V80, P1251, DOI 10.1038/labinvest.3780133; Wang YZ, 2001, DIFFERENTIATION, V68, P270, DOI 10.1046/j.1432-0436.2001.680414.x; Yardy GW, 2005, PROSTATE CANCER P D, V8, P119, DOI 10.1038/sj.pcan.4500794	39	756	832	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1696	1708		10.1038/sj.onc.1209327	http://dx.doi.org/10.1038/sj.onc.1209327			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16449977				2022-12-28	WOS:000236013700002
J	Gordon, S; Akopyan, G; Garban, H; Bonavida, B				Gordon, S; Akopyan, G; Garban, H; Bonavida, B			Transcription factor YY1: structure, function, and therapeutic implications in cancer biology	ONCOGENE			English	Review						transcription suppression; transcription activation; gene expression regulation; DNA-binding proteins; epigenetic regulation; apoptosis; cell cycle	NF-KAPPA-B; INTERFERON-GAMMA PROMOTER; SERUM RESPONSE FACTOR; ZINC-FINGER PROTEIN; YIN YANG-1 YY1; GENE-EXPRESSION; NITRIC-OXIDE; CELL-CYCLE; NUCLEAR-FACTOR; C-MYC	The ubiquitous transcription factor Yin Yang 1 (YY1) is known to have a fundamental role in normal biologic processes such as embryogenesis, differentiation, replication, and cellular proliferation. YY1 exerts its effects on genes involved in these processes via its ability to initiate, activate, or repress transcription depending upon the context in which it binds. Mechanisms of action include direct activation or repression, indirect activation or repression via cofactor recruitment, or activation or repression by disruption of binding sites or conformational DNA changes. YY1 activity is regulated by transcription factors and cytoplasmic proteins that have been shown to abrogate or completely inhibit YY1-mediated activation or repression; however, these mechanisms have not yet been fully elucidated. Since expression and function of YY1 are known to be intimately associated with progression through phases of the cell cycle, the physiologic significance of YY1 activity has recently been applied to models of tumor biology. The majority of the data are consistent with the hypothesis that YY1 overexpression and/or activation is associated with unchecked cellular proliferation, resistance to apoptotic stimuli, tumorigenesis and metastatic potential. Studies involving hemato-poetic tumors, epithelial-based tumors, endocrine organ malignancies, hepatocellular carcinoma, and retinoblastoma support this hypothesis. Molecular mechanisms that have been investigated include YY1-mediated downregulation of p53 activity, interference with poly-ADP-ribose polymerase, alteration in c-myc and nuclear factor-kappa B (NF-kappa B) expression, regulation of death genes and gene products, and differential YY1 binding in the presence of inflammatory mediators. Further, recent findings implicate YY1 in the regulation of tumor cell resistance to chemotherapeutics and immune-mediated apoptotic stimuli. Taken together, these findings provide strong support of the hypothesis that YY1, in addition to its regulatory roles in normal biologic processes, may possess the potential to act as an initiator of tumorigenesis and may thus serve as both a diagnostic and prognostic tumor marker; furthermore, it may provide an effective target for antitumor chemotherapy and/or immunotherapy.	Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Surg, Div Transplantat, Transplant Ctr, Los Angeles, CA USA; Univ Calif Los Angeles, Div Surg Oncol, Dept Surg, Los Angeles, CA USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, David Geffen Sch Med, Los Angeles, CA USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Bonavida, B (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, 10833 Conte Ave,A2-060 CHS, Los Angeles, CA 90095 USA.	bbonavida@mednet.ucla.edu		Garban, Hermes/0000-0001-7754-5357	NATIONAL CENTER FOR RESEARCH RESOURCES [K12RR017611] Funding Source: NIH RePORTER; NCRR NIH HHS [K12RR017611] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Amati Bruno, 1998, Frontiers in Bioscience, V3, pD250; Austen M, 1998, ONCOGENE, V17, P511, DOI 10.1038/sj.onc.1201968; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Beier UH, 2005, INT J CANCER, V115, P6, DOI 10.1002/ijc.20851; BERNS KI, 1987, ADV VIRUS RES, V32, P243, DOI 10.1016/S0065-3527(08)60479-0; Brankin B, 1998, CANCER EPIDEM BIOMAR, V7, P1109; Chan YJ, 1996, J VIROL, V70, P8590, DOI 10.1128/JVI.70.12.8590-8605.1996; CHANG LS, 1989, J VIROL, V63, P3479, DOI 10.1128/JVI.63.8.3479-3488.1989; Chen RF, 2005, WORLD J GASTROENTERO, V11, P726, DOI 10.3748/wjg.v11.i5.726; CHEN S, 1992, J VIROL, V66, P4304, DOI 10.1128/JVI.66.7.4304-4314.1992; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; Cicatiello L, 2004, MOL CELL BIOL, V24, P7260, DOI 10.1128/MCB.24.16.7260-7274.2004; DONG XP, 1994, INT J CANCER, V58, P803, DOI 10.1002/ijc.2910580609; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; Garban HJ, 2001, J IMMUNOL, V167, P75, DOI 10.4049/jimmunol.167.1.75; Gronroos E, 2004, P NATL ACAD SCI USA, V101, P12165, DOI 10.1073/pnas.0402283101; Guo B, 1997, BIOCHEMISTRY-US, V36, P14447, DOI 10.1021/bi971781s; GUO B, 1995, P NATL ACAD SCI USA, V92, P10526, DOI 10.1073/pnas.92.23.10526; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; He GC, 2002, MOL CELL BIOL, V22, P2965, DOI 10.1128/MCB.22.9.2965-2973.2002; Hilbi H, 1997, INFECT IMMUN, V65, P5165, DOI 10.1128/IAI.65.12.5165-5170.1997; Hiromura M, 2003, J BIOL CHEM, V278, P14046, DOI 10.1074/jbc.M300789200; HONGO F, 2004, P AACR WASH DC, V45; Houbaviy HB, 1996, P NATL ACAD SCI USA, V93, P13577, DOI 10.1073/pnas.93.24.13577; Huang NE, 2003, BIOCHEM BIOPH RES CO, V306, P267, DOI 10.1016/S0006-291X(03)00966-5; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Huerta-Yepez S, 2004, ONCOGENE, V23, P4993, DOI 10.1038/sj.onc.1207655; HUERTAYEPEZ S, 2005, P AACR AN CA, V46; Jazirehi AR, 2005, CANCER RES, V65, P264; Kano A, 1997, J BIOCHEM-TOKYO, V121, P677; Kappes F, 2004, MOL CELL BIOL, V24, P6011, DOI 10.1128/MCB.24.13.6011-6020.2004; Karantzoulis-Fegaras F, 1999, J BIOL CHEM, V274, P3076, DOI 10.1074/jbc.274.5.3076; Kim JS, 1996, NUCLEIC ACIDS RES, V24, P4341, DOI 10.1093/nar/24.21.4341; Kurisaki K, 2003, MOL CELL BIOL, V23, P4494, DOI 10.1128/MCB.23.13.4494-4510.2003; LASTER SM, 1988, J IMMUNOL, V141, P2629; Lee HY, 1998, ONCOGENE, V16, P3039, DOI 10.1038/sj.onc.1201843; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Lee KH, 2004, DEVELOPMENT, V131, P4709, DOI 10.1242/dev.01344; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; Li CQ, 2004, CANCER RES, V64, P3022, DOI 10.1158/0008-5472.CAN-03-1880; Lichy JH, 1996, NUCLEIC ACIDS RES, V24, P4700, DOI 10.1093/nar/24.23.4700; LU SY, 1994, MOL CELL BIOL, V14, P6253, DOI 10.1128/MCB.14.9.6253; Luo JL, 2004, CANCER CELL, V6, P297, DOI 10.1016/j.ccr.2004.08.012; Martelli F, 1996, J VIROL, V70, P1433, DOI 10.1128/JVI.70.3.1433-1438.1996; MAY M, 1994, EMBO J, V13, P1460, DOI 10.1002/j.1460-2075.1994.tb06400.x; McNeil S, 1998, J CELL BIOCHEM, V68, P500, DOI 10.1002/(SICI)1097-4644(19980315)68:4<500::AID-JCB9>3.3.CO;2-T; Morgan MJ, 2004, J BIOL CHEM, V279, P46826, DOI 10.1074/jbc.M406140200; Nayak BK, 2002, ONCOGENE, V21, P7226, DOI 10.1038/sj.onc.1205889; Nayak BK, 1999, MOL BIOL REP, V26, P223, DOI 10.1023/A:1007006011253; Nguyen N, 2004, J BIOL CHEM, V279, P25927, DOI 10.1074/jbc.M402525200; Oei SL, 2001, BIOCHEM BIOPH RES CO, V285, P27, DOI 10.1006/bbrc.2001.5115; Oei SL, 2001, BIOCHEM BIOPH RES CO, V284, P450, DOI 10.1006/bbrc.2001.4985; Osborne A, 2001, MOL CELL BIOL, V21, P6495, DOI 10.1128/MCB.21.19.6495-6506.2001; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; Palko L, 2004, J CELL SCI, V117, P465, DOI 10.1242/jcs.00870; Parija T, 2003, MOL BIOL REP, V30, P41, DOI 10.1023/A:1022207630482; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; Patten M, 2000, J MOL CELL CARDIOL, V32, P1341, DOI 10.1006/jmcc.2000.1169; Petkova V, 2001, J BIOL CHEM, V276, P7932, DOI 10.1074/jbc.M007411200; Pilarsky C, 2004, NEOPLASIA, V6, P744, DOI 10.1593/neo.04277; PISANESCHI G, 1994, BIOCHEM BIOPH RES CO, V205, P1236, DOI 10.1006/bbrc.1994.2797; Rahman KMW, 2005, CANCER RES, V65, P364; RAUGHT B, 1994, MOL CELL BIOL, V14, P1752, DOI 10.1128/MCB.14.3.1752; Reed WP, 2004, SURG ENDOSC, V18, P11, DOI 10.1007/s00464-003-8913-3; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Sagoo P, 2004, INVEST OPHTH VIS SCI, V45, P3964, DOI 10.1167/iovs.04-0439; SATYAMOORTHY K, 1993, MOL CELL BIOL, V13, P6621, DOI 10.1128/MCB.13.11.6621; Seligson D, 2005, INT J ONCOL, V27, P131; Sepulveda MA, 2004, J IMMUNOL, V172, P1054, DOI 10.4049/jimmunol.172.2.1054; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; Sitwala KV, 2002, ONCOGENE, V21, P8862, DOI 10.1038/sj.onc.1206041; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Sweetser MT, 1998, J BIOL CHEM, V273, P34775, DOI 10.1074/jbc.273.52.34775; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; VEGA M, 2005, ONCOGENE; Vega MI, 2005, J IMMUNOL, V175, P2174, DOI 10.4049/jimmunol.175.4.2174; Walowitz JL, 1998, J BIOL CHEM, V273, P6656, DOI 10.1074/jbc.273.12.6656; Wang CY, 2004, J BIOL CHEM, V279, P17750, DOI 10.1074/jbc.M310532200; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; Wang ZX, 2001, BRIT J CANCER, V85, P1162, DOI 10.1054/bjoc.2001.2059; Weill L, 2003, J VIROL, V77, P2903, DOI 10.1128/JVI.77.5.2903-2914.2003; WIESCHAUS E, 1984, DEV BIOL, V104, P172, DOI 10.1016/0012-1606(84)90046-0; Wolf BB, 2002, CURR BIOL, V12, pR177, DOI 10.1016/S0960-9822(02)00736-4; Yakovleva T, 2004, BIOCHEM BIOPH RES CO, V318, P615, DOI 10.1016/j.bbrc.2004.04.065; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yao YL, 1998, NUCLEIC ACIDS RES, V26, P3776, DOI 10.1093/nar/26.16.3776; YE JP, 1994, J BIOL CHEM, V269, P25728; Yengi L, 1996, CANCER RES, V56, P1974; Zhao RY, 2005, CELL RES, V15, P143, DOI 10.1038/sj.cr.7290279	95	538	561	2	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1125	1142		10.1038/sj.onc.1209080	http://dx.doi.org/10.1038/sj.onc.1209080			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16314846				2022-12-28	WOS:000235537500001
J	Cheng, JCH; Chou, CH; Kuo, ML; Hsieh, CY				Cheng, J. C-H; Chou, C. H.; Kuo, M. L.; Hsieh, C-Y			Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappa B signal transduction pathway	ONCOGENE			English	Article						radiation; hepatocellular carcinoma; invasion; signal transduction	INDUCED MATRIX-METALLOPROTEINASE-9 EXPRESSION; FACTOR-KAPPA-B; INDUCED INCREASE; GENE-EXPRESSION; DOWN-REGULATION; MELANOMA-CELLS; KINASE PATHWAY; CANCER; MIGRATION; RADIOTHERAPY	This study is to investigate the molecular mechanism of radiation-enhanced cell invasiveness of hepatocellular carcinoma (HCC) correlating with clinical patients undergoing radiotherapy and subsequently developing metastasis. Three HCC cell lines (HepG2, Hep3B and Huh7) and normal hepatocyte cell line (CL-48) were irradiated with different doses. The effect of radiation on cell invasiveness was determined using the Boyden chamber assay. Radiation-enhanced invasion capability was evident in HCC cells but not in normal hepatocytes. Invasion was observed in gelatin-coated but not fibronectin-coated or type I collagen-coated membranes. Radiation upregulated matrix metalloproteinase-9 (MMP-9) mRNA level, MMP-9 protein level and MMP-9 activity. MMP-9 antisense oligonucleotides inhibited radiation-induced MMP-9 expression and thereby significantly inhibited radiation-induced HCC invasion. Furthermore, phosphatidylinositol 3-kinase (PI3K)/Akt chemical inhibitors LY294002 and wortmannin suppressed radiation-induced MMP-9 mRNA expression. Transient transfection with dominant-negative Akt plasmid also showed that the PI3K/Akt-signaling pathway was involved in this radiation-induced MMP-9 expression. Moreover, nuclear factor-kappa B (NF-kappa B) decoy oligodeoxynucleotide suppressed radiation enhanced MMP-9 promoter activity completely. PI3K/Akt chemical inhibitors inhibited radiation-induced NF-kappa B-driven luciferase promoter activity. Taken together, our results indicated that sublethal dose of radiation could enhance HCC cell invasiveness by MMP-9 expression through the PI3K/Akt/NF-kappa B signal transduction pathway.	Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Oncol, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Hsieh, CY (corresponding author), Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, 7 Chung Shan S Rd, Taipei 100, Taiwan.	cheng38@ms15.hinet.net	Kuo, Min-Liang/C-4872-2009	KUO, MIN-LIANG/0000-0002-7139-0144; CHENG, JASON CHIA-HSIEN/0000-0002-2007-0220				Agarwal A, 2005, ONCOGENE, V24, P1021, DOI 10.1038/sj.onc.1208296; Aguayo A, 2001, SEMIN ONCOL, V28, P503, DOI 10.1053/sonc.2001.26953; Akimoto T, 1998, INT J RADIAT ONCOL, V41, P1171, DOI 10.1016/S0360-3016(98)00176-X; Amin ARMR, 2003, GENES CELLS, V8, P515, DOI 10.1046/j.1365-2443.2003.00652.x; Camphausen K, 2001, CANCER RES, V61, P2207; Cheng JCH, 2001, INT J CANCER, V96, P243, DOI 10.1002/ijc.1022; Chung TW, 2004, FASEB J, V18, P1123, DOI 10.1096/fj.03-1429fje; Criswell T, 2003, ONCOGENE, V22, P5813, DOI 10.1038/sj.onc.1206680; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; FU KK, 1991, HEMATOL ONCOL CLIN N, V5, P737, DOI 10.1016/S0889-8588(18)30413-1; Hegedus B, 2004, J NEURO-ONCOL, V67, P147, DOI 10.1023/B:NEON.0000021826.73020.f3; Huang SC, 2005, BIOCHEM PHARMACOL, V69, P221, DOI 10.1016/j.bcp.2004.09.019; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Kuyvenhoven JP, 2003, THROMB HAEMOSTASIS, V89, P718, DOI 10.1055/s-0037-1613578; Liang SX, 2005, CANCER-AM CANCER SOC, V103, P2181, DOI 10.1002/cncr.21012; London CA, 2003, CANCER GENE THER, V10, P823, DOI 10.1038/sj.cgt.7700642; Moon SK, 2004, J CELL PHYSIOL, V198, P417, DOI 10.1002/jcp.10435; Murawaki Y, 2000, RES COMMUN MOL PATH, V108, P351; Nakashio A, 2002, INT J CANCER, V98, P36, DOI 10.1002/ijc.10166; Nirmala C, 2000, INT J CANCER, V88, P766, DOI 10.1002/1097-0215(20001201)88:5<766::AID-IJC13>3.0.CO;2-Y; O-Charoenrat P, 2004, INT J CANCER, V111, P174, DOI 10.1002/ijc.20228; ONODA JM, 1992, RADIAT RES, V130, P281, DOI 10.2307/3578372; Qian LW, 2002, CLIN CANCER RES, V8, P1223; SATO H, 1993, ONCOGENE, V8, P395; Steinle JJ, 2002, J BIOL CHEM, V277, P43830, DOI 10.1074/jbc.M207221200; Sugioka Y, 2004, INT J CANCER, V109, P867, DOI 10.1002/ijc.20095; Susskind H, 2003, INT J RADIAT ONCOL, V56, P1161, DOI 10.1016/S0360-3016(03)00161-5; Thant AA, 2001, CLIN EXP METASTAS, V18, P423, DOI 10.1023/A:1010921730952; Wang JL, 2000, MOL CARCINOGEN, V27, P252, DOI 10.1002/(SICI)1098-2744(200004)27:4<252::AID-MC2>3.0.CO;2-3; Wei LH, 2005, ONCOGENE, V24, P390, DOI 10.1038/sj.onc.1208192; Wild-Bode C, 2001, CANCER RES, V61, P2744; Woo JH, 2003, CANCER RES, V63, P3430; Yao JHS, 2004, CIRC RES, V95, P364, DOI 10.1161/01.RES.0000138581.04174.2f; Zijlstra A, 2002, CANCER RES, V62, P7083	34	264	280	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2006	25	53					7009	7018		10.1038/sj.onc.1209706	http://dx.doi.org/10.1038/sj.onc.1209706			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16732316				2022-12-28	WOS:000241910500001
J	Baillat, D; Leprivier, G; Regnier, D; Vintonenko, N; Begue, A; Stehelin, D; Aumercier, M				Baillat, D.; Leprivier, G.; Regnier, D.; Vintonenko, N.; Begue, A.; Stehelin, D.; Aumercier, M.			Stromelysin-1 expression is activated in vivo by Ets-1 through palindromic head-to-head Ets binding sites present in the promoter	ONCOGENE			English	Article						Ets-1; MMP-3; gene regulation; synovial fibroblasts cell transcription	TRANSCRIPTION FACTOR EXPRESSION; MATRIX-METALLOPROTEINASE GENES; DNA-BINDING; RHEUMATOID-ARTHRITIS; ANGIOGENESIS; FUMAGILLIN; PROTEIN; ELEMENTS; RAS; INHIBITION	Regulation of the gene expression of Stromelysin-1 (matrix metalloproteinase-3), a member of the matrix metalloproteinase family, is critical for tissue homeostasis. The Stromelysin-1 promoter is known to be transactivated by Ets proteins through palindromic head-to-head Ets binding sites (EBS), an unusual configuration among metalloproteinase promoters. Patterns of increased co-expression of Stromelysin-1 and Ets-1 genes have been observed in pathological processes such as rheumatoid arthritis, glomerulonephritis and tumor invasion. In this context, we show in a synovial fibroblastic model cell line (HIG-82), which is able to co-express Stromelysin-1 and Ets-1, that the EBS palindrome is essential for the expression of Stromelysin-1. More precisely, using electrophoretic mobility shift assays, DNA affinity purification and chromatin immunoprecipitation, we demonstrate that endogenous Ets-1, but not Ets-2, is present on this palindrome. The use of a dominant-negative form of Ets-1 and the decrease of Ets-1 amount either by fumagillin, an antiangiogenic compound, or by short interfering RNA show that the activation rate of the promoter and the expression of Stromelysin-1 correlate with the level of endogenous Ets-1. Thus, it is the first demonstration, using this cellular model, that endogenously expressed Ets-1 is actually a main activator of the Stromelysin-1 promoter through its effective binding to the EBS palindrome.	Univ Lille 2, Inst Biol Lille, UMR 8526, Inst Pasteur Lille,CNRS, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Aumercier, M (corresponding author), Univ Lille 2, Inst Biol Lille, UMR 8526, Inst Pasteur Lille,CNRS, 1 Rue Prof Calmette,BP 447, F-59021 Lille, France.	marc.aumercier@ibl.fr		Aumercier, Marc/0000-0002-0370-3452				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Baillat D, 2002, J BIOL CHEM, V277, P29386, DOI 10.1074/jbc.M200088200; Barrett JM, 2002, BREAST CANCER RES TR, V72, P227, DOI 10.1023/A:1014993006190; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; Bernier SG, 2004, P NATL ACAD SCI USA, V101, P10768, DOI 10.1073/pnas.0404105101; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Calmels TPG, 1995, BIOL CELL, V84, P53, DOI 10.1016/0248-4900(96)81318-9; Catalano A, 2001, AM J PATHOL, V159, P721, DOI 10.1016/S0002-9440(10)61743-9; CHEN JH, 1990, ONCOGENE RES, V5, P277; Chen YF, 2005, DNA CELL BIOL, V24, P126, DOI 10.1089/dna.2005.24.126; Constantin A, 2002, ARTHRITIS RHEUM, V46, P1754, DOI 10.1002/art.10336; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; Datta B, 2004, BIOCHEMISTRY-US, V43, P14821, DOI 10.1021/bi049172p; DITTMER J, 1998, BIOCHIM BIOPHYS ACTA, V1377, P1; FRISCH SM, 1987, P NATL ACAD SCI USA, V84, P2600, DOI 10.1073/pnas.84.9.2600; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gaire M, 1996, MOL CARCINOGEN, V15, P124, DOI 10.1002/(SICI)1098-2744(199602)15:2<124::AID-MC5>3.0.CO;2-J; GALANG CK, 1994, ONCOGENE, V9, P2913; GEORGESCU HI, 1988, IN VITRO CELL DEV B, V24, P1015; Ghilardi G, 2002, CLIN CANCER RES, V8, P3820; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Hodge DR, 1996, ONCOGENE, V12, P11; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Kirstein M, 1996, J BIOL CHEM, V271, P18231, DOI 10.1074/jbc.271.30.18231; Kria L, 1998, CURR EYE RES, V17, P986, DOI 10.1076/ceyr.17.10.986.5245; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin CW, 1996, EXP CELL RES, V223, P117, DOI 10.1006/excr.1996.0064; Lowther WT, 2000, BBA-PROTEIN STRUCT M, V1477, P157, DOI 10.1016/S0167-4838(99)00271-X; MAJERUS MA, 1992, NUCLEIC ACIDS RES, V20, P2699, DOI 10.1093/nar/20.11.2699; MALEMUD CJ, 1999, FRONT BIOSCI, V4, P762; Man AK, 2003, MOL CELL BIOL, V23, P8614, DOI 10.1128/MCB.23.23.8614-8625.2003; Maroulakou IG, 2000, ONCOGENE, V19, P6432, DOI 10.1038/sj.onc.1204039; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; Mukherjee T, 2003, J CANCER RES CLIN, V129, P430, DOI 10.1007/s00432-003-0457-3; Naito T, 2000, J AM SOC NEPHROL, V11, P2243, DOI 10.1681/ASN.V11122243; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Ozaki I, 2003, HEPATOL RES, V27, P288, DOI 10.1016/S1386-6346(03)00268-7; Paumelle R, 2002, ONCOGENE, V21, P2309, DOI 10.1038/sj.onc.1205297; Pufall MA, 2005, SCIENCE, V309, P142, DOI 10.1126/science.1111915; Pufall MA, 2002, ANNU REV CELL DEV BI, V18, P421, DOI 10.1146/annurev.cellbio.18.031502.133614; QUINONES S, 1994, BIOCHEM J, V302, P471, DOI 10.1042/bj3020471; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Redlich K, 2001, ARTHRITIS RHEUM, V44, P266, DOI 10.1002/1529-0131(200102)44:2<266::AID-ANR43>3.3.CO;2-7; Rekdal C, 2000, J BIOL CHEM, V275, P40288, DOI 10.1074/jbc.M006978200; Rodriguez-Nieto S, 2001, ANTICANCER RES, V21, P3457; Rothhammer T, 2004, CELL MOL LIFE SCI, V61, P118, DOI 10.1007/s00018-003-3337-8; Sato Y, 2000, ADV EXP MED BIOL, V476, P109; Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099; Singh S, 2002, CURR DRUG TARGETS, V3, P359, DOI 10.2174/1389450023347489; Span PN, 2002, ONCOGENE, V21, P8506, DOI 10.1038/sj.onc.1206040; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Sternlicht MD, 1999, GUIDEBOOK EXTRACELLU, P505; Sun HB, 2001, BONE, V28, P303, DOI 10.1016/S8756-3282(00)00454-3; Terashima M, 1999, CIRCULATION, V99, P2717, DOI 10.1161/01.CIR.99.21.2717; Tokuhara K, 2003, INT SURG, V88, P25; Trojanowska M, 2000, ONCOGENE, V19, P6464, DOI 10.1038/sj.onc.1204043; Vetter M, 2005, ONCOGENE, V24, P650, DOI 10.1038/sj.onc.1208234; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; Wang JY, 2000, J CELL BIOCHEM, V77, P465, DOI 10.1002/(SICI)1097-4644(20000601)77:3<465::AID-JCB11>3.3.CO;2-D; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; Wernert N, 1999, ANGEW CHEM INT EDIT, V38, P3228, DOI 10.1002/(SICI)1521-3773(19991102)38:21<3228::AID-ANIE3228>3.0.CO;2-8; WERNERT N, 1994, CANCER RES, V54, P5683; Yamamoto H, 1998, GENE DEV, V12, P1315, DOI 10.1101/gad.12.9.1315; Yang BS, 1996, MOL CELL BIOL, V16, P538; Ye S, 1999, FEBS LETT, V450, P268, DOI 10.1016/S0014-5793(99)00509-8; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P6427, DOI 10.1073/pnas.97.12.6427; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	72	23	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2006	25	42					5764	5776		10.1038/sj.onc.1209583	http://dx.doi.org/10.1038/sj.onc.1209583			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16652151				2022-12-28	WOS:000240765800007
J	Hirohashi, Y; Wang, Q; Liu, Q; Du, X; Zhang, H; Sato, N; Greene, MI				Hirohashi, Y.; Wang, Q.; Liu, Q.; Du, X.; Zhang, H.; Sato, N.; Greene, M. I.			p78/MCRS1 forms a complex with centrosomal protein Nde1 and is essential for cell viability	ONCOGENE			English	Article						centrosome; cancer; mitosis; spindle; microtubule	GAMMA-TUBULIN; CYTOPLASMIC DYNEIN; TRANSFORMING ACTIVITY; CANCER PROGRESSION; MITOTIC SPINDLE; LIVING CELLS; RING COMPLEX; FHA DOMAIN; DYNAMICS; DEFECTS	The centrosome, an organelle that functions as the major microtubule-organizing center, plays an essential role in the formation of the mitotic spindle and guiding accurate chromosome segregation. Centrosome aberrations are frequently associated with various forms of human cancers and it is thought that defects in this organelle contribute to genomic instability and malignant transformation. We recently identified and characterized a centrosome-localized protein complex that is comprised of Su48 and Nde1. Disruption of the normal function of these proteins leads to abnormal cell division. To extend our understanding of how this protein complex operates, we sought to identify Nde1-interacting molecules by the yeast two-hybrid screening method. Here, we demonstrate that both Nde1 and Su48 can associate with p78/MCRS1, a protein implicated in cancer development. We found that, whereas the majority of p78 localizes to the nucleus as reported in earlier studies, a fraction of the p78 protein can be detected in the centrosome. Moreover, we determined that a region containing the forkhead-associated domain of p78 is involved in association with Nde1 and Su48, as well as in centrosomal localization. We also provide evidence that the association between p78 and Nde1 is regulated by phosphorylation on Nde1. Furthermore, abrogation of the endogenous p78 function by small interfering RNA knockdown causes cell death and a modest delay in mitosis. These results indicate that a subset of the p78 proteins comprises a component of the centrosome and that p78 is essential for cell viability.	Univ Penn, Dept Pathol & Lab Med, Sch Med, Philadelphia, PA 19104 USA; Sapporo Med Univ, Sch Med, Dept Pathol, Chuo Ku, Sapporo, Hokkaido, Japan	University of Pennsylvania; Sapporo Medical University	Greene, MI (corresponding author), Univ Penn, Dept Pathol & Lab Med, Sch Med, 252 John Morgan Bldg,36th Hamilton Walk, Philadelphia, PA 19104 USA.	greene@reo.med.upenn.edu	Hirohashi, Yoshihiko/AFQ-4227-2022; Wang, Qiang/N-7310-2015	Wang, Qiang/0000-0001-9409-0251; Zhang, Hongtao/0000-0001-9173-0049				Bader AG, 2001, ONCOGENE, V20, P7524, DOI 10.1038/sj.onc.1204938; Bruni R, 1998, J VIROL, V72, P8525, DOI 10.1128/JVI.72.11.8525-8531.1998; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Durocher D, 2002, FEBS LETT, V513, P58, DOI 10.1016/S0014-5793(01)03294-X; Efimov VP, 2000, J CELL BIOL, V150, P681, DOI 10.1083/jcb.150.3.681; ENGEL E, 1969, NATURE, V223, P152, DOI 10.1038/223152a0; ENGEL E, 1969, J CELL SCI, V5, P93; Faulkner NE, 2000, NAT CELL BIOL, V2, P784, DOI 10.1038/35041020; Feng YY, 2004, NEURON, V44, P279, DOI 10.1016/j.neuron.2004.09.023; Feng YY, 2000, NEURON, V28, P665, DOI 10.1016/S0896-6273(00)00145-8; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; Howell BJ, 2004, CURR BIOL, V14, P953, DOI 10.1016/j.cub.2004.05.053; Lin DY, 2002, J BIOL CHEM, V277, P25446, DOI 10.1074/jbc.M200633200; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Moritz M, 1998, J CELL BIOL, V142, P775, DOI 10.1083/jcb.142.3.775; MORITZ M, 1995, NATURE, V378, P638, DOI 10.1038/378638a0; Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Okumura K, 2005, P NATL ACAD SCI USA, V102, P2703, DOI 10.1073/pnas.0409370102; Paluh JL, 2000, MOL BIOL CELL, V11, P1225, DOI 10.1091/mbc.11.4.1225; Pihan GA, 2001, CANCER RES, V61, P2212; Pihan GA, 1998, CANCER RES, V58, P3974; Prigozhina NL, 2004, MOL BIOL CELL, V15, P1374, DOI 10.1091/mbc.E03-06-0405; Quintyne NJ, 2005, SCIENCE, V307, P127, DOI 10.1126/science.1104905; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; Sasaki S, 2000, NEURON, V28, P681, DOI 10.1016/S0896-6273(00)00146-X; Sato N, 1999, CLIN CANCER RES, V5, P963; Schnackenberg BJ, 1998, P NATL ACAD SCI USA, V95, P9295, DOI 10.1073/pnas.95.16.9295; Shono M, 2001, LAB INVEST, V81, P945, DOI 10.1038/labinvest.3780306; Song H, 2004, BIOCHEM BIOPH RES CO, V316, P1116, DOI 10.1016/j.bbrc.2004.02.166; Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004; Strome S, 2001, MOL BIOL CELL, V12, P1751, DOI 10.1091/mbc.12.6.1751; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Wang Q, 2004, DNA CELL BIOL, V23, P475, DOI 10.1089/1044549041562276; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Yan XM, 2003, MOL CELL BIOL, V23, P1239, DOI 10.1128/MCB.23.4.1239-1250.2003; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	39	29	29	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2006	25	35					4937	4946		10.1038/sj.onc.1209500	http://dx.doi.org/10.1038/sj.onc.1209500			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16547491				2022-12-28	WOS:000239687100011
J	Aguilera, O; Fraga, MF; Ballestar, E; Paz, MF; Herranz, M; Espada, J; Garcia, JM; Munoz, A; Esteller, M; Gonzalez-Sancho, JM				Aguilera, O.; Fraga, M. F.; Ballestar, E.; Paz, M. F.; Herranz, M.; Espada, J.; Garcia, J. M.; Munoz, A.; Esteller, M.; Gonzalez-Sancho, J. M.			Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer	ONCOGENE			English	Article						DICKKOPF-1; Wnt; promoter methylation; colorectal cancer	BETA-CATENIN/TCF; TUMOR-SUPPRESSOR; DNA METHYLATION; MECHANISM; PROTEINS; HYPERMETHYLATION; INHIBITION; TARGET; MODEL	Colorectal cancer is a major cause of cancer death worldwide. A number of key oncogenes and tumor suppressor genes have been proposed to drive progression from healthy colonic epithelia to malignant tumors, including members of the Wnt/beta-catenin pathway. Recently, CpG island promoter hypermethylation was shown to cause inactivation of two extracellular Wnt inhibitors in colon cancer: secreted frizzled-related proteins (sFRPs) and Wnt inhibitory factor-1 (WIF-1). Here, we show for the first time that another extracellular Wnt inhibitor, the DICKKOPF-1 (DKK-1) gene, is transcriptionally silenced by CpG island promoter hypermethylation in colon cancercell lines (n = 9), whereas treatment with the DNA-demethylating agent 5-aza-2-deoxycytidine restored DKK-1 expression. Restoration of DKK-1 function in non-expressing cells bearing a truncated APC (Adenomatous Polyposis Coli) gene had no effect on beta-catenin/T-cell factor-dependent transcription, but induced tumor suppressor-like features such as reduced colony formation density and tumor growth inhibition in nude mice. These results suggest additional functions for DKK-1 other than inhibiting canonical Wnt signaling. In primary colorectal tumors, DKK-1 was found hypermethylated in 17% (nine of 54) of cases. Furthermore, while for both SFRP-1 and WIF-1 methylation- associated silencing occurred across the whole spectrum of colorectal tumorigenesis, DKK-1 promoter was selectively hypermethylated in advanced colorectal neoplasms (Duke's C and D tumors).	Spanish Natl Canc Ctr, CNIO, Canc Epigenet Lab, Mol Pathol Programme, Madrid 28029, Spain; Univ Autonoma Madrid, CSIC, Fac Med, Inst Invest Biomed Alberto Sols, Madrid, Spain; Univ Autonoma Madrid, CSIC, Fac Med, Dept Bioquim, Madrid, Spain; Hosp Univ Puerta Hierro, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Hospital Puerta de Hierro-Majadahonda	Esteller, M (corresponding author), Spanish Natl Canc Ctr, CNIO, Canc Epigenet Lab, Mol Pathol Programme, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	mesteller@cnio.es	Gonzalez-Sancho, Jose/AAA-6010-2019; Fraga, Mario F/H-7824-2017; Munoz, Alberto/O-6393-2014; Ballestar, Esteban/ABG-8561-2020; Herranz, Michel/L-2561-2016; Espada, Jesús/AAA-3198-2019; Esteller, Manel/L-5956-2014	Gonzalez-Sancho, Jose/0000-0001-5875-1964; Fraga, Mario F/0000-0001-8450-2603; Munoz, Alberto/0000-0003-3890-4251; Espada, Jesús/0000-0002-4202-4938; Esteller, Manel/0000-0003-4490-6093; Ballestar, Esteban/0000-0002-1400-2440				Alaminos M, 2005, CANCER RES, V65, P2565, DOI 10.1158/0008-5472.CAN-04-4283; Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Ballestar E, 2002, CARCINOGENESIS, V23, P1103, DOI 10.1093/carcin/23.7.1103; Chamorro MN, 2005, EMBO J, V24, P73, DOI 10.1038/sj.emboj.7600460; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Fraga MF, 2004, CANCER RES, V64, P5527, DOI 10.1158/0008-5472.CAN-03-4061; Gonzalex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; He BA, 2005, ONCOGENE, V24, P3054, DOI 10.1038/sj.onc.1208511; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Lee AY, 2004, BIOCHEM BIOPH RES CO, V323, P1246, DOI 10.1016/j.bbrc.2004.09.001; Maeda K, 2003, ONCOL REP, V10, P935; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389; Mikheev AM, 2004, CARCINOGENESIS, V25, P47, DOI 10.1093/carcin/bgg190; Miller JR, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2001-3-1-reviews3001; Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Ries LAG, 2003, ONCOLOGIST, V8, P541; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Zou HZ, 2002, CLIN CANCER RES, V8, P188	30	273	294	0	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2006	25	29					4116	4121		10.1038/sj.onc.1209439	http://dx.doi.org/10.1038/sj.onc.1209439			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16491118				2022-12-28	WOS:000238802400012
J	Ferraro, D; Corso, S; Fasano, E; Panieri, E; Santangelo, R; Borrello, S; Giordano, S; Pani, G; Galeotti, T				Ferraro, D.; Corso, S.; Fasano, E.; Panieri, E.; Santangelo, R.; Borrello, S.; Giordano, S.; Pani, G.; Galeotti, T.			Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS)	ONCOGENE			English	Article						signal transduction; c-Met; reactive oxygen species; metastasis; Rac-1	PROTEIN-TYROSINE-PHOSPHATASE; GROWTH-FACTOR RECEPTOR; REDOX REGULATION; CELL-ADHESION; SUPEROXIDE-DISMUTASE; SCATTER-FACTOR; KINASE; RHO; ACTIVATION; INACTIVATION	Overexpression of the c-Met/hepatocyte growth factor receptor( HGF-R) proto-oncogene and abnormal generation of intracellular oxygen species ( reactive oxygen species ( ROS)) have been linked, by independent lines of evidence, to cell transformation and to malignant growth. By comparing two subpopulations of the B16 mouse melanoma ( B16-F0 and B16-F10) endowed with different lung metastasis capacities ( low and high, respectively) we found that both the expression/phosphorylation of c-Met and the steady-state levels of ROS positively correlated with metastatic growth. shRNA-mediated downregulation of c-Met in F10 cells led to a parallel decrease in the generation of oxygen species and in metastatic capacity, suggesting that oxidants may mediate the pro-metastatic activity of the HGF receptor. c-Met activation by a ligand elicits the formation of oxidant species through the oxidase-coupled small GTPase Rac-1, a relevant downstream target of the HGF-R. Moreover, cell treatment with the catalytic ROS scavengers EUK-134 and EUK-189 attenuates Met signaling to ERKs and inhibits the anchorage-independent growth of F10 cells, consistent with a critical role for oxygen species in HGF signaling and in aggressive cell behavior. Finally, genetic manipulation of the Rac-ROS cascade at different levels demonstrated its crucial role in the pro-metastatic activity of c- Met in vivo. Thus, we have outlined a novel cascade triggered by c- Met and mediated by ROS, linked to metastasis and potentially targetable by new antimetastatic, redox-based therapies.	Catholic Univ, Sch Med, Inst Gen Pathol, I-00168 Rome, Italy; Univ Turin, Sch Med, Inst Canc Res & Treatment, Div Mol Oncol,IRCC, Turin, Italy; Catholic Univ, Sch Med, Inst Microbiol, Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Pani, G (corresponding author), Catholic Univ, Sch Med, Inst Gen Pathol, Largo F Vito 1 Largo A Gemelli 1, I-00168 Rome, Italy.	gpani@rm.unicatt.it	Santangelo, Rosaria/AAL-1213-2020; Giordano, Silvia/J-9858-2018; Panieri, Emiliano/AAB-9028-2021; Pani, Giovambattista/AAB-1446-2019	Giordano, Silvia/0000-0003-1854-1086; Panieri, Emiliano/0000-0001-7989-7145; Pani, Giovambattista/0000-0001-7133-8728; Santangelo, Rosaria/0000-0002-8056-218X; CORSO, Simona/0000-0002-5069-1503				Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bedogni B, 2003, J BIOL CHEM, V278, P16510, DOI 10.1074/jbc.M301089200; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bouzahzah B, 2001, MOL MED, V7, P816, DOI 10.1007/BF03401974; Caplan JF, 2004, J BIOL CHEM, V279, P7740, DOI 10.1074/jbc.M313049200; Chiarugi P, 2003, J CELL BIOL, V161, P933, DOI 10.1083/jcb.200211118; Chiarugi P, 2001, J BIOL CHEM, V276, P33478, DOI 10.1074/jbc.M102302200; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Colavitti R, 2002, J BIOL CHEM, V277, P3101, DOI 10.1074/jbc.M107711200; Comoglio PM, 2001, SEMIN CANCER BIOL, V11, P153, DOI 10.1006/scbi.2000.0366; Comoglio PM, 2003, CURR OPIN CELL BIOL, V15, P565, DOI 10.1016/S0955-0674(03)00096-6; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Corso S, 2005, TRENDS MOL MED, V11, P284, DOI 10.1016/j.molmed.2005.04.005; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; FIDLER IJ, 1975, CANCER RES, V35, P218; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; FIDLER IJ, 1976, JNCI-J NATL CANCER I, V57, P1199, DOI 10.1093/jnci/57.5.1199; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Fischer OM, 2004, J BIOL CHEM, V279, P28970, DOI 10.1074/jbc.M402508200; Fu XW, 2000, P NATL ACAD SCI USA, V97, P4374, DOI 10.1073/pnas.97.8.4374; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Liu RG, 2001, ONCOGENE, V20, P1486, DOI 10.1038/sj.onc.1204214; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Pani G, 2000, J BIOL CHEM, V275, P38891, DOI 10.1074/jbc.M007319200; PONZETTO C, 1991, ONCOGENE, V6, P553; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Rhee S G, 2000, Sci STKE, V2000, ppe1; Ridley A, 2000, NATURE, V406, P466, DOI 10.1038/35020170; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Rong YQ, 1999, P NATL ACAD SCI USA, V96, P9897, DOI 10.1073/pnas.96.17.9897; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; RUSCIANO D, 1995, ONCOGENE, V11, P1979; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Shinomiya N, 2004, CANCER RES, V64, P7962, DOI 10.1158/0008-5472.CAN-04-1043; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Terman JR, 2002, CELL, V109, P887, DOI 10.1016/S0092-8674(02)00794-8; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Ventura A., 2002, SCI STKE, V2002, pPE44; Villa-Moruzzi E, 1998, BIOCHEM J, V336, P235, DOI 10.1042/bj3360235; Wells A, 2000, ADV CANCER RES, V78, P31; Werner E, 2002, J CELL BIOL, V158, P357, DOI 10.1083/jcb.200111028; Xu D, 2002, DEV CELL, V2, P251, DOI 10.1016/S1534-5807(02)00132-6; Zeng QH, 2002, J BIOL CHEM, V277, P25203, DOI 10.1074/jbc.M201598200; ZHU DZ, 1991, P NATL ACAD SCI USA, V88, P9568, DOI 10.1073/pnas.88.21.9568	53	103	107	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3689	3698		10.1038/sj.onc.1209409	http://dx.doi.org/10.1038/sj.onc.1209409			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16462764				2022-12-28	WOS:000238448300008
J	Sasaki, M; Sugimoto, K; Tamayose, K; Ando, M; Tanaka, Y; Oshimi, K				Sasaki, M.; Sugimoto, K.; Tamayose, K.; Ando, M.; Tanaka, Y.; Oshimi, K.			Spindle checkpoint protein Bub1 corrects mitotic aberrancy induced by human T-cell leukemia virus type I Tax	ONCOGENE			English	Article						spindle checkpoint; chromosomal instability; Bub1; Tax; mitotic lobulation	MUTATION ANALYSIS; CANCER; GENE; LYMPHOMA; HBUB1; TRANSFORMATION; LOCALIZATION; ONCOPROTEIN; MICRONUCLEI; EXPRESSION	Bub1 is a component of the mitotic spindle checkpoint apparatus. Abnormality of this apparatus is known to cause multinuclei formation, a hallmark of chromosomal instability ( CIN). A549, aneuploid cell line, aberrantly passed through the mitotic phase and became multinuclei morphology in the presence of nocodazole. Time-lapse videomicroscopy showed unreported bizarre morphology, which we named 'mitotic lobulation' in A549 cells just before the exit from mitosis and multinuclei formation. External expression of wild-type Bub1-EGFP clearly suppressed the multinuclei formation by retaining A549 cells at the mitotic phase during 48 h of time-lapse observation. This suppressive effect on mitotic aberrancy should not be mere restoration of normal Bub1 function, because A549 cells express proper amount of Bub1, which distributed cytoplasm during interphase and concentrated at kinetochore in metaphase. Furthermore, external expression of wild-type Bub1-EGFP suppressed multinuclei formation induced by Tax both in A549 and HeLa cells. Tax is known to induce mitotic abnormality by binding and inactivating Mad1. These observations, therefore, suggest functional redundancy between Bub1 and other mitotic checkpoint protein( s) and a possibility of correction of mitotic aberrancy by external Bub1 expression.	Juntendo Univ, Sch Med, Dept Internal Med, Div Hematol,Bunkyo Ku, Tokyo 1138421, Japan; Univ Ryukyus, Grad Sch Med, Dept Immunol, Nishihara, Okinawa, Japan	Juntendo University; University of the Ryukyus	Sugimoto, K (corresponding author), Juntendo Univ, Sch Med, Dept Internal Med, Div Hematol,Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	ksugimot@med.juntendo.ac.jp	Pillay, Nischalan/F-9536-2012					Bahar R, 2002, J BIOL CHEM, V277, P40012, DOI 10.1074/jbc.M205345200; Burton M, 2000, J VIROL, V74, P2351, DOI 10.1128/JVI.74.5.2351-2364.2000; Cahill DP, 1999, GENOMICS, V58, P181, DOI 10.1006/geno.1999.5831; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen JG, 2002, CANCER RES, V62, P1935; Hempen PM, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9120; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Isaka T, 2003, J HISTOCHEM CYTOCHEM, V51, P1343, DOI 10.1177/002215540305101011; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; KAMADA N, 1992, CANCER RES, V52, P1481; KIKUCHI M, 1986, HEMATOL ONCOL, V4, P67, DOI 10.1002/hon.2900040109; Knecht H, 1996, ONCOGENE, V13, P947; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Ohshima K, 2000, CANCER LETT, V158, P141, DOI 10.1016/S0304-3835(00)00512-7; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Ru HY, 2002, ONCOGENE, V21, P4673, DOI 10.1038/sj.onc.1205585; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; Shimura M, 1999, FASEB J, V13, P621, DOI 10.1096/fasebj.13.6.621; TAGUCHI H, 1993, CANCER, V71, P133, DOI 10.1002/1097-0142(19930101)71:1<133::AID-CNCR2820710121>3.0.CO;2-G; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TANAKA Y, 1990, JPN J CANCER RES, V81, P225, DOI 10.1111/j.1349-7006.1990.tb02554.x; Tashiro S, 1996, ONCOGENE, V12, P2165; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; Yamaguchi K, 1999, CANCER LETT, V139, P183, DOI 10.1016/S0304-3835(99)00035-X; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4	33	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3621	3627		10.1038/sj.onc.1209404	http://dx.doi.org/10.1038/sj.onc.1209404			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16449967				2022-12-28	WOS:000238448300001
J	Sridhar, SC; Miranti, CK				Sridhar, SC; Miranti, CK			Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases	ONCOGENE			English	Review						tetraspanin; integrin; c-Met; HGF; metastasis	HEPATOCYTE GROWTH-FACTOR; PROSTATE-CANCER CELLS; FOCAL ADHESION KINASE; FREQUENT DOWN-REGULATION; METASTASIS-SUPPRESSOR; TRANSMEMBRANE-4 SUPERFAMILY; GENE-EXPRESSION; EGF RECEPTOR; LUNG-CANCER; ALPHA-6-BETA-4 INTEGRIN	KAI1/CD82, a tetraspanin protein, was. first identified as a metastasis suppressor in prostate cancer. How loss of CD82 expression promotes cancer metastasis is unknown. Restoration of CD82 expression to physiological levels in the metastatic prostate cell line PC3 inhibits integrinmediated cell migration and invasion, but does not affect integrin expression. Integrin-dependent activation of the receptor kinase c-Met is dramatically reduced in CD82expressing cells, as is c-Met activation by its ligand HGF/SF. CD82 expression also reduced integrin-induced activation and phosphorylation of the cytoplasmic tyrosine kinase Src, and its downstream substrates p130Cas and FAK Y861. Inhibition of c-Met expression or Src kinase function reduced matrigel invasion of PC3 cells to the same extent as CD82 expression. These data indicate that CD82 functions to suppress integrin-induced invasion by regulating signaling to c-Met and Src kinases, and suggests that CD82 loss may promote metastasis by removing a negative regulator of c-Met and Src signaling.	Van Andel Res Inst, Lab Integrin Signaling & Tumorigenesis, Grand Rapids, MI 49503 USA	Van Andel Institute	Miranti, CK (corresponding author), Van Andel Res Inst, Lab Integrin Signaling & Tumorigenesis, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA.	cindy.miranti@vai.org	Miranti, Cindy/AAJ-3783-2020					Adachi M, 1996, CANCER RES, V56, P1751; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Berditchevski F, 2001, J CELL SCI, V114, P4143; Bill HM, 2004, MOL CELL BIOL, V24, P8586, DOI 10.1128/MCB.24.19.8586-8599.2004; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Birchmeier W, 1997, CIBA F SYMP, V212, P230; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Bouchard P, 2001, ORG DIVERS EVOL, V1, P17, DOI 10.1078/1439-6092-00003; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Brader S, 2004, TUMORI J, V90, P2, DOI 10.1177/030089160409000102; Brunton VG, 2005, CANCER RES, V65, P1335, DOI 10.1158/0008-5472.CAN-04-1949; Cannon KS, 2001, EMBO J, V20, P2443, DOI 10.1093/emboj/20.10.2443; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Chung J, 2004, J BIOL CHEM, V279, P32287, DOI 10.1074/jbc.M403809200; Clezardin P, 1998, CELL MOL LIFE SCI, V54, P541, DOI 10.1007/s000180050182; Danilkovitch-Miagkova A, 2000, J BIOL CHEM, V275, P14783, DOI 10.1074/jbc.C000028200; Davies G, 2004, PROSTATE, V60, P317, DOI 10.1002/pros.20068; Davis TL, 2001, PROSTATE, V46, P240; De Miguel MP, 1999, CYTOKINE, V11, P722, DOI 10.1006/cyto.1998.0443; Di Lorenzo D, 2002, ENDOCRINOLOGY, V143, P4544, DOI 10.1210/en.2002-220448; Dong Jin-Tang, 1997, Current Opinion in Oncology, V9, P101; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Dong JT, 1996, CANCER RES, V56, P4387; FIXMAN ED, 1995, ONCOGENE, V10, P237; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Guo XZ, 1996, CANCER RES, V56, P4876; Hammond C, 1998, J IMMUNOL, V161, P3282; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; Hay RV, 2003, CLIN CANCER RES, V9, p3839S; He B, 2005, J BIOL CHEM, V280, P3346, DOI 10.1074/jbc.M406680200; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002-9440(10)65639-8; HUMPHREY PA, 1995, AM J PATHOL, V147, P386; IMAI T, 1995, J IMMUNOL, V155, P1229; Jee B, 2003, EXP MOL MED, V35, P30, DOI 10.1038/emm.2003.5; Kim SJ, 2003, CLIN CANCER RES, V9, P5161; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Knudsen BS, 2004, ADV CANCER RES, V91, P31, DOI 10.1016/S0065-230X(04)91002-0; Knudsen BS, 2002, UROLOGY, V60, P1113, DOI 10.1016/S0090-4295(02)01954-4; Lagaudriere-Gesbert C, 1998, EUR J IMMUNOL, V28, P4332, DOI 10.1002/(SICI)1521-4141(199812)28:12<4332::AID-IMMU4332>3.0.CO;2-8; Lee CC, 2004, ONCOGENE, V23, P5193, DOI 10.1038/sj.onc.1207646; Lee JH, 2004, CANCER RES, V64, P4235, DOI 10.1158/0008-5472.CAN-04-0275; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Liu FS, 2000, GYNECOL ONCOL, V78, P10, DOI 10.1006/gyno.2000.5801; Liu FS, 2001, AM J PATHOL, V159, P1629, DOI 10.1016/S0002-9440(10)63009-X; Liu L, 2003, WORLD J GASTROENTERO, V9, P1231, DOI 10.3748/wjg.v9.i6.1231; Lombardi DP, 1999, CANCER RES, V59, P5724; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Maggiora P, 1997, J CELL PHYSIOL, V173, P183, DOI 10.1002/(SICI)1097-4652(199711)173:2<183::AID-JCP18>3.3.CO;2-Y; Mannion BA, 1996, J IMMUNOL, V157, P2039; MAYGARDEN SJ, 1992, ARCH PATHOL LAB MED, V116, P269; Miranti CK, 2002, METHOD CELL BIOL, V69, P359, DOI 10.1016/S0091-679X(02)69023-5; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Miyazaki T, 2000, CANCER-AM CANCER SOC, V89, P955, DOI 10.1002/1097-0142(20000901)89:5<955::AID-CNCR3>3.0.CO;2-Z; Mora LB, 2002, CANCER RES, V62, P6659; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Nakaigawa N, 2000, ONCOGENE, V19, P2996, DOI 10.1038/sj.onc.1203628; Nakashiro K, 2003, ONCOL REP, V10, P1149; Nishimura K, 1999, PROSTATE, V41, P145; Nishimura K, 1998, Int J Urol, V5, P276, DOI 10.1111/j.1442-2042.1998.tb00603.x; Odintsova E, 2000, CURR BIOL, V10, P1009, DOI 10.1016/S0960-9822(00)00652-7; Odintsova E, 2003, J CELL SCI, V116, P4557, DOI 10.1242/jcs.00793; Ono M, 2000, BIOCHEM BIOPH RES CO, V279, P744, DOI 10.1006/bbrc.2000.4030; Owens DM, 2001, CANCER RES, V61, P5248; Perlino E, 2000, AM J PATHOL, V157, P1727, DOI 10.1016/S0002-9440(10)64809-2; PISTERS LL, 1995, J UROLOGY, V154, P293, DOI 10.1016/S0022-5347(01)67297-5; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RADFORD KJ, 1995, INT J CANCER, V62, P631, DOI 10.1002/ijc.2910620523; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; Schmelz M, 2002, NEOPLASIA, V4, P243, DOI 10.1038/sj.neo.7900223; Schoenfeld N, 2004, FASEB J, V18, P158, DOI 10.1096/fj.03-0420fje; Shinomiya N, 2004, CANCER RES, V64, P7962, DOI 10.1158/0008-5472.CAN-04-1043; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Skacel M, 2001, HUM PATHOL, V32, P1392, DOI 10.1053/hupa.2001.29676; SRIDHAR SC, 2005, IN PRESS; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; Takaoka A, 1998, ONCOGENE, V16, P1443, DOI 10.1038/sj.onc.1201648; Tamura M, 1999, JNCI-J NATL CANCER I, V91, P1820, DOI 10.1093/jnci/91.21.1820; Testa JE, 1999, CANCER RES, V59, P3812; Timpson P, 2001, CURR BIOL, V11, P1836, DOI 10.1016/S0960-9822(01)00583-8; Tokuhara T, 2001, CLIN CANCER RES, V7, P4109; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Uchida S, 1999, BRIT J CANCER, V79, P1168, DOI 10.1038/sj.bjc.6690186; van Leenders G, 2002, PROSTATE, V51, P98, DOI 10.1002/pros.10073; Vogt AB, 2002, IMMUNOL REV, V189, P136, DOI 10.1034/j.1600-065X.2002.18912.x; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wang R, 1996, P NATL ACAD SCI USA, V93, P8425, DOI 10.1073/pnas.93.16.8425; Wang R, 2001, J CELL BIOL, V153, P1023, DOI 10.1083/jcb.153.5.1023; Westhoff MA, 2004, MOL CELL BIOL, V24, P8113, DOI 10.1128/MCB.24.18.8113-8133.2004; White A, 1998, ONCOGENE, V16, P3143, DOI 10.1038/sj.onc.1201852; Wu De-hua, 2003, Di Yi Jun Yi Da Xue Xue Bao, V23, P714; Yu Y, 1997, CLIN CANCER RES, V3, P1045; Yunta M, 2003, CELL SIGNAL, V15, P559, DOI 10.1016/S0898-6568(02)00147-X; Zhang XA, 2003, CANCER RES, V63, P2665; Zhang XA, 2003, J BIOL CHEM, V278, P27319, DOI 10.1074/jbc.M303039200; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200	102	130	140	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2367	2378		10.1038/sj.onc.1209269	http://dx.doi.org/10.1038/sj.onc.1209269			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16331263				2022-12-28	WOS:000236764300009
J	Rubio, MF; Werbajh, S; Cafferata, EGA; Quaglino, A; Colo, GP; Nojek, IM; Kordon, EC; Nahmod, VE; Costas, MA				Rubio, MF; Werbajh, S; Cafferata, EGA; Quaglino, A; Colo, GP; Nojek, IM; Kordon, EC; Nahmod, VE; Costas, MA			TNF-alpha enhances estrogen-induced cell proliferation of estrogen-dependent breast tumor cells through a complex containing nuclear factor-kappa B	ONCOGENE			English	Article						NF-kB; nuclear receptor coactivators; breast tumor; TNF-alpha; estrogen receptor	CYCLIN D1 EXPRESSION; CANCER CELLS; CROSS-TALK; RECEPTOR; ACTIVATION; GROWTH; AIB1; PROGRESSION; INDUCTION; MECHANISM	Breast tumors are usually classified according to their response to estrogens as hormone-dependent or -independent. In this work, we investigated the role of the proinflammatory cytokine TNF-alpha on the estrogen-receptor-positive T47D breast ductal tumor cells. We have found that TNF-alpha exerts a mitogenic effect, inducing cyclin D1 expression and activation of the transcription factor NF-kappa B. Importantly, activation of NF-kappa B was required for estrogen-induced proliferation and cyclin D1 expression. TNF-alpha enhanced the estrogen response by increasing the levels and availability of NF-kappa B. Chromatin immunoprecipitation analysis suggested that the action of estrogens is mediated by a protein complex that contains the activated estrogen receptor, the nuclear receptor coactivator RAC3 and a member of the NF-kappa B family. Finally, our results demonstrate that activation of this transcription factor could be one of the key signals for estrogen-mediated response.	Univ Buenos Aires, CONICET, IDIM, Dept Sustancias Vasoact,Fac Med,Lab Biol Mol & Ap, Buenos Aires, DF, Argentina; FIL, ANLIS, Ctr Genet Med, Buenos Aires, DF, Argentina; Consejo Nacl Invest Cient & Tecn, Div Med, Inst Invest Hematol, Acad Nacl Med, Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Buenos Aires National Academy of Medicine; IIHEMA - Instituto de Investigaciones Hematologicas; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Costas, MA (corresponding author), Univ Buenos Aires, CONICET, IDIM, Dept Sustancias Vasoact,Fac Med,Lab Biol Mol & Ap, Combatients Malvinas 3150, Buenos Aires, DF, Argentina.	mcostas@lanari.fmed.uba.ar		Costas, Monica/0000-0002-4773-3389; Cafferata, Eduardo G/0000-0001-5089-3757				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Biswas DK, 2001, P NATL ACAD SCI USA, V98, P10386, DOI 10.1073/pnas.151257998; Cafferata EGA, 2001, J BIOL CHEM, V276, P15441, DOI 10.1074/jbc.M010061200; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; Chen F, 2001, AM J PATHOL, V159, P387, DOI 10.1016/S0002-9440(10)61708-7; Chouchane L, 1997, CANCER, V80, P1489, DOI 10.1002/(SICI)1097-0142(19971015)80:8<1489::AID-CNCR17>3.0.CO;2-1; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Costas M, 1996, J CLIN INVEST, V98, P1409, DOI 10.1172/JCI118928; Costas MA, 2000, BBA-MOL CELL RES, V1499, P122, DOI 10.1016/S0167-4889(00)00113-0; Evans MJ, 2001, CIRC RES, V89, P823, DOI 10.1161/hh2101.098543; Franco D, 2002, CELL DEATH DIFFER, V9, P1090, DOI 10.1038/sj.cdd.4401074; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hamelers IHL, 2003, ENDOCR-RELAT CANCER, V10, P331, DOI 10.1677/erc.0.0100331; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hinz M, 1999, MOL CELL BIOL, V19, P2690; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hsu SM, 2000, BIOCHEM BIOPH RES CO, V279, P47, DOI 10.1006/bbrc.2000.3891; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; Kato S, 2000, GENES CELLS, V5, P593, DOI 10.1046/j.1365-2443.2000.00354.x; Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; List HJ, 2001, J BIOL CHEM, V276, P23763, DOI 10.1074/jbc.M102397200; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; MORA JF, 2000, MOL CELL BIOL, V20, P5041; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; PARTANEN R, 1995, OCCUP ENVIRON MED, V52, P316, DOI 10.1136/oem.52.5.316; Planas-Silva MD, 2001, CANCER RES, V61, P3858; Pratt MAC, 2003, MOL CELL BIOL, V23, P6887, DOI 10.1128/MCB.23.19.6887-6900.2003; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Speir E, 2000, CIRC RES, V87, P1006, DOI 10.1161/01.RES.87.11.1006; Tsai EM, 2001, CANCER RES, V61, P8390; Valentine JE, 2000, J BIOL CHEM, V275, P25322, DOI 10.1074/jbc.M002497200; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Werbajh S, 2000, FEBS LETT, V485, P195, DOI 10.1016/S0014-5793(00)02223-7; Westerheide SD, 2001, MOL CELL BIOL, V21, P8428, DOI 10.1128/MCB.21.24.8428-8436.2001; Wu RC, 2002, MOL CELL BIOL, V22, P3549, DOI 10.1128/MCB.22.10.3549-3561.2002; Zornig M., 2001, BIOCHIM BIOPHYS ACTA, V1551, P1; ZYAD A, 1994, CANCER RES, V54, P825	50	75	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1367	1377		10.1038/sj.onc.1209176	http://dx.doi.org/10.1038/sj.onc.1209176			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16331275				2022-12-28	WOS:000235708200010
J	Chen, SY; Cai, C; Fisher, CJ; Zheng, Z; Omwancha, J; Hsieh, CL; Shemshedini, L				Chen, S-Y; Cai, C.; Fisher, C. J.; Zheng, Z.; Omwancha, J.; Hsieh, C-L; Shemshedini, L.			c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation	ONCOGENE			English	Article						androgen receptor; c-Jun; coactivation proliferation	TRANSCRIPTIONAL ACTIVITY; RESPONSE ELEMENT; SERINE-PROTEASE; AMINO-TERMINUS; TMPRSS2 GENE; EXPRESSION; PROGRESSION; ACTIVATION; LNCAP; DIMERIZATION	Androgens and the androgen receptor (AR) are involved in the growth and progression of prostate cancer. Our previous studies suggest that the proto-oncoprotein c-Jun is an AR coactivator that stimulates AR transactivation by mediating receptor dimerization and subsequent DNA binding. To study the physiological relevance of this c-Jun activity on AR, we have generated stable LNCaP cell lines expressing different levels of c-Jun. These cell lines exhibit a direct correlation between endogenous c-Jun levels and AR transcriptional activity and expression of endogenous androgen-regulated genes. Disruption by antisense RNA of endogenous c-Jun expression in LNCaP cells strongly compromises the androgen-dependent proliferation of these cells. In contrast, expression of a c-Jun mutant, which is fully active in coactivation of AR but deficient in AP-1 transactivation, significantly enhances androgen-dependent proliferation. This. nding indicates that the coactivation function of c-Jun is sufficient for regulating androgen-induced growth of LNCaP cells. c-Jun also enhances AR transactivtion in androgen-independent LNCaP cells, which closely mimic hormone-refractory prostate cancer cells in gene expression and growth behavior. Importantly, siRNA-mediated repression of endogenous c-Jun expression results in markedly reduced growth of these cells, strongly suggesting an important biological role for c-Jun in hormone-efractory prostate cancer.	Univ Toledo, Dept Sci Biol, Toledo, OH 43603 USA	University System of Ohio; University of Toledo	Shemshedini, L (corresponding author), Univ Toledo, Dept Sci Biol, 2801,W Bancroft Ave, Toledo, OH 43603 USA.	lshemsh@utnet.utoledo.edu	CHEN, Shaoyong/ABF-3357-2021; Cai, Changmeng/AAE-6835-2020	Cai, Changmeng/0000-0002-8701-2586				Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; Acevedo ML, 2004, ESSAYS BIOCHEM, V40, P73, DOI 10.1042/bse0400073; Ameyar M, 2003, BIOCHIMIE, V85, P747, DOI 10.1016/j.biochi.2003.09.006; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Arnold JT, 2002, ENDOCR-RELAT CANCER, V9, P61, DOI 10.1677/erc.0.0090061; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Belandia B, 2005, MOL CELL BIOL, V25, P1425, DOI 10.1128/MCB.25.4.1425-1436.2005; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Bubulya A, 2001, J BIOL CHEM, V276, P44704, DOI 10.1074/jbc.M107346200; Bubulya A, 1996, J BIOL CHEM, V271, P24583, DOI 10.1074/jbc.271.40.24583; Bubulya A, 2000, ENDOCRINE, V13, P55, DOI 10.1385/ENDO:13:1:55; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Culig Z, 2000, MICROSC RES TECHNIQ, V51, P447; Culig Z, 2004, J STEROID BIOCHEM, V92, P265, DOI 10.1016/j.jsbmb.2004.10.003; Debes JD, 2002, CANCER RES, V62, P5632; Dotzlaw H, 2002, MOL ENDOCRINOL, V16, P661, DOI 10.1210/me.16.4.661; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; GLEAVE ME, 1992, CANCER RES, V52, P1598; Gross M, 2004, ONCOGENE, V23, P3059, DOI 10.1038/sj.onc.1207443; Haelens A, 2003, BIOCHEM J, V369, P141, DOI 10.1042/BJ20020912; Han GZ, 2005, P NATL ACAD SCI USA, V102, P1151, DOI 10.1073/pnas.0408925102; Heisler LE, 1997, MOL CELL ENDOCRINOL, V126, P59, DOI 10.1016/S0303-7207(96)03970-6; Henttu P, 1998, BIOCHEM BIOPH RES CO, V244, P167, DOI 10.1006/bbrc.1998.8238; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Isaacs JT, 1999, UROL CLIN N AM, V26, P263, DOI 10.1016/S0094-0143(05)70066-5; Jenster G, 1999, SEMIN ONCOL, V26, P407; Korkmaz CG, 2004, J ENDOCRINOL, V182, P377, DOI 10.1677/joe.0.1820377; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LEE C, 1995, ENDOCRINOLOGY, V136, P796, DOI 10.1210/en.136.2.796; Lin BY, 1999, CANCER RES, V59, P4180; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; Linja MJ, 2004, J STEROID BIOCHEM, V92, P255, DOI 10.1016/j.jsbmb.2004.10.012; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; MURTHA P, 1993, BIOCHEMISTRY-US, V32, P6459, DOI 10.1021/bi00076a020; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; PaoloniGiacobino A, 1997, GENOMICS, V44, P309, DOI 10.1006/geno.1997.4845; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Salas TR, 2004, J BIOL CHEM, V279, P19191, DOI 10.1074/jbc.M309560200; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHUURMANS ALG, 1988, PROSTATE, V12, P55, DOI 10.1002/pros.2990120108; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; Shenk JL, 2001, J BIOL CHEM, V276, P38472, DOI 10.1074/jbc.M103652200; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Song LN, 2004, MOL ENDOCRINOL, V18, P70, DOI 10.1210/me.2003-0189; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Tillman K, 1998, ENDOCRINE, V9, P193, DOI 10.1385/ENDO:9:2:193; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Vaarala MH, 2001, INT J CANCER, V94, P705, DOI 10.1002/ijc.1526; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Wise SC, 1998, ONCOGENE, V16, P2001, DOI 10.1038/sj.onc.1201697; Yeap BB, 1999, ENDOCRINOLOGY, V140, P3282, DOI 10.1210/en.140.7.3282; Zheng Z, 2006, J BIOL CHEM, V281, P4002, DOI 10.1074/jbc.M509260200; Zhou HJ, 2005, CANCER RES, V65, P7976, DOI 10.1158/0008-5472.CAN-04-4076	60	51	52	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	54					7212	7223		10.1038/sj.onc.1209705	http://dx.doi.org/10.1038/sj.onc.1209705			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16732317				2022-12-28	WOS:000242046900010
J	Shimazu, T; Komatsu, Y; Nakayama, KI; Fukazawa, H; Horinouchi, S; Yoshida, M				Shimazu, T.; Komatsu, Y.; Nakayama, K. I.; Fukazawa, H.; Horinouchi, S.; Yoshida, M.			Regulation of SV40 large T-antigen stability by reversible acetylation	ONCOGENE			English	Article						SV40 T-Ag; acetylation; TSA; HDAC	ANCHORAGE-INDEPENDENT GROWTH; HISTONE DEACETYLASE; DNA-REPLICATION; TRICHOSTATIN-A; IN-VIVO; P53; PHOSPHORYLATION; SIMIAN-VIRUS-40; PROTEIN; P300	Reversible acetylation on protein lysine residues has been shown to regulate the function of both nuclear proteins such as histones and p53 and cytoplasmic proteins such as alpha-tubulin. To identify novel acetylated proteins, we purified several proteins by the affinity to an anti-acetylated-lysine antibody from cells treated with trichostatin A (TSA). Among the proteins identified, here we report acetylation of the SV40 large T antigen (T-Ag). The acetylation site was determined to be lysine-697, which is located adjacent to the C-terminal Cdc4 phosphodegron (CPD). Overexpression of the CBP acetyltransferase acetylated T-Ag, whereas HDAC1, HDAC3 and SIRT1 bound and deacetylated T-Ag. The acetylation and deacetylation occurred independently of p53, a binding partner of T-Ag, but the acetylation was enhanced in the presence of p53. T-Ag in the cells treated with TSA and NA or the acetylation mimic mutant (K697Q) became unstable in COS-7 cells, suggesting that acetylation regulates stability of T-Ag. Indeed, NIH3T3 cells stably expressing K697Q showed decreased anchorage-independent growth compared with those expressing wild type or the K697R mutant. These results demonstrate that acetylation destabilizes T-Ag and regulates the transforming activity of T-Ag in NIH3T3 cells.	RIKEN, Chem Genet Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo, Japan; Adv Life Sci Inst Inc, Wako, Saitama, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Fukuoka 812, Japan; Natl Inst Infect Dis, Dept Bioact Mol, Shinjuku Ku, Tokyo, Japan	RIKEN; University of Tokyo; Kyushu University; National Institute of Infectious Diseases (NIID)	Yoshida, M (corresponding author), RIKEN, Chem Genet Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	yoshidam@riken.jp	SHIMAZU, Tadahiro/ABC-3950-2020; Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674; Komatsu, Yasuhiko/0000-0003-1739-8222				Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; Caron C, 2003, BIOESSAYS, V25, P58, DOI 10.1002/bies.10202; Caron C, 2005, BIOESSAYS, V27, P408, DOI 10.1002/bies.20210; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Fukazawa H, 2004, MOL CANCER THER, V3, P1281; FUKAZAWA H, 1995, ANAL BIOCHEM, V228, P83, DOI 10.1006/abio.1995.1318; Furumai R, 2001, P NATL ACAD SCI USA, V98, P87, DOI 10.1073/pnas.011405598; Giandomenico V, 2003, MOL CELL BIOL, V23, P2587, DOI 10.1128/MCB.23.7.2587-2599.2003; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Komatsu Y, 2003, J IMMUNOL METHODS, V272, P161, DOI 10.1016/S0022-1759(02)00500-8; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; LEDUC C, 2006, IN PRESS ONCOGENE; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Muth V, 2001, EMBO J, V20, P1353, DOI 10.1093/emboj/20.6.1353; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Polesskaya A, 2000, J BIOL CHEM, V275, P34359, DOI 10.1074/jbc.M003815200; Poulin DL, 2004, J VIROL, V78, P8245, DOI 10.1128/JVI.78.15.8245-8253.2004; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; SPENCE SL, 1994, J VIROL, V68, P4227, DOI 10.1128/JVI.68.7.4227-4240.1994; STACY T, 1989, J VIROL, V63, P5208, DOI 10.1128/JVI.63.12.5208-5215.1989; Sullivan CS, 2002, MICROBIOL MOL BIOL R, V66, P179, DOI 10.1128/MMBR.66.2.179-202.2002; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Welcker M, 2005, J BIOL CHEM, V280, P7654, DOI 10.1074/jbc.M413377200; Xie AY, 2002, MOL CELL BIOL, V22, P7907, DOI 10.1128/MCB.22.22.7907-7918.2002; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	41	33	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	56					7391	7400		10.1038/sj.onc.1209731	http://dx.doi.org/10.1038/sj.onc.1209731			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16767160				2022-12-28	WOS:000242419100008
J	Doig, J; Anderson, C; Lawrence, NJ; Selfridge, J; Brownstein, DG; Melton, DW				Doig, J.; Anderson, C.; Lawrence, N. J.; Selfridge, J.; Brownstein, D. G.; Melton, D. W.			Mice with skin-specific DNA repair gene (Ercc1) inactivation are hypersensitive to ultraviolet irradiation-induced skin cancer and show more rapid actinic progression	ONCOGENE			English	Article						Ercc1; nucleotide; excision repair; skin cancer; ultraviolet irradiation	TRANSCRIPTION-COUPLED REPAIR; STEM-CELLS; HPRT GENE; DEFICIENCY; EXPRESSION; LACKING; TUMORS; CARCINOGENESIS; SUSCEPTIBILITY; DISRUPTION	Ercc1 has an essential role in the nucleotide excision repair (NER) pathway that protects against ultraviolet (UV)-induced DNA damage and is also involved in additional repair pathways. The premature death of simple Ercc1 mouse knockouts meant that we were unable to study the role of Ercc1 in the skin. To do this, we have used the Cre-lox system to generate a skin-specific Ercc1 knockout. With a Cre transgene under control of the bovine keratin 5 promoter we achieved 100% recombination of the Ercc1 gene in the epidermis. Hairless mice with Ercc1-deficient skin were hypersensitive to the short-term effects of UV irradiation, showing a very low minimal erythemal dose and a dramatic hyperproliferative response. Ultraviolet-irradiated mice with Ercc1-deficient skin developed epidermal skin tumours much more rapidly than controls. These tumours appeared to arise earlier in actinic progression and grew more rapidly than tumours on control mice. These responses are more pronounced than have been reported for other NER-deficient mice, demonstrating that Ercc1 has a keyrole in protecting against UV-induced skin cancer.	Univ Edinburgh, Western Gen Hosp, Sir Alastair Currie Canc Res UK Labs, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland; Royal Infirm Edinburgh NHS Trust, Dept Pathol, Edinburgh, Midlothian, Scotland; Univ Edinburgh, Queens Med Res Inst, Res Anim Pathol Core Lab, Edinburgh, Midlothian, Scotland	University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh	Melton, DW (corresponding author), Univ Edinburgh, Western Gen Hosp, Sir Alastair Currie Canc Res UK Labs, Mol Med Ctr, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	David.Melton@ed.ac.uk		SELFRIDGE, JIM/0000-0003-2473-4386				Berg RJW, 2000, CANCER RES, V60, P2858; Berg RJW, 1997, CANCER RES, V57, P581; CANFIELD PJ, 1988, PATHOLOGY, V20, P109, DOI 10.3109/00313028809066620; Chipchase MD, 2002, DNA REPAIR, V1, P335, DOI 10.1016/S1568-7864(02)00010-1; de Boer J, 1999, CANCER RES, V59, P3489; de Vries A, 1998, ONCOGENE, V16, P2205, DOI 10.1038/sj.onc.1201744; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; GALLAGHER CH, 1984, J INVEST DERMATOL, V83, P169, DOI 10.1111/1523-1747.ep12263512; Hsia KT, 2003, DEVELOPMENT, V130, P369, DOI 10.1242/dev.00221; Itoh T, 2004, P NATL ACAD SCI USA, V101, P2052, DOI 10.1073/pnas.0306551101; Kuhn Ralf, 2002, Methods Mol Biol, V180, P175; MAGIN TM, 1992, GENE, V122, P289, DOI 10.1016/0378-1119(92)90217-D; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/ng1193-217; MOORE RC, 1995, BIO-TECHNOL, V13, P999, DOI 10.1038/nbt0995-999; NAKANE H, 1995, NATURE, V377, P165, DOI 10.1038/377165a0; Nunez F, 2000, FASEB J, V14, P1073, DOI 10.1096/fasebj.14.9.1073; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; Ramirez A, 2004, GENESIS, V39, P52, DOI 10.1002/gene.20025; Remenyik E, 2003, ONCOGENE, V22, P6369, DOI 10.1038/sj.onc.1206657; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0; Selbert S, 1998, TRANSGENIC RES, V7, P387, DOI 10.1023/A:1008848304391; SELFRIDGE J, 1992, SOMAT CELL MOLEC GEN, V18, P325, DOI 10.1007/BF01235756; Selfridge J, 2001, NUCLEIC ACIDS RES, V29, P4541, DOI 10.1093/nar/29.22.4541; STACEY A, 1994, MOL CELL BIOL, V14, P1009, DOI 10.1128/MCB.14.2.1009; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; van Schanke A, 2005, J INVEST DERMATOL, V124, P241, DOI 10.1111/j.0022-202X.2004.23551.x; vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8	29	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2006	25	47					6229	6238		10.1038/sj.onc.1209642	http://dx.doi.org/10.1038/sj.onc.1209642			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	094CY	16682947				2022-12-28	WOS:000241218200001
J	Chapman, EJ; Hurst, CD; Pitt, E; Chambers, P; Aveyard, JS; Knowles, MA				Chapman, E. J.; Hurst, C. D.; Pitt, E.; Chambers, P.; Aveyard, J. S.; Knowles, M. A.			Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway	ONCOGENE			English	Article						urothelial; immortalisation; telomerase; p16; p53	HUMAN UROEPITHELIAL CELLS; REPLICATIVE LIFE-SPAN; BLADDER-CANCER; TELOMERASE ACTIVITY; CELLULAR SENESCENCE; ECTOPIC EXPRESSION; COPY NUMBER; 20Q GAIN; P53; PROLIFERATION	The CDKN2A locus is frequently inactivated in urothelial cell carcinoma (UCC), yet how this alteration contributes to bladder tumorigenesis is not known. Although most UCC express telomerase, inactivation of the p16/Rb pathway is generally required for in vitro immortalisation. This and the involvement of p16 in senescence of normal human urothelial cells (NHUC) suggest that CDKN2A deletion may aid bypass of senescence and allow immortalisation. CDKN2A encodes p16 and p14(ARF) and therefore inactivation of this locus can disrupt both the Rb and p53 tumour suppressor pathways. Retrovirus-mediated transduction was used to specifically modulate the p16/Rband/or p53 tumour suppressor pathways in NHUC and to express human telomerase reverse transcriptase (hTERT). Expression of hTERT bypassed Rb and p53 pathway-dependent barriers to proliferation and immortalised NHUC. TERT-NHUC had normal karyotypes, were non-tumorigenic and unexpectedly retained CDKN2A. Thus, the phenotypic significance of inactivation of CDKN2A in UCC may not be solely related to bypass of senescence. Phenotypic assays in human urothelial cells have relied on cell strains derived from invasive tumours or NHUC immortalised by expression of SV40-large T. The production of genetically normal but immortal NHUC lines now provides a valuable platform for experiments to examine the timing and combination of events necessary for UCC tumorigenesis.	St James Univ Hosp, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England; St James Univ Hosp, Canc Res UK Mutat Detect Facil, Leeds LS9 7TF, W Yorkshire, England	Cancer Research UK; Saint James's University Hospital; University of Leeds; Saint James's University Hospital	Knowles, MA (corresponding author), St James Univ Hosp, Canc Res UK Clin Ctr, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	margaret.knowles@cancer.org.uk	Chambers, Philip/AAK-8549-2020; Chapman, Emma/AAD-7425-2019	Chambers, Philip/0000-0002-0926-717X; Chapman, Emma/0000-0003-2859-2020; Knowles, Margaret/0000-0002-9363-8657				Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Aveyard JS, 2004, J MOL DIAGN, V6, P356, DOI 10.1016/S1525-1578(10)60532-6; Belair CD, 1997, P NATL ACAD SCI USA, V94, P13677, DOI 10.1073/pnas.94.25.13677; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bond J, 2004, EXP CELL RES, V292, P151, DOI 10.1016/j.yexcr.2003.09.021; Bond JA, 1999, MOL CELL BIOL, V19, P3103; Chapman EJ, 2005, CLIN CANCER RES, V11, P5740, DOI 10.1158/1078-0432.CCR-05-0411; Cote RJ, 1998, CANCER RES, V58, P1090; Counter CM, 1998, ONCOGENE, V16, P1217, DOI 10.1038/sj.onc.1201882; Cuthill S, 1999, GENE CHROMOSOME CANC, V26, P304, DOI 10.1002/(SICI)1098-2264(199912)26:4<304::AID-GCC4>3.0.CO;2-1; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Diggle CP, 2000, J LIPID RES, V41, P1509; Drayton S, 2002, CURR OPIN GENET DEV, V12, P98, DOI 10.1016/S0959-437X(01)00271-4; Elmore LW, 2002, J BIOL CHEM, V277, P35509, DOI 10.1074/jbc.M205477200; Esteller M, 2000, CANCER RES, V60, P129; Farwell DG, 2000, AM J PATHOL, V156, P1537, DOI 10.1016/S0002-9440(10)65025-0; Harada H, 2003, MOL CANCER RES, V1, P729; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; HUTTON KAR, 1993, J UROLOGY, V150, P721, DOI 10.1016/S0022-5347(17)35597-0; Knowles MA, 2001, J CLIN PATHOL-MOL PA, V54, P215, DOI 10.1136/mp.54.4.215; Lin M, 2004, BIOINFORMATICS, V20, P1233, DOI 10.1093/bioinformatics/bth069; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Markl IDC, 1998, CANCER RES, V58, P5348; Muntoni A, 2003, ONCOGENE, V22, P7804, DOI 10.1038/sj.onc.1207085; O'Hare MJ, 2001, P NATL ACAD SCI USA, V98, P646, DOI 10.1073/pnas.98.2.646; Puthenveettil JA, 1999, ADV EXP MED BIOL, V462, P83; Rahat MA, 1999, CANCER, V85, P919; Rahman R, 2005, ONCOGENE, V24, P1320, DOI 10.1038/sj.onc.1208232; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Reznikoff CA, 1996, CANCER RES, V56, P2886; Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157-5172.2002; Sarkar S, 2000, CANCER RES, V60, P3862; Savelieva E, 1997, ONCOGENE, V14, P551, DOI 10.1038/sj.onc.1200868; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Wootton M, 2003, HUM GENE THER, V14, P1473, DOI 10.1089/104303403769211682; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; YEAGER T, 1995, CANCER RES, V55, P493; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163	46	77	77	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					5037	5045		10.1038/sj.onc.1209513	http://dx.doi.org/10.1038/sj.onc.1209513			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16619045				2022-12-28	WOS:000239921300009
J	Kuphal, S; Lodermeyer, S; Bataille, F; Schuierer, M; Hoang, BH; Bosserhoff, AK				Kuphal, S.; Lodermeyer, S.; Bataille, F.; Schuierer, M.; Hoang, B. H.; Bosserhoff, A. K.			Expression of Dickkopf genes is strongly reduced in malignant melanoma	ONCOGENE			English	Article						Dickkopf; tumor-suppressor gene; Wnt signaling; malignant melanoma; cancer	BETA-CATENIN; BREAST-CARCINOMA; REPRESSOR SNAIL; CELL-LINES; INVASION; TARGET; GROWTH; CANCER; HYPERMETHYLATION; DIFFERENTIATION	The Dickkopf (DKK) genes were originally identified as factors inducing head formation in Xenopus. The genes code for inhibitors that are involved in Wnt signaling. We speculate that loss of DKK expression plays a role in development or progression of malignant melanoma. Thus, we evaluated melanoma cell lines and tissue samples of malignant melanoma for loss of DKK, especially DKK-3 transcription. We found that DKK-1, -2 and -3 were downregulated or lost in all cell lines and in most of the tumor samples analysed. Reduced DKK-3 expression occurred as early as in primary tumors detected by both immunohistochemical and reverse transcription-polymerase chain reaction RT-PCR analysis. Functional assays with stable DKK-3 transfected cell lines revealed that DKK-3 expression increased cell-cell adhesion and decreased cell migration. Further, downregulation of bronectin, snail-1 and re-expression of E-cadherin was found in the DKK-3 expressing cell clones supporting a role of DKK-3 in tumor progression. Our studies thus indicate that loss of DKK-3 expression may contribute to melanoma progression.	Univ Regensburg, Inst Pathol, D-93053 Regensburg, Germany; Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Dept Orthopaed Surg, Irvine, CA 92717 USA	University of Regensburg; University of California System; University of California Irvine	Bosserhoff, AK (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.	anja.bosserhoff@klinik.uni-regensburg.de	Kuphal, Silke/AAW-2702-2020; Bosserhoff, Anja/GNH-4801-2022	Bosserhoff, Anja/0000-0001-8147-394X				Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Behrmann I, 2003, AM J PATHOL, V163, P683, DOI 10.1016/S0002-9440(10)63695-4; Berking C, 2004, CANCER RES, V64, P807, DOI 10.1158/0008-5472.CAN-03-3438; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; De Langhe SP, 2005, DEV BIOL, V277, P316, DOI 10.1016/j.ydbio.2004.09.023; Gilles C, 1997, LAB INVEST, V76, P651; Gilles C, 2003, CANCER RES, V63, P2658; Gilles C, 2001, J CELL SCI, V114, P2967; Gilles C, 1997, CLIN EXP METASTAS, V15, P519, DOI 10.1023/A:1018427027270; Gonzalex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303; Haass NK, 2004, J MOL HISTOL, V35, P309; Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008-5472.CAN-03-1952; Hsieh SY, 2004, ONCOGENE, V23, P9183, DOI 10.1038/sj.onc.1208138; Jacob K, 1998, MELANOMA RES, V8, P211, DOI 10.1097/00008390-199806000-00003; Kobayashi K, 2002, GENE, V282, P151, DOI 10.1016/S0378-1119(01)00838-1; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Laux H, 2004, LAB INVEST, V84, P1372, DOI 10.1038/labinvest.3700158; Lee AY, 2004, BIOCHEM BIOPH RES CO, V323, P1246, DOI 10.1016/j.bbrc.2004.09.001; Li G, 2004, EXP CELL RES, V297, P142, DOI 10.1016/j.yexcr.2004.03.012; Monaghan AP, 1999, MECH DEVELOP, V87, P45, DOI 10.1016/S0925-4773(99)00138-0; Pham K, 2003, J CLIN PATHOL-MOL PA, V56, P280, DOI 10.1136/mp.56.5.280; Pla P, 2001, J CELL PHYSIOL, V189, P121, DOI 10.1002/jcp.10008; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Roman-Gomez J, 2004, BRIT J CANCER, V91, P707, DOI 10.1038/sj.bjc.6602008; Tester AM, 2001, CLIN EXP METASTAS, V18, P553, DOI 10.1023/A:1011953118186; Tsuji T, 2000, BIOCHEM BIOPH RES CO, V268, P20, DOI 10.1006/bbrc.1999.2067; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Yamaguchi Y, 2004, J CELL BIOL, V165, P275, DOI 10.1083/jcb.200311122; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; ZIEGLERHEITBROCK HWL, 1985, CANCER RES, V45, P1344	31	140	151	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					5027	5036		10.1038/sj.onc.1209508	http://dx.doi.org/10.1038/sj.onc.1209508			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568085				2022-12-28	WOS:000239921300008
J	Hartl, M; Karagiannidis, AI; Bister, K				Hartl, M.; Karagiannidis, A. I.; Bister, K.			Cooperative cell transformation by Myc/Mil(Raf) involves induction of AP-1 and activation of genes implicated in cell motility and metastasis	ONCOGENE			English	Article						activator protein-1; transcriptional control; gene regulation; osteopontin; target gene; cell transformation	OSTEOPONTIN EXPRESSION; DNA-BINDING; C-MYC; TRANSCRIPTION FACTOR; CHICKEN OSTEOPONTIN; STRUCTURAL-ANALYSIS; MELANOMA-CELLS; BREAST-CANCER; S100 PROTEINS; TARGET GENE	Avian fibroblasts transformed simultaneously by the v-myc and v-mil(raf) oncogenes of acute leukemia and carcinoma virus MH2 contain elevated levels of c-Fos and c-Jun, major components of the transcription factor complex AP-1. To de. ne specific transcriptional targets in these cells, subtractive hybridization techniques were employed leading to the identification of strongly upregulated genes including OPN (osteopontin), 126MRP, and rac2. OPN is a cytokine and cell attachment protein which has been implicated in human tumor progression and metastasis, the calcium binding 126MRP protein is related to the human S100 protein family involved in invasive cell growth, and the Rac2 protein belongs to the Rho family of small GTPases regulating actin reorganization and cell migration. Promoter analysis indicated that OPN activation is mediated by a non-consensus AP-1 binding site located close to the transcription start site. Electrophoretic mobility shift assays, chromatin immuno-precipitation and transcriptional reporter gene analyses showed that c-Fos and c-Jun bind specifically to this site and that c-Fos efficiently transactivates the OPN promoter. High-level expression of OPN, 126MRP, or Rac2 proteins from a retroviral vector led to partial cell transformation, documented by morphological changes and anchorage-independent growth. The specific activation in v-myc/v-mil(raf)-transformed cells of target genes with intrinsic oncogenic potential may provide an explanation for the longstanding observation that concomitant expression of these oncogenes leads to strongly enhanced oncogenicity in vivo and in vitro compared to cell transformation by v-myc or v-mil( raf) alone.	Univ Innsbruck, Inst Biochem, A-6020 Innsbruck, Austria; Univ Innsbruck, CMBI, A-6020 Innsbruck, Austria	University of Innsbruck; University of Innsbruck	Hartl, M (corresponding author), Univ Innsbruck, Inst Biochem, Peter Mayr Str 1A, A-6020 Innsbruck, Austria.	markus.hartl@uibk.ac.at	Bister, Klaus/AFA-9400-2022; Hartl, Markus/O-4655-2014	Hartl, Markus/0000-0001-7447-5920; Bister, Klaus/0000-0001-6545-5653	Austrian Science Fund FWF [P 18148, P 17041] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Bader AG, 2001, ONCOGENE, V20, P7524, DOI 10.1038/sj.onc.1204938; Bidder M, 2002, J BIOL CHEM, V277, P44485, DOI 10.1074/jbc.M206235200; BISTER K, 1986, ADV CANCER RES, V47, P99, DOI 10.1016/S0065-230X(08)60199-2; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CASTAGNOLA P, 1991, J BIOL CHEM, V266, P9944; Chamboredon S, 2003, ONCOGENE, V22, P4047, DOI 10.1038/sj.onc.1206713; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; Dang CV, 1999, MOL CELL BIOL, V19, P1; Denhardt DT, 2001, ANNU REV PHARMACOL, V41, P723, DOI 10.1146/annurev.pharmtox.41.1.723; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; DUESBERG PH, 1977, P NATL ACAD SCI USA, V74, P4320, DOI 10.1073/pnas.74.10.4320; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; El-Tanani M, 2004, J BIOL CHEM, V279, P20794, DOI 10.1074/jbc.M311131200; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hartl M, 1998, ONCOGENE, V17, P2901, DOI 10.1038/sj.onc.1202219; Hartl M, 2003, J MOL BIOL, V333, P33, DOI 10.1016/j.jmb.2003.08.018; Hartl M, 2001, P NATL ACAD SCI USA, V98, P13601, DOI 10.1073/pnas.241451198; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; JANSEN HW, 1983, J VIROL, V48, P61, DOI 10.1128/JVI.48.1.61-73.1983; JANSEN HW, 1983, EMBO J, V2, P1969, DOI 10.1002/j.1460-2075.1983.tb01686.x; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; Kurisu S, 2005, ONCOGENE, V24, P1309, DOI 10.1038/sj.onc.1208177; Kuykindoll RJ, 2000, J EXP BIOL, V203, P273; Lefevre G, 2003, ONCOGENE, V22, P8813, DOI 10.1038/sj.onc.1207099; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V322, P1111, DOI 10.1016/j.bbrc.2004.07.096; Merezak C, 2001, J VIROL, V75, P6977, DOI 10.1128/JVI.75.15.6977-6988.2001; Mi ZY, 2004, J BIOL CHEM, V279, P46659, DOI 10.1074/jbc.M407952200; Moye VE, 2004, BRIT J CANCER, V90, P1796, DOI 10.1038/sj.bjc.6601683; NAKANO T, 1992, ONCOGENE, V7, P527; PATSCHINSKY T, 1988, ONCOGENE, V3, P357; Polsky D, 2003, ONCOGENE, V22, P3087, DOI 10.1038/sj.onc.1206449; RAFIDI K, 1994, GENE, V140, P163, DOI 10.1016/0378-1119(94)90540-1; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; RAPP UR, 1994, ONCOGENE, V9, P3493; Rittling SR, 2004, BRIT J CANCER, V90, P1877, DOI 10.1038/sj.bjc.6601839; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sakata R, 2004, BIOCHEM BIOPH RES CO, V315, P959, DOI 10.1016/j.bbrc.2004.01.152; SENGER DR, 1979, CELL, V16, P885, DOI 10.1016/0092-8674(79)90103-X; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Sherwood DR, 2005, CELL, V121, P951, DOI 10.1016/j.cell.2005.03.031; SHYY JYJ, 1995, P NATL ACAD SCI USA, V92, P8069, DOI 10.1073/pnas.92.17.8069; Simpson PT, 2003, INT J EXP PATHOL, V84, P173, DOI 10.1046/j.1365-2613.2003.00350.x; SORENSEN ES, 1995, PROTEIN SCI, V4, P2040, DOI 10.1002/pro.5560041009; SUTRAVE P, 1984, NATURE, V309, P85, DOI 10.1038/309085a0; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; Teramoto H, 2005, ONCOGENE, V24, P489, DOI 10.1038/sj.onc.1208209; TIKHONENKO AT, 1992, J VIROL, V66, P946, DOI 10.1128/JVI.66.2.946-955.1992; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Vogt PK, 2002, NAT REV CANCER, V2, P465, DOI 10.1038/nrc818; Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498	62	24	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2006	25	29					4043	4055		10.1038/sj.onc.1209441	http://dx.doi.org/10.1038/sj.onc.1209441			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16491116				2022-12-28	WOS:000238802400005
J	Hashiramoto, A; Mizukami, H; Yamashita, T				Hashiramoto, A.; Mizukami, H.; Yamashita, T.			Ganglioside GM3 promotes cell migration by regulating MAPK and c-Fos/AP-1	ONCOGENE			English	Article						GM3; MAPK; cell cycle; c-Fos; AP-1	SIGNAL-TRANSDUCTION; MICE LACKING; C-FOS; GROWTH; KINASE; EXPRESSION; PROLIFERATION; ACTIVATION; APOPTOSIS; TRANSFORMATION	Gangliosides have been proposed as modulators of transmembrane signaling. Recently, GM3, a glycosphingolipid containing monosaialic acids, is thought to be one of the key molecules of signal transduction in mammalian cells. In this study, we used mouse embryonic fibroblast cell lines (MEFs) established from sialyltransferase-I knockout mice (GM3 synthase KO mice) to evaluate the regulation of mitogenic signals by gangliosides. Cell proliferation assay revealed a higher growth potential of GM3 KO MEFs. Immunoblots showed upregulation of Ras/Raf/MEK/ERK pathway in GM3 KO MEFs, and these signals resulted in enhanced translocation of ERK into the nuclei. Further, both exogenous and endogenous add-back of GM3 decreased the activities of MAPK in GM3 KO MEFs. In addition, GM3 KO MEFs formed foci in high-density culture condition, and analyses of cell cycle modulators revealed the resistance of GM3 KO MEFs for entering cell cycle arrest. Finally, sustained expressions of c-Fos in GM3 KO MEFs were shown to correlate with DNA-binding activity between c-Fos and AP-1. These results demonstrate that the deletion of sialyltransferase-I changes the character of MEFs to a highly activated state of the MAPK pathway, indicating the critical role of GM3 as a regulator of membrane-transmitted signals.	Kobe Univ, Dept Rheumatol, FHS Sch Med, Kobe, Hyogo 6540142, Japan; NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; Hirosaki Univ, Sch Med, Dept Pathol, Hirosaki, Aomori 036, Japan; Univ Tokyo, Inst Med Sci, Dept Cell Proc, Tokyo, Japan	Kobe University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Hirosaki University; University of Tokyo	Hashiramoto, A (corresponding author), Kobe Univ, Dept Rheumatol, FHS Sch Med, 7-10-2 Tomogaoka, Kobe, Hyogo 6540142, Japan.	hash@kobe-u.ac.jp	Mizukami, Hiroki/ABE-7877-2021	Mizukami, Hiroki/0000-0003-2920-582X				Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Blagosklonny MV, 1999, BIOESSAYS, V21, P704, DOI 10.1002/(SICI)1521-1878(199908)21:8<704::AID-BIES10>3.0.CO;2-5; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cullen PJ, 2001, CURR BIOL, V11, pR342, DOI 10.1016/S0960-9822(01)00189-0; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Garofalo T, 2002, J LIPID RES, V43, P971; Gorbacheva VY, 2002, J BIOL CHEM, V277, P6080, DOI 10.1074/jbc.M110542200; Gouni-Berthold L, 2001, HYPERTENSION, V38, P1030, DOI 10.1161/hy1101.093104; Groth A, 2005, CELL SIGNAL, V17, P1063, DOI 10.1016/j.cellsig.2004.11.021; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Hakomori SI, 1998, ANN NY ACAD SCI, V845, P1, DOI 10.1111/j.1749-6632.1998.tb09657.x; HANAI N, 1988, J BIOL CHEM, V263, P10915; Hashiramoto A, 1999, ARTHRITIS RHEUM, V42, P954, DOI 10.1002/1529-0131(199905)42:5<954::AID-ANR14>3.0.CO;2-J; Hoffmann E, 2005, J BIOL CHEM, V280, P9706, DOI 10.1074/jbc.M407071200; Huwiler A, 2000, BBA-MOL CELL BIOL L, V1485, P63, DOI 10.1016/S1388-1981(00)00042-1; Itano N, 2002, P NATL ACAD SCI USA, V99, P3609, DOI 10.1073/pnas.052026799; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; Kono M, 1998, BIOCHEM BIOPH RES CO, V253, P170, DOI 10.1006/bbrc.1998.9768; Li A, 2001, NAT CELL BIOL, V3, pE182, DOI 10.1038/35087119; Li RX, 2000, J BIOL CHEM, V275, P34213, DOI 10.1074/jbc.M906368199; Li RX, 2001, J BIOL CHEM, V276, P42782, DOI 10.1074/jbc.M101481200; MATYAS GR, 1987, P NATL ACAD SCI USA, V84, P6065, DOI 10.1073/pnas.84.17.6065; Monje P, 2003, MOL CELL BIOL, V23, P7030, DOI 10.1128/MCB.23.19.7030-7043.2003; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nakatsuji Y, 2001, J NEUROSCI RES, V66, P487, DOI 10.1002/jnr.1240; NANAI N, 1998, J BIOL CHEM, V263, P10915; Noll ENE, 2001, EXP NEUROL, V168, P300, DOI 10.1006/exnr.2000.7603; PALLER AS, 1993, J INVEST DERMATOL, V100, P841, DOI 10.1111/1523-1747.ep12476755; Pestana ES, 1999, ONCOGENE, V18, P4069, DOI 10.1038/sj.onc.1202794; Radeff-Huang J, 2004, J CELL BIOCHEM, V92, P949, DOI 10.1002/jcb.20094; Scorrano L, 1999, J BIOL CHEM, V274, P24657, DOI 10.1074/jbc.274.35.24657; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; VANBROCKLYN J, 1993, J NEUROCHEM, V61, P371; VANMEER G, 2000, BIOCHIM BIOPHYS ACTA, V26, P145; Wang XQ, 2003, J BIOL CHEM, V278, P48770, DOI 10.1074/jbc.M308818200; Wang XQ, 2001, GLYCOBIOLOGY, V11, P515, DOI 10.1093/glycob/11.7.515; Yamashita T, 2003, P NATL ACAD SCI USA, V100, P3445, DOI 10.1073/pnas.0635898100; Zou YP, 1998, INT J MOL MED, V1, P827	45	37	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3948	3955		10.1038/sj.onc.1209416	http://dx.doi.org/10.1038/sj.onc.1209416			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16491123				2022-12-28	WOS:000238668800008
J	Kawakami, T; Zhang, C; Okada, Y; Okamoto, K				Kawakami, T.; Zhang, C.; Okada, Y.; Okamoto, K.			Erasure of methylation imprint at the promoter and CTCF-binding site upstream of H19 in human testicular germ cell tumors of adolescents indicate their fetal germ cell origin	ONCOGENE			English	Article						testicular cancer; methylation; imprinting; DNA reprogramming; H19	GROWTH-FACTOR-II; CARCINOMA-IN-SITU; X-LINKED GENES; WILMS-TUMOR; DNA METHYLATION; MAMMALIAN DEVELOPMENT; BIALLELIC EXPRESSION; COLORECTAL-CANCER; MOUSE EMBRYO; IGF2 GENE	Genome-wide epigenetic modi. cation plays a crucial role in regulating genome functions at critical stages of development. In particular, DNA methylation is known to be reprogrammed on a genome-wide level in germ cells and in preimplantation embryos, although it is relatively stable in somatic cells. In this reprogramming process, the genome becomes demethylated, and methylated de novo during later stages of development. Reprogramming of DNA methylation in male germ cells has not been fully investigated. Testicular germ cell tumors (TGCTs) possess a pluripotential nature and display protean histology from germ cells to embryonal and somatic cell differentiation. These properties make TGCT a unique model for studying germ cell development and gametogenesis in respect of DNA reprogramming. In order to obtain an insight into the epigenetic dynamics of TGCTs, we conducted a comprehensive analysis of differential methylated regions (DMRs) on H19 and IGF2 in TGCTs compared with testicular malignant lymphomas. In the present study, we show that methylation imprint at the promoter and CTCF-binding site upstream of H19 was completely erased in both seiminomatous and non-seminomatous TGCTs, whereas differential methylation was observed in testicular lymphomas. The erasure of methylation imprint was also observed in TGCTs with malignant transformation. We found biallelic unmethylation at the promoter and the CTCF-binding site upstream of H19 is required, but not sufficient for the biallelic expression of H19 in TGCTs. These data suggest that factors other than methylation contribute to transcriptional regulation of imprinted genes in TGCTs. The present data have shown that TGCTs carry distinctive epigenetic profiles at the core-imprinting domain of H19/IGF2 from other neoplasms of somatic cell origin. The data also suggest that both seminomatous and nonseminomatous TGCTs carry methylation profiles similar to fetal germ cells, but not adult germ cells, indicating the origin of TGCTs as fetal germ cells.	Shiga Univ Med Sci, Dept Urol, Otsu, Shiga 5202192, Japan	Shiga University of Medical Science	Kawakami, T (corresponding author), Shiga Univ Med Sci, Dept Urol, Otsu, Shiga 5202192, Japan.	keisei@belle.shiga-med.ac.jp						ALLEN RC, 1992, AM J HUM GENET, V51, P1229; BARLOW DP, 1993, SCIENCE, V260, P309, DOI 10.1126/science.8469984; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cui HM, 2001, CANCER RES, V61, P4947; Davis TL, 2000, HUM MOL GENET, V9, P2885, DOI 10.1093/hmg/9.19.2885; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; Frevel MAE, 1999, J BIOL CHEM, V274, P29331, DOI 10.1074/jbc.274.41.29331; GRANT M, 1992, NAT GENET, V2, P161, DOI 10.1038/ng1092-161; Hajkova P, 2002, MECH DEVELOP, V117, P15, DOI 10.1016/S0925-4773(02)00181-8; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Holstein A. F., 1993, European Urology, V23, P9; Huber R, 1999, P NATL ACAD SCI USA, V96, P616, DOI 10.1073/pnas.96.2.616; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; Jinno Y, 1996, HUM MOL GENET, V5, P1155, DOI 10.1093/hmg/5.8.1155; JORGENSEN N, 1995, LAB INVEST, V72, P223; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; Kato Y, 1999, DEVELOPMENT, V126, P1823; Kawakami T, 2004, LANCET, V363, P40, DOI 10.1016/S0140-6736(03)15170-7; Kawakami T, 2004, ONCOGENE, V23, P6163, DOI 10.1038/sj.onc.1207808; Kawakami T, 2003, J UROLOGY, V169, P1546, DOI 10.1097/01.ju.0000044927.23323.5a; Kerjean A, 2000, HUM MOL GENET, V9, P2183, DOI 10.1093/hmg/9.14.2183; KIRCHGESSNER CU, 1995, J MED GENET, V32, P925, DOI 10.1136/jmg.32.12.925; Klenova EA, 2002, SEMIN CANCER BIOL, V12, P399, DOI 10.1016/S1044-579X(02)00060-3; Lee J, 2002, DEVELOPMENT, V129, P1807; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Looijenga LHJ, 2003, CANCER RES, V63, P2244; Loukinov DI, 2002, P NATL ACAD SCI USA, V99, P6806, DOI 10.1073/pnas.092123699; MOLLER H, 1989, J NATL CANCER I, V81, P1668, DOI 10.1093/jnci/81.21.1668-a; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; Nakagawa H, 2001, P NATL ACAD SCI USA, V98, P591, DOI 10.1073/pnas.011528698; Nonomura N, 1997, J UROLOGY, V157, P1977, DOI 10.1016/S0022-5347(01)64913-9; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Oosterhuis JW, 2005, NAT REV CANCER, V5, P210, DOI 10.1038/nrc1568; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; Rajpert-De Meyts E, 2004, HUM REPROD, V19, P1338, DOI 10.1093/humrep/deh265; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Ross JA, 1999, CANCER, V85, P1389, DOI 10.1002/(SICI)1097-0142(19990315)85:6<1389::AID-CNCR24>3.0.CO;2-V; Shiota K, 2002, DIFFERENTIATION, V69, P162, DOI 10.1046/j.1432-0436.2002.690406.x; SKAKKEBAEK NE, 1972, LANCET, V2, P516; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; Smiraglia DJ, 2002, ONCOGENE, V21, P3909, DOI 10.1038/sj.onc.1205488; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; Sullivan MJ, 1999, ONCOGENE, V18, P7527, DOI 10.1038/sj.onc.1203096; SZABO PE, 1995, GENE DEV, V9, P1857, DOI 10.1101/gad.9.15.1857; Szabo PE, 1995, GENE DEV, V9, P3097, DOI 10.1101/gad.9.24.3097; Tada T, 1998, DEV GENES EVOL, V207, P551, DOI 10.1007/s004270050146; Takai D, 2001, HUM MOL GENET, V10, P2619, DOI 10.1093/hmg/10.23.2619; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Ulaner GA, 2003, ENDOCRINOLOGY, V144, P4420, DOI 10.1210/en.2003-0681; ULBRIGHT TM, 1993, AM J SURG PATHOL, V17, P1075, DOI 10.1097/00000478-199311000-00001; VANGURP RJHLM, 1994, JNCI-J NATL CANCER I, V86, P1070, DOI 10.1093/jnci/86.14.1070; Verkerk AJMH, 1997, ONCOGENE, V14, P95, DOI 10.1038/sj.onc.1200802; VILLAR AJ, 1995, DEV BIOL, V172, P264, DOI 10.1006/dbio.1995.0021; Vu TH, 2000, GENOMICS, V64, P132, DOI 10.1006/geno.1999.6094; Yun K, 1999, J PATHOL, V187, P518, DOI 10.1002/(SICI)1096-9896(199904)187:5<518::AID-PATH276>3.0.CO;2-3; Zhang C, 2005, GENE CHROMOSOME CANC, V43, P104, DOI 10.1002/gcc.20160; ZHANG YH, 1993, AM J HUM GENET, V53, P113	63	36	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3225	3236		10.1038/sj.onc.1209362	http://dx.doi.org/10.1038/sj.onc.1209362			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16434968				2022-12-28	WOS:000237951200001
J	Metzler, M; Forster, A; Pannell, R; Arends, MJ; Daser, A; Lobato, MN; Rabbitts, TH				Metzler, M.; Forster, A.; Pannell, R.; Arends, M. J.; Daser, A.; Lobato, M. N.; Rabbitts, T. H.			A conditional model of MLL-AF4 B-cell tumourigenesis using invertor technology	ONCOGENE			English	Article						MLL; AF4; chromosomal translocations; invertor model; Cre-loxP; leukaemia	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHROMOSOMAL TRANSLOCATIONS; RETROVIRAL INSERTION; HUMAN CANCER; WILD-TYPE; CRE-LOXP; MLL-ELL; GENE; MICE	MLL-AF4 fusion is the most common consequence of chromosomal translocations in infant leukaemia and is associated witha poor prognosis. MLL-AF4 is thought to be required in haematopoietic stem cells to elicit leukaemia and may be involved in tumour phenotype specification as it is only found in B-cell tumours in humans. We have employed the invertor conditional technology to create a model of MLL-AF4, in which a floxed AF4 cDNA was knocked into Mll in the opposite orientation for transcription. Cell-specific Cre expression was used to generate Mll-AF4 expression. The mice develop exclusively B-cell lineage neoplasias, whether the Cre gene was controlled by B- or T-cell promoters, but of a more mature phenotype than normally observed in childhood leukaemia. These findings show that the MLL-AF4 fusion protein does not have a mandatory role in multi-potent haematopoietic stem cells to cause cancer and indicates that MLL-AF4 has an instructive function in the phenotype of the tumour.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England	MRC Laboratory Molecular Biology; University of Cambridge	Rabbitts, TH (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	thr@mrc-lmb.cam.ac.uk	Metzler, Markus/AAS-2066-2021; Rabbitts, Terence/D-6262-2016	Metzler, Markus/0000-0002-4523-1676; Rabbitts, Terence/0000-0002-4982-2609	Medical Research Council [G0600914] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ALBERT H, 1995, PLANT J, V7, P649, DOI 10.1046/j.1365-313X.1995.7040649.x; Alizadeh AA, 2001, J PATHOL, V195, P41, DOI 10.1002/path.889; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Christiansen DH, 2001, LEUKEMIA, V15, P1848, DOI 10.1038/sj.leu.2402246; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; Codrington R, 2005, PLOS BIOL, V3, P1459, DOI 10.1371/journal.pbio.0030242; Collins EC, 2000, EMBO REP, V1, P127, DOI 10.1093/embo-reports/kvd021; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; Daser A, 2004, GENE DEV, V18, P965, DOI 10.1101/gad.1195504; DiMartino JF, 2002, BLOOD, V99, P3780, DOI 10.1182/blood.V99.10.3780; DiMartino JF, 2000, BLOOD, V96, P3887, DOI 10.1182/blood.V96.12.3887.h8003887_3887_3893; Dobson CL, 2000, EMBO J, V19, P843, DOI 10.1093/emboj/19.5.843; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; Drynan LF, 2005, EMBO J, V24, P3136, DOI 10.1038/sj.emboj.7600760; Forster A, 2005, NAT METHODS, V2, P27, DOI 10.1038/NMETH727; Forster A, 2003, CANCER CELL, V3, P449, DOI 10.1016/S1535-6108(03)00106-5; Greaves MF, 2003, BLOOD, V102, P2321, DOI 10.1182/blood-2002-12-3817; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; HOESS RH, 1982, P NATL ACAD SCI-BIOL, V79, P3398, DOI 10.1073/pnas.79.11.3398; Hotfilder M, 2005, CANCER RES, V65, P1442, DOI 10.1158/0008-5472.CAN-04-1356; Jamal R, 2001, GENE CHROMOSOME CANC, V31, P187; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Martin ME, 2003, CANCER CELL, V4, P197, DOI 10.1016/S1535-6108(03)00214-9; McCormack MP, 2003, MOL CELL BIOL, V23, P9003, DOI 10.1128/MCB.23.24.9003-9013.2003; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Mori H, 2002, P NATL ACAD SCI USA, V99, P8242, DOI 10.1073/pnas.112218799; Morse HC, 2002, BLOOD, V100, P246, DOI 10.1182/blood.V100.1.246; Nakamura T, 1996, ONCOGENE, V13, P2235; Nam CH, 2006, MOL THER, V13, P15, DOI 10.1016/j.ymthe.2005.09.010; Peham M, 2002, BRIT J HAEMATOL, V117, P315, DOI 10.1046/j.1365-2141.2002.03428.x; Pui CH, 2002, LANCET, V359, P1909, DOI 10.1016/S0140-6736(02)08782-2; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RUBNITZ JE, 1994, BLOOD, V84, P1747; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; So CW, 2003, CANCER CELL, V4, P99, DOI 10.1016/S1535-6108(03)00188-0; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Wright G, 2003, P NATL ACAD SCI USA, V100, P9991, DOI 10.1073/pnas.1732008100	39	77	78	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3093	3103		10.1038/sj.onc.1209636	http://dx.doi.org/10.1038/sj.onc.1209636			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16607274				2022-12-28	WOS:000237951000001
J	Richardson, DS; Lai, AZ; Mulligan, LM				Richardson, D. S.; Lai, A. Z.; Mulligan, L. M.			RET ligand-induced internalization and its consequences for downstream signaling	ONCOGENE			English	Article						RET; receptor mediated endocytosis; Akt; MAP kinase	CLATHRIN-MEDIATED ENDOCYTOSIS; RECEPTOR TYROSINE KINASE; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; DYNAMIN BINDS; SH3 DOMAINS; MAP KINASE; ACTIVATION; CELLS; TRANSDUCTION	RET is a receptor tyrosine kinase (RTK) with roles in cell growth, differentiation and survival. Ligand-induced activation of RET results in stimulation of multiple signal transduction pathways, including the MAP kinase/Erk and PI3 kinase/Akt pathways. However, the mechanisms governing receptor internalization and signal downregulation have not been explored. As other RTKs are internalized through the clathrin-coated pit pathway in a ligand-dependant manner, we have investigated whether RET is internalized through a similar process. Using a highly sensitive fluorescence resonance energy transfer (FRET)-based assay, we have shown that RET is internalized from the plasma membrane in a ligand-dependant manner that requires RET kinase activity as well as the GTPase activity of the clathrin-coated vesicle scission protein dynamin 2. Further, we have demonstrated that RET colocalizes with Rab5a, a marker of clathrin-coated vesicles and early endosomes, after internalization. Finally, we demonstrated that RET internalization is required for complete activation of Erk1/2, but not for activation of Akt signaling. Our data suggest that ligand-induced internalization of RET not only plays an overall role in downregulation and termination of signaling, but also functions to traffic RET to subcellular locations where it can fully activate certain downstream signaling pathways.	Queens Univ, Canc Res Inst, Dept Pathol & Mol Med, Div Canc Biol & Genet, Kingston, ON K7L 3N6, Canada	McMaster University; Queens University - Canada	Mulligan, LM (corresponding author), Queens Univ, Canc Res Inst, Dept Pathol & Mol Med, Div Canc Biol & Genet, Rm 329 Botterell Hall, Kingston, ON K7L 3N6, Canada.	mulligal@post.queensu.ca	Richardson, Douglas/K-9922-2016	Richardson, Douglas/0000-0002-3189-2190				Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Arighi E, 2005, CYTOKINE GROWTH F R, V16, P441, DOI 10.1016/j.cytogfr.2005.05.010; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Foster-Barber A, 1998, P NATL ACAD SCI USA, V95, P4673, DOI 10.1073/pnas.95.8.4673; Freche B, 2005, J BIOL CHEM, V280, P36584, DOI 10.1074/jbc.M505707200; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Grimes ML, 1996, J NEUROSCI, V16, P7950; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Kirchhausen T, 2002, CELL, V109, P413, DOI 10.1016/S0092-8674(02)00751-1; Kodama Y, 2005, CANCER SCI, V96, P143, DOI 10.1111/j.1349-7006.2005.00023.x; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Maeda K, 2004, BIOCHEM BIOPH RES CO, V323, P345, DOI 10.1016/j.bbrc.2004.08.095; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Myers SM, 2004, CANCER RES, V64, P4453, DOI 10.1158/0008-5472.CAN-03-3605; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; Okamoto PM, 2001, J BIOL CHEM, V276, P48458, DOI 10.1074/jbc.M104927200; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Santoro M, 2004, ENDOCRINOLOGY, V145, P5448, DOI 10.1210/en.2004-0922; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Schuetz G, 2004, J CELL BIOL, V167, P945, DOI 10.1083/jcb.200404108; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Teis D, 2002, DEV CELL, V3, P803, DOI 10.1016/S1534-5807(02)00364-7; Torrisi MR, 1999, MOL BIOL CELL, V10, P417, DOI 10.1091/mbc.10.2.417; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; van Rheenen J, 2004, BIOPHYS J, V86, P2517, DOI 10.1016/S0006-3495(04)74307-6; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wiedlocha A, 2004, CURR TOP MICROBIOL, V286, P45; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Wunderlich L, 1999, CELL SIGNAL, V11, P25, DOI 10.1016/S0898-6568(98)00027-8; Zaccolo M, 2000, IUBMB LIFE, V49, P375	38	58	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3206	3211		10.1038/sj.onc.1209349	http://dx.doi.org/10.1038/sj.onc.1209349			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16418724				2022-12-28	WOS:000237951000011
J	Warbrick, E				Warbrick, E.			A functional analysis of PCNA-binding peptides derived from protein sequence, interaction screening and rational design	ONCOGENE			English	Article						PCNA; peptides; interaction; screening	CELL NUCLEAR ANTIGEN; DNA-POLYMERASE-DELTA; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; REPLICATION; P21; INHIBITOR; PHOSPHORYLATION; GADD45; MOTIF	Proliferating cell nuclear antigen ( PCNA) has no intrinsic enzymatic function, but functions as a sliding platform to mediate protein interactions with the DNA strand. Many proteins interact with PCNA through a small conserved motif with consensus QxxLxxFF. This work uses Schizosaccharomyces pombe and human cells to analyse the function of PCNA- binding peptides. Interacting peptides were identified using two- hybrid screening; one ( pep102) binds directly to a physiologically relevant site on PCNA. The EGFP- pep102 overexpression phenotype is consistent with competitive blocking of PCNA - protein interactions. Various PCNA- binding peptides were all shown to inhibit PCNA function by competitive binding in both human and S. pombe cells as EGFP fusion proteins. The action of a p21( WAF1/ Cip1)- derived peptide was complicated by the presence of additional functional domains and possible post- translational modi. cation. The activity of pep102 was hampered by low expression in both model systems. The peptide derived from rational design ( con1) was stable, highly active in inhibiting PCNA function both S. pombe and human cells and showed a high affinity for PCNA both in vitro and in vivo. These results validate the use of functional screening in yeast to identify peptide aptamers that are functional in mammalian cells; such aptamers provide excellent leads for small molecule antiproliferative therapies.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland	University of Dundee	Warbrick, E (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland.	e.warbrick@dundee.ac.uk	Warbrick, Emma/C-6424-2008		Cancer Research UK [A6613] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Adams PD, 1996, MOL CELL BIOL, V16, P6623; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; CHEN IT, 1995, ONCOGENE, V11, P1931; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Craven RA, 1998, GENE, V221, P59, DOI 10.1016/S0378-1119(98)00434-X; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HALL PA, 1995, ONCOGENE, V10, P2427; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Kamb A, 2001, CURR OPIN CHEM BIOL, V5, P74, DOI 10.1016/S1367-5931(00)00160-5; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; Kontopidis G, 2005, P NATL ACAD SCI USA, V102, P1871, DOI 10.1073/pnas.0406540102; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; MacNeill SA, 1996, EMBO J, V15, P4613, DOI 10.1002/j.1460-2075.1996.tb00839.x; Mattock H, 2001, EXP CELL RES, V265, P242, DOI 10.1006/excr.2001.5181; Mattock H, 2001, EXP CELL RES, V265, P234, DOI 10.1006/excr.2001.5160; Moggs JG, 2000, MOL CELL BIOL, V20, P1206, DOI 10.1128/MCB.20.4.1206-1218.2000; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Reynolds N, 2000, EMBO J, V19, P1108, DOI 10.1093/emboj/19.5.1108; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; SAZER S, 1990, J CELL SCI, V97, P509; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Tournier S, 1996, MOL BIOL CELL, V7, P651, DOI 10.1091/mbc.7.4.651; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Warbrick E, 1998, NUCLEIC ACIDS RES, V26, P3925, DOI 10.1093/nar/26.17.3925; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; WASEEM NH, 1992, EMBO J, V11, P5111, DOI 10.1002/j.1460-2075.1992.tb05618.x; Xu H, 2001, BIOCHEMISTRY-US, V40, P4512, DOI 10.1021/bi010103+; Xu X, 2001, NAT GENET, V27, P23, DOI 10.1038/83717; YANG MJ, 1995, NUCLEIC ACIDS RES, V23, P1152, DOI 10.1093/nar/23.7.1152; Zheleva DI, 2002, J PEPT RES, V60, P257, DOI 10.1034/j.1399-3011.2002.21014.x; Zheleva DI, 2000, BIOCHEMISTRY-US, V39, P7388, DOI 10.1021/bi992498r	39	32	35	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2850	2859		10.1038/sj.onc.1209320	http://dx.doi.org/10.1038/sj.onc.1209320			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16407840	Green Accepted, Bronze			2022-12-28	WOS:000237448200003
J	Yao, H; Dashner, EJ; van Golen, CM; van Golen, KL				Yao, H; Dashner, EJ; van Golen, CM; van Golen, KL			RhoC GTPase is required for PC-3 prostate cancer cell invasion but not motility	ONCOGENE			English	Article						RhoC GTPase; Rac1 GTPase; insulin-like growth factor-1; collagen 1	INFLAMMATORY BREAST-CANCER; GROWTH-FACTOR-I; ACTIVATED PROTEIN-KINASE; ACTIN STRESS FIBERS; BINDING PROTEINS; BOTULINUM ADP-RIBOSYLTRANSFERASE-C3; METASTATIC VARIANTS; CYCLE PROGRESSION; GENE-EXPRESSION; FACTOR RECEPTOR	It is projected that in 2005, approximately 220 900 men will be newly diagnosed with carcinoma of the prostate (CaP). Men who are diagnosed with locally advanced or metastatic disease undergo androgen ablation therapy and most will relapse and progress within 18 months. Metastasis to bone is the major clinical concern during CaP progression, as it is associated with intractable pain, bone fracture and paralysis resulting from spinal cord compression. Therefore, an understanding of the key mechanisms involved in CaP cell bone metastasis is vital to development of novel treatments. The Rho GTPases are molecular switches involved in cell survival, motility and invasion. Increased expression of RhoC GTPase is linked to enhanced metastatic potential in multiple cancers; however, the role of RhoC GTPase in CaP metastasis has not been addressed. In the current study, we demonstrate that RhoC GTPase is expressed and active in PC-3 CaP cells. RhoC inhibition, either pharmacologically with C3 exotransferase or molecularly through expression of a dominant-negative RhoC, promotes IGF-I stimulated random motility but decreases in vitro invasion and experimental metastases. Inhibition of RhoC activity results in drastic morphologic changes and alterations in the expression and distribution of focal adhesion-related proteins. These data suggest that RhoC inhibition leads to activation of other GTPases involved in nondirected motility and that expression of active RhoC is required for the invasive phenotype of PC-3 cells.	Univ Michigan, Ctr Comprehens Canc, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Neurol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	van Golen, KL (corresponding author), Univ Michigan, Ctr Canc, Dept Internal Med, 200 Zina Pitcher Pl,R-4048A Kresge 2, Ann Arbor, MI 48109 USA.	Kgolen@umich.edu			NATIONAL CANCER INSTITUTE [P50CA069568, P30CA046592] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA69568, 5 P30 CA46592] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; Alcover J, 1994, Actas Urol Esp, V18 Suppl, P409; Bockhorn M, 2004, CANCER RES, V64, P2469, DOI 10.1158/0008-5472.CAN-03-0256; Carr KM, 2003, ONCOGENE, V22, P3076, DOI 10.1038/sj.onc.1206448; Chang FM, 2003, INT J ONCOL, V22, P469; Chung LWK, 2005, J UROLOGY, V173, P10, DOI 10.1097/01.ju.0000141582.15218.10; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cooper CR, 2000, PROSTATE CANCER P D, V3, P6, DOI 10.1038/sj.pcan.4500387; Danen EHJ, 2000, J CELL BIOL, V151, P1413, DOI 10.1083/jcb.151.7.1413; del Peso L, 1997, ONCOGENE, V15, P3047; DIEKMANN D, 1995, METHOD ENZYMOL, V256, P207; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Evers EE, 2000, METHOD ENZYMOL, V325, P403; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Garber K, 2005, J NATL CANCER I, V97, P790, DOI 10.1093/jnci/97.11.790; Geyer M, 1997, CURR OPIN STRUC BIOL, V7, P786, DOI 10.1016/S0959-440X(97)80147-9; Greenberg DL, 2003, BIOCHEMISTRY-US, V42, P702, DOI 10.1021/bi027100x; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; Hellawell GO, 2002, CANCER RES, V62, P2942; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; Hodge JC, 2003, CANCER RES, V63, P1359; Horiuchi A, 2003, LAB INVEST, V83, P861, DOI 10.1097/01.LAB.0000073128.16098.31; Imamura F, 1999, CLIN EXP METASTAS, V17, P141, DOI 10.1023/A:1006598531238; IWAMURA M, 1993, PROSTATE, V22, P243, DOI 10.1002/pros.2990220307; Jackson JG, 2001, ONCOGENE, V20, P7318, DOI 10.1038/sj.onc.1204920; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Kamai T, 2003, CLIN CANCER RES, V9, P2632; Kaverina I, 2002, INT J BIOCHEM CELL B, V34, P746, DOI 10.1016/S1357-2725(01)00171-6; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Kiefer JA, 2001, MATRIX BIOL, V20, P429, DOI 10.1016/S0945-053X(01)00159-7; Kimura G, 1996, Int J Urol, V3, P39; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Kleer CG, 2002, AM J PATHOL, V160, P579, DOI 10.1016/S0002-9440(10)64877-8; Kondo T, 2004, PATHOBIOLOGY, V71, P19, DOI 10.1159/000072958; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Marionnet C, 2003, ONCOGENE, V22, P3500, DOI 10.1038/sj.onc.1206571; Meyer GE, 2001, ONCOGENE, V20, P7542, DOI 10.1038/sj.onc.1204927; Mitsiades CS, 2005, EXPERT REV ANTICANC, V5, P487, DOI 10.1586/14737140.5.3.487; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; MOSCOW JA, 1994, ONCOGENE, V9, P189; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Olson MF, 1996, J MOL MED-JMM, V74, P563, DOI 10.1007/s001090050060; PIENTA KJ, 1999, CANC MANAGEMENT MULT, P193; Price LS, 2001, SEMIN CANCER BIOL, V11, P167, DOI 10.1006/scbi.2000.0367; RIDLEY AJ, 1992, COLD SPRING HARB SYM, V57, P661, DOI 10.1101/SQB.1992.057.01.072; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2001, J CELL SCI, V114, P2713; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rubin J, 2004, PROSTATE, V58, P41, DOI 10.1002/pros.10299; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Shinto Eiji, 2003, Nihon Rinsho, V61 Suppl 7, P215; Somlyo AV, 2003, FASEB J, V17, P223, DOI 10.1096/fj.02-0655com; Somlyo AV, 2000, BIOCHEM BIOPH RES CO, V269, P652, DOI 10.1006/bbrc.2000.2343; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tanno S, 2001, CANCER RES, V61, P589; Thalmann GN, 2000, PROSTATE, V44, P91; Turner CE, 2000, J CELL SCI, V113, P4139; van Golen KL, 1999, CLIN CANCER RES, V5, P2511; van Golen KL, 2000, CANCER RES, V60, P5832; van Golen KL, 2003, BREAST CANCER RES, V5, P174, DOI 10.1186/bcr598; van Golen KL, 2002, MOL CANCER THER, V1, P575; van Golen KL, 2002, CLIN EXP METASTAS, V19, P301, DOI 10.1023/A:1015518114931; van Golen KL, 2000, NEOPLASIA, V2, P418, DOI 10.1038/sj.neo.7900115; Wang W, 2003, WORLD J GASTROENTERO, V9, P1950, DOI 10.3748/wjg.v9.i9.1950; WEST K, 2004, J CELL BIOL, V154, P161, DOI DOI 10.1083/JCB.200101039; Yin JJ, 2005, CELL RES, V15, P57, DOI 10.1038/sj.cr.7290266; Zaidel-Bar R, 2003, J CELL SCI, V116, P4605, DOI 10.1242/jcs.00792; Zhang H, 2004, EXPERT OPIN INV DRUG, V13, P1569, DOI 10.1517/13543784.13.12.1569; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775; 1999, CANC MANAGEMENT MULT	78	53	66	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2285	2296		10.1038/sj.onc.1209260	http://dx.doi.org/10.1038/sj.onc.1209260			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16314838				2022-12-28	WOS:000236764300001
J	Sanchez-Aguilera, A; Garcia, JF; Sanchez-Beato, M; Piris, MA				Sanchez-Aguilera, A; Garcia, JF; Sanchez-Beato, M; Piris, MA			Hodgkin's lymphoma cells express alternatively spliced forms of HDM2 with multiple effects on cell cycle control	ONCOGENE			English	Article						HDM2; MDM2; splicing; cell cycle; Hodgkin's lymphoma	MDM2 GENE AMPLIFICATION; MESSENGER-RNA; P53 PROTEIN; TRANSCRIPTS; OVEREXPRESSION; ONCOGENE; BREAST; VARIANTS; GROWTH; DOMAIN	The HDM2 oncoprotein is a cellular inhibitor of p53 and is frequently deregulated in human cancer. However, the HDM2 gene encodes alternatively spliced variants whose functional significance is poorly understood. We had previously reported the detection of alternative HDM2 forms in Hodgkin's lymphoma ( HL)-derived cell lines. Here, we have cloned several of these transcripts, including the previously described HDM2-A, -B and -C ( which encode the COOH terminus of HDM2), and two novel variants ( HDM2-HL1 and -HL2) containing a complete p53 interaction domain. Real-time PCR assays demonstrated that HDM2-A and -B were selectively expressed by HL cell lines and primary tumors, compared with their non-neoplastic counterparts. In transient transfection experiments, alternatively spliced HDM2 isoforms were partially or totally localized within the cytoplasm. HDM2-HL2 was able to inhibit transactivation of a p53-inducible reporter construct and induced a partial relocalization of p53 to the cytoplasm. Expression of HDM2-A and -B caused the activation of p53/p21 and induced growth arrest in primary cells, but also increased the expression levels of cyclins D1 and E. Other possible genes regulated by HDM2-A and -B were identified using cDNA microarray technology. These results imply that HDM2 isoforms may have multiple effects on cell cycle control, and provide insight into the mechanisms through which these molecules contribute to tumorigenesis.	Ctr Nacl Invest Oncol, Mol Pathol Programme, Lymphoma Grp, E-28029 Madrid, Spain		Sanchez-Aguilera, A (corresponding author), Ctr Nacl Invest Oncol, Mol Pathol Programme, Lymphoma Grp, Melchor Fernandez Almagro,3, E-28029 Madrid, Spain.	asanchez@cnio.es	Piris, Miguel A/AAP-1445-2020; Piris, Miguel A/B-7067-2008; Sanchez-Beato, Margarita/G-8753-2012	Piris, Miguel A/0000-0001-5839-3634; Piris, Miguel A/0000-0001-5839-3634; Sanchez-Beato, Margarita/0000-0002-0058-7599				BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Bartel F, 2001, ONCOL RES, V12, P451, DOI 10.3727/096504001108747459; Bartel F, 2001, INT J CANCER, V95, P168, DOI 10.1002/1097-0215(20010520)95:3<168::AID-IJC1029>3.0.CO;2-A; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; Dang JJ, 2002, CANCER RES, V62, P1222; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Evans SC, 2001, ONCOGENE, V20, P4041, DOI 10.1038/sj.onc.1204533; Evdokiou A, 2001, INT J ONCOL, V19, P625; Fridman JS, 2003, CANCER RES, V63, P5703; Garcia JF, 2003, BLOOD, V101, P681, DOI 10.1182/blood-2002-04-1128; Garcia JF, 2002, AM J PATHOL, V160, P569, DOI 10.1016/S0002-9440(10)64876-6; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hori M, 2000, PATHOL INT, V50, P786, DOI 10.1046/j.1440-1827.2000.01119.x; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Kapp U, 1999, J EXP MED, V189, P1939, DOI 10.1084/jem.189.12.1939; Kraus A, 1999, INT J CANCER, V80, P930, DOI 10.1002/(SICI)1097-0215(19990315)80:6<930::AID-IJC20>3.3.CO;2-D; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lukas J, 2001, CANCER RES, V61, P3212; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Matsumoto R, 1998, CANCER RES, V58, P609; MAXWELL SA, 1994, ANTICANCER RES, V14, P2541; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Nelsen CJ, 2005, J BIOL CHEM, V280, P768, DOI 10.1074/jbc.M407105200; Oelmann E, 2002, BLOOD, V99, P258, DOI 10.1182/blood.V99.1.258; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Ongkeko WM, 1999, CURR BIOL, V9, P829, DOI 10.1016/S0960-9822(99)80367-4; Pinkas J, 1999, INT J CANCER, V81, P292, DOI 10.1002/(SICI)1097-0215(19990412)81:2<292::AID-IJC20>3.3.CO;2-9; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Sanchez-Aguilera A, 2002, BLOOD, V99, P1411, DOI 10.1182/blood.V99.4.1411; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; Steinman HA, 2004, J BIOL CHEM, V279, P4877, DOI 10.1074/jbc.M305966200; Tamborini E, 2001, INT J CANCER, V92, P790, DOI 10.1002/ijc.1271; Tracey L, 2002, AM J PATHOL, V161, P1825, DOI 10.1016/S0002-9440(10)64459-8; Tzankov A, 2003, J PATHOL, V199, P201, DOI 10.1002/path.1279; WATANABE T, 1994, BLOOD, V84, P3158; Weiss RH, 2003, CANCER CELL, V4, P425, DOI 10.1016/S1535-6108(03)00308-8; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	43	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2565	2574		10.1038/sj.onc.1209282	http://dx.doi.org/10.1038/sj.onc.1209282			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16331255				2022-12-28	WOS:000237099400001
J	Kawano, Y; Kitaoka, M; Hamada, Y; Walker, MM; Waxman, J; Kypta, RM				Kawano, Y.; Kitaoka, M.; Hamada, Y.; Walker, M. M.; Waxman, J.; Kypta, R. M.			Regulation of prostate cell growth and morphogenesis by Dickkopf-3	ONCOGENE			English	Article						Dkk-3; prostate cancer; proliferation; immunohistochemistry; acinar formation	BETA-CATENIN; PROMOTER-HYPERMETHYLATION; ALPHA-6-BETA-1 INTEGRIN; ACINAR DIFFERENTIATION; REDUCED EXPRESSION; GENE-EXPRESSION; DOWN-REGULATION; CANCER; REIC/DKK-3; PROLIFERATION	Wnt signalling plays a critical role in the development of cancer. Recent studies indicate that Wnt signalling is negatively regulated by secreted Wnt antagonists such as secreted frizzled related proteins (sFRPs) and Dick-kopfs (Dkks). We compared Dkk family expression levels in normal prostate and prostate cancer cells and found a reduction in Dkk-3 expression in cancer cells. Ectopic expression of Dkk-3 inhibited colony formation in LNCaP and PC3 prostate cancer cell lines and inducible expression of Dkk-3 reduced LNCaP cell proliferation. Moreover, small interfering RNA-mediated downregulation of Dkk-3 enhanced cell cycle progression in untransformed RWPE-1 prostate epithelial cells. Immunohistochemical analysis revealed that Dkk-3 is expressed in a subset of normal prostate gland acini and that Dkk-3 expression is reduced in prostate tumours, particularly those with a high Gleason grade, suggesting a role for Dkk-3 in postmitotic differentiation. Consistent with this, depletion of Dkk-3 disrupted acinar morphogenesis of RWPE-1 cells in a three-dimensional cell culture model. Our results are consistent with the loss of Dkk-3 expression resulting in impairment of glandular structure and uncontrolled prostate epithelial cell ( PrEC) proliferation,	Univ London Imperial Coll Sci Technol & Med, Prostate Canc Res Grp, Harris Lab, Dept Oncol,Div SORA, London W12 0NN, England; Kumamoto Gen Hosp, Kumamoto, Japan; Univ London Imperial Coll Sci Technol & Med, Dept Histopathol, London, England; Cell Biol & Stem Cells Unit, CIC BioGUNE, Bizkaia, Spain	Imperial College London; Imperial College London; CIC bioGUNE	Kawano, Y (corresponding author), Univ London Imperial Coll Sci Technol & Med, Prostate Canc Res Grp, Harris Lab, Dept Oncol,Div SORA, DuCane Rd, London W12 0NN, England.	y.kawano@ic.ac.uk; rkypta@cicbiogune.es	Kypta, Robert/F-7699-2011; Walker, Marjorie Mary/F-6504-2013; cancer, biogune/H-7276-2012	Kypta, Robert/0000-0002-2389-310X; 				Abarzua F, 2005, CANCER RES, V65, P9617, DOI 10.1158/0008-5472.CAN-05-0829; Barrantes ID, 2006, MOL CELL BIOL, V26, P2317, DOI 10.1128/MCB.26.6.2317-2326.2006; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215; Bello-DeOcampo D, 2001, MUTAT RES-FUND MOL M, V480, P209, DOI 10.1016/S0027-5107(01)00201-9; Bello-Deocampo D, 2001, PROSTATE, V46, P142, DOI 10.1002/1097-0045(20010201)46:2<142::AID-PROS1018>3.0.CO;2-B; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Byun T, 2005, J CLIN PATHOL, V58, P515, DOI 10.1136/jcp.2004.018598; Caricasole A, 2003, J BIOL CHEM, V278, P37024, DOI 10.1074/jbc.M300191200; Cheng L, 2000, CLIN CANCER RES, V6, P1896; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Gamble SC, 2004, ONCOGENE, V23, P2996, DOI 10.1038/sj.onc.1207444; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Halvorsen OJ, 2003, CLIN CANCER RES, V9, P1474; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008-5472.CAN-03-1952; Hoffman MP, 1996, J CELL SCI, V109, P2013; Hsieh SY, 2004, ONCOGENE, V23, P9183, DOI 10.1038/sj.onc.1208138; Huppi K, 2005, MOL CELL, V17, P1, DOI 10.1016/j.molcel.2004.12.017; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kobayashi K, 2002, GENE, V282, P151, DOI 10.1016/S0378-1119(01)00838-1; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Kurose K, 2004, J UROLOGY, V171, P1314, DOI 10.1097/01.ju.0000101047.64379.d4; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Li XF, 2005, NAT GENET, V37, P945, DOI 10.1038/ng1614; Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Mazor M, 2004, ONCOGENE, V23, P7882, DOI 10.1038/sj.onc.1208068; Menko AS, 2002, DEV DYNAM, V224, P321, DOI 10.1002/dvdy.10111; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Naylor MJ, 2005, J CELL BIOL, V171, P717, DOI 10.1083/jcb.200503144; Nozaki I, 2001, INT J ONCOL, V19, P117; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Roman-Gomez J, 2004, BLOOD, V104, P2492, DOI 10.1182/blood-2004-03-0954; Roman-Gomez J, 2004, BRIT J CANCER, V91, P707, DOI 10.1038/sj.bjc.6602008; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; Suwa T, 2003, J ENDOCRINOL, V178, P149, DOI 10.1677/joe.0.1780149; Tsuji T, 2000, BIOCHEM BIOPH RES CO, V268, P20, DOI 10.1006/bbrc.1999.2067; Tsuji T, 2001, BIOCHEM BIOPH RES CO, V289, P257, DOI 10.1006/bbrc.2001.5972; Waltregny D, 2001, MOL ENDOCRINOL, V15, P765, DOI 10.1210/me.15.5.765; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Webber MM, 1997, CARCINOGENESIS, V18, P1225, DOI 10.1093/carcin/18.6.1225; Zhu HN, 2004, CANCER RES, V64, P7918, DOI 10.1158/0008-5472.CAN-04-2704	49	100	104	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2006	25	49					6528	6537		10.1038/sj.onc.1209661	http://dx.doi.org/10.1038/sj.onc.1209661			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16751809				2022-12-28	WOS:000241395100009
J	Mitra, SK; Mikolon, D; Molina, JE; Hsia, DA; Hanson, DA; Chi, A; Lim, ST; Bernard-Trifilo, JA; Ilic, D; Stupack, DG; Cheresh, DA; Schlaepfer, DD				Mitra, S. K.; Mikolon, D.; Molina, J. E.; Hsia, D. A.; Hanson, D. A.; Chi, A.; Lim, S-T; Bernard-Trifilo, J. A.; Ilic, D.; Stupack, D. G.; Cheresh, D. A.; Schlaepfer, D. D.			Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors	ONCOGENE			English	Article						FAK; FRNK; VEGF; tumor growth; angiogenesis	FOCAL-ADHESION KINASE; ENDOTHELIAL GROWTH-FACTOR; HUMAN BREAST; CELL MOTILITY; IN-VIVO; ONCOGENIC TRANSFORMATION; PROTEIN-KINASE; CANCER; SRC; PATHWAYS	Elevated focal adhesion kinase (FAK) expression occurs in advanced cancers, yet a signaling role for FAK in tumor progression remains undefined. Here, we suppressed FAK activity in 4T1 breast carcinoma cells resulting in reduced FAK Y925 phosphorylation, Grb2 adaptor protein binding to FAK, and signaling to mitogen-activated protein (MAP) kinase (MAPK). Loss of a FAK-Grb2-MAPK linkage did not affect 4T1 cell proliferation or survival in culture, yet FAK inhibition reduced vascular endothelial growth factor (VEGF) expression and resulted in small avascular tumors in mice. This FAK-Grb2-MAPK linkage was essential in promoting angiogenesis as reconstitution experiments using Src-transformed FAK-null fibroblasts revealed that point mutations affecting FAK catalytic activity (R454) or Y925 phosphorylation (F925) disrupted the ability of FAK to promote MAPK- and VEGF-associated tumor growth. Notably, in both FAK- inhibited 4T1 and Src-transformed FAK- null cells, constitutively activated (CA) mitogen-activated protein kinase kinase 1 (MEK1) restored VEGF production and CA-MEK1 or added VEGF rescued tumor growth and angiogenesis. These studies provide the first biological support for Y925 FAK phosphorylation and de. ne a novel role for FAK activity in promoting a MAPK- associated angiogenic switch during tumor progression.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; StemLifeLine Inc, San Carlos, CA USA	Scripps Research Institute; University of California System; University of California San Diego	Schlaepfer, DD (corresponding author), Scripps Res Inst, Dept Immunol, IMM 21,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	dschlaep@scripps.edu		ILIC, DUSKO/0000-0003-1647-0026; Lim, Steve/0000-0003-0323-8607	NCI NIH HHS [CA087652, CA95262, CA50286, CA45726, CA107263, CA78045, CA102310] Funding Source: Medline; NEI NIH HHS [EY14174] Funding Source: Medline; NIAID NIH HHS [T32 AI07606] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA087652, P01CA078045, R01CA102310, R01CA050286, R01CA095262, R01CA107263, R37CA050286, R01CA045726] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R24EY014174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007606] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barberis L, 2000, J BIOL CHEM, V275, P36532, DOI 10.1074/jbc.M002487200; Barr MP, 2005, BRIT J CANCER, V92, P328, DOI 10.1038/sj.bjc.6602308; Benlimame N, 2005, J CELL BIOL, V171, P505, DOI 10.1083/jcb.200504124; Boudreau N, 2003, BREAST CANCER RES, V5, P140, DOI 10.1186/bcr589; Cance WG, 2000, CLIN CANCER RES, V6, P2417; De S, 2005, P NATL ACAD SCI USA, V102, P7589, DOI 10.1073/pnas.0502935102; Ding Q, 2005, J BIOL CHEM, V280, P6802, DOI 10.1074/jbc.M409180200; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; Ghiso JAA, 2002, ONCOGENE, V21, P2513, DOI 10.1038/sj/onc/1205342; Golubovskaya V, 2002, J BIOL CHEM, V277, P38978, DOI 10.1074/jbc.M205002200; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanks SK, 2003, FRONT BIOSCI-LANDMRK, V8, pD982, DOI 10.2741/1114; Haskell H, 2003, CLIN CANCER RES, V9, P2157; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; Hecker TP, 2003, FRONT BIOSCI-LANDMRK, V8, pS705, DOI 10.2741/1115; Heppner GH, 2000, BREAST CANCER RES, V2, P331; Hood JD, 2003, J CELL BIOL, V162, P933, DOI 10.1083/jcb.200304105; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Ilic D, 2003, CIRC RES, V92, P300, DOI 10.1161/01.RES.0000055016.36679.23; Ilic D, 1998, J CELL BIOL, V143, P547; ILLC D, 1995, NATURE, V377, P539; Jiang BH, 1997, CANCER RES, V57, P5328; Kornberg LJ, 2004, INVEST OPHTH VIS SCI, V45, P4463, DOI 10.1167/iovs.03-1201; Kranenburg O, 2004, BBA-REV CANCER, V1654, P23, DOI 10.1016/j.bbcan.2003.09.004; LARK AL, 2005, MOD PATHOL; Li N, 2005, EMBO J, V24, P1942, DOI 10.1038/sj.emboj.7600674; Lightfoot HM, 2004, BREAST CANCER RES TR, V88, P109, DOI 10.1007/s10549-004-1022-8; McLean GW, 2004, GENE DEV, V18, P2998, DOI 10.1101/gad.316304; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mitra SK, 2006, ONCOGENE, V25, P4429, DOI 10.1038/sj.onc.1209482; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Moissoglu K, 2003, J BIOL CHEM, V278, P47946, DOI 10.1074/jbc.M302720200; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Pages G, 2005, CARDIOVASC RES, V65, P564, DOI 10.1016/j.cardiores.2004.09.032; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Peng X, 2004, CARDIOVASC RES, V64, P421, DOI 10.1016/j.cardiores.2004.07.012; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Seko Y, 1999, BIOCHEM BIOPH RES CO, V262, P290, DOI 10.1006/bbrc.1999.1185; Shen TL, 2005, J CELL BIOL, V169, P941, DOI 10.1083/jcb.200411155; Sieg DJ, 1999, J CELL SCI, V112, P2677; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Storgard Chris, 2004, V294, P123; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tschan MP, 2003, J BIOL CHEM, V278, P42750, DOI 10.1074/jbc.M307067200; van Nimwegen MJ, 2005, CANCER RES, V65, P4698, DOI 10.1158/0008-5472.CAN-04-4126; Wang DY, 2000, J CELL SCI, V113, P4221; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199	59	128	140	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2006	25	44					5969	5984		10.1038/sj.onc.1209588	http://dx.doi.org/10.1038/sj.onc.1209588			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16682956				2022-12-28	WOS:000240826300006
J	Reed-Inderbitzin, E; Moreno-Miralles, I; Vanden-Eynden, SK; Xie, J; Lutterbach, B; Durst-Goodwin, KL; Luce, KS; Irvin, BJ; Cleary, ML; Brandt, SJ; Hiebert, SW				Reed-Inderbitzin, E.; Moreno-Miralles, I.; Vanden-Eynden, S. K.; Xie, J.; Lutterbach, B.; Durst-Goodwin, K. L.; Luce, K. S.; Irvin, B. J.; Cleary, M. L.; Brandt, S. J.; Hiebert, S. W.			RUNX1 associates with histone deacetylases and SUV39H1 to repress transcription	ONCOGENE			English	Article						Suv39h1; RUNX1; AML1; histone; deacetylase	ACUTE MYELOID-LEUKEMIA; MYOSIN HEAVY-CHAIN; SYNERGISTICALLY ACTIVATE; DEPENDENT ACTIVATION; AUTO-INHIBITION; NUCLEAR-MATRIX; FUSION PROTEIN; N-COR; GENE; T(8-21)	RUNX1 (AML1) is a gene that is frequently disrupted by chromosomal translocations in acute leukemia. Like its Drosophila homolog Runt, RUNX1 both activates and represses transcription. Both Runt and RUNX1 are required for gene silencing during development and a central domain of RUNX1, termed repression domain 2 (RD2), was defined as being required for transcriptional repression and for the silencing of CD4 during T-cell maturation in thymic organ cultures. Although transcriptional co-repressors are known to contact other repression domains in RUNX1, the factors that bind to RD2 had not been defined. Therefore, we tested whether RD2 contacts histone-modifying enzymes that may mediate both repression and gene silencing. We found that RD2 contacts SUV39H1, a histone methyltransferase, via two motifs and that endogenous Suv39h1 associates with a Runx1-regulated repression element in murine erythroleukemia cells. In addition, one of these SUV39H1-binding motifs is also sufficient for binding to histone deacetylases 1 and 3, and both of these domains are required for full RUNX1-mediated transcriptional repression. The association between RUNX1, histone deacetylases and SUV39H1 provides a molecular mechanism for repression and possibly gene silencing mediated by RUNX1.	Vanderbilt Univ, Sch Med, Dept Biochem, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; Tennessee Valley VA Healthcare Syst, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Hiebert, SW (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, Vanderbilt Ingram Canc Ctr, Preston Res Bldg,Rm 512,23rd & Pierce, Nashville, TN 37232 USA.	scott.hiebert@vanderbilt.edu	Hiebert, Scott W/C-9979-2010		NCI NIH HHS [R01-CA64140, R01-CA77274, CA68485] Funding Source: Medline; NHLBI NIH HHS [R01-HL49118] Funding Source: Medline; PHS HHS [R01-87549] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064140, P30CA068485, R01CA077274] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049118] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; Cameron ER, 2004, ONCOGENE, V23, P4308, DOI 10.1038/sj.onc.1207130; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Chakraborty S, 2003, ONCOGENE, V22, P5229, DOI 10.1038/sj.onc.1206600; Durst KL, 2003, MOL CELL BIOL, V23, P607, DOI 10.1128/MCB.23.2.607-619.2003; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ERICKSON PF, 1994, CANCER RES, V54, P1782; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Firestein R, 2000, MOL CELL BIOL, V20, P4900, DOI 10.1128/MCB.20.13.4900-4909.2000; GERGEN JP, 1985, DEV BIOL, V109, P321, DOI 10.1016/0012-1606(85)90459-2; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; Guidez F, 2000, BLOOD, V96, P2557; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; Imai Y, 2004, MOL CELL BIOL, V24, P1033, DOI 10.1128/MCB.24.3.1033-1043.2004; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; Javed A, 2000, J CELL SCI, V113, P2221; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; LENNY N, 1995, ONCOGENE, V11, P1761; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Lutterbach B, 1999, P NATL ACAD SCI USA, V96, P12822, DOI 10.1073/pnas.96.22.12822; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Nishimura M, 2004, BLOOD, V103, P562, DOI 10.1182/blood-2003-06-2109; NUCIFORA G, 1995, P NATL ACAD SCI USA, V92, P4917; Peterson LF, 2004, ONCOGENE, V23, P4255, DOI 10.1038/sj.onc.1207727; RAYNAUD S, 1995, GENE, V159, P245; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Swantek D, 2004, DEVELOPMENT, V131, P2281, DOI 10.1242/dev.01109; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Telfer JC, 2004, J IMMUNOL, V172, P4359, DOI 10.4049/jimmunol.172.7.4359; van Wijnen AJ, 2004, ONCOGENE, V23, P4209, DOI 10.1038/sj.onc.1207758; Wheeler JC, 2002, NAT GENET, V32, P206, DOI 10.1038/ng942; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	46	60	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2006	25	42					5777	5786		10.1038/sj.onc.1209591	http://dx.doi.org/10.1038/sj.onc.1209591			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16652147				2022-12-28	WOS:000240765800008
J	Carujo, S; Estanyol, JM; Ejarque, A; Agell, N; Bachs, O; Pujol, MJ				Carujo, S.; Estanyol, J. M.; Ejarque, A.; Agell, N.; Bachs, O.; Pujol, M. J.			Glyceraldehyde 3-phosphate dehydrogenase is a SET-binding protein and regulates cyclin B-cdk1 activity	ONCOGENE			English	Article						SET; GAPDH; cyclin B; cdk1; cell cycle	TANDEM MASS-SPECTROMETRY; ACTIVATING FACTOR-I; GRANZYME-A; PHOSPHATASE 2A; CELL-CYCLE; DNA; IDENTIFICATION; COMPLEX; TRANSCRIPTION; REPLICATION	We report here that glyceraldehyde-3-phosphate dehydrogenase (GAPDH) interacts in vitro and in vivo with the protein SET. This interaction is performed through the acidic domain of SET located at the carboxy terminal region. On analysing the functional relevance of SET-GAPDH interaction, we observed that GAPDH reverses in a dose-dependent manner, the inhibition of cyclin B-cdk1 activity produced by SET. Similarly to SET, GAPDH associates with cyclin B, suggesting that the regulation of cyclin B-cdk1 activity might be mediated not only by the interaction of GAPDH with SET but also with cyclin B. To analyse the putative role of GAPDH on cell cycle progression, HCT116 cells were transfected with a GAPDH expression vector. Results indicate that overexpression of GAPDH does not affect the timing of DNA replication but induces an increase in the number of mitosis, an advancement of the peak of cyclin B-cdk1 activity and an acceleration of cell cycle progression. All these results suggest that GAPDH might be involved in cell cycle regulation by modulating cyclin B-cdk1 activity.	Univ Barcelona, Fac Med, Dept Biol & Cellular & Anat Patol, E-08036 Barcelona, Spain	University of Barcelona	Bachs, O (corresponding author), Univ Barcelona, Fac Med, Dept Biol & Cellular & Anat Patol, Casanova 143, E-08036 Barcelona, Spain.	obachs@ub.edu	Estanyol, Josep M/I-1039-2015; Agell, Neus/E-9640-2016	Estanyol, Josep M/0000-0001-8621-0057; Agell, Neus/0000-0002-1205-6074				ADACHI Y, 1994, J BIOL CHEM, V269, P2258; Adler HT, 1997, J BIOL CHEM, V272, P28407, DOI 10.1074/jbc.272.45.28407; Beresford PJ, 2001, J BIOL CHEM, V276, P43285, DOI 10.1074/jbc.M108137200; Canela N, 2003, J BIOL CHEM, V278, P1158, DOI 10.1074/jbc.M207497200; Carrascal M, 2002, PROTEOMICS, V2, P455, DOI 10.1002/1615-9861(200204)2:4<455::AID-PROT455>3.0.CO;2-E; Cervoni N, 2002, J BIOL CHEM, V277, P25026, DOI 10.1074/jbc.M202256200; Chai ZL, 2001, J BIOL CHEM, V276, P33665, DOI 10.1074/jbc.M007681200; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chuang DM, 2005, ANNU REV PHARMACOL, V45, P269, DOI 10.1146/annurev.pharmtox.45.120403.095902; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Fan ZS, 2002, MOL CELL BIOL, V22, P2810, DOI 10.1128/MCB.22.8.2810-2820.2002; GLASER PE, 1995, BIOCHEMISTRY-US, V34, P12193, DOI 10.1021/bi00038a013; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; Kawase H, 1996, GENES CELLS, V1, P1045, DOI 10.1046/j.1365-2443.1996.d01-223.x; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; Krynetski EY, 2001, MOL PHARMACOL, V59, P367, DOI 10.1124/mol.59.2.367; Krynetski EY, 2003, CANCER RES, V63, P100; Kutney SN, 2004, J BIOL CHEM, V279, P30850, DOI 10.1074/jbc.M404969200; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Lieberman J, 2003, CURR OPIN IMMUNOL, V15, P553, DOI 10.1016/S0952-7915(03)00108-0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUMOTO K, 1993, J BIOL CHEM, V268, P10582; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; Nakagawa T, 2003, J BIOL CHEM, V278, P20395, DOI 10.1074/jbc.M210824200; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; Okuwaki M, 1998, J BIOL CHEM, V273, P34511, DOI 10.1074/jbc.273.51.34511; Ozbun LL, 2001, GENOMICS, V73, P179, DOI 10.1006/geno.2001.6505; Pandey AV, 2003, J BIOL CHEM, V278, P2837, DOI 10.1074/jbc.M209527200; Qu DB, 2002, J BIOL CHEM, V277, P7324, DOI 10.1074/jbc.M107270200; ROBBINS AR, 1995, J CELL BIOL, V130, P1093, DOI 10.1083/jcb.130.5.1093; Sanchez-Piris M, 2002, J BIOL CHEM, V277, P17722, DOI 10.1074/jbc.M200104200; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Shen HH, 2001, GENOMICS, V71, P21, DOI 10.1006/geno.2000.6397; Shevchenko A, 2000, METH MOL B, V146, P1, DOI 10.1385/1-59259-045-4:1; Shikama N, 2000, MOL CELL BIOL, V20, P8933, DOI 10.1128/MCB.20.23.8933-8943.2000; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; Sundararaj KP, 2004, J BIOL CHEM, V279, P6152, DOI 10.1074/jbc.M310549200; Tisdale EJ, 2001, J BIOL CHEM, V276, P2480, DOI 10.1074/jbc.M007567200; Vogel T, 1998, CYTOGENET CELL GENET, V81, P265, DOI 10.1159/000015042; VON LM, 1992, MOL CELL BIOL, V12, P3346; Wen CH, 2000, P NATL ACAD SCI USA, V97, P14524, DOI 10.1073/pnas.011446498; Yi MY, 2000, J VIROL, V74, P6459, DOI 10.1128/JVI.74.14.6459-6468.2000; Zheng L, 2003, CELL, V114, P255, DOI 10.1016/S0092-8674(03)00552-X	47	52	56	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2006	25	29					4033	4042		10.1038/sj.onc.1209433	http://dx.doi.org/10.1038/sj.onc.1209433			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16474839				2022-12-28	WOS:000238802400004
J	Ueno, T; Sasaki, K; Yoshida, S; Kajitani, N; Satsuka, A; Nakamura, H; Sakai, H				Ueno, T.; Sasaki, K.; Yoshida, S.; Kajitani, N.; Satsuka, A.; Nakamura, H.; Sakai, H.			Molecular mechanisms of hyperplasia induction by human papillomavirus E7	ONCOGENE			English	Article						HPV; E7; hyperplasia; pRb; p130; pocket proteins	RETINOBLASTOMA TUMOR-SUPPRESSOR; TYPE-16 E7; E6 ONCOPROTEIN; EPITHELIAL HYPERPLASIA; HUMAN KERATINOCYTES; CERVICAL-CARCINOMA; PROTEIN FAMILY; CELLULAR DNA; GENE; DIFFERENTIATION	Infections of human papillomavirus (HPV) induce a variety of benign tumors, such as warts and condylomas. During the process of aberrant cell proliferation, genetic mutations are accumulated in the cells, from which malignant tumor cells arise. The viral oncoproteins E6 and E7 are known to help disrupt the cell cycle checkpoint machinery and accelerate chromosomal instability, events which are critical in malignant conversion. However, the mechanisms involved in the hyperplasia caused by HPV infection have remained unknown. We analysed the effects of regulatory genes of HPV18, a typical high-risk-type HPV, on the formation of the epithelial organ by using an organotypic culture system, and found that E7 had potent activity to induce hyperplasia, to which the disruption of the pRb pathway was well correlated. However, analysis with the E7 variants indicated that other pocket proteins are also involved in the activity.	Kyoto Univ, Inst Virus Res, Lab Gene Anal, Dept Viral Oncol,Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Sakai, H (corresponding author), Kyoto Univ, Inst Virus Res, Lab Gene Anal, Dept Viral Oncol,Sakyo Ku, 53 Kawahara Cho, Kyoto 6068507, Japan.	hsakai@virus.kyoto-u.ac.jp						BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; Balsitis SJ, 2003, MOL CELL BIOL, V23, P9094, DOI 10.1128/MCB.23.24.9094-9103.2003; Basile JR, 2001, J BIOL CHEM, V276, P22522, DOI 10.1074/jbc.M010505200; BLANTON RA, 1992, CELL GROWTH DIFFER, V3, P791; Boutwell R K, 1989, Prog Clin Biol Res, V298, P3; Boyer SN, 1996, CANCER RES, V56, P4620; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; Chien WM, 2000, CELL GROWTH DIFFER, V11, P425; CHOO KB, 1987, VIROLOGY, V161, P259, DOI 10.1016/0042-6822(87)90195-4; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; CORMACK B, 1987, CURRENT PROTOCOLS MO; Davy CE, 2002, J VIROL, V76, P9806, DOI 10.1128/JVI.76.19.9806-9818.2002; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; DOLLARD SC, 1992, GENE DEV, V6, P1131, DOI 10.1101/gad.6.7.1131; DOWHANICK JJ, 1995, J VIROL, V69, P7791, DOI 10.1128/JVI.69.12.7791-7799.1995; Duensing S, 2003, J VIROL, V77, P12331, DOI 10.1128/JVI.77.22.12331-12335.2003; Duensing S, 2001, J VIROL, V75, P7712, DOI 10.1128/JVI.75.16.7712-7716.2001; Duensing S, 2001, CANCER RES, V61, P2356; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Frattini MG, 1996, P NATL ACAD SCI USA, V93, P3062, DOI 10.1073/pnas.93.7.3062; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Gulliver GA, 1997, J VIROL, V71, P5905, DOI 10.1128/JVI.71.8.5905-5914.1997; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; Helt AM, 2002, J VIROL, V76, P10559, DOI 10.1128/JVI.76.20.10559-10568.2002; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; Howley P. M., 2001, FIELDS VIROLOGY, V2, P2197; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Majewski S, 2003, EXP DERMATOL, V12, P721, DOI 10.1111/j.0906-6705.2003.00125.x; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MEYERS C, 1992, SCIENCE, V257, P971, DOI 10.1126/science.1323879; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Munger K, 2004, J VIROL, V78, P11451, DOI 10.1128/JVI.78.21.11451-11460.2004; Nakahara T, 2002, J VIROL, V76, P10914, DOI 10.1128/JVI.76.21.10914-10920.2002; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Nishimura A, 2000, J VIROL, V74, P3752, DOI 10.1128/JVI.74.8.3752-3760.2000; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Pfister Herbert, 2003, J Natl Cancer Inst Monogr, P52; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; Sambrook J, 1989, MOL CLONING LAB MANU, V3, P18; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; Steenbergen RDM, 1998, J VIROL, V72, P749, DOI 10.1128/JVI.72.1.749-757.1998; Thompson DA, 2001, ONCOGENE, V20, P3629, DOI 10.1038/sj.onc.1204483; TSUNENAGA M, 1994, JPN J CANCER RES, V85, P238, DOI 10.1111/j.1349-7006.1994.tb02088.x; Williams SMG, 2005, CANCER RES, V65, P6534, DOI 10.1158/0008-5472.CAN-05-0083; Zhang BY, 2006, P NATL ACAD SCI USA, V103, P437, DOI 10.1073/pnas.0510012103; Zhang JY, 2004, GENE DEV, V18, P17, DOI 10.1101/gad.1160904; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	63	20	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	30					4155	4164		10.1038/sj.onc.1209445	http://dx.doi.org/10.1038/sj.onc.1209445			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16501608				2022-12-28	WOS:000239004800003
J	Linghu, H; Tsuda, M; Makino, Y; Sakai, M; Watanabe, T; Ichihara, S; Sawa, H; Nagashima, K; Mochizuki, N; Tanaka, S				Linghu, H.; Tsuda, M.; Makino, Y.; Sakai, M.; Watanabe, T.; Ichihara, S.; Sawa, H.; Nagashima, K.; Mochizuki, N.; Tanaka, S.			Involvement of adaptor protein Crk in malignant feature of human ovarian cancer cell line MCAS	ONCOGENE			English	Article						Crk; C3G; Rac; dock180; siRNA; human cancer	V-CRK; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE-C; ACTIVATION; C3G; MIGRATION; COMPLEX; KINASE; MEMBRANE; ADHESION	Signaling adaptor protein Crk regulates cell motility and growth through its targets Dock180 and C3G, those are the guanine-nucleotide exchange factors (GEFs) for small GTPases Rac and Rap, respectively. Recently, overexpression of Crk has been reported in various human cancers. To de. ne the role for Crk in human cancer cells, Crk expression was targeted in the human ovarian cancer cell line MCAS through RNA interference, resulting in the establishment of three Crk knockdown cell lines. These cell lines exhibited disorganized actin fibers, reduced number of focal adhesions, and abolishment of lamellipodia formation. Decreased Rac activity was demonstrated by pull-down assay and FRET-based time-lapse microscopy, in association with suppression of both motility and invasion by phagokinetic track assay and transwell assay in these cells. Furthermore, Crk knockdown cells exhibited slow growth rates in culture and suppressed anchorage-dependent growth in soft agar. Tumor forming potential in nude mice was attenuated, and intraperitoneal dissemination was not observed when Crk knockdown cells were injected into the peritoneal cavity. These results suggest that the Crk is a key component of focal adhesion and involved in cell growth, invasion, and dissemination of human ovarian cancer cell line MCAS.	Hokkaido Univ, Lab Mol & Cellular Pathol, Sch Med, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Natl Cardiovasc Ctr Hosp & Res Inst, Osaka, Japan	Hokkaido University; National Cerebral & Cardiovascular Center - Japan	Tanaka, S (corresponding author), Hokkaido Univ, Lab Mol & Cellular Pathol, Sch Med, Kita Ku, N 15,W7, Sapporo, Hokkaido 0608638, Japan.	tanaka@med.hokudai.ac.jp	Tanaka, Shinya/D-3586-2011; Sawa, Hirofumi/F-6954-2012; Sawa, Hirofumi/AAW-8816-2021	Sawa, Hirofumi/0000-0003-2569-2755; 				Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Brugge JS, 1998, NAT GENET, V19, P309, DOI 10.1038/1189; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Chen ZC, 2001, CANCER-AM CANCER SOC, V92, P3068, DOI 10.1002/1097-0142(20011215)92:12<3068::AID-CNCR10149>3.0.CO;2-5; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Hemmeryckx B, 2002, ONCOGENE, V21, P3225, DOI 10.1038/sj.onc.1205452; Imaizumi T, 1999, BIOCHEM BIOPH RES CO, V266, P569, DOI 10.1006/bbrc.1999.1869; Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582-6591.2002; Iwahara T, 2003, ONCOGENE, V22, P5946, DOI 10.1038/sj.onc.1206633; Judson PL, 1999, CANCER, V86, P1551, DOI 10.1002/(SICI)1097-0142(19991015)86:6<1551::AID-CNCR23>3.0.CO;2-P; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Liu EB, 2000, CANCER RES, V60, P2361; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATSUDA M, 1992, J VIROL, V66, P115, DOI 10.1128/JVI.66.1.115-121.1992; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Miller CT, 2003, ONCOGENE, V22, P7950, DOI 10.1038/sj.onc.1206529; Mochizuki N, 2000, J BIOL CHEM, V275, P12667, DOI 10.1074/jbc.275.17.12667; Nagashima KI, 2002, MOL BIOL CELL, V13, P4231, DOI 10.1091/mbc.E02-04-0181; Nishihara H, 2002, BIOCHEM BIOPH RES CO, V296, P716, DOI 10.1016/S0006-291X(02)00931-2; Nishihara H, 2002, CANCER LETT, V180, P55, DOI 10.1016/S0304-3835(01)00763-7; Nishihara H, 2002, BLOOD, V100, P3968, DOI 10.1182/blood-2001-11-0032; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Sheetz MP, 1998, TRENDS CELL BIOL, V8, P51, DOI 10.1016/S0962-8924(98)80005-6; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Takino T, 2003, CANCER RES, V63, P2335; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Tsuda M, 2002, CELL GROWTH DIFFER, V13, P131; Yano H, 2000, P NATL ACAD SCI USA, V97, P9076, DOI 10.1073/pnas.97.16.9076	38	49	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3547	3556		10.1038/sj.onc.1209398	http://dx.doi.org/10.1038/sj.onc.1209398			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16491127				2022-12-28	WOS:000238448200007
J	Chattopadhyay, S; Machado-Pinilla, R; Manguan-Garcia, C; Belda-Iniesta, C; Moratilla, C; Cejas, P; Fresno-Vara, JA; de Castro-Carpeno, J; Nistal, M; Gonzalez-Baron, M; Perona, R				Chattopadhyay, S.; Machado-Pinilla, R.; Manguan-Garcia, C.; Belda-Iniesta, C.; Moratilla, C.; Cejas, P.; Fresno-Vara, J. A.; de Castro-Carpeno, J.; Nistal, M.; Gonzalez-Baron, M.; Perona, R.			MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer	ONCOGENE			English	Article						non-small-cell lung cancer; MKP1; CL100; siRNA; Jun kinase; cisplatin	PROTEIN-KINASE PHOSPHATASE-1; N-TERMINAL KINASE; JUN ACTIVATION DOMAIN; C-JUN; MAP KINASE; OVARIAN-CARCINOMA; MKP-1 EXPRESSION; STRESS; APOPTOSIS; SPECIFICITY	Non-small-cell lung cancer (NSCLC) represents the most frequent and therapy-refractive sub-class of lung cancer. Improving apoptosis induction in NSCLC represents a logical way forward in treating this tumor. Cisplatin, a commonly used therapeutic agent in NSCLC, induces activation of N-terminal-c-Jun kinase (JNK) that, in turn, mediates induction of apoptosis. In analysing surgical tissue samples of NSCLC, we found that expression of MKP1/CL100, a negative regulator of JNK, showed a strong nuclear staining for tumor cells, whereas, in normal bronchial epithelia, MKP1 was localized in the cytoplasm as well as in nuclei. In the NSCLC-derived cell lines H460 and H-23, we found that MKP1 was constitutively expressed. Expressing a small-interfering RNA (siRNA) vector for MKP1 in H-460 cells resulted in a more efficient activation by cisplatin of JNK and p38 than in the parental cells, and this correlated with a 10-fold increase in sensitivity to cisplatin. A similar response was also observed in H-460 and H-23 cells when treated with the MKP1 expression inhibitor RO-31-8220. Moreover, expression of a siRNA-MKP2, an MKP1-related phosphatase, had no effect on H-460 cell viability response to cisplatin. Tumors induced by H-460 cells expressing MKP1 siRNA grew slower in nu(-)/nu(-) mice and showed more susceptibility to cisplatin than parental cells, and resulted in an impaired growth of the tumor in mice. On the other hand, overexpression of MKP1 in the H-1299 NSCLC-derived cell line resulted in further resistance to cisplatin. Overall, the results showed that inhibition of MKP1 expression contributes to a slow down in cell growth in mice and an increase of cisplatin-induced cell death in NSCLC. As such, MKP1 can be an attractive target in sensitizing cells to cisplatin to increase the effectiveness of the drug in treating NSCLC.	UAM, CSIC, Inst Invest Biomed, Translat Oncol Unit, Madrid 28029, Spain; Hosp La Paz, Med Oncol Serv, Madrid, Spain; Hosp La Paz, Serv Anat Patol, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital Universitario La Paz; Hospital Universitario La Paz	Perona, R (corresponding author), UAM, CSIC, Inst Invest Biomed, Translat Oncol Unit, C-Arturo Duperier 4, Madrid 28029, Spain.	RPerona@iib.uam.es	Vara, Juan Ángel Fresno/Y-9928-2019; Fresno Vara, Juan Angel/F-6702-2010	Vara, Juan Ángel Fresno/0000-0003-1527-1252; Fresno Vara, Juan Angel/0000-0003-1527-1252; Belda Iniesta, Cristobal/0000-0003-3254-7492				Alpert D, 1999, J BIOL CHEM, V274, P22176, DOI 10.1074/jbc.274.32.22176; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Denkert C, 2002, INT J CANCER, V102, P507, DOI 10.1002/ijc.10746; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; EASTMAN A, 1985, BIOCHEMISTRY-US, V24, P5027, DOI 10.1021/bi00340a011; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirsch DD, 1997, J BIOL CHEM, V272, P4568, DOI 10.1074/jbc.272.7.4568; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; Kim DH, 2003, CANCER RES, V63, P6206; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEVIN WJ, 1994, CHEST, V106, pS372, DOI 10.1378/chest.106.6.372S; Li J, 2001, MOL CELL BIOL, V21, P8213, DOI 10.1128/MCB.21.23.8213-8224.2001; Liao Q, 2003, GASTROENTEROLOGY, V124, P1830, DOI 10.1016/S0016-5085(03)00398-6; Lim EH, 2003, CLIN CANCER RES, V9, P5980; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; Mizuno R, 2004, J UROLOGY, V172, P723, DOI 10.1097/01.ju.0000124990.37563.00; Perona R, 2004, BRIT J CANCER, V90, P573, DOI 10.1038/sj.bjc.6601552; Persons DL, 1999, CLIN CANCER RES, V5, P1007; Sanchez-Perez I, 2000, ONCOGENE, V19, P5142, DOI 10.1038/sj.onc.1203887; Sanchez-Perez I, 1999, FEBS LETT, V453, P151, DOI 10.1016/S0014-5793(99)00690-0; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; SLEBOS RJC, 1989, EUR RESPIR J, V2, P461; Small GW, 2004, MOL PHARMACOL, V66, P1478, DOI 10.1124/mol.104.003400; Srikanth S, 1999, MOL CELL BIOCHEM, V199, P169, DOI 10.1023/A:1006980326855; Standaert ML, 1999, ENDOCRINOLOGY, V140, P2145, DOI 10.1210/en.140.5.2145; Vicent S, 2004, CLIN CANCER RES, V10, P3639, DOI 10.1158/1078-0432.CCR-03-0771; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang HY, 2003, CANCER LETT, V191, P229, DOI 10.1016/S0304-3835(02)00612-2; Wiest JS, 1997, J CELL BIOCHEM, P64; Woessmann W, 2002, CANCER CHEMOTH PHARM, V50, P397, DOI 10.1007/s00280-002-0502-y; Wu JJ, 2005, J BIOL CHEM, V280, P16461, DOI 10.1074/jbc.M501762200	34	78	83	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3335	3345		10.1038/sj.onc.1209364	http://dx.doi.org/10.1038/sj.onc.1209364			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16462770				2022-12-28	WOS:000237951200012
J	Thornton, JK; Dalgleish, C; Venables, JP; Sergeant, KA; Ehrmann, IE; Lu, X; Saunders, PTK; Elliott, DJ				Thornton, J. K.; Dalgleish, C.; Venables, J. P.; Sergeant, K. A.; Ehrmann, I. E.; Lu, X.; Saunders, P. T. K.; Elliott, D. J.			The tumour-suppressor protein ASPP1 is nuclear in human germ cells and can modulate ratios of CD44 exon V5 spliced isoforms in vivo	ONCOGENE			English	Article						spermatogenesis; gene expression; tumour suppressor	MESSENGER-RNA EXPRESSION; KH-DOMAIN; FUNCTIONAL INTERACTION; CYCLE PROGRESSION; SAM68; P53; FAMILY; GENE; INTERACTS; MEMBERS	The ASPP1 (Apoptosis Stimulating Protein of p53) protein is an important tumour-suppressor. We have detected a novel protein interaction between the human ASPP1 (hASPP1) protein and the predominantly nuclear adaptor protein SAM68. In the human testis, full-length endogenous hASPP1 protein is located in the nucleus like SAM68, predominantly within meiotic and postmeiotic cells. Mouse ASPP1 (mASPP1) protein is mainly expressed in the brain and testis. The interaction with nuclear SAM68 is likely to be restricted to human germ cells, since endogenous mASPP1 protein is exclusively cytoplasmic. The C-terminal region of hASPP1 efficiently targeted a fused GFP molecule to the nucleus, whereas the N-terminus of hASPP1 targeted GFP to the cytoplasm. In the context of the full-length molecule this cytoplasmic targeting sequence is dominant in HEK293 and Saos-2 cells, since full-length hASPP1-GFP is almost exclusively cytoplasmic. Despite its predominantly cytoplasmic location, we show that ASPP1-GFP expression in HEK293 cells can regulate the ratio of alternative spliced isoforms derived from a pre-mRNA regulated downstream of cytoplasmic signalling pathways, and our data suggest that ASPP1 may operate in this case downstream or parallel to RAS signalling pathways.	Newcastle Univ, Inst Human Genet, Int Ctr Life, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England; UCL, Ludwig Inst Canc Res, London, England; MRC, Ctr Reprod Biol, Human Reprod Sci Unit, Edinburgh, Midlothian, Scotland	Newcastle University - UK; Ludwig Institute for Cancer Research; University of London; University College London	Elliott, DJ (corresponding author), Newcastle Univ, Inst Human Genet, Int Ctr Life, Cent Pkwy, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.	david.elliott@ncl.ac.uk	Saunders, Philippa TK/C-7489-2013	Saunders, Philippa TK/0000-0001-9051-9380; Lu, Xin/0000-0002-6587-1152; Elliott, David/0000-0002-6930-0699	MRC [MC_U127685844, MC_U127685841] Funding Source: UKRI; Medical Research Council [MC_U127685841, MC_U127661055, U.1276.00.002(61055), MC_U127685844] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; Coutts AS, 2005, BIOCHEM BIOPH RES CO, V331, P778, DOI 10.1016/j.bbrc.2005.03.150; Di Fruscio M, 1998, J BIOL CHEM, V273, P30122, DOI 10.1074/jbc.273.46.30122; Elliott DJ, 2000, P NATL ACAD SCI USA, V97, P5717, DOI 10.1073/pnas.97.11.5717; Elliott DJ, 2000, HUM MOL GENET, V9, P2117, DOI 10.1093/hmg/9.14.2117; Forch P, 2000, MOL CELL, V6, P1089, DOI 10.1016/S1097-2765(00)00107-6; Grossman JS, 1998, RNA, V4, P613, DOI 10.1017/S1355838298971448; Harfmann AM, 1999, MOL BIOL CELL, V10, P3909, DOI 10.1091/mbc.10.11.3909; Harlow ED., 1999, USING ANTIBODIES; Hong W, 2002, MOL CANCER RES, V1, P48; Liu ZJ, 2005, FEBS LETT, V579, P1587, DOI 10.1016/j.febslet.2005.01.069; Liu ZJ, 2004, LEUKEMIA, V18, P880, DOI 10.1038/sj.leu.2403300; Lukong KE, 2003, BBA-REV CANCER, V1653, P73, DOI 10.1016/j.bbcan.2003.09.001; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; Paronetto MP, 2003, ONCOGENE, V22, P8707, DOI 10.1038/sj.onc.1207016; Pillay I, 1996, CELL GROWTH DIFFER, V7, P1487; Reddy TR, 2002, J BIOL CHEM, V277, P5778, DOI 10.1074/jbc.M106836200; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Sjoblom T, 1996, ONCOGENE, V12, P2499; Slee EA, 2004, ONCOGENE, V23, P9007, DOI 10.1038/sj.onc.1208088; Slee EA, 2003, TOXICOL LETT, V139, P81, DOI 10.1016/S0378-4274(02)00421-6; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Stamm S, 2002, HUM MOL GENET, V11, P2409, DOI 10.1093/hmg/11.20.2409; Takahashi N, 2004, BIOCHEM BIOPH RES CO, V315, P434, DOI 10.1016/j.bbrc.2004.01.079; Taylor SJ, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-5; Venables JP, 2004, HUM MOL GENET, V13, P1525, DOI 10.1093/hmg/ddh165; Venables JP, 1999, HUM MOL GENET, V8, P959, DOI 10.1093/hmg/8.6.959; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wyckoff GJ, 2000, NATURE, V403, P304, DOI 10.1038/35002070; Yang HP, 2002, ONCOGENE, V21, P7187, DOI 10.1038/sj.onc.1205759; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904; Zhang XW, 2005, LEUKEMIA RES, V29, P179, DOI 10.1016/j.leukres.2004.07.001	38	14	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3104	3112		10.1038/sj.onc.1209341	http://dx.doi.org/10.1038/sj.onc.1209341			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16474851				2022-12-28	WOS:000237951000002
J	Rouget-Quermalet, V; Giustiniani, J; Marie-Cardine, A; Beaud, G; Besnard, F; Loyaux, D; Ferrara, P; Leroy, K; Shimizu, N; Gaulard, P; Bensussan, A; Schmitt, C				Rouget-Quermalet, V; Giustiniani, J; Marie-Cardine, A; Beaud, G; Besnard, F; Loyaux, D; Ferrara, P; Leroy, K; Shimizu, N; Gaulard, P; Bensussan, A; Schmitt, C			Protocadherin 15 (PCDH15): a new secreted isoformand a potential marker for NK/T cell lymphomas	ONCOGENE			English	Article						NK/T lymphomas; isoforms; PCDH15; RT-PCR	T-CELL; EXPRESSION; RECEPTORS; MUTANT; LINES; GENE	Natural killer cells are well known to play an important role in immune defense against tumor development and viral infections. To further characterize new functionally relevant structures in these cells, we studied a series of monoclonal antibodies that we have raised against the NK cell line YT. One of these antibodies previously described as AY19, recognizes a 85 kD surface glycoprotein. Here we report the identification of a new secreted isoform of protocadherin 15, PCDH15C, which represents a potential associated protein for p85. Importantly, whereas protocadherins are absent from the surface of normal hematopoietic cells, we describe, for the first time, that PCDH15 is expressed in cytotoxic tumor-derived T- and NK-cell lines as well as in biopsies of nasal NK/T-cell lymphomas.	INSERM, Fac Med, U659, F-94010 Creteil, France; Sanofi Aventis, Rueil Malmaison, France; Sanofi Aventis, Labege, France; CHU Henri Mondor, Dept Pathol, INSERM, U 617,AP HP, F-94010 Creteil, France; Med Res Inst, Dept Virol, Tokyo, Japan	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Sanofi-Aventis; Sanofi-Aventis; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Schmitt, C (corresponding author), INSERM, Fac Med, U659, 8 Rue Gen Sarrail, F-94010 Creteil, France.	christian.schmitt@im3.inserm.fr	Bensussan, Armand/E-5434-2017; Leroy, Karen/E-9235-2011	Leroy, Karen/0000-0002-4379-0140; Bensussan, Armand/0000-0002-0409-2497; Giustiniani, Jerome/0000-0002-4612-0759				Ahmed ZM, 2003, HUM MOL GENET, V12, P3215, DOI 10.1093/hmg/ddg358; Ahmed ZM, 2001, AM J HUM GENET, V69, P25, DOI 10.1086/321277; Alagramam KN, 2001, NAT GENET, V27, P99, DOI 10.1038/83837; Chen MW, 2002, ONCOGENE, V21, P7861, DOI 10.1038/sj.onc.1205991; Frank M, 2002, CURR OPIN CELL BIOL, V14, P557, DOI 10.1016/S0955-0674(02)00365-4; Kanavaros P, 2000, LEUKEMIA LYMPHOMA, V38, P317, DOI 10.3109/10428190009087022; Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526; Le Bouteiller P, 2002, P NATL ACAD SCI USA, V99, P16963, DOI 10.1073/pnas.012681099; MANSUR IG, 1993, HUM IMMUNOL, V37, P31, DOI 10.1016/0198-8859(93)90140-V; Moretta L, 2004, EMBO J, V23, P255, DOI 10.1038/sj.emboj.7600019; Nagata H, 2001, BLOOD, V97, P708, DOI 10.1182/blood.V97.3.708; Nava VE, 2005, ADV ANAT PATHOL, V12, P27, DOI 10.1097/01.pap.0000151318.34752.80; Sherwood DR, 2005, CELL, V121, P951, DOI 10.1016/j.cell.2005.03.031; VILMER E, 1988, BLOOD, V72, P841; YING L, 2005, ONCOGENE, DOI DOI 10.1038	15	21	23	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2807	2811		10.1038/sj.onc.1209301	http://dx.doi.org/10.1038/sj.onc.1209301			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16369489				2022-12-28	WOS:000237272900012
J	Aung, PP; Oue, N; Mitani, Y; Nakayama, H; Yoshida, K; Noguchi, T; Bosserhoff, AK; Yasui, W				Aung, PP; Oue, N; Mitani, Y; Nakayama, H; Yoshida, K; Noguchi, T; Bosserhoff, AK; Yasui, W			Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer	ONCOGENE			English	Article						gastric cancer; MIA; MMP10; DKK4; SAGE; tumor serum marker	SQUAMOUS-CELL CARCINOMA; CLINICAL-IMPLICATIONS; MALIGNANT-MELANOMA; METASTATIC CANCER; TISSUE INHIBITORS; SERIAL ANALYSIS; FUNCTIONAL-ROLE; PHASE-I; EXPRESSION; PROTEIN	Gastric cancer ( GC) is one of the most common malignancies worldwide. Genes expressed only in cancer tissue will be useful molecular markers for diagnosis and may also be good therapeutic targets. However, little is known about cancer-specific genes, at least in GC. In this study, we searched for GC-specific genes by serial analysis of gene expression ( SAGE) data analysis and quantitative reverse transcription (RT)-PCR. Comparing GC SAGE libraries with those of various normal tissues in the SAGEmap database, we identified 54 candidate GC-specific genes. Quantitative RT-PCR analysis of these candidates revealed that APin protein (APIN), taxol resistance-associated gene 3 (TRAG3), cytochrome P450, family 2, subfamily W, polypeptide 1 (CYP2W1), melanoma inhibitory activity (MIA), matrix metalloproteinase-10 (MMP-10), dickkopf homolog 4 (DKK4), GW112, regenerating islet-derived family, member 4 (REGIV), and HORMA domain-containing 1 (HOR-MAD1) were expressed much more highly in GC than in 14 kinds of normal tissues. Immunohistochemical staining for MIA, MMP-10, and DKK4 was found in 47 (31.1%), 68 (45.0%), and two (1.3%) of 151 GCs, respectively, and staining for both MIA and MMP-10 was correlated with poor prognosis in advanced GC (P = 0.0001 and 0.0141, respectively). Moreover, enzyme-linked immunosorbent assay showed high levels of MMP-10 (65/69, 94.2%) in serum samples from patients with GC. Levels of MIA were raised in a small proportion of serum samples from patients with GC (4/69, 5.8%). In Boyden chamber invasion assays, MIA-transfected GC cells were up to three times more invasive than cells transfected with empty vector. Taken together, these results suggest that MMP-10 is a good marker for the detection of GC and that MIA and MMP-10 are prognostic factors for GC. As expression of MIA and MMP-10 is narrowly restricted in cancer, these two molecules may be good therapeutic targets for GC.	Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Pathol, Minami Ku, Hiroshima 7348551, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Surg Oncol, Hiroshima, Japan; Oita Univ, Fac Med, Dept Oncol Sci, Oita, Japan; Univ Regensburg, Inst Pathol, Regensburg, Germany	Hiroshima University; Hiroshima University; Oita University; University of Regensburg	Yasui, W (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Pathol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	wyasui@hiroshima-u.ac.jp	Bosserhoff, Anja/GNH-4801-2022; Mitani, Yoshitsugu/ABA-2736-2021	Mitani, Yoshitsugu/0000-0002-8661-4702; Aung, Phyu/0000-0002-3398-0573; Bosserhoff, Anja/0000-0001-8147-394X				ALLEY MC, 1988, CANCER RES, V48, P589; Amatschek S, 2004, CANCER RES, V64, P844, DOI 10.1158/0008-5472.CAN-03-2361; Bando E, 1999, AM J SURG, V178, P256, DOI 10.1016/S0002-9610(99)00162-2; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; BLESCH A, 1994, CANCER RES, V54, P5695; Bodey B, 2000, ANTICANCER RES, V20, P4585; Bosserhoff AK, 1999, J PATHOL, V187, P446, DOI 10.1002/(SICI)1096-9896(199903)187:4<446::AID-PATH267>3.0.CO;2-Y; Bosserhoff AK, 1997, CANCER RES, V57, P3149; Bosserhoff AK, 2001, MELANOMA RES, V11, P417, DOI 10.1097/00008390-200108000-00013; Buckhaults P, 2001, CANCER RES, V61, P6996; Clark HF, 2003, GENOME RES, V13, P2265, DOI 10.1101/gr.1293003; Dietz UH, 1996, J BIOL CHEM, V271, P3311, DOI 10.1074/jbc.271.6.3311; El Fitori J, 2005, CANCER CELL INT, V5, DOI 10.1186/1475-2867-5-3; Hau P, 2004, ONCOL REP, V12, P1355; Hau P, 2002, ANTICANCER RES, V22, P577; HEMBRY RM, 1995, ANN RHEUM DIS, V54, P25, DOI 10.1136/ard.54.1.25; Hohenberger P, 2003, LANCET, V362, P305, DOI 10.1016/S0140-6736(03)13975-X; Kevorkian L, 2004, ARTHRITIS RHEUM-US, V50, P131, DOI 10.1002/art.11433; KOGA T, 1987, JPN J SURG, V17, P342, DOI 10.1007/BF02470632; Kondo T, 2004, CANCER RES, V64, P523, DOI 10.1158/0008-5472.CAN-03-1196; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Lal A, 1999, CANCER RES, V59, P5403; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Mao BY, 2003, GENE, V302, P179, DOI 10.1016/S0378-1119(02)01106-X; Mathew R, 2002, CANCER DETECT PREV, V26, P222, DOI 10.1016/S0361-090X(02)00035-1; MOLNAR IG, 1976, GASTROENTEROLOGY, V70, P513; MULLER D, 1991, INT J CANCER, V48, P550, DOI 10.1002/ijc.2910480412; Nakamura H, 1998, EUR J BIOCHEM, V253, P67, DOI 10.1046/j.1432-1327.1998.2530067.x; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Nomura H, 1996, INT J CANCER, V69, P9, DOI 10.1002/(SICI)1097-0215(19960220)69:1<9::AID-IJC3>3.0.CO;2-8; OHGAKI H, 2003, WORLD CANC REPORT, P197; Oue N, 2005, J PATHOL, V207, P185, DOI 10.1002/path.1827; Oue N, 2004, CANCER RES, V64, P2397, DOI 10.1158/0008-5472.CAN-03-3514; Poser I, 2004, ONCOGENE, V23, P6115, DOI 10.1038/sj.onc.1207797; Ramos MC, 2004, BIOL CHEM, V385, P75, DOI 10.1515/BC.2004.010; Rizvi NA, 2004, CLIN CANCER RES, V10, P1963, DOI 10.1158/1078-0432.CCR-1183-02; Rudek MA, 2001, J CLIN ONCOL, V19, P584, DOI 10.1200/JCO.2001.19.2.584; Saghizadeh M, 2001, AM J PATHOL, V158, P723, DOI 10.1016/S0002-9440(10)64015-1; Sharma R, 2004, ONCOLOGY-BASEL, V67, P300, DOI 10.1159/000081331; SHIMIZU N, 1987, ONCOLOGY, V44, P240, DOI 10.1159/000226486; SOBIN LH, 2002, TNM CLASSIFICATION M, P65; Solomon A, 2003, J LAB CLIN MED, V142, P348, DOI 10.1016/S0022-2143(03)00149-5; Thorns V, 2003, ANTICANCER RES, V23, P3937; Ushijima T, 2004, CANCER CELL, V5, P121, DOI 10.1016/S1535-6108(04)00033-9; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Yamashita K, 1998, INT J CANCER, V79, P187; Yasui W, 2004, CANCER SCI, V95, P385, DOI 10.1111/j.1349-7006.2004.tb03220.x; Yasui Wataru, 2000, Journal of Gastroenterology, V35, P111; Zhang XW, 2004, CANCER RES, V64, P2474, DOI 10.1158/0008-5472.CAN-03-3443; Zucker S, 1999, ANN NY ACAD SCI, V878, P212, DOI 10.1111/j.1749-6632.1999.tb07687.x	51	137	153	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2546	2557		10.1038/sj.onc.1209279	http://dx.doi.org/10.1038/sj.onc.1209279			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16331256				2022-12-28	WOS:000236948000013
J	Chattopadhyay, A; Tate, SA; Beswick, RW; Wagner, SD; Ferrigno, PK				Chattopadhyay, A; Tate, SA; Beswick, RW; Wagner, SD; Ferrigno, PK			A peptide aptamer to antagonize BCL-6 function	ONCOGENE			English	Article						peptide aptamer; BCL-6; B-cell lymphoma	GERMINAL-CENTER FORMATION; FINGER PROTEIN; POZ DOMAIN; BTB DOMAIN; TRANSCRIPTION; DIFFERENTIATION; IDENTIFICATION; INFLAMMATION; COREPRESSOR; RECRUITMENT	BCL-6 is a transcription factor essential for germinal centre B-cell development. The BCL-6 gene is involved in diffuse large-cell lymphoma and overexpressed in other types of non-Hodgkin's lymphoma and in high-grade breast cancer. BCL-6 is a transcriptional repressor whose N-terminal POZ domain mediates protein-protein interactions to exert its effects. Reasoning that disruption of POZ domain-mediated interactions may be an effective route to antagonizing the effects of BCL-6 in lymphoma, we screened a library for peptide aptamers that specifically bind to BCL-6 POZ and not the POZ domains of related proteins and describe here the first of these reagents, Apt48. Apt 48 binds BCL-6 POZ in a manner distinct from the transcriptional corepressor SMRT, yet was found to prevent BCL-6-mediated repression of a luciferase reporter gene. Apt48 also reproduced several previously validated effects of BCL-6 inhibition. Not ably, expression of the differentiation markers CD69, Blimp-1 and cyclin D2 was increased in B-cell lines when Apt48 was expressed. W e also show that expression of Apt48 restores cytokine-mediated growth arrest to BCL-6 over-expressing cells. Thus, we have identified a peptide aptamer that affects a function of BCL-6 that is required to prevent differentiation of proliferating B cells.	Hammersmith Hosp, Imperial Coll London, Div Invest Sci, Dept Haematol, London W12 0NN, England; MRC, Canc Cell Unit, Hutchison MRC Res Ctr, Cambridge, England; Univ Cambridge, Canc Res UK, Dept Oncol, Hutchison MRC Res Ctr, Cambridge, England	Imperial College London; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Wagner, SD (corresponding author), Hammersmith Hosp, Imperial Coll London, Div Invest Sci, Dept Haematol, Du Cane Rd, London W12 0NN, England.	simon.wagner@imperial.ac.uk; pkf@hutchison-mrc.cam.ac.uk		Wagner, Simon/0000-0002-8914-0370; Ko Ferrigno, Paul/0000-0002-5922-4100	MRC [MC_U105359876] Funding Source: UKRI; Medical Research Council [MC_U105359876] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; Ahmad KF, 2003, MOL CELL, V12, P1551, DOI 10.1016/S1097-2765(03)00454-4; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chevallier N, 2004, BLOOD, V103, P1454, DOI 10.1182/blood-2003-06-2081; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Crawford Margaret, 2003, Briefings in Functional Genomics & Proteomics, V2, P72, DOI 10.1093/bfgp/2.1.72; Davies JM, 1999, ONCOGENE, V18, P365, DOI 10.1038/sj.onc.1202332; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; Dhordain P, 2000, ONCOGENE, V19, P6240, DOI 10.1038/sj.onc.1203976; Fujita N, 2004, CELL, V119, P75, DOI 10.1016/j.cell.2004.09.014; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; GOLEMIS EA, 1999, CURRENT PROTOCOS MOL; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Harris MB, 1999, MOL CELL BIOL, V19, P7264; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; Logarajah S, 2003, ONCOGENE, V22, P5572, DOI 10.1038/sj.onc.1206689; Melnick A, 2000, MOL CELL BIOL, V20, P6550, DOI 10.1128/MCB.20.17.6550-6567.2000; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; Muto A, 1998, EMBO J, V17, P5734, DOI 10.1093/emboj/17.19.5734; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; Okabe S, 1998, MOL CELL BIOL, V18, P4235, DOI 10.1128/MCB.18.7.4235; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; Polo JM, 2004, NAT MED, V10, P1329, DOI 10.1038/nm1134; Reljic R, 2000, J EXP MED, V192, P1841, DOI 10.1084/jem.192.12.1841; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 2001, MOL CLONING LAB MANU; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; YE BHH, 1993, CANCER RES, V53, P2732	35	41	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2223	2233		10.1038/sj.onc.1209252	http://dx.doi.org/10.1038/sj.onc.1209252			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16331266				2022-12-28	WOS:000236581200009
J	Ehrlich, M; Woods, CB; Yu, MC; Dubeau, L; Yang, F; Campan, M; Weisenberger, DJ; Long, TI; Youn, B; Fiala, ES; Laird, PW				Ehrlich, M; Woods, CB; Yu, MC; Dubeau, L; Yang, F; Campan, M; Weisenberger, DJ; Long, TI; Youn, B; Fiala, ES; Laird, PW			Quantitative analysis of associations between DNA hypermethylation, hypomethylation, and DNMT RNA levels in ovarian tumors	ONCOGENE			English	Article						DNA hypomethylation; DNA hypermethylation; DNA methyltransferases; ovarian tumors	DE-NOVO METHYLATION; CPG ISLAND METHYLATION; SATELLITE DNA; WILMS-TUMORS; ICF SYNDROME; FREQUENT HYPOMETHYLATION; METHYLTRANSFERASE GENE; PROMOTER METHYLATION; PERICENTROMERIC DNA; CELL-PROLIFERATION	How hypermethylation and hypomethylation of different parts of the genome in cancer are related to each other and to DNA methyltransferase ( DNMT) gene expression is ill defined. We used ovarian epithelial tumors of different malignant potential to look for associations between 5'-gene region or promoter hypermethylation, satellite, or global DNA hypomethylation, and RNA levels for ten DNMT isoforms. In the quantitative MethyLight assay, six of the 55 examined gene loci ( LTB4R, MTHFR, CDH13, PGR, CDH1, and IGSF4) were significantly hypermethylated relative to the degree of malignancy ( after adjustment for multiple comparisons; P < 0.001). Importantly, hypermethylation of these genes was associated with degree of malignancy independently of the association of satellite or global DNA hypomethylation with degree of malignancy. Cancer-related increases in methylation of only two studied genes, LTB4R and MTHFR, which were appreciably methylated even in control tissues, were associated with DNMT1 RNA levels. Cancer-linked satellite DNA hypomethylation was independent of RNA levels for all DNMT3B isoforms, despite the ICF syndrome-linked DNMT3B deficiency causing juxtacentromeric satellite DNA hypomethylation. Our results suggest that there is not a simple association of gene hypermethylation in cancer with altered DNMT RNA levels, and that this hypermethylation is neither the result nor the cause of satellite and global DNA hypomethylation.	Tulane Med Sch, Human Genet Program SL31, New Orleans, LA 70112 USA; Tulane Med Sch, Tulane Canc Ctr, Dept Biochem, New Orleans, LA 70112 USA; Univ Minnesota, Ctr Canc, Minneapolis, MN USA; Univ So Calif, Dept Pathol, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biochem, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90089 USA; Univ So Calif, Dept Surg & Mol Biol, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90089 USA; Amer Hlth Fdn, Dept Biochem Pharmacol, Valhalla, NY 10595 USA; NYU, Sch Med, Tuxedo Pk, NY USA	Tulane University; Tulane University; University of Minnesota System; University of Minnesota Twin Cities; University of Southern California; University of Southern California; University of Southern California; American Health Foundation; New York University	Ehrlich, M (corresponding author), Tulane Med Sch, Human Genet Program SL31, 1430 Tulane Ave, New Orleans, LA 70112 USA.	ehrlich@tulane.edu	Laird, Peter W/G-8683-2012; Weisenberger, Daniel/AAA-8314-2020	Laird, Peter W/0000-0001-9117-3641; Weisenberger, Daniel/0000-0001-8303-2603	NATIONAL CANCER INSTITUTE [P01CA070972, R01CA081506, P01CA046589, R01CA096958] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA096958, CA96958, P01 CA070972, P01CA46589, R01 CA081506, CA81506, P01 CA70972] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agoston AT, 2005, J BIOL CHEM, V280, P18302, DOI 10.1074/jbc.M501675200; Ahluwalia A, 2001, GYNECOL ONCOL, V82, P261, DOI 10.1006/gyno.2001.6291; Bariol C, 2003, AM J PATHOL, V162, P1361, DOI 10.1016/S0002-9440(10)63932-6; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Broday L, 1999, MOL CELL BIOL, V19, P3198; Chedin F, 2002, P NATL ACAD SCI USA, V99, P16916, DOI 10.1073/pnas.262443999; Chen TP, 2002, J BIOL CHEM, V277, P38746, DOI 10.1074/jbc.M205312200; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; Draper N.R., 1998, APPL REGRESSION ANAL, P79; Dubeau L, 1999, GYNECOL ONCOL, V72, P437, DOI 10.1006/gyno.1998.5275; Eads CA, 2001, CANCER RES, V61, P3410; Eads CA, 1999, CANCER RES, V59, P2302; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; EHRLICH M, 1982, NUCLEIC ACIDS RES, V10, P2709, DOI 10.1093/nar/10.8.2709; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Ehrlich M, 2003, CLIN IMMUNOL, V109, P17, DOI 10.1016/S1521-6616(03)00201-8; Ehrlich M, 2003, CANCER GENET CYTOGEN, V141, P97, DOI 10.1016/S0165-4608(02)00668-4; Ehrlich M, 2002, ONCOGENE, V21, P6694, DOI 10.1038/sj.onc.1205890; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Feinberg AP, 2002, SEMIN CANCER BIOL, V12, P389, DOI 10.1016/S1044-579X(02)00059-7; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; Gowher H, 2002, J BIOL CHEM, V277, P20409, DOI 10.1074/jbc.M202148200; Graff JR, 1998, CANCER RES, V58, P2063; Grunau C, 2005, GENE CHROMOSOME CANC, V43, P11, DOI 10.1002/gcc.20155; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Hermann A, 2003, J BIOL CHEM, V278, P31717, DOI 10.1074/jbc.M305448200; Hernandez R, 1997, CYTOGENET CELL GENET, V76, P196, DOI 10.1159/000134548; Hibi K, 2004, BRIT J CANCER, V90, P1030, DOI 10.1038/sj.bjc.6601647; Hollander M., 2014, NONPARAMETRIC STAT M, V3rd ed.; ISAACS WB, 1995, CANCER SURV, V23, P19; Issa Jean-Pierre, 2000, P311; Jackson K, 2004, CANCER BIOL THER, V3, P1225, DOI 10.4161/cbt.3.12.1222; Jacobsen SE, 1997, SCIENCE, V277, P1100, DOI 10.1126/science.277.5329.1100; Jansen M, 2002, CANCER BIOL THER, V1, P293, DOI 10.4161/cbt.84; JEANPIERRE M, 1993, HUM MOL GENET, V2, P731, DOI 10.1093/hmg/2.6.731; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kaneda A, 2004, CANCER SCI, V95, P58, DOI 10.1111/j.1349-7006.2004.tb03171.x; Kawakami M, 1999, INT J ONCOL, V15, P715; Kimura F, 2003, INT J CANCER, V104, P568, DOI 10.1002/ijc.10988; KOKALJVOKAC N, 1993, CYTOGENET CELL GENET, V63, P11, DOI 10.1159/000133492; Kondo T, 2000, HUM MOL GENET, V9, P597, DOI 10.1093/hmg/9.4.597; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; Li JD, 2005, GYNECOL ONCOL, V96, P150, DOI 10.1016/j.ygyno.2004.08.050; McCluskey Lisa L., 1997, Current Opinion in Oncology, V9, P465, DOI 10.1097/00001622-199709050-00011; Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V; Nishiyama R, 2005, CANCER BIOL THER, V4, P440; Nishiyama R, 2005, MOL CANCER RES, V3, P617, DOI 10.1158/1541-7786.MCR-05-0146; Okada H, 2005, INT J ONCOL, V26, P369; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pogribny IP, 1997, CANCER LETT, V115, P31, DOI 10.1016/S0304-3835(97)04708-3; Qu GZ, 1999, CANCER GENET CYTOGEN, V109, P34, DOI 10.1016/S0165-4608(98)00143-5; Qu GZ, 1999, NUCLEIC ACIDS RES, V27, P2332, DOI 10.1093/nar/27.11.2332; Qu GZ, 1999, MUTAT RES-FUND MOL M, V423, P91, DOI 10.1016/S0027-5107(98)00229-2; Rathi A, 2002, CLIN CANCER RES, V8, P3324; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Saito Y, 2002, P NATL ACAD SCI USA, V99, P10060, DOI 10.1073/pnas.152121799; Santourlidis S, 1999, PROSTATE, V39, P166; Sasaki M, 2003, MOL CELL ENDOCRINOL, V202, P201, DOI 10.1016/S0303-7207(03)00084-4; Strathdee G, 2004, CARCINOGENESIS, V25, P693, DOI 10.1093/carcin/bgh066; Tang LY, 2003, J BIOL CHEM, V278, P33613, DOI 10.1074/jbc.C300255200; Taniguchi T, 2003, NAT MED, V9, P568, DOI 10.1038/nm852; Viel A, 1997, BRIT J CANCER, V75, P1105, DOI 10.1038/bjc.1997.191; Wei SH, 2002, CLIN CANCER RES, V8, P2246; Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987; Weisenberger DJ, 2004, MOL CANCER RES, V2, P62; Widschwendter M, 2004, CANCER RES, V64, P4472, DOI 10.1158/0008-5472.CAN-04-0238; ZHENG JP, 1995, J NATL CANCER I, V87, P1146, DOI 10.1093/jnci/87.15.1146; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	72	102	113	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2636	2645		10.1038/sj.onc.1209145	http://dx.doi.org/10.1038/sj.onc.1209145			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16532039	Green Accepted			2022-12-28	WOS:000237099400007
J	Leivonen, SK; Ala-aho, R; Koli, K; Grenman, R; Peltonen, J; Kahari, VM				Leivonen, SK; Ala-aho, R; Koli, K; Grenman, R; Peltonen, J; Kahari, VM			Activation of Smad signaling enhances collagenase-3 (MMP-13) expression and invasion of head and neck squamous carcinoma cells	ONCOGENE			English	Article						TGF-beta; Smad; matrix metalloproteinase; collagenase; squamous cell carcinoma	GROWTH-FACTOR-BETA; HUMAN GINGIVAL FIBROBLASTS; TGF-BETA; IN-VITRO; MATRIX METALLOPROTEINASE-13; MEDIATED TRANSCRIPTION; SUPPRESSES METASTASIS; HUMAN KERATINOCYTES; GENE-EXPRESSION; KINASE PATHWAY	Squamous cell carcinoma ( SCC) cells of the head and neck specifically express collagenase-3 ( matrix metalloproteinase-13 ( MMP-13)), the expression of which correlates with their invasion capacity. Transforming growth factor-beta ( TGF-beta) enhances MMP-13 and collagenase-1( MMP-1) expression and invasion of SCC cells via p38 mitogen-activated protein kinase. Here, we have examined the role of Smad signaling in regulating MMP-13 expression and in invasion of head and neck SCC cells. Treatment with TGF-beta resulted in activation of Smad2 and Smad3 in SCC cells, but had no effect on their proliferation or viability. Basal activation of Smad3 and p38 was noted in SCC cells without exogenous TGF-beta stimulation, and adenoviral delivery of Smad7 and dominant-negative Smad3 inhibited p38 activation in these cells. Adenoviral overexpression of Smad3 augmented the upregulatory effect of TGF-beta on MMP-13 expression by SCC cells. Disruption of Smad signaling by adenoviral expression of kinase-defective TGF-b type I receptor ( activin-receptor-like kinase-5),Smad7, and dominant-negative Smad3 potently suppressed the basal and TGF-beta-induced expression of MMP-13 and MMP-1 in SCC cells, and inhibited their basal and TGF-beta-induced invasion through Matrigel and type I collagen. Adenoviral overexpression of Smad7 in cutaneous and oral SCC cells significantly inhibited their implantation in skin of SCID mice and growth of xenografts in vivo, as compared to LacZ adenovirus-transduced control cells. Together, these results show that Smad signaling plays an important role in promoting the invasive phenotype of human head and neck SCC cells by upregulating their collagenase expression.	Univ Turku, Dept Dermatol, Dept Med Biochem & Mol Biol, FI-20521 Turku, Finland; Univ Turku, MediCity Res Lab, FI-20521 Turku, Finland; Univ Turku, Turku Grad Sch Biomed Sci, FI-20521 Turku, Finland; Univ Helsinki, Dept Virol, Helsinki, Finland; Univ Helsinki, Dept Pathol, Haartman Inst, Helsinki, Finland; Univ Helsinki, Helsinki Univ Hosp, Helsinki, Finland; Turku Univ, Cent Hosp, Dept Otorhinolaryngol Head & Neck Surg, Turku, Finland; Univ Oulu, Dept Anat & Cell Biol, Oulu, Finland	University of Turku; University of Turku; University of Turku; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Turku; University of Oulu	Kahari, VM (corresponding author), Univ Turku, Dept Dermatol, Dept Med Biochem & Mol Biol, POB 52, FI-20521 Turku, Finland.	veli-matti.kahari@utu.fi	Leivonen, Suvi-Katri/AAK-3096-2021; Peltonen, Juha/O-7159-2019; Kahari, Veli-Matti/E-5144-2011	Peltonen, Juha/0000-0002-5732-4167; Kahari, Veli-Matti/0000-0003-2421-9368; Leivonen, Suvi-Katri/0000-0003-3224-0757				ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Airola K, 1999, BRIT J CANCER, V80, P733, DOI 10.1038/sj.bjc.6690417; Airola K, 1997, J INVEST DERMATOL, V109, P225, DOI 10.1111/1523-1747.ep12319441; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Ala-aho R, 2000, ONCOGENE, V19, P248, DOI 10.1038/sj.onc.1203306; Ala-aho R, 2004, ONCOGENE, V23, P5111, DOI 10.1038/sj.onc.1207678; Ala-Aho R, 2005, BIOCHIMIE, V87, P273, DOI 10.1016/j.biochi.2004.12.009; Ala-Aho R, 2002, INT J CANCER, V97, P283, DOI 10.1002/ijc.1619; Ala-Aho R, 2002, ONCOGENE, V21, P1187, DOI 10.1038/sj.onc.1205198; BOUKAMP P, 1990, CANCER RES, V50, P2840; BOYCE ST, 1983, J INVEST DERMATOL, V81, pS33, DOI 10.1111/1523-1747.ep12540422; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; Cazorla M, 1998, J PATHOL, V186, P144, DOI 10.1002/(SICI)1096-9896(1998100)186:2<144::AID-PATH147>3.0.CO;2-#; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Dooley S, 2001, FEBS LETT, V502, P4, DOI 10.1016/S0014-5793(01)02656-4; Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hu PPC, 1998, ENDOCR REV, V19, P349, DOI 10.1210/er.19.3.349; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Javelaud D, 2005, ONCOGENE, V24, P7624, DOI 10.1038/sj.onc.1208900; Johansson N, 2000, J CELL SCI, V113, P227; Johansson N, 1999, AM J PATHOL, V154, P469, DOI 10.1016/S0002-9440(10)65293-5; Johansson N, 1997, DEV DYNAM, V208, P387, DOI 10.1002/(SICI)1097-0177(199703)208:3<387::AID-AJA9>3.0.CO;2-E; Johansson N, 1997, CELL GROWTH DIFFER, V8, P243; Johansson N, 1997, AM J PATHOL, V151, P499; KESKIOJA J, 1988, J BIOL CHEM, V263, P3111; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; LANSDORF CD, 1999, HUMAN CELL CULTURE, V2; Leivonen SK, 2002, J BIOL CHEM, V277, P46338, DOI 10.1074/jbc.M206535200; Li AG, 2004, CANCER RES, V64, P7836, DOI 10.1158/0008-5472.CAN-04-1331; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Moustakas A, 2001, J CELL SCI, V114, P4359; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nikkola J, 2001, MELANOMA RES, V11, P157, DOI 10.1097/00008390-200104000-00011; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Piek E, 1999, INT J CANCER, V80, P756, DOI 10.1002/(SICI)1097-0215(19990301)80:5<756::AID-IJC21>3.0.CO;2-N; Ravanti L, 2001, FASEB J, V15, P1098, DOI 10.1096/fj.00-0588fje; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rodeck U, 1999, CANCER RES, V59, P547; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; StahleBackdahl M, 1997, LAB INVEST, V76, P717; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; Tian F, 2004, CANCER RES, V64, P4523, DOI 10.1158/0008-5472.CAN-04-0030; Tian F, 2003, CANCER RES, V63, P8284; Uhl M, 2004, CANCER RES, V64, P7954, DOI 10.1158/0008-5472.CAN-04-1013; Ungefroren H, 2003, J BIOL CHEM, V278, P11041, DOI 10.1074/jbc.M300035200; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	61	77	80	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2588	2600		10.1038/sj.onc.1209291	http://dx.doi.org/10.1038/sj.onc.1209291			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16407850				2022-12-28	WOS:000237099400003
J	Wang, X; Wang, TT; White, JH; Studzinski, GP				Wang, X.; Wang, T-T; White, J. H.; Studzinski, G. P.			Induction of kinase suppressor of RAS-1( KSR-1) gene by 1, alpha 25-dihydroxyvitamin D-3 in human leukemia HL60 cells through a vitamin D response element in the 5 '-flanking region	ONCOGENE			English	Article						KSR; differentiation; vitamin D; vitamin D receptor; VDRE; RXRalfa; MAPK	ACTIVATED PROTEIN-KINASE; 1,25-DIHYDROXYVITAMIN D-3; MONOCYTIC DIFFERENTIATION; SIGNAL-TRANSDUCTION; HL-60 CELLS; D-RECEPTOR; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; TRANSCRIPTIONAL ACTIVATION; MYELOID-LEUKEMIA; BINDING PROTEINS	Differentiation therapy is being developed as an additional therapeutic option for the treatment of several forms of cancer, including myeloid leukemia. In model systems, the physiologically active form of vitamin D, 1, alpha 25-dihydroxyvitamin D-3 (1,25D), induces monocytic differentiation of human myeloid cells, but the mechanism is not clear. We report here, the first direct connection between the signal provided by 1,25D and the molecular circuitry known to be involved in monocytic differentiation. Specifically, we show that 1,25D selectively increases the expression of the gene encoding kinase suppressor of Ras-1 (KSR-1) in HL60 cells, while other differentiation-inducing agents such as 12-O-tetradecanoylphorbol-13-acetate, retinoic acid or dimethyl sulfoxide do not significantly increase KSR-1 expression. Further, the upregulation of KSR-1 gene by 1,25D is competed by ZK159222, an antagonist of vitamin D receptor (VDR) action, and can occur in the presence of protein synthesis inhibitor cycloheximide, showing that the effect is direct. Most importantly, we have identified a vitamin D responsive element (VDRE) in the promoter region of the human KSR-1 gene, to which VDR binds in a 1,25D-dependent manner, in vitro and in vivo. This binding is paralleled by increased association of RNA polymerase II with the transcription start site of KSR-1 gene, and the VDRE is functional in reporter assays. Our findings offer a potential mechanism for a signaling pathway that contributes to 1,25D-induced monocytic differentiation of human myeloid leukemia cells.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pathol & Lab Med, Newark, NJ 07103 USA; McGill Univ, Dept Physiol, Montreal, PQ, Canada	Rutgers State University New Brunswick; Rutgers State University Medical Center; McGill University	Studzinski, GP (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pathol & Lab Med, 185 S Orange Ave,C543, Newark, NJ 07103 USA.	studzins@umdnj.edu	white, john h/N-9782-2013	white, john h/0000-0002-4785-2687	NCI NIH HHS [R01 CA044722-16, R01 CA044722, R01-CA44722-16] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044722] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE E, 1981, P NATL ACAD SCI-BIOL, V78, P4990, DOI 10.1073/pnas.78.8.4990; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BIELAWSKA A, 1992, FEBS LETT, V307, P211, DOI 10.1016/0014-5793(92)80769-D; BUNCE CM, 1983, EXP HEMATOL, V11, P828; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; CHOMIENNE C, 1990, BLOOD, V76, P1710; Christakos S, 2003, J CELL BIOCHEM, V88, P238, DOI 10.1002/jcb.10349; Dhawan P, 2005, MOL CELL BIOL, V25, P472, DOI 10.1128/MCB.25.1.472-487.2005; FERRARA J, 1994, J BIOL CHEM, V269, P2971; FRETZ JA, 2006, MOL ENDOCRINOL; Herdick M, 2000, J BIOL CHEM, V275, P16506, DOI 10.1074/jbc.M910000199; Ikezoe T, 2005, CANCER RES, V65, P4762, DOI 10.1158/0008-5472.CAN-03-3619; Ji Y, 2004, CANCER RES, V64, P370, DOI 10.1158/0008-5472.CAN-03-3029; Kolesnick R, 2004, J CLIN INVEST, V114, P1233, DOI 10.1172/JCI200423441; KOLLA SS, 1994, CANCER RES, V54, P1418; Lamkin TJ, 2006, J CELL BIOCHEM, V97, P1328, DOI 10.1002/jcb.20745; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Lin R, 2004, BIOESSAYS, V26, P21, DOI 10.1002/bies.10368; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Marcinkowska E, 2001, ANTICANCER RES, V21, P499; Ory S, 2004, CURR BIOL, V14, pR277, DOI 10.1016/j.cub.2004.03.023; Pan Z, 1999, J BIOL CHEM, V274, P23242, DOI 10.1074/jbc.274.33.23242; Qi XM, 2002, J BIOL CHEM, V277, P25884, DOI 10.1074/jbc.M203039200; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; Roy F, 2002, CURR BIOL, V12, pR325, DOI 10.1016/S0960-9822(02)00831-X; SIEGEL MR, 1963, NATURE, V200, P675, DOI 10.1038/200675a0; Song XD, 1998, ENDOCRINOLOGY, V139, P457, DOI 10.1210/en.139.2.457; Studzinski GP, 2005, J STEROID BIOCHEM, V97, P47, DOI 10.1016/j.jsbmb.2005.06.010; STUDZINSKI GP, 1985, P SOC EXP BIOL MED, V179, P288; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Wang Q, 2005, J CELL PHYSIOL, V204, P962, DOI 10.1002/jcp.20355; Wang Q, 2003, J CELL BIOCHEM, V89, P1087, DOI 10.1002/jcb.10595; Wang QM, 1996, CANCER RES, V56, P264; Wang TT, 2005, MOL ENDOCRINOL, V19, P2685, DOI 10.1210/me.2005-0106; Wang XN, 2004, J CELL PHYSIOL, V198, P333, DOI 10.1002/jcp.10443; Wang XN, 2001, J CELL BIOCHEM, V80, P471, DOI 10.1002/1097-4644(20010315)80:4<471::AID-JCB1001>3.0.CO;2-J; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	37	29	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2006	25	53					7078	7085		10.1038/sj.onc.1209697	http://dx.doi.org/10.1038/sj.onc.1209697			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16732322	Green Accepted			2022-12-28	WOS:000241910500007
J	Lin, YT; Chen, Y; Wu, G; Lee, WH				Lin, Y-T; Chen, Y.; Wu, G.; Lee, W-H			Hec1 sequentially recruits Zwint-1 and ZW10 to kinetochores for faithful chromosome segregation and spindle checkpoint control	ONCOGENE			English	Article						mitosis; kinetochores; spindle checkpoint; chromosome segregation and microtubule	MITOTIC CHECKPOINT; BUDDING YEAST; CELL-CYCLE; MICROTUBULE ATTACHMENT; MAMMALIAN-CELLS; NDC80 COMPLEX; MOLECULAR ANALYSIS; OUTER KINETOCHORE; DROSOPHILA ZW10; GENE-PRODUCT	Faithful chromosome segregation is essential for maintaining the genomic integrity, which requires coordination among chromosomes, kinetochores, centrosomes and spindles during mitosis. Previously, we discovered a novel coiled-coil protein, highly expressed in cancer 1 (Hec1), which is indispensable for this process. However, the precise underlying mechanism remains unclear. Here, we show that Hec1 directly interacts with human ZW10 interacting protein (Zwint-1), a binding partner of Zeste White 10 ( ZW10) that is required for chromosome motility and spindle checkpoint control. In mitotic cells, Hec1 transiently forms complexes with Zwint-1 and ZW10 in a temporal and spatial manner. Although the three proteins have variable cell cycle-dependent expression profiles, they can only be co-immunoprecipitated during M phase. Immunofluorescent study showed that Hec1 and Zwint-1 co-localize at kinetochores beginning at prophase and that ZW10 joins them later at prometaphase. Depletion of Hec1 impairs the recruitment of both Zwint-1 and ZW10 to kinetochores, while depletion of Zwint-1 abrogates the kinetochore localization of ZW10 but not Hec1. The results suggest that the localization of Hec1 at kinetochores is required for the sequential recruitment of Zwint-1 and ZW10. Disrupting this recruitment by inhibiting the expression of Hec1 or Zwint-1 causes chromosome missegregation, spindle checkpoint failure, and eventually cell death upon cytokinesis. Taken together, these results, at least in part, provide a molecular basis to explain how Hec1 plays a crucial role for spindle checkpoint control and faithful chromosome segregation.	Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX USA	University of California System; University of California Irvine; University of Texas System; University of Texas Health San Antonio	Lee, WH (corresponding author), Univ Calif Irvine, Dept Biol Chem, 124 Sprague Hall, Irvine, CA 92697 USA.	whlee@uci.edu			NCI NIH HHS [CA 107568] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA107568] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Basto R, 2000, NAT CELL BIOL, V2, P939, DOI 10.1038/35046592; Bharadwaj R, 2004, J BIOL CHEM, V279, P13076, DOI 10.1074/jbc.M310224200; Biggins S, 2001, GENE DEV, V15, P3118, DOI 10.1101/gad.934801; BRINKLEY BR, 1966, CHROMOSOMA, V19, P28, DOI 10.1007/BF00332792; Chan GK, 2005, TRENDS CELL BIOL, V15, P589, DOI 10.1016/j.tcb.2005.09.010; Chan GKT, 2000, NAT CELL BIOL, V2, P944, DOI 10.1038/35046598; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Cheeseman IM, 2002, J CELL BIOL, V157, P199, DOI 10.1083/jcb.200201052; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chen Y, 1997, J BIOL CHEM, V272, P24081, DOI 10.1074/jbc.272.38.24081; Chen YM, 1997, MOL CELL BIOL, V17, P6049, DOI 10.1128/MCB.17.10.6049; Chen YM, 2002, J BIOL CHEM, V277, P49408, DOI 10.1074/jbc.M207069200; Ciferri C, 2005, J BIOL CHEM, V280, P29088, DOI 10.1074/jbc.M504070200; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Craig JM, 1999, EXP CELL RES, V246, P249, DOI 10.1006/excr.1998.4278; De Wulf P, 2003, GENE DEV, V17, P2902, DOI 10.1101/gad.1144403; DeLuca JG, 2005, MOL BIOL CELL, V16, P519, DOI 10.1091/mbc.E04-09-0852; Desai A, 2003, GENE DEV, V17, P2421, DOI 10.1101/gad.1126303; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; EARNSHAW WC, 1987, J CELL BIOL, V104, P817, DOI 10.1083/jcb.104.4.817; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Emanuele MJ, 2005, MOL BIOL CELL, V16, P4882, DOI 10.1091/mbc.E05-03-0239; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; He XW, 2001, CELL, V106, P195, DOI 10.1016/S0092-8674(01)00438-X; Hori T, 2003, J CELL SCI, V116, P3347, DOI 10.1242/jcs.00645; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Janke C, 2001, EMBO J, V20, P777, DOI 10.1093/emboj/20.4.777; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kitagawa K, 2001, NAT REV MOL CELL BIO, V2, P678, DOI 10.1038/35089568; Kniola B, 2001, MOL BIOL CELL, V12, P2767, DOI 10.1091/mbc.12.9.2767; Kops GJPL, 2005, J CELL BIOL, V169, P49, DOI 10.1083/jcb.200411118; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Lou Y, 2004, J BIOL CHEM, V279, P20049, DOI 10.1074/jbc.M314205200; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; McCleland ML, 2004, CURR BIOL, V14, P131, DOI 10.1016/j.cub.2003.12.058; McCleland ML, 2003, GENE DEV, V17, P101, DOI 10.1101/gad.1040903; McEwen BF, 1998, CHROMOSOMA, V107, P366, DOI 10.1007/s004120050320; Meraldi P, 2004, DEV CELL, V7, P45, DOI 10.1016/j.devcel.2004.06.006; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Mikami Y, 2005, MOL CELL BIOL, V25, P1958, DOI 10.1128/MCB.25.5.1958-1970.2005; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Obuse C, 2004, NAT CELL BIOL, V6, P1135, DOI 10.1038/ncb1187; PALMER DK, 1987, J CELL BIOL, V104, P805, DOI 10.1083/jcb.104.4.805; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Savoian MS, 2000, NAT CELL BIOL, V2, P948, DOI 10.1038/35046605; Sharp DJ, 2000, NAT CELL BIOL, V2, P922, DOI 10.1038/35046574; Starr DA, 2000, J CELL SCI, V113, P1939; Starr DA, 1998, J CELL BIOL, V142, P763, DOI 10.1083/jcb.142.3.763; Starr DA, 1997, J CELL BIOL, V138, P1289, DOI 10.1083/jcb.138.6.1289; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Tanaka TU, 2002, CELL, V108, P317, DOI 10.1016/S0092-8674(02)00633-5; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Wang HM, 2004, J BIOL CHEM, V279, P54590, DOI 10.1074/jbc.M407588200; Wei RR, 2005, P NATL ACAD SCI USA, V102, P5363, DOI 10.1073/pnas.0501168102; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; Wigge PA, 2001, J CELL BIOL, V152, P349, DOI 10.1083/jcb.152.2.349; Wigge PA, 1998, J CELL BIOL, V141, P967, DOI 10.1083/jcb.141.4.967; Williams BC, 2003, MOL BIOL CELL, V14, P1379, DOI 10.1091/mbc.E02-09-0624; WILLIAMS BC, 1992, J CELL BIOL, V118, P759, DOI 10.1083/jcb.118.4.759; WILLIAMS BC, 1994, J CELL SCI, V107, P785; Xiao J, 2001, J BIOL CHEM, V276, P6105, DOI 10.1074/jbc.M008893200; Zheng L, 1999, MOL CELL BIOL, V19, P5417; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; ZINKOWSKI RP, 1991, J CELL BIOL, V113, P1091, DOI 10.1083/jcb.113.5.1091	73	51	59	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	52					6901	6914		10.1038/sj.onc.1209687	http://dx.doi.org/10.1038/sj.onc.1209687			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16732327				2022-12-28	WOS:000241732300001
J	Huang, Y; Zhao, Q; Zhou, CX; Gu, ZM; Li, D; Xu, HZ; Sims, PJ; Zhao, KW; Chen, GQ				Huang, Y.; Zhao, Q.; Zhou, C-X; Gu, Z-M; Li, D.; Xu, H-Z; Sims, P. J.; Zhao, K-W; Chen, G-Q			Antileukemic roles of human phospholipid scramblase 1 gene, evidence from inducible PLSCR1-expressing leukemic cells	ONCOGENE			English	Article						PLSCR1; proliferation; differentiation; apoptosis; leukemia; gene regulation	KINASE-C-DELTA; GROWTH-FACTOR RECEPTOR; UV-INDUCED APOPTOSIS; PLASMA-MEMBRANE; MYELOID-LEUKEMIA; RETINOIC ACID; C/EBP-ALPHA; INDUCED-DIFFERENTIATION; TRANSBILAYER MOVEMENT; MEDIATED DEGRADATION	Phospholipid scramblase 1 (PLSCR1) is a multiply palmitoylated protein which is localized in either the cell membrane or nucleus depending on its palmitoylated state. The increasing evidence showed the biological roles of PLSCR1 in cell signaling, maturation and apoptosis. To investigate the functions of PLSCR1 in leukemic cells, we generated an inducible PLSCR1-expressing cell line using myeloid leukemic U937 cells. In this cell line, PLSCR1 was tightly regulated and induced upon tetracycline withdrawal. Our results showed that inducible PLSCR1 expression arrested the proliferation of U937 cells at G(1) phase. Meanwhile, PLSCR1-overexpressing U937 cells also underwent granulocyte-like differentiation with increased sensitivity to etoposide-induced apoptosis. Furthermore, we also found that PLSCR1 induction increased cyclin-dependent kinase inhibitors p27(Kip1) and p21(Cip1) proteins, together with downregulation of S phase kinase-associated protein 2 (SKP2), an F-box subunit of the ubiquitin-ligase complex that targets proteins for degradation. Additionally, PLSCR1 induction significantly decreased c-Myc protein and antiapoptotic Bcl-2 protein. Although the exact mechanism by which PLSCR1 regulates these cellular events and gene expression remains unresolved, our results suggest that PLSCR1 plays the antagonistic role regarding leukemia development. These data will shed new insights into understanding the biochemical and biological functions of PLSCR1 protein.	Shanghai Jiao Tong Univ, Sch Med, Key Lab Cell Differentiat & Apoptosis Chinese Min, Dept Pathophysiol, Shanghai 200025, Peoples R China; Shanghai Jiao Tong Univ, Sch Med, Inst Hlth Sci, Shanghai Inst Biol Sci, Shanghai 200030, Peoples R China; Shanghai Jiao Tong Univ, Sch Med, Grad Sch, Chinese Acad Sci, Shanghai 200030, Peoples R China; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA USA	Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Jiao Tong University; Scripps Research Institute	Chen, GQ (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Key Lab Cell Differentiat & Apoptosis Chinese Min, Dept Pathophysiol, 280,Chong Qing S Rd, Shanghai 200025, Peoples R China.	chengq@shsmu.edu.cn	Li, Dong/C-7344-2011	chen, guo qiang/0000-0003-4936-2363	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036946, R01HL076215] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL076215, HL036946] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bailey K, 2005, BBA-MOL CELL BIOL L, V1733, P199, DOI 10.1016/j.bbalip.2004.12.013; Basse F, 1996, J BIOL CHEM, V271, P17205, DOI 10.1074/jbc.271.29.17205; Ben-Efraim I, 2004, BIOCHEMISTRY-US, V43, P3518, DOI 10.1021/bi0356911; Boer J, 1998, MOL CELL BIOL, V18, P1236, DOI 10.1128/MCB.18.3.1236; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chen MH, 2005, J BIOL CHEM, V280, P10599, DOI 10.1074/jbc.M413194200; Cheng T, 2000, NAT MED, V6, P1235, DOI 10.1038/81335; COLBY WW, 1983, NATURE, V301, P722, DOI 10.1038/301722a0; Coleman ML, 2003, EMBO J, V22, P2036, DOI 10.1093/emboj/cdg189; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; Friedman AD, 2002, J CELL BIOCHEM, V86, P624, DOI 10.1002/jcb.10271; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; Jiang Y, 2005, LEUKEMIA, V19, P1239, DOI 10.1038/sj.leu.2403734; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Kasukabe T, 1998, BIOCHEM BIOPH RES CO, V249, P449, DOI 10.1006/bbrc.1998.9190; Kasukabe T, 1997, BLOOD, V89, P2975, DOI 10.1182/blood.V89.8.2975; Kikuchi J, 1997, BLOOD, V89, P3980, DOI 10.1182/blood.V89.11.3980; Koschmieder S, 2005, INT J HEMATOL, V81, P368, DOI 10.1532/IJH97.05051; LARSSON LG, 1994, ONCOGENE, V9, P1247; Li LW, 1999, MOL CELL BIOL, V19, P8547; Matassa AA, 2001, J BIOL CHEM, V276, P29719, DOI 10.1074/jbc.M100273200; Mitani K, 2004, ONCOGENE, V23, P4263, DOI 10.1038/sj.onc.1207777; Munoz-Alonso MJ, 2005, J BIOL CHEM, V280, P18120, DOI 10.1074/jbc.M500758200; Nakajima H, 1996, LEUKEMIA RES, V20, P665, DOI 10.1016/0145-2126(96)00020-3; Nakamaki T, 2002, EXP HEMATOL, V30, P421, DOI 10.1016/S0301-472X(02)00779-8; Nanjundan M, 2003, J BIOL CHEM, V278, P37413, DOI 10.1074/jbc.M306182200; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Rots NY, 1999, BLOOD, V93, P2721, DOI 10.1182/blood.V93.8.2721.408k28_2721_2729; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Silverman RH, 2002, CANCER RES, V62, P397; Song MG, 2005, BLOOD, V105, P3714, DOI 10.1182/blood-2004-10-4011; Stegmaier K, 2004, NAT GENET, V36, P257, DOI 10.1038/ng1305; Steinman RA, 2002, ONCOGENE, V21, P3403, DOI 10.1038/sj.onc.1205325; Sun J, 2002, BIOCHEMISTRY-US, V41, P6338, DOI 10.1021/bi025610l; Sun J, 2001, J BIOL CHEM, V276, P28984, DOI 10.1074/jbc.M102505200; Wang ZL, 1998, EXP CELL RES, V244, P105, DOI 10.1006/excr.1998.4191; Wiedmer T, 2003, BIOCHEMISTRY-US, V42, P1227, DOI 10.1021/bi026679w; Yamanaka R, 1998, INT J MOL MED, V1, P213; Yokoyama A, 2004, LEUKEMIA RES, V28, P149, DOI 10.1016/S0145-2126(03)00189-9; Yu A, 2003, J BIOL CHEM, V278, P9706, DOI 10.1074/jbc.M204614200; Zhao J, 1998, BIOCHEMISTRY-US, V37, P6361, DOI 10.1021/bi980218m; Zhao KW, 2005, J BIOL CHEM, V280, P42707, DOI 10.1074/jbc.M506178200; Zhao KW, 2004, BLOOD, V104, P3731, DOI 10.1182/blood-2004-04-1630; Zhou QS, 2005, J BIOL CHEM, V280, P35062, DOI 10.1074/jbc.M504821200; Zhou QS, 2002, BLOOD, V99, P4030, DOI 10.1182/blood-2001-12-0271; ZHU J, 1995, LEUKEMIA, V9, P302	49	48	55	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	50					6618	6627		10.1038/sj.onc.1209677	http://dx.doi.org/10.1038/sj.onc.1209677			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16702944				2022-12-28	WOS:000241569700006
J	Yeh, AH; Bohula, EA; Macaulay, VM				Yeh, A. H.; Bohula, E. A.; Macaulay, V. M.			Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs	ONCOGENE			English	Article						IGF1R; melanoma; B-RAF; siRNA; apoptosis; chemosensitization	GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTOR; BREAST-CANCER CELLS; METASTATIC MELANOMA; ONCOGENIC MUTATIONS; SIGNALING PATHWAY; BRAF; IGF-1; B-V599E-RAF; SENSITIVITY	The type 1 insulin-like growth factor receptor (IGF1R) is overexpressed by malignant melanomas compared with benign naevi, and mediates proliferation, motility and protection from apoptosis. However, the utility of IGF1R targeting as anti-cancer therapy may be limited by activating mutations in downstream signaling intermediates. We previously showed that IGF1R knockdown blocked survival of prostate cancer cells in which Akt activation was deregulated by PTEN loss. The current study investigated effects of IGF1R targeting in cells harboring activating RAS-RAF mutations, found in 70-80% of human melanomas. We assembled a panel of eight human melanoma cell lines: two expressing wild-type (WT) B-RAF and N-RAS, two with activating N-RAS mutations and four harboring V600E B-RAF. We also generated isogenic cell populations overexpressing WT or V600E BRAF. Cells expressing V600E B-RAF were relatively resistant to apoptosis. However, IGF1R gene silencing was capable of inducing significant inhibition of survival, enhancement of apoptosis, and similar to two-fold sensitization to cisplatin and temozolomide. These effects were independent of mutation status and were associated with reduced activation of Akt and also, unexpectedly, of ERKs. These results support development of IGF1R targeting as therapy for melanoma, regardless of the presence of activating mutations in the RAS-RAF pathway.	Univ Oxford, Weatherall Inst Mol Med, ICF Grp, Canc Res UK Labs, Oxford OX1 2JD, England	Cancer Research UK; University of Oxford	Macaulay, VM (corresponding author), Weatherall Inst Mol Med, ICF Grp, Mol Oncol Labs, Oxford OX3 9DS, England.	macaulay@cancer.org.uk	Bohula, Erin/AAW-7276-2020					Benini S, 2004, INT J CANCER, V108, P358, DOI 10.1002/ijc.11576; Bohula EA, 2003, ANTI-CANCER DRUG, V14, P669, DOI 10.1097/01.cad.0000092782.37568.04; Bohula EA, 2003, J BIOL CHEM, V278, P15991, DOI 10.1074/jbc.M300714200; BOS JL, 1989, CANCER RES, V49, P4682; Brose MS, 2002, CANCER RES, V62, P6997; Camp ER, 2005, CLIN CANCER RES, V11, P397; Danson S, 2003, J CLIN ONCOL, V21, P2551, DOI 10.1200/JCO.2003.10.039; Danson S J, 2001, Expert Rev Anticancer Ther, V1, P13, DOI 10.1586/14737140.1.1.13; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dong JL, 2003, CANCER RES, V63, P3883; Dunn SE, 1997, CANCER RES, V57, P2687; Garber K, 2005, J NATL CANCER I, V97, P790, DOI 10.1093/jnci/97.11.790; GEIER A, 1995, J CELL PHYSIOL, V163, P570, DOI 10.1002/jcp.1041630318; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Gorden A, 2003, CANCER RES, V63, P3955; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hellawell GO, 2003, BJU INT, V91, P271, DOI 10.1046/j.1464-410X.2003.04061.x; Hingorani SR, 2003, CANCER RES, V63, P5198; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kanter-Lewensohn L, 2000, GROWTH FACTORS, V17, P193, DOI 10.3109/08977190009001068; Kumar R, 2003, CLIN CANCER RES, V9, P3362; LeRoith D, 2000, ENDOCRINOLOGY, V141, P1287, DOI 10.1210/en.141.4.1287; Macaluso M, 2002, J CELL PHYSIOL, V192, P125, DOI 10.1002/jcp.10109; Macaulay VM, 2001, ONCOGENE, V20, P4029, DOI 10.1038/sj.onc.1204565; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; McMenamin ME, 1999, CANCER RES, V59, P4291; Min YF, 2003, CANCER RES, V63, P6432; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; O'Connor R, 2003, HORM METAB RES, V35, P771; Park S, 2005, ONCOGENE, V24, P3535, DOI 10.1038/sj.onc.1208435; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; RESNICOFF M, 1994, CANCER RES, V54, P4848; Rochester MA, 2005, CANCER GENE THER, V12, P90, DOI 10.1038/sj.cgt.7700775; Sato S, 2004, J BIOL CHEM, V279, P33759, DOI 10.1074/jbc.M402055200; SELL C, 1995, CANCER RES, V55, P303; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiao D, 2005, MOL CARCINOGEN, V43, P130, DOI 10.1002/mc.20099	45	46	48	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	50					6574	6581		10.1038/sj.onc.1209674	http://dx.doi.org/10.1038/sj.onc.1209674			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16715137				2022-12-28	WOS:000241569700002
J	Jackson-Fisher, AJ; Bellinger, G; Shum, E; Duong, JK; Perkins, AS; Gassmann, M; Muller, W; Lloyd, KCK; Stern, DF				Jackson-Fisher, A. J.; Bellinger, G.; Shum, E.; Duong, J. K.; Perkins, A. S.; Gassmann, M.; Muller, W.; Lloyd, K. C. Kent; Stern, D. F.			Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4	ONCOGENE			English	Article						ErbB; HER-4; breast cancer; MMTV-Neu; carcinoma	GROWTH-FACTOR RECEPTOR; BREAST-CANCER CELLS; CONSTITUTIVELY ACTIVE ERBB4; TRANSGENIC MICE; NEU PROTOONCOGENE; TYROSINE KINASES; PROGNOSTIC-SIGNIFICANCE; ACTIVATING MUTATIONS; NEUREGULIN RECEPTOR; MESSENGER-RNA	The four members of the ErbB family of receptor tyrosine kinases are involved in development and tumorigenesis of the mammary gland. Whereas the epidermal growth factor receptor, ErbB2 and ErbB3 are positively associated with various cancers, clinical studies of ErbB4 in breast cancer are contradictory. Results from tissue culture analyses and some clinical studies suggested that ErbB4 is either a tumor suppressor or is a negative regulator of ErbB2-driven tumors. Neu-Cre-ErbB4(flox/null) mice in which ErbB4 was inactivated by Cre-lox-mediated recombination in the mammary gland developed MMTV-Neu-driven mammary tumors with a similar latency period to mice with one or two wild-type ErbB4 alleles. Moreover, there was no difference in the histologies of tumors that developed, nor in the propensity to form lung metastases. Taken together these results suggest that ErbB4 is not a potent, highly penetrant tumor suppressor, nor is it a factor in Neu-mediated tumorigenesis in this model.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Columbia Univ, Sch Publ Hlth, New York, NY USA; Univ Basel, Dept Physiol, Biozentrum, Pharmazentrum, Basel, Switzerland; McGill Univ, Royal Univ Hosp, Mol Oncol Grp, Montreal, PQ, Canada; Univ Calif Davis, Sch Vet Med, Ctr Comparat Med, Davis, CA 95616 USA	Yale University; Columbia University; University of Basel; McGill University; University of Saskatchewan; University of California System; University of California Davis	Stern, DF (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St,Room BML 342,POB 208023, New Haven, CT 06520 USA.	df.stern@yale.edu		Lloyd, David/0000-0002-5656-0571; Gassmann, Martin/0000-0001-6201-3032	NATIONAL CANCER INSTITUTE [R01CA080065] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA80065] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abd El-Rehim DM, 2004, BRIT J CANCER, V91, P1532, DOI 10.1038/sj.bjc.6602184; Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Bacus SS, 1996, AM J PATHOL, V148, P549; Barnes NLP, 2005, CLIN CANCER RES, V11, P2163, DOI 10.1158/1078-0432.CCR-04-1633; Bieche I, 2003, INT J CANCER, V106, P758, DOI 10.1002/ijc.11273; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Cohen BM, 1996, J BIOL CHEM, V271, P4813; DiGiovanna MP, 2005, J CLIN ONCOL, V23, P1152, DOI 10.1200/JCO.2005.09.055; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; Elenius K, 1999, ONCOGENE, V18, P2607, DOI 10.1038/sj.onc.1202612; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Gilbertson RJ, 1997, CANCER RES, V57, P3272; Gullick WJ, 2003, J PATHOL, V200, P279, DOI 10.1002/path.1335; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Haugen DRF, 1996, CANCER RES, V56, P1184; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Junttila TT, 2003, CLIN CANCER RES, V9, P5346; Kew TY, 2000, BRIT J CANCER, V82, P1163, DOI 10.1054/bjoc.1999.1057; Knowlden JM, 1998, ONCOGENE, V17, P1949, DOI 10.1038/sj.onc.1202107; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Lodge AJ, 2003, J CLIN PATHOL, V56, P300, DOI 10.1136/jcp.56.4.300; Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maatta JA, 2006, MOL BIOL CELL, V17, P67, DOI 10.1091/mbc.E05-05-0402; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pawlowski V, 2000, CLIN CANCER RES, V6, P4217; Penington DJ, 2002, CELL GROWTH DIFFER, V13, P247; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Sartor CI, 2001, MOL CELL BIOL, V21, P4265, DOI 10.1128/MCB.21.13.4265-4275.2001; Schroeder JA, 1998, CELL GROWTH DIFFER, V9, P451; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; Soung YH, 2006, INT J CANCER, V118, P1426, DOI 10.1002/ijc.21507; Srinivasan R, 2000, CANCER RES, V60, P1483; Srinivasan R, 1998, J PATHOL, V185, P236, DOI 10.1002/(SICI)1096-9896(199807)185:3<236::AID-PATH118>3.0.CO;2-7; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; Stern DF, 2000, BREAST CANCER RES, V2, P176, DOI 10.1186/bcr51; Suo Z, 2002, J PATHOL, V196, P17, DOI 10.1002/path.1003; Suo ZH, 2001, VIRCHOWS ARCH, V439, P62, DOI 10.1007/s004280000392; Tang CK, 1999, CANCER RES, V59, P5315; Tang CK, 1998, CANCER RES, V58, P3415; Thor AD, 2002, HUM PATHOL, V33, P628, DOI 10.1053/hupa.2002.124034; Thuret S, 2004, J NEUROCHEM, V91, P1302, DOI 10.1111/j.1471-4159.2004.02809.x; Tidcombe H, 2003, P NATL ACAD SCI USA, V100, P8281, DOI 10.1073/pnas.1436402100; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; von Mehren M, 2005, J CLIN ONCOL, V23, P8, DOI 10.1200/JCO.2005.09.961; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Williams EE, 2003, CANCER LETT, V192, P67, DOI 10.1016/S0304-3835(02)00690-0; Witton CJ, 2003, J PATHOL, V200, P290, DOI 10.1002/path.1370; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215	55	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2006	25	41					5664	5672		10.1038/sj.onc.1209574	http://dx.doi.org/10.1038/sj.onc.1209574			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16652155				2022-12-28	WOS:000240599100008
J	Ruminy, P; Jardin, F; Picquenot, JM; Gaulard, P; Parmentier, F; Buchonnet, G; Maisonneuve, C; Tilly, H; Bastard, C				Ruminy, P.; Jardin, F.; Picquenot, J. M.; Gaulard, P.; Parmentier, F.; Buchonnet, G.; Maisonneuve, C.; Tilly, H.; Bastard, C.			Two patterns of chromosomal breakpoint locations on the immunoglobulin heavy-chain locus in B-cell lymphomas with t(3;14)(q27;q32): relevance to histology	ONCOGENE			English	Article						non-Hodgkin's B-cell lymphoma; BCL6; t(3;14)(q27;q32)	NON-HODGKINS-LYMPHOMAS; FOLLICULAR LYMPHOMA; GENE FUSION; MESSENGER-RNA; BCL6 GENE; GRADE 3B; TRANSLOCATIONS; EXPRESSION; REARRANGEMENT; 3Q27	The t(3;14)(q27;q32) is the most common translocation involving BCL6 in B-cell lymphoma. Although this translocation was predominantly associated with diffuse large B-cell lymphoma (DLBCL), recent studies have shown that it can also be found in follicular lymphomas (FL), often associated with a large cell component. To further investigate the relationship that might exist between this translocation and the phenotype of the tumors, we studied 34 lymphomas with a t(3;14)(q27;q32). Twenty cases were DLBCL, 14 FL and most cases, regardless of histology, were negative for the expression of CD10 (26/32, 81%). We identified the IGH switch region involved in the translocation for 32 cases. Our data indicate that in DLBCL most breakpoints involve the switch mu (17/19; 89%), whereas in FL most involve a switch gamma (9/13; 70%) (P = 0.0016, Fisher's exact test). This correlation between the histology and the structure of the translocated allele suggests that the lymphomas with S mu and S gamma translocations may originate from different cells, or that the substituted regulatory regions that come to deregulate BCL6 may affect the presentation of the disease.	INSERM, Ctr Henri Becquerel, Grp Etud Proliferat Lymphoides, U614,IFR23, Rouen, France; CHU Henri Mondor, Dept Pathol, INSERM, U617, F-94010 Creteil, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Henri Becquerel; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Bastard, C (corresponding author), INSERM, Ctr Henri Becquerel, Grp Etud Proliferat Lymphoides, U614,IFR23, Rue Amiens, Rouen, France.	chrbas@rouen.fnclcc.fr						Akasaka H, 2000, CANCER RES, V60, P2335; Akasaka T, 2000, BLOOD, V96, P2907; Akasaka T, 2003, BLOOD, V102, P1443, DOI 10.1182/blood-2002-08-2482; Barrans SL, 2002, BRIT J HAEMATOL, V117, P322, DOI 10.1046/j.1365-2141.2002.03435.x; BASTARD C, 1994, BLOOD, V83, P2423; Bosga-Bouwer AG, 2003, BLOOD, V101, P1149, DOI 10.1182/blood.V101.3.1149; Butler MP, 2002, CANCER RES, V62, P4089; Falini B, 2000, BLOOD, V95, P2084, DOI 10.1182/blood.V95.6.2084; HORSMAN DE, 1995, BRIT J HAEMATOL, V89, P569, DOI 10.1111/j.1365-2141.1995.tb08365.x; ISLAM KB, 1994, CLIN EXP IMMUNOL, V95, P3; Jaffe E.S., 2001, PATHOLOGY GENETICS T, VVolume 3; Jardin F, 2003, BLOOD, V102, P1872, DOI 10.1182/blood-2002-12-3630; Jardin F, 2002, LEUKEMIA, V16, P2318, DOI 10.1038/sj.leu.2402657; Katzenberger T, 2004, AM J PATHOL, V165, P481, DOI 10.1016/S0002-9440(10)63313-5; Kawakami K, 2004, INT J HEMATOL, V79, P474, DOI 10.1532/IJH97.03105; Kawamata N, 1998, BRIT J HAEMATOL, V100, P484, DOI 10.1046/j.1365-2141.1998.00603.x; LO CF, 1994, BLOOD, V83, P1757; Lossos IS, 2003, LEUKEMIA, V17, P1390, DOI 10.1038/sj.leu.2402997; Lossos IS, 2001, BLOOD, V98, P945, DOI 10.1182/blood.V98.4.945; MERTENS F, 1995, CANCER GENET CYTOGEN, V83, P176, DOI 10.1016/0165-4608(95)00066-X; Nagaoka H, 2002, J EXP MED, V195, P529, DOI 10.1084/jem.20012144; NERI A, 1988, P NATL ACAD SCI USA, V85, P2748, DOI 10.1073/pnas.85.8.2748; OFFIT K, 1994, NEW ENGL J MED, V331, P74, DOI 10.1056/NEJM199407143310202; OTSUKI T, 1995, BLOOD, V85, P2877, DOI 10.1182/blood.V85.10.2877.bloodjournal85102877; Ott G, 2002, BLOOD, V99, P3806, DOI 10.1182/blood.V99.10.3806; Polo JM, 2004, NAT MED, V10, P1329, DOI 10.1038/nm1134; Schaffer A, 1999, J IMMUNOL, V162, P5327; STAVNEZERNORDGREN J, 1986, EMBO J, V5, P95, DOI 10.1002/j.1460-2075.1986.tb04182.x; Ueda C, 2002, BLOOD, V99, P2624, DOI 10.1182/blood-2001-11-0117; Ueda C, 2002, LEUKEMIA LYMPHOMA, V43, P1375, DOI 10.1080/10428190290033305; Willis TG, 2000, BLOOD, V96, P808, DOI 10.1182/blood.V96.3.808.015k30_808_822; WLODARSKA I, 1995, GENE CHROMOSOME CANC, V14, P1, DOI 10.1002/gcc.2870140102; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x	35	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2006	25	35					4947	4954		10.1038/sj.onc.1209512	http://dx.doi.org/10.1038/sj.onc.1209512			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16619046				2022-12-28	WOS:000239687100012
J	Goldsmith, KC; Liu, X; Dam, V; Morgan, BT; Shabbout, M; Cnaan, A; Letai, A; Korsmeyer, SJ; Hogarty, MD				Goldsmith, K. C.; Liu, X.; Dam, V.; Morgan, B. T.; Shabbout, M.; Cnaan, A.; Letai, A.; Korsmeyer, S. J.; Hogarty, M. D.			BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastoma	ONCOGENE			English	Article						apoptosis; neuroblastoma; Bcl-2 homologues; programmed cell death; MYCN	HUMAN NEURO-BLASTOMA; CELL-LINES; CANCER-CELLS; IN-VIVO; P53; PROTEINS; DOMAINS; TUMOR; RESISTANCE; MUTATIONS	The major impediment to cure for many malignancies is the development of therapy resistance with resultant tumor progression. Genetic alterations leading to subversion of inherent apoptosis pathways are common themes in therapy resistance. Bcl-2 family proteins play a critical role in regulating mitochondrial apoptosis that governs chemotherapeutic effects, and defective engagement of these pathways contributes to treatment failure. We have studied the efficacy of BH3 peptidomimetics consisting of the minimal death, or BH3, domains of the proapoptotic BH3-only proteins Bid and Bad to induce apoptosis using neuroblastoma (NB) as a model system. We demonstrate that BH3 peptides, modified with an arginine homopolymer for membrane transduction (called r8-BidBH3 and r8-BadBH3, respectively), potently induce apoptosis in NB cells, including those with MYCN amplification. Cell death is caspase 9 dependent, consistent with a requirement for the intrinsic mitochondrial pathway. Substitutions at highly conserved residues within the r8-BidBH3 peptide abolish apoptotic efficacy supporting activity through specific BH domain interactions. Concomitant exposure to r8-BadBH3 and r8-BidBH3 at sublethal monotherapy doses revealed potent synergy consistent with a competitive displacement model, whereby BH3 peptides displace sequestered BH3 proteins to induce cell death. Further, BH3 peptides demonstrate antitumor efficacy in a xenograft model of NB in the absence of additional genotoxic or trophic stressors. These data provide proof of principle that targeted re-engagement of apoptosis pathways may be of therapeutic utility, and BH3-like compounds are attractive lead agents to re-establish therapy-induced apoptosis in refractory malignancies.	Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Biostat & Epidemiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute	Hogarty, MD (corresponding author), Childrens Hosp Philadelphia, Div Oncol, 9 N ARC,Suite 902C,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	hogartym@email.chop.edu			NATIONAL CANCER INSTITUTE [P01CA097323] Funding Source: NIH RePORTER; NCI NIH HHS [CA97323] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIEDLER JL, 1976, J NATL CANCER I, V57, P683, DOI 10.1093/jnci/57.3.683; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cooperman J, 2004, STEM CELLS, V22, P1111, DOI 10.1634/stemcells.22-6-1111; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Dive C, 1992, Semin Cancer Biol, V3, P417; FEDER MK, 1983, J NATL CANCER I, V70, P1051; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hersey P, 2003, J CELL PHYSIOL, V196, P9, DOI 10.1002/jcp.10256; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; Jacks T, 2002, CELL, V111, P923, DOI 10.1016/S0092-8674(02)01229-1; Keshelava N, 2001, CANCER RES, V61, P6185; KORSMEYER SJ, 1992, CANCER SURV, V15, P105; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Letai A, 2004, CANCER CELL, V6, P241, DOI 10.1016/j.ccr.2004.07.011; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Moreau C, 2003, J BIOL CHEM, V278, P19426, DOI 10.1074/jbc.M209472200; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; SCHLESINGER HR, 1976, CANCER RES, V36, P3094; SCHMECHEL D, 1978, NATURE, V276, P834, DOI 10.1038/276834a0; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; Tajiri T, 2003, CLIN CANCER RES, V9, P3345; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; Tweddle DA, 2001, CANCER RES, V61, P8; Valsesia-Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108	39	47	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2006	25	33					4525	4533		10.1038/sj.onc.1209489	http://dx.doi.org/10.1038/sj.onc.1209489			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16568093				2022-12-28	WOS:000239457500003
J	Geserick, C; Tejera, A; Gonzalez-Suarez, E; Klatt, P; Blasco, MA				Geserick, C.; Tejera, A.; Gonzalez-Suarez, E.; Klatt, P.; Blasco, M. A.			Expression of mTert in primary murine cells links the growth-promoting effects of telomerase to transforming growth factor-beta signaling	ONCOGENE			English	Article						telomerase; immortalization; proliferation; gene expression profiling; transforming growth factor-beta	KRUPPEL-LIKE FACTOR-4; CATALYTIC SUBUNIT; GENE-EXPRESSION; DOWN-REGULATION; LIFE-SPAN; DIFFERENTIAL REGULATION; TRANSGENIC MICE; CANCER; IDENTIFICATION; SENESCENCE	Here, we show that ectopic expression of the catalytic subunit of mouse telomerase (mTert) confers a growth advantage to primary murine embryonic fibroblasts (MEFs), which have very long telomeres, as well as facilitates their spontaneous immortalization and increases their colony-forming capacity upon activation of oncogenes. We demonstrate that these telomere length-independent growth-promoting effects of mTert overexpression require catalytically active mTert, as well as the formation of mTert/Terc complexes. The gene expression profile of mTert-overexpressing MEFs indicates that telomerase enhances growth in these cells through the repression of growth-inhibiting genes of the transforming growth factor-beta (TGF-beta) signaling network. We functionally validate this result by showing that mTert abrogates the growth-inhibitory effect of TGF-beta in MEFs, thus demonstrating that telomerase increments the proliferative potential of primary mouse embryonic fibroblasts by targeting the TGF-beta pathway.	Spanish Natl Canc Ctr, CNIO, Mol Oncol Program, Telomeres & Telomerase Grp, E-28029 Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO)	Blasco, MA (corresponding author), Spanish Natl Canc Ctr, CNIO, Mol Oncol Program, Telomeres & Telomerase Grp, Melchor Fernandez Almagro,3, E-28029 Madrid, Spain.	mblasco@cnio.es	Gonzalez-Suarez, Eva/L-6298-2014; Tejera, Agueda M./AAU-2000-2021; Blasco, Maria A./M-1694-2014; Tejera, Agueda/L-1946-2015; Tejera, Agueda/Z-1938-2019	Gonzalez-Suarez, Eva/0000-0003-0858-8171; Blasco, Maria A./0000-0002-4211-233X; Tejera, Agueda M/0000-0002-6703-9466				Artandi SE, 2002, P NATL ACAD SCI USA, V99, P8191, DOI 10.1073/pnas.112515399; Balasubramanian S, 2002, J BIOL CHEM, V277, P1828, DOI 10.1074/jbc.M110376200; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blasco MA, 2002, NAT REV CANCER, V2, P627, DOI 10.1038/nrc862; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Canela A, 2004, MOL CELL BIOL, V24, P4275, DOI 10.1128/MCB.24.10.4275-4293.2004; Cayuela ML, 2005, EMBO REP, V6, P268, DOI 10.1038/sj.embor.7400359; Chen ZY, 2005, MOL PHARMACOL, V68, P1203, DOI 10.1124/mol.105.014944; Chung HK, 2003, J CLIN ENDOCR METAB, V88, P3913, DOI 10.1210/jc.2002-022031; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Dang DT, 2003, ONCOGENE, V22, P3424, DOI 10.1038/sj.onc.1206413; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Flores I, 2005, SCIENCE, V309, P1253, DOI 10.1126/science.1115025; Furukawa T, 1998, CYTOGENET CELL GENET, V82, P156, DOI 10.1159/000015091; Furukawa T, 2003, AM J PATHOL, V162, P1807, DOI 10.1016/S0002-9440(10)64315-5; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Gonzalez-Suarez E, 2005, ONCOGENE, V24, P2256, DOI 10.1038/sj.onc.1208413; Gonzalez-Suarez E, 2002, MOL CELL BIOL, V22, P7291, DOI 10.1128/MCB.22.20.7291-7301.2002; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Goytisolo FA, 2002, ONCOGENE, V21, P584, DOI 10.1038/sj.onc.1205085; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Hu YH, 2004, CANCER RES, V64, P7748, DOI 10.1158/0008-5472.CAN-04-1827; Huang QH, 2004, P NATL ACAD SCI USA, V101, P3456, DOI 10.1073/pnas.0308562100; Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928; Karnik SK, 2003, DEVELOPMENT, V130, P411, DOI 10.1242/dev.00223; Keeton AB, 2003, ENDOCRINOLOGY, V144, P5402, DOI 10.1210/en.2003-0592; Kondratyev AD, 1996, CANCER RES, V56, P1498; Kopp JB, 1996, LAB INVEST, V74, P991; Krag S, 2000, LAB INVEST, V80, P1855, DOI 10.1038/labinvest.3780196; Kuribara R, 1999, MOL CELL BIOL, V19, P2754; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Liao L, 2005, BIOCHEM BIOPH RES CO, V336, P854, DOI 10.1016/j.bbrc.2005.08.180; Lim JY, 2005, J MOL CELL CARDIOL, V39, P627, DOI 10.1016/j.yjmcc.2005.06.016; LIM RW, 1995, BBA-MOL CELL RES, V1266, P91, DOI 10.1016/0167-4889(94)00226-5; Liu JH, 2003, AM J PHYSIOL-LUNG C, V285, pL1106, DOI 10.1152/ajplung.00180.2003; Martin-Rivera L, 1998, P NATL ACAD SCI USA, V95, P10471, DOI 10.1073/pnas.95.18.10471; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; Mulsow JJW, 2005, ANN SURG, V242, P880, DOI 10.1097/01.sla.0000189606.58343.cd; Ohnishi S, 2003, BIOCHEM BIOPH RES CO, V308, P251, DOI 10.1016/S0006-291X(03)01356-1; Palmero I, 2001, METHOD ENZYMOL, V333, P247; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Reinholz MM, 2004, BREAST CANCER RES TR, V86, P75, DOI 10.1023/B:BREA.0000032926.74216.7d; Rittling SR, 1996, EXP CELL RES, V229, P7, DOI 10.1006/excr.1996.0337; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Ryu MS, 2004, EXP CELL RES, V299, P159, DOI 10.1016/j.yexcr.2004.05.014; Sachsinger J, 2001, CANCER RES, V61, P5580; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHARMA K, 1994, AM J PHYSIOL, V266, pF829, DOI 10.1152/ajprenal.1994.266.6.F829; Shay JW, 2002, CANCER CELL, V2, P257, DOI 10.1016/S1535-6108(02)00159-9; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Simmen RCM, 2004, J BIOL CHEM, V279, P29286, DOI 10.1074/jbc.M403139200; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Smith TG, 2005, DEVELOPMENT, V132, P1305, DOI 10.1242/dev.01699; Stampfer MR, 1997, MOL BIOL CELL, V8, P2391, DOI 10.1091/mbc.8.12.2391; Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998; Sun LH, 2003, MOL BIOL REP, V30, P249, DOI 10.1023/A:1026370726763; Unoki M, 2001, ONCOGENE, V20, P4457, DOI 10.1038/sj.onc.1204608; Wang J, 2005, J BIOL CHEM, V280, P22776, DOI 10.1074/jbc.M500032200; Wang N, 2002, WORLD J GASTROENTERO, V8, P966, DOI 10.3748/wjg.v8.i6.966; Wang T, 2005, J BIOL CHEM, V280, P12593, DOI 10.1074/jbc.M410982200; Wei DY, 2005, CANCER RES, V65, P2746, DOI 10.1158/0008-5472.CAN-04-3619; Yoon YS, 2005, ONCOGENE, V24, P1895, DOI 10.1038/sj.onc.1208262; Zhang X, 2002, J CLIN ENDOCR METAB, V87, P1262, DOI 10.1210/jc.87.3.1262; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067	74	51	59	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2006	25	31					4310	4319		10.1038/sj.onc.1209465	http://dx.doi.org/10.1038/sj.onc.1209465			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16501597				2022-12-28	WOS:000239240100006
J	Chao, OSP; Clement, MV				Chao, O. S. P.; Clement, M-V			Epidermal growth factor and serum activate distinct pathways to inhibit the BH3 only protein BAD in prostate carcinoma LNCaP cells	ONCOGENE			English	Article						LNCaP; BAD; BAX; survival; prostate carcinoma; phosphatidylinositol 3-kinase	CANCER CELLS; IN-VITRO; SIGNALING PATHWAY; INDUCED APOPTOSIS; BCL-XL; SURVIVAL; KINASE; OVEREXPRESSION; PHOSPHORYLATION; EXPRESSION	A better understanding of pathways involved in survival of prostate cancer cells is the key to develop effective and target-selective therapies. Presence of serum or epidermal growth factor in the culture medium of LNCaP cells decreases apoptosis induced by the inhibition of phosphatidylinositol 3-kinase with LY294002. However, intracellular pathway(s) involved in this survival signaling are not well defined. Here, we investigated the mechanism(s) involved in serum or epidermal growth factor-mediated inhibition of LY294002-induced death in LNCaP cells. Cell death was assessed by the percentage of cells in sub-G1 phase and caspase 3 activity. Phosphorylation status of BAD, ERK1/2 and RSKs were assessed by Western blot. Specific gene expression knock down of BAD, BAX, RSK1 and RSK2 were performed using siRNA transfections. Our results demonstrate that cell death induced by LY294002 is mediated by translocation of BAD and BAX proteins from the cytosol to the mitochondria. Whereas, epidermal growth factor activates a MAPK/ERK/RSK1 module leading to inactivation of BAD via Ser75 phosphorylation, the presence of serum, on the other hand, induces a nonconducive intracellular environment for mitochondrial translocation of dephosphorylated BAD. Taken together, these results indicate that phosphorylation of BAD or inhibition of its translocation to the mitochondria are critical phosphatidylinositol 3-kinase-independent survival pathways in LNCaP cells.	Natl Univ Singapore, Dept Biochem, Fac Med, Singapore 117597, Singapore; NUS Grad Sch Integrat Sci & Engn, Singapore, Singapore	National University of Singapore; National University of Singapore	Clement, MV (corresponding author), Natl Univ Singapore, Dept Biochem, Fac Med, 8 Med Dr,MD7, Singapore 117597, Singapore.	bchmvc@nus.edu.sg						Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Boldt S, 2004, CURR PHARM DESIGN, V10, P1885, DOI 10.2174/1381612043384420; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Carson JP, 1999, CANCER RES, V59, P1449; Chang FM, 2003, INT J ONCOL, V22, P469; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Eisenmann KM, 2003, CANCER RES, V63, P8330; Gardai SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Kajiwara T, 1999, INT J UROL, V6, P520, DOI 10.1046/j.1442-2042.1999.00102.x; Kooijman R, 2003, CELL SIGNAL, V15, P1091, DOI 10.1016/S0898-6568(03)00069-X; Lebedeva I, 2000, CANCER RES, V60, P6052; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li XY, 2001, CANCER RES, V61, P1699; Linseman DA, 2004, J NEUROSCI, V24, P9993, DOI 10.1523/JNEUROSCI.2057-04.2004; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Lutz RJ, 2000, BIOCHEM SOC T, V28, P51, DOI 10.1042/bst0280051; Lyons-Darden T, 2004, J MOL ENDOCRINOL, V33, P165, DOI 10.1677/jme.0.0330165; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; McConkey DJ, 1996, CANCER RES, V56, P5594; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; McEleny KR, 2002, PROSTATE, V51, P133, DOI 10.1002/pros.10061; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; Nomura T, 2003, UROL RES, V31, P37, DOI 10.1007/s00240-003-0300-y; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; RAFFO AJ, 1995, CANCER RES, V55, P4438; Sato S, 2004, J BIOL CHEM, V279, P33759, DOI 10.1074/jbc.M402055200; Shahbazi M, 2002, LANCET, V359, P397, DOI 10.1016/S0140-6736(02)07600-6; Shi XB, 2001, CANCER BIOTHER RADIO, V16, P421, DOI 10.1089/108497801753354320; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Torring N, 2003, PROSTATE, V56, P142, DOI 10.1002/pros.10245; Yang CC, 2003, J BIOL CHEM, V278, P25872, DOI 10.1074/jbc.M301744200; Yarden Y, 2001, EUR J CANCER, V37, pS3; Zhang M, 2005, PROSTATE, V64, P293, DOI 10.1002/pros.20263	37	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	32					4458	4469		10.1038/sj.onc.1209421	http://dx.doi.org/10.1038/sj.onc.1209421			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16767165				2022-12-28	WOS:000239326000009
J	Zheng, Z; Cantor, A; Bepler, G				Zheng, Z.; Cantor, A.; Bepler, G.			A global genome damage score predictive of lung cancer patients outcome	ONCOGENE			English	Article						lung cancer; chromosome aberrations; prognosis; survival	PROGNOSTIC-SIGNIFICANCE; DNA; HETEROZYGOSITY; CARCINOMAS; MECHANISMS; NEOPLASIA; REGIONS; GENE; 18Q	Genome damage is a hallmark of human cancer. Efforts at assessing the impact of genome damage on tumor phenotype and patients outcome have focused on measurements of the relative DNA content in tumor cells compared to normal cells and the assessment of allelic loss at single or multiple selected loci that are thought to harbor genes important in cancer biology. We adapted a global, high-resolution genotyping method for determination of global and unbiased allelic loss. We generated a score, termed global genome damage score (GGDS), that is a continuous variable from zero to one and a measure of the extent of damaged DNA in individual tumors. In 71 patients with completely resected non-small-cell lung cancer, the GGDS ranged from 0.0006 to 0.5530 with a median value of 0.0401 indicating that between 0.06 and 55.3% of the genome has allelic loss. Patients with high scores (> 0.04) had a significantly worse outcome than those with low scores (median overall survival time 35.5 vs > 120.0 months, P = 0.006 log-rank test; median disease free survival 28.3 vs > 120.0 months, P = 0.003 log-rank test). This suggests that the clinical behavior of lung tumors with low GGDS is relatively benign whereas tumors with high GGDS are aggressive resulting in early death of patients.	H Lee Moffit Canc Ctr & Res Inst, Thorac Oncol Program, Tampa, FL 33612 USA		Bepler, G (corresponding author), H Lee Moffit Canc Ctr & Res Inst, Thorac Oncol Program, MRC-4W,12902 Magnolia Dr, Tampa, FL 33612 USA.	beplerg@moffitt.usf.edu			NATIONAL CANCER INSTITUTE [U01CA101222, R01CA102726] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA102726, U01 CA101222] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; AUER G, 1984, CANCER RES, V44, P394; BARLOGIE B, 1982, CANCER GENET CYTOGEN, V6, P17, DOI 10.1016/0165-4608(82)90017-6; BELL GI, 1982, NATURE, V295, P31, DOI 10.1038/295031a0; Bepler G, 2002, J CLIN ONCOL, V20, P1353, DOI 10.1200/JCO.20.5.1353; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; Contal C, 1999, COMPUT STAT DATA AN, V30, P253, DOI 10.1016/S0167-9473(98)00096-6; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FONG KM, 1995, CANCER RES, V55, P220; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; Mandrekar J, 2003, SUGI, V28, P261; Mitsudomi T, 1996, CLIN CANCER RES, V2, P1185; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; ROYLE NJ, 1988, GENOMICS, V3, P352, DOI 10.1016/0888-7543(88)90127-9; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOLM M, 1985, CANCER-AM CANCER SOC, V56, P1396, DOI 10.1002/1097-0142(19850915)56:6<1396::AID-CNCR2820560630>3.0.CO;2-L; WOLLEY RC, 1982, J NATL CANCER I, V69, P15; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310	22	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	32					4491	4494		10.1038/sj.onc.1209476	http://dx.doi.org/10.1038/sj.onc.1209476			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16518406				2022-12-28	WOS:000239326000012
J	Pretto, D; Barco, R; Rivera, J; Neel, N; Gustavson, MD; Eid, JE				Pretto, D.; Barco, R.; Rivera, J.; Neel, N.; Gustavson, M. D.; Eid, J. E.			The synovial sarcoma translocation protein SYT-SSX2 recruits beta-catenin to the nucleus andassociates with it in an active complex	ONCOGENE			English	Article						synovial sarcoma; SYT-SSX2; beta-catenin	WNT SIGNALING PATHWAY; SYT-SSX; P120 CATENIN; ACTIVATION; EXPRESSION; GENE; LOCALIZATION; ACCUMULATION; INTERACTS; DOMAINS	Localization of beta-catenin in the cell is a key determinant in its decision to function as a critical mediator of cell adhesion at the surface or a transcription activator in the nucleus. SYT-SSX2 is the fusion product of the chromosomal translocation, t( X; 18)( p11.2; q11.2), which occurs in synovial sarcoma, a soft tissue tumor. SYT-SSX2 is known to associate with chromatin remodeling complexes and is proposed to be involved in controlling gene expression. We report that SYT-SSX2 plays a direct role in b-catenin regulation. When expressed in mammalian cells, SYT-SSX2-induced beta-catenin recruitment to the nucleus. Interestingly, known target genes of canonical Wnt were not activated as a result of SYT-SSX2 expression, nor was the nuclear localization of beta-catenin due to one of the signaling pathways normally implicated in this event. beta-Catenin accumulation in the nucleus led to the formation of a transcriptionally active nuclear complex that contained SYT-SSX2 and beta-catenin. More importantly, depletion of SYT-SSX2 in primary synovial sarcoma cells resulted in loss of nuclear beta-catenin signal and a significant decrease in its signaling activity. These results unravel a novel pathway in the control of beta-catenin cellular transport and strongly suggest that SYT-SSX2 contributes to tumor development, in part through beta-catenin signaling.	Vanderbilt Univ, Ctr Med, Dept Canc Biol, Nashville, TN 37232 USA	Vanderbilt University	Eid, JE (corresponding author), Vanderbilt Univ, Ctr Med, Dept Canc Biol, 23d Ave S Pierce PRB 740, Nashville, TN 37232 USA.	josiane.eid@vanderbilt.edu			NCI NIH HHS [CA68485, CA 15751, R01CA106481-01, K22 CA098008-01] Funding Source: Medline; NIBIB NIH HHS [EB00672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA015751, P30CA068485, R01CA015751, R01CA106481, K22CA098008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R21EB000672, R33EB000672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Allander SV, 2002, AM J PATHOL, V161, P1587, DOI 10.1016/S0002-9440(10)64437-9; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Bienz M, 2005, CURR BIOL, V15, pR64, DOI 10.1016/j.cub.2004.12.058; Brembeck FH, 2004, GENE DEV, V18, P2225, DOI 10.1101/gad.317604; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; dos Santos NR, 2000, EXP CELL RES, V256, P192, DOI 10.1006/excr.2000.4813; dos Santos NR, 2001, GENE CHROMOSOME CANC, V30, P1, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G; dosSantos NR, 1997, HUM MOL GENET, V6, P1549, DOI 10.1093/hmg/6.9.1549; Doucas H, 2005, EUR J CANCER, V41, P365, DOI 10.1016/j.ejca.2004.11.005; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Hasegawa T, 2001, HUM PATHOL, V32, P257, DOI 10.1053/hupa.2001.22764; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Ladanyi M, 2002, CANCER RES, V62, P135; Ladanyi M, 2001, ONCOGENE, V20, P5755, DOI 10.1038/sj.onc.1204601; Miyagishi M, 2000, J BIOL CHEM, V275, P35170, DOI 10.1074/jbc.C000258200; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; Prieve MG, 1999, MOL CELL BIOL, V19, P4503; Soulez M, 1999, ONCOGENE, V18, P2739, DOI 10.1038/sj.onc.1202613; Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo-reports/kvf002; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; Thompson B, 2002, NAT CELL BIOL, V4, P367, DOI 10.1038/ncb786; Tissier F, 2005, CANCER RES, V65, P7622, DOI 10.1158/0008-5472.CAN-05-0593; van Es JH, 2003, CURR OPIN GENET DEV, V13, P28, DOI 10.1016/S0959-437X(02)00012-6; Xie YT, 2002, CANCER RES, V62, P3861	34	56	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3661	3669		10.1038/sj.onc.1209413	http://dx.doi.org/10.1038/sj.onc.1209413			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16462762				2022-12-28	WOS:000238448300005
J	Gotzmann, J; Fischer, ANM; Zojer, M; Mikula, M; Proell, V; Huber, H; Jechlinger, M; Waerner, T; Weith, A; Beug, H; Mikulits, W				Gotzmann, J.; Fischer, A. N. M.; Zojer, M.; Mikula, M.; Proell, V.; Huber, H.; Jechlinger, M.; Waerner, T.; Weith, A.; Beug, H.; Mikulits, W.			A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes	ONCOGENE			English	Review						hepatocytes; epithelial to mesenchymal transition; expression profiling; PDGF	GROWTH-FACTOR-BETA; EPITHELIAL-MESENCHYMAL TRANSITIONS; E-CADHERIN EXPRESSION; HUMAN HEPATOCELLULAR-CARCINOMA; TRANSCRIPTION FACTOR SNAIL; JUN NH2-TERMINAL KINASE-1; HEPATIC STELLATE CELLS; BREAST-CANCER; GENE-EXPRESSION; TUMOR-CELLS	Polarized hepatocytes expressing hyperactive Ha-Ras adopt an invasive and metastatic phenotype in cooperation with transforming growth factor (TGF)-beta. This dramatic increase in malignancy is displayed by an epithelial to mesenchymal transition (EMT), which mimics the TGF-beta-mediated progression of human hepatocellular carcinomas. In culture, hepatocellular EMT occurs highly synchronously, facilitating the analysis of molecular events underlying the various stages of this process. Here, we show that in response to TGF-beta, phosphorylated Smads rapidly translocated into the nucleus and activated transcription of target genes such as E-cadherin repressors of the Snail superfamily, causing loss of cell adhesion. Within the TGF-beta superfamily of cytokines, TGF-beta 1, -beta 2 and -beta 3 were specific for the induction of hepatocellular EMT. Expression pro. ling of EMT kinetics revealed 78 up- and 235 downregulated genes, which preferentially modulate metabolic activities, extracellular matrix composition, transcriptional activities and cell survival. Independent of the genetic background, platelet-derived growth factor (PDGF)- A ligand and both PDGF receptor subunits were highly elevated, together with autocrine secretion of bioactive PDGF. Interference with PDGF signalling by employing hepatocytes expressing the dominant-negative PDGF-alpha receptor revealed decreased TGF-beta-induced migration in vitro and efficient suppression of tumour growth in vivo. In conclusion, these results provide evidence for a crucial role of PDGF in TGF-beta-mediated tumour progression of hepatocytes and suggest PDGF as a target for therapeutic intervention in liver cancer.	Med Univ Vienna, Dept Med 1, Div Inst Canc Res, A-1090 Vienna, Austria; Boehringer Ingelheim KG, Genom Grp, Biberach, Germany; Res Inst Mol Pharmacol, Vienna, Austria	Medical University of Vienna; Boehringer Ingelheim	Mikulits, W (corresponding author), Med Univ Vienna, Dept Med 1, Div Inst Canc Res, Borschke Gasse 8A, A-1090 Vienna, Austria.	wolfgang.mikulits@meduniwien.ac.at	Jechlinger, Martin/AAC-9442-2020; Mikulits, Wolfgang/AAH-4043-2021	Jechlinger, Martin/0000-0002-3710-4466; Mikula, Mario/0000-0001-5782-0681; Mikulits, Wolfgang/0000-0003-4612-7106; Gotzmann, Josef/0000-0001-6392-2115				Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; Bates RC, 2003, CURR BIOL, V13, P1721, DOI 10.1016/j.cub.2003.09.002; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BATTEGAY EJ, 1994, J CELL BIOL, V125, P917, DOI 10.1083/jcb.125.4.917; Behrens J, 1992, Semin Cell Biol, V3, P169; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Cai J, 1998, INT J MOL MED, V1, P273; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carloni V, 2001, HEPATOLOGY, V34, P42, DOI 10.1053/jhep.2001.25224; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Coyle B, 2003, J BIOL CHEM, V278, P5920, DOI 10.1074/jbc.M211300200; Croom KF, 2003, DRUGS, V63, P513, DOI 10.2165/00003495-200363050-00005; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Deininger MWN, 2004, J CANCER RES CLIN, V130, P59, DOI 10.1007/s00432-003-0502-2; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dubois CM, 2001, AM J PATHOL, V158, P305, DOI 10.1016/S0002-9440(10)63970-3; Dumont N, 2000, BREAST CANCER RES, V2, P125, DOI 10.1186/bcr44; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; EHRMANN RL, 1956, J NATL CANCER I, V16, P1375; Fischer ANM, 2005, CARCINOGENESIS, V26, P931, DOI 10.1093/carcin/bgi043; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; George D, 2001, SEMIN ONCOL, V28, P27, DOI 10.1053/sonc.2001.29185; Germain S, 2000, GENE DEV, V14, P435; Gotzmann J, 2004, MUTAT RES-REV MUTAT, V566, P9, DOI 10.1016/S1383-5742(03)00033-4; Gotzmann J, 2002, J CELL SCI, V115, P1189; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Hajra KM, 2002, CANCER RES, V62, P1613; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Hawley TS, 2001, BIOTECHNIQUES, V30, P1028, DOI 10.2144/01305rr01; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; HELDIN P, 1991, EXP CELL RES, V193, P364, DOI 10.1016/0014-4827(91)90108-7; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; Hosono S, 2000, J BIOL CHEM, V275, P10943, DOI 10.1074/jbc.275.15.10943; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; ITO N, 1991, CANCER RES, V51, P4080; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Jechlinger M, 2003, ONCOGENE, V22, P7155, DOI 10.1038/sj.onc.1206887; JIANG WG, 1995, CANCER RES, V55, P5043; Joensuu H, 2002, MED KLIN, V97, P28; Joensuu H, 2001, ANN MED, V33, P451, DOI 10.3109/07853890109002093; Kilic T, 2000, CANCER RES, V60, P5143; Kim SJ, 2004, CANCER RES, V64, P4201, DOI 10.1158/0008-5472.CAN-03-3763; Knittel T, 1999, GASTROENTEROLOGY, V117, P1205, DOI 10.1016/S0016-5085(99)70407-5; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; Mahadevappa M, 1999, NAT BIOTECHNOL, V17, P1134, DOI 10.1038/15124; Matsuzaki K, 2000, CANCER RES, V60, P1394; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Mikula M, 2004, HEPATOLOGY, V39, P628, DOI 10.1002/hep.20084; Mikula M, 2003, ONCOGENE, V22, P6725, DOI 10.1038/sj.onc.1206781; Mikulits W, 2000, FASEB J, V14, P1641, DOI 10.1096/fj.14.11.1641; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Newton Herbert B, 2003, Expert Rev Anticancer Ther, V3, P595, DOI 10.1586/14737140.3.5.595; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Ostman A, 2001, ADV CANCER RES, V80, P1, DOI 10.1016/S0065-230X(01)80010-5; Paulsson Y, 1988, GROWTH FACTORS, V1, P19, DOI 10.3109/08977198809000243; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; PINZANI M, 1994, HEPATOLOGY, V19, P701, DOI 10.1002/hep.1840190323; Pinzani M, 1996, AM J PATHOL, V148, P785; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Pradet-Balade B, 2001, TRENDS BIOCHEM SCI, V26, P225, DOI 10.1016/S0968-0004(00)01776-X; Proell V, 2005, BBA-MOL CELL RES, V1744, P76, DOI 10.1016/j.bbamcr.2004.12.009; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynolds AB, 1996, EXP CELL RES, V225, P328, DOI 10.1006/excr.1996.0183; Risau W, 1992, GROWTH FACTORS, V7, P261, DOI 10.3109/08977199209046408; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rossmanith W, 2001, MICROSC RES TECHNIQ, V52, P430, DOI 10.1002/1097-0029(20010215)52:4<430::AID-JEMT1028>3.0.CO;2-3; Saha D, 2001, J BIOL CHEM, V276, P29531, DOI 10.1074/jbc.M100069200; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; SHIRAI Y, 1994, CANCER, V73, P2275, DOI 10.1002/1097-0142(19940501)73:9<2275::AID-CNCR2820730907>3.0.CO;2-T; SOMA Y, 1989, J CELL PHYSIOL, V140, P246, DOI 10.1002/jcp.1041400209; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tsou AP, 1998, GENOMICS, V50, P331, DOI 10.1006/geno.1998.5338; Tsuda T, 2001, DEV DYNAM, V222, P89, DOI 10.1002/dvdy.1172; Uehara H, 2003, J NATL CANCER I, V95, P458, DOI 10.1093/jnci/95.6.458; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; VONRUDEN T, 1988, EMBO J, V7, P2749, DOI 10.1002/j.1460-2075.1988.tb03129.x; Witz IP, 2000, J CELL BIOCHEM, P61; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; XU JM, 1995, J BIOL CHEM, V270, P6308, DOI 10.1074/jbc.270.11.6308; Xu XR, 2001, P NATL ACAD SCI USA, V98, P15089, DOI 10.1073/pnas.241522398; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yu JH, 2000, J BIOL CHEM, V275, P19076, DOI 10.1074/jbc.M910329199; Yu JH, 2003, J BIOL CHEM, V278, P49582, DOI 10.1074/jbc.M309986200; Yue JB, 2000, J BIOL CHEM, V275, P35656; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069	107	169	174	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3170	3185		10.1038/sj.onc.1209083	http://dx.doi.org/10.1038/sj.onc.1209083			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16607286				2022-12-28	WOS:000237951000008
J	Clement, G; Braunschweig, R; Pasquier, N; Bosman, FT; Benhattar, J				Clement, G.; Braunschweig, R.; Pasquier, N.; Bosman, F. T.; Benhattar, J.			Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus	ONCOGENE			English	Article						Barrett's esophagus; Wnt pathway; DNA methylation; APC; SFRP	BETA-CATENIN EXPRESSION; FREQUENT UP-REGULATION; PRIMARY GASTRIC-CANCER; APC GENE; HUMAN MESOTHELIOMA; COLORECTAL-CANCER; DNA METHYLATION; COLON-CANCER; E-CADHERIN; ADENOCARCINOMA	Aberrant activation of the Wnt signaling pathway has been reported during neoplastic progression in Barrett's esophagus (BE). However, mutations in APC and CTNNB1 genes were rarely observed. In this study, expression pattern of Wnt ligands, Frizzled receptors and APC, as well as the methylation status of the APC, SFRP1 and SFRP2 promoter genes were investigated in normal esophageal mucosa and in preneoplastic and neoplastic lesions of BE patients. Promoter methylation of APC was found in all BE samples and in 95% of esophageal adenocarcinomas (EAC). Full methylation of APC correlated with lack of expression. In EAC, nuclear translocation of ss-catenin was observed regardless of the expression of APC. WNT2 expression was higher in dysplasia and EAC than in BE, with 20/26 (77%) of the EAC showing high expression of WNT2. SFRP1 methylation occurred in all BE samples and in 96% of EAC, while SFRP2 was methylated in 73% of the normal squamous esophageal mucosa samples. In conclusion, (1) alterations of key regulators of the Wnt signaling are frequent in the pathogenesis of BE; (2) the APC and SFRP1 genes are inactivated by promoter methylation in BE; (3) the WNT2 gene is upregulated along the progression from low-grade dysplasia to EAC.	CHU Vaudois, Inst Pathol, CH-1011 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Benhattar, J (corresponding author), CHU Vaudois, Inst Pathol, Bugnon 25, CH-1011 Lausanne, Switzerland.	Jean.Benhattar@chuv.hospvd.ch						Baisse B, 2000, BIOTECHNIQUES, V28, P856; Benhattar Jean, 2004, Methods Mol Biol, V287, P181; Bian YS, 2000, AM J CLIN PATHOL, V114, P583, DOI 10.1309/3QLC-5MF1-JYXU-A5XX; Bian YS, 2001, BIOTECHNIQUES, V30, P66, DOI 10.2144/01301st02; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BLASBAND A, 1992, ONCOGENE, V7, P153; Blot WJ, 1999, SEMIN ONCOL, V26, P2; Brabender J, 2004, ONCOGENE, V23, P4780, DOI 10.1038/sj.onc.1207663; Bui TD, 1997, BRIT J CANCER, V75, P1131, DOI 10.1038/bjc.1997.195; Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; Clement G, 2004, CANCER RES, V64, P6867, DOI 10.1158/0008-5472.CAN-03-2503; Clement G, 2005, J CLIN PATHOL, V58, P155, DOI 10.1136/jcp.2004.021147; Falk GW, 2002, GASTROENTEROLOGY, V122, P1569, DOI 10.1053/gast.2002.33427; Flejou JF, 2005, GUT, V54, pI6, DOI 10.1136/gut.2004.041525; Gonzalez MV, 1997, J CLIN PATHOL, V50, P212, DOI 10.1136/jcp.50.3.212; Guillou L, 2001, HUM PATHOL, V32, P105, DOI 10.1053/hupa.2001.21130; He B, 2005, CANCER RES, V65, P743; Holcombe RF, 2002, J CLIN PATHOL-MOL PA, V55, P220, DOI 10.1136/mp.55.4.220; HORII A, 1993, HUM MOL GENET, V2, P283, DOI 10.1093/hmg/2.3.283; Howng SL, 2002, CANCER LETT, V183, P95, DOI 10.1016/S0304-3835(02)00085-X; Jenkins GJS, 2002, BRIT J SURG, V89, P824, DOI 10.1046/j.1365-2168.2002.02107.x; Katoh M, 2001, INT J ONCOL, V19, P1003; Katoh M, 2003, INT J MOL MED, V12, P811; Katoh M, 2001, INT J MOL MED, V8, P657; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kitadai Y, 1998, CLIN CANCER RES, V4, P2195; Kobayashi K, 2002, GENE, V282, P151, DOI 10.1016/S0378-1119(01)00838-1; Koppert LB, 2004, BRIT J CANCER, V90, P892, DOI 10.1038/sj.bjc.6601589; Le Floch N, 2004, FASEB J, V18, P144, DOI 10.1096/fj.04-2373fje; Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; McManus DT, 2004, CANCER RES, V64, P1561, DOI 10.1158/0008-5472.CAN-03-2438; Metzger R, 2004, ONKOLOGIE, V27, P200, DOI 10.1159/000076913; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NISHIHIRA T, 1993, J CANCER RES CLIN, V119, P441, DOI 10.1007/BF01215923; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Osterheld MC, 2002, AM J CLIN PATHOL, V117, P451; Pham K, 2003, J CLIN PATHOL-MOL PA, V56, P280, DOI 10.1136/mp.56.5.280; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2000, GENE DEV, V14, P1837; Rhee CS, 2002, ONCOGENE, V21, P6598, DOI 10.1038/sj.onc.1205920; Ricken A, 2002, ENDOCRINOLOGY, V143, P2741, DOI 10.1210/en.143.7.2741; Rockett JC, 1997, BRIT J CANCER, V75, P258, DOI 10.1038/bjc.1997.42; Saitoh T, 2002, INT J MOL MED, V9, P515; Seery JP, 1999, ACTA ONCOL, V38, P945, DOI 10.1080/028418699432635; Shih IM, 2000, CANCER RES, V60, P1671; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704; Verma UN, 2003, CLIN CANCER RES, V9, P1291; Worm J, 2004, ONCOGENE, V23, P5215, DOI 10.1038/sj.onc.1207647	51	95	102	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					3084	3092		10.1038/sj.onc.1209338	http://dx.doi.org/10.1038/sj.onc.1209338			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16407829				2022-12-28	WOS:000237950800014
J	Kato, Y; Ying, H; Zhao, L; Furuya, F; Araki, O; Willingham, MC; Cheng, SY				Kato, Y; Ying, H; Zhao, L; Furuya, F; Araki, O; Willingham, MC; Cheng, SY			PPAR gamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappa B signaling pathway	ONCOGENE			English	Article						thyroid cancer; mutant thyroid hormone receptor; PPAR gamma; NF-kappa B; mouse model; apoptosis	HORMONE RECEPTOR-BETA; HUMAN PROSTATE-CANCER; INHIBITS CELL-GROWTH; MOUSE MODEL; TRANSCRIPTIONAL ACTIVITY; GENERALIZED RESISTANCE; LIPOPROTEIN-LIPASE; TARGETED MUTATION; CARCINOMA CELLS; TRANSGENIC MICE	The molecular genetic events underlying thyroid carcinogenesis are poorly understood. Mice harboring a knock-in dominantly negative mutant thyroid hormone receptor beta (TR beta(PV/PV) mouse) spontaneously develop follicular thyroid carcinoma similar to human thyroid cancer. Using this mutant mouse, we tested the hypothesis that the peroxisome proliferator-activated receptor gamma (PPAR gamma) could function as a tumor suppressor in thyroid cancer in vivo. Using the offspring from the cross of TR beta(PV/+) and PPAR gamma(+/-) mice, we found that thyroid carcinogenesis progressed significantly faster in TRbPV/PV mice with PPAR gamma insufficiency from increased cell proliferation and reduced apoptosis. Reduced PPAR gamma protein abundance led to the activation of the nuclear factor-kappa B signaling pathway, resulting in the activation of cyclin D1 and repression of critical genes involved in apoptosis. Treatment of TR beta PV/PV mice with a PPAR gamma agonist, rosiglitazone, delayed the progression of thyroid carcinogenesis by decreasing cell proliferation and activation of apoptosis. These results suggest that PPAR gamma is a critical modi. er in thyroid carcinogenesis and could be tested as a therapeutic target in thyroid follicular carcinoma.	NCI, Mol Biol Lab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; Wake Forest Univ, Sch Med, Dept Pathol, Winston Salem, NC 27109 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Wake Forest University	Cheng, SY (corresponding author), NCI, Mol Biol Lab, Canc Res Ctr, NIH, 37 Convent Dr,Room 5128, Bethesda, MD 20892 USA.	chengs@mail.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC008752, ZIABC008752] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama TE, 2002, MOL CELL BIOL, V22, P2607, DOI 10.1128/MCB.22.8.2607-2619.2002; Asou H, 1999, INT J ONCOL, V15, P1027; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Cheung L, 2003, J CLIN ENDOCR METAB, V88, P354, DOI 10.1210/jc.2002-021020; Chevillard S, 2004, CLIN CANCER RES, V10, P6586, DOI 10.1158/1078-0432.CCR-04-0053; COOPER DS, 1981, J CLIN ENDOCR METAB, V52, P294, DOI 10.1210/jcem-52-2-294; Demetri GD, 1999, P NATL ACAD SCI USA, V96, P3951, DOI 10.1073/pnas.96.7.3951; Fan WQ, 2005, ENDOCRINOLOGY, V146, P85, DOI 10.1210/en.2004-1046; FLEISS JL, 1981, STAT METHODS RATES; Furumoto H, 2005, MOL CELL BIOL, V25, P124, DOI 10.1128/MCB.25.1.124-135.2005; Goldberg IJ, 2001, FRONT BIOSCI-LANDMRK, V6, pD388, DOI 10.2741/Goldberg; Guan You-Fei, 1999, Neoplasia (New York), V1, P330, DOI 10.1038/sj.neo.7900050; Gustafson KS, 2003, AM J CLIN PATHOL, V120, P175, DOI 10.1309/2E6QGJRGGETVT8K9; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Jeker LT, 1999, BIOCHEM BIOPH RES CO, V257, P511, DOI 10.1006/bbrc.1999.0468; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kaneshige M, 2000, P NATL ACAD SCI USA, V97, P13209, DOI 10.1073/pnas.230285997; Kato Y, 2004, ENDOCRINOLOGY, V145, P4430, DOI 10.1210/en.2004-0612; Keelan JA, 1999, BIOCHEM BIOPH RES CO, V262, P579, DOI 10.1006/bbrc.1999.1257; Klopper JP, 2004, MOL CANCER THER, V3, P1011; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Kubota T, 1998, CANCER RES, V58, P3344; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; Lee E, 2013, STAT METHODS SURVIVA; MAZZAFERRI EL, 1993, NEW ENGL J MED, V328, P553; MEIER CA, 1992, MOL ENDOCRINOL, V6, P248, DOI 10.1210/me.6.2.248; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; Motomura W, 2000, CANCER RES, V60, P5558; Mueller E, 2000, P NATL ACAD SCI USA, V97, P10990, DOI 10.1073/pnas.180329197; Nikiforova MN, 2002, AM J SURG PATHOL, V26, P1016, DOI 10.1097/00000478-200208000-00006; Nishida K, 2002, BRIT J CANCER, V86, P1303, DOI 10.1038/sj.bjc.6600241; Ohta K, 2001, J CLIN ENDOCR METAB, V86, P2170, DOI 10.1210/jc.86.5.2170; ONO S, 1991, J CLIN ENDOCR METAB, V73, P990, DOI 10.1210/jcem-73-5-990; Park JW, 2005, THYROID, V15, P222, DOI 10.1089/thy.2005.15.222; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; Rivas M, 2003, MOL CELL ENDOCRINOL, V213, P31, DOI 10.1016/j.mce.2003.10.029; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Setoguchi K, 2001, J CLIN INVEST, V108, P1667; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; Suzuki H, 2003, MOL ENDOCRINOL, V17, P1647, DOI 10.1210/me.2003-0114; Suzuki H, 2003, MOL ENDOCRINOL, V17, P895, DOI 10.1210/me.2002-0326; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; SYLVIA L, 2004, MOL BASIS THYROID CA, P23; Takahashi N, 1999, FEBS LETT, V455, P135, DOI 10.1016/S0014-5793(99)00871-6; Tsubouchi Y, 2000, BIOCHEM BIOPH RES CO, V270, P400, DOI 10.1006/bbrc.2000.2436; Wang NP, 2002, J BIOL CHEM, V277, P34176, DOI 10.1074/jbc.M203436200; Yen PM, 2003, TRENDS ENDOCRIN MET, V14, P327, DOI 10.1016/S1043-2760(03)00114-0; Ying H, 2003, CANCER RES, V63, P5274; Ying H, 2003, CARCINOGENESIS, V24, P1467, DOI 10.1093/carcin/bgg111; Zeiger MA, 1997, ENDOCRINOLOGY, V138, P3133, DOI 10.1210/en.138.8.3133	53	85	90	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2736	2747		10.1038/sj.onc.1209299	http://dx.doi.org/10.1038/sj.onc.1209299			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16314832				2022-12-28	WOS:000237272900005
J	Peng, M; Litman, R; Jin, Z; Fong, G; Cantor, SB				Peng, M; Litman, R; Jin, Z; Fong, G; Cantor, SB			BACH1 is a DNA repair protein supporting BRCA1 damage response	ONCOGENE			English	Article						BRCA1; BACH1; FA-J; BRIP1; DNA repair	FANCONI-ANEMIA; HELICASE BRIP1; NUCLEAR FOCI; HISTONE H2AX; PHOSPHORYLATION; PHOSPHOPEPTIDE; TUMORIGENESIS; RECOGNITION; ASSOCIATION; DEFICIENT	The link between defects in BRCA1 and breast cancer development may be best understood by deciphering the role of associated proteins. BRCA1 associated C-terminal helicase (BACH1) interacts directly with the BRCA1 C-terminal BRCT repeats, which are important for BRCA1 DNA repair and are mutated in the majority of BRCA1 familial cancers. Thus, BACH1 is a likely candidate for mediating BRCA1 DNA repair and tumor suppression functions. Although previous evidence using overexpression of a dominant negative BACH1 has suggested that BACH1 is involved in BRCA1-DNA repair function, our results using BACH1 deficient cells provide direct evidence for involvement of BACH1 in DNA repair as well as for localizing BRCA1. Following DNA damage BACH1 is modified by phosphorylation, displays a BRCA1-like nuclear foci pattern and colocalizes with gamma-H2AX. Given that the BACH1/BRCA1 complex is unaltered by DNA damage and the intensity of BRCA1 foci is diminished in BACH1 deficient cells, BACH1 may serve to not only facilitate DNA repair, but also maintain BRCA1 in DNA damage foci.	UMASS Med Sch, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Cantor, SB (corresponding author), UMASS Med Sch, 364 Plantat St LRB 415, Worcester, MA 01605 USA.	Sharon.Cantor@umassmed.edu	Fong, Geoffrey T/H-2810-2014	Fong, Geoffrey T/0000-0001-9098-6472				Au WWY, 2005, J BIOL CHEM, V280, P6993, DOI 10.1074/jbc.M408879200; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Botuyan MVE, 2004, STRUCTURE, V12, P1137, DOI 10.1016/j.str.2004.06.002; Bridge WL, 2005, NAT GENET, V37, P953, DOI 10.1038/ng1627; Cantor S, 2004, P NATL ACAD SCI USA, V101, P2357, DOI 10.1073/pnas.0308717101; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Clapperton JA, 2004, NAT STRUCT MOL BIOL, V11, P512, DOI 10.1038/nsmb775; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Jasin M, 2002, ONCOGENE, V21, P8981, DOI 10.1038/sj.onc.1206176; Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505; Kim SS, 2004, MOL CELL BIOL, V24, P9498, DOI 10.1128/MCB.24.21.9498-9507.2004; Kutler DI, 2003, BLOOD, V101, P1249, DOI 10.1182/blood-2002-07-2170; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Levitus M, 2004, BLOOD, V103, P2498, DOI 10.1182/blood-2003-08-2915; Levitus M, 2005, NAT GENET, V37, P934, DOI 10.1038/ng1625; Levran O, 2005, NAT GENET, V37, P931, DOI 10.1038/ng1624; Litman R, 2005, CANCER CELL, V8, P255, DOI 10.1016/j.ccr.2005.08.004; Liu YL, 2002, BREAST CANCER RES, V4, P9, DOI 10.1186/bcr417; Lou ZK, 2003, J BIOL CHEM, V278, P13599, DOI 10.1074/jbc.C300060200; MacLachlan TK, 2002, MOL CELL BIOL, V22, P4280, DOI 10.1128/MCB.22.12.4280-4292.2002; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Monteiro ANA, 2002, CANCER BIOL THER, V1, P187, DOI 10.4161/cbt.66; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Rodriguez M, 2003, J BIOL CHEM, V278, P52914, DOI 10.1074/jbc.C300407200; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Shiozaki EN, 2004, MOL CELL, V14, P405, DOI 10.1016/S1097-2765(04)00238-2; Snouwaert JN, 1999, FASEB J, V13, pA1538; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	42	68	71	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2245	2253		10.1038/sj.onc.1209257	http://dx.doi.org/10.1038/sj.onc.1209257			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16462773				2022-12-28	WOS:000236581200011
J	Williamson, EA; Wolf, I; O'Kelly, J; Bose, S; Tanosaki, S; Koeffler, HP				Williamson, EA; Wolf, I; O'Kelly, J; Bose, S; Tanosaki, S; Koeffler, HP			BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27(Kip1)	ONCOGENE			English	Article						FOXA1; BRCA1; cell cycle regulation	TRANSCRIPTION FACTOR HNF3; GENE-EXPRESSION; FORK-HEAD; BREAST-CANCER; MAMMARY-GLAND; MOUSE EMBRYO; IN-VIVO; BINDING; HELIX; DNA	We have previously shown that the breast cancer susceptibility gene, BRCA1, can transcriptionally activate the p27(Kip1) promoter. The BRCA1-responsive element was defined as a 35 bp region from position -545 to -511. We next determined that within this region is also a potential binding site for the transcription factor Forkhead box (FOX)A1. RNA and protein analysis as well as immunohistochemistry showed that expression of FOXA1 correlated with the expression of the estrogen receptor in a panel of breast cancer cell lines and tissues. In transient transfection reporter assays, FOXA1 could activate the p27(Kip1) promoter. Cotransfection of BRCA1 and FOXA1 resulted in a synergistic activation of the p27(Kip1) promoter. Mutation of the FOXA1 DNA-binding site in the p27(Kip1) promoter-luciferase construct significantly diminished the activity of FOXA1 alone or in combination with BRCA1. Cotransfection of FOXA1 and BRCA1 resulted in a greater amount of each protein compared to transfection of each expression vector alone. The half-life of FOXA1 was increased when coexpressed with BRCA1. Electrophoretic mobility shift assay analysis demonstrated that FOXA1 could bind to a wild-type oligonucleotide containing the FOXA1 binding site in the p27(Kip1) promoter, but this binding was lost upon mutation of this FOXA1 binding site. The protein-DNA binding complex could be supershifted with an antibody directed against FOXA1. The activity of the p27(Kip1) promoter as well as FOXA1 expression was reduced in cells treated with BRCA1 siRNA, thus silencing the expression of BRCA1 protein. In summary, we identified a FOXA1 binding site within the BRCA1-responsive element of the p27(Kip1) promoter and showed that FOXA1 activated the promoter alone and in conjunction with BRCA1. Furthermore, we identified high expression of FOXA1 in breast cancer cell lines and tissues, discovered a role for BRCA1 in the regulation of p27(Kip1) transcription and a possible interaction with BRCA1.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Dept Med Hematol Oncol, Los Angeles, CA USA; Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Dept Pathol, Los Angeles, CA USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Williamson, EA (corresponding author), Univ New Mexico, Canc Res Facil, 1UNM MSCO8 4630,Room 117, Albuquerque, NM 87131 USA.	ewilliamson@salud.unm.edu						Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Cable PL, 2003, MOL CARCINOGEN, V38, P85, DOI 10.1002/mc.10148; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Ciaparrone M, 1998, CANCER RES, V58, P114; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Cordon-Cardo C, 1998, JNCI-J NATL CANCER I, V90, P1284, DOI 10.1093/jnci/90.17.1284; COSTA RH, 2001, CELL MOL PHYSL, V280, pL823; Crowe AJ, 1999, J BIOL CHEM, V274, P25113, DOI 10.1074/jbc.274.35.25113; Cunningham MA, 2004, MOL ENDOCRINOL, V18, P1756, DOI 10.1210/me.2004-0071; Deans AJ, 2004, ONCOGENE, V23, P6136, DOI 10.1038/sj.onc.1207805; Fan SJ, 2001, ONCOGENE, V20, P8215, DOI 10.1038/sj.onc.1205033; Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8; Houvras Y, 2000, J BIOL CHEM, V275, P36230, DOI 10.1074/jbc.M002539200; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; Jin GS, 2004, ACTA MED OKAYAMA, V58, P197; Kaestner KH, 2000, GENE DEV, V14, P142; Kaestner KH, 1999, GENE DEV, V13, P495, DOI 10.1101/gad.13.4.495; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; Masciullo V, 1999, CANCER RES, V59, P3790; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; Robyr D, 2000, J BIOL CHEM, V275, P28291; SASAKI H, 1993, DEVELOPMENT, V118, P47; Shim EY, 1998, GENE DEV, V12, P5, DOI 10.1101/gad.12.1.5; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Verbeek W, 1999, BLOOD, V93, P3327, DOI 10.1182/blood.V93.10.3327; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Williamson EA, 2002, ONCOGENE, V21, P3199, DOI 10.1038/sj.onc.1205461; Wolfrum C, 2003, P NATL ACAD SCI USA, V100, P11624, DOI 10.1073/pnas.1931483100; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zaret K, 1999, DEV BIOL, V209, P1, DOI 10.1006/dbio.1999.9228; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	42	60	69	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 2	2006	25	9					1391	1399		10.1038/sj.onc.1209170	http://dx.doi.org/10.1038/sj.onc.1209170			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16331276				2022-12-28	WOS:000235708200012
J	Wendt, J; Radetzki, S; von Haefen, C; Hemmati, PG; Guner, D; Schulze-Osthoff, K; Dorken, B; Daniel, PT				Wendt, J; Radetzki, S; von Haefen, C; Hemmati, PG; Guner, D; Schulze-Osthoff, K; Dorken, B; Daniel, PT			Induction of p21(CIP/WAF-1) and G2 arrest by ionizing irradiation impedes caspase-3-mediated apoptosis in human carcinoma cells	ONCOGENE			English	Article						ionizing irradiation; DNA damage; G2 cell cycle arrest; apoptosis; resistance	DRUG-INDUCED APOPTOSIS; CYCLE ARREST; MITOTIC CATASTROPHE; CD95/FAS RECEPTOR; MITOCHONDRIAL; BAX; DEATH; ACTIVATION; CANCER; P53	There is an ongoing controversy regarding the relevance of apoptosis induction by ionizing irradiation as compared with other end points including transient or permanent cell cycle arrest of damaged cells. Here, we show that such permanent cell cycle arrest and apoptosis represent two sides of the same coin. MCF-7 cells fail to express procaspase-3, which results in resistance to apoptosis induced by anticancer drugs. Conversely, restoration of procaspase-3 sensitizes MCF- 7 cells to chemotherapeutics including epirubicine, etoposide and taxol. In contrast, irradiation does not trigger apoptotic cell death but results in prolonged arrest in the G2 phase of the cell division cycle regardless of procaspase-3 expression. This suggested that the propensity of MCF-7 cells to arrest at the G2 checkpoint results in resistance to apoptosis upon gamma-irradiation. This G2 arrest was associated with upregulation of p21(CIP/WAF-1). Inhibition of DNA-damage-induced stress kinases and p21(CIP/WAF-1) expression by caffeine abrogated G2 arrest and induced apoptosis of the irradiated cells in a caspase-3-dependent manner. Inhibition of cell cycle progression by adenoviral expression of the cyclin dependent kinase inhibitor p21(CIP/WAF-1) prevented apoptosis upon caffeine treatment indicating that cell cycle progression, that is, G2-release, is required for induction of apoptosis. Likewise, cells homozygously deleted for p21(CIP/WAF-1) (HCT116 p21(-/-)) display enhanced irradiation-induced apoptosis via a caspase-3-dependent mechanism. These data indicate that the disruption of G2 checkpoint control overcomes cell cycle arrest and resistance to gamma-irradiation-induced cell death. Thus, DNA damage may trigger a permanent G2 arrest as an initial inactivation step of tumor cells where the phenomenon of apoptosis is hidden unless cell cycle arrest is overcome. The efficient induction of apoptosis upon G2 release thereby depends on the propensity to activate the key executioner caspase-3. This finding is of crucial importance for the understanding of molecular steps underlying the efficacy of ionizing radiation to delete tumor cells.	Humboldt Univ, Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Univ Dusseldorf, Inst Mol Med, D-4000 Dusseldorf, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Heinrich Heine University Dusseldorf	Daniel, PT (corresponding author), Humboldt Univ, Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Lindenberger Weg 80,Campus Berlin Buch, D-13125 Berlin, Germany.	pdaniel@mdc-berlin.de	Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				Bhonde MR, 2005, ONCOGENE, V24, P148, DOI 10.1038/sj.onc.1207842; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; Chu K, 2004, RADIAT RES, V162, P270, DOI 10.1667/RR3221; Daniel PT, 1999, ANAL BIOCHEM, V266, P110, DOI 10.1006/abio.1998.2929; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Guner Dilek, 2003, Curr Med Chem Anticancer Agents, V3, P319, DOI 10.2174/1568011033482369; Hasenjager A, 2004, ONCOGENE, V23, P4523, DOI 10.1038/sj.onc.1207594; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hemmati PG, 2005, ONCOGENE, V24, P4114, DOI 10.1038/sj.onc.1208579; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Janicke RU, 2001, ONCOGENE, V20, P5043, DOI 10.1038/sj.onc.1204659; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Javelaud D, 2002, J BIOL CHEM, V277, P37949, DOI 10.1074/jbc.M204497200; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Klopfer A, 2004, ONCOGENE, V23, P9408, DOI 10.1038/sj.onc.1207975; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Motwani M, 1999, CLIN CANCER RES, V5, P1876; Mrozek A, 2003, CELL DEATH DIFFER, V10, P461, DOI 10.1038/sj.cdd.4401193; Normand G, 2005, J BIOL CHEM, V280, P7118, DOI 10.1074/jbc.M412330200; Prokop A, 2003, ONCOGENE, V22, P9107, DOI 10.1038/sj.onc.1207196; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Rau B, 2003, J CLIN ONCOL, V21, P3391, DOI 10.1200/JCO.2003.07.077; Rudner J, 2001, J CELL SCI, V114, P4161; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Sturm I, 1999, J CLIN ONCOL, V17, P1364, DOI 10.1200/JCO.1999.17.5.1364; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Xaus J, 1999, IMMUNITY, V11, P103, DOI 10.1016/S1074-7613(00)80085-0; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	41	62	63	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					972	980		10.1038/sj.onc.1209031	http://dx.doi.org/10.1038/sj.onc.1209031			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16331277				2022-12-28	WOS:000235361000002
J	Liu, L; Li, F; Cardelli, JA; Martin, KA; Blenis, J; Huang, S				Liu, L.; Li, F.; Cardelli, J. A.; Martin, K. A.; Blenis, J.; Huang, S.			Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways	ONCOGENE			English	Article						rapamycin; mTOR; S6K1; 4E-BP1; eIF4E; motility	TOP MESSENGER-RNAS; MAMMALIAN TARGET; ACTIN CYTOSKELETON; SIGNALING PATHWAY; INDUCED APOPTOSIS; INDUCED MIGRATION; BINDING PARTNER; GROWTH; PHOSPHORYLATION; TRANSLATION	Rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), inhibits tumor cell motility. However, the underlying mechanism is poorly understood. Here, we show that rapamycin inhibited type I insulin-like growth factor (IGF-I)-stimulated motility of a panel of cell lines. Expression of a rapamycin-resistant mutant of mTOR (mTORrr) prevented rapamycin inhibition of cell motility. However, cells expressing a kinase-dead mTORrr remained sensitive to rapamycin. Downregulation of raptor or rictor by RNA interference (RNAi) decreased cell motility. However, only downregulation of raptor mimicked the effect of rapamycin, inhibiting phosphorylation of S6 kinase 1 (S6K1) and 4E-BP1. Cells infected with an adenovirus expressing constitutively active and rapamycin-resistant mutant of p70 S6K1, but not with an adenovirus expressing wild-type S6K1, or a control virus, conferred to resistance to rapamycin. Further, IGF-I failed to stimulate motility of the cells, in which S6K1 was downregulated by RNAi. Moreover, downregulation of eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) by RNAi-attenuated rapamycin inhibition of cell motility. In contrast, expression of constitutively active 4E-BP1 dramatically inhibited IGF-I-stimulated cell motility. The results indicate that both S6K1 and 4E-BP1 pathways, regulated by TORC1, are required for cell motility. Rapamycin inhibits IGF-I-stimulated cell motility, through suppression of both S6K1 and 4E-BP1/ eIF4E-signaling pathways, as a consequence of inhibition of mTOR kinase activity.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol & Immunol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, FeistWeiller Canc Ctr, Shreveport, LA 71130 USA; Dartmouth Med Sch, Dept Surg, Lebanon, NH USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Dartmouth College; Harvard University; Harvard Medical School	Huang, S (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway, Shreveport, LA 71130 USA.	shuan1@lsuhsc.edu	Huang, Shile/I-1632-2019	Huang, Shile/0000-0002-3239-1072; Martin, Kathleen/0000-0002-1748-0034				Andre F, 1999, INT J CANCER, V83, P497, DOI 10.1002/(SICI)1097-0215(19991112)83:4<497::AID-IJC11>3.3.CO;2-4; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Berven LA, 2004, EXP CELL RES, V296, P183, DOI 10.1016/j.yexer.2003.12.032; Beuvink I, 2005, CELL, V120, P747, DOI 10.1016/j.cell.2004.12.040; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Boffa DJ, 2004, CLIN CANCER RES, V10, P293, DOI 10.1158/1078-0432.CCR-0629-3; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Cartwright JE, 2002, EXP CELL RES, V279, P219, DOI 10.1006/excr.2002.5616; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; Erbay E, 2001, J BIOL CHEM, V276, P36079, DOI 10.1074/jbc.C100406200; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Gallicchio MA, 2003, J CELL PHYSIOL, V197, P131, DOI 10.1002/jcp.10352; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Gomez-Cambronero J, 2003, FEBS LETT, V550, P94, DOI 10.1016/S0014-5793(03)00828-7; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hassid A, 1999, AM J PHYSIOL-HEART C, V277, pH1014, DOI 10.1152/ajpheart.1999.277.3.H1014; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Hosoi H, 1998, MOL PHARMACOL, V54, P815, DOI 10.1124/mol.54.5.815; Hosoi H, 1999, CANCER RES, V59, P886; Huang S, 2003, MOL CELL, V11, P1491, DOI 10.1016/S1097-2765(03)00180-1; Huang S, 2003, CURR OPIN PHARMACOL, V3, P371, DOI 10.1016/S1471-4892(03)00071-7; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kwon YS, 2005, INVEST OPHTH VIS SCI, V46, P454, DOI 10.1167/iovs.04-0753; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Luan FL, 2003, KIDNEY INT, V63, P917, DOI 10.1046/j.1523-1755.2003.00805.x; Martin DE, 2005, CURR OPIN CELL BIOL, V17, P158, DOI 10.1016/j.ceb.2005.02.008; Martin KA, 2004, AM J PHYSIOL-CELL PH, V286, pC507, DOI 10.1152/ajpcell.00201.2003; Meyer GE, 2001, ONCOGENE, V20, P7542, DOI 10.1038/sj.onc.1204927; MINNITI CP, 1992, J BIOL CHEM, V267, P9000; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Poon M, 1996, J CLIN INVEST, V98, P2277, DOI 10.1172/JCI119038; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rodriguez Luis G., 2004, V294, P23; Rowinsky EK, 2004, CURR OPIN ONCOL, V16, P564, DOI 10.1097/01.cco.0000143964.74936.d1; Sakakibara K, 2005, AM J PHYSIOL-HEART C, V288, pH2861, DOI 10.1152/ajpheart.00561.2004; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schalm SS, 2005, J BIOL CHEM, V280, P11101, DOI 10.1074/jbc.M413995200; Sekulic A, 2000, CANCER RES, V60, P3504; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; Shu LL, 2002, J BIOL CHEM, V277, P16726, DOI 10.1074/jbc.M112285200; Stolovich M, 2002, MOL CELL BIOL, V22, P8101, DOI 10.1128/MCB.22.23.8101-8113.2002; Sun J, 2001, CIRCULATION, V103, P2967, DOI 10.1161/01.CIR.103.24.2967; Tai YT, 2003, CANCER RES, V63, P5850; TAKAISHI K, 1995, METHOD ENZYMOL, V256, P336; Tang H, 2001, MOL CELL BIOL, V21, P8671, DOI 10.1128/MCB.21.24.8671-8683.2001; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; Wan XL, 2005, CANCER RES, V65, P2406, DOI 10.1158/0008-5472.CAN-04-3135; Wong AST, 2004, EXP CELL RES, V299, P248, DOI 10.1016/j.yexcr.2004.06.002; Yuan Q, 2000, AM J PHYSIOL-GASTR L, V278, pG49, DOI 10.1152/ajpgi.2000.278.1.G49; Zhang DL, 2003, ONCOGENE, V22, P974, DOI 10.1038/sj.onc.1206197	60	153	166	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2006	25	53					7029	7040		10.1038/sj.onc.1209691	http://dx.doi.org/10.1038/sj.onc.1209691			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16715128				2022-12-28	WOS:000241910500003
J	Alchanati, I; Nallar, SC; Sun, P; Gao, L; Hu, J; Stein, A; Yakirevich, E; Konforty, D; Alroy, I; Zhao, X; Reddy, SP; Resnick, MB; Kalvakolanu, DV				Alchanati, I.; Nallar, S. C.; Sun, P.; Gao, L.; Hu, J.; Stein, A.; Yakirevich, E.; Konforty, D.; Alroy, I.; Zhao, X.; Reddy, S. P.; Resnick, M. B.; Kalvakolanu, D. V.			A proteomic analysis reveals the loss of expression of the cell death regulatory gene GRIM-19 in human renal cell carcinomas	ONCOGENE			English	Article						cell growth; cancer; cytokines; tumor suppression; transcription	ACID-ACTIVATED REGULATOR; TUMOR-SUPPRESSOR GENE; RETINOIC ACID; IN-VIVO; C-MET; GROWTH-SUPPRESSION; SIGNAL TRANSDUCER; CANCER-CELLS; COMPLEX-I; IFN-BETA	Gene associated with retinoid interferon-induced mortality (GRIM)-19, an inhibitor of transcription factor STAT3, was originally identified as a critical regulatory protein in a genetic screen that was designed to identify the gene products necessary for Interferon (IFN)-beta-and retinoic acid-induced cell death. Over expression of GRIM-19 activates cell death. Conversely, inactivation of its expression promotes cell growth. STAT3 is a transcription factor that regulates gene expression in response to multiple extra cellular growth factors. In contrast to its normal feedback inhibition, a constitutive activation of STAT3 has been documented in several tumors. Although many STAT3-inhibitors are described, their relevance to human cancer is unclear. In an attempt to de. ne the molecular alterations associated with human renal cell carcinoma (RCC) using mass spectrometry, we have discovered that expression of GRIM-19 is lost or severely depressed in a number of primary RCC and in some urinogenital tumors. Using an RCC cell line, we show that down regulation of GRIM-19 promotes tumor growth via an augmentation of STAT3-dependent gene expression. These studies for the. rst time show a tumor-suppressor like activity of GRIM-19.	Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Proteol Ltd, Rehovot, Israel; Jilin Univ, Sch Basic Med, Dept Pathophysiol, Changchun 130023, Peoples R China; Carmel Hosp, Dept Urol, Haifa, Israel; Rhode Isl Hosp, Dept Pathol, Providence, RI 02902 USA; Brown Univ, Sch Med, Providence, RI 02912 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA	University System of Maryland; University of Maryland Baltimore; Jilin University; Clalit Health Services; Carmel Medical Center; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Kalvakolanu, DV (corresponding author), Univ Maryland, Sch Med, Greenebaum Canc Ctr, 660 W Redwood St,Howard Hall Room 324, Baltimore, MD 21201 USA.	dkalvako@umaryland.edu	Resnick, Murray/U-2986-2019		NATIONAL CANCER INSTITUTE [R01CA105005] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R56ES011863, R01ES011863] Funding Source: NIH RePORTER; NCI NIH HHS [CA105005, CA78286] Funding Source: Medline; NHLBI NIH HHS [HL66109] Funding Source: Medline; NIEHS NIH HHS [ES11863] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Angell JE, 2000, J BIOL CHEM, V275, P33416, DOI 10.1074/jbc.M003929200; BAGGETTO LG, 1992, BIOCHIMIE, V74, P959, DOI 10.1016/0300-9084(92)90016-8; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buettner R, 2002, CLIN CANCER RES, V8, P945; Chidambaram NV, 2000, J INTERF CYTOK RES, V20, P661, DOI 10.1089/107999000414844; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; Fearnley IM, 2001, J BIOL CHEM, V276, P38345, DOI 10.1074/jbc.C100444200; Fischer J, 1998, ONCOGENE, V17, P733, DOI 10.1038/sj.onc.1201983; Gao AC, 1999, PROSTATE, V38, P46, DOI 10.1002/(SICI)1097-0045(19990101)38:1<46::AID-PROS6>3.0.CO;2-9; Gao LF, 2005, CLIN CANCER RES, V11, P6333, DOI 10.1158/1078-0432.CCR-05-0148; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gresser I, 2002, CYTOKINE GROWTH F R, V13, P111, DOI 10.1016/S1359-6101(01)00035-1; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Hu JD, 2002, J INTERF CYTOK RES, V22, P1017, DOI 10.1089/107999002760624242; Huang GC, 2004, MOL CELL BIOL, V24, P8447, DOI 10.1128/MCB.24.19.8447-8456.2004; Ikeda H, 2002, CYTOKINE GROWTH F R, V13, P95, DOI 10.1016/S1359-6101(01)00038-7; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Kalvakolanu DV, 2004, CYTOKINE GROWTH F R, V15, P169, DOI 10.1016/j.cytogfr.2004.01.002; Kalvakolanu DV, 2001, MOL BASIS CANC, P503; Katula KS, 1997, CELL GROWTH DIFFER, V8, P811; Klosek SK, 2004, ONCOL REP, V12, P293; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Lang R, 2003, NAT IMMUNOL, V4, P546, DOI 10.1038/ni932; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lindner DJ, 2002, CLIN CANCER RES, V8, P3210; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Lubensky IA, 1999, AM J PATHOL, V155, P517, DOI 10.1016/S0002-9440(10)65147-4; Lufei CC, 2003, EMBO J, V22, P1325, DOI 10.1093/emboj/cdg135; Maximo V, 2005, BRIT J CANCER, V92, P1892, DOI 10.1038/sj.bjc.6602547; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MOORE DM, 1994, SEMIN HEMATOL, V31, P31; Morris MR, 2004, J CLIN PATHOL, V57, P706, DOI 10.1136/jcp.2003.011767; Pingoud-Meier C, 2003, CLIN CANCER RES, V9, P6401; Pollard PJ, 2003, ANN MED, V35, P632, DOI 10.1080/07853890310018458; Pollard PJ, 2005, HUM MOL GENET, V14, P2231, DOI 10.1093/hmg/ddi227; Radaeva S, 2002, GASTROENTEROLOGY, V122, P1020, DOI 10.1053/gast.2002.32388; Schmidt PR, 1997, J ANTHROPOL ARCHAEOL, V16, P73, DOI 10.1006/jaar.1997.0305; Seo T, 2002, J VIROL, V76, P8797, DOI 10.1128/JVI.76.17.8797-8807.2002; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Simpson RJ, 2003, PROTEINS PROTEOMICS; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; Thacher SM, 2000, CURR PHARM DESIGN, V6, P25, DOI 10.2174/1381612003401415; Trovato M, 2004, EUR J HISTOCHEM, V48, P291; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Xu Q, 2005, ONCOGENE, V24, P5552, DOI 10.1038/sj.onc.1208719; Yang J, 2005, CANCER RES, V65, P939; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Zhang J, 2003, P NATL ACAD SCI USA, V100, P9342, DOI 10.1073/pnas.1633516100; Zhang XW, 2004, CANCER RES, V64, P2474, DOI 10.1158/0008-5472.CAN-03-3443; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727	62	83	97	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	54					7138	7147		10.1038/sj.onc.1209708	http://dx.doi.org/10.1038/sj.onc.1209708			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16732315				2022-12-28	WOS:000242046900003
J	Brocke-Heidrich, K; Ge, B; Cvijic, H; Pfeifer, G; Loffler, D; Henze, C; McKeithan, TW; Horn, F				Brocke-Heidrich, K.; Ge, B.; Cvijic, H.; Pfeifer, G.; Loeffler, D.; Henze, C.; McKeithan, T. W.; Horn, F.			BCL3 is induced by IL-6 via Stat3 binding to intronic enhancer HS4 and represses its own transcription	ONCOGENE			English	Article						BCL3; IL-6; Stat3; myeloma	NF-KAPPA-B; CANDIDATE PROTOONCOGENE BCL-3; MULTIPLE-MYELOMA CELLS; ONCOPROTEIN BCL-3; GENE-EXPRESSION; P50 HOMODIMERS; ENCODES; PHOSPHORYLATION; ACTIVATION; INDUCTION	BCL3 is a proto-oncogene affected by chromosomal translocations in some patients with chronic lymphocytic leukemia. It is an IKB family protein that is involved in transcriptional regulation of a number of NF-KB target genes. In this study, interleukin (IL)-6-induced BCL3 expression and its effect on survival of multiple myeloma ( MM) cells were examined. We demonstrate the upregulation of BCL3 by IL-6 in INA-6 and other MM cell lines. Sequence analysis of the BCL3 gene locus revealed four potential signal transducer and activator of transcription (Stat) binding sites within two conserved intronic enhancers regions: one located within enhancer HS3 and three within HS4. Chromatin immunoprecipitation experiments showed increased Stat3 binding to both enhancers upon IL-6 stimulation. Silencing Stat3 expression by small interfering RNA ( siRNA) abrogated BCL3 expression by IL-6. Using reporter gene assays, we demonstrate that BCL3 transcription depends on HS4. Mutation of the Stat motifs within HS4 abolished IL-6-dependent BCL3 induction. Furthermore, BCL3 transcription was inhibited by its own gene product. This repressive feedback is mediated by NF-KB sites within the promoter and HS3. Finally, we show that overexpression of BCL3 increases apoptosis, whereas BCL3-specific siRNA does not affect the viability of INA-6 cells suggesting that BCL3 is not essential for the survival of these cells.	Univ Leipzig, Inst Clin Immunol & Transfus Med, D-04103 Leipzig, Germany; Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE 68182 USA	Leipzig University; University of Nebraska System; University of Nebraska Medical Center	Brocke-Heidrich, K (corresponding author), Univ Leipzig, Inst Clin Immunol & Transfus Med, Johannisallee 30, D-04103 Leipzig, Germany.	kheid@medizin.uni-leipzig.de		McKeithan, Timothy/0000-0003-2242-3074				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Brasier AR, 2001, J BIOL CHEM, V276, P32080, DOI 10.1074/jbc.M102949200; Brocke-Heidrich K, 2004, BLOOD, V103, P242, DOI 10.1182/blood-2003-04-1048; Bundy DL, 1997, J BIOL CHEM, V272, P33132, DOI 10.1074/jbc.272.52.33132; Burger R, 2001, Hematol J, V2, P42, DOI 10.1038/sj.thj.6200075; Chatterjee M, 2004, BLOOD, V104, P3712, DOI 10.1182/blood-2004-04-1670; CHEN HM, 1995, ONCOGENE, V11, P1549; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Elliott SF, 2002, ARTHRITIS RHEUM-US, V46, P3230, DOI 10.1002/art.10675; Feinman R, 1999, BLOOD, V93, P3044; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Ge BS, 2003, J IMMUNOL, V171, P4210, DOI 10.4049/jimmunol.171.8.4210; Holtick U, 2005, LEUKEMIA, V19, P936, DOI 10.1038/sj.leu.2403750; INOUE J, 1993, ONCOGENE, V8, P2067; Jamaluddin M, 2005, J VIROL, V79, P15302, DOI 10.1128/JVI.79.24.15302-15313.2005; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; Kordula T, 1998, J BIOL CHEM, V273, P4112, DOI 10.1074/jbc.273.7.4112; Kuwata H, 2003, BLOOD, V102, P4123, DOI 10.1182/blood-2003-04-1228; MCKEITHAN TW, 1990, GENE CHROMOSOME CANC, V1, P247, DOI 10.1002/gcc.2870010310; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; Mitchell TC, 2001, NAT IMMUNOL, V2, P397, DOI 10.1038/87692; Nishikori M, 2003, BLOOD, V101, P2789, DOI 10.1182/blood-2002-08-2464; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; Ong ST, 1998, ONCOGENE, V16, P2333, DOI 10.1038/sj.onc.1201771; Rebollo A, 2000, MOL CELL BIOL, V20, P3407, DOI 10.1128/MCB.20.10.3407-3416.2000; Richard M, 1999, BLOOD, V93, P4318, DOI 10.1182/blood.V93.12.4318.412k09_4318_4327; Thornburg NJ, 2003, CANCER RES, V63, P8293; Viatour P, 2004, MOL CELL, V16, P35, DOI 10.1016/j.molcel.2004.09.004; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; Yamazaki S, 2005, J BIOL CHEM, V280, P1678, DOI 10.1074/jbc.M409983200	35	54	57	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	55					7297	7304		10.1038/sj.onc.1209711	http://dx.doi.org/10.1038/sj.onc.1209711			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16732314				2022-12-28	WOS:000242244700008
J	Darbro, BW; Lee, KM; Nguyen, NK; Domann, FE; Klingelhutz, AJ				Darbro, B. W.; Lee, K. M.; Nguyen, N. K.; Domann, F. E.; Klingelhutz, A. J.			Methylation of the p16(INK4a) promoter region in telomerase immortalized human keratinocytes co-culturedwith feeder cells	ONCOGENE			English	Article						hTERT; CDKN2A; senescence; epigenetic; Rb; telomeres	MAMMARY EPITHELIAL-CELLS; HUMAN UROEPITHELIAL CELLS; HUMAN ORAL KERATINOCYTES; DNA METHYLATION; PROGNOSTIC-SIGNIFICANCE; P16 EXPRESSION; HUMAN CANCER; REPLICATIVE SENESCENCE; GROWTH-CONDITIONS; P16/PRB PATHWAY	Human keratinocytes grown in co-culture with fibroblast feeder cells have an extended in vitro lifespan and delayed accumulation of the tumor suppressor protein p16(INK4a) when compared to the same cells grown on tissue culture plastic alone. Previous studies have indicated that human keratinocytes can be immortalized by telomerase activity alone when grown in co-culture with feeder cells, suggesting that loss of the p16(INK4a)/Rb pathway is not required for immortalization. Using two independent human keratinocyte cell strains, we found that exogenous telomerase expression and co-culture with feeder cells results in efficient extension of lifespan without an apparent crisis. However, when these cells were transferred from the co-culture environment to plastic alone they experienced only a brief period of slowed growth before continuing to proliferate indefinitely. Examination of immortal cell lines demonstrated p16(INK4a) promoter methylation had occurred in both the absence and presence of feeder cells. Reintroduction of p16INK4a into immortal cell lines resulted in rapid growth arrest. Our results suggest that p16(INK4a)/Rb-induced telomere-independent senescence, although delayed in the presence of feeders, still provides a proliferation barrier to human keratinocytes in this culture system and that extended culture of telomerase-transduced keratinocytes on feeders can lead to the methylation of p16(INK4a).	Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA; Univ Iowa, Holden Canc Ctr, Iowa City, IA 52242 USA; Univ Iowa, Interdisciplinary Program Mol Biol, Iowa City, IA 52242 USA; Univ Iowa, Med Scientist Training Program, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiat Oncol, Iowa City, IA 52242 USA; Univ Iowa, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa; University of Iowa; University of Iowa	Klingelhutz, AJ (corresponding author), Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA.	al-klingelhutz@uiowa.edu	Klingelhutz, Aloysius/L-9081-2018	Klingelhutz, Aloysius/0000-0003-4258-5046; Darbro, Benjamin/0000-0001-9279-356X; Domann, Frederick/0000-0002-0489-2179	NATIONAL CANCER INSTITUTE [R01CA073612] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007638] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018265] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA73612, R01 CA073612] Funding Source: Medline; NHLBI NIH HHS [T32 HL07638, T32 HL007638] Funding Source: Medline; NIA NIH HHS [R01 AG18265, R01 AG018265] Funding Source: Medline; NIGMS NIH HHS [T32 GM07337, T32 GM007337] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baek JH, 2003, INT J MOL MED, V12, P319; BLANTON RA, 1991, AM J PATHOL, V138, P673; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; Chakravarti A, 2003, J CLIN ONCOL, V21, P3328, DOI 10.1200/JCO.2003.12.151; Cody DT, 1999, ORAL ONCOL, V35, P516, DOI 10.1016/S1368-8375(99)00026-3; Curtis CD, 2005, METH MOLEC MED, V103, P123; Darbro BW, 2005, J INVEST DERMATOL, V125, P499, DOI 10.1111/j.0022-202X.2005.23844.x; Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Esteller M, 2001, J CLIN ONCOL, V19, P299, DOI 10.1200/JCO.2001.19.2.299; Farwell DG, 2000, AM J PATHOL, V156, P1537, DOI 10.1016/S0002-9440(10)65025-0; Foster SA, 1996, ONCOGENE, V12, P1773; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; Fu BJ, 2003, CANCER RES, V63, P7815; Govindarajan B, 2002, MOL MED, V8, P1; Groeger AM, 1999, J THORAC CARDIOV SUR, V118, P529, DOI 10.1016/S0022-5223(99)70192-3; Harada H, 2003, MOL CANCER RES, V1, P729; Herbert BS, 2002, ONCOGENE, V21, P7897, DOI 10.1038/sj.onc.1205902; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Jacobs JJL, 2004, CURR BIOL, V14, P2302, DOI 10.1016/j.cub.2004.12.025; Jarmalaite S, 2003, INT J CANCER, V106, P913, DOI 10.1002/ijc.11322; Jarrard DF, 1999, CANCER RES, V59, P2957; Jung A, 2001, AM J PATHOL, V159, P1613, DOI 10.1016/S0002-9440(10)63007-6; Kang MK, 2004, J CELL PHYSIOL, V199, P364, DOI 10.1002/jcp.10410; Kang MK, 2003, EXP CELL RES, V287, P272, DOI 10.1016/S0014-4827(03)00061-2; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Klingelhutz AJ, 2005, VIROLOGY, V340, P237, DOI 10.1016/j.virol.2005.06.027; Korkolopoulou P, 2001, EUR UROL, V39, P167, DOI 10.1159/000052432; Lewis A, 2004, NAT GENET, V36, P1291, DOI 10.1038/ng1468; Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197; Liu LM, 2005, INT J ONCOL, V26, P275; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; Natarajan E, 2003, AM J PATHOL, V163, P477, DOI 10.1016/S0002-9440(10)63677-2; Nilsson K, 2004, MODERN PATHOL, V17, P1464, DOI 10.1038/modpathol.3800220; Noble JR, 2004, ONCOGENE, V23, P3116, DOI 10.1038/sj.onc.1207440; Partridge M, 2005, CANCER METAST REV, V24, P71, DOI 10.1007/s10555-005-5048-0; Paz MF, 2003, CANCER RES, V63, P1114; Puthenveettil JA, 1999, ADV EXP MED BIOL, V462, P83; Ramirez RD, 2003, ONCOGENE, V22, P433, DOI 10.1038/sj.onc.1206046; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; REZNIKOFF CA, 1987, J CELL PHYSIOL, V131, P285, DOI 10.1002/jcp.1041310302; Reznikoff CA, 1996, CANCER RES, V56, P2886; Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157-5172.2002; Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149; Romanenko A, 2002, DIAGN MOL PATHOL, V11, P163, DOI 10.1097/00019606-200209000-00007; Sandhu C, 2000, CANCER RES, V60, P2616; Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021; Stampfer MR, 2003, CANCER LETT, V194, P199, DOI 10.1016/S0304-3835(02)00707-3; Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998; Svensson S, 2003, CANCER RES, V63, P1737; Taylor LM, 2004, J BIOL CHEM, V279, P43634, DOI 10.1074/jbc.M402388200; Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x; Timmermann S, 1998, ONCOGENE, V17, P3445, DOI 10.1038/sj.onc.1202244; Tsihlias J, 1999, ANNU REV MED, V50, P401; Tsutsui T, 2002, CARCINOGENESIS, V23, P2111, DOI 10.1093/carcin/23.12.2111; Wang J, 2000, NATURE, V405, P755, DOI 10.1038/35015674; Wege H, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng003; Weinberger PM, 2004, CLIN CANCER RES, V10, P5684, DOI 10.1158/1078-0432.CCR-04-0448; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Wong DJ, 1997, CANCER RES, V57, P2619; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Zhao W, 2005, J BIOCHEM, V137, P431, DOI 10.1093/jb/mvi048; Zohn IE, 1998, MOL CELL BIOL, V18, P1225, DOI 10.1128/MCB.18.3.1225; Zongaro S, 2005, CANCER RES, V65, P11411, DOI 10.1158/0008-5472.CAN-05-1140	66	25	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	56					7421	7433		10.1038/sj.onc.1209729	http://dx.doi.org/10.1038/sj.onc.1209729			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16767161	Green Accepted			2022-12-28	WOS:000242419100011
J	Davies, GC; Ryan, PE; Rahman, L; Zajac-Kaye, M; Lipkowitz, S				Davies, G. C.; Ryan, P. E.; Rahman, L.; Zajac-Kaye, M.; Lipkowitz, S.			EGFRvIII undergoes activation-dependent downregulation mediated by the Cbl proteins	ONCOGENE			English	Article						EGFRvIII; Cbl proteins; ubiquitin; cancer	EPIDERMAL-GROWTH-FACTOR; MUTANT EGF-RECEPTOR; CONFERS ENHANCED TUMORIGENICITY; HUMAN GLIOBLASTOMA CELLS; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; KINASE INHIBITORS; RING FINGER; CANCER; EXPRESSION	The overexpression or mutation of tyrosine kinases (TKs), such as the epidermal growth factor receptor (EGFR), can lead to the development of cancer. The most common mutation of the EGFR in glioblastomas is the deletion of exons 2-7 known as the EGFRvIII. This mutant receptor cannot bind EGF but, instead, is constitutively active. The Cbl family of ubiquitin ligases (Cbl, Cbl-b, and Cbl-c) targets the activated EGFR for degradation. As the EGFRvIII is transforming, we investigated whether it could be downregulated by the Cbl proteins. The overexpression of all three Cbl proteins resulted in the ubiquitination and degradation of the EGFRvIII. As with the wild-type EGFR, the TK-binding domain and the RING finger of Cbl-b are sufficient for the downregulation of the EGFRvIII. Also, we found that Cbl-b is recruited to the EGFRvIII and inhibits the transformation of NIH 3T3 cells by the EGFRvIII. Mutation of the Cbl-binding site (Y1045F) in the EGFRvIII inhibits its ubiquitination and downregulation by Cbl-b and enhances its ability to transform. Furthermore, the EGFR TK inhibitor, AG 1478, prevents the downregulation of the EGFRvIII by the Cbl proteins and antagonizes the ability of an immunotoxin directed against the EGFRvIII to kill cells expressing this receptor. In conclusion, the EGFRvIII does not transform by escaping regulation by Cbl proteins and this activation-induced downregulation of the EGFRvIII has an important role in mediating the toxicity of anti-EGFRvIII immunotoxins.	NCI, LCMB, CCR, NIH, Bethesda, MD 20892 USA; George Washington Univ, Inst Biomed Sci, Washington, DC USA; NCI, Mol Therapeut Program, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); George Washington University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lipkowitz, S (corresponding author), NCI, LCMB, CCR, NIH, Bldg 37,Rm 2066,37 Convent Dr, Bethesda, MD 20892 USA.	LipkowiS@mail.nih.gov			Intramural NIH HHS [Z99 CA999999] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01SC007263] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abulrob A, 2004, ONCOGENE, V23, P6967, DOI 10.1038/sj.onc.1207911; Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; Beers R, 2000, CLIN CANCER RES, V6, P2835; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Damstrup L, 2002, INT J CANCER, V97, P7, DOI 10.1002/ijc.1572; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; Ettenberg S A, 1999, Mol Cell Biol Res Commun, V2, P111, DOI 10.1006/mcbr.1999.0157; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; Ettenberg SA, 2001, J BIOL CHEM, V276, P27677, DOI 10.1074/jbc.M102641200; Fernandes H, 2001, J BIOL CHEM, V276, P5375, DOI 10.1074/jbc.M005599200; GARCIA DP, 1993, CANCER RES, V53, P3217; Han YC, 1996, CANCER RES, V56, P3859; Heimberger AB, 2005, CLIN CANCER RES, V11, P1462, DOI 10.1158/1078-0432.CCR-04-1737; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Johns TG, 2003, P NATL ACAD SCI USA, V100, P15871, DOI 10.1073/pnas.2036503100; Keane MM, 1996, CANCER RES, V56, P4791; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; Kuan CT, 2000, INT J CANCER, V88, P962, DOI 10.1002/1097-0215(20001215)88:6<962::AID-IJC20>3.0.CO;2-U; Kuan CT, 2001, ENDOCR-RELAT CANCER, V8, P83, DOI 10.1677/erc.0.0080083; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Luwor RB, 2004, ONCOGENE, V23, P6095, DOI 10.1038/sj.onc.1207870; Mancini A, 2002, J BIOL CHEM, V277, P14635, DOI 10.1074/jbc.M109214200; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Montgomery RB, 2002, INT J CANCER, V101, P111, DOI 10.1002/ijc.10560; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Moscatello DK, 1996, ONCOGENE, V13, P85; Nagane M, 1996, CANCER RES, V56, P5079; Nau MM, 2003, GENE, V308, P103, DOI 10.1016/S0378-1119(03)00471-2; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; O'Rourke DM, 1998, ONCOGENE, V16, P1197, DOI 10.1038/sj.onc.1201635; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; Pedersen MW, 2004, INT J CANCER, V108, P643, DOI 10.1002/ijc.11566; Pedersen MW, 2001, ANN ONCOL, V12, P745, DOI 10.1023/A:1011177318162; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; REIST CJ, 1995, CANCER RES, V55, P4375; Schmidt MHH, 2003, P NATL ACAD SCI USA, V100, P6505, DOI 10.1073/pnas.1031790100; Shinojima N, 2003, CANCER RES, V63, P6962; Tang CK, 2000, CANCER RES, V60, P3081; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707	49	25	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2006	25	49					6497	6509		10.1038/sj.onc.1209662	http://dx.doi.org/10.1038/sj.onc.1209662			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16702950	Green Accepted			2022-12-28	WOS:000241395100006
J	Chou, YT; Wang, H; Chen, Y; Danielpour, D; Yang, YC				Chou, Y-T; Wang, H.; Chen, Y.; Danielpour, D.; Yang, Y-C			Cited2 modulates TGF-beta-mediated upregulation of MMP9	ONCOGENE			English	Article						Cited2; TGF-beta; MMP9; Smad3; p300	GROWTH-FACTOR-BETA; BREAST-CANCER CELLS; CREB-BINDING-PROTEIN; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; MELANOCYTE-SPECIFIC GENE; MATRIX METALLOPROTEINASES; TRANSFORMING GROWTH-FACTOR-BETA-1; SMAD PROTEINS; TRANSCRIPTIONAL COACTIVATOR; P300/CREB-BINDING PROTEIN	Cited ((C) under bar BP/p300-interacting transactivators with glutamic acid ((E) under bar )n/ aspartic acid ((D) under bar)-rich C-terminal domain) 2, which is a CBP/p300-binding transcription co-activator without typical DNA-binding domains, has been implicated in control of cell growth and malignant transformation in Rat1 cells. In this report, we provide evidence that Cited2 is an important regulator of transforming growth factor (TGF)-beta signaling. Overexpression of Cited2 enhanced TGF-beta-mediated transcription of a Smad-Binding Element-containing luciferase reporter construct, SBE4-Luc. This may occur through a direct physical association of Cited2 with Smads 2 and 3, as supported by co-immunoprecipitation, mammalian two-hybrid and glutathione S-transferase- pull down assays. The transcription factor p300, which binds to Smad3, was shown to further enhance the interaction between Cited2 and Smad3, and the transcriptional responses of Smad3 by Cited2 in reporter assays. Cited2 enhances TGF-beta-mediated upregulation of matrix metalloproteinase 9 (MMP9) in Cited2 inducible mouse embryo. broblasts. Overexpression of Cited2 enhanced TGF-beta-mediated MMP9 promoter reporter activity. Moreover, knockdown of Cited2 in MDA-MB-231 cells attenuated TGF-beta-mediated upregulation of MMP9 and TGF-beta-mediated cell invasion. Chromatin immunoprecipitation showed that Cited2 and Smad3 were recruited to MMP9 promoter upon TGF-beta stimulation. This is the first demonstration that Cited2 functions as a Smad3/p300-interacting transcriptional coactivator in modulating the expression of MMP9, which could affect tumor cell invasion mediated by TGF-beta.	Case Western Reserve Univ, Dept Pharmacol, Sch Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Canc, Sch Med, Cleveland, OH 44106 USA; Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46204 USA; Walther Canc Inst, Indianapolis, IN USA	Case Western Reserve University; Case Western Reserve University; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Yang, YC (corresponding author), Case Western Reserve Univ, Dept Pharmacol, Sch Med, 2109 Adelbert Rd,W353, Cleveland, OH 44106 USA.	yxy36@cwru.edu		Chou, Yu-Ting/0000-0001-9274-8603	NATIONAL CANCER INSTITUTE [R01CA078433] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA78433] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrews JE, 2000, MECH DEVELOP, V95, P305, DOI 10.1016/S0925-4773(00)00362-2; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bamforth SD, 2001, NAT GENET, V29, P469, DOI 10.1038/ng768; Bandyopadhyay A, 1999, CANCER RES, V59, P5041; Bannikov GA, 2002, J BIOL CHEM, V277, P16022, DOI 10.1074/jbc.M110931200; Barbera JPM, 2002, HUM MOL GENET, V11, P283, DOI 10.1093/hmg/11.3.283; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Braganca J, 2003, J BIOL CHEM, V278, P16021, DOI 10.1074/jbc.M208144200; Braganca J, 2002, J BIOL CHEM, V277, P8559, DOI 10.1074/jbc.M110850200; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Dennler S, 2005, ONCOGENE, V24, P1936, DOI 10.1038/sj.onc.1208343; Dunwoodie SL, 1998, MECH DEVELOP, V72, P27, DOI 10.1016/S0925-4773(98)00011-2; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Fox SB, 2004, CANCER RES, V64, P6075, DOI 10.1158/0008-5472.CAN-04-0708; Freedman SJ, 2003, NAT STRUCT BIOL, V10, P504, DOI 10.1038/nsb936; Fridman R, 2003, CANCER METAST REV, V22, P153, DOI 10.1023/A:1023091214123; Futaki S, 2003, J BIOL CHEM, V278, P50691, DOI 10.1074/jbc.M304985200; Glenn DJ, 1999, J BIOL CHEM, V274, P36159, DOI 10.1074/jbc.274.51.36159; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Guo BL, 2005, KIDNEY INT, V68, P972, DOI 10.1111/j.1523-1755.2005.00491.x; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8; Ilunga K, 2004, INT J EXP PATHOL, V85, P373, DOI 10.1111/j.0959-9673.2004.00406.x; Itoh T, 1999, CLIN EXP METASTAS, V17, P177, DOI 10.1023/A:1006603723759; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Javelaud D, 2005, ONCOGENE, V24, P7624, DOI 10.1038/sj.onc.1208900; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kranc KR, 2003, MOL CELL BIOL, V23, P7658, DOI 10.1128/MCB.23.21.7658-7666.2003; Leung MK, 1999, GENOMICS, V61, P307, DOI 10.1006/geno.1999.5970; Luo XP, 2005, ENDOCRINOLOGY, V146, P1097, DOI 10.1210/en.2004-1377; Lynch CC, 2002, DIFFERENTIATION, V70, P561, DOI 10.1046/j.1432-0436.2002.700909.x; Ma ZD, 2004, MOL CELL BIOL, V24, P5496, DOI 10.1128/MCB.24.12.5496-5509.2004; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MELCHIORI A, 1987, ANTICANCER RES, V7, P475; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Ogawa K, 2004, BIOCHEM J, V381, P413, DOI 10.1042/BJ20040058; Okamoto T, 2001, J BIOL CHEM, V276, P29596, DOI 10.1074/jbc.M102417200; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Santibanez JF, 2002, BIOCHEM BIOPH RES CO, V296, P267; SATO H, 1993, ONCOGENE, V8, P395; Selvamurugan N, 2004, J BIOL CHEM, V279, P27764, DOI 10.1074/jbc.M312870200; Selvamurugan N, 2004, J BIOL CHEM, V279, P19327, DOI 10.1074/jbc.M314048200; Selvamurugan N, 2002, FEBS LETT, V532, P31, DOI 10.1016/S0014-5793(02)03620-7; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shioda T, 1998, P NATL ACAD SCI USA, V95, P9785, DOI 10.1073/pnas.95.17.9785; Shioda T, 1996, P NATL ACAD SCI USA, V93, P12298, DOI 10.1073/pnas.93.22.12298; Shioda T, 1997, GENE, V204, P235, DOI 10.1016/S0378-1119(97)00551-9; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun HB, 1998, P NATL ACAD SCI USA, V95, P13555, DOI 10.1073/pnas.95.23.13555; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Tardif G, 2001, J RHEUMATOL, V28, P1631; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Tien ES, 2004, J BIOL CHEM, V279, P24053, DOI 10.1074/jbc.M401489200; Tobin SW, 2002, ONCOGENE, V21, P108, DOI 10.1038/sj.onc.1205026; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Warner DR, 2004, BIOCHEM BIOPH RES CO, V324, P70, DOI 10.1016/j.bbrc.2004.09.017; WILLIAMS DA, 1988, MOL CELL BIOL, V8, P3864, DOI 10.1128/MCB.8.9.3864; Yahata T, 2000, J BIOL CHEM, V275, P8825, DOI 10.1074/jbc.275.12.8825; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yin Z, 2002, P NATL ACAD SCI USA, V99, P10488, DOI 10.1073/pnas.162371799; Yokota H, 2003, J BIOL CHEM, V278, P47275, DOI 10.1074/jbc.M304652200; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zimmerman CM, 2000, GENE, V249, P17, DOI 10.1016/S0378-1119(00)00162-1	74	79	84	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2006	25	40					5547	5560		10.1038/sj.onc.1209552	http://dx.doi.org/10.1038/sj.onc.1209552			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16619037				2022-12-28	WOS:000240370400008
J	Tilki, D; Irmak, S; Oliveira-Ferrer, L; Hauschild, J; Miethe, K; Atakaya, H; Hammerer, P; Friedrich, MG; Schuch, G; Galalae, R; Stief, CG; Kilic, E; Huland, H; Ergun, S				Tilki, D.; Irmak, S.; Oliveira-Ferrer, L.; Hauschild, J.; Miethe, K.; Atakaya, H.; Hammerer, P.; Friedrich, M. G.; Schuch, G.; Galalae, R.; Stief, C. G.; Kilic, E.; Huland, H.; Ergun, S.			CEA-related cell adhesion molecule-1 is involved in angiogenic switch in prostate cancer	ONCOGENE			English	Article						CEACAM1; prostate cancer; angiogenesis; Ang1; siRNA; vascular destabilization	ENDOTHELIAL GROWTH-FACTOR; BILIARY GLYCOPROTEIN; C-CAM; COLORECTAL CARCINOMAS; CD66A BGP; CEACAM1; EXPRESSION; ANTIGEN; FAMILY; MECHANISMS	We demonstrate here that epithelial carcinoembryonic antigen (CEA)-related cell adhesion molecule-1 (CEACAM1) downregulation in prostate intraepithelial neoplasia (PIN) is inversely correlated with its upregulation in adjacent blood vessels. CEACAM1 silencing in prostate cancer cell line DU-145 via small interfering ribonucleic acid (siRNA) increased but its overexpression suppressed the expression of angiogenic/lymphangiogenic factors such as vascular endothelial growth factor (VEGF)-A, -C and -D, and angiogenic inhibitor collagen 18/endostatin. Furthermore, CEACAM1 overexpression in DU-145 cells increased but CEACAM1 silencing reduced angiopoietin-1 expression. Inverse relation was found for angiopoietin-2. Supernatant of CEACAM1-overexpressing DU-145 suppressed but that of CEACAM1-silenced increased the VEGF-induced endothelial tubes. Electron microscopically the majority of PIN-associated blood vessels was structurally destabilized exhibiting endothelial fenestration, trans- and inter-endothelial gaps. In some PIN areas, invasion of single tumor cells into the destabilized blood vessels was observed. These data show that disappearance of epithelial CEACAM1 in PIN is accompanied by its upregulation in adjacent vasculature which apparently correlates with vascular destabilization and increased vascularization of prostate cancer. Strategies to either conserve the epithelial CEACAM1 or to target endothelial CEACAM1 might be useful for an anti-angiogenic therapy of prostate cancer.	Univ Hamburg Hosp, Ctr Expt Med, Inst Anat, D-20246 Hamburg, Germany; Univ Hamburg Hosp, Ctr Surg, Urol Clin, D-20246 Hamburg, Germany; Univ Hamburg Hosp, Ctr Theoret Med, Inst Pathol, D-20246 Hamburg, Germany; Univ Hamburg Hosp, Dept Haematol & Oncol, Ctr Internal Med, D-20246 Hamburg, Germany; Univ Hosp Kiel, Dept Radiat Oncol, Kiel, Germany; Univ Hosp, Dept Urol, Munich, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Kiel; Schleswig Holstein University Hospital; University of Munich	Ergun, S (corresponding author), Univ Hamburg Hosp, Ctr Expt Med, Inst Anat, Martinistr 52, D-20246 Hamburg, Germany.	erguen@uke.uni-hamburg.de						Alitalo K, 2002, CANCER CELL, V1, P219, DOI 10.1016/S1535-6108(02)00051-X; Bamberger AM, 1998, AM J PATHOL, V152, P1401; BARNETT TR, 1993, MOL CELL BIOL, V13, P1273, DOI 10.1128/MCB.13.2.1273; Brummer J, 2001, AM J PATHOL, V159, P537, DOI 10.1016/S0002-9440(10)61725-7; Busch C, 2002, HUM PATHOL, V33, P290, DOI 10.1053/hupa.2002.32218; Cao RH, 2004, CIRC RES, V94, P664, DOI 10.1161/01.RES.0000118600.91698.BB; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chalajour F, 2004, EXP CELL RES, V298, P455, DOI 10.1016/j.yexcr.2004.04.034; Ebrahimnejad A, 2000, EXP CELL RES, V260, P365, DOI 10.1006/excr.2000.5026; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Ergun S, 1996, CELL TISSUE RES, V286, P93, DOI 10.1007/s004410050678; Ergun S, 2000, MOL CELL, V5, P311, DOI 10.1016/S1097-2765(00)80426-8; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HIXSON DC, 1985, CANCER RES, V45, P3742; Hong YK, 2004, NAT GENET, V36, P683, DOI 10.1038/ng1383; Huss WJ, 2001, CANCER RES, V61, P2736; Iijima H, 2004, J EXP MED, V199, P471, DOI 10.1084/jem.20030437; Izzi L, 1999, ONCOGENE, V18, P5563, DOI 10.1038/sj.onc.1202935; Kilic N, 2005, J BIOL CHEM, V280, P2361, DOI 10.1074/jbc.M409407200; KILIC N, 2001, METASTASIS RES PROTO; KUROKI M, 1991, BIOCHEM BIOPH RES CO, V176, P578, DOI 10.1016/S0006-291X(05)80223-2; LIN SH, 1991, BIOCHEM J, V278, P155, DOI 10.1042/bj2780155; Lin SH, 1999, SEMIN ONCOL, V26, P227; Luo WP, 1999, CANCER GENE THER, V6, P313, DOI 10.1038/sj.cgt.7700055; Mazzucchelli R, 2000, PROSTATE, V45, P72; McDonald DM, 2003, NAT MED, V9, P713, DOI 10.1038/nm0603-713; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nollau P, 1997, AM J PATHOL, V151, P521; Nollau P, 1997, CANCER RES, V57, P2354; Oh P, 2004, NATURE, V429, P629, DOI 10.1038/nature02580; Oliveira-Ferrer L, 2004, CANCER RES, V64, P8932, DOI 10.1158/0008-5472.CAN-04-0505; Poy MN, 2002, NAT GENET, V30, P270, DOI 10.1038/ng840; Riethdorf L, 1997, J HISTOCHEM CYTOCHEM, V45, P957, DOI 10.1177/002215549704500705; ROBERTS WG, 1995, J CELL SCI, V108, P2369; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; Saaristo A, 2002, FASEB J, V16, P1041, DOI 10.1096/fj.01-1042com; Singer BB, 2000, CANCER RES, V60, P1236; Volpert O, 2002, J BIOL CHEM, V277, P35696, DOI 10.1074/jbc.M205319200; Wagener C, 2000, EXP CELL RES, V261, P19, DOI 10.1006/excr.2000.5038	39	53	58	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2006	25	36					4965	4974		10.1038/sj.onc.1209514	http://dx.doi.org/10.1038/sj.onc.1209514			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568082				2022-12-28	WOS:000239921300002
J	Arnesen, T; Gromyko, D; Pendino, F; Ryningen, A; Varhaug, J; Lillehaug, J				Arnesen, T.; Gromyko, D.; Pendino, F.; Ryningen, A.; Varhaug, J. E.; Lillehaug, J. R.			Induction of apoptosis in human cells by RNAi-mediated knockdown of hARD1 and NATH, components of the protein N-alpha-acetyltransferase complex	ONCOGENE			English	Article						apoptosis; NATH; hARD1; protein N-acetylation; siRNA; daunorubicin	TERMINAL ACETYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; ARD1 GENE; IDENTIFICATION; ACETYLATION; YEAST; DESTABILIZATION; HIF-1-ALPHA; EXPRESSION; HYPOXIA	Protein N-epsilon-acetylation is recognized as an important modi. cation influencing many biological processes, and protein deacetylase inhibitors leading to N-epsilon-hyperacetylation of histones are being clinically tested for their potential as anticancer drugs. In contrast to N-epsilon-acetyltransferases, the N-alpha-acetyltransferases transferring acetyl groups to the alpha-amino groups of protein N-termini have only been briefly described in mammalians. Human arrest defective 1(hARD1), the only described human enzyme in this class, complexes with N-acetyltransferase human (NATH) and cotranslationally transfers acetyl groups to the N-termini of nascent polypeptides. Here, we demonstrate that knockdown of NATH and/or hARD1 triggers apoptosis in human cell lines. Knockdown of hARD1 also sensitized cells to daunorubicin-induced apoptosis, potentially pointing at the NATH-hARD1 acetyltransferase complex as a novel target for chemotherapy. Our results argue for an essential role of the NATH-hARD1 complex in cell survival and underscore the importance of protein N-alpha-acetylation in mammalian cells.	Univ Bergen, Dept Mol Biol, Bergen High Technol Ctr, N-5020 Bergen, Norway; Univ Bergen, Dept Surg Sci, N-5020 Bergen, Norway; Haukeland Univ Hosp, Dept Med, N-5021 Bergen, Norway	University of Bergen; University of Bergen; University of Bergen; Haukeland University Hospital	Arnesen, T (corresponding author), Univ Bergen, Dept Mol Biol, Bergen High Technol Ctr, Thormohlensgate 55, N-5020 Bergen, Norway.	thomas.arnesen@mbi.uib.no	Arnesen, Thomas/Q-8117-2019; PENDINO, Frederic/G-6630-2017; Arnesen, Thomas/J-7139-2017	Arnesen, Thomas/0000-0002-3005-147X; Arnesen, Thomas/0000-0002-3005-147X				Arnesen T, 2005, FEBS LETT, V579, P6428, DOI 10.1016/j.febslet.2005.10.036; Arnesen T, 2005, THYROID, V15, P1131, DOI 10.1089/thy.2005.15.1131; Arnesen T, 2005, BIOCHEM J, V386, P433, DOI 10.1042/BJ20041071; Benoit G, 1999, EMBO J, V18, P7011, DOI 10.1093/emboj/18.24.7011; Bilton R, 2005, J BIOL CHEM, V280, P31132, DOI 10.1074/jbc.M504482200; Di Gennaro E, 2004, AMINO ACIDS, V26, P435, DOI 10.1007/s00726-004-0087-3; DRIESSEN HPC, 1985, CRIT REV BIOCHEM MOL, V18, P281, DOI 10.3109/10409238509086784; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Fisher TS, 2005, J BIOL CHEM, V280, P17749, DOI 10.1074/jbc.M412055200; Fluge O, 2002, ONCOGENE, V21, P5056, DOI 10.1038/sj.onc.1205687; Gautschi M, 2003, MOL CELL BIOL, V23, P7403, DOI 10.1128/MCB.23.20.7403-7414.2003; Harborth J, 2001, J CELL SCI, V114, P4557; Ingram AK, 2000, MOL BIOCHEM PARASIT, V111, P309, DOI 10.1016/S0166-6851(00)00322-4; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; LEE FJS, 1989, J BACTERIOL, V171, P5795, DOI 10.1128/jb.171.11.5795-5802.1989; Midorikawa Y, 2002, JPN J CANCER RES, V93, P636, DOI 10.1111/j.1349-7006.2002.tb01301.x; Morley SJ, 2005, CELL DEATH DIFFER, V12, P571, DOI 10.1038/sj.cdd.4401591; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; PARK EC, 1992, EMBO J, V11, P2087, DOI 10.1002/j.1460-2075.1992.tb05267.x; Polevoda B, 2003, BIOCHEM BIOPH RES CO, V308, P1, DOI 10.1016/S0006-291X(03)01316-0; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; Ryningen A, 2005, LEUKEMIA RES, V29, P185, DOI 10.1016/j.leukres.2004.06.008; Sonnichsen B, 2005, NATURE, V434, P462, DOI 10.1038/nature03353; Sowter HM, 2001, CANCER RES, V61, P6669; Sugiura N, 2003, J BIOL CHEM, V278, P40113, DOI 10.1074/jbc.M301218200; WHITEWAY M, 1987, MOL CELL BIOL, V7, P3713, DOI 10.1128/MCB.7.10.3713; WHITEWAY M, 1985, CELL, V43, P483, DOI 10.1016/0092-8674(85)90178-3	27	80	85	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2006	25	31					4350	4360		10.1038/sj.onc.1209469	http://dx.doi.org/10.1038/sj.onc.1209469			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16518407				2022-12-28	WOS:000239240100010
J	Sharif, A; Prevot, V; Renault-Mihara, F; Allet, C; Studler, JM; Canton, B; Chneiweiss, H; Junier, MP				Sharif, A.; Prevot, V.; Renault-Mihara, F.; Allet, C.; Studler, J-M; Canton, B.; Chneiweiss, H.; Junier, M-P			Transforming growth factor alpha acts as a gliatrophin for mouse and human astrocytes	ONCOGENE			English	Article						erbB1; apoptosis; survival; trophic factor; oncogenesis; EGF	FEMALE SEXUAL DEVELOPMENT; FACTOR RECEPTOR; TYROSINE KINASE; ERBB RECEPTORS; TGF-ALPHA; PHOSPHATIDYLINOSITOL 3-KINASE; UP-REGULATION; MICE LACKING; RAT-BRAIN; EGF	Astrocyte death has been implicated in several neuropathological diseases, but the identification of molecules susceptible of promoting astrocyte survival has been elusive. We investigated whether transforming growth factor alpha (TGF alpha), an erbB1/EGFR ligand, which promotes glioma progression and affects astrocyte metabolism at embryonic and adult stages, regulates astrocyte survival. Primary serum-free astrocyte cultures from postnatal mouse and fetal human cortices were used. Transforming growth factor alpha protected both species of astrocytes from staurosporine-induced apoptosis. In serum-free medium, mouse astrocytes did not survive beyond 2 months while TGF alpha-treated astrocytes survived up to 12 months. Transforming growth factor alpha also promoted long-term survival of human astrocytes. We additionally extended TGFa proliferative effects to human astrocytes. After 3 days of permanent application, TGFa induced a major downregulation of both erbB1 and erbB2. This downregulation did not impair the functional activation of the receptors, as ascertained by their tyrosine phosphorylation and the continuous stimulation of both ERK/MAPK and PI3K/Akt pathways up to 7 days, the longest time examined. The full cellular effects of TGF alpha required activation of both transduction pathways. Enhanced proliferation and survival thus de. ne TGF alpha as a gliatrophin for mammalian astrocytes. These results demonstrate that in normal, non-transformed astrocytes, sustained and functional erbBs activation is achieved without bypassing ligand-induced receptors downregulation.	INSERM, U752, F-75013 Paris, France; Univ Paris 05, F-75013 Paris, France; INSERM, U114, F-75005 Paris, France; INSERM, U816, F-59000 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Junier, MP (corresponding author), INSERM, U752, F-75013 Paris, France.	marie-pierre.junier@college-de-france.fr	, Renault-Mihara/L-3320-2013; Prevot, Vincent/E-5720-2016; Sharif, Ariane/AGW-8363-2022; herve, chneiweiss/Q-6818-2019	Prevot, Vincent/0000-0001-7185-3615; herve, chneiweiss/0000-0001-7675-5061; ALLET, Cecile/0000-0003-1294-9064; Sharif, Ariane/0000-0003-0810-400X				Bakhiet M, 2001, NAT CELL BIOL, V3, P150, DOI 10.1038/35055057; Barna BP, 2001, CELL IMMUNOL, V208, P18, DOI 10.1006/cimm.2001.1768; Beck G, 2002, NEURON, V33, P673, DOI 10.1016/S0896-6273(02)00619-0; Bergmann A, 2002, DEV CELL, V2, P159, DOI 10.1016/S1534-5807(02)00116-8; Boillee S, 2001, J NEUROSCI, V21, P7079, DOI 10.1523/JNEUROSCI.21-18-07079.2001; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Chakravarti A, 2002, CANCER RES, V62, P4307; Ciardiello F, 2003, EUR J CANCER, V39, P1348, DOI 10.1016/S0959-8049(03)00235-1; Di Iorio P, 2004, GLIA, V46, P356, DOI 10.1002/glia.20002; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Erlich S, 2000, MOL CELL NEUROSCI, V16, P597, DOI 10.1006/mcne.2000.0894; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fernandez PA, 2000, NEURON, V28, P81, DOI 10.1016/S0896-6273(00)00087-8; Francis A, 1999, J NEUROSCI RES, V57, P487, DOI 10.1002/(SICI)1097-4547(19990815)57:4<487::AID-JNR8>3.0.CO;2-W; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Gerecke KM, 2001, J COMP NEUROL, V433, P86, DOI 10.1002/cne.1127; Giffard RG, 2005, GLIA, V50, P299, DOI 10.1002/glia.20167; Hanson MG, 1998, J NEUROSCI, V18, P7361; Hertz L, 2004, TRENDS NEUROSCI, V27, P735, DOI 10.1016/j.tins.2004.10.008; Hidalgo A, 2001, DEV CELL, V1, P679, DOI 10.1016/S1534-5807(01)00074-0; Junier MP, 2000, PROG NEUROBIOL, V62, P443, DOI 10.1016/S0301-0082(00)00017-4; Justicia C, 1999, J CEREBR BLOOD F MET, V19, P128, DOI 10.1097/00004647-199902000-00002; Justman QA, 2002, J BIOL CHEM, V277, P20618, DOI 10.1074/jbc.M111359200; Kari C, 2003, CANCER RES, V63, P1; Kerr DA, 2003, J NEUROSCI, V23, P5131; Klapper LN, 1999, P NATL ACAD SCI USA, V96, P4995, DOI 10.1073/pnas.96.9.4995; Kornblum HI, 1998, J NEUROSCI RES, V53, P697, DOI 10.1002/(SICI)1097-4547(19980915)53:6<697::AID-JNR8>3.3.CO;2-M; Kornblum HI, 1999, EUR J NEUROSCI, V11, P3236, DOI 10.1046/j.1460-9568.1999.00744.x; KRUEGER BK, 1995, J NEUROSCI, V15, P3366; LEE DC, 1995, PHARMACOL REV, V47, P51; Lemke G, 2001, ANNU REV NEUROSCI, V24, P87, DOI 10.1146/annurev.neuro.24.1.87; LEUTZ A, 1981, CELL TISSUE RES, V220, P393; Levison SW, 2000, GLIA, V32, P328, DOI 10.1002/1098-1136(200012)32:3<328::AID-GLIA110>3.0.CO;2-7; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; MORRISON RS, 1987, SCIENCE, V238, P72, DOI 10.1126/science.3498986; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; PinkasKramarski R, 1997, ONCOGENE, V15, P2803, DOI 10.1038/sj.onc.1201466; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Prevot V, 2005, ENDOCRINOLOGY, V146, P1465, DOI 10.1210/en.2004-1146; Prevot V, 2003, J NEUROSCI, V23, P230; Rabchevsky AG, 1998, J NEUROSCI, V18, P10541, DOI 10.1523/jneurosci.18-24-10541.1998; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rodriguez D, 2001, AM J HUM GENET, V69, P1134, DOI 10.1086/323799; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; Saas P, 2002, NEUROREPORT, V13, P1921, DOI 10.1097/00001756-200210280-00018; Schlessinger J, 2004, SCIENCE, V306, P1506, DOI 10.1126/science.1105396; Schreiner B, 2003, GENE CHROMOSOME CANC, V38, P240, DOI 10.1002/gcc.10285; Schreiner B, 2003, ONCOGENE, V22, P6802, DOI 10.1038/sj.onc.1206836; Sibilia M, 1998, EMBO J, V17, P719, DOI 10.1093/emboj/17.3.719; SORIANO E, 1993, J HISTOCHEM CYTOCHEM, V41, P819, DOI 10.1177/41.6.8315274; Sweeney C, 2004, BRIT J CANCER, V90, P289, DOI 10.1038/sj.bjc.6601500; Takuma K, 2004, PROG NEUROBIOL, V72, P111, DOI 10.1016/j.pneurobio.2004.02.001; Tang P, 1997, J NEURO-ONCOL, V35, P303, DOI 10.1023/A:1005824802617; THOMAS LB, 1995, EXP NEUROL, V133, P265, DOI 10.1006/exnr.1995.1029; Thompson KA, 2001, ANN NEUROL, V49, P745, DOI 10.1002/ana.1011; Tokita Y, 2001, J NEUROSCI, V21, P1257; Waterman H, 1998, J BIOL CHEM, V273, P13819, DOI 10.1074/jbc.273.22.13819; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; WEICKERT CS, 1995, DEV BRAIN RES, V86, P203, DOI 10.1016/0165-3806(95)00026-A; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8; Wu CJ, 2000, ONCOGENE, V19, P3999, DOI 10.1038/sj.onc.1203748; Xian CJ, 1999, MOL NEUROBIOL, V20, P157, DOI 10.1007/BF02742440; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; YOKOYAMA M, 1993, EXP NEUROL, V124, P377, DOI 10.1006/exnr.1993.1209; Zelenaia O, 2000, MOL PHARMACOL, V57, P667, DOI 10.1124/mol.57.4.667	69	24	27	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2006	25	29					4076	4085		10.1038/sj.onc.1209443	http://dx.doi.org/10.1038/sj.onc.1209443			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16532035				2022-12-28	WOS:000238802400008
J	Ma, W; Xia, X; Stafford, LJ; Yu, C; Wang, F; LeSage, G; Liu, M				Ma, W.; Xia, X.; Stafford, L. J.; Yu, C.; Wang, F.; LeSage, G.; Liu, M.			Expression of GCIP in transgenic mice decreases susceptibility to chemical hepatocarcinogenesis	ONCOGENE			English	Article						GCIP; CCNDBP1; DIP1/HHM; transgenic mouse; hepatocarcinogenesis; diethylnitrosamine; HLH-zipper proteins	LOOP-HELIX PROTEINS; DNA-BINDING PROTEINS; ID PROTEINS; CYCLIN D1; HEPATOCELLULAR-CARCINOMA; CELL-CYCLE; MYELOID DIFFERENTIATION; TRANSCRIPTION FACTORS; NEGATIVE REGULATOR; GENE-EXPRESSION	Transcription factors with helix-loop-helix (HLH) motif play critical roles in controlling the expression of genes involved in lineage commitment, cell fate determination, proliferation, and tumorigenesis. To examine whether the newly identified HLH protein GCIP/CCNDBP1 modulates cell fate determination and plays a role in hepatocyte growth, proliferation, and hepatocarcinogenesis, we generated transgenic mice with human GCIP gene driven by a liver-specific albumin promoter. We demonstrated that in GCIP transgenic mice, the overall liver growth and regeneration occurred normally after liver injury induced by carbon tetrachloride (CCl4). In the diethylnitrosamine (DEN)-induced mouse hepatocarcinogenesis, we demonstrated that overexpression of GCIP in mouse liver suppressed DEN-induced hepatocarcinogenesis at an early stage of tumor development. The number of hepatic adenomas at 24 weeks was significantly lower or not detected in GCIP transgenic male mice compared to the control mice under the same treatment. Although GCIP has little inhibition on the number of hepatic tumors at later stages (40 weeks), hepatocellular tumors in GCIP transgenic mice are smaller and well-differentiated compared to the poorly differentiated tumors in wildtype mice. Furthermore, we demonstrate that GCIP functions as a transcriptional suppressor, regulates the expression of cyclin D1, and inhibits anchorage-independent cell growth and colony formation in HepG2 cells, suggesting a significant role of GCIP in tumor initiation and development.	Texas A&M Univ, Alkek Inst Biosci & Technol, Syst Hlth Sci Ctr, Houston, TX 77030 USA; Texas A&M Univ, Ctr Canc Biol & Nutr, Syst Hlth Sci Ctr, Houston, TX 77030 USA; Texas A&M Univ, Dept Mol & Cellular Med, Syst Hlth Sci Ctr, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Grad Sch Biomed Sci, Houston, TX USA; Univ Texas, Hlth Sci Ctr, Dept Internal Med, Houston, TX 77225 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Liu, M (corresponding author), Texas A&M Univ, Alkek Inst Biosci & Technol, Syst Hlth Sci Ctr, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	mliu@ibt.tamhsc.edu		Ma, Wenbin/0000-0001-8774-7593	NCI NIH HHS [1R01CA106479] Funding Source: Medline; NHLBI NIH HHS [5R01HL064792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106479] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barndt RJ, 2000, MOL CELL BIOL, V20, P6677, DOI 10.1128/MCB.20.18.6677-6685.2000; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Conner EA, 2000, ONCOGENE, V19, P5054, DOI 10.1038/sj.onc.1203885; Cooper TA, 2005, CELL, V120, P1, DOI 10.1016/j.cell.2004.12.030; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; Deane NG, 2004, CANCER RES, V64, P1315, DOI 10.1158/0008-5472.CAN-03-1772; Deane NG, 2001, CANCER RES, V61, P5389; DIWAN BA, 1976, CANCER LETT, V1, P249; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; Hwang SY, 1997, DEV DYNAM, V209, P217, DOI 10.1002/(SICI)1097-0177(199706)209:2<217::AID-AJA7>3.0.CO;2-L; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Kee BL, 2000, IMMUNOL REV, V175, P138, DOI 10.1111/j.1600-065X.2000.imr017514.x; Kenny FS, 1999, CLIN CANCER RES, V5, P2069; Knight B, 2000, J EXP MED, V192, P1809, DOI 10.1084/jem.192.12.1809; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Ledda-Columbano GM, 2002, HEPATOLOGY, V36, P1098, DOI 10.1053/jhep.2002.36159; Lee C, 2005, BRIEF BIOINFORM, V6, P23, DOI 10.1093/bib/6.1.23; Lee GH, 1998, CANCER RES, V58, P1665; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Lemmer ER, 2004, CARCINOGENESIS, V25, P1257, DOI 10.1093/carcin/bgh129; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MOORE MR, 1981, CANCER RES, V41, P1585; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Nakatani T, 2001, JPN J CANCER RES, V92, P249, DOI 10.1111/j.1349-7006.2001.tb01089.x; Natrajan R, 2003, CANCER RES, V63, P7657; Nishida N, 1997, HISTOL HISTOPATHOL, V12, P1019; NISHIDA N, 1994, CANCER RES, V54, P3107; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; Pin CL, 2001, J CELL BIOL, V155, P519, DOI 10.1083/jcb.200105060; RECKNAGEL RO, 1989, PHARMACOL THERAPEUT, V43, P139, DOI 10.1016/0163-7258(89)90050-8; Rivera R, 2001, ONCOGENE, V20, P8308, DOI 10.1038/sj.onc.1205091; Rivera RR, 2000, IMMUNITY, V12, P17, DOI 10.1016/S1074-7613(00)80155-7; Roskams TA, 2003, SEMIN LIVER DIS, V23, P385; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; SHIRAKATA M, 1995, EMBO J, V14, P1766, DOI 10.1002/j.1460-2075.1995.tb07165.x; Sierralta J, 2004, BRAIN RES REV, V47, P105, DOI 10.1016/j.brainresrev.2004.06.002; Sikder H, 2003, CANCER CELL, V4, P291, DOI 10.1016/S1535-6108(03)00245-9; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; Stamm S, 2005, GENE, V344, P1, DOI 10.1016/j.gene.2004.10.022; SUGIHARA S, 1992, CANCER, V70, P1488, DOI 10.1002/1097-0142(19920915)70:6<1488::AID-CNCR2820700607>3.0.CO;2-J; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Sun Y, 2001, CELL, V104, P365, DOI 10.1016/S0092-8674(01)00224-0; Suzui M, 2002, CANCER RES, V62, P3997; Takami T, 2005, GASTROENTEROLOGY, V128, P1369, DOI 10.1053/j.gastro.2005.03.014; Terai S, 2000, HEPATOLOGY, V32, P357, DOI 10.1053/jhep.2000.9092; Theise ND, 2003, HISTOPATHOLOGY, V43, P263, DOI 10.1046/j.1365-2559.2003.01707.x; Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910; VESSELINOVITCH SD, 1987, TOXICOL PATHOL, V15, P221, DOI 10.1177/019262338701500216; VORONOVA AF, 1994, P NATL ACAD SCI USA, V91, P5952, DOI 10.1073/pnas.91.13.5952; WROBLEWSKI F, 1959, AM J MED, V27, P911, DOI 10.1016/0002-9343(59)90175-5; Xia CZ, 2000, J BIOL CHEM, V275, P20942, DOI 10.1074/jbc.M002598200; Yao Y, 2000, EXP CELL RES, V257, P22, DOI 10.1006/excr.2000.4884; Yokota Y, 2002, J CELL PHYSIOL, V190, P21, DOI 10.1002/jcp.10042; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092; Zhao XF, 1999, J BIOL CHEM, V274, P1388, DOI 10.1074/jbc.274.3.1388; ZHUANG Y, 1992, P NATL ACAD SCI USA, V89, P12132, DOI 10.1073/pnas.89.24.12132	68	22	22	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	30					4207	4216		10.1038/sj.onc.1209450	http://dx.doi.org/10.1038/sj.onc.1209450			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16501603				2022-12-28	WOS:000239004800008
J	Pasder, O; Shpungin, S; Salem, Y; Makovsky, A; Vilchick, S; Michaeli, S; Malovani, H; Nir, U				Pasder, O.; Shpungin, S.; Salem, Y.; Makovsky, A.; Vilchick, S.; Michaeli, S.; Malovani, H.; Nir, U.			Downregulation of Fer induces PP1 activation and cell-cycle arrest in malignant cells	ONCOGENE			English	Article						malignant cells; Fer kinase; cell; cycle; PP1; pRB	TYROSINE KINASE FER; SERINE/THREONINE PROTEIN PHOSPHATASES; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; CATALYTIC SUBUNIT; G(1)/S TRANSITION; CANCER-CELLS; HELPER-FREE; HIGH-TITER; IN-VIVO	Fer is a nuclear and cytoplasmic intracellular tyrosine kinase. Herein we show that Fer is required for cell-cycle progression in malignant cells. Decreasing the level of Fer using the RNA interference (RNAi) approach impeded the proliferation of prostate and breast carcinoma cells and led to their arrest at the G0/G1 phase. At the molecular level, knockdown of Fer resulted in the activation of the retinoblastoma protein (pRB), and this was reflected by profound hypo-phosphorylation of pRB on both cyclin-dependent kinase CDK4 and CDK2 phosphorylation sites. Dephosphorylation of pRB was not seen upon the direct targeting of either CDK4 or CDK2 expression, and was only partially achieved by the simultaneous depletion of these two kinases. Amino-acid sequence analysis revealed two protein phosphatase 1 (PP1) binding motifs in the kinase domain of Fer and the association of Fer with the pRB phosphatase PP1 alpha was verified using co-immunoprecipitation analysis. Downregulation of Fer potentiated the activation of PP1 alpha and overexpression of Fer decreased the enzymatic activity of that phosphatase. Our findings portray Fer as a regulator of cell-cycle progression in malignant cells and as a potential target for cancer intervention.	Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, IL-52900 Ramat Gan, Israel	Bar Ilan University	Nir, U (corresponding author), Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, IL-52900 Ramat Gan, Israel.	nir@mail.biu.ac.il	SILVERSTEIN, ADAR MAKOVSKI/P-1300-2019; Michaeli, Shulamit/AAC-8255-2022					ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; Allard P, 2000, MOL CELL ENDOCRINOL, V159, P63, DOI 10.1016/S0303-7207(99)00205-1; Ayllon V, 2002, EUR J IMMUNOL, V32, P1847, DOI 10.1002/1521-4141(200207)32:7<1847::AID-IMMU1847>3.0.CO;2-7; Ben-Dor I, 1999, CELL GROWTH DIFFER, V10, P113; Bennett D, 2002, NAT GENET, V31, P419, DOI 10.1038/ng938; Berndt N, 1997, CURR BIOL, V7, P375, DOI 10.1016/S0960-9822(06)00185-0; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; Ceulemans H, 2002, BIOESSAYS, V24, P371, DOI 10.1002/bies.10069; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chow JPH, 2003, MOL BIOL CELL, V14, P3989, DOI 10.1091/mbc.E03-03-0168; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Craig AWB, 2002, MOL CELL BIOL, V22, P6363, DOI 10.1128/MCB.22.18.6363-6374.2002; Craig AWB, 2001, MOL CELL BIOL, V21, P603, DOI 10.1128/MCB.21.2.603-613.2001; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; FISCHMAN K, 1990, MOL CELL BIOL, V10, P146, DOI 10.1128/MCB.10.1.146; Garcia A, 2003, BIOCHIMIE, V85, P721, DOI 10.1016/j.biochi.2003.09.004; Greer P, 2002, NAT REV MOL CELL BIO, V3, P278, DOI 10.1038/nrm783; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Honkanen RE, 2002, CURR MED CHEM, V9, P2055, DOI 10.2174/0929867023368836; Iwanishi M, 2000, J BIOL CHEM, V275, P38995, DOI 10.1074/jbc.M006665200; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Kim L, 1998, J BIOL CHEM, V273, P23542, DOI 10.1074/jbc.273.36.23542; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Kogata N, 2003, MOL BIOL CELL, V14, P3553, DOI 10.1091/mbc.E03-02-0080; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; LETWIN K, 1988, ONCOGENE, V3, P621; Liu CWY, 1999, J BIOL CHEM, V274, P29470, DOI 10.1074/jbc.274.41.29470; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; Lunter PC, 2002, BIOCHEM BIOPH RES CO, V296, P904, DOI 10.1016/S0006-291X(02)02007-7; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Miravet S, 2003, MOL CELL BIOL, V23, P7391, DOI 10.1128/MCB.23.20.7391-7402.2003; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Orlovsky K, 2000, BIOCHEMISTRY-US, V39, P11084, DOI 10.1021/bi0005153; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Pan WJ, 1998, CARCINOGENESIS, V19, P765, DOI 10.1093/carcin/19.5.765; PENHALLOW RC, 1995, J BIOL CHEM, V270, P23362, DOI 10.1074/jbc.270.40.23362; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Priel-Halachmi S, 2000, J BIOL CHEM, V275, P28902, DOI 10.1074/jbc.M003402200; Reed SI, 1997, CANCER SURV, V29, P7; Rosato R, 1998, MOL CELL BIOL, V18, P5762, DOI 10.1128/MCB.18.10.5762; Rubin E, 2001, ONCOGENE, V20, P3776, DOI 10.1038/sj.onc.1204518; Salem Y, 2005, CELL SIGNAL, V17, P341, DOI 10.1016/j.cellsig.2004.08.001; Sellin JH, 2001, CANCER RES, V61, P2899; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sugiyama K, 2002, ONCOGENE, V21, P3103, DOI 10.1038/sj.onc.1205432; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; Wang RH, 2001, ONCOGENE, V20, P6111, DOI 10.1038/sj.onc.1204829; Yamasaki Lili, 2003, Cancer Treat Res, V115, P209; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	60	37	39	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	30					4194	4206		10.1038/sj.onc.1209695	http://dx.doi.org/10.1038/sj.onc.1209695			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16732323				2022-12-28	WOS:000239004800007
J	Schmidt, MHH; Husnjak, K; Szymkiewicz, I; Haglund, K; Dikic, I				Schmidt, M. H. H.; Husnjak, K.; Szymkiewicz, I.; Haglund, K.; Dikic, I.			Cbl escapes Cdc42-mediated inhibition by downregulation of the adaptor molecule beta Pix	ONCOGENE			English	Article						Cbl; Cdc42; beta Pix; ubiquitylation; degradation	RECEPTOR TYROSINE KINASES; NUCLEOTIDE EXCHANGE FACTOR; P21-ACTIVATED KINASES; BINDING PARTNERS; C-CBL; ENDOCYTOSIS; PROTEINS; FAMILY; DEGRADATION; MECHANISMS	The Pix/Cool proteins are involved in the regulation of cell morphology by binding to small Rho GTPases and kinases of the Pak family. Recently, it has been shown that ss Pix/Cool-1 associates with the ubiquitin ligase Cbl, which appears to be a critical step in Cdc42- mediated inhibition of epidermal-growth-factor-receptor(EGFR) ubiquitylation and downregulation. Here we show that the SH3 domain of ss Pix specifically interacts with a proline arginine motif (PxxxPR) present within the ubiquitin ligase Cbl and Pak1 kinase. Owing to targeting of the same sequence, Cbl and Pak1 compete for binding to ss Pix. In this complex, Cbl mediates ubiquitylation and subsequent degradation of ss Pix. Our findings reveal a double feedback loop in which the Cdc42/ss Pix complex blocks Cbl's ability to downregulate EGFR, while Cbl in turn promotes degradation of ss Pix in order to escape this inhibition. Such a relationship provides a mechanism to tune-tune the kinetics of RTK endocytosis and degradation depending on the pool of active Cdc42 and the duration of EGFR signaling.	Univ Frankfurt, Univ Hosp, Inst Biochem 2, Frankfurt, Germany; Rudjer Boskovic Inst, Div Mol Med, Mol Oncol Lab, Zagreb, Croatia	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Rudjer Boskovic Institute	Dikic, I (corresponding author), Univ Frankfurt, Sch Med, Inst Biochem 2, D-60590 Frankfurt, Germany.	ivan.dikic@biochem2.de	Haglund, Kaisa/B-3927-2017; Schmidt, Mirko H. H./ABI-6650-2020; Husnjak, Koraljka/C-3717-2015; Dikic, Ivan/O-4650-2015; Pilecka, Iwona/AAT-9114-2021	Haglund, Kaisa/0000-0002-7946-3299; Schmidt, Mirko H. H./0000-0001-7411-8835; Husnjak, Koraljka/0000-0003-0573-6239; Dikic, Ivan/0000-0001-8156-9511; Pilecka, Iwona/0000-0002-5057-346X				Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Carpino N, 2004, IMMUNITY, V20, P37, DOI 10.1016/S1074-7613(03)00351-0; Dikic I, 2002, FEBS LETT, V529, P110, DOI 10.1016/S0014-5793(02)03188-5; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Feng QY, 2004, EMBO J, V23, P3492, DOI 10.1038/sj.emboj.7600331; Feng QY, 2002, J BIOL CHEM, V277, P5644, DOI 10.1074/jbc.M107704200; Feshchenko EA, 2004, ONCOGENE, V23, P4690, DOI 10.1038/sj.onc.1207627; Flanders JA, 2003, FEBS LETT, V550, P119, DOI 10.1016/S0014-5793(03)00853-6; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Haglund K, 2005, EMBO REP, V6, P635, DOI 10.1038/sj.embor.7400453; Hall AB, 2003, CURR BIOL, V13, P308, DOI 10.1016/S0960-9822(03)00086-1; Jozic D, 2005, NAT STRUCT MOL BIOL, V12, P972, DOI 10.1038/nsmb1000; Kowanetz K, 2004, J BIOL CHEM, V279, P32786, DOI 10.1074/jbc.M403759200; Kowanetz K, 2003, J BIOL CHEM, V278, P39735, DOI 10.1074/jbc.M304541200; Lee J, 2005, EXP CELL RES, V307, P315, DOI 10.1016/j.yexcr.2005.03.028; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Rosenberger G, 2003, HUM MOL GENET, V12, P155, DOI 10.1093/hmg/ddg019; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Schmidt MHH, 2005, NAT REV MOL CELL BIO, V6, P907, DOI 10.1038/nrm1762; Shin EY, 2002, J BIOL CHEM, V277, P44417, DOI 10.1074/jbc.M203754200; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Szymkiewicz I, 2002, J BIOL CHEM, V277, P39666, DOI 10.1074/jbc.M205535200; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Wu WJ, 2003, CELL, V114, P715, DOI 10.1016/S0092-8674(03)00688-3	26	38	39	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					3071	3078		10.1038/sj.onc.1209329	http://dx.doi.org/10.1038/sj.onc.1209329			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16407834				2022-12-28	WOS:000237950800012
J	Wang, RA; Zhang, H; Balasenthil, S; Medina, D; Kumar, R				Wang, R-A; Zhang, H.; Balasenthil, S.; Medina, D.; Kumar, R.			PAK1 hyperactivation is sufficient for mammary gland tumor formation	ONCOGENE			English	Article						PAK1; transgenic mice; mammary tumors; breast cancer	P21-ACTIVATED-KINASE-1; KINASES; EXPRESSION; PHOSPHORYLATES; ORGANIZATION; HYPERPLASIA; ONCOGENE; REGION; ALPHA; CDC42	Emerging data suggest that p21- activated kinase 1 ( Pak1), a downstream signaling molecule of the small GTPases, growth factors, and lipid signaling, is upregulated or hyperactivated in human breast cancer. Until now, however, no direct causative role had been found for Pak1 in mammary tumor formation. We therefore sought to identify the role that Pak1 plays in mammary gland tumorigenesis. Our results showed that in a transgenic mouse model, overexpression of catalytically active Pak1 leads to the development of malignant mammary tumors and to a variety of other breast lesions, including focal solid nodules, ductal hyperplasia, and mini- intraductal neoplasm and adenoma. We also found that Pak1 hyperactivation increases the stimulation of downstream proliferative signaling effectors MEK1/ 2 and p38- MAPK in mammary tumor epithelial cells. Moreover, in our study, we detected expression of estrogen receptor- alpha expression and progesterone receptor expression during early stages of the lesions, but their expression was lost during the cells' transition to malignant invasive tumors. Finally, we found that consistent with a role in breast tumor progression, Pak1 expression and its nuclear accumulation was increased progressively during the transition from ductal hyperplasia to ductal carcinoma in situ to adenocarcinoma in widely used multistep polyoma- middle T- antigen transgenic mice. Together, these findings provide the first direct evidence that Pak1 deregulation may be sufficient for the formation of mammary gland tumors.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org	Wang, Brian/HGA-9535-2022		NCI NIH HHS [CA 65746, CA 90970] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065746, R01CA090970, U01CA065746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200; BARKAN D, 2004, MOUSE MODELS HUMAN C, P103; Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699; Bocchinfuso WP, 1999, CANCER RES, V59, P1869; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Knowles HJ, 2001, ANTICANCER RES, V21, P2305; Kumar R, 2002, MICROSC RES TECHNIQ, V59, P49, DOI 10.1002/jemt.10176; Kumar R, 2002, J CELL PHYSIOL, V193, P133, DOI 10.1002/jcp.10167; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Medina D, 2003, CANCER RES, V63, P1067; Medina D, 2000, METHODS MAMMARY GLAN, P101; Salh B, 2002, INT J CANCER, V98, P148, DOI 10.1002/ijc.10147; Schraml P, 2003, AM J PATHOL, V163, P985, DOI 10.1016/S0002-9440(10)63458-X; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Singh RR, 2005, J BIOL CHEM, V280, P18130, DOI 10.1074/jbc.M412607200; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Wang RA, 2003, J CELL BIOL, V161, P583, DOI 10.1083/JCB.200212066; Wang RA, 2002, EMBO J, V21, P5437, DOI 10.1093/emboj/cdf543; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	24	98	102	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2931	2936		10.1038/sj.onc.1209309	http://dx.doi.org/10.1038/sj.onc.1209309			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16331248				2022-12-28	WOS:000237448200011
J	Ahsan, MK; Masutani, H; Yamaguchi, Y; Kim, YC; Nosaka, K; Matsuoka, M; Nishinaka, Y; Maeda, M; Yodoi, J				Ahsan, MK; Masutani, H; Yamaguchi, Y; Kim, YC; Nosaka, K; Matsuoka, M; Nishinaka, Y; Maeda, M; Yodoi, J			Loss of interleukin-2-dependency in HTLV-I-infected T cells on gene silencing of thioredoxin-binding protein-2	ONCOGENE			English	Article						HTLV-I; ATL; TBP-2/ VDUP1; DNA-methylation; histone deacetylation; interleukin-2	UP-REGULATED PROTEIN-1; VIRUS TYPE-I; LEUKEMIA; CANCER; GROWTH; LINES; D-3; IDENTIFICATION; TRANSFORMATION; METHYLATION	The transition from interleukin-2 (IL-2)-dependent to IL-2-independent growth is considered one of the key steps in the transformation of human T-cell leukemia virus type-I (HTLV-I)-infected T cells. The expression of thioredoxin-binding protein-2 (TBP-2) is lost during the transition of HTLV-I-infected T-cell lines. Here, we analysed the mechanism of loss of TBP-2 expression and the role of TBP-2 in IL-2-dependent growth in the in vitro model to investigate multistep transformation of HTLV-I. CpGs in the TBP-2 gene are methylated in IL-2-independent but not in IL-2-dependent cells. Sequential treatment with 5-aza-2'-deoxycytidine and a histone deacetylase inhibitor augmented histone acetylation and TBP-2 expression, suggesting that loss of TBP-2 expression is due to DNA methylation and histone deacetylation. In IL-2-dependent cells, a basal level of TBP-2 expression was maintained by IL-2 associated with cellular growth, whereas TBP-2 expression was upregulated on deprivation of IL-2 associated with growth suppression. Overexpression of TBP-2 in IL-2-independent cells suppressed the growth and partially restored responsiveness to IL-2. Knockdown of TBP-2 caused the IL-2-dependent cells to show partial growth without IL- 2. These results suggested that epigenetic silencing of the TBP-2 gene results in a loss of responsiveness to IL- 2, contributing to uncontrolled IL- 2- independent growth in HTLV-I-infected T-cell lines.	Kyoto Univ, Inst Virus Res, Dept Biol Responses, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Inst Virus Res, Res Ctr Acquired Immunofef Syndrome, Sakyo Ku, Kyoto, Japan	Kyoto University; Kyoto University	Masutani, H (corresponding author), Kyoto Univ, Inst Virus Res, Dept Biol Responses, Sakyo Ku, 53 Shogoin, Kyoto 6068507, Japan.	hmasutan@virus.kyoto-u.ac.jp	Masutani, Hiroshi/B-5114-2014	Masutani, Hiroshi/0000-0001-7633-2827; Matsuoka, Masao/0000-0002-0473-754X				Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CHEN KS, 1994, BBA-GENE STRUCT EXPR, V1219, P26, DOI 10.1016/0167-4781(94)90242-9; Coombes MM, 2003, ONCOGENE, V22, P8902, DOI 10.1038/sj.onc.1207050; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Goldberg SF, 2003, CANCER RES, V63, P432; Han SH, 2003, ONCOGENE, V22, P4035, DOI 10.1038/sj.onc.1206610; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; Maeda M, 1992, Hum Cell, V5, P70; MAEDA M, 1985, J EXP MED, V162, P2169, DOI 10.1084/jem.162.6.2169; MAKINO S, 1992, IMMUNOLOGY, V76, P578; Masutani H, 2002, METHOD ENZYMOL, V347, P279; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; Nishinaka Y, 2004, J BIOL CHEM, V279, P37559, DOI 10.1074/jbc.M405473200; Nishinaka Y, 2004, CANCER RES, V64, P1287, DOI 10.1158/0008-5472.CAN-03-0908; Nishiyama A, 1999, J BIOL CHEM, V274, P21645, DOI 10.1074/jbc.274.31.21645; Nosaka K, 2000, CANCER RES, V60, P1043; OKAMOTO T, 1989, JPN J CANCER RES, V80, P191; Satoh A, 2003, CANCER RES, V63, P8606; Spencer VA, 2003, METHODS, V31, P67, DOI 10.1016/S1046-2023(03)00089-6; TAGAYA Y, 1989, EMBO J, V13, P2244; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; Ushijima T, 2005, CANCER SCI, V96, P206, DOI 10.1111/j.1349-7006.2005.00035.x; Yasunaga J, 2004, CANCER RES, V64, P6002, DOI 10.1158/0008-5472.CAN-04-1422; YODOI J, 1974, NEW ENGL J MED, V290, P572; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	29	51	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2181	2191		10.1038/sj.onc.1209256	http://dx.doi.org/10.1038/sj.onc.1209256			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16314839				2022-12-28	WOS:000236581200005
J	Watanabe, J; Nishiyama, H; Matsui, Y; Ito, M; Kawanishi, H; Kamoto, T; Ogawa, O				Watanabe, J; Nishiyama, H; Matsui, Y; Ito, M; Kawanishi, H; Kamoto, T; Ogawa, O			Dicoumarol potentiates cisplatin-induced apoptosis mediated by c-Jun N-terminal kinase in p53 wild-type urogenital cancer cell lines	ONCOGENE			English	Article						urogenital cancer; cisplatin; dicoumarol; p53; JNK	SUSTAINED ACTIVATION; CARCINOMA-CELLS; BLADDER-CANCER; JNK; OXIDOREDUCTASE-1; PHOSPHORYLATION; INDUCTION; PATHWAYS; JNK/P38; ROS	3-3'-Methylene-bis [4-hydroxycoumarin] (dicoumarol), an inhibitor of NADPH: quinone oxidoreductase 1, has been reported to possess potential antineoplastic effects and the ability to abrogate p53 protein. In the present study, we investigated the cytotoxic effects of dicoumarol in combination with cisplatin ( CDDP), using four bladder (RT112, 253J, J82 and UMUC3) and two prostate (LNCap and PC3) cancer cell lines. Single treatment with 100 mu M dicoumarol suppressed cell proliferation but did not induce apoptosis at 24 h in all cell lines examined. On the other hand, pretreatment with dicoumarol enhanced cytotoxicity of CDDP in three cell lines with wild type of p53(RT112, 253J and LNCap), but not in three other cell lines with mutant p53 or in RT112 stable transfectants with a dominant-negative mutant of p53. In RT112 and LNCap, CDDP induced p53 and p21 expression, while pretreatment of dicoumarol suppressed induction of p53/p21 and resulted in sequential activation of c-Jun N-terminal kinase (JNK) in a time-dependent manner. Furthermore, inhibition of JNK, using SP600125, completely suppressed activity of caspases and poly-(ADP-ribose) polymerase cleavage, leading to suppression of enhancement of CDDP-mediated apoptosis by dicoumarol. These results suggested that dicoumarol could enhance cytotoxicity of CDDP in urogenital cancer cells with wild-type p53 through the p53/p21/JNK pathways.	Kyoto Univ, Grad Sch Med, Dept Urol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Ogawa, O (corresponding author), Kyoto Univ, Grad Sch Med, Dept Urol, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	ogawao@kuhp.kyoto-u.ac.jp						Anwar A, 2003, J BIOL CHEM, V278, P10368, DOI 10.1074/jbc.M211981200; Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; Brozovic A, 2004, INT J CANCER, V112, P974, DOI 10.1002/ijc.20522; Cote RJ, 1997, NATURE, V385, P123, DOI 10.1038/385123b0; Danson S, 2004, CANCER TREAT REV, V30, P437, DOI 10.1016/j.ctrv.2004.01.002; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; Goktas S, 1999, SEMIN ONCOL, V26, P162; Huang S, 2003, MOL CELL, V11, P1491, DOI 10.1016/S1097-2765(03)00180-1; Lewis A, 2004, CLIN CANCER RES, V10, P4550, DOI 10.1158/1078-0432.CCR-03-0667; Madari H, 2003, CANCER RES, V63, P1214; Mansouri A, 2003, J BIOL CHEM, V278, P19245, DOI 10.1074/jbc.M208134200; Martinez LA, 2002, CARCINOGENESIS, V23, P1289, DOI 10.1093/carcin/23.8.1289; Nishiyama H, 2004, EUR UROL, V45, P176, DOI 10.1016/j.eururo.2003.09.011; Siegel D, 2004, MOL PHARMACOL, V65, P1238, DOI 10.1124/mol.65.5.1238; SOUTHGATE J, 1994, LAB INVEST, V71, P583; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Vasilevskaya IA, 2004, MOL PHARMACOL, V65, P235, DOI 10.1124/mol.65.1.235; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Watanabe J, 2004, UROLOGY, V63, P989, DOI 10.1016/j.urology.2003.11.031; Weller M, 1998, CELL TISSUE RES, V292, P435, DOI 10.1007/s004410051072; Wu GS, 2004, CANCER BIOL THER, V3, P156, DOI 10.4161/cbt.3.2.614; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200; Zhang YD, 2004, CANCER RES, V64, P1902, DOI 10.1158/0008-5472.CAN-03-3361	25	40	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2500	2508		10.1038/sj.onc.1209162	http://dx.doi.org/10.1038/sj.onc.1209162			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16518417				2022-12-28	WOS:000236948000008
J	Shishodia, S; Aggarwal, BB				Shishodia, S; Aggarwal, BB			Diosgenin inhibits osteoclastogenesis, invasion, and proliferation through the downregulation of Akt, I kappa B kinase activation and NF-kappa B-regulated gene expression	ONCOGENE			English	Article						NF-kappa B; IKK; Akt; invasion; osteoclastogenesis; diosgenin	TRIGONELLA-FOENUM-GRAECUM; NECROSIS-FACTOR-ALPHA; CELL-CYCLE ARREST; FENUGREEK SEEDS; CARCINOMA-CELLS; CANCER-CELLS; HEL CELLS; APOPTOSIS; INDUCTION; CYCLOOXYGENASE-2	Diosgenin, a steroidal saponin present in fenugreek ( Trigonella foenum graecum) and other plants, has been shown to suppress inflammation, inhibit proliferation, and induce apoptosis in a variety of tumor cells, but through a mechanism that is poorly understood. In the present study, we report that diosgenin inhibits receptor-activated nuclear factor-kappaB ligand-induced osteoclastogenesis, suppresses tumor necrosis factor (TNF)-induced invasion, and blocks the proliferation of tumor cells, all activities known to be regulated by NF-kappa B. Diosgenin suppressed TNF-induced NF-kappa B activation as determined by DNA binding, activation of I kappa B alpha kinase, I kappa B alpha phosphorylation, I kappa B alpha degradation, p65 phosphorylation, and p65 nuclear translocation through inhibition of Akt activation. NF-kappa B-dependent reporter gene expression was also abrogated by diosgenin. TNF-induced expression of NF-kappa B-regulated gene products involved in cell proliferation (cyclin D1, COX-2, c-myc), antiapoptosis (IAP1, Bcl-2, Bcl-X-L, Bfl-1/A1, TRAF1 and cFLIP), and invasion (MMP-9) were also downregulated by the saponin. Diosgenin also potentiated the apoptosis induced by TNF and chemotherapeutic agents. Overall, our results suggest that diosgenin suppresses proliferation, inhibits invasion, and suppresses osteoclastogenesis through inhibition of NF-kappa B-regulated gene expression and enhances apoptosis induced by cytokines and chemotherapeutic agents.	Univ Texas, MD Anderson Canc Ctr, Cytokine Res Lab, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Cytokine Res Lab, Dept Expt Therapeut, Box 143,1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013		NATIONAL CANCER INSTITUTE [P01CA091844] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA91844] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AbuAmer Y, 1997, NAT MED, V3, P1189, DOI 10.1038/nm1197-1189; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168; Attiga FA, 2000, CANCER RES, V60, P4629; Bharti AC, 2004, J BIOL CHEM, V279, P6065, DOI 10.1074/jbc.M308062200; Bharti AC, 2003, BLOOD, V101, P1053, DOI 10.1182/blood-2002-05-1320; Bottero V, 2001, CANCER RES, V61, P7785; Corbiere C, 2004, CELL RES, V14, P188, DOI 10.1038/sj.cr.7290219; Corbiere C, 2003, INT J ONCOL, V22, P899; DASGUPTA B, 1970, EXPERIENTIA, V26, P475, DOI 10.1007/BF01898450; DJERASSI C, 1992, SCIENCE, V258, P203, DOI 10.1126/science.1411515; Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gupta A, 2001, J Assoc Physicians India, V49, P1057; HEBLE MR, 1968, SCIENCE, V161, P1145, DOI 10.1126/science.161.3846.1145; Hibasami H, 2003, INT J MOL MED, V11, P23; Higdon K, 2001, Biomed Sci Instrum, V37, P281; Leger DY, 2004, INT J ONCOL, V25, P555; Liagre B, 2004, ARTHRITIS RES THER, V6, pR373, DOI 10.1186/ar1199; Liotta L A, 1982, Cancer Metastasis Rev, V1, P277, DOI 10.1007/BF00124213; Liu MJ, 2005, CANCER CHEMOTH PHARM, V55, P79, DOI 10.1007/s00280-004-0849-3; MADAR Z, 1988, EUR J CLIN NUTR, V42, P51; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; Moalic S, 2001, FEBS LETT, V506, P225, DOI 10.1016/S0014-5793(01)02924-6; NAPPEZ C, 1995, CANCER LETT, V96, P133, DOI 10.1016/0304-3835(95)03923-K; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Ondeyka JG, 2005, MOL DIVERS, V9, P123, DOI 10.1007/s11030-005-1296-8; Ozes ON, 1999, NATURE, V401, P82; Pandian RS, 2002, J ETHNOPHARMACOL, V81, P393, DOI 10.1016/S0378-8741(02)00117-4; PURI HS, 1976, PLANTA MED, V30, P118, DOI 10.1055/s-0028-1097704; Raju J, 2004, CANCER EPIDEM BIOMAR, V13, P1392; SAUVAIRE Y, 1991, LIPIDS, V26, P191, DOI 10.1007/BF02543970; Scott A, 2001, Biomed Sci Instrum, V37, P13; SEGAL R, 1977, LLOYDIA, V40, P604; SHARMA RD, 1990, EUR J CLIN NUTR, V44, P301; Shishodia S, 2004, J BIOL CHEM, V279, P47148, DOI 10.1074/jbc.M408093200; Shishodia S, 2004, BIOCHEM PHARMACOL, V68, P1071, DOI 10.1016/j.bcp.2004.04.026; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; VALETTE G, 1984, ATHEROSCLEROSIS, V50, P105, DOI 10.1016/0021-9150(84)90012-1; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang SL, 2004, J ASIAN NAT PROD RES, V6, P115, DOI 10.1080/1028602031000147357; Yamada T, 1997, AM J PHYSIOL-GASTR L, V273, pG355, DOI 10.1152/ajpgi.1997.273.2.G355; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yin J, 2004, PLANTA MED, V70, P220, DOI 10.1055/s-2004-815538; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	48	140	149	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1463	1473		10.1038/sj.onc.1209194	http://dx.doi.org/10.1038/sj.onc.1209194			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16331273				2022-12-28	WOS:000235890400004
J	Mangoura, D; Sun, Y; Li, C; Singh, D; Gutmann, DH; Flores, A; Ahmed, M; Vallianatos, G				Mangoura, D; Sun, Y; Li, C; Singh, D; Gutmann, DH; Flores, A; Ahmed, M; Vallianatos, G			Phosphorylation of neurofibromin by PKC is a possible molecular switch in EGF receptor signaling in neural cells	ONCOGENE			English	Article						neurofibromin; tumor suppressor; EGF signaling; PKC	NF1 GENE-PRODUCT; PROTEIN-KINASE; TYPE-1 GENE; TARGETED DISRUPTION; F-ACTIN; RAS; ACTIVATION; DOMAIN; GAP; EXPRESSION	Children with neurofibromatosis (NF1) typically develop central nervous system (CNS) abnormalities, including aberrant proliferation of astrocytes and formation of benign astrocytomas. The NF1 gene encodes neurofibromin, a Ras-GAP, highly expressed in developing neural cells; the mechanism of regulation of neurofibromin as a Ras-GAP, remains however unknown. We now show that, in response to EGF, neurofibromin is in vivo phosphorylated on serine residues by PKC-alpha, in human, rat, and avian CNS cells and cell lines. EGF-induced PKC phosphorylation was prominent in the cysteine/serine-rich domain (CSRD) of neurofibromin, which lies in the N-terminus and upstream of the Ras-GAP domain (GRD), and this modification significantly increased the association of neurofibromin with actin in co-immunoprecipitations. In addition, we show that Ras activation in response to EGF was significantly lowered when C62B cells overexpressed a construct encoding both CSRD+GRD. Moreover, when PKC-alpha was downregulated, the Ras-GAP activity of CSRD+GRD was significantly diminished, whereas overexpressed GRD alone acted as a weaker GAP and in a PKC-independent manner. Most importantly, functional Ras inhibition and EGF signaling shifts were established at the single cell level in C6-derived cell lines stably overexpressing CSRD+GRD, when transient co-overexpression of Ras and PKC-depletion prior to stimulation with EGF-induced mitosis. Taken together, these data provide the first evidence of a functional, allosteric regulation of GRD by CSRD, which requires neurofibromin phosphorylation by PKC and association with the actin cytoskeleton. Our data may suggest a novel mechanism for regulating biological responses to EGF and provide a new aspect for the understanding of the aberrant proliferation seen in the CNS of children with NF1.	Inst Biomed Res, Div Neurosci, GR-11527 Athens, Greece; Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; Washington Univ, Dept Neurol, St Louis, MO USA	University of Chicago; Washington University (WUSTL)	Mangoura, D (corresponding author), Inst Biomed Res, Div Neurosci, 4 Soranou Efesiou, GR-11527 Athens, Greece.	mangoura@bioacademy.gr	Vallianatos, George/AAF-2973-2019	Gutmann, David/0000-0002-3127-5045	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD009402] Funding Source: NIH RePORTER; NICHD NIH HHS [HD09402] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; Brodie C, 1998, J BIOL CHEM, V273, P30713, DOI 10.1074/jbc.273.46.30713; Burrows RC, 1997, NEURON, V19, P251, DOI 10.1016/S0896-6273(00)80937-X; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; Chen JS, 2004, J BIOL CHEM, V279, P22076, DOI 10.1074/jbc.M311033200; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; Cheng Y, 2000, J BIOL CHEM, V275, P23326, DOI 10.1074/jbc.M001837200; Cheng Y, 2000, J CELL SCI, V113, P3161; Chidiac P, 1999, J BIOL CHEM, V274, P19639, DOI 10.1074/jbc.274.28.19639; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Chodniewicz D, 2004, J BIOL CHEM, V279, P24460, DOI 10.1074/jbc.M312764200; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; Crespo NC, 2002, CELL DEATH DIFFER, V9, P702, DOI 10.1038/sj.cdd.4401023; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Drugan JK, 2000, J BIOL CHEM, V275, P35021, DOI 10.1074/jbc.M004386200; Duchek P, 2001, SCIENCE, V291, P131, DOI 10.1126/science.291.5501.131; Edamatsu H, 1998, FEBS LETT, V440, P231, DOI 10.1016/S0014-5793(98)01457-4; Fahsold R, 2000, AM J HUM GENET, V66, P790, DOI 10.1086/302809; Faul C, 2005, J CELL BIOL, V169, P415, DOI 10.1083/jcb.200411169; Frazier JA, 1997, CURR BIOL, V7, pR414, DOI 10.1016/S0960-9822(06)00205-3; Fricker-Gates RA, 2000, EXP NEUROL, V165, P237, DOI 10.1006/exnr.2000.7482; Goya L, 1996, INT J DEV NEUROSCI, V14, P409, DOI 10.1016/S0736-5748(96)00026-3; Gutmann DH, 1995, PROG BRAIN RES, V105, P327; Hiatt KK, 2001, J BIOL CHEM, V276, P7240, DOI 10.1074/jbc.M009202200; Koehler JA, 2001, BIOCHEM BIOPH RES CO, V283, P888, DOI 10.1006/bbrc.2001.4889; Kornblum HI, 1999, EUR J NEUROSCI, V11, P3236, DOI 10.1046/j.1460-9568.1999.00744.x; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Li CJ, 2001, DEV BRAIN RES, V130, P231, DOI 10.1016/S0165-3806(01)00190-0; Mangoura D, 1998, J NEUROCHEM, V70, P130; Mangoura D, 1997, J NEUROSCI RES, V50, P391, DOI 10.1002/(SICI)1097-4547(19971101)50:3<391::AID-JNR5>3.0.CO;2-D; MANGOURA D, 1993, P NATL ACAD SCI USA, V90, P2915, DOI 10.1073/pnas.90.7.2915; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Raucher D, 1999, J CELL BIOL, V144, P497, DOI 10.1083/jcb.144.3.497; Represa A, 2001, EUR J NEUROSCI, V14, P452, DOI 10.1046/j.0953-816x.2001.01660.x; Riccardi VM, 1999, NEUROFIBROMATOSIS PH; Rose SD, 2001, J BIOL CHEM, V276, P36757, DOI 10.1074/jbc.M006518200; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; Shiraha H, 2002, MOL CELL BIOL, V22, P2716, DOI 10.1128/MCB.22.8.2716-2727.2002; Sibilia M, 1998, EMBO J, V17, P719, DOI 10.1093/emboj/17.3.719; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Tong JY, 2002, NAT NEUROSCI, V5, P95, DOI 10.1038/nn792; Vandenbroucke I, 2004, FEBS LETT, V560, P98, DOI 10.1016/S0014-5793(04)00078-X; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Xie H, 1998, J CELL SCI, V111, P615; Yamashiro S, 2003, MOL BIOL CELL, V14, P1745, DOI 10.1091/mbc.E02-07-0427; YAN N, 1995, CANCER RES, V55, P3569	52	57	61	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					735	745		10.1038/sj.onc.1209113	http://dx.doi.org/10.1038/sj.onc.1209113			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16314845				2022-12-28	WOS:000235068800009
J	Holcomb, VB; Vogel, H; Marple, T; Kornegay, RW; Hasty, P				Holcomb, V. B.; Vogel, H.; Marple, T.; Kornegay, R. W.; Hasty, P.			Ku80 and p53 suppress medulloblastoma that arise independent of Rag-1-induced DSBs	ONCOGENE			English	Article						Ku80; p53; nonhomologous end joining; Rag-1; medulloblastoma; DNA double-strand breaks	MAJOR BREAKPOINT REGION; END-JOINING PATHWAY; V(D)J RECOMBINATION; EMBRYONIC LETHALITY; DNA-REPAIR; GENOMIC STABILITY; MICE; DEFICIENT; CELLS; GENE	Ku80 maintains the genome by repairing DNA double-strand breaks (DSBs) through nonhomologous end joining (NHEJ), a pathway that repairs nonspecific DSBs and Rag-1 Rag-2 (Rag)-specific DSBs. As a result, Ku80 deletion results in phenotypes characteristic of defective repair for both nonspecific DSBs (c-radiation hypersensitivity and genomic instability) and Rag-specific DSBs (immunodeficiency). ku80(-/)-mice also exhibit neuronal apoptosis, but we do not know the type of DSBs responsible for this response. In spite of genomic instability and immunodeficiency, cancer incidence is not increased in ku80(-/-)mice. However, deletion of the tumor suppressor, p53 greatly increases pro-B-cell lymphoma in ku80(-/-)mice due to IgH/ c-Myc translocations suggesting that responses to Rag-specific DNA DSBs suppress cancer. Like suppression of pro-B-cell lymphoma, neuronal apoptosis requires p53 presenting the intriguing possibility that Rag-specific DSBs mediate neuronal development as they do lymphocyte development. Here we delete Rag-1 from ku80(-/)-p53(-/-)mice to differentiate the impact nonspecific vs Rag-specific DSBs have on ku80(-/-)mice. We find that deleting Rag-1 prevents pro-B cell lymphoma confirming Rag-induced DSBs induce this form of cancer. Both the triple mutant mice and the p53(-/-)rag-1(-/)-mice exhibit T-cell lymphoma and medulloblastoma; incidence of T-cell lymphoma is the same for both cohorts whereas incidence of medulloblastoma is higher for the triple-mutant cohort. Thus, p53-mediated neuronal apoptosis likely suppresses medulloblastoma in Ku80-deleted mice and Ku80 likely suppresses medulloblastoma by repairing nonspecific DNA DSBs instead of Rag-specific DSBs. Our observations are the first to show that Ku80 suppresses cancer caused by nonspecific DNA damage and we present a novel mouse model for medulloblastoma.	Univ Texas, Hlth Sci Ctr San Antonio, Dept Mol Med, Inst Biotechnol, 15355 Lambda Dr, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr San Antonio, Lab Anim Resources, San Antonio, TX 78245 USA; Stanford Univ, Med Ctr, Dept Pathol, Palo Alto, CA 94304 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Stanford University	Hasty, P (corresponding author), Univ Texas, Hlth Sci Ctr San Antonio, Dept Mol Med, Inst Biotechnol, 15355 Lambda Dr, San Antonio, TX 78245 USA.	hastye@uthscsa.edu		Hasty, Paul/0000-0003-3046-0131; Vogel, Otto Hannes/0000-0002-0960-3508	NATIONAL CANCER INSTITUTE [R01CA076317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG017242] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA76317-05A1] Funding Source: Medline; NIA NIH HHS [P01 AG17242] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; Daniel R, 1999, SCIENCE, V284, P644, DOI 10.1126/science.284.5414.644; Difilippantonio MJ, 2002, J EXP MED, V196, P469, DOI 10.1084/jem.20020851; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Dolle MET, 2000, P NATL ACAD SCI USA, V97, P8403, DOI 10.1073/pnas.97.15.8403; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Frank KM, 2000, MOL CELL, V5, P993, DOI 10.1016/S1097-2765(00)80264-6; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Gladdy RA, 2003, CANCER CELL, V3, P37, DOI 10.1016/S1535-6108(02)00236-2; Gu YS, 2000, P NATL ACAD SCI USA, V97, P2668, DOI 10.1073/pnas.97.6.2668; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Karanjawala ZE, 1999, CURR BIOL, V9, P1501, DOI 10.1016/S0960-9822(00)80123-2; Karanjawala ZE, 2002, DNA REPAIR, V1, P1017, DOI 10.1016/S1568-7864(02)00151-9; Lee CJ, 2005, J NEURO-ONCOL, V73, P101, DOI 10.1007/s11060-004-4598-2; Lee Y, 2002, CANCER RES, V62, P6395; Liao MJ, 1998, MOL CELL BIOL, V18, P3495, DOI 10.1128/MCB.18.6.3495; Lieber MR, 2004, DNA REPAIR, V3, P817, DOI 10.1016/j.dnarep.2004.03.015; Lim DS, 2000, MOL CELL BIOL, V20, P3772, DOI 10.1128/MCB.20.11.3772-3780.2000; Lin WS, 2004, J NEUROSCI, V24, P10074, DOI 10.1523/JNEUROSCI.2604-04.2004; Marino S, 2005, TRENDS MOL MED, V11, P17, DOI 10.1016/j.molmed.2004.11.008; Maser RS, 2003, CANCER CELL, V3, P4, DOI 10.1016/S1535-6108(02)00243-X; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Muotri AR, 2005, NATURE, V435, P903, DOI 10.1038/nature03663; Nacht M, 1998, CELL GROWTH DIFFER, V9, P131; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Raghavan SC, 2005, MOL CELL BIOL, V25, P6475, DOI 10.1128/MCB.25.15.6475-6484.2005; Raghavan SC, 2005, MOL CELL BIOL, V25, P5904, DOI 10.1128/MCB.25.14.5904-5919.2005; Raghavan SC, 2004, NATURE, V428, P88, DOI 10.1038/nature02355; Roth DB, 1998, CELL, V94, P411, DOI 10.1016/S0092-8674(00)81580-9; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Vanasse GJ, 1999, J CLIN INVEST, V103, P1669, DOI 10.1172/JCI6658; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5	46	34	36	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	54					7159	7165		10.1038/sj.onc.1209704	http://dx.doi.org/10.1038/sj.onc.1209704			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16751807				2022-12-28	WOS:000242046900005
J	Watari, A; Takaki, K; Higashiyama, S; Li, Y; Satomi, Y; Takao, T; Tanemura, A; Yamaguchi, Y; Katayama, I; Shimakage, M; Miyashiro, I; Takami, K; Kodama, K; Yutsudo, M				Watari, A.; Takaki, K.; Higashiyama, S.; Li, Y.; Satomi, Y.; Takao, T.; Tanemura, A.; Yamaguchi, Y.; Katayama, I.; Shimakage, M.; Miyashiro, I.; Takami, K.; Kodama, K.; Yutsudo, M.			Suppression of tumorigenicity, but not anchorage independence, of human cancer cells by new candidate tumor suppressor gene CapG	ONCOGENE			English	Article						CapG; tumor suppressor gene; multistep tumorigenesis; gastric cancer; lung cancer	GELSOLIN; PROTEIN; EXPRESSION	Previously, we isolated a series of cell lines from a human diploid fibroblast lineage as a model for multistep tumorigenesis in humans. After passaging a single LT-transfected fibroblast clone, differently progressed cell lines were obtained, including immortalized, anchorage-independent and tumorigenic cell lines. In the present paper, we analysed the gene expression profiles of these model cell lines, and observed that expression of the CapG protein was lost in the tumorigenic cell line. To examine the possibility that loss of CapG protein expression was required for tumorigenic progression, we transfected CapG cDNA into the tumorigenic cell line and tested for tumor-forming ability in nude mice. Results showed that ectopic expression of CapG suppressed tumorigenicity, but not growth in soft agar or liquid medium. We also found that certain cancer cell lines including stomach cancer, lung cancer and melanoma had also lost CapG expression. One such cancer cell line AZ521 also became non-tumorigenic after the introduction of CapG cDNA. Moreover, we showed that CapG expression was repressed in small-cell lung cancer tissues. Together, our findings indicated that CapG is a new tumor suppressor gene involved in the tumorigenic progression of certain cancers.	Osaka Univ, Res Inst Microbial Dis, Suita, Osaka 5650871, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Natl Hosp, Chuo, Osaka, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Higashinari, Osaka, Japan	Osaka University; Osaka University; Osaka University; Osaka National Hospital; Osaka Medical Center for Cancer & Cardiovascular Diseases	Yutsudo, M (corresponding author), Osaka Univ, Res Inst Microbial Dis, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	yutsudo@biken.osaka-u.ac.jp	Yamaguchi, Yuji/B-9312-2008; Yamaguchi, Yuji/X-6681-2019	Satomi, Yoshinori/0000-0002-8991-1040; Yamaguchi, Yuji/0000-0003-4338-2662				Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; DABIRI GA, 1992, J BIOL CHEM, V267, P16545; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Corte V, 2004, J CELL SCI, V117, P5283, DOI 10.1242/jcs.01410; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Lal A, 1999, CANCER RES, V59, P5403; Oka K, 1999, GENE CHROMOSOME CANC, V26, P47, DOI 10.1002/(SICI)1098-2264(199909)26:1<47::AID-GCC7>3.0.CO;2-8; Pellieux C, 2003, J BIOL CHEM, V278, P29136, DOI 10.1074/jbc.M300598200; PRENDERGAST GC, 1991, EMBO J, V10, P757, DOI 10.1002/j.1460-2075.1991.tb08007.x; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Rajagopalan H, 2003, NAT REV CANCER, V3, P695, DOI 10.1038/nrc1165; Sagawa N, 2003, BRIT J CANCER, V88, P606, DOI 10.1038/sj.bjc.6600739; Silacci P, 2004, CELL MOL LIFE SCI, V61, P2614, DOI 10.1007/s00018-004-4225-6; TANAKA M, 1995, CANCER RES, V55, P3228; Van Ginkel PR, 1998, BBA-MOL CELL RES, V1448, P290, DOI 10.1016/S0167-4889(98)00133-5; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912	16	31	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	56					7373	7380		10.1038/sj.onc.1209732	http://dx.doi.org/10.1038/sj.onc.1209732			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16767159				2022-12-28	WOS:000242419100006
J	Marderosian, M; Sharma, AP; Funk, AP; Vartanian, R; Masri, J; Jo, OD; Gera, JF				Marderosian, M.; Sharma, A. P.; Funk, A. P.; Vartanian, R.; Masri, J.; Jo, O. D.; Gera, J. F.			Tristetraprolin regulates Cyclin D1 and c-myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling	ONCOGENE			English	Article						akt; mTOR; rapamycin; cyclin D1; c-myc; tristetraprolin; mRNA stability	ACTIVATED PROTEIN-KINASE; AU-RICH ELEMENTS; ENHANCED SENSITIVITY; BINDING PROTEIN; DOWN-REGULATION; CELL-GROWTH; EXPRESSION; TRANSLATION; INVOLVEMENT; TURNOVER	The differential expression of the critical cell cycle control proteins cyclin D1 and c-myc has been shown to result in Akt-dependent hypersensitivity of tumor cells to mTOR inhibitors. We have previously demonstrated that the differential utilization of internal ribosome entry sites within the mRNAs of these transcripts allows maintenance of protein synthesis in the face of rapamycin ( rapa) exposure in an Akt-dependent manner. Here, we demonstrate that in addition to this mechanism, cyclin D1 and c-myc mRNA stability is also coordinately regulated following rapa treatment depending on Akt activity status. We identify A/U-rich response elements within the 3' untranslated regions ( UTRs) of these transcripts, which confer the observed differential stabilities and show that the RNA-binding protein, tristetraprolin (TTP), interacts with these elements. We also present evidence that TTP accumulates in response to rapa exposure, binds to the cis-acting elements within the cyclin D1 and c-myc 3' UTRs and is differentially serine phosphorylated in an Akt-dependent manner. Furthermore, the differential phosphorylation status of TTP results in its sequestration by 14-3-3 proteins in quiescent Akt-containing cells. Finally, siRNA-mediated knockdown of TTP expression or inhibiting a known regulator of TTP phosphorylation, p38 MAP kinase, abolishes the effects on cyclin D1 and c-myc mRNA stability. We assume that the differential control of cyclin D1 and c-myc mRNA stability and translational efficiency constitutes a coordinate response to rapa contributing to the maintenance of expression of these determinants in rapa-resistant quiescent Akt-containing cells following exposure.	Greater Los Angeles VA Healthcare Syst, Dept Res & Dev, Sepulveda, CA 91343 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Gera, JF (corresponding author), Greater Los Angeles VA Healthcare Syst, Dept Res & Dev, Bldg 1,Rm C111A, Sepulveda, CA 91343 USA.	gera@ucla.edu	Sharma, Anil/AAY-4145-2021	Gera, Joseph/0000-0002-2908-6894	NCI NIH HHS [R01-CA-109312] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA109312] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2005, CURR BIOL, V15, pR139, DOI 10.1016/j.cub.2005.02.015; Anderson P, 2002, J CELL SCI, V115, P3227; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; Brooks SA, 2004, J IMMUNOL, V172, P7263, DOI 10.4049/jimmunol.172.12.7263; Brooks SA, 2002, ARTHRITIS RHEUM, V46, P1362, DOI 10.1002/art.10235; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; Dean JLE, 2003, J BIOL CHEM, V278, P39470, DOI 10.1074/jbc.M306345200; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dougherty MK, 2004, J CELL SCI, V117, P1875, DOI 10.1242/jcs.01171; Easton JB, 2004, EXPERT OPIN THER TAR, V8, P551, DOI 10.1517/14728222.8.6.551; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; Han QW, 2002, J BIOL CHEM, V277, P48379, DOI 10.1074/jbc.M209542200; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230; Houghton PJ, 2003, CURR TOP MICROBIOL, V279, P339; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Jing Q, 2005, CELL, V120, P623, DOI 10.1016/j.cell.2004.12.038; Kahvejian A, 2001, COLD SPRING HARB SYM, V66, P293, DOI 10.1101/sqb.2001.66.293; Kedersha N, 2002, BIOCHEM SOC T, V30, P963, DOI 10.1042/BST0300963; Kim DH, 2003, CURR TOP MICROBIOL, V279, P259; Lai WS, 2005, J BIOL CHEM, V280, P34365, DOI 10.1074/jbc.M506757200; Lemm I, 2002, MOL CELL BIOL, V22, P3959, DOI 10.1128/MCB.22.12.3959-3969.2002; Liao Y, 2003, MOL CELL BIOL, V23, P6836, DOI 10.1128/MCB.23.19.6836-6848.2003; Lin SK, 2000, MOL CELL BIOL, V20, P7903, DOI 10.1128/MCB.20.21.7903-7913.2000; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; Meyer S, 2004, CRIT REV BIOCHEM MOL, V39, P197, DOI 10.1080/10409230490513991; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schmidlin M, 2004, EMBO J, V23, P4760, DOI 10.1038/sj.emboj.7600477; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; Shi YJ, 2002, CANCER RES, V62, P5027; Shim J, 2002, MOL CELLS, V14, P323; Stiles B, 2002, MOL CELL BIOL, V22, P3842, DOI 10.1128/MCB.22.11.3842-3851.2002; Stoecklin G, 2004, EMBO J, V23, P1313, DOI 10.1038/sj.emboj.7600163; Stoecklin G, 2002, EMBO J, V21, P4709, DOI 10.1093/emboj/cdf444; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2004, J BIOL CHEM, V279, P48376, DOI 10.1074/jbc.M409014200; Wilson GM, 2003, J BIOL CHEM, V278, P33029, DOI 10.1074/jbc.M305772200; Wilusz CJ, 2004, TRENDS GENET, V20, P491, DOI 10.1016/j.tig.2004.07.011	52	123	129	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2006	25	47					6277	6290		10.1038/sj.onc.1209645	http://dx.doi.org/10.1038/sj.onc.1209645			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	094CY	16702957	Bronze			2022-12-28	WOS:000241218200005
J	Dumitru, CA; Gulbins, E				Dumitru, C. A.; Gulbins, E.			TRAIL activates acid sphingomyelinase via a redox mechanism and releases ceramide to trigger apoptosis	ONCOGENE			English	Article						ceramide; acid sphingomyelinase; TRAIL; apoptosis; tumor therapy; redox	RICH MEMBRANE RAFTS; CYTOTOXIC LIGAND TRAIL; COLON-CANCER CELLS; LIPID RAFTS; SIGNALING COMPLEX; DEATH RECEPTOR; CASPASE-8 ACTIVATION; DENDRITIC CELLS; DOWN-REGULATION; IN-VIVO	We have previously shown that activation of the acid sphingomyelinase (ASM), the release of ceramide and the formation of ceramide-enriched membrane domains are central for the induction of apoptosis by CD95. Here, we demonstrate that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and CD95 activate the ASM via a redox mechanism resulting in release of ceramide and formation of ceramide-enriched membrane platforms. Ceramide-enriched membrane platforms serve to cluster DR5 upon stimulation. Antioxidants prevent TRAIL-mediated stimulation of ASM, the release of ceramide, the formation of ceramide-enriched membrane platforms and the induction of apoptosis by TRAIL. Further, ASM-deficient splenocytes fail to cluster DR5 in ceramide-enriched membrane domains upon TRAIL stimulation and resist TRAIL-induced apoptosis, events that were restored by addition of natural C-16-ceramide. A dose-response analysis indicates that ceramide-enriched membrane platforms greatly sensitized tumor cells to TRAIL-induced apoptosis. Our data indicate that ceramide-enriched membrane platforms are required for the signaling of TRAIL-DR5 complexes under physiological conditions.	Univ Duisburg Essen, Dept Mol Biol, D-45122 Essen, Germany	University of Duisburg Essen	Gulbins, E (corresponding author), Univ Duisburg Essen, Dept Mol Biol, Hufeandstr 55, D-45122 Essen, Germany.	erich.gulbins@uni-essen.de	Gulbins, Erich/L-6989-2014	Gulbins, Erich/0000-0002-3117-1342				Andrieu-Abadie N, 1999, FASEB J, V13, P1501, DOI 10.1096/fasebj.13.12.1501; Aouad SM, 2004, J IMMUNOL, V172, P2316, DOI 10.4049/jimmunol.172.4.2316; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Belka C, 2004, INT J RADIAT ONCOL, V58, P542, DOI 10.1016/j.ijrobp.2003.09.067; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Bhardwaj A, 2003, J CLIN IMMUNOL, V23, P317, DOI 10.1023/A:1025319031417; Bock J, 2003, FEBS LETT, V534, P169, DOI 10.1016/S0014-5793(02)03784-5; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; Delmas D, 2004, ONCOGENE, V23, P8979, DOI 10.1038/sj.onc.1208086; Delmas D, 2003, J BIOL CHEM, V278, P41482, DOI 10.1074/jbc.M304896200; Delpy E, 1999, CARDIOVASC RES, V43, P398, DOI 10.1016/S0008-6363(99)00142-X; El-Zawahry A, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-2; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Eramo A, 2004, EUR J IMMUNOL, V34, P1930, DOI 10.1002/eji.200324786; Esen M, 2001, APOPTOSIS, V6, P431, DOI 10.1023/A:1012445925628; Fanzo JC, 2003, CANCER BIOL THER, V2, P392, DOI 10.4161/cbt.2.4.442; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Fulda S, 2004, BBA-REV CANCER, V1705, P27, DOI 10.1016/j.bbcan.2004.09.003; Grassme H, 2003, ONCOGENE, V22, P5457, DOI 10.1038/sj.onc.1206540; Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; Grassme H, 2002, J IMMUNOL, V168, P298, DOI 10.4049/jimmunol.168.1.298; Grassme H, 2001, BIOCHEM BIOPH RES CO, V284, P1016, DOI 10.1006/bbrc.2001.5045; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; GRAZIADEI L, 1990, NATURE, V347, P396, DOI 10.1038/347396a0; Gulbins E, 1996, IMMUNOLOGY, V89, P205, DOI 10.1046/j.1365-2567.1996.d01-743.x; Gulbins E, 2000, METHOD ENZYMOL, V322, P382; Hayakawa Y, 2004, J IMMUNOL, V172, P123, DOI 10.4049/jimmunol.172.1.123; Hueber AO, 2002, EMBO REP, V3, P190, DOI 10.1093/embo-reports/kvf022; Janssen EM, 2005, NATURE, V434, P88, DOI 10.1038/nature03337; Jendrossek V, 2003, ONCOGENE, V22, P2621, DOI 10.1038/sj.onc.1206355; Jendrossek V, 2002, CANCER CHEMOTH PHARM, V50, P71, DOI 10.1007/s00280-002-0440-8; Lacour S, 2004, CANCER RES, V64, P3593, DOI 10.1158/0008-5472.CAN-03-2787; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Mariani SM, 1997, J CELL BIOL, V137, P221, DOI 10.1083/jcb.137.1.221; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Nurminen TA, 2002, J AM CHEM SOC, V124, P12129, DOI 10.1021/ja017807r; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Qiu HW, 2003, J BIOL CHEM, V278, P32744, DOI 10.1074/jbc.M303022200; Reinehr R, 2005, J BIOL CHEM, V280, P27179, DOI 10.1074/jbc.M414361200; Rohn TA, 2001, ONCOGENE, V20, P4128, DOI 10.1038/sj.onc.1204534; ROSENMAN SJ, 1993, J LEUKOCYTE BIOL, V53, P1; Scheel-Toellner D, 2004, BIOCHEM SOC T, V32, P679, DOI 10.1042/BST0320679; Scheel-Toellner D, 2004, BLOOD, V104, P2557, DOI 10.1182/blood-2004-01-0191; Scheel-Toellner D, 2002, BIOCHEM BIOPH RES CO, V297, P876, DOI 10.1016/S0006-291X(02)02311-2; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Shakor ABA, 2004, J BIOL CHEM, V279, P36778, DOI 10.1074/jbc.M402170200; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Um HD, 1996, J IMMUNOL, V156, P3469; Ursini-Siegel J, 2002, J IMMUNOL, V169, P5505, DOI 10.4049/jimmunol.169.10.5505; Vidalain PO, 2000, EMBO J, V19, P3304, DOI 10.1093/emboj/19.13.3304; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Voelkel-Johnson C, 2005, MOL CANCER THER, V4, P1320, DOI 10.1158/1535-7163.MCT-05-0086; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1999, CANCER RES, V59, P2770; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; YIN XM, 2005, HEPATOLOGY, V42, P956	68	123	129	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2006	25	41					5612	5625		10.1038/sj.onc.1209568	http://dx.doi.org/10.1038/sj.onc.1209568			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16636669				2022-12-28	WOS:000240599100003
J	Pramoonjago, P; Baras, AS; Moskaluk, CA				Pramoonjago, P.; Baras, A. S.; Moskaluk, C. A.			Knockdown of Sox4 expression by RNAi induces apoptosis in ACC3 cells	ONCOGENE			English	Article						adenoid cystic carcinoma; Sox4; RNAi; apoptosis	ADENOID CYSTIC CARCINOMA; TRANSCRIPTIONAL PROFILES; CANCER; GENE; PROTEINS; DEATH; MICE; IDENTIFICATION; ACTIVATION; PATHWAY	Microarray RNA gene expression pro. ling analysis has shown that Sox4 (Sry-related high mobility group (HMG) box 4) is one of the most upregulated genes in adenoid cystic carcinoma (ACC), relative to non-neoplastic tissue of origin. Here, we show that Sox4 protein is similarly upregulated in ACC by immunohistochemistry of 28 primary cancers and 20 normal tissues. To elucidate the functional significance of these findings, RNA interference (RNAi)-mediated RNA silencing was used to down-regulate Sox4 expression in the ACC-derived cell line, ACC3. With confirmed knockdown of Sox4 protein, cell viability was reduced by 51%, with a corresponding increase of apoptosis to 85% as compared to 12% in controls. Apoptosis was confirmed by cell morphology, DNA fragmentation and flow cytometry. Cells could be rescued from the proapoptotic effects of Sox4 RNAi by co-transfection with a construct expressing functional Sox4. Microarray gene expression pro. ling of RNAi knockdown experiments shows that downregulation of Sox4-modulated expression of critical genes involved in apoptosis and cell cycle control. Overall, our findings suggest that Sox4 contributes to the malignant phenotype of ACC cells by promoting cell survival.	Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Moskaluk, CA (corresponding author), Univ Virginia, Dept Pathol, POB 800214, Charlottesville, VA 22908 USA.	cam5p@virginia.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007267] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01-DE-14694] Funding Source: Medline; NIGMS NIH HHS [T32 GM007267] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; CHENG J, 1995, VIRCHOWS ARCH, V426, P577; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Du Y, 2005, BLOOD, V106, P2498, DOI 10.1182/blood-2004-12-4840; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FARR CJ, 1993, MAMM GENOME, V4, P577, DOI 10.1007/BF00361388; Frierson HF, 2002, AM J PATHOL, V161, P1315, DOI 10.1016/S0002-9440(10)64408-2; HE RG, 1988, W CHIN J STOMATOL, V6, P1; Hunt SMN, 1999, BIOL REPROD, V61, P476, DOI 10.1095/biolreprod61.2.476; Hur EH, 2004, BIOCHEM BIOPH RES CO, V325, P59, DOI 10.1016/j.bbrc.2004.09.215; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jiang XJ, 2003, SCIENCE, V299, P223, DOI 10.1126/science.1076807; Kan LX, 2004, DEV BIOL, V269, P580, DOI 10.1016/j.ydbio.2004.02.005; Kimura S, 1999, J BIOCHEM-TOKYO, V125, P406, DOI 10.1093/oxfordjournals.jbchem.a022301; Lu HF, 2004, FOOD CHEM TOXICOL, V42, P1543, DOI 10.1016/j.fct.2003.06.001; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; McCracken S, 1997, ONCOGENE, V15, P2929, DOI 10.1038/sj.onc.1201474; McEleny K, 2004, BJU INT, V94, P402, DOI 10.1111/j.1464-410X.2004.04936.x; Munakata R, 1996, J ORAL PATHOL MED, V25, P441, DOI 10.1111/j.1600-0714.1996.tb00294.x; Nguyen JT, 2003, P NATL ACAD SCI USA, V100, P7533, DOI 10.1073/pnas.1031631100; Panda DK, 2001, J BIOL CHEM, V276, P41229, DOI 10.1074/jbc.M104231200; Reichling T, 2005, CANCER RES, V65, P166; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; Schmahl J, 2000, DEVELOPMENT, V127, P65; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Sowter HM, 2001, CANCER RES, V61, P6669; Su AI, 2001, CANCER RES, V61, P7388; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tamm I, 1998, CANCER RES, V58, P5315; Van Huffel S, 2001, J BIOL CHEM, V276, P30216, DOI 10.1074/jbc.M100048200; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Vander Poorten VLM, 1999, CANCER, V85, P2255, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2255::AID-CNCR22>3.3.CO;2-4; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Welsh JB, 2001, CANCER RES, V61, P5974; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794	40	80	85	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2006	25	41					5626	5639		10.1038/sj.onc.1209566	http://dx.doi.org/10.1038/sj.onc.1209566			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16636670				2022-12-28	WOS:000240599100004
J	Karakas, B; Weeraratna, A; Abukhdeir, A; Blair, BG; Konishi, H; Arena, S; Becker, K; Wood, W; Argani, P; De Marzo, AM; Bachman, KE; Park, BH				Karakas, B.; Weeraratna, A.; Abukhdeir, A.; Blair, B. G.; Konishi, H.; Arena, S.; Becker, K.; Wood, W., III; Argani, P.; De Marzo, A. M.; Bachman, K. E.; Park, B. H.			Interleukin-1 alpha mediates the growth proliferative effects of transforming growth factor-beta in p21 null MCF-10A human mammary epithelial cells	ONCOGENE			English	Article						p21; TGF-beta; IL-1alpha; breast cancer	BREAST-CANCER CELLS; TGF-BETA; CYCLE ARREST; EXPRESSION; BINDING; GENE; REPRESSION; TGF-BETA-1; LINES; CDK	Transforming growth factor-beta type 1 (TGF-beta) has been implicated as both a tumor suppressor and a tumor promoter in many solid epithelial cancers. We have previously demonstrated that the cyclin dependent kinase (CDK) inhibitor p21 acts as a molecular switch in determining a growth inhibitory versus growth proliferative response to TGF-beta in the spontaneously immortalized human mammary epithelial cell line MCF-10A. We now demonstrate that this proliferative effect of TGF-beta is mediated through the proinflammatory cytokine, interleukin-1 alpha (IL-1 alpha). Using gene expression array analysis, we identified IL-1 alpha as a cytokine specifically upregulated only in cells lacking p21 and only upon TGF-beta stimulation. Cell proliferation assays verified that recombinant IL-1 alpha was capable of inducing a growth proliferative response in p21 null MCF-10A cells, while neutralizing antibodies against IL-1 alpha prevented the growth proliferative effects of TGF-beta. Mechanistically, both the CDK and proliferating cell nuclear antigen (PCNA) inhibitory functions of p21 were responsible for preventing TGF-beta induced cell proliferation, but only PCNA inhibition by p21 regulated IL-1 alpha gene expression. These studies demonstrate a novel role for IL-1 alpha in mediating a proliferative response to TGF-beta signaling, and suggest that therapies directed against IL-1 alpha could abate the growth proliferative effects of TGF-beta without compromising its tumor suppressive function.	Johns Hopkins Univ, Dept Oncol, Sch Med, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21231 USA; NIA, Baltimore, MD 21224 USA; Johns Hopkins Univ, Dept Pathol, Sch Med, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21231 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA	Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University; Johns Hopkins Medicine; University System of Maryland; University of Maryland Baltimore	Park, BH (corresponding author), Johns Hopkins Univ, Dept Oncol, Sch Med, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, 1650 Orleans St,Room 1M42, Baltimore, MD 21231 USA.	bpark2@jhmi.edu	Arena, Sabrina/H-4985-2012	Arena, Sabrina/0000-0002-1318-2494; Abukhdeir, Abde/0000-0003-1172-5819; Konishi, Hiroyuki/0000-0003-1131-4905; Becker, Kevin/0000-0002-6794-6656	NATIONAL CANCER INSTITUTE [R01CA109274, P50CA088843] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [P50 CA88843, R01CA109274-01A2] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachman KE, 2005, CURR OPIN ONCOL, V17, P49, DOI 10.1097/01.cco.0000143682.45316.ae; Bachman KE, 2004, CANCER BIOL THER, V3, P221, DOI 10.4161/cbt.3.2.666; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chou JL, 1999, BREAST CANCER RES TR, V55, P267, DOI 10.1023/A:1006217413089; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Grille SJ, 2003, CANCER RES, V63, P2172; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Iavarone A, 1997, NATURE, V387, P417; Islam S, 2000, J CELL BIOCHEM, V78, P141, DOI 10.1002/(SICI)1097-4644(20000701)78:1<141::AID-JCB13>3.0.CO;2-R; KLOEN P, 1994, EUR J CANCER, V30A, P678, DOI 10.1016/0959-8049(94)90544-4; KLOEN P, 1994, INT J CANCER, V58, P440, DOI 10.1002/ijc.2910580323; Lei XF, 2002, ONCOGENE, V21, P7514, DOI 10.1038/sj.onc.1205966; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Theocharis SE, 2004, HISTOPATHOLOGY, V45, P103, DOI 10.1111/j.1365-2559.2004.01922.x; TURNER M, 1989, J IMMUNOL, V143, P3556; WAKEFIELD LM, 1990, J CLIN INVEST, V86, P1976, DOI 10.1172/JCI114932; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523	23	18	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2006	25	40					5561	5569		10.1038/sj.onc.1209540	http://dx.doi.org/10.1038/sj.onc.1209540			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16619041				2022-12-28	WOS:000240370400009
J	Masumi, A; Fukazawa, H; Shimazu, T; Yoshida, M; Ozato, K; Komuro, K; Yamaguchi, K				Masumi, A.; Fukazawa, H.; Shimazu, T.; Yoshida, M.; Ozato, K.; Komuro, K.; Yamaguchi, K.			Nucleolin is involved in interferon regulatory factor-2-dependent transcriptional activation	ONCOGENE			English	Article						IRF-2; nucleolin; acetylation	HISTONE ACETYLASE PCAF; H4 GENE-TRANSCRIPTION; HIV-1 TAT; BINDING PROTEIN; FACTOR FAMILY; IRF FAMILY; P300; ACETYLTRANSFERASE; FACTOR-2; COMPLEX	We have previously shown that interferon regulatory factor-2 (IRF-2) is acetylated in a cell growth-dependent manner, which enables it to contribute to the transcription of cell growth-regulated promoters. To clarify the function of acetylation of IRF-2, we investigated the proteins that associate with acetylated IRF-2. In 293T cells, the transfection of p300/CBP-associated factor (PCAF) enhanced the acetylation of IRF-2. In cells transfected with both IRF-2 and PCAF, IRF-2 associated with endogenous nucleolin, while in contrast, minimal association was observed when IRF-2 was transfected with a PCAF histone acetyl transferase (HAT) deletion mutant. In a pull-down experiment using stable transfectants, acetylation-defective mutant IRF-2 (IRF-2K75R) recruited nucleolin to a much lesser extent than wild-type IRF-2, suggesting that nucleolin preferentially associates with acetylated IRF-2. Nucleolin in the presence of PCAF enhanced IRF-2-dependent H4 promoter activity in NIH3T3 cells. Nucleolin knock-down using siRNA reduced the IRF-2/PCAF-mediated promoter activity. Chromatin immunoprecipitation analysis indicated that PCAF transfection increased nucleolin binding to IRF-2 bound to the H4 promoter. We conclude that nucleolin is recruited to acetylated IRF-2, thereby contributing to gene regulation crucial for the control of cell growth.	Natl Inst Infect Dis, Dept Safety Res Blood & Biol Prod, Tokyo 2080011, Japan; Natl Inst Infect Dis, Dept Bioact Mol, Tokyo, Japan; RIKEN, Chem Genet Lab, Wako, Saitama, Japan; NICHHD, Lab Mol Growth & Regulat, NIH, Bethesda, MD 20892 USA	National Institute of Infectious Diseases (NIID); National Institute of Infectious Diseases (NIID); RIKEN; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Masumi, A (corresponding author), Natl Inst Infect Dis, Dept Safety Res Blood & Biol Prod, 4-7-1,Gakuen, Tokyo 2080011, Japan.	amasumi@nih.go.jp	Yoshida, Minoru/C-8049-2014; SHIMAZU, Tadahiro/ABC-3950-2020	Yoshida, Minoru/0000-0002-4376-5674; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001310] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001310] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bannister AJ, 2000, CELL MOL LIFE SCI, V57, P1184, DOI 10.1007/PL00000758; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; Caillaud A, 2002, J BIOL CHEM, V277, P49417, DOI 10.1074/jbc.M207484200; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Chow WA, 2000, J IMMUNOL, V164, P3512, DOI 10.4049/jimmunol.164.7.3512; Daniely Y, 2002, MOL CELL BIOL, V22, P6014, DOI 10.1128/MCB.22.16.6014-6022.2002; Deng LW, 2000, VIROLOGY, V277, P278, DOI 10.1006/viro.2000.0593; Ginisty H, 1999, J CELL SCI, V112, P761; Grinstein E, 2002, J EXP MED, V196, P1067, DOI 10.1084/jem.20011053; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Harrod R, 2000, J BIOL CHEM, V275, P11852, DOI 10.1074/jbc.275.16.11852; Hirano M, 2003, J BIOL CHEM, V278, P5109, DOI 10.1074/jbc.M207629200; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Klibanov SA, 2001, J CELL SCI, V114, P1867; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lang SE, 2003, ONCOGENE, V22, P2836, DOI 10.1038/sj.onc.1206376; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; Lau OD, 2000, J BIOL CHEM, V275, P21953, DOI 10.1074/jbc.M003219200; Lau OD, 2000, MOL CELL, V5, P589, DOI 10.1016/S1097-2765(00)80452-9; Levy L, 2004, MOL CELL BIOL, V24, P3404, DOI 10.1128/MCB.24.8.3404-3414.2004; Li JW, 2000, MOL CELL BIOL, V20, P2031, DOI 10.1128/MCB.20.6.2031-2042.2000; Luo W, 1996, J BIOL CHEM, V271, P23445, DOI 10.1074/jbc.271.38.23445; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Masumi A, 2003, J BIOL CHEM, V278, P25401, DOI 10.1074/jbc.M213037200; Masumi A, 2001, J BIOL CHEM, V276, P20973, DOI 10.1074/jbc.M101707200; Masumi A, 1999, MOL CELL BIOL, V19, P1810; Ott M, 1999, CURR BIOL, V9, P1489, DOI 10.1016/S0960-9822(00)80120-7; Patel JH, 2004, MOL CELL BIOL, V24, P10826, DOI 10.1128/MCB.24.24.10826-10834.2004; Polesskaya A, 2001, MOL CELL BIOL, V21, P5312, DOI 10.1128/MCB.21.16.5312-5320.2001; Santos-Rosa H, 2003, NUCLEIC ACIDS RES, V31, P4285, DOI 10.1093/nar/gkg655; Schaefer BC, 1997, MOL CELL BIOL, V17, P873, DOI 10.1128/MCB.17.2.873; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Spilianakis C, 2000, MOL CELL BIOL, V20, P8489, DOI 10.1128/MCB.20.22.8489-8498.2000; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Stellacci E, 2004, BIOCHEM J, V377, P367, DOI 10.1042/BJ20031166; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Suhara W, 2002, J BIOL CHEM, V277, P22304, DOI 10.1074/jbc.M200192200; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Trievel RC, 2000, ANAL BIOCHEM, V287, P319, DOI 10.1006/abio.2000.4855; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; Vaughan PS, 1998, J BIOL CHEM, V273, P194, DOI 10.1074/jbc.273.1.194; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Wang IM, 1996, MOL CELL BIOL, V16, P6313; Wolf D, 2002, J BIOL CHEM, V277, P25562, DOI 10.1074/jbc.M201196200; Xie RL, 2001, J BIOL CHEM, V276, P18624, DOI 10.1074/jbc.M010391200; YAMAMOTO H, 1994, ONCOGENE, V9, P1423; Yamauchi T, 2000, P NATL ACAD SCI USA, V97, P11303, DOI 10.1073/pnas.97.21.11303; Yanagida M, 2001, PROTEOMICS, V1, P1390, DOI 10.1002/1615-9861(200111)1:11<1390::AID-PROT1390>3.0.CO;2-Z; Ying GG, 2000, J BIOL CHEM, V275, P4152, DOI 10.1074/jbc.275.6.4152; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087	52	26	26	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2006	25	37					5113	5124		10.1038/sj.onc.1209522	http://dx.doi.org/10.1038/sj.onc.1209522			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16582966				2022-12-28	WOS:000240063700004
J	Ma, Z; Izumi, H; Kanai, M; Kabuyama, Y; Ahn, NG; Fukasawa, K				Ma, Z.; Izumi, H.; Kanai, M.; Kabuyama, Y.; Ahn, N. G.; Fukasawa, K.			Mortalin controls centrosome duplication via modulating centrosomal localization of p53	ONCOGENE			English	Article						mortalin; p53; centrosome; centrosome duplication	CHROMOSOME INSTABILITY; FAMILY; CELLS; CYCLE; PHOSPHORYLATION; AMPLIFICATION; INDUCTION; ARREST; MEMBER; BINDS	Abnormal amplification of centrosomes, commonly found in human cancer, is the major cause of mitotic defects and chromosome instability in cancer cells. Like DNA, centrosomes duplicate once in each cell cycle, hence the defect in the mechanism that ensures centrosome duplication to occur once and only once in each cell cycle results in abnormal amplification of centrosomes and mitotic defects. Centrosomes are non-membranous organelles, and undergo dynamic changes in its constituents during the centrosome duplication cycle. Through a comparative mass spectrometric analysis of unduplicated and duplicated centrosomes, we identified mortalin, a member of heat shock protein family, as a protein that associates preferentially with duplicated centrosomes. Further analysis revealed that mortalin localized to centrosomes in late G1 before centrosome duplication, remained at centrosomes during S and G2, and dissociated from centrosomes during mitosis. Overexpression of mortalin overrides the p53-dependent suppression of centrosome duplication, and mortalin-driven centrosome duplication requires physical interaction between mortalin and p53. Moreover, mortalin promotes dissociation of p53 from centrosomes through physical interaction. The p53 mutant that lacks the ability to bind to mortalin remains at centrosomes, and suppresses centrosome duplication in a transactivation function-independent manner. Thus, our present findings not only identify mortalin as an upstream molecule of p53 but also provide evidence for the involvement of centrosomally localized p53 in the regulation of centrosome duplication.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	University System of Ohio; University of Cincinnati; University of Colorado System; University of Colorado Boulder	Fukasawa, K (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, POB 670521, Cincinnati, OH 45267 USA.	kenji.fukasawa@uc.edu			NCI NIH HHS [CA90522, CA95925] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090522, R01CA095925] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Hadari YR, 1997, J BIOL CHEM, V272, P657; Hinchcliffe EH, 2002, ONCOGENE, V21, P6154, DOI 10.1038/sj.onc.1205826; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Kaul SC, 2002, EXP GERONTOL, V37, P1157, DOI 10.1016/S0531-5565(02)00135-3; Kaul SC, 2001, NEOPLASIA, V3, P110, DOI 10.1038/sj.neo.7900139; Kawamura K, 2004, CANCER RES, V64, P4800, DOI 10.1158/0008-5472.CAN-03-3908; Lange BMH, 1996, TRENDS CELL BIOL, V6, P348, DOI 10.1016/0962-8924(96)10033-7; Morris VB, 2000, EXP CELL RES, V256, P122, DOI 10.1006/excr.2000.4800; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Oakley BR, 2000, CURR TOP DEV BIOL, V49, P27; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Ran QT, 2000, BIOCHEM BIOPH RES CO, V275, P174, DOI 10.1006/bbrc.2000.3237; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; STEWART N, 1995, ONCOGENE, V10, P109; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Tarapore P, 2001, ONCOGENE, V20, P6851, DOI 10.1038/sj.onc.1204848; TIMSON J, 1975, MUTAT RES, V32, P115, DOI 10.1016/0165-1110(75)90002-0; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; WADHWA R, 1995, EXP CELL RES, V216, P101, DOI 10.1006/excr.1995.1013; WADHWA R, 1993, EXP CELL RES, V207, P442, DOI 10.1006/excr.1993.1213; Wadhwa R, 1998, J BIOL CHEM, V273, P29586, DOI 10.1074/jbc.273.45.29586; Wadhwa R, 2002, EXP CELL RES, V274, P246, DOI 10.1006/excr.2002.5468; ZAJDEL MEB, 1988, ONCOGENE, V2, P579	31	69	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	39					5377	5390		10.1038/sj.onc.1209543	http://dx.doi.org/10.1038/sj.onc.1209543			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16619038				2022-12-28	WOS:000240144900003
J	Zhang, Z; Huettner, PC; Nguyen, L; Bidder, M; Funk, MC; Li, J; Rader, JS				Zhang, Z.; Huettner, P. C.; Nguyen, L.; Bidder, M.; Funk, M. C.; Li, J.; Rader, J. S.			Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer	ONCOGENE			English	Article						POU2F3; promoter; hypermethylation; cervical cancer	HISTONE DEACETYLASE INHIBITION; HUMAN CHROMOSOME-11; DOMAIN FACTORS; EXPRESSION; TRANSCRIPTION; DIFFERENTIATION; CELLS; HETEROZYGOSITY; DEMETHYLATION; CARCINOMA	POU2F3 (OCT11, Skn-1a) is a keratinocyte-specific POU transcription factor whose expression is tied to squamous epithelial strati. cation. It is also a candidate tumor suppressor gene in cervical cancer (CC) because it lies in a critical loss of heterozygosity region on11q23.3 in that cancer, and its expression is lost in more than 50% of CC tumors and cell lines. We now report that the loss of POU2F3 expression is tied to the hypermethylation of CpG islands in the POU2F3 promoter. Bisulfite sequencing analysis revealed that methylation of specific CpG sites (-287 to -70 bp) correlated with POU2F3 expression, which could be reactivated with a demethylating agent. Combined bisulfite restriction analysis revealed aberrant methylation of the POU2F3 promoter in 18 of 46 (39%) cervical tumors but never in normal epithelium. POU2F3 expression was downregulated and inversely correlated with promoter hypermethylation in 10 out of 11 CC cell lines. Immunohistochemical analysis on a cervical tissue microarray detected POU2F3 protein in the epithelium above the basal layer. As the disease progressed, expression also decreased, especially in invasive squamous cell cancer (70% loss). Thus, aberrant DNA methylation of the CpG island in POU2F3 promoter appears to play a key role in silencing this gene expression in human CC. The results suggested that POU2F3 might be one of the CC-related tumor suppressor genes, which are disrupted by both epigenetic and genetic mechanisms.	Washington Univ, Sch Med, Dept Obstet & Gynecol, Div Gynecol Oncol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Rader, JS (corresponding author), Washington Univ, Sch Med, Dept Obstet & Gynecol, Div Gynecol Oncol, 4911 Barnes Jewish Hosp Plaza,Campus Box 8064, St Louis, MO 63110 USA.	raderj@wustl.edu	Funk, Margo/AAC-2265-2020		NATIONAL CANCER INSTITUTE [R01CA094141, P30CA091842] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA91842, CA94141-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; Andersen B, 1997, J BIOL CHEM, V272, P15905, DOI 10.1074/jbc.272.25.15905; Andersen B, 2001, ENDOCR REV, V22, P2, DOI 10.1210/er.22.1.2; Avvakumov N, 2003, ONCOGENE, V22, P3833, DOI 10.1038/sj.onc.1206562; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Davey CS, 2004, NUCLEIC ACIDS RES, V32, P4322, DOI 10.1093/nar/gkh749; Enomoto Y, 2004, ONCOGENE, V23, P5014, DOI 10.1038/sj.onc.1207653; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; Gius D, 2004, CANCER CELL, V6, P361, DOI 10.1016/j.ccr.2004.08.029; GOLDSBOROUGH AS, 1993, NUCLEIC ACIDS RES, V21, P127, DOI 10.1093/nar/21.1.127; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hietala KA, 1997, J PATHOL, V183, P305; Hildesheim J, 2001, J CELL SCI, V114, P1913; HOWLEY PM, 1991, CANCER RES, V51, pS5019; Huettner PC, 1998, HUM PATHOL, V29, P364, DOI 10.1016/S0046-8177(98)90117-4; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kukimoto I, 2001, J VIROL, V75, P9302, DOI 10.1128/JVI.75.19.9302-9311.2001; Li JD, 2005, GYNECOL ONCOL, V96, P150, DOI 10.1016/j.ygyno.2004.08.050; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; O'Sullivan MJ, 2001, HUM PATHOL, V32, P475, DOI 10.1053/hupa.2001.24317; Pennings Sari, 2005, Briefings in Functional Genomics & Proteomics, V3, P351, DOI 10.1093/bfgp/3.4.351; Rader JS, 1996, ONCOGENE, V13, P2737; RADER JS, 1990, ONCOGENE, V5, P571; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; YUKAWA K, 1993, GENE, V133, P163; Yukawa K, 1996, J VIROL, V70, P10, DOI 10.1128/JVI.70.1.10-16.1996; Zhang ZY, 2005, GENE CHROMOSOME CANC, V43, P95, DOI 10.1002/gcc.20151	30	32	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2006	25	39					5436	5445		10.1038/sj.onc.1209530	http://dx.doi.org/10.1038/sj.onc.1209530			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16607278				2022-12-28	WOS:000240144900008
J	La, P; Desmond, A; Hou, Z; Silva, AC; Schepp, RW; Hua, X				La, P.; Desmond, A.; Hou, Z.; Silva, A. C.; Schepp, R. W.; Hua, X.			Tumor suppressor menin: the essential role of nuclear localization signal domains in coordinating gene expression	ONCOGENE			English	Article						menin; MEN1; nuclear localization signals; gene transcription; tumorigenesis; tumor suppressor	ENDOCRINE NEOPLASIA TYPE-1; HISTONE METHYLTRANSFERASE COMPLEX; JUND-ACTIVATED TRANSCRIPTION; BETA-INDUCED TRANSCRIPTION; INHIBITOR-1 GENE; EPITHELIAL-CELLS; SMAD PROTEINS; DNA-DAMAGE; INSULINOMA; CHROMATIN	Menin is encoded by the tumor suppressor gene MEN1 that is mutated in patients with an inherited tumor syndrome, multiple endocrine neoplasia type 1 ( MEN1). Although menin is a nuclear protein and directly binds to DNA through its nuclear localization signals (NLSs), the precise role for each of the NLSs in nuclear translocation and gene expression remains to be elucidated. Here, we show that point mutations in three individual NLSs, NLS1, NLS2, and a novel accessory NLS, NLSa, do not block nuclear translocation, but compromise the ability of menin to repress expression of the endogenous insulin-like growth factor binding protein-2 (IGFBP-2) gene. This repression is not released by an inhibitor of histone deacetylases. Although subtle mutations in menin NLSs do not affect menin association with chromatin, they abolish menin binding to the IGFBP-2 promoter in vivo. Furthermore, each of the NLSs is also crucial for menin-mediated induction of caspase 8 expression. Together, these results suggest that menin may act as a scaffold protein in coordinating activation and repression of gene transcription and that its NLSs play a more important role in controlling gene transcription than merely targeting menin into the nucleus.	Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Abramson Canc Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Hua, X (corresponding author), Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Abramson Canc Ctr, 412 BRB2-3,421 Curied Blvd, Philadelphia, PA 19104 USA.	huax@mail.med.upenn.edu	Desmond, Angela/GZG-5470-2022	Desmond, Angela/0000-0002-8325-713X	NCI NIH HHS [R01 CA113962, R01 CA100912] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100912, R01CA113962] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Busygina V, 2004, HUM MOL GENET, V13, P2399, DOI 10.1093/hmg/ddh271; Chandrasekharappa SC, 2003, J INTERN MED, V253, P606, DOI 10.1046/j.1365-2796.2003.01165.x; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Gobl AE, 1999, BBA-GENE STRUCT EXPR, V1447, P51, DOI 10.1016/S0167-4781(99)00132-3; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4; Jin SH, 2003, CANCER RES, V63, P4204; Kaji H, 2001, P NATL ACAD SCI USA, V98, P3837, DOI 10.1073/pnas.061358098; Kim H, 2003, CANCER RES, V63, P6135; Kim YS, 1999, ONCOGENE, V18, P5936, DOI 10.1038/sj.onc.1203005; Komeili A, 2001, ANNU REV GENET, V35, P341, DOI 10.1146/annurev.genet.35.102401.090720; La P, 2004, J BIOL CHEM, V279, P49045, DOI 10.1074/jbc.M409358200; La P, 2004, ENDOCRINOLOGY, V145, P3443, DOI 10.1210/en.2004-0124; La P, 2003, ONCOGENE, V22, P198, DOI 10.1038/sj.onc.1206100; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; Moroianu J, 1999, J CELL BIOCHEM, P76; Pannett AAJ, 1999, ENDOCR-RELAT CANCER, V6, P449, DOI 10.1677/erc.0.0060449; Poisson A, 2003, CANCER LETT, V189, P1, DOI 10.1016/S0304-3835(02)00509-8; Qiao FY, 2001, J BIOL CHEM, V276, P23391, DOI 10.1074/jbc.M101855200; Ratineau C, 2004, J BIOL CHEM, V279, P24477, DOI 10.1074/jbc.M401835200; Sayo Y, 2002, ENDOCRINOLOGY, V143, P2437, DOI 10.1210/en.143.6.2437; SCAPPATICCI S, 1992, CANCER GENET CYTOGEN, V63, P17, DOI 10.1016/0165-4608(92)90057-F; Schnepp RW, 2004, CANCER RES, V64, P6791, DOI 10.1158/0008-5472.CAN-04-0724; Schnepp RW, 2004, J BIOL CHEM, V279, P10685, DOI 10.1074/jbc.M308073200; Wu JS, 2000, TRENDS BIOCHEM SCI, V25, P619, DOI 10.1016/S0968-0004(00)01718-7; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; Zaidi SK, 2001, J CELL SCI, V114, P3093	31	70	75	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3537	3546		10.1038/sj.onc.1209400	http://dx.doi.org/10.1038/sj.onc.1209400			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16449969				2022-12-28	WOS:000238448200006
J	Hooi, CSF; Blancher, C; Qiu, W; Revet, IM; Williams, LH; Ciavarella, ML; Anderson, RL; Thompson, EW; Connor, A; Phillips, WA; Campbell, IG				Hooi, C. S-F; Blancher, C.; Qiu, W.; Revet, I. M.; Williams, L. H.; Ciavarella, M. L.; Anderson, R. L.; Thompson, E. W.; Connor, A.; Phillips, W. A.; Campbell, I. G.			ST7-mediated suppression of tumorigenicity of prostate cancer cells is characterized by remodeling of the extracellular matrix	ONCOGENE			English	Article						ST7; tumor suppressor; prostate cancer; breast cancer; microarray analysis	SPARC-NULL MICE; FREQUENT LOSS; FUNCTIONAL EVIDENCE; CHROMOSOME 7Q31; ENHANCED GROWTH; POOR-PROGNOSIS; SQUAMOUS-CELL; ST7 GENE; HETEROZYGOSITY; EXPRESSION	Multiple lines of evidence have provided compelling evidence for the existence of a tumor suppressor gene (TSG) on chromosome 7q31.1. ST7 may be the target of this genetic instability but its designation as a TSG is controversial. In this study, we show that, functionally, ST7 behaves as a tumor suppressor in human cancer. ST7 suppressed growth of PC-3 prostate cancer cells inoculated subcutaneously into severe combined immunodeficient mice, and increased the latency of tumor detection from 13 days in control tumors to 23 days. Re-expression of ST7 was also associated with suppression of colony formation under anchorage-independent conditions in MDA-MB-231 breast cancer cells and ST7 mRNA expression was downregulated in 44% of primary breast cancers. Expression pro. ling of PC-3 cells revealed that ST7 predominantly induces changes in genes involved in re-modeling the extracellular matrix such as SPARC, IGFBP5 and several matrix metalloproteinases. These data indicate that ST7 may mediate tumor suppression through modi. cation of the tumor microenvironment.	Peter MacCallum Canc Ctr, Div Res, VBCRC Canc Genet Lab, Melbourne, Vic 8006, Australia; Peter MacCallum Canc Ctr, Surg Oncol Res Lab, Melbourne, Vic, Australia; Peter MacCallum Canc Ctr, Canc Biol Lab, Melbourne, Vic, Australia; St Vincents Inst Med Res, VBCRC Invas & Metastasis Grp, Fitzroy, Vic 3065, Australia; Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia; Univ Melbourne, Dept Surg, St Vincents Hosp, Melbourne, Vic, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; St. Vincent's Institute of Medical Research; University of Melbourne; St Vincent's Hospital Melbourne; University of Melbourne	Campbell, IG (corresponding author), Peter MacCallum Canc Ctr, Div Res, VBCRC Canc Genet Lab, Level 2,Locked Bag 1 A Beckett St, Melbourne, Vic 8006, Australia.	ian.campbell@petermac.org	Anderson, Robin/I-2306-2013; Thompson, Erik/GPK-2067-2022; Revet, Ingrid/C-7256-2009; Thompson, Erik W/A-1425-2009; Anderson, Robin/K-6966-2019; Phillips, Wayne A/H-8070-2013; Anderson, Robin/S-1005-2017	Thompson, Erik/0000-0002-9723-4924; Thompson, Erik W/0000-0002-9723-4924; Phillips, Wayne A/0000-0002-7961-638X; Campbell, Ian/0000-0002-7773-4155; Anderson, Robin/0000-0002-6841-7422				Achille A, 1996, CANCER RES, V56, P3808; Barker TH, 2005, J BIOL CHEM, V280, P36483, DOI 10.1074/jbc.M504663200; Barker TH, 2005, AM J PATHOL, V166, P923, DOI 10.1016/S0002-9440(10)62312-7; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; Brekken RA, 2003, J CLIN INVEST, V111, P487, DOI 10.1172/JCI200316804; Brown VL, 2002, BRIT J CANCER, V87, P208, DOI 10.1038/sj.bjc.6600418; Chin D, 2005, INT J CANCER, V113, P789, DOI 10.1002/ijc.20608; Chlenski A, 2004, CANCER RES, V64, P7420, DOI 10.1158/0008-5472.CAN-04-2141; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dong SM, 2002, CLIN CANCER RES, V8, P2939; Hughes KA, 2001, NAT GENET, V29, P380, DOI 10.1038/ng783; Jones C, 2004, CANCER RES, V64, P3037, DOI 10.1158/0008-5472.CAN-03-2028; Kato Y, 2005, INT J ONCOL, V27, P759; Katoh M, 2002, INT J ONCOL, V20, P1247; Koike M, 1997, GENE CHROMOSOME CANC, V19, P1, DOI 10.1002/(SICI)1098-2264(199705)19:1<1::AID-GCC1>3.0.CO;2-3; Koukourakis MI, 2003, CANCER RES, V63, P5376; Kruzelock RP, 2000, ONCOGENE, V19, P6277, DOI 10.1038/sj.onc.1204013; Latil A, 1995, CLIN CANCER RES, V1, P1385; Le Bail B, 1999, J PATHOL, V189, P46; Lu C, 2003, WORLD J GASTROENTERO, V9, P2662; Lussier C, 2001, J CELL BIOCHEM, V81, P463, DOI 10.1002/1097-4644(20010601)81:3<463::AID-JCB1060>3.3.CO;2-C; Moschos SJ, 2002, ONCOLOGY-BASEL, V63, P317, DOI 10.1159/000066230; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; Pal S, 2004, MOL CELL BIOL, V24, P9630, DOI 10.1128/MCB.24.21.9630-9645.2004; Palmer RE, 2001, CURR BIOL, V11, P1805, DOI 10.1016/S0960-9822(01)00560-7; Paoni NF, 2003, PHYSIOL GENOMICS, V15, P228, DOI 10.1152/physiolgenomics.00078.2003; Puolakkainen PA, 2004, MOL CANCER RES, V2, P215; Rosenblatt S, 1997, BIOCHEM J, V324, P311, DOI 10.1042/bj3240311; Sassetti C, 1998, J EXP MED, V187, P1965, DOI 10.1084/jem.187.12.1965; Shih SC, 2002, AM J PATHOL, V161, P35, DOI 10.1016/S0002-9440(10)64154-5; Shridhar V, 1997, ONCOGENE, V15, P2727, DOI 10.1038/sj.onc.1201448; Stanhope-Baker P, 2004, J BIOL CHEM, V279, P33575, DOI 10.1074/jbc.M404787200; TAKAHASHI S, 1995, CANCER RES, V55, P4114; Thomas NA, 2001, NAT GENET, V29, P379, DOI 10.1038/ng784; Thomas R, 2000, CLIN CANCER RES, V6, P1140; Vincent JB, 2002, GENOMICS, V80, P283, DOI 10.1006/geno.2002.6835; Vincent JB, 2000, AM J HUM GENET, V67, P510, DOI 10.1086/303005; Yiu GK, 2001, AM J PATHOL, V159, P609, DOI 10.1016/S0002-9440(10)61732-4; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; Zenklusen JC, 2001, NAT GENET, V27, P392, DOI 10.1038/86891; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; Zenklusen JC, 2000, ONCOGENE, V19, P1729, DOI 10.1038/sj.onc.1203488; Zhang JS, 1998, ONCOGENE, V17, P789, DOI 10.1038/sj.onc.1201996	46	17	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3924	3933		10.1038/sj.onc.1209418	http://dx.doi.org/10.1038/sj.onc.1209418			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16474848				2022-12-28	WOS:000238668800005
J	Sawai, H; Okada, Y; Funahashi, H; Matsuo, Y; Takahashi, H; Takeyama, H; Manabe, T				Sawai, H.; Okada, Y.; Funahashi, H.; Matsuo, Y.; Takahashi, H.; Takeyama, H.; Manabe, T.			Integrin-linked kinase activity is associated with interleukin-1a-induced progressive behavior of pancreatic cancer and poor patient survival	ONCOGENE			English	Article						integrins; integrin-linked kinase; interleukin; pancreatic cancer	EXPRESSION; APOPTOSIS; ILK; BETA-1-INTEGRIN; ADENOCARCINOMA; ACTIVATION; INHIBITION; GROWTH; PHOSPHORYLATION; MIGRATION	Cancer cell adhesion and invasion into extracellular matrix are regulated by integrin-linked kinase ( ILK) activity in a phosphatidylinositol 3-kinase (PI3-K)-dependent manner. In this study, we demonstrated that ILK and beta(1)-integrin play important roles in interleukin (IL)-1 alpha-induced enhancement of adhesion and invasion of pancreatic cancer cells through p38 mitogen-activated protein kinase ( MAPK) signaling pathway and activator protein-1 (AP-1) activation. Alteration of ILK kinase activity controlled IL-1 alpha-induced p38 MAPK phosphorylation and its downstream AP-1 activation with subsequent regulation of pancreatic cancer cell adhesion and invasion. Overexpressed ILK enhances the IL-1 alpha-induced p38 MAPK phosphorylation more strongly through glycogen synthase kinase 3 (GSK-3) activation, and subsequently induces AP-1 activation, which promotes aggressive capabilities of pancreatic cancer cells. In contrast, knockdown of ILK kinase activity inhibits the IL-1 alpha-induced activation of MAPK/AP-1 pathway via inhibition of GSK-3 phosphorylation. In immunohistochemical analysis, statistically significant association between strong expression of ILK and poor prognosis of pancreatic cancer patients were observed, and strong expression of ILK in cancerous tissues can be a significant prognostic indicator of pancreatic cancer patients. Our results suggest that ILK is involved with aggressive capability in pancreatic cancer and that these regulations can be helpful to understand biological processes for a better translational treatment for pancreatic cancer patients.	Nagoya City Univ, Grad Sch Med Sci, Dept Surg Gastroenterol, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya City University	Sawai, H (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Surg Gastroenterol, Mizuho Ku, Kawasumi 1, Nagoya, Aichi 4678601, Japan.	cb8h-swi@asahi-net.or.jp	Sawai, Hirozumi/AAZ-1639-2020	Sawai, Hirozumi/0000-0002-2534-5959				Ahmed N, 2005, BRIT J CANCER, V92, P1475, DOI 10.1038/sj.bjc.6602495; Ahmed N, 2004, CLIN CANCER RES, V10, P2415, DOI 10.1158/1078-0432.CCR-03-0042; Buda A, 2003, GUT, V52, P729, DOI 10.1136/gut.52.5.729; Chen P, 2004, INT J CANCER, V111, P881, DOI 10.1002/ijc.20340; Chua YJ, 2005, J CLIN ONCOL, V23, P4532, DOI 10.1200/JCO.2005.17.954; Dai DL, 2003, CLIN CANCER RES, V9, P4409; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Duxbury MS, 2005, CLIN CANCER RES, V11, P3433, DOI 10.1158/1078-0432.CCR-04-1510; Edwards LA, 2005, ONCOGENE, V24, P3596, DOI 10.1038/sj.onc.1208427; Feng H, 2004, ONCOGENE, V23, P7310, DOI 10.1038/sj.onc.1208041; Filipenko NR, 2005, ONCOGENE, V24, P5837, DOI 10.1038/sj.onc.1208737; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hwang YS, 2004, ONCOGENE, V23, P6603, DOI 10.1038/sj.onc.1207867; Jung YD, 2002, CYTOKINE, V18, P206, DOI 10.1006/cyto.2002.1034; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Leung-Hagesteijn C, 2005, MOL CELL BIOL, V25, P3648, DOI 10.1128/MCB.25.9.3648-3657.2005; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Marotta A, 2001, ONCOGENE, V20, P6250, DOI 10.1038/sj.onc.1204791; Mayoral R, 2005, CARCINOGENESIS, V26, P753, DOI 10.1093/carcin/bgi022; Menendez JA, 2005, ONCOGENE, V24, P761, DOI 10.1038/sj.onc.1208238; Nho RS, 2005, J BIOL CHEM, V280, P26630, DOI 10.1074/jbc.M411798200; Park S, 2004, J CELL BIOCHEM, V91, P973, DOI 10.1002/jcb.10768; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Qian Y, 2005, ONCOGENE, V24, P3154, DOI 10.1038/sj.onc.1208525; Sawai H, 2003, DIGEST DIS SCI, V48, P1241, DOI 10.1023/A:1024276821731; Sawai H, 2003, ONCOLOGY-BASEL, V65, P167, DOI 10.1159/000072343; Seales EC, 2005, CANCER RES, V65, P4645, DOI 10.1158/0008-5472.CAN-04-3117; Sobin L., 1997, UICC TNM CLASSIFICAT, P184; Stocken DD, 2005, BRIT J CANCER, V92, P1372, DOI 10.1038/sj.bjc.6602513; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Tong L, 2004, CELL SIGNAL, V16, P1123, DOI 10.1016/j.cellsig.2004.03.003; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; van Golen CM, 2003, ONCOGENE, V22, P2664, DOI 10.1038/sj.onc.1206362; Vellon L, 2005, ONCOGENE, V24, P3759, DOI 10.1038/sj.onc.1208452; Vogelmann R, 1999, INT J CANCER, V80, P791, DOI 10.1002/(SICI)1097-0215(19990301)80:5<791::AID-IJC25>3.0.CO;2-4; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025	40	51	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3237	3246		10.1038/sj.onc.1209356	http://dx.doi.org/10.1038/sj.onc.1209356			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16407822				2022-12-28	WOS:000237951200002
J	Wojcik, EJ; Sharifpoor, S; Miller, NA; Wright, TG; Watering, R; Tremblay, E; Swan, K; Mueller, CR; Elliott, BE				Wojcik, EJ; Sharifpoor, S; Miller, NA; Wright, TG; Watering, R; Tremblay, E; Swan, K; Mueller, CR; Elliott, BE			A novel activating function of c-Src and Stat3 on HGF transcription in mammary carcinoma cells	ONCOGENE			English	Article						HGF expression; Src; Stat3; breast carcinoma cells	HEPATOCYTE GROWTH-FACTOR; FACTOR GENE PROMOTER; FACTOR SCATTER FACTOR; FACTOR EXPRESSION; BREAST-CARCINOMA; DNA-BINDING; SIGNAL TRANSDUCERS; MET/HGF RECEPTOR; MET RECEPTOR; CANCER	In the normal breast, hepatocyte growth factor (HGF) is primarily expressed by stromal cells, and stimulates in a paracrine manner epithelial cells expressing the HGF receptor ( Met). In invasive human breast carcinomas, HGF and Met are frequently overexpressed, possibly establishing an autocrine HGF/Met loop that promotes tumour cell invasion. However, the mechanisms leading to autocrine HGF expression in carcinoma cells are not known. We previously demonstrated a cooperative effect between c-Src and Stat3 in the activation of HGF transcription in mammary carcinoma cells. The present report defines a novel Stat3 consensus site at nt - 95 in the HGF promoter that is highly conserved in human and mouse, and is required for c-Src and Stat3 to activate HGF transcription in breast epithelial cells. DNA - protein binding studies demonstrated high affinity binding of a Stat3-containing complex to the nt -95 site. Endogenous Stat3 binding to this region of the HGF promoter in carcinoma cells expressing HGF was demonstrated using a chromatin immunoprecipitation assay. In addition, coexpression of Stat3 and activated c-Src caused increased expression of endogenous HGF mRNA and protein and marked cell scattering in breast epithelial cells. Our results delineate a novel c-Src/Stat3-dependent mechanism that regulates HGF promoter activity, and is linked to transformation of mammary epithelial cells.	Queens Univ, Inst Canc Res, Dept Pathol & Lab Med, Div Canc Biol & Genet, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Elliott, BE (corresponding author), Queens Univ, Inst Canc Res, Dept Pathol & Lab Med, Div Canc Biol & Genet, 10 Stuart St, Kingston, ON K7L 3N6, Canada.	elliottb@post.queensu.ca						Andermarcher E, 1996, DEV GENET, V18, P254, DOI 10.1002/(SICI)1520-6408(1996)18:3<254::AID-DVG6>3.0.CO;2-8; Atlas E, 2000, ONCOGENE, V19, P1933, DOI 10.1038/sj.onc.1203516; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Bell AW, 1998, J BIOL CHEM, V273, P6900, DOI 10.1074/jbc.273.12.6900; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Braunstein J, 2003, J BIOL CHEM, V278, P34133, DOI 10.1074/jbc.M304531200; BUSSOLINO F, 1992, J CELL BIOL, V119, P929; BYERS S, 1994, BREAST CANCER RES TR, V31, P203, DOI 10.1007/BF00666154; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; DIRENZO MF, 1995, CANCER RES, V55, P1129; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; Dolled-Filhart M, 2003, CLIN CANCER RES, V9, P594; Elliott BE, 2002, CAN J PHYSIOL PHARM, V80, P91, DOI 10.1139/y02-010; Gallego MI, 2003, ONCOGENE, V22, P8498, DOI 10.1038/sj.onc.1207063; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Hung W, 2001, J BIOL CHEM, V276, P12395, DOI 10.1074/jbc.M010715200; Jiang JG, 2000, BIOCHEM BIOPH RES CO, V272, P882, DOI 10.1006/bbrc.2000.2848; Jiang JG, 2000, ONCOGENE, V19, P2786, DOI 10.1038/sj.onc.1203581; Jiang JG, 1997, MOL CELL BIOL, V17, P5758, DOI 10.1128/MCB.17.10.5758; Jiang JG, 2001, J BIOL CHEM, V276, P25049, DOI 10.1074/jbc.M101611200; Jin L, 1997, CANCER, V79, P749, DOI 10.1002/(SICI)1097-0142(19970215)79:4<749::AID-CNCR12>3.0.CO;2-#; Klosek SK, 2004, ONCOL REP, V12, P293; LIU YH, 1994, J BIOL CHEM, V269, P4152; LIU YH, 1994, MOL CELL BIOL, V14, P7046, DOI 10.1128/MCB.14.11.7046; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Olivero M, 1996, BRIT J CANCER, V74, P1862, DOI 10.1038/bjc.1996.646; Paz K, 2004, ONCOGENE, V23, P8455, DOI 10.1038/sj.onc.1207803; PLASCHKESCHLUTTER A, 1995, J BIOL CHEM, V270, P830, DOI 10.1074/jbc.270.2.830; Rahimi N, 1996, CELL GROWTH DIFFER, V7, P263; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Siegfried JM, 1997, CANCER RES, V57, P433; Tomida M, 2004, ONCOGENE, V23, P679, DOI 10.1038/sj.onc.1207190; Trovato M, 2004, EUR J HISTOCHEM, V48, P291; Tuck AB, 1996, AM J PATHOL, V148, P225; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Vultur A, 2004, ONCOGENE, V23, P2600, DOI 10.1038/sj.onc.1207378; WANG Y, 1994, AM J PATHOL, V144, P675; Watson CJ, 2001, J MAMMARY GLAND BIOL, V6, P115, DOI 10.1023/A:1009524817155; YAMASHITA J, 1994, CANCER RES, V54, P1630; Yang J, 2005, CANCER RES, V65, P939; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhang YW, 2002, ONCOGENE, V21, P217, DOI 10.1038/sj/onc/1205004	50	47	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2773	2784		10.1038/sj.onc.1209306	http://dx.doi.org/10.1038/sj.onc.1209306			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16407846				2022-12-28	WOS:000237272900008
J	Lu, Z; Lam, KS; Wang, N; Xu, X; Cortes, M; Andersen, B				Lu, Z.; Lam, K. S.; Wang, N.; Xu, X.; Cortes, M.; Andersen, B.			LMO4 can interact with Smad proteins and modulate transforming growth factor-beta signaling in epithelial cells	ONCOGENE			English	Article						LMO4; transforming growth factor-beta; Smads; mammary gland epithelial cells; cellular proliferation	LIM-ONLY PROTEIN; HOMEODOMAIN TRANSCRIPTION FACTORS; DOMAIN-BINDING-PROTEIN; NEURAL-TUBE CLOSURE; ACTIVITY IN-VIVO; ADULT-MOUSE; PLASMINOGEN-ACTIVATOR; MAMMARY-GLAND; KNOCKOUT MICE; BREAST-CANCER	LIM- only protein 4 ( LMO4) plays critical roles in mammalian development, and has been proposed to play roles in epithelial oncogenesis, including breast cancer. As LMO4 is highly expressed in the epithelial compartments at locations of active mesenchymal - epithelial interactions, we reasoned that LMO4 might act by modulating signaling pathways involved in mesenchymal - epithelial signaling. One such candidate signal is the transforming growth factor- beta ( TGF beta) cytokine pathway, which plays important roles both in development and cancer. We show here that the transcriptional response to TGFb in epithelial cells is sensitive to LMO4 levels; both up- and downregulation of LMO4 can enhance TGF beta signaling as assessed by a TGF beta- responsive reporter gene. Furthermore, LMO4 can interact with the MH1 and linker domains of receptor- mediated Smad proteins, and associate with the endogenous TGF beta- responsive Plasminogen Activator Inhibitor- 1 gene promoter in a TGF beta- dependent manner, suggesting that such interactions may mediate the effects of LMO4 on TGFb signaling. When introduced into mammary epithelial cells, LMO4 potentiated the growth- inhibitory effects of TGF beta in those cells. These results de. ne a new function for LMO4 as a coactivator in TGFb signaling, and provide a potential novel mechanism for LMO4- mediated regulation in development and oncogenesis.	Univ Calif Irvine, Dept Med, Div Endocrinol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92717 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Andersen, B (corresponding author), Univ Calif Irvine, Dept Med, Div Endocrinol, Sprague Hall,Room 206, Irvine, CA 92697 USA.	bogi@uci.edu	Lu, ZX/G-4586-2010		NIAMS NIH HHS [AR44882] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044882] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; Aoyama M, 2005, CANCER RES, V65, P4587, DOI 10.1158/0008-5472.CAN-04-4630; Arias AM, 2001, CELL, V105, P425, DOI 10.1016/S0092-8674(01)00365-8; Bach I, 1999, NAT GENET, V22, P394, DOI 10.1038/11970; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Bach I, 1997, GENE DEV, V11, P1370, DOI 10.1101/gad.11.11.1370; Berk M, 1997, GENE DEV, V11, P2029, DOI 10.1101/gad.11.16.2029; Chang H, 1999, DEVELOPMENT, V126, P1631; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Colland F, 2004, GENOME RES, V14, P1324, DOI 10.1101/gr.2334104; de la Calle-Mustienes E, 2003, DEV BIOL, V264, P564, DOI 10.1016/j.ydbio.2003.09.002; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dong-Le Bourhis X, 1998, BRIT J CANCER, V77, P396, DOI 10.1038/bjc.1998.63; Grutz G, 1998, ONCOGENE, V17, P2799, DOI 10.1038/sj.onc.1202502; Hahm KM, 2004, MOL CELL BIOL, V24, P2074, DOI 10.1128/MCB.24.5.2074-2082.2004; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hermanson O, 1999, CELL MOL BIOL, V45, P677; Hinks GL, 1997, J NEUROSCI, V17, P5549; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; Kenny DA, 1998, P NATL ACAD SCI USA, V95, P11257, DOI 10.1073/pnas.95.19.11257; Kudryavtseva EI, 2003, DEV DYNAM, V226, P604, DOI 10.1002/dvdy.10255; Kurisaki K, 2003, MOL CELL BIOL, V23, P4494, DOI 10.1128/MCB.23.13.4494-4510.2003; Lee K, 2004, J IMMUNOL, V172, P6539, DOI 10.4049/jimmunol.172.11.6539; Lee SK, 2003, NEURON, V38, P731, DOI 10.1016/S0896-6273(03)00296-4; Lee SK, 2005, MOL CELL NEUROSCI, V28, P205, DOI 10.1016/j.mcn.2004.04.010; Lin KK, 2004, P NATL ACAD SCI USA, V101, P15955, DOI 10.1073/pnas.0407114101; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; Manetopoulos C, 2003, BIOCHEM BIOPH RES CO, V307, P891, DOI 10.1016/S0006-291X(03)01298-1; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Matsuda K, 2002, CANCER RES, V62, P5611; Matthews JM, 2003, EMBO REP, V4, P1132, DOI 10.1038/sj.embor.7400030; McMahon JA, 1998, GENE DEV, V12, P1438, DOI 10.1101/gad.12.10.1438; Milan M, 1999, MOL CELL, V4, P267, DOI 10.1016/S1097-2765(00)80374-3; Milan M, 1998, GENE DEV, V12, P2912, DOI 10.1101/gad.12.18.2912; Milan M, 2000, DEVELOPMENT, V127, P3069; Mizunuma H, 2003, BRIT J CANCER, V88, P1543, DOI 10.1038/sj.bjc.6600952; Mousses S, 2002, CANCER RES, V62, P1256; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; Racevskis J, 1999, BBA-GENE STRUCT EXPR, V1445, P148, DOI 10.1016/S0167-4781(99)00037-8; Ramain P, 2000, MOL CELL, V6, P781, DOI 10.1016/S1097-2765(05)00079-1; Sanford LP, 1997, DEVELOPMENT, V124, P2659; Sugihara TM, 2001, J BIOL CHEM, V276, P33036, DOI 10.1074/jbc.M103000200; Sugihara TM, 1998, P NATL ACAD SCI USA, V95, P15418, DOI 10.1073/pnas.95.26.15418; Sum EYM, 2005, P NATL ACAD SCI USA, V102, P7659, DOI 10.1073/pnas.0502990102; Sum EYM, 2005, J HISTOCHEM CYTOCHEM, V53, P475, DOI 10.1369/jhc.4A6553.2005; Sum EYM, 2005, ONCOGENE, V24, P4820, DOI 10.1038/sj.onc.1208638; Sum EYM, 2002, J BIOL CHEM, V277, P7849, DOI 10.1074/jbc.M110603200; Thaler JP, 2002, CELL, V110, P237, DOI 10.1016/S0092-8674(02)00823-1; Torigoi E, 2000, P NATL ACAD SCI USA, V97, P2686, DOI 10.1073/pnas.050586397; Tse E, 2004, MOL CELL BIOL, V24, P2063, DOI 10.1128/MCB.24.5.2063-2073.2004; van Meyel DJ, 1999, MOL CELL, V4, P259, DOI 10.1016/S1097-2765(00)80373-1; Visvader JE, 1997, P NATL ACAD SCI USA, V94, P13707, DOI 10.1073/pnas.94.25.13707; Visvader JE, 2001, P NATL ACAD SCI USA, V98, P14452, DOI 10.1073/pnas.251547698; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Waite KA, 2003, NAT REV GENET, V4, P763, DOI 10.1038/nrg1178; Wang N, 2004, ONCOGENE, V23, P1507, DOI 10.1038/sj.onc.1207288; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; Zeng CY, 1998, P NATL ACAD SCI USA, V95, P10637, DOI 10.1073/pnas.95.18.10637	63	35	37	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2920	2930		10.1038/sj.onc.1209318	http://dx.doi.org/10.1038/sj.onc.1209318			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16331278				2022-12-28	WOS:000237448200010
J	Su, ZZ; Lebedeva, IV; Sarkar, D; Emdad, L; Gupta, P; Kitada, S; Dent, P; Reed, JC; Fisher, PB				Su, ZZ; Lebedeva, IV; Sarkar, D; Emdad, L; Gupta, P; Kitada, S; Dent, P; Reed, JC; Fisher, PB			Ionizing radiation enhances therapeutic activity of mda-7/IL-24: overcoming radiation- and mda-7/IL-24-resistance in prostate cancer cells overexpressing the antiapoptotic proteins bcl-x(L) or bcl-2	ONCOGENE			English	Article						mda-7/1L-24; prostate cancer; ionizing radiation; apoptosis; bcl-family	DIFFERENTIATION-ASSOCIATED GENE-7; IN-VITRO; IMMUNOHISTOCHEMICAL ANALYSIS; INHIBITS GROWTH; GAMMA-RADIATION; APOPTOSIS; DEATH; RADIOSENSITIVITY; ACTIVATION; EXPRESSION	Subtraction hybridization applied to terminally differentiating human melanoma cells identified mda-7/IL-24, a cytokine belonging to the IL-10 gene superfamily. Adenoviral-mediated delivery of mda-7/IL-24 (Ad. mda7) provokes apoptosis selectively in a wide spectrum of cancers in vitro in cell culture, in vivo in human tumor xenograft animal models and in patients with advanced carcinomas and melanomas. In human prostate cancer cells, a role for mitochondrial dysfunction and induction of reactive oxygen species in the apoptotic process has been established. Ectopic overexpression of bcl-x(L) and bcl-2 prevents these changes including apoptosis induction in prostate tumor cells by Ad.mda-7. We now document that this resistance to apoptosis can be reversed by treating bcl-2 family overexpressing prostate tumor cells with ionizing radiation in combination with Ad.mda-7 or purified GSTMDA-7 protein. Additionally, radiation augments apoptosis induction by mda-7/IL-24 in parental and neomycin-resistant prostate tumor cells. Radiosensitization to mda7/IL-24 is dependent on JNK signaling, as treatment with the JNK 1/2/3 inhibitor SP600125 abolishes this effect. Considering that elevated expression of bcl-x(L) and bcl-2 are frequent events in prostate cancer development and progression, the present studies support the use of ionizing radiation in combination with mda-7/IL-24 as a means of augmenting the therapeutic benefit of this gene in prostate cancer, particularly in the context of tumors displaying resistance to radiation therapy owing to bcl-2family member overexpression.	Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, Med Ctr, New York, NY 10032 USA; Burnham Inst, La Jolla, CA 92037 USA; Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA USA; Columbia Univ Coll Phys & Surg, Dept Urol, Herbert Irving Comprehens Canc Ctr, Med Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg, Herbert Irving Comprehens Canc Ctr, Med Ctr, New York, NY 10032 USA	Columbia University; Sanford Burnham Prebys Medical Discovery Institute; Virginia Commonwealth University; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, Med Ctr, 630 W 168th St, New York, NY 10032 USA.	pbf1@columbia.edu	Lebedeva, Irina V/A-3156-2008	Lebedeva, Irina V/0000-0002-1693-9392	NATIONAL CANCER INSTITUTE [R01CA098712, R01CA097318, R01CA088906, P01CA104177] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060554] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA88906, R01 CA72955, P01 CA104177, R01 CA097318, R01 CA098712] Funding Source: Medline; NIDDK NIH HHS [DK52585] Funding Source: Medline; NIGMS NIH HHS [GM60554] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAE VL, 1994, INT J CANCER, V58, P721, DOI 10.1002/ijc.2910580517; Bai XZ, 1999, INT J ONCOL, V14, P785; Bauer JJ, 1996, J UROLOGY, V156, P1511, DOI 10.1016/S0022-5347(01)65641-6; Catz SD, 2003, APOPTOSIS, V8, P29, DOI 10.1023/A:1021692801278; Chada S, 2004, MOL THER, V10, P1085, DOI 10.1016/j.ymthe.2004.08.020; Chaudhary KS, 1999, ENVIRON HEALTH PERSP, V107, P49, DOI 10.2307/3434471; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; COLOMBEL M, 1993, AM J PATHOL, V143, P390; Cooperberg MR, 2004, ONCOLOGY-NY, V18, P1239; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; Fisher PB, 2003, CANCER BIOL THER, V2, pS23; FISHER PB, 2005, IN PRESS CANC RES; Gopalkrishnan RV, 2001, J CELL PHYSIOL, V189, P245, DOI 10.1002/jcp.10023; GUPTA P, 2005, IN PRESS PHARM THER; Kajiwara T, 1999, INT J UROL, V6, P520, DOI 10.1046/j.1442-2042.1999.00102.x; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Kawabe S, 2002, MOL THER, V6, P637, DOI 10.1006/mthe.2002.0714; Keshgegian AA, 1998, AM J CLIN PATHOL, V110, P443; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Krajewska M, 1996, AM J PATHOL, V148, P1567; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; Lebedeva I, 2000, CANCER RES, V60, P6052; Lebedeva IV, 2003, ONCOGENE, V22, P8758, DOI 10.1038/sj.onc.1206891; Lebedeva IV, 2005, MOL THER, V11, P4, DOI 10.1016/j.ymthe.2004.08.012; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; Li XY, 2001, CANCER RES, V61, P1699; Liu QY, 1997, CLIN CANCER RES, V3, P2039; Mabjeesh NJ, 2002, ENDOCR-RELAT CANCER, V9, DOI 10.1677/erc.0.0090115; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; Saito Y, 2005, CANCER GENE THER, V12, P238, DOI 10.1038/sj.cgt.7700780; Sarkar D, 2005, P NATL ACAD SCI USA, V102, P14034, DOI 10.1073/pnas.0506837102; Sauane M, 2004, ONCOGENE, V23, P7679, DOI 10.1038/sj.onc.1207958; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; Su ZZ, 2001, P NATL ACAD SCI USA, V98, P10332, DOI 10.1073/pnas.171315198; Su ZZ, 2003, ONCOGENE, V22, P1164, DOI 10.1038/sj.onc.1206062; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; SU ZZ, 2005, ONCOGENE, V24; Yacoub A, 2004, CANCER BIOL THER, V3, P739, DOI 10.4161/cbt.3.8.968; Yacoub A, 2003, CANCER BIOL THER, V2, P347, DOI 10.4161/cbt.2.4.422; Yacoub A, 2003, CLIN CANCER RES, V9, P3272; Yacoub A, 2003, MOL CANCER THER, V2, P623	44	70	80	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2339	2348		10.1038/sj.onc.1209271	http://dx.doi.org/10.1038/sj.onc.1209271			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16331261				2022-12-28	WOS:000236764300006
J	Saxena, A; Rorie, CJ; Dimitrov, D; Daniely, Y; Borowiec, JA				Saxena, A.; Rorie, C. J.; Dimitrov, D.; Daniely, Y.; Borowiec, J. A.			Nucleolin inhibits Hdm2 by multiple pathways leading to p53 stabilization	ONCOGENE			English	Article						ARF; Mdm2; nucleolin; p53; ubiquitination	ARF TUMOR-SUPPRESSOR; PRE-RIBOSOMAL-RNA; REPLICATION PROTEIN-A; UBIQUITIN LIGASE ACTIVITY; DNA-DAMAGE; ONCOPROTEIN MDM2; GENOTOXIC STRESS; IN-VITRO; P53-DEPENDENT APOPTOSIS; EMBRYONIC LETHALITY	Nucleolin is a c-Myc-induced gene product with defined roles in ribosomal RNA processing and the inhibition of chromosomal DNA replication following stress. Here we find that changes in nucleolin protein levels in unstressed cells cause parallel changes in the amount of p53 protein. Alterations in p53 levels arise from nucleolin binding to the p53 antagonist Hdm2, resulting in the inhibition of both p53 ubiquitination and Hdm2 auto-ubiquitination. Nucleolin does not alter p53 ubiquitination by human papillomavirus E6, indicating that the effect is specific for Hdm2. Although the inhibition of ligase activity would be expected to stabilize Hdm2, we instead find that nucleolin also reduces Hdm2 protein levels, demonstrating that nucleolin inhibits Hdm2 using multiple mechanisms. Increases in nucleolin levels in unstressed cells led to higher expression of p21(cip1/waf1), a reduced rate of cellular proliferation, and an increase in apoptosis. Thus, nucleolin has a number of properties in common with the tumor suppressor ARF (alternate reading frame). We propose that nucleolin, like ARF, responds to hyperproliferative signals by upregulation of p53 through Hdm2 inhibition.	NYU, Sch Med, Dept Biochem, New York, NY 10016 USA; NYU, Sch Med, Inst Canc, New York, NY 10016 USA	New York University; New York University	Borowiec, JA (corresponding author), NYU, Sch Med, Dept Biochem, 550 1St Ave, New York, NY 10016 USA.	james.borowiec@med.nyu.edu	Saxena, Anjana/AAZ-5244-2020	Saxena, Anjana/0000-0001-8884-5179; Borowiec, James/0000-0003-4117-0826	NIAID NIH HHS [AI29963] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029963] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allemand I, 1999, ONCOGENE, V18, P6521, DOI 10.1038/sj.onc.1203052; Anderson-Cook CM, 2004, PHARM STAT, V3, P247, DOI 10.1002/pst.138; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Borovjagin AV, 2004, RNA, V10, P942, DOI 10.1261/rna.5256704; BOUCHE G, 1984, NUCLEIC ACIDS RES, V12, P3025, DOI 10.1093/nar/12.7.3025; Brooks CL, 2004, CELL CYCLE, V3, P895; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Daniely Y, 2000, J CELL BIOL, V149, P799, DOI 10.1083/jcb.149.4.799; Daniely Y, 2002, MOL CELL BIOL, V22, P6014, DOI 10.1128/MCB.22.16.6014-6022.2002; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; EGYHAZI E, 1988, EXP CELL RES, V178, P264, DOI 10.1016/0014-4827(88)90397-7; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Ginisty H, 1999, J CELL SCI, V112, P761; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; Godley LA, 1996, GENE DEV, V10, P836, DOI 10.1101/gad.10.7.836; Greasley PJ, 2000, NUCLEIC ACIDS RES, V28, P446, DOI 10.1093/nar/28.2.446; Gronroos E, 2004, P NATL ACAD SCI USA, V101, P12165, DOI 10.1073/pnas.0402283101; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; GULLI MP, 1995, NUCLEIC ACIDS RES, V23, P1912, DOI 10.1093/nar/23.11.1912; Hannan KM, 1998, FRONT BIOSCI, V3, P376, DOI [10.2741/A282, DOI 10.2741/A282]; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kim K, 2005, MOL CELL BIOL, V25, P2463, DOI 10.1128/MCB.25.6.2463-2474.2005; KONDO K, 1992, J BIOL CHEM, V267, P16252; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; LEE WC, 1992, MOL CELL BIOL, V12, P3865, DOI 10.1128/MCB.12.9.3865; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Li LM, 2001, P NATL ACAD SCI USA, V98, P1619, DOI 10.1073/pnas.98.4.1619; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; LUNA RMD, 1995, NATURE, V378, P203; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Moss T, 2004, CURR OPIN GENET DEV, V14, P210, DOI 10.1016/j.gde.2004.02.005; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Olson Mark O J, 2004, Sci STKE, V2004, ppe10; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Park YB, 2002, CANCER GENET CYTOGEN, V133, P105, DOI 10.1016/S0165-4608(01)00575-1; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Saez-Vasquez J, 2004, MOL CELL BIOL, V24, P7284, DOI 10.1128/MCB.24.16.7284-7297.2004; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; Sengupta TK, 2004, J BIOL CHEM, V279, P10855, DOI 10.1074/jbc.M309111200; Sirri V, 1997, CYTOMETRY, V28, P147, DOI 10.1002/(SICI)1097-0320(19970601)28:2<147::AID-CYTO8>3.3.CO;2-G; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vassin VM, 2004, MOL CELL BIOL, V24, P1930, DOI 10.1128/MCB.24.5.1930-1943.2004; Verschuren EW, 2002, CANCER CELL, V2, P229, DOI 10.1016/S1535-6108(02)00123-X; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Wang YZ, 2001, J BIOL CHEM, V276, P20579, DOI 10.1074/jbc.M100874200; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wesierska-Gadek J, 2003, ANN NY ACAD SCI, V1010, P266, DOI 10.1196/annals.1299.046; Yang C, 2002, NUCLEIC ACIDS RES, V30, P2251, DOI 10.1093/nar/30.10.2251; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zheng X, 2005, BIOCHEM BIOPH RES CO, V329, P95, DOI 10.1016/j.bbrc.2005.01.105; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	93	67	69	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	55					7274	7288		10.1038/sj.onc.1209714	http://dx.doi.org/10.1038/sj.onc.1209714			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16751805				2022-12-28	WOS:000242244700006
J	Takada, H; Imoto, I; Tsuda, H; Nakanishi, Y; Sakakura, C; Mitsufuji, S; Hirohashi, S; Inazawa, J				Takada, H.; Imoto, I.; Tsuda, H.; Nakanishi, Y.; Sakakura, C.; Mitsufuji, S.; Hirohashi, S.; Inazawa, J.			Genomic loss and epigenetic silencing of very-low-density lipoprotein receptor involved in gastric carcinogenesis	ONCOGENE			English	Article						array-CGH; gastric cancer; VLDLR; homozygous deletion; methylation	CANCER CELL-LINES; LUNG-CANCER; HOMOZYGOUS DELETIONS; PANCREATIC-CARCINOMA; DNA METHYLATION; VLDL RECEPTOR; BREAST-CANCER; LDL RECEPTOR; SHORT ARM; GENE	Homozygous loss in the genomic sequence, a mechanism for inactivating tumor-suppressor genes (TSGs) in cancer, has been used as a tag for the identification of novel TSGs, and array-based comparative genomic hybridization (array-CGH) has a great potential for high-throughput identification of this change. We identified a homozygous loss of the very-low-density lipoprotein receptor (VLDLR) gene (9p24.2) from genome-wide screening for copy-number alterations in 32 gastric cancer ( GC) cell lines using array-CGH. Although previous reports demonstrated mRNA or protein expression of VLDLR in various cancers including GC, the association between genomic losses or epigenetic silencing of this gene and carcinogenesis has never been reported before. Homozygous deletion of VLDLR was also seen in primary GCs, albeit infrequently, and about half of GC cell lines showed lost or reduced VLDLR expression. The VLDLR expression was restored in gene-silenced GC cells after treatment with 5-aza 2'-deoxycytidine. According to methylation analyses, hypermethylation of the VLDLR promoter region, which all of GC lines without its expression showed, occurred in some primary GCs. Restoration of VLDLR type I expression in GC cells reduced colony formation. These results suggest that not only the expression of VLDLR but also genetic or epigenetic silencing of this gene may contribute to tumor formation and be involved in gastric carcinogenesis.	Tokyo Med & Dent Univ, Dept Mol Cytogenet, Med Res Inst, Bunkyo Ku, Tokyo 1138510, Japan; Grad Sch Biomed Sci, Tokyo, Japan; Kyoto Prefectural Univ Med, Grad Sch Med Sci, Div Gastroenterol & Hepatol, Kyoto, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Tokyo, Japan; Kyoto Prefectural Univ Med, Grad Sch Med Sci, Div Digest Surg, Kyoto, Japan; Tokyo Med & Dent Univ, COE Program Frontier Res Mol Destruct & Reconstit, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Kyoto Prefectural University of Medicine; National Cancer Center - Japan; Kyoto Prefectural University of Medicine; Tokyo Medical & Dental University (TMDU)	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Dept Mol Cytogenet, Med Res Inst, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	Imoto, Issei/AAD-5799-2020; imoto, Issei/D-8065-2012					An HX, 1999, CANCER RES, V59, P3941; Baylin SB, 1998, ADV CANCER RES, V72, P141; Chen T, 2005, WORLD J GASTROENTERO, V11, P2817, DOI 10.3748/wjg.v11.i18.2817; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; Fukuda Y, 2000, GENE CHROMOSOME CANC, V29, P315, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1047>3.0.CO;2-E; Heidenblad M, 2004, CANCER RES, V64, P3052, DOI 10.1158/0008-5472.CAN-03-3159; Hembrough TA, 2001, J BIOL CHEM, V276, P12241, DOI 10.1074/jbc.M010395200; Hiltunen TP, 1998, CIRCULATION, V97, P1079, DOI 10.1161/01.CIR.97.11.1079; Inazawa J, 2004, CANCER SCI, V95, P559, DOI 10.1111/j.1349-7006.2004.tb02486.x; Kim SK, 1997, CANCER RES, V57, P400; Martensen PM, 1997, EUR J BIOCHEM, V248, P583, DOI 10.1111/j.1432-1033.1997.00583.x; Nakamura Y, 2000, ARCH PATHOL LAB MED, V124, P119; Near SE, 2001, J HUM GENET, V46, P490, DOI 10.1007/s100380170051; Noguchi M, 1997, PATHOL INT, V47, P685, DOI 10.1111/j.1440-1827.1997.tb04442.x; Reisman DN, 2003, CANCER RES, V63, P560; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SAKATA K, 1995, JPN J CANCER RES, V86, P333, DOI 10.1111/j.1349-7006.1995.tb03060.x; Sarkar S, 2002, J BIOL CHEM, V277, P36585, DOI 10.1074/jbc.M204244200; Sato M, 2005, GENE CHROMOSOME CANC, V44, P405, DOI 10.1002/gcc.20253; Sato N, 2006, GASTROENTEROLOGY, V130, P548, DOI 10.1053/j.gastro.2005.11.008; Shim YH, 2000, LAB INVEST, V80, P689, DOI 10.1038/labinvest.3780072; Sonoda I, 2004, CANCER RES, V64, P3741, DOI 10.1158/0008-5472.CAN-04-0172; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; SUZUKI J, 1995, BIOCHEM BIOPH RES CO, V206, P835, DOI 10.1006/bbrc.1995.1119; Takada H, 2005, ONCOGENE, V24, P8051, DOI 10.1038/sj.onc.1208952; Takada H, 2005, CANCER SCI, V96, P100, DOI 10.1111/j.1349-7006.2005.00016.x; TAKAHASHI S, 1995, J BIOL CHEM, V270, P15747, DOI 10.1074/jbc.270.26.15747; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; Tanabe C, 2003, GENE CHROMOSOME CANC, V38, P168, DOI 10.1002/gcc.10269; Tanami H, 2005, LAB INVEST, V85, P1118, DOI 10.1038/labinvest.3700312; Vo QN, 2002, HUM PATHOL, V33, P1200, DOI 10.1053/hupa.2002.130108; Wada Y, 2000, HEART VESSELS, V15, P74, DOI 10.1007/s003800070035; Webb DJ, 1999, J BIOL CHEM, V274, P7412, DOI 10.1074/jbc.274.11.7412; WEBB JC, 1994, HUM MOL GENET, V3, P531, DOI 10.1093/hmg/3.4.531; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yamano M, 2000, AM J PATHOL, V156, P2123, DOI 10.1016/S0002-9440(10)65083-3; Yuki Y, 2004, CANCER SCI, V95, P503, DOI 10.1111/j.1349-7006.2004.tb03240.x	38	29	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2006	25	49					6554	6562		10.1038/sj.onc.1209657	http://dx.doi.org/10.1038/sj.onc.1209657			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16715143				2022-12-28	WOS:000241395100012
J	Neiman, PE; Kimmel, R; Icreverzi, A; Elsaesser, K; Bowers, SJ; Burnside, J; Delrow, J				Neiman, P. E.; Kimmel, R.; Icreverzi, A.; Elsaesser, K.; Bowers, S. -J.; Burnside, J.; Delrow, J.			Genomic instability during myc-induced lymphomagenesis in the bursa of fabricius	ONCOGENE			English	Article						myc oncogene; gene amplification; DNA palindromes	B-CELL DEVELOPMENT; SHORT INVERTED REPEATS; LARGE DNA PALINDROME; GENE AMPLIFICATION; HUMAN CANCERS; HL60 CELLS; CHICKEN; EXPRESSION; CDNA; HAMSTER	Retroviral vector-mediated overexpression of c-myc in embryonic bursal precursors induces multi-staged tumorigenesis beginning with preneoplastic-transformed follicles (TF) and progressing to clonal metastatic B-cell lymphomas. Using a 13K chicken cDNA microarray, specifically enriched for chicken immune system expressed sequence tagged (ESTs), we carried out array-based comparative genomic hybridization (array-CGH) and detected significant DNA copy number change at many loci on most or all chromosomes in both early TF and end-stage lymphomas. Formation of long palindromes, through breakage-fusion-bridge cycles, is thought to play an early role in gene amplification. Employing genome-wide analysis of palindrome formation (GAPF), we detected extensive palindrome formation in early TF and end-stage lymphomas. The population of loci showing amplification by array-CGH was enriched for palindromes detected by GAPF providing strong evidence for genetic instability early in Myc-induced tumorigenesis and further support for the role of palindromes in gene amplification. Comparing gene copy number change and RNA expression changes pro. led on the same cDNA array, we detected very little consistent contribution of gene copy number change to RNA expression changes. Palindromic loci in TF and tumors, however, were expressed, many at high levels, suggesting an abundance of RNA species with long double-stranded segments generated during tumorigenesis.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA; Univ Delaware, Dept Anim & Food Sci, Newark, DE USA; Fred Hutchinson Canc Res Ctr, DNA Array Facil, Seattle, WA 98104 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Delaware; Fred Hutchinson Cancer Center	Neiman, PE (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N,C2-023, Seattle, WA 98109 USA.	pneiman@fhcrc.org	Nolen, Danielle/A-5250-2010; Crozier, Laura B/C-5891-2011		NATIONAL CANCER INSTITUTE [R01CA020068, R01CA109365] Funding Source: NIH RePORTER; NCI NIH HHS [CA-20068, CA-109365] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boardman PE, 2002, CURR BIOL, V12, P1965, DOI 10.1016/S0960-9822(02)01296-4; Brandvold KA, 2000, ONCOGENE, V19, P2780, DOI 10.1038/sj.onc.1203589; Brown CY, 2004, DEV COMP IMMUNOL, V28, P619, DOI 10.1016/j.dci.2003.09.017; Burnside J, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-13; Butler DK, 1996, CELL, V87, P1115, DOI 10.1016/S0092-8674(00)81805-X; Chang H, 2004, CHROMOSOME RES, V12, P299, DOI 10.1023/B:CHRO.0000021947.17128.96; Ellerman V., 1908, ZENTR BAKTERIOL PARA, V46, P595; ENRIETTO PJ, 1983, CELL, V35, P369, DOI 10.1016/0092-8674(83)90170-8; ESKOLA J, 1974, CELL IMMUNOL, V13, P459, DOI 10.1016/0008-8749(74)90265-2; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Feo S, 1996, ONCOGENE, V13, P1521; FORD M, 1986, CELL, V45, P425, DOI 10.1016/0092-8674(86)90328-4; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hillier LW, 2004, NATURE, V432, P695, DOI 10.1038/nature03154; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Kittler R, 2004, NATURE, V432, P1036, DOI 10.1038/nature03159; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LOONEY JE, 1987, MOL CELL BIOL, V7, P569, DOI 10.1128/MCB.7.2.569; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; Mai S, 1996, ONCOGENE, V12, P277; Mai S, 1996, CHROMOSOME RES, V4, P365, DOI 10.1007/BF02257272; Mangano R, 1998, ONCOGENE, V17, P2771, DOI 10.1038/sj.onc.1202434; MILLER AD, 1991, J VIROL, V65, P2220, DOI 10.1128/JVI.65.5.2220-2224.1991; NEIMAN P, 1985, P NATL ACAD SCI USA, V82, P222, DOI 10.1073/pnas.82.1.222; NEIMAN P, 1980, J VIROL, V34, P178, DOI 10.1128/JVI.34.1.178-186.1980; NEIMAN P, 2006, REV PROTOCOLS DT40 R; NEIMAN PE, 1975, CELL, V4, P311; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NEIMAN PE, 1994, ADV IMMUNOL, V56, P467, DOI 10.1016/S0065-2776(08)60457-5; Neiman PE, 2003, ONCOGENE, V22, P1073, DOI 10.1038/sj.onc.1206070; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Tanaka H, 2005, NAT GENET, V37, P320, DOI 10.1038/ng1515; Tanaka H, 2002, P NATL ACAD SCI USA, V99, P8772, DOI 10.1073/pnas.132275999; THOMPSON CB, 1987, CELL, V51, P371, DOI 10.1016/0092-8674(87)90633-7; Tlsty TD, 1997, CURR TOP MICROBIOL, V221, P37; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; YASUDA LF, 1991, CELL, V67, P505, DOI 10.1016/0092-8674(91)90525-4; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	42	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2006	25	47					6325	6335		10.1038/sj.onc.1209646	http://dx.doi.org/10.1038/sj.onc.1209646			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	094CY	16652139				2022-12-28	WOS:000241218200009
J	Billottet, C; Grandage, VL; Gale, RE; Quattropani, A; Rommel, C; Vanhaesebroeck, B; Khwaja, A				Billottet, C.; Grandage, V. L.; Gale, R. E.; Quattropani, A.; Rommel, C.; Vanhaesebroeck, B.; Khwaja, A.			A selective inhibitor of the p110 delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16	ONCOGENE			English	Article						AML; PI3K; P110 delta; Akt; PKB; VP16; NF-kappa B	ACUTE MYELOID-LEUKEMIA; PHOSPHOINOSITIDE 3-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; B-CELL; SIGNALING PATHWAY; DRUG-RESISTANCE; HUMAN CANCER; P110 DELTA; KAPPA-B; MUTATIONS	Current therapy for acute myeloid leukaemia (AML) is suboptimal with a high incidence of relapse. There is strong evidence that constitutive phosphoinositide 3-kinase (PI3K) activity plays a significant role in the pathophysiology of AML. PI3K products are derived from the activity of a number of PI3K catalytic isoforms (class I, II and III) but the relative contribution of these enzymes in AML remains unknown. As non-isoform-selective inhibitors of PI3K such as LY294002 may produce unwanted toxicity to normal tissues, we have investigated the role of the leukocyte-restricted p110 delta PI3K isoform in 14 cases of AML. p110d was detected in all cases whereas the expression levels of the other class I PI3Ks varied more widely, and were often undetectable. The p110 delta-selective compound IC87114 inhibited constitutive phosphorylation of the PI3K target Akt/PKB and reduced cell number to a mean of 66 +/- 5% (range 14-88%). In eight cases, the combination of IC87114 and VP16 (a topoisomerase II inhibitor) was synergistic in reducing viable cell number, and was associated with a reduction in constitutive NF-kappa B activity. IC87114 did not have direct adverse effects or enhance the activity of VP16 on the proliferation and survival of normal haemopoietic progenitors. Overall, our results identify the p110d isoform as a potential therapeutic target in AML and support a clinical approach to use isoform-selective over broad-spectrum PI3K inhibitors.	Ludwig Inst Canc Res, London W1W 7BS, England; UCL, Dept Haematol, London, England; UCL, Sch Med, London W1N 8AA, England; Serono Pharmaceut Res Inst, Geneva, Switzerland; UCL, Dept Biochem & Mol Biol, London, England	Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London; UCL Medical School; University of London; University College London	Vanhaesebroeck, B (corresponding author), Ludwig Inst Canc Res, 91 Riding House St, London W1W 7BS, England.	bartvanh@ludwig.ucl.ac.uk; a.khwaja@ucl.ac.uk	Khwaja, Asim/C-1509-2008; SHAKOORI, ABDUL RAUF/Q-9373-2019	Billottet, Clotilde/0000-0003-1819-984X				Aggerholm A, 2000, EUR J HAEMATOL, V65, P109, DOI 10.1034/j.1600-0609.2000.90181.x; Ali K, 2004, NATURE, V431, P1007, DOI 10.1038/nature02991; Avellino R, 2005, BLOOD, V106, P1400, DOI 10.1182/blood-2005-03-0929; Bayascas JR, 2005, MOL CELL, V18, P143, DOI 10.1016/j.molcel.2005.03.020; Bilancio A, 2006, BLOOD, V107, P642, DOI 10.1182/blood-2005-07-3041; Bousquet M, 2005, BRIT J HAEMATOL, V131, P411, DOI 10.1111/j.1365-2141.2005.05784.x; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Brognard J, 2001, CANCER RES, V61, P3986; Camps M, 2005, NAT MED, V11, P936, DOI 10.1038/nm1284; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; Cheong JW, 2003, BRIT J HAEMATOL, V122, P454, DOI 10.1046/j.1365-2141.2003.04452.x; Clayton E, 2002, J EXP MED, V196, P753, DOI 10.1084/jem.20020805; Cornillet-Lefebvre P, 2006, LEUKEMIA, V20, P374, DOI 10.1038/sj.leu.2404054; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Fruman DA, 2004, BIOCHEM SOC T, V32, P315, DOI 10.1042/BST0320315; Grandage VL, 2005, LEUKEMIA, V19, P586, DOI 10.1038/sj.leu.2403653; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959-8049(98)00228-7; Hill K, 2000, J BIOL CHEM, V275, P3741, DOI 10.1074/jbc.275.6.3741; Jackson SP, 2005, NAT MED, V11, P507, DOI 10.1038/nm1232; Jou ST, 2002, MOL CELL BIOL, V22, P8580, DOI 10.1128/MCB.22.24.8580-8591.2002; Kang S, 2005, CELL CYCLE, V4, P578, DOI 10.4161/cc.4.4.1593; Kaspers GJL, 2003, RECENT RES CANCER, V161, P196; Kelly LM, 2002, ANNU REV GENOM HUM G, V3, P179, DOI 10.1146/annurev.genom.3.032802.115046; Knight ZA, 2004, BIOORGAN MED CHEM, V12, P4749, DOI 10.1016/j.bmc.2004.06.022; Koizumi T., 2002, Patent US, Patent No. [6,403,588 B1, 11, 6403588]; Kubota Y, 2004, LEUKEMIA, V18, P1438, DOI 10.1038/sj.leu.2403402; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Luo JM, 2003, LEUKEMIA, V17, P1, DOI 10.1038/sj.leu.2402725; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Min YH, 2003, LEUKEMIA, V17, P995, DOI 10.1038/sj.leu.2402874; Nanri T, 2005, LEUKEMIA, V19, P1361, DOI 10.1038/sj.leu.2403803; NEUBAUER A, 1994, BLOOD, V83, P1603; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Odero MD, 2000, GENE CHROMOSOME CANC, V29, P333, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1040>3.3.CO;2-Q; Okkenhaug K, 2004, BIOCHEM SOC T, V32, P332, DOI 10.1042/BST0320332; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Okkenhaug K, 2002, SCIENCE, V297, P1031; Parsons R, 2004, SEMIN CELL DEV BIOL, V15, P171, DOI 10.1016/j.semcdb.2003.12.021; Reif K, 2004, J IMMUNOL, V173, P2236, DOI 10.4049/jimmunol.173.4.2236; ROBERTSON AJ, 2001, Patent No. 0153266; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Sadhu C, 2003, J IMMUNOL, V170, P2647, DOI 10.4049/jimmunol.170.5.2647; Sadhu C, 2001, [No title captured], Patent No. [WO0181346, 0181346]; Samuels Y, 2004, CELL CYCLE, V3, P1221, DOI 10.4161/cc.3.10.1164; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sargent JM, 2003, RECENT RESULTS CANC, V161, P13; Sawyer C, 2003, CANCER RES, V63, P1667; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Stirewalt DL, 2003, NAT REV CANCER, V3, P650, DOI 10.1038/nrc1169; Sujobert P, 2005, BLOOD, V106, P1063, DOI 10.1182/blood-2004-08-3225; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; WANTZIN GL, 1977, EUR J CANCER, V13, P647, DOI 10.1016/0014-2964(77)90050-0; Warner JK, 2004, ONCOGENE, V23, P7164, DOI 10.1038/sj.onc.1207933; Watts MJ, 2002, BRIT J HAEMATOL, V118, P117, DOI 10.1046/j.1365-2141.2002.03561.x; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Wymann MP, 2003, TRENDS PHARMACOL SCI, V24, P366, DOI 10.1016/S0165-6147(03)00163-9; Xu Q, 2003, BLOOD, V102, P972, DOI 10.1182/blood-2002-11-3429; Zhao S, 2004, LEUKEMIA, V18, P267, DOI 10.1038/sj.leu.2403220	67	133	195	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	50					6648	6659		10.1038/sj.onc.1209670	http://dx.doi.org/10.1038/sj.onc.1209670			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16702948				2022-12-28	WOS:000241569700009
J	Dias, SS; Milne, DM; Meek, DW				Dias, S. S.; Milne, D. M.; Meek, D. W.			c-Abl phosphorylates Hdm2 at tyrosine 276 in response to DNA damage and regulates interaction with ARF	ONCOGENE			English	Article						Hdm2; p53; c-Abl; ARF; phosphorylation; DNA damage	POSTTRANSLATIONAL MODIFICATIONS; P53; MDM2; ACTIVATION	The p53 tumour-suppressor protein is tightly regulated through its association with the Hdm2 E3 ligase. Activation of p53 by DNA strand breaks is orchestrated by the ataxia-telangiectasia mutated (ATM) protein kinase and involves interruption of Hdm2-mediated p53 degradation. As part of this mechanism ATM itself, and the ATM-activated protein tyrosine kinase, c-Abl, inhibit Hdm2 function through phosphorylation of serine 395 and tyrosine 394 (Y394), respectively. In the present study, we have identified a novel target of c-Abl in the Hdm2 protein, tyrosine 276 (Y276). We show that c-Abl phosphorylates this residue in vitro and confirm that Y394 is a target of c-Abl. We also show that Y276 is phosphorylated in a c-Abl-dependent manner in cultured cells and provide evidence that Y276 is phosphorylated in response to DNA damage coincident with the activation of c-Abl. Finally, we show that Y276 phosphorylation stimulates interaction with ARF, leading to increased levels of nucleolar Hdm2 and decreased turnover of p53. These data establish Y276 as a physiological target of c-Abl that contributes functionally to the induction of p53.	Univ Dundee, Ninewells Hosp & Med Sch, Mol Signalling Grp, Biomed Res Ctr, Dundee DD1 9SY, Scotland	University of Dundee	Meek, DW (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Mol Signalling Grp, Biomed Res Ctr, Dundee DD1 9SY, Scotland.	david.meek@cancer.org.uk						Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Lu X, 2005, CURR OPIN GENET DEV, V15, P27, DOI 10.1016/j.gde.2004.12.008; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Meek DW, 2003, MOL CANCER RES, V1, P1017; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; Shaul Y, 2005, CELL RES, V15, P33, DOI 10.1038/sj.cr.7290261; Sionov RV, 2001, MOL CELL BIOL, V21, P5869; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Wu JJ, 2002, COMB CHEM HIGH T SCR, V5, P83, DOI 10.2174/1386207023330516	16	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	50					6666	6671		10.1038/sj.onc.1209671	http://dx.doi.org/10.1038/sj.onc.1209671			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16702947				2022-12-28	WOS:000241569700011
J	Kostenko, O; Tsacoumangos, A; Crooks, D; Kil, SJ; Carlin, C				Kostenko, O.; Tsacoumangos, A.; Crooks, D.; Kil, S. J.; Carlin, C.			Gab1 signaling is regulated by EGF receptor sorting in early endosomes	ONCOGENE			English	Article						EGF receptor; endocytosis; Gab1; MAPK	EPIDERMAL-GROWTH-FACTOR; PLECKSTRIN HOMOLOGY DOMAIN; ACTIVATED PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASES; DOCKING PROTEIN; GRB2-ASSOCIATED BINDER-1; TRANSFERRIN RECEPTORS; ENDOCYTIC PATHWAY; NOONAN-SYNDROME	Although combinatorial signaling through the ErbB network is implicated in certain types of human cancer, the specifics of how particular receptors contribute to the transformed phenotype are not well understood. The goal of this study was to identify epidermal growth factor (EGF) receptor-dependent cell signaling abnormalities specifically associated with mutations in a previously described 679-LL lysosomal sorting signal, which restrict ligand-dependent receptor downregulation by promoting recycling. Importantly, the 679-LL signal is not conserved in any of the other members of the ErbB receptor family suggesting its physiological function may be tightly regulated during EGF receptor-dependent signaling. Our data indicate that cells expressing receptors with an inactive 679-AA signal are rapidly transported to Rab4(+) early endosomes after they are internalized in contrast to wild-type receptors that are localized to early endocytic antigen 1 (EEA1)(+) early endosomes. Divergent trafficking in early endosomes is associated with prolonged activation of p44/42 mitogen-activated protein kinases (MAPK) but not Akt. Gab1 appears to be the critical signaling molecule facilitating prolonged MAPK signaling, and activated Gab1 is recruited to early endosomes in 679-AA receptor-expressing cells. Activated Gab1 is also recruited to early endosomes in breast cancer cells characterized by high levels of EGF receptor-ErbB2 heterodimers, suggesting 679-AA expressing cells recapitulate certain aspects of EGF receptor signaling and transformation by activated ErbB2. Phosphatidylinositol 3-kinase (PI3K)-dependent membrane translocation known to be important for maintaining Gab1 activity in other settings was dispensable. We conclude that 679-LL has dual functions in EGF receptor trafficking and threshold signaling through a subset of signaling molecules including p44/42 MAPK and Gab1.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Canc, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Carlin, C (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.	cathleen.carlin@case.edu			NIGMS NIH HHS [R01 GM64243] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Baulida J, 1996, J BIOL CHEM, V271, P5251; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Cai T, 2002, J CELL BIOL, V159, P103, DOI 10.1083/jcb.200205017; Chakraborty A, 2002, HOSP MED, V63, P743, DOI 10.12968/hosp.2002.63.12.1896; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Chen XM, 2001, EMBO REP, V2, P842, DOI 10.1093/embo-reports/kve179; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Citri A, 2003, EXP CELL RES, V284, P54, DOI 10.1016/S0014-4827(02)00101-5; Crooks D, 2000, MOL BIOL CELL, V11, P3559, DOI 10.1091/mbc.11.10.3559; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; Cunnick JM, 2001, J BIOL CHEM, V276, P24380, DOI 10.1074/jbc.M010275200; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; De Renzis S, 2002, NAT CELL BIOL, V4, P124, DOI 10.1038/ncb744; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; Fragale A, 2004, HUM MUTAT, V23, P267, DOI 10.1002/humu.20005; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; Harlow E, 1988, ANTIBODIES LAB MANUA, P139; Hendriks BS, 2003, J BIOL CHEM, V278, P23343, DOI 10.1074/jbc.M300477200; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Jones SM, 2002, AM J PHYSIOL-CELL PH, V282, pC420, DOI 10.1152/ajpcell.00253.2001; Kameda H, 2001, MOL CELL BIOL, V21, P6895, DOI 10.1128/MCB.21.20.6895-6905.2001; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kil SJ, 1999, J BIOL CHEM, V274, P3141, DOI 10.1074/jbc.274.5.3141; Kil SJ, 2000, J CELL PHYSIOL, V185, P47, DOI 10.1002/1097-4652(200010)185:1<47::AID-JCP4>3.3.CO;2-F; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; Krendel M, 2005, PHYSIOLOGY, V20, P239, DOI 10.1152/physiol.00014.2005; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB JE, 1983, J BIOL CHEM, V258, P8751; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; MARGOLIS B, 1994, J AM SOC NEPHROL, V5, P1288; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Maroun CR, 1999, J BIOL CHEM, V274, P31719, DOI 10.1074/jbc.274.44.31719; Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsacoumango A, 2005, J CELL SCI, V118, P3959, DOI 10.1242/jcs.02527; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; Vitale G, 1998, EMBO J, V17, P1941, DOI 10.1093/emboj/17.7.1941; Wang ZX, 1999, MOL BIOL CELL, V10, P1621, DOI 10.1091/mbc.10.5.1621; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; WEIDNER KM, 1996, NATURE, V173, P384; WEIEL JE, 1984, BIOCHEM BIOPH RES CO, V119, P598, DOI 10.1016/S0006-291X(84)80291-0; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8; Wilson JM, 2000, MOL BIOL CELL, V11, P2657, DOI 10.1091/mbc.11.8.2657; Wolf I, 2002, MOL CELL BIOL, V22, P231, DOI 10.1128/MCB.22.1.231-244.2002; Yamasaki S, 2003, ONCOGENE, V22, P1546, DOI 10.1038/sj.onc.1206284; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	71	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	50					6604	6617		10.1038/sj.onc.1209675	http://dx.doi.org/10.1038/sj.onc.1209675			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16715136				2022-12-28	WOS:000241569700005
J	Ohlenschlager, O; Seiboth, T; Zengerling, H; Briese, L; Marchanka, A; Ramachandran, R; Baum, M; Korbas, M; Meyer-Klaucke, W; Durst, M; Gorlach, M				Ohlenschlaeger, O.; Seiboth, T.; Zengerling, H.; Briese, L.; Marchanka, A.; Ramachandran, R.; Baum, M.; Korbas, M.; Meyer-Klaucke, W.; Duerst, M.; Goerlach, M.			Solution structure of the partially folded high-risk human papilloma virus 45 oncoprotein E7	ONCOGENE			English	Article						human papilloma virus; E7; carcinogenesis; NMR solution structure	HUMAN-PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA TUMOR-SUPPRESSOR; TORSION ANGLE DYNAMICS; E7 ONCOPROTEIN; HPV E7; HUMAN KERATINOCYTES; ADENOVIRUS E1A; ZINC-BINDING; RB BINDING; PROTEIN	The oncoprotein E7 of human papilloma viruses (HPV) is involved in the pathogenesis and maintenance of human cervical cancers. The most prevalent HPV types found in cervix carcinomas are HPV16, 18 and 45. The structure of the E7 dimer from HPV45 (PDB 2F8B) was determined by nuclear magnetic resonance spectroscopy. Each monomer comprises an unfolded N-terminus and a well-structured C-terminal domain with a beta 1 beta 2 alpha 1 beta 3 alpha 2 topology representing a unique zinc-binding fold found only for E7. Dimerization occurs through the alpha 1/alpha 1' helices and intermolecular beta-sheet formation but excludes the zinc-binding sites. E7 is reported to interact with a number of cellular proteins (e.g. pRb, p21(CIP1)). Binding of a peptide derived from the C-terminus of p21(CIP1) to the C-terminal domain of E7 was characterized by monitoring chemical shift perturbations of the amide groups of E7. This provides direct evidence that a shallow groove situated between alpha 1 and beta 1 of the E7 C-terminal domain is interacting with the C-terminus of p21CIP1. Intriguingly, this binding site overlaps with the low-affinity binding site on E7 for the C-domain of pRb.	Fritz Lipmann Inst, NMR Spectroscopy, D-07745 Jena, Germany; DESY, European Mol Biol Lab, D-2000 Hamburg, Germany; Univ Jena, Frauenklin, D-6900 Jena, Germany	Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Friedrich Schiller University of Jena	Gorlach, M (corresponding author), Fritz Lipmann Inst, NMR Spectroscopy, Beutenbergstr 11, D-07745 Jena, Germany.	mago@fli-leibniz.de	Korbas, Malgorzata/B-4024-2009; Meyer-Klaucke, Wolfram/G-1148-2010	Korbas, Malgorzata/0000-0003-3064-0132; Ohlenschlaeger, Oliver/0000-0002-6428-4423; Marchanka, Alexander/0000-0003-0810-2020				Alonso LG, 2002, BIOCHEMISTRY-US, V41, P10510, DOI 10.1021/bi025579n; Avvakumov N, 2003, ONCOGENE, V22, P3833, DOI 10.1038/sj.onc.1206562; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BARBOSA MS, 1989, J VIROL, V63, P1404, DOI 10.1128/JVI.63.3.1404-1407.1989; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BINSTED N, 1992, BIOCHEMISTRY-US, V31, P12117, DOI 10.1021/bi00163a021; Bischof O, 2005, MOL CELL BIOL, V25, P1013, DOI 10.1128/MCB.25.3.1013-1024.2005; Bosch F Xavier, 2003, J Natl Cancer Inst Monogr, P3; Braspenning J, 1998, ONCOGENE, V16, P1085, DOI 10.1038/sj.onc.1201617; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Clements A, 2000, BIOCHEMISTRY-US, V39, P16033, DOI 10.1021/bi002111g; de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Guntert P, 1998, J BIOMOL NMR, V12, P543, DOI 10.1023/A:1008391403193; Helt AM, 2002, J VIROL, V76, P10559, DOI 10.1128/JVI.76.20.10559-10568.2002; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kriwacki RW, 1996, P NATL ACAD SCI USA, V93, P11504, DOI 10.1073/pnas.93.21.11504; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Liu X, 2006, J BIOL CHEM, V281, P578, DOI 10.1074/jbc.M508455200; Mannhardt B, 2000, MOL CELL BIOL, V20, P6483, DOI 10.1128/MCB.20.17.6483-6495.2000; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Munger K, 2004, J VIROL, V78, P11451, DOI 10.1128/JVI.78.21.11451-11460.2004; MUNGER K, 1989, J VIROL, V63, P4417; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; Schlott B, 2002, J MOL BIOL, V318, P533, DOI 10.1016/S0022-2836(02)00014-1; Singh M, 2005, J BIOL CHEM, V280, P37868, DOI 10.1074/jbc.M504877200; Villa LL, 1997, ADV CANCER RES, V71, P321, DOI 10.1016/S0065-230X(08)60102-5; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Xiao B, 2003, P NATL ACAD SCI USA, V100, P2363, DOI 10.1073/pnas.0436813100; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q; Zwerschke W, 2000, ADV CANCER RES, V78, P1	43	82	86	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2006	25	44					5953	5959		10.1038/sj.onc.1209584	http://dx.doi.org/10.1038/sj.onc.1209584			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16636661				2022-12-28	WOS:000240826300004
J	Noda, D; Itoh, S; Watanabe, Y; Inamitsu, M; Dennler, S; Itoh, F; Koike, S; Danielpour, D; ten Dijke, P; Kato, M				Noda, D.; Itoh, S.; Watanabe, Y.; Inamitsu, M.; Dennler, S.; Itoh, F.; Koike, S.; Danielpour, D.; Dijke, P. ten; Kato, M.			ELAC2, a putative prostate cancer susceptibility gene product, potentiates TGF-beta/Smad-induced growth arrest of prostate cells	ONCOGENE			English	Article						ELAC2; cell proliferation; p21; Smad TGF-beta	BETA TYPE-I; SMAD PROTEINS; SIGNALING PATHWAY; EPITHELIAL-CELLS; FAMILY-MEMBERS; RECEPTOR; EXPRESSION; PROMOTER; SP1; ACTIVATION	Transforming growth factor-beta (TGF-beta) elicits a potent growth inhibitory effect on many normal cells by binding to specific serine/threonine kinase receptors and activating specific Smad proteins, which regulate the expression of cell cycle genes, including the p21 cyclin-dependent kinase (CDK) inhibitor gene. Interestingly, cancer cells are often insensitive to the anti-mitogenic effects of TGF-beta for which the molecular mechanisms are not well understood. In this study, we found that the candidate prostate cancer susceptibility gene ELAC2 potentiates TGF-beta/Smad-induced transcriptional responses. ELAC2 associates with activated Smad2; the C-terminal MH2 domain of Smad2 interacts with the N-terminal region of ELAC2. Small interfering siRNA-mediated knock-down of ELAC2 in prostate cells suppressed TGF-beta-induced growth arrest. Moreover, ELAC2 was shown to specifically associate with the nuclear Smad2 partner, FAST-1 and to potentiate the interaction of activated Smad2 with transcription factor Sp1. Furthermore, activation of the p21 CDK inhibitor promoter by TGF-beta is potentiated by ELAC2. Taken together our data indicate an important transcriptional scaffold function for ELAC2 in TGF-beta/Smad signaling mediated growth arrest.	Univ Tsukuba, Dept Expt Pathol, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058575, Japan; Yamagata Univ, Sch Med, Dept Otolaryngol, Yamagata 990, Japan; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Case Western Reserve Univ, Sch Med, Div Gen Med Sci Oncol, Cleveland, OH 44106 USA; Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2300 RA Leiden, Netherlands	University of Tsukuba; Yamagata University; Netherlands Cancer Institute; Case Western Reserve University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Itoh, S (corresponding author), Univ Tsukuba, Dept Expt Pathol, Grad Sch Comprehens Human Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	sitoh@md.tsukuba.ac.jp	Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Itoh, Susumu/0000-0002-7967-0730; Itoh, Fumiko/0000-0002-6134-5331				Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Chen GC, 2005, J BIOL CHEM, V280, P36355, DOI 10.1074/jbc.M506147200; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen Y, 2005, BMC MOL BIOL, V6, DOI 10.1186/1471-2199-6-12; Danielpour D, 2005, EUR J CANCER, V41, P846, DOI 10.1016/j.ejca.2004.12.027; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; Guo YP, 1999, CANCER RES, V59, P1366; Guo YP, 1997, INT J CANCER, V71, P573, DOI 10.1002/(SICI)1097-0215(19970516)71:4<573::AID-IJC11>3.3.CO;2-1; Guo YP, 1998, CELL GROWTH DIFFER, V9, P185; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Itoh S, 2003, J BIOL CHEM, V278, P3751, DOI 10.1074/jbc.M208258200; Itoh S, 2000, NUCLEIC ACIDS RES, V28, P4291, DOI 10.1093/nar/28.21.4291; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kim IY, 1996, CLIN CANCER RES, V2, P1255; Korver W, 2003, INT J CANCER, V104, P283, DOI 10.1002/ijc.10945; Kundu SD, 2000, PROSTATE, V43, P118; Larisch-Bloch S, 2000, CELL GROWTH DIFFER, V11, P1; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Minagawa A, 2005, CANCER LETT, V222, P211, DOI 10.1016/j.canlet.2004.09.013; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Moustakas A, 2001, J CELL SCI, V114, P4359; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nicolas FJ, 2004, J CELL SCI, V117, P4113, DOI 10.1242/jcs.01289; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shea PR, 2002, HUM GENET, V111, P398, DOI 10.1007/s00439-002-0816-1; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; SONG K, 2000, CANCER RES, V63, P4358; Takaku H, 2003, NUCLEIC ACIDS RES, V31, P2272, DOI 10.1093/nar/gkg337; Tang BW, 1999, CANCER RES, V59, P4834; Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Wang L, 2001, CANCER RES, V61, P6494; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	45	33	36	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2006	25	41					5591	5600		10.1038/sj.onc.1209571	http://dx.doi.org/10.1038/sj.onc.1209571			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16636667				2022-12-28	WOS:000240599100001
J	Vakifahmetoglu, H; Olsson, M; Orrenius, S; Zhivotovsky, B				Vakifahmetoglu, H.; Olsson, M.; Orrenius, S.; Zhivotovsky, B.			Functional connection between p53 and caspase-2 is essential for apoptosis induced by DNA damage	ONCOGENE			English	Article						apoptosis; caspase-2; PIDDosome complex; p53; 5-FU	CYTOCHROME-C RELEASE; CELL-DEATH; ACTIVATION; PROTEIN; PIDD; TRANSCRIPTION; LOCALIZATION; MITOCHONDRIA; REQUIREMENT; INHIBITOR	Recent findings have established caspase-2 as an important apical regulator in apoptotic pathways leading from DNA damage to release of mitochondrial cytochrome c and subsequent activation of effector caspases. Yet, the molecular map connecting the embarking stimuli of genotoxic stress with caspase-2 activation remains to be elucidated. Here, we address the question of potential caspase-2 regulators by examining 5-fluorouracil (5-FU)-induced apoptosis in wild-type and p53-deficient human colon carcinoma cells. Apoptosis was observed only in p53(+/+) cells and was preceded by caspase-2 activation. Hence, although no direct interaction between p53 and caspase-2 was observed in the cell system used, our data clearly demonstrate that a functional connection between these two proteins is essential for initiation of the 5-FU-induced apoptotic process. Proposed mediators of caspase-2 activation include PIDDosome complex proteins PIDD and RAIDD. Surprisingly, the presence of a complex encompassing at least RAIDD, PIDD and caspase-2 was verified in both p53(+/+) and p53(-/-) cells, also in the absence of 5-FU treatment. Thus, our results confirm the participation of PIDD and RAIDD in PIDDosome complex formation but question their role as sole mediators of caspase-2 activation. This assumption was further supported by siRNA transfections targeting PIDD or RAIDD. In conclusion, our findings support the hypothesis of p53 as an upstream regulator of caspase activity and provide data concerning caspase-2 processing mechanisms. As suppression of caspase-2 expression in 5-FU-treated cells also affects the level of the p53 protein, possibilities of a reciprocal interaction between these proteins are discussed.	Karolinska Inst, Inst Environm Med, Div Toxicol, SE-17177 Stockholm, Sweden	Karolinska Institutet	Zhivotovsky, B (corresponding author), Karolinska Inst, Inst Environm Med, Div Toxicol, Box 210, SE-17177 Stockholm, Sweden.	Boris.Zhivotovsky@imm.ki.se	Zhivotovsky, Boris/A-4346-2014; Olsson, Magnus/E-3140-2012	Zhivotovsky, Boris/0000-0002-2238-3482; Olsson, Magnus/0000-0002-6370-8423				Baliga BC, 2004, CELL DEATH DIFFER, V11, P1234, DOI 10.1038/sj.cdd.4401492; Baliga BC, 2003, J BIOL CHEM, V278, P4899, DOI 10.1074/jbc.M211512200; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Berube C, 2005, P NATL ACAD SCI USA, V102, P14314, DOI 10.1073/pnas.0506475102; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Ding HF, 2000, J BIOL CHEM, V275, P38905, DOI 10.1074/jbc.M004714200; Enoksson M, 2004, J BIOL CHEM, V279, P49575, DOI 10.1074/jbc.C400374200; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; Ho PK, 2005, FEBS J, V272, P1401, DOI 10.1111/j.1742-4658.2005.04573.x; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Jiang M, 2003, GENE DEV, V17, P832, DOI 10.1101/gad.252603; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Levav-Cohen Y, 2005, BIOCHEM BIOPH RES CO, V331, P737, DOI 10.1016/j.bbrc.2005.03.152; Lin CF, 2005, J BIOL CHEM, V280, P23758, DOI 10.1074/jbc.M412292200; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Marsden VS, 2004, J CELL BIOL, V165, P775, DOI 10.1083/jcb.200312030; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Park HH, 2006, J MOL BIOL, V357, P358, DOI 10.1016/j.jmb.2005.12.082; Paroni G, 2001, J BIOL CHEM, V276, P21907, DOI 10.1074/jbc.M011565200; Ren JY, 2005, P NATL ACAD SCI USA, V102, P565, DOI 10.1073/pnas.0408744102; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Robertson JD, 2004, EMBO REP, V5, P643, DOI 10.1038/sj.embor.7400153; Rotter B, 2004, BIOCHEM J, V378, P161, DOI 10.1042/BJ20030955; Scholz C, 2005, ONCOGENE, V24, P1904, DOI 10.1038/sj.onc.1208233; Schuler M, 2005, TRENDS GENET, V21, P182, DOI 10.1016/j.tig.2005.01.001; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Seth R, 2005, J BIOL CHEM, V280, P31230, DOI 10.1074/jbc.M503305200; Shearwin-Whyatt LM, 2000, CELL DEATH DIFFER, V7, P155, DOI 10.1038/sj.cdd.4400632; Shikama Y, 2001, EXP CELL RES, V264, P315, DOI 10.1006/excr.2000.5153; Tang J, 2005, CANCER BIOL THER, V4, P645, DOI 10.4161/cbt.4.6.1729; Telliez JB, 2000, BBA-PROTEIN STRUCT M, V1478, P280, DOI 10.1016/S0167-4838(00)00029-7; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Troy CM, 2001, J NEUROSCI, V21, P5007, DOI 10.1523/JNEUROSCI.21-14-05007.2001; Wang Q, 2006, CELL DEATH DIFFER, V13, P75, DOI 10.1038/sj.cdd.4401690; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378	44	84	89	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2006	25	41					5683	5692		10.1038/sj.onc.1209569	http://dx.doi.org/10.1038/sj.onc.1209569			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16652156				2022-12-28	WOS:000240599100010
J	Gaffre, M; Dupre, A; Valuckaite, R; Suziedelis, K; Jessus, C; Haccard, O				Gaffre, M.; Dupre, A.; Valuckaite, R.; Suziedelis, K.; Jessus, C.; Haccard, O.			Deciphering the H-Ras pathway in Xenopus oocyte	ONCOGENE			English	Article						Ras; Xenopus oocyte; meiotic maturation; Cdc2; MAPK; PI3K	CLASSICAL PROGESTERONE-RECEPTOR; MATURATION-PROMOTING FACTOR; MOS PROTO-ONCOGENE; MEIOTIC MATURATION; CELL-CYCLE; SIGNALING PATHWAY; MAP KINASE; C-MOS; PHOSPHOINOSITIDE 3-KINASE; DISTINCT MECHANISMS	Xenopus oocytes are arrested in prophase of the first meiotic division. In response to progesterone, they re-enter meiosis and arrest again in metaphase of the second meiotic division. This process, called meiotic maturation, is under the control of the Cyclin B-Cdc2 complex, Mphase promoting factor (MPF). Injection of a constitutively active Xenopus H-Ras protein activates MPF, suggesting that Ras proteins could be implicated in the progesterone transduction pathway. The aim of this study was (1) to elucidate the pathway triggered by H-Ras leading to MPF activation in Xenopus oocytes and (2) to investigate whether endogenous H-Ras is involved in the physiological process of meiotic maturation. We generated three constitutively active double mutants, each of them recruiting a single effector in mammalian cells, mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K) or RalGDS. Our results show that the activation of a PI3K-related enzyme is crucial for H-Ras-induced MPF activation, whereas the recruitment of either MAPK or RalGDS is not. However, although the H-Ras/PI3K pathway is functional in Xenopus oocytes, it is not the physiological transducer of progesterone responsible for meiotic resumption.	Univ Paris 06, CNRS, UMR 7622, Dev Biol Lab, F-75252 Paris 05, France; Vilnius State Univ, Dept Biochem & Biophys, Vilnius, Lithuania; Inst Oncol, Vilnius, Lithuania	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Vilnius University	Haccard, O (corresponding author), Univ Paris 06, CNRS, UMR 7622, Dev Biol Lab, Boite 24,9 Quai St Bernard, F-75252 Paris 05, France.	olh@ccr.jussieu.fr		Haccard, Olivier/0000-0002-4305-2746				Abrieu A, 1997, EMBO J, V16, P6407, DOI 10.1093/emboj/16.21.6407; Andersen CB, 1998, J BIOL CHEM, V273, P18705, DOI 10.1074/jbc.273.30.18705; ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; Bayaa M, 2000, P NATL ACAD SCI USA, V97, P12607, DOI 10.1073/pnas.220302597; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Castro A, 2001, BIOL CELL, V93, P15, DOI 10.1016/S0248-4900(01)01128-5; De Smedt V, 2002, J BIOL CHEM, V277, P28592, DOI 10.1074/jbc.M202742200; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Dupre A, 2002, EMBO J, V21, P4026, DOI 10.1093/emboj/cdf400; Dupre A, 2002, ONCOGENE, V21, P6425, DOI 10.1038/sj.onc.1205827; Fisher DL, 2000, EMBO J, V19, P1516, DOI 10.1093/emboj/19.7.1516; Frank-Vaillant M, 1999, MOL BIOL CELL, V10, P3279, DOI 10.1091/mbc.10.10.3279; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; Gross SD, 2000, CURR BIOL, V10, P430, DOI 10.1016/S0960-9822(00)00425-5; Haccard O, 2006, EMBO REP, V7, P321, DOI 10.1038/sj.embor.7400611; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hiraoka D, 2004, DEV BIOL, V276, P330, DOI 10.1016/j.ydbio.2004.08.036; Hochegger H, 2001, DEVELOPMENT, V128, P3795; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; Jessus C, 1998, BIOL CELL, V90, P573, DOI 10.1016/S0248-4900(99)80015-X; JESSUS C, 1991, DEVELOPMENT, V111, P813; Karaiskou A, 1999, J CELL SCI, V112, P3747; Karaiskou A, 2001, BIOL CELL, V93, P35, DOI 10.1016/S0248-4900(01)01126-1; Kinashi T, 2000, J BIOL CHEM, V275, P22590, DOI 10.1074/jbc.M000633200; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lebreton S, 2004, MECH DEVELOP, V121, P1481, DOI 10.1016/j.mod.2004.07.008; LEGUELLEC R, 1991, BIOL CELL, V72, P39, DOI 10.1016/0248-4900(91)90076-Y; Liu XS, 2005, DEV BIOL, V283, P180, DOI 10.1016/j.ydbio.2005.04.011; Liu YS, 2005, CHEM BIOL, V12, P99, DOI 10.1016/j.chembiol.2004.11.009; MALLER JL, 1977, J BIOL CHEM, V252, P1712; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Perdiguero E, 2004, CELL CYCLE, V3, P733; Peyssonnaux C, 2000, MOL CELL BIOL, V20, P7068, DOI 10.1128/MCB.20.19.7068-7079.2000; Prober DA, 2002, GENE DEV, V16, P2286, DOI 10.1101/gad.991102; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; STACEY DW, 1991, ONCOGENE, V6, P2297; Tian JD, 2000, P NATL ACAD SCI USA, V97, P14358, DOI 10.1073/pnas.250492197; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Wang J, 2004, J CELL SCI, V117, P5107, DOI 10.1242/jcs.01383; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2231, DOI 10.1073/pnas.0336132100	52	7	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2006	25	37					5155	5162		10.1038/sj.onc.1209523	http://dx.doi.org/10.1038/sj.onc.1209523			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16607282				2022-12-28	WOS:000240063700008
J	Keren-Paz, A; Bercovich, Z; Porat, Z; Erez, O; Brener, O; Kahana, C				Keren-Paz, A.; Bercovich, Z.; Porat, Z.; Erez, O.; Brener, O.; Kahana, C.			Overexpression of antizyme-inhibitor in NIH3T3 fibroblasts provides growth advantage through neutralization of antizyme functions	ONCOGENE			English	Article						antizyme inhibitor; antizyme; ornithine decarboxylase; polyamines; cell growth; cellular transformation	ORNITHINE-DECARBOXYLASE ACTIVITY; TISSUE-CULTURE CELLS; POLYAMINE TRANSPORT; GENE-EXPRESSION; TRANSGENIC MICE; REQUIRES INTERACTION; RETICULOCYTE LYSATE; NEGATIVE REGULATION; HOMOLOGOUS PROTEIN; PROSTATE-CANCER	Antizyme inhibitor (AzI) is a homolog of ornithine decarboxylase (ODC), a key enzyme of polyamine synthesis. Antizyme inhibitor retains no enzymatic activity, but exhibits high affinity to antizyme (Az), a negative regulator of polyamine homeostasis. As polyamines are involved in maintaining cellular proliferation, and since AzI may negate Az functions, we have investigated the role of AzI in regulating cell growth. We show here that overexpression of AzI in NIH3T3 cells increased growth rate, enabled growth in low serum, and permitted anchorage-independent growth in soft agar, while reduction of AzI levels by AzI siRNA reduced cellular proliferation. Moreover, AzI overproducing cells gave rise to tumors when injected into nude mice. AzI overexpression resulted in elevation of ODC activity and of polyamine uptake. These effects of AzI are a result of its ability to neutralize Az, as overexpression of an AzI mutant with reduced Az binding failed to alter cellular polyamine metabolism and growth properties. We also demonstrate upregulation of AzI in Ras transformed cells, suggesting its relevance to some naturally occurring transformations. Finally, increased uptake activity rendered AzI overproducing and Ras-transformed cells more sensitive to toxic polyamine analogs. Our results therefore imply that AzI has a central and meaningful role in modulation of polyamine homeostasis, and in regulating cellular proliferation and transformation properties.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Vet Resources, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Kahana, C (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	chaim.kahana@weizmann.ac.il	Porat, Ziv/K-1672-2012	Porat, Ziv/0000-0003-3059-181X				AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Bercovich Z, 2004, J BIOL CHEM, V279, P54097, DOI 10.1074/jbc.M410234200; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; BEY P, 1978, J MED CHEM, V21, P50, DOI 10.1021/jm00199a009; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BRUMMELKAMP TR, 2002, SCIENCE, V21, P21; Choi KS, 2005, BIOCHEM BIOPH RES CO, V328, P206, DOI 10.1016/j.bbrc.2004.11.172; CLIFFORD A, 1995, CANCER RES, V55, P1680; DON S, 1975, CANCER RES, V35, P3618; Feith DJ, 2001, CANCER RES, V61, P6073; Fong LYY, 2003, CANCER RES, V63, P3945; FUJITA K, 1982, BIOCHEM J, V204, P647, DOI 10.1042/bj2040647; Gandre S, 2002, EUR J BIOCHEM, V269, P1316, DOI 10.1046/j.1432-1033.2002.02774.x; GAZDAR AF, 1976, NATURE, V262, P696, DOI 10.1038/262696a0; Gerner EW, 2004, NAT REV CANCER, V4, P781, DOI 10.1038/nrc1454; GILMOUR SK, 1985, J BIOL CHEM, V260, P6439; HADDOX MK, 1980, CANCER RES, V40, P604; HE Y, 1994, BIOCHEM BIOPH RES CO, V203, P608, DOI 10.1006/bbrc.1994.2226; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; HOLTTA E, 1993, J CELL BIOL, V122, P903, DOI 10.1083/jcb.122.4.903; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; Janne J, 1983, Spec Top Endocrinol Metab, V5, P227; JANNE J, 1991, ANN MED, V23, P241, DOI 10.3109/07853899109148056; Jung MH, 2000, GENOMICS, V69, P281, DOI 10.1006/geno.2000.6338; KAHANA C, 1984, P NATL ACAD SCI-BIOL, V81, P3645, DOI 10.1073/pnas.81.12.3645; KATZ A, 1989, EMBO J, V8, P1163, DOI 10.1002/j.1460-2075.1989.tb03487.x; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KITANI T, 1989, BIOCHIM BIOPHYS ACTA, V991, P44, DOI 10.1016/0304-4165(89)90026-3; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; LUK GD, 1984, NEW ENGL J MED, V311, P80, DOI 10.1056/NEJM198407123110202; MAMROUDKIDRON E, 1994, EUR J BIOCHEM, V226, P547, DOI 10.1111/j.1432-1033.1994.tb20079.x; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MEGOSH L, 1995, CANCER RES, V55, P4205; MITCHELL JLA, 1994, BIOCHEM J, V299, P19, DOI 10.1042/bj2990019; Mitchell JLA, 2002, BIOCHEM J, V366, P663, DOI 10.1042/BJ20011612; Moinard C, 2005, CLIN NUTR, V24, P184, DOI 10.1016/j.clnu.2004.11.001; MOSHIER JA, 1993, CANCER RES, V53, P2618; MURAKAMI Y, 1989, BIOCHEM J, V259, P839, DOI 10.1042/bj2590839; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; Murakami Y, 1996, J BIOL CHEM, V271, P3340, DOI 10.1074/jbc.271.7.3340; Nilsson J, 2000, BIOCHEM J, V346, P699, DOI 10.1042/0264-6021:3460699; Nilsson JA, 2005, CANCER CELL, V7, P433, DOI 10.1016/j.ccr.2005.03.036; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1995, J CELL BIOCHEM, P132; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; Sakata K, 2000, BIOCHEM J, V347, P297, DOI 10.1042/0264-6021:3470297; Sakata K, 1997, BIOCHEM BIOPH RES CO, V238, P415, DOI 10.1006/bbrc.1997.7266; Schaner ME, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-26; Seiler N, 1970, Methods Biochem Anal, V18, P259, DOI 10.1002/9780470110362.ch5; SHANTZ LM, 1994, CANCER RES, V54, P2313; Shantz LM, 1998, CANCER RES, V58, P2748; Shantz LM, 2004, BIOCHEM J, V377, P257, DOI 10.1042/BJ20030778; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SUZUKI T, 1994, P NATL ACAD SCI USA, V91, P8930, DOI 10.1073/pnas.91.19.8930; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TOBIAS KE, 1993, BIOCHEMISTRY-US, V32, P5842, DOI 10.1021/bi00073a017; TONIN PN, 1989, ONCOGENE, V4, P1117; Valasinas A, 2003, BIOORGAN MED CHEM, V11, P4121, DOI 10.1016/S0968-0896(03)00453-X; van Duin M, 2005, GENE CHROMOSOME CANC, V44, P438, DOI 10.1002/gcc.20259; YUSPA SH, 1976, NATURE, V262, P402, DOI 10.1038/262402a0	61	55	67	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2006	25	37					5163	5172		10.1038/sj.onc.1209521	http://dx.doi.org/10.1038/sj.onc.1209521			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16568078				2022-12-28	WOS:000240063700009
J	Estecio, MRH; Youssef, EM; Rahal, P; Fukuyama, EE; Gois, JF; Maniglia, JV; Goloni-Bertollo, EM; Issa, JPJ; Tajara, EH				Estecio, M. R. H.; Youssef, E. M.; Rahal, P.; Fukuyama, E. E.; Gois-Filho, J. F.; Maniglia, J. V.; Goloni-Bertollo, E. M.; Issa, J-P J.; Tajara, E. H.			LHX6 is a sensitive methylation marker in head and neck carcinomas	ONCOGENE			English	Article						DNA methylation; head and neck cancer; solid tumors; early diagnosis; circulating DNA	DNA METHYLATION; PROMOTER HYPERMETHYLATION; CELL CARCINOMAS; CANCER PATIENTS; GENOMIC DNA; GENES; IDENTIFICATION; EXPRESSION; SEQUENCES; FREQUENT	Head and neck cancer remains a morbid and often fatal disease and at the present time few effective molecular markers have been identified. The purpose of the present work was to identify new molecular markers for head and neck squamous cell carcinoma (HNSCC). We applied methylation-sensitive arbitrarily primed PCR (MS/APPCR) to isolate sequences differentially methylated in HNSCC. The most frequently hypermethylated fragment we found maps close to a cytosine guanine dinucleotide (CpG) island on chromosome 9q33.2, and hypermethylation of this CpG island was associated with transcriptional silencing of an alternative transcript of the LHX6 gene. Using combined bisulfite restriction analysis (COBRA), hypermethylation of this fragment was detected in 13 of 14 (92.8%) HNSCC cell lines studied and 21 of 32 (65.6%) primary tumors, whereas little or no methylation was seen in 10 normal oral mucosa samples. We extended this investigation to other cancer cell lines and methylation was found in those derived from colon, breast, leukemia and lung, and methylation was also found in 12/14 primary colon tumors. These findings suggest that differentially methylated (DIME)-6 hypermethylation is a good cancer marker in HNSCC as well as in other kinds of neoplasias and confirm the importance of searching for markers of epigenetic dysregulation in cancer.	Sch Med, FAMERP, Dept Mol Biol, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil; Sch Med, FAMERP, Dept Surg, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil; Sch Med, FAMERP, Dept Mol Biol, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil; UNESP, IBILCE, Dept Biol, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil; Arnaldo Vieira Carvalho Hosp, Dept Head & Neck & Skull Base Surg, Sao Paulo, Brazil; Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA	Universidade de Sao Paulo; Faculdade de Medicina de Sao Jose do Rio Preto (FAMERP); Universidade de Sao Paulo; Faculdade de Medicina de Sao Jose do Rio Preto (FAMERP); Universidade de Sao Paulo; Faculdade de Medicina de Sao Jose do Rio Preto (FAMERP); Universidade Estadual Paulista; University of Texas System; UTMD Anderson Cancer Center	Tajara, EH (corresponding author), Sch Med, FAMERP, Dept Mol Biol, Av Brig Faria Lima 5416, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil.	tajara@famerp.br	Goloni-Bertollo, Eny Maria/B-8405-2012; Maniglia, José V/K-3129-2016; Tajara, Eloiza H/G-7586-2012; Rahal, Paula/D-3871-2012	Goloni-Bertollo, Eny Maria/0000-0002-2622-4673; Maniglia, José V/0000-0002-9765-2659; Tajara, Eloiza H/0000-0002-2603-2057; Rahal, Paula/0000-0001-5693-6148; Estecio, Marcos/0000-0002-6874-7413; Issa, Jean-Pierre/0000-0003-2258-5030	NCI NIH HHS [R33CA89837] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R33CA089837] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alves G, 1996, GENE, V176, P39, DOI 10.1016/0378-1119(96)00205-3; Casiglia Jeffrey, 2001, General Dentistry, V49, P72; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Esteller M, 1999, CANCER RES, V59, P67; Florl AR, 1999, BRIT J CANCER, V80, P1312, DOI 10.1038/sj.bjc.6690524; Gonzalgo ML, 1997, CANCER RES, V57, P594; Grati FR, 2000, CANCER GENET CYTOGEN, V118, P57, DOI 10.1016/S0165-4608(99)00199-5; Grigoriou M, 1998, DEVELOPMENT, V125, P2063; International Union Against Cancer, 1992, UICC TNM ATL ILL GUI, V3rd, P50; Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0; Jones P A, 1990, Adv Cancer Res, V54, P1, DOI 10.1016/S0065-230X(08)60806-4; KAWAI J, 1993, NUCLEIC ACIDS RES, V21, P5604, DOI 10.1093/nar/21.24.5604; Li J, 2005, CANCER-AM CANCER SOC, V104, P771, DOI 10.1002/cncr.21215; Macluskey M, 2000, Dent Update, V27, P148; Reichart P A, 2001, Clin Oral Investig, V5, P207, DOI 10.1007/s00784-001-0132-5; Shintani S, 2001, ORAL ONCOL, V37, P498, DOI 10.1016/S1368-8375(00)00142-1; Toyota M, 1999, CANCER RES, V59, P2307; Viswanathan M, 2003, INT J CANCER, V105, P41, DOI 10.1002/ijc.11028; Wong DTW, 1996, CRIT REV ORAL BIOL M, V7, P319, DOI 10.1177/10454411960070040201; Wong IHN, 1999, CANCER RES, V59, P71; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Xu J, 1998, CANCER-AM CANCER SOC, V83, P204, DOI 10.1002/(SICI)1097-0142(19980715)83:2<204::AID-CNCR2>3.0.CO;2-Q; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	23	42	44	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					5018	5026		10.1038/sj.onc.1209509	http://dx.doi.org/10.1038/sj.onc.1209509			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16732332				2022-12-28	WOS:000239921300007
J	Nguyen-Khac, F; Della Valle, V; Lopez, RG; Ravet, E; Mauchauffe, M; Friedman, AD; Huang, LE; Fichelson, S; Ghysdael, J; Bernard, OA				Nguyen-Khac, F.; Della Valle, V.; Lopez, R. G.; Ravet, E.; Mauchauffe, M.; Friedman, A. D.; Huang, L. E.; Fichelson, S.; Ghysdael, J.; Bernard, O. A.			Functional analyses of the TEL-ARNT fusion protein underscores a role for oxygen tension in hematopoietic cellular differentiation	ONCOGENE			English	Article						TEL/ETV6; ARNT; transcription factor; leukemia; differentiation block	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; ACUTE MYELOID-LEUKEMIA; ENDOTHELIAL-CELLS; TUMOR-SUPPRESSOR; FACTOR 1-ALPHA; TRANSCRIPTION; GROWTH; TRANSLOCATION; METABOLISM; ACTIVATION	The transcription factor hypoxia inducible factor 1 (HIF1), an HIF1 alpha-aryl hydrocarbon receptor nuclear translocator ( ARNT) dimeric factor, is essential to the cellular response to hypoxia. We described a t(1;12)(q21;p13) chromosomal translocation in human acute myeloblastic leukemia that involves the translocated Ets leukemia (TEL/ETV6) and the ARNT genes and results in the expression of a TEL-ARNT fusion protein. Functional studies show that TEL-ARNT interacts with HIF1 alpha and the complex binds to consensus hypoxia response element. In low oxygen tension conditions, the HIF1 alpha/TEL-ARNT complex does not activate transcription but exerts a dominant-negative effect on normal HIF1 activity. Differentiation of normal human CD34+ progenitors cells along all the erythrocytic, megakaryocytic and granulocytic pathways was accelerated in low versus high oxygen tension conditions. Murine 32Dcl3 myeloid cells also show accelerated granulocytic differentiation in low oxygen tension in response to granulocyte colony-stimulating factor. Interestingly, stable expression of the TEL-ARNT in 32Dcl3 subclones resulted in impaired HIF1-mediated transcriptional response and inhibition of differentiation enhancement in hypoxic conditions. Taken together, our results underscore the role of oxygen tension in the modulation of normal hematopoietic differentiation, whose targeting can participate in human malignancies.	Grp Hosp Pitie Salpetriere, Serv Hematol Biol, F-75013 Paris, France; Univ Paris 05, INSERM, Hop Necker Enfants Malad, IRNEM, Paris, France; CNRS, Inst Curie, UMR 146, F-91405 Orsay, France; CNRS, Inst Cochin Genet Mol, Dept Hematol, INSERM,U567,UMR 8104, Paris, France; INSERM, U674, Paris, France; Johns Hopkins Oncol Ctr, Div Pediat Oncol, Baltimore, MD USA; NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Nguyen-Khac, F (corresponding author), Grp Hosp Pitie Salpetriere, Serv Hematol Biol, Pavillon Laveran 47-83 Bd Hop, F-75013 Paris, France.	florence.nguyen@psl.aphp.fr	GHYSDAEL, Jacques/F-3377-2013; Bernard, Olivier A./E-5721-2016	Bernard, Olivier/0000-0002-0463-9747; Nguyen-Khac, Florence/0000-0003-3107-6668; Huang, Eric/0000-0002-6444-1708				Acker T, 2005, CANCER CELL, V8, P131, DOI 10.1016/j.ccr.2005.07.003; Adelman DM, 1999, GENE DEV, V13, P2478, DOI 10.1101/gad.13.19.2478; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Ciofani M, 2005, NAT IMMUNOL, V6, P881, DOI 10.1038/ni1234; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jiang Y, 2005, LEUKEMIA, V19, P1239, DOI 10.1038/sj.leu.2403734; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; Kline DD, 2002, P NATL ACAD SCI USA, V99, P821, DOI 10.1073/pnas.022634199; Kojima H, 2002, P NATL ACAD SCI USA, V99, P2170, DOI 10.1073/pnas.052706699; Kotch LE, 1999, DEV BIOL, V209, P254, DOI 10.1006/dbio.1999.9253; Kroon ME, 2001, J CELL SCI, V114, P825; Lacaud G, 2002, BLOOD, V100, P458, DOI 10.1182/blood-2001-12-0321; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Li J, 2002, J CELL SCI, V115, P1951; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Liu W, 2006, BLOOD, V107, P698, DOI 10.1182/blood-2005-03-1278; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Maxwell PH, 2001, CURR OPIN GENET DEV, V11, P293, DOI 10.1016/S0959-437X(00)00193-3; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Ramirez-Bergeron DL, 2004, DEVELOPMENT, V131, P4623, DOI 10.1242/dev.01310; Rubnitz JE, 1999, LEUKEMIA, V13, P6, DOI 10.1038/sj.leu.2401258; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181; Salomon-Nguyen F, 2000, P NATL ACAD SCI USA, V97, P6757, DOI 10.1073/pnas.120162297; Semenza GL, 2000, GENE DEV, V14, P1983; Speck NA, 2001, CURR OPIN HEMATOL, V8, P192, DOI 10.1097/00062752-200107000-00002; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zelzer E, 2001, MECH DEVELOP, V106, P97, DOI 10.1016/S0925-4773(01)00428-2	45	17	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2006	25	35					4840	4847		10.1038/sj.onc.1209503	http://dx.doi.org/10.1038/sj.onc.1209503			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16547490				2022-12-28	WOS:000239687100002
J	Robinson, HMR; Jones, R; Walker, M; Zachos, G; Brown, R; Cassidy, J; Gillespie, DAF				Robinson, H. M. R.; Jones, R.; Walker, M.; Zachos, G.; Brown, R.; Cassidy, J.; Gillespie, D. A. F.			Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil	ONCOGENE			English	Article						Chk1; 5-fluorouracil; cell cycle checkpoint	DNA-DAMAGE; CHECKPOINT ABROGATION; CHK1; MECHANISMS; PATHWAYS; ARREST; ACTIVATION; SURVIVAL; CANCER; RNA	Chk1 plays a crucial role in the DNA damage and replication checkpoints in vertebrates and may therefore be an important determinant of tumour cell responses to genotoxic anticancer drugs. To evaluate this concept we compared the effects of the nucleoside analogue 5-fluorouracil (5FU) on cell cycle progression and clonogenic survival in DT40 B-lymphoma cells with an isogenic mutant derivative in which Chk1 function was ablated by gene targeting. We show that 5FU activates Chk1 in wild-type DT40 cells and that 5FU-treated cells accumulate in the S phase of the cell cycle due to slowing of the overall rate of DNA replication. In marked contrast, Chk1-deficient DT40 cells fail to slow DNA replication upon initial exposure to 5FU, despite equivalent inhibition of the target enzyme thymidylate synthase, and instead accumulate progressively in the G1 phase of the following cell cycle. This G1 accumulation cannot be reversed rapidly by exogenous thymidine or removal of 5FU, and is associated with increased incorporation of 5FU into genomic DNA and severely diminished clonogenic survival. Taken together, these results demonstrate that a Chk1-dependent replication checkpoint which slows S phase progression can protect tumour cells against the cytotoxic effects of 5FU.	Univ Glasgow, Canc Res Campaign Beatson Lab, Inst Biomed & Life Sci, Glasgow G61 1BD, Lanark, Scotland; Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; Univ Glasgow, CRUK Ctr Oncol & Appl Pharmacol, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute; University of Glasgow; Beatson Institute; Beatson Institute; University of Glasgow	Gillespie, DAF (corresponding author), Univ Glasgow, Canc Res Campaign Beatson Lab, Inst Biomed & Life Sci, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	d.gillespie@beatson.gla.ac.uk	Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544; Brown, Robert/0000-0001-7960-5755				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; GLAZER RI, 1982, MOL PHARMACOL, V21, P468; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; HEIDELBERGER C, 1983, ADV ENZYMOL RAMB, V54, P57; INGRAHAM HA, 1986, BIOCHEMISTRY-US, V25, P3225, DOI 10.1021/bi00359a022; INGRAHAM HA, 1980, CANCER RES, V40, P998; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; KUFE DW, 1981, J BIOL CHEM, V256, P9802; Liu XJ, 2005, CANCER RES, V65, P6874, DOI 10.1158/0008-5472.CAN-05-0288; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; MAURO DJ, 1993, MOL PHARMACOL, V43, P854; Meyers M, 2005, J BIOL CHEM, V280, P5516, DOI 10.1074/jbc.M412105200; Meyers M, 2001, CANCER RES, V61, P5193; Morgan MA, 2005, CANCER RES, V65, P6835, DOI 10.1158/0008-5472.CAN-04-2246; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Rhind N, 2000, J CELL SCI, V113, P3889; Sampath D, 2003, ONCOGENE, V22, P9063, DOI 10.1038/sj.onc.1207229; SANTI DV, 1974, BIOCHEMISTRY-US, V13, P471, DOI 10.1021/bi00700a012; Shi Z, 2001, CANCER RES, V61, P1065; Tajima A, 2004, GASTROENTEROLOGY, V127, P1678, DOI 10.1053/j.gastro.2004.10.001; Xiao Z, 2005, ONCOGENE, V24, P1403, DOI 10.1038/sj.onc.1208309; Zachos G, 2005, MOL CELL BIOL, V25, P563, DOI 10.1128/MCB.25.2.563-574.2005; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	27	40	40	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	39					5359	5369		10.1038/sj.onc.1209532	http://dx.doi.org/10.1038/sj.onc.1209532			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16619043				2022-12-28	WOS:000240144900001
J	Bianchi, T; Rufer, N; MacDonald, HR; Migliaccio, M				Bianchi, T.; Rufer, N.; MacDonald, H. R.; Migliaccio, M.			The tumor suppressor p16(Ink4a) regulates T lymphocyte survival	ONCOGENE			English	Article						p16(Ink4a); T lymphocyte; apoptosis; cell stress	OXIDATIVE-STRESS; INK4 FAMILY; APOPTOSIS; MICE; TUMORIGENESIS; FIBROBLASTS; SENESCENCE; EXPRESSION; INHIBITORS; DEATH	In contrast to other cell cycle inhibitors, the tumor suppressor p16(Ink4a) is not detectable or expressed at very low levels in embryonic and adult mouse tissues, and therefore it has often been considered as a specialized checkpoint protein that does not participate in the control of normal cell cycle progression. However, Ink4a(-/-) mice possess increased thymus size and cellularity, thus suggesting the involvement of p16(Ink4a) in the control of thymocyte proliferation. In this study, we found increased numbers of CD8 and CD4 T lymphocytes in thymus and spleen from Ink4a(-/-) mice. Unexpectedly, this was not related to an increase in T-cell division rates, which were similar in lymphoid organs of Ink4a(-/-) and wild-type mice. In contrast, T-cell apoptosis rates were significantly decreased in thymus and spleen from Ink4a(-/-) mice. Moreover, whereas p16(Ink4a)-deficient and wild-type T cells were equally sensitive to Fas or TCR-mediated apoptosis, the former were clearly more resistant to apoptosis induced by oxidative stress or gamma irradiation. Our results indicate that p16(Ink4a) function is associated with T-cell apoptosis, and subsequently contributes to the control of T-cell population size in lymphoid organs.	Swiss Inst Expt Canc Res, NCCR, Mol Oncol Program, Swiss Natl Sci Fdn, CH-1066 Epalinges, Switzerland; Ludwig Inst Canc Res, CH-1066 Epalinges, Switzerland	Swiss Institute Experimental Cancer Research; Ludwig Institute for Cancer Research	Migliaccio, M (corresponding author), Swiss Inst Expt Canc Res, NCCR, Mol Oncol Program, Swiss Natl Sci Fdn, Ch Boveresses 155, CH-1066 Epalinges, Switzerland.	marcomv@romandie.com						Al-Mohanna MA, 2004, ONCOGENE, V23, P201, DOI 10.1038/sj.onc.1206927; Amstad PA, 2001, REDOX REP, V6, P351, DOI 10.1179/135100001101536535; Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309; Azenabor AA, 1999, J APPL PHYSIOL, V86, P1823, DOI 10.1152/jappl.1999.86.6.1823; Cayota A, 1996, BLOOD, V87, P4746, DOI 10.1182/blood.V87.11.4746.bloodjournal87114746; Cemerski S, 2003, EUR J IMMUNOL, V33, P2178, DOI 10.1002/eji.200323898; Chazal M, 2002, ONCOGENE, V21, P2652, DOI 10.1038/sj.onc.1205349; Chen JH, 2004, J BIOL CHEM, V279, P49439, DOI 10.1074/jbc.M409153200; Cope AP, 2002, ARTHRITIS RES THER, V4, pS197, DOI 10.1186/ar557; de Magalhaes JP, 2002, FEBS LETT, V523, P157, DOI 10.1016/S0014-5793(02)02973-3; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; Hingorani R, 2000, J IMMUNOL, V164, P4032, DOI 10.4049/jimmunol.164.8.4032; Holler N, 2003, MOL CELL BIOL, V23, P1428, DOI 10.1128/MCB.23.4.1428-1440.2003; Kim HJ, 2005, J IMMUNOL, V175, P2948, DOI 10.4049/jimmunol.175.5.2948; Lagresle C, 2002, J IMMUNOL, V168, P2325, DOI 10.4049/jimmunol.168.5.2325; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; Marrack P, 2004, ANNU REV IMMUNOL, V22, P765, DOI 10.1146/annurev.immunol.22.012703.104554; Migliaccio M, 2005, J IMMUNOL, V174, P3335, DOI 10.4049/jimmunol.174.6.3335; Quadrilatero J, 2004, BIOCHEM BIOPH RES CO, V319, P894, DOI 10.1016/j.bbrc.2004.05.068; Remans PHJ, 2004, J IMMUNOL, V173, P920, DOI 10.4049/jimmunol.173.2.920; Rodriguez-Mora OG, 2005, FREE RADICAL BIO MED, V38, P1653, DOI 10.1016/j.freeradbiomed.2005.02.035; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Sachs Z, 2004, J VIROL, V78, P3304, DOI 10.1128/JVI.78.7.3304-3311.2004; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	29	18	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2006	25	29					4110	4115		10.1038/sj.onc.1209437	http://dx.doi.org/10.1038/sj.onc.1209437			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16491120				2022-12-28	WOS:000238802400011
J	Cayrol, C; Clerc, P; Bertrand, C; Gigoux, V; Portolan, G; Fourmy, D; Dufresne, M; Seva, C				Cayrol, C.; Clerc, P.; Bertrand, C.; Gigoux, V.; Portolan, G.; Fourmy, D.; Dufresne, M.; Seva, C.			Cholecystokinin-2 receptor modulates cell adhesion through beta 1-integrin in human pancreatic cancer cells	ONCOGENE			English	Article						gastrin; integrin; pancreatic cancer; cell adhesion	GROWTH-FACTOR ACTION; TYROSINE PHOSPHORYLATION; CYCLOOXYGENASE-2 EXPRESSION; MOLECULAR-MECHANISMS; SIGNALING PATHWAY; MURINE PANCREAS; MESSENGER-RNA; GASTRIN; INTEGRIN; ACTIVATION	Several lines of evidence suggest that gastrin and the CCK-2 receptor (CCK2R) could contribute to pancreatic carcinogenesis by modulating processes such as proliferation, cell adhesion or migration. In the current study, we used a 'cancer gene array' and identified beta 1-integrin subunit as a new gastrin-regulated gene in human pancreatic cancer cells. We also demonstrated that Src family kinases and the phosphatidylinositol-3-kinase (PI-3-kinase) pathway play a crucial role in the expression of beta 1-integrin induced by gastrin. Our results also showed that gastrin modulates cell-substrate adhesion via beta 1-integrin. Indeed, using blocking anti-beta 1-integrin monoclonal antibodies, we completely reversed the increase in cell substrate adhesion induced by gastrin. In addition, we observed that in response to gastrin, beta 1-integrin is tyrosine phosphorylated by Src family kinases and associates with paxillin, a scaffold protein involved in focal adhesion and integrin signalling. This mechanism might be involved in gastrin-induced cell adhesion. Moreover, we showed in vivo that targeted CCK2R expression in the pancreas of Elas-CCK2 mice leads to the overexpression of beta 1-integrin. This process may contribute to pancreatic tumour development observed in these transgenic animals.	INSERM, U531, IFR31, Inst Louis Bugnard, F-31432 Toulouse 4, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Seva, C (corresponding author), INSERM, U531, IFR31, Inst Louis Bugnard, F-31432 Toulouse 4, France.	sevac@toulouse.inserm.fr	Gigoux, Véronique/AAE-6090-2020; Dufresne, Marlène/M-6332-2014; SEVA, Catherine/O-9166-2014; Fourmy, Daniel/AAE-3703-2019	Gigoux, Véronique/0000-0003-1408-5335; SEVA, Catherine/0000-0002-4265-7372; Fourmy, Daniel/0000-0001-9910-4827				Aly A, 2004, BBA-REV CANCER, V1704, P1, DOI 10.1016/j.bbcan.2004.01.004; Bierkamp C, 2004, AM J PATHOL, V165, P2135, DOI 10.1016/S0002-9440(10)63263-4; Bierkamp C, 2002, ONCOGENE, V21, P7656, DOI 10.1038/sj.onc.1205999; Butler B, 2005, J BIOL CHEM, V280, P14556, DOI 10.1074/jbc.M411765200; Calderwood DA, 2003, P NATL ACAD SCI USA, V100, P2272, DOI 10.1073/pnas.262791999; Calderwood DA, 2004, J CELL SCI, V117, P657, DOI 10.1242/jcs.01014; Caplin M, 2000, BRIT J SURG, V87, P1035, DOI 10.1046/j.1365-2168.2000.01488.x; CHAO JT, 2005, AM J PHYSL CELL PHYS; Chiu SJ, 2002, J BIOMED SCI, V9, P261, DOI 10.1159/000059427; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Clerc P, 2002, GASTROENTEROLOGY, V122, P428, DOI 10.1053/gast.2002.30984; Colucci R, 2005, BRIT J PHARMACOL, V144, P338, DOI 10.1038/sj.bjp.0706053; Daulhac L, 1999, J BIOL CHEM, V274, P20657, DOI 10.1074/jbc.274.29.20657; Daulhac L, 1999, FEBS LETT, V445, P251, DOI 10.1016/S0014-5793(99)00129-5; de Weerth A, 1999, HEPATO-GASTROENTEROL, V46, P472; Eliceiri BP, 2000, CANCER J, V6, pS245; Felsenfeld DP, 1999, NAT CELL BIOL, V1, P200, DOI 10.1038/12021; Ferrand A, 2005, J BIOL CHEM, V280, P10710, DOI 10.1074/jbc.M413309200; Ferrand A, 2004, EXP CELL RES, V301, P128, DOI 10.1016/j.yexcr.2004.07.037; Fontana MG, 1999, EUR SURG RES, V31, P406, DOI 10.1159/000008719; Fukui H, 1998, GASTROENTEROLOGY, V115, P1483, DOI 10.1016/S0016-5085(98)70027-7; Funahashi H, 2003, PANCREAS, V27, P190, DOI 10.1097/00006676-200308000-00013; Gao CL, 2005, J BIOL CHEM, V280, P15422, DOI 10.1074/jbc.M414457200; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; Grippo PJ, 2003, CANCER RES, V63, P2016; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Guo YS, 2002, J BIOL CHEM, V277, P48755, DOI 10.1074/jbc.M209016200; Halatsch ME, 1997, CANCER LETT, V118, P7, DOI 10.1016/S0304-3835(97)00217-6; Hocker M, 2004, ANN NY ACAD SCI, V1014, P97, DOI 10.1196/annals.1294.010; Jenkins AL, 1998, J BIOL CHEM, V273, P13878, DOI 10.1074/jbc.273.22.13878; Kaufmann R, 1997, NEUROPEPTIDES, V31, P573, DOI 10.1016/S0143-4179(97)90003-2; KowalskiChauvel A, 1996, J BIOL CHEM, V271, P26356, DOI 10.1074/jbc.271.42.26356; Lohr M, 1996, PANCREAS, V12, P248; Noble PJM, 2003, AM J PHYSIOL-GASTR L, V284, pG75, DOI 10.1152/ajpgi.00300.2002; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Prasad NB, 2005, CANCER RES, V65, P1619, DOI 10.1158/0008-5472.CAN-04-1413; Ross RS, 2004, CARDIOVASC RES, V63, P381, DOI 10.1016/j.cardiores.2004.04.027; Shimoyama S, 1995, INT J PANCREATOL, V18, P227; Sinclair NF, 2004, AM J PHYSIOL-GASTR L, V286, pG992, DOI 10.1152/ajpgi.00206.2002; Slice LW, 2003, J CELL PHYSIOL, V196, P454, DOI 10.1002/jcp.10304; Smith JP, 1999, CANCER LETT, V135, P107; Smith JP, 1998, INT J MOL MED, V2, P309; SMITH JP, 1995, AM J PHYSIOL-REG I, V268, pR135, DOI 10.1152/ajpregu.1995.268.1.R135; Smith JP, 1996, AM J PHYSIOL-REG I, V270, pR1078, DOI 10.1152/ajpregu.1996.270.5.R1078; Stepan VM, 1999, AM J PHYSIOL-GASTR L, V276, pG1363, DOI 10.1152/ajpgi.1999.276.6.G1363; Stepan VM, 1999, AM J PHYSIOL-GASTR L, V276, pG415, DOI 10.1152/ajpgi.1999.276.2.G415; TANIGUCHI T, 1994, ONCOGENE, V9, P861; Taniguchi T, 1996, ONCOGENE, V12, P1357; Todisco A, 1997, AM J PHYSIOL-GASTR L, V273, pG891, DOI 10.1152/ajpgi.1997.273.4.G891; Turner CE, 2000, J CELL SCI, V113, P4139; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Wagner M, 1998, GASTROENTEROLOGY, V115, P1254, DOI 10.1016/S0016-5085(98)70098-8; Wang JY, 1995, AM J PHYSIOL-CELL PH, V269, pC1474, DOI 10.1152/ajpcell.1995.269.6.C1474; Wroblewski LE, 2002, BIOCHEM J, V365, P873, DOI 10.1042/BJ20020068; Zhukova E, 2001, J CELL PHYSIOL, V189, P291, DOI 10.1002/jcp.10018	55	19	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	32					4421	4428		10.1038/sj.onc.1209484	http://dx.doi.org/10.1038/sj.onc.1209484			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16547500				2022-12-28	WOS:000239326000005
J	Egwuagu, CE; Li, W; Yu, CR; Lin, MCM; Chan, CC; Nakamura, T; Chepelinsky, AB				Egwuagu, CE; Li, W; Yu, CR; Lin, MCM; Chan, CC; Nakamura, T; Chepelinsky, AB			Interferon-gamma induces regression of epithelial cell carcinoma: critical roles of IRF-1 and ICSBP transcription factors	ONCOGENE			English	Article						IFN gamma; epithelial cell carcinoma; SV40 T-antigen; IRF-1; ICSBP; apoptosis	SEQUENCE-BINDING-PROTEIN; REGULATORY FACTOR-I; HUMAN-PAPILLOMAVIRUS INFECTION; FAS-MEDIATED APOPTOSIS; LARGE T-ANTIGEN; TRANSGENIC MICE; IFN-GAMMA; MAMMALIAN LENS; RISK FACTOR; EXPRESSION	We have developed an epithelial cell carcinoma model for studying efficacy of IFN gamma gene therapy and have identified components of IFN gamma-signaling pathway responsible for its direct anti-tumor actions. The tumor results from ectopic expression of SV40 Large T-Antigen ( SV40 T-Ag) oncogene in lens of transgenic mouse ( alpha T3) and complete regression of the tumor is induced by targeting expression of IFN gamma into malignant lens cells. In. ammatory cells are absent in lens of aT3 or DT ( co-expressing IFN gamma and SV40-T-Antigen) mice and the transformed lens cells are non-immunogenic, suggesting non- involvement of immunologic cells. We show that IFN gamma has direct growth-inhibitory effects on tumor cells, induces death of tumor cells by apoptosis and that these effects are mediated by two transcription factors, IRF-1 ( interferon-regulatory factor-1) and ICSBP ( interferon-consensus sequence-binding protein) induced by IFN gamma. Furthermore, stable transfection with ICSBP or IRF-1 construct inhibits lens carcinoma cell growth by upregulating Caspase-1, p21(WAF1) and p27 expression. In contrast, tumor progression in aT3 lens correlates with inhibition of IRF-1 and ICSBP expression. Our results suggest that IFN gamma gene therapy maybe effective in malignant diseases for which DNA tumor viruses are etiologic agents and that antitumor actions of IRF-1/ICSBP can be exploited therapeutically to circumvent adverse clinical effects associated with IFN therapy.	NEI, Lab Immunol Mol, Immunol Sect, NIH, Bethesda, MD 20892 USA; Mol & Dev Biol Natl Eye Inst, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Egwuagu, CE (corresponding author), NEI, Lab Immunol Mol, Immunol Sect, NIH, Bldg 10,Room 10N116,10 Ctr Dr, Bethesda, MD 20892 USA.	egwuaguc@nei.nih.gov		Yu, Cheng-Rong/0000-0001-7246-0362	NATIONAL EYE INSTITUTE [Z01EY000222, Z01EY000315, Z01EY000253, ZIAEY000315, ZIAEY000222] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Asamoto M, 2001, CANCER RES, V61, P4693; Awasthi N, 2004, INVEST OPHTH VIS SCI, V45, P222, DOI 10.1167/iovs.03-0571; Bjorge T, 2002, BRIT J CANCER, V87, P61, DOI 10.1038/sj.bjc.6600350; BOULTWOOD J, 1993, BLOOD, V82, P2611; Bowie ML, 2004, ONCOGENE, V23, P8743, DOI 10.1038/sj.onc.1208120; CHEPELINSKY AB, 1987, ENVIRON HEALTH PERSP, V75, P17, DOI 10.2307/3430571; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; De Vita VT, 2001, CANC PRINCIPLES PRAC; Detjen KM, 2001, GUT, V49, P251, DOI 10.1136/gut.49.2.251; Duan WM, 2005, ONCOGENE, V24, P1510, DOI 10.1038/sj.onc.1208229; Ebong S, 2004, MOL VIS, V10, P122; Ebong S, 2004, INVEST OPHTH VIS SCI, V45, P872, DOI 10.1167/iovs.03-0311; EGWUAGU CE, 1994, DEV BIOL, V166, P557, DOI 10.1006/dbio.1994.1337; Egwuagu CE, 1999, CLIN IMMUNOL, V91, P196, DOI 10.1006/clim.1999.4701; Egwuagu CE, 1999, J IMMUNOL, V162, P510; Gabril MY, 2005, MOL THER, V11, P348, DOI 10.1016/j.ymthe.2004.12.005; Garcia-Espana A, 2005, CANCER RES, V65, P1150, DOI 10.1158/0008-5472.CAN-04-2074; Garson K, 2003, J SOC GYNECOL INVEST, V10, P244, DOI 10.1016/S1071-5576(03)00073-X; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Horiuchi M, 1999, HYPERTENSION, V33, P162, DOI 10.1161/01.HYP.33.1.162; Hughes RS, 2005, AM J MED SCI, V329, P29; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; Janeway C.A., 1999, IMMUNOBIOLOGY IMMUNE; Jin M, 2004, J MED VIROL, V74, P668, DOI 10.1002/jmv.20219; JOLICOEUR C, 1994, P NATL ACAD SCI USA, V91, P6707, DOI 10.1073/pnas.91.14.6707; Jung YK, 1997, ONCOGENE, V14, P1207, DOI 10.1038/sj.onc.1200943; Kano A, 1999, BIOCHEM BIOPH RES CO, V257, P672, DOI 10.1006/bbrc.1999.0276; Lai JC, 1998, INVEST OPHTH VIS SCI, V39, P2049; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; Li WM, 1999, J BIOL CHEM, V274, P9686, DOI 10.1074/jbc.274.14.9686; Li WM, 1999, DEV BIOL, V210, P44, DOI 10.1006/dbio.1999.9267; Liu KB, 2003, J IMMUNOL, V170, P6329, DOI 10.4049/jimmunol.170.12.6329; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MCAVOY JW, 1980, DIFFERENTIATION, V17, P137, DOI 10.1111/j.1432-0436.1980.tb01091.x; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Mork J, 2001, NEW ENGL J MED, V344, P1125, DOI 10.1056/NEJM200104123441503; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; Pfeffer LM, 1998, CANCER RES, V58, P2489; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Schaeffer AJ, 2004, CANCER RES, V64, P538, DOI 10.1158/0008-5472.CAN-03-0124; Schreiber K, 2004, ONCOGENE, V23, P3972, DOI 10.1038/sj.onc.1207507; Sharf R, 1997, J BIOL CHEM, V272, P9785; Tagliaferri P, 2005, CANCER IMMUNOL IMMUN, V54, P1, DOI 10.1007/s00262-004-0549-1; TANIGUCHI T, 1995, J CANCER RES CLIN, V121, P516, DOI 10.1007/BF01197763; Tomita Y, 2003, INT J CANCER, V104, P400, DOI 10.1002/ijc.10956; Vilchez RA, 2004, CLIN MICROBIOL REV, V17, P495, DOI [10.1128/CMR.17.3.495-508.2004, 10.1128/cmr.17.3.495-508.2004]; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YAMADA T, 1990, CURR EYE RES, V9, P31, DOI 10.3109/02713689009000052; YE XH, 1994, P NATL ACAD SCI USA, V91, P3916, DOI 10.1073/pnas.91.9.3916; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; Yu CR, 2003, J BIOL CHEM, V278, P29752, DOI 10.1074/jbc.M300489200	54	42	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 22	2006	25	26					3670	3679		10.1038/sj.onc.1209402	http://dx.doi.org/10.1038/sj.onc.1209402			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16462767				2022-12-28	WOS:000238448300006
J	Wang, P; Greiner, TC; Lushnikova, T; Eischen, CM				Wang, P.; Greiner, T. C.; Lushnikova, T.; Eischen, C. M.			Decreased Mdm2 expression inhibits tumor development induced by loss of ARF	ONCOGENE			English	Article						Mdm2; ARF; p53; transformation; tumor	MYC-INDUCED LYMPHOMAGENESIS; CELL-CYCLE ARREST; P53-INDEPENDENT FUNCTIONS; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; SUPPRESSOR PROTEIN; DEFICIENT MICE; DNA-DAMAGE; P53; P19(ARF)	The tumor suppressor p14/p19(ARF) regulates Mdm2, which is known for controlling the p53 tumor suppressor. Here we report that loss of one allele of Mdm2 in cells that lack ARF resulted in a decreased rate of proliferation, fewer chromosomal aberrations, and suppression of Ras-induced transformation. Moreover, a haploinsufficiency of Mdm2 inhibited spontaneous tumor development in ARF-null mice. Remarkably, Mdm2(+/-) ARF(-/-) mice survived an average of 6 months longer than Mdm2(+/-) ARF(-/-) mice. The spectrum of tumors that arose in Mdm2(+/-) ARF(-/-) mice did not significantly differ from those that developed in mice lacking only ARF. However, the extended tumor latency allowed for the emergence of multiple primary tumors in a third of the Mdm2(+/-) ARF(-/-) mice, as compared to the single tumor type that arose in ARF null only mic e. Therefore, a decrease in Mdm2 levels restored regulation of critical cellular processes that are altered during transformation and that occur in the absence of ARF. Our findings also indicate that Mdm2 can function independently from ARF and imply that targeting Mdm2 in tumors that lack ARF expression should be an effective therapeutic approach.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA; Univ Nebraska, Ctr Med, Dept Pathol & Microbiol, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System	Eischen, CM (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc, 600 S 42nd St, Omaha, NE 68198 USA.	ceischen@unmc.edu			NCI NIH HHS [CA098139] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098139] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alt JR, 2005, J BIOL CHEM, V280, P18771, DOI 10.1074/jbc.M413387200; Alt JR, 2003, EMBO J, V22, P1442, DOI 10.1093/emboj/cdg133; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; de Rozieres S, 2000, ONCOGENE, V19, P1691, DOI 10.1038/sj.onc.1203468; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Eischen CM, 2004, ONCOGENE, V23, P8931, DOI 10.1038/sj.onc.1208052; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2002, CANCER RES, V62, P2184; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISCELLA M, 1993, ONCOGENE, V8, P1519; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Ganguli G, 2003, MOL CANCER RES, V1, P1027; Garcia-Cao I, 2002, EMBO J, V21, P6225, DOI 10.1093/emboj/cdf595; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Iwakuma T, 2003, MOL CANCER RES, V1, P993; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KAMB A, 1994, SCIENCE, V264, P440; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; LUNA RMD, 1995, NATURE, V378, P203; Martin-Caballero J, 2004, ONCOGENE, V23, P8231, DOI 10.1038/sj.onc.1207863; Matheu A, 2004, GENE DEV, V18, P2736, DOI 10.1101/gad.310304; MAYR GA, 1995, CANCER RES, V55, P2410; McDonnell TJ, 1999, J PATHOL, V188, P322, DOI 10.1002/(SICI)1096-9896(199907)188:3<322::AID-PATH372>3.0.CO;2-F; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Mendrysa SM, 2000, MOL CELL BIOL, V20, P2023, DOI 10.1128/MCB.20.6.2023-2030.2000; Moore L, 2003, ONCOGENE, V22, P7831, DOI 10.1038/sj.onc.1206985; O'Leary KA, 2004, MOL CELL BIOL, V24, P186, DOI 10.1128/MCB.24.1.186-191.2004; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Randle DH, 2001, P NATL ACAD SCI USA, V98, P9654, DOI 10.1073/pnas.171217498; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	46	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3708	3718		10.1038/sj.onc.1209411	http://dx.doi.org/10.1038/sj.onc.1209411			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16491126				2022-12-28	WOS:000238448300010
J	Malinge, S; Monni, R; Bernard, O; Penard-Lacronique, V				Malinge, S.; Monni, R.; Bernard, O.; Penard-Lacronique, V.			Activation of the NF-kappa B pathway by the leukemogenic TEL-Jak2 and TEL-Abl fusion proteins leads to the accumulation of antiapoptotic IAP proteins and involves IKK alpha	ONCOGENE			English	Article							BCR-ABL; TRANSCRIPTION FACTOR; MYELOPROLIFERATIVE DISEASE; TYROSINE PHOSPHORYLATION; LYMPHOBLASTIC-LEUKEMIA; CELL-RECEPTOR; BINDING-SITE; KINASE; EXPRESSION; INDUCE	Abnormal activation of tyrosine kinases and of signaling pathways they control plays a critical role in the neoplastic process of human hematopoietic malignancy. The nuclear factor-kappa B (NF-kappa B) pathway is one of the signalings activated by the TEL-Jak2 and TEL-Abl oncoproteins and required for their antiapoptotic activity. To define the signal relay responsible for this activation, we used mouse embryonic fibroblast (MEF) cells and observed that TEL-Jak2- and TEL-Abl-mediated NF-kappa B induction was abolished in cells lacking the I kappa B kinase (IKK)alpha but not in IKK beta(-/-) cells. Similar observations were performed with oncogenic forms of the FMS-like tyrosine kinase 3 (Flt-3) involved in the pathogenesis of one-third of acute myeloid leukemias. Rescue of TEL-Jak2-mediated NF-kappa B activation was obtained with a kinase-proficient form of IKK alpha in IKK alpha(-/-) MEF. Hematopoietic cells transformed by TEL-Jak2 and TEL-Abl showed sustained IKK alpha activity without promotion of NF-kappa B2/p100 processing, generally associated to IKK alpha functions. Furthermore, IAP1, IAP2 and XIAP, which are central regulators of the NF-kappa B-mediated survival pathway, were highly expressed in cells transformed by these oncoproteins. Our results indicate that these oncogenic tyrosine kinases preferentially use an IKK alpha-dependent mechanism to induce a persistent NF-kappa B activity and allow the production of antiapoptotic effectors that participate to their leukemogenic properties.	Hop Necker Enfants Malad, F-75743 Paris, France; INSERM, U528, Sect Rech, Inst Curie, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Penard-Lacronique, V (corresponding author), Hop Necker Enfants Malad, EMI 0210,Tour Pasteur,149 Rue Sevres, F-75743 Paris, France.	penard@necker.fr	Malinge, Sebastien/AAK-1158-2021; Penard-Lacronique, Virginie/R-1938-2019; Malinge, Sebastien/AAP-9452-2021; Penard-Lacronique, Virginie/E-5729-2016; Malinge, Sebastien/B-3507-2014; Bernard, Olivier A./E-5721-2016	Malinge, Sebastien/0000-0002-9533-7778; Penard-Lacronique, Virginie/0000-0001-9435-7331; Penard-Lacronique, Virginie/0000-0001-9435-7331; Malinge, Sebastien/0000-0002-9533-7778; Bernard, Olivier/0000-0002-0463-9747				Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Baumgartner B, 2002, LEUKEMIA, V16, P2062, DOI 10.1038/sj.leu.2402641; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Deng JO, 2002, CANCER CELL, V2, P323, DOI 10.1016/S1535-6108(02)00154-X; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Feinman R, 1999, BLOOD, V93, P3044; Fuchs SY, 2004, ONCOGENE, V23, P2028, DOI 10.1038/sj.onc.1207389; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Guasch G, 2001, MOL CELL BIOL, V21, P8129, DOI 10.1128/MCB.21.23.8129-8142.2001; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Hanson JL, 2003, J BIOL CHEM, V278, P34910, DOI 10.1074/jbc.M304189200; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huang WC, 2003, J IMMUNOL, V170, P4767, DOI 10.4049/jimmunol.170.9.4767; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Kashkar H, 2003, J EXP MED, V198, P341, DOI 10.1084/jem.20021279; Kelly LM, 2002, BLOOD, V99, P310, DOI 10.1182/blood.V99.1.310; Kirchner D, 2003, EXP HEMATOL, V31, P504, DOI 10.1016/S0301-472X(03)00069-9; Kordes U, 2000, LEUKEMIA, V14, P399, DOI 10.1038/sj.leu.2401705; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luftig M, 2004, P NATL ACAD SCI USA, V101, P141, DOI 10.1073/pnas.2237183100; Matta H, 2004, P NATL ACAD SCI USA, V101, P9399, DOI 10.1073/pnas.0308016101; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Million RP, 2004, MOL CELL BIOL, V24, P4685, DOI 10.1128/MCB.24.11.4685-4695.2004; Million RP, 2002, BLOOD, V99, P4568, DOI 10.1182/blood-2001-12-0244; Minami Y, 2003, BLOOD, V102, P2969, DOI 10.1182/blood-2002-12-3813; Monni R, 2001, ONCOGENE, V20, P849, DOI 10.1038/sj.onc.1204201; Mordmuller B, 2003, EMBO REP, V4, P82, DOI 10.1038/embor710; Nawata R, 2003, ONCOGENE, V22, P7774, DOI 10.1038/sj.onc.1206901; OMAHONY AM, 2004, J BIOL CHEM, V12, P12; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Perrotti D, 2004, ONCOGENE, V23, P3222, DOI 10.1038/sj.onc.1207543; Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745; Piccolella E, 2003, J IMMUNOL, V170, P2895, DOI 10.4049/jimmunol.170.6.2895; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Santos SCR, 2001, FEBS LETT, V497, P148; SAVAGE KJ, 2003, BLOOD, V106, P1392; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Tang ED, 2003, J BIOL CHEM, V278, P37297, DOI 10.1074/jbc.M303389200; Ten RM, 1999, J IMMUNOL, V163, P3851; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; Voss J, 2000, ONCOGENE, V19, P1684, DOI 10.1038/sj.onc.1203467; Weil R, 2004, CURR OPIN IMMUNOL, V16, P374, DOI 10.1016/j.coi.2004.03.003; Xiao GT, 2004, J BIOL CHEM, V279, P30099, DOI 10.1074/jbc.M401428200; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805	67	23	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3589	3597		10.1038/sj.onc.1209390	http://dx.doi.org/10.1038/sj.onc.1209390			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16434962				2022-12-28	WOS:000238448200011
J	Gu, Y; Siefring, JE; Wang, L; Chae, HD; Bailey, JR; Zheng, Y				Gu, Y.; Siefring, J. E.; Wang, L.; Chae, H-D; Bailey, J. R.; Zheng, Y.			Oncogenic Vav1 induces Rac-dependent apoptosis via inhibition of Bcl-2 family proteins and collaborates with p53 deficiency to promote hematopoietic progenitor cell proliferation	ONCOGENE			English	Article						Vav1 proto-oncogene; Rac GTPase; hematopoietic progenitor cell; proliferation; apoptosis	GUANINE-NUCLEOTIDE EXCHANGE; TYROSINE PHOSPHORYLATION; RHO GTPASE; T-CELLS; ACTIVATION; PROTOONCOGENE; EXPRESSION; SURVIVAL; GENE; MEMBER	Vav1 is an hematopoietic-specific Rho guanine nucleotide exchange factor coupling tyrosine kinase receptors and Rac GTPases, and has been implicated in transformation of fibroblasts and pancreas. To determine the biologic effect and oncogenic potential of Vav1 in hematopoietic lineages, we stably express oncogenic mutant of Vav1 in primary bone marrow cells using retrovirus-mediated gene transfer. Contrary to the growth stimulatory effects observed in. broblasts, oncogenic Vav1 inhibits hematopoietic stem cell/progenitor engraftment in vivo and progenitor cell expansion in vitro via inducing apoptosis. The oncogenic Vav1-induced apoptosis is associated with reduced expression of Bcl-2 and Bcl-xL proteins and effectively suppressed by transgenic overexpression of Bcl-2, suggesting Vav1-mediated signaling via Bcl-2 in apoptosis. Also, oncogenic Vav1 stimulates sustained activation of Rac GTPases and the biologic effects of oncogenic Vav1 are Rac-dependent. Further, when expressed in the p53-deficient cells, which express elevated Bcl-2 and Bcl-xL and are resistant to the apoptosis, oncogenic Vav1 enhances both proliferation and self-renewal of hematopoietic progenitor cells. These results demonstrate clear phenotypic differences between wild-type and p53(-/-) hematopoietic cells expressing oncogenic Vav1, and suggest oncogenic potential of Vav1-mediated pathways in primary hematopoietic cell when they collaborate with additional genetic hits that affect the p53 pathway.	Univ Cincinnati, Childrens Hosp, Coll Med, Med Ctr,Res Fdn,Div Expt Hematol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Gu, Y (corresponding author), Univ Cincinnati, Childrens Hosp, Coll Med, Med Ctr,Res Fdn,Div Expt Hematol, 3333 Burnet Ave,Mail Locat 7013, Cincinnati, OH 45229 USA.	yi.gu@cchmc.org	Chae, Hee-Don/D-2620-2011; Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NATIONAL CANCER INSTITUTE [K01CA107110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053943] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA107110] Funding Source: Medline; NIGMS NIH HHS [R01 GM53943] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; ALAI M, 1992, J BIOL CHEM, V267, P18021; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Betz R, 2003, NEUROSCI LETT, V339, P37, DOI 10.1016/S0304-3940(02)01457-X; Bronson SK, 1996, P NATL ACAD SCI USA, V93, P9067, DOI 10.1073/pnas.93.17.9067; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Debreceni B, 2004, J BIOL CHEM, V279, P3777, DOI 10.1074/jbc.M308282200; Dibbert B, 1998, BLOOD, V92, P778, DOI 10.1182/blood.V92.3.778.415k38_778_783; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; Esteve P, 1998, ONCOGENE, V17, P1855, DOI 10.1038/sj.onc.1202082; Fernandez-Zapico ME, 2005, CANCER CELL, V7, P39, DOI 10.1016/j.ccr.2004.11.024; Filippi MD, 2004, NAT IMMUNOL, V5, P744, DOI 10.1038/ni1081; Fujikawa K, 2003, J EXP MED, V198, P1595, DOI 10.1084/jem.20030874; Gakidis MAM, 2004, J CELL BIOL, V166, P273, DOI 10.1083/jcb.200404166; Gu Y, 2005, BLOOD, V105, P1467, DOI 10.1182/blood-2004-04-1604; Gu Y, 2003, SCIENCE, V302, P445, DOI 10.1126/science.1088485; Gu Y, 2001, J BIOL CHEM, V276, P15929, DOI 10.1074/jbc.M010445200; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Hanenberg H, 1997, HUM GENE THER, V8, P2193, DOI 10.1089/hum.1997.8.18-2193; Hornstein I, 2003, J PATHOL, V199, P526, DOI 10.1002/path.1314; Joneson T, 1999, MOL CELL BIOL, V19, P5892; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Kuhne MR, 2000, J BIOL CHEM, V275, P2185, DOI 10.1074/jbc.275.3.2185; Lassus P, 2000, ONCOGENE, V19, P2377, DOI 10.1038/sj.onc.1203553; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Manetz TS, 2001, MOL CELL BIOL, V21, P3763, DOI 10.1128/MCB.21.11.3763-3774.2001; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; MOLL J, 1991, ONCOGENE, V6, P863; Movilla N, 1999, MOL CELL BIOL, V19, P7870; NAKAHATA T, 1982, J CELL PHYSIOL, V111, P239, DOI 10.1002/jcp.1041110304; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; Nishida K, 1999, ONCOGENE, V18, P407, DOI 10.1038/sj.onc.1202301; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schuebel KE, 1996, ONCOGENE, V13, P363; SHIRSAT NV, 1990, ONCOGENE, V5, P769; Wahlers A, 2001, GENE THER, V8, P477, DOI 10.1038/sj.gt.3301426; Walmsley MJ, 2003, SCIENCE, V302, P459, DOI 10.1126/science.1089709; Wang XW, 1999, ANTICANCER RES, V19, P4759; Williams DA, 2000, BLOOD, V96, P1646; Yang FC, 2000, IMMUNITY, V12, P557, DOI 10.1016/S1074-7613(00)80207-1; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZMUIDZINAS A, 1995, EMBO J, V14, P1	47	7	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3963	3972		10.1038/sj.onc.1209427	http://dx.doi.org/10.1038/sj.onc.1209427			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16474842				2022-12-28	WOS:000238668800010
J	Landis, MD; Seachrist, DD; Abdul-Karim, FW; Keri, RA				Landis, M. D.; Seachrist, D. D.; Abdul-Karim, F. W.; Keri, R. A.			Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors	ONCOGENE			English	Article						gene expression profiling; ErbB2/Neu/HER2; transgenic mice; parity; breast cancer; mammary gland	BREAST-CANCER RISK; ATOMIC-BOMB SURVIVORS; ACID-COA LIGASE-4; LUTEINIZING-HORMONE; TRANSIENT INCREASE; NEU PROTOONCOGENE; EXPRESSION; CARCINOGENESIS; RECEPTOR; MICE	Epidemiological studies indicate that parity enhances HER2/ErbB2/Neu-induced breast tumorigenesis. Furthermore, recent studies using multiparous, ErbB2/Neu-overexpressing mouse mammary tumor virus (MMTV-Neu) mice have shown that parity induces a population of cells that are targeted for ErbB2/Neuinduced transformation. Although parity accelerates mammary tumorigenesis, the pattern of tumor development in multiparous MMTV-Neu mice remains stochastic, suggesting that additional events are required for ErbB2/Neu to cause mammary tumors. Whether such events are genetic in nature or reflective of the dynamic hormonal control of the gland that occurs with pregnancy remains unclear. We postulated that young age at pregnancy initiation or chronic trophic maintenance of mammary epithelial cells might provide a cellular environment that significantly increases susceptibility toErbB2/Neu-induced tumorigenesis. MMTV-Neu mice that were maintained pregnant or lactating beginning at 3 weeks of age demonstrated accelerated tumorigenesis, but this process was still stochastic, indicating that early pregnancy does not provide the requisite events of tumorigenesis. However, bitransgenic mice that were generated by breeding MMTV-Neu mice with a luteinizing hormone-overexpressing mouse model of ovarian hyperstimulation developed multifocal mammary tumors in an accelerated, synchronous manner compared to virgin MMTV-Neu animals. This synchrony of tumor development in the bitransgenic mice suggests that trophic maintenance of the mammary gland provides the additional events required for tumor formation and maintains the population of cells that are targeted by ErbB2/Neu for transformation. Both the synchrony of tumor appearance and the ability to characterize a window of commitment by ovariectomy/palpation studies permitted microarray analysis to evaluate changes in gene expression over a defined timeline that spans the progression from normal to preneoplastic mammary tissue. These approaches led to identification of several candidate genes whose expression changes in the mammary gland with commitment to ErbB2/Neu-induced tumorigenesis, suggesting that they may either be regulated by ErbB2/Neu and/or contribute to tumor formation.	Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Div Gen Med Sci Oncol, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Keri, RA (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 2109 Adelbert Rd RT300, Cleveland, OH 44106 USA.	ruth.keri@case.edu	Keri, Ruth/ABF-2209-2021	Keri, Ruth/0000-0002-1640-3088	NCI NIH HHS [R01-CA90398, P30 CA043703, R01 CA090398, P30-CA43703] Funding Source: Medline; NIGMS NIH HHS [GM08803, T32 GM008803] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090398, P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008803] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrechek ER, 2004, P NATL ACAD SCI USA, V101, P4984, DOI 10.1073/pnas.0306802101; Anisimov VN, 2003, CANCER LETT, V193, P49, DOI 10.1016/S0304-3835(02)00721-8; Beckmann MW, 1997, J MOL MED, V75, P429, DOI 10.1007/s001090050128; BOARD M, 1990, BIOCHEM J, V265, P503, DOI 10.1042/bj2650503; Boutros R, 2004, BIOCHEM BIOPH RES CO, V325, P1115, DOI 10.1016/j.bbrc.2004.10.112; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Cao Y, 2001, CANCER RES, V61, P8429; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Cardiff RD, 1999, J MAMMARY GLAND BIOL, V4, P105, DOI 10.1023/A:1018712905244; DUTU R, 1980, ACTA CYTOL, V24, P160; Gebre-Medhin M, 2001, AM J PATHOL, V158, P1217, DOI 10.1016/S0002-9440(10)64071-0; GUNZBURG WH, 1992, BIOCHEM J, V283, P625; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HANCOCK SL, 1993, J NATL CANCER I, V85, P25, DOI 10.1093/jnci/85.1.25; Hennighausen L, 2001, DEV CELL, V1, P467, DOI 10.1016/S1534-5807(01)00064-8; HENNIPMAN A, 1987, TUMOR BIOL, V8, P251, DOI 10.1159/000217529; Henry MD, 2004, ONCOGENE, V23, P6980, DOI 10.1038/sj.onc.1207827; KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115; Kero J, 2000, J CLIN INVEST, V105, P633, DOI 10.1172/JCI7716; Kurokawa Y, 2004, J EXP CLIN CANC RES, V23, P135; LAMBE M, 1994, NEW ENGL J MED, V331, P5, DOI 10.1056/NEJM199407073310102; Land CE, 2003, RADIAT RES, V160, P707, DOI 10.1667/RR3082; Landis MD, 2005, ONCOGENE, V24, P5173, DOI 10.1038/sj.onc.1208712; Liang YC, 2005, WORLD J GASTROENTERO, V11, P2557, DOI 10.3748/wjg.v11.i17.2557; Liu Q, 2002, CANCER CAUSE CONTROL, V13, P299, DOI 10.1023/A:1015287208222; Macheda ML, 2005, J CELL PHYSIOL, V202, P654, DOI 10.1002/jcp.20166; Mazurek S, 2002, BRIT J NUTR, V87, pS23, DOI [10.1079/BJN2001455, 10.1079/BJN2001454]; MCDERMOTT EWM, 1990, BRIT J SURG, V77, P1179, DOI 10.1002/bjs.1800771029; Milliken EL, 2002, ENDOCRINOLOGY, V143, P3671, DOI 10.1210/en.2002-220228; Reed W, 2003, INT J SURG PATHOL, V11, P65, DOI 10.1177/106689690301100201; RISMA KA, 1995, P NATL ACAD SCI USA, V92, P1322, DOI 10.1073/pnas.92.5.1322; Robertson C, 1997, INT J CANCER, V73, P1; Russo IH, 1998, J MAMMARY GLAND BIOL, V3, P49, DOI 10.1023/A:1018770218022; Russo J, 1996, BREAST CANCER RES TR, V39, P7, DOI 10.1007/BF01806074; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SINGLETARY KW, 1991, NUTR CANCER, V16, P13, DOI 10.1080/01635589109514136; Stighall M, 2005, INT J CANCER, V115, P403, DOI 10.1002/ijc.20875; Sung YK, 2003, CANCER SCI, V94, P421, DOI 10.1111/j.1349-7006.2003.tb01458.x; TOKUNAGA M, 1979, J NATL CANCER I, V62, P1347; TREURNIET HF, 1992, CANCER RES, V52, P2344; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wu KD, 2002, CANCER RES, V62, P6376; Yang XH, 2003, CANCER RES, V63, P2425	46	21	22	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3325	3334		10.1038/sj.onc.1209365	http://dx.doi.org/10.1038/sj.onc.1209365			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16434967	Green Accepted			2022-12-28	WOS:000237951200011
J	Yue, J; Xiong, W; Ferrell, JE				Yue, J; Xiong, W; Ferrell, JE			B-Raf and C-Raf are required for Ras-stimulated p42 MAP kinase activation in Xenopus egg extracts	ONCOGENE			English	Article						B-Raf; C-Raf; Mos; Ras; p42; MAPK; MEK1	SPINDLE ASSEMBLY CHECKPOINT; MAMMALIAN SOMATIC-CELLS; PROTEIN-KINASE; OOCYTE MATURATION; A-RAF; MITOTIC PROGRESSION; SIGNALING PATHWAY; P34CDC2 KINASE; BRAF MUTATIONS; ONCOGENIC RAS	During mitosis, a select pool of MEK1 and p42/p44 MAPK becomes activated at the kinetochores and spindle poles, without substantial activation of the bulk of the cytoplasmic p42/p44 MAPK. Recently, we set out to identify the MAP kinase kinase kinase ( MAPKKK) responsible for this mitotic activation, using cyclin-treated Xenopus egg extracts as a model system, and presented evidence that Mos was the relevant MAPKKK. However, a second MAPKKK distinct from Mos was readily detectable as well. Here, we partially purify this second MAPKKK and identify it as B-Raf. No changes in the activity of B-Raf were detectable during progesterone-induced oocyte maturation, after egg fertilization, or during the early embryonic cell cycle, arguing against a role for B-Raf in the mitotic activation of MEK1 and p42 MAPK. Ras proteins can bring about activation of MEK1 and p42 MAPK in extracts, and Ras may contribute to signaling from the classical progesterone receptor during oocyte maturation and from receptor tyrosine kinases during early embryogenesis. We found that both B-Raf and C-Raf, but not Mos, are required for Ras-induced MEK1 and p42 MAPK activation. These data indicate that two upstream stimuli, active Ras and active Cdc2, utilize different MAPKKKs to activate MEK1 and p42 MAPK.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Yue, J (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, CCSR Room 3160,269 W Campus Dr, Stanford, CA 94305 USA.	jyue@stanford.edu	Yue, Jianbo/AAC-4588-2019; Yue, Jianbo/C-4463-2009; Yue, Jianbo/K-8002-2015	Yue, Jianbo/0000-0001-6384-5447	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046383] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46383] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; Bagowski CP, 2001, J BIOL CHEM, V276, P1459, DOI 10.1074/jbc.M008050200; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; Bayaa M, 2000, P NATL ACAD SCI USA, V97, P12607, DOI 10.1073/pnas.220302597; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; CATLING AD, 1994, J BIOL CHEM, V269, P30014; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Colanzi A, 2003, J CELL BIOL, V161, P27, DOI 10.1083/jcb.200208099; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; EYCHENE A, 1995, ONCOGENE, V10, P1159; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; Ferrell JE, 1999, BIOESSAYS, V21, P866, DOI 10.1002/(SICI)1521-1878(199910)21:10<866::AID-BIES9>3.0.CO;2-1; Ferrell JE, 1999, BIOESSAYS, V21, P833, DOI 10.1002/(SICI)1521-1878(199910)21:10<833::AID-BIES5>3.0.CO;2-P; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; FUKUDA M, 1994, J BIOL CHEM, V269, P33097; Guadagno TM, 1998, SCIENCE, V282, P1312, DOI 10.1126/science.282.5392.1312; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; HATTORI S, 1992, J BIOL CHEM, V267, P20346; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Maller JL, 2003, SCIENCE, V300, P594, DOI 10.1126/science.1083725; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; MURAKAMI MS, 2001, SCI STKE, pPE30; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; Nebreda AR, 2000, CURR OPIN CELL BIOL, V12, P666, DOI 10.1016/S0955-0674(00)00150-2; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; Park JY, 2004, SCIENCE, V303, P682, DOI 10.1126/science.1092463; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pollock PM, 2002, CANCER CELL, V2, P5, DOI 10.1016/S1535-6108(02)00089-2; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; SADLER SE, 1990, MOL CELL BIOL, V10, P1689, DOI 10.1128/MCB.10.4.1689; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; Sohaskey ML, 1999, MOL BIOL CELL, V10, P3729, DOI 10.1091/mbc.10.11.3729; Tian JD, 2000, P NATL ACAD SCI USA, V97, P14358, DOI 10.1073/pnas.250492197; VANRENTERGHEM B, 1993, J BIOL CHEM, V268, P19935; Walter SA, 1997, MOL BIOL CELL, V8, P2157, DOI 10.1091/mbc.8.11.2157; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; WANG XM, 1994, P NATL ACAD SCI USA, V91, P8329, DOI 10.1073/pnas.91.18.8329; Wang XM, 1997, J CELL BIOL, V137, P433, DOI 10.1083/jcb.137.2.433; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wu XY, 1996, J BIOL CHEM, V271, P3265, DOI 10.1074/jbc.271.6.3265; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; Yue JB, 2004, CURR BIOL, V14, P1581, DOI 10.1016/j.cub.2004.08.056; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547	64	4	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 1	2006	25	23					3307	3315		10.1038/sj.onc.1209354	http://dx.doi.org/10.1038/sj.onc.1209354			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16434971				2022-12-28	WOS:000237951200009
J	Milton, A; Luoto, K; Ingram, L; Munro, S; Logan, N; Graham, AL; Brummelkamp, TR; Hijmans, EM; Bernards, R; La Thangue, NB				Milton, A.; Luoto, K.; Ingram, L.; Munro, S.; Logan, N.; Graham, A. L.; Brummelkamp, T. R.; Hijmans, E. M.; Bernards, R.; La Thangue, N. B.			A functionally distinct member of the DP family of E2F subunits	ONCOGENE			English	Article						cancer; cell cycle; E2F; DP	NUCLEAR ACCUMULATION; TRANSCRIPTION; COMPONENT; PROTEIN; RECOGNITION; MECHANISMS; APOPTOSIS; PARTNER; EXTENDS; PRB	E2F transcription factors regulate genes involved in cell-cycle progression. In mammalian cells, physiological E2F exists as an E2F/DP heterodimer. Currently, eight E2F and two DP subunits have been characterized. We report here the characterization of a new member of the DP family, DP-4. While DP-4 exhibits certain similarities with members of the DP family, it also possesses a number of significant differences. Thus, DP-4 forms a heterodimer with E2F subunits, binds to the E2F site and associates with pocket proteins including pRb. In contrast to DP-1, however, DP-4/E2F-1 complexes exhibit reduced DNA binding activity. Furthermore, DP-4 interferes with E2F-1- dependent transcription and delays cell-cycle progression. These results highlight an emerging complexity in the DP family of E2F subunits, and suggest that DP-4 may endow E2F heterodimers with distinct transcription properties.	Univ Oxford, Canc Biol Lab, Nuffield Dept Clin Lab Sci, Div Med Sci,John Radcliffe Hosp, Oxford, Oxon, England; Netherlands Canc Inst, Amsterdam, Netherlands	University of Oxford; Netherlands Cancer Institute	La Thangue, NB (corresponding author), Univ Oxford, Canc Biol Lab, Nuffield Dept Clin Lab Sci, Div Med Sci, Oxford, Oxon, England.	nick.lathangue@ndcls.ox.ac.uk		Bernards, Rene/0000-0001-8677-3423; Hijmans, Marielle/0000-0003-4847-9412	Cancer Research UK [13058] Funding Source: Medline; Medical Research Council [G0500905, G9400953] Funding Source: Medline; MRC [G0500905, G9400953] Funding Source: UKRI	Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Allen KE, 1997, J CELL SCI, V110, P2819; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; de la Luna S, 1999, EMBO J, V18, P212, DOI 10.1093/emboj/18.1.212; delaLuna S, 1996, J CELL SCI, V109, P2443; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; Kohn MJ, 2004, MOL CELL BIOL, V24, P7197, DOI 10.1128/MCB.24.16.7197-7205.2004; Kohn MJ, 2003, DEVELOPMENT, V130, P1295, DOI 10.1242/dev.00355; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Logan N, 2004, ONCOGENE, V23, P5138, DOI 10.1038/sj.onc.1207649; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; Rogers KT, 1996, P NATL ACAD SCI USA, V93, P7594, DOI 10.1073/pnas.93.15.7594; Stevens C, 2003, ARCH BIOCHEM BIOPHYS, V412, P157, DOI 10.1016/S0003-9861(03)00054-7; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; ZHANG YH, 1995, ONCOGENE, V10, P2085; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459	20	24	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3212	3218		10.1038/sj.onc.1209343	http://dx.doi.org/10.1038/sj.onc.1209343			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16418725	Green Published			2022-12-28	WOS:000237951000012
J	Xu, L; Chen, S; Bergan, RC				Xu, L.; Chen, S.; Bergan, R. C.			MAPKAPK2 and HSP27 are downstream effectors of p38MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer	ONCOGENE			English	Article						transforming growth factor beta; prostate cancer; invasion; mitogen-activated protein kinase-activated protein kinase 2; heat-shock protein 27; matrix metalloproteinase-2	HEAT-SHOCK PROTEINS; MAP KINASE; SIGNAL-TRANSDUCTION; FOCAL ADHESION; SMOOTH-MUSCLE; EXPRESSION; HEAT-SHOCK-PROTEIN-27; PHOSPHORYLATION; INHIBITOR; MECHANISMS	Although cell invasion is a necessary early step in cancer metastasis, its regulation is not well understood. We have previously shown, in human prostate cancer, that transforming growth factor ss (TGF ss)-mediated increases in cell invasion are dependent upon activation of the serine/threonine kinase, p38 MAP kinase. In the current study, downstream effectors of p38 MAP kinase were sought by first screening for proteins phosphorylated after TGF ss treatment, only in the absence of chemical inhibitors of p38 MAP kinase. This led us to investigate mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2), a known substrate of p38 MAP kinase, as well as heat-shock protein 27 (HSP27), a known substrate of MAPKAPK2, in both PC3 and PC3-M human prostate cells. After transient transfection, wildtype MAPKAPK2 and HSP27 both increased TGF ss-mediated matrix metalloproteinase type 2 (MMP-2) activity, as well as cell invasion, which in turn was inhibited by SB203580, an inhibitor of p38 MAP kinase. Conversely, dominant-negative MAPKAPK2 blocked phosphorylation of HSP27, whereas dominant-negative MAPKAPK2 or mutant, non-phosphorylateable, HSP27 each blocked TGF ss-mediated increases in MMP-2, as well as cell invasion. Similarly, knock down of MAPKAPK2, HSP27 or both together, by siRNA, also blocked TGF ss-mediated cell invasion. This study demonstrates that both MAPKAPK2 and HSP27 are necessary for TGF ss-mediated increases in MMP-2 and cell invasion in human prostate cancer.	Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Canc Ctr, Chicago, IL USA	Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Bergan, RC (corresponding author), Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, McGaw 2301,240 E Huron St, Chicago, IL 60611 USA.	r-bergan@northwestern.edu	xu, li/D-5310-2009	xu, li/0000-0002-2153-1471	NATIONAL CANCER INSTITUTE [P50CA090386] Funding Source: NIH RePORTER; NCI NIH HHS [CA90386] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aldrian S, 2002, CELL STRESS CHAPERON, V7, P177, DOI 10.1379/1466-1268(2002)007<0177:OOHATM>2.0.CO;2; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; CARROLL PR, 2001, CANC PRINCIPLES PRAC, P1418; Cornford PA, 2000, CANCER RES, V60, P7099; Gerthoffer WT, 2001, J APPL PHYSIOL, V91, P963, DOI 10.1152/jappl.2001.91.2.963; Guay J, 1997, J CELL SCI, V110, P357; Hansen RK, 2001, BIOCHEM BIOPH RES CO, V282, P186, DOI 10.1006/bbrc.2001.4548; Hatakeyama D, 2002, BBA-MOL CELL RES, V1589, P15, DOI 10.1016/S0167-4889(01)00183-5; Hayes SA, 2003, ONCOGENE, V22, P4841, DOI 10.1038/sj.onc.1206730; Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211; Huang XK, 2005, CANCER RES, V65, P3470, DOI 10.1158/0008-5472.CAN-04-2807; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kotlyarov A, 2002, MOL CELL BIOL, V22, P4827, DOI 10.1128/MCB.22.13.4827-4835.2002; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; Liu YQ, 2001, PROSTATE CANCER P D, V4, P81, DOI 10.1038/sj.pcan.4500506; Liu YQ, 2000, CLIN EXP METASTAS, V18, P203, DOI 10.1023/A:1006729106034; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; Munshi HG, 2004, J BIOL CHEM, V279, P39042, DOI 10.1074/jbc.M404958200; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Rocchi P, 2004, CANCER RES, V64, P6595, DOI 10.1158/0008-5472.CAN-03-3998; Ruoslahti E, 1996, SCI AM, V275, P72, DOI 10.1038/scientificamerican0996-72; Schafer C, 1999, AM J PHYSIOL-CELL PH, V277, pC1032; Schwartz GN, 1998, ANTISENSE NUCLEIC A, V8, P329, DOI 10.1089/oli.1.1998.8.329; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sporn MB, 1996, LANCET, V347, P1377, DOI 10.1016/S0140-6736(96)91015-6; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Wilson KP, 1997, CHEM BIOL, V4, P423, DOI 10.1016/S1074-5521(97)90194-0; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F	33	156	183	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					2987	2998		10.1038/sj.onc.1209337	http://dx.doi.org/10.1038/sj.onc.1209337			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16407830				2022-12-28	WOS:000237950800003
J	Louhelainen, JP; Hurst, CD; Pitt, E; Nishiyama, H; Pickett, HA; Knowles, MA				Louhelainen, JP; Hurst, CD; Pitt, E; Nishiyama, H; Pickett, HA; Knowles, MA			DBC1 re-expression alters the expression of multiple components of the plasminogen pathway	ONCOGENE			English	Article						DBC1; bladder cancer; tumour suppressor gene; expression microarray	TUMOR-SUPPRESSOR REGION; BLADDER-CANCER; HOMOZYGOUS DELETION; IN-VITRO; CELL; METALLOTHIONEIN; ACTIVATOR; UROKINASE; IDENTIFICATION; RECEPTOR	Deleted in bladder cancer 1 (DBC1) is a candidate gene for the bladder tumour suppressor locus at 9q33.1. The function of the gene is currently unknown but a cross-species sequence comparison suggests an important role, as it is highly evolutionarily conserved. Here, we transfected a nonexpressing human bladder cancer cell line with a set of human DBC1 cDNA constructs. The effect on global expression patterns was assessed using cDNA microarrays. The cell clone with the lowest level of DBC1 expression showed induced expression of 26 genes including plasminogen activator inhibitor 2 (SERPINB5; 4.6-fold), heparin-binding EGF-like growth factor precursor ( DTR; 4.2-fold), small proline-rich protein 2B (SPRR2B; 3.6-fold), metallothionein 1 isoforms (MT1B/ MT1A/MT-1F; from 2.9- to 3.2-fold), tissue-type plasminogen activator precursor ( PLAT; 2.8-fold) and urokinasetype plasminogen activator precursor (PLAU; 2.7fold). In clustering analysis, both PLAT and PLAU clustered with the functionally related urokinase plasminogen activator surface receptor (PLAUR; 1.9-fold). Furthermore, 14 human bladder tumours were analysed by real-time quantitative PCR using gene-specific primers for selected (n = 20) genes. The expression levels of SERPINB5, PLAU, PLAUR and MT1 correlated with the DBC1 levels, suggesting previously unknown involvement of DBC1 in the urokinase-plasminogen pathway.	St James Univ Hosp, Canc Res UK, Ctr Clin, Leeds LS9 7TF, W Yorkshire, England	Cancer Research UK; Saint James's University Hospital	Knowles, MA (corresponding author), St James Univ Hosp, Canc Res UK, Ctr Clin, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	margaret.knowles@cancer.org.uk		Knowles, Margaret/0000-0002-9363-8657; Louhelainen, Jari/0000-0001-8680-8614	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BACHMANN F, 1995, THROMB HAEMOSTASIS, V74, P172; Barradas M, 2002, EXP CELL RES, V273, P127, DOI 10.1006/excr.2001.5434; Champelovier P, 2002, UROL RES, V30, P301, DOI 10.1007/s00240-002-0270-5; COHEN RL, 1989, J BIOL CHEM, V264, P8375; ELLER MS, 1995, J CELL SCI, V108, P2741; FOUCRE D, 1991, BRIT J CANCER, V64, P926, DOI 10.1038/bjc.1991.428; Fujiwara H, 2001, J HUM GENET, V46, P372, DOI 10.1007/s100380170056; Fujiyama C, 2001, BRIT J CANCER, V84, P558, DOI 10.1054/bjoc.2000.1641; Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165; Habuchi T, 1997, HUM MOL GENET, V6, P913, DOI 10.1093/hmg/6.6.913; Habuchi T, 2001, ONCOGENE, V20, P531, DOI 10.1038/sj.onc.1204122; Hamada T, 1996, BIOCHEM BIOPH RES CO, V219, P829, DOI 10.1006/bbrc.1996.0318; Hasui Y, 1997, J NATL CANCER I, V89, P678, DOI 10.1093/jnci/89.10.678; Hudson MA, 1997, J NATL CANCER I, V89, P709, DOI 10.1093/jnci/89.10.709; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; Hurst RE, 1999, ADV EXP MED BIOL, V462, P449; Ioachim EE, 2001, ANTICANCER RES, V21, P1757; JENSEN PH, 1994, BRIT J CANCER, V70, P834, DOI 10.1038/bjc.1994.407; Kawano H, 2004, MOL BRAIN RES, V125, P60, DOI 10.1016/j.molbrainres.2004.04.001; Knowles MA, 1999, ELECTROPHORESIS, V20, P269, DOI 10.1002/(SICI)1522-2683(19990201)20:2<269::AID-ELPS269>3.3.CO;2-Z; KONDO Y, 1994, J PHARMACOL EXP THER, V270, P1313; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; Mouton RE, 2000, MECH AGEING DEV, V113, P169, DOI 10.1016/S0047-6374(99)00105-0; Nishiyama H, 1999, GENE CHROMOSOME CANC, V26, P171, DOI 10.1002/(SICI)1098-2264(199910)26:2<171::AID-GCC10>3.3.CO;2-2; Nishiyama H, 2001, ONCOGENE, V20, P2956, DOI 10.1038/sj.onc.1204432; Sens MA, 2000, ENVIRON HEALTH PERSP, V108, P413; Serakinci N, 2004, ONCOGENE, V23, P5095, DOI 10.1038/sj.onc.1207651; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Simpkins CO, 2000, CELL MOL BIOL, V46, P465; Stadler WM, 2001, CLIN CANCER RES, V7, P1676; Toshiyuki N, 2004, MOL BRAIN RES, V125, P47, DOI 10.1016/j.molbrainres.2004.03.017; Tsangaris GT, 1998, ANTICANCER RES, V18, P2423; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Williams SV, 2002, GENE CHROMOSOME CANC, V34, P86, DOI 10.1002/gcc.10050; Wright KO, 2004, ONCOGENE, V23, P82, DOI 10.1038/sj.onc.1206642; Wright KO, 2002, J UROLOGY, V168, P2645, DOI 10.1016/S0022-5347(05)64236-X; Yu J, 2003, CELL RES, V13, P319, DOI 10.1038/sj.cr.7290177	37	17	18	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2409	2419		10.1038/sj.onc.1209228	http://dx.doi.org/10.1038/sj.onc.1209228			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16369496				2022-12-28	WOS:000236764300012
J	Li, R; Wang, H; Bekele, BN; Yin, Z; Caraway, NP; Katz, RL; Stass, SA; Jiang, F				Li, R; Wang, H; Bekele, BN; Yin, Z; Caraway, NP; Katz, RL; Stass, SA; Jiang, F			Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach	ONCOGENE			English	Article						lung cancer; microarrays; proteomics; tissue microarray	CANCER TISSUES; EXPRESSION; PROTEIN; HYBRIDIZATION; DNA; AMPLIFICATION; PROFILES; CELLS	Amplification and overexpression of putative oncogenes confer growth advantages for tumor development. We used a functional genomic approach that integrated simultaneous genomic and transcript microarray, proteomics, and tissue microarray analyses to directly identify putative oncogenes in lung adenocarcinoma. We first identified 183 genes with increases in both genomic copy number and transcript in six lung adenocarcinoma cell lines. Next, we used two-dimensional polyacrylamide gel electrophoresis and mass spectrometry to identify 42 proteins that were overexpressed in the cancer cells relative to normal cells. Comparing the 183 genes with the 42 proteins, we identified four genes - PRDX1, EEF1A2, CALR, and KCIP-1-in which elevated protein expression correlated with both increased DNA copy number and increased transcript levels ( all r > 0.84, two-sided P < 0.05). These findings were validated by Southern, Northern, and Western blotting. Specific inhibition of EEF1A2 and KCIP-1 expression with siRNA in the four cell lines tested suppressed proliferation and induced apoptosis. Parallel fluorescence in situ hybridization and immunohistochemical analyses of EEF1A2 and KCIP-1 in tissue microarrays from patients with lung adenocarcinoma showed that gene amplification was associated with high protein expression for both genes and that protein overexpression was related to tumor grade, disease stage, Ki-67 expression, and a shorter survival of patients. The amplification of EEF1A2 and KCIP-1 and the presence of overexpressed protein in tumor samples strongly suggest that these genes could be oncogenes and hence potential targets for diagnosis and therapy in lung adenocarcinoma.	Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Internal Med, Houston, TX 77030 USA	University System of Maryland; University of Maryland Baltimore; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Jiang, F (corresponding author), Univ Maryland, Sch Med, Dept Pathol, 10 S Pine St,MSTF 7th Floor, Baltimore, MD 21201 USA.	fjiang@som.umaryland.edu			NCI NIH HHS [CA113707-01, P50 CA70907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA113707, P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anand N, 2002, NAT GENET, V31, P301, DOI 10.1038/ng904; Barrett MT, 2004, P NATL ACAD SCI USA, V101, P17765, DOI 10.1073/pnas.0407979101; Chen GA, 2002, MOL CELL PROTEOMICS, V1, P304, DOI 10.1074/mcp.M200008-MCP200; Feng J, 2004, NEOPLASIA, V6, P623, DOI 10.1593/neo.04142; Hyman E, 2002, CANCER RES, V62, P6240; Jiang F, 2005, ONCOGENE, V24, P3409, DOI 10.1038/sj.onc.1208459; Jiang F, 2002, J MOL DIAGN, V4, P144, DOI 10.1016/S1525-1578(10)60695-2; Kim HJ, 2003, CELL BIOL TOXICOL, V19, P285, DOI 10.1023/B:CBTO.0000004952.07979.3d; Lee Jonathan M, 2003, Reprod Biol Endocrinol, V1, P69, DOI 10.1186/1477-7827-1-69; Luk C, 2001, CANCER GENET CYTOGEN, V125, P87, DOI 10.1016/S0165-4608(00)00363-0; Martin B, 2004, BRIT J CANCER, V91, P2018, DOI 10.1038/sj.bjc.6602233; Oates J, 2000, HISTOPATHOLOGY, V36, P341; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Qi WQ, 2005, INT J CANCER, V113, P359, DOI 10.1002/ijc.20492; Ross JS, 1999, SEMIN CANCER BIOL, V9, P125, DOI 10.1006/scbi.1998.0083; Shen JJ, 2004, CANCER RES, V64, P9018, DOI 10.1158/0008-5472.CAN-04-3262; Thomas D, 2005, CURR TOP DEV BIOL, V67, P285, DOI 10.1016/S0070-2153(05)67009-3; Tonon G, 2005, P NATL ACAD SCI USA, V102, P9625, DOI 10.1073/pnas.0504126102; Wang HJ, 2005, INT J CANCER, V116, P285, DOI 10.1002/ijc.21035	19	98	111	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2628	2635		10.1038/sj.onc.1209289	http://dx.doi.org/10.1038/sj.onc.1209289			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16369491				2022-12-28	WOS:000237099400006
J	Mangan, JK; Tantravahi, RV; Rane, SG; Reddy, EP				Mangan, JK; Tantravahi, RV; Rane, SG; Reddy, EP			Granulocyte colony-stimulating factor-induced upregulation of Jak3 transcription during granulocytic differentiation is mediated by the cooperative action of Sp1 and Stat3	ONCOGENE			English	Article						granulopoiesis; Jaks; STATs; transcription; cytokines; promoter analysis	MICE LACKING JAK3; PROGENITOR-CELL LINE; MYELOID CELLS; DNA-BINDING; IN-VIVO; PROMOTER; GENE; ACTIVATION; EXPRESSION; PROLIFERATION	We previously demonstrated that Jak3 is a primary response gene for G-CSF and ectopic overexpression of Jak3 can accelerate granulocytic differentiation of normal mouse bone marrow cells induced by G-CSF and GMCSF. To gain insight into the regulation of G-CSF-induced transcription of Jak3, we constructed deletion and linker scanning mutants of the Jak3 promoter sequences and performed luciferase reporter assays in the murine myeloid cell line 32Dcl3, with and without G-CSF stimulation. These experiments showed that mutation of a -67 to -85 element, which contained a putative Sp1 binding site, or mutation of a -44 to -53 GAS element resulted in a marked reduction of Jak3 promoter activity. Electrophoretic mobility shift assays revealed that Sp1 and Stat3 present in nuclear lysates of 32Dcl3 cells stimulated with G-CSF can bind to the -67 to -85 element and -44 to -53 GAS element, respectively. In addition, cotransfection of a constitutively active mutant of Stat3 along with a Jak3 promoter/luciferase reporter resulted in enhanced Jak3 promoter activity. Together, these results demonstrate that activation of Jak3 transcription during G-CSF-induced granulocytic differentiation is mediated by the combined action of Sp1 and Stat3, a mechanism also shown to be important in IL-6-induced monocytic differentiation.	Temple Univ, Inst Canc Res & Mol Biol, Sch Med, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Reddy, EP (corresponding author), Temple Univ, Inst Canc Res & Mol Biol, Sch Med, 3307 N Broad St,AHP Room 154, Philadelphia, PA 19140 USA.	reddy@temple.edu	Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [R01CA068239, R24CA088261, R01CA079086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009225] Funding Source: NIH RePORTER; NCI NIH HHS [CA79086, R24 CA88261, CA68239] Funding Source: Medline; NIEHS NIH HHS [ES09225] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aringer M, 2003, J IMMUNOL, V170, P6057, DOI 10.4049/jimmunol.170.12.6057; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; Chakraborty A, 1998, LEUKEMIA LYMPHOMA, V30, P433, DOI 10.3109/10428199809057555; CHEN HM, 1993, J BIOL CHEM, V268, P8230; de Koning JP, 2000, ONCOGENE, V19, P3290, DOI 10.1038/sj.onc.1203627; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; Grossman WJ, 1999, BLOOD, V94, P932, DOI 10.1182/blood.V94.3.932.415k30_932_939; Hauses M, 1998, J BIOL CHEM, V273, P31844, DOI 10.1074/jbc.273.48.31844; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Kao WY, 1997, J CELL BIOCHEM, V65, P231, DOI 10.1002/(SICI)1097-4644(199705)65:2<231::AID-JCB8>3.0.CO;2-V; Khanna-Gupta A, 2000, BLOOD, V95, P3734; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Kumar A, 2001, GENE, V270, P221, DOI 10.1016/S0378-1119(01)00473-5; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; Mangan JK, 2004, BLOOD, V103, P4093, DOI 10.1182/blood-2003-06-2165; Martino A, 2001, J IMMUNOL, V166, P1723, DOI 10.4049/jimmunol.166.3.1723; McLemore ML, 2001, IMMUNITY, V14, P193, DOI 10.1016/S1074-7613(01)00101-7; Nelson BH, 1998, ADV IMMUNOL, V70, P1, DOI 10.1016/S0065-2776(08)60386-7; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; Noti JD, 1996, MOL CELL BIOL, V16, P2940; Nuchprayoon I, 1999, J BIOL CHEM, V274, P1085, DOI 10.1074/jbc.274.2.1085; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Park SY, 1995, IMMUNITY, V3, P771, DOI 10.1016/1074-7613(95)90066-7; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; Piedrafita FJ, 1996, J BIOL CHEM, V271, P14412, DOI 10.1074/jbc.271.24.14412; Rane SG, 2002, ONCOGENE, V21, P3334, DOI 10.1038/sj.onc.1205398; Rane SG, 2002, BLOOD, V100, P2753, DOI 10.1182/blood.V100.8.2753; Rane SG, 2000, ONCOGENE, V19, P5662, DOI 10.1038/sj.onc.1203925; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Rosmarin AG, 1998, J BIOL CHEM, V273, P13097, DOI 10.1074/jbc.273.21.13097; ROVERA G, 1987, ONCOGENE, V1, P29; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sjin RMTT, 1999, J BIOL CHEM, V274, P28697, DOI 10.1074/jbc.274.40.28697; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; Tomita K, 2001, J BIOL CHEM, V276, P25378, DOI 10.1074/jbc.M011363200; VALTIERI M, 1987, J IMMUNOL, V138, P3829; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yu B, 2003, NUCLEIC ACIDS RES, V31, P5368, DOI 10.1093/nar/gkg706; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469; ZHANG DE, 1994, J BIOL CHEM, V269, P11425	45	7	7	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2489	2499		10.1038/sj.onc.1209280	http://dx.doi.org/10.1038/sj.onc.1209280			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16518416				2022-12-28	WOS:000236948000007
J	Zhang, L; Wang, C				Zhang, L; Wang, C			F-box protein Skp2: a novel transcriptional target of E2F	ONCOGENE			English	Article						transcription; SCFskp2; E2F; cell cycle	SCFSKP2 UBIQUITIN LIGASE; CELL-CYCLE; IN-VITRO; CHROMATIN IMMUNOPRECIPITATION; S-PHASE; C-MYC; DEGRADATION; EXPRESSION; COMPLEX; PROTEOLYSIS	The F-box-containing protein Skp2 plays a critical role in coordinating the G1/S transition and progression through the S phase of the mammalian cell cycle. Skp2 is overexpressed in a broad spectrum of human cancers and the expression level correlates with tumor malignancy. However, the Skp2 gene is neither amplified nor rearranged in most human cancers and the underlying mechanism of Skp2 overexpression remains poorly understood. We show here that the Skp2 gene contains a functional E2F response element ( hSRE2). Ectopic expression of E2F1 induces expression of the endogenous Skp2 gene in human fibroblast cells, whereas antisense-mediated knockdown of E2F1 in human tumor cell lines reduces expression of endogenous Skp2 gene. The hSRE2 element not only participates in activation of Skp2 promoter function during normal cell cycle progression into S phase, it is also required for the high-level Skp2 gene expression in many human tumor cell lines. These results reveal Skp2 as a novel target for E2F regulation that is disrupted in several human tumor cell lines.	Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Wang, C (corresponding author), Univ Illinois, Ctr Mol Biol Oral Dis, 801 S Paulina St,Room 530E,M-C 860, Chicago, IL 60612 USA.	chiayeng@uic.edu			NATIONAL CANCER INSTITUTE [R29CA074907, R01CA074907] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA074907, R29 CA074907, CA074907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amati B, 2004, P NATL ACAD SCI USA, V101, P8843, DOI 10.1073/pnas.0403046101; Ausubel F, 1990, CURRENT PROTOCOLS MO, V1; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bashir T, 2004, CELL CYCLE, V3, P850; Bhattacharya S, 2003, ONCOGENE, V22, P2443, DOI 10.1038/sj.onc.1206339; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Cao Y, 2000, J BIOL CHEM, V275, P9854, DOI 10.1074/jbc.275.13.9854; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Carrano AC, 2001, J CELL BIOL, V153, P1381, DOI 10.1083/jcb.153.7.1381; Ciechanover A, 2004, BBA-MOL CELL RES, V1695, P3, DOI 10.1016/j.bbamcr.2004.09.018; Coe BR, 2005, GENE CHROMOSOME CANC, V42, P308, DOI 10.1002/gcc.20137; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; Dow R, 2001, J BIOL CHEM, V276, P45945, DOI 10.1074/jbc.M103593200; Dowen SE, 2003, ONCOGENE, V22, P2531, DOI 10.1038/sj.onc.1206296; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Imaki H, 2003, CANCER RES, V63, P4607; Jin JP, 2003, CANCER CELL, V3, P517, DOI 10.1016/S1535-6108(03)00145-4; Kamura T, 2003, P NATL ACAD SCI USA, V100, P10231, DOI 10.1073/pnas.1831009100; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Koga H, 2003, HEPATOLOGY, V37, P1086, DOI 10.1053/jhep.2003.50186; Koziczak M, 2000, MOL CELL BIOL, V20, P2014, DOI 10.1128/MCB.20.6.2014-2022.2000; Kurland JF, 2004, CANCER CELL, V5, P305, DOI 10.1016/S1535-6108(04)00091-1; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; Li XH, 2003, J BIOL CHEM, V278, P30854, DOI 10.1074/jbc.C300251200; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; MERCOLA M, 1985, SCIENCE, V227, P266, DOI 10.1126/science.3917575; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Ohta T, 2001, CANCER RES, V61, P1347; Oliveira AM, 2003, J CLIN ONCOL, V21, P722, DOI 10.1200/JCO.2003.05.112; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; QIN XQ, 1995, MOL CELL BIOL, V15, P742; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ross JF, 2001, GENE DEV, V15, P392, DOI 10.1101/gad.858501; Simile MM, 2004, CARCINOGENESIS, V25, P333, DOI 10.1093/carcin/bgh014; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vernell R, 2003, J BIOL CHEM, V278, P46124, DOI 10.1074/jbc.M304930200; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; Willems AR, 2004, BBA-MOL CELL RES, V1695, P133, DOI 10.1016/j.bbamcr.2004.09.027; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Yeh KH, 2001, BIOCHEM BIOPH RES CO, V281, P884, DOI 10.1006/bbrc.2001.4442; Yokoi S, 2004, AM J PATHOL, V165, P175, DOI 10.1016/S0002-9440(10)63286-5; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	65	104	107	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2615	2627		10.1038/sj.onc.1209286	http://dx.doi.org/10.1038/sj.onc.1209286			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16331253	Green Accepted			2022-12-28	WOS:000237099400005
J	Engle, LJ; Simpson, CL; Landers, JE				Engle, LJ; Simpson, CL; Landers, JE			Using high-throughput SNP technologies to study cancer	ONCOGENE			English	Review						SNP; polymorphisms; cancer; genotyping	SINGLE-NUCLEOTIDE POLYMORPHISMS; ACUTE LYMPHOBLASTIC-LEUKEMIA; GENOME-WIDE ASSOCIATION; PROSTATE-CANCER; METHYLENETETRAHYDROFOLATE REDUCTASE; BREAST-CANCER; COLORECTAL-CANCER; COMPLEX DISEASE; GASTRIC-CANCER; 5,10-METHYLENETETRAHYDROFOLATE REDUCTASE	Identifying genes involved in the development of cancer is crucial to fully understanding cancer biology, for developing novel therapeutics for cancer treatment and for providing methods for cancer prevention and early diagnosis. The use of polymorphic markers, in particular single nucleotide polymorphisms ( SNPs), promises to provide a comprehensive tool for analysing the human genome and identifying those genes and genomic regions contributing to the cancer phenotype. This review summarizes the various analytical methodologies in which SNPs are used and presents examples of how each of these methodologies have been used to locate genes and genomic regions of interest for various cancer types. Additionally many of the current SNP-analysing technologies will be reviewed with particular attention paid to the advantages and disadvantages of each and how each technology can be applied to the analysis of the genome for identifying cancer-related genes.	Cetek Corp, Marlborough, MA USA; Kings Coll London, Inst Psychiat, London WC2R 2LS, England; Massachusetts Gen Hosp, Day Lab Neuromuscular Res, Charlestown, MA USA	University of London; King's College London; Harvard University; Massachusetts General Hospital	Landers, JE (corresponding author), 13th St,CNY149-3-3310, Charlestown, MA 02129 USA.	jelanders@partners.org		Simpson, Claire/0000-0003-2244-7690; Landers, John/0000-0001-8084-5043				Avi-Itzhak Hadar I, 2003, Pac Symp Biocomput, P466; Badano JL, 2002, NAT REV GENET, V3, P779, DOI 10.1038/nrg910; Bell PA, 2002, BIOTECHNIQUES, P70; BELL PA, 2002, BIOTECHNIQUES S, V32, P76; BELL PA, 2002, BIOTECHNIQUES S, V32, P74; Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Carlini LE, 2005, CLIN CANCER RES, V11, P1226; Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000; Chen J, 2005, CANCER RES, V65, P1606, DOI 10.1158/0008-5472.CAN-04-2630; Cvetkovic D, 2004, GYNECOL ONCOL, V95, P449, DOI 10.1016/j.ygyno.2004.08.051; Dean FB, 2002, P NATL ACAD SCI USA, V99, P5261, DOI 10.1073/pnas.082089499; Emahazion T, 2001, TRENDS GENET, V17, P407, DOI 10.1016/S0168-9525(01)02342-3; Freedman ML, 2005, CANCER RES, V65, P7516, DOI 10.1158/0008-5472.CAN-05-0132; Freedman ML, 2004, HUM MOL GENET, V13, P2431, DOI 10.1093/hmg/ddh270; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Geesaman BJ, 2003, P NATL ACAD SCI USA, V100, P14115, DOI 10.1073/pnas.1936249100; Gershoni-Baruch R, 2000, EUR J CANCER, V36, P2313, DOI 10.1016/S0959-8049(00)00306-3; Gissen P, 2004, NAT GENET, V36, P400, DOI 10.1038/ng1325; Graziano F, 2006, INT J CANCER, V118, P628, DOI 10.1002/ijc.21397; Gunderson KL, 2005, NAT GENET, V37, P549, DOI 10.1038/ng1547; Haiman CA, 2003, HUM MOL GENET, V12, P2679, DOI 10.1093/hmg/ddg294; Halldorsson BV, 2004, GENOME RES, V14, P1633, DOI 10.1101/gr.2570004; Han J, 2004, BRIT J CANCER, V91, P1604, DOI 10.1038/sj.bjc.6602174; Han JL, 2004, CANCER RES, V64, P3009, DOI 10.1158/0008-5472.CAN-04-0246; Hao BT, 2004, CANCER RES, V64, P4378, DOI 10.1158/0008-5472.CAN-04-0372; Herr A, 2005, GENOMICS, V85, P392, DOI 10.1016/j.ygeno.2004.07.015; Hinds DA, 2004, AM J HUM GENET, V74, P317, DOI 10.1086/381716; Hu N, 2005, CANCER RES, V65, P2542, DOI 10.1158/0008-5472.CAN-04-3247; Hu ZB, 2005, CLIN CANCER RES, V11, P5433, DOI 10.1158/1078-0432.CCR-05-0311; Huang Jing, 2004, Human Genomics, V1, P287; Irving JAE, 2005, CANCER RES, V65, P3053, DOI 10.1158/0008-5472.CAN-04-2604; Ishikawa S, 2005, BIOCHEM BIOPH RES CO, V333, P1309, DOI 10.1016/j.bbrc.2005.06.040; Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437; Janecke AR, 2004, NAT GENET, V36, P850, DOI 10.1038/ng1394; Janne PA, 2004, ONCOGENE, V23, P2716, DOI 10.1038/sj.onc.1207329; Jiang QT, 2005, CANCER DETECT PREV, V29, P146, DOI 10.1016/j.cdp.2004.11.004; John S, 2004, AM J HUM GENET, V75, P54, DOI 10.1086/422195; Jordan B, 2002, P NATL ACAD SCI USA, V99, P2942, DOI 10.1073/pnas.261710699; Ju H, 2005, INT J CANCER, V117, P957, DOI 10.1002/ijc.21281; Kennedy GC, 2003, NAT BIOTECHNOL, V21, P1233, DOI 10.1038/nbt869; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Koed K, 2005, CANCER RES, V65, P34; Kono S, 2005, CANCER SCI, V96, P535, DOI 10.1111/j.1349-7006.2005.00090.x; Koppert LB, 2004, BRIT J CANCER, V90, P892, DOI 10.1038/sj.bjc.6601589; Krajinovic M, 2004, BLOOD, V103, P252, DOI 10.1182/blood-2003-06-1794; LANDEGREN U, 1988, SCIENCE, V241, P1077, DOI 10.1126/science.3413476; Larson GP, 2005, CANCER RES, V65, P805; Li DH, 2005, CANCER EPIDEM BIOMAR, V14, P1470, DOI 10.1158/1055-9965.EPI-04-0894; Lieberfarb ME, 2003, CANCER RES, V63, P4781; Lin M, 2004, BIOINFORMATICS, V20, P1233, DOI 10.1093/bioinformatics/bth069; Lindmark F, 2005, BRIT J CANCER, V93, P493, DOI 10.1038/sj.bjc.6602729; Livak KJ, 1999, GENET ANAL-BIOMOL E, V14, P143, DOI 10.1016/S1050-3862(98)00019-9; LIVAK KJ, 1995, PCR METH APPL, V4, P357; Loukola A, 2004, EUR J HUM GENET, V12, P321, DOI 10.1038/sj.ejhg.5201101; Maitra A, 2005, NAT GENET, V37, P1099, DOI 10.1038/ng1631; Maris JM, 2005, GENOME RES, V15, P1168, DOI 10.1101/gr.3865305; Matsuzaki H, 2004, GENOME RES, V14, P414, DOI 10.1101/gr.2014904; Metherell LA, 2005, NAT GENET, V37, P166, DOI 10.1038/ng1501; Mi HY, 2005, NUCLEIC ACIDS RES, V33, pD284, DOI 10.1093/nar/gki078; Middleton FA, 2004, AM J HUM GENET, V74, P886, DOI 10.1086/420775; Murray SS, 2004, NAT METHODS, V1, P113, DOI 10.1038/NMETH712; NIKIFOROV TT, 1994, NUCLEIC ACIDS RES, V22, P4167, DOI 10.1093/nar/22.20.4167; Otterness D, 1997, CLIN PHARMACOL THER, V62, P60, DOI 10.1016/S0009-9236(97)90152-1; Ozaki K, 2002, NAT GENET, V32, P650, DOI 10.1038/ng1047; Packer BR, 2004, NUCLEIC ACIDS RES, V32, pD528, DOI 10.1093/nar/gkh005; Puffenberger EG, 2004, P NATL ACAD SCI USA, V101, P11689, DOI 10.1073/pnas.0401194101; Raghavan M, 2005, CANCER RES, V65, P375; Reumers J, 2005, NUCLEIC ACIDS RES, V33, pD527; Roshani L, 2005, CANCER GENET CYTOGEN, V158, P137, DOI 10.1016/j.cancergencyto.2004.08.034; Saba TG, 2005, HUM GENET, V116, P167, DOI 10.1007/s00439-004-1193-8; Sawcer S, 2005, AM J HUM GENET, V77, P454; Sawcer SJ, 2004, HUM MOL GENET, V13, P1943, DOI 10.1093/hmg/ddh202; Schaid DJ, 2004, AM J HUM GENET, V75, P948, DOI 10.1086/425870; Sellick GS, 2003, DIABETES, V52, P2636, DOI 10.2337/diabetes.52.10.2636; Shen HB, 2001, INT J CANCER, V95, P332, DOI 10.1002/1097-0215(20010920)95:5&lt;332::AID-IJC1058&gt;3.0.CO;2-9; Shrimpton AE, 2004, AM J HUM GENET, V75, P92, DOI 10.1086/422015; SPIELMAN RS, 1994, AM J HUM GENET, V54, P559; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Stanulla M, 2005, JAMA-J AM MED ASSOC, V293, P1485, DOI 10.1001/jama.293.12.1485; Stephens LA, 2005, THYROID, V15, P100, DOI 10.1089/thy.2005.15.100; Sun JL, 2005, JNCI-J NATL CANCER I, V97, P525, DOI 10.1093/jnci/dji070; Teh MT, 2005, CANCER RES, V65, P8597, DOI 10.1158/0008-5472.CAN-05-0842; Thompson ER, 2005, HUM MUTAT, V26, P384, DOI 10.1002/humu.20220; Uhlenberg B, 2004, AM J HUM GENET, V75, P251, DOI 10.1086/422763; Ulvik A, 2004, CANCER EPIDEM BIOMAR, V13, P2175; Wong KK, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh072; Yuan E, 2005, MOL CANCER RES, V3, P493, DOI 10.1158/1541-7786.MCR-05-0082; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847; Zhao XJ, 2004, CANCER RES, V64, P3060, DOI 10.1158/0008-5472.CAN-03-3308; Zhou XF, 2004, HUM GENET, V115, P327, DOI 10.1007/s00439-004-1163-1	91	91	97	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	11					1594	1601		10.1038/sj.onc.1209368	http://dx.doi.org/10.1038/sj.onc.1209368			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020JL	16550159				2022-12-28	WOS:000235904700001
J	Knudsen, KE; Diehl, JA; Haiman, CA; Knudsen, ES				Knudsen, KE; Diehl, JA; Haiman, CA; Knudsen, ES			Cyclin D1: polymorphism, aberrant splicing and cancer risk	ONCOGENE			English	Review						cell cycle; cyclin-dependent kinase; alternative splicing; nuclear localization; retinoblastoma tumor suppressor	SQUAMOUS-CELL CARCINOMA; AGE-OF-ONSET; DEPENDENT-KINASE; RETINOBLASTOMA-PROTEIN; G870A POLYMORPHISM; ANDROGEN RECEPTOR; GENE POLYMORPHISM; MESSENGER-RNA; ALTERNATIVE TRANSCRIPTS; CCND1 POLYMORPHISM	The cyclin D1 proto-oncogene exercises powerful control over the mechanisms that regulate the mitotic cell cycle, and excessive cyclin D1 expression and/or activity is common in human cancers. Although somatic mutations of the cyclin D1 locus are rarely observed, mounting evidence demonstrates that a specific polymorphism of cyclin D1 (G/A870) and a protein product of a potentially related alternate splicing event (cyclin D1b) may influence cancer risk and outcome. Herein, we review the epidemiological and functional literatures that link these alterations of cyclin D1 to human tumor development and progression.	Univ Cincinnati, Ctr Canc, Ctr Environm Genet, Dept Cell Biol, Cincinnati, OH 45267 USA; Univ Penn, Abramson Family Canc Res Inst, Ctr Canc, Philadelphia, PA 19104 USA; Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA	University System of Ohio; University of Cincinnati; University of Pennsylvania; Pennsylvania Medicine; University of Southern California	Knudsen, KE (corresponding author), Univ Cincinnati, Ctr Canc, Ctr Environm Genet, Dept Cell Biol, 3125 Eden Ave, Cincinnati, OH 45267 USA.	erik.knudsen@uc.edu		Knudsen, Karen/0000-0002-1301-890X	NATIONAL CANCER INSTITUTE [R01CA099996, R01CA111360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES011038] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA099996, 1R01CA111360] Funding Source: Medline; NIEHS NIH HHS [U01-ES011038] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Bala S, 2001, CANCER RES, V61, P6042; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Bergsagel PL, 2005, J CLIN ONCOL, V23, P6333, DOI 10.1200/JCO.2005.05.021; BETTICHER DC, 1995, ONCOGENE, V11, P1005; Bienvenu F, 2001, J BIOL CHEM, V276, P16840, DOI 10.1074/jbc.M100795200; Bigoni R, 1996, ONCOGENE, V13, P797; BOSCH F, 1994, BLOOD, V84, P2726; Buch S, 2005, MOL CARCINOGEN, V42, P222, DOI 10.1002/mc.20086; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Burd CJ, 2005, MOL ENDOCRINOL, V19, P607, DOI 10.1210/me.2004-0266; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Canhoto AJ, 2000, ONCOGENE, V19, P5116, DOI 10.1038/sj.onc.1203893; Casson AG, 2005, CANCER-AM CANCER SOC, V104, P730, DOI 10.1002/cncr.21229; Catarino R, 2005, CANCER GENET CYTOGEN, V160, P49, DOI 10.1016/j.cancergencyto.2004.11.017; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Cortessis VK, 2003, CARCINOGENESIS, V24, P1645, DOI 10.1093/carcin/bgg128; Costea I, 2003, PHARMACOGENETICS, V13, P577, DOI 10.1097/00008571-200309000-00006; Deng L, 2002, ACTA BIOCH BIOPH SIN, V34, P16; DEWOLFPEETERS C, 1994, ANN ONCOL, V5, pS35, DOI 10.1093/annonc/5.suppl_1.S35; Dhar KK, 1999, INT J GYNECOL CANCER, V9, P342, DOI 10.1046/j.1525-1438.1999.99048.x; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Dragnev KH, 2001, ANN NY ACAD SCI, V952, P13, DOI 10.1111/j.1749-6632.2001.tb02724.x; Dufourny B, 2000, J ENDOCRINOL, V166, P329, DOI 10.1677/joe.0.1660329; Ewen ME, 2004, TRENDS MOL MED, V10, P158, DOI 10.1016/j.molmed.2004.02.005; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fry DW, 2004, MOL CANCER THER, V3, P1427; GEDDERT H, 2005, J CANCER RES CLIN, V131, P1; Gijtenbeek JMM, 2005, J NEURO-ONCOL, V74, P261, DOI 10.1007/s11060-004-7326-z; GILLETT C, 1994, CANCER RES, V54, P1812; Gladden AB, 2005, J CELL BIOCHEM, V96, P906, DOI 10.1002/jcb.20613; Grieu F, 2003, ANTICANCER RES, V23, P4257; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HERBER B, 1994, ONCOGENE, V9, P1295; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Holley SL, 2005, INT J CANCER, V114, P364, DOI 10.1002/ijc.20750; Holley SL, 2005, ORAL ONCOL, V41, P156, DOI 10.1016/j.oraloncology.2004.08.005; Holley SL, 2001, AM J PATHOL, V159, P1917, DOI 10.1016/S0002-9440(10)63038-6; Hong Y, 2005, EUR J CANCER, V41, P1037, DOI 10.1016/j.ejca.2005.01.009; Hosokawa Y, 1997, CANCER LETT, V113, P123, DOI 10.1016/S0304-3835(97)04605-3; HOSOKAWA Y, 1995, CANCER LETT, V93, P165, DOI 10.1016/0304-3835(95)03805-7; Hosokawa Y, 1999, INT J CANCER, V81, P616, DOI 10.1002/(SICI)1097-0215(19990517)81:4<616::AID-IJC18>3.3.CO;2-J; Hou XW, 2005, INT J HEMATOL, V82, P206, DOI 10.1532/IJH97.A10418; Howe D, 2001, HAEMATOLOGICA, V86, P563; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Ito M, 2004, UROLOGY, V64, P74, DOI 10.1016/j.urology.2004.03.001; Jeffrey PD, 2000, GENE DEV, V14, P3115, DOI 10.1101/gad.851100; Jeon YT, 2005, CANCER LETT, V223, P259, DOI 10.1016/j.canlet.2004.12.024; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1992, CANCER RES, V52, P2980; KATO J, 1993, GENE DEV, V7, P331; KELLEY MJ, 1995, JNCI-J NATL CANCER I, V87, P756, DOI 10.1093/jnci/87.10.756; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Knudsen KE, 1999, CANCER RES, V59, P2297; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Koike H, 2003, ANTICANCER RES, V23, P4947; Kong SM, 2001, JNCI-J NATL CANCER I, V93, P1106, DOI 10.1093/jnci/93.14.1106; Kong SM, 2000, CANCER RES, V60, P249; Krippl P, 2003, BREAST CANCER RES TR, V82, P165, DOI 10.1023/B:BREA.0000004372.20461.33; Ladha MH, 1998, MOL CELL BIOL, V18, P6605, DOI 10.1128/MCB.18.11.6605; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Lamb J, 2000, MOL CELL BIOL, V20, P8667, DOI 10.1128/MCB.20.23.8667-8675.2000; Le Marchand L, 2003, JAMA-J AM MED ASSOC, V290, P2843, DOI 10.1001/jama.290.21.2843; Leng XH, 2002, MOL CELL BIOL, V22, P2242, DOI 10.1128/MCB.22.7.2242-2254.2002; Lewis RC, 2003, CANCER RES, V63, P8549; Lin SK, 2000, MOL CELL BIOL, V20, P7903, DOI 10.1128/MCB.20.21.7903-7913.2000; Liu EB, 2004, J BIOL CHEM, V279, P17283, DOI 10.1074/jbc.C300549200; Liu F, 2005, CELL CYCLE, V4, P63, DOI 10.4161/cc.4.1.1366; Lu FM, 2003, CANCER RES, V63, P7056; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Matthias C, 1998, CLIN CANCER RES, V4, P2411; McKay JA, 2000, INT J CANCER, V88, P77, DOI 10.1002/1097-0215(20001001)88:1<77::AID-IJC12>3.0.CO;2-O; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; Mumberg D, 1997, NUCLEIC ACIDS RES, V25, P2098, DOI 10.1093/nar/25.11.2098; Nishimoto IN, 2004, ORAL ONCOL, V40, P604, DOI 10.1016/j.oraloncology.2003.12.009; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Oyama T, 1998, CANCER RES, V58, P2876; Pakakasama S, 2004, ONCOGENE, V23, P4789, DOI 10.1038/sj.onc.1207499; Palmero I, 1996, CANCER SURV, V27, P351; Petre CE, 2002, J BIOL CHEM, V277, P2207, DOI 10.1074/jbc.M106399200; Petre-Draviam CE, 2005, ONCOGENE, V24, P431, DOI 10.1038/sj.onc.1208200; Pibiri M, 2001, FASEB J, V15, P1006, DOI 10.1096/fj.00-0416com; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Porter DC, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.23.e101; Porter TR, 2002, ONCOGENE, V21, P1928, DOI 10.1038/sj.onc.1205245; Qin CH, 2003, CANCER RES, V63, P958; Ratineau C, 2002, J BIOL CHEM, V277, P8847, DOI 10.1074/jbc.M110747200; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; RYDZANICZ M, 2005, EUR ARCH OTORHINOLAR; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Sanyal S, 2004, CARCINOGENESIS, V25, P729, DOI 10.1093/carcin/bgh058; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHERR CJ, 1992, CIBA F SYMP, V170, P209; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Shi QL, 2003, CARCINOGENESIS, V24, P1499, DOI 10.1093/carcin/bgg035; Shu XO, 2005, CANCER EPIDEM BIOMAR, V14, P91; Simpson DJ, 2001, CARCINOGENESIS, V22, P1801, DOI 10.1093/carcin/22.11.1801; Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Toogood PL, 2005, J MED CHEM, V48, P2388, DOI 10.1021/jm049354h; Wang LZ, 2003, INT J CANCER, V103, P116, DOI 10.1002/ijc.10793; Wang LZ, 2002, CARCINOGENESIS, V23, P257, DOI 10.1093/carcin/23.2.257; Wang Rui, 2003, Zhonghua Yi Xue Za Zhi, V83, P1089; WIERINGA B, 1983, NATURE, V301, P38, DOI 10.1038/301038a0; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; Wong YK, 2003, J ORAL PATHOL MED, V32, P265, DOI 10.1034/j.1600-0714.2003.00131.x; Yu JG, 2004, J UROLOGY, V172, P2410, DOI 10.1097/01.ju.0000138156.24384.16; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zatyka M, 2002, CANCER RES, V62, P3803; Zhang JH, 2003, INT J CANCER, V105, P281, DOI 10.1002/ijc.11067; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350; Zhang YJ, 2002, MOL CARCINOGEN, V33, P125, DOI 10.1002/mc.10028; Zhang ZZ, 2004, CLIN CHIM ACTA, V342, P137, DOI 10.1016/j.cccn.2003.12.010; Zheng YX, 2001, CARCINOGENESIS, V22, P1195, DOI 10.1093/carcin/22.8.1195; Zukerberg LR, 1996, BLOOD, V88, P268, DOI 10.1182/blood.V88.1.268.bloodjournal881268; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	136	301	315	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	11					1620	1628		10.1038/sj.onc.1209371	http://dx.doi.org/10.1038/sj.onc.1209371			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020JL	16550162				2022-12-28	WOS:000235904700004
J	Villa-Morales, M; Santos, J; Fernandez-Piqueras, J				Villa-Morales, M; Santos, J; Fernandez-Piqueras, J			Functional Fas (Cd95/Apo-1) promoter polymorphisms in inbred mouse strains exhibiting different susceptibility to gamma-radiation-induced thymic lymphoma	ONCOGENE			English	Article						Fas (Apo-1/CD95); functional polymorphisms; cancer-genetic-susceptibility; thymic lymphoma	TUMOR-SUPPRESSOR GENE; NF-KAPPA-B; SELECTION IN-VIVO; NEGATIVE SELECTION; TRANSCRIPTIONAL REGULATION; INDUCED APOPTOSIS; T-CELLS; THYMOCYTES; EXPRESSION; LIGAND	The Fas death receptor is a cell surface molecule involved in apoptosis as well as in proliferative or activating signals of many cells types, including T lymphocytes. Using quantitative real-time reverse transcription - PCR analysis, we confirm that expression of this gene is scarcely perceptible in thymic lymphomas induced by c-irradiation in C57BL/6J mice. Notably, we also demonstrate for the first time that Fas expression is significantly upregulated in vivo both after single high dose of radiation and in thymic lymphoma-free mice. In addition, we determined its levels of expression in five mouse strains exhibiting different degrees of susceptibility (SPRET/Ei, SEG/Pas, BALB/cJ, C57BL/6J and RF/J). Interestingly, we found the highest levels of expression in SPRET/Ei and SEG/Pas strains ( both derived from the Mus spretus species), which are known to have the most resistant phenotype, and the lowest levels in the most susceptible strains C57BL/6J and RF/J. DNA sequencing of the Fas promoter in all five strains showed many polymorphisms that can be classified into three functional haplotypes by using luciferase assays: (1) C57BL/6J and RF/J, ( 2) BALB/cJ and ( 3) SPRET/Ei and SEG/Pas. Promoter activities in response to single high doses of radiation correlated well with the levels of Fas expression and are consistent with the degree of strain susceptibility.	Univ Autonoma Madrid, Dept Biol, Lab Genet Mol Humana, E-28049 Madrid, Spain	Autonomous University of Madrid	Fernandez-Piqueras, J (corresponding author), Univ Autonoma Madrid, Dept Biol, Lab Genet Mol Humana, E-28049 Madrid, Spain.	jf.piqueras@uam.es	VILLA-MORALES, MARIA C./H-8797-2015; Santos, Javier/ABF-5755-2021	VILLA-MORALES, MARIA C./0000-0001-7906-0169; Santos, Javier/0000-0002-4168-6251				Adachi M, 1996, P NATL ACAD SCI USA, V93, P2131, DOI 10.1073/pnas.93.5.2131; Booker JK, 1998, J IMMUNOL, V161, P4536; Castro JE, 1996, IMMUNITY, V5, P617, DOI 10.1016/S1074-7613(00)80275-7; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; DeRyckere D, 2003, J IMMUNOL, V171, P802, DOI 10.4049/jimmunol.171.2.802; Feuk L, 2003, HUM MUTAT, V21, P53, DOI 10.1002/humu.10148; Fleck M, 1998, J IMMUNOL, V160, P3766; Hettmann T, 2000, J IMMUNOL, V165, P5004, DOI 10.4049/jimmunol.165.9.5004; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Hoogendoorn B, 2003, HUM MOL GENET, V12, P2249, DOI 10.1093/hmg/ddg246; Kishimoto H, 1998, J EXP MED, V187, P1427, DOI 10.1084/jem.187.9.1427; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kurasawa K, 1999, CELL IMMUNOL, V194, P127, DOI 10.1006/cimm.1999.1502; Lai HC, 2003, INT J CANCER, V103, P221, DOI 10.1002/ijc.10800; Maas K, 2005, ARTHRITIS RHEUM-US, V52, P1047, DOI 10.1002/art.20931; Melendez B, 1999, ONCOGENE, V18, P4166, DOI 10.1038/sj.onc.1202826; Muschen M, 2000, J MOL MED-JMM, V78, P312, DOI 10.1007/s001090000112; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; NISHIMURA Y, 1995, J IMMUNOL, V154, P4395; OGASAWARA J, 1995, J EXP MED, V181, P485, DOI 10.1084/jem.181.2.485; Oukka M, 1998, IMMUNITY, V9, P295, DOI 10.1016/S1074-7613(00)80612-3; Pinkoski MJ, 1999, CELL DEATH DIFFER, V6, P1174, DOI 10.1038/sj.cdd.4400611; RATHMELL JC, 2002, CELL S, V109, P97; Reap EA, 1997, P NATL ACAD SCI USA, V94, P5750, DOI 10.1073/pnas.94.11.5750; Santos J, 1996, ONCOGENE, V12, P669; Santos J, 2002, ONCOGENE, V21, P6680, DOI 10.1038/sj.onc.1205846; Santos J, 2001, ONCOGENE, V20, P2186, DOI 10.1038/sj.onc.1204297; Schmitz I, 2003, INT IMMUNOL, V15, P1237, DOI 10.1093/intimm/dxg125; Sibley K, 2003, CANCER RES, V63, P4327; Siegel RM, 2000, NAT IMMUNOL, V1, P469, DOI 10.1038/82712; Zheng Y, 2001, J IMMUNOL, V166, P4949, DOI 10.4049/jimmunol.166.8.4949	31	21	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2022	2029		10.1038/sj.onc.1209234	http://dx.doi.org/10.1038/sj.onc.1209234			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16301997				2022-12-28	WOS:000236359700005
J	Wang, G; Jones, SJM; Marra, MA; Sadar, MD				Wang, G.; Jones, S. J. M.; Marra, M. A.; Sadar, M. D.			Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cells	ONCOGENE			English	Article						prostate cancer; androgen receptor; Affymetrix; LNCaP hollow fiber model; cross-talk; PKA	PROTEIN-KINASE; MOLECULAR CHARACTERIZATION; HORMONAL-REGULATION; EXPRESSION PROFILE; RESPONSIVE GENES; TUMOR-SUPPRESSOR; REGULATED GENES; DOWN-REGULATION; AMINO-TERMINUS; RECEPTOR	Progression of prostate cancer to androgen independence is suspected to involve the androgen and protein kinase A (PKA) signaling pathways. Here for the first time, the transcriptomes associated with each pathway and common transcriptional targets in response to stimulation of both pathways were identified in human prostate cancer cells using Affymetrix GeneChip technology (Human Genome U133 plus2). Statistically significant changes in the levels of 858 genes in response to androgen and 303 genes in response to activation of the PKA pathway were determined using GeneSpring software. Expression of a subset of these genes (22) that were transcriptional targets for the androgen and/or PKA pathways were validated by reverse transcriptase-polymerase chain reaction and Western blot analyses. Application of small interfering RNAs to the androgen receptor (AR) revealed that in addition to KLK3, levels of expression of KLK2 and SESN1 were regulated by AR activated by both the androgen and PKA signaling pathways. SESN1 was identified as a gene repressed by activated AR. These results provide a broad view of the effects of the androgen and PKA signaling pathways on the transcriptional program of prostate cancer cells and indicate that only a limited number of genes are targeted by cross-talk between AR and PKA pathways.	British Columbia Canc Agcy, Genome Sci Ctr, Vancouver, BC V5Z 1L3, Canada	British Columbia Cancer Agency	Sadar, MD (corresponding author), British Columbia Canc Agcy, Genome Sci Ctr, 675 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	msadar@bcgsc.ca	Sadar, Marianne/E-9136-2012; Jones, Steven J/C-3621-2009; Marra, Marco A/B-5987-2008	Sadar, Marianne/0000-0003-0599-9215; Jones, Steven J/0000-0003-3394-2208; Marra, Marco A/0000-0001-7146-7175	NCI NIH HHS [CA105403] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agus DB, 1999, J NATL CANCER I, V91, P1869, DOI 10.1093/jnci/91.21.1869; Amler LC, 2000, CANCER RES, V60, P6134; BANG YJ, 1994, P NATL ACAD SCI USA, V91, P5330, DOI 10.1073/pnas.91.12.5330; Bouchal J, 2005, J PHARM PHARMACOL, V57, P83, DOI 10.1211/0022357055164; Chen TS, 1999, CANCER RES, V59, P213; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Culig Z, 1997, PROSTATE, V32, P106, DOI 10.1002/(SICI)1097-0045(19970701)32:2<106::AID-PROS5>3.0.CO;2-K; DAGA A, 1993, J BIOL CHEM, V268, P8123; Daniel PB, 1998, ANNU REV NUTR, V18, P353, DOI 10.1146/annurev.nutr.18.1.353; Day CL, 2004, BIOCHEM J, V377, P597, DOI 10.1042/BJ20031251; Debes JD, 2004, NEW ENGL J MED, V351, P1488, DOI 10.1056/NEJMp048178; DePrimo SE, 2002, GENOME BIOL, V3; Dotzlaw H, 2002, MOL ENDOCRINOL, V16, P661, DOI 10.1210/me.16.4.661; Farini D, 2003, ENDOCRINOLOGY, V144, P1631, DOI 10.1210/en.2002-221009; Gobert GN, 2001, HISTOCHEM CELL BIOL, V115, P381; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Holzbeierlein J, 2004, AM J PATHOL, V164, P217, DOI 10.1016/S0002-9440(10)63112-4; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; Huggins C, 2002, J UROLOGY, V168, P9, DOI 10.1016/S0022-5347(05)64820-3; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jung M, 2003, PROSTATE, V55, P89, DOI 10.1002/pros.10194; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; LEE C, 1995, ENDOCRINOLOGY, V136, P796, DOI 10.1210/en.136.2.796; MORRIS DI, 1991, J BIOL CHEM, V266, P13377; Nakhla AM, 1999, STEROIDS, V64, P213, DOI 10.1016/S0039-128X(98)00084-1; Nantermet PV, 2004, J BIOL CHEM, V279, P1310, DOI 10.1074/jbc.M310206200; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Prins G S, 2000, Mayo Clin Proc, V75 Suppl, pS32; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; Robles LD, 2002, J BIOL CHEM, V277, P25431, DOI 10.1074/jbc.M201199200; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; Rokhlin OW, 2005, ONCOGENE, V24, P6773, DOI 10.1038/sj.onc.1208833; Sadar MD, 1999, ENDOCR-RELAT CANCER, V6, P487, DOI 10.1677/erc.0.0060487; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Sadar MD, 2002, MOL CANCER THER, V1, P629; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; Segawa T, 2002, ONCOGENE, V21, P8749, DOI 10.1038/sj.onc.1205992; SHAH GV, 1994, ENDOCRINOLOGY, V134, P596, DOI 10.1210/en.134.2.596; Shenk JL, 2001, J BIOL CHEM, V276, P38472, DOI 10.1074/jbc.M103652200; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; Stroud RM, 1999, CURR OPIN STRUC BIOL, V9, P754, DOI 10.1016/S0959-440X(99)00040-8; Tao WK, 2001, GENE DEV, V15, P1796, DOI 10.1101/gad.894301; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; Tepper CG, 2002, CANCER RES, V62, P6606; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van Bokhoven A, 2003, PROSTATE, V57, P205, DOI 10.1002/pros.10290; VANPATTEN SM, 1991, P NATL ACAD SCI USA, V88, P5383, DOI 10.1073/pnas.88.12.5383; Velasco-Miguel S, 1999, ONCOGENE, V18, P127, DOI 10.1038/sj.onc.1202274; Vilaboa N, 2004, NUCLEIC ACIDS RES, V32, P6454, DOI 10.1093/nar/gkh981; Waghray A, 2001, PROTEOMICS, V1, P1327, DOI 10.1002/1615-9861(200110)1:10<1327::AID-PROT1327>3.3.CO;2-2; Wang G, 2006, J CELL BIOCHEM, V98, P36, DOI 10.1002/jcb.20802; Wright ME, 2003, MOL ENDOCRINOL, V17, P1726, DOI 10.1210/me.2003-0031; Xu LL, 2001, INT J CANCER, V92, P322, DOI 10.1002/ijc.1196; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; YOUNG CYF, 1992, BIOCHEMISTRY-US, V31, P818, DOI 10.1021/bi00118a026; YOUNG CYF, 1991, CANCER RES, V51, P3748; Zeng CQ, 2000, MICROSC RES TECHNIQ, V49, P467, DOI 10.1002/(SICI)1097-0029(20000601)49:5<467::AID-JEMT9>3.3.CO;2-M; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208; Zou ZQ, 2002, CLIN CANCER RES, V8, P1172; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051	63	54	64	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	55					7311	7323		10.1038/sj.onc.1209715	http://dx.doi.org/10.1038/sj.onc.1209715			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16751804				2022-12-28	WOS:000242244700010
J	Wen, XF; Yang, G; Mao, W; Thornton, A; Liu, J; Bast, RC; Le, XF				Wen, X-F; Yang, G.; Mao, W.; Thornton, A.; Liu, J.; Bast, R. C., Jr.; Le, X-F			HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy	ONCOGENE			English	Article						HER2; trastuzumab; TSP-1; IL-8; VEGF; p38; PI3K; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; METASTATIC BREAST-CANCER; KINASE INHIBITOR P27(KIP1); RECEPTOR TYROSINE KINASES; CELL-CYCLE ARREST; P38 MAP KINASE; TUMOR-GROWTH; ANTI-HER2 ANTIBODY; UP-REGULATION; IN-VITRO	We determined the impact of HER2 signaling on two proangiogenic factors, vascular endothelial growth factor ( VEGF) and interleukin-8(IL-8), and on an antiangiogenic factor, thrombospondin-1 (TSP-1). Re-expression of HER2 in MCF-7 and T-47D breast cancer cells that endogenously express low levels of HER2 resulted in elevated expression of VEGF and IL-8 and decreased expression of TSP-1. Inhibition of HER2 with a humanized anti-HER2 antibody ( trastuzumab, or Herceptin (R)) or a retrovirus-mediated small interfering RNA against HER2 (siHER2) decreased VEGF and IL-8 expression, but increased TSP-1 expression in BT474 breast cancer cells that express high levels of HER2. These in vitro results were further evaluated by treatment of BT474 xenografts in immunosuppressed mice with trastuzumab. Trastuzumab inhibited growth of BT474 xenografts and decreased microvascular density associated with down-regulation of VEGF and IL-8 and with upregulation of TSP-1 expression. Inhibiting the PI3K-AKT pathway decreased VEGF and IL-8 expression. AKT1 overexpession increased VEGF and IL-8 expression, but did not increase TSP- 1 expression. A p38 kinase inhibitor, SB203580, instead blocked TSP- 1 expression and a p38 activator, MKK6, increased TSP- 1 expression. Trastuzumab stimulated sustained p38 activation and SB203580 attenuated the TSP- 1 upregulation induced by trastuzumab. HER2 signaling therefore influences the equilibrium between pro- and antiangiogenic factors via distinct signaling pathways. Trastuzumab inhibits angiogenesis and tumor growth, at least in part, through activation of the HER2-p38-TSP-1 pathway and inhibition of the HER2-PI3K-AKT-VEGF/IL-8 pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Div Canc Med,Unit 355, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Le, XF (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Div Canc Med,Unit 355, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rbast@mdanderson.org; xfle@mdanderson.org	Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462	NCI NIH HHS [CA39930, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA039930] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bagheri-Yarmand R, 2000, J BIOL CHEM, V275, P39451, DOI 10.1074/jbc.M006150200; Bar-Eli M, 1999, PATHOBIOLOGY, V67, P12, DOI 10.1159/000028045; Baselga J, 2004, SEMIN ONCOL, V31, P51, DOI 10.1053/j.seminoncol.2004.07.022; Baselga J, 1998, CANCER RES, V58, P2825; Benoy IH, 2004, CLIN CANCER RES, V10, P7157, DOI 10.1158/1078-0432.CCR-04-0812; Bulavin DV, 2004, ADV CANCER RES, V92, P95, DOI 10.1016/S0065-230X(04)92005-2; Chelouche-Lev D, 2004, EUR J CANCER, V40, P2509, DOI 10.1016/j.ejca.2004.05.024; Chen JJW, 2003, CLIN CANCER RES, V9, P729; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Crown J, 2003, BREAST CANCER RES TR, V79, pS11; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; De Larco JE, 2001, AM J PATHOL, V158, P639, DOI 10.1016/S0002-9440(10)64005-9; Dimmeler S, 2000, CIRC RES, V86, P4, DOI 10.1161/01.RES.86.1.4; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Finn Richard S, 2003, Cancer Chemother Biol Response Modif, V21, P223; Freund A, 2003, ONCOGENE, V22, P256, DOI 10.1038/sj.onc.1206113; Green AR, 1997, INT J CANCER, V72, P937; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harmey JH, 2002, BIOESSAYS, V24, P280, DOI 10.1002/bies.10043; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Izumi Y, 2002, NATURE, V416, P279, DOI 10.1038/416279b; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kos KS, 2003, CANCER-AM CANCER SOC, V98, P1377, DOI 10.1002/cncr.11656; Kumar R, 2001, SEMIN ONCOL, V28, P27, DOI 10.1016/S0093-7754(01)90279-9; Le XF, 2005, CELL CYCLE, V4, P87, DOI 10.4161/cc.4.1.1360; Le XF, 2005, J BIOL CHEM, V280, P2092, DOI 10.1074/jbc.M403080200; Le XF, 2003, J BIOL CHEM, V278, P23441, DOI 10.1074/jbc.M300848200; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; Le XF, 2000, CANCER RES, V60, P3522; Loureiro RMB, 2005, BIOCHEM BIOPH RES CO, V326, P455, DOI 10.1016/j.bbrc.2004.11.053; Marmor MD, 2004, INT J RADIAT ONCOL, V58, P903, DOI 10.1016/j.ijrobp.2003.06.002; Miller KD, 2005, J CLIN ONCOL, V23, P792, DOI 10.1200/JCO.2005.05.098; Nahta R, 2003, CLIN CANCER RES, V9, P5078; Naito T, 2004, AM J PHYSIOL-RENAL, V286, pF278, DOI 10.1152/ajprenal.00139.2003; Pegram MD, 2002, SEMIN ONCOL, V29, P29, DOI 10.1053/sonc.2002.34053; Petit AMV, 1997, AM J PATHOL, V151, P1523; Price DJ, 2001, CELL GROWTH DIFFER, V12, P129; Ribatti D, 1998, INT J CANCER, V77, P449; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; Rofstad EK, 2002, BRIT J CANCER, V86, P301, DOI 10.1038/sj.bjc.6600052; Sargiannidou I, 2001, EXP BIOL MED, V226, P726, DOI 10.1177/153537020222600803; Shahied LS, 2004, J BIOL CHEM, V279, P53907, DOI 10.1074/jbc.M407888200; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Spiridon CI, 2004, CLIN CANCER RES, V10, P3542, DOI 10.1158/1078-0432.CCR-03-0549; Stein Steven, 2004, Clin Breast Cancer, V4 Suppl 3, pS117, DOI 10.3816/CBC.2004.s.005; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Xiong SB, 2001, CANCER RES, V61, P1727; Yang G, 2004, J BIOL CHEM, V279, P4339, DOI 10.1074/jbc.M311153200; Yen L, 2002, MOL BIOL CELL, V13, P4029, DOI 10.1091/mbc.e02-02-0084; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Zhang HT, 2003, CANCER BIOL THER, V2, pS122	55	131	135	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	52					6986	6996		10.1038/sj.onc.1209685	http://dx.doi.org/10.1038/sj.onc.1209685			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16715132				2022-12-28	WOS:000241732300009
J	Palacios, G; Moll, UM				Palacios, G.; Moll, U. M.			Mitochondrially targeted wild-type p53 suppresses growth of mutant p53 lymphomas in vivo	ONCOGENE			English	Article						p53; apoptosis; mitochondria; E mu-Myc lymphoma	MEMBRANE PERMEABILIZATION; GENE-THERAPY; APOPTOSIS; TRANSLOCATION; DEATH; PROTEIN; CELLS; BAX; DISRUPTION; ACTIVATION	The complex apoptotic functions of the p53 tumor suppressor are central to its antineoplastic activity in vivo. Besides its well-known action as a transcriptional activator of apoptotic genes, p53 exerts a direct proapoptotic role at the mitochondria via protein-protein interactions with Bcl2 family members, thus executing the shortest known circuitry of p53 death signaling. We recently reported that exclusive delivery of p53 to mitochondria exerts a significant in vivo tumor suppressor activity in p53-null lymphomas. However, it was unknown whether mitochondrially targeted p53 has suppressor activities in tumors harboring missense mutants, which constitute the vast majority of p53 alterations in human tumors. Here, we show that targeting p53 to mitochondria does confer a significant growth disadvantage in B-lymphomas expressing various point mutants of p53, resulting in efficient apoptosis induction in vitro and in vivo in mice.	SUNY Stony Brook, Stony Brook Univ, Dept Pathol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Moll, UM (corresponding author), SUNY Stony Brook, Stony Brook Univ, Dept Pathol, BSTL9,Room 134, Stony Brook, NY 11794 USA.	umoll@notes.cc.sunysb.edu						Arima Y, 2005, J BIOL CHEM, V280, P19166, DOI 10.1074/jbc.M410691200; Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Erster S, 2005, BIOCHEM BIOPH RES CO, V331, P843, DOI 10.1016/j.bbrc.2005.03.187; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; Essmann F, 2005, J BIOL CHEM, V280, P37169, DOI 10.1074/jbc.M502052200; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Lim DS, 2006, HUM GENE THER, V17, P347, DOI 10.1089/hum.2006.17.347; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Nemajerova A, 2005, FEBS LETT, V579, P6079, DOI 10.1016/j.febslet.2005.09.074; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Peng ZH, 2005, HUM GENE THER, V16, P1016, DOI 10.1089/hum.2005.16.1016; PETROS AM, 2004, FEBS LETT, P1; Roth JA, 2006, EXPERT OPIN BIOL TH, V6, P55, DOI 10.1517/14712598.6.1.55; Sansome C, 2001, FEBS LETT, V488, P110, DOI 10.1016/S0014-5793(00)02368-1; Sauthoff H, 2006, CANCER GENE THER, V13, P686, DOI 10.1038/sj.cgt.7700936; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Talos F, 2005, CANCER RES, V65, P9971, DOI 10.1158/0008-5472.CAN-05-1084; Yin SM, 2006, INT J ONCOL, V28, P781; Zhao YF, 2005, CANCER RES, V65, P3745, DOI 10.1158/0008-5472.CAN-04-3835	30	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6133	6139		10.1038/sj.onc.1209641	http://dx.doi.org/10.1038/sj.onc.1209641			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16682948				2022-12-28	WOS:000241101200011
J	Singh, SR; Zhen, W; Zheng, Z; Wang, H; Oh, SW; Liu, W; Zbar, B; Schmidt, LS; Hou, SX				Singh, S. R.; Zhen, W.; Zheng, Z.; Wang, H.; Oh, S-W; Liu, W.; Zbar, B.; Schmidt, L. S.; Hou, S. X.			The Drosophila homolog of the human tumor suppressor gene BHD interacts with the JAK-STAT and Dpp signaling pathways in regulating male germline stem cell maintenance	ONCOGENE			English	Article						tumor suppressor; Drosophila BHD homolog; male germline stem cell; stem cell maintenance; JAK/STAT signaling pathway; Dpp signaling pathway	SELF-RENEWAL; SPONTANEOUS PNEUMOTHORAX; DIFFERENTIATION; PROTEIN; MUTATIONS; FOLLICLE; ENCODES	Birt-Hogg-Dube syndrome (BHD) is a rare, inherited genodermatosis characterized by hair follicle hamartomas, kidney tumors and spontaneous pneumothorax. The BHD locus was mapped to chromosome 17p11.2 by linkage analysis, and germ line mutations in a novel gene ( BHD) were identified in a panel of BHD families. Using RNA interference to decrease expression of the Drosophila BHD homolog (DBHD), we have demonstrated that DBHD is required for male germline stem cell (GSC) maintenance in the fly testis. Reduction of DBHD gene activity suppresses the GSC overproliferation phenotype associated with overexpression of either unpaired (upd) or decapentaplegic (dpp). Further genetic interaction experiments suggest that DBHD regulates GSC maintenance downstream or in parallel of the JAK/STAT and Dpp signal-transduction pathways. These findings suggest that the BHD protein may regulate tumorigenesis through modulating stem cells in human.	NCI, Mouse Canc Genet Program, NIH, Frederick, MD 21702 USA; NCI, Immunobiol Lab, NIH, Frederick, MD 21702 USA; NCI, Basic Res Program, SAIC Frederick Inc, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Singh, SR (corresponding author), NCI, Mouse Canc Genet Program, NIH, Frederick, MD 21702 USA.	sshreeram@ncifcrf.gov; shou@mail.ncifcrf.gov	Singh/B-7614-2008	Singh/0000-0001-6545-583X	NATIONAL CANCER INSTITUTE [Z01SC006659, Z01BC010738] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 CA999999] Funding Source: Medline; NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baksa K, 2002, DEV BIOL, V243, P166, DOI 10.1006/dbio.2001.0539; BIRT AR, 1977, ARCH DERMATOL, V113, P1674, DOI 10.1001/archderm.113.12.1674; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brawley C, 2004, SCIENCE, V304, P1331, DOI 10.1126/science.1097676; Chen DH, 2005, CURR BIOL, V15, P179, DOI 10.1016/j.cub.2005.01.004; Chen DH, 2003, CURR BIOL, V13, P1786, DOI 10.1016/j.cub.2003.09.033; Chen HW, 2002, GENE DEV, V16, P388, DOI 10.1101/gad.955202; CHOMETTE G, 1985, TESTICULAR CANC, P35; Fabrizio JJ, 2003, DEV BIOL, V258, P117, DOI 10.1016/S0012-1606(03)00127-1; Fuller Margaret T., 1993, P71; Fuller MT, 1998, SEMIN CELL DEV BIOL, V9, P433, DOI 10.1006/scdb.1998.0227; Gilboa L, 2004, CURR BIOL, V14, P981, DOI 10.1016/j.cub.2004.05.049; Giordano E, 2002, GENETICS, V160, P637; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Kawase E, 2004, DEVELOPMENT, V131, P1365, DOI 10.1242/dev.01025; Kiger AA, 2000, NATURE, V407, P750, DOI 10.1038/35037606; Kiger AA, 2001, SCIENCE, V294, P2542, DOI 10.1126/science.1066707; Lingaas F, 2003, HUM MOL GENET, V12, P3043, DOI 10.1093/hmg/ddg336; Nickerson ML, 2002, CANCER CELL, V2, P157, DOI 10.1016/S1535-6108(02)00104-6; Okimoto K, 2004, P NATL ACAD SCI USA, V101, P2023, DOI 10.1073/pnas.0308071100; Pavlovich CP, 2002, AM J SURG PATHOL, V26, P1542, DOI 10.1097/00000478-200212000-00002; Pignoni F, 1997, DEVELOPMENT, V124, P271; Schmidt LS, 2001, AM J HUM GENET, V69, P876, DOI 10.1086/323744; Szakmary A, 2005, CURR BIOL, V15, P171, DOI 10.1016/j.cub.2005.01.005; Tran J, 2000, NATURE, V407, P754, DOI 10.1038/35037613; Tulina N, 2001, SCIENCE, V294, P2546, DOI 10.1126/science.1066700; Vocke CD, 2005, J NATL CANCER I, V97, P931, DOI 10.1093/jnci/dji154; Youngren KK, 2005, NATURE, V435, P360, DOI 10.1038/nature03595; Zbar B, 2002, CANCER EPIDEM BIOMAR, V11, P393	29	43	45	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2006	25	44					5933	5941		10.1038/sj.onc.1209593	http://dx.doi.org/10.1038/sj.onc.1209593			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16636660				2022-12-28	WOS:000240826300002
J	Pole, JCM; Courtay-Cahen, C; Garcia, MJ; Blood, KA; Cooke, SL; Alsop, AE; Tse, DML; Caldas, C; Edwards, PAW				Pole, J. C. M.; Courtay-Cahen, C.; Garcia, M. J.; Blood, K. A.; Cooke, S. L.; Alsop, A. E.; Tse, D. M. L.; Caldas, C.; Edwards, P. A. W.			High-resolution analysis of chromosome rearrangements on 8p in breast, colon and pancreatic cancer reveals a complex pattern of loss, gain and translocation	ONCOGENE			English	Article						8p12; breast cancer; array CGH; chromosome translocation; chromosome inversion; deletion	COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER; IN-SITU HYBRIDIZATION; CARCINOMA CELL-LINES; GAMMA-HEREGULIN; CYTOGENETIC ANALYSIS; COLORECTAL-CANCER; BLADDER-CANCER; POOR-PROGNOSIS; GROWTH-FACTOR	The short arm of chromosome 8, 8p, is often rearranged in carcinomas, typically showing distal loss by unbalanced translocation. We analysed 8p rearrangements in 48 breast, pancreatic and colon cancer cell lines by fluorescence in situ hybridization (FISH) and array comparative genomic hybridization, with a tiling path of 0.2 Mb resolution over 8p12 and 1 Mb resolution over chromosome 8. Selected breast lines (MDA-MB-134, MDA-MB-175, MDA-MB-361, T-47D and ZR-75-1) were analysed further. Most cell lines showed loss of 8p distal to a break that was between 31 Mb (5' to NRG1) and the centromere, but the translocations were accompanied by variable amplifications, deletions and inversions proximal to this break. The 8p12 translocation in T-47D was flanked by an inversion of 4 Mb, with a 100 kb deletion at the proximal end. The dicentric t(8; 11) in ZR-75-1 carries multiple rearrangements including interstitial deletions, a triplicated translocation junction between NRG1 and a fragment of 11q (unconnected to CCND1), and two separate amplifications, of FGFR1 and CCND1. We conclude that if there is a tumour suppressor gene on 8p it may be near 31 Mb, for example WRN; but the complexity of 8p rearrangements suggests that they target various genes proximal to 31 Mb including NRG1 and the amplicon centred around ZNF703/FLJ14299.	Univ Cambridge, Hutchison MRC Res Ctr, Dept Pathol, Canc Genom Program, Cambridge CB2 2XZ, England; Univ Cambridge, Hutchison MRC Res Ctr, Dept Oncol, Cambridge CB2 2XZ, England	University of Cambridge; University of Cambridge	Edwards, PAW (corresponding author), Univ Cambridge, Hutchison MRC Res Ctr, Dept Pathol, Canc Genom Program, Cambridge CB2 2XZ, England.	pawe1@cam.ac.uk	Edwards, Paul A/M-8291-2014; Caldas, Carlos/U-7250-2019; Caldas, Carlos/A-7543-2008; García, María J/G-1361-2016	Edwards, Paul A/0000-0002-4789-3374; Caldas, Carlos/0000-0003-3547-1489; García, María J/0000-0002-2236-9912	Breast Cancer Now [2005NOV68] Funding Source: Medline	Breast Cancer Now		Abdel-Rahman WM, 2001, P NATL ACAD SCI USA, V98, P2538, DOI 10.1073/pnas.041603298; Adams J, 2005, CANCER RES, V65, P66; Adelaide J, 2003, GENE CHROMOSOME CANC, V37, P333, DOI 10.1002/gcc.10218; Alsop AE, 2006, CANCER GENET CYTOGEN, V164, P97, DOI 10.1016/j.cancergencyto.2005.09.011; Arakawa H, 2004, NAT REV CANCER, V4, P978, DOI 10.1038/nrc1504; Asatiani E, 2005, CANCER RES, V65, P1164, DOI 10.1158/0008-5472.CAN-04-2688; Bautista S, 1998, GENE CHROMOSOME CANC, V22, P268, DOI 10.1002/(SICI)1098-2264(199808)22:4<268::AID-GCC2>3.0.CO;2-T; Bernardino L, 1998, GENE CHROMOSOME CANC, V23, P100, DOI 10.1002/(SICI)1098-2264(199810)23:2<100::AID-GCC2>3.0.CO;2-6; Birnbaum D, 2003, LANCET ONCOL, V4, P639, DOI 10.1016/S1470-2045(03)01225-7; Courtay-Cahen C, 2000, GENOMICS, V66, P15, DOI 10.1006/geno.2000.6178; Davidson JM, 2000, BRIT J CANCER, V83, P1309, DOI 10.1054/bjoc.2000.1458; DIB A, 1995, ONCOGENE, V10, P995; Douglas EJ, 2004, CANCER RES, V64, P4817, DOI 10.1158/0008-5472.CAN-04-0328; Dutrillaux B, 1995, ADV CANCER RES, V67, P59, DOI 10.1016/S0065-230X(08)60710-1; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Garcia MJ, 2005, ONCOGENE, V24, P5235, DOI 10.1038/sj.onc.1208741; Gribble SM, 2005, J MED GENET, V42, P8, DOI 10.1136/jmg.2004.024141; GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155; Hinck L, 2004, DEV CELL, V7, P783, DOI 10.1016/j.devcel.2004.11.002; Huang HE, 2004, CANCER RES, V64, P6840, DOI 10.1158/0008-5472.CAN-04-1762; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; Hwang ES, 2004, CLIN CANCER RES, V10, P5160, DOI 10.1158/1078-0432.CCR-04-0165; Karan D, 2003, INT J CANCER, V103, P285, DOI 10.1002/ijc.10813; Klaus M, 2003, CANCER GENET CYTOGEN, V144, P36, DOI 10.1016/S0165-4608(02)00876-2; Krane IM, 1996, ONCOGENE, V12, P1781; Lemieux N, 1996, CANCER GENET CYTOGEN, V90, P75, DOI 10.1016/0165-4608(96)00061-1; Liu XF, 1999, ONCOGENE, V18, P7110, DOI 10.1038/sj.onc.1203136; Mann SM, 1997, CHROMOSOME RES, V5, P145, DOI 10.1023/A:1018426426477; Margolin AA, 2005, BIOINFORMATICS, V21, P3308, DOI 10.1093/bioinformatics/bti500; Morris JS, 1997, GENE CHROMOSOME CANC, V20, P120, DOI 10.1002/(SICI)1098-2264(199710)20:2<120::AID-GCC3>3.0.CO;2-5; Nakao K, 2004, CARCINOGENESIS, V25, P1345, DOI 10.1093/carcin/bgh134; Orsetti B, 2004, CANCER RES, V64, P6453, DOI 10.1158/0008-5472.CAN-04-0756; Paris PL, 2003, AM J PATHOL, V162, P763, DOI 10.1016/S0002-9440(10)63873-4; Prentice LM, 2005, ONCOGENE, V24, P7281, DOI 10.1038/sj.onc.1208892; Ray ME, 2004, CANCER RES, V64, P40, DOI 10.1158/0008-5472.CAN-03-1022; Rousseau-Merck MF, 1999, CANCER RES, V59, P3152; Schaefer G, 1997, ONCOGENE, V15, P1385, DOI 10.1038/sj.onc.1201317; Sinclair PB, 2000, BLOOD, V95, P738, DOI 10.1182/blood.V95.3.738.003k21_738_743; Sirivatanauksorn V, 2001, INT J CANCER, V91, P350, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.3.CO;2-3; Teixeira MR, 2002, GENE CHROMOSOME CANC, V33, P1, DOI 10.1002/gcc.1206; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; Toomes C, 2003, GENE CHROMOSOME CANC, V37, P132, DOI 10.1002/gcc.10191; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Van Limbergen H, 2001, GENE CHROMOSOME CANC, V30, P274, DOI 10.1002/1098-2264(2000)9999:9999<1::AID-GCC1089>3.3.CO;2-T; VANDENENGH G, 1992, SCIENCE, V257, P1410, DOI 10.1126/science.1388286; Veltman JA, 2003, CANCER RES, V63, P2872; Volik S, 2003, P NATL ACAD SCI USA, V100, P7696, DOI 10.1073/pnas.1232418100; Wang XZ, 1999, ONCOGENE, V18, P5718, DOI 10.1038/sj.onc.1202950	48	71	76	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2006	25	41					5693	5706		10.1038/sj.onc.1209570	http://dx.doi.org/10.1038/sj.onc.1209570			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16636668				2022-12-28	WOS:000240599100011
J	Gloire, G; Charlier, E; Rahmouni, S; Volanti, C; Chariot, A; Erneux, C; Piette, J				Gloire, G.; Charlier, E.; Rahmouni, S.; Volanti, C.; Chariot, A.; Erneux, C.; Piette, J.			Restoration of SHIP-1 activity in human leukemic cells modifies NF-kappa B activation pathway and cellular survival upon oxidative stress	ONCOGENE			English	Article						NF-kappa B; oxidative stress; SHIP-1; IKK; leukemic cells; apoptosis	TYROSINE PHOSPHORYLATION; PHOSPHOINOSITIDE 3-KINASE; HEMATOPOIETIC-CELLS; 5-PHOSPHATASE SHIP; INVOLVEMENT; ALPHA; PHOSPHATASE; APOPTOSIS; TRANSDUCTION; COMPLEX	Nuclear factor-kappa B (NF-kappa B) is an important prosurvival transcription factor activated in response to a large array of external stimuli, including reactive oxygen species (ROS). Previous works have shown that NF-kappa B activation by ROS involved tyrosine phosphorylation of the inhibitor I kappa B alpha through an I kappa B kinase (IKK)-independent mechanism. In the present work, we investigated with more details NF-kappa B redox regulation in human leukemic cells. By using different cell lines (CEM, Jurkat and the subclone Jurkat JR), we clearly showed that NF-kappa B activation by hydrogen peroxide (H2O2) is cell-type dependent: it activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha in Jurkat cells, whereas it induces an IKK-mediated I kappa B alpha phosphorylation on S32 and 36 in CEM and Jurkat JR cells. We showed that this H2O2-induced IKK activation in CEM and Jurkat JR cells is mediated by SH2-containing inositol 5'-phosphatase 1 (SHIP-1), a lipid phosphatase that is absent in Jurkat cells. Indeed, the complementation of SHIP-1 in Jurkat cells made them shift to an IKK-dependent mechanism upon oxidative stress stimulation. We also showed that Jurkat cells expressing SHIP-1 are more resistant to H2O2-induced apoptosis than the parental cells, suggesting that SHIP-1 has an important role in leukemic cell responses to ROS in terms of signal transduction pathways and apoptosis resistance, which can be of interest in improving ROS-mediated chemotherapies.	CBIG, GIGA, Virol & Immunol Unit, Inst Pathol, B-4000 Liege, Belgium; Univ Liege, Virol Immunol Unit, B-4000 Liege, Belgium; Univ Liege, Pathol Unit, B-4000 Liege, Belgium; Univ Liege, CBIG, GIGA, Med Chem Unit, B-4000 Liege, Belgium; Univ Brussels, IRIBHM, Brussels, Belgium	University of Liege; University of Liege; University of Liege; Universite Libre de Bruxelles	Piette, J (corresponding author), CBIG, GIGA, Virol & Immunol Unit, Inst Pathol, B23, B-4000 Liege, Belgium.	jpiette@ulg.ac.be		Chariot, Alain/0000-0002-1691-4347				Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Ambruso DR, 2004, MOL GENET METAB, V81, P313, DOI 10.1016/j.ymgme.2004.01.009; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Backers K, 2003, ADV ENZYME REGUL, V43, P15, DOI 10.1016/S0065-2571(02)00043-2; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Boer AK, 2001, LEUKEMIA, V15, P1750, DOI 10.1038/sj.leu.2402261; Bruyns C, 1999, BIOL CHEM, V380, P969, DOI 10.1515/BC.1999.120; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chandra J, 2003, BLOOD, V102, P4512, DOI 10.1182/blood-2003-02-0562; Chou WC, 2005, CURR OPIN HEMATOL, V12, P1, DOI 10.1097/01.moh.0000148552.93303.45; Drayer AL, 1996, BIOCHEM BIOPH RES CO, V225, P243, DOI 10.1006/bbrc.1996.1161; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Fang HQ, 2004, J IMMUNOL, V173, P360, DOI 10.4049/jimmunol.173.1.360; Freeburn RW, 2002, J IMMUNOL, V169, P5441, DOI 10.4049/jimmunol.169.10.5441; Genova ML, 2004, ANN NY ACAD SCI, V1011, P86, DOI 10.1196/annals.1293.010; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Hildeman DA, 2004, FREE RADICAL BIO MED, V36, P1496, DOI 10.1016/j.freeradbiomed.2004.03.023; Horn S, 2004, LEUKEMIA, V18, P1839, DOI 10.1038/sj.leu.2403529; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Karin M, 2005, IUBMB LIFE, V57, P283, DOI 10.1080/15216540500097111; Kim H, 2005, ONCOGENE, V24, P1252, DOI 10.1038/sj.onc.1208282; Krystal G, 2000, SEMIN IMMUNOL, V12, P397, DOI 10.1006/smim.2000.0222; Lemay S, 2000, MOL CELL BIOL, V20, P2743, DOI 10.1128/MCB.20.8.2743-2754.2000; Livolsi A, 2001, EUR J BIOCHEM, V268, P1508, DOI 10.1046/j.1432-1327.2001.02028.x; Muraille E, 1999, BIOCHEM J, V342, P697, DOI 10.1042/0264-6021:3420697; Ogawa Y, 2003, INT J MOL MED, V11, P27; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Ravet E, 2002, J HEMATOTH STEM CELL, V11, P327, DOI 10.1089/152581602753658510; Robson JD, 2004, MOL CELL BIOL, V24, P2332, DOI 10.1128/MCB.24.6.2332-2343.2004; Rohrschneider LR, 2000, GENE DEV, V14, P505; Sattler M, 1997, ONCOGENE, V15, P2379, DOI 10.1038/sj.onc.1201422; Schoonbroodt S, 2000, J IMMUNOL, V164, P4292, DOI 10.4049/jimmunol.164.8.4292; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; Tomlinson MG, 2004, J BIOL CHEM, V279, P55089, DOI 10.1074/jbc.M408141200; van Dijk TB, 2000, BLOOD, V96, P3406; Volanti C, 2002, PHOTOCHEM PHOTOBIOL, V75, P36, DOI 10.1562/0031-8655(2002)075<0036:IOOSIN>2.0.CO;2	38	46	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2006	25	40					5485	5494		10.1038/sj.onc.1209542	http://dx.doi.org/10.1038/sj.onc.1209542			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16619039				2022-12-28	WOS:000240370400002
J	Hsu, LC; Huang, X; Seasholtz, S; Potter, DM; Gollin, SM				Hsu, L-C; Huang, X.; Seasholtz, S.; Potter, D. M.; Gollin, S. M.			Gene amplification and overexpression of protein phosphatase 1 alpha in oral squamous cell carcinoma cell lines	ONCOGENE			English	Article						PP1 alpha; cyclin D1; gene amplification; OSCC tumorigenesis	ANTISENSE CYCLIN D1; CATALYTIC SUBUNIT; HUMAN CANCER; RETINOBLASTOMA PROTEIN; HEPATOMA-CELLS; BAND 11Q13; HEAD; NECK; ONCOGENES; TYPE-1	Gene amplification of chromosomal band 11q13 is observed frequently in oral squamous cell carcinomas (OSCC). Several genes have been identified in the 11q13 amplicon, including FGF3, FGF4, CCND1, EMS1 and TAOS1. Some of these genes show good correlation between gene copy number and gene expression, and are thought to play a role in driving 11q13 amplification. The PPP1CA gene, which encodes the catalytic subunit of serine/threonine protein phosphatase protein phosphatase 1 alpha (PP1 alpha), is also located in 11q13. Protein phosphatase 1a, one of the isoforms of PP1, regulates critical cellular events, such as cell cycle progression, and apoptosis. We sought to explore the possibility that PPP1CA was amplified and overexpressed in OSCC cells. Indeed, some OSCC cell lines had PPP1CA gene amplification, as analysed by fluorescence in situ hybridization. We have also demonstrated that PPP1CA gene copy number is increased in 21% of the OSCC cell lines determined by quantitative microsatellite analysis. PP1a RNA expression determined by quantitative reverse transcription-polymerase chain reaction was significantly higher in OSCC cell lines with 11q13 amplification compared to those without 11q13 amplification (P= 0.011). The difference was even more significant between cell lines with at least three copies of the PPP1CA gene and those with less than three copies of the gene (P= 0.00045). Relative PP1a protein levels were also significantly associated with PPP1CA gene copy number (P= 0.014). Furthermore, knockdown of PP1 alpha and/or cyclin D1 by small interfering RNA suppressed OSCC cell growth, at least in part by modulating pRB phosphorylation, resulting in G0 growth arrest. These data suggest that like the cyclin D1 gene, CCND1, amplification and overexpression of the PP1a gene, PPP1CA, may be involved in OSCC tumorigenesis and/or progression.	Univ Pittsburgh, Dept Obstet Gynecol & Reprod Sci, Sch Med, Magee Womens Res Inst, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hsu, LC (corresponding author), Univ Pittsburgh, Dept Obstet Gynecol & Reprod Sci, Sch Med, Magee Womens Res Inst, 204 Craft Ave, Pittsburgh, PA 15213 USA.	rsilh@mwri.magee.edu		Gollin, Susanne/0000-0001-5438-6808; HSU, LIH-CHING/0000-0002-7816-3825	NCI NIH HHS [P30 CA47904, R01 CA111436] Funding Source: Medline; NIDCR NIH HHS [R01 DE14729] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA047904, R01CA111436] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014729] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AKERVALL JA, 1995, CANCER, V76, P853, DOI 10.1002/1097-0142(19950901)76:5<853::AID-CNCR2820760520>3.0.CO;2-6; ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; Ayllon V, 2001, J IMMUNOL, V166, P7345, DOI 10.4049/jimmunol.166.12.7345; BARKER HM, 1990, GENOMICS, V7, P159, DOI 10.1016/0888-7543(90)90536-4; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; Chu EC, 2004, MED SCI MONITOR, V10, pRA235; Cohen PTW, 2002, J CELL SCI, V115, P241; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; Ginzinger DG, 2000, CANCER RES, V60, P5405; Gollin SM, 2001, HEAD NECK-J SCI SPEC, V23, P238, DOI 10.1002/1097-0347(200103)23:3<238::AID-HED1025>3.0.CO;2-H; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Huang X, 2002, P NATL ACAD SCI USA, V99, P11369, DOI 10.1073/pnas.172285799; Imai Y, 1999, INT J ONCOL, V14, P121; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Jin YS, 1998, GENE CHROMOSOME CANC, V22, P312, DOI 10.1002/(SICI)1098-2264(199808)22:4<312::AID-GCC7>3.0.CO;2-Y; Kohno T, 1999, CANCER RES, V59, P4170; LESE CM, 1995, GENE CHROMOSOME CANC, V12, P288, DOI 10.1002/gcc.2870120409; Liu Y, 2002, CANCER RES, V62, P6357; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; PARK NH, 1991, CARCINOGENESIS, V12, P1627, DOI 10.1093/carcin/12.9.1627; Reshmi SC, 2004, GENE CHROMOSOME CANC, V41, P38, DOI 10.1002/gcc.20064; SAADAT M, 1995, CANCER LETT, V94, P165, DOI 10.1016/0304-3835(95)03846-O; Savelyeva L, 2001, CANCER LETT, V167, P115, DOI 10.1016/S0304-3835(01)00472-4; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; Schwab M, 1998, BIOESSAYS, V20, P473, DOI 10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.3.CO;2-N; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Shuster MI, 2000, GENE CHROMOSOME CANC, V28, P153, DOI 10.1002/(SICI)1098-2264(200006)28:2<153::AID-GCC4>3.0.CO;2-9; Sogawa K, 1997, CANCER LETT, V112, P263, DOI 10.1016/S0304-3835(96)04589-2; Wang MB, 1998, OTOLARYNG HEAD NECK, V119, P593, DOI 10.1016/S0194-5998(98)70017-8; Wang SJ, 2001, OTOLARYNG HEAD NECK, V124, P656, DOI 10.1067/mhn.2001.116039	35	36	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2006	25	40					5517	5526		10.1038/sj.onc.1209563	http://dx.doi.org/10.1038/sj.onc.1209563			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16619035				2022-12-28	WOS:000240370400005
J	Fulda, S; Debatin, KM				Fulda, S.; Debatin, K-M			5-aza-2 '-deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8	ONCOGENE			English	Article						caspase-8; apoptosis; TRAIL; interferon-gamma; resistance	DRUG-INDUCED APOPTOSIS; BREAST-TUMOR CELLS; NEUROBLASTOMA-CELLS; DEATH RECEPTOR; INTERFERON-GAMMA; DNA METHYLATION; DECOY RECEPTORS; CANCER-THERAPY; CD95 APO-1/FAS; EXPRESSION	Resistance of tumors to cytotoxic therapy remains a major obstacle in cancer treatment and is often caused by defects in apoptosis programs. Caspase-8, a key mediator of death receptor-induced apoptosis, has previously been reported to be frequently inactivated by epigenetic silencing in many tumors, for example in neuroblastoma or medulloblastoma. Here, we provide for the first time evidence that combined treatment with suboptimal concentrations of the demethylating agent 5-Aza-2'-deoxycytidine (5-dAzaC) and interferon-gamma (IFN-gamma) cooperated to upregulate caspase-8 expression in neuroblastoma and medulloblastoma cells lacking caspase-8. Consequently, activation of caspase-8 and downstream caspases upon addition of TNF-related apoptosis-inducing ligand (TRAIL) was restored by pretreatment with 5-dAzaC and IFN-gamma. Importantly, pretreatment with 5-dAzaC and IFN-gamma acted in concert to significantly enhance TRAIL-induced apoptosis in neuroblastoma and medulloblastoma cells. Inhibition of caspase-8 by dominant-negative caspase-8 or by the relatively specific caspase-8 inhibitior zIETD.fmk inhibited the increase in apoptosis provided by 5-dAzaC and IFN-gamma, indicating that caspase-8 is a key mediator of this sensitization effect. Thus, by demonstrating that 5-dAzaC and IFN-gamma at relatively low individual concentrations cooperate to restore caspase-8 expression and sensitize resistant neuroblastoma and medulloblastoma cells to TRAIL-induced apoptosis, our findings have important implications for novel strategies targeting defective apoptosis pathways in neuroectodermal tumors.	Univ Childrens Hosp, Dept Hematol Oncol, D-89075 Ulm, Germany	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf	Fulda, S (corresponding author), Univ Childrens Hosp, Dept Hematol Oncol, Eythstr 24, D-89075 Ulm, Germany.	simone.fulda@uniklinik-ulm.de	Fulda, Simone/D-5864-2011; Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Banelli B, 2002, NAT MED, V8, P1333, DOI 10.1038/nm1202-1333; Baylin SB, 2002, SEMIN CANCER BIOL, V12, P331, DOI 10.1016/S1044-579X(02)00053-6; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Casciano I, 2004, CELL DEATH DIFFER, V11, P131, DOI 10.1038/sj.cdd.4401327; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Eggert A, 2001, CANCER RES, V61, P1314; Esteller M, 2005, CURR OPIN ONCOL, V17, P55, DOI 10.1097/01.cco.0000147383.04709.10; Fan WM, 1998, ONCOL REP, V5, P1035; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Fulda S, 2004, CURR CANCER DRUG TAR, V4, P569, DOI 10.2174/1568009043332763; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Fulda S, 2004, VITAM HORM, V67, P275; Grotzer MA, 2000, ONCOGENE, V19, P4604, DOI 10.1038/sj.onc.1203816; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hopkins-Donaldson S, 2003, CELL DEATH DIFFER, V10, P356, DOI 10.1038/sj.cdd.4401157; Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jonasch E, 2001, ONCOLOGIST, V6, P34, DOI 10.1634/theoncologist.6-1-34; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kontny HU, 2001, CELL DEATH DIFFER, V8, P506, DOI 10.1038/sj.cdd.4400836; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Pingoud-Meier C, 2003, CLIN CANCER RES, V9, P6401; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; Ruiz-Ruiz C, 2004, J BIOL CHEM, V279, P19712, DOI 10.1074/jbc.M313023200; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Yang XZ, 2003, CANCER RES, V63, P1122	35	78	84	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2006	25	37					5125	5133		10.1038/sj.onc.1209518	http://dx.doi.org/10.1038/sj.onc.1209518			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16607283				2022-12-28	WOS:000240063700005
J	Liu, L; Andrews, L; Tollefsbol, TO				Liu, L.; Andrews, L. G.; Tollefsbol, T. O.			Loss of the human polycomb group protein BMI1promotes cancer-specific cell death	ONCOGENE			English	Article						BMI1; cancer stem cells; telomerase; INK4A-ARF; PcG proteins	LIFE-SPAN; SELF-RENEWAL; BMI-1 ONCOPROTEIN; LEUKEMIA-CELLS; MYC; IDENTIFICATION; TRANSFORMATION; PROLIFERATION; TUMORIGENESIS; SENESCENCE	The polycomb group protein BMI1 has been shown to support normal stem cell proliferation via its putative stem cell factor function, but it is not known if BMI1 may also act as a cancer stem cell factor to promote cancer development. To determine the role of human BMI1 in cancer growth and survival, we performed a loss-of-function analysis of BMI1 by RNA interference (RNAi) in both normal and malignant human cells. Our results indicate that BMI1 is crucial for the short-term survival of cancer cells but not of normal cells. We also demonstrated that loss of BMI1 was more effective in suppressing cancer cell growth than retinoid-treatment, and surviving cancer cells showed significantly reduced tumorigenicity. The cancer-specific growth retardation was mediated by an increased level of apoptosis and a delayed cell cycle progression due to the loss of BMI1. By comparison, BMI1 deficiency caused only a moderate inhibition of the cell cycle progression in normal lung cells. In both normal and cancer cells, the loss of BMI1 led to an upregulation of INK4A-ARF, but with no significant effect on the level of telomerase gene expression, suggesting that other BMI1-cooperative factors in addition to INK4A-ARF activation may be involved in the BMI1-dependent cancer-specific growth retardation. Thus, human BMI1 is critical for the short-term survival of cancer cells, and inhibition of BMI1 has minimal effect on the survival of normal cells. These findings provide a foundation for developing a cancer-specific therapy targeting BMI1.	Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Ctr Aging, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Liu, L (corresponding author), Univ Alabama Birmingham, Dept Biol, 175 Campbell Hall,1300 Univ Blvd, Birmingham, AL 35294 USA.	liangliu@uab.edu		Tollefsbol, Trygve/0000-0002-0284-1511	NATIONAL CANCER INSTITUTE [R21CA114019] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG020375] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA114019, R21 CA114019-02] Funding Source: Medline; NIA NIH HHS [R03 AG020375-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bea S, 2001, CANCER RES, V61, P2409; Blair A, 1997, BLOOD, V89, P3104, DOI 10.1182/blood.V89.9.3104; Bruggeman SWM, 2005, GENE DEV, V19, P1438, DOI 10.1101/gad.1299305; Casillas MA, 2003, GENE, V316, P57, DOI 10.1016/S0378-1119(03)00739-X; Cohen KJ, 1996, MOL CELL BIOL, V16, P5527; Dimri GP, 2002, CANCER RES, V62, P4736; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Itahana K, 2003, MOL CELL BIOL, V23, P389, DOI 10.1128/MCB.23.1.389-401.2003; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; KAKUNAGA T, 1985, TRANSFORMATION ASSAY; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Liu L, 2004, MOL CANCER THER, V3, P1003; Mihara K, 2006, BLOOD, V107, P305, DOI 10.1182/blood-2005-06-2393; Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Mori T, 2005, MOL CELL BIOL, V25, P5183, DOI 10.1128/MCB.25.12.5183-5195.2005; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Shakhova O, 2005, J MOL MED, V83, P596, DOI 10.1007/s00109-005-0682-0; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Takeda Y, 2004, J GENE MED, V6, P833, DOI 10.1002/jgm.583; Terai M, 2005, MOL BIOL CELL, V16, P1491, DOI 10.1091/mbc.e04-07-0652; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Vonlanthen S, 2001, BRIT J CANCER, V84, P1372, DOI 10.1054/bjoc.2001.1791	28	69	84	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2006	25	31					4370	4375		10.1038/sj.onc.1209454	http://dx.doi.org/10.1038/sj.onc.1209454			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16501599	Green Accepted			2022-12-28	WOS:000239240100012
J	De la Cueva, E; Garcia-Cao, I; Herranz, M; Lopez, P; Garcia-Palencia, P; Flores, JM; Serrano, M; Fernandez-Piqueras, J; Martin-Caballero, J				De la Cueva, E.; Garcia-Cao, I.; Herranz, M.; Lopez, P.; Garcia-Palencia, P.; Flores, J. M.; Serrano, M.; Fernandez-Piqueras, J.; Martin-Caballero, J.			Tumorigenic activity of p21(Waf1/Cip1) in thymic lymphoma	ONCOGENE			English	Article						p21; p53; apoptosis; cell cycle; lymphoma	TUMOR-FORMATION; INHIBITOR P21; SKIN CARCINOGENESIS; MICE LACKING; P21(CIP1); DEFICIENCY; P27(KIP1); RADIATION; APOPTOSIS; P53	The cell cycle inhibitor p21(Waf1/Cip1) is among the most important mediators of the tumor suppressor p53. However, there is increasing evidence indicating that p21 could favor tumorigenesis in specific cell types. In particular, the absence of p21 delays the development of thymic lymphomas induced either by ataxia-telangiectasia mutated deficiency or by ionizing irradiation. Here, we extend these observations to the context of p53-deficient mice. The absence of p21 results in a significant extension of the lifespan of p53-null and p53-haploin sufficient mice, and this effect can be attributed exclusively to a decrease in the incidence of spontaneous thymic lymphomas. Specifically, despite the occurrence of a variety of tumor types in the context of p53 deficiency, the only tumors that were significantly impaired by the absence of p21 were thymic lymphomas. Moreover, the absence of p21 also delays the incidence of radiation-induced thymic lymphomas in p53-deficient mice. Interestingly, p21-deficient lymphomas have a higher apoptotic rate than p21-proficient lymphomas, and this could be on the basis of the delayed incidence of thymic lymphomas in the absence of p21. Together, our results indicate that p21 plays an oncogenic role restricted to thymic lymphomas that is mechanistically independent of p53 and associated to a lower tumor apoptotic rate.	Spanish Natl Canc Ctr CNIO, Dept Mol Oncol, Unit Anim Experimentat, Madrid 28029, Spain; Spanish Natl Canc Ctr CNIO, Tumor Suppress Grp, Madrid 28029, Spain; Spanish Natl Canc Ctr CNIO, Canc Epigenet Grp, Madrid 28029, Spain; Univ Autonoma Madrid, Human Mol Genet Lab, Madrid, Spain; Univ Complutense Madrid, Sch Vet, Dept Anim Surg & Med, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Autonomous University of Madrid; Complutense University of Madrid	Serrano, M (corresponding author), Spanish Natl Canc Ctr CNIO, Dept Mol Oncol, Unit Anim Experimentat, 3 Melchor Fernandez Almagro St, Madrid 28029, Spain.	mserrano@cnio.es	Herranz, Michel/L-2561-2016; Serrano, Manuel/H-2634-2015	Serrano, Manuel/0000-0001-7177-9312; de la Cueva, Ernesto/0000-0001-7078-0901; Garcia Palencia, Pilar/0000-0002-4077-3732				Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Balomenos D, 2000, NAT MED, V6, P171, DOI 10.1038/72272; Bearss DJ, 2002, CANCER RES, V62, P2077; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Garcia-Cao I, 2002, EMBO J, V21, P6225, DOI 10.1093/emboj/cdf595; Gartel AL, 2002, MOL CANCER THER, V1, P639; HARPER JW, 1993, CELL, V75, P805; Jackson RJ, 2003, CANCER RES, V63, P3021; Jackson RJ, 2002, ONCOGENE, V21, P8486, DOI 10.1038/sj.onc.1205946; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Martin-Caballero J, 2004, ONCOGENE, V23, P8231, DOI 10.1038/sj.onc.1207863; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Poole AJ, 2004, ONCOGENE, V23, P8128, DOI 10.1038/sj.onc.1207994; Salvador JM, 2002, IMMUNITY, V16, P499, DOI 10.1016/S1074-7613(02)00302-3; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Weinberg WC, 1999, CANCER RES, V59, P2050; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu SQ, 2000, BIOCHEM BIOPH RES CO, V269, P179, DOI 10.1006/bbrc.2000.2247; Yang WC, 2005, AM J PATHOL, V166, P1239, DOI 10.1016/S0002-9440(10)62342-5; Yang WC, 2001, CANCER RES, V61, P565	29	58	61	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2006	25	29					4128	4132		10.1038/sj.onc.1209432	http://dx.doi.org/10.1038/sj.onc.1209432			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16462758				2022-12-28	WOS:000238802400014
J	Jiang, M; Wei, Q; Wang, J; Du, Q; Yu, J; Zhang, L; Dong, Z				Jiang, M.; Wei, Q.; Wang, J.; Du, Q.; Yu, J.; Zhang, L.; Dong, Z.			Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis	ONCOGENE			English	Article						p53; PUMA; mitochondria; cisplatin; apoptosis; nephrotoxicity	BCL-X-L; COLORECTAL-CANCER CELLS; PROXIMAL TUBULE CELLS; MITOCHONDRIAL DYSFUNCTION; INDUCED NEPHROTOXICITY; DEATH; BAX; PATHWAYS; EXPRESSION; GENE	Nephrotoxicity is a major side effect of cisplatin, a widely used cancer therapy drug. Depending on its concentration, cisplatin induces necrosis or apoptosis of tubular cells in the kidneys, whereas the underlying injury mechanism is unclear. Our recent work has suggested a critical role for p53 in cisplatin-induced tubular cell apoptosis; nevertheless, the apoptotic events triggered by p53 remain elusive. The current study has examined Bcl-2 family proteins, critical regulators of apoptosis that may be subjected to p53 regulation. Following cisplatin treatment, the expression of Bcl-xL, an antiapoptotic molecule, was suppressed, while the expression of Bak, a proapoptotic molecule, increased slightly. Of interest, PUMA-alpha, a newly identified p53-responsive proapoptotic Bcl-2 family protein, was drastically induced by cisplatin. PUMA-alpha induction preceded or paralleled the development of apoptosis. Induced PUMA-alpha was localized in mitochondria and appeared to antagonize Bcl-xL via molecular interaction. PUMA-alpha induction during cisplatin treatment was attenuated by pifithrin-alpha, a pharmacological inhibitor of p53, which was accompanied by the amelioration of Bax activation, cytochrome c release and apoptosis. Moreover, PUMA-alpha induction was suppressed by dominant-negative p53. Importantly, cisplatin-induced apoptosis was ameliorated in PUMA-alpha knockout cells. In vivo, cisplatin induced PUMA-alpha in the kidneys, and the inductive response was abrogated in p53-deficient animals. Together, this study has demonstrated the first compelling evidence for the involvement of PUMA-alpha in p53-mediated renal cell apoptosis during cisplatin nephrotoxicity.	Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA; Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA; Univ Pittsburgh, Inst Canc, Dept Pathol, Pittsburgh, PA USA; Univ Pittsburgh, Inst Canc, Dept Pharmacol, Pittsburgh, PA USA; Dept Vet Affairs Med Ctr, Med Res Serv, Augusta, GA USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Dong, Z (corresponding author), Med Coll Georgia, Dept Cellular Biol & Anat, 1459 Laney Walker Blvd,CB2917, Augusta, GA 30912 USA.	zdong@mail.mcg.edu	Yu, Jian/A-8301-2009; Zhang, Lin/A-7389-2009	Yu, Jian/0000-0002-4021-1000; Zhang, Lin/0000-0003-0018-3903; Livingston, Man/0000-0001-8638-0902; Du, Quansheng/0000-0003-4079-8662				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Akeshima R, 2001, BRIT J CANCER, V84, P1551, DOI 10.1054/bjoc.2001.1812; Arany I, 2003, SEMIN NEPHROL, V23, P460, DOI 10.1016/S0270-9295(03)00089-5; Arany I, 2004, AM J PHYSIOL-RENAL, V287, pF543, DOI 10.1152/ajprenal.00112.2004; Baliga R, 1998, KIDNEY INT, V53, P394, DOI 10.1046/j.1523-1755.1998.00767.x; Chang JS, 2005, LIFE SCI, V76, P1883, DOI 10.1016/j.lfs.2004.11.003; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Cummings BS, 2002, J PHARMACOL EXP THER, V302, P8, DOI 10.1124/jpet.302.1.8; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Dong Z, 2004, J BIOL CHEM, V279, P9215, DOI 10.1074/jbc.M312225200; Dong Z, 2003, AM J PATHOL, V163, P663, DOI 10.1016/S0002-9440(10)63693-0; Fuertes MA, 2003, CURR MED CHEM, V10, P257, DOI 10.2174/0929867033368484; Gottlieb RA, 2002, METHODS, V26, P341, DOI 10.1016/S1046-2023(02)00040-3; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gudkov AV, 2005, BIOCHEM BIOPH RES CO, V331, P726, DOI 10.1016/j.bbrc.2005.03.153; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Jiang M, 2004, AM J PHYSIOL-RENAL, V287, pF1140, DOI 10.1152/ajprenal.00262.2004; Kaushal GP, 2001, KIDNEY INT, V60, P1726, DOI 10.1046/j.1523-1755.2001.00026.x; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Li SY, 2004, AM J PHYSIOL-RENAL, V287, pF990, DOI 10.1152/ajprenal.00206.2004; Liu H, 2003, KIDNEY INT, V63, P1687, DOI 10.1046/j.1523-1755.2003.00908.x; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Megyesi J, 1998, J CLIN INVEST, V101, P777, DOI 10.1172/JCI1497; MIYASHITA T, 1995, CELL, V80, P293; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Niedner H, 2001, MOL PHARMACOL, V60, P1153, DOI 10.1124/mol.60.6.1153; Nowak G, 2002, J BIOL CHEM, V277, P43377, DOI 10.1074/jbc.M206373200; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Park MS, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134858; Ramesh G, 2002, J CLIN INVEST, V110, P835, DOI 10.1172/JCI200215606; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Sheikh-Hamad D, 2004, ARCH TOXICOL, V78, P147, DOI 10.1007/s00204-003-0521-4; Shen ZN, 2005, BIOCHEM BIOPH RES CO, V328, P375, DOI 10.1016/j.bbrc.2004.12.186; Shiraishi F, 2000, AM J PHYSIOL-RENAL, V278, pF726, DOI 10.1152/ajprenal.2000.278.5.F726; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Tomasoni S, 2004, CURR GENE THER, V4, P115, DOI 10.2174/1566523044578013; Tomita N, 2004, CURR DRUG TARGETS, V5, P717, DOI 10.2174/1389450043345146; Tsuruya K, 2003, KIDNEY INT, V63, P72, DOI 10.1046/j.1523-1755.2003.00709.x; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang JZ, 2004, J BIOL CHEM, V279, P19948, DOI 10.1074/jbc.M313629200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei QQ, 2005, AM J NEPHROL, V25, P491, DOI 10.1159/000088171; Woost PG, 1996, KIDNEY INT, V50, P125, DOI 10.1038/ki.1996.295; Yi XL, 2003, J BIOL CHEM, V278, P16992, DOI 10.1074/jbc.M300039200; Yu F, 2005, AM J PHYSIOL-RENAL, V289, pF514, DOI 10.1152/ajprenal.00101.2005; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	52	167	174	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2006	25	29					4056	4066		10.1038/sj.onc.1209440	http://dx.doi.org/10.1038/sj.onc.1209440			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16491117				2022-12-28	WOS:000238802400006
J	Hao, B; Miao, X; Li, Y; Zhang, X; Sun, T; Liang, G; Zhao, Y; Zhou, Y; Wang, H; Chen, X; Zhang, L; Tan, W; Wei, Q; Lin, D; He, F				Hao, B.; Miao, X.; Li, Y.; Zhang, X.; Sun, T.; Liang, G.; Zhao, Y.; Zhou, Y.; Wang, H.; Chen, X.; Zhang, L.; Tan, W.; Wei, Q.; Lin, D.; He, F.			A novel T-77C polymorphism in DNA repair gene XRCC1 contributes to diminished promoter activity and increased risk of non-small cell lung cancer	ONCOGENE			English	Article						base excision repair; non-small cell lung cancer; single nucleotide polymorphism; transcription regulation	ACID SUBSTITUTION VARIANTS; LINKAGE PHASE; ASSOCIATIONS; TRANSCRIPTION; ADDUCTS; XPD; SUSCEPTIBILITY; IDENTIFICATION; CARCINOGENS; BIOMARKERS	X-ray repair cross-complementing 1 (XRCC1) plays a key role in DNA base excision repair and cells lacking its activity are hypersensitive to DNA damage. Recently, we reported a SNP (rs3213245, -77T > C) in the XRCC1 gene 5' untranslated region (UTR) was significantly associated with the risk of developing esophageal squamous-cell carcinoma. Computer analysis predicted that this SNP was in the core of Sp1-binding motif, which suggested its functional significance. Gel shift and super shift assays confirmed that -77T > C polymorphic site in the XRCC1 promoter was within the Sp1-binding motif and the T > C substitution greatly enhanced the binding affinity of Sp1 to this region. Luciferase assays indicated that the Sp1-high-affinity C-allelic XRCC1 promoter was associated with a reduced transcriptional activity. The association between -77T > C and three other amino-acid substitution-causing polymorphisms in XRCC1 and risk of lung cancer was examined in 1024 patients and 1118 controls and the results showed that only the -77T > C polymorphism was significantly associated with an increased risk of developing lung cancer. Multivariate logistic regression analysis found that an increased risk of lung cancer was associated with the variant XRCC1 -77 genotypes (TC and CC) compared with the TT genotype (OR 1.46, 95% CI 1.18-1.82; P = 0.001) and the increased risk was more pronounced in smokers (OR 1.63, 95% CI 1.20-2.21) than in non-smokers (OR 1.28, 95% CI 0.94-1.76). Taken together, these results showed that the functional SNP -77T > C in XRCC1 5'UTR was associated with cancer development owing to the decreased transcriptional activity of C-allele-containing promoter with higher affinity to Sp1 binding.	Chinese Acad Med Sci, Dept Etiol & Carcinogenesis, Canc Inst & Hosp, Beijing 100037, Peoples R China; Peking Union Med Coll, Beijing, Peoples R China; Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China; Beijing Inst Radiat Med, Lab Syst Biol, Beijing, Peoples R China; Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Tsinghua University; Academy of Military Medical Sciences - China; University of Texas System; UTMD Anderson Cancer Center	Lin, D (corresponding author), Chinese Acad Med Sci, Dept Etiol & Carcinogenesis, Inst Canc, Beijing 100021, Peoples R China.	dlin@public.bta.net.cn; hefc@nic.bmi.ac.cn	miao, xiaoping/C-4336-2011; Zhao, Yanlin/L-2773-2013; Wang, Weili/D-1546-2011; zhang, xuemei/F-3818-2010; Zhao, Yanlin/M-2360-2013; hao, Bingtao/G-6648-2011	miao, xiaoping/0000-0002-6818-9722; Zhao, Yanlin/0000-0002-0278-7543; Zhao, Yanlin/0000-0002-0278-7543; hao, Bingtao/0000-0003-1997-9338				Caldecott KW, 2003, DNA REPAIR, V2, P955, DOI 10.1016/S1568-7864(03)00118-6; Dean G, 2000, J BIOL CHEM, V275, P32664, DOI 10.1074/jbc.275.42.32664; Ding KY, 2003, BIOINFORMATICS, V19, P2147, DOI 10.1093/bioinformatics/btg276; Duell EJ, 2000, CARCINOGENESIS, V21, P965, DOI 10.1093/carcin/21.5.965; GONZALEZ FJ, 1995, CANCER RES, V55, P710; Goode EL, 2002, CANCER EPIDEM BIOMAR, V11, P1513; Hao BT, 2004, CANCER RES, V64, P4378, DOI 10.1158/0008-5472.CAN-04-0372; Hecht SS, 2003, NAT REV CANCER, V3, P733, DOI 10.1038/nrc1190; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hu JJ, 2001, CARCINOGENESIS, V22, P917, DOI 10.1093/carcin/22.6.917; Hu ZB, 2005, PHARMACOGENET GENOM, V15, P457, DOI 10.1097/01.fpc.0000167329.85163.0d; Ioannidis JPA, 2003, LANCET, V361, P567, DOI 10.1016/S0140-6736(03)12516-0; Kelsey KT, 2004, CANCER EPIDEM BIOMAR, V13, P1337; Lake SL, 2003, HUM HERED, V55, P56, DOI 10.1159/000071811; Li J, 2001, J VIROL, V75, P8400, DOI 10.1128/JVI.75.18.8400-8406.2001; Liang G, 2003, INT J CANCER, V105, P669, DOI 10.1002/ijc.11136; Lunn RM, 1999, CANCER RES, V59, P2557; Matullo G, 2001, INT J CANCER, V92, P562, DOI 10.1002/ijc.1228; Matullo G, 2001, CARCINOGENESIS, V22, P1437, DOI 10.1093/carcin/22.9.1437; Mohrenweiser HW, 2002, CANCER EPIDEM BIOMAR, V11, P1054; NAKACHI K, 1993, CANCER RES, V53, P2994; Pagliuca A, 1998, J BIOL CHEM, V273, P7668, DOI 10.1074/jbc.273.13.7668; Palli D, 2001, INT J CANCER, V94, P121, DOI 10.1002/ijc.1433; Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688; Shen MR, 1998, CANCER RES, V58, P604; Shou YP, 1998, J BIOL CHEM, V273, P5716, DOI 10.1074/jbc.273.10.5716; Shu XO, 2003, CANCER EPIDEM BIOMAR, V12, P1462; Sturgis EM, 1999, CARCINOGENESIS, V20, P2125, DOI 10.1093/carcin/20.11.2125; Sun T, 2004, JNCI-J NATL CANCER I, V96, P1030, DOI 10.1093/jnci/djh187; Tebbs RS, 1999, DEV BIOL, V208, P513, DOI 10.1006/dbio.1999.9232; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; Vineis P, 1997, INT J CANCER, V71, P1, DOI 10.1002/(SICI)1097-0215(19970328)71:1<1::AID-IJC1>3.0.CO;2-Y; Wang HJ, 2003, CANCER RES, V63, P8057; Wang YF, 2003, DNA REPAIR, V2, P901, DOI 10.1016/S1568-7864(03)00085-5; WEINFELD M, 2001, CELL, V104, P107; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; Xing DY, 2002, INT J CANCER, V100, P600, DOI 10.1002/ijc.10528; Zhou W, 2003, CANCER EPIDEM BIOMAR, V12, P359	39	99	107	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3613	3620		10.1038/sj.onc.1209355	http://dx.doi.org/10.1038/sj.onc.1209355			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16652158				2022-12-28	WOS:000238448200014
J	Jubb, AM; Chalasani, S; Frantz, GD; Smits, R; Grabsch, HI; Kavi, V; Maughan, NJ; Hillan, KJ; Quirke, P; Koeppen, H				Jubb, AM; Chalasani, S; Frantz, GD; Smits, R; Grabsch, HI; Kavi, V; Maughan, NJ; Hillan, KJ; Quirke, P; Koeppen, H			Achaete-scute like 2 (ascl2) is a target of Wnt signalling and is upregulated in intestinal neoplasia	ONCOGENE			English	Article						small intestinal cancer; colorectal cancer; colorectal adenomas; Wnt signalling; achaete-scute like 2	CANCER CELLS; COLON-CANCER; EXPRESSION; TRANSCRIPTION; METHYLATION; SURVIVIN; PROTEINS; FEATURES; TISSUE; CYCLE	Achaete-scute like (ASCL)2 is a basic helix-loop-helix transcription factor essential for the maintenance of proliferating trophoblasts during placental development. Using oligonucleotide microarrays we identified ascl2 as a gene significantly upregulated in colorectal adenocarcinomas (n=36 cancers, n=16 normals; 15-fold, P < 0.0001). This finding was confirmed by quantitative reverse transcriptase (RT)-PCR on large intestinal cancers (n=29 cancers, n=16 normals; 10-fold, P < 0.0001). In situ hybridization for ascl2 demonstrated expression at the base of small and large intestinal crypts (n=304), but in no other normal tissues excepting placenta. By in situ hybridization, 52-71% of colorectal adenomas (n=187), 50-73% of large (n=327) and 33-64% of small intestinal adenocarcinomas (n=124) were positive for ascl2 expression. Upregulation of murine ascl2 was also observed using oligonucleotide microarrays, quantitative RT-PCR and in situ hybridization on apc(min/+) and apc(1638N/+) smad4(-/+) tumours. Tumour cell lines stably transfected with LEF1(DN) or APC2, or transiently transfected with short-interfering RNA (siRNA) against beta-catenin showed a significant downregulation of ascl2. Colocalization of ascl2 with nuclear beta-catenin was observed in 73 small intestinal adenocarcinomas (P < 0.0008) and apc(min/+) tumours. Preliminary in vitro data suggest ascl2 may promote progression through the G2/M cell cycle checkpoint. In summary, ascl2 is a putative regulator of proliferation that is overexpressed in intestinal neoplasia.	Univ Leeds, Acad Unit Pathol, Leeds Inst Mol Med, St James Hosp, Leeds LS9 7TF, W Yorkshire, England; Erasmus Univ, Med Ctr, Rotterdam, Netherlands; Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA	Saint James's University Hospital; University of Leeds; Erasmus University Rotterdam; Erasmus MC; Roche Holding; Genentech	Jubb, AM (corresponding author), Univ Leeds, Acad Unit Pathol, Leeds Inst Mol Med, St James Hosp, Level 4,IMMECR JIF Bldg, Leeds LS9 7TF, W Yorkshire, England.	adrianjubb@gmail.com	Quirke, Philip/AAI-1362-2019	Quirke, Philip/0000-0002-3597-5444				Alders M, 1997, HUM MOL GENET, V6, P859, DOI 10.1093/hmg/6.6.859; Banerjea A, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-21; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; GUILLEMOT F, 1995, NAT GENET, V9, P235, DOI 10.1038/ng0395-235; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hernandez S, 2001, LAB INVEST, V81, P465, DOI 10.1038/labinvest.3780254; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; Jubb AM, 2003, J PATHOL, V200, P577, DOI 10.1002/path.1371; Leow CC, 2004, CANCER RES, V64, P6050, DOI 10.1158/0008-5472.CAN-04-0290; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Miyamoto T, 2002, J ASSIST REPROD GEN, V19, P240, DOI 10.1023/A:1015362903486; Morison IM, 2005, TRENDS GENET, V21, P457, DOI 10.1016/j.tig.2005.06.008; Myohanen SK, 1998, CANCER RES, V58, P591; Olmeda D, 2003, MOL BIOL CELL, V14, P2844, DOI 10.1091/mbc.E03-01-0865; Rodel F, 2005, CANCER RES, V65, P4881, DOI 10.1158/0008-5472.CAN-04-3028; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Westerman Ba, 2002, CLIN CANCER RES, V8, P1082; Westerman BA, 2001, PLACENTA, V22, P511, DOI 10.1053/plac.2001.0695; Yang SY, 2002, ARTERIOSCL THROM VAS, V22, P1797, DOI 10.1161/01.ATV.0000038995.31179.24; Zhang T, 2001, CANCER RES, V61, P8664; Zheng SC, 2000, CARCINOGENESIS, V21, P2057, DOI 10.1093/carcin/21.11.2057	25	100	110	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 8	2006	25	24					3445	3457		10.1038/sj.onc.1209382	http://dx.doi.org/10.1038/sj.onc.1209382			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16568095				2022-12-28	WOS:000238448100009
J	Ellerhorst, JA; Ekmekcioglu, S; Johnson, MK; Cooke, CP; Johnson, MM; Grimm, EA				Ellerhorst, J. A.; Ekmekcioglu, S.; Johnson, M. K.; Cooke, C. P.; Johnson, M. M.; Grimm, E. A.			Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma	ONCOGENE			English	Article						N-Ras; B-Raf; ERK; iNOS; melanoma	NITRIC-OXIDE SYNTHASE; KAPPA-B; RAS MUTATIONS; N-RAS; MELANOCYTIC LESIONS; TUMOR PROGRESSION; GENE-EXPRESSION; BRAF GENE; CANCER; CELLS	Activating mutations of the genes for NRAS and BRAF, components of the p44/42 mitogen-activated protein kinase (MAPK) pathway, are common findings in melanoma. Recent evidence in several nonmelanoma cell systems supports the regulation of the inducible nitric oxide synthase ( iNOS) gene by this pathway. On the basis of our data showing that melanoma iNOS expression predicts shortened patient survival, we formulated the hypothesis that activating mutations of NRAS or BRAF, which lead to constitutive activation of the p44/42 MAPK pathway, drive iNOS expression in human melanoma. In the present study, we have shown that inhibition of melanoma iNOS activity by S-methylisothiourea leads to decreased cell proliferation, confirming the importance of iNOS activity for melanoma cell growth. Regulation of melanoma iNOS expression by the p44/42 MAPK pathway was demonstrated by inhibition of the pathway by U0126, and by BRAF RNA interference. To explore this regulatory pathway in human tissue, 20 melanoma tumors were examined for NRAS and BRAF mutations, immunohistochemical evidence of ERK phosphorylation, and iNOS expression. A significant association was found among these three features. We conclude that in human melanoma, activating mutations of NRAS and BRAF drive constitutive iNOS expression and, implicitly, nitric oxide production, contributing to the poor survival of these patients.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Ellerhorst, JA (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Unit 362, Houston, TX 77030 USA.	jaellerh@mdanderson.org	Ekmekcioglu, Suhendan/A-9686-2009		NCI NIH HHS [P50 CA093459, CA16672, R01 CA90282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090282, P30CA016672, P50CA093459] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bhat NR, 2002, BRAIN RES, V948, P93, DOI 10.1016/S0006-8993(02)02953-0; Brose MS, 2002, CANCER RES, V62, P6997; Colasanti M, 2000, TRENDS PHARMACOL SCI, V21, P249, DOI 10.1016/S0165-6147(00)01499-1; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Demunter A, 2001, J INVEST DERMATOL, V117, P1483, DOI 10.1046/j.0022-202x.2001.01601.x; Ekmekcioglu S, 2003, MOL CANCER THER, V2, P9; Ekmekcioglu S, 2000, CLIN CANCER RES, V6, P4768; Gay RD, 1998, BBA-GENE STRUCT EXPR, V1443, P315, DOI 10.1016/S0167-4781(98)00234-6; Goodall J, 2004, MOL CELL BIOL, V24, P2923, DOI 10.1128/MCB.24.7.2923-2931.2004; Gorden A, 2003, CANCER RES, V63, P3955; Guan KL, 2000, J BIOL CHEM, V275, P27354; Jaramillo M, 2003, J IMMUNOL, V171, P4243, DOI 10.4049/jimmunol.171.8.4243; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; Jiang BB, 2004, J BIOL CHEM, V279, P1323, DOI 10.1074/jbc.M307521200; Kleinert H, 2003, BIOL CHEM, V384, P1343, DOI 10.1515/BC.2003.152; Kristof AS, 2001, J BIOL CHEM, V276, P8445, DOI 10.1074/jbc.M009563200; Liu XJ, 2002, J BIOL CHEM, V277, P39312, DOI 10.1074/jbc.M205107200; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Massi D, 2001, J PATHOL, V194, P194, DOI 10.1002/1096-9896(200106)194:2<194::AID-PATH851>3.0.CO;2-S; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Omholt K, 2002, CLIN CANCER RES, V8, P3468; Park SK, 1997, BIOCHEM J, V322, P609, DOI 10.1042/bj3220609; Perrotta C, 2004, CANCER RES, V64, P3767, DOI 10.1158/0008-5472.CAN-04-0668; Salvucci O, 2001, CANCER RES, V61, P318; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; SZABO C, 1994, P NATL ACAD SCI USA, V91, P12472, DOI 10.1073/pnas.91.26.12472; Tang CH, 2004, J BIOL CHEM, V279, P288, DOI 10.1074/jbc.M310821200; Wink DA, 1998, FREE RADICAL BIO MED, V25, P434, DOI 10.1016/S0891-5849(98)00092-6; Wink DA, 2003, FREE RADICAL BIO MED, V34, P951, DOI 10.1016/S0891-5849(02)01362-X; Yazdi AS, 2003, J INVEST DERMATOL, V121, P1160, DOI 10.1046/j.1523-1747.2003.12559.x; Zheng MZ, 2004, MELANOMA RES, V14, P165, DOI 10.1097/01.cmr.0000129374.76399.19	31	35	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3956	3962		10.1038/sj.onc.1209419	http://dx.doi.org/10.1038/sj.onc.1209419			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16474847				2022-12-28	WOS:000238668800009
J	Luo, W; Wang, X; Kageshita, T; Wakasugi, S; Karpf, AR; Ferrone, S				Luo, W.; Wang, X.; Kageshita, T.; Wakasugi, S.; Karpf, A. R.; Ferrone, S.			Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells	ONCOGENE			English	Article						HMW-MAA expression; melanoma cell lines and lesions; promoter DNA methylation; 5-aza 2 '-deoxycytidine	CHONDROITIN SULFATE PROTEOGLYCAN; ACRAL LENTIGINOUS MELANOMA; MONOCLONAL-ANTIBODY MK2-23; CPG ISLANDS; TUMOR; 5-AZA-2'-DEOXYCYTIDINE; LESIONS; CANCER; ACTIVATION; INDUCTION	The human high molecular weight- melanoma associated antigen ( HMW- MAA) is a membrane- bound chondroitin sulfate proteoglycan that is variably expressed in a high percentage of melanoma cell lines and tumors. Since the mechanism( s) regulating HMW- MAA expression has( ve) not been defined, in this study, we have examined whether promoter DNA methylation regulates the level of HMW-MAA expression. In melanoma cell lines, the level of HMW- MAA mRNA and protein expression is coordinately regulated, implicating a transcriptional control mechanism. Consistent with a role for regulation by DNA methylation, we have found that a dense CpG island flanks the human HMW- MAA gene transcriptional start site. Methylation- specific PCR and sodium bisulfite DNA sequencing analyses indicate that the HMW- MAA promoter is heavily methylated in melanoma cell lines, melanoma lesions and normal lymphocytes that do not express HMW- MAA; in contrast, the HMW- MAA promoter is not methylated in melanoma cell lines and tumors that express this antigen. In addition, HMW-MAA expression is markedly induced in HMW- MAA-negative melanoma cell lines by incubation with the DNA methyltransferase inhibitor 5- aza- 2'- deoxycytidine. In summary, our results establish DNA methylation as a key regulator of HMW- MAA expression by human melanoma cells. This information represents a useful background to optimize immunotherapeutic strategies targeting HMW- MAA.	New York State Dept Hlth, Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA; New York State Dept Hlth, Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Kumamoto Univ, Grad Sch Med Sci, Dept Dermatol, Kumamoto, Japan	Roswell Park Cancer Institute; Roswell Park Cancer Institute; Kumamoto University	Ferrone, S (corresponding author), New York State Dept Hlth, Roswell Pk Canc Inst, Dept Immunol, Elm & Carlton St, Buffalo, NY 14263 USA.	soldano.ferrone@roswellpark.org		Karpf, Adam/0000-0002-0866-0666	NCI NIH HHS [P01 CA89480, R01 CA105500, R01 CA116674-01A1, R01 CA116674] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA105500, P01CA089480, R01CA116674] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bestor TH, 2003, ANN NY ACAD SCI, V983, P22, DOI 10.1111/j.1749-6632.2003.tb05959.x; Burg MA, 1998, J CELL PHYSIOL, V177, P299, DOI 10.1002/(SICI)1097-4652(199811)177:2<299::AID-JCP12>3.3.CO;2-0; Campoli MR, 2004, CRIT REV IMMUNOL, V24, P267, DOI 10.1615/CritRevImmunol.v24.i4.40; Chekenya M, 1999, INT J DEV NEUROSCI, V17, P421, DOI 10.1016/S0736-5748(99)00019-2; Ching TT, 2005, NAT GENET, V37, P645, DOI 10.1038/ng1563; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; DE SC, 1996, P NATL ACAD SCI USA, V93, P7149, DOI DOI 10.1073/PNAS.93.14.7149; Eisenmann KM, 1999, NAT CELL BIOL, V1, P507, DOI 10.1038/70302; Fang XX, 1999, MOL BIOL CELL, V10, P3373, DOI 10.1091/mbc.10.10.3373; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Hafner C, 2005, INT J CANCER, V114, P426, DOI 10.1002/ijc.20769; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Iida J, 1996, SEMIN CANCER BIOL, V7, P155, DOI 10.1006/scbi.1996.0021; Iida J, 2001, J BIOL CHEM, V276, P18786, DOI 10.1074/jbc.M010053200; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; KAGESHITA T, 1991, CANCER RES, V51, P1726; KAGESHITA T, 1993, CANCER RES, V53, P2830; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; Karpf AR, 2004, MOL PHARMACOL, V65, P18, DOI 10.1124/mol.65.1.18; Kawasaki H, 2004, NATURE, V431, P211, DOI 10.1038/nature02889; KUSAMA M, 1989, J IMMUNOL, V143, P3844; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Liu G, 2004, CANCER RES, V64, P4980, DOI 10.1158/0008-5472.CAN-03-3504; MITTELMAN A, 1992, P NATL ACAD SCI USA, V89, P466, DOI 10.1073/pnas.89.2.466; MITTELMAN A, 1994, CANCER RES, V54, P415; Morris KV, 2004, SCIENCE, V305, P1289, DOI 10.1126/science.1101372; Serrano A, 2001, INT J CANCER, V94, P243, DOI 10.1002/ijc.1452; Sigalotti L, 2002, J IMMUNOTHER, V25, P16, DOI 10.1097/00002371-200201000-00002; Song F, 2005, P NATL ACAD SCI USA, V102, P3336, DOI 10.1073/pnas.0408436102; TEMPONI M, 1992, CANCER RES, V52, P2497; WEBER J, 1994, CANCER RES, V54, P1766; Yang JB, 2004, J CELL BIOL, V165, P881, DOI 10.1083/jcb.200403174	35	30	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2873	2884		10.1038/sj.onc.1209319	http://dx.doi.org/10.1038/sj.onc.1209319			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16407841				2022-12-28	WOS:000237448200005
J	Wang, Z; Rong, YP; Malone, MH; Davis, MC; Zhong, F; Distelhorst, CW				Wang, Z; Rong, YP; Malone, MH; Davis, MC; Zhong, F; Distelhorst, CW			Thioredoxin-interacting protein (txnip) is a glucocorticoid-regulated primary response gene involved in mediating glucocorticoid-induced apoptosis	ONCOGENE			English	Article						glucocorticoid; apoptosis; lymphoma; dexamethasone-induced gene; thioredoxin-interacting protein; txnip	LEUKEMIC-CELLS; OXIDATIVE STRESS; T-CELLS; IN-VIVO; RECEPTOR; EXPRESSION; ACTIVATION; DEATH; IDENTIFICATION; DEXAMETHASONE	Glucocorticoid hormones induce apoptosis in lymphoid cells. This process is transcriptionally regulated and requires de novo RNA/protein synthesis. However, the full spectrum of glucocorticoid-regulated genes mediating this cell death process is unknown. Through gene expression pro. ling we discovered that the expression of thioredoxin-intereacting protein (txnip) mRNA is significantly induced by the glucocorticoid hormone dexamethasone not only in the murine T-cell lymphoma line WEHI7.2, but also in normal mouse thymocytes. This result was confirmed by Northern blot analysis in multiple models of dexamethasone-induced apoptosis. The induction of txnip mRNA by dexamethasone appears to be mediated through the glucocorticoid receptor as it is blocked in the presence of RU486, a glucocorticoid receptor antagonist. Deletion and mutation analysis of the txnip promoter identified a functional glucocorticoid response element in the txnip promoter. Reporter assays demonstrated that this glucocorticoid response element was necessary and sufficient for induction of txnip by dexamethasone. Expression of a GFP-TXNIP fusion protein was sufficient to induce apoptosis in WEHI7.2 cells, and repression of endogenous txnip by RNA interference inhibited dexamethasone-induced apoptosis in WEHI7.2 cells. Together, these findings indicate that txnip is a novel glucocorticoid-induced primary target gene involved in mediating glucocorticoid- induced apoptosis.	Case Western Reserve Univ, Sch Med, Ctr Comprehens Canc, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Comprehens Canc, Dept Pharmacol, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Distelhorst, CW (corresponding author), Case Western Reserve Univ, Sch Med, Ctr Comprehens Canc, Dept Med, WRB 3-133,10900 Euclid Ave, Cleveland, OH 44106 USA.	cwd@case.edu	Davis, Michael C/L-8920-2013	Davis, Michael C/0000-0003-2293-5694	NCI NIH HHS [CP30 CA43703, T32 CA59366, R01 CA42755] Funding Source: Medline; NHLBI NIH HHS [T32 HL07147] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA059366, P30CA043703, R01CA042755] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007147] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309; Baker A, 1997, CANCER RES, V57, P5162; Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; CAIRNS C, 1991, MOL ENDOCRINOL, V5, P598, DOI 10.1210/mend-5-4-598; Chapman MS, 1996, MOL ENDOCRINOL, V10, P967, DOI 10.1210/me.10.8.967; Chauhan D, 2002, ONCOGENE, V21, P1346, DOI 10.1038/sj.onc.1205205; CHEN KS, 1994, BBA-GENE STRUCT EXPR, V1219, P26, DOI 10.1016/0167-4781(94)90242-9; COHEN JJ, 1984, J IMMUNOL, V132, P38; DIEKEN ES, 1992, MOL CELL BIOL, V12, P589, DOI 10.1128/MCB.12.2.589; Han SH, 2003, ONCOGENE, V22, P4035, DOI 10.1038/sj.onc.1206610; HARMON JM, 1979, J CELL PHYSIOL, V98, P267, DOI 10.1002/jcp.1040980203; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; Jondal M, 2004, TRENDS IMMUNOL, V25, P595, DOI 10.1016/j.it.2004.09.003; Junn E, 2000, J IMMUNOL, V164, P6287, DOI 10.4049/jimmunol.164.12.6287; Kim KY, 2004, BIOCHEM BIOPH RES CO, V315, P369, DOI 10.1016/j.bbrc.2004.01.047; Malone MH, 2004, J BIOL CHEM, V279, P52850, DOI 10.1074/jbc.M408040200; Minn AH, 2005, ENDOCRINOLOGY, V146, P2397, DOI 10.1210/en.2004-1378; Mullick J, 2001, J BIOL CHEM, V276, P18007, DOI 10.1074/jbc.M100671200; Nishinaka Y, 2001, REDOX REP, V6, P289, DOI 10.1179/135100001101536427; Nishiyama A, 1999, J BIOL CHEM, V274, P21645, DOI 10.1074/jbc.274.31.21645; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; Oberg HH, 2004, CELL DEATH DIFFER, V11, P674, DOI 10.1038/sj.cdd.4401407; Park CG, 1996, IMMUNITY, V4, P583, DOI 10.1016/S1074-7613(00)80484-7; Planey SL, 2003, CANCER RES, V63, P172; Powis G, 2001, ANNU REV BIOPH BIOM, V30, P421, DOI 10.1146/annurev.biophys.30.1.421; Prefontaine GG, 1998, MOL CELL BIOL, V18, P3416, DOI 10.1128/MCB.18.6.3416; Qian N, 1997, HUM MOL GENET, V6, P2021, DOI 10.1093/hmg/6.12.2021; Ramdas J, 1998, ENDOCRINOLOGY, V139, P3813, DOI 10.1210/en.139.9.3813; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Rho J, 2001, MOL CELL BIOL, V21, P8365, DOI 10.1128/MCB.21.24.8365-8370.2001; Saitoh T, 2001, J NEUROCHEM, V78, P1267, DOI 10.1046/j.1471-4159.2001.00505.x; Schmidt S, 2004, CELL DEATH DIFFER, V11, pS45, DOI 10.1038/sj.cdd.4401456; Schoneveld OJLM, 2004, BBA-GENE STRUCT EXPR, V1680, P114, DOI 10.1016/j.bbaexp.2004.09.004; Thompson EB, 1998, STEROIDS, V63, P368, DOI 10.1016/S0039-128X(98)00045-2; Tome ME, 2001, CANCER RES, V61, P2766; Tonomura N, 2003, J IMMUNOL, V170, P2469, DOI 10.4049/jimmunol.170.5.2469; Torres-Roca JF, 2000, J IMMUNOL, V165, P4822, DOI 10.4049/jimmunol.165.9.4822; TRUSS M, 1990, P NATL ACAD SCI USA, V87, P7180, DOI 10.1073/pnas.87.18.7180; Wang RX, 1998, J IMMUNOL, V161, P2201; Wang YL, 2002, J BIOL CHEM, V277, P26496, DOI 10.1074/jbc.M202133200; Wang ZQ, 2003, J BIOL CHEM, V278, P23861, DOI 10.1074/jbc.M301843200; Wang ZQ, 2003, J BIOL CHEM, V278, P27053, DOI 10.1074/jbc.M303723200; Webb MS, 2003, J STEROID BIOCHEM, V85, P183, DOI 10.1016/S0960-0760(03)00194-8; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yamawaki H, 2005, J CLIN INVEST, V115, P733, DOI 10.1172/JCI200523001	46	87	87	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1903	1913		10.1038/sj.onc.1209218	http://dx.doi.org/10.1038/sj.onc.1209218			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16301999				2022-12-28	WOS:000236224800007
J	Nagar, S; Remmel, RP				Nagar, S; Remmel, RP			Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer	ONCOGENE			English	Review						drug metabolism; uridine diphosphoglucuronosyltransferase; genetic polymorphisms	HUMAN UDP-GLUCURONOSYLTRANSFERASE; HUMAN LIVER-MICROSOMES; SINGLE-NUCLEOTIDE POLYMORPHISMS; SERUM BILIRUBIN CONCENTRATIONS; UGT1A1 PROMOTER POLYMORPHISM; 1A7 GENETIC POLYMORPHISMS; IN-VITRO GLUCURONIDATION; CRIGLER-NAJJAR-SYNDROME; N-HYDROXY-PHIP; GILBERTS-SYNDROME	The uridine diphosphoglucuronosyltransferases (UGTs) belong to a superfamily of enzymes that catalyse the glucuronidation of numerous endobiotics and xenobiotics. Several human hepatic and extrahepatic UGT isozymes have been characterized with respect to their substrate specificity, tissue expression and gene structure. Genetic polymorphisms have been identified for almost all the UGT family members. A wide variety of anticancer drugs, dietary chemopreventives and carcinogens are known to be conjugated by members of both UGT1A and UGT2B subfamilies. This review examines in detail each UGT isozyme known to be associated with cancer and carcinogenesis. The cancer-related substrates for several UGTs are summarized, and the functionally relevant genetic polymorphisms of UGTs are reviewed. A number of genotype-phenotype association studies have been carried out to characterize the role of UGT pharmacogenetics in several types of cancer, and these examples are discussed here. In summary, this review focuses on the role of the human UGT genetic polymorphisms in carcinogenesis, chemoprevention and cancer risk.	Temple Univ, Sch Pharm, Dept Pharmaceut Sci, Philadelphia, PA 19140 USA; Univ Minnesota, Coll Pharm, Dept Med Chem, Minneapolis, MN USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Minnesota System; University of Minnesota Twin Cities	Nagar, S (corresponding author), Temple Univ, Sch Pharm, Dept Pharmaceut Sci, 3307 N Broad St, Philadelphia, PA 19140 USA.	swati.nagar@temple.edu	Remmel, Rory/N-2453-2015; , Swati/AAC-3195-2020					Adegoke OJ, 2004, BREAST CANCER RES TR, V85, P239, DOI 10.1023/B:BREA.0000025419.26423.b8; Andersen A, 1999, CANCER CHEMOTH PHARM, V44, P422, DOI 10.1007/s002800050999; Ando M, 2002, JPN J CANCER RES, V93, P591, DOI 10.1111/j.1349-7006.2002.tb01295.x; Ando Y, 1998, PHARMACOGENETICS, V8, P357, DOI 10.1097/00008571-199808000-00010; Ando Y, 2000, CANCER RES, V60, P6921; AONO S, 1993, BIOCHEM BIOPH RES CO, V197, P1239, DOI 10.1006/bbrc.1993.2610; Araki J, 2005, EUR J CANCER, V41, P2360, DOI 10.1016/j.ejca.2005.04.043; Balram C, 2002, PHARMACOGENETICS, V12, P81, DOI 10.1097/00008571-200201000-00012; Barbier O, 2000, DRUG METAB DISPOS, V28, P497; Barua AB, 2004, J NUTR, V134, p286S, DOI 10.1093/jn/134.1.286S; Belanger A, 2003, TRENDS ENDOCRIN MET, V14, P473, DOI 10.1016/j.tem.2003.10.005; Beutler E, 1998, P NATL ACAD SCI USA, V95, P8170, DOI 10.1073/pnas.95.14.8170; Bhasker CR, 2000, PHARMACOGENETICS, V10, P679, DOI 10.1097/00008571-200011000-00002; Bigler J, 2001, CANCER RES, V61, P3566; Biondi ML, 1999, CLIN CHEM, V45, P897; Borlak J, 2000, HEPATOLOGY, V32, P792, DOI 10.1053/jhep.2000.18193; BOSMA PJ, 1994, J BIOL CHEM, V269, P17960; BOSMA PJ, 1995, NEW ENGL J MED, V333, P1171, DOI 10.1056/NEJM199511023331802; BURCHELL B, 1989, PHARMACOL THERAPEUT, V43, P261, DOI 10.1016/0163-7258(89)90122-8; Burchell Brian, 2003, Am J Pharmacogenomics, V3, P37, DOI 10.2165/00129785-200303010-00006; Butler LM, 2005, CANCER EPIDEM BIOMAR, V14, P1626, DOI 10.1158/1055-9965.EPI-04-0682; Carlini LE, 2005, CLIN CANCER RES, V11, P1226; Chan AT, 2005, JNCI-J NATL CANCER I, V97, P457, DOI 10.1093/jnci/dji066; Chen YK, 2005, WORLD J GASTROENTERO, V11, P118, DOI 10.3748/wjg.v11.i1.118; Cheng ZQ, 1998, ARCH BIOCHEM BIOPHYS, V356, P301, DOI 10.1006/abbi.1998.0781; Cheng ZQ, 1998, TOXICOL SCI, V45, P52, DOI 10.1006/toxs.1998.2494; Chouinard S, 2004, ENDOCR RES, V30, P717, DOI 10.1081/ERC-200044014; Ciotti M, 1997, PHARMACOGENETICS, V7, P485, DOI 10.1097/00008571-199712000-00007; Clarke DJ, 1997, BIOCHEM SOC T, V25, pS562, DOI 10.1042/bst025s562; Coffman BL, 1997, DRUG METAB DISPOS, V25, P1; Court MH, 2001, J PHARMACOL EXP THER, V299, P998; Court MH, 2004, J PHARMACOL EXP THER, V310, P656, DOI 10.1124/jpet.104.067660; Daidoji T, 2005, DRUG METAB DISPOS, V33, P1466, DOI 10.1124/dmd.105.004416; Desai AA, 2003, PHARMACOGENETICS, V13, P517, DOI 10.1097/00008571-200308000-00010; Duguay Y, 2004, CLIN PHARMACOL THER, V75, P223, DOI 10.1016/j.clpt.2003.10.006; Duguay Y, 2004, CANCER RES, V64, P1202, DOI 10.1158/0008-5472.CAN-03-3295; Ehmer U, 2004, HEPATOLOGY, V39, P970, DOI 10.1002/hep.20131; Elahi A, 2003, CANCER-AM CANCER SOC, V98, P872, DOI 10.1002/cncr.11587; Fang JL, 2004, CANCER EPIDEM BIOMAR, V13, P102, DOI 10.1158/1055-9965.EPI-03-0070; Fisher MB, 2000, DRUG METAB DISPOS, V28, P560; Gagne JF, 2002, MOL PHARMACOL, V62, P608, DOI 10.1124/mol.62.3.608; Gestl SA, 2002, AM J PATHOL, V160, P1467, DOI 10.1016/S0002-9440(10)62572-2; Girard H, 2004, PHARMACOGENETICS, V14, P501, DOI 10.1097/01.fpc.0000114754.08559.27; Gong QH, 2001, PHARMACOGENETICS, V11, P357, DOI 10.1097/00008571-200106000-00011; GREEN MD, 1994, DRUG METAB DISPOS, V22, P799; Green MD, 1998, DRUG METAB DISPOS, V26, P507; Gregory PA, 2000, PHARMACOGENETICS, V10, P809, DOI 10.1097/00008571-200012000-00006; Guillemette C, 2000, PHARMACOGENETICS, V10, P629, DOI 10.1097/00008571-200010000-00006; Guillemette C, 2000, CANCER RES, V60, P950; Guillemette C, 2001, CANCER EPIDEM BIOMAR, V10, P711; Hagenauer B, 2001, DRUG METAB DISPOS, V29, P407; Hirota T, 2003, DRUG METAB DISPOS, V31, P677, DOI 10.1124/dmd.31.5.677; Holthe M, 2003, PHARMACOGENOMICS J, V3, P17, DOI 10.1038/sj.tpj.6500139; Holthe M, 2002, EUR J CLIN PHARMACOL, V58, P353, DOI 10.1007/s00228-002-0490-1; Huang YH, 2002, PHARMACOGENETICS, V12, P287, DOI 10.1097/00008571-200206000-00004; Iida A, 2002, J HUM GENET, V47, P505, DOI 10.1007/s100380200075; Innocenti F, 2005, PHARMACOGENET GENOM, V15, P295, DOI 10.1097/01213011-200505000-00004; Innocenti F, 2004, J CLIN ONCOL, V22, P1382, DOI 10.1200/JCO.2004.07.173; Innocenti F, 2001, DRUG METAB DISPOS, V29, P686; Ito M, 2002, EUR J CLIN PHARMACOL, V58, P11, DOI 10.1007/s00228-001-0417-2; Iwai M, 2004, J HUM GENET, V49, P123, DOI 10.1007/s10038-003-0119-y; Iyer L, 1999, CLIN PHARMACOL THER, V65, P576, DOI 10.1016/S0009-9236(99)70078-0; Jeong EJ, 2005, DRUG METAB DISPOS, V33, P785, DOI 10.1124/dmd.104.001883; Jinno H, 2003, J PHARMACOL EXP THER, V306, P688, DOI 10.1124/jpet.103.051250; Jinno H, 2003, DRUG METAB DISPOS, V31, P528, DOI 10.1124/dmd.31.5.528; Jinno H, 2003, DRUG METAB DISPOS, V31, P108, DOI 10.1124/dmd.31.1.108; Kaku T, 2004, BIOCHEM PHARMACOL, V67, P2093, DOI 10.1016/j.bcp.2004.02.014; Kalies KU, 1998, EUR J BIOCHEM, V254, P1, DOI 10.1046/j.1432-1327.1998.2540001.x; Kaniwa N, 2005, DRUG METAB DISPOS, V33, P458, DOI 10.1124/dmd.104.001800; Kiang TKL, 2005, PHARMACOL THERAPEUT, V106, P97, DOI 10.1016/j.pharmthera.2004.10.013; King CD, 1999, ARCH BIOCHEM BIOPHYS, V365, P156, DOI 10.1006/abbi.1999.1155; Kohle C, 2003, BIOCHEM PHARMACOL, V65, P1521, DOI 10.1016/S0006-2952(03)00074-1; KOIWAI O, 1995, HUM MOL GENET, V4, P1183, DOI 10.1093/hmg/4.7.1183; Krishnaswamy S, 2005, J PHARMACOL EXP THER, V313, P1331, DOI 10.1124/jpet.104.081950; Krishnaswamy S, 2005, J PHARMACOL EXP THER, V313, P1340, DOI 10.1124/jpet.104.081968; Krishnaswamy S, 2003, DRUG METAB DISPOS, V31, P133, DOI 10.1124/dmd.31.1.133; Kuehl GE, 2003, DRUG METAB DISPOS, V31, P1361, DOI 10.1124/dmd.31.11.1361; Lampe JW, 1999, PHARMACOGENETICS, V9, P341, DOI 10.1097/00008571-199906000-00009; Lampe JW, 2000, CANCER EPIDEM BIOMAR, V9, P329; Lazarus P, 2005, PHARMACOGENET GENOM, V15, P769, DOI 10.1097/01.fpc.0000175596.52443.ef; Lepine J, 2004, J CLIN ENDOCR METAB, V89, P5222, DOI 10.1210/jc.2004-0331; Levesque B, 1999, PHARMACOGENETICS, V9, P207; Levesque E, 1998, ENDOCRINOLOGY, V139, P2375, DOI 10.1210/en.139.5.2375; Levesque E, 1997, PHARMACOGENETICS, V7, P317, DOI 10.1097/00008571-199708000-00007; Levesque E, 2001, BIOCHEMISTRY-US, V40, P3869, DOI 10.1021/bi002607y; Lin GF, 2005, TOXICOL SCI, V85, P502, DOI 10.1093/toxsci/kfi068; Lu H, 2003, DRUG METAB DISPOS, V31, P452, DOI 10.1124/dmd.31.4.452; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; MacLeod SL, 2000, ANN SURG ONCOL, V7, P777, DOI 10.1007/s10434-000-0777-3; Malfatti MA, 2004, CHEM RES TOXICOL, V17, P1137, DOI 10.1021/tx049898m; Malfatti MA, 2001, CARCINOGENESIS, V22, P1087, DOI 10.1093/carcin/22.7.1087; Marcuello E, 2004, BRIT J CANCER, V91, P678, DOI 10.1038/sj.bjc.6602042; Mathijssen RHJ, 2003, CLIN CANCER RES, V9, P3246; MCCAGUE R, 1990, BIOCHEM PHARMACOL, V39, P1459, DOI 10.1016/0006-2952(90)90427-M; Meech R, 1998, ARCH BIOCHEM BIOPHYS, V356, P77, DOI 10.1006/abbi.1998.0750; MINERS JO, 1991, PHARMACOL THERAPEUT, V51, P347, DOI 10.1016/0163-7258(91)90065-T; Mojarrabi B, 1996, BIOCHEM BIOPH RES CO, V225, P785, DOI 10.1006/bbrc.1996.1251; Monaghan G, 1997, MAMM GENOME, V8, P692, DOI 10.1007/s003359900539; Monaghan G, 1996, LANCET, V347, P578, DOI 10.1016/S0140-6736(96)91273-8; Nagar S, 2004, PHARMACOGENETICS, V14, P487, DOI 10.1097/01.fpc.0000114771.78957.cb; Nakajima Miki, 2005, Drug Metab Pharmacokinet, V20, P227, DOI 10.2133/dmpk.20.227; Nong SH, 2005, J PAEDIATR CHILD H, V41, P300, DOI 10.1111/j.1440-1754.2005.00616.x; Nowell SA, 2005, BREAST CANCER RES TR, V91, P249, DOI 10.1007/s10549-004-7751-x; Ockenga J, 2003, GASTROENTEROLOGY, V124, P1802, DOI 10.1016/S0016-5085(03)00294-4; Oguri T, 2004, ANTICANCER RES, V24, P2893; Ouzzine M, 1999, J BIOL CHEM, V274, P31401, DOI 10.1074/jbc.274.44.31401; OWENS IS, 1995, PROG NUCLEIC ACID RE, V51, P305, DOI 10.1016/S0079-6603(08)60882-X; Paoluzzi L, 2004, J CLIN PHARMACOL, V44, P854, DOI 10.1177/0091270004267159; Park J, 2004, J UROLOGY, V171, P2484, DOI 10.1097/01.ju.0000117748.44313.43; Peters WHM, 2003, J HEPATOL, V38, P3, DOI 10.1016/S0168-8278(02)00306-9; Platzer P, 1998, ANTICANCER RES, V18, P2695; Riedy M, 2000, PHARMACOGENETICS, V10, P251, DOI 10.1097/00008571-200004000-00006; RITTER JK, 1991, J BIOL CHEM, V266, P1043; Rosing H, 1998, ANTI-CANCER DRUG, V9, P587, DOI 10.1097/00001813-199808000-00002; Rouits E, 2004, CLIN CANCER RES, V10, P5151, DOI 10.1158/1078-0432.CCR-03-0548; Saeki M, 2004, DRUG METAB DISPOS, V32, P1048; Saeki Mayumi, 2005, Drug Metab Pharmacokinet, V20, P144, DOI 10.2133/dmpk.20.144; Saeki Mayumi, 2005, Drug Metab Pharmacokinet, V20, P85, DOI 10.2133/dmpk.20.85; Saeki Mayumi, 2003, Drug Metab Pharmacokinet, V18, P146, DOI 10.2133/dmpk.18.146; Saeki Mayumi, 2002, Drug Metab Pharmacokinet, V17, P488, DOI 10.2133/dmpk.17.488; Sai K, 2004, CLIN PHARMACOL THER, V75, P501, DOI 10.1016/j.clpt.2004.01.010; Samokyszyn VM, 2000, J BIOL CHEM, V275, P6908, DOI 10.1074/jbc.275.10.6908; Sparks R, 2004, BREAST CANCER RES, V6, pR488, DOI 10.1186/bcr818; Staines AG, 2004, BIOCHEM J, V384, P637, DOI 10.1042/BJ20040997; Strassburg CP, 1998, MOL PHARMACOL, V54, P647; Strassburg CP, 1999, BIOCHEM J, V338, P489, DOI 10.1042/0264-6021:3380489; Strassburg CP, 2002, GUT, V50, P851, DOI 10.1136/gut.50.6.851; Tang KS, 2005, WORLD J GASTROENTERO, V11, P3250, DOI 10.3748/wjg.v11.i21.3250; te Morsche RHM, 2001, HEPATOLOGY, V33, P765, DOI 10.1053/jhep.2001.0103303le03; Tseng CS, 2005, AM J GASTROENTEROL, V100, P1758, DOI 10.1111/j.1572-0241.2005.41857.x; Tukey RH, 2000, ANNU REV PHARMACOL, V40, P581, DOI 10.1146/annurev.pharmtox.40.1.581; Turgeon D, 2003, DRUG METAB DISPOS, V31, P670, DOI 10.1124/dmd.31.5.670; van der Logt EMJ, 2004, CARCINOGENESIS, V25, P2407, DOI 10.1093/carcin/bgh251; Verlaan M, 2005, J MED GENET, V42, DOI 10.1136/jmg.2005.032599; Verlaan M, 2004, PHARMACOGENETICS, V14, P351, DOI 10.1097/00008571-200406000-00004; Villeneuve L, 2003, J PHARMACOL EXP THER, V307, P117, DOI 10.1124/jpet.103.054072; Vogel A, 2002, Z GASTROENTEROL, V40, P497, DOI 10.1055/s-2002-32805; Vogel A, 2001, GASTROENTEROLOGY, V121, P1136, DOI 10.1053/gast.2001.28655; Wang Y, 2004, CLIN CANCER RES, V10, P2441, DOI 10.1158/1078-0432.CCR-1187-3; Watanabe Y, 2003, DRUG METAB DISPOS, V31, P589, DOI 10.1124/dmd.31.5.589; Wells PG, 2004, DRUG METAB DISPOS, V32, P281, DOI 10.1124/dmd.32.3.281; Wiener D, 2004, DRUG METAB DISPOS, V32, P72, DOI 10.1124/dmd.32.1.72; Wiener D, 2004, CANCER RES, V64, P1190, DOI 10.1158/0008-5472.CAN-03-3219; Yamanaka H, 2005, DRUG METAB DISPOS, V33, P23, DOI 10.1124/dmd.104.001701; Yamanaka H, 2004, PHARMACOGENETICS, V14, P329, DOI 10.1097/00008571-200405000-00008; Yueh MF, 2001, CARCINOGENESIS, V22, P943, DOI 10.1093/carcin/22.6.943; Zenser TV, 2002, MUTAT RES-FUND MOL M, V506, P29, DOI 10.1016/S0027-5107(02)00149-5; Zheng Z, 2001, JNCI-J NATL CANCER I, V93, P1411, DOI 10.1093/jnci/93.18.1411; Zhou QY, 2005, BRIT J CLIN PHARMACO, V59, P415, DOI 10.1111/j.1365-2125.2004.02330.x	149	132	138	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	11					1659	1672		10.1038/sj.onc.1209375	http://dx.doi.org/10.1038/sj.onc.1209375			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020JL	16550166				2022-12-28	WOS:000235904700008
J	Vinall, RL; Tepper, CG; Shi, XB; Xue, LA; Gandour-Edwards, R; White, RWV				Vinall, RL; Tepper, CG; Shi, XB; Xue, LA; Gandour-Edwards, R; White, RWV			The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7	ONCOGENE			English	Article						mutant p53; prostate cancer; relaxin	GAIN-OF-FUNCTION; REFRACTORY PROSTATE-CANCER; PROTEIN-COUPLED RECEPTORS; SUPPRESSOR GENE P53; MUTANT P53; FUNCTION PHENOTYPE; FACTOR-I; CELLS; EXPRESSION; CARCINOMA	Mutations in p53 occur at a rate of approximately 70% in hormone-refractory prostate cancer (CaP), suggesting that p53 mutations facilitate the progression of CaP to androgen-independent ( AI) growth. We have previously reported that transfection of p53 gain of function mutant alleles into LNCaP, an androgen-sensitive cell line, allows for AI growth of LNCaP in vitro. We herein confirm the in vivo relevance of those findings by demonstrating that the R273H p53 mutation ( p53(R273H)) facilitates AI growth in castrated nude mice. In addition, we demonstrate that H2 relaxin is responsible for facilitating p53(R273H)-mediated AI CaP. H2 relaxin is overexpressed in the LNCaP-R273H subline. Downregulation of H2 relaxin expression results in significant inhibition of AI growth, whereas addition of recombinant human H2 relaxin to parental LNCaP promotes AI growth. Inhibition of AI growth was also achieved by blocking expression of LGR7, the cognate receptor of H2 relaxin. Chromatin immunoprecipitation analysis was used to demonstrate that p53(R273H) binds directly to the relaxin promoter, further confirming a role for H2 relaxin signaling in p53(R273H)-mediated AI CaP. Lastly, we used a reporter gene assay to demonstrate that H2 relaxin can induce the expression of prostate-specific antigen via an androgen receptor-mediated pathway.	Univ Calif Davis, Med Ctr, Dept Urol, Sch Med & Canc Ctr, Sacramento, CA 95817 USA; Univ Calif Davis, Sch Med & Canc Ctr, Dept Biol Chem, Sacramento, CA 95817 USA; Univ Calif Davis, Sch Med & Canc Ctr, Dept Pathol, Sacramento, CA USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	White, RWV (corresponding author), Univ Calif Davis, Med Ctr, Dept Urol, Sch Med & Canc Ctr, 4860 Y St,Suite 3500, Sacramento, CA 95817 USA.	ralph.devere-white@ucdmc.ucdavis.edu	Vinall, Ruth/L-7026-2019; Tepper, Clifford G/H-6527-2011		NATIONAL CANCER INSTITUTE [R01CA077612] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA77612] Funding Source: Medline; PHS HHS [R0192069] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Amorino GP, 2004, CRIT REV EUKAR GENE, V14, P287, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i4.40; Bartsch O, 2001, MOL HUM REPROD, V7, P799, DOI 10.1093/molehr/7.9.799; Bathgate RAD, 2003, TRENDS ENDOCRIN MET, V14, P207, DOI 10.1016/S1043-2760(03)00081-X; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Culig Z, 2005, ENDOCR-RELAT CANCER, V12, P229, DOI 10.1677/erc.1.00775a; CULIG Z, 1994, CANCER RES, V54, P5474; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEB SP, 1994, ONCOGENE, V9, P1341; DINJENS WNM, 1994, INT J CANCER, V56, P630, DOI 10.1002/ijc.2910560504; El-Hizawi S, 2002, CANCER RES, V62, P3264; Figueiredo KA, 2005, ANN NY ACAD SCI, V1041, P320, DOI 10.1196/annals.1282.051; Garibay-Tupas JL, 2000, J MOL ENDOCRINOL, V24, P241, DOI 10.1677/jme.0.0240241; GITTES RF, 1991, NEW ENGL J MED, V324, P236, DOI 10.1056/NEJM199101243240406; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HEIDENBERG HB, 1995, J UROLOGY, V154, P414, DOI 10.1016/S0022-5347(01)67065-4; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Hsu SY, 2000, MOL ENDOCRINOL, V14, P1257, DOI 10.1210/me.14.8.1257; Huggins C, 1972, CA Cancer J Clin, V22, P232, DOI 10.3322/canjclin.22.4.232; IVELL R, 1989, MOL CELL ENDOCRINOL, V66, P251, DOI 10.1016/0303-7207(89)90037-3; Ivell R, 2002, TRENDS ENDOCRIN MET, V13, P343, DOI 10.1016/S1043-2760(02)00664-1; Kasamon KM, 2004, CURR OPIN UROL, V14, P185, DOI 10.1097/00042307-200405000-00008; Koul HK, 2004, ANN NY ACAD SCI, V1030, P243, DOI 10.1196/annals.1329.030; KYPRIANOU N, 1990, CANCER RES, V50, P3748; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; Lee LF, 2004, ONCOGENE, V23, P2197, DOI 10.1038/sj.onc.1207344; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAVONE NM, 1993, J NATL CANCER I, V85, P1657, DOI 10.1093/jnci/85.20.1657; Nesslinger NJ, 2003, CANCER RES, V63, P2228; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Palejwala S, 2002, BIOL REPROD, V66, P1743, DOI 10.1095/biolreprod66.6.1743; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Raj GV, 2002, J UROLOGY, V167, P1458, DOI 10.1016/S0022-5347(05)65345-1; Roemer K, 1999, BIOL CHEM, V380, P879, DOI 10.1515/BC.1999.108; Samuel CS, 2003, LAB INVEST, V83, P1055, DOI 10.1097/01.LAB.0000079784.81186.B9; Scian MJ, 2004, ONCOGENE, V23, P4430, DOI 10.1038/sj.onc.1207553; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Sherwood OD, 2004, ENDOCR REV, V25, P205, DOI 10.1210/er.2003-0013; Shi XB, 2004, BJU INT, V94, P996, DOI 10.1111/j.1464-410X.2004.05093.x; Shi XB, 2004, PROSTATE, V60, P257, DOI 10.1002/pros.20039; Shi XB, 2002, PROSTATE, V51, P59, DOI 10.1002/pros.10072; Silvertown JD, 2006, INT J CANCER, V118, P62, DOI 10.1002/ijc.21288; Silvertown JD, 2003, INT J CANCER, V107, P513, DOI 10.1002/ijc.11424; Silvertown JD, 2003, ENDOCRINOLOGY, V144, P3683, DOI 10.1210/en.2003-0248; STEMMERMANN GN, 1994, J ENDOCRINOL, V140, P321, DOI 10.1677/joe.0.1400321; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; TASHIMA LS, 1994, J MOL ENDOCRINOL, V12, P351, DOI 10.1677/jme.0.0120351; Tepper CG, 2005, PROSTATE, V65, P375, DOI 10.1002/pros.20308; van Oijen MGCT, 2000, CLIN CANCER RES, V6, P2138; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Welsh JB, 2003, P NATL ACAD SCI USA, V100, P3410, DOI 10.1073/pnas.0530278100; Zhang Q, 2002, J CELL BIOCHEM, V85, P536, DOI 10.1002/jcb.10150; AFFYMETRIX GENECHIP	55	35	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2082	2093		10.1038/sj.onc.1209246	http://dx.doi.org/10.1038/sj.onc.1209246			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16434975				2022-12-28	WOS:000236359700011
J	Cavard, C; Terris, B; Grimber, G; Christa, L; Audard, V; Bussiere, BR; Simon, MT; Renard, CA; Buendia, MA; Perret, C				Cavard, C; Terris, B; Grimber, G; Christa, L; Audard, V; Bussiere, BR; Simon, MT; Renard, CA; Buendia, MA; Perret, C			Overexpression of regenerating islet-derived 1 alpha and 3 alpha genes in human primaryliver tumors with beta-catenin mutations	ONCOGENE			English	Article						beta-catenin; REG1A; REG3A; hepatocellular; carcinoma; hepatoblastoma; Wnt signaling	PANCREATITIS-ASSOCIATED PROTEIN; HUMAN HEPATOCELLULAR CARCINOMAS; REG-I; CHILDHOOD HEPATOBLASTOMA; LIVER-REGENERATION; CANCER-CELLS; EXPRESSION; ADENOMAS; GROWTH; CHOLANGIOCARCINOMA	The Wnt/beta-catenin signaling pathways activated in many human hepatocellular carcinomas (HCC). We tried to identify the genes involved in carcinogenesis and progression of HCC with beta-catenin mutations. We used PCR-based subtractive hybridization to compare gene expression between malignant and benign components of a human HCC occurring in pre-existing adenoma activated for beta-catenin. Two of the genes identified belong to the Regenerating gene (REG) family. They encode the Regenerating islet-derived 3 alpha (REG3A/HIP/PAP/ REG-III) and 1 alpha (REG1A) proteins, both involved in liver and pancreatic regeneration and proliferation. Using siRNA directed against beta-catenin, we demonstrated that REG3A is a target of beta-catenin signaling in Huh7 hepatoma cells. The upregulation of REG3A and REG1A expression is significantly correlated to the beta-catenin status in 42 HCC and 28 hepatoblastomas characterized for their b-catenin status. Thus, we report strong evidence that both genes are downstream targets of the Wnt pathway during liver tumorigenesis.	Univ Paris 05, INSERM, U567, CNRS,UMR 8104,Inst Cochin,Dept GDPM, F-75014 Paris, France; Univ Paris 05, Hop Cochin, Serv Anat Pathol, F-75014 Paris, France; Univ Paris 05, Inst Necker Pasteur, INSERM, U370, F-75014 Paris, France; Inst Pasteur, INSERM, U579, Unite Oncogenese & Virol Mol, F-75724 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Cavard, C (corresponding author), Univ Paris 05, INSERM, U567, CNRS,UMR 8104,Inst Cochin,Dept GDPM, 24 Rue Faubourg St Jacques, F-75014 Paris, France.	cavard@cochin.inserm.fr	Terris, Benoit/P-1497-2017; Perret-Mayeux, Christine/L-3297-2017	perret, christine/0000-0003-4710-7051				Andreu P, 2005, DEVELOPMENT, V132, P1443, DOI 10.1242/dev.01700; Bernard-Perrone FR, 1999, J HISTOCHEM CYTOCHEM, V47, P863, DOI 10.1177/002215549904700703; Bioulac-Sage P, 2003, HEPATOLOGY, V37, P480, DOI 10.1053/jhep.2003.50058; Bluteau O, 2002, NAT GENET, V32, P312, DOI 10.1038/ng1001; Bruix J, 2004, CANCER CELL, V5, P215, DOI 10.1016/S1535-6108(04)00058-3; Buckhaults P, 2001, CANCER RES, V61, P6996; Buendia MA, 2002, MED PEDIATR ONCOL, V39, P530, DOI 10.1002/mpo.10180; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Cadoret A, 2002, ONCOGENE, V21, P8293, DOI 10.1038/sj.onc.1206118; Chen YW, 2002, HEPATOLOGY, V36, P927, DOI 10.1053/jhep.2002.36126; Christa L, 1999, AM J PATHOL, V155, P1525, DOI 10.1016/S0002-9440(10)65468-5; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Dhar DK, 2004, CANCER-AM CANCER SOC, V100, P1130, DOI 10.1002/cncr.20097; DUSETTI NJ, 1994, GENOMICS, V19, P108, DOI 10.1006/geno.1994.1019; El-Serag HB, 2002, HEPATOLOGY, V36, pS74, DOI 10.1053/jhep.2002.36807; Fukui H, 2004, DIGESTION, V69, P177, DOI 10.1159/000078762; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Harada K, 2001, HEPATOLOGY, V33, P1036, DOI 10.1053/jhep.2001.24168; IOVANNA J, 1991, J BIOL CHEM, V266, P24664; LASSERRE C, 1992, CANCER RES, V52, P5089; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Levy L, 2002, J BIOL CHEM, V277, P42386, DOI 10.1074/jbc.M207418200; Macadam RCA, 2000, BRIT J CANCER, V83, P188; Malka D, 2000, GASTROENTEROLOGY, V119, P816, DOI 10.1053/gast.2000.16491; Ortiz EM, 1998, GASTROENTEROLOGY, V114, P808, DOI 10.1016/S0016-5085(98)70595-5; Ovejero C, 2004, HEPATOLOGY, V40, P167, DOI 10.1002/hep.20286; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Perilongo G, 2004, EUR J CANCER, V40, P411, DOI 10.1016/j.ejca.2003.06.003; Polakis P, 2000, GENE DEV, V14, P1837; Rechreche H, 1999, INT J CANCER, V81, P688, DOI 10.1002/(SICI)1097-0215(19990531)81:5<688::AID-IJC3>3.0.CO;2-R; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Simon MT, 2003, FASEB J, V17, P1441, DOI 10.1096/fj.02-1013com; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Takayasu H, 2002, HUM PATHOL, V33, P852, DOI 10.1053/hupa.2002.125771; Takayasu H, 2001, CLIN CANCER RES, V7, P901; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; TERAZONO K, 1988, J BIOL CHEM, V263, P2111; Terris B, 1999, ONCOGENE, V18, P6583, DOI 10.1038/sj.onc.1203051; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Verma UN, 2003, CLIN CANCER RES, V9, P1291; WATANABE T, 1994, P NATL ACAD SCI USA, V91, P3589, DOI 10.1073/pnas.91.9.3589; White P, 2005, J BIOL CHEM, V280, P3715, DOI 10.1074/jbc.M410844200; Yamamoto Y, 2003, HEPATOLOGY, V37, P528, DOI 10.1053/jhep.2003.50029; Yamaoka T, 2000, BIOCHEM BIOPH RES CO, V278, P368, DOI 10.1006/bbrc.2000.3813; Yuan RH, 2005, CLIN CANCER RES, V11, P2568, DOI 10.1158/1078-0432.CCR-04-2039; Zhang YW, 2003, WORLD J GASTROENTERO, V9, P2635; ZUCMANROSSI J, UNPUB COMP EVALUATIO	47	74	77	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					599	608		10.1038/sj.onc.1208860	http://dx.doi.org/10.1038/sj.onc.1208860			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16314847				2022-12-28	WOS:000234897400011
J	Jarvinen, AK; Autio, R; Haapa-Paananen, S; Wolf, M; Saarela, M; Grenman, R; Leivo, I; Kallioniemi, O; Makitie, AA; Monni, O				Jarvinen, A-K; Autio, R.; Haapa-Paananen, S.; Wolf, M.; Saarela, M.; Grenman, R.; Leivo, I.; Kallioniemi, O.; Makitie, A. A.; Monni, O.			Identification of target genes in laryngeal squamous cell carcinoma by high-resolution copy number and gene expression microarray analyses	ONCOGENE			English	Article						head and neck cancer; cDNA microarrays; oligonucleotide microarrays; comparative genomic hybridization	BREAST-CANCER; CDNA MICROARRAYS; MOLECULAR CLASSIFICATION; 17Q23 AMPLICON; HIGH-FREQUENCY; NECK-CANCER; PHASE-II; HEAD; RECURRENT; PATTERNS	Molecular mechanisms contributing to initiation and progression of head and neck squamous cell carcinoma are still poorly known. Numerous genetic alterations have been described, but molecular consequences of such alterations in most cases remain unclear. Here, we performed an integrated high-resolution microarray analysis of gene copy number and expression in 20 laryngeal cancer cell lines and primary tumors. Our aim was to identify genetic alterations that play a key role in disease pathogenesis and pinpoint genes whose expression is directly impacted by these events. Integration of DNA level data from array-based comparative genomic hybridization with RNA level information from oligonucleotide microarrays was achieved with custom-developed bioinformatic methods. High-level amplifications had a clear impact on gene expression. Across the genome, overexpression of 739 genes could be attributed to gene amplification events in cell lines, with 325 genes showing the same phenomenon in primary tumors including FADD and PPFIA1 at 11q13. The analysis of gene ontology and pathway distributions further pinpointed genes that may identify potential targets of therapeutic intervention. Our data highlight genes that may be critically important to laryngeal cancer progression and offer potential therapeutic targets.	Univ Helsinki, Biomedicum Biochip Ctr, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biomed, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Otorhinolaryngol Head & Neck Surg, Helsinki, Finland; Tampere Univ Technol, Inst Signal Proc, FIN-33101 Tampere, Finland; VTT Tech Res Ctr Finland, Turku, Finland; Turku Univ, FIN-20520 Turku, Finland; Turku Univ, Cent Hosp, Dept Otorhinolaryngol Head & Neck Surg, Turku, Finland; Turku Univ, Dept Biochem Med, Turku, Finland; Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Tampere University; VTT Technical Research Center Finland; University of Turku; University of Turku; University of Turku; University of Helsinki	Monni, O (corresponding author), Univ Helsinki, Biomedicum Biochip Ctr, POB 63,Rm A415B,Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	outi.monni@helsinki.fi	Autio, Reija/D-2037-2014; Haapa-Paananen, Saija/D-3075-2012; Kallioniemi, Olli P/H-5111-2011	Kallioniemi, Olli P/0000-0002-3231-0332; Autio, Reija/0000-0002-6519-2715				Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Autio R, 2003, BIOINFORMATICS, V19, P1714, DOI 10.1093/bioinformatics/btg230; Baldwin C, 2005, CANCER RES, V65, P7561, DOI 10.1158/0008-5472.CAN-05-1513; Baselga J, 2005, J CLIN ONCOL, V23, P2445, DOI 10.1200/JCO.2005.11.890; Baudis M, 2001, BIOINFORMATICS, V17, P1228, DOI 10.1093/bioinformatics/17.12.1228; Belbin TJ, 2002, CANCER RES, V62, P1184; Choi P, 2005, CANCER-AM CANCER SOC, V104, P1113, DOI 10.1002/cncr.21293; Chung CH, 2004, CANCER CELL, V5, P489, DOI 10.1016/S1535-6108(04)00112-6; Cohen EEW, 2003, J CLIN ONCOL, V21, P1980, DOI 10.1200/JCO.2003.10.051; Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345; Dong YY, 2005, CLIN CANCER RES, V11, P259; Garcia MJ, 2005, ONCOGENE, V24, P5235, DOI 10.1038/sj.onc.1208741; Ginos MA, 2004, CANCER RES, V64, P55, DOI 10.1158/0008-5472.CAN-03-2144; Gollin SM, 2001, HEAD NECK-J SCI SPEC, V23, P238, DOI 10.1002/1097-0347(200103)23:3<238::AID-HED1025>3.0.CO;2-H; GRENMAN R, 1992, ARCH OTOLARYNGOL, V118, P542; Hautaniemi S, 2004, J FRANKLIN I, V341, P77, DOI 10.1016/j.jfranklin.2003.12.005; Heidenblad M, 2005, ONCOGENE, V24, P1794, DOI 10.1038/sj.onc.1208383; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Hyman E, 2002, CANCER RES, V62, P6240; Imoto I, 2001, CANCER RES, V61, P6629; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Joslyn CA, 2004, BIOINFORMATICS, V20, P169, DOI 10.1093/bioinformatics/bth921; LANSFORD CD, 1999, HUMAN CELL CULTURE, V2, P185; Lin M, 2006, ONCOGENE, V25, P1424, DOI 10.1038/sj.onc.1209166; Mao EJ, 1998, J ORAL PATHOL MED, V27, P297; Mao L, 2004, CANCER CELL, V5, P311, DOI 10.1016/S1535-6108(04)00090-X; Miller CT, 2003, CANCER RES, V63, P4136; Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298; Nawata S, 2003, ELECTROPHORESIS, V24, P2277, DOI 10.1002/elps.200305501; Newton K, 2000, EMBO J, V19, P931, DOI 10.1093/emboj/19.5.931; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Redon R, 2002, CANCER RES, V62, P6211; Reed AL, 1996, CANCER RES, V56, P3630; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Sinclair CS, 2003, BREAST CANCER RES TR, V78, P313, DOI 10.1023/A:1023081624133; Soulieres D, 2004, J CLIN ONCOL, V22, P77, DOI 10.1200/JCO.2004.06.075; Strojan P, 2004, BRIT J CANCER, V90, P1961, DOI 10.1038/sj.bjc.6601830; Strome SE, 2003, CANCER RES, V63, P6501	40	81	82	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	52					6997	7008		10.1038/sj.onc.1209690	http://dx.doi.org/10.1038/sj.onc.1209690			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16715129				2022-12-28	WOS:000241732300010
J	Brenet, F; Dussault, N; Delfino, C; Boudouresque, F; Chinot, O; Martin, PM; Ouafik, LH				Brenet, F.; Dussault, N.; Delfino, C.; Boudouresque, F.; Chinot, O.; Martin, P-M; Ouafik, L. H.			Identification of secondary structure in the 5 '-untranslated region of the human adrenomedullin mRNA with implications for the regulation of mRNA translation	ONCOGENE			English	Article						adrenomedullin mRNA; 5 ' UTR; translational control; stem-loop structure; RNA-binding proteins	INTERNAL RIBOSOME ENTRY; TUMOR-CELL LINES; GROWTH-FACTOR; 3'-UNTRANSLATED REGION; DELETION MUTAGENESIS; UNTRANSLATED REGION; PROTEIN BINDS; MICE LACKING; EXPRESSION; SEQUENCES	Adrenomedullin (AM) is a multifunctional regulatory peptide with important angiogenic and mitogenic properties. Here we identify a region of stable secondary structure in the 5'-untranslated region ( 50 UTR) of human AM mRNA. Reverse transcriptase-polymerase chain reaction of the 50 UTR consistently resulted, in addition to the product with the expected size of 155 base pair ( bp), in a second product with an similar to 65-bp deletion from the central region of the 50 UTR, suggesting the presence of a secondary structure. The presence of a stem-loop structure was confirmed by probing the 50 UTR with RNases with selectivity for single- or double-stranded RNA. We investigated the role of this stem-loop structure in expression of luciferase reporter gene in cultured cell lines. Reporter assays using a chimeric mRNA that combined luciferase and the 50 UTR of AM mRNA demonstrated a dramatic decrease of the reporter activity owing to a decreased translation, whereas the deletion of the stem-loop structure localized between nt + 31 and + 95 from the capsite led to the recovery of activity. Gel migration shift assays using cytosolic extracts from mammalian cell lines demonstrate a specific binding of a cytosolic protein to riboprobes containing the 50 UTR of AM but not to riboprobes either corresponding to other areas of the message or containing the 50 UTR but lacking the region of secondary structure. Although we conclude that the 50 UTR of the human AM mRNA can modulate the translation of AM mRNA in vivo, and that the predicted stem-loop structure is necessary for this inhibition, the functional consequences of the cis element-binding activity remain to be determined.	Univ Aix Marseille 2, Expt Cancerol Lab, INSERM, EMI 0359, Marseille 20, France; Univ Mediterranee, Lab Transfert Oncol Biol, Fac Med Secteur Nord, IFR Jean Roche, F-13916 Marseille 20, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite	Ouafik, LH (corresponding author), Univ Aix Marseille 2, Expt Cancerol Lab, INSERM, EMI 0359, Marseille 20, France.	ouafik.h@jean-roche.univ-mrs.fr	Brenet, Fabienne/R-1881-2016; CHINOT, Olivier/M-9196-2018	Brenet, Fabienne/0000-0003-4098-1096; CHINOT, Olivier/0000-0001-6317-9691; Ouafik, L'Houcine/0000-0002-4848-1232				Ben-Asouli Y, 2002, CELL, V108, P221, DOI 10.1016/S0092-8674(02)00616-5; Bernstein J, 1997, J BIOL CHEM, V272, P9356; Brenet F, 2005, MOL CELL BIOL, V25, P7505, DOI 10.1128/MCB.25.17.7505-7521.2005; Canceill D, 1996, P NATL ACAD SCI USA, V93, P6647, DOI 10.1073/pnas.93.13.6647; CARIELLO NF, 1991, GENE, V99, P105, DOI 10.1016/0378-1119(91)90040-I; Caron KM, 2001, P NATL ACAD SCI USA, V98, P615, DOI 10.1073/pnas.021548898; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Creancier L, 2000, J CELL BIOL, V150, P275, DOI 10.1083/jcb.150.1.275; ElMeskini R, 1997, ENDOCRINOLOGY, V138, P5256, DOI 10.1210/en.138.12.5256; FENG Y, 1995, SCIENCE, V268, P731, DOI 10.1126/science.7732383; Fernandez-Sauze S, 2004, INT J CANCER, V108, P797, DOI 10.1002/ijc.11663; Fraboulet S, 1998, ENDOCRINOLOGY, V139, P894, DOI 10.1210/en.139.3.894; Galy B, 2001, ONCOGENE, V20, P1669, DOI 10.1038/sj.onc.1204271; Garayoa M, 2000, MOL ENDOCRINOL, V14, P848, DOI 10.1210/me.14.6.848; GLICKMAN BW, 1984, P NATL ACAD SCI-BIOL, V81, P512, DOI 10.1073/pnas.81.2.512; Hata K, 2000, MOL HUM REPROD, V6, P867, DOI 10.1093/molehr/6.10.867; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; Imai T, 2001, MOL CELL BIOL, V21, P3888, DOI 10.1128/MCB.21.12.3888-3900.2001; Ishikawa T, 2003, ONCOGENE, V22, P1238, DOI 10.1038/sj.onc.1206207; ISHIMITSU T, 1994, BIOCHEM BIOPH RES CO, V203, P631, DOI 10.1006/bbrc.1994.2229; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V194, P720, DOI 10.1006/bbrc.1993.1881; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAING LG, 1994, J MOL BIOL, V237, P577, DOI 10.1006/jmbi.1994.1256; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Letizia C, 1998, CLIN ENDOCRINOL, V48, P145, DOI 10.1046/j.1365-2265.1998.3531170.x; Miller MJ, 1996, J BIOL CHEM, V271, P23345; Morrisey K, 2001, AM J PATHOL, V159, P1905, DOI 10.1016/S0002-9440(10)63037-4; Murakami Y, 1998, LIFE SCI, V63, pPL337, DOI 10.1016/S0024-3205(98)00503-7; ODELBERG SJ, 1995, NUCLEIC ACIDS RES, V23, P2049, DOI 10.1093/nar/23.11.2049; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Ouafik L, 2002, AM J PATHOL, V160, P1279, DOI 10.1016/S0002-9440(10)62555-2; Paraskeva E, 1999, MOL CELL BIOL, V19, P807; PELLETIER J, 1987, BIOCHEM CELL BIOL, V65, P576, DOI 10.1139/o87-074; Pewitt EB, 1999, ENDOCRINOLOGY, V140, P2382, DOI 10.1210/en.140.5.2382; Ranganathan G, 2000, J BIOL CHEM, V275, P40986, DOI 10.1074/jbc.M008775200; Rocchi P, 2001, CANCER RES, V61, P1196; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; SAKATA J, 1994, FEBS LETT, V352, P105, DOI 10.1016/0014-5793(94)00928-7; Shindo T, 2001, CIRCULATION, V104, P1964, DOI 10.1161/hc4101.097111; SONENBERG N, 1994, CURR OPIN GENET DEV, V4, P310, DOI 10.1016/S0959-437X(05)80059-0; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; WILUSZ J, 1988, CELL, V52, P221, DOI 10.1016/0092-8674(88)90510-7; Zhao Y, 1998, ONCOGENE, V16, P409, DOI 10.1038/sj.onc.1201768; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	51	8	9	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2006	25	49					6510	6519		10.1038/sj.onc.1209672	http://dx.doi.org/10.1038/sj.onc.1209672			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16715138	Green Submitted			2022-12-28	WOS:000241395100007
J	Sekine, Y; Tsuji, S; Ikeda, O; Sato, N; Aoki, N; Aoyama, K; Sugiyama, K; Matsuda, T				Sekine, Y.; Tsuji, S.; Ikeda, O.; Sato, N.; Aoki, N.; Aoyama, K.; Sugiyama, K.; Matsuda, T.			Regulation of STAT3-mediated signaling by LMW-DSP2	ONCOGENE			English	Article						IL-6; LIF; STAT3; phosphatase; transcriptional regulation	DUAL-SPECIFICITY PHOSPHATASE; PROTEIN-TYROSINE-PHOSPHATASE; CELL ANTIGEN RECEPTOR; FUNCTIONAL INTERACTIONS; NEGATIVE REGULATOR; STATS; TRANSDUCTION; ACTIVATION; PATHWAY; CLONING	Signal transducer and activator of transcription 3 (STAT3), which mediates biological actions in many physiological processes, is activated by cytokines and growth factors, and has been reported to be constitutively activated in numerous cancer cells. In this study, we examined whether low molecular weight-dual specificity phosphatase two (LMW-DSP2) is involved in the regulation of the interleukin 6 (IL-6)/leukemia inhibitory factor (LIF)/STAT3-mediated signaling pathway. IL-6/LIF-induced LMW-DSP2 expression in murine testicular or hepatoma cell lines, while LMW-DSP2 overexpression in 293T cells suppressed IL-6-induced phosphorylation and activation of STAT3. Furthermore, LMW-DSP2 suppressed the expression of IL-6-induced endogenous genes. In contrast, small-interfering RNA-mediated reduction of LMW-DSP2 expression enhanced IL-6-induced STAT3-dependent transcription. In fact, LMW-DSP2 interacted with STAT3 in vivo and endogenous LMW-DSP2 bound to STAT3 in murine testicular GC-1 cells. These results strongly suggest that LMW-DSP2 acts as a negative regulator of the IL-6/LIF/STAT3-mediated signaling pathway.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Mie Univ, Dept Life Sci, Fac Bioresources, Lab Mol Food Chem & Biochem, Tsu, Mie 514, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Chikusa Ku, Nagoya, Aichi, Japan; Nippon Boehringer Ingelheim Co Ltd, Kawanishi Pharma Res Inst, Kawanishi, Hyogo, Japan	Hokkaido University; Mie University; Nagoya University; Boehringer Ingelheim	Matsuda, T (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, Kita 12 Nishi 6, Sapporo, Hokkaido 0600812, Japan.	tmatsuda@pharm.hokudai.ac.jp	Sekine, Yuichi/S-8813-2019; Matsuda, Tadashi/A-3835-2012	Sekine, Yuichi/0000-0002-2861-603X; Matsuda, Tadashi/0000-0002-3089-3757				Alonso A, 2004, TOP CURR GENET, V5, P333; Alonso A, 2002, J BIOL CHEM, V277, P5524, DOI 10.1074/jbc.M107653200; Alonso A, 2001, J BIOL CHEM, V276, P4766, DOI 10.1074/jbc.M006497200; Aoki N, 2002, MOL ENDOCRINOL, V16, P58, DOI 10.1210/me.16.1.58; Aoki N, 2001, J BIOCHEM, V130, P133, DOI 10.1093/oxfordjournals.jbchem.a002952; Aoyama K, 2001, J BIOL CHEM, V276, P27575, DOI 10.1074/jbc.M100408200; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Chen AJ, 2002, J BIOL CHEM, V277, P36592, DOI 10.1074/jbc.M200453200; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Imoto S, 2003, J BIOL CHEM, V278, P34253, DOI 10.1074/jbc.M304961200; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Muromoto R, 2004, J IMMUNOL, V172, P2985, DOI 10.4049/jimmunol.172.5.2985; Najarro P, 2001, J VIROL, V75, P3185, DOI 10.1128/JVI.75.7.3185-3196.2001; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Sekine Y, 2005, J BIOL CHEM, V280, P8188, DOI 10.1074/jbc.M411692200; Shen Y, 2001, P NATL ACAD SCI USA, V98, P13613, DOI 10.1073/pnas.231499098; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Simoncic PD, 2002, CURR BIOL, V12, P446, DOI 10.1016/S0960-9822(02)00697-8; Yamamoto T, 2002, BIOCHEM BIOPH RES CO, V297, P811, DOI 10.1016/S0006-291X(02)02291-X; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143	25	62	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2006	25	42					5801	5806		10.1038/sj.onc.1209578	http://dx.doi.org/10.1038/sj.onc.1209578			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16636663	Bronze, Green Submitted			2022-12-28	WOS:000240765800010
J	Liu, L; Gao, Y; Qiu, H; Miller, WT; Poli, V; Reich, NC				Liu, L.; Gao, Y.; Qiu, H.; Miller, W. T.; Poli, V.; Reich, N. C.			Identification of STAT3 as a specific substrate of breast tumor kinase	ONCOGENE			English	Article						tyrosine phosphorylation; transcription factor; signal transduction	NONRECEPTOR TYROSINE KINASE; MAMMARY EPITHELIAL-CELLS; GASTROINTESTINAL-TRACT; THERAPEUTIC TARGET; BRK; PROTEINS; ACTIVATION; EXPRESSION; RECEPTOR; BINDING	Breast tumor kinase (Brk) is a non-receptor tyrosine kinase distantly related to the Src family kinase. It is expressed in more than 60% of breast tumors, but the biological role of this kinase remains to be determined. Only a limited number of substates have been identified for Brk, and the link of Brk to tumorigenesis remains largely unknown. In this study, we provide evidence that the signal transducer and activator of transcription 3, STAT3, is a physiological target of Brk. Activation of STAT3 previously has been linked to oncogenesis, and results in this study demonstrate that STAT3 is tyrosine phosphorylated and transcriptionally activated in cells expressing endogenous Brk. Signal transducer and activator of transcription 3 is specifically targeted since other STAT members are not responsive to Brk expression. Signal transducer and activator of transcription 3 activation requires the catalytic activity of Brk, and expression of both STAT3 and Brk stimulate cellular proliferation. In addition, we have identified a negative regulator of Brk, the suppressor of cytokine signaling, SOCS3. The SOCS3 protein is known to block signaling mediated by cytokine receptors, and here we find that SOCS3 is able to repress the activity of the Brk nonreceptor tyrosine kinase.	SUNY Stony Brook, Dept Microbiol & Mol Genet, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Univ Turin, Dept Genet Biol & Biochem, Turin, Italy	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Turin	Reich, NC (corresponding author), SUNY Stony Brook, Dept Microbiol & Mol Genet, Nicolls Rd,Life Sci Rm 168, Stony Brook, NY 11794 USA.	nreich@notes.cc.sunysb.edu	Poli, Valeria/A-9215-2012	Poli, Valeria/0000-0002-3739-3966	NCI NIH HHS [R01CA50773] Funding Source: Medline; PHS HHS [PPGCA28146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050773] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138; Banninger G, 2004, J BIOL CHEM, V279, P39199, DOI 10.1074/jbc.M400815200; Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chen HY, 2004, MOL CELL BIOL, V24, P10558, DOI 10.1128/MCB.24.24.10558-10572.2004; Chiarle R, 2005, NAT MED, V11, P623, DOI 10.1038/nm1249; Coppo P, 2003, ONCOGENE, V22, P4102, DOI 10.1038/sj.onc.1206607; Coyle JH, 2003, MOL CELL BIOL, V23, P92, DOI 10.1128/MCB.23.1.92-103.2003; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Decker T, 1999, CELL MOL LIFE SCI, V55, P1505, DOI 10.1007/s000180050390; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Derry JJ, 2003, ONCOGENE, V22, P4212, DOI 10.1038/sj.onc.1206465; Easty DJ, 1997, INT J CANCER, V71, P1061, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1061::AID-IJC24>3.0.CO;2-F; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Faruqi TR, 2001, P NATL ACAD SCI USA, V98, P9014, DOI 10.1073/pnas.161281298; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Haegebarth A, 2004, J BIOL CHEM, V279, P54398, DOI 10.1074/jbc.M409579200; Harvey AJ, 2003, ONCOGENE, V22, P5006, DOI 10.1038/sj.onc.1206577; HENNIPMAN A, 1989, CANCER RES, V49, P516; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Kamalati T, 2000, ONCOGENE, V19, P5471, DOI 10.1038/sj.onc.1203931; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; Kang KN, 2002, BBA-GENE STRUCT EXPR, V1574, P365, DOI 10.1016/S0167-4781(02)00234-8; Kim HI, 2005, J BIOL CHEM, V280, P28973, DOI 10.1074/jbc.M504568200; Krebs DL, 2000, J CELL SCI, V113, P2813; Lacronique V, 2000, BLOOD, V95, P2076, DOI 10.1182/blood.V95.6.2076; Leong PL, 2003, P NATL ACAD SCI USA, V100, P4138, DOI 10.1073/pnas.0534764100; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Liu L, 2005, P NATL ACAD SCI USA, V102, P8150, DOI 10.1073/pnas.0501643102; Llor X, 1999, CLIN CANCER RES, V5, P1767; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; Minoguchi M, 2003, J BIOL CHEM, V278, P11182, DOI 10.1074/jbc.M211230200; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; Mitchell PJ, 1997, ONCOGENE, V15, P1497, DOI 10.1038/sj.onc.1201292; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Qiu HQ, 2005, ONCOGENE, V24, P5656, DOI 10.1038/sj.onc.1208721; Qiu HQ, 2004, ONCOGENE, V23, P2216, DOI 10.1038/sj.onc.1207339; Qiu HQ, 2002, J BIOL CHEM, V277, P34634, DOI 10.1074/jbc.M203877200; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Serfas MS, 2003, ONCOL RES, V13, P409; SIYANOVA EY, 1994, ONCOGENE, V9, P2053; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; VANDENBRULE FA, 1992, INT J CANCER, V52, P653, DOI 10.1002/ijc.2910520426; VASIOUKHIN V, 1995, ONCOGENE, V10, P349; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	55	68	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2006	25	35					4904	4912		10.1038/sj.onc.1209501	http://dx.doi.org/10.1038/sj.onc.1209501			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16568091				2022-12-28	WOS:000239687100008
J	Honeycutt, KA; Chen, Z; Koster, MI; Miers, M; Nuchtern, J; Hicks, J; Roop, DR; Shohet, JM				Honeycutt, K. A.; Chen, Z.; Koster, M. I.; Miers, M.; Nuchtern, J.; Hicks, J.; Roop, D. R.; Shohet, J. M.			Deregulated minichromosomal maintenance protein MCM7 contributes to oncogene driven tumorigenesis	ONCOGENE			English	Article						minichromosomal maintenance protein 7; oncogene; Ras; K14 promoter; transgenic mouse; topical carcinogenesis	MOUSE SKIN TUMORS; DNA-REPLICATION; C-MYC; LICENSING FACTOR; GENE-EXPRESSION; STEM-CELLS; CARCINOGENESIS; PROLIFERATION; CANCER; IDENTIFICATION	Minichromosomal maintenance protein 7 (MCM7) is an essential component of the replication helicase complex (MCM2-7) required for DNA replication. Although this function is highly conserved among eukaryotes, additional functions for the MCM molecules continue to be described. Minichromosomal maintenance protein 7 is a marker for proliferation and is upregulated in a variety of tumors including neuroblastoma, prostate, cervical and hypopharyngeal carcinomas. To further investigate the general role of MCM7 in tumorigenesis, we generated a mouse model with deregulated MCM7 expression targeted to the basal layer of the epidermis using the keratin 14 (K14) promoter (K14. MCM7). When subjected to a two-stage chemical carcinogenesis protocol (dimethylbenz[alpha] anthracene (DMBA) initiation with 12-ortho-tetradecanoylphorbol-13-acetate promotion), K14. MCM7 mice showed significantly increased incidence and prevalence of tumor development relative to controls. Furthermore, within 40 weeks of treatment over 45% K14. MCM7 mice exhibited tumors that had converted to squamous cell carcinomas versus none in the control group. As predicted from previous skin carcinogenesis studies using DMBA as the initiating agent, Ras mutations where found in more than 90% of tumors isolated from K14. MCM7 mice. Whereas previous studies have shown that MCM7 is useful as a proliferation marker, our data suggest that deregulated MCM7 expression actively contributes to tumor formation, progression and malignant conversion.	Baylor Coll Med, Dept Pediat, Texas Childrens Canc Ctr, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA	Baylor College of Medicine; Texas Children's Cancer Center; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Shohet, JM (corresponding author), Baylor Coll Med, Dept Pediat, Texas Childrens Canc Ctr, 1 Baylor Pl, Houston, TX 77030 USA.	jmshohet@texaschildrenshospital.org		Koster, Maranke/0000-0003-4448-8119	NATIONAL CANCER INSTITUTE [K08CA090517] Funding Source: NIH RePORTER; NCI NIH HHS [K08 CA90517-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arin MJ, 2001, J CELL BIOL, V152, P645, DOI 10.1083/jcb.152.3.645; ASHMAN LK, 1982, CARCINOGENESIS, V3, P99, DOI 10.1093/carcin/3.1.99; BARRETT JC, 1993, MOL CARCINOGEN, V7, P1, DOI 10.1002/mc.2940070102; Berton TR, 2000, GENESIS, V26, P160, DOI 10.1002/(SICI)1526-968X(200002)26:2<160::AID-GENE20>3.0.CO;2-#; Brake T, 2003, CANCER RES, V63, P8173; BREMNER R, 1994, MOL CARCINOGEN, V11, P90, DOI 10.1002/mc.2940110206; Cao TY, 2001, J CELL BIOL, V152, P651, DOI 10.1083/jcb.152.3.651; Chan KK, 2000, J CELL BIOCHEM, V76, P499, DOI 10.1002/(SICI)1097-4644(20000301)76:3<499::AID-JCB16>3.0.CO;2-4; Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345; DGIOVANNI J, 1987, GENETIC FACTORS CONT; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; Freeman A, 1999, CLIN CANCER RES, V5, P2121; Going JJ, 2002, GUT, V50, P373, DOI 10.1136/gut.50.3.373; Grutzmann R, 2004, NEOPLASIA, V6, P611, DOI 10.1593/neo.04295; Homesley L, 2000, GENE DEV, V14, P913; Kukimoto I, 1998, BIOCHEM BIOPH RES CO, V249, P258, DOI 10.1006/bbrc.1998.9066; Nallamshetty S, 2005, FEBS LETT, V579, P6529, DOI 10.1016/j.febslet.2005.10.028; NELSON MA, 1992, P NATL ACAD SCI USA, V89, P6398, DOI 10.1073/pnas.89.14.6398; Padmanabhan V, 2004, J CLIN PATHOL, V57, P1057, DOI 10.1136/jcp.2004.016436; Pasion SG, 2001, GENET ENG P, V23, P129; REN B, 2005, ONCOGENE; Shohet JM, 2002, CANCER RES, V62, P1123; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Tye BK, 2004, FRONT BIOSCI-LANDMRK, V9, P2548, DOI 10.2741/1416; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Waikel RL, 1999, ONCOGENE, V18, P4870, DOI 10.1038/sj.onc.1203040; Waikel RL, 2001, NAT GENET, V28, P165, DOI 10.1038/88889; Wang Y, 2000, FEBS LETT, V484, P17, DOI 10.1016/S0014-5793(00)02117-7; Wharton SB, 2004, BRIT J CANCER, V91, P262, DOI 10.1038/sj.bjc.6601949; Wharton SB, 2001, NEUROPATH APPL NEURO, V27, P305, DOI 10.1046/j.0305-1846.2001.00333.x; Woodworth CD, 2004, CARCINOGENESIS, V25, P1771, DOI 10.1093/carcin/bgh170; Yoshida K, 2003, FEBS LETT, V553, P213, DOI 10.1016/S0014-5793(03)01018-4; YUSPA SH, 1988, ADV CANCER RES, V50, P25, DOI 10.1016/S0065-230X(08)60434-0	36	88	94	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2006	25	29					4027	4032		10.1038/sj.onc.1209435	http://dx.doi.org/10.1038/sj.onc.1209435			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16518415				2022-12-28	WOS:000238802400003
J	Gudi, R; Barkinge, J; Hawkins, S; Chu, F; Manicassamy, S; Sun, Z; Duke-Cohan, JS; Prasad, KVS				Gudi, R.; Barkinge, J.; Hawkins, S.; Chu, F.; Manicassamy, S.; Sun, Z.; Duke-Cohan, J. S.; Prasad, K. V. S.			Siva-1 negatively regulates NF-kappa B activity: effect on T-cell receptor-mediated activation-induced cell death (AICD)	ONCOGENE			English	Article						TCR; apoptosis; NF-kappa B; Bcl-xL; c-FLIP; AICD	APOPTOSIS; INTERACTS; PATHWAY; BINDING; FAMILY; MEMBER; CD27	Ligation of TCRs on stimulated T cells leads to activation-induced cell death (AICD) resulting in the downregulation of immune responses, a process essential for T-cell homeostasis. In this study, using transformed T-cell lines such as Jurkat and Do11.10 as cellular models of TCR-mediated AICD, we have demonstrated that the proapoptotic protein Siva-1 is required for TCR-induced apoptosis. Knockdown of Siva-1 rendered T cells specifically resistant to anti-CD3 but not Fas-induced apoptosis. Further, we observed that in Siva-1 knockout Jurkat cells, TCR-mediated activation of the canonical and non-canonical limbs of the NF-kappa B pathway are significantly enhanced as reflected by elevated nuclear levels of p65 and RelB, respectively. In addition, loss of endogenous Siva-1 also resulted in the enhanced expression of NF-kappa B-responsive anti-apoptotic genes such as Bcl-xL and c-FLIP. Interestingly, the c-FLIPshort was detected only in TCR-ligated Siva-1 knockdown Jurkat cells. These results demonstrate a significant role for endogenous Siva-1, through its inhibitory effect on NF-kappa B activity, in TCR-mediated AICD with implications in peripheral tolerance, T-cell homeostasis and cancer.	Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Prasad, KVS (corresponding author), Univ Illinois, Dept Microbiol & Immunol, 835 S Wolcott Ave,Room 820, Chicago, IL 60612 USA.	kanteti@uic.edu	Duke-Cohan, Jonathan/A-5812-2010	Duke-Cohan, Jonathan/0000-0002-9478-9609				Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cao C, 2001, J BIOL CHEM, V276, P11465, DOI 10.1074/jbc.C100050200; Chu F, 2005, CANCER RES, V65, P5301, DOI 10.1158/0008-5472.CAN-04-3270; Chu F, 2004, APOPTOSIS, V9, P83, DOI 10.1023/B:APPT.0000012125.01799.4c; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Green DR, 2003, IMMUNOL REV, V193, P70, DOI 10.1034/j.1600-065X.2003.00051.x; Hauer J, 2005, P NATL ACAD SCI USA, V102, P2874, DOI 10.1073/pnas.0500187102; Henke A, 2000, J VIROL, V74, P4284, DOI 10.1128/JVI.74.9.4284-4290.2000; Hildeman DA, 2002, CURR OPIN IMMUNOL, V14, P354, DOI 10.1016/S0952-7915(02)00335-7; Li YQ, 2005, J BIOL CHEM, V280, P1217, DOI 10.1074/jbc.M409492200; MULLER MM, 1989, NUCLEIC ACIDS RES, V17, P6420, DOI 10.1093/nar/17.15.6420; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; Prasad KVS, 1997, P NATL ACAD SCI USA, V94, P6346, DOI 10.1073/pnas.94.12.6346; Schmitz I, 2004, J IMMUNOL, V172, P2194, DOI 10.4049/jimmunol.172.4.2194; Spinicelli S, 2002, CELL DEATH DIFFER, V9, P1382, DOI 10.1038/sj.cdd.4401140; Wan YSY, 2003, IMMUNITY, V18, P331, DOI 10.1016/S1074-7613(03)00053-0; XIAO N, 2005, LYMPHOMA J INVEST DE, V124, P741; Xue L, 2002, P NATL ACAD SCI USA, V99, P6925, DOI 10.1073/pnas.102182299; Yoon Y, 1999, ONCOGENE, V18, P7174, DOI 10.1038/sj.onc.1203144	20	33	36	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3458	3462		10.1038/sj.onc.1209381	http://dx.doi.org/10.1038/sj.onc.1209381			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16491128				2022-12-28	WOS:000238448100010
J	Sensi, M; Nicolini, G; Petti, C; Bersani, I; Lozupone, F; Molla, A; Vegetti, C; Nonaka, D; Mortarini, R; Parmiani, G; Fais, S; Anichini, A				Sensi, M.; Nicolini, G.; Petti, C.; Bersani, I.; Lozupone, F.; Molla, A.; Vegetti, C.; Nonaka, D.; Mortarini, R.; Parmiani, G.; Fais, S.; Anichini, A.			Mutually exclusive NRAS(Q61R) and BRAF(V600E) mutations at the single-cell level in the same human melanoma	ONCOGENE			English	Article						melanoma; BRAF; NRAS; MASA-PCR; SCID	N-RAS MUTATIONS; B-RAF; BRAF MUTATIONS; COLORECTAL TUMORS; K-RAS; EXPRESSION; KINASE; GROWTH; GENE; ACTIVATION	BRAF or NRAS mutations have been found in 80% of human sporadic melanomas, but only one of these genetic alterations could be detected in each tumour. This suggests that BRAF and NRAS 'double mutants' may not provide advantage for tumour growth, or may even be selected against during tumorigenesis. However, by applying mutant-allele-specific-amplification-PCR method to short-term melanoma lines, one out of 14 tumours was found to harbour both BRAF(V600E) and the activating NRAS(Q61R) mutations. On the other hand, analysis of 21 melanoma clones isolated by growth in soft agar from this tumour indicated that 16/21 clones harboured a BRAF(V600E), but were wild-type for NRAS, whereas the remaining had the opposite genotype (NRAS(Q61R)/wild-type BRAF). When compared to BRAF(V600E) clones, NRAS(Q61R) clones displayed reduced growth in soft agar, but higher proliferative ability in vitro in liquid medium and even in vivo after grafting into SCID/SCID mice. These data suggest that NRAS and BRAF activating mutations can coexist in the same melanoma, but are mutually exclusive at the single-cell level. Moreover, the presence of NRAS(Q61R) or BRAF(V600E) is associated with distinct in vitro and in vivo growth properties of neoplastic cells.	Ist Nazl Studio & Cura Tumori, Dept Expt Oncol, Human Tumor Immunobiol Unit, I-20133 Milan, Italy; Ist Nazl Studio & Cura Tumori, Dept Pathol, I-20133 Milan, Italy; Ist Super Sanita, Dept Drug Res & Evaluat Pharmacogenet, Drug Resistance & Expt Therapeut Sect, I-00161 Rome, Italy; Ist Nazl Studio & Cura Tumori, Unit Immunotherapy Human Tumors, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Istituto Superiore di Sanita (ISS); Fondazione IRCCS Istituto Nazionale Tumori Milan	Sensi, M (corresponding author), Ist Nazl Studio & Cura Tumori, Dept Expt Oncol, Human Tumor Immunobiol Unit, Via Venezian 1, I-20133 Milan, Italy.	marialuisa.sensi@istitutotumori.mi.it	Mortarini, Roberta/C-9483-2017; Fais, Stefano/J-8638-2016; Lozupone, Francesco/H-2998-2016; Sensi, Marialuisa/K-5631-2014; Anichini, Andrea/K-1434-2016	Mortarini, Roberta/0000-0001-7732-0561; Fais, Stefano/0000-0001-9060-2766; Lozupone, Francesco/0000-0002-4959-9400; Sensi, Marialuisa/0000-0002-7643-0248; Anichini, Andrea/0000-0001-5096-5538				ANICHINI A, 1989, J IMMUNOL, V142, P3692; BALL NJ, 1994, J INVEST DERMATOL, V102, P285, DOI 10.1111/1523-1747.ep12371783; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; Bloethner S, 2005, CARCINOGENESIS, V26, P1224, DOI 10.1093/carcin/bgi066; Brose MS, 2002, CANCER RES, V62, P6997; Daniotti M, 2004, ONCOGENE, V23, P5968, DOI 10.1038/sj.onc.1207780; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Downward J, 2004, ONCOGENE, V23, P8376, DOI 10.1038/sj.onc.1208073; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; Gorden A, 2003, CANCER RES, V63, P3955; Gray-Schopfer VC, 2005, CANCER METAST REV, V24, P165, DOI 10.1007/s10555-005-5865-1; HASEGAWA Y, 1995, ONCOGENE, V10, P1441; Hendrix MJC, 2003, ANN NY ACAD SCI, V995, P151, DOI 10.1111/j.1749-6632.2003.tb03218.x; Jiveskog S, 1998, J INVEST DERMATOL, V111, P757, DOI 10.1046/j.1523-1747.1998.00376.x; Joyce JA, 2005, CANCER CELL, V7, P513, DOI 10.1016/j.ccr.2005.05.024; Lilleberg SL, 2004, ANN NY ACAD SCI, V1022, P250, DOI 10.1196/annals.1318.039; Linard B, 2002, J IMMUNOL, V168, P4802, DOI 10.4049/jimmunol.168.9.4802; Loewe R, 2004, J INVEST DERMATOL, V123, P733, DOI 10.1111/j.0022-202X.2004.23402.x; Lozupone F, 2004, CANCER RES, V64, P378, DOI 10.1158/0008-5472.CAN-03-1501; LUPETTI R, 1994, MELANOMA RES, V4, P11, DOI 10.1097/00008390-199402000-00003; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Miller CJ, 2004, J INVEST DERMATOL, V123, P990, DOI 10.1111/j.0022-202X.2004.23468.x; Omholt K, 2003, CLIN CANCER RES, V9, P6483; Pavey S, 2004, ONCOGENE, V23, P4060, DOI 10.1038/sj.onc.1207563; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Rak J, 2004, SEMIN CANCER BIOL, V14, P93, DOI 10.1016/j.semcancer.2003.09.014; Repasky GA, 2004, TRENDS CELL BIOL, V14, P639, DOI 10.1016/j.tcb.2004.09.014; Satyamoorthy K, 2003, CANCER RES, V63, P756; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Sivertsson A, 2002, CLIN CHEM, V48, P2164; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Strumberg D, 2005, J CLIN ONCOL, V23, P965, DOI 10.1200/JCO.2005.06.124; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Xu XL, 2003, CANCER RES, V63, P4561	39	134	136	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3357	3364		10.1038/sj.onc.1209379	http://dx.doi.org/10.1038/sj.onc.1209379			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16462768				2022-12-28	WOS:000238448100001
J	Konishi, T; Sasaki, S; Watanabe, T; Kitayama, J; Nagawa, H				Konishi, T.; Sasaki, S.; Watanabe, T.; Kitayama, J.; Nagawa, H.			Overexpression of hRFI inhibits 5-fluorouracil-induced apoptosis in colorectal cancer cells via activation of NF-kappa B andupregulation of BCL-2 and BCL-XL	ONCOGENE			English	Article						hRFI; apoptosis; 5-FU; colorectal cancer; Bcl-2 family; NF-kappa B	UBIQUITIN-PROTEIN LIGASE; CYTOCHROME-C; TRANSCRIPTIONAL REGULATION; DEATH; EXPRESSION; BCL-X(L); FAMILY; GENE; REGULATORS; MITOCHONDRIA	Resistance to apoptosis is one of the important determinants of resistance to 5-fluorouracil (5-FU) in colorectal cancer cells. Human Ring-Finger homologous to Inhibitor of apoptosis protein type (hRFI) is a newly discovered gene that has been shown to inhibit death receptor-mediated apoptosis in colorectal cancer cells. However, the molecular mechanism of the inhibition of apoptosis is presently unknown. In order to investigate the molecular function of hRFI in the regulation of 5-FU-induced apoptosis in colorectal cancer cells, HCT116 cells were stably transfected with hRFI or LacZ as a control. hRFI overexpression resulted in cellular resistance to 5-FU through an inhibition of the mitochondrial apoptotic pathway and specific upregulation of Bcl-2 and Bcl-XL. Futhermore, hRFI overexpression resulted in the activation of nuclear factor-kappa B (NF-kappa B). Inhibition of NF-kappa B effectively reversed the resistance to apoptosis as well as the upregulation of Bcl-2 and Bcl-XL in the hRFI transfectant, indicating that the activation of NF-kappa B is the key mechanism for all these findings. Overexpression of hRFI in SW480 and COLO320 colorectal cancer cells similarly resulted in resistance to 5-FU with the activation of NF-kappa B and up regulation of Bcl-2 and Bcl-XL. hRFI might be a novel therapeutic target for gene therapy in colorectal cancer.	Univ Tokyo, Dept Surg Oncol, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo	Konishi, T (corresponding author), Univ Tokyo, Dept Surg Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	konishit-sur@h.u-tokyo.ac.jp; sasaki-lsu@h.u-tokyo.ac.jp						BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beinke S, 2004, BIOCHEM J, V382, P393, DOI 10.1042/BJ20040544; Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cusack JC, 2000, CANCER RES, V60, P2323; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; Holcik M, 2001, APOPTOSIS, V6, P253, DOI 10.1023/A:1011379307472; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Huang HK, 2000, J BIOL CHEM, V275, P26661; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Kahlenberg MS, 2003, SURG ONCOL, V12, P173, DOI 10.1016/S0960-7404(03)00006-9; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Konishi T, 2005, MOL CANCER THER, V4, P743, DOI 10.1158/1535-7163.MCT-05-0020; KORSMEYER SJ, 1992, BLOOD, V80, P879; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Martinou JC, 2000, NAT CELL BIOL, V2, pE41, DOI 10.1038/35004069; Maurer CA, 1998, DIGEST DIS SCI, V43, P2641, DOI 10.1023/A:1026695025990; MIYASHITA T, 1993, BLOOD, V81, P151; Mori N, 2001, VIRUS GENES, V22, P279, DOI 10.1023/A:1011158021749; Nita ME, 2000, JPN J CANCER RES, V91, P825, DOI 10.1111/j.1349-7006.2000.tb01020.x; Nita ME, 1998, BRIT J CANCER, V78, P986, DOI 10.1038/bjc.1998.617; Ogura E, 1999, ONCOL REP, V6, P365; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Panwalkar A, 2004, CANCER-AM CANCER SOC, V100, P1578, DOI 10.1002/cncr.20182; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; Renard P, 2001, Nucleic Acids Res, V29, pE21, DOI 10.1093/nar/29.4.e21; Rigas A, 2002, CANCER INVEST, V20, P657, DOI 10.1081/CNV-120002491; Sasaki S, 2004, JPN J CLIN ONCOL, V34, P584, DOI 10.1093/jjco/hyh106; Sasaki S, 2004, J EXP CLIN CANC RES, V23, P507; Sasaki S, 2002, ONCOGENE, V21, P5024, DOI 10.1038/sj.onc.1205627; Sasaki Shin, 2003, Nihon Rinsho, V61 Suppl 7, P242; Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595; Sun YJ, 2002, CANCER RES, V62, P6323; Syken J, 2003, ONCOGENE, V22, P4636, DOI 10.1038/sj.onc.1206569; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; Tsujimoto Y, 2000, J NEURAL TRANSM-SUPP, P41; Violette S, 2002, INT J CANCER, V98, P498, DOI 10.1002/ijc.10146; Voboril R, 2004, J SURG RES, V120, P178, DOI 10.1016/j.jss.2003.11.023; Wang W, 2003, BRIT J CANCER, V88, P624, DOI 10.1038/sj.bjc.6600753; Wang WG, 2003, INT J CANCER, V104, P504, DOI 10.1002/ijc.10972; Yang L, 2003, CANCER RES, V63, P6815; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yang YL, 2003, FASEB J, V17, P790, DOI 10.1096/fj.02-0654rev	50	27	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3160	3169		10.1038/sj.onc.1209342	http://dx.doi.org/10.1038/sj.onc.1209342			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16407826				2022-12-28	WOS:000237951000007
J	Hatada, I; Fukasawa, M; Kimura, M; Morita, S; Yamada, K; Yoshikawa, T; Yamanaka, S; Endo, C; Sakurada, A; Sato, M; Kondo, T; Horii, A; Ushijima, T; Sasaki, H				Hatada, I.; Fukasawa, M.; Kimura, M.; Morita, S.; Yamada, K.; Yoshikawa, T.; Yamanaka, S.; Endo, C.; Sakurada, A.; Sato, M.; Kondo, T.; Horii, A.; Ushijima, T.; Sasaki, H.			Genome-wide profiling of promoter methylation in human	ONCOGENE			English	Article						DNA methylation; genome-wide profiling; epigenetics; microarray	DNA METHYLATION; CPG-ISLANDS	DNA methylation in the promoter region of a gene is associated with a loss of that gene's expression and plays an important role in gene silencing. The inactivation of tumor-suppressor genes by aberrant methylation in the promoter region is well recognized in carcinogenesis. However, there has been little study in this area when it comes to genome-wide profiling of the promoter methylation. Here, we developed a genome-wide profiling method called Microarray-based Integrated Analysis of Methylation by Isoschizomers to analyse the DNA methylation of promoter regions of 8091 human genes. With this method, resistance to both the methylation-sensitive restriction enzyme HpaII and the methylation-insensitive isoschizomer MspI was compared between samples by using a microarray with promoter regions of the 8091 genes. The reliability of the difference in HpaII resistance was judged using the difference in MspI resistance. We demonstrated the utility of this method by finding epigenetic mutations in cancer. Aberrant hypermethylation is known to inactivate tumour suppressor genes. Using this method, we found that frequency of the aberrant promoter hypermethylation in cancer is higher than previously hypothesized. Aberrant hypomethylation is known to induce activation of oncogenes in cancer. Genome-wide analysis of hypomethylated promoter sequences in cancer demonstrated low CG/GC ratio of these sequences, suggesting that CpG-poor genes are sensitive to demethylation activity in cancer.	Gunma Univ, Dept Mol & Cellular Biol, Lab Genome Sci, Biosignal Genome Resource Ctr, Maebashi, Gumma 3718512, Japan; PRESTO, JST, Kawaguchi, Japan; RIKEN, Brain Sci Inst, Lab Mol Psychiat, Wako, Saitama, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Thorac Surg, Sendai, Miyagi, Japan; Tohoku Univ, Sch Med, Dept Mol Pathol, Sendai, Miyagi, Japan; Natl Canc Ctr, Res Inst, Div Carcinogenesis, Chuo Ku, Tokyo 104, Japan; Natl Inst Genet, Res Org Informat & Syst, Div Human Genet, Mishima, Shizuoka, Japan; Grad Univ Adv Studies, Sch Life Sci, Dept Genet, Mishima, Shizuoka, Japan	Gunma University; Japan Science & Technology Agency (JST); RIKEN; Tohoku University; Tohoku University; National Cancer Center - Japan; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Graduate University for Advanced Studies - Japan	Hatada, I (corresponding author), Gunma Univ, Dept Mol & Cellular Biol, Lab Genome Sci, Biosignal Genome Resource Ctr, 3-39-15 Showa Machi, Maebashi, Gumma 3718512, Japan.	ihatada@showa.gunma-u.ac.jp	Ushijima, Toshikazu/AAP-5742-2021; Horii, Akira/AAW-2839-2021; Yoshikawa, Takeo/F-9599-2019	Ushijima, Toshikazu/0000-0003-3405-7817; Horii, Akira/0000-0002-3967-3291; 				Abujiang P, 1998, ONCOGENE, V17, P3029, DOI 10.1038/sj.onc.1202230; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Baylin SB, 1998, ADV CANCER RES, V72, P141; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; Hatada I, 2002, J HUM GENET, V47, P448, DOI 10.1007/s100380200063; Heisler LE, 2005, NUCLEIC ACIDS RES, V33, P2952, DOI 10.1093/nar/gki582; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Jager AC, 1997, AM J HUM GENET, V61, P129, DOI 10.1086/513896; Lipkin SM, 2000, NAT GENET, V24, P27, DOI 10.1038/71643; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Rozen S, 2000, Methods Mol Biol, V132, P365; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598; Yan PS, 2001, CANCER RES, V61, P8375	16	97	109	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					3059	3064		10.1038/sj.onc.1209331	http://dx.doi.org/10.1038/sj.onc.1209331			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16407832	Green Submitted			2022-12-28	WOS:000237950800010
J	Bian, D; Mahanivong, C; Yu, J; Frisch, SM; Pan, ZK; Ye, RD; Huang, S				Bian, D; Mahanivong, C; Yu, J; Frisch, SM; Pan, ZK; Ye, RD; Huang, S			The G(12/13)-RhoA signaling pathway contributes to efficient lysophosphatidic acid-stimulated cell migration	ONCOGENE			English	Article						LPA; FAK; cell migration	OVARIAN-CANCER CELLS; FOCAL ADHESION KINASE; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE-D; RAC ACTIVATION; RHO-GTPASES; EXPRESSION; LPA; RECEPTORS	The membrane redistribution and phosphorylation of focal adhesion kinase (FAK) have been reported to be important for cell migration. We previously showed that Lysophosphatidic acid (LPA) induced FAK membrane redistribution and autophosphorylation in ovarian cancer SK-OV3 cells and the signaling pathway consisting of G(i)-Ras-MEKK1 mediated LPA-induced FAK membrane redistribution but not FAK autophosphorylation. We also showed that the disruption of the Gi-Ras-MEKK1 pathway led to a significant reduction in LPA-stimulated cell migration. These findings raised the question of whether LPA-induced FAK autophosphorylation was required for LPA-stimulated cell migration and what signaling mechanism was involved in LPA-induced FAK autophosphorylation. In this study, we expressed the membrane anchored wild-type FAK (CD2-FAK) in SK-OV3 cells and found that the expression of CD2-FAK greatly rescued LPA-stimulated cell migration in G(i) or Ras-inhibited cells. However, Gi inhibitor pertussis toxin or dominant-negative H-Ras still significantly inhibited LPA-stimulated cell migration in cells expressing the membrane anchored FAK containing a mutation in the autophosphorylation site [CD2-FAK(Y397A)]. These results suggest that FAK autophosphorylation plays a role in LPA-stimulated cell migration. With the aid of p115Rho-GEF-RGS, G(12) and G(13) minigenes to inhibit G12/13, we found that the G12/13 pathway was required for LPA-induced FAK autophosphorylation and efficient cell migration. Moreover, LPA activated RhoA and Rho kinase (ROCK) in a G(12/13)-dependent manner and their activities were required for LPA-induced FAK autophosphorylation. However, Rho or ROCK inhibitors displayed no effect on LPA-induced FAK membrane redistribution although they abolished LPA-induced cytoskeleton reorganization. Our studies show that the G(12/13)-RhoA-ROCK signaling pathway mediates LPA-induced FAK autophosphorylation and contributes to LPA-stimulated cell migration.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; W Virginia Univ, Sch Med, Morgantown, WV USA; Med Coll Ohio, Dept Med Microbiol & Immunol, Toledo, OH USA; Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL USA	Scripps Research Institute; West Virginia University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Huang, S (corresponding author), Scripps Res Inst, Dept Immunol, IMM19,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	shuang@scripps.edu	Ye, Richard/O-5223-2016; Ye, Richard/ABF-2413-2020	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620	NCI NIH HHS [R01 CA93926] Funding Source: Medline; NIAID NIH HHS [R01 AI043524, R01 AI043524-11] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043524] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bian DF, 2004, CANCER RES, V64, P4209, DOI 10.1158/0008-5472.CAN-04-0060; Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; CHAN PY, 1994, J BIOL CHEM, V269, P20567; Daaka Y, 2002, BBA-MOL CELL BIOL L, V1582, P265, DOI 10.1016/S1388-1981(02)00180-4; Dutt P, 2002, FEBS LETT, V531, P565, DOI 10.1016/S0014-5793(02)03625-6; Eder AM, 2000, CLIN CANCER RES, V6, P2482; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fang XJ, 2004, J BIOL CHEM, V279, P9653, DOI 10.1074/jbc.M306662200; Fang XJ, 2000, ANN NY ACAD SCI, V905, P188; Fishman DA, 2001, CANCER RES, V61, P3194; Frankel A, 1996, CLIN CANCER RES, V2, P1307; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Fujita T, 2003, CANCER LETT, V192, P161, DOI 10.1016/S0304-3835(02)00713-9; Gschwind A, 2002, CANCER RES, V62, P6329; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Han QW, 2002, J BIOL CHEM, V277, P48379, DOI 10.1074/jbc.M209542200; Holinstat M, 2003, J BIOL CHEM, V278, P28793, DOI 10.1074/jbc.M303900200; Hu YL, 2001, J NATL CANCER I, V93, P762, DOI 10.1093/jnci/93.10.762; Hunger-Glaser I, 2003, J BIOL CHEM, V278, P22631, DOI 10.1074/jbc.M210876200; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Ishibe S, 2004, MOL CELL, V16, P257, DOI 10.1016/j.molcel.2004.10.006; Khyrul WAKM, 2004, J BIOL CHEM, V279, P54131, DOI 10.1074/jbc.M410051200; Kitayama J, 2004, BREAST CANCER RES, V6, pR640, DOI 10.1186/bcr935; KOZASA T, 2004, G PROTEIN SIGNALING, P153; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Li HB, 2005, J BIOL CHEM, V280, P10564, DOI 10.1074/jbc.M412152200; Linseman DA, 2000, J NEUROCHEM, V74, P2010, DOI 10.1046/j.1471-4159.2000.0742010.x; Luquain C, 2003, J LIPID RES, V44, P1963, DOI 10.1194/jlr.M300188-JLR200; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; Mukai M, 1999, INT J CANCER, V81, P918, DOI 10.1002/(SICI)1097-0215(19990611)81:6<918::AID-IJC13>3.0.CO;2-E; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; Panetti TS, 2000, ARTERIOSCL THROM VAS, V20, P1013, DOI 10.1161/01.ATV.20.4.1013; Pustilnik TB, 1999, CLIN CANCER RES, V5, P3704; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sawada K, 2002, GYNECOL ONCOL, V87, P252, DOI 10.1006/gyno.2002.6831; Sawada K, 2002, CANCER RES, V62, P6015; SCHALLER MD, 2003, BIOCHIM BIOPHYS ACTA, V1540, P1; Schwartz BM, 2001, GYNECOL ONCOL, V81, P291, DOI 10.1006/gyno.2001.6124; Sengupta S, 2004, SEMIN CELL DEV BIOL, V15, P503, DOI 10.1016/j.semcdb.2004.05.003; Shen ZZ, 1998, GYNECOL ONCOL, V71, P364, DOI 10.1006/gyno.1998.5193; Shida D, 2004, LAB INVEST, V84, P1352, DOI 10.1038/labinvest.3700146; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Stahle M, 2003, J CELL SCI, V116, P3835, DOI 10.1242/jcs.00679; Sundberg LJ, 2003, J BIOL CHEM, V278, P29783, DOI 10.1074/jbc.M303771200; Symowicz J, 2005, CANCER RES, V65, P2234, DOI 10.1158/0008.5472.CAN-04-2781; Tanyi JL, 2003, CANCER RES, V63, P1073; van Leeuwen FN, 2003, BIOCHEM SOC T, V31, P1209; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; Wang F, 1997, BIOCHEM J, V324, P481, DOI 10.1042/bj3240481; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Xie YH, 2002, BBA-MOL CELL BIOL L, V1582, P270, DOI 10.1016/S1388-1981(02)00181-6; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Xu Y, 1995, CLIN CANCER RES, V1, P1223; Yuan JZ, 2003, J BIOL CHEM, V278, P4882, DOI 10.1074/jbc.M211175200; Zeng HY, 2002, J BIOL CHEM, V277, P46791, DOI 10.1074/jbc.M206133200	61	91	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2234	2244		10.1038/sj.onc.1209261	http://dx.doi.org/10.1038/sj.onc.1209261			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16301993				2022-12-28	WOS:000236581200010
J	Matei, D; Emerson, RE; Lai, YC; Baldridge, LA; Rao, J; Yiannoutsos, C; Donner, DB				Matei, D; Emerson, RE; Lai, YC; Baldridge, LA; Rao, J; Yiannoutsos, C; Donner, DB			Autocrine activation of PDGFR alpha promotes the progression of ovarian cancer	ONCOGENE			English	Article						ovarian epithelial cancer; platelet-derived growth factor receptor; autocrine	GROWTH-FACTOR-RECEPTOR; PROGNOSTIC-SIGNIFICANCE; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL-3 KINASE; C-KIT; BETA; CARCINOMA; CELLS; MUTATIONS; RECURRENT	Platelet-derived growth factor receptor ( PDGFR) a expression was found in ovarian cancer cells and tumors by microarray hybridization. This led us to test whether ovarian cancers also produce ligands for this receptor, as this would demonstrate that such malignancies support their own growth and spread through autocrine activation. We assayed the expression of ligands for the PDGFR in ovarian tumors, cell lines and peritoneal fluid using RT-PCR, immunohistochemistry (IHC) and ELISA. We detected strong mRNA expression for the PDGFR alpha ligands in most ovarian tumors. Receptor and ligand expressions (PDGFR alpha and PDGF AB) were also detected by IHC in, respectively, 34 and 32 of 47 ovarian tumors. The stainings for PDGFR alpha and PDGF AB were strongly correlated (P-value = 0.014), suggesting that an autocrine loop is functional in ovarian cancer. PDGF AA and BB were quantified in peritoneal fluid by ELISA. Both ligands are secreted at higher levels in ovarian cancer ascites specimens (n = 54) than in fluid from nonmalignant disorders (n = 8). PDGF was detected in media conditioned by ovarian cancer cells. Such conditioned media induced activation of the PDGFR, Akt and MAPK and stimulated cell proliferation. A neutralizing PDGF antibody blocked these effects. Specific PDGFR inhibition by siRNA or a neutralizing antibody to the receptor inhibited PDGF-stimulated receptor activation and cell proliferation, suggesting that receptor targeting has a role in ovarian cancer treatment.	Indiana Univ, Sch Med, Div Hematol Oncol, Dept Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Ctr Canc, Indianapolis, IN USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN USA; Indiana Univ, Sch Med, Dept Pathol & Lab Med, Indianapolis, IN USA; Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA USA; Indiana Univ, Sch Med, Dept Biostat, Indianapolis, IN USA; Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Matei, D (corresponding author), Indiana Univ, Sch Med, Div Hematol Oncol, Dept Med, RT-457,535 Barnhill Dr, Indianapolis, IN 46202 USA.	dmatei@iupui.edu		Matei, Daniela/0000-0003-2169-5035				Aase K, 2002, MECH DEVELOP, V110, P187, DOI 10.1016/S0925-4773(01)00560-3; Bookman MA, 2003, J CLIN ONCOL, V21, P283, DOI 10.1200/JCO.2003.10.104; Dong JY, 2004, EMBO J, V23, P2800, DOI 10.1038/sj.emboj.7600289; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FRANKLIN WA, 1990, CANCER RES, V50, P6344; Gillan L, 2002, CANCER RES, V62, P5358; Gordon AN, 2001, J CLIN ONCOL, V19, P3312, DOI 10.1200/JCO.2001.19.14.3312; GREENHALGH DG, 1990, AM J PATHOL, V136, P1235; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; HENRIKSEN R, 1993, CANCER RES, V53, P4550; Hu YH, 1998, FASEB J, V12, P1135, DOI 10.1096/fasebj.12.12.1135; HUANG JS, 1984, CELL, V39, P79, DOI 10.1016/0092-8674(84)90193-4; Ikeda K, 2003, INT J GYNECOL CANCER, V13, P776, DOI 10.1111/j.1525-1438.2003.13381.x; Ismail RS, 2000, CANCER RES, V60, P6744; JENSEN RA, 1992, BIOCHEMISTRY-US, V31, P10887, DOI 10.1021/bi00159a032; KARLAN BY, 1995, GYNECOL ONCOL, V59, P67, DOI 10.1006/gyno.1995.1269; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Lassus H, 2004, BRIT J CANCER, V91, P2048, DOI 10.1038/sj.bjc.6602252; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Loizos N, 2005, MOL CANCER THER, V4, P369; Lokker NA, 2002, CANCER RES, V62, P3729; Matei D, 2004, CLIN CANCER RES, V10, P681, DOI 10.1158/1078-0432.CCR-0754-03; Matei D, 2002, ONCOGENE, V21, P6289, DOI 10.1038/sj.onc.1205785; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; OZOLS RF, 1997, CANC PRINCIPLES PRAC, V1, P1502; Pietras K, 2002, CANCER RES, V62, P5476; Schmandt RE, 2003, CANCER-AM CANCER SOC, V98, P758, DOI 10.1002/cncr.11561; Sihto H, 2005, J CLIN ONCOL, V23, P49, DOI 10.1200/JCO.2005.02.093; Spentzos D, 2004, J CLIN ONCOL, V22, P4700, DOI 10.1200/JCO.2004.04.070; UREN A, 1994, BIOCHEM BIOPH RES CO, V204, P628, DOI 10.1006/bbrc.1994.2505; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VERSNEL MA, 1994, CANCER GENET CYTOGEN, V73, P60, DOI 10.1016/0165-4608(94)90183-X; Wilczynski SP, 2005, HUM PATHOL, V36, P242, DOI 10.1016/j.humpath.2004.11.009; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YU JC, 1994, J BIOL CHEM, V269, P10668; Yu JH, 2001, BIOCHEM BIOPH RES CO, V282, P697, DOI 10.1006/bbrc.2001.4622; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	40	95	102	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2060	2069		10.1038/sj.onc.1209232	http://dx.doi.org/10.1038/sj.onc.1209232			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16331269				2022-12-28	WOS:000236359700009
J	Kjaer, S; Kurokawa, K; Perrinjaquet, M; Abrescia, C; Ibanez, CF				Kjaer, S.; Kurokawa, K.; Perrinjaquet, M.; Abrescia, C.; Ibanez, C. F.			Self-association of the transmembrane domain of RET underlies oncogenic activation by MEN2A mutations	ONCOGENE			English	Article						GDNF; ret; Hirschsprung; ToxCAT	NEOPLASIA TYPE 2B; ERYTHROPOIETIN RECEPTOR; GXXXG MOTIF; HIRSCHSPRUNGS-DISEASE; DRIVE ASSOCIATION; TRANSFORMING GENE; MEMBRANE-PROTEINS; TYROSINE KINASE; ERBB RECEPTORS; PROTOONCOGENE	In patients with medullary thyroid carcinoma (MTC) and type 2A multiple endocrine neoplasia (MEN2A), mutations of cysteine residues in the extracellular juxta-membrane region of the RET receptor tyrosine kinase cause the formation of covalent receptor dimers linked by intermolecular disulfide bonds between unpaired cysteines, followed by oncogenic activation of the RET kinase. The close proximity to the plasma membrane of the affected cysteine residues prompted us to investigate the possible role of the transmembrane (TM) domain of RET (RET-TM) in receptor-receptor interactions underlying dimer formation. Strong self-association of the RET-TM was observed in a biological membrane. Mutagenesis studies indicated the involvement of the evolutionary conserved residues Ser-649 and Ser-653 in RET-TM oligomerization. Unexpectedly, RET-TM interactions were also abrogated in the A639G/A641R double mutant, first identified in a sporadic case of MTC. In agreement with this, no transforming activity could be detected in full-length RET carrying the A639G and A641R mutations, which remained fully responsive to glial cell-line-derived neurotrophic factor (GDNF) stimulation. When introduced in the context of C634R-a cysteine replacement that is prevalent in MEN2A cases-the A639G/A641R mutations significantly reduced dimer formation and transforming activity in this otherwise highly oncogenic RET variant. These data suggest that a strong propensity to self-association in the RET-TM underlies-and may be required for-dimer formation and oncogenic activation of juxtamembrane cysteine mutants of RET, and explains the close proximity to the plasma membrane of cysteine residues implicated in MEN2A and MTC syndromes.	Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, S-17177 Stockholm, Sweden	Karolinska Institutet	Kjaer, S (corresponding author), Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, Berzelius Vag 35, S-17177 Stockholm, Sweden.	sven.kjaer@cancer.org.uk; carlos.ibanez@neuro.ki.se		Kjaer, Susanne/0000-0002-8347-1398				Abrescia C, 2005, FEBS LETT, V579, P3789, DOI 10.1016/j.febslet.2005.05.075; Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Arighi E, 2004, MOL ENDOCRINOL, V18, P1004, DOI 10.1210/me.2003-0173; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Asai N, 1999, BIOCHEM BIOPH RES CO, V255, P587, DOI 10.1006/bbrc.1999.0237; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Bongarzone I, 1998, ONCOGENE, V16, P2295, DOI 10.1038/sj.onc.1201759; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; Cerchia L, 2003, BIOCHEM J, V372, P897, DOI 10.1042/BJ20021530; Chappuis-Flament S, 1998, ONCOGENE, V17, P2851, DOI 10.1038/sj.onc.1202202; Dawson JP, 2002, J MOL BIOL, V316, P799, DOI 10.1006/jmbi.2001.5353; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; Geneste O, 1999, HUM MOL GENET, V8, P1989, DOI 10.1093/hmg/8.11.1989; Gimm O, 1997, J CLIN ENDOCR METAB, V82, P3902, DOI 10.1210/jc.82.11.3902; Gratkowski H, 2001, P NATL ACAD SCI USA, V98, P880, DOI 10.1073/pnas.98.3.880; Gurezka R, 1999, J BIOL CHEM, V274, P9265, DOI 10.1074/jbc.274.14.9265; Hahn M, 2001, P NATL ACAD SCI USA, V98, P1053, DOI 10.1073/pnas.021558598; Hoppner W, 1997, HUM MOL GENET, V6, P587, DOI 10.1093/hmg/6.4.587; Hoppner W, 1998, HUM MUTAT, pS128; Horenstein J, 2001, NAT NEUROSCI, V4, P477, DOI 10.1038/87425; Iwashita T, 1999, ONCOGENE, V18, P3919, DOI 10.1038/sj.onc.1202742; Iwashita T, 2001, GASTROENTEROLOGY, V121, P24, DOI 10.1053/gast.2001.25515; Jhiang SM, 1996, THYROID, V6, P115, DOI 10.1089/thy.1996.6.115; Jiang GQ, 1999, CURR BIOL, V9, pR568, DOI 10.1016/S0960-9822(99)80357-1; Kalinin VN, 2001, J MOL MED-JMM, V79, P609, DOI 10.1007/s001090100250; Kashuk CS, 2005, P NATL ACAD SCI USA, V102, P8949, DOI 10.1073/pnas.0503259102; Kjaer S, 2003, HUM MOL GENET, V12, P2133, DOI 10.1093/hmg/ddg227; Kubatzky KF, 2005, J BIOL CHEM, V280, P14844, DOI 10.1074/jbc.M411251200; Kubatzky KF, 2001, CURR BIOL, V11, P110, DOI 10.1016/S0960-9822(01)00018-5; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; Li E, 2005, BIOCHEMISTRY-US, V44, P352, DOI 10.1021/bi048480k; Li RH, 2004, J BIOL CHEM, V279, P26666, DOI 10.1074/jbc.M314168200; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Marx SJ, 2005, NAT REV CANCER, V5, P367, DOI 10.1038/nrc1610; Mcclain MS, 2003, J BIOL CHEM, V278, P12101, DOI 10.1074/jbc.M212595200; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Miyauchi A, 1999, JPN J CANCER RES, V90, P1; Moriki T, 2001, J MOL BIOL, V311, P1011, DOI 10.1006/jmbi.2001.4923; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; Roy R, 2004, BIOCHEMISTRY-US, V43, P4964, DOI 10.1021/bi0362875; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schneider D, 2004, J MOL BIOL, V343, P799, DOI 10.1016/j.jmb.2004.08.083; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Senes A, 2004, CURR OPIN STRUC BIOL, V14, P465, DOI 10.1016/j.sbi.2004.07.007; Seubert N, 2003, MOL CELL, V12, P1239, DOI 10.1016/S1097-2765(03)00389-7; Stanley AM, 2005, J MOL BIOL, V347, P759, DOI 10.1016/j.jmb.2005.01.059; Sulistijo ES, 2003, J BIOL CHEM, V278, P51950, DOI 10.1074/jbc.M308429200; Takahashi M, 1999, HUM MUTAT, V13, P331, DOI 10.1002/(SICI)1098-1004(1999)13:4<331::AID-HUMU11>3.3.CO;2-R; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; Vidal M, 2005, CANCER RES, V65, P3538, DOI 10.1158/0008-5472.CAN-04-4561; Young MT, 2003, J BIOL CHEM, V278, P32954, DOI 10.1074/jbc.M302527200; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698	63	38	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2006	25	53					7086	7095		10.1038/sj.onc.1209698	http://dx.doi.org/10.1038/sj.onc.1209698			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16732321				2022-12-28	WOS:000241910500008
J	Difeo, A; Narla, G; Camacho-Vanegas, O; Nishio, H; Rose, SL; Buller, RE; Friedman, SL; Walsh, MJ; Martignetti, JA				DiFeo, A.; Narla, G.; Camacho-Vanegas, O.; Nishio, H.; Rose, S. L.; Buller, R. E.; Friedman, S. L.; Walsh, M. J.; Martignetti, J. A.			E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor	ONCOGENE			English	Article						KLF6; KLF6-SV1; E-cadherin; alternative splicing; ovarian cancer	KRUPPEL-LIKE FACTOR-6; CELL LUNG-CANCER; PROSTATE-CANCER; GENE-EXPRESSION; OVARIAN-CANCER; GROWTH; ACTIVATION; PROTEIN; INHIBITION; CARCINOMA	The tumor suppressor KLF6 is a member of the Kruppel-like family of transcription factors, which has been implicated in the pathogenesis of several human carcinomas. Uncovering the transcriptional targets relevant for its tumorigenic properties, including cellular proliferation and invasion, will be essential to understanding possible mechanisms by which KLF6 and its antagonistic splice form, KLF6-SV1, regulate this development. To begin de. ning possible metastatic-related pathways, we analysed the effect of KLF6 dysregulation on a recognized suppressor of cellular invasion, E-cadherin. Targeted KLF6 reduction in an ovarian cancer cell line, SKOV-3, resulted in a 50% reduction of E-cadherin expression (P < 0.01) and conversely, KLF6-SV1 silencing upregulated E-cadherin approximately fivefold (P < 0.0001). These changes resulted from KLF6 directly transactivating the E-cadherin promoter as demonstrated by luciferase promoter assay and chromatin immunoprecipitation (ChIP). KLF6-mediated changes in E-cadherin levels were accompanied by downstream changes in both the subcellular localization of beta-catenin and c-myc expression levels. Moreover, and consistent with these experimental findings, patient-derived epithelial ovarian tumors with low KLF6 and high KLF6-SV1 expression ratios had significantly decreased E-cadherin expression (P < 0.0001). These combined findings highlight the E-cadherin pathway as a novel and functionally important mediator by which changes in KLF6 and KLF6-SV1 can directly alter ovarian tumor invasion and metastasis.	Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Univ Iowa Hosp & Clin, Div Gynecol Oncol, Iowa City, IA 52242 USA; Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Iowa; Icahn School of Medicine at Mount Sinai	Martignetti, JA (corresponding author), Mt Sinai Sch Med, Dept Human Genet, 1425 Madison Ave,Box 1498, New York, NY 10029 USA.	john.martignetti@mssm.edu	Narla, Goutham/AAZ-5710-2020	Narla, Goutham/0000-0003-4098-4203; DiFeo, Analisa/0000-0001-8319-6763				Ananthanarayanan M, 2004, J BIOL CHEM, V279, P54348, DOI 10.1074/jbc.M410021200; Benzeno S, 2004, CANCER RES, V64, P3885, DOI 10.1158/0008-5472.CAN-03-2818; Berchuck A, 1997, BIOCHEM PHARMACOL, V54, P541, DOI 10.1016/S0006-2952(97)00061-0; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Chen CS, 2003, AM J PATHOL, V162, P1349, DOI 10.1016/S0002-9440(10)63930-2; Chen Han-kui, 2002, Ai Zheng, V21, P1047; Cho YG, 2005, ONCOGENE, V24, P4588, DOI 10.1038/sj.onc.1208670; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; DIFEO A, 2006, IN PRESS CLIN CANC R; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Gabbert HE, 1996, INT J CANCER, V69, P184, DOI 10.1002/(SICI)1097-0215(19960621)69:3<184::AID-IJC6>3.0.CO;2-W; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Hosono S, 2000, J BIOL CHEM, V275, P10943, DOI 10.1074/jbc.275.15.10943; Ito G, 2004, CANCER RES, V64, P3838, DOI 10.1158/0008-5472.CAN-04-0185; Jeng YM, 2003, INT J CANCER, V105, P625, DOI 10.1002/ijc.11123; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kettunen E, 2004, CANCER GENET CYTOGEN, V149, P98, DOI 10.1016/s0165-4608(03)00300-5; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Kremer-Tal S, 2004, HEPATOLOGY, V40, P1047, DOI 10.1002/hep.20460; Macleod K, 2005, CANCER RES, V65, P6789, DOI 10.1158/0008-5472.CAN-04-2684; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; Narla G, 2005, CANCER RES, V65, P5761, DOI 10.1158/0008-5472.CAN-05-0217; Narla G, 2005, CANCER RES, V65, P1213, DOI 10.1158/0008-5472.CAN-04-4249; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Reeves HL, 2004, GASTROENTEROLOGY, V126, P1090, DOI 10.1053/j.gastro.2004.01.005; Rubinstein M, 2004, ENDOCRINOLOGY, V145, P3769, DOI 10.1210/en.2004-0173; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Slavin DA, 2004, ONCOGENE, V23, P8196, DOI 10.1038/sj.onc.1208020; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; TALKREMER S, 2004, HEPATOLOGY, V40, P1047; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M	33	65	68	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2006	25	44					6026	6031		10.1038/sj.onc.1209611	http://dx.doi.org/10.1038/sj.onc.1209611			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16702959				2022-12-28	WOS:000240826300011
J	Benoit, V; de Moraes, E; Dar, NA; Taranchon, E; Bours, V; Hautefeuille, A; Taniere, P; Chariot, A; Scoazec, JY; Gallo, CVD; Merville, MP; Hainaut, P				Benoit, V.; de Moraes, E.; Dar, N. A.; Taranchon, E.; Bours, V.; Hautefeuille, A.; Taniere, P.; Chariot, A.; Scoazec, J-Y; Gallo, C. V. de Moura; Merville, M-P; Hainaut, P.			Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB	ONCOGENE			English	Article						p53; NF-kappaB; cyclooxygenase-2 esophageal cancer; Barrett's metaplasia	SQUAMOUS-CELL CARCINOMA; BARRETTS-ESOPHAGUS; GENE-EXPRESSION; UP-REGULATION; COLON-CANCER; B ACTIVATION; COX-2; INHIBITION; PROTEIN; INDUCTION	Overexpression of cyclooxygenase-2 (Cox-2) is thought to exert antiapoptotic effects in cancer. Here we show that the tumor suppressor p53 upregulated Cox-2 in esophageal and colon cancer cell lines by inducing the binding of nuclear factor-kappaB (NF-kappaB) to its response element in the COX-2 promoter. Inhibition of NF-kappaB prevented p53 induction of Cox-2 expression. Cooperation between p53 and NF-kappaB was required for activation of COX-2 promoter in response to daunomycin, a DNA-damaging agent. Pharmacological inhibition of Cox-2 enhanced apoptosis in response to daunomycin, in particular in cells containing active p53. In esophageal cancer, there was a correlation between Cox-2 expression and wild-type TP53 in Barrett's esophagus (BE) and in adenocarcinoma, but not in squamous cell carcinoma (P < 0.01). These results suggest that p53 and NF-kappaB cooperate in upregulating Cox-2 expression, promoting cell survival in inflammatory precursor lesions such as BE.	Int Agcy Res Canc, Grp Mol Carcinogenesis, F-69372 Lyon, France; Univ Liege, Lab Med Chem & Human Genet, Ctr Biomed Integrated Genoproteom, Liege, Belgium; Hop Edouard Herriot, Dept Pathol, Lyon, France; State Uni Rio de Janeiro, Dept Cellular Biol & Genet, Rio De Janeiro, Brazil	World Health Organization; International Agency for Research on Cancer (IARC); University of Liege; CHU Lyon; Universidade do Estado do Rio de Janeiro	Hainaut, P (corresponding author), Int Agcy Res Canc, Grp Mol Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon, France.	hainaut@iarc.fr	Dar, NAZIR AHMAD/AAX-2763-2020; Hainaut, Pierre/B-6018-2012	Dar, NAZIR AHMAD/0000-0002-9517-9458; Hainaut, Pierre/0000-0002-1303-1610; Chariot, Alain/0000-0002-1691-4347; BENOIT, Valerie/0000-0002-1098-9452				Barnas C, 1997, INT J CANCER, V71, P79, DOI 10.1002/(SICI)1097-0215(19970328)71:1<79::AID-IJC14>3.0.CO;2-4; Beltrami E, 2004, J BIOL CHEM, V279, P2077, DOI 10.1074/jbc.M309479200; Benoit V, 2000, ONCOGENE, V19, P4787, DOI 10.1038/sj.onc.1203831; Bentires-Alj M, 1999, CANCER RES, V59, P811; Bentires-Alj M, 2001, ONCOGENE, V20, P2805, DOI 10.1038/sj.onc.1204343; Bentires-Alj M, 1999, DRUG RESIST UPDATE, V2, P274, DOI 10.1054/drup.1999.0093; Birkenkamp-Demtroder K, 2005, GUT, V54, P374, DOI 10.1136/gut.2003.036848; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Buskens CJ, 2003, GUT, V52, P1678, DOI 10.1136/gut.52.12.1678; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Corcoran CA, 2005, ONCOGENE, V24, P1634, DOI 10.1038/sj.onc.1208353; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Gilroy DW, 2001, FASEB J, V15, P288; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Han JH, 2004, MECH AGEING DEV, V125, P359, DOI 10.1016/j.mad.2004.02.002; Harris RE, 2000, CANCER RES, V60, P2101; Hla T, 1999, INT J BIOCHEM CELL B, V31, P551, DOI 10.1016/S1357-2725(98)00152-6; Jeong SJ, 2005, J BIOL CHEM, V280, P10326, DOI 10.1074/jbc.M412643200; Jiang XH, 2002, ONCOGENE, V21, P6113, DOI 10.1038/sj.onc.1205778; Jobin C, 1998, IMMUNOLOGY, V95, P537; Kaur BS, 2002, AM J PHYSIOL-GASTR L, V283, pG327, DOI 10.1152/ajpgi.00543.2001; Kaur BS, 2002, GASTROENTEROLOGY, V123, P60, DOI 10.1053/gast.2002.34244; Konturek PC, 2004, DIGEST DIS SCI, V49, P1075, DOI 10.1023/B:DDAS.0000037790.11724.70; Krysan K, 2004, FASEB J, V18, P205, DOI 10.1096/fj.03-0369fje; Krysan K, 2004, CANCER RES, V64, P6359, DOI 10.1158/0008-5472.CAN-04-1681; Kuo KT, 2003, ANN THORAC SURG, V76, P909, DOI 10.1016/S0003-4975(03)00717-3; Lagorce C, 2003, HISTOPATHOLOGY, V42, P457, DOI 10.1046/j.1365-2559.2003.01627.x; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; North S, 2002, MOL CARCINOGEN, V33, P181, DOI 10.1002/mc.10038; Oshima M, 2001, CANCER RES, V61, P1733; Rockwell P, 2004, CELL SIGNAL, V16, P343, DOI 10.1016/j.cellsig.2003.08.006; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Sawaoka H, 1998, AM J PHYSIOL-GASTR L, V274, pG1061, DOI 10.1152/ajpgi.1998.274.6.G1061; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; Sepehr A, 2001, ONCOGENE, V20, P7368, DOI 10.1038/sj.onc.1204912; Shamma A, 2000, CLIN CANCER RES, V6, P1229; Shirvani VN, 2000, GASTROENTEROLOGY, V118, P487, DOI 10.1016/S0016-5085(00)70254-X; Siewert JR, 1998, BRIT J SURG, V85, P1457; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Smith GV, 2005, AM J CLIN PATHOL, V123, P415, DOI 10.1309/263A4PQ83R9OCRUF; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3; Swamy MV, 2003, CANCER RES, V63, P5239; Tanabe T, 2002, PROSTAG OTH LIPID M, V68-9, P95, DOI 10.1016/S0090-6980(02)00024-2; Tsuji S, 2001, J EXP CLIN CANC RES, V20, P117; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Wu KK, 2005, ARTERIOSCL THROM VAS, V25, P679, DOI 10.1161/01.ATV.0000157899.35660.61; Yang D, 2004, P NATL ACAD SCI USA, V101, P15100, DOI 10.1073/pnas.0406665101; Yu HP, 2003, CANCER LETT, V198, P193, DOI 10.1016/S0304-3835(03)00340-9; Zhu Y, 2002, J BIOL CHEM, V277, P6923, DOI 10.1074/jbc.M108075200; Zimmermann KC, 1999, CANCER RES, V59, P198	56	45	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2006	25	42					5708	5718		10.1038/sj.onc.1209579	http://dx.doi.org/10.1038/sj.onc.1209579			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16682957	Green Published			2022-12-28	WOS:000240765800002
J	Marini, P; Denzinger, S; Schiller, D; Kauder, S; Welz, S; Humphreys, R; Daniel, PT; Jendrossek, V; Budach, W; Belka, C				Marini, P.; Denzinger, S.; Schiller, D.; Kauder, S.; Welz, S.; Humphreys, R.; Daniel, P. T.; Jendrossek, V.; Budach, W.; Belka, C.			Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo	ONCOGENE			English	Article						TRAIL receptor antibodies; HGS-ETR1; HGS-ETR2; radiotherapy; apoptosis; molecular targeted therapy	APOPTOSIS-INDUCING LIGAND; IRRADIATION-INDUCED APOPTOSIS; CELL-DEATH PATHWAY; NF-KAPPA-B; IONIZING-RADIATION; MONOCLONAL-ANTIBODIES; CANCER-THERAPY; CYTOCHROME-C; DNA-DAMAGE; BAX	We and others have demonstrated already that TRAIL (TNF-related apoptosis-inducing ligand) is a very promising candidate for molecular targeted anticancer therapy, especially when combined with ionizing radiation or other DNA-damaging agents. Agonist monoclonal antibodies that activate and are specific for the death signaling TRAIL receptors are an alternative method to stimulate the programmed cell death pathway. Phase 1 clinical trials have subsequently been conducted and shown a very good tolerability of these antibodies. In order to assess the efficacy of TRAIL receptor stimulation to induce cell death by this alternate method, we studied the combination of the agonistic-TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 with radiation in vitro and in vivo. Induction of apoptosis after combined treatment with TRAIL receptor antibodies HGS-ETR1 and/or HGS-ETR2 (0.01, 0.1, 1.0 mg/ml) and irradiation with 2, 5 or 10 Gy was determined by fluorescence microscopy and Western blot analysis of caspase-8 and PARP. The colorectal tumour cell lines Colo 205, HCT 116 and HCT-15 were used for in vitro experiments. Growth delay experiments were performed with combined treatment with fractionated irradiation (days 1-5 and 3Gy single dose/day) and the receptor antibodies (intraperitonially, three different concentrations, application on days 1, 4 and 8) on Colo 205 xenograft-bearing NMRI (nu/nu) nude mice. HGS-ETR1 and HGS-ETR2 induced apoptotic cell death in a dose-dependent fashion and significantly increased cell death in combination with irradiation in vitro when compared to either irradiation or antibody treatment alone. The efficacy of the combined treatment seems to be at least partially Bax-dependent. Similar to the results from cell culture experiments, in vivo experiments demonstrated a dose-dependent delay in tumour growth after combined treatment. In vivo, in the Colo205 xenograft model, HGS-ETR2 revealed a higher activity than HGS-ETR1. This is the first study to demonstrate significant efficacy of combined treatment with the monoclonal agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and ionising radiation in in vitro and in vivo models. We postulate that HGS-ETR1 and HGS-ETR2 will be very promising new agents in the field of molecular targeted multi-modality anticancer therapy.	Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany; Univ Dusseldorf, Dept Radiat Oncol & Radiotherapy, D-4000 Dusseldorf, Germany; Human Genome Sci Inc, Dev Sci & Res, Rockville, MD USA; Humboldt Univ, Berlin, Germany	Eberhard Karls University of Tubingen; Heinrich Heine University Dusseldorf; GlaxoSmithKline; Human Genome Sciences Inc; Humboldt University of Berlin	Belka, C (corresponding author), Univ Tubingen, Dept Radiat Oncol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	claus.belka@uni-tuebingen.de	Jendrossek, Verena/AAH-4967-2019	Jendrossek, Verena/0000-0003-1058-2107				ALDERSON RF, 2003, 94 AACR ANN M; Almasan A, 2003, CYTOKINE GROWTH F R, V14, P337, DOI 10.1016/S1359-6101(03)00029-7; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; ATTARD G, 2005, AACRNCIEORTC INT C M; Belka C, 2004, INT J RADIAT ONCOL, V58, P542, DOI 10.1016/j.ijrobp.2003.09.067; Belka C, 2003, ONCOGENE, V22, P176, DOI 10.1038/sj.onc.1206103; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Broaddus VC, 2005, J BIOL CHEM, V280, P12486, DOI 10.1074/jbc.M408190200; Buchsbaum DJ, 2003, CLIN CANCER RES, V9, P3731; Cecconi F, 1999, CELL DEATH DIFFER, V6, P1087, DOI 10.1038/sj.cdd.4400602; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Chuntharapai A, 2001, J IMMUNOL, V166, P4891, DOI 10.4049/jimmunol.166.8.4891; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; DEBONO JS, 2004, 16 EORTCNCIAACR S MO; El-Zawahry A, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-2; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; FUDLA S, 2002, NAT MED, V8, P808; Griffith TS, 1999, J IMMUNOL, V162, P2597; Hamasu T, 2005, J RADIAT RES, V46, P103, DOI 10.1269/jrr.46.103; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; HOTTE SJ, 2004, 94 AACR ANN M GEN SW; Jendrossek V, 2003, ONCOGENE, V22, P2621, DOI 10.1038/sj.onc.1206355; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kim MR, 2001, FEBS LETT, V505, P179, DOI 10.1016/S0014-5793(01)02816-2; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luciano F, 2002, LEUKEMIA, V16, P700, DOI 10.1038/sj.leu.2402401; Marini P, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-5; Marini P, 2003, RADIOTHER ONCOL, V68, P189, DOI 10.1016/S0167-8140(03)00186-5; Marini Patrizia, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P334, DOI 10.2174/1568011033482297; MIYASHITA T, 1995, CELL, V80, P293; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532; Pukac L, 2005, BRIT J CANCER, V92, P1430, DOI 10.1038/sj.bjc.6602487; Rohn TA, 2001, ONCOGENE, V20, P4128, DOI 10.1038/sj.onc.1204534; Rudner J, 2005, ONCOGENE, V24, P130, DOI 10.1038/sj.onc.1208191; Rubel A, 2006, RADIAT ONCOL, V1, DOI 10.1186/1748-717X-1-6; SALCEDO TW, 2002, AM ASS CANC RES 93 A; SARANTOPOULOS J, 2005, AACRNCIEORTC INT C M; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Shankar S, 2004, PROSTATE, V61, P35, DOI 10.1002/pros.20069; Shankar S, 2004, INT J ONCOL, V24, P1133; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Stuben G, 1994, Strahlenther Onkol, V170, P36; STUSCHKE M, 1990, RADIAT RES, V122, P172, DOI 10.2307/3577603; TOLCHER AW, 2004, AM SOC CLIN ONC ANN; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Weinmann M, 2004, INT J RADIAT ONCOL, V58, P386, DOI 10.1016/j.ijrobp.2003.09.052; Weinmann M, 2004, FASEB J, V18, P1906, DOI 10.1096/fj.04-1918fje; Wendt J, 2005, ONCOGENE, V24, P4052, DOI 10.1038/sj.onc.1208580; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	58	91	96	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2006	25	37					5145	5154		10.1038/sj.onc.1209516	http://dx.doi.org/10.1038/sj.onc.1209516			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16636678				2022-12-28	WOS:000240063700007
J	Werbowetski-Ogilvie, TE; Sadr, MS; Jabado, N; Angers-Loustau, A; Agar, NYR; Wu, J; Bjerkvig, R; Antel, JP; Faury, D; Rao, Y; Del Maestro, RF				Werbowetski-Ogilvie, T. E.; Sadr, M. Seyed; Jabado, N.; Angers-Loustau, A.; Agar, N. Y. R.; Wu, J.; Bjerkvig, R.; Antel, J. P.; Faury, D.; Rao, Y.; Del Maestro, R. F.			Inhibition of medulloblastoma cell invasion by Slit	ONCOGENE			English	Article						Slit; medulloblastoma; glioma; invasion; inhibitor	ROUNDABOUT RECEPTOR; AXON GUIDANCE; CANCER-CELLS; TUMOR; MIGRATION; CDC42; GENE; PROTEINS; GLIOMAS; GROWTH	Invasion of brain tumor cells has made primary malignant brain neoplasms among the most recalcitrant to therapeutic strategies. We tested whether the secreted protein Slit2, which guides the projection of axons and developing neurons, could modulate brain tumor cell invasion. Slit2 inhibited the invasion of medulloblastoma cells in a variety of in vitro models. The effect of Slit2 was inhibited by the Robo ectodomain. Time-lapse videomicroscopy indicated that Slit2 reduced medulloblastoma invasion rate without affecting cell direction or proliferation. Both medulloblastoma and glioma tumors express Robo1 and Slit2, but only medulloblastoma invasion is inhibited by recombinant Slit2 protein. Downregulation of activated Cdc42 may contribute to this differential response. Our findings reinforce the concept that neurodevelopmental cues such as Slit2 may provide insights into brain tumor invasion.	Montreal Neurol Hosp & Inst, Brain Tumor Res Ctr, Montreal, PQ H3A 2B4, Canada; McGill Univ, Montreal Neurol Inst, Brain Tumor Res Ctr, Montreal, PQ, Canada; Montreal Childrens Hosp, Inst Res, Dept Pediat, Montreal, PQ H3H 1P3, Canada; Northwestern Univ, Feinberg Med Sch, Robert H Lurie Comprehens Canc Ctr, Ctr Genet Med, Chicago, IL 60611 USA; Univ Bergen, Dept Anat & Cell Biol, Bergen, Norway; McGill Univ, Montreal Neurol Inst, Neuroimmunol Unit, Montreal, PQ, Canada; Northwestern Univ, Feinberg Med Sch, Dept Neurol, Chicago, IL 60611 USA	McGill University; McGill University; McGill University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; University of Bergen; McGill University; Northwestern University; Feinberg School of Medicine	Del Maestro, RF (corresponding author), Montreal Neurol Hosp & Inst, Brain Tumor Res Ctr, 3801 Rue Univ St,BT 210, Montreal, PQ H3A 2B4, Canada.	y-rao@northwestern.edu; rolando.delmaestro@mcgill.ca	Xiao, Yang/B-5668-2012; Jabado, Nada/AAN-4026-2020	Angers-Loustau, Alexandre/0000-0003-1425-4143; antel, jack/0000-0002-5148-0636; Werbowetski-Ogilvie, Tamra/0000-0002-5469-0559	NCI NIH HHS [R01 CA114197-01A2, R01 CA114197] Funding Source: Medline; NEI NIH HHS [R01 EY014576, R01 EY014576-03] Funding Source: Medline; NIGMS NIH HHS [R01 GM070967, R01 GM070967-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA114197] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY014576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070967] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Astuti D, 2004, BRIT J CANCER, V90, P515, DOI 10.1038/sj.bjc.6601447; Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1; Corcoran A, 2003, NEUROSURGERY, V53, P174, DOI 10.1227/01.NEU.0000072442.26349.14; Dallol A, 2003, ONCOGENE, V22, P4611, DOI 10.1038/sj.onc.1206687; Dallol A, 2003, CANCER RES, V63, P1054; Dallol A, 2002, CANCER RES, V62, P5874; Del Duca D, 2004, J NEURO-ONCOL, V67, P295, DOI 10.1023/B:NEON.0000024220.07063.70; Del Maestro R, 2001, J NEURO-ONCOL, V53, P87, DOI 10.1023/A:1012236830230; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Fan XP, 2003, NEURON, V40, P113, DOI 10.1016/S0896-6273(03)00591-9; Gilthorpe JD, 2002, DEVELOPMENT, V129, P4719; Gomes ER, 2005, CELL, V121, P451, DOI 10.1016/j.cell.2005.02.022; JACOBSEN PF, 1985, J NEUROPATH EXP NEUR, V44, P472, DOI 10.1097/00005072-198509000-00003; Jen JC, 2004, SCIENCE, V304, P1509, DOI 10.1126/science.1096437; Joki T, 2001, NAT BIOTECHNOL, V19, P35, DOI 10.1038/83481; Keles GE, 1995, ONCOL RES, V7, P493; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; Louis DN, 2002, CANCER CELL, V1, P125, DOI 10.1016/S1535-6108(02)00040-5; Lundstrom A, 2004, GENE DEV, V18, P2161, DOI 10.1101/gad.310204; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Marillat V, 2004, NEURON, V43, P69, DOI 10.1016/j.neuron.2004.06.018; Marillat V, 2002, J COMP NEUROL, V442, P130, DOI 10.1002/cne.10068; Mason HA, 2001, J NEUROSCI, V21, P7654, DOI 10.1523/JNEUROSCI.21-19-07654.2001; Nguyen-Ba-Charvet KT, 2004, J NEUROSCI, V24, P1497, DOI 10.1523/JNEUROSCI.4729-03.2004; Palazzo AF, 2001, CURR BIOL, V11, P1536, DOI 10.1016/S0960-9822(01)00475-4; Park KW, 2003, DEV BIOL, V261, P251, DOI 10.1016/S0012-1606(03)00258-6; Prasad A, 2004, J BIOL CHEM, V279, P9115, DOI 10.1074/jbc.M308083200; RAFFEL C, 1993, NEUROSURGERY, V33, P301, DOI 10.1227/00006123-199308000-00018; Raffel C, 2004, NEOPLASIA, V6, P310, DOI 10.1593/neo.03454; RAFFEL C, 1995, NEUROSURGERY, V36, P971, DOI 10.1227/00006123-199505000-00013; Read TA, 2001, NAT BIOTECHNOL, V19, P29, DOI 10.1038/83471; Rossi MR, 2005, GENE, V356, P85, DOI 10.1016/j.gene.2005.04.018; Rubin JB, 2003, P NATL ACAD SCI USA, V100, P13513, DOI 10.1073/pnas.2235846100; Ruffini F, 2004, AM J PATHOL, V165, P2167, DOI 10.1016/S0002-9440(10)63266-X; Sanai N, 2005, NEW ENGL J MED, V353, P811, DOI 10.1056/NEJMra043666; Wang B, 2003, CANCER CELL, V4, P19, DOI 10.1016/S1535-6108(03)00164-8; Werbowetski T, 2004, J NEUROBIOL, V60, P71, DOI 10.1002/neu.10335; Werbowetski-Ogilvie TE, 2006, CANCER RES, V66, P1464, DOI 10.1158/0008-5472.CAN-05-1913; Wong K, 2002, CURR OPIN GENET DEV, V12, P583, DOI 10.1016/S0959-437X(02)00343-X; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X; Wu JY, 2001, NATURE, V410, P948, DOI 10.1038/35073616; Zhao YX, 2004, ANAL CHEM, V76, P1817, DOI 10.1021/ac0354037	43	54	62	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2006	25	37					5103	5112		10.1038/sj.onc.1209524	http://dx.doi.org/10.1038/sj.onc.1209524			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16636676	Green Accepted			2022-12-28	WOS:000240063700003
J	Lim, CP; Phan, TT; Lim, IJ; Cao, X				Lim, C. P.; Phan, T-T; Lim, I. J.; Cao, X.			Stat3 contributes to keloid pathogenesis via promoting collagen production, cell proliferation and migration	ONCOGENE			English	Article						Stat3; keloid; scar; fibroblasts; collagen; migration	POTENT ANTITUMOR-ACTIVITY; GROWTH-FACTOR-BETA; GENE-REGULATION; CANCER-CELLS; FIBROBLASTS; ACTIVATION; SCAR; TRANSCRIPTION; DISRUPTION; EXPRESSION	Keloids, partially considered as benign tumors, represent the most extreme example of cutaneous scarring that uniquely afflicts humans as a pathological response to wound healing. It is characterized by excessive deposition of collagen and other extracellular matrix components by dermal fibroblasts. Upon cutaneous injury, cocktails of chemokines, cytokines and growth factors are secreted temporally and spatially to direct appropriate responses from neutrophils, macrophages, keratinocytes and fibroblasts to facilitate normal wound healing. Signal transducer and activator of transcription 3 (Stat3) is an oncogene and a latent transcription factor activated by various cytokines and growth factors. We investigated the possible role of Stat3 in keloid scar pathogenesis by examining skin tissue and cultured fibroblasts from keloid-scarred patients. We observed enhanced expression and phosphorylation of Stat3 in keloid scar tissue, and in cultured keloid fibroblasts (KFs) in vitro. Increased activation of Janus kinase (Jak)2, but not Jak1, was detected in KFs, and suppression of Jak2 by its inhibitor repressed Stat3 Y705 phosphorylation. Inhibition of Stat3 expression and phosphorylation by short interfering RNA or Cucurbitacin I resulted in the loss of collagen production, impaired proliferation and delayed cell migration in KFs. We show, for the first time, a role of Stat3 in keloid pathogenesis. Inhibitors of Stat3 may be useful therapeutic strategies for the prospective treatment of keloid scars.	Inst Mol & Cell Biol, Cell Signaling Lab, Proteos, Singapore 138673, Singapore; Natl Univ Singapore, Dept Surg, Singapore 117548, Singapore; Natl Univ Singapore, Dept Bioengn, Singapore 117548, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore	Cao, X (corresponding author), Inst Mol & Cell Biol, Cell Signaling Lab, Proteos, 61 Biopolis Dr, Singapore 138673, Singapore.	mcbcaoxm@imcb.a-star.edu.sg	Phan, Toan Thang/A-5527-2009					ABERGEL RP, 1985, J INVEST DERMATOL, V84, P384, DOI 10.1111/1523-1747.ep12265471; Alster TS, 2003, AM J CLIN DERMATOL, V4, P235, DOI 10.2165/00128071-200304040-00003; BABU M, 1992, J INVEST DERMATOL, V99, P650, DOI 10.1111/1523-1747.ep12668146; BABU M, 1989, MOL CELL BIOL, V9, P1642, DOI 10.1128/MCB.9.4.1642; Blaskovich MA, 2003, CANCER RES, V63, P1270; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Calderon M, 1996, J SURG RES, V61, P343, DOI 10.1006/jsre.1996.0127; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; COSMAN B, 1961, PLAST RECONSTR SURG, V27, P335, DOI 10.1097/00006534-196104000-00001; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dauer DJ, 2005, ONCOGENE, V24, P3397, DOI 10.1038/sj.onc.1208469; DIEGELMANN RF, 1979, J CELL PHYSIOL, V98, P341, DOI 10.1002/jcp.1040980210; Edmondson SR, 2003, ENDOCR REV, V24, P737, DOI 10.1210/er.2002-0021; HAISA M, 1994, J INVEST DERMATOL, V103, P560, DOI 10.1111/1523-1747.ep12396856; Lee TY, 1999, ANN PLAS SURG, V43, P179; Leong PL, 2003, P NATL ACAD SCI USA, V100, P4138, DOI 10.1073/pnas.0534764100; Lim IJ, 2002, AM J PHYSIOL-CELL PH, V283, pC212, DOI 10.1152/ajpcell.00555.2001; Mustoe TA, 2004, BRIT MED J, V328, P1329, DOI 10.1136/bmj.328.7452.1329; Naitoh M, 2001, BIOCHEM BIOPH RES CO, V280, P1316, DOI 10.1006/bbrc.2001.4257; Ng DCH, 2006, J CELL BIOL, V172, P245, DOI 10.1083/jcb.200503021; Ragoowansi R, 2001, BRIT J PLAST SURG, V54, P504, DOI 10.1054/bjps.2001.3656; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Song H, 2005, P NATL ACAD SCI USA, V102, P4700, DOI 10.1073/pnas.0409894102; Sun JZ, 2005, ONCOGENE, V24, P3236, DOI 10.1038/sj.onc.1208470; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Takeda K, 2000, CYTOKINE GROWTH F R, V11, P199, DOI 10.1016/S1359-6101(00)00005-8; Tuan TL, 1998, MOL MED TODAY, V4, P19, DOI 10.1016/S1357-4310(97)80541-2; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; Wu YD, 2004, AM J PHYSIOL-CELL PH, V286, pC905, DOI 10.1152/ajpcell.00200.2003; Xue H, 2000, J SURG RES, V89, P74, DOI 10.1006/jsre.1999.5805; Yang GP, 2003, WOUND REPAIR REGEN, V11, P411, DOI 10.1046/j.1524-475X.2003.11604.x; Yoshimoto H, 1999, AM J PATHOL, V154, P883, DOI 10.1016/S0002-9440(10)65335-7; YOUNAI S, 1994, ANN PLAS SURG, V33, P148, DOI 10.1097/00000637-199408000-00005	38	82	99	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2006	25	39					5416	5425		10.1038/sj.onc.1209531	http://dx.doi.org/10.1038/sj.onc.1209531			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16619044				2022-12-28	WOS:000240144900006
J	Ribatti, D; Nico, B; Vacca, A				Ribatti, D.; Nico, B.; Vacca, A.			Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma	ONCOGENE			English	Review						angiogenesis; bone marrow; microenvironment; multiple myeloma	ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE INHIBITOR; RECEPTOR C-MET; NF-KAPPA-B; CELL-GROWTH; DRUG-RESISTANCE; UP-REGULATION; PLASMA-CELLS; FACTOR VEGF; HEMATOLOGIC MALIGNANCIES	Tumor microenvironment is essential for tumor cell proliferation, angiogenesis, invasion and metastasis through its provision of survival signals, secretion of growth and pro-angiogenic factors, and direct adhesion molecule interactions. This review examines its importance in the induction of an angiogenic response in multiple myeloma (MM). The encouraging results of preclinical and clinical trials in which MM has been treated by targeting the tumor microenvironment are also discussed.	Univ Bari, Sch Med, Dept Human Anat & Histol, Policlin, I-70124 Bari, Italy; Univ Bari, Sch Med, Dept Internal Med & Clin Oncol, I-70124 Bari, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Ribatti, D (corresponding author), Univ Bari, Sch Med, Dept Human Anat & Histol, Policlin, Piazza Giulio Cesare,11, I-70124 Bari, Italy.	ribatti@anatomia.uniba.it	Vacca, Angelo/AAC-9558-2022	Vacca, Angelo/0000-0002-4567-8216				Akiyama M, 2002, CANCER RES, V62, P3876; Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Andersen NF, 2005, BRIT J HAEMATOL, V128, P210, DOI 10.1111/j.1365-2141.2004.05299.x; Asosingh K, 2004, BLOOD, V103, P3131, DOI 10.1182/blood-2003-08-2946; Barille S, 1997, BLOOD, V90, P1649, DOI 10.1182/blood.V90.4.1649.1649_1649_1655; Bellamy WT, 1999, CANCER RES, V59, P728; Bernardini G, 2003, J IMMUNOL METHODS, V273, P83, DOI 10.1016/S0022-1759(02)00420-9; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; Bisping G, 2003, BLOOD, V101, P2775, DOI 10.1182/blood-2002-09-2907; Borset M, 1996, J BIOL CHEM, V271, P24655, DOI 10.1074/jbc.271.40.24655; Borset M, 1996, BLOOD, V88, P3998, DOI 10.1182/blood.V88.10.3998.bloodjournal88103998; Broek IV, 2004, LEUKEMIA, V18, P976, DOI 10.1038/sj.leu.2403331; Bruno B, 2005, LEUKEMIA, V19, P1729, DOI 10.1038/sj.leu.2403905; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Costes V, 1998, BRIT J HAEMATOL, V103, P1152, DOI 10.1046/j.1365-2141.1998.01101.x; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; Crivellato E, 2003, LEUKEMIA LYMPHOMA, V44, P517, DOI 10.1080/1042819021000047001; Crivellato E, 2002, LEUKEMIA LYMPHOMA, V43, P2201, DOI 10.1080/1042819021000016159; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Dankbar B, 2000, BLOOD, V95, P2630, DOI 10.1182/blood.V95.8.2630; Davies FE, 2003, BLOOD, V102, P4504, DOI 10.1182/blood-2003-01-0016; De Vos J, 2002, ONCOGENE, V21, P6848, DOI 10.1038/sj.onc.1205868; Derksen PWB, 2003, LEUKEMIA, V17, P764, DOI 10.1038/sj.leu.2402875; Derksen PWB, 2002, BLOOD, V99, P1405, DOI 10.1182/blood.V99.4.1405; Dhodapkar MV, 1998, BLOOD, V91, P2679, DOI 10.1182/blood.V91.8.2679.2679_2679_2688; Di Raimondo F, 2000, HAEMATOLOGICA, V85, P800; Dominici M, 2001, LEUKEMIA, V15, P171, DOI 10.1038/sj.leu.2401984; Ferlin M, 2000, BRIT J HAEMATOL, V111, P626, DOI 10.1046/j.1365-2141.2000.02364.x; GEN I, 2000, BLOOD, V96, P2856; Giuliani N, 2003, BLOOD, V102, P638, DOI 10.1182/blood-2002-10-3257; Grand EK, 2004, LEUKEMIA, V18, P962, DOI 10.1038/sj.leu.2403347; GRUBER BL, 1995, BLOOD, V86, P2488; Gupta D, 2001, LEUKEMIA, V15, P1950, DOI 10.1038/sj.leu.2402295; Hayashi T, 2004, CLIN CANCER RES, V10, P7540, DOI 10.1158/1078-0432.CCR-04-0632; Hazlehurst LA, 2003, CANCER RES, V63, P7900; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Hedvat CV, 2003, BRIT J HAEMATOL, V122, P728, DOI 10.1046/j.1365-2141.2003.04481.x; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2005, BEST PRACT RES CL HA, V18, P509, DOI 10.1016/j.beha.2005.01.003; Hideshima T, 2004, ONCOGENE, V23, P8766, DOI 10.1038/sj.onc.1208118; Hideshima T, 2003, ONCOGENE, V22, P8386, DOI 10.1038/sj.onc.1207170; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hideshima T, 2002, MOL CANCER THER, V1, P539; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623; Hu LP, 2003, BLOOD, V101, P3126, DOI 10.1182/blood-2002-08-2640; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; Johnson LL, 1998, CURR OPIN CHEM BIOL, V2, P466, DOI 10.1016/S1367-5931(98)80122-1; Jourdan M, 2003, ONCOGENE, V22, P2950, DOI 10.1038/sj.onc.1206423; Kaushal GP, 1999, BRIT J HAEMATOL, V104, P365, DOI 10.1046/j.1365-2141.1999.01180.x; Khakoo AY, 2005, ANNU REV MED, V56, P79, DOI 10.1146/annurev.med.56.090203.104149; Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746; Kumar S, 2005, LEUKEMIA, V19, P1466, DOI 10.1038/sj.leu.2403823; Kumar S, 2004, BLOOD, V104, P1159, DOI 10.1182/blood-2003-11-3811; Le Gouill S, 2004, BLOOD, V104, P2886, DOI 10.1182/blood-2004-05-1760; LeBlanc R, 2002, CANCER RES, V62, P4996; Leek RD, 1999, BRIT J CANCER, V79, P991, DOI 10.1038/sj.bjc.6690158; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; Lin B, 2002, CANCER RES, V62, P5019; Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; MOTRO B, 1990, P NATL ACAD SCI USA, V87, P3092, DOI 10.1073/pnas.87.8.3092; Munshi NC, 2004, BLOOD, V103, P1799, DOI 10.1182/blood-2003-02-0402; Nakagawa M, 2000, FEBS LETT, V473, P161, DOI 10.1016/S0014-5793(00)01520-9; Nakayama T, 2004, J CLIN INVEST, V114, P1317, DOI 10.1172/JCI200422089; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Niida S, 1999, J EXP MED, V190, P293, DOI 10.1084/jem.190.2.293; Ochiai N, 2003, BLOOD, V102, P3349, DOI 10.1182/blood-2003-03-0851; Ogata A, 1997, J IMMUNOL, V159, P2212; Paget S, 1989, LANCET, V8, P98, DOI [DOI 10.1016/S0140-6736(00)49915-0, 10.1016/S0140-6736(00)49915-0]; Pellegrino A, 2005, BRIT J HAEMATOL, V129, P248, DOI 10.1111/j.1365-2141.2005.05443.x; Pellegrino A, 2004, CANCER LETT, V207, P221, DOI 10.1016/j.canlet.2003.10.036; Podar K, 2005, BLOOD, V105, P1383, DOI 10.1182/blood-2004-07-2909; Podar K, 2004, BLOOD, V103, P3474, DOI 10.1182/blood-2003-10-3527; Podar K, 2002, J BIOL CHEM, V277, P7875, DOI 10.1074/jbc.M109068200; Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428; Qiang YW, 2002, BLOOD, V99, P4138, DOI 10.1182/blood.V99.11.4138; Ria R, 2004, THROMB HAEMOSTASIS, V92, P1438, DOI 10.1160/TH04-06-0334; Ria R, 2003, LEUKEMIA, V17, P1961, DOI 10.1038/sj.leu.2403076; Ribatti D, 2005, LEUKEMIA, V19, P1525, DOI 10.1038/sj.leu.2403852; Ribatti D, 2004, J CELL MOL MED, V8, P294, DOI 10.1111/j.1582-4934.2004.tb00319.x; Ribatti D, 2004, CLIN EXP ALLERGY, V34, P1660, DOI 10.1111/j.1365-2222.2004.02104.x; Ribatti D, 1999, BRIT J CANCER, V79, P451, DOI 10.1038/sj.bjc.6690070; Ribatti D, 2003, J HEMATOTH STEM CELL, V12, P11, DOI 10.1089/152581603321210091; Roccaro AM, 2006, CANCER RES, V66, P184, DOI 10.1158/0008-5472.CAN-05-1195; Sato N, 2002, JPN J CANCER RES, V93, P459, DOI 10.1111/j.1349-7006.2002.tb01278.x; Seidel C, 1998, BLOOD, V91, P806, DOI 10.1182/blood.V91.3.806.806_806_812; Sezer O, 2001, EUR J HAEMATOL, V66, P83, DOI 10.1034/j.1600-0609.2001.00348.x; Tai YT, 2002, BLOOD, V99, P1419, DOI 10.1182/blood.V99.4.1419; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Trudel S, 2005, BLOOD, V105, P2941, DOI 10.1182/blood-2004-10-3913; Trudel S, 2004, BLOOD, V103, P3521, DOI 10.1182/blood-2003-10-3650; Tu YP, 2000, CANCER RES, V60, P6763; Urashima M, 1996, BLOOD, V87, P1928; Urashima M, 1997, BLOOD, V90, P754, DOI 10.1182/blood.V90.2.754.754_754_765; Vacca A, 2006, LEUKEMIA, V20, P193, DOI 10.1038/sj.leu.2404067; Vacca A, 2005, J CLIN ONCOL, V23, P5334, DOI 10.1200/JCO.2005.03.723; Vacca A, 1999, BLOOD, V93, P3064; Vacca A, 2003, BLOOD, V102, P3340, DOI 10.1182/blood-2003-04-1338; Vacca A, 2003, HAEMATOLOGICA, V88, P176; Vacca A, 2001, EXP HEMATOL, V29, P993, DOI 10.1016/S0301-472X(01)00674-9; VACCA A, 1994, BRIT J HAEMATOL, V87, P503, DOI 10.1111/j.1365-2141.1994.tb08304.x; Van Valckenborgh E, 2005, LEUKEMIA, V19, P1628, DOI 10.1038/sj.leu.2403866; Van Valckenborgh E, 2002, INT J CANCER, V101, P512, DOI 10.1002/ijc.10642; Van Valckenborgh E, 2002, BRIT J CANCER, V86, P796, DOI 10.1038/sj.bjc.6600137; VANDERKERKEN K, 1977, BRIT J CANCER, V76, P451; Vincent L, 2005, CANCER RES, V65, P3185, DOI 10.1158/0008-5472.CAN-04-3598; Wuilleme-Toumi S, 2005, LEUKEMIA, V19, P1248, DOI 10.1038/sj.leu.2403784; Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhang H, 2005, BLOOD, V105, P3286, DOI 10.1182/blood-2004-06-2101; Zhang H, 2003, BLOOD, V101, P2253, DOI 10.1182/blood-2002-02-0629	118	134	137	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2006	25	31					4257	4266		10.1038/sj.onc.1209456	http://dx.doi.org/10.1038/sj.onc.1209456			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16518413				2022-12-28	WOS:000239240100001
J	Glaviano, A; Nayak, V; Cabuy, E; Baird, DM; Yin, Z; Newson, R; Ladon, D; Rubio, MA; Slijepcevic, P; Lyng, F; Mothersill, C; Case, CP				Glaviano, A.; Nayak, V.; Cabuy, E.; Baird, D. M.; Yin, Z.; Newson, R.; Ladon, D.; Rubio, M. A.; Slijepcevic, P.; Lyng, F.; Mothersill, C.; Case, C. P.			Effects of hTERT on metal ion-induced genomic instability	ONCOGENE			English	Article						chromium; vanadium; hTERT; genomic instability; carcinogenesis	TELOMERE LENGTH; CHROMOSOMAL INSTABILITY; GENE-EXPRESSION; HUMAN-CELLS; IONIZING-RADIATION; CELLULAR-RESPONSE; HUMAN FIBROBLASTS; LETHAL MUTATIONS; MAMMALIAN-CELLS; ANEUPLOID CELLS	There is currently a great interest in delayed chromosomal and other damaging effects of low-dose exposure to a variety of pollutants which appear collectively to act through induction of stress-response pathways related to oxidative stress and ageing. These have been studied mostly in the radiation field but evidence is accumulating that the mechanisms can also be triggered by chemicals, especially heavy metals. Humans are exposed to metals, including chromium (Cr) (VI) and vanadium (V) (V), from the environment, industry and surgical implants. Thus, the impact of low-dose stress responses may be larger than expected from individual toxicity projections. In this study, a short (24 h) exposure of human fibroblasts to low doses of Cr (VI) and V (V) caused both acute chromosome damage and genomic instability in the progeny of exposed cells for at least 30 days after exposure. Acutely, Cr (VI) caused chromatid breaks without aneuploidy while V (V) caused aneuploidy without chromatid breaks. The longer-term genomic instability was similar but depended on hTERT positivity. In telomerase-negative hTERT - cells, Cr (VI) and V (V) caused a long lasting and transmissible induction of dicentric chromosomes, nucleoplasmic bridges, micronuclei and aneuploidy. There was also a long term and transmissible reduction of clonogenic survival, with an increased beta-galactosidase staining and apoptosis. This instability was not present in telomerase-positive hTERT+ cells. In contrast, in hTERT+ cells the metals caused a persistent induction of tetraploidy, which was not noted in hTERT - cells. The growth and survival of both metal-exposed hTERT+ and hTERT+ cells differed if they were cultured at subconfluent levels or plated out as colonies. Genomic instability is considered to be a driving force towards cancer. This study suggests that the type of genomic instability in human cells may depend critically on whether they are telomerase-positive or - negative and that their sensitivities to metals could depend on whether they are clustered or diffuse.	Univ Bristol, Bristol Implant Res Ctr, Bristol BS10 5NB, Avon, England; Dublin Inst Technol, Radiat & Environm Sci Ctr, Dublin 8, Ireland; Brunel Univ, Uxbridge UB8 3PH, Middx, England; Cardiff Univ, Dept Pathol, Sch Med, Cardiff, S Glam, Wales; Kings Coll London, Dept Publ Hlth Serv, London WC2R 2LS, England; Netherlands Canc Inst, Amsterdam, Netherlands	University of Bristol; Technological University Dublin; Brunel University; Cardiff University; University of London; King's College London; Netherlands Cancer Institute	Case, CP (corresponding author), Univ Bristol, Bristol Implant Res Ctr, Bristol BS10 5NB, Avon, England.	cpcase@hotmail.com	Baird, Duncan M/C-9671-2011; Lyng, Fiona/AAD-2842-2020	Baird, Duncan M/0000-0001-8408-5467; Lyng, Fiona/0000-0002-9876-963X				Andreassen PR, 2003, MUTAT RES-FUND MOL M, V532, P245, DOI 10.1016/j.mrfmmm.2003.08.020; Baird DM, 2003, NAT GENET, V33, P203, DOI 10.1038/ng1084; Bindra RS, 2005, MUTAT RES-FUND MOL M, V569, P75, DOI 10.1016/j.mrfmmm.2004.03.013; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Cabuy E, 2004, CYTOM PART A, V62A, P150, DOI 10.1002/cyto.a.20096; Chan SWL, 2003, MOL CELL, V11, P1379, DOI 10.1016/S1097-2765(03)00174-6; Cheng RYS, 2003, TOXICOL APPL PHARM, V191, P22, DOI 10.1016/S0041-008X(03)00228-X; Coen N, 2003, BRIT J CANCER, V88, P548, DOI 10.1038/sj.bjc.6600758; Coen N, 2001, J PATHOL, V195, P293; CORINNA M, 2003, CARCINOGENESIS, V24, P1183; Cui W, 2002, J BIOL CHEM, V277, P38531, DOI 10.1074/jbc.M205981200; der-Sarkissian H, 2004, ONCOGENE, V23, P1221, DOI 10.1038/sj.onc.1207152; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DUTRILLAUX B, 1991, BREAST CANCER RES TR, V19, P245, DOI 10.1007/BF01961161; FENECH M, 1985, MUTAT RES, V147, P29, DOI 10.1016/0165-1161(85)90015-9; Fenech M, 2000, MUTAT RES-FUND MOL M, V455, P81, DOI 10.1016/S0027-5107(00)00065-8; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; Ha LN, 2004, CARCINOGENESIS, V25, P2265, DOI 10.1093/carcin/bgh242; Hackett JA, 2001, CELL, V106, P275, DOI 10.1016/S0092-8674(01)00457-3; HARDIN J, 2001, COLLEGE STATION; Henegariu O, 2001, CYTOMETRY, V43, P101, DOI 10.1002/1097-0320(20010201)43:2<101::AID-CYTO1024>3.0.CO;2-8; IARC, 1990, MON EV CARC RISK HUM; Ivancsits S, 2002, MUTAT RES-GEN TOX EN, V519, P25, DOI 10.1016/S1383-5718(02)00138-9; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; Karlseder J, 2004, PLOS BIOL, V2, P1150, DOI 10.1371/journal.pbio.0020240; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kerr J. F., 1991, APOPTOSIS MOL BASIS, V3, P5; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Koizumi S, 2003, J OCCUP HEALTH, V45, P331, DOI 10.1539/joh.45.331; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Little JB, 2003, ONCOGENE, V22, P6978, DOI 10.1038/sj.onc.1206988; Luther MJ, 2005, AM J PHYSIOL-ENDOC M, V288, pE502, DOI 10.1152/ajpendo.00424.2004; McClintock B, 1941, GENETICS, V26, P234; McIlrath J, 2001, CANCER RES, V61, P912; Mese H, 2001, CHEMOTHERAPY, V47, P136, DOI 10.1159/000048513; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Mothersill C, 1998, INT J RADIAT BIOL, V74, P673, DOI 10.1080/095530098140934; Mothersill C, 2004, MUTAT RES-FUND MOL M, V568, P121, DOI 10.1016/j.mrfmmm.2004.06.050; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nijjar T, 2005, ONCOGENE, V24, P3369, DOI 10.1038/sj.onc.1208482; NIOSH (National Institute for Occupational Safety and Health), 1997, NIOSH POCK GUID CHEM; Noble JR, 2004, ONCOGENE, V23, P3116, DOI 10.1038/sj.onc.1207440; O'Brien TJ, 2003, MUTAT RES-FUND MOL M, V533, P3, DOI 10.1016/j.mrfmmm.2003.09.006; Obe G, 2002, MUTAT RES-FUND MOL M, V504, P17, DOI 10.1016/S0027-5107(02)00076-3; Park HR, 2004, J CUTAN PATHOL, V31, P544, DOI 10.1111/j.0303-6987.2004.00228.x; Piboonniyom SO, 2003, CANCER RES, V63, P476; Pritchard DE, 2001, CELL GROWTH DIFFER, V12, P487; PUCK TT, 1956, J EXP MED, V103, P653, DOI 10.1084/jem.103.5.653; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Ramirez P, 1997, MUTAT RES-REV MUTAT, V386, P291, DOI 10.1016/S1383-5742(97)00018-5; REID BJ, 1987, GASTROENTEROLOGY, V93, P1; Risques RA, 2003, CANCER RES, V63, P7206; Rubio MA, 2004, EXP CELL RES, V298, P17, DOI 10.1016/j.yexcr.2004.04.004; Rubio MA, 2002, J BIOL CHEM, V277, P28609, DOI 10.1074/jbc.M203747200; SABATIER L, 1994, INT J RADIAT BIOL, V66, P611, DOI 10.1080/09553009414551701; Sciandrello G, 2004, CARCINOGENESIS, V25, P413, DOI 10.1093/carcin/bgh029; SEONE AI, 2001, MUTAT RES, V490, P99; Seymour CB, 2003, BRIT J CANCER, V89, P1979, DOI 10.1038/sj.bjc.6601361; SEYMOUR CB, 1986, INT J RADIAT BIOL, V50, P167, DOI 10.1080/09553008614550541; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; SMORGORZEWSKA A, 2002, CURR BIOL, V12, P1635; Sorensen M, 2005, CANCER EPIDEM BIOMAR, V14, P1340, DOI 10.1158/1055-9965.EPI-04-0899; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Sugden Kent D., 2000, Journal of Environmental Pathology Toxicology and Oncology, V19, P215; Thomas P, 2003, MUTAGENESIS, V18, P187, DOI 10.1093/mutage/18.2.187; TSUNETA Y, 1980, THORAX, V35, P294, DOI 10.1136/thx.35.4.294; Tsutsui T, 2002, CARCINOGENESIS, V23, P2111, DOI 10.1093/carcin/23.12.2111; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; Urushibara A, 2004, BIOCHEM BIOPH RES CO, V313, P1037, DOI 10.1016/j.bbrc.2003.12.039; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wong C, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-6; Wood LD, 2001, ONCOGENE, V20, P278, DOI 10.1038/sj.onc.1204072; World Health Organization (WHO), 2001, VAN PENT OTH IN VAN; Zhang Y, 2005, EUR J PHARMACOL, V516, P1, DOI 10.1016/j.ejphar.2005.04.022	76	30	30	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3424	3435		10.1038/sj.onc.1209399	http://dx.doi.org/10.1038/sj.onc.1209399			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16449970	Bronze			2022-12-28	WOS:000238448100007
J	Sun, Q; Matta, H; Lu, G; Chaudhary, PM				Sun, Q; Matta, H; Lu, G; Chaudhary, PM			Induction of IL-8 expression by human herpesvirus 8 encoded vFLIP K13 via NF-kappa B activation	ONCOGENE			English	Article						vFLIP; KSHV; HHV-8; IL-8; K13; NF-kappa B	SARCOMA-ASSOCIATED HERPESVIRUS; ECTODERMAL DYSPLASIA RECEPTOR; PROTEIN-COUPLED RECEPTOR; KAPOSIS-SARCOMA; INTERLEUKIN-8 GENE; SIGNAL-TRANSDUCTION; SPINDLE CELLS; KINASE; APOPTOSIS; TRANSCRIPTION	Human herpesvirus 8 (HHV-8) encodes a viral FLICE inhibitory protein (vFLIP), called K13, with homology to the prodomain of caspase 8. K13 has been postulated to protect virally infected cells against death receptor-induced apoptosis. We report that K13 leads to constitutive upregulation of IL-8 secretion by transcriptional upregulation of its promoter. K13-induced IL-8 promoter activation is dependent on an intact NF-kappa B-binding site and is associated with increased binding of classical NF-kappa B pathway subunits p65, c-Rel and p50, respectively. IL-8 production is defective in K13 mutants defective in classical NF-kappa B activation and is blocked by genetic and pharmacological inhibitors of this pathway. In contrast, K13 failed to activate the JNK/AP-1 pathway and deletion of AP-1-binding site in the IL-8 promoter or use of a specific JNK inhibitor had only a partial effect on K13-induced IL-8 promoter activation. Collectively, above results demonstrate that K13 is a major mediator of IL-8 production and therapeutic agents targeting K13-induced NF-kappa B pathway may have a role in the treatment of conditions in which HHV-8-induced IL-8 production plays a pathogenic role.	Univ Pittsburgh, Dept Med, Div Hematol Oncol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Med, Hillman Canc Ctr, Pittsburgh, PA USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chaudhary, PM (corresponding author), Univ Pittsburgh, Dept Med, Div Hematol Oncol, 5117 Ctr Ave,Suite 1-19A, Pittsburgh, PA 15213 USA.	chaudharypm@upmc.edu	Chaudhary, Preet/E-1970-2018		NATIONAL CANCER INSTITUTE [R01CA085177] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA85177] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams J, 2000, ONCOGENE, V19, P6687, DOI 10.1038/sj.onc.1204088; An JB, 2003, ONCOGENE, V22, P3371, DOI 10.1038/sj.onc.1206407; Bais C, 2003, CANCER CELL, V3, P131, DOI 10.1016/S1535-6108(03)00024-2; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chaudhary PM, 1999, J BIOL CHEM, V274, P19211, DOI 10.1074/jbc.274.27.19211; Dourmishev LA, 2003, MICROBIOL MOL BIOL R, V67, P175, DOI 10.1128/MMBR.67.2.175-212.2003; ENSOLI B, 1995, P ASSOC AM PHYSICIAN, V107, P8; Falvo JV, 2000, MOL CELL BIOL, V20, P4814, DOI 10.1128/MCB.20.13.4814-4825.2000; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Hu SM, 1997, J BIOL CHEM, V272, P9621; Jiang GQ, 2003, J BIOL CHEM, V278, P180, DOI 10.1074/jbc.M205565200; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Lane BR, 2002, J VIROL, V76, P11570, DOI 10.1128/JVI.76.22.11570-11583.2002; Lane BR, 2001, J VIROL, V75, P8195, DOI 10.1128/JVI.75.17.8195-8202.2001; Le XD, 2000, J INTERF CYTOK RES, V20, P935, DOI 10.1089/10799900050198372; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Masood R, 2001, CLIN CANCER RES, V7, P2693; Masood Rizwan, 1993, Current Opinion in Oncology, V5, P831, DOI 10.1097/00001622-199309000-00010; Matta H, 2004, P NATL ACAD SCI USA, V101, P9399, DOI 10.1073/pnas.0308016101; Matta H, 2003, J BIOL CHEM, V278, P52406, DOI 10.1074/jbc.M307308200; Moore PS, 2003, ANNU REV MICROBIOL, V57, P609, DOI 10.1146/annurev.micro.57.030502.090824; Mori N, 1998, CANCER RES, V58, P3993; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; Nurnberg W, 1999, J PATHOL, V189, P546, DOI 10.1002/(SICI)1096-9896(199912)189:4<546::AID-PATH487>3.0.CO;2-L; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Roussel RR, 2000, ARCH BIOCHEM BIOPHYS, V377, P204, DOI 10.1006/abbi.2000.1770; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; Schulz TF, 1998, J GEN VIROL, V79, P1573, DOI 10.1099/0022-1317-79-7-1573; Singh RK, 1999, MELANOMA RES, V9, P383, DOI 10.1097/00008390-199908000-00007; Sinha SK, 2002, J BIOL CHEM, V277, P44953, DOI 10.1074/jbc.M207923200; Sinha SK, 2004, J BIOL CHEM, V279, P41873, DOI 10.1074/jbc.M407363200; SMITH DR, 1994, J EXP MED, V179, P1409, DOI 10.1084/jem.179.5.1409; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Sturzl M, 1999, J NATL CANCER I, V91, P1725, DOI 10.1093/jnci/91.20.1725; Sun QM, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-9; Sun QM, 2003, J BIOL CHEM, V278, P52437, DOI 10.1074/jbc.M304199200; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; UEDA T, 1994, J GASTROENTEROL, V29, P423, DOI 10.1007/BF02361238; Verma SC, 2003, FEMS MICROBIOL LETT, V222, P155, DOI 10.1016/S0378-1097(03)00261-1; Wang JF, 2004, BBA-MOL CELL RES, V1691, P129, DOI 10.1016/j.bbamcr.2004.01.002; WATANABE K, 1989, BIOCHEM BIOPH RES CO, V161, P1093, DOI 10.1016/0006-291X(89)91355-7; Wu GD, 1997, J BIOL CHEM, V272, P2396; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Yokoe T, 1997, ANTICANCER RES, V17, P695	53	69	71	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2717	2726		10.1038/sj.onc.1209298	http://dx.doi.org/10.1038/sj.onc.1209298			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16418726				2022-12-28	WOS:000237272900003
J	Dolznig, H; Grebien, F; Deiner, EM; Stangl, K; Kolbus, A; Habermann, B; Kerenyi, MA; Kieslinger, M; Moriggl, R; Beug, H; Mullner, E				Dolznig, H.; Grebien, F.; Deiner, E. M.; Stangl, K.; Kolbus, A.; Habermann, B.; Kerenyi, M. A.; Kieslinger, M.; Moriggl, R.; Beug, H.; Muellner, E. W.			Erythroid progenitor renewal versus differentiation: genetic evidence for cell autonomous, essential functions of EpoR, Stat5 and the GR	ONCOGENE			English	Article						erythroid progenitor self-renewal; terminal erythropoiesis; Stat5; glucocorticoid receptor; erythropoietin receptor; Bcl-X-L	BCL-X-L; STEM-CELL; GLUCOCORTICOID-RECEPTOR; DNA-BINDING; C-KIT; ERYTHROPOIETIN; EXPRESSION; MECHANISMS; APOPTOSIS; BCL-X(L)	The balance between hematopoietic progenitor commitment and self- renewal versus differentiation is controlled by various transcriptional regulators cooperating with cytokine receptors. Disruption of this balance is increasingly recognized as important in the development of leukemia, by causing enhanced renewal and differentiation arrest. We studied regulation of renewal versus differentiation in primary murine erythroid progenitors that require cooperation of erythropoietin receptor ( EpoR), the receptor tyrosine kinase c- Kit and a transcriptional regulator ( glucocorticoid receptor; GR) for sustained renewal. However, mice defective for GR- ( GR(dim/ dim)), EpoR- ( EpoR(H)) or STAT5ab function ( Stat5ab (-/ -)) show no severe erythropoiesis defects in vivo. Using primary erythroblast cultures from these mutants, we present genetic evidence that functional GR, EpoR, and Stat5 are essential for erythroblast renewal in vitro. Cells from GRdim/ dim, Epo RH, and Stat5ab -/ - mice showed enhanced differentiation instead of renewal, causing accumulation of mature cells and gradual proliferation arrest. Stat5ab was additionally required for Epo- induced terminal differentiation: differentiating Stat5ab (-/ -) erythroblasts underwent apoptosis instead of erythrocyte maturation, due to absent induction of the antiapoptotic protein Bcl- X-L. This defect could be fully rescued by exogenous Bcl- X-L. These data suggest that signaling molecules driving leukemic proliferation may also be essential for prolonged self- renewal of normal erythroid progenitors.	Inst Mol Pathol, VBC, A-1030 Vienna, Austria; Med Univ Vienna, Div Mol Biol, Dept Med Biochem, Max F Perutz Labs, Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Beug, H (corresponding author), Inst Mol Pathol, VBC, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	beug@imp.univie; ernst.muellner@univie.ac.at	Moriggl, Richard/H-8118-2019; Grebien, Florian/H-9234-2019; Dolznig, Helmut/L-7005-2015; Habermann, Bianca/N-4886-2016	Moriggl, Richard/0000-0003-0918-9463; Grebien, Florian/0000-0003-4289-2281; Dolznig, Helmut/0000-0002-6063-3585; Habermann, Bianca/0000-0002-2457-7504	Austrian Science Fund FWF [F 2809, F 2807, F 2802, F 2801] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Bauer A, 1999, GENE DEV, V13, P2996, DOI 10.1101/gad.13.22.2996; BAUER A, 2001, HEMATOPOIESIS DEV AP, P368; BEUG H, 1995, ONCOGENE, V11, P59; BEUG H, 1996, BIOCHIM BIOPHYS ACTA, V1128, pM35; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; Carotta S, 2004, BLOOD, V104, P1873, DOI 10.1182/blood-2004-02-0570; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; Cui Y, 2004, MOL CELL BIOL, V24, P8037, DOI 10.1128/MCB.24.18.8037-8047.2004; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; Dolznig H, 2004, METH MOLEC MED, V105, P323; Dolznig H, 2002, CURR BIOL, V12, P1076, DOI 10.1016/S0960-9822(02)00930-2; Dolznig H, 2001, FASEB J, V15, P1442, DOI 10.1096/fj.00-0705fje; Doppler W, 2000, ADV EXP MED BIOL, V480, P139; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Kieslinger M, 2000, GENE DEV, V14, P232; Kolbus A, 2002, J EXP MED, V196, P1347, DOI 10.1084/jem.20020562; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Li K, 2003, BLOOD, V102, P3147, DOI 10.1182/blood-2003-01-0078; MIKULITS W, 1995, NUCLEIC ACIDS RES, V23, P2342, DOI 10.1093/nar/23.12.2342; Moriggl R, 2005, CANCER CELL, V7, P87, DOI 10.1016/j.ccr.2004.12.010; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Motoyama N, 1999, J EXP MED, V189, P1691, DOI 10.1084/jem.189.11.1691; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Onnebo SMN, 2005, EXP HEMATOL, V33, P182, DOI 10.1016/j.exphem.2004.10.019; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; SAWADA K, 1990, J CELL PHYSIOL, V142, P219, DOI 10.1002/jcp.1041420202; Schulte CE, 2002, EMBO J, V21, P4297, DOI 10.1093/emboj/cdf429; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; Shet AS, 2002, LEUKEMIA, V16, P1402, DOI 10.1038/sj.leu.2402577; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Stirewalt DL, 2003, NAT REV CANCER, V3, P650, DOI 10.1038/nrc1169; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; von Lindern M, 2004, CELL CYCLE, V3, P876; von Lindern M, 1999, BLOOD, V94, P550, DOI 10.1182/blood.V94.2.550.414k39_550_559; von Lindern M, 2001, ONCOGENE, V20, P3651, DOI 10.1038/sj.onc.1204494; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; YU H, 2004, NAT REV CANCER, V4, P655; Zang HS, 2001, EMBO J, V20, P3156, DOI 10.1093/emboj/20.12.3156	48	44	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2890	2900		10.1038/sj.onc.1209308	http://dx.doi.org/10.1038/sj.onc.1209308			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16407844	Green Accepted			2022-12-28	WOS:000237448200007
J	Furuta, T; Hayward, RL; Meng, LH; Takemura, H; Aune, GJ; Bonner, WM; Aladjem, MI; Kohn, KW; Pommier, Y				Furuta, T.; Hayward, R. L.; Meng, L-H; Takemura, H.; Aune, G. J.; Bonner, W. M.; Aladjem, M. I.; Kohn, K. W.; Pommier, Y.			P21(CDKN1A) allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine	ONCOGENE			English	Article						UCN-01 (7-hydroxystaurosporine); p21; p53; gamma H2AX; camptothecin; cell cycle; DNA repair; DNA double-strand break	CELL-CYCLE ARREST; HISTONE H2AX PHOSPHORYLATION; HUMAN COLON-CARCINOMA; S-PHASE CHECKPOINT; DAMAGE CHECKPOINT; PROTEIN-KINASE; CLEAVAGE COMPLEXES; UP-REGULATION; CANCER CELLS; G(2) ARREST	This study provides evidence for the importance of p21(CDKN1A) for the repair of replication- mediated DNA double- strand breaks ( DSBs) induced by topoisomerase I. We report that defects of p21(CDKN1A) and p53 enhance camptothecin- induced histone H2AX phosphorylation ( gamma H2AX), a marker for DNA DSBs. In human colon carcinoma HCT116 cells with wild- type ( wt) p53, gamma H2AX reverses after camptothecin removal. By contrast, gamma H2AX increases after camptothecin removal in HCT116 cells deficient for p53 ( p53-/-) or p21(CDKN1A) ( p21-/-) as the cells reach the late- S and G2 phases. Since p21-/- cells exhibit similar S- phase arrest as wt cells in response to camptothecin and aphidicolin does not abrogate the enhanced gamma H2AX formation in p21-/- cells, we conclude that enhanced gamma H2AX formation in p21-/- cells is not due to re- replication. The cell cycle checkpoint abrogator and Chk1/ Chk2 inhibitor 7- hydroxystaurosporine ( UCN- 01) also increases camptothecin- induced gamma H2AX formation and inhibits camptothecin- induced p21(CDKN1A) upregulation in HCT116 wt cells. TUNEL ( terminal deoxynucleotidyl transferase ( TdT)- mediated dUTP- biotin nick end labeling) assays demonstrate that gamma H2AX formation in late S and G2 cells following CPT treatment corresponds to DNA breaks. However, these breaks are not related to apoptotic DNA fragmentation. We propose that p21(CDKN1A) prevents the collapse of replication forks damaged by stabilized topoisomerase I cleavage complexes.	NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pommier, Y (corresponding author), NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, 37 Convent Dr,Bldg 37,Room 5060, Bethesda, MD 20892 USA.	pommier@nih.gov	Aune, Gregory/I-5895-2015; meng, linghua/Y-8110-2019; Aladjem, Mirit/G-2169-2010	Aune, Gregory/0000-0002-2750-6461; Aladjem, Mirit/0000-0002-1875-3110	NATIONAL CANCER INSTITUTE [ZIABC006150, Z01BC006150] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Abraham RT, 2004, DNA REPAIR, V3, P883, DOI 10.1016/j.dnarep.2004.04.002; Antony S, 2004, NUCLEIC ACIDS RES, V32, P5685, DOI 10.1093/nar/gkh902; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Busby EC, 2000, CANCER RES, V60, P2108; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Dancey J, 2003, NAT REV DRUG DISCOV, V2, P296, DOI 10.1038/nrd1066; FAN SJ, 1995, CANCER RES, V55, P1649; Foiani M, 1998, BIOL CHEM, V379, P1019; Fujimori A, 1996, MOL PHARMACOL, V50, P1472; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Godthelp BC, 2002, NUCLEIC ACIDS RES, V30, P2172, DOI 10.1093/nar/30.10.2172; Goldwasser F, 1996, CANCER RES, V56, P4430; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; Guo CY, 1999, RADIAT RES, V151, P125, DOI 10.2307/3579762; Gupta M, 1997, CLIN CANCER RES, V3, P1653; Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200; Hayward RL, 2003, CLIN CANCER RES, V9, P2856; Hinz JM, 2003, CARCINOGENESIS, V24, P249, DOI 10.1093/carcin/24.2.249; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Huang X, 2004, CYTOM PART A, V58A, P99, DOI 10.1002/cyto.a.20018; HUBERMAN JA, 1981, CELL, V23, P647, DOI 10.1016/0092-8674(81)90426-8; Kachnic LA, 1999, J BIOL CHEM, V274, P13111, DOI 10.1074/jbc.274.19.13111; Kohn EA, 2002, J BIOL CHEM, V277, P26553, DOI 10.1074/jbc.M202040200; Kohn KW, 2005, BIOCHEM BIOPH RES CO, V331, P816, DOI 10.1016/j.bbrc.2005.03.186; Larminat F, 2004, BIOL CELL, V96, P545, DOI 10.1016/j.biolcel.2004.06.001; Levesque AA, 2005, ONCOGENE, V24, P3786, DOI 10.1038/sj.onc.1208451; Liu LF, 2000, ANN NY ACAD SCI, V922, P1; Liu WM, 1998, INT J ONCOL, V12, P793; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Monks A, 2000, INVEST NEW DRUG, V18, P95, DOI 10.1023/A:1006313611677; Motoyama N, 2004, CURR OPIN GENET DEV, V14, P11, DOI 10.1016/j.gde.2003.12.003; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Pommier Y, 2005, CURR PHARM DESIGN, V11, P2855, DOI 10.2174/1381612054546716; Pommier Y, 2005, TRENDS PHARMACOL SCI, V26, P138, DOI 10.1016/j.tips.2005.01.008; Pommier Y, 2003, MUTAT RES-FUND MOL M, V532, P173, DOI 10.1016/j.mrfmmm.2003.08.016; Pommier Y, 2002, J BIOL CHEM, V277, P13666, DOI 10.1074/jbc.M200209200; Pommier Y, 2000, P NATL ACAD SCI USA, V97, P2040, DOI 10.1073/pnas.040397497; POMMIER Y, 2006, PROG NUCL ACID RES M; Pourquier P, 2001, ADV CANCER RES, V80, P189, DOI 10.1016/S0065-230X(01)80016-6; Raderschall E, 2002, J CELL SCI, V115, P153; Rao VA, 2005, MOL CELL BIOL, V25, P8925, DOI 10.1128/MCB.25.20.8925-8937.2005; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sato S, 2002, ONCOGENE, V21, P1727, DOI 10.1038/sj.onc.1205225; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038/sj.onc.1206954; Senderowicz AM, 2002, ONCOLOGIST, V7, P12; Shao RG, 2004, ACTA PHARMACOL SIN, V25, P756; Shao RG, 1997, CANCER RES, V57, P4029; Shao RG, 1997, EXP CELL RES, V234, P388, DOI 10.1006/excr.1997.3650; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; Shi Z, 2001, CANCER RES, V61, P1065; Shieh SY, 2000, GENE DEV, V14, P289; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Stivala LA, 2001, ONCOGENE, V20, P563, DOI 10.1038/sj.onc.1204132; Strumberg D, 2000, MOL CELL BIOL, V20, P3977, DOI 10.1128/MCB.20.11.3977-3987.2000; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; TORNUSCIOLO DRZ, 1995, BIOTECHNIQUES, V19, P800; Tse AN, 2004, CANCER RES, V64, P6635, DOI 10.1158/0008-5472.CAN-04-0841; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Waga S, 1998, MOL CELL BIOL, V18, P4177, DOI 10.1128/MCB.18.7.4177; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wan SH, 1999, YEAST, V15, P821, DOI 10.1002/(SICI)1097-0061(199907)15:10A<821::AID-YEA422>3.3.CO;2-R; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Wu JX, 2002, MOL PHARMACOL, V61, P742, DOI 10.1124/mol.61.4.742; Wyllie FS, 1996, ONCOGENE, V12, P1077; Yu Q, 2002, CANCER RES, V62, P5743; Zhivotovsky B, 2004, NAT REV MOL CELL BIO, V5, P752, DOI 10.1038/nrm1443	79	37	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2839	2849		10.1038/sj.onc.1209313	http://dx.doi.org/10.1038/sj.onc.1209313			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16407843				2022-12-28	WOS:000237448200002
J	Campbell, MR; Wang, Y; Andrew, SE; Liu, Y				Campbell, MR; Wang, Y; Andrew, SE; Liu, Y			Msh2 deficiency leads to chromosomal abnormalities, centrosome amplification, and telomere capping defect	ONCOGENE			English	Article						mismatch repair; centrosome amplification; telomere capping; chromosomal abnormalities	DNA MISMATCH REPAIR; CANCER-CELLS; GENE; SUSCEPTIBILITY; PROLIFERATION; RECOMBINATION; ABERRATIONS; MUTATION; MOUSE; MICE	Msh2 is a key mammalian DNA mismatch repair (MMR) gene and mutations or deficiencies in mammalian Msh2 gene result in microsatellite instability (MSI+) and the development of cancer. Here, we report that primary mouse embryonic fibroblasts (MEFs) deficient in the murine MMR gene Msh2 (Msh2(-/-)) showed a significant increase in chromosome aneuploidy, centrosome amplification, and defective mitotic spindle organization and unequal chromosome segregation. Although Msh2(-/-) mouse tissues or primary MEFs had no apparent change in telomerase activity, telomere length, or recombination at telomeres, Msh2(-/-) MEFs showed an increase in chromosome end-to-end fusions or chromosome ends without detectable telomeric DNA. These data suggest that MSH2 helps to maintain genomic stability through the regulation of the centrosome and normal telomere capping in vivo and that defects in MMR can contribute to oncogenesis through multiple pathways.	Oak Ridge Natl Lab, Div Life Sci, Oak Ridge, TN 37831 USA; Univ Alberta, Dept Med Genet, Edmonton, AB, Canada	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Alberta	Liu, Y (corresponding author), Oak Ridge Natl Lab, Div Life Sci, Oak Ridge, TN 37831 USA.	liuy3@ornl.gov						Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Bailey SM, 2004, NUCLEIC ACIDS RES, V32, P3743, DOI 10.1093/nar/gkh691; Bechter OE, 2004, CANCER RES, V64, P3444, DOI 10.1158/0008-5472.CAN-04-0323; Bellacosa A, 2001, CELL DEATH DIFFER, V8, P1076, DOI 10.1038/sj.cdd.4400948; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Doxsey S, 2005, TRENDS CELL BIOL, V15, P303, DOI 10.1016/j.tcb.2005.04.008; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; ELANGE T, 2002, ONCOGENE, V21, P532; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Pickett HA, 2004, ONCOGENE, V23, P3434, DOI 10.1038/sj.onc.1207477; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Rizki A, 2001, NATURE, V411, P713, DOI 10.1038/35079641; Rufer N, 1998, NAT BIOTECHNOL, V16, P743, DOI 10.1038/nbt0898-743; Saunders W, 2005, SEMIN CANCER BIOL, V15, P25, DOI 10.1016/j.semcancer.2004.09.003; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	20	36	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2531	2536		10.1038/sj.onc.1209277	http://dx.doi.org/10.1038/sj.onc.1209277			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16331258				2022-12-28	WOS:000236948000011
J	Larsen, E; Reite, K; Nesse, G; Gran, C; Seeberg, E; Klungland, A				Larsen, E; Reite, K; Nesse, G; Gran, C; Seeberg, E; Klungland, A			Repair and mutagenesis at oxidized DNA lesions in the developing brain of wild-type and Ogg1(-/-) mice	ONCOGENE			English	Article						OGG1; DNA damage; mouse; brain; mutagenesis; DNA repair	BASE EXCISION-REPAIR; MUTATIONAL SPECTRUM; MMH/OGG1 GENE; DAMAGE; HOGG1; OGG1; 8-HYDROXYGUANINE; CANCER; ENZYME; POLYMORPHISM	OGG1 (8-oxoguanine DNA glycosylase-1) is one of the main DNA glycosylases present in mammalian cells. The enzyme removes 7,8-dihydro-8-oxoguanine (8-oxoG) lesions, believed to be the most important oxidized lesions due to their relatively high incidence and their miscoding properties. This study shows that in prenatal mice brains the repair capacity for 8-oxoG is 5-10-fold higher than in adult mice brains. Western blot analysis and repair activity in extracts from Ogg1(-/-) mice revealed that OGG1 was responsible for the efficient 8-oxoG removal from prenatal mice. To investigate how OGG1 protects against oxidative stress-induced mutagenesis, pregnant Big Blue/wild-type and Big Blue/Ogg1(-/-) mice were exposed to nontoxic doses of gamma radiation. A 2.5-fold increase in the mutation frequency in Ogg1(-/-) mouse brains was obtained by exposure to 3.5 Gy at day 19 postfertilization. This was largely due to GC to TA transversions, believed to originate from 8-oxoG mispairing with A during replication. Furthermore, rapid cell divisions seemed to be required for fixation of mutations, as a similar dose of radiation did not increase the mutation frequency, or the frequency of GC to TA transversion, in the adult brain.	Univ Oslo, Natl Hosp, Ctr Mol Biol & Neurosci, N-0027 Oslo, Norway; Univ Oslo, Natl Hosp, Inst Med Microbiol, Oslo, Norway; Univ Oslo, Inst Basic Med Sci, Dept Nutr, Oslo, Norway	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; University of Oslo	Larsen, E (corresponding author), Univ Oslo, Natl Hosp, Ctr Mol Biol & Neurosci, N-0027 Oslo, Norway.	elisabeth.larsen@medisin.uio.no	Klungland, Arne/X-1233-2019	Klungland, Arne/0000-0001-7274-3661				Aburatani H, 1997, CANCER RES, V57, P2151; Achanta G, 2004, CANCER RES, V64, P6233, DOI 10.1158/0008-5472.CAN-04-0494; AMES BN, 1989, MUTAT RES, V214, P41, DOI 10.1016/0027-5107(89)90196-6; Andrew SE, 1997, ONCOGENE, V15, P123, DOI 10.1038/sj.onc.1201180; Andrew SE, 1998, P NATL ACAD SCI USA, V95, P1126, DOI 10.1073/pnas.95.3.1126; Arai T, 2003, CANCER RES, V63, P4287; Audebert M, 2000, CANCER RES, V60, P4740; Bjelland S, 2003, MUTAT RES-FUND MOL M, V531, P37, DOI 10.1016/j.mrfmmm.2003.07.002; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; Bohr VA, 2002, FREE RADICAL BIO MED, V32, P804, DOI 10.1016/S0891-5849(02)00787-6; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; Dianov GL, 2001, PROG NUCLEIC ACID RE, V68, P285; Dou H, 2003, J BIOL CHEM, V278, P49679, DOI 10.1074/jbc.M308658200; Elahi A, 2002, CARCINOGENESIS, V23, P1229, DOI 10.1093/carcin/23.7.1229; FRANKS LM, 1974, GERONTOLOGY, V20, P21, DOI 10.1159/000211994; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hyun JW, 2000, ONCOGENE, V19, P4476, DOI 10.1038/sj.onc.1203787; Ishida T, 1999, INT J CANCER, V80, P18; Karahalil B, 2002, FASEB J, V16, P1895, DOI 10.1096/fj.02-0463com; Kasai H, 1997, MUTAT RES-REV MUTAT, V387, P147, DOI 10.1016/S1383-5742(97)00035-5; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; KOHLER SW, 1991, ENVIRON MOL MUTAGEN, V18, P316, DOI 10.1002/em.2850180421; Korr H, 1980, Adv Anat Embryol Cell Biol, V61, P1; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Kucherlapati M, 2002, P NATL ACAD SCI USA, V99, P9924, DOI 10.1073/pnas.152321699; Larsen E, 2003, MOL CELL BIOL, V23, P5346, DOI 10.1128/MCB.23.15.5346-5353.2003; Le Marchand L, 2002, CANCER EPIDEM BIOMAR, V11, P409; Lin LH, 2000, J NEUROCHEM, V74, P1098; Lipton L, 2003, CANCER RES, V63, P7595; Lovell MA, 2000, BRAIN RES, V855, P116, DOI 10.1016/S0006-8993(99)02335-5; Lovell MA, 1999, J NEUROCHEM, V72, P771, DOI 10.1046/j.1471-4159.1999.0720771.x; Ludwig DL, 1998, MUTAT RES-DNA REPAIR, V409, P17, DOI 10.1016/S0921-8777(98)00039-1; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3629, DOI 10.1093/nar/19.13.3629; Minowa O, 2000, P NATL ACAD SCI USA, V97, P4156, DOI 10.1073/pnas.050404497; Morland I, 2002, NUCLEIC ACIDS RES, V30, P4926, DOI 10.1093/nar/gkf618; Nishino H, 1996, MUTAT RES-FUND MOL M, V372, P97, DOI 10.1016/S0027-5107(96)00172-8; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rosenquist TA, 2003, DNA REPAIR, V2, P581, DOI 10.1016/S1568-7864(03)00025-9; Sakumi K, 2003, CANCER RES, V63, P902; Shinmura K, 1998, JPN J CANCER RES, V89, P825, DOI 10.1111/j.1349-7006.1998.tb00635.x; Sieber OM, 2003, NEW ENGL J MED, V348, P791, DOI 10.1056/NEJMoa025283; Stuart GR, 2000, GENETICS, V154, P1291; Sugo N, 2000, EMBO J, V19, P1397, DOI 10.1093/emboj/19.6.1397; Tebbs RS, 1999, DEV BIOL, V208, P513, DOI 10.1006/dbio.1999.9232; VERJAT T, 2000, MUTAT RES, V25, P127; Wikman H, 2000, INT J CANCER, V88, P932, DOI 10.1002/1097-0215(20001215)88:6<932::AID-IJC15>3.0.CO;2-P; Xie YL, 2004, CANCER RES, V64, P3096, DOI 10.1158/0008-5472.CAN-03-3834	53	43	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2425	2432		10.1038/sj.onc.1209284	http://dx.doi.org/10.1038/sj.onc.1209284			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16369492				2022-12-28	WOS:000236948000001
J	Ogata, H; Chinen, T; Yoshida, T; Kinjyo, I; Takaesu, G; Shiraishi, H; Iida, M; Kobayashi, T; Yoshimura, A				Ogata, H; Chinen, T; Yoshida, T; Kinjyo, I; Takaesu, G; Shiraishi, H; Iida, M; Kobayashi, T; Yoshimura, A			Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-beta 1 production	ONCOGENE			English	Article						SOCS; STAT; TGF-beta 1; liver fibrosis	GROWTH-FACTOR-BETA; PHYSIOLOGICAL NEGATIVE REGULATOR; HUMAN HEPATOCELLULAR-CARCINOMA; GP130 MUTANT MICE; TGF-BETA; CYTOKINE SIGNALING-3; IMMUNE-RESPONSES; CELL-GROWTH; HEPATITIS-C; IN-VIVO	Recently, DNA methylation and reduced expression of the suppressor of the cytokine signaling-3 (SOCS3) gene in human hepatocellular carcinoma (HCC) patients have been reported. However, the roles of SOCS3 in HCC development in vivo have not been clarified. Using RT-PCR analysis and Western blotting, we confirmed that SOCS3 expression was reduced in HCC patients. However, reduced expression of SOCS3 occurred not only in HCC but also in nontumor regions, and this reduction was stronger as the fibrosis grade increased. Furthermore, SOCS3 levels were inversely correlated with signal transducers and activators of transcription-3 (STAT3) activation as well as transforming growth factor (TGF)-beta 1 levels in the non-HCC region. To de. ne the molecular consequences of SOCS3 silencing/STAT3 hyperactivation and liver fibrosis, we examined liver-specific SOCS3-deficient mice. We demonstrated that SOCS3 deletion in the liver resulted in hyperactivation of STAT3 and promoted ConA- and chemical-induced liver fibrosis. The expression of TGF-beta 1, a mediator of fibrosis, was enhanced by SOCS3 gene deletion, but suppressed by the overexpression of a dominant-negative STAT3 or SOCS3 both in vivo and in vitro. These data suggest that TGF-beta 1 is a target gene of STAT3 and could be one of the mechanisms for enhanced fibrosis in SOCS3-deficient mice. Thus, our present study provides a novel role of SOCS3 and STAT3 in HCC development: in addition to the previously characterized oncogenic potentials, STAT3 enhances hepatic fibrosis through the upregulation of TGF-beta 1 expression, and SOCS3 prevents this process.	Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Med & Clin Sci, Fukuoka, Japan	Kyushu University; Kyushu University	Yoshimura, A (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yakihiko@bioreg.kyushu-u.ac.jp	Yoshimura, Akihiko/K-5515-2013	Kinjyo, Ichiko/0000-0001-7051-3790; Takaesu, Giichi/0000-0002-1581-1055				Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201; Bissell DM, 2001, EXP MOL MED, V33, P179, DOI 10.1038/emm.2001.31; BISSELL DM, 1995, J CLIN INVEST, V96, P447, DOI 10.1172/JCI118055; Bode JG, 1999, FEBS LETT, V463, P365, DOI 10.1016/S0014-5793(99)01662-2; Boer AK, 2002, BLOOD, V100, P467, DOI 10.1182/blood.V100.2.467; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; CHOI I, 1994, CLIN EXP IMMUNOL, V95, P530; Croker BA, 2004, IMMUNITY, V20, P153, DOI 10.1016/S1074-7613(04)00022-6; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; Factor VM, 1997, CANCER RES, V57, P2089; Gorelik L, 2001, NAT MED, V7, P1118, DOI 10.1038/nm1001-1118; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Huang KC, 2003, FEBS LETT, V555, P385, DOI 10.1016/S0014-5793(03)01297-3; Jenkins BJ, 2005, NAT MED, V11, P845, DOI 10.1038/nm1282; Jo D, 2005, NAT MED, V11, P892, DOI 10.1038/nm1269; Kamio M, 2004, ONCOGENE, V23, P3107, DOI 10.1038/sj.onc.1207453; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kimura A, 2004, J BIOL CHEM, V279, P6905, DOI 10.1074/jbc.C300496200; Kinjyo I, 2002, IMMUNITY, V17, P583, DOI 10.1016/S1074-7613(02)00446-6; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Mori H, 2004, NAT MED, V10, P739, DOI 10.1038/nm1071; Nakamura T, 2000, HEPATOLOGY, V32, P247, DOI 10.1053/jhep.2000.9109; Natsume M, 1999, J LEUKOCYTE BIOL, V66, P601, DOI 10.1002/jlb.66.4.601; Niwa Y, 2005, ONCOGENE, V24, P6406, DOI 10.1038/sj.onc.1208788; Postic C, 2000, GENESIS, V26, P149, DOI 10.1002/(SICI)1526-968X(200002)26:2<149::AID-GENE16>3.0.CO;2-V; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Saeki A, 2000, CANCER, V88, P1025, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1025::AID-CNCR11>3.0.CO;2-U; Saxena NK, 2002, HEPATOLOGY, V35, P762, DOI 10.1053/jhep.2002.32029; Shouda T, 2001, J CLIN INVEST, V108, P1781, DOI 10.1172/JCI200113568; Tebbutt NC, 2002, NAT MED, V8, P1089, DOI 10.1038/nm763; Theiss AL, 2005, GASTROENTEROLOGY, V129, P204, DOI 10.1053/j.gastro.2005.05.019; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Weber A, 2005, ONCOGENE, V24, P6699, DOI 10.1038/sj.onc.1208818; Wei DY, 2003, ONCOGENE, V22, P319, DOI 10.1038/sj.onc.1206122; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938; Yoshida T, 2004, J EXP MED, V199, P1701, DOI 10.1084/jem.20031675; Yoshida T, 2002, J EXP MED, V196, P641, DOI 10.1084/jem.20012127; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Yoshimura A, 2005, ARTHRITIS RES THER, V7, P100, DOI 10.1186/ar1741	42	192	205	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2520	2530		10.1038/sj.onc.1209281	http://dx.doi.org/10.1038/sj.onc.1209281			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16474852				2022-12-28	WOS:000236948000010
J	Britschgi, C; Rizzi, M; Grob, TJ; Tschan, MP; Hugli, B; Reddy, VA; Andres, AC; Torbett, BE; Tobler, A; Fey, MF				Britschgi, C; Rizzi, M; Grob, TJ; Tschan, MP; Hugli, B; Reddy, VA; Andres, AC; Torbett, BE; Tobler, A; Fey, MF			Identification of the p53 family-responsive element in the promoter region of the tumor suppressor gene hypermethylated in cancer 1	ONCOGENE			English	Article						HIC1; p53; transcriptional target; HIC1.PRE; p73	HUMAN BREAST-CANCER; DNA-BINDING; COLORECTAL-CANCER; HIC-1; P73; EXPRESSION; CELLS; SITE; PCR; TUMORIGENESIS	The tumor suppressor gene hypermethylated in cancer 1 (HIC1), located on human chromosome 17p13.3, is frequently silenced in cancer by epigenetic mechanisms. Hypermethylated in cancer 1 belongs to the bric a brac/ poxviruses and zinc-finger family of transcription factors and acts by repressing target gene expression. It has been shown that enforced p53 expression leads to increased HIC1 mRNA, and recent data suggest that p53 and Hic1 cooperate in tumorigenesis. In order to elucidate the regulation of HIC1 expression, we have analysed the HIC1 promoter region for p53-dependent induction of gene expression. Using progressively truncated luciferase reporter gene constructs, we have identified a p53-responsive element (PRE) 500 bp upstream of the TATA-box containing promoter P0 of HIC1, which is sequence specifically bound by p53 in vitro as assessed by electrophoretic mobility shift assays. We demonstrate that this HIC1 p53-responsive element ( HIC1. PRE) is necessary and sufficient to mediate induction of transcription by p53. This result is supported by the observation that abolishing endogenous wild-type p53 function prevents HIC1 mRNA induction in response to UV-induced DNA damage. Other members of the p53 family, notably TAp73 beta and Delta Np63 alpha, can also act through this HIC1. PRE to induce transcription of HIC1, and finally, hypermethylation of the HIC1 promoter attenuates inducibility by p53.	Inselspital Bern, CH-3010 Bern, Switzerland; Univ Bern, Dept Clin Res, Bern, Switzerland; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA USA; Univ Bern, Dept Clin Res, Tiefenau Labs, Bern, Switzerland	University of Bern; Scripps Research Institute; University of Bern	Fey, MF (corresponding author), Inselspital Bern, CH-3010 Bern, Switzerland.	martin.fey@insel.ch	Rizzi, Mattia/ABE-3996-2021; Rizzi, Mattia/AHE-4168-2022	Rizzi, Mattia/0000-0001-6987-0678; Britschgi, Christian/0000-0001-8831-1564; Tschan, Mario P./0000-0001-5897-3647; Grob, Tobias/0000-0002-6298-9796	NIAID NIH HHS [AI49165] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049165] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahuja N, 1997, CANCER RES, V57, P3370; Arnold CN, 2003, INT J CANCER, V106, P66, DOI 10.1002/ijc.11176; Bahia H, 2002, INT J ONCOL, V20, P489; Beillard E, 2003, LEUKEMIA, V17, P2474, DOI 10.1038/sj.leu.2403136; Benard J, 2003, HUM MUTAT, V21, P182, DOI 10.1002/humu.10172; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CHEN W, 2005, P AM ASSOC CANC RES, V46, P114; Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077; Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030; de Almodovar CR, 2004, J BIOL CHEM, V279, P4093, DOI 10.1074/jbc.M311243200; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976; Galimi F, 2002, BLOOD, V100, P2732, DOI 10.1182/blood-2002-04-1245; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Guerardel C, 2001, J BIOL CHEM, V276, P3078, DOI 10.1074/jbc.M008690200; Issa JPJ, 1997, CANCER RES, V57, P1678; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Liu G, 2004, MOL CELL BIOL, V24, P487, DOI 10.1128/MCB.24.2.487-501.2004; Liu XG, 2004, CANCER RES, V64, P5078, DOI 10.1158/0008-5472.CAN-04-1195; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Moll UM, 2004, MOL CANCER RES, V2, P371; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; Nicoll G, 2001, BRIT J CANCER, V85, P1878, DOI 10.1054/bjoc.2001.2163; Obad S, 2004, ONCOGENE, V23, P4050, DOI 10.1038/sj.onc.1207524; Pinte S, 2004, J BIOL CHEM, V279, P38313, DOI 10.1074/jbc.M401610200; Pinte S, 2004, ONCOGENE, V23, P4023, DOI 10.1038/sj.onc.1207504; Qian H, 2002, ONCOGENE, V21, P7901, DOI 10.1038/sj.onc.1205974; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Tschan MP, 2003, J BIOL CHEM, V278, P42750, DOI 10.1074/jbc.M307067200; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Wolcke J, 2003, J BIOL CHEM, V278, P32587, DOI 10.1074/jbc.M303615200; Wu GJ, 2005, CANCER RES, V65, P758	42	44	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2030	2039		10.1038/sj.onc.1209240	http://dx.doi.org/10.1038/sj.onc.1209240			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16301995				2022-12-28	WOS:000236359700006
J	Wang, L; Weinshilboum, R				Wang, L; Weinshilboum, R			Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions	ONCOGENE			English	Review						TPMT; 6-mercaptopurine; azathioprine; pharmacogenomics; proteasome degradation; aggresome	ACUTE LYMPHOBLASTIC-LEUKEMIA; INFLAMMATORY-BOWEL-DISEASE; GENETIC-POLYMORPHISM; BIOCHEMICAL-PROPERTIES; ERYTHROCYTE CORRELATION; FUNCTIONAL GENOMICS; AGGRESOME FORMATION; CATALYTIC ACTIVITY; DRUG RESPONSE; TANDEM REPEAT	The thiopurine S-methyltransferase (TPMT) genetic polymorphism is one of the most 'mature' examples in pharmacogenetics. That is true because of its importance clinically for the individualization of thiopurine drug therapy and also because TPMT has provided novel insights into molecular mechanisms responsible for the functional effects of common genetic polymorphisms. This review will summarize the development of our understanding of the role of inheritance in the regulation of TPMT as well as the clinical implications of that genetic regulation. It will also summarize recent studies in which TPMT pharmacogenetics has enhanced our understanding of molecular mechanisms by which common polymorphisms influence or alter function. TPMT pharmacogenetics highlights the potential clinical importance of the translation of pharmacogenetics from bench to bedside, the potential for basic pharmacogenetic research to provide insight into mechanisms by which genetic polymorphisms can alter function, and the challenges associated with the achievement of both of those goals.	Mayo Clin Rochester, Coll Med, Dept Mol Pharmaceut & Expt Therapeut, Div Clin Pharmacol, Rochester, MN 55905 USA	Mayo Clinic	Wang, L (corresponding author), Mayo Clin Rochester, Coll Med, Dept Mol Pharmaceut & Expt Therapeut, Div Clin Pharmacol, 200 1st St SW, Rochester, MN 55905 USA.	wang.liewei@mayo.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028157, U01GM061388] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM35720, R01 GM28157, U01 GM61388] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adjei AA, 2003, BRIT J PHARMACOL, V139, P1373, DOI 10.1038/sj.bjp.0705369; Branca MA, 2005, NAT REV DRUG DISCOV, V4, P615, DOI 10.1038/nrd1812; Cheng Q, 2005, NAT GENET, V37, P878, DOI 10.1038/ng1612; Collie-Duguid ESR, 1999, PHARMACOGENETICS, V9, P37, DOI 10.1097/00008571-199902000-00006; Coulthard SA, 1998, BLOOD, V92, P2856, DOI 10.1182/blood.V92.8.2856.420k05_2856_2862; de la Moureyre CSV, 1999, PHARMACOGENETICS, V9, P189; de la Moureyre CSV, 1998, BRIT J PHARMACOL, V125, P879, DOI 10.1038/sj.bjp.0702152; Dervieux T, 2001, CANCER RES, V61, P5810; Dubinsky MC, 2002, GASTROENTEROLOGY, V122, P904, DOI 10.1053/gast.2002.32420; EVANS WE, 1991, J PEDIATR-US, V119, P985, DOI 10.1016/S0022-3476(05)83063-X; Fessing MY, 1998, EUR J BIOCHEM, V256, P510, DOI 10.1046/j.1432-1327.1998.2560510.x; Freimuth RR, 2001, PHARMACOGENETICS, V11, P747, DOI 10.1097/00008571-200112000-00002; Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x; Gearry RB, 2005, J GASTROEN HEPATOL, V20, P1149, DOI 10.1111/j.1440-1746.2005.03832.x; GUERCIOLINI R, 1989, FASEB Journal, V3, pA428; Hamdan-Khalil R, 2005, BIOCHEM PHARMACOL, V69, P525, DOI 10.1016/j.bcp.2004.10.011; Hohfeld J, 2001, EMBO REP, V2, P885, DOI 10.1093/embo-reports/kve206; Hon YY, 1999, HUM MOL GENET, V8, P371, DOI 10.1093/hmg/8.2.371; HONCHEL R, 1993, MOL PHARMACOL, V43, P878; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Ji Y, 2005, J NEUROCHEM, V95, P1766, DOI 10.1111/j.1471-4159.2005.03453.x; Johnston JA, 2002, CELL MOTIL CYTOSKEL, V53, P26, DOI 10.1002/cm.10057; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Krynetski E, 2003, ONCOGENE, V22, P7403, DOI 10.1038/sj.onc.1206944; KRYNETSKI EY, 1995, P NATL ACAD SCI USA, V92, P949, DOI 10.1073/pnas.92.4.949; *LAB MED, 1991, LAB MED B MAYO FDN, V14, P1; LENNARD L, 1987, CLIN PHARMACOL THER, V41, P18, DOI 10.1038/clpt.1987.4; LENNARD L, 1992, EUR J CLIN PHARMACOL, V43, P329, DOI 10.1007/BF02220605; LENNARD L, 1990, LANCET, V336, P225, DOI 10.1016/0140-6736(90)91745-V; LENNARD L, 1989, CLIN PHARMACOL THER, V46, P149, DOI 10.1038/clpt.1989.119; LENNARD L, 1983, BRIT J CLIN PHARMACO, V16, P359, DOI 10.1111/j.1365-2125.1983.tb02178.x; Lindqvist M, 2004, PHARMACOGENETICS, V14, P261, DOI 10.1097/00008571-200404000-00006; McLeod HL, 2000, LEUKEMIA, V14, P567, DOI 10.1038/sj.leu.2401723; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Nebert Daniel W, 2003, Am J Pharmacogenomics, V3, P361, DOI 10.2165/00129785-200303060-00002; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Otterness D, 1997, CLIN PHARMACOL THER, V62, P60, DOI 10.1016/S0009-9236(97)90152-1; Otterness DM, 1998, J CLIN INVEST, V101, P1036, DOI 10.1172/JCI1004; PATERSON ARP, 1975, 6 THIOPURINES; Relling MV, 1999, LANCET, V354, P34, DOI 10.1016/S0140-6736(98)11079-6; REMY CN, 1963, J BIOL CHEM, V238, P1078; Salavaggione OE, 2005, PHARMACOGENET GENOM, V15, P801, DOI 10.1097/01.fpc.0000174788.69991.6b; Schaeffeler E, 2003, LEUKEMIA, V17, P1422, DOI 10.1038/sj.leu.2402981; Schaeffeler E, 2004, PHARMACOGENETICS, V14, P407, DOI 10.1097/01.fpc.0000114745.08559.db; Szumlanski C, 1996, DNA CELL BIOL, V15, P17, DOI 10.1089/dna.1996.15.17; SZUMLANSKI CL, 1992, PHARMACOGENETICS, V2, P148, DOI 10.1097/00008571-199208000-00002; Tai HL, 1999, PHARMACOGENETICS, V9, P641, DOI 10.1097/01213011-199910000-00011; Tai HL, 1996, AM J HUM GENET, V58, P694; Tai HL, 1997, P NATL ACAD SCI USA, V94, P6444, DOI 10.1073/pnas.94.12.6444; TAY BS, 1969, BIOCHEM PHARMACOL, V18, P934, DOI 10.1016/0006-2952(69)90069-0; Thomae B. A., 2002, Pharmacogenomics Journal, V2, P48, DOI 10.1038/sj.tpj.6500089; Thomae BA, 2003, J NEUROCHEM, V87, P809, DOI 10.1046/j.1471-4159.2003.02027.x; VANLOON JA, 1982, BIOCHEM GENET, V20, P637, DOI 10.1007/BF00483962; Wang LW, 2003, PHARMACOGENETICS, V13, P555, DOI 10.1097/00008571-200309000-00004; Wang LW, 2005, P NATL ACAD SCI USA, V102, P9394, DOI 10.1073/pnas.0502352102; Weinshilboum R, 2004, NAT REV DRUG DISCOV, V3, P739, DOI 10.1038/nrd1497; Weinshilboum R, 2001, DRUG METAB DISPOS, V29, P601; Weinshilboum R, 2004, CLIN PHARMACOL THER, V75, P253, DOI 10.1016/j.clpt.2003.12.002; Weinshilboum R, 2003, NEW ENGL J MED, V348, P529, DOI 10.1056/NEJMra020021; WEINSHILBOUM RM, 1980, AM J HUM GENET, V32, P651; WEINSHILBOUM RM, 1978, CLIN CHIM ACTA, V85, P323, DOI 10.1016/0009-8981(78)90311-X; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WOODSON LC, 1982, J PHARMACOL EXP THER, V222, P174; WOODSON LC, 1983, BIOCHEM PHARMACOL, V32, P819, DOI 10.1016/0006-2952(83)90582-8; Yan L, 2000, CLIN PHARMACOL THER, V68, P210, DOI 10.1067/mcp.2000.108674; Yates CR, 1997, ANN INTERN MED, V126, P608, DOI 10.7326/0003-4819-126-8-199704150-00003; [No title captured]	69	137	152	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	11					1629	1638		10.1038/sj.onc.1209372	http://dx.doi.org/10.1038/sj.onc.1209372			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020JL	16550163				2022-12-28	WOS:000235904700005
J	Mulholland, DJ; Dedhar, S; Wu, H; Nelson, CC				Mulholland, DJ; Dedhar, S; Wu, H; Nelson, CC			PTEN and GSK3 beta: Key regulators of progression to androgen- independent prostate cancer	ONCOGENE			English	Review						PTEN; GSK3 beta; androgen; independent; prostate cancer	INTEGRIN-LINKED KINASE; GROWTH-FACTOR-I; TUMOR-SUPPRESSOR GENE; NUCLEAR BETA-CATENIN; CELL-CYCLE ARREST; GLYCOGEN-SYNTHASE KINASE-3-BETA; INTRAEPITHELIAL NEOPLASIA; MAMMALIAN TARGET; TRANSCRIPTIONAL ACTIVITY; INCREASED EXPRESSION	Prostate cancer (PrCa) is characterized by progression from an androgen-dependent phenotype to one that is inevitably androgen independent (AI) and lethal. Recent evidence strongly suggests that the phosphatidylinositol-3-kinase/Akt (PI3K/Akt) and androgen receptor (AR) signalling pathways provide prostatic epithelium with the necessary signalling events to escape the apoptotic response associated with androgen withdrawal therapy. Silencing of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) and glycogen synthase kinase beta (GSK3b) are frequently associated with advanced PrCa systems and likely serve critical roles in promoting AR and PI3K/Akt gain-of-function. That PTEN negatively regulates AR and is sufficient to promote metastatic PrCa in murine models strongly implies its role as a gatekeeper of progressive PrCa. In human PrCa, PTEN loss is correlated with substantial increases in Akt(Ser473) and integrin-linked kinase expression, both of which promote Ser(9) phospho-inhibition of GSK3 beta and inactivation of apoptotic factors. Sufficient evidence also suggests that GSK3 beta is not only a critical regulator of proproliferative signalling but also a promiscuous one as PI3K/Akt pools of GSK3 beta are, at least in part, functionally interchangeable with those of the Wnt/beta-catenin pathway. Thus, GSK3 beta may serve not only as a mediator of PI3K/ Akt activation but may also regulate the potent transactivation and proproliferative effects that Wnt3a and beta-catenin confer upon AR. These data suggest that prostate-specific activation of GSK3 beta may serve as a viable pharmacological option. Thus, in this review, we emphasize that temporal changes in GSK3 beta and PTEN expression during progression to AI PrCa are important factors when considering the potential for therapies targeting the oncogenic contributions of PI3K/Akt and AR signalling pathways.	Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Vancouver Gen Hosp, Prostate Ctr, Vancouver, BC, Canada	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of British Columbia	Mulholland, DJ (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, 650 Charles E Young Dr S, Los Angeles, CA 90095 USA.	dmulholland@mednet.ucla.edu		Dedhar, Shoukat/0000-0003-4355-1657				Altuwaijri S, 2004, ENDOCRINE, V25, P27, DOI 10.1385/ENDO:25:1:27; Anna CH, 2003, TOXICOL APPL PHARM, V190, P135, DOI 10.1016/S0041-008X(03)00170-4; Asatiani E, 2005, CANCER RES, V65, P1164, DOI 10.1158/0008-5472.CAN-04-2688; Bernard D, 2003, J CLIN INVEST, V112, P1724; Bierie B, 2003, ONCOGENE, V22, P3875, DOI 10.1038/sj.onc.1206426; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; Bowen C, 2000, CANCER RES, V60, P6111; Campbell RB, 2003, J BIOL CHEM, V278, P33617, DOI 10.1074/jbc.C300296200; Carter Michael D, 2004, J Biomol Tech, V15, P257; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen GP, 2004, CANCER-AM CANCER SOC, V101, P1345, DOI 10.1002/cncr.20518; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Cinar B, 2005, CANCER RES, V65, P2547, DOI 10.1158/0008-5472.CAN-04-3411; Comuzzi B, 2003, AM J PATHOL, V162, P233, DOI 10.1016/S0002-9440(10)63814-X; CULIG Z, 1994, CANCER RES, V54, P5474; Davies MA, 1999, CANCER RES, V59, P2551; de la Taille A, 2003, CLIN CANCER RES, V9, P1801; DeFeo-Jones D, 2005, MOL CANCER THER, V4, P271; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Dreher T, 2004, VIRCHOWS ARCH, V444, P509, DOI 10.1007/s00428-004-1004-6; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Fu MF, 2004, BIOCHEM PHARMACOL, V68, P1199, DOI 10.1016/j.bcp.2004.05.037; Fu MF, 2003, J STEROID BIOCHEM, V85, P133, DOI 10.1016/S0960-0760(03)00223-1; Fu MF, 2003, MOL CELL BIOL, V23, P8563, DOI 10.1128/MCB.23.23.8563-8575.2003; Gao N, 2003, BIOCHEM BIOPH RES CO, V310, P1124, DOI 10.1016/j.bbrc.2003.09.132; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Gingrich JR, 1999, PROSTATE CANCER P D, V2, P70, DOI 10.1038/sj/pcan/4500296; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Gounari F, 2002, ONCOGENE, V21, P4099, DOI 10.1038/sj.onc.1205562; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Graff JR, 2001, CLIN CANCER RES, V7, P1987; Gregory CW, 2001, CANCER RES, V61, P4315; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; He WW, 1997, GENOMICS, V43, P69, DOI 10.1006/geno.1997.4715; Heisler LE, 1997, MOL CELL ENDOCRINOL, V126, P59, DOI 10.1016/S0303-7207(96)03970-6; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Huang HJ, 2004, J BIOL CHEM, V279, P13866, DOI 10.1074/jbc.M314143200; Isaacs W, 2001, EPIDEMIOL REV, V23, P36, DOI 10.1093/oxfordjournals.epirev.a000794; Kalesnikoff J, 2004, REV PHYSIOL BIOCH P, V149, P87, DOI 10.1007/s10254-003-0016-y; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; Kim J, 2004, J CELL BIOCHEM, V93, P233, DOI 10.1002/jcb.20228; Koivisto P, 1997, CANCER RES, V57, P314; Koksal IT, 2004, UROL ONCOL-SEMIN ORI, V22, P307, DOI 10.1016/j.urolonc.2004.01.009; Kreisberg JI, 2004, CANCER RES, V64, P5232, DOI 10.1158/0008-5472.CAN-04-0272; Krueckl SL, 2004, CANCER RES, V64, P8620, DOI 10.1158/0008-5472.CAN-04-2446; Li HW, 2004, J BIOL CHEM, V279, P4212, DOI 10.1074/jbc.M311374200; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Li PF, 2001, J BIOL CHEM, V276, P20444, DOI 10.1074/jbc.M010226200; Liao XB, 2004, ENDOCRINOLOGY, V145, P2941, DOI 10.1210/en.2003-1519; Lin HK, 2004, MOL ENDOCRINOL, V18, P2409, DOI 10.1210/me.2004-0117; Lin HK, 2003, J BIOL CHEM, V278, P50902, DOI 10.1074/jbc.M300676200; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Lin JQ, 1999, CANCER RES, V59, P2891; Lu S, 2000, MOL ENDOCRINOL, V14, P753, DOI 10.1210/me.14.5.753; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Malik SN, 2002, CLIN CANCER RES, V8, P1168; Masiello D, 2004, MOL ENDOCRINOL, V18, P2388, DOI 10.1210/me.2003-0436; MASSENKEIL G, 1994, ANTICANCER RES, V14, P2785; McDavid K, 2004, PUBLIC HEALTH REP, V119, P174, DOI 10.1177/003335490411900211; McMenamin ME, 1999, CANCER RES, V59, P4291; Meijer L, 2004, TRENDS PHARMACOL SCI, V25, P471, DOI 10.1016/j.tips.2004.07.006; Mohler JL, 2004, CLIN CANCER RES, V10, P440, DOI 10.1158/1078-0432.CCR-1146-03; Mulholland DJ, 2003, ONCOGENE, V22, P5602, DOI 10.1038/sj.onc.1206802; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; Nan B, 2003, J MOL ENDOCRINOL, V31, P169, DOI 10.1677/jme.0.0310169; Nazareth LV, 1999, MOL ENDOCRINOL, V13, P2065, DOI 10.1210/me.13.12.2065; Nickerson T, 1999, UROLOGY, V54, P1120, DOI 10.1016/S0090-4295(99)00421-5; Nickerson T, 2001, CANCER RES, V61, P6276; Pawlowski JE, 2002, J BIOL CHEM, V277, P20702, DOI 10.1074/jbc.M200545200; Perez JJ, 2002, CURR MED CHEM, V9, P2209, DOI 10.2174/0929867023368683; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; PHILLIPS SMA, 1994, BRIT J UROL, V73, P390, DOI 10.1111/j.1464-410X.1994.tb07602.x; Qi Xiao-ping, 2005, Zhonghua Nan Ke Xue, V11, P34; Radu A, 2003, MOL CELL BIOL, V23, P6139, DOI 10.1128/MCB.23.17.6139-6149.2003; Ratliff Timothy L, 2005, J Urol, V174, P1149; Salas TR, 2004, J BIOL CHEM, V279, P19191, DOI 10.1074/jbc.M309560200; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sharma M, 2002, J BIOL CHEM, V277, P30935, DOI 10.1074/jbc.M201919200; Sharp ZD, 2005, J GERONTOL A-BIOL, V60, P293, DOI 10.1093/gerona/60.3.293; Song LN, 2003, MOL CELL BIOL, V23, P1674, DOI 10.1128/MCB.23.5.1674-1687.2003; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stiles B, 2004, DEV BIOL, V273, P175, DOI 10.1016/j.ydbio.2004.06.008; Sumitomo M, 2004, CANCER CELL, V5, P67, DOI 10.1016/S1535-6108(03)00331-3; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; THOMPSON TC, 1995, ONCOGENE, V10, P869; Truica CI, 2000, CANCER RES, V60, P4709; Van der Poel HG, 2004, J UROLOGY, V172, P1333, DOI 10.1097/01.ju.0000138829.97838.19; van Es JH, 2003, CURR OPIN GENET DEV, V13, P28, DOI 10.1016/S0959-437X(02)00012-6; Verras M, 2005, MOL ENDOCRINOL, V19, P391, DOI 10.1210/me.2004-0208; Verras M, 2004, CANCER RES, V64, P8860, DOI 10.1158/0008-5472.CAN-04-2370; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang QC, 2004, INT J CANCER, V111, P508, DOI 10.1002/ijc.20286; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Warshamana-Greene GS, 2004, MOL CANCER THER, V3, P527; Wen Y, 2000, CANCER RES, V60, P6841; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720; Wong HY, 2004, BIOCHEM J, V383, P267, DOI 10.1042/BJ20040683; Wu LC, 2005, CANCER RES, V65, P2825, DOI 10.1158/0008-5472.CAN-04-3137; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Xin L, 2003, P NATL ACAD SCI USA, V100, P11896, DOI 10.1073/pnas.1734139100; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; YUAN SX, 1993, CANCER RES, V53, P1304; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008; Zhang LQ, 2003, CANCER RES, V63, P4552; Zhang XJ, 2000, PROSTATE, V43, P278; Zhao H, 2004, ONCOGENE, V23, P786, DOI 10.1038/sj.onc.1207162; Zhu HN, 2004, CANCER RES, V64, P7918, DOI 10.1158/0008-5472.CAN-04-2704	117	176	180	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					329	337		10.1038/sj.onc.1209020	http://dx.doi.org/10.1038/sj.onc.1209020			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16421604				2022-12-28	WOS:000234714100001
J	Kiser, KF; Colombi, M; Moroni, C				Kiser, K. F.; Colombi, M.; Moroni, C.			Isolation and characterization of dominant and recessive IL-3-independent hematopoietic transformants	ONCOGENE			English	Article						mutagenesis; Raf-1; ICR191; mast cells; stat	COLONY-STIMULATING FACTOR; ABROGATE CYTOKINE DEPENDENCY; MESSENGER-RNA TURNOVER; BCR-ABL; AUTOCRINE TRANSFORMATION; DIFFERENTIAL ABILITIES; SIGNAL-TRANSDUCTION; FACTOR-INDEPENDENCE; PREVENT APOPTOSIS; BETA-SUBUNIT	Retroviral integration mutagenesis and treatment with the frameshift mutagen ICR191 were used to transform v-H-ras expressing PB-3c cells to interleukin-3 (IL-3) independence. Six clones displayed viral integrations into the 30 region of the IL-3 gene thus acting posttranscriptionally by disrupting the AU-rich instability element. Two clones contained reverse orientation integration into the raf-1 gene revealing an enhancer insertion mechanism. Growth by this mechanism was sensitive to the Raf-1 inhibitor BAY 43-9006 and the Mek inhibitor U0126. Following treatment with ICR191, IL-3-independent clones were recovered and studied by cell fusion. With 21/22 clones, IL-3 independence resulted from a recessive mechanism as cellular hybrids with parental cells reverted to IL-3 dependence. Recessive clone D2c displayed increased phospho-Erk1/2 levels and was growth sensitive to U0126, but not to BAY43-9006. The single dominant clone, D5a, showed no signs of mitogen-activated protein kinases pathway activation but displayed constitutive phosphorylation of Stat5. We conclude that PB-3c has several options to acquire IL-3 growth autonomy involving transcriptional or posttranscriptional mechanisms affecting the distal regulators Erk or Stat5. The reported panel of independent dominant and recessive transformants should provide a useful tool for inhibitor profiling.	Univ Basel, Dept Clin Biol Sci, Inst Med Microbiol, CH-4051 Basel, Switzerland	University of Basel	Moroni, C (corresponding author), Univ Basel, Dept Clin Biol Sci, Inst Med Microbiol, Peterspl 10, CH-4051 Basel, Switzerland.	christoph.moroni@unibas.ch						ALGATE PA, 1993, ONCOGENE, V8, P1221; ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; Benjamin D, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh086; Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; Blalock WL, 2000, ONCOGENE, V19, P526, DOI 10.1038/sj.onc.1203337; DANDREA R, 1994, BLOOD, V83, P2802, DOI 10.1182/blood.V83.10.2802.2802; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HANNEMANN J, 1995, MOL CELL BIOL, V15, P2402; Hayakawa F, 2000, ONCOGENE, V19, P624, DOI 10.1038/sj.onc.1203354; HIRSCH HH, 1993, J EXP MED, V178, P403, DOI 10.1084/jem.178.2.403; Hoyle PE, 2000, LEUKEMIA, V14, P642, DOI 10.1038/sj.leu.2401720; IHLE JN, 1981, J IMMUNOL, V127, P2565; Jiang XY, 2002, BLOOD, V100, P3731, DOI 10.1182/blood-2002-05-1324; Joung YH, 2003, EXP MOL MED, V35, P350, DOI 10.1038/emm.2003.46; Liu CB, 1999, J BIOL CHEM, V274, P6342, DOI 10.1074/jbc.274.10.6342; McCormack MP, 1997, BLOOD, V90, P1471, DOI 10.1182/blood.V90.4.1471.1471_1471_1481; McCubrey JA, 2004, ONCOGENE, V23, P7810, DOI 10.1038/sj.onc.1208055; McCubrey JA, 1998, LEUKEMIA, V12, P1903, DOI 10.1038/sj.leu.2401215; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Nagata Y, 1996, BIOCHEM BIOPH RES CO, V221, P785, DOI 10.1006/bbrc.1996.0674; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; Nosaka T, 2002, EXP HEMATOL, V30, P697, DOI 10.1016/S0301-472X(02)00808-1; Onishi M, 1996, BLOOD, V88, P1399, DOI 10.1182/blood.V88.4.1399.bloodjournal8841399; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Onishi M, 1996, EXP HEMATOL, V24, P324; OVERELL RW, 1987, MOL CELL BIOL, V7, P3394, DOI 10.1128/MCB.7.10.3394; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; Piao XH, 1996, BLOOD, V87, P3117, DOI 10.1182/blood.V87.8.3117.bloodjournal8783117; Shelton JG, 2003, ONCOGENE, V22, P2478, DOI 10.1038/sj.onc.1206321; SHOUNAN Y, 1995, EXP HEMATOL, V23, P492; Steelman LS, 2004, LEUKEMIA, V18, P189, DOI 10.1038/sj.leu.2403241; Stoecklin G, 2003, ONCOGENE, V22, P3554, DOI 10.1038/sj.onc.1206418; STOECKLIN G, 1994, J BIOL CHEM, V269, P28591; Stoecklin G, 2002, EMBO J, V21, P4709, DOI 10.1093/emboj/cdf444; Testa U, 2004, LEUKEMIA, V18, P219, DOI 10.1038/sj.leu.2403224; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0	38	4	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2006	25	50					6595	6603		10.1038/sj.onc.1209673	http://dx.doi.org/10.1038/sj.onc.1209673			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16702946				2022-12-28	WOS:000241569700004
J	VanderBorght, A; Valckx, A; Van Dun, J; Grand-Perret, T; De Schepper, S; Vialard, J; Janicot, M; Arts, J				VanderBorght, A.; Valckx, A.; Van Dun, J.; Grand-Perret, T.; De Schepper, S.; Vialard, J.; Janicot, M.; Arts, J.			Effect of an hdm-2 antagonist peptide inhibitor on cell cycle progression in p53-deficient H1299 human lung carcinoma cells	ONCOGENE			English	Article						hdm-2; antagonistic peptide; p-53 deficient	MDM2 ONCOPROTEIN; IN-VIVO; P53; PROTEIN; DNA; ABNORMALITIES; PATHWAY; P73	The hdm-2 oncogene is overexpressed in several types of malignancies including osteosarcomas, soft tissue sarcomas and gliomas and hdm-2 has been associated with accelerated tumor formation in both hereditary and sporadic cancers. Among the other key binding partners, hdm-2 forms a complex with the tumor suppressor p53, resulting in a rapid proteasome-mediated degradation of the p53 protein. This positions the hdm-2-p53 complex as an attractive target for the development of anticancer therapy and recently the first small molecule hdm-2 antagonist has been reported. Development of hdm-2 antagonists is currently focused on malignancies containing a wild-type p53 genotype, which is the case in approximately half of human cancer indications. However, hdm-2 has also been implicated in oncogenesis in the absence of p53. We therefore studied the effect of hdm-2 antagonists in p53-deficient human H1299 lung carcinoma cells. The hdm-2 antagonistic peptide caused G1 cell cycle arrest, inhibited colony growth and induced expression of G1 checkpoint regulatory proteins, such as p21(waf1,cip1). These data demonstrate that hdm-2 regulates the G1 cell cycle checkpoint in a p53-independent manner, suggesting that hdm-2 antagonists represent a novel class of anticancer therapeutics with broad applicability towards tumors with different p53 genetic backgrounds.	Johnson & Johnson Pharmaceut Res & Dev, Oncol Dicovery Res & Early Dev, B-2340 Beerse, Belgium	Johnson & Johnson; Janssen Pharmaceuticals	Arts, J (corresponding author), Johnson & Johnson Pharmaceut Res & Dev, Oncol Dicovery Res & Early Dev, Turnhoutseweg 30, B-2340 Beerse, Belgium.	jarts@prdbe.jnj.com						Blattner C, 1999, MOL CELL BIOL, V19, P3704; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; CORDONCARDO C, 1994, CANCER RES, V54, P794; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; FAKHARZADEH SS, 1993, GENOMICS, V15, P283, DOI 10.1006/geno.1993.1058; Fischer PM, 2004, TRENDS PHARMACOL SCI, V25, P343, DOI 10.1016/j.tips.2004.04.011; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LANE DP, 1992, NATURE, V358, P16; Lorens JB, 2000, MOL THER, V1, P438, DOI 10.1006/mthe.2000.0063; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Momand J, 1997, J CELL BIOCHEM, V64, P343; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; SWIFT S, 1999, CURRENT PROTOCOLS S, V31; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; VINDELOV LL, 1983, CYTOMETRY, V3, P332, DOI 10.1002/cyto.990030505; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200	22	19	20	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2006	25	50					6672	6677		10.1038/sj.onc.1209667	http://dx.doi.org/10.1038/sj.onc.1209667			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16732328				2022-12-28	WOS:000241569700012
J	Sung, YM; He, G; Hwang, DH; Fischer, SM				Sung, Y. M.; He, G.; Hwang, D. H.; Fischer, S. M.			Overexpression of the prostaglandin E2 receptor EP2 results in enhanced skin tumor development	ONCOGENE			English	Article						prostaglandin E2; EP2 transgenic mice; proliferation; angiogenesis; skin carcinogenesis	NF-KAPPA-B; MULTISTAGE CARCINOGENESIS; GROWTH-FACTOR; SUBTYPE EP4; MOUSE SKIN; EXPRESSION; CELLS; E-2; PROMOTION; APOPTOSIS	We previously showed that the EP2 knockout mice were resistant to chemically induced skin carcinogenesis. The purpose of this study was to investigate the role of the overexpression of the EP2 receptor in mouse skin carcinogenesis. To determine the effect of overexpression of EP2, we used EP2 transgenic (TG) mice and wild-type (WT) mice in a DMBA (7,12-dimethylbenz[alpha]anthracene)/TPA (12-O-tetradecanoylphorbol-13-acetate) two-stage carcinogenesis protocol. EP2 TG mice developed significantly more tumors compared with WT mice. Overexpression of the EP2 receptor increased TPA-induced keratinocyte proliferation both in vivo and in vitro. In addition, the epidermis of EP2 TG mice 48 h after topical TPA treatment was significantly thicker compared to that of WT mice. EP2 TG mice showed significantly increased cyclic adenosine monophosphate levels in the epidermis after prostaglandin E2 (PGE2) treatment. The inflammatory response to TPA was increased in EP2 TG mice, as demonstrated by an increased number of macrophages in the dermis. Tumors and 7 x TPA-treated and DMBA-TPA-treated ( 6 weeks) skins from EP2 TG mice produced more blood vessels than those of WT mice as determined by CD-31 immunostaining. Vascular endothelial growth factor (VEGF) protein expression was significantly increased in squamous cell carcinoma (SCC) samples from EP2 TG mice compared that of WT mice. There was, however, no difference in the number of apoptotic cells in tumors from WT and EP2 TG mice. Together, our results suggest that the overexpression of the EP2 receptor plays a significant role in the protumorigenic action of PGE2 in mouse skin.	Univ Texas, MD Anderson Canc Ctr, Sci Pk Res Div, Smithville, TX 78957 USA; Univ Calif Davis, USDA, ARS, Western Human Nutr Res Ctr, Davis, CA 95616 USA	University of Texas System; UTMD Anderson Cancer Center; United States Department of Agriculture (USDA); University of California System; University of California Davis	Fischer, SM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Sci Pk Res Div, Smithville, TX 78957 USA.	smficher@mdanderson.org			NATIONAL CANCER INSTITUTE [P30CA016672, R01CA100140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA100140] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Cao Y, 2002, J CELL PHYSIOL, V190, P279, DOI 10.1002/jcp.10068; Chang SH, 2004, P NATL ACAD SCI USA, V101, P591, DOI 10.1073/pnas.2535911100; Chang SH, 2005, PROSTAG OTH LIPID M, V76, P48, DOI 10.1016/j.prostaglandins.2004.12.001; Chang SH, 2005, CANCER RES, V65, P4496, DOI 10.1158/0008-5472.CAN-05-0129; Conconi MT, 1996, ANN ANAT, V178, P229, DOI 10.1016/S0940-9602(96)80055-0; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; FISCHER SM, 1990, CARCINOGENESIS, V11, P991, DOI 10.1093/carcin/11.6.991; Fischer SM, 1999, MOL CARCINOGEN, V25, P231; FURSTENBERGER G, 1989, CARCINOGENESIS, V10, P91, DOI 10.1093/carcin/10.1.91; Hoper MM, 1997, AM J RESP CELL MOL, V17, P748; Kawamori T, 2005, CARCINOGENESIS, V26, P353, DOI 10.1093/carcin/bgh322; Kitamura T, 2003, CANCER SCI, V94, P618, DOI 10.1111/j.1349-7006.2003.tb01492.x; LU XJ, 1995, P NATL ACAD SCI USA, V92, P7961, DOI 10.1073/pnas.92.17.7961; MULLERDECKER K, 1995, MOL CARCINOGEN, V12, P31, DOI 10.1002/mc.2940120106; Murphy JE, 2003, J IMMUNOL, V170, P5697, DOI 10.4049/jimmunol.170.11.5697; Mutoh M, 2002, CANCER RES, V62, P28; Nishihara H, 2003, P NATL ACAD SCI USA, V100, P8921, DOI 10.1073/pnas.1533221100; Seno H, 2002, CANCER RES, V62, P506; Shao JY, 2004, J BIOL CHEM, V279, P14287, DOI 10.1074/jbc.M313276200; Shao JY, 2003, CANCER RES, V63, P5218; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Sheng HM, 1998, CANCER RES, V58, P362; Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Sung YM, 2005, CANCER RES, V65, P9304, DOI 10.1158/0008-5472.CAN-05-1015; Suzukawa K, 2002, ENVIRON HEALTH PERSP, V110, P865, DOI 10.1289/ehp.02110865; Tiano HF, 2002, CANCER RES, V62, P3395; Ueda T, 2001, FEBS LETT, V491, P40, DOI 10.1016/S0014-5793(01)02145-7; Watanabe H, 1999, ANN ONCOL, V10, P136, DOI 10.1023/A:1008330012536; Young MR, 2003, TRENDS MOL MED, V9, P36, DOI 10.1016/S1471-4914(02)00009-6; YUSPA SH, 1974, EXP CELL RES, V86, P95, DOI 10.1016/0014-4827(74)90653-3	31	52	53	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2006	25	40					5507	5516		10.1038/sj.onc.1209538	http://dx.doi.org/10.1038/sj.onc.1209538			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16607275				2022-12-28	WOS:000240370400004
J	Foster, KSJ; McCrary, WJ; Ross, JS; Wright, CF				Foster, K. S. J.; McCrary, W. J.; Ross, J. S.; Wright, C. F.			Members of the hSWI/SNF chromatin remodeling complex associate with. and are phosphorylated by protein kinase B/Akt	ONCOGENE			English	Article						hSWI/SNF; INI1; BAF155; Akt	RHABDOID TUMOR-CELLS; BAF COMPLEX; ENDOTHELIAL-CELLS; SWI/SNF COMPLEX; CYCLE ARREST; BRG1; GENES; INI1; AKT; TRANSCRIPTION	In an adenosine triphosphate (ATP)-dependent process, the hSWI/SNF chromatin remodeling complex functions to alter chromatin structure, thereby regulating transcription factor access to DNA. In addition to interactions with transcription factors and recognition of acetylated histone residues, the chromatin remodeling activity of hSWI/SNF has also been shown to respond to a variety of cell signaling pathways. Our results demonstrate a novel interaction between the serine/threonine kinase Akt and members of the hSWI/SNF chromatin remodeling complex. Activation of Akt in HeLa cells resulted in its association with hSWI/SNF subunits: INI1, BAF155 and BAF170, as well as actin. BAF155 became preferentially recognized by an antibody that detects phosphorylated Akt substrates upon activation of Akt, suggesting that BAF155 may be an in vivo target for phosphorylation by Akt. Gtutathione-S-transferase (GST) pulldown experiments demonstrated that INI1 and BAF155 were both capable of directly interacting with Akt. Finally, in vitro kinase assays provided additional evidence that BAF155 and potentially INI1 are substrates for Akt phosphorylation. These data provide the first evidence that Akt signaling may modulate function of the hSWI/SNF complex.	Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; Med Univ S Carolina, Coll Med, Charleston, SC 29425 USA; Fayetteville State Univ, Dept Nat Sci, Fayetteville, NC USA	Medical University of South Carolina; Medical University of South Carolina; University of North Carolina; Fayetteville State University	Wright, CF (corresponding author), Med Univ S Carolina, Dept Pathol & Lab Med, 165 Ashley Ave,Suite 309,POB 250908, Charleston, SC 29425 USA.	wrightcf@musc.edu		Wright, Cynthia/0000-0003-0442-1665	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T35HL007769] Funding Source: NIH RePORTER; NHLBI NIH HHS [T35 HL007769-14] Funding Source: Medline; NIDDK NIH HHS [T32 DK007431-21] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Banine F, 2005, CANCER RES, V65, P3542, DOI 10.1158/0008-5472.CAN-04-3554; Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412; Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706; Biegel JA, 1999, CANCER RES, V59, P74; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; Chai JJ, 2005, CANCER RES, V65, P10192, DOI 10.1158/0008-5472.CAN-05-1896; Chen JG, 2005, MOL CELL BIOL, V25, P9016, DOI 10.1128/MCB.25.20.9016-9027.2005; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Craig E, 2002, EMBO J, V21, P31, DOI 10.1093/emboj/21.1.31; Cui KR, 2004, MOL CELL BIOL, V24, P4476, DOI 10.1128/MCB.24.10.4476-4486.2004; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; Doan DN, 2004, ONCOGENE, V23, P3462, DOI 10.1038/sj.onc.1207472; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; FRANKE TF, 1999, NEURAL NOTES, V5, P3; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Gresh L, 2005, EMBO J, V24, P3313, DOI 10.1038/sj.emboj.7600802; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; Huang M, 2002, NAT CELL BIOL, V4, P774, DOI 10.1038/ncb855; Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097-2765(03)00034-0; Kang H, 2004, MOL CELL BIOL, V24, P1188, DOI 10.1128/MCB.24.3.1188-1199.2004; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; Link KA, 2005, MOL CELL BIOL, V25, P2200, DOI 10.1128/MCB.25.6.2200-2215.2005; Liu H, 2002, MOL CELL BIOL, V22, P6471, DOI 10.1128/MCB.22.18.6471-6479.2002; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Miyauchi H, 2004, EMBO J, V23, P212, DOI 10.1038/sj.emboj.7600045; Morozov A, 1998, P NATL ACAD SCI USA, V95, P1120, DOI 10.1073/pnas.95.3.1120; Oruetxebarria I, 2004, J BIOL CHEM, V279, P3807, DOI 10.1074/jbc.M309333200; Pattenden SG, 2002, EMBO J, V21, P1978, DOI 10.1093/emboj/21.8.1978; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Rando OJ, 2002, P NATL ACAD SCI USA, V99, P2824, DOI 10.1073/pnas.032662899; Reincke BS, 2003, J CELL PHYSIOL, V194, P303, DOI 10.1002/jcp.10201; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Schonherr E, 2001, J BIOL CHEM, V276, P40687, DOI 10.1074/jbc.M105426200; Simone C, 2004, NAT GENET, V36, P738, DOI 10.1038/ng1378; Versteege I, 2002, ONCOGENE, V21, P6403, DOI 10.1038/sj.onc.1205841; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wu DY, 2002, J BIOL CHEM, V277, P27706, DOI 10.1074/jbc.M200955200; Xu WP, 2003, CANCER RES, V63, P7777; Zhang ZK, 2002, MOL CELL BIOL, V22, P5975, DOI 10.1128/MCB.22.16.5975-5988.2002; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	45	24	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2006	25	33					4605	4612		10.1038/sj.onc.1209496	http://dx.doi.org/10.1038/sj.onc.1209496			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16568092				2022-12-28	WOS:000239457500010
J	Joliot, V; Cormier, F; Medyouf, H; Alcalde, H; Ghysdael, J				Joliot, V.; Cormier, F.; Medyouf, H.; Alcalde, H.; Ghysdael, J.			Constitutive STAT5 activation specifically cooperates with the loss of p53 function in B-cell lymphomagenesis	ONCOGENE			English	Article						STAT5; p53; leukemia; lymphoma; B lymphocytes; oncogenic cooperation	IN-VIVO; SIGNAL TRANSDUCER; POLYCYTHEMIA-VERA; T-CELLS; MICE; TRANSCRIPTION; PROTEINS; LEUKEMIA; LEUKEMOGENESIS; PHOSPHATASE	Signal transducers and activator of transcription 5 (STAT5) A and B are transcriptional regulators that play a central role in cytokine signaling in the hematopoietic lineage and which are frequently activated in a persistent manner in human leukemia/lymphoma, as assessed by their constitutive tyrosine phosphorylation and DNA-binding activity. To study the intrinsic oncogenic properties of persistent STAT5 activation, we generated transgenic mice in which a constitutively activated point mutant of STAT5A, STAT5A(S711F), was expressed at physiological level in their lymphoid compartment. In this model, persistent STAT5 activation is weakly oncogenic, leading to the late emergence of clonal B-cell lymphoma/leukemia at a low incidence. In contrast, STAT5(S711F) was found to cooperate with the loss of function of the p53 tumor suppressor gene to both accelerate disease onset and to skew the large tumor spectrum that normally characterize p53-deficient mice to strongly favor B-cell lymphoma/leukemia. The emergence of STAT5A(S711F)-induced B-cell tumors is associated with the activation of STAT5 tyrosine phosphorylation and DNA-binding activity, indicating that activation of STAT5 oncogenic properties in transgenic STAT5A (TgSTAT5A) (S711F) mice involves the deregulation of STAT5 phosphorylation dynamics.	Ctr Univ Orsay, CNRS, Inst Curie, UMR 146, F-91405 Orsay, France; Univ Paris 07, UFR Biochim, Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite	Ghysdael, J (corresponding author), Ctr Univ Orsay, CNRS, Inst Curie, UMR 146, Bat 110, F-91405 Orsay, France.	acques.ghysdael@curie.u-psud.fr	GHYSDAEL, Jacques/F-3377-2013	Medyouf, Hind/0000-0003-4652-9455; Cormier, Francoise/0000-0002-6904-5122				Abraham N, 2005, ONCOGENE, V24, P5252, DOI 10.1038/sj.onc.1208726; Aoki N, 2000, J BIOL CHEM, V275, P39718, DOI 10.1074/jbc.M005615200; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bunting KD, 2002, BLOOD, V99, P479, DOI 10.1182/blood.V99.2.479; Burchill MA, 2003, J IMMUNOL, V171, P5853, DOI 10.4049/jimmunol.171.11.5853; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Carron C, 2000, BLOOD, V95, P3891; Chen Y, 2003, J BIOL CHEM, V278, P16520, DOI 10.1074/jbc.M210572200; Cui Y, 2004, MOL CELL BIOL, V24, P8037, DOI 10.1128/MCB.24.18.8037-8047.2004; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Fleming HE, 2004, J IMMUNOL, V173, P2542, DOI 10.4049/jimmunol.173.4.2542; Fritsche M, 1998, MOL CELL ENDOCRINOL, V143, P143, DOI 10.1016/S0303-7207(98)00140-3; Goetz CA, 2005, J IMMUNOL, V174, P7753, DOI 10.4049/jimmunol.174.12.7753; Goetz CA, 2004, J IMMUNOL, V172, P4770, DOI 10.4049/jimmunol.172.8.4770; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Kang JS, 2004, J IMMUNOL, V173, P2307, DOI 10.4049/jimmunol.173.4.2307; Kelly J, 2003, J IMMUNOL, V170, P210, DOI 10.4049/jimmunol.170.1.210; Kelly JA, 2003, J EXP MED, V198, P79, DOI 10.1084/jem.20021548; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Krug U, 2002, ONCOGENE, V21, P3475, DOI 10.1038/sj.onc.1205322; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lebigot I, 2003, BLOOD, V102, P4555, DOI 10.1182/blood-2003-06-2077; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Mizuki M, 2000, BLOOD, V96, P3907, DOI 10.1182/blood.V96.12.3907; Moriggl R, 2005, CANCER CELL, V7, P87, DOI 10.1016/j.ccr.2004.12.010; Moriggl R, 1999, IMMUNITY, V11, P225, DOI 10.1016/S1074-7613(00)80097-7; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Reddy J, 2005, ONCOGENE, V24, P732, DOI 10.1038/sj.onc.1208032; Sambroock J., 1989, MOL CLONING LAB MANU; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Snow JW, 2002, BLOOD, V99, P95, DOI 10.1182/blood.V99.1.95; Sommer VH, 2004, LEUKEMIA, V18, P1288, DOI 10.1038/sj.leu.2403385; Sternberg DW, 2004, J CLIN ONCOL, V22, P361, DOI 10.1200/JCO.2004.10.124; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; WeberNordt RM, 1996, BLOOD, V88, P809	51	28	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2006	25	33					4573	4584		10.1038/sj.onc.1209480	http://dx.doi.org/10.1038/sj.onc.1209480			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16532027				2022-12-28	WOS:000239457500007
J	Phillips, A; Darley, M; Blaydes, J				Phillips, A.; Darley, M.; Blaydes, J. P.			GC-selective DNA-binding antibiotic, Mithramycin A, reveals multiple points of control in the regulation of Hdm2 protein synthesis	ONCOGENE			English	Article						Hdm2; Mdm2; transcription; mRNA export; promoter	SINGLE NUCLEOTIDE POLYMORPHISM; OPEN READING FRAMES; MESSENGER-RNA; MDM2 EXPRESSION; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; NUCLEAR EXPORT; P53; GENE; ACTIVATION	The primary role of the Hdm2/Mdm2 oncoprotein is to regulate the levels and activity of the transcription factor p53. Hdm2 synthesis is itself tightly controlled and, as demonstrated by a recently described SNP (SNP309) in the hdm2-P2 promoter, minor variations in Hdm2 expression have phenotypic consequences on radiation sensitivity and cancer predisposition. To further de. ne mechanisms regulating Hdm2 expression, we have investigated the effects of the GC-selective DNA-binding drug, Mithramycin A ( MA) on hdm2 mRNA transcription, trafficking, and translation. Firstly we show that the constitutive hdm2-P1 promoter is inhibited by MA. We de. ne, for the first time, the minimal sequence elements that are required for P1-promoter activity and identify those which confer MA sensitivity. Secondly, MA induces p53-dependent transcription from the hdm2-P2 promoter. Thirdly, and critically, MA also inhibits Hdm2 synthesis at the post-transcriptional level, with negative effects on hdm2 mRNA nuclear export and translation. This study highlights the complex interplay between the pathways that regulate Hdm2 protein synthesis in cancer cells, and furthermore emphasizes the export of hdm2 mRNA from the nucleus to the cytoplasm as a key point of control in this process.	Univ Southampton, Southampton Gen Hosp, Canc Sci Div, Sch Med, Southampton SO16 6YD, Hants, England	University of Southampton	Blaydes, J (corresponding author), Univ Southampton, Southampton Gen Hosp, Canc Sci Div, Sch Med, Somers Canc Res Bldg,MP 824, Southampton SO16 6YD, Hants, England.	j.p.blaydes@soton.ac.uk	Blaydes, Jeremy/AAC-6939-2019	Blaydes, Jeremy/0000-0001-8525-0209				Arriola EL, 1999, ONCOGENE, V18, P1081, DOI 10.1038/sj.onc.1202391; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Bar-Or RL, 2000, P NATL ACAD SCI USA, V97, P11250, DOI 10.1073/pnas.210171597; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Blaydes JP, 1998, ONCOGENE, V16, P3317, DOI 10.1038/sj.onc.1201880; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; Bond GL, 2005, CANCER RES, V65, P5481, DOI 10.1158/0008-5472.CAN-05-0825; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Brown CY, 1999, ONCOGENE, V18, P5631, DOI 10.1038/sj.onc.1202949; Chang CJ, 2004, J BIOL CHEM, V279, P29841, DOI 10.1074/jbc.M401488200; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Culjkovic B, 2005, J CELL BIOL, V169, P245, DOI 10.1083/jcb.200501019; Erkmann JA, 2004, EXP CELL RES, V296, P12, DOI 10.1016/j.yexcr.2004.03.015; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Ferrante RJ, 2004, J NEUROSCI, V24, P10335, DOI 10.1523/JNEUROSCI.2599-04.2004; Harris SL, 2005, P NATL ACAD SCI USA, V102, P16297, DOI 10.1073/pnas.0508390102; Hsing A, 2000, J BIOL CHEM, V275, P26024, DOI 10.1074/jbc.M002455200; Huang QH, 2004, P NATL ACAD SCI USA, V101, P3456, DOI 10.1073/pnas.0308562100; Inoue T, 2001, FEBS LETT, V490, P196, DOI 10.1016/S0014-5793(01)02123-8; Jin XP, 2003, J BIOL CHEM, V278, P25716, DOI 10.1074/jbc.M300316200; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Keene JD, 2003, NAT GENET, V33, P111, DOI 10.1038/ng0203-111; Kentsis A, 2004, P NATL ACAD SCI USA, V101, P18105, DOI 10.1073/pnas.0406927102; Koutsodontis G, 2004, ONCOGENE, V23, P9190, DOI 10.1038/sj.onc.1208141; Landers JE, 1997, CANCER RES, V57, P3562; LUNA RMD, 1995, NATURE, V378, P203; Ma L, 2005, P NATL ACAD SCI USA, V102, P14266, DOI 10.1073/pnas.0501352102; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meek DW, 2003, MOL CANCER RES, V1, P1017; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; MILLER DM, 1987, AM J MED SCI, V294, P388, DOI 10.1097/00000441-198711000-00015; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Onel K, 2004, MOL CANCER RES, V2, P1; Phelps M, 2005, J BIOL CHEM, V280, P16651, DOI 10.1074/jbc.M412334200; Phelps M, 2003, CANCER RES, V63, P2616; Phillips A, 2006, FEBS LETT, V580, P300, DOI 10.1016/j.febslet.2005.12.026; Qi JS, 1999, MOL CELL BIOL, V19, P864; Remsing LL, 2003, J AM CHEM SOC, V125, P5745, DOI 10.1021/ja034162h; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Slack A, 2005, P NATL ACAD SCI USA, V102, P731, DOI 10.1073/pnas.0405495102; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wynford-Thomas D, 1998, CARCINOGENESIS, V19, P29, DOI 10.1093/carcin/19.1.29; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zhang TT, 2001, J BIOL CHEM, V276, P29702, DOI 10.1074/jbc.M011326200	56	10	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	30					4183	4193		10.1038/sj.onc.1209451	http://dx.doi.org/10.1038/sj.onc.1209451			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16501602	Green Accepted			2022-12-28	WOS:000239004800006
J	Wang, S; Zhan, M; Yin, J; Abraham, JM; Mori, Y; Sato, F; Xu, Y; Olaru, A; Berki, AT; Li, H; Schulmann, K; Kan, T; Hamilton, JP; Paun, B; Yu, MM; Jin, Z; Cheng, Y; Ito, T; Mantzur, C; Greenwald, BD; Meltzer, SJ				Wang, S.; Zhan, M.; Yin, J.; Abraham, J. M.; Mori, Y.; Sato, F.; Xu, Y.; Olaru, A.; Berki, A. T.; Li, H.; Schulmann, K.; Kan, T.; Hamilton, J. P.; Paun, B.; Yu, M. M.; Jin, Z.; Cheng, Y.; Ito, T.; Mantzur, C.; Greenwald, B. D.; Meltzer, S. J.			Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis	ONCOGENE			English	Article						Barrett's esophagus; esophageal adenocarcinoma; transcriptional profiling; bioinformatics; early detection	GENE-EXPRESSION PROFILE; INTESTINAL METAPLASIA; MICROSATELLITE INSTABILITY; TUMOR PROGRESSION; OXIDATIVE DAMAGE; BETA-CATENIN; DIAGNOSIS; PROTEIN; HETEROZYGOSITY; EPIDEMIOLOGY	To investigate the relationship between Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC), we determined gene expression profiles of discrete pathological stages of esophageal neoplasia using a sequence-verified human cDNA microarray. Fifty one RNAs, comprising 24 normal esophagi ( NE), 18 BEs, and nine EACs were hybridized to cDNA microarrays. Five statistical analyses were used for the data analysis. Genes showing significantly different expression levels among the three sample groups were identified. Genes were grouped into functional categories based on the Gene Ontology Consortium. Surprisingly, the expression pattern of BE was significantly more similar to EAC than to NE, notwithstanding the known histopathologic differences between BE and EAC. The pattern of NE was clearly distinct from that of EAC. Thirty-six genes were the most differentially modulated, according to these microarray data, in BE-associated neoplastic progression. Twelve genes were significantly differentially expressed in cancer-associated BE's plus EAC (as a single combined tissue group) vs noncancer-associated BE's. These genes represent potential biomarkers to diagnose EAC at its early stages. Our results demonstrate that molecular events at the transcriptional level in BE are remarkably similar to BE's-associated adenocarcinoma of the esophagus. This finding alarmingly implies that BE is biologically closer to cancer than to normal esophagus, and that the cancer risk of BE is perhaps higher than we had imagined. These findings suggest that changes modulated at the molecular biologic level supervene earlier than histologic changes, and that BE is an early intermediate stage in the process of EAC.	Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Div Gastroenterol, Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; Baltimore VA Hosp, Baltimore, MD USA; NIA, Bioinformat Unit, NIH, Baltimore, MD 21224 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Meltzer, SJ (corresponding author), Univ Maryland, Sch Med, Greenebaum Canc Ctr, 22 S Greene St,Rm N3W62, Baltimore, MD 21201 USA.	smeltzer@medicine.umaryland.edu	Schulmann, Karsten/N-2230-2016	Berki, Agnes/0000-0003-1515-016X	NCI NIH HHS [CA95323, CA01808, CA85069, CA10676] Funding Source: Medline; NIDDK NIH HHS [T32 DK067872, DK67872] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA085069, R01CA001808, R01CA095323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK067872] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham JM, 1996, CELL GROWTH DIFFER, V7, P855; Blot WJ, 1999, SEMIN ONCOL, V26, P2; BOYNTON RF, 1991, CANCER RES, V51, P5766; Brabender J, 2004, ONCOGENE, V23, P4780, DOI 10.1038/sj.onc.1207663; Burdiles P, 2003, REV MED CHILE, V131, P587; Buttar NS, 2002, GASTROENTEROLOGY, V122, P1101, DOI 10.1053/gast.2002.32371; Cameron AJ, 2002, DIS ESOPHAGUS, V15, P106, DOI 10.1046/j.1442-2050.2002.00216.x; Cesar ACG, 2004, CANCER GENET CYTOGEN, V153, P127, DOI 10.1016/j.cancergencyto.2004.01.017; Chang Y, 2004, WORLD J GASTROENTERO, V10, P3194; Chen XX, 2000, CARCINOGENESIS, V21, P257, DOI 10.1093/carcin/21.2.257; Chen XX, 2001, CARCINOGENESIS, V22, P1119, DOI 10.1093/carcin/22.8.1119; Chen XX, 2002, CARCINOGENESIS, V23, P2095, DOI 10.1093/carcin/23.12.2095; Chung GG, 2004, CANCER, V100, P2084, DOI 10.1002/cncr.20232; Cossentino Mark J, 2003, Semin Gastrointest Dis, V14, P128; Ferguson MK, 2002, J GASTROINTEST SURG, V6, P29, DOI 10.1016/S1091-255X(01)00052-X; Fujii T, 2003, ONCOL REP, V10, P427; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Going JJ, 2002, GUT, V50, P373, DOI 10.1136/gut.50.3.373; Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Hyun DH, 2004, J NEUROCHEM, V90, P422, DOI 10.1111/j.1471-4159.2004.02493.x; Kimos MC, 2004, INT J CANCER, V111, P415, DOI 10.1002/ijc.20267; Li AH, 2004, CLIN EXP METASTAS, V21, P571; LI H, 1994, SURGERY, V115, P176; Matsushima T, 1998, ONCOL REP, V5, P73; McManus DT, 2004, CANCER RES, V64, P1561, DOI 10.1158/0008-5472.CAN-03-2438; Meighan-Mantha RL, 1999, J BIOL CHEM, V274, P33166, DOI 10.1074/jbc.274.46.33166; MELTZER SJ, 1994, CANCER RES, V54, P3379; Mori M, 2002, SURGERY, V131, pS39, DOI 10.1067/msy.2002.119292; Mori Y, 2003, CANCER RES, V63, P4577; Offner FA, 1996, HUM PATHOL, V27, P885, DOI 10.1016/S0046-8177(96)90213-0; Powell J, 1992, Eur J Cancer Prev, V1, P265, DOI 10.1097/00008469-199204000-00008; RASKIND WH, 1992, CANCER RES, V52, P2946; REID BJ, 1987, GASTROENTEROLOGY, V93, P1; Sanz-Ortega J, 2003, HEPATO-GASTROENTEROL, V50, P404; Schwartz DR, 2003, CANCER RES, V63, P2913; Selaru FM, 2002, ONCOGENE, V21, P475, DOI 10.1038/sj.onc.1205111; Shirvani VN, 2000, GASTROENTEROLOGY, V118, P487, DOI 10.1016/S0016-5085(00)70254-X; Spechler SJ, 2002, MED CLIN N AM, V86, P1423, DOI 10.1016/S0025-7125(02)00082-2; Stoltzing O, 1998, Langenbecks Arch Chir Suppl Kongressbd, V115, P485; Suspiro A, 2003, AM J GASTROENTEROL, V98, P728, DOI 10.1016/S0002-9270(03)00129-1; Tamoto E, 2004, CLIN CANCER RES, V10, P3629, DOI 10.1158/1078-0432.CCR-04-0048; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Umansky M, 2001, ONCOGENE, V20, P7987, DOI 10.1038/sj.onc.1204947; von Rahden Burkhard H A, 2003, Curr Oncol Rep, V5, P203; Wang SN, 2003, ONCOGENE, V22, P467, DOI 10.1038/sj.onc.1206125; Wiley SR, 2003, CYTOKINE GROWTH F R, V14, P241, DOI 10.1016/S1359-6101(03)00019-4; Wilson KT, 1998, CANCER RES, V58, P2929; Xu Y, 2002, CANCER RES, V62, P3493; Yamamoto H, 2004, CARCINOGENESIS, V25, P325, DOI 10.1093/carcin/bgh011; Zhai Y, 2002, AM J PATHOL, V160, P1229, DOI 10.1016/S0002-9440(10)62550-3	53	98	100	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3346	3356		10.1038/sj.onc.1209357	http://dx.doi.org/10.1038/sj.onc.1209357			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16449976				2022-12-28	WOS:000237951200013
J	Yamada, HY; Gorbsky, GJ				Yamada, HY; Gorbsky, GJ			Tumor suppressor candidate TSSC5 is regulated by UbcH6 and a novel ubiquitin ligase RING105	ONCOGENE			English	Article						TSSC5; protease associated; RING finger; ubiquitin ligase; UbcH6; 11p15.5	RETICULUM-ASSOCIATED DEGRADATION; CHROMOSOME 11P15.5; POLYSPECIFIC TRANSPORTER; IMPRINTED GENE; PROTEIN; IDENTIFICATION; KINETOCHORES; ASSOCIATION; PROTEOLYSIS; MUTATIONS	The region of human chromosome 11p15.5 is linked with Beckwith-Wiedemann syndrome that is associated with susceptibility to Wilms' tumor, rhabdomyosarcoma and hepatoblastoma. TSSC5 (tumor-suppressing subchromo-somal transferable fragment cDNA; also known as ORCTL2/IMPT1/BWR1A/SLC22A1L) is located in the region. The expression of TSSC5 and other genes in the region is regulated through paternal imprinting. Mutations and/or reduced expression of TSSC5 have been found in certain tumors. TSSC5 encodes an efflux transporter-like protein with 10 transmembrane domains, whose regulation may affect drug sensitivity, cellular metabolism and growth. Here, we present evidences indicating that RING105, a novel conserved RING-finger protein with a PA (protease-associated) domain and a PEST sequence, is a ubiquitin ligase for TSSC5 that can function in concert with the ubiquitin-conjugating enzyme UbcH6. The polyubiquitin target site on TSSC5 was mapped to a region in the 6th hydrophilic loop. Ectopic expression of RING105 in HeLa cells caused an accumulation of cells during G1 that was not observed with the expression of a form of RING105 in which a residue within the RING finger was mutated to inactivate its ligase activity. UbcH6-RING105 may de. ne a novel ubiquitin-proteasome pathway that targets TSSC5 in mammalian cells.	OMRF, Mol Cell & Dev Biol Res Program, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation	Yamada, HY (corresponding author), OMRF, Mol Cell & Dev Biol Res Program, 825 NE 13th St MS48, Oklahoma City, OK 73104 USA.	Hiroshi-yamada@omrf.ouhsc.edu		Yamada, Hiroshi/0000-0002-0536-5581; Gorbsky, Gary/0000-0003-3076-4725	NIGMS NIH HHS [R01-GM50412, R01 GM050412, R01 GM050412-07] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050412] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albrecht S, 2004, INT J CANCER, V111, P627, DOI 10.1002/ijc.20280; Almond JB, 2002, LEUKEMIA, V16, P433, DOI 10.1038/sj.leu.2402417; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Cooper PR, 1998, GENOMICS, V49, P38, DOI 10.1006/geno.1998.5221; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Dao D, 1998, HUM MOL GENET, V7, P597, DOI 10.1093/hmg/7.4.597; Feinberg AP, 1999, CANCER RES, V59, p1743S; FEINBERG AP, 1994, J CELL SCI, P7; Gilon T, 2000, MOL CELL BIOL, V20, P7214, DOI 10.1128/MCB.20.19.7214-7219.2000; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hirsch C, 2004, BBA-MOL CELL RES, V1695, P215, DOI 10.1016/j.bbamcr.2004.10.006; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; Kallio MJ, 2002, J CELL BIOL, V158, P841, DOI 10.1083/jcb.200201135; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; Lee MP, 1998, CANCER RES, V58, P4155; Lewis A, 2004, CURR BIOL, V14, pR284, DOI 10.1016/j.cub.2004.03.026; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; Mahon P, 2000, PROTEIN SCI, V9, P1930, DOI 10.1110/ps.9.10.1930; McCracken AA, 2003, BIOESSAYS, V25, P868, DOI 10.1002/bies.10320; Pagano M, 1997, FASEB J, V11, P1067, DOI 10.1096/fasebj.11.13.9367342; Paulsen M, 1998, HUM MOL GENET, V7, P1149, DOI 10.1093/hmg/7.7.1149; Poirier K, 2003, J PATHOL, V201, P473, DOI 10.1002/path.1477; Ptak C, 2001, MOL CELL BIOL, V21, P6537, DOI 10.1128/MCB.21.19.6537-6548.2001; Ravenel JD, 2001, JNCI-J NATL CANCER I, V93, P1698, DOI 10.1093/jnci/93.22.1698; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Reece M, 1998, FEBS LETT, V433, P245, DOI 10.1016/S0014-5793(98)00907-7; Romisch K, 2005, ANNU REV CELL DEV BI, V21, P435, DOI 10.1146/annurev.cellbio.21.012704.133250; Sagne C, 1996, BIOCHEM J, V316, P825, DOI 10.1042/bj3160825; Schwienbacher C, 1998, P NATL ACAD SCI USA, V95, P3873, DOI 10.1073/pnas.95.7.3873; Schwienbacher C, 2000, P NATL ACAD SCI USA, V97, P5445, DOI 10.1073/pnas.090087497; Topper LM, 2001, J CELL BIOL, V154, P707, DOI 10.1083/jcb.200104130	37	28	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1330	1339		10.1038/sj.onc.1209167	http://dx.doi.org/10.1038/sj.onc.1209167			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16314844	Green Accepted			2022-12-28	WOS:000235708200006
J	Pietsch, EC; Humbey, O; Murphy, ME				Pietsch, EC; Humbey, O; Murphy, ME			Polymorphisms in the p53 pathway	ONCOGENE			English	Review						p53; p21/ waf1; MDM2; polymorphism; apoptosis	DEPENDENT KINASE INHIBITOR; LUNG-CANCER SUSCEPTIBILITY; TUMOR-SUPPRESSOR GENE; CODON 72 POLYMORPHISM; SQUAMOUS-CELL CARCINOMA; GERM-LINE POLYMORPHISMS; FAMILIAL BREAST-CANCER; CERVICAL-CANCER; NASOPHARYNGEAL CARCINOMA; PROSTATE-CANCER	The p53 tumor suppressor gene continues to be distinguished as the most frequently mutated gene in human cancer; this gene can be found mutated in up to 50% of human tumors of diverse histological type. It is generally accepted that the ability of p53 to induce either growth arrest or programmed cell death in response to diverse stimuli underlies the powerful selection against this protein in the development of cancer. It is somewhat surprising, then, to find p53 and several target genes in this pathway containing polymorphisms that impair their function. The nature of these polymorphic variants, and the mechanism whereby they impair the function of the p53 pathway, are reviewed here-in. The impact of these polymorphisms on cancer risk and the efficacy of therapy are only now becoming unraveled. Of particular relevance in these efforts will be the generation of mouse models of polymorphic variants in p53 and its target genes. Equally important will be better-controlled human studies, wherein haplotypes for p53 (that is, combinations of different polymorphisms in the p53 gene) and for p53-target genes are taken into account, instead of analyses of single gene variants, which have largely predominated to date. Studies in both regards should shed light on an emerging area in cancer biology, the significance of inter-individual differences in genotype on cancer risk, prognosis, and the efficacy of cancer therapy.	Fox Chase Canc Ctr, Div Med Sci, Program Cell & Dev Biol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Murphy, ME (corresponding author), Fox Chase Canc Ctr, Div Med Sci, Program Cell & Dev Biol, 3333 Cottman Ave, Philadelphia, PA 19111 USA.	Maureen.Murphy@FCCC.edu		Murphy, Maureen/0000-0001-7644-7296				Arva NC, 2005, J BIOL CHEM, V280, P26776, DOI 10.1074/jbc.M505203200; Bahl R, 2000, ONCOGENE, V19, P323, DOI 10.1038/sj.onc.1203325; Bastiaens MT, 2001, MOL CARCINOGEN, V30, P56, DOI 10.1002/1098-2744(200101)30:1<56::AID-MC1013>3.0.CO;2-2; BECKMAN G, 1994, HUM HERED, V44, P266, DOI 10.1159/000154228; BHATIA K, 1995, CANCER RES, V55, P1431; Birgander R, 1996, HUM HERED, V46, P148, DOI 10.1159/000154344; Biros E, 2000, NEOPLASMA, V47, P303; Biros E, 2002, LUNG CANCER-J IASLC, V35, P231, DOI 10.1016/S0169-5002(01)00446-9; Biros E, 2001, LUNG CANCER, V31, P157, DOI 10.1016/S0169-5002(00)00188-4; Bonafe M, 2003, CLIN CANCER RES, V9, P4860; Bonafe M, 2002, BIOCHEM BIOPH RES CO, V299, P539, DOI 10.1016/S0006-291X(02)02691-8; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; BOUGEARD G, 2005, J MED GENET     1028; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buyru N, 2005, ANTICANCER RES, V25, P2767; Buyru N, 2003, ONCOL REP, V10, P711; CHEDID M, 1994, ONCOGENE, V9, P3021; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen WC, 2002, UROL ONCOL, V7, P63, DOI 10.1016/S1078-1439(01)00152-1; Chen YC, 2003, J ENVIRON SCI HEAL A, V38, P201, DOI 10.1081/ESE-120016889; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; de Oliveira WRP, 2004, INT J DERMATOL, V43, P489, DOI 10.1111/j.1365-4632.2004.02289.x; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Deshpande A, 2005, ONCOGENE, V24, P2909, DOI 10.1038/sj.onc.1208618; Dokianakis DN, 2000, INT J MOL MED, V5, P405; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FACHER EA, 1995, CANCER, V79, P2424; Fan R, 2000, CANCER EPIDEM BIOMAR, V9, P1037; FELLEYBOSCO E, 1993, AM J HUM GENET, V53, P752; Fiszer-Maliszewska L, 2003, J APPL GENET, V44, P547; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GAO X, 1995, ONCOGENE, V11, P1395; Gemignani F, 2004, ONCOGENE, V23, P1954, DOI 10.1038/sj.onc.1207305; GONG JZ, 1995, HEMATOL PATHOL, V9, P171; Gottschlich S, 2000, ANTICANCER RES, V20, P2613; Granja F, 2004, CANCER LETT, V210, P151, DOI 10.1016/j.canlet.2004.01.016; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Hachiya T, 1999, GYNECOL ONCOL, V72, P187, DOI 10.1006/gyno.1998.5247; Harima Y, 2001, INT J MOL MED, V7, P261; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; Henner WD, 2001, PROSTATE, V49, P263, DOI 10.1002/pros.10021; Hillebrandt S, 1997, MUTAT RES-FUND MOL M, V381, P201, DOI 10.1016/S0027-5107(97)00169-3; Huang SP, 2004, CANCER EPIDEM BIOMAR, V13, P2217; HUPPI K, 1994, ONCOGENE, V9, P3017; Jin SK, 2001, J CELL SCI, V114, P4139; Jones JS, 2004, CLIN CANCER RES, V10, P5845, DOI 10.1158/1078-0432.CCR-03-0590; Kang Shan, 2004, Zhonghua Fu Chan Ke Za Zhi, V39, P754; Kawaguchi H, 2000, CANCER RES, V60, P2753; Keshava C, 2002, CANCER EPIDEM BIOMAR, V11, P127; Khaliq S, 2000, GENET TEST, V4, P23, DOI 10.1089/109065700316435; Khrunin AV, 2005, MOL GENET GENOMICS, V272, P666, DOI 10.1007/s00438-004-1091-8; Kibel AS, 2003, CANCER RES, V63, P2033; Klug SJ, 2001, CANCER EPIDEM BIOMAR, V10, P1009; Konishi R, 2000, J DERMATOL SCI, V24, P177, DOI 10.1016/S0923-1811(00)00096-7; KOOPMANN J, 1995, BRIT J CANCER, V72, P1230, DOI 10.1038/bjc.1995.491; Koushik A, 2004, CANCER EPIDEM BIOMAR, V13, P11, DOI 10.1158/1055-9965.EPI-083-3; Kuroda Y, 2003, CANCER LETT, V189, P77, DOI 10.1016/S0304-3835(02)00518-9; Langerod A, 2002, CANCER EPIDEM BIOMAR, V11, P1684; LAW JC, 1995, HUM GENET, V95, P459; Lehman TA, 2000, CANCER RES, V60, P1062; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Li XX, 2005, J BIOL CHEM, V280, P24245, DOI 10.1074/jbc.M414637200; LI YJ, 1995, ONCOGENE, V10, P599; Lukas J, 1997, AM J PATHOL, V150, P167; Luo JL, 2001, ONCOGENE, V20, P320, DOI 10.1038/sj.onc.1204080; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Makni H, 2000, INT J CANCER, V87, P528, DOI 10.1002/1097-0215(20000815)87:4&lt;528::AID-IJC11&gt;3.0.CO;2-O; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; McKenzie KE, 1997, CLIN CANCER RES, V3, P1669; Milner BJ, 1996, EUR J CANCER, V32A, P2360, DOI 10.1016/S0959-8049(96)00306-1; Mitra S, 2005, J CLIN PATHOL, V58, P26, DOI 10.1136/jcp.2004.019315; MOUSSES S, 1995, HUM MOL GENET, V4, P1089, DOI 10.1093/hmg/4.6.1089; Nelson HH, 2005, CARCINOGENESIS, V26, P1770, DOI 10.1093/carcin/bgi125; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ohayon T, 2005, BRIT J CANCER, V92, P1144, DOI 10.1038/sj.bjc.6602451; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Pegoraro RJ, 2002, INT J GYNECOL CANCER, V12, P383, DOI 10.1046/j.1525-1438.2002.01109.x; Phelps M, 2003, CANCER RES, V63, P2616; Pim D, 2004, INT J CANCER, V108, P196, DOI 10.1002/ijc.11548; Powell BL, 2002, CARCINOGENESIS, V23, P311, DOI 10.1093/carcin/23.2.311; Ralhan R, 2000, CLIN CANCER RES, V6, P2440; RODRIGUES FC, CANC GENET CYTOGENET, V142, P92; Roh JW, 2004, GYNECOL ONCOL, V93, P499, DOI 10.1016/j.ygyno.2004.02.005; Roh JW, 2001, CANCER LETT, V165, P59, DOI 10.1016/S0304-3835(01)00401-3; RUNNEBAUM IB, 1995, LANCET, V345, P994, DOI 10.1016/S0140-6736(95)90745-9; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Schuler M, 2005, TRENDS GENET, V21, P182, DOI 10.1016/j.tig.2005.01.001; Shen HB, 2004, ONCOL REP, V11, P1115; Shen HB, 2003, J INVEST DERMATOL, V121, P1510, DOI 10.1046/j.1523-1747.2003.12648.x; Shen HB, 2002, CANCER LETT, V183, P123, DOI 10.1016/S0304-3835(02)00117-9; Shi Y, 1996, BRIT J CANCER, V74, P1336, DOI 10.1038/bjc.1996.546; Shih CM, 2000, JPN J CANCER RES, V91, P9, DOI 10.1111/j.1349-7006.2000.tb00854.x; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; Sjalander A, 1996, HUM HERED, V46, P221, DOI 10.1159/000154357; SJALANDER A, 1995, HUM HERED, V45, P144, DOI 10.1159/000154275; Soulitzis N, 2002, CANCER LETT, V179, P175, DOI 10.1016/S0304-3835(01)00867-9; Sourvinos G, 2001, ORAL ONCOL, V37, P572, DOI 10.1016/S1368-8375(00)00139-1; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Su L, 2003, LUNG CANCER-J IASLC, V40, P259, DOI 10.1016/S0169-5002(03)00081-3; Su L, 2003, CANCER EPIDEM BIOMAR, V12, P174; Sullivan A, 2004, ONCOGENE, V23, P3328, DOI 10.1038/sj.onc.1207428; SUN Y, 1995, CANCER EPIDEM BIOMAR, V4, P261; Suzuki K, 2003, J BIOMED SCI, V10, P430, DOI 10.1159/000071162; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Terry LA, 1996, MOL CARCINOGEN, V16, P221, DOI 10.1002/(SICI)1098-2744(199608)16:4<221::AID-MC6>3.0.CO;2-I; Thomas M, 1999, MOL CELL BIOL, V19, P1092; Tiwawech D, 2003, CANCER LETT, V198, P69, DOI 10.1016/S0304-3835(03)00283-0; Tommiska J, 2005, CLIN CANCER RES, V11, P5098, DOI 10.1158/1078-0432.CCR-05-0173; Tsai MH, 2002, J CLIN LAB ANAL, V16, P146, DOI 10.1002/jcla.10032; Tsai MH, 2002, LARYNGOSCOPE, V112, P116, DOI 10.1097/00005537-200201000-00020; Vikhanskaya F, 2005, CLIN CANCER RES, V11, P4348, DOI 10.1158/1078-0432.CCR-04-1547; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wan M, 1996, BRIT J CANCER, V73, P1398, DOI 10.1038/bjc.1996.265; Wang YC, 1999, CLIN CANCER RES, V5, P129; Wang-Gohrke S, 1999, BRIT J CANCER, V81, P179, DOI 10.1038/sj.bjc.6690669; Weston A, 1997, ENVIRON HEALTH PERSP, V105, P919, DOI 10.2307/3433304; Wu MT, 2004, CANCER LETT, V205, P61, DOI 10.1016/j.canlet.2003.11.026; Wu MT, 2003, CANCER LETT, V201, P175, DOI 10.1016/S0304-3835(03)00469-5; Wu XF, 2002, JNCI-J NATL CANCER I, V94, P681; Xi YG, 2004, CARCINOGENESIS, V25, P2201, DOI 10.1093/carcin/bgh229; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu Y, 2005, CLIN CANCER RES, V11, P7328, DOI 10.1158/1078-0432.CCR-05-0507; Zhang Jian-hui, 2003, Zhonghua Zhongliu Zazhi, V25, P365	134	185	190	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	11					1602	1611		10.1038/sj.onc.1209367	http://dx.doi.org/10.1038/sj.onc.1209367			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020JL	16550160				2022-12-28	WOS:000235904700002
J	Balkhi, MY; Trivedi, AK; Geletu, M; Christopeit, M; Bohlander, SK; Behre, HM; Behre, G				Balkhi, M. Y.; Trivedi, A. K.; Geletu, M.; Christopeit, M.; Bohlander, S. K.; Behre, H. M.; Behre, G.			Proteomics of acute myeloid leukaemia: cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications	ONCOGENE			English	Article						acute myeloid leukaemia; proteomics; post-translational modification; mass spectrometry	N-ARGININE METHYLATION; C/EBP-ALPHA; O-GLCNAC; EXPRESSION; CANCER; IDENTIFICATION; GLYCOSYLATION; SUPPRESSES; DISEASE; CEBPA	Acute myeloid leukaemia (AML) is characterized by specific cytogenetic aberrations that are strong determinants of prognostic outcome and therapeutic response. Because the pathological outcome of AML patients with cytogenetic abnormalities differs considerably, we hypothesized that their proteome may also differ specifically in their expression pattern, protein interaction pathways and post-translational modifications (PTM). We performed this study using 42 AML patients diagnosed for various cytogenetic abnormalities based on two-dimensional gel electrophoresis and matrix-assisted laser desorption/ ionization time of flight mass spectrometry (MS) and MSMS tandem MS. We could identify signi. cant differences in the proteome and PTM of peptides, later confirmed by other methods, between cytogenetic groups. The interactome analysis based on computational bioinformatics reveals major regulating networks: MAPK8 and MYC for complex aberrant karyotype, TP53 for t(8; 21), TP53-MYC-PRKAC for 11q23 and JUN and MYC for Inv(16). Further, we analysed 42 MS spectra representative of hnRNPH1, calreticulin and hnRNPA2/ B1 in a peak explorer, which reveals a cytogenetic-specific PTM of beta-O-linked N-acetyl glucosamine (O-GlcNAc) of hnRNPH1 in AML patients with 11q23 translocation, an acetylation of calreticulin in t(8; 21) translocation and methylation of hnRNPA2/ B1 in patients with translocations of t(8; 21) and inv(16). This report may lead to a new thinking about AML pathogenesis, as differences at PTM level could be used to distinguish different subtypes of AML.	Univ Halle Wittenberg, Bone Marrow Transplantat Sect, Dept Internal Med Hematol & Oncol 4, State Ctr Cell & Gene Therapy, D-06097 Halle, Germany; Univ Munich, Dept Med 3, Munich, Germany; Univ Halle Wittenberg, Dept Urol, Androl Sect, D-06097 Halle, Germany	Martin Luther University Halle Wittenberg; University of Munich; Martin Luther University Halle Wittenberg	Behre, G (corresponding author), Univ Halle Wittenberg, Bone Marrow Transplantat Sect, Dept Internal Med Hematol & Oncol 4, State Ctr Cell & Gene Therapy, Ernst Grube Str 40, D-06097 Halle, Germany.	gerhard.behre@medizin.uni-halle.de	Trivedi, Arun Kumar/W-1883-2019	Trivedi, Arun Kumar/0000-0002-6316-0947; Bohlander, Stefan/0000-0002-2202-9088; Christopeit, Maximilian/0000-0003-4627-0412				Bienz M, 2005, CLIN CANCER RES, V11, P1416, DOI 10.1158/1078-0432.CCR-04-1552; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; Cristea IM, 2004, BLOOD, V103, P3624, DOI 10.1182/blood-2003-09-3295; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Gurbuxani S, 2005, P NATL ACAD SCI USA, V102, P11480, DOI 10.1073/pnas.0500303102; Haferlach T., 2004, Annals of Hematology, V83, pS97; Helbling D, 2005, BLOOD, V106, P1369, DOI 10.1182/blood-2004-11-4392; Helbling D, 2004, P NATL ACAD SCI USA, V101, P13312, DOI 10.1073/pnas.0404731101; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; IGARASHI K, 1995, P NATL ACAD SCI USA, V92, P7445, DOI 10.1073/pnas.92.16.7445; Khidekel N, 2004, P NATL ACAD SCI USA, V101, P13132, DOI 10.1073/pnas.0403471101; Li C, 1998, ARCH BIOCHEM BIOPHYS, V351, P53, DOI 10.1006/abbi.1997.0526; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lin CH, 2000, J BIOCHEM, V128, P493, DOI 10.1093/oxfordjournals.jbchem.a022779; Lominadze G, 2005, J IMMUNOL, V174, P7257, DOI 10.4049/jimmunol.174.11.7257; Mann M, 2003, NAT BIOTECHNOL, V21, P255, DOI 10.1038/nbt0303-255; Marcucci G, 2004, J CLIN ONCOL, V22, P2410, DOI 10.1200/JCO.2004.03.023; Nedelkov D, 2005, P NATL ACAD SCI USA, V102, P10852, DOI 10.1073/pnas.0500426102; Petricoin EF, 2005, J CLIN ONCOL, V23, P3614, DOI 10.1200/JCO.2005.02.509; Sagil D, 2005, PROTEOMICS, V5, P2689, DOI 10.1002/pmic.200401312; Satterwhite E, 2001, BLOOD, V98, P3413, DOI 10.1182/blood.V98.12.3413; Schoch C, 2005, GENE CHROMOSOME CANC, V43, P227, DOI 10.1002/gcc.20193; Timchenko LT, 2002, MOL CELL BIOL, V22, P7242, DOI 10.1128/MCB.22.20.7242-7257.2002; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Vosseller K, 2001, BIOCHIMIE, V83, P575, DOI 10.1016/S0300-9084(01)01295-0; Wang ZF, 2004, CELL, V119, P831, DOI 10.1016/j.cell.2004.11.010; Wells L, 2003, BIOCHEM BIOPH RES CO, V302, P435, DOI 10.1016/S0006-291X(03)00175-X; Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481; Zhou J, 2001, LUNG CANCER, V34, P341, DOI 10.1016/S0169-5002(01)00254-9	29	40	43	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2006	25	53					7041	7058		10.1038/sj.onc.1209689	http://dx.doi.org/10.1038/sj.onc.1209689			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16732326				2022-12-28	WOS:000241910500004
J	Burks, J; Agazie, YM				Burks, J.; Agazie, Y. M.			Modulation of alpha-catenin Tyr phosphorylation by SHP2 positively effects cell transformation induced by the constitutively active FGFR3	ONCOGENE			English	Article						FGFR3; SHP2; alpha catenin; transformation; adhesion; migration	GROWTH-FACTOR RECEPTOR; PROTEIN-TYROSINE PHOSPHATASES; E-CADHERIN; KINASE ACTIVATION; SKELETAL DYSPLASIA; INSULIN-RECEPTOR; BETA-CATENIN; P120 CATENIN; SH2 DOMAINS; MAP KINASE	The Src homology 2 phosphotyrosyl phosphatase (SHP2) is a nonreceptor-type phosphatase that acts as a positive transducer of receptor Tyr kinase (RTK) signaling, particularly the Ras-REK and PI3K-Akt pathways. Recently, we have demonstrated that SHP2 is required for cell transformation induced by the constitutively active fibroblast growth factor receptor 3 (K/E-FR3) (Oncogene, 22, 6909 -6918). In that study, we had detected a phosphotyrosyl protein of similar to 100 KDa (p100) in cells expressing dominant-negative SHP2 (R/ E-SHP2), but its identity and relevance in SHP2-meditaed transformation was not known. Here, we report the identification of p100 as alpha-catenin, a vinculin-related protein involved in adherens junction-mediated intercellular adhesion. We show that a-catenin becomes Tyr phosphorylated in intercellular adhesion-dependent manner and this event is counteracted by SHP2. Substrate trapping in intact cells and immunocomplex phosphatse assays confirmed that a-catenin is in deed an SHP2 substrate. Tyr phosphorylation of alpha-catenin enhances its translocation to the plasma membrane and its interaction with beta-catenin, leading to enhanced actin polymerization and stabilization of adherens junction-mediated intercellular adhesion, a phenomenon commensurate with loss of the transformation phenotype. Site-directed mutagenesis studies also suggested that Tyr phosphorylation of a-catenin enhances its inhibitory role on cell transformation. Based on our previous work and the current report, we demonstrate that mediation of cell transformation by SHP2 is a complex process that involves modulation of the Ras-ERK and PI3K-Akt signaling pathways, intercellular adhesion, focal adhesion and actin cytoskeletal reorganization. To our knowledge, this is the first report showing regulation of a-catenin function by Tyr phosphorylation and its inhibitory effect on cell transformation.	W Virginia Univ, Dept Mol Pharmacol & Biochem, Robert C Byrd Hlth Sci Ctr, Morgantown, WV 26506 USA; W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA	West Virginia University; West Virginia University	Agazie, YM (corresponding author), W Virginia Univ, Dept Mol Pharmacol & Biochem, Robert C Byrd Hlth Sci Ctr, Morgantown, WV 26506 USA.	yagazie@hsc.wvu.edu	Ladoux, Benoit/A-9879-2013					Aberle H, 1996, J BIOL CHEM, V271, P1520, DOI 10.1074/jbc.271.3.1520; ABERLE H, 1994, J CELL SCI, V107, P3655; Abutaily AS, 2003, J PATHOL, V201, P355, DOI 10.1002/path.1458; Agazie Y, 2002, ONCOGENE, V21, P697, DOI 10.1038/sj.onc.1205115; Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; Agazie YM, 2003, ONCOGENE, V22, P6909, DOI 10.1038/sj.onc.1206798; Agazie YM, 2003, J BIOL CHEM, V278, P13952, DOI 10.1074/jbc.M210670200; Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Araki T, 2003, J BIOL CHEM, V278, P41677, DOI 10.1074/jbc.M306461200; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Bellus GA, 2000, AM J HUM GENET, V67, P1411, DOI 10.1086/316892; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Bentires-Alj M, 2004, CANCER RES, V64, P8816, DOI 10.1158/0008-5472.CAN-04-1923; Bullions LC, 1997, MOL CELL BIOL, V17, P4501, DOI 10.1128/MCB.17.8.4501; Cleghon V, 1998, MOL CELL, V2, P719, DOI 10.1016/S1097-2765(00)80287-7; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Deb TB, 1998, J BIOL CHEM, V273, P16643, DOI 10.1074/jbc.273.27.16643; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Frearson JA, 1998, J EXP MED, V187, P1417, DOI 10.1084/jem.187.9.1417; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hakak Y, 2000, ONCOGENE, V19, P3164, DOI 10.1038/sj.onc.1203655; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Hu PQ, 2001, J INVEST DERMATOL, V117, P1059, DOI 10.1046/j.0022-202x.2001.01523.x; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Inagaki K, 2000, EMBO J, V19, P6721, DOI 10.1093/emboj/19.24.6721; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Kapus A, 2000, J BIOL CHEM, V275, P32289, DOI 10.1074/jbc.M003172200; Kobielak A, 2004, NAT REV MOL CELL BIO, V5, P614, DOI 10.1038/nrm1433; Kodama A, 2000, MOL BIOL CELL, V11, P2565, DOI 10.1091/mbc.11.8.2565; Krautwald S, 1996, MOL CELL BIOL, V16, P5955; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Lacalle RA, 2002, J CELL BIOL, V157, P277, DOI 10.1083/jcb.200109031; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; Merdek KD, 2004, MOL CELL BIOL, V24, P2410, DOI 10.1128/MCB.24.6.2410-2422.2004; Mohi MG, 2005, CANCER CELL, V7, P179, DOI 10.1016/j.ccr.2005.01.010; MORTON RA, 1993, CANCER RES, V53, P3585; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; O'Reilly AM, 2000, MOL CELL BIOL, V20, P299, DOI 10.1128/MCB.20.1.299-311.2000; Ozawa M, 2001, J CELL SCI, V114, P503; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Saxton TM, 2000, NAT GENET, V24, P420, DOI 10.1038/74279; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Seki N, 2002, ARTERIOSCL THROM VAS, V22, P1081, DOI 10.1161/01.ATV.0000022878.37277.EC; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Tavormina PL, 1999, AM J HUM GENET, V64, P722, DOI 10.1086/302275; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; Tonks NK, 2003, FEBS LETT, V546, P140, DOI 10.1016/S0014-5793(03)00603-3; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X	59	28	30	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	54					7166	7179		10.1038/sj.onc.1209728	http://dx.doi.org/10.1038/sj.onc.1209728			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16767162				2022-12-28	WOS:000242046900006
J	Martel, V; Filhol, O; Colas, P; Cochet, C				Martel, V.; Filhol, O.; Colas, P.; Cochet, C.			p53-dependent inhibition of mammalian cell survival by a genetically selected peptide aptamer that targets the regulatory subunit of protein kinase CK2	ONCOGENE			English	Article						CK2 beta subunit; peptidic inhibitors; IE2 protein; p53 activation; cell apoptosis	HETEROGENEOUS RIBONUCLEOPROTEIN-K; BETA-SUBUNIT; ALPHA-SUBUNIT; DNA-DAMAGE; INDUCED APOPTOSIS; CRYSTAL-STRUCTURE; CK2-BETA SUBUNIT; P53; EXPRESSION; BINDING	Based on the perturbation of its expression in human cancers and on its involvement in transformation and tumorigenesis, protein kinase CK2 has recently attracted attention as a potential therapeutic target. To assess the value of CK2 as a target for antiproliferative strategies, we have initiated a program aiming to develop inhibitors targeting specifically the regulatory CK2 beta subunit. Here, we use a two-hybrid approach to isolate from combinatorial libraries, peptide aptamers that specifically interact with CK2b. One of these (P1), which has significant sequence homology to the cytomegalovirus IE2 protein, binds with high affinity to the N-terminal domain of CK2b without disrupting the formation of the CK2 holoenzyme. Expression of green fluorescent protein (GFP)-P1 in different mammalian cell lines activates p53 phosphorylation on serine 15, induces an upregulation of p21 and the release of the Cyt-C and apoptosis-inducing factor proapoptotic proteins triggering caspase-dependent and caspase-independent apoptosis. GFP-P1-induced apoptosis is associated with a p53-dependent pathwayas cell death was abrogated in p53 knocked out cells. In summary, our data show that genetically selected peptide aptamers that specifically target CK2b can induce apoptosis in mammalian cells through the recruitment of a p53-dependent apoptosis pathway. They also emphasize the critical role of CK2b for cell survival and might allow the design of novel proapoptotic agents targeting this protein.	CEA, INSERM EMI0104, Dept Reponse & Dynam Cellulaire, F-38054 Grenoble, France; Aptanomics SA, Lyon, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)	Cochet, C (corresponding author), CEA, INSERM EMI0104, Dept Reponse & Dynam Cellulaire, 17 Rue Martyrs, F-38054 Grenoble, France.	ccochet1@cea.fr	Martel-Frachet, Veronique/B-8657-2014; Filhol-Cochet, Odile/I-3962-2016; Frachet, Véronique/B-8418-2018	Frachet, Véronique/0000-0001-6739-7901; Filhol, Odile/0000-0003-1964-7958; Colas, Pierre/0000-0001-7436-3718; Cochet, Claude/0000-0002-1772-4270				Abraham MC, 2004, TRENDS CELL BIOL, V14, P184, DOI 10.1016/j.tcb.2004.03.002; Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; Andreau K, 2004, J BIOL CHEM, V279, P55937, DOI 10.1074/jbc.M406411200; Bibby AC, 2005, INT J BIOL SCI, V1, P67; Bjorling-Poulsen M, 2005, ONCOGENE, V24, P6194, DOI 10.1038/sj.onc.1208762; Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; Buchou T, 2003, MOL CELL BIOL, V23, P908, DOI 10.1128/MCB.23.3.908-915.2003; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Chantalat L, 1999, EMBO J, V18, P2930, DOI 10.1093/emboj/18.11.2930; Chiou SH, 2001, J IMMUNOL, V167, P4098, DOI 10.4049/jimmunol.167.7.4098; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Colman-Lerner A, 2001, CELL, V107, P739, DOI 10.1016/S0092-8674(01)00596-7; Dagher MC, 1997, BIOTECHNIQUES, V22, P916, DOI 10.2144/97225st05; DOBROWOLSKA G, 1992, EUR J BIOCHEM, V204, P299, DOI 10.1111/j.1432-1033.1992.tb16637.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Fabbrizio E, 1999, ONCOGENE, V18, P4357, DOI 10.1038/sj.onc.1202825; Ferri KF, 2000, NAT CELL BIOL, V2, pE63, DOI 10.1038/35008692; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; Filhol O, 2004, EMBO REP, V5, P351, DOI 10.1038/sj.embor.7400115; Filhol O, 2003, MOL CELL BIOL, V23, P975, DOI 10.1128/MCB.23.3.975-987.2003; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Geyer CR, 2000, METHOD ENZYMOL, V328, P171, DOI 10.1016/S0076-6879(00)28398-5; Ghavidel A, 2001, CELL, V106, P575, DOI 10.1016/S0092-8674(01)00473-1; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; Grein S, 1999, MOL CELL BIOCHEM, V191, P105, DOI 10.1023/A:1006814428582; Guerra B, 1999, FEBS LETT, V462, P353, DOI 10.1016/S0014-5793(99)01553-7; Guerra B, 1999, PHARMACOL THERAPEUT, V82, P303, DOI 10.1016/S0163-7258(98)00064-3; Guerra B, 2003, ONCOGENE, V22, P4933, DOI 10.1038/sj.onc.1206721; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; Leroy D, 1999, MOL CELL BIOCHEM, V191, P43, DOI 10.1023/A:1006832312169; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Loizou JI, 2004, CELL, V117, P17, DOI 10.1016/S0092-8674(04)00206-5; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Luo H, 2004, MOL CELL BIOL, V24, P8356, DOI 10.1128/MCB.24.19.8356-8365.2004; Maizel A, 2002, DEVELOPMENT, V129, P3545; Martel V, 2002, ANN NY ACAD SCI, V973, P272, DOI 10.1111/j.1749-6632.2002.tb04648.x; MESSERLE M, 1991, J VIROL, V65, P1638, DOI 10.1128/JVI.65.3.1638-1643.1991; Niefind K, 2001, EMBO J, V20, P5320, DOI 10.1093/emboj/20.19.5320; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Ruzzene M, 2002, BIOCHEM J, V364, P41, DOI 10.1042/bj3640041; Shimada K, 2004, MICROBIOL IMMUNOL, V48, P205, DOI 10.1111/j.1348-0421.2004.tb03507.x; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; STIGARE J, 1993, MOL CELL BIOCHEM, V129, P77, DOI 10.1007/BF00926578; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Theis-Febvre N, 2003, ONCOGENE, V22, P220, DOI 10.1038/sj.onc.1206107; Unger GM, 2004, CURR CANCER DRUG TAR, V4, P77, DOI 10.2174/1568009043481687; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wadd S, 1999, J BIOL CHEM, V274, P28991, DOI 10.1074/jbc.274.41.28991; Wiebusch L, 2001, EMBO J, V20, P1086, DOI 10.1093/emboj/20.5.1086; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zhou MM, 1995, J BIOL CHEM, V270, P31119, DOI 10.1074/jbc.270.52.31119	60	20	21	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	56					7343	7353		10.1038/sj.onc.1209722	http://dx.doi.org/10.1038/sj.onc.1209722			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16751801				2022-12-28	WOS:000242419100003
J	Paruchuri, S; Mezhybovska, M; Juhas, M; Sjolander, A				Paruchuri, S.; Mezhybovska, M.; Juhas, M.; Sjolander, A.			Endogenous production of leukotriene D-4 mediates autocrine survival and proliferation via CysLT(1) receptor signalling in intestinal epithelial cells	ONCOGENE			English	Article						CysLT(1) receptor; apoptosis; caspase-3; epithelial cells	CANCER; DISRUPTION; INHIBITORS; APOPTOSIS; PROTEIN	The cysteinyl leukotriene(1) (CysLT(1)) receptor (CysLT(1)R) enhances survival and proliferation of intestinal cells via distinct pathways. Here, we have demonstrated that there is significant endogenous production of CysLTs from both non-tumour-and tumour-derived intestinal epithelial cells. Treatment of two non-tumour cell lines, Int 407 and IEC-6, with CysLT1R antagonists led to shrinkage and detachment of cells, confirmed as apoptotic cell death, and a dose-dependent reduction in proliferation. However, in the tumour intestinal cell lines Caco-2, SW480, HCT-116 and HT-29, treatment with CysLT1R antagonists significantly reduced proliferation, but had no effect on apoptosis. A unique characteristic of intestinal cancer cells is the presence of nuclear CysLT(1)Rs, which are inaccessible to receptor antagonists. In these cells, inhibition of the endogenous production of CysLTs indirectly, by 5-lipoxygenase inhibition, impaired CysLT1R signalling throughout the cell, and resulted in apoptosis of the tumour cells. These data reveal the existence of constitutive CysLT1R signalling that mediates both survival and proliferation in intestinal cells. Importantly, we propose that tumour-derived intestinal cells are resistant to CysLT(1)R antagonist-induced apoptosis, a phenomena that could be explained by nuclear CysLT1R signalling.	Lund Univ, Malmo Univ Hosp, Dept Lab Med, SE-20502 Malmo, Sweden	Lund University; Skane University Hospital	Sjolander, A (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Lab Med, SE-20502 Malmo, Sweden.	anita.sjolander@exppat.mas.lu.se						Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; Claesson HE, 1999, J INTERN MED, V245, P205, DOI 10.1046/j.1365-2796.1999.00418.x; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Ghosh J, 1998, P NATL ACAD SCI USA, V95, P13182, DOI 10.1073/pnas.95.22.13182; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Hennig R, 2004, CANCER LETT, V210, P41, DOI 10.1016/j.canlet.2004.02.023; Lee E, 2000, AM J RESP CRIT CARE, V161, P1881, DOI 10.1164/ajrccm.161.6.9907054; Lynch KR, 1999, NATURE, V399, P789; Maekawa A, 2002, J BIOL CHEM, V277, P20820, DOI 10.1074/jbc.M203163200; Mann JR, 2004, CANCER J, V10, P145, DOI 10.1097/00130404-200405000-00001; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Nielsen CK, 2005, CANCER RES, V65, P732; Ohd JF, 2000, GASTROENTEROLOGY, V119, P1007, DOI 10.1053/gast.2000.18141; Ohd JF, 2003, GASTROENTEROLOGY, V124, P57, DOI 10.1053/gast.2003.50011; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; Pachernik J, 2002, ARCH DERMATOL RES, V293, P626, DOI 10.1007/s00403-001-0288-5; Paruchuri S, 2003, J BIOL CHEM, V278, P45577, DOI 10.1074/jbc.M302881200; Paruchuri S, 2002, J CELL SCI, V115, P1883; Shi ZZ, 2001, MOL CELL BIOL, V21, P5389, DOI 10.1128/MCB.21.16.5389-5395.2001; Wkstrom K, 2003, BIOCHEM J, V371, P115; Wu X, 2003, CELL BIOL TOXICOL, V19, P135, DOI 10.1023/A:1024789810277	21	45	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	50					6660	6665		10.1038/sj.onc.1209666	http://dx.doi.org/10.1038/sj.onc.1209666			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16715140				2022-12-28	WOS:000241569700010
J	Bindels, S; Mestdagt, M; Vandewalle, C; Jacobs, N; Volders, L; Noel, A; van Roy, F; Berx, G; Foidart, JM; Gilles, C				Bindels, S.; Mestdagt, M.; Vandewalle, C.; Jacobs, N.; Volders, L.; Noel, A.; van Roy, F.; Berx, G.; Foidart, J-M; Gilles, C.			Regulation of vimentin by SIP1 in human epithelial breast tumor cells	ONCOGENE			English	Article						vimentin; SIP1; cell migration	SMAD-INTERACTING PROTEIN-1; REPRESSES E-CADHERIN; INTERMEDIATE-FILAMENTS; BETA-CATENIN; MESENCHYMAL TRANSITIONS; TRANSCRIPTION FACTORS; SNAIL; EXPRESSION; GENE; INVASION	The expression of Smad interacting protein-1 (SIP1; ZEB2) and the de novo expression of vimentin are frequently involved in epithelial-to-mesenchymal transitions (EMTs) under both normal and pathological conditions. In the present study, we investigated the potential role of SIP1 in the regulation of vimentin during the EMT associated with breast tumor cell migration and invasion. Examining several breast tumor cell lines displaying various degrees of invasiveness, we found SIP1 and vimentin expression only in invasive cell lines. Also, using a model of cell migration with human mammary MCF10A cells, we showed that SIP1 is induced specifically in vimentin-positive migratory cells. Furthermore, transfection of SIP1 cDNA in MCF10A cells increased their vimentin expression both at the mRNA and protein levels and enhanced their migratory abilities in Boyden Chamber assays. Inversely, inhibition of SIP1 expression by RNAi strategies in BT-549 cells and MCF10A cells decreased vimentin expression. We also showed that SIP1 transfection did not activate the TOP-FLASH reporter system, suggesting that the beta-catenin/TCF pathway is not implicated in the regulation of vimentin by SIP1. Our results therefore implicate SIP1 in the regulation of vimentin observed in the EMT associated with breast tumor cell migration, a pathway that may contribute to the metastatic progression of breast cancer.	Univ Liege, CHU Sart Tilman, Lab Tumor & Dev Biol, Ctr Biomed Integrated Genoproteom, B-4000 Liege, Belgium; Univ Ghent VIB, Dept Mol Biomed Res, B-9000 Ghent, Belgium; Univ Liege, CHU Sart Tilman, Lab Anatomopathol, Ctr Biomed Integrated Genoproteom, B-4000 Liege, Belgium	University of Liege; Flanders Institute for Biotechnology (VIB); Ghent University; University of Liege	Gilles, C (corresponding author), Univ Liege, CHU Sart Tilman, Lab Tumor & Dev Biol, Ctr Biomed Integrated Genoproteom, Tour Pathol B23, B-4000 Liege, Belgium.	cgilles@ulg.ac.be	van Roy, Frans M/C-6123-2009	van Roy, Frans M/0000-0003-4358-1039; Noel, Agnes/0000-0002-7670-6179; Jacobs, Nathalie/0000-0002-9895-8465; Berx, Geert/0000-0001-5770-2458				Bienz M, 2005, CURR BIOL, V15, pR64, DOI 10.1016/j.cub.2004.12.058; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Come C, 2004, J MAMMARY GLAND BIOL, V9, P183, DOI 10.1023/B:JOMG.0000037161.91969.de; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Duband JL, 1995, ACTA ANAT, V154, P63; Eckes B, 1998, J CELL SCI, V111, P1897; Eckes B, 2000, J CELL SCI, V113, P2455; Eisaki A, 2000, BIOCHEM BIOPH RES CO, V271, P151, DOI 10.1006/bbrc.2000.2545; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gilles C, 1999, J CELL SCI, V112, P4615; Gilles C, 2003, CANCER RES, V63, P2658; Gilles C, 1996, BREAST JOURNAL, VOL 2, NO 1, JANUARY/FEBRUARY 1996, P83; GILLES C, 2004, RISE FALL EPITHELIAL, pCH2; Goldman RD, 1999, FASEB J, V13, pS261, DOI 10.1096/fasebj.13.9002.S261; Gonzales M, 2001, MOL BIOL CELL, V12, P85, DOI 10.1091/mbc.12.1.85; Gotzmann J, 2004, MUTAT RES-REV MUTAT, V566, P9, DOI 10.1016/S1383-5742(03)00033-4; GUARINO M, 1995, HISTOL HISTOPATHOL, V10, P171; Hajra KM, 2002, CANCER RES, V62, P1613; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; Helfand BT, 2004, J CELL SCI, V117, P133, DOI 10.1242/jcs.00936; Hendrix MJC, 1997, AM J PATHOL, V150, P483; Hendrix MJC, 1996, CANCER METAST REV, V15, P507, DOI 10.1007/BF00054016; Homan SM, 1998, J CELL SCI, V111, P2717; Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kreis S, 2005, EXP CELL RES, V305, P110, DOI 10.1016/j.yexcr.2004.12.023; Maeda M, 2005, J CELL SCI, V118, P873, DOI 10.1242/jcs.01634; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; Million K, 2001, AM J RESP CELL MOL, V25, P744, DOI 10.1165/ajrcmb.25.6.4549; Miyoshi A, 2004, BRIT J CANCER, V90, P1265, DOI 10.1038/sj.bjc.6601685; NAWROCKI RB, 2001, INT J CANCER, V93, P644; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Ohkubo T, 2004, J CELL SCI, V117, P1675, DOI 10.1242/jcs.01004; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp; RAMAEKERS FCS, 1983, P NATL ACAD SCI-BIOL, V80, P2618, DOI 10.1073/pnas.80.9.2618; Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Singh S, 2003, CANCER RES, V63, P2306; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo-reports/kvf002; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Svitkina TM, 1996, J CELL BIOL, V135, P991, DOI 10.1083/jcb.135.4.991; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Tsuruta D, 2003, J CELL SCI, V116, P4977, DOI 10.1242/jcs.00823; Tucker RP, 2004, INT J BIOCHEM CELL B, V36, P173, DOI 10.1016/S1357-2725(03)00243-7; Ui-Tei K, 2004, NUCLEIC ACIDS RES, V32, P936, DOI 10.1093/nar/gkh247; Van Aken E, 2001, VIRCHOWS ARCH, V439, P725, DOI 10.1007/S004280100516; Van de Putte T, 2003, AM J HUM GENET, V72, P465, DOI 10.1086/346092; van Grunsven LA, 2003, J BIOL CHEM, V278, P26135, DOI 10.1074/jbc.M300597200; van Grunsven LA, 2000, MECH DEVELOP, V94, P189, DOI 10.1016/S0925-4773(00)00318-X; Vandewalle C, 2005, NUCLEIC ACIDS RES, V33, P6566, DOI 10.1093/nar/gki965; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Wu AL, 1999, MOL CELL, V4, P619, DOI 10.1016/S1097-2765(00)80212-9; Yokoyama K, 2003, INT J ONCOL, V22, P891	61	149	153	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					4975	4985		10.1038/sj.onc.1209511	http://dx.doi.org/10.1038/sj.onc.1209511			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568083	Green Submitted			2022-12-28	WOS:000239921300003
J	Leduc, C; Claverie, P; Eymin, B; Col, E; Khochbin, S; Brambilla, E; Gazzeri, S				Leduc, C.; Claverie, P.; Eymin, B.; Col, E.; Khochbin, S.; Brambilla, E.; Gazzeri, S.			p14(ARF) promotes RB accumulation through inhibition of its Tip60-dependent acetylation	ONCOGENE			English	Article						p14(ARF); RB; acetylation; Tip60; DNA damage	DEGRADATION; P53; PROTEIN; MDM2; DIFFERENTIATION; PATHWAY; TUMORS; DEATH; TIP60; E2F1	p14(ARF) is a tumour suppressor which plays a critical role in p53-dependent or -independent cell growth control. Several studies have recently provided evidence that p14(ARF) can also interfere either directly or indirectly with some components of the RB signalling pathway to mediate its antiproliferative activity. The aim of this study was to explore the existence of direct relationships between p14(ARF) and RB proteins. We show that p14(ARF) promotes the accumulation of a hypoacetylated RB protein, when it is upregulated in a model of stable-inducible clones or physiologically induced following cell exposure to cytotoxic agents. Looking for the mechanisms involved in this process, we demonstrate that the histone acetyl transferase Tip60 directly interacts with RB and stimulates its degradation by the proteasome through acetylation of its C-terminus. Furthermore, and consistent with p14(ARF)-induced RB accumulation, we provide evidence that p14(ARF) prevents Tip60-mediated RB acetylation, therefore precluding its proteasomal degradation. Overall, our results identify a novel mechanism by which p14(ARF) controls the RB pathway to trigger its antiproliferative function.	Univ Grenoble 1, INSERM, U578,Grp Rech Canc Poumon, Inst Albert Bonniot,Fac Med, F-38706 La Tronche, France; Univ Grenoble 1, INSERM, U309, Inst Albert Bonniot,Lab Biol Mol & Cellulaire Dif, F-38706 La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Gazzeri, S (corresponding author), Univ Grenoble 1, INSERM, U578,Grp Rech Canc Poumon, Inst Albert Bonniot,Fac Med, F-38706 La Tronche, France.	sylvie.gazzeri@ujf-grenoble.fr	eymin, beatrice/U-4670-2019; Khochbin, Saadi/M-8090-2013; Eymin, Beatrice/M-1962-2013; gazzeri, sylvie/M-1961-2013; gazzeri, sylvie/U-4669-2019	eymin, beatrice/0000-0002-7311-3810; Khochbin, Saadi/0000-0002-0455-0857; Eymin, Beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839; gazzeri, sylvie/0000-0001-5817-1839				Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Caron C, 2005, BIOESSAYS, V27, P408, DOI 10.1002/bies.20210; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; Datta A, 2002, MOL CELL BIOL, V22, P8398, DOI 10.1128/MCB.22.24.8398-8408.2002; Eymin B, 2002, ONCOGENE, V21, P2750, DOI 10.1038/sj.onc.1205359; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Legube G, 2002, EMBO J, V21, P1704, DOI 10.1093/emboj/21.7.1704; Lemercier C, 2003, J BIOL CHEM, V278, P4713, DOI 10.1074/jbc.M211811200; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Mason SL, 2002, ONCOGENE, V21, P4220, DOI 10.1038/sj.onc.1205524; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Uchida CH, 2005, EMBO J, V24, P160, DOI 10.1038/sj.emboj.7600486	23	48	52	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	30					4147	4154		10.1038/sj.onc.1209446	http://dx.doi.org/10.1038/sj.onc.1209446			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16501607				2022-12-28	WOS:000239004800002
J	Moretti, S; Macchiarulo, A; De Falco, V; Avenia, N; Barbi, F; Carta, C; Cavaliere, A; Melillo, RM; Passeri, L; Santeusanio, F; Tartaglia, M; Santoro, M; Puxeddu, E				Moretti, S.; Macchiarulo, A.; De Falco, V.; Avenia, N.; Barbi, F.; Carta, C.; Cavaliere, A.; Melillo, R. M.; Passeri, L.; Santeusanio, F.; Tartaglia, M.; Santoro, M.; Puxeddu, E.			Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma	ONCOGENE			English	Article						papillary thyroid carcinoma; BRAF mutation; kinase assay; molecular dynamic simulation	BRAF MUTATIONS; ACTIVATION; CANCER; GENE; PREVALENCE; MECHANISM; PATHWAY	Activating mutations of the BRAF gene are the most common genetic alterations in papillary thyroid carcinomas (PTCs) and the T1799A transversion, resulting in BRAF(V600E), appeared virtually unique in this cancer type. Here, we report on the identification in a classic PTC of a novel BRAF mutation, namely a 1795GTT insertion, resulting in BRAF(V599Ins), and describe its biochemical and molecular characterization. Kinase assays carried out on BRAF(V599Ins) and BRAF(V600E) revealed a three- to five-fold increase in the enzymatic activity of both mutants with respect to BRAF(WT). Similarly, evaluation of BRAF-induced phosphorylation of MEK, MAPK and RSK revealed a significant MAPK cascade activation in cells expressing BRAF(V599Ins) or BRAF(V600E), but not in cells expressing BRAF(WT). Molecular dynamic simulations showed a destabilization of the inactive conformation of the enzyme in both BRAF(V599Ins) and BRAF(V600E) mutants, but not in BRAF(WT). The analysis of the interaction energies inside the catalytic site allowed to demonstrate the presence of repulsive electrostatic forces acting on the activation loop and moving from inward to outward of the mutant enzymes. Finally, focus assays in NIH-3T3 cells confirmed a high transformation rate in the cells transfected either with BRAF(V599Ins) or BRAF(V600E). In conclusion, this study demonstrated that BRAF(V599Ins), as BRAF(V600E), is a 'gain of function' mutation, characterized by a constitutive catalytic activation, which accounts for its causative role in the studied PTC.	Univ Perugia, Dipartimento Med Interna, Sez MISEM, I-06126 Perugia, Italy; Univ Perugia, Dipartimento Chim & Tecnol Farm, I-06126 Perugia, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, Naples, Italy; Univ Perugia, Ctr Riferimento Reg Endocrinochirurg, I-06126 Perugia, Italy; Ist Super Sanita, Dipartimento Biol Cellulare & Neurosci, I-00161 Rome, Italy; Univ Perugia, Ist Anat Patol, I-06126 Perugia, Italy	University of Perugia; University of Perugia; University of Naples Federico II; University of Perugia; Istituto Superiore di Sanita (ISS); University of Perugia	Puxeddu, E (corresponding author), Univ Perugia, Dipartimento Med Interna, Sez MISEM, Via Enrico dal Pozzo, I-06126 Perugia, Italy.	efisio@dimisem.med.unipg.it	Puxeddu, Efisio/I-8188-2012; Macchiarulo, Antonio/L-2846-2017; DE FALCO, VALENTINA/C-2061-2015; Carta, Claudio/A-7305-2013; Avenia, Nicola/AAL-4546-2021; melillo, rosa marina/O-5255-2015; Tartaglia, Marco/K-2955-2018	Macchiarulo, Antonio/0000-0001-9535-4183; DE FALCO, VALENTINA/0000-0002-8972-7921; Carta, Claudio/0000-0003-3545-198X; Tartaglia, Marco/0000-0001-7736-9672; MELILLO, Rosa Marina/0000-0002-9233-5275				Bennasroune A, 2004, CRIT REV ONCOL HEMAT, V50, P23, DOI 10.1016/j.critrevonc.2003.08.004; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Carta C, 2006, CLIN ENDOCRINOL, V64, P105, DOI 10.1111/j.1365-2265.2005.02401.x; Ciampi R, 2005, J CLIN INVEST, V115, P94, DOI 10.1172/JCI200523237; Cichowski K, 2001, CELL, V104, P593, DOI 10.1016/S0092-8674(01)00245-8; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dibb NJ, 2004, NAT REV CANCER, V4, P718, DOI 10.1038/nrc1434; Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8; Greene F, 2002, AJCC CANC STAGING MA, P77; GRUBMULLER H, 1996, SOLVATE V10 THEORETI; Jerome L, 2003, ENDOCR-RELAT CANCER, V10, P561, DOI 10.1677/erc.0.0100561; Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Melillo RM, 2005, J CLIN INVEST, V115, P1068, DOI 10.1172/JCI22758; Oler G, 2005, CLIN ENDOCRINOL, V62, P509, DOI 10.1111/j.1365-2265.2005.02235.x; Puxeddu E, 2004, J CLIN ENDOCR METAB, V89, P2414, DOI 10.1210/jc.2003-031425; Santoro M, 2004, ENDOCRINOLOGY, V145, P5448, DOI 10.1210/en.2004-0922; Tartaglia M, 2004, CURR OPIN HEMATOL, V11, P44, DOI 10.1097/00062752-200401000-00007; Trovisco V, 2005, VIRCHOWS ARCH, V446, P589, DOI 10.1007/s00428-005-1236-0; Trovisco V, 2005, HUM PATHOL, V36, P694, DOI 10.1016/j.humpath.2005.04.011; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Xing M, 2005, ENDOCR-RELAT CANCER, V12, P245, DOI 10.1677/erc.1.0978	23	46	47	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	30					4235	4240		10.1038/sj.onc.1209448	http://dx.doi.org/10.1038/sj.onc.1209448			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16501605				2022-12-28	WOS:000239004800011
J	Lynch, CJ; Milner, J				Lynch, C. J.; Milner, J.			Loss of one p53 allele results in four-fold reduction of p53 mRNA and protein: a basis for p53 haplo-insufficiency	ONCOGENE			English	Article						p53; haplo-insufficiency; Li-Fraumeni; survivin; SIRT1; mRNA	WILD-TYPE P53; P53-MEDIATED G(1) ARREST; TUMOR-SUPPRESSOR GENES; LI-FRAUMENI-SYNDROME; DNA-DAMAGE; HUMAN CANCERS; IN-VIVO; MODEL; TRANSCRIPTION; ACTIVATION	A haploid genotype may be insufficient to support normal wild-type function. Such haplo-insufficiency has recently been documented for numerous tumour suppressor genes. p53 is a crucial tumour suppressor governing DNA repair, cell cycle arrest and apoptosis via its role as a stress-responsive transcription factor. p53 haplo-insufficiency has been observed in vivo with human familial cancer in Li-Fraumeni Syndrome (LFS) and in mouse p53-knockout models of LFS. The increased tumorigenesis associated with loss of one p53 allele has been attributed to reduced p53-dependent stress responses. However, the underlying biochemical basis for such attenuated responses in p53(+/-) cells remains unclear. Here we have determined basal p53 messenger RNA ( mRNA) and protein levels, and compared the p53 stress response in p53+/+, p53+/- and p53-/- isogenic clones derived from HCT116 cells. Basal expression of p53 in p53+/- cells was 25% relative to p53+/+ cells, and this differential was maintained following oncogenic stress. This deficiency was manifested at both p53 mRNA and protein levels and resulted in attenuated p53 stress responses, in particular for p21(waf1) upregulation and survivin downregulation, and reduced G1 arrest and apoptosis. These observations identify a molecular basis for wild-type p53 haplo-insufficiency, which may explain the attenuated tumour-suppressive phenotype observed in cells with a single wild-type p53 allele and in humans with LFS.	Univ York, Res Grp YCR p53, Res Lab YCR p53, Dept Biol, York YO10 5DD, N Yorkshire, England	University of York - UK	Lynch, CJ (corresponding author), Univ York, Res Grp YCR p53, Res Lab YCR p53, Dept Biol, Zone 14, York YO10 5DD, N Yorkshire, England.	ajm24@york.ac.uk	Lynch, Christopher J./E-6875-2010; Lynch, Cian/AIC-5510-2022; Stoklosa, Tomasz A/I-8825-2017; Lynch, Cian J/K-2191-2017	Lynch, Christopher J./0000-0003-2453-5838; Lynch, Cian/0000-0003-0187-3527; Lynch, Cian J/0000-0003-0187-3527				Allison SJ, 2003, CANCER RES, V63, P6674; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CAMPLEJOHN RS, 1995, BRIT J CANCER, V72, P654, DOI 10.1038/bjc.1995.390; Cook WD, 2000, ONCOGENE, V19, P3434, DOI 10.1038/sj.onc.1203653; de Moor CH, 2005, SEMIN CELL DEV BIOL, V16, P49, DOI 10.1016/j.semcdb.2004.11.007; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; FOFO T, 2002, DRUG RESIST UPDAT, V50, P209; Ford J, 2005, CANCER RES, V65, P10457, DOI 10.1158/0008-5472.CAN-05-1923; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Fu LN, 1999, ONCOGENE, V18, P6419, DOI 10.1038/sj.onc.1203064; GENG L, 2004, NAT GENET, V36, P63; Giannakou ME, 2004, TRENDS CELL BIOL, V14, P408, DOI 10.1016/j.tcb.2004.07.006; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hu VW, 2001, FASEB J, V15, P1562, DOI 10.1096/fj.01-0102com; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Komarova EA, 1998, SEMIN CANCER BIOL, V8, P389, DOI 10.1006/scbi.1998.0101; Latonen L, 2005, BBA-REV CANCER, V1755, P71, DOI 10.1016/j.bbcan.2005.04.003; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Mirzayans R, 2003, ONCOGENE, V22, P5562, DOI 10.1038/sj.onc.1206514; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; Parant JM, 2003, HUM MUTAT, V21, P321, DOI 10.1002/humu.10186; Payne SR, 2005, CARCINOGENESIS, V26, P2031, DOI 10.1093/carcin/bgi223; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082; Santarosa M, 2004, BBA-REV CANCER, V1654, P105, DOI 10.1016/j.bbcan.2004.01.001; Soussi T, 2005, BIOCHEM BIOPH RES CO, V331, P834, DOI 10.1016/j.bbrc.2005.03.190; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Venkatachalam S, 2001, TOXICOL PATHOL, V29, P147, DOI 10.1080/019262301753178555; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; WALDMAN T, 1995, CANCER RES, V55, P5187; Williams KJ, 1997, ONCOGENE, V14, P277, DOI 10.1038/sj.onc.1200838; Yanokura M, 2000, INT J RADIAT BIOL, V76, P295, DOI 10.1080/095530000138637	49	46	49	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3463	3470		10.1038/sj.onc.1209387	http://dx.doi.org/10.1038/sj.onc.1209387			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16449974				2022-12-28	WOS:000238448100011
J	Yang, X; Chen, MW; Terry, S; Vacherot, F; Bemis, DL; Capodice, J; Kitajewski, J; de la Taille, A; Benson, MC; Guo, Y; Buttyan, R				Yang, X.; Chen, M. -W.; Terry, S.; Vacherot, F.; Bemis, D. L.; Capodice, J.; Kitajewski, J.; de la Taille, A.; Benson, M. C.; Guo, Y.; Buttyan, R.			Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells	ONCOGENE			English	Article						androgen receptor; Wnt signaling; beta-catenin; PCDH-PC; Akt; MDM2	BETA-CATENIN MUTATIONS; GENE; TRANSCRIPTION; PROGRESSION; ACTIVATION; AKT; PHOSPHORYLATION; PATHWAY; GROWTH; ALPHA	beta-Catenin, a component of the Wnt signaling pathway, is a coactivator of human androgen receptor (hAR) transcriptional activity. Here, we show that Wnt signaling also influences androgen-mediated signaling through its ability to regulate hAR mRNA and protein in prostate cancer (PCa) cells. Three functional LEF-1/TCF binding sites lie within the promoter of the hAR gene as shown by CHIP assays that captured beta-catenin-bound chromatin from Wnt-activated LNCaP cells. Chimeric reporter vectors that use the hAR gene promoter to drive luciferase expression confirmed that these LEF-1/TCF binding elements are able to confer robust upregulation of luciferase expression when stimulated by Wnt-1 or by transfection with beta-catenin and that dominant-negative TCF or mutations within the dominant TCF-binding element abrogated the response. Semi-quantitative and real time RT-PCR assays confirmed that Wnt activation upregulates hAR mRNA in PCa cells. In contrast, hAR protein expression was strongly suppressed by Wnt activation. The reduction of hAR protein is consistent with evidence that Wnt signaling increased phosphorylation of Akt and its downstream target, MDM2 that promotes degradation of hAR protein through a proteasomal pathway. These data indicate that the hAR gene is a direct target of LEF-1/TCF transcriptional regulation in PCa cells but also show that the expression of the hAR protein is suppressed by a degradation pathway regulated by cross-talk of Wnt to Akt that is likely mediated by Wnt-directed degradation of the B regulatory subunit of protein phosphatase, PP2A.	Columbia Univ, Dept Urol, Med Ctr, New York, NY 10032 USA; Columbia Univ, Med Ctr, Dept Pathol, New York, NY USA; Univ Paris 12, AP HP, CHU Henri Mondor, INSERM,E03 37, Creteil, France; Peking Univ, Hosp 1, Dept Urol, Beijing, Peoples R China	Columbia University; Columbia University; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Peking University	Buttyan, R (corresponding author), Columbia Univ, Dept Urol, Med Ctr, Irving Pavilion-11,161 Ft Washington Ave, New York, NY 10032 USA.	rb46@columbia.edu	Vacherot, Francis/R-6588-2018; Terry, Stephane/K-5351-2013; de la taille, Alex/ABE-8422-2021	Vacherot, Francis/0000-0002-3677-1267; Terry, Stephane/0000-0003-3089-7886; 	NATIONAL CANCER INSTITUTE [R01CA111618] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA111618-04, R01 CA111618] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Barker N, 2000, BIOESSAYS, V22, P961; CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10; CHEN G, 2004, CANCER, V10, P1345; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W; Craft N, 1999, CANCER RES, V59, P5030; de la Taille A, 2003, CLIN CANCER RES, V9, P1801; de Medina SGD, 1998, HUM PATHOL, V29, P1005, DOI 10.1016/S0046-8177(98)90208-8; Ford OH, 2003, J UROLOGY, V170, P1817, DOI 10.1097/01.ju.0000091873.09677.f4; Ghosh PM, 2003, CURR DRUG METAB, V4, P487, DOI 10.2174/1389200033489226; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Kau TR, 2003, CANCER CELL, V4, P463, DOI 10.1016/S1535-6108(03)00303-9; Koh SS, 2002, J BIOL CHEM, V277, P26031, DOI 10.1074/jbc.M110865200; Latil A, 2001, CANCER RES, V61, P1919; Li HW, 2004, J BIOL CHEM, V279, P4212, DOI 10.1074/jbc.M311374200; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Miyamoto H, 2004, PROSTATE, V61, P332, DOI 10.1002/pros.20115; Ohigashi T, 2005, PROSTATE, V62, P61, DOI 10.1002/pros.20117; Rahman M, 2004, CLIN CANCER RES, V10, P2208, DOI 10.1158/1078-0432.CCR-0746-3; Ratcliffe MJ, 2000, J BIOL CHEM, V275, P35680, DOI 10.1074/jbc.C000639200; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; Shi XB, 2004, PROSTATE, V60, P257, DOI 10.1002/pros.20039; Song LN, 2003, MOL CELL BIOL, V23, P1674, DOI 10.1128/MCB.23.5.1674-1687.2003; STACK S, 2004, J BIOL CHEM, V279, P47732; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tilley WD, 1996, CLIN CANCER RES, V2, P277; Truica CI, 2000, CANCER RES, V60, P4709; Verras M, 2004, CANCER RES, V64, P8860, DOI 10.1158/0008-5472.CAN-04-2370; Voeller HJ, 1998, CANCER RES, V58, P2520; Watanabe M, 1996, JPN J CLIN ONCOL, V26, P77, DOI 10.1093/oxfordjournals.jjco.a023188; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yang XZ, 2005, CANCER RES, V65, P5263, DOI 10.1158/0008-5472.CAN-05-0162; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474	37	87	90	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3436	3444		10.1038/sj.onc.1209366	http://dx.doi.org/10.1038/sj.onc.1209366			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16474850	Green Accepted			2022-12-28	WOS:000238448100008
J	Dumay, A; Laulier, C; Bertrand, P; Saintigny, Y; Lebrun, F; Vayssiere, JL; Lopez, BS				Dumay, A.; Laulier, C.; Bertrand, P.; Saintigny, Y.; Lebrun, F.; Vayssiere, J-L; Lopez, B. S.			Bax and Bid, two proapoptotic Bcl-2 family members, inhibit homologous recombination, independently of apoptosis regulation	ONCOGENE			English	Article						homologous recombination; double-strand break repair; genetic instability; Bcl-2 family; BAX; BID; apoptosis	NUCLEOTIDE EXCISION-REPAIR; DEPENDENT PROTEIN-KINASE; DNA-DAMAGE RESPONSE; MAMMALIAN-CELLS; DIRECTED REPAIR; C-TERMINUS; RAD51; MITOCHONDRIA; SUPPRESSION; MUTAGENESIS	In order to analyse the relationships between regulation of apoptosis and homologous recombination (HR), we over-expressed proapoptotic Bax or only-BH3 Bid proteins or antiapoptotic Bcl-2 or Bcl-XL, in hamster CHO cells or in SV40-transformed human fibroblasts. We measured HR induced by gamma-rays, UVC or a specific double-strand cleavage targeted in the recombination substrate by the meganuclease I-SceI. We show here that the induction of both recombinant cells and recombinant colonies was impaired when expressing Bcl-2 family members, in hamster as well as in human cells. Moreover, the pro- as well as antiapoptotic Bcl-2 family members inhibited HR, independently of degradation of the RAD51 recombination protein and of their impact on apoptosis. These data reveal a mechanism of HR downregulation by potentially proapoptotic proteins, distinct from and parallel to degradation of recombination proteins, a situation that should also optimize the efficiency of programmed cell death.	CEA, CNRS, UMR 217, DSV,DRR, F-92265 Fontenay Aux Roses, France; Univ Versailles, Lab Genet & Biol Cellulaire, CNRS, FRE 2445, F-78000 Versailles, France	CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Lopez, BS (corresponding author), CEA, CNRS, UMR 217, DSV,DRR, 18 Route Panorama,BP06, F-92265 Fontenay Aux Roses, France.	bernard.lopez@cea.fr	Lopez, Bernard S/O-7308-2017; Saintigny, Yannick/C-2697-2008	Lopez, Bernard S/0000-0001-5088-0155; Saintigny, Yannick/0000-0002-3839-3562; BERTRAND, Pascale/0000-0002-9019-742X; dumay, anne/0000-0002-8188-4658				Ausubel F., 1999, CURRENT PROTOCOLS MO; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; CherbonnelLasserre C, 1996, ONCOGENE, V13, P1489; Cho SH, 2002, EXP CELL RES, V278, P158, DOI 10.1006/excr.2002.5572; Delsite RL, 2003, MUTAGENESIS, V18, P497, DOI 10.1093/mutage/geg027; Flygare J, 1998, FEBS LETT, V427, P247, DOI 10.1016/S0014-5793(98)00433-5; FRIEDBERG EC, 1995, DNA REPAIR; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Han ZY, 1996, J BIOL CHEM, V271, P25035, DOI 10.1074/jbc.271.40.25035; Heimlich G, 2004, BIOCHEM J, V378, P247, DOI 10.1042/BJ20031152; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Huang YY, 1999, MOL CELL BIOL, V19, P2986; Kamer I, 2005, CELL, V122, P593, DOI 10.1016/j.cell.2005.06.014; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; Kitao H, 2002, J BIOL CHEM, V277, P48944, DOI 10.1074/jbc.M208151200; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kuo ML, 1999, MOL PHARMACOL, V55, P894; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; Lambert S, 2002, ONCOGENE, V21, P4065, DOI 10.1038/sj.onc.1205535; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Liu YF, 1997, CANCER RES, V57, P1650; MacLachlan TK, 2000, J BIOL CHEM, V275, P31869, DOI 10.1074/jbc.M003338200; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Priault M, 2003, CELL DEATH DIFFER, V10, P1068, DOI 10.1038/sj.cdd.4401270; Radman M, 1975, Basic Life Sci, V5A, P355; Saintigny Y, 2001, EMBO J, V20, P2596, DOI 10.1093/emboj/20.10.2596; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Sambrook J, 1989, MOL CLONING; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Smith GCM, 1999, MOL CELL BIOL, V19, P6076; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tremblais K, 1999, BIOCHEM BIOPH RES CO, V260, P582, DOI 10.1006/bbrc.1999.0904; Wiese C, 2002, CANCER RES, V62, P1279; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Youn CK, 2005, NAT CELL BIOL, V7, P137, DOI 10.1038/ncb1215; Yuan SSF, 2003, MUTAT RES-FUND MOL M, V525, P85, DOI 10.1016/S0027-5107(03)00009-5; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022	45	33	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3196	3205		10.1038/sj.onc.1209344	http://dx.doi.org/10.1038/sj.onc.1209344			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16407825				2022-12-28	WOS:000237951000010
J	Kreppel, M; Aryee, DNT; Schaefer, KL; Amann, G; Kofler, R; Poremba, C; Kovar, H				Kreppel, M; Aryee, DNT; Schaefer, KL; Amann, G; Kofler, R; Poremba, C; Kovar, H			Suppression of KCMF1 by constitutive high CD99 expression is involved in the migratory ability of Ewing's sarcoma cells	ONCOGENE			English	Article						Ewing's sarcoma; EWS-FL11; CD99; migration; ion channels	PRIMITIVE NEUROECTODERMAL TUMORS; REED-STERNBERG PHENOTYPE; MIC2 EXPRESSION; PSEUDOAUTOSOMAL GENE; PERIPHERAL-BLOOD; DOWN-REGULATION; ENGAGEMENT; ADHESION; FAMILY; ACTIVATION	High CD99 expression levels and rearrangements of the EWS gene with ETS transcription factor genes characterize the Ewing's sarcoma family of tumors (ESFT). CD99 is a cell surface glycoprotein whose engagement has been implicated in cell proliferation as well as upregulation and transport of several transmembrane proteins in hematopoietic cells. In ESFT, antibody ligation of CD99 induces fast homotypic cell aggregation and cell death although its functional role in these processes remains largely unknown. Here, using an RNAi approach, we studied for the first time the consequences of modulated CD99 expression in six different ESFT cell lines, representing the most frequent variant forms of EWS gene rearrangement. CD99 suppression resulted in growth inhibition and reduced migration of ESFT cells. Among genes whose expression changes in response to CD99 modulation, the potassium-channel modulatory factor KCMF1 was consistently upregulated. In a series of 22 primary ESFT, KCMF1 expression levels inversely correlated with CD99 abundancy. Cells forced to express ectopic KCMF1 showed a similar reduction in migratory ability as CD99 silenced ESFT cells. Our results suggest that in ESFT, high CD99 expression levels contribute to the malignant properties of ESFT by promoting growth and migration of tumor cells and identify KCMF1 as a potential metastasis suppressor gene downregulated by high constitutive CD99 expression in ESFT.	Univ Dusseldorf, Inst Pathol, D-4000 Dusseldorf, Germany; Med Univ Vienna, Inst Pathol, Vienna, Austria; Tyrolean Canc Res Inst, Innsbruck, Austria	Heinrich Heine University Dusseldorf; Medical University of Vienna	Kovar, H (corresponding author), St Anna Childrens Hosp, Childrens Canc Res Inst, Kinderspitalgasse 6, A-1090 Vienna, Austria.	heinrich.kovar@ccri.univie.ac.at		Kovar, Heinrich/0000-0001-6873-9109				Alberti I, 2002, FASEB J, V16, P1946, DOI 10.1096/fj.02-0049fje; AMBROS IM, 1991, CANCER, V67, P1886, DOI 10.1002/1097-0142(19910401)67:7<1886::AID-CNCR2820670712>3.0.CO;2-U; Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; Bernard G, 1997, J IMMUNOL, V158, P2543; BERNARD G, 1995, J IMMUNOL, V154, P26; Bertaux K, 2005, J BONE MINER METAB, V23, P114, DOI 10.1007/s00774-004-0549-4; Cerisano V, 2004, ONCOGENE, V23, P5664, DOI 10.1038/sj.onc.1207741; Choi FY, 1998, J IMMUNOL, V161, P749; Conti DJ, 2004, AM J TRANSPLANT, V4, P166; Dworzak MN, 1999, BRIT J HAEMATOL, V105, P690, DOI 10.1046/j.1365-2141.1999.01426.x; DWORZAK MN, 1994, BLOOD, V83, P415, DOI 10.1182/blood.V83.2.415.bloodjournal832415; FELLINGER EJ, 1991, AM J PATHOL, V139, P317; GELIN C, 1989, EMBO J, V8, P3253, DOI 10.1002/j.1460-2075.1989.tb08485.x; GOODFELLOW PN, 1988, PHILOS T ROY SOC B, V322, P145, DOI 10.1098/rstb.1988.0122; Hahn JH, 1997, J IMMUNOL, V159, P2250; Hahn MJ, 2000, FEBS LETT, V470, P350, DOI 10.1016/S0014-5793(00)01330-2; Hu-Lieskovan S, 2005, CANCER RES, V65, P4633, DOI 10.1158/0008-5472.CAN-04-2857; Jang JH, 2004, FEBS LETT, V578, P21, DOI 10.1016/j.febslet.2004.10.071; Kasinrerk W, 2000, IMMUNOL LETT, V71, P33, DOI 10.1016/S0165-2478(99)00165-0; Kim SH, 1998, BLOOD, V92, P4287, DOI 10.1182/blood.V92.11.4287.423k41_4287_4295; Kim SH, 2000, BLOOD, V95, P294; KOVAR H, 1990, ONCOGENE, V5, P1067; LEE YS, 1993, CELL SIGNAL, V5, P803, DOI 10.1016/0898-6568(93)90041-J; Li ZX, 2003, BIOCHEM BIOPH RES CO, V306, P623, DOI 10.1016/S0006-291X(03)00875-1; Park SH, 2005, GENE, V353, P177, DOI 10.1016/j.gene.2005.04.023; Rorie CJ, 2004, CANCER RES, V64, P1266, DOI 10.1158/0008-5472.CAN-03-3274; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Scotlandi K, 2000, CANCER RES, V60, P5134; Sohn HW, 1998, AM J PATHOL, V153, P1937, DOI 10.1016/S0002-9440(10)65707-0; Sohn HW, 2001, J IMMUNOL, V166, P787, DOI 10.4049/jimmunol.166.2.787; Waclavicek M, 1998, J IMMUNOL, V161, P4671	31	34	36	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2795	2800		10.1038/sj.onc.1209300	http://dx.doi.org/10.1038/sj.onc.1209300			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16314831				2022-12-28	WOS:000237272900010
J	Chang, PC; Chi, CW; Chau, GY; Li, FY; Tsai, YH; Wu, JC; Lee, YHW				Chang, PC; Chi, CW; Chau, GY; Li, FY; Tsai, YH; Wu, JC; Lee, YHW			DDX3, a DEAD box RNA helicase, is deregulated in hepatitis virus-associated hepatocellular carcinoma and is involved in cell growth control	ONCOGENE			English	Article						DDX3; hepatocellular carcinoma; small interfering RNA; p21(WAF1); proliferation; apoptosis	CYCLIN D1 OVEREXPRESSION; CORE PROTEIN INTERACTS; C-MYC; DECREASED EXPRESSION; GENETIC ALTERATIONS; TUMOR PROGRESSION; P53 MUTATION; CANCER; PATHOGENESIS; RECEPTOR	Hepatocellular carcinoma (HCC) is one of the leading causes of cancer deaths worldwide and is highly correlated with hepatitis virus infection. Our previous report shows that a DEAD box RNA helicase, DDX3, is targeted and regulated by hepatitis C virus (HCV) core protein, which implicates the involvement of DDX3 in HCV-related HCC development. In this study, the potential role of DDX3 in hepatocarcinogenesis is investigated by examining its expression in surgically excised human HCC specimens. Here we report the differential deregulation of DDX3 expression in hepatitis virus-associated HCC. A significant downregulation of DDX3 expression is found in HCCs from hepatitis B virus (HBV)-positive patients, but not from HCV-positive ones, compared to the corresponding nontumor tissues. The expression of DDX3 is differentially regulated by the gender and, moreover, there is a tendency that the downregulation of DDX3 expression in HCCs is more frequent in males than in females. Genetic knockdown of DDX3 with small interfering RNAs (siRNA) in a nontransformed mouse fibroblast cell line, NIH-3T3, results in a premature entry to S phase and an enhancement of cell growth. This enhanced cell cycle progression is linked to the upregulation of cyclin D1 and the downregulation of p21(WAF1) in the DDX3 knockdown cells. In addition, constitutive reduction of DDX3 expression increases the resistance of NIH-3T3 cells to serum depletion-induced apoptosis and enhances the ras-induced anchorage-independent growth, indicating the involvement of DDX3 in cell growth control. These findings together with the previous study suggest that the deregulation of DDX3, a DEAD box RNA helicase with cell growth-regulatory functions, is involved in HBV- and HCV-associated pathogenesis.	Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Pharmacol, Taipei, Taiwan; Taipei Vet Gen Hosp, Dept Surg, Taipei, Taiwan; Natl Yang Ming Univ, Dept Pathol, Taipei, Taiwan; Natl Yang Ming Univ, Inst Clin Med, Taipei, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Lee, YHW (corresponding author), Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan.	yhwulee@ym.edu.tw		Lee Wu, Yan-Hwa/0000-0001-7299-7354				Ahn J, 2004, DM-DIS MON, V50, P556, DOI 10.1016/j.disamonth.2004.10.001; Alarcon-Vargas D, 2002, CANCER BIOL THER, V1, P237, DOI 10.4161/cbt.74; Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Brechot C, 2004, GASTROENTEROLOGY, V127, pS56, DOI 10.1053/j.gastro.2004.09.016; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Causevic M, 2001, ONCOGENE, V20, P7734, DOI 10.1038/sj.onc.1204976; Chen CJ, 2002, JPN J CLIN ONCOL, V32, pS66, DOI 10.1093/jjco/hye138; De Petro G, 1998, CANCER RES, V58, P2234; Deane NG, 2001, CANCER RES, V61, P5389; El-Serag H, 2003, ANN INTERN MED, V139, P817, DOI 10.7326/0003-4819-139-10-200311180-00009; El-Serag HB, 2004, GASTROENTEROLOGY, V127, pS27, DOI 10.1053/j.gastro.2004.09.013; Endo K, 2000, LIVER, V20, P209, DOI 10.1034/j.1600-0676.2000.020003209.x; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Fukushima K, 2001, HEPATOL RES, V20, P52, DOI 10.1016/S1386-6346(00)00122-4; Furutani M, 1997, CANCER LETT, V111, P191, DOI 10.1016/S0304-3835(96)04509-0; Godbout R, 1998, J BIOL CHEM, V273, P21161, DOI 10.1074/jbc.273.33.21161; Gregory RI, 2005, CANCER RES, V65, P3509, DOI 10.1158/0008-5472.CAN-05-0298; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hsu HC, 1997, CANCER RES, V57, P5179; Huang JS, 2004, BIOCHEM BIOPH RES CO, V315, P950, DOI 10.1016/j.bbrc.2004.01.151; Hui AM, 2000, CANCER LETT, V154, P93, DOI 10.1016/S0304-3835(00)00385-2; Hui AM, 1997, HEPATOLOGY, V25, P575, DOI 10.1002/hep.510250314; Huynh H, 2004, CARCINOGENESIS, V25, P1485, DOI 10.1093/carcin/bgh154; Joo M, 2001, LIVER, V21, P89, DOI 10.1034/j.1600-0676.2001.021002089.x; Jung YJ, 2001, CANCER LETT, V168, P57, DOI 10.1016/S0304-3835(01)00403-7; Kahlina K, 2004, J BIOL CHEM, V279, P44872, DOI 10.1074/jbc.M402467200; Kawate S, 1999, ONCOLOGY-BASEL, V57, P157, DOI 10.1159/000012024; Kim YS, 2001, MOL CELLS, V12, P209; Kobayashi T, 2002, AM J GASTROENTEROL, V97, P3166; Kobayashi Y, 2000, J HEPATOL, V32, P612, DOI 10.1016/S0168-8278(00)80223-8; Lahn BT, 1997, SCIENCE, V278, P675, DOI 10.1126/science.278.5338.675; Lee JO, 2005, ONCOGENE, V24, P6617, DOI 10.1038/sj.onc.1208827; Liang TJ, 2004, GASTROENTEROLOGY, V127, pS62, DOI 10.1053/j.gastro.2004.09.017; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Lukas J, 1997, AM J PATHOL, V150, P167; Luking A, 1998, CRIT REV BIOCHEM MOL, V33, P259, DOI 10.1080/10409239891204233; Macaluso M, 2003, ONCOGENE, V22, P6472, DOI 10.1038/sj.onc.1206955; Mamiya N, 1999, J BIOL CHEM, V274, P15751, DOI 10.1074/jbc.274.22.15751; Marchetti A, 1996, ONCOGENE, V12, P1319; Masaki T, 2003, HEPATOLOGY, V37, P534, DOI 10.1053/jhep.2003.50112; Matsushita K, 1996, INT J CANCER, V69, P259, DOI 10.1002/(SICI)1097-0215(19960822)69:4<259::AID-IJC3>3.3.CO;2-D; MURAKAMI Y, 1991, CANCER RES, V51, P5520; Nagano H, 2003, ONCOGENE, V22, P4656, DOI 10.1038/sj.onc.1206588; Nakagawa Y, 1999, BRIT J CANCER, V80, P914, DOI 10.1038/sj.bjc.6690441; NISHIDA N, 1993, CANCER RES, V53, P368; OGATA N, 1991, HEPATOLOGY, V13, P31, DOI 10.1002/hep.1840130106; Owsianka AM, 1999, VIROLOGY, V257, P330, DOI 10.1006/viro.1999.9659; Paik SY, 2003, MODERN PATHOL, V16, P86, DOI 10.1097/01.MP.0000047308.03300.9C; Pang R, 2004, ONCOGENE, V23, P4182, DOI 10.1038/sj.onc.1207493; Park SH, 1998, CYTOGENET CELL GENET, V81, P178, DOI 10.1159/000015022; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Qin LF, 1998, INT J CANCER, V79, P424, DOI 10.1002/(SICI)1097-0215(19980821)79:4<424::AID-IJC19>3.0.CO;2-4; Rashid A, 1999, BRIT J CANCER, V80, P59, DOI 10.1038/sj.bjc.6690321; Rocak S, 2004, NAT REV MOL CELL BIO, V5, P232, DOI 10.1038/nrm1335; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Sato Y, 1999, J GASTROENTEROL, V34, P486, DOI 10.1007/s005350050301; Shackelford J, 2004, MOL CELL BIOL, V24, P5089, DOI 10.1128/MCB.24.12.5089-5093.2004; Shi YZ, 2000, BRIT J CANCER, V83, P50; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; Suriawinata A, 2004, SEMIN LIVER DIS, V24, P77; TANAKA S, 1993, CANCER RES, V53, P2884; Tannapfel A, 2000, INT J CANCER, V89, P350, DOI 10.1002/1097-0215(20000720)89:4<350::AID-IJC6>3.0.CO;2-3; Tannapfel A, 2002, VIRCHOWS ARCH, V440, P345, DOI 10.1007/s00428-002-0617-x; TaylorRobinson SD, 1997, LANCET, V350, P1142, DOI 10.1016/S0140-6736(05)63789-0; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Torbenson M, 2002, HUM PATHOL, V33, P871, DOI 10.1053/hupa.2002.128061; Tron VA, 1996, AM J PATHOL, V149, P1139; Ueki T, 1997, HEPATOLOGY, V25, P862, DOI 10.1002/hep.510250413; Wei Y, 2002, HEPATOLOGY, V36, P692, DOI 10.1053/jhep.2002.35342; Xie HL, 2004, WORLD J GASTROENTERO, V10, P1125; Yan J, 2004, ONCOGENE, V23, P1939, DOI 10.1038/sj.onc.1207306; Yedavalli VSRK, 2004, CELL, V119, P381, DOI 10.1016/j.cell.2004.09.029; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Yu MC, 2004, GASTROENTEROLOGY, V127, pS72, DOI 10.1016/j.gastro.2004.09.018; Yuen MF, 2001, CANCER, V91, P106, DOI 10.1002/1097-0142(20010101)91:1<106::AID-CNCR14>3.0.CO;2-2; Zhang J, 2004, WORLD J GASTROENTERO, V10, P830; ZHANG XK, 1990, ONCOGENE, V5, P909; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031	81	119	124	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					1991	2003		10.1038/sj.onc.1209239	http://dx.doi.org/10.1038/sj.onc.1209239			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16301996				2022-12-28	WOS:000236359700002
J	Heidenblad, M; Hallor, KH; Staaf, J; Jonsson, G; Borg, A; Hoglund, M; Mertens, F; Mandahl, N				Heidenblad, M.; Hallor, K. H.; Staaf, J.; Jonsson, G.; Borg, A.; Hoglund, M.; Mertens, F.; Mandahl, N.			Genomic profiling of bone and soft tissue tumors with supernumerary ring chromosomes using tiling resolution bacterial artificial chromosome microarrays	ONCOGENE			English	Article						sarcoma; array-based CGH; genome-wide; gene amplification; ring chromosome	MALIGNANT FIBROUS HISTIOCYTOMAS; HUMAN SARCOMAS; LIPOMATOUS TUMORS; HYBRIDIZATION ANALYSIS; DEDIFFERENTIATED LIPOSARCOMAS; PAROSTEAL OSTEOSARCOMA; MARKER CHROMOSOMES; SEQUENCES; IDENTIFICATION; AMPLICON	Ring chromosomes and/or giant marker chromosomes have been observed in a variety of human tumor types, but they are particularly common in a subgroup of mesenchymal tumors of low-grade or borderline malignancy. These rings and markers have been shown to contain amplified material predominantly from 12q13-15, but also sequences from other chromosomes. Such amplified sequences were mapped in detail by genome-wide array comparative genomic hybridization in ring-containing tumor samples from soft tissue (n = 15) and bone (n = 6), using tiling resolution microarrays, encompassing 32 433 bacterial artificial chromosome clones. The DNA copy number profiles revealed multiple amplification targets, in many cases highly discontinuous, leading to delineation of large numbers of very small amplicons. A total number of 356 (median size: 0.64 Mb) amplicons were seen in the soft tissue tumors and 90 (median size: 1.19 Mb) in the bone tumors. Notably, more than 40% of all amplicons in both soft tissue and bone tumors were mapped to chromosome 12, and at least one of the previously reported recurrent amplifications in 12q13.3-14.1 and 12q15.1, including SAS and CDK4, and MDM2, respectively, were present in 85% of the soft tissue tumors and in all of the bone tumors. Although chromosome 12 was the only chromosome displaying recurrent amplification in the bone tumors, the soft tissue tumors frequently showed recurrent amplicons mapping to other chromosomes, that is, 1p32, 1q23-24, 3p11-12, 6q24-25 and 20q11-12. Of particular interest, amplicons containing genes involved in the c-jun NH2-terminal kinase/mitogen-activated protein kinase pathway, that is, JUN in 1p32 and MAP3K7IP2 (TAB2) in 6q24-25, were found to be independently amplified in eight of 11 cases with 12q amplification, providing strong support for the notion that aberrant expression of this pathway is an important step in the dedifferentiation of liposarcomas.	Univ Lund Hosp, Dept Clin Genet, SE-22185 Lund, Sweden; Univ Lund Hosp, Dept Oncol, SE-22185 Lund, Sweden	Lund University; Skane University Hospital; Lund University; Skane University Hospital	Heidenblad, M (corresponding author), Univ Lund Hosp, Dept Clin Genet, SE-22185 Lund, Sweden.	markus.heidenblad@med.lu.se	Jönsson, Göran/D-1212-2014	Hansen Nord, Karolin/0000-0002-2397-2254; Hoglund, Mattias/0000-0001-9283-4421; Mertens, Fredrik/0000-0002-6278-5232				Autio R, 2003, BIOINFORMATICS, V19, P1714, DOI 10.1093/bioinformatics/btg230; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; Chibon F, 2004, GENE CHROMOSOME CANC, V40, P32, DOI 10.1002/gcc.20012; Chibon F, 2002, CANCER GENET CYTOGEN, V139, P24, DOI 10.1016/S0165-4608(02)00614-3; Coindre JM, 2004, J PATHOL, V203, P822, DOI 10.1002/path.1579; Coindre JM, 2003, MODERN PATHOL, V16, P256, DOI 10.1097/01.MP.0000056983.78547.77; Dahlen A, 2003, INT J CANCER, V103, P616, DOI 10.1002/ijc.10864; DALCIN P, 1993, CANCER GENET CYTOGEN, V68, P85, DOI 10.1016/0165-4608(93)90001-3; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P15, DOI 10.1002/gcc.2870140104; Forus A, 1998, BRIT J CANCER, V78, P495, DOI 10.1038/bjc.1998.521; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P8, DOI 10.1002/gcc.2870140103; GAMBERI G, 2000, CLIN ORTHOP RELAT R, V377, P195; Gisselsson D, 2002, GENE CHROMOSOME CANC, V33, P133, DOI 10.1002/gcc.1219; Heidenblad M, 2005, ONCOGENE, V24, P1794, DOI 10.1038/sj.onc.1208383; Jonsson G, 2005, JNCI-J NATL CANCER I, V97, P1377, DOI 10.1093/jnci/dji280; Kanoe H, 1999, ONCOGENE, V18, P721, DOI 10.1038/sj.onc.1202364; Kresse SH, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-39; Mairal A, 1999, CANCER GENET CYTOGEN, V111, P134, DOI 10.1016/S0165-4608(98)00227-1; Mansoor A, 2004, CANCER GENET CYTOGEN, V152, P61, DOI 10.1016/j.cancergencyto.2003.10.004; MELTZER PS, 1991, CELL GROWTH DIFFER, V2, P495; Mertens F, 2004, CYTOGENET GENOME RES, V106, P33, DOI 10.1159/000078557; Mertens F, 1998, GENE CHROMOSOME CANC, V22, P16, DOI 10.1002/(SICI)1098-2264(199805)22:1<16::AID-GCC3>3.0.CO;2-A; Meza-Zepeda LA, 2002, ONCOGENE, V21, P2261, DOI 10.1038/sj.onc.1205339; Meza-Zepeda LA, 2001, GENE CHROMOSOME CANC, V31, P264, DOI 10.1002/gcc.1143; Micci F, 2002, CYTOGENET GENOME RES, V97, P13, DOI 10.1159/000064038; Mitelman F, 2005, MITELMAN DATABASE CH; NILBERT M, 1994, GENE CHROMOSOME CANC, V9, P261, DOI 10.1002/gcc.2870090406; Nilsson M, 2004, INT J CANCER, V109, P363, DOI 10.1002/ijc.11716; ORNDAL C, 1992, CANCER GENET CYTOGEN, V60, P170, DOI 10.1016/0165-4608(92)90011-V; PEDEUTOUR F, 1994, GENE CHROMOSOME CANC, V10, P85, DOI 10.1002/gcc.2870100203; Pedeutour F, 1999, GENE CHROMOSOME CANC, V24, P30, DOI 10.1002/(SICI)1098-2264(199901)24:1<30::AID-GCC5>3.0.CO;2-P; Platzer P, 2002, CANCER RES, V62, P1134; Saal LH, 2002, GENOME BIOL, V3; Sabah M, 2005, VIRCHOWS ARCH, V447, P842, DOI 10.1007/s00428-005-0024-1; Simons A, 2000, CANCER GENET CYTOGEN, V118, P89, DOI 10.1016/S0165-4608(99)00178-8; Sirvent N, 2003, GENE CHROMOSOME CANC, V37, P1, DOI 10.1002/gcc.10202; Smith DI, 2006, CANCER LETT, V232, P48, DOI 10.1016/j.canlet.2005.06.049; Szymanska J, 1996, GENE CHROMOSOME CANC, V16, P31; Szymanska J, 1997, CANCER GENET CYTOGEN, V99, P14, DOI 10.1016/S0165-4608(96)00436-0; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15	40	35	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2006	25	53					7106	7116		10.1038/sj.onc.1209693	http://dx.doi.org/10.1038/sj.onc.1209693			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16732325				2022-12-28	WOS:000241910500010
J	Bellovin, DI; Simpson, KJ; Danilov, T; Maynard, E; Rimm, DL; Oettgen, P; Mercurio, AM				Bellovin, D. I.; Simpson, K. J.; Danilov, T.; Maynard, E.; Rimm, D. L.; Oettgen, P.; Mercurio, A. M.			Reciprocal regulation of RhoA and RhoC characterizes the EMT and identifies RhoC as a prognostic marker of colon carcinoma	ONCOGENE			English	Article						RhoC; epithelial mesenchymal transition; colorectal carcinoma	EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTIONAL REPRESSOR SNAIL; INFLAMMATORY BREAST-CANCER; ETS-1 PROTOONCOGENE; GENOMIC ANALYSIS; METASTASIS; EXPRESSION; PHENOTYPE; ORGANOIDS; SURVIVAL	Understanding how RhoC expression and activation are regulated is essential for deciphering its contribution to tumorigenesis. Here, we report that RhoC expression and activation are induced by the epithelial to mesenchymal transition (EMT) of colon carcinoma. Using LIM 1863 colon cancer cells, RhoC protein expression and subsequent activation were detected coincident with the loss of E-cadherin and acquisition of mesenchymal characteristics. Several Ets-1 binding sites were identified in the RhoC promoter, and evidence was obtained using chromatin immunoprecipitation that Ets-1 can regulate RhoC expression during the EMT. Interestingly, a marked decrease in RhoA activation associated with the EMT was observed that corresponds to the increase in RhoC expression. Use of shRNA established that RhoA inhibits and RhoC promotes post-EMT cell migration, demonstrating functional significance for their coordinate regulation. To assess the importance of RhoC expression in colon cancer, immunohistochemistry was performed on 566 colorectal tumors with known clinical outcome. The level of RhoC ranged from no expression to high expression, and statistical analysis revealed that elevated RhoC expression correlates with poor outcome as well as aberrant expression and localization of E-cadherin. These data provide one mechanism for how RhoC expression is regulated in colon carcinoma and substantiate its utility as a prognostic marker.	Beth Israel Deaconess Med Ctr, Dept Pathol, Div Canc Biol & Angiogenesis, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA; Beth Israel Deaconess Med Ctr, Div Prevent Cardiol, Boston, MA 02215 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Yale University	Mercurio, AM (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, LRB-408,364 Plantat St, Worcester, MA 01605 USA.	arthur.mercurio@umassmed.edu	Oettgen, Peter/AAF-5026-2021	Rimm, David/0000-0001-5820-4397; Simpson, Kaylene/0000-0001-9136-1781	NCI NIH HHS [CA107548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA107548] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alipov G, 2005, HISTOPATHOLOGY, V46, P202, DOI 10.1111/j.1365-2559.2005.02059.x; Bates RC, 2005, J CLIN INVEST, V115, P339, DOI 10.1172/JCI200523183; Bates RC, 2003, CURR BIOL, V13, P1721, DOI 10.1016/j.cub.2003.09.002; Bates RC, 2003, MOL BIOL CELL, V14, P1790, DOI 10.1091/mbc.E02-09-0583; Bellovin DI, 2005, CANCER RES, V65, P10938, DOI 10.1158/0008-5472.CAN-05-1947; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Dube A, 1999, CIRC RES, V84, P1177, DOI 10.1161/01.RES.84.10.1177; Hakem A, 2005, GENE DEV, V19, P1974, DOI 10.1101/gad.1310805; Hu M, 2005, CANCER RES, V65, P8715, DOI 10.1158/0008-5472.CAN-05-0700; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Roy HK, 2005, DIGEST DIS SCI, V50, P42, DOI 10.1007/s10620-005-1275-z; Sato Y, 1998, Hum Cell, V11, P207; Schwiebert LM, 1997, AM J RESP CELL MOL, V17, P106, DOI 10.1165/ajrcmb.17.1.2775; Shikada Y, 2003, CLIN CANCER RES, V9, P5282; Simpson KJ, 2004, CANCER RES, V64, P8694, DOI 10.1158/0008-5472.CAN-04-2247; Span PN, 2002, ONCOGENE, V21, P8506, DOI 10.1038/sj.onc.1206040; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008-5472.CAN-05-0616; Tootle TL, 2005, BIOESSAYS, V27, P285, DOI 10.1002/bies.20198; van Golen KL, 1999, CLIN CANCER RES, V5, P2511; van Golen KL, 2000, CANCER RES, V60, P5832; Wang H, 2004, CLIN CANCER RES, V10, P1633, DOI 10.1158/1078-0432.CCR-0829-3; Wang W, 2004, BRIT J CANCER, V90, P2349, DOI 10.1038/sj.bjc.6601749; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	28	102	114	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	52					6959	6967		10.1038/sj.onc.1209682	http://dx.doi.org/10.1038/sj.onc.1209682			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16715134				2022-12-28	WOS:000241732300006
J	Myllykangas, S; Himberg, J; Bohling, T; Nagy, B; Hollmen, J; Knuutila, S				Myllykangas, S.; Himberg, J.; Bohling, T.; Nagy, B.; Hollmen, J.; Knuutila, S.			DNA copy number amplification profiling of human neoplasms	ONCOGENE			English	Article						cancer; gene amplification; fragile site; bioinformatics; data mining; molecular pathology	ACUTE LYMPHOBLASTIC-LEUKEMIA; DIHYDROFOLATE-REDUCTASE GENE; COMMON FRAGILE SITES; WILD-TYPE P53; MICROARRAY ANALYSIS; BREAST-CANCER; TUMORS; CELLS; CHROMOSOMES; IMBALANCES	DNA copy number amplications activate oncogenes and are hallmarks of nearly all advanced tumors. Amplified genes represent attractive targets for therapy, diagnostics and prognostics. To investigate DNA amplications in different neoplasms, we performed a bibliomics survey using 838 published chromosomal comparative genomic hybridization studies and collected amplification data at chromosome band resolution from more than 4500 cases. Amplification profiles were determined for 73 distinct neoplasms. Neoplasms were clustered according to the amplification profiles, and frequently amplificed chromosomal loci (amplification hot spots) were identified using computational modeling. To investigate the site specificity and mechanisms of gene amplifications, colocalization of amplification hot spots, cancer genes, fragile sites, virus integration sites and gene size cohorts were tested in a statistical framework. Amplification-based clustering demonstrated that cancers with similar etiology, cell-of-origin or topographical location have a tendency to obtain convergent amplification profiles. The identified amplification hot spots were colocalized with the known fragile sites, cancer genes and virus integration sites, but global statistical significance could not be ascertained. Large genes were significantly over-represented on the fragile sites and the reported amplifcation hot spots. These findings indicate that amplifications are selected in the cancer tissue environment according to the qualitative traits and localization of cancer genes.	Univ Helsinki, Haartman Inst, Dept Pathol, FI-00014 Helsinki, Finland; Univ Helsinki, HUSLAB, FI-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Helsinki, Finland; Helsinki Univ Technol, Lab Comp & Informat Sci, FIN-02150 Espoo, Finland; Scmmclwcis Univ, Dept Obstet & Gynecol 1, Budapest, Hungary	University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Aalto University	Myllykangas, S (corresponding author), Univ Helsinki, Haartman Inst, Dept Pathol, POB 21, FI-00014 Helsinki, Finland.	samuel.myllykangas@helsinki.fi	Nagy, Balint/F-6943-2012					Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; [Anonymous], [No title captured]; Atiye J, 2005, GENE CHROMOSOME CANC, V42, P158, DOI 10.1002/gcc.20120; Bernasconi P, 2005, CANCER GENET CYTOGEN, V162, P146, DOI 10.1016/j.cancergencyto.2005.04.002; Birney E, 2004, GENOME RES, V14, P925, DOI 10.1101/gr.1860604; Buttel I, 2004, ANN NY ACAD SCI, V1028, P14, DOI 10.1196/annals.1322.002; El-Rifai W, 1998, AM J PATHOL, V153, P985, DOI 10.1016/S0002-9440(10)65640-4; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; GOKER E, 1995, BLOOD, V86, P677, DOI 10.1182/blood.V86.2.677.bloodjournal862677; Good P, 2000, PERMUTATION TESTS PR; Graux C, 2004, NAT GENET, V36, P1084, DOI 10.1038/ng1425; GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155; HAHN PJ, 1993, BIOESSAYS, V15, P477, DOI 10.1002/bies.950150707; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; Himberg J, 2004, NEUROIMAGE, V22, P1214, DOI 10.1016/j.neuroimage.2004.03.027; HIMBERG J, 2001, 3 INT WORKSH IND COM, P552; Hyman E, 2002, CANCER RES, V62, P6240; ISCN, 1995, INT SYST HUM CYT NOM; JOHNSTON RN, 1983, P NATL ACAD SCI-BIOL, V80, P3711, DOI 10.1073/pnas.80.12.3711; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Looijenga LHJ, 1999, REV REPROD, V4, P90, DOI 10.1530/ror.0.0040090; MAURER BJ, 1987, NATURE, V327, P434, DOI 10.1038/327434a0; Monni O, 1999, LEUKEMIA LYMPHOMA, V34, P45, DOI 10.3109/10428199909083379; Myllykangas S, 2006, CANCER LETT, V232, P79, DOI 10.1016/j.canlet.2005.07.045; Ozaki T, 2002, INT J CANCER, V102, P355, DOI 10.1002/ijc.10709; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Rieker RJ, 2002, INT J CANCER, V99, P68, DOI 10.1002/ijc.10287; Roumier C, 2003, LEUKEMIA, V17, P9, DOI 10.1038/sj.leu.2402766; Schwab M, 1998, BIOESSAYS, V20, P473, DOI 10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.3.CO;2-N; Schwab M, 2004, CANCER LETT, V204, P179, DOI 10.1016/S0304-3835(03)00454-3; Sell S, 2004, CRIT REV ONCOL HEMAT, V51, P1, DOI 10.1016/j.critrevonc.2004.04.007; Shannon KM, 2002, CANCER CELL, V2, P99, DOI 10.1016/S1535-6108(02)00101-0; Torchia EC, 2003, CANCER RES, V63, P3464; WAHL GM, 1979, J BIOL CHEM, V254, P8679; Weng WH, 2003, BRIT J CANCER, V89, P720, DOI 10.1038/sj.bjc.6601069; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Zatkova A, 2004, GENE CHROMOSOME CANC, V39, P263, DOI 10.1002/gcc.20002	41	81	85	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	55					7324	7332		10.1038/sj.onc.1209717	http://dx.doi.org/10.1038/sj.onc.1209717			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16751803				2022-12-28	WOS:000242244700011
J	Yan, H; Thomas, J; Liu, T; Raj, D; London, N; Tandeski, T; Leachman, SA; Lee, RM; Grossman, D				Yan, H.; Thomas, J.; Liu, T.; Raj, D.; London, N.; Tandeski, T.; Leachman, S. A.; Lee, R. M.; Grossman, D.			Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable survivin antagonist	ONCOGENE			English	Article						survivin; apoptosis; melanoma; TAT; xenograft	PROTEIN TRANSDUCTION; MAMMALIAN-CELLS; IN-VIVO; CANCER; EXPRESSION; GENE; DIVISION; INTERFERENCE; CHECKPOINT; THERAPY	The inhibitor of apoptosis gene family member Survivin is highly expressed in most tumors, and appears to be a promising target for cancer therapy. Although a variety of Survivin antagonists have been shown to induce apoptosis in malignant cells, the potential utility of these agents is limited by inefficient delivery and cell impermeability. We generated recombinant fusion proteins containing the TAT protein transduction domain and either wild-type Survivin (TAT-Surv-WT) or a dominant-negative mutant (TAT-Surv-T34A). The TAT-Surv proteins were purified by sequential affinity and ion-exchange chromatography, and at 30 nM concentration demonstrated rapid entry into cells at 30 min. Whereas TAT-Surv-WT had minimal effect on YUSAC2 or WM793 melanoma cells, TAT-Surv-T34A induced cell detachment, DNA fragmentation, caspase-3 activation and mitochondrial release of apoptosis-inducing factor at low mu M concentrations. Intraperitoneal (i.p.)injection of mice bearing subcutaneous YUSAC2 xenografts with TAT-Surv-T34A (10 mg/ kg) was associated with rapid tumor accumulation at 1 h, and increased tumor cell apoptosis and aberrant nuclei formation in situ. Repeated i.p. injection of TAT- Surv-T34A resulted in a 40-50% reduction in growth and mass of established tumors, compared to those similarly injected with saline buffer or TAT-Surv-WT. These studies demonstrate the feasibility of systemic tumor treatment using a cell-permeable Survivin antagonist.	Univ Utah, Huntsman Canc Inst, Dept Dermatol & Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Dermatol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Grossman, D (corresponding author), Univ Utah, Huntsman Canc Inst, Dept Dermatol & Oncol Sci, 2000 Circle Hope,Suite 5243, Salt Lake City, UT 84112 USA.	doug.grossman@hci.utah.edu			NIAMS NIH HHS [AR050102, R01 AR050102-03, R01 AR050102] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050102] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Azuhata T, 2001, J PEDIATR SURG, V36, P1785, DOI 10.1053/jpsu.2001.28839; Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186; Beltrami E, 2004, J BIOL CHEM, V279, P2077, DOI 10.1074/jbc.M309479200; Caldas H, 2005, ONCOGENE, V24, P1994, DOI 10.1038/sj.onc.1208350; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Fortugno P, 2003, P NATL ACAD SCI USA, V100, P13791, DOI 10.1073/pnas.2434345100; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; Kanwar JR, 2001, J NATL CANCER I, V93, P1541, DOI 10.1093/jnci/93.20.1541; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li FZ, 1999, CANCER RES, V59, P3143; Ling X, 2004, BIOTECHNIQUES, V36, P450, DOI 10.2144/04363RR01; Liu T, 2004, ONCOGENE, V23, P39, DOI 10.1038/sj.onc.1206978; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Muchmore SW, 2000, MOL CELL, V6, P173, DOI 10.1016/S1097-2765(00)00018-6; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Pennati M, 2002, J CLIN INVEST, V109, P285; Plescia J, 2005, CANCER CELL, V7, P457, DOI 10.1016/j.ccr.2005.03.035; Satyamoorthy K, 2003, CANCER RES, V63, P756; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Shankar SL, 2001, J NEUROCHEM, V79, P426, DOI 10.1046/j.1471-4159.2001.00596.x; Takeuchi H, 2005, INT J CANCER, V117, P1032, DOI 10.1002/ijc.21267; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Vong QP, 2005, SCIENCE, V310, P1499, DOI 10.1126/science.1120160	30	44	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	52					6968	6974		10.1038/sj.onc.1209676	http://dx.doi.org/10.1038/sj.onc.1209676			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16702945	Green Accepted			2022-12-28	WOS:000241732300007
J	Zhang, L; D'Costa, J; Kummalue, T; Civin, CI; Friedman, AD				Zhang, L.; D'Costa, J.; Kummalue, T.; Civin, C. I.; Friedman, A. D.			Identification of a region on the outer surface of the CBF beta-SMMHC myeloid oncoprotein assembly competence domain critical for multimerization	ONCOGENE			English	Article						CBF beta-SMMHC; myosin; ACD; proliferation; RUNX1	MYOSIN HEAVY-CHAIN; COILED-COIL ROD; CELL-CYCLE; TRANSCRIPTION FACTOR; GENE CBFB-MYH11; FUSION GENE; LEUKEMIA; BINDING; PROLIFERATION; HEMATOPOIESIS	In the core binding factor (CBF) beta-smooth muscle myosin heavy chain (SMMHC) acute myeloid leukemia (AML) oncoprotein, CBF beta lies N-terminal to the alpha-helical rod domain of SMMHC. Deletion of the SMMHC assembly competence domain (ACD), conserved among skeletal, smooth and nonmuscle myosins, prevents multimerization, inhibition of CBF and inhibition of cell proliferation. To de. ne the amino acids critical for ACD function, three outer surface residues of ACD helices A-D, the subsequent helices E-H or the more N-terminal X or Z helices were now mutated. Variants were assessed for multimerization in low ionic strength in vitro and for nuclear localization as a measure of in vivo multimerization. Mutation of individual helices C-H reduced multimerization, with alteration of the outer surface of helices D or E having the greatest effect. The ability of these SMMHC variants to slow murine myeloid progenitor proliferation largely paralleled their effects on multimerization. Divergence at the boundaries of the ACD may reflect quantitative differences between in vitro and in vivo filament assembly. Each helix mutant retained the ability to bind the mSin3A corepressor. Agents interacting with the outer surface of the CBF beta-SMMHC ACD that prevent multimerization may be effective as novel therapeutics in AML.	Johns Hopkins Univ, Div Pediat Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Div Immunol & Hematopoiesis, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins University	Friedman, AD (corresponding author), Johns Hopkins Univ, Div Pediat Oncol, Canc Res Bldg,Room 253,1650 Orleans St, Baltimore, MD 21231 USA.	afriedm2@jhmi.edu			NATIONAL CANCER INSTITUTE [R01CA098805] Funding Source: NIH RePORTER; NCI NIH HHS [CA070970, CA098805] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATKINSON SJ, 1991, J CELL SCI, V99, P823; Bernardin F, 2002, ONCOGENE, V21, P3247, DOI 10.1038/sj.onc.1205447; Bernardin-Fried F, 2004, J BIOL CHEM, V279, P15678, DOI 10.1074/jbc.M310023200; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Cao WS, 1998, J BIOL CHEM, V273, P31534, DOI 10.1074/jbc.273.47.31534; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Cohen C, 1998, J STRUCT BIOL, V122, P180, DOI 10.1006/jsbi.1998.3983; D'Costa J, 2005, LEUKEMIA, V19, P921, DOI 10.1038/sj.leu.2403755; Durst KL, 2003, MOL CELL BIOL, V23, P607, DOI 10.1128/MCB.23.2.607-619.2003; FINER MH, 1994, BLOOD, V83, P43; Friedman AD, 1999, LEUKEMIA, V13, P1932, DOI 10.1038/sj.leu.2401590; Hoppe PE, 1996, J CELL BIOL, V135, P371, DOI 10.1083/jcb.135.2.371; Kummalue T, 2002, MOL CELL BIOL, V22, P8278, DOI 10.1128/MCB.22.23.8278-8291.2002; Landrette SF, 2005, BLOOD, V105, P2900, DOI 10.1182/blood-2004-09-3630; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Liu PP, 1996, GENE CHROMOSOME CANC, V16, P77, DOI 10.1002/(SICI)1098-2264(199606)16:2<77::AID-GCC1>3.0.CO;2-#; Lou JR, 2000, ONCOGENE, V19, P2695, DOI 10.1038/sj.onc.1203588; Moreno-Miralles I, 2005, J BIOL CHEM, V280, P40097, DOI 10.1074/jbc.M506855200; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nakasawa T, 2005, BIOCHEMISTRY-US, V44, P174, DOI 10.1021/bi048807h; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Sohn RL, 1997, J MOL BIOL, V266, P317, DOI 10.1006/jmbi.1996.0790; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Yang YD, 2002, CANCER RES, V62, P2232; Yoshida N, 2005, MOL CELL BIOL, V25, P1003, DOI 10.1128/MCB.25.3.1003-1012.2005	29	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	55					7289	7296		10.1038/sj.onc.1209725	http://dx.doi.org/10.1038/sj.onc.1209725			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16767164				2022-12-28	WOS:000242244700007
J	Roylance, R; Gorman, P; Papior, T; Wan, YL; Ives, M; Watson, JE; Collins, C; Wortham, N; Langford, C; Fiegler, H; Carter, N; Gillett, C; Sasieni, P; Pinder, S; Hanby, A; Tomlinson, I				Roylance, R.; Gorman, P.; Papior, T.; Wan, Y-L; Ives, M.; Watson, J. E.; Collins, C.; Wortham, N.; Langford, C.; Fiegler, H.; Carter, N.; Gillett, C.; Sasieni, P.; Pinder, S.; Hanby, A.; Tomlinson, I.			A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH	ONCOGENE			English	Article						array CGH; Chromosome 169; breast cancer	COMPARATIVE GENOMIC HYBRIDIZATION; DIFFERENT GENETIC PATHWAYS; TUMOR-SUPPRESSOR GENES; E-CADHERIN; HISTOLOGICAL GRADE; ALLELIC IMBALANCE; RECEPTOR STATUS; CANCER; HETEROZYGOSITY; CARCINOGENESIS	We analysed chromosome 16q in 106 breast cancers using tiling-path array-comparative genomic hybridization (aCGH). About 80% of ductal cancers (IDCs) and all lobular cancers (ILCs) lost at least part of 16q. Grade I (GI) IDCs and ILCs often lost the whole chromosome arm. Grade II (GII) and grade III ( GIII) IDCs showed less frequent whole-arm loss, but often had complex changes, typically small regions of gain together with larger regions of loss. The boundaries of gains/losses tended to cluster, common sites being 54.5-55.5 Mb and 57.4-58.8 Mb. Overall, the peak frequency of loss (83% cancers) occurred at 61.9-62.9 Mb. We also found several 'minimal' regions of loss/gain. However, no mutations in candidate genes (TRADD, CDH5, CDH8 and CDH11) were detected. Cluster analysis based on copy number changes identified a large group of cancers that had lost most of 16q, and two smaller groups ( one with few changes, one with a tendency to show copy number gain). Although all morphological types occurred in each cluster group, IDCs ( especially GII/GIII) were relatively over-represented in the smaller groups. Cluster groups were not independently associated with survival. Use of tiling-path aCGH prompted re-evaluation of the hypothetical pathways of breast carcinogenesis. ILCs have the simplest changes on 16q and probably diverge from the IDC lineage close to the stage of 16q loss. Higher-grade IDCs probably develop from low-grade lesions in most cases, but there remains evidence that some GII/GIII IDCs arise without a GI precursor.	Canc Res UK, Mol & Populat Genet Lab, London WC2A 3PX, England; UCSF, Collins Lab, S151, Ctr Canc, San Francisco, CA USA; Wellcome Trust Sanger Inst, Cambridge, England; Guys Hosp, CRUK Breast Pathol Lab, London SE1 9RT, England; Barts & London Med Sch, London, England; Addenbrookes Hosp, Dept Histopathol, Cambridge, England; St James Univ Hosp, Dept Histopathol, Leeds LS9 7TF, W Yorkshire, England; Univ Leeds, Acad Unit Pathol, Leeds LS2 9JT, W Yorkshire, England	Cancer Research UK; University of California System; University of California San Francisco; Wellcome Trust Sanger Institute; Guy's & St Thomas' NHS Foundation Trust; University of London; Queen Mary University London; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Saint James's University Hospital; University of Leeds	Roylance, R (corresponding author), Canc Res UK, Mol & Populat Genet Lab, Lincolns Inn Fields, London WC2A 3PX, England.	rebecca.roylance@cancer.org.uk	Wan, Y Louise/AAU-1839-2021	Wan, Y Louise/0000-0003-1441-6050; Sasieni, Peter/0000-0003-1509-8744; /0000-0003-4167-8910	Wellcome Trust [077008] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Barnes DM, 2004, ENDOCR-RELAT CANCER, V11, P85, DOI 10.1677/erc.0.0110085; Berx G, 1996, ONCOGENE, V13, P1919; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Buerger H, 1999, J PATHOL, V189, P521, DOI 10.1002/(SICI)1096-9896(199912)189:4<521::AID-PATH472>3.0.CO;2-B; Cleton-Jansen AM, 2004, GENE CHROMOSOME CANC, V41, P109, DOI 10.1002/gcc.20070; Cleton-Jansen AM, 2002, BREAST CANCER RES, V4, P5, DOI 10.1186/bcr416; Cleton-Jansen AM, 1999, BRIT J CANCER, V79, P1049, DOI 10.1038/sj.bjc.6690168; Cleton-Jansen AM, 2001, CANCER RES, V61, P1171; Cooper LS, 1999, CANCER-AM CANCER SOC, V86, P2053, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2053::AID-CNCR24>3.0.CO;2-H; Crawford J, 1999, GENOMICS, V56, P90, DOI 10.1006/geno.1998.5676; Devilee P, 2001, TRENDS GENET, V17, P569, DOI 10.1016/S0168-9525(01)02416-7; DORIONBONNET F, 1995, GENE CHROMOSOME CANC, V14, P171, DOI 10.1002/gcc.2870140304; Douglas EJ, 2004, CANCER RES, V64, P4817, DOI 10.1158/0008-5472.CAN-04-0328; Droufakou S, 2001, INT J CANCER, V92, P404, DOI 10.1002/ijc.1208; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Frengen E, 2000, GENOMICS, V70, P273, DOI 10.1006/geno.2000.6389; Hwang ES, 2004, CANCER, V100, P2562, DOI 10.1002/cncr.20273; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Kern SE, 2002, CANCER BIOL THER, V1, P571, DOI 10.4161/cbt.1.5.225; Korsching E, 2004, BRIT J CANCER, V90, P1422, DOI 10.1038/sj.bjc.6601658; Millis RR, 1998, EUR J CANCER, V34, P548, DOI 10.1016/S0959-8049(97)10072-7; Nishizaki T, 1997, INT J CANCER, V74, P513, DOI 10.1002/(SICI)1097-0215(19971021)74:5<513::AID-IJC6>3.3.CO;2-X; Pandis N, 1996, INT J CANCER, V66, P191, DOI 10.1002/(SICI)1097-0215(19960410)66:2<191::AID-IJC9>3.0.CO;2-Y; Quon KC, 2001, GENE DEV, V15, P2917, DOI 10.1101/gad.949001; Roylance R, 1999, CANCER RES, V59, P1433; Roylance R, 2003, J PATHOL, V200, P53, DOI 10.1002/path.1326; Roylance R, 2002, J PATHOL, V196, P32, DOI 10.1002/path.1006; Santarosa M, 2004, BBA-REV CANCER, V1654, P105, DOI 10.1016/j.bbcan.2004.01.001; Sharp AJ, 2005, AM J HUM GENET, V77, P78, DOI 10.1086/431652; Tomlinson IPM, 2002, GENE CHROMOSOME CANC, V34, P349, DOI 10.1002/gcc.10085; TSUDA H, 1994, CANCER RES, V54, P513; Watson JEV, 2004, ONCOGENE, V23, P3487, DOI 10.1038/sj.onc.1207474; Whitmore SA, 1998, GENOMICS, V50, P1, DOI 10.1006/geno.1998.5316	34	58	60	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2006	25	49					6544	6553		10.1038/sj.onc.1209659	http://dx.doi.org/10.1038/sj.onc.1209659			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16702952	Green Accepted			2022-12-28	WOS:000241395100011
J	Wani, AA; Sharma, N; Shouche, YS; Bapat, SA				Wani, A. A.; Sharma, N.; Shouche, Y. S.; Bapat, S. A.			Nuclear-mitochondrial genomic profiling reveals a pattern of evolution in epithelial ovarian tumor stem cells	ONCOGENE			English	Article						ovarian cancer; tumor stem cells; mtDNA; CREBBP; mutational profiling	TRANSCRIPTIONAL COACTIVATOR CBP; RUBINSTEIN-TAYBI-SYNDROME; DNA; CANCER; IDENTIFICATION; PROGRESSION; ACTIVATION; MUTATIONS; ACETYLATION; BROMODOMAIN	Analyses of genome orthologs in cancer on the background of tumor heterogeneity, coupled with the recent identification that the tumor propagating capacity resides within a very small fraction of cells ( the tumor stem cells-TSCs), has not been achieved. Here, we describe a strategy to explore genetic drift in the mitochondrial genome accompanying varying stem cell dynamics in epithelial ovarian cancer. A major and novel outcome is the identification of a specific mutant mitochondrial DNA pro. le associated with the TSC lineage that is drastically different from the germ line pro. le. This pro. le, however, is often camouflaged in the primary tumor, and sometimes may not be detected even after metastases, questioning the validity of whole tumor pro. ling towards determining individual prognosis. Continuing mutagenesis in subsets with a mutant mitochondrial genome could result in transformation through a cooperative effect with nuclear genes - a representative example in our study is a tumor suppressor gene viz. cAMP responsive element binding binding protein. This specific pro. le could be a critical predisposing step undertaken by a normal stem cell to overcome a tightly regulated mutation rate and DNA repair in its evolution towards tumorigenesis. Our findings suggest that varying stem cell dynamics and mutagenesis de. ne TSC progression that may clinically translate into increasing tumor aggression with serious implications for prognosis.	Natl Ctr Cell Sci, Pune 411007, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Bapat, SA (corresponding author), Natl Ctr Cell Sci, NCCS Complex,Pune Univ Campus,Ganeskkhind, Pune 411007, Maharashtra, India.	sabapat@nccs.res.in	Bapat, Sharmila/AGU-4130-2022; SHOUCHE, YOGESH/C-1231-2009; Sharma, Neeti/L-6282-2019	Bapat, Sharmila/0000-0002-9557-2233; Sharma, Neeti/0000-0002-4457-5717				Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alonso A, 2005, J CLIN PATHOL, V58, P83, DOI 10.1136/jcp.2004.017673; Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779; Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931; Beckman RA, 2005, GENETICS, V171, P2123, DOI 10.1534/genetics.105.040840; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Calabrese P, 2004, AM J PATHOL, V164, P1337, DOI 10.1016/S0002-9440(10)63220-8; Choi JH, 2000, BIOINFORMATICS, V16, P1056, DOI 10.1093/bioinformatics/16.11.1056; Coller HA, 2005, MUTAT RES-FUND MOL M, V578, P256, DOI 10.1016/j.mrfmmm.2005.05.014; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Deng Z, 2003, MOL CELL BIOL, V23, P2633, DOI 10.1128/MCB.23.8.2633-2644.2003; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; Florian S, 2006, LEUKEMIA LYMPHOMA, V47, P207, DOI 10.1080/10428190500272507; Goodman RH, 2000, GENE DEV, V14, P1553; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Hayashida K, 2005, CELL BIOL INT, V29, P472, DOI 10.1016/j.cellbi.2004.09.016; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Knudson AG, 1996, J CANCER RES CLIN, V122, P135, DOI 10.1007/BF01366952; Kung AL, 2000, GENE DEV, V14, P272; Michor F, 2004, NAT REV CANCER, V4, P197, DOI 10.1038/nrc1295; *MITOMAP, 2005, HUM MIT GEN DAT; Murata T, 2001, HUM MOL GENET, V10, P1071, DOI 10.1093/hmg/10.10.1071; O'Brien TW, 2005, GENE, V354, P147, DOI 10.1016/j.gene.2005.03.026; Pakendorf B, 2005, ANNU REV GENOM HUM G, V6, P165, DOI 10.1146/annurev.genom.6.080604.162249; Palanichamy MG, 2004, AM J HUM GENET, V75, P966, DOI 10.1086/425871; Parfait B, 1998, BIOCHEM BIOPH RES CO, V247, P57, DOI 10.1006/bbrc.1998.8666; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Rieder MJ, 1998, NUCLEIC ACIDS RES, V26, P967, DOI 10.1093/nar/26.4.967; Schmid M, 2004, CYTOGENET GENOME RES, V104, P277, DOI 10.1159/000077502; Shigeno K, 2004, CANCER LETT, V213, P11, DOI 10.1016/S0304-3835(03)00442-7; Shin MG, 2004, BLOOD, V103, P553, DOI 10.1182/blood-2003-05-1724; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; Singh KK, 2005, GENE, V354, P140, DOI 10.1016/j.gene.2005.03.027; Singh SK, 2003, CANCER RES, V63, P5821; van Tilborg AAG, 2000, HUM MOL GENET, V9, P2973, DOI 10.1093/hmg/9.20.2973	37	31	33	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2006	25	47					6336	6344		10.1038/sj.onc.1209649	http://dx.doi.org/10.1038/sj.onc.1209649			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	094CY	16732329				2022-12-28	WOS:000241218200010
J	Keating, AK; Salzberg, DB; Sather, S; Liang, X; Nickoloff, S; Anwar, A; DeRyckere, D; Hill, K; Joung, D; Sawczyn, KK; Park, J; Curran-Everett, D; McGavran, L; Meltesen, L; Gore, L; Johnson, GL; Graham, DK				Keating, A. K.; Salzberg, D. B.; Sather, S.; Liang, X.; Nickoloff, S.; Anwar, A.; DeRyckere, D.; Hill, K.; Joung, D.; Sawczyn, K. K.; Park, J.; Curran-Everett, D.; McGavran, L.; Meltesen, L.; Gore, L.; Johnson, G. L.; Graham, D. K.			Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase	ONCOGENE			English	Article						receptor tyrosine kinase; MerTK; leukemia; lymphoma; transgenic mouse	GENE-EXPRESSION; V-RYK; LEUKEMIA; GROWTH; MYC; CELLS; MOUSE; PROTOONCOGENE; MICROARRAYS; ACTIVATION	Mer (MerTK) is a receptor tyrosine kinase important in platelet aggregation, as well as macrophage cytokine secretion and clearance of apoptotic cells. Mer is not normally expressed in thymocytes or lymphocytes; however, ectopic Mer RNA transcript and protein expression is found in a subset of acute lymphoblastic leukemia cell lines and patient samples, suggesting a role in leukemogenesis. To investigate the oncogenic potential of Mer in vivo, we created a transgenic mouse line (Mer(Tg)) that expresses Mer in the hematopoietic lineage under control of the Vav promoter. Ectopic expression and activation of the transgenic Mer protein was demonstrated in lymphocytes and thymocytes of the Mer(Tg) mice. At 12 - 24 months of age, greater than 55% of the Mer(Tg) mice, compared to 12% of the wild type, developed adenopathy, hepatosplenomegaly, and circulating lymphoblasts. Histopathological analysis and flow cytometry were consistent with T-cell lymphoblastic leukemia/lymphoma. Mer may contribute to leukemogenesis by activation of Akt and ERK1/2 anti-apoptotic signals, which were upregulated in MerTg mice. Additionally, a significant survival advantage was noted in MerTg lymphocytes compared to wild-type lymphocytes after dexamethasone treatment. These data suggest that Mer plays a cooperative role in leukemogenesis and may be an effective target for biologically based leukemia/lymphoma therapy.	Univ Colorado Denver & Hlth Sci Ctr, Dept Pathol, Denver, CO USA; Natl Jewish Med & Res Ctr, Div Biostat, Denver, CO USA; Univ Colorado Denver & Hlth Sci Ctr, Dept Pediat, Denver, CO USA; Univ Colorado Denver & Hlth Sci Ctr, Dept Prevent Med, Denver, CO USA; Univ Colorado Denver & Hlth Sci Ctr, Dept Biometr, Denver, CO USA; Univ Colorado Denver & Hlth Sci Ctr, Dept Physiol & Biophys, Denver, CO USA; Univ Colorado Denver & Hlth Sci Ctr, Colorado Cytogenet, Denver, CO USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC USA	University of Colorado System; University of Colorado Anschutz Medical Campus; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of North Carolina; University of North Carolina Chapel Hill	Graham, DK (corresponding author), Univ Colorado Denver & Hlth Sci Ctr, Dept Pediat, Mail Stop 8302,Bldg RC-1 N,POB 6511,12800 E 19th, Aurora, CO 80045 USA.	doug.graham@uchsc.edu			NATIONAL CANCER INSTITUTE [T32CA082086] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA86068604, T32 CA082086] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1999, ONCOGENE, V18, P5268, DOI 10.1038/sj.onc.1202997; Anderson KE, 2003, INT J BIOCHEM CELL B, V35, P1028, DOI 10.1016/S1357-2725(02)00270-4; Behrens EM, 2003, EUR J IMMUNOL, V33, P2160, DOI 10.1002/eji.200324076; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Borgel D, 2006, CRIT CARE MED, V34, P219, DOI 10.1097/01.CCM.0000195014.56254.8A; Chen J, 1997, ONCOGENE, V14, P2033, DOI 10.1038/sj.onc.1201039; Curran-Everett D, 2000, AM J PHYSIOL-REG I, V279, pR1, DOI 10.1152/ajpregu.2000.279.1.R1; Dirks W, 1999, LEUKEMIA RES, V23, P643, DOI 10.1016/S0145-2126(99)00075-2; Dormady SP, 2000, P NATL ACAD SCI USA, V97, P12260, DOI 10.1073/pnas.97.22.12260; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Ek S, 2002, CANCER RES, V62, P4398; Evans CO, 2001, J CLIN ENDOCR METAB, V86, P3097, DOI 10.1210/jc.86.7.3097; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Georgescu MM, 1999, MOL CELL BIOL, V19, P1171; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; GRAHAM DK, 1995, ONCOGENE, V10, P2349; GRAHAM DK, 2006, IN PRESS CLIN CANC R, V12; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Grandage VL, 2005, LEUKEMIA, V19, P586, DOI 10.1038/sj.leu.2403653; Graux C, 2004, NAT GENET, V36, P1084, DOI 10.1038/ng1425; Guttridge KL, 2002, J BIOL CHEM, V277, P24057, DOI 10.1074/jbc.M112086200; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HENZE G, 1991, BLOOD, V78, P1166; JIA R, 1992, J VIROL, V66, P5975, DOI 10.1128/JVI.66.10.5975-5987.1992; JIA R, 1994, J BIOL CHEM, V269, P1839; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389; LING L, 1995, MOL CELL BIOL, V15, P6582; Naf D, 2002, CANCER RES, V62, P1235; Ogilvy S, 1999, BLOOD, V94, P1855; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Pui CH, 1998, NEW ENGL J MED, V339, P605, DOI 10.1056/NEJM199808273390907; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Sattler M, 2004, LEUKEMIA RES, V28, pS11, DOI 10.1016/j.leukres.2003.10.004; Savage DG, 2002, NEW ENGL J MED, V346, P683, DOI 10.1056/NEJMra013339; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schrappe M, 2000, LEUKEMIA, V14, P2193, DOI 10.1038/sj.leu.2401977; Silverman LB, 2001, BLOOD, V97, P1211, DOI 10.1182/blood.V97.5.1211; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Tibes R, 2005, ANNU REV PHARMACOL, V45, P357, DOI 10.1146/annurev.pharmtox.45.120403.100124; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wolfraim LA, 2004, NEW ENGL J MED, V351, P552, DOI 10.1056/NEJMoa031197; Wu CW, 2002, ANTICANCER RES, V22, P1071; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6	49	68	81	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6092	6100		10.1038/sj.onc.1209633	http://dx.doi.org/10.1038/sj.onc.1209633			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16652142				2022-12-28	WOS:000241101200006
J	Manuvakhova, M; Thottassery, JV; Hays, S; Qu, Z; Rentz, SS; Westbrook, L; Kern, FG				Manuvakhova, M.; Thottassery, J. V.; Hays, S.; Qu, Z.; Rentz, S. S.; Westbrook, L.; Kern, F. G.			Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells	ONCOGENE			English	Article						breast cancer; antiestrogen resistance; FGF; SNT-1 PTB domain; signal transduction	P70 S6 KINASE; SIGNAL-TRANSDUCTION PATHWAYS; DOCKING-PROTEIN FRS2-ALPHA; PC12 CELLS; FACTOR RECEPTORS; TYROSINE KINASE; RAPAMYCIN TOR; MCF-7 CELLS; NUDE-MICE; FACTOR-IV	Fibroblast growth factor (FGF) signaling can bypass the requirement for estrogen receptor (ER) activation in the growth of ER-positive (ER+) breast cancer cells. Fibroblast growth factor-1 stimulation leads to phosphorylation of the adaptor protein Suc1-associated neurotrophic factor-induced tyrosine-phosphorylated target (SNT-1) on C-terminal tyrosine residues, whereas it is constitutively bound through its N-terminal phosphotyrosine-binding domain (PTB) to FGF receptors (FGFRs). By expressing the PTB domain of SNT-1 (SNT-1 PTB) in an inducible manner in an ER+ breast carcinoma line, ML20, we asked whether we could uncouple FGFR activation from its downstream signaling components and abrogate FGF-1-induced antiestrogen-resistant growth. Induction of SNT-1 PTB resulted in a significant decrease of FGF-1-dependent tyrosine phosphorylation of endogenous SNT-1, strong inhibition of complex formation between SNT-1, Gab-1 and Sos-1, and reduced activation of Ras, mitogen-activated protein kinase (MAP kinase), and Akt. SNT-1 PTB also inhibited the phosphorylation of p70S6K on Thr421/Ser424 and Ser411, which may result from the abrogation of MAP kinase activity. Moreover, we also observed a decreased phosphorylation of the MAP kinase-independent site Thr389. This may reflect both inhibition of PI-3 kinase pathways and mammalian target of rapamycin (mTOR)-dependent signaling, as the phosphorylation of Thr389 site was sensitive to treatment with the PI3-K and mTOR inhibitors, LY294002 and rapamycin, respectively. Collectively these results suggest that SNT-1 plays a pivotal role in FGF-dependent activation of the Ras-MAP kinase, PI-3 kinase, and mTOR pathways in these cells. Fibroblast growth factor-1 dependent colony formation of ML20 cells in media containing the pure antiestrogen ICI 182,780 was also markedly inhibited upon induction of SNT-1 PTB, suggesting that blockade of FGFR-SNT-1 interactions might abrogate FGF-mediated antiestrogen resistance in breast cancers.	Lexicon Genet Inc, Div Pharmaceut Biol, The Woodlands, TX 77381 USA; So Res Inst, Drug Discovery Div, Dept Biochem & Mol Biol, Birmingham, AL 35255 USA; UAB Comprehens Canc Ctr, Birmingham, AL USA	Lexicon Pharmaceuticals; University of Alabama System; University of Alabama Birmingham	Kern, FG (corresponding author), Lexicon Genet Inc, Div Pharmaceut Biol, 8800 Technol Forest Pl, The Woodlands, TX 77381 USA.	fkern@lexgen.com			NCI NIH HHS [CA50376, P30CA13148] Funding Source: Medline; NIAID NIH HHS [P30AI27767] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013148, R01CA050376] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027767] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; Califano D, 2000, J BIOL CHEM, V275, P19297, DOI 10.1074/jbc.M905866199; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; Dennis PB, 1998, J BIOL CHEM, V273, P14845, DOI 10.1074/jbc.273.24.14845; Dhalluin C, 2000, MOL CELL, V6, P921, DOI 10.1016/S1097-2765(00)00089-7; Dunican DJ, 2001, CELL GROWTH DIFFER, V12, P255; Ehrhard KN, 2000, NAT BIOTECHNOL, V18, P1075, DOI 10.1038/80274; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Gonzalez-Garcia A, 2002, J BIOL CHEM, V277, P1500, DOI 10.1074/jbc.M103808200; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Iijima Y, 2002, J BIOL CHEM, V277, P23065, DOI 10.1074/jbc.M200328200; JAAKKOLA S, 1993, INT J CANCER, V54, P378, DOI 10.1002/ijc.2910540305; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kimpinski K, 2001, J NEUROSCI RES, V63, P486, DOI 10.1002/jnr.1043; Klint P, 1999, ONCOGENE, V18, P3354, DOI 10.1038/sj.onc.1202680; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Koziczak M, 2004, ONCOGENE, V23, P3501, DOI 10.1038/sj.onc.1207331; KUREBAYASHI J, 1993, CANCER RES, V53, P2178; Kurokawa K, 2001, ONCOGENE, V20, P1929, DOI 10.1038/sj.onc.1204290; Lamothe B, 2004, MOL CELL BIOL, V24, P5657, DOI 10.1128/MCB.24.13.5657-5666.2004; Lax I, 2002, MOL CELL, V10, P709, DOI 10.1016/S1097-2765(02)00689-5; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; McLeskey SW, 1998, CLIN CANCER RES, V4, P697; MCLESKEY SW, 1993, CANCER RES, V53, P2168; McLeskey SW, 1996, BREAST CANCER RES TR, V39, P103, DOI 10.1007/BF01806082; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; Moffa AB, 2004, MOL CANCER RES, V2, P643; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; Ong SH, 1996, BIOCHEM BIOPH RES CO, V225, P1021, DOI 10.1006/bbrc.1996.1288; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; PRICE DJ, 1991, J BIOL CHEM, V266, P16281; Qu ZC, 2004, GENE, V327, P61, DOI 10.1016/j.gene.2003.10.029; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Romanelli A, 2002, J BIOL CHEM, V277, P40281, DOI 10.1074/jbc.M205168200; Stoletov KV, 2002, FASEB J, V16, P1283, DOI 10.1096/fj.01-0835fje; Tsoulfas P, 1996, J BIOL CHEM, V271, P5691, DOI 10.1074/jbc.271.10.5691; Urlinger S, 2000, P NATL ACAD SCI USA, V97, P7963, DOI 10.1073/pnas.130192197; Wang F, 2002, IN VITRO CELL DEV-AN, V38, P178; Wang JK, 1996, ONCOGENE, V13, P721; Wu YJ, 2003, BIOL CHEM, V384, P1215, DOI 10.1515/BC.2003.134; XIE WQ, 1991, BIOTECHNIQUES, V11, P324; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; Xu H, 2001, J BIOL CHEM, V276, P13049, DOI 10.1074/jbc.M009925200; Yonezawa K, 2004, BIOCHEM BIOPH RES CO, V313, P437, DOI 10.1016/j.bbrc.2003.07.018; Yoshimura N, 1998, CLIN IMMUNOL IMMUNOP, V89, P28, DOI 10.1006/clin.1998.4551; Yuen EC, 1999, EXP NEUROL, V159, P297, DOI 10.1006/exnr.1999.7148; Zhang LR, 1997, ONCOGENE, V15, P2093, DOI 10.1038/sj.onc.1201386; Zhang YG, 2001, J BIOL CHEM, V276, P20913, DOI 10.1074/jbc.M009047200; Zhang YY, 2004, J BIOL CHEM, V279, P55348, DOI 10.1074/jbc.M409230200	59	15	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2006	25	44					6003	6014		10.1038/sj.onc.1209592	http://dx.doi.org/10.1038/sj.onc.1209592			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16682955				2022-12-28	WOS:000240826300009
J	Tomkova, K; El-Rifai, W; Vilgelm, A; Kelly, MC; Wang, TC; Zaika, AI				Tomkova, K.; El-Rifai, W.; Vilgelm, A.; Kelly, M. C.; Wang, T. C.; Zaika, A. I.			The gastrin gene promoter is regulated by p73 isoforms in tumor cells	ONCOGENE			English	Article						p53; p63; p73; gastric tumor; esophageal tumor; colorectal tumor	INTESTINAL EPITHELIAL-CELLS; GLYCINE-EXTENDED GASTRIN; WILD-TYPE P73; COLORECTAL-CARCINOMA; TRANSGENIC MICE; FAMILY-MEMBERS; HUMAN CANCERS; LUNG-CANCER; IN-VITRO; EXPRESSION	p73, a new p53 family member, is a transcription factor that is increasingly recognized in cancer research as an important player in tumorigenesis as well as in chemotherapeutic drug sensitivity. Despite the substantial structural and functional similarities to p53, accumulating evidence suggests that p53 and p73 may differently regulate their transcriptional targets. In this study, we have investigated the role of p73 in regulation of the gastrin gene promoter. Gastrin is a peptide hormone and an important factor in determining the progression of a number of human malignancies. Our results show that p73 can bind to the gastrin promoter. This leads to transcriptional upregulation of gastrin mRNA. We also found that the levels of gastrin and p73 transcripts correlate in primary gastric tumors. Taken together, our results demonstrate a novel mechanism for regulation of gastrin gene transcription and support a concept that p53 and p73 may have different biological roles in tumors.	Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Columbia Univ, Med Ctr, Div Digest & Liver Dis, New York, NY USA	Vanderbilt University; Vanderbilt University; Columbia University	Zaika, AI (corresponding author), Vanderbilt Univ, Med Ctr, Dept Surg, 1255 Light Hall, Nashville, TN 37232 USA.	alex.zaika@vanderbilt.edu		Vilgelm, Anna/0000-0002-4446-913X; Tomkova, Katarina/0000-0003-0482-5707; Wang, Timothy/0000-0001-5730-3019	NCI NIH HHS [CA-108956] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA108956] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aly A, 2004, BBA-REV CANCER, V1704, P1, DOI 10.1016/j.bbcan.2004.01.004; Aly A, 2001, INT J CANCER, V94, P307, DOI 10.1002/ijc.1483; Baldwin GS, 2001, J BIOL CHEM, V276, P7791, DOI 10.1074/jbc.M009985200; Benard J, 2003, HUM MUTAT, V21, P182, DOI 10.1002/humu.10172; Brown D, 2003, ENDOCRINOLOGY, V144, P201, DOI 10.1210/en.2002-220501; Caplin M, 2000, BRIT J SURG, V87, P1035, DOI 10.1046/j.1365-2168.2000.01488.x; CICCOTOSTO GD, 1995, GASTROENTEROLOGY, V109, P1142, DOI 10.1016/0016-5085(95)90572-3; Cobb S, 2004, CANCER-AM CANCER SOC, V100, P1311, DOI 10.1002/cncr.20094; Daulhac L, 1999, J BIOL CHEM, V274, P20657, DOI 10.1074/jbc.274.29.20657; FINLEY GG, 1993, CANCER RES, V53, P2919; Fox JG, 2003, GASTROENTEROLOGY, V124, P1879, DOI 10.1016/S0016-5085(03)00406-2; Goetze JP, 2000, CANCER, V88, P2487, DOI 10.1002/1097-0142(20000601)88:11<2487::AID-CNCR9>3.0.CO;2-E; Guan M, 2003, JPN J CLIN ONCOL, V33, P215, DOI 10.1093/jjco/hyg045; Han S, 1999, EUR J SURG ONCOL, V25, P194, DOI 10.1053/ejso.1998.0626; HANSEN OH, 1976, GUT, V17, P536, DOI 10.1136/gut.17.7.536; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Kang MJ, 2000, CLIN CANCER RES, V6, P1767; KOCHMAN ML, 1992, BIOCHEM BIOPH RES CO, V189, P1165, DOI 10.1016/0006-291X(92)92326-S; Koh TJ, 2000, J CLIN INVEST, V106, P533, DOI 10.1172/JCI9476; Koh TJ, 1999, J CLIN INVEST, V103, P1119, DOI 10.1172/JCI4910; Koh TJ, 2004, CANCER RES, V64, P196, DOI 10.1158/0008-5472.CAN-03-2112; Liu L, 2001, J INT MED RES, V29, P297, DOI 10.1177/147323000102900406; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; Ng SW, 2000, ONCOGENE, V19, P1885, DOI 10.1038/sj.onc.1203512; Nimura Y, 1998, INT J CANCER, V78, P437, DOI 10.1002/(SICI)1097-0215(19981109)78:4<437::AID-IJC8>3.0.CO;2-V; Pilozzi E, 2003, J CLIN PATHOL-MOL PA, V56, P60, DOI 10.1136/mp.56.1.60; SEVA C, 1994, SCIENCE, V265, P410, DOI 10.1126/science.8023165; Seva C, 1996, FEBS LETT, V378, P74, DOI 10.1016/0014-5793(95)01414-4; Singh P, 2000, GASTROENTEROLOGY, V119, P162, DOI 10.1053/gast.2000.8527; Singh P, 2003, AM J PHYSIOL-GASTR L, V284, pG328, DOI 10.1152/ajpgi.00351.2002; Stiewe T, 2004, CLIN CANCER RES, V10, P626, DOI 10.1158/1078-0432.CCR-0153-03; Sun XF, 2002, CLIN CANCER RES, V8, P165; Tannapfel A, 1999, J NATL CANCER I, V91, P1154, DOI 10.1093/jnci/91.13.1154; Tannapfel A, 2001, J PATHOL, V195, P163, DOI 10.1002/path.947; Tokuchi Y, 1999, BRIT J CANCER, V80, P1623, DOI 10.1038/sj.bjc.6690572; Tomkova K, 2004, CANCER RES, V64, P6390, DOI 10.1158/0008-5472.CAN-04-2176; Wang TC, 1996, J CLIN INVEST, V98, P1918, DOI 10.1172/JCI118993; Wang TC, 2000, GASTROENTEROLOGY, V118, P36, DOI 10.1016/S0016-5085(00)70412-4; Weber A, 2002, INT J CANCER, V99, P22, DOI 10.1002/ijc.10296; Zaika AI, 1999, CANCER RES, V59, P3257; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179	41	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2006	25	44					6032	6036		10.1038/sj.onc.1209610	http://dx.doi.org/10.1038/sj.onc.1209610			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16636659				2022-12-28	WOS:000240826300012
J	Mizumoto, Y; Kyo, S; Ohno, S; Hashimoto, M; Nakamura, M; Maida, Y; Sakaguchi, J; Takakura, M; Inoue, M; Kiyono, T				Mizumoto, Y.; Kyo, S.; Ohno, S.; Hashimoto, M.; Nakamura, M.; Maida, Y.; Sakaguchi, J.; Takakura, M.; Inoue, M.; Kiyono, T.			Creation of tumorigenic human endometrial epithelial cells with intact chromosomes by introducing defined genetic elements	ONCOGENE			English	Article						endometrial cancer; carcinogenesis; immortalization; tumorigenicity; K-ras	COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN TUMOR-CELLS; MICROSATELLITE INSTABILITY; 3T3-L1 ADIPOCYTES; IN-VITRO; PTEN; SUPPRESSOR; CARCINOGENESIS; CARCINOMA; HYPERPLASIA	Several genetic mutations have been identified in human endometrial cancers, but the specific combinations of mutations required to form endometrial cancer cells remain unknown. In the present study, we established an in vitro model of endometrial carcinogenesis, in which defined genetic elements were introduced into endometrial epithelial cells to create transformed endometrial cells at different stages. Introduction of the human papillomavirus type 16 E6/E7 gene and the human telomerase reverse transcriptase (hTERT) gene into human primary endometrial epithelial cells was sufficient to generate immortalized cells. Introduction of hTERT in early passages stabilized telomeres and created immortalized cells with normal karyotype, whereas introduction of hTERT in later passages generated immortalized cells but with widespread chromosome abnormalities. However, neither of those two immortalized cell lines exhibited tumorigenic phenotypes. Tumorigenic endometrial epithelial cells with invasive capacity were created by introducing a mutant K-ras allele into immortalized cells, keeping their chromosomes intact. Inhibiting the PTEN gene and activating Akt pathways did not create tumorigenic phenotypes, although the latter conferred anchorage-independent growth capacity. These findings suggest that neoplastic transformation of human endometrial cells can occur in the absence of widespread chromosomal abnormality, and that the combination of Rb inactivation, telomerase activation and altered K-ras signaling is sufficient for in vitro neoplastic transformation. The present experimental model can help clarify the genetic requirements for endometrial carcinogenesis, and it is useful for testing and developing specific inhibitors of specific oncogenic pathways.	Kanazawa Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, Kanazawa, Ishikawa 9208641, Japan; Natl Canc Ctr, Res Inst, Div Virol, Kanazawa, Ishikawa, Japan	Kanazawa University; National Cancer Center - Japan	Kyo, S (corresponding author), Kanazawa Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.	satoruky@med.kanazawa-u.ac.jp	Kiyono, Tohru/H-5834-2011; Takakura, Masahiro/E-1080-2011					Akoum A, 1996, J REPROD MED, V41, P555; Arnold JT, 2001, HUM REPROD, V16, P836, DOI 10.1093/humrep/16.5.836; Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Berger R, 2004, CANCER RES, V64, P8867, DOI 10.1158/0008-5472.CAN-04-2938; Boland CR, 1998, CANCER RES, V58, P5248; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; ClassenLinke I, 1997, CELL TISSUE RES, V287, P171; ENOMOTO T, 1991, CANCER RES, V51, P5308; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hirasawa A, 2003, CLIN CANCER RES, V9, P5675; Inoue M, 2001, INT J GYNECOL CANCER, V11, P339, DOI 10.1046/j.1525-1438.2001.01046.x; Kanaya T, 2005, AM J CLIN PATHOL, V124, P89, DOI 10.1309/PAACLG8DXDK0X2B1; KATABUCHI H, 1995, CANCER RES, V55, P5556; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kyo S, 2003, AM J PATHOL, V163, P2259, DOI 10.1016/S0002-9440(10)63583-3; Levine RL, 1998, CANCER RES, V58, P3254; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maxwell GL, 1998, CANCER RES, V58, P2500; Mutter GL, 1999, J CLIN PATHOL-MOL PA, V52, P257, DOI 10.1136/mp.52.5.257; Niemann TH, 1997, GYNECOL ONCOL, V65, P232, DOI 10.1006/gyno.1997.4664; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sawada M, 2004, CELL DEATH DIFFER, V11, P997, DOI 10.1038/sj.cdd.4401438; Semczuk Andrzej, 2004, Archives of Gynecology and Obstetrics, V269, P104, DOI 10.1007/s00404-002-0449-6; Sonoda G, 1997, GENE CHROMOSOME CANC, V18, P115, DOI 10.1002/(SICI)1098-2264(199702)18:2<115::AID-GCC6>3.0.CO;2-5; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tang XQ, 2005, J BIOL CHEM, V280, P22523, DOI 10.1074/jbc.M501949200; Tashiro H, 1997, CANCER RES, V57, P3935; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6; Zimonjic D, 2001, CANCER RES, V61, P8838	31	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2006	25	41					5673	5682		10.1038/sj.onc.1209575	http://dx.doi.org/10.1038/sj.onc.1209575			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16636665				2022-12-28	WOS:000240599100009
J	Cuevas, BD; Winter-Vann, AM; Johnson, NL; Johnson, GL				Cuevas, B. D.; Winter-Vann, A. M.; Johnson, N. L.; Johnson, G. L.			MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer	ONCOGENE			English	Article						breast cancer; metastasis; kinase; proteinase; MAPK; knockout	UROKINASE PLASMINOGEN-ACTIVATOR; HUMAN-BREAST-CANCER; DEFICIENT MICE; GROWTH-FACTOR; REDUCED METASTASIS; GENE DISRUPTION; ERK/MAP KINASE; MESSENGER-RNA; IN-VITRO; EXPRESSION	Mammary tumor cells are required to degrade the surrounding matrix and disseminate in order to metastasize, and both of these processes are controlled by a tumor cell-signaling network that remains poorly defined. MEKK1 is a MAPKKK that regulates both the extracellular signal regulated kinase (ERK1/2) and the c-Jun amino terminal kinase (JNK) signaling pathways. MEKK1 signaling regulates migration through control of cell adhesion and is required for inducible expression of urokinase-type plasminogen activator (uPA). MEKK1-deficient mice with mammary gland-targeted expression of the polyoma middle T antigen (PyMT) transgene develop primary mammary tumors at a rate and frequency similar to wild-type littermates, indicating that MEKK1 deficiency does not affect PyMT-mediated transformation. However, MEKK1-/- mice display significantly delayed tumor cell dissemination and lung metastasis. Delayed MEKK1-dependent tumor dissemination is associated with markedly reduced tumor uPA expression, gelatinase activity, and prolonged tumor basement membrane integrity. siRNA-mediated MEKK1 knockdown inhibits uPA activity, cell migration and invasion in MDA-MB-231 human breast cancer cells. Thus MEKK1 controls tumor progression by regulating both the migration and proteolysis aspects of tumor cell invasiveness. To our knowledge, this is the first example of a MAPKKK that regulates metastasis through control of tumor invasiveness.	Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Cuevas, BD (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, 1108 Mary Ellen Jones Bldg,Campus Box 7365, Chapel Hill, NC 27599 USA.	bruce_cuevas@med.unc.edu; glj@med.unc.edu	, Pathology Services Core/CEZ-2246-2022		NIDDK NIH HHS [DK37871] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed F, 2002, CANCER RES, V62, P7166; Almholt K, 2005, INT J CANCER, V113, P525, DOI 10.1002/ijc.20631; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Balduyck M, 2000, CLIN EXP METASTAS, V18, P171, DOI 10.1023/A:1006762425323; Bianco FJ, 1998, CLIN CANCER RES, V4, P3011; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; BRONZERT DA, 1987, P NATL ACAD SCI USA, V84, P5763, DOI 10.1073/pnas.84.16.5763; Bugge TH, 1998, ONCOGENE, V16, P3097, DOI 10.1038/sj.onc.1201869; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Christensen L, 1996, INT J CANCER, V66, P441; Cirillo G, 1999, MOL CELL BIOL, V19, P6240; Cuevas BD, 2005, ONCOGENE, V24, P801, DOI 10.1038/sj.onc.1208239; Cuevas BD, 2003, EMBO J, V22, P3346, DOI 10.1093/emboj/cdg322; D'Orazio D, 1997, GENE, V201, P179, DOI 10.1016/S0378-1119(97)00445-9; DAVIES B, 1993, CANCER RES, V53, P5365; Duffy MJ, 2004, ANN CLIN BIOCHEM, V41, P370, DOI 10.1258/0004563041731529; Duffy MJ, 2004, CLIN BIOCHEM, V37, P541, DOI 10.1016/j.clinbiochem.2004.05.013; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; ELYAZIDI I, 1995, ANTICANCER RES, V15, P783; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FIDLER IJ, 1991, ACTA ONCOL, V30, P669, DOI 10.3109/02841869109092438; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Frederiks WM, 2004, J HISTOCHEM CYTOCHEM, V52, P711, DOI 10.1369/jhc.4R6251.2004; Fuchs SY, 1996, ONCOGENE, V13, P1531; Gelder MEV, 2004, CANCER RES, V64, P4563, DOI 10.1158/0008-5472.CAN-03-3848; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hamasaki T, 1998, UROL RES, V26, P371, DOI 10.1007/s002400050071; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Itoh T, 1998, CANCER RES, V58, P1048; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001; Lijnen HR, 1998, ARTERIOSCL THROM VAS, V18, P1035, DOI 10.1161/01.ATV.18.7.1035; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Manders P, 2004, CANCER-AM CANCER SOC, V101, P486, DOI 10.1002/cncr.20374; Nielsen BS, 1996, LAB INVEST, V74, P168; Nielsen BS, 2001, LAB INVEST, V81, P1485, DOI 10.1038/labinvest.3780363; Scacheri PC, 2004, P NATL ACAD SCI USA, V101, P1892, DOI 10.1073/pnas.0308698100; Schweinitz A, 2004, J BIOL CHEM, V279, P33613, DOI 10.1074/jbc.M314151200; Sidenius N, 2003, CANCER METAST REV, V22, P205, DOI 10.1023/A:1023099415940; Sieuwerts AM, 1999, BREAST CANCER RES TR, V55, P9, DOI 10.1023/A:1006190729866; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Tanaka Y, 2004, GYNECOL ONCOL, V94, P725, DOI 10.1016/j.ygyno.2004.06.012; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Witowsky J, 2003, J BIOL CHEM, V278, P5941, DOI 10.1074/jbc.M212363200; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	49	47	48	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					4998	5010		10.1038/sj.onc.1209507	http://dx.doi.org/10.1038/sj.onc.1209507			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568086				2022-12-28	WOS:000239921300005
J	Silva, FP; Hamamoto, R; Furukawa, Y; Nakamura, Y				Silva, F. P.; Hamamoto, R.; Furukawa, Y.; Nakamura, Y.			TIPUH1 encodes a novel KRAB zinc-finger protein highly expressed in human hepatocellular carcinomas	ONCOGENE			English	Article						TIPUH1; hepatocellular carcinoma; TIF1 beta; hnRNPU; nucleolin	MECHANISMS; CANCER; GENE; CARCINOGENESIS; INVOLVEMENT; FAMILY	To achieve a better understanding of mechanisms that underlie hepatocarcinogenesis and to identify novel target molecules for diagnosis and therapy of hepatocellular carcinoma (HCC), we previously analysed gene-expression profiles of 20 HCC tissues on a cDNA microarray. Among the genes upregulated in the tumor tissues compared with their nontumor counterparts, we focused on a novel gene termed transcription-involved protein upregulated in HCC (TIPUH1) that putatively encoded a 500-amino-acid protein containing 12 zinc-finger domains and a Kruppel-associated box domain. Multiple-tissue northern blot analysis revealed it's testis- and placenta-specific expression in normal tissues. Colony-formation assay in soft agar showed that TIPUH1 conferred anchorage-independent growth to NIH3T3 cells, suggesting its oncogenic activity. Conversely, specific siRNA for TIPUH1 knocked down its expression in HCC cells, which resulted in their growth inhibition. We identified four TIPUH1-interacting proteins including TIF1 beta, a transcription-intermediary protein, and three involved in pre-mRNA processing (hnRNPU, hnRNPF, and Nucleolin), suggesting that overexpressed TIPUH1 may play a role in hepatocarcinogenesis by regulating transcription and/or RNA processing of growth control genes. These data may contribute to a better understanding of liver neoplasia, and to the development of novel strategy for treatment of HCCs.	Univ Tokyo, Inst Med Sci, Human Genome Ctr, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Human Genome Ctr, Mol Med Lab,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Hamamoto, Ryuji/AAF-9600-2019; Silva, Fabio Pittella/B-2621-2013	Hamamoto, Ryuji/0000-0002-2632-1334; Silva, Fabio Pittella/0000-0002-9644-7098				Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; Feitelson MA, 2002, ONCOGENE, V21, P2593, DOI 10.1038/sj.onc.1205434; Ford LP, 2002, ONCOGENE, V21, P580, DOI 10.1038/sj.onc.1205086; Grisham JW, 2002, MOLECULAR BASIS OF HUMAN CANCER, P269; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Howell M, 2004, J BIOL CHEM, V279, P26300, DOI 10.1074/jbc.M401070200; Kim GJ, 2003, CANCER GENET CYTOGEN, V142, P129, DOI 10.1016/S0165-4608(02)00834-8; Looman C, 2002, MOL BIOL EVOL, V19, P2118, DOI 10.1093/oxfordjournals.molbev.a004037; Mark C, 1999, DNA CELL BIOL, V18, P381, DOI 10.1089/104454999315277; Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385; Oguri T, 1998, GENE, V222, P61, DOI 10.1016/S0378-1119(98)00464-8; Okabe H, 2001, CANCER RES, V61, P2129; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Raidl M, 2004, J HEPATOL, V40, P660, DOI 10.1016/j.jhep.2003.12.020; Reed R, 2001, NAT CELL BIOL, V3, pE201, DOI 10.1038/ncb0901-e201; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Shimokawa T, 2003, CANCER RES, V63, P6116; Silva FP, 2005, NEOPLASIA, V7, P348, DOI 10.1593/neo.04544; TANAKA S, 1993, CANCER RES, V53, P2884; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; Urrutia R, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-231; Wilkens L, 2001, J PATHOL, V193, P476, DOI 10.1002/path.825; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514	25	21	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					5063	5070		10.1038/sj.onc.1209517	http://dx.doi.org/10.1038/sj.onc.1209517			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568080				2022-12-28	WOS:000239921300012
J	Yan, B; Wang, H; Wang, H; Zhuo, D; Li, F; Kon, T; Dewhirst, M; Li, CY				Yan, B.; Wang, H.; Wang, H.; Zhuo, D.; Li, F.; Kon, T.; Dewhirst, M.; Li, C-Y			Apoptotic DNA fragmentation factor maintains chromosome stability in a P53-independent manner	ONCOGENE			English	Article						apoptosis; DNA fragmentation; chromosome instability; tumor/cancer	CELL-CYCLE CHECKPOINTS; THYMIDINE KINASE LOCUS; SACCHAROMYCES-CEREVISIAE; NEUROBLASTOMA TUMORS; COLORECTAL CANCERS; MUTATION ASSAY; ENDONUCLEASE-G; DEGRADATION; INSTABILITY; LINE	DNA fragmentation factor (DFF)/caspase-activated DNase (CAD) is responsible for DNA fragmentation, a hallmark event during apoptosis. Although DNA fragmentation is an evolutionarily conserved process across species, its biological function is not clearly understood. In this study, we constructed cell lines expressing a mutant ICAD (inhibitor of CAD) protein that is resistant to caspase cleavage and therefore constantly binds to DFF/CAD and inhibits DNA fragmentation. We found that irradiation of these cells led to increased chromosome aberrations and aneuploidy when compared with their parental controls. The increased chromosome instability is observed irrespective of cellular P53 status, suggesting that the effect of DFF/CAD is independent of P53. Inhibition of apoptotic DNA fragmentation resulted in increased clonogenic survival of irradiated cells and a delay in removal of cells with DNA damages induced by radiation, an effect similar to that in cells with p53 mutations. Consistent with DFF/CAD's effect on clonogenic survival, tumors established from cells deficient in DNA fragmentation showed enhanced growth in nude mice. Therefore, our results suggest that DFF/CAD plays an important and P53-independent role in maintaining chromosome stability and suppressing tumor development.	Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Sichuan Univ, W China Affiliated Hosp 2, Chengdu, Peoples R China	Duke University; Duke University; Sichuan University	Li, CY (corresponding author), Duke Univ, Med Ctr, Dept Radiat Oncol, Box 3455, Durham, NC 27710 USA.	chuanyuan.li@duke.edu	Dewhirst, Mark/Q-1302-2019; Li, Chuan-Yuan/H-4148-2013	Dewhirst, Mark/0000-0003-3459-6546; 				Abel F, 2004, INT J ONCOL, V25, P1297; Abel F, 2002, BRIT J CANCER, V86, P596, DOI 10.1038/sj.bjc.6600111; Caron H, 1996, NEW ENGL J MED, V334, P225, DOI 10.1056/NEJM199601253340404; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; HOYT MA, 1990, MOL CELL BIOL, V10, P223, DOI 10.1128/MCB.10.1.223; Judson H, 2000, HUM GENET, V106, P406, DOI 10.1007/s004390000257; Kawane K, 2003, NAT IMMUNOL, V4, P138, DOI 10.1038/ni881; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Konishi S, 2002, CANCER-AM CANCER SOC, V95, P2473, DOI 10.1002/cncr.10987; Lechardeur D, 2000, J CELL BIOL, V150, P321, DOI 10.1083/jcb.150.2.321; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; LIBER HL, 1982, MUTAT RES, V94, P467, DOI 10.1016/0027-5107(82)90308-6; LITTLE JB, 1995, J BIOL CHEM, V270, P11033, DOI 10.1074/jbc.270.19.11033; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARIS JM, 1995, CANCER RES, V55, P4664; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; SKOPEK TR, 1978, BIOCHEM BIOPH RES CO, V84, P411, DOI 10.1016/0006-291X(78)90185-7; Slane JM, 2000, BRAIN RES, V867, P70, DOI 10.1016/S0006-8993(00)02258-7; SPENCER F, 1990, GENETICS, V124, P237; Van Gele M, 1998, CANCER RES, V58, P1503; Van Gele M, 1998, GENE CHROMOSOME CANC, V23, P67, DOI 10.1002/(SICI)1098-2264(199809)23:1<67::AID-GCC10>3.0.CO;2-B; van Loo G, 2001, CELL DEATH DIFFER, V8, P1136, DOI 10.1038/sj.cdd.4400944; Yan B, 2006, P NATL ACAD SCI USA, V103, P1504, DOI 10.1073/pnas.0507779103; Yan B, 2003, J BIOL CHEM, V278, P45358, DOI 10.1074/jbc.M307933200; YANDELL DW, 1986, CANCER GENET CYTOGEN, V20, P231, DOI 10.1016/0165-4608(86)90078-6	34	20	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	39					5370	5376		10.1038/sj.onc.1209535	http://dx.doi.org/10.1038/sj.onc.1209535			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16619042				2022-12-28	WOS:000240144900002
J	Baraz, L; Haupt, Y; Elkin, M; Peretz, T; Vlodavsky, I				Baraz, L.; Haupt, Y.; Elkin, M.; Peretz, T.; Vlodavsky, I.			Tumor suppressor p53 regulates heparanase gene expression	ONCOGENE			English	Article						heparanase; p53; gene expression; promoter activity	WILD-TYPE P53; TATA-BINDING PROTEIN; MAMMALIAN HEPARANASE; TRANSCRIPTIONAL REPRESSION; EXTRACELLULAR-MATRIX; MEDIATED DEGRADATION; MOLECULAR-PROPERTIES; BASEMENT-MEMBRANES; HUMAN FIBROBLASTS; CANCER	Mammalian heparanase degrades heparan sulfate, the most prominent polysaccharide of the extracellular matrix. Causal involvement of heparanase in tumor progression is well documented. Little is known, however, about mechanisms that regulate heparanase gene expression. Mutational inactivation of tumor suppressor p53 is the most frequent genetic alteration in human tumors. p53 is a transcription factor that regulates a wide variety of cellular promoters. In this study, we demonstrate that wild-type (wt) p53 binds to heparanase promoter and inhibits its activity, whereas mutant p53 variants failed to exert an inhibitory effect. Moreover, p53-H175R mutant even activated heparanase promoter activity. Elimination or inhibition of p53 in several cell types resulted in a significant increase in heparanase gene expression and enzymatic activity. Trichostatin A abolished the inhibitory effect of wt p53, suggesting the involvement of histone deacetylation in negative regulation of the heparanase promoter. Altogether, our results indicate that the heparanase gene is regulated by p53 under normal conditions, while mutational inactivation of p53 during cancer development leads to induction of heparanase expression, providing a possible explanation for the frequent increase of heparanase levels observed in the course of tumorigenesis.	Hadassah Univ, Med Ctr, Dept Oncol, Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, Jerusalem, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Vlodavsky, I (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, POB 9649, IL-31096 Haifa, Israel.	vlodavsk@cc.huji.ac.il			NCI NIH HHS [R01 CA 106456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allison SJ, 2004, CARCINOGENESIS, V25, P1551, DOI 10.1093/carcin/bgh212; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; de Mestre AM, 2003, J BIOL CHEM, V278, P50377, DOI 10.1074/jbc.M310154200; El-Assal ON, 2001, CLIN CANCER RES, V7, P1299; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elkin M, 2003, CANCER RES, V63, P8821; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Friedmann Y, 2000, AM J PATHOL, V157, P1167, DOI 10.1016/S0002-9440(10)64632-9; Gohji K, 2001, INT J CANCER, V95, P295, DOI 10.1002/1097-0215(20010920)95:5<295::AID-IJC1051>3.0.CO;2-A; Goldshmidt O, 2001, J BIOL CHEM, V276, P29178, DOI 10.1074/jbc.M102462200; Gurova KV, 2002, ONCOGENE, V21, P153, DOI 10.1038/sj.onc.1205001; Haupt S, 2004, CELL CYCLE, V3, P912; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Jiang P, 2002, J BIOL CHEM, V277, P8989, DOI 10.1074/jbc.M105682200; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Kiaris H, 2005, CANCER RES, V65, P1627, DOI 10.1158/0008-5472.CAN-04-3791; Koliopanos A, 2001, CANCER RES, V61, P4655; Kosir MA, 1999, J SURG RES, V81, P42, DOI 10.1006/jsre.1998.5519; Kussie PH, 1999, BIOCHEM BIOPH RES CO, V261, P183, DOI 10.1006/bbrc.1999.0962; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Lu WC, 2003, ONCOGENE, V22, P919, DOI 10.1038/sj.onc.1206201; Marchetti D, 2000, CANCER RES, V60, P4767; Maxhimer JB, 2005, DIABETES, V54, P2172, DOI 10.2337/diabetes.54.7.2172; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Milyavsky M, 2003, CANCER RES, V63, P7147; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; MIYASHITA T, 1995, CELL, V80, P293; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nadav L, 2002, J CELL SCI, V115, P2179; O'Doherty U, 2000, J VIROL, V74, P10074, DOI 10.1128/JVI.74.21.10074-10080.2000; Ogishima T, 2005, CLIN CANCER RES, V11, P1028; Ogishima T, 2005, ONCOGENE, V24, P6765, DOI 10.1038/sj.onc.1208811; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Rohloff J, 2002, BRIT J CANCER, V86, P1270, DOI 10.1038/sj.bjc.6600232; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shteper PJ, 2003, ONCOGENE, V22, P7737, DOI 10.1038/sj.onc.1207056; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; VLODAVSKY I, 1983, CANCER RES, V43, P2704; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Weisz L, 2004, CANCER RES, V64, P8318, DOI 10.1158/0008-5472.CAN-04-1145; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zcharia E, 2005, AM J PATHOL, V166, P999, DOI 10.1016/S0002-9440(10)62321-8; Zcharia E, 2001, J MAMMARY GLAND BIOL, V6, P311, DOI 10.1023/A:1011375624902; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	55	78	86	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3939	3947		10.1038/sj.onc.1209425	http://dx.doi.org/10.1038/sj.onc.1209425			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16474844				2022-12-28	WOS:000238668800007
J	Huang, MC; Chen, HY; Huang, HC; Huang, J; Liang, JT; Shen, TL; Lin, NY; Ho, CC; Cho, IM; Hsu, SM				Huang, MC; Chen, HY; Huang, HC; Huang, J; Liang, JT; Shen, TL; Lin, NY; Ho, CC; Cho, IM; Hsu, SM			C2GnT-M is downregulated in colorectal cancer and its re-expression causes growth inhibition of colon cancer cells	ONCOGENE			English	Article						C2GnT-M; colon cancer; apoptosis; migration; invasion	O-GLYCAN BIOSYNTHESIS; CORE 2 BETA-1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE; EXTRACELLULAR-MATRIX; MOLECULAR-CLONING; TUMOR PROGRESSION; BRANCH FORMATION; PROSTATE-CANCER; GENE-TRANSFER; TN-EPITOPES; EXPRESSION	Changes in carbohydrates on the cell surface are associated with tumor malignancy. The mucin-type core 2 beta-1,6- N-acetylglucosaminyltransferase (C2GnT-M) is highly expressed in the gastrointestinal tract and catalyses the formation of core 2, core 4, and blood group I branches on O-glycans. In the present study, we evaluated the role of C2GnT-M in colorectal cancer. C2GnT-M downexpression was observed in 73.6% of the primary tumors from colorectal cancer patients (39 of 53) analysed by cancer pro. ling array. Consistently, the majority of colon cancer cell lines and primary colon tumors expressed lower levels of C2GnT-M than did normal colon tissues by RT-PCR. HCT116 cells stably transfected with C2GnT-M inhibited expression of the core 1 structure, Gal beta 1,3GalNAc alpha 1-Ser/Thr, on the cell surface. Moreover, C2GnT-M expression suppressed cell adhesion, motility, and invasion as well as colony formation ability. The growth of C2GnT-M-transfected HCT116 and SW480 cells was dramatically suppressed, and the cell death induced by C2GnT-M was demonstrated by an increase in the annexin V-positive cells. Interestingly, C2GnT-M inhibited cell adhesion to collagen IV and fibronectin, and decreased tyrosine phosphorylation of paxillin, indicating that the changes in cancer behavior may be partly mediated by integrin-signaling pathways. Tumor growth in vivo was also significantly suppressed by C2GnT-M in the xenografts of nude mice. These results demonstrate that C2GnT-M is frequently downregulated in colorectal cancer and suppresses colon cancer cell growth.	Natl Taiwan Univ, Coll Med, Inst Anat & Cell Biol, Taipei, Taiwan; Anim Technol Inst Taiwan, Miaoli, Taiwan; Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Pathol, Taipei 100, Taiwan; Natl Taiwan Univ, Dept Plant Pathol & Microbiol, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University	Huang, MC (corresponding author), Natl Taiwan Univ, Coll Med, Inst Anat & Cell Biol, 1 Sec 1 Ren Ai Rd, Taipei, Taiwan.	mchuang@ha.mc.ntu.edu.tw	Shen, Tang-Long/C-7460-2011	Liang, Jin-Tung/0000-0002-0264-7735; HO, CHAO-CHI/0000-0002-8156-2413; HUANG, MIN-CHUAN/0000-0002-0704-3447; LIN, NENG-YU/0000-0003-0746-0483; Shen, Tang-Long/0000-0001-6264-3608				Baldus SE, 2000, CANCER-AM CANCER SOC, V88, P1536, DOI 10.1002/(SICI)1097-0142(20000401)88:7<1536::AID-CNCR6>3.3.CO;2-N; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Brockhausen I, 1999, BBA-GEN SUBJECTS, V1473, P67, DOI 10.1016/S0304-4165(99)00170-1; Brockhausen I, 1998, GLYCOCONJUGATE J, V15, P595, DOI 10.1023/A:1006967910803; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CAO Y, 1995, CANCER-AM CANCER SOC, V76, P1700, DOI 10.1002/1097-0142(19951115)76:10<1700::AID-CNCR2820761005>3.0.CO;2-Z; Clement M, 2004, J CELL SCI, V117, P5059, DOI 10.1242/jcs.01350; Duncan G, 2001, J CLIN INVEST, V108, P511, DOI 10.1172/JCI200113737; Fukuda M, 1996, CANCER RES, V56, P2237; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; Hanisch FG, 1997, HISTOL HISTOPATHOL, V12, P263; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Huang MC, 2002, J BIOL CHEM, V277, P47786, DOI 10.1074/jbc.M208283200; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Inaba Y, 2003, INT J CANCER, V107, P949, DOI 10.1002/ijc.11513; Iwai T, 2005, P NATL ACAD SCI USA, V102, P4572, DOI 10.1073/pnas.0407983102; Khaldoyanidi SK, 2003, J BIOL CHEM, V278, P4127, DOI 10.1074/jbc.M209590200; Lamorte L, 2003, MOL BIOL CELL, V14, P2818, DOI 10.1091/mbc.E02-08-0497; LIOTTA LA, 1991, CANCER RES, V51, pS5054; OVADIA H, 1975, EUR J CANCER, V11, P413, DOI 10.1016/0014-2964(75)90072-9; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Quattrocchi CC, 2002, J BIOL CHEM, V277, P303, DOI 10.1074/jbc.M106996200; Schneider F, 2001, CANCER RES, V61, P4605; Schwientek T, 2000, J BIOL CHEM, V275, P11106, DOI 10.1074/jbc.275.15.11106; Schwientek T, 1999, J BIOL CHEM, V274, P4504, DOI 10.1074/jbc.274.8.4504; Shimodaira K, 1997, CANCER RES, V57, P5201; Springer GF, 1997, J MOL MED, V75, P594, DOI 10.1007/s001090050144; SPRINGER GF, 1984, SCIENCE, V224, P1198, DOI 10.1126/science.6729450; Steiner MS, 2000, CANCER RES, V60, P4419; Tsubouchi A, 2002, J CELL BIOL, V159, P673, DOI 10.1083/jcb.200202117; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VAVASSEUR F, 1995, GLYCOBIOLOGY, V5, P351, DOI 10.1093/glycob/5.3.351; VAVASSEUR F, 1994, EUR J BIOCHEM, V222, P415, DOI 10.1111/j.1432-1033.1994.tb18880.x; Xia LJ, 2004, J CELL BIOL, V164, P451, DOI 10.1083/jcb.200311112; YANG JM, 1994, GLYCOBIOLOGY, V4, P873, DOI 10.1093/glycob/4.6.873; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215	38	63	66	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 1	2006	25	23					3267	3276		10.1038/sj.onc.1209350	http://dx.doi.org/10.1038/sj.onc.1209350			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16418723				2022-12-28	WOS:000237951200005
J	Lannutti, BJ; Minear, J; Blake, N; Drachman, JG				Lannutti, B. J.; Minear, J.; Blake, N.; Drachman, J. G.			Increased megakaryocytopoiesis in Lyn-deficient mice	ONCOGENE			English	Article						megakaryocyte; Lyn; Mp1; MAPK; Akt	SRC-FAMILY KINASES; PROTEIN-TYROSINE KINASES; THROMBOPOIETIN-INDUCED PROLIFERATION; PRIMARY MURINE MEGAKARYOCYTES; SIGNAL-TRANSDUCTION; CELL-LINES; MAST-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; SUSTAINED ACTIVATION; AUTOIMMUNE-DISEASE	Previous studies in cell lines have shown Lyn kinase to be a negative regulator of thrombopoietin (TPO)-induced proliferation. To further investigate the role of Lyn during megakaryocytopoiesis, Lyn-deficient mice (lyn(-/-)) were analyzed. We observed that lyn(-/-) mice have more bone marrow-derived GPIIB (CD41) and Mpl(+) cells when compared to their wild-type littermates. In addition, colony-forming unit-megakaryocytes (CFU-MK) are increased and TPO-induced expansion of primary marrow cells yielded a greater number of mature megakaryocytes (MKs) with increased nuclear ploidy. Histopathology of bone marrow and spleens from lyn(-/-) mice showed an increase in the number of MKs. Mechanistic studies revealed that TPO stimulation of MKs from lyn(-/-) mice did not affect phosphorylation of Janus kinase 2 (JAK2), signal transducer and activator of transcription ( STAT) 3, STAT5, or MAP kinase kinase (MEK). Lyn-deficient MKs supported greater TPO-mediated phosphorylation and kinase activity of both Erk1/2 (mitogen-activated protein kinase, MAPK) and Akt. In contrast, there was a reduction of tyrosine phosphorylation of the inositol phosphatase, SHIP. This is the first direct evidence using primary MKs from Lyn-deficient mice that confirms our prior data from cell lines that Lyn kinase is a negative regulator of TPO signaling.	Univ Washington, Puget Sound Blood Ctr, Seattle, WA 98195 USA; Univ Washington, Med Ctr, Div Hematol, Seattle, WA 98195 USA	Puget Sound Blood Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Lannutti, BJ (corresponding author), Univ Washington, Puget Sound Blood Ctr, 921 Terry Ave, Seattle, WA 98195 USA.	brianl@psbc.org			NHLBI NIH HHS [R01HL65498] Funding Source: Medline; NIDDK NIH HHS [K01DK065129] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK065129] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON SM, 1995, J IMMUNOL, V155, P1660; Baran CP, 2003, J BIOL CHEM, V278, P38628, DOI 10.1074/jbc.M305021200; Beavitt SJE, 2005, J IMMUNOL, V175, P1867, DOI 10.4049/jimmunol.175.3.1867; Chan VWF, 1998, CURR BIOL, V8, P545, DOI 10.1016/S0960-9822(98)70223-4; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; Cheng JJ, 2001, J BIOL CHEM, V276, P31368, DOI 10.1074/jbc.M011317200; Corey SJ, 1999, BLOOD, V93, P1, DOI 10.1182/blood.V93.1.1; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; Cornall RJ, 1998, IMMUNITY, V8, P497, DOI 10.1016/S1074-7613(00)80554-3; Drachman JG, 1999, J BIOL CHEM, V274, P13480, DOI 10.1074/jbc.274.19.13480; Drachman JG, 1997, BLOOD, V89, P483, DOI 10.1182/blood.V89.2.483; DRACHMAN JG, 1995, J BIOL CHEM, V270, P4979, DOI 10.1074/jbc.270.10.4979; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; Ezumi Y, 1998, EUR J BIOCHEM, V258, P976, DOI 10.1046/j.1432-1327.1998.2580976.x; Filippi MD, 2002, BLOOD, V99, P1174, DOI 10.1182/blood.V99.4.1174; Freeburn RW, 2002, J IMMUNOL, V169, P5441, DOI 10.4049/jimmunol.169.10.5441; Gardai S, 2002, J BIOL CHEM, V277, P5236, DOI 10.1074/jbc.M110005200; Gauld SB, 2004, ONCOGENE, V23, P8001, DOI 10.1038/sj.onc.1208075; Geddis AE, 2002, CYTOKINE GROWTH F R, V13, P61, DOI 10.1016/S1359-6101(01)00030-2; Geddis AE, 2001, J BIOL CHEM, V276, P34473, DOI 10.1074/jbc.M105178200; Hallek M, 1997, EXP HEMATOL, V25, P1367; Harder KW, 2001, IMMUNITY, V15, P603, DOI 10.1016/S1074-7613(01)00208-4; Hernandez-Hansen V, 2004, J IMMUNOL, V173, P100, DOI 10.4049/jimmunol.173.1.100; Hernandez-Hansen V, 2004, J LEUKOCYTE BIOL, V75, P143, DOI 10.1189/jlb.0503224; Hibbs ML, 2002, J EXP MED, V196, P1593, DOI 10.1084/jem.20020515; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; Horn S, 2004, LEUKEMIA, V18, P1839, DOI 10.1038/sj.leu.2403529; Kamata T, 2004, BLOOD, V103, P2568, DOI 10.1182/blood-2003-06-1803; Kitaura J, 2000, J EXP MED, V192, P729, DOI 10.1084/jem.192.5.729; Lannutti BJ, 2005, BLOOD, V105, P3875, DOI 10.1182/blood-2004-10-3934; Lannutti BJ, 2004, BLOOD, V103, P3736, DOI 10.1182/blood-2003-10-3566; Lannutti BJ, 2003, EXP HEMATOL, V31, P1268, DOI 10.1016/j.exphem.2003.09.009; Maxwell MJ, 2004, J BIOL CHEM, V279, P32196, DOI 10.1074/jbc.M400746200; Miyakawa Y, 2001, J BIOL CHEM, V276, P2494, DOI 10.1074/jbc.M002633200; Nishizumi H, 1997, J IMMUNOL, V158, P2350; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; Pereira S, 2003, J IMMUNOL, V171, P1319, DOI 10.4049/jimmunol.171.3.1319; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; Rojnuckarin P, 1999, BLOOD, V94, P1273, DOI 10.1182/blood.V94.4.1273.416k04_1273_1282; Rojnuckarin P, 2001, J BIOL CHEM, V276, P41014, DOI 10.1074/jbc.M106508200; Rouyez MC, 1997, MOL CELL BIOL, V17, P4991, DOI 10.1128/MCB.17.9.4991; Santini V, 2002, HAEMATOLOGICA, V87, P1242; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; Smith KGC, 1998, J EXP MED, V187, P807, DOI 10.1084/jem.187.5.807; Stafford S, 2002, J IMMUNOL, V168, P1978, DOI 10.4049/jimmunol.168.4.1978; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; Vara JAF, 2001, MOL BIOL CELL, V12, P2171, DOI 10.1091/mbc.12.7.2171; Wang JY, 1996, J EXP MED, V184, P831, DOI 10.1084/jem.184.3.831	50	37	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3316	3324		10.1038/sj.onc.1209351	http://dx.doi.org/10.1038/sj.onc.1209351			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16418722				2022-12-28	WOS:000237951200010
J	Uenoyama, Y; Seno, H; Fukuda, A; Sekikawa, A; Nanakin, A; Sawabu, T; Kawada, M; Kanda, N; Suzuki, K; Yada, N; Fukui, H; Chiba, T				Uenoyama, Y.; Seno, H.; Fukuda, A.; Sekikawa, A.; Nanakin, A.; Sawabu, T.; Kawada, M.; Kanda, N.; Suzuki, K.; Yada, N.; Fukui, H.; Chiba, T.			Hypoxia induced by benign intestinal epithelial cells is associated with cyclooxygenase-2 expression in stromal cells through AP-1-dependent pathway	ONCOGENE			English	Article						colorectal tumor; fibroblast; cell density	EPIDERMAL-GROWTH-FACTOR; NF-KAPPA-B; PROSTAGLANDIN E-2; GENE-EXPRESSION; UP-REGULATION; CANCER CELLS; COLORECTAL ADENOMAS; SIGNALING PATHWAYS; C-JUN; ANGIOGENESIS	Cyclooxygenase-2 (COX-2) plays important roles in tumor development. Especially in the early-stage colorectal tumors, COX-2 expression is often observed in the tumor stroma. However, the mechanism regulating such stromal expression of COX-2 remains unknown. In the present study, we simulated the indirect interaction between epithelial cells and stromal cells in the process of colorectal tumor development using an in vitro co-culture model in which NIH3T3 fibroblasts were co-cultured with 'sparsely' or 'densely' populated intestinal epithelial cells, Intestine-407 as a model of premalignant or benign intestinal epithelial cells, and DLD-1 and Caco-2 as models of malignant epithelial cells. COX-2 expression in NIH3T3 fibroblasts was upregulated when co-cultured with the 'dense' epithelial cells regardless of their character. Interestingly, there was pericellular hypoxia in the vicinity of NIH3T3 fibroblasts when cocultured with 'dense' epithelial cells, and the recovery of the partial pressure of oxygen level resulted in the reduction of enhanced COX-2 expression only in NIH3T3 fibroblasts co-cultured with 'dense' Intestine-407 cells. Furthermore, COX-2 expression was also reduced by the inhibition of transcription factor AP-1. Thus, pericellular hypoxia of the stromal cells caused by densely populated epithelial cells may be one of the potent COX-2 enhancers before completion of malignant transformation during intestinal tumor development.	Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Seno, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, Shogoin Kawara Cho 54, Kyoto 6068507, Japan.	seno@kuhp.kyoto-u.ac.jp		Seno, Hiroshi/0000-0002-8509-8128				BATES SE, 1990, ENDOCRINOLOGY, V126, P596, DOI 10.1210/endo-126-1-596; Boman BM, 2004, AM J PATHOL, V165, P1489, DOI 10.1016/S0002-9440(10)63407-4; Chapple KS, 2002, J PATHOL, V198, P435, DOI 10.1002/path.1223; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Fujita T, 1998, CANCER RES, V58, P4823; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Han C, 2004, J BIOL CHEM, V279, P44344, DOI 10.1074/jbc.M404852200; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hoper MM, 1997, AM J RESP CELL MOL, V17, P748; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; Jobin C, 1997, J IMMUNOL, V158, P226; Kawada M, 2003, DIGESTION, V67, P20, DOI 10.1159/000069708; Kim H, 2005, J BIOL CHEM, V280, P21237, DOI 10.1074/jbc.M413842200; Kim HJ, 2004, J INVEST DERMATOL, V123, P547, DOI 10.1111/j.0022-202X.2004.23317.x; Ko SC, 2002, ONCOGENE, V21, P7175, DOI 10.1038/sj.onc.1205869; Kondoh N, 1999, CANCER RES, V59, P4990; Li QF, 2004, CANCER RES, V64, P7078, DOI 10.1158/0008-5472.CAN-04-1152; Liu WV, 2003, CANCER RES, V63, P3632; LU YP, 1994, CARCINOGENESIS, V15, P2363, DOI 10.1093/carcin/15.10.2363; Masferrer JL, 2000, CANCER RES, V60, P1306; Montano X, 2004, FEBS LETT, V571, P1, DOI 10.1016/j.febslet.2004.06.088; Nordsmark M, 1996, RADIOTHER ONCOL, V41, P31, DOI 10.1016/S0167-8140(96)91811-3; Oshima M, 2005, BIOCHEM BIOPH RES CO, V330, P928, DOI 10.1016/j.bbrc.2005.03.060; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Park CH, 2005, J BIOCHEM MOL BIOL, V38, P474; Preston SL, 2003, CANCER RES, V63, P3819; Ricchi P, 2003, BRIT J CANCER, V88, P803, DOI 10.1038/sj.bjc.6600829; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Seno H, 2002, CANCER RES, V62, P506; Sheares KKK, 2004, AM J PHYSIOL-LUNG C, V287, pL919, DOI 10.1152/ajplung.00012.2004; Sheta EA, 2001, ONCOGENE, V20, P7624, DOI 10.1038/sj.onc.1204972; Slice LW, 2005, J BIOL CHEM, V280, P1582, DOI 10.1074/jbc.M408172200; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Sol VVD, 2005, J IMMUNOL, V174, P2825, DOI 10.4049/jimmunol.174.5.2825; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Tamura M, 2002, J BIOL CHEM, V277, P26208, DOI 10.1074/jbc.M201347200; Tanaka Y, 2004, J BIOL CHEM, V279, P8567, DOI 10.1074/jbc.M309131200; Tokuda Y, 2000, J CELL PHYSIOL, V182, P414, DOI 10.1002/(SICI)1097-4652(200003)182:3<414::AID-JCP12>3.0.CO;2-5; Vultur A, 2004, ONCOGENE, V23, P2600, DOI 10.1038/sj.onc.1207378; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Wu GF, 2003, AM J PHYSIOL-HEART C, V285, pH2420, DOI 10.1152/ajpheart.00187.2003; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Xu Q, 2000, J BIOL CHEM, V275, P24583, DOI 10.1074/jbc.M003894200; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang KX, 2004, MOL CANCER RES, V2, P242	47	6	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3277	3285		10.1038/sj.onc.1209359	http://dx.doi.org/10.1038/sj.onc.1209359			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16407821	Green Submitted			2022-12-28	WOS:000237951200006
J	Li, DWC; Liu, JP; Schmid, PC; Schlosser, R; Feng, H; Liu, WB; Yan, Q; Gong, L; Sun, SM; Deng, M; Liu, Y				Li, D. W-C; Liu, J-P; Schmid, P. C.; Schlosser, R.; Feng, H.; Liu, W-B; Yan, Q.; Gong, L.; Sun, S-M; Deng, M.; Liu, Y.			Protein serine/threonine phosphatase-1 dephosphorylates p53 at Ser-15 and Ser-37 to modulate its transcriptional and apoptotic activities	ONCOGENE			English	Review						p53; PP-1; dephosphorylation; apoptosis; RNAi; phosphorylation and signal transduction	TUMOR-SUPPRESSOR P53; EPITHELIAL-CELL APOPTOSIS; DAMAGE-INDUCED PHOSPHORYLATION; JUN NH2-TERMINAL KINASE; DNA-BINDING FUNCTION; ALPHA-B-CRYSTALLIN; LARGE-T-ANTIGEN; OKADAIC ACID; P53-DEPENDENT APOPTOSIS; IN-VITRO	We have previously demonstrated that the serine/threonine protein phosphatase-1 (PP-1) plays an important role in promoting cell survival. However, the molecular mechanisms by which PP-1 promotes survival remain largely unknown. In the present study, we provide evidence to show that PP-1 can directly dephosphorylate a master regulator of apoptosis, p53, to negatively modulate its transcriptional and apoptotic activities, and thus to promote cell survival. As a transcriptional factor, the function of p53 can be greatly regulated by phosphorylation and dephosphorylation. While the kinases responsible for phosphorylation of the 17 serine/threonine sites have been identified, the dephosphorylation of these sites remains largely unknown. In the present study, we demonstrate that PP-1 can dephosphorylate p53 at Ser-15 and Ser-37 through co-immunoprecipitation, in vitro and in vivo dephosphorylation assays, overexpression and silence of the gene encoding the catalytic subunit for PP-1. We further show that mutations mimicking constitutive dephosphorylation or phosphorylation of p53 at these sites attenuate or enhance its transcriptional activity, respectively. As a result of the changed p53 activity, expression of the downstream apoptosis-related genes such as bcl-2 and bax is accordingly altered and the apoptotic events are either largely abrogated or enhanced. Thus, our results demonstrate that PP-1 directly dephosphorylates p53, and dephosphorylation of p53 has as important impact on its functions as phosphorylation does. In addition, our results reveal that one of the molecular mechanisms by which PP-1 promotes cell survival is to dephosphorylate p53, and thus negatively regulate p53-dependent death pathway.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Hunan Normal Univ, Coll Life Sci, Changsha, Hunan, Peoples R China	University of Minnesota System; Hunan Normal University	Li, DWC (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	dwli1688@hotmail.com	Gong, Lili/F-8452-2014; Yan, Qin/F-5161-2012; Yan, Qin/K-3539-2013; Deng, Mi/K-8699-2012; Li, David/AAN-9205-2021	Gong, Lili/0000-0002-6533-5333; Yan, Qin/0000-0002-6344-6398; Deng, Mi/0000-0003-4291-0144; 	NEI NIH HHS [EY15765, R01 EY015765] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY015765] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ayllon V, 2000, EMBO J, V19, P2237, DOI 10.1093/emboj/19.10.2237; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Bastians H, 1996, J CELL SCI, V109, P2865; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Blaydes JP, 2001, J BIOL CHEM, V276, P4699, DOI 10.1074/jbc.M003485200; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buschmann T, 2000, CANCER RES, V60, P896; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; Chernov MV, 2001, J BIOL CHEM, V276, P31819, DOI 10.1074/jbc.M103170200; CHIESA R, 1989, BIOCHEM BIOPH RES CO, V162, P1494, DOI 10.1016/0006-291X(89)90843-7; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; DEPAOLIROACH AA, 2003, HDB CELLULAR SIGNALI, V1, P613; Dohoney KM, 2004, ONCOGENE, V23, P49, DOI 10.1038/sj.onc.1207005; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Feng H, 2004, ONCOGENE, V23, P7310, DOI 10.1038/sj.onc.1208041; FernandezSanchez MT, 1996, FEBS LETT, V398, P106, DOI 10.1016/S0014-5793(96)01192-1; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Franklin RA, 2000, LEUKEMIA, V14, P2019, DOI 10.1038/sj.leu.2401967; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Garcia A, 2003, BIOCHIMIE, V85, P721, DOI 10.1016/j.biochi.2003.09.004; Gatti A, 2000, BIOCHEMISTRY-US, V39, P9837, DOI 10.1021/bi992454i; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GJERTSEN BT, 1995, BBA-MOL CELL RES, V1269, P187, DOI 10.1016/0167-4889(95)00117-B; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Haneda M, 2004, FEBS LETT, V567, P171, DOI 10.1016/j.febslet.2004.04.066; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang XZ, 1998, J BIOL CHEM, V273, P1462, DOI 10.1074/jbc.273.3.1462; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIDA Y, 1992, J CELL PHYSIOL, V150, P484, DOI 10.1002/jcp.1041500308; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; Kaeser MD, 2004, J BIOL CHEM, V279, P7598, DOI 10.1074/jbc.M311732200; KAIGHN ME, 1979, INVEST UROL, V17, P16; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; KIGUCHI K, 1994, CELL GROWTH DIFFER, V5, P995; Klumpp S, 2002, CURR OPIN PHARMACOL, V2, P458, DOI 10.1016/S1471-4892(02)00176-5; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LASSUS P, 2002, SCI STKE, V147, pPL13; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Li DWC, 1998, EUR J BIOCHEM, V257, P351, DOI 10.1046/j.1432-1327.1998.2570351.x; Li DWC, 2005, MOL BIOL CELL, V16, P4437, DOI 10.1091/mbc.E05-01-0010; Li DWC, 2003, INVEST OPHTH VIS SCI, V44, P5277, DOI 10.1167/iovs.03-0348; Li DWC, 2001, INVEST OPHTH VIS SCI, V42, P2603; Li DWC, 2001, EXP CELL RES, V266, P279, DOI 10.1006/excr.2001.5223; LI DWC, 2004, INVEST OPHTHALMOL  S, V45, pE401; Li HH, 2004, MOL CELL, V13, P867, DOI 10.1016/S1097-2765(04)00123-6; Li LW, 2000, J BIOL CHEM, V275, P2410, DOI 10.1074/jbc.275.4.2410; Li WC, 1996, FREE RADICAL BIO MED, V20, P301, DOI 10.1016/0891-5849(96)02050-3; LI WC, 1995, J CELL BIOL, V130, P169, DOI 10.1083/jcb.130.1.169; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Long X, 2002, APOPTOSIS, V7, P31, DOI 10.1023/A:1013508811252; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; Manfredi JJ, 2003, MOL CELL, V11, P552, DOI 10.1016/S1097-2765(03)00106-0; Mao YW, 2004, CELL DEATH DIFFER, V11, P512, DOI 10.1038/sj.cdd.4401384; Mao YW, 2001, J BIOL CHEM, V276, P43435, DOI 10.1074/jbc.M102195200; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; MELLGREN G, 1993, EXP CELL RES, V205, P293, DOI 10.1006/excr.1993.1089; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; NEVINS JR, 1992, SCIENCE, V258, P424; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; PARK IK, 1994, J BIOL CHEM, V269, P944; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Qu LK, 2004, GENE DEV, V18, P261, DOI 10.1101/gad.1165804; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Scacheri PC, 2004, P NATL ACAD SCI USA, V101, P1892, DOI 10.1073/pnas.0308698100; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; Schuler M, 2005, TRENDS GENET, V21, P182, DOI 10.1016/j.tig.2005.01.001; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; She QB, 2002, ONCOGENE, V21, P1580, DOI 10.1038/sj.onc.1205239; Sheikh MS, 1996, CELL GROWTH DIFFER, V7, P1599; Shen Y, 2001, ADV CANCER RES, V82, P55, DOI 10.1016/S0065-230X(01)82002-9; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WALTER G, 2003, HDB CELL SIGNALING, V1, P621; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELLER M, 1995, EXP CELL RES, V221, P395, DOI 10.1006/excr.1995.1390; Wen-Schaub LB, 1995, MOL CELL BIOL, V15, P3032; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Xiang H, 2000, BIOCHEM BIOPH RES CO, V278, P503, DOI 10.1006/bbrc.2000.3834; Xiang H, 2002, ONCOGENE, V21, P3784, DOI 10.1038/sj.onc.1205455; Yan Y, 1997, J BIOL CHEM, V272, P15220, DOI 10.1074/jbc.272.24.15220; Yeh PY, 2001, BIOCHEM BIOPH RES CO, V284, P880, DOI 10.1006/bbrc.2001.5043; Yu J, 2001, VIROLOGY, V290, P192, DOI 10.1006/viro.2001.1204; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhu JW, 1999, CELL GROWTH DIFFER, V10, P829; Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100; Zuo Z, 1998, J BIOL CHEM, V273, P12250, DOI 10.1074/jbc.273.20.12250	133	80	87	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					3006	3022		10.1038/sj.onc.1209334	http://dx.doi.org/10.1038/sj.onc.1209334			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16501611	Bronze			2022-12-28	WOS:000237950800005
J	Rodriguez-Antona, C; Ingelman-Sundberg, M				Rodriguez-Antona, C; Ingelman-Sundberg, M			Cytochrome P450 pharmacogenetics and cancer	ONCOGENE			English	Review						genetic polymorphism; pharmacogenomics; carcinogens; anticancer drugs; metabolic activation; tamoxifen	HUMAN LIVER-MICROSOMES; CYP1B1 DETERMINES SUSCEPTIBILITY; SINGLE-NUCLEOTIDE POLYMORPHISMS; INOPERABLE PANCREATIC-CARCINOMA; BENIGN PROSTATE HYPERPLASIA; HUMAN CYP2B6 GENE; BREAST-CANCER; INTERINDIVIDUAL DIFFERENCES; OVARIAN-CANCER; IN-VITRO	The cytochromes P450 (CYPs) are key enzymes in cancer formation and cancer treatment. They mediate the metabolic activation of numerous precarcinogens and participate in the inactivation and activation of anticancer drugs. Since all CYPs that metabolize xenobiotics are polymorphic, much emphasis has been put on the investigation of a relationship between the distribution of specific variant CYP alleles and risk for different types of cancer, but a consistent view does not yet exist. This is to a great extent explained by the fact that the CYPs involved in activation of precarcinogens are in general not functionally polymorphic. This is in contrast to CYPs that are active in drug biotransformation where large inter-individual differences in the capacity to metabolize therapeutic drugs are seen as a consequence of polymorphic alleles with altered function. This includes also some anticancer drugs like tamoxifen and cyclophosphamide metabolized by CYP2D6, CYP2C19 and CYP2B6. Some P450 forms are also selectively expressed in tumours, and this could provide a mechanism for drug resistance, but also future therapies using these enzymes as drug targets can be envisioned. This review gives an up-to-date description of our current knowledge in these areas.	Karolinska Inst, Dept Physiol & Pharmacol, SE-17177 Stockholm, Sweden; Spanish Natl Canc Ctr, Endocrine Canc Grp, Madrid, Spain	Karolinska Institutet; Centro Nacional de Investigaciones Oncologicas (CNIO)	Ingelman-Sundberg, M (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, SE-17177 Stockholm, Sweden.	magnus.ingelman-sundberg@ki.se	Rodriguez-Antona, Cristina/E-1073-2011; Ingelman-Sundberg, Magnus/ABD-9302-2021	Rodriguez-Antona, Cristina/0000-0001-8750-7338; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060548] Funding Source: NIH RePORTER; NIGMS NIH HHS [1-R01 GM60548] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agundez JAG, 2004, CURR DRUG METAB, V5, P211, DOI 10.2174/1389200043335621; Aklillu E, 2002, MOL PHARMACOL, V61, P586, DOI 10.1124/mol.61.3.586; Aklillu E, 2005, CANCER RES, V65, P5105, DOI 10.1158/0008-5472.CAN-05-0113; Aklillu E, 2003, MOL PHARMACOL, V64, P659, DOI 10.1124/mol.64.3.659; Aklillu E, 1996, J PHARMACOL EXP THER, V278, P441; Ariyoshi N, 2002, CANCER EPIDEM BIOMAR, V11, P890; Bournique B, 2002, DRUG METAB DISPOS, V30, P1149, DOI 10.1124/dmd.30.11.1149; Buters J, 2003, CARCINOGENESIS, V24, P327, DOI 10.1093/carcin/24.2.327; Buters JTM, 1999, P NATL ACAD SCI USA, V96, P1977, DOI 10.1073/pnas.96.5.1977; Chen JK, 2001, MOL CELL BIOL, V21, P6322, DOI 10.1128/MCB.21.18.6322-6331.2001; Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937; Crewe HK, 2002, DRUG METAB DISPOS, V30, P869, DOI 10.1124/dmd.30.8.869; Dachs GU, 2005, ANTI-CANCER DRUG, V16, P349, DOI 10.1097/00001813-200504000-00001; Dai D, 2001, PHARMACOGENETICS, V11, P597, DOI 10.1097/00008571-200110000-00006; Daigo S, 2002, PHARMACOGENETICS, V12, P299, DOI 10.1097/00008571-200206000-00005; Dally H, 2003, PHARMACOGENETICS, V13, P607, DOI 10.1097/00008571-200310000-00004; DeMichele A, 2005, J CLIN ONCOL, V23, P5552, DOI 10.1200/JCO.2005.06.208; Desta Z, 2002, CLIN PHARMACOKINET, V41, P913, DOI 10.2165/00003088-200241120-00002; Dhaini HR, 2003, J CLIN ONCOL, V21, P2481, DOI 10.1200/JCO.2003.06.015; Downie D, 2005, CLIN CANCER RES, V11, P7369, DOI 10.1158/1078-0432.CCR-05-0466; Ekins S, 1998, J PHARMACOL EXP THER, V286, P1253; Engels FK, 2004, CLIN PHARMACOL THER, V75, P448, DOI 10.1016/j.clpt.2004.01.001; Friedman HS, 1999, J CLIN ONCOL, V17, P1516, DOI 10.1200/JCO.1999.17.5.1516; Gambier N, 2005, PHARMACOGENOMICS J, V5, P271, DOI 10.1038/sj.tpj.6500314; Gervot L, 1999, PHARMACOGENETICS, V9, P295, DOI 10.1097/00008571-199906000-00004; Gharavi N, 2004, CURR DRUG METAB, V5, P203, DOI 10.2174/1389200043489045; Gibson P, 2003, MOL CANCER THER, V2, P527; Goh BC, 2002, J CLIN ONCOL, V20, P3683, DOI 10.1200/JCO.2002.01.025; Gonzalez FJ, 2003, DRUG METAB REV, V35, P319, DOI 10.1081/DMR-120026496; Goodwin B, 2001, MOL PHARMACOL, V60, P427; GORIAGATTI L, 1992, CARCINOGENESIS, V13, P799, DOI 10.1093/carcin/13.5.799; Gribben JG, 2005, CLIN CANCER RES, V11, P4430, DOI 10.1158/1078-0432.CCR-04-2111; Guengerich FP, 1999, MUTAT RES-FUND MOL M, V428, P115, DOI 10.1016/S1383-5742(99)00039-3; Han XM, 2002, BRIT J CLIN PHARMACO, V54, P540, DOI 10.1046/j.1365-2125.2002.01686.x; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HARRIS JW, 1994, J MED CHEM, V37, P706, DOI 10.1021/jm00031a022; HAYASHI S, 1991, J BIOCHEM-TOKYO, V110, P559, DOI 10.1093/oxfordjournals.jbchem.a123619; Henningsson A, 2005, CLIN CANCER RES, V11, P8097, DOI 10.1158/1078-0432.CCR-05-1152; Hesse LM, 2004, PHARMACOGENETICS, V14, P225, DOI 10.1097/00008571-200404000-00002; Hirth J, 2000, CLIN CANCER RES, V6, P1255; Huang ZQ, 2000, CANCER GENE THER, V7, P1034, DOI 10.1038/sj.cgt.7700200; Huang ZQ, 2000, BIOCHEM PHARMACOL, V59, P961, DOI 10.1016/S0006-2952(99)00410-4; Ingelman-Sundberg M, 2005, PHARMACOGENOMICS J, V5, P6, DOI 10.1038/sj.tpj.6500285; Ingelman-Sundberg M, 2005, PHILOS T R SOC B, V360, P1563, DOI 10.1098/rstb.2005.1685; Ingelman-Sundberg M, 2004, TRENDS PHARMACOL SCI, V25, P193, DOI 10.1016/j.tips.2004.02.007; Ingelman-Sundberg M, 2004, N-S ARCH PHARMACOL, V369, P89, DOI 10.1007/s00210-003-0819-z; Jacobson PA, 2002, CANCER CHEMOTH PHARM, V49, P461, DOI 10.1007/s00280-002-0453-3; Jiang JG, 2005, CANCER RES, V65, P4707, DOI 10.1158/0008-5472.CAN-04-4173; Jin Y, 2005, JNCI-J NATL CANCER I, V97, P30, DOI 10.1093/jnci/dji005; JOHANSSON I, 1993, P NATL ACAD SCI USA, V90, P11825, DOI 10.1073/pnas.90.24.11825; JORDAN VC, 1977, J ENDOCRINOL, V75, P305, DOI 10.1677/joe.0.0750305; KAIJSER GP, 1993, ANTICANCER RES, V13, P1311; Kaiser R, 2002, J CLIN ONCOL, V20, P2805, DOI 10.1200/JCO.2002.09.064; KARLGREN M, UNPUB; Karlgren Maria, 2005, Toxicol Appl Pharmacol, V207, P57, DOI 10.1016/j.taap.2004.12.022; Kirchheiner J, 2005, CLIN PHARMACOL THER, V77, P1, DOI 10.1016/j.clpt.2004.08.009; Klein K, 2005, PHARMACOGENET GENOM, V15, P861, DOI 10.1097/01213011-200512000-00004; Komatsu T, 2000, DRUG METAB DISPOS, V28, P1457; Kuehl P, 2001, NAT GENET, V27, P383, DOI 10.1038/86882; Kumarakulasingham M, 2005, CLIN CANCER RES, V11, P3758, DOI 10.1158/1078-0432.CCR-04-1848; Lacroix D, 1997, EUR J BIOCHEM, V247, P625, DOI 10.1111/j.1432-1033.1997.00625.x; Landi S, 2005, PHARMACOGENET GENOM, V15, P535, DOI 10.1097/01.fpc.0000165904.48994.3d; Lang T, 2004, J PHARMACOL EXP THER, V311, P34, DOI 10.1124/jpet.104.068973; Lang T, 2001, PHARMACOGENETICS, V11, P399, DOI 10.1097/00008571-200107000-00004; Lee SJ, 2003, PHARMACOGENETICS, V13, P461, DOI 10.1097/00008571-200308000-00004; Leong CO, 2003, BRIT J CANCER, V88, P470, DOI 10.1038/sj.bjc.6600719; Li AP, 1995, TOXICOLOGY, V104, P1, DOI 10.1016/0300-483X(95)03155-9; Libby RT, 2003, SCIENCE, V299, P1578, DOI 10.1126/science.1080095; Lohr M, 2001, LANCET, V357, P1591, DOI 10.1016/S0140-6736(00)04749-8; Malaiyandi V, 2005, CLIN PHARMACOL THER, V77, P145, DOI 10.1016/j.clpt.2004.10.011; Martinez C, 2005, BRIT J CLIN PHARMACO, V59, P62, DOI 10.1111/j.1365-2125.2004.02183.x; Masson LF, 2005, AM J EPIDEMIOL, V161, P901, DOI 10.1093/aje/kwi121; Mathijssen RHJ, 2002, J NATL CANCER I, V94, P1247, DOI 10.1093/jnci/94.16.1247; Mathijssen RHJ, 2004, JNCI-J NATL CANCER I, V96, P1585, DOI 10.1093/jnci/djh298; McFadyen MCE, 1999, J HISTOCHEM CYTOCHEM, V47, P1457, DOI 10.1177/002215549904701111; McFadyen MCE, 2004, MOL CANCER THER, V3, P363; McFadyen MCE, 2001, BRIT J CANCER, V85, P242, DOI 10.1054/bjoc.2001.1907; McFadyen MCE, 2001, BIOCHEM PHARMACOL, V62, P207, DOI 10.1016/S0006-2952(01)00643-8; Miksys S, 2003, NEUROPHARMACOLOGY, V45, P122, DOI 10.1016/S0028-3908(03)00136-9; Miyoshi Y, 2002, INT J CANCER, V97, P129, DOI 10.1002/ijc.1568; Miyoshi Yasuo, 2005, Breast Cancer, V12, P11, DOI 10.2325/jbcs.12.11; Murray GI, 1997, CANCER RES, V57, P3026; Nakajima M, 2005, J CLIN PHARMACOL, V45, P674, DOI 10.1177/0091270005276204; Nakajima M, 2001, CLIN PHARMACOL THER, V69, P72, DOI 10.1067/mcp.2001.112688; Nebert DW, 2004, J BIOL CHEM, V279, P23847, DOI 10.1074/jbc.R400004200; Nelson DR, 2004, PHARMACOGENETICS, V14, P1, DOI 10.1097/00008571-200401000-00001; Niemi M, 2003, CLIN PHARMACOL THER, V74, P380, DOI 10.1016/S0009-9236(03)00228-5; Oscarson M, 1999, FEBS LETT, V448, P105, DOI 10.1016/S0014-5793(99)00359-2; Oscarson M, 2001, DRUG METAB DISPOS, V29, P91; Oyama T, 2004, FRONT BIOSCI-LANDMRK, V9, P1967, DOI 10.2741/1378; Ozdemir V, 2000, PHARMACOGENETICS, V10, P373, DOI 10.1097/00008571-200007000-00001; Paris PL, 1999, CANCER EPIDEM BIOMAR, V8, P901; Potter GA, 2002, BRIT J CANCER, V86, P774, DOI 10.1038/sj.bjc.6600197; Pozzi A, 2005, J BIOL CHEM, V280, P27138, DOI 10.1074/jbc.M501730200; Rae JM, 2002, DRUG METAB DISPOS, V30, P525, DOI 10.1124/dmd.30.5.525; Rasmussen BB, 2002, PHARMACOGENETICS, V12, P473, DOI 10.1097/00008571-200208000-00008; Rebbeck TR, 1998, J NATL CANCER I, V90, P1225, DOI 10.1093/jnci/90.16.1225; Riddick DS, 2005, DRUG METAB DISPOS, V33, P1083, DOI 10.1124/dmd.105.004374; Rieger MA, 2004, CANCER RES, V64, P2357, DOI 10.1158/0008-5472.CAN-03-0849; Rochat B, 2001, J PHARMACOL EXP THER, V296, P537; Rodriguez-Antona C, 2005, BIOCHEM BIOPH RES CO, V338, P299, DOI 10.1016/j.bbrc.2005.09.020; Rooseboom M, 2004, PHARMACOL REV, V56, P53, DOI 10.1124/pr.56.1.3; ROY P, 2005, IN PRESS TOXICOL IN; Sachse C, 1999, BRIT J CLIN PHARMACO, V47, P445, DOI 10.1046/j.1365-2125.1999.00898.x; Salmons B, 2003, J GASTROENTEROL, V38, P78; Savas O, 2005, ARCH BIOCHEM BIOPHYS, V436, P377, DOI 10.1016/j.abb.2005.02.022; Sim SC, 2005, PHARMACOGENET GENOM, V15, P625, DOI 10.1097/01.fpc.0000171516.84139.89; SIM SC, 2005, IN PRESS CLIN PHARM; Spurdle AB, 2002, PHARMACOGENETICS, V12, P355, DOI 10.1097/00008571-200207000-00003; Takada K, 2004, ARTHRITIS RHEUM-US, V50, P2202, DOI 10.1002/art.20338; Tanaka T, 2004, INT J CANCER, V111, P617, DOI 10.1002/ijc.20289; Taniguchi R, 2005, J PHARMACOL SCI, V97, P83, DOI 10.1254/jphs.FP0040603; Tayeb MT, 2003, BRIT J CANCER, V88, P928, DOI 10.1038/sj.bjc.6600825; Tayeb MT, 2002, ONCOL REP, V9, P653; Timm R, 2005, PHARMACOGENOMICS J, V5, P365, DOI 10.1038/sj.tpj.6500330; Tokizane T, 2005, CLIN CANCER RES, V11, P5793, DOI 10.1158/1078-0432.CCR-04-2545; Tsuchiya K, 2004, BIOCHEM BIOPH RES CO, V319, P1322, DOI 10.1016/j.bbrc.2004.05.116; Vineis P, 2002, TOXICOLOGY, V181, P457, DOI 10.1016/S0300-483X(02)00450-X; Wang HB, 2003, J BIOL CHEM, V278, P14146, DOI 10.1074/jbc.M212482200; WANG J, 2005, IN PRESS PHARMACOGEN; WANG J, 2003, BIOCHEM BIOPH RES CO, V340, P491; WESTLINDJOHNSSO.A, 2006, IN PRESS CLIN PHARM; Williams JA, 2002, DRUG METAB DISPOS, V30, P883, DOI 10.1124/dmd.30.8.883; Xie HJ, 2003, PHARMACOGENOMICS J, V3, P53, DOI 10.1038/sj.tpj.6500157; Yamamoto N, 2005, J CLIN ONCOL, V23, P1061, DOI 10.1200/JCO.2005.11.036; Yasar U, 2002, BIOCHEM BIOPH RES CO, V299, P25, DOI 10.1016/S0006-291X(02)02592-5; Yengi LG, 2003, ANAL BIOCHEM, V316, P103, DOI 10.1016/S0003-2697(03)00042-3; Yu AM, 2005, ENDOCRINOLOGY, V146, P2911, DOI 10.1210/en.2004-1248	128	410	429	2	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	11					1679	1691		10.1038/sj.onc.1209377	http://dx.doi.org/10.1038/sj.onc.1209377			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020JL	16550168				2022-12-28	WOS:000235904700010
J	Deng, R; Li, W; Guan, Z; Zhou, JM; Wang, Y; Mei, YP; Li, MT; Feng, GK; Huang, W; Liu, ZC; Han, Y; Zeng, YX; Zhu, XF				Deng, R.; Li, W.; Guan, Z.; Zhou, J-M; Wang, Y.; Mei, Y-P; Li, M-T; Feng, G-K; Huang, W.; Liu, Z-C; Han, Y.; Zeng, Y-X; Zhu, X-F			Acetylcholinesterase expression mediated by c-Jun-NH2-terminal kinase pathway during anticancer drug-induced apoptosis	ONCOGENE			English	Article						acetylcholinesterase (AChE); c-Jun NH2-terminal kinase (JNK); apoptosis; mitogen-activated protein kinase ( MAPK); extracellular signal regulated kinase ( ERK)	CYTOCHROME-C RELEASE; JUN; ACTIVATION; JNK; CELLS; DEATH; BAX; PHOSPHORYLATION; INDUCTION; RAT	It has been shown that acetylcholinesterase (AChE) expression was induced during apoptosis and the antisense oligonucleotides and siRNA of AChE may prevent apoptosis in various cell types. However, the mechanisms underlying AChE upregulation remain elusive. We demonstrated here that c-Jun NH2-terminal kinase (JNK) could mediate AChE expression. In this study, both etoposide and excisanin A, two anticancer agents, induced apoptosis in colon cancer cell line SW620 as determined by Annexin V staining, the cleavage of caspase-3 and the proteolytic degradation of poly (ADPribose) polymerase (PARP). The results showed that both the agents upregulated AChE in SW620 cells. In the meantime, JNK was also activated and the expression and phosphorylation of c-Jun increased in SW620 cells exposed to the two agents. The induced AChE mRNA and protein expression could be blocked by SP600125, a specific inhibitor of SAPK/JNK, and small interfering RNA directed against JNK1/2. Transfection with adenovirus-mediated dominant negative c-Jun also blocked the upregulation of AChE expression. Together, these results suggest that AChE expression may be mediated by the activation of JNK pathway during apoptosis through a c-Jun-dependent mechanism.	Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol So China, Guangzhou 510060, Peoples R China; Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Sun Yat Sen Univ, Dept Pharmacol, Proteom Lab, Guangzhou, Peoples R China	Sun Yat Sen University; Hong Kong University of Science & Technology; Sun Yat Sen University	Zhu, XF (corresponding author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol So China, 651 DongFeng Rd E, Guangzhou 510060, Peoples R China.	bcyfhan@ust.hk; xfzhu70@public.guangzhou.gd.cn		Han, Yifan/0000-0002-5833-069X				Chen YR, 2000, INT J ONCOL, V16, P651; Cohen TV, 2004, J NEUROCHEM, V90, P1059, DOI 10.1111/j.1471-4159.2004.02564.x; Collett GP, 2004, CARCINOGENESIS, V25, P2183, DOI 10.1093/carcin/bgh233; Cuadrado A, 2004, ONCOGENE, V23, P4673, DOI 10.1038/sj.onc.1207636; Eminel S, 2004, J BIOL CHEM, V279, P55385, DOI 10.1074/jbc.M405858200; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; GAO YH, 2000, CHIN TRADIT HERB DRU, V31, P645; GETMAN DK, 1995, J BIOL CHEM, V270, P23511, DOI 10.1074/jbc.270.40.23511; Grisaru D, 1999, EUR J BIOCHEM, V264, P672, DOI 10.1046/j.1432-1327.1999.00693.x; Gururajan M, 2005, BLOOD, V106, P1382, DOI 10.1182/blood-2004-10-3819; Hamdi M, 2005, ONCOGENE, V24, P7135, DOI 10.1038/sj.onc.1208875; KARPEL R, 1994, EXP CELL RES, V210, P268, DOI 10.1006/excr.1994.1039; Khelifi AF, 2005, CELL DEATH DIFFER, V12, P724, DOI 10.1038/sj.cdd.4401559; Kirkland RA, 2003, ANTIOXID REDOX SIGN, V5, P589, DOI 10.1089/152308603770310257; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kuntzen C, 2005, CANCER RES, V65, P6780, DOI 10.1158/0008-5472.CAN-04-2618; Kurinna SM, 2004, CANCER RES, V64, P7852, DOI 10.1158/0008-5472.CAN-04-1552; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Meshorer E, 2005, MOL PSYCHIATR, V10, P985, DOI 10.1038/sj.mp.4001735; Meshorer E, 2004, J BIOL CHEM, V279, P29740, DOI 10.1074/jbc.M402752200; Park SE, 2004, CANCER RES, V64, P2652, DOI 10.1158/0008-5472.CAN-04-0649; Perry C, 2002, ONCOGENE, V21, P8428, DOI 10.1038/sj.onc.1205945; Small DH, 1996, NEUROCHEM INT, V28, P453, DOI 10.1016/0197-0186(95)00099-2; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Teraishi F, 2005, CANCER RES, V65, P6380, DOI 10.1158/0008-5472.CAN-05-0575; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; TRANUMJENSEN J, 1981, EUR J CELL BIOL, V24, P281; Yin D, 2005, ONCOGENE, V24, P344, DOI 10.1038/sj.onc.1208225; Zhang XJ, 2002, CELL DEATH DIFFER, V9, P790, DOI 10.1038/sj.cdd.4401034; Zhou JM, 2006, ONCOGENE, V25, P503, DOI 10.1038/sj.onc.1209067; Zhu XF, 2005, MOL PHARMACOL, V67, P1444, DOI 10.1124/mol.104.009894; Zhu XF, 2002, LIFE SCI, V70, P1259, DOI 10.1016/S0024-3205(01)01501-6; Zou W, 2004, CANCER RES, V64, P7570, DOI 10.1158/0008-5472.CAN-04-1238	34	58	60	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2006	25	53					7070	7077		10.1038/sj.onc.1209686	http://dx.doi.org/10.1038/sj.onc.1209686			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16715131				2022-12-28	WOS:000241910500006
J	Barber, RC; Hickenbotham, P; Hatch, T; Kelly, D; Topchiy, N; Almeida, GM; Jones, GDD; Johnson, GE; Parry, JM; Rothkamm, K; Dubrova, YE				Barber, R. C.; Hickenbotham, P.; Hatch, T.; Kelly, D.; Topchiy, N.; Almeida, G. M.; Jones, G. D. D.; Johnson, G. E.; Parry, J. M.; Rothkamm, K.; Dubrova, Y. E.			Radiation-induced transgenerational alterations in genome stability and DNA damage	ONCOGENE			English	Editorial Material						radiation; transgenerational instability; mutations; DNA damage; mouse; germ line	F-1 MICE BORN; IONIZING-RADIATION; MULTIPLE MUTATIONS; DEFICIENT MICE; COMET ASSAY; IN-VITRO; INSTABILITY; CANCER; INDUCTION; EXPOSURE	Mutation induction in directly exposed cells is currently regarded as the main component of the genetic risk of ionizing radiation for humans. However, recent data on the transgenerational increases in mutation rates in the offspring of irradiated parents indicate that the genetic risk could be greater than predicted previously. Here, we have analysed transgenerational changes in mutation rates and DNA damage in the germline and somatic tissues of non-exposed first-generation offspring of irradiated inbred male CBA/Ca and BALB/c mice. Mutation rates at an expanded simple tandem repeat DNA locus and a protein-coding gene (hprt) were significantly elevated in both the germline (sperm) and somatic tissues of all the offspring of irradiated males. The transgenerational changes in mutation rates were attributed to the presence of a persistent subset of endogenous DNA lesions (double- and single-strand breaks), measured by the phosphorylated form of histone H2AX (gamma-H2AX) and alkaline Comet assays. Such remarkable transgenerational destabilization of the F-1 genome may have important implications for cancer aetiology and genetic risk estimates. Our data also provide important clues on the still unknown mechanisms of radiation-induced genomic instability.	Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England; Univ Leicester, Dept Canc Studies & Mol Med, Leicester LE1 7RH, Leics, England; Univ Coll Swansea, Ctr Mol Genet & Toxicol, Swansea, W Glam, Wales; Gray Canc Inst, Northwood, Middx, England	University of Leicester; University of Leicester; Swansea University; University of Oxford	Dubrova, YE (corresponding author), Univ Leicester, Dept Genet, Adrian Bldg,Univ Rd, Leicester LE1 7RH, Leics, England.	yed2@le.ac.uk	Rothkamm, Kai/A-2164-2014; Almeida, Gabriela/A-8160-2012; Dubrova, Yuri/ABA-7148-2020; Topchiy, Nataliya/AAD-5215-2020; Barber, Ruth/A-1051-2008; Almeida, Gabriela/GXV-3687-2022; Johnson, George/J-2488-2014	Rothkamm, Kai/0000-0001-7414-5729; Almeida, Gabriela/0000-0001-8712-7394; Dubrova, Yuri/0000-0001-5281-7539; Johnson, George/0000-0001-5643-9942; Jones, George/0000-0002-9543-2206; Topchiy, Nataliya/0000-0003-4694-5707	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Almeida GM, 2006, DNA REPAIR, V5, P219, DOI 10.1016/j.dnarep.2005.09.010; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Barber R, 2002, P NATL ACAD SCI USA, V99, P6877, DOI 10.1073/pnas.102015399; Barber RC, 2004, MUTAT RES-FUND MOL M, V554, P287, DOI 10.1016/j.mrfmmm.2004.05.003; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bol SAM, 1998, CANCER RES, V58, P2850; Breger KS, 2004, CANCER RES, V64, P8231, DOI 10.1158/0008-5472.CAN-04-0879; Collins Andrew R, 2002, Methods Mol Biol, V186, P147; Cosentino L, 2000, MUTAT RES-FUND MOL M, V454, P1, DOI 10.1016/S0027-5107(00)00125-1; Dubrova YE, 2005, RADIAT RES, V163, P200, DOI 10.1667/RR3296; Dubrova YE, 2000, NATURE, V405, P37, DOI 10.1038/35011135; Dubrova YE, 2003, ONCOGENE, V22, P7087, DOI 10.1038/sj.onc.1206993; FRIEDBERG EC, 1995, DNA REPAIR REPAIR MU; FURTH EE, 1981, ANAL BIOCHEM, V110, P1, DOI 10.1016/0003-2697(81)90103-2; Garcia CL, 2001, MUTAT RES-GEN TOX EN, V492, P59, DOI 10.1016/S1383-5718(01)00149-8; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; Huang L, 2003, ONCOGENE, V22, P5848, DOI 10.1038/sj.onc.1206697; Jackson AL, 2001, MUTAT RES-FUND MOL M, V477, P7, DOI 10.1016/S0027-5107(01)00091-4; Kassie F, 2000, MUTAT RES-REV MUTAT, V463, P13, DOI 10.1016/S1383-5742(00)00041-7; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; Lorimore SA, 2003, ONCOGENE, V22, P7058, DOI 10.1038/sj.onc.1207044; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Niwa O, 2001, P NATL ACAD SCI USA, V98, P1705, DOI 10.1073/pnas.031439298; Nomura T, 2003, MUTAT RES-REV MUTAT, V544, P425, DOI 10.1016/j.mrrev.2003.06.006; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shiraishi K, 2002, RADIAT RES, V157, P661, DOI 10.1667/0033-7587(2002)157[0661:PIOSRO]2.0.CO;2; Tawn EJ, 2005, MUTAT RES-GEN TOX EN, V583, P198, DOI 10.1016/j.mrgentox.2005.03.007; Yauk CL, 2002, MUTAT RES-FUND MOL M, V500, P147, DOI 10.1016/S0027-5107(02)00005-2; Zheng NJ, 2000, ENVIRON MOL MUTAGEN, V36, P134, DOI 10.1002/1098-2280(2000)36:2<134::AID-EM8>3.0.CO;2-D	33	98	108	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	56					7336	7342		10.1038/sj.onc.1209723	http://dx.doi.org/10.1038/sj.onc.1209723			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16751800				2022-12-28	WOS:000242419100002
J	Gort, EH; Groot, AJ; van de Ven, TLPD; van der Groep, P; Verlaan, I; van Laar, T; van Diest, PJ; van der Wall, E; Shvarts, A				Gort, E. H.; Groot, A. J.; van de Ven, T. L. P. Derks; van der Groep, P.; Verlaan, I.; van Laar, T.; van Diest, P. J.; van der Wall, E.; Shvarts, A.			Hypoxia-inducible factor-1 alpha expression requires PI 3-kinase activity and correlates with Akt1 phosphorylation in invasive breast carcinomas	ONCOGENE			English	Article						HIF-1 alpha; PI 3-kinase; Akt; hypoxia; breast cancer	ENDOTHELIAL GROWTH-FACTOR; PROTEIN-KINASE-B; FACTOR 1-ALPHA; PROLYL HYDROXYLATION; GENE-TRANSCRIPTION; PROSTATE-CANCER; HIF-ALPHA; ACTIVATION; PATHWAY; CELLS	Hypoxia-inducible factor-1 alpha (HIF-1 alpha) is the regulatory subunit of the heterodimeric transcription factor HIF-1 and the key factor in cellular response to low oxygen tension. Expression of HIF-1 alpha protein is associated with poor patient survival and therapy resistance in many types of solid tumors. Insight into HIF-1 alpha regulation in solid tumors is important for therapeutic strategies. In this study, we determined the pathophysiological relevance of HIF-1 alpha regulation by the oncogenic phosphatidylinositol 3'-kinase (PI 3-kinase)/Akt signaling pathway. We modeled the physiology of hypoxic tumor regions by culturing carcinoma cells under low oxygen tension in the absence of serum. We observed that hypoxic induction of HIF-1 alpha protein was decreased by serum deprivation. Overexpression of dominant-active Akt1 restored HIF-1 alpha expression, whereas inhibition of PI 3-kinase activity reduced hypoxic HIF-1 alpha protein levels to a similar extent as serum deprivation. Immunohistochemical analysis of 95 human breast cancers revealed that lack of Akt1 phosphorylation correlates with low HIF-1 alpha levels. To our knowledge, this is the first reported comparison between HIF-1 alpha expression and Akt phosphorylation in human carcinomas. We conclude that Akt activity is physiologically relevant for HIF-1 alpha expression in breast cancer. This implies that HIF-1 alpha function might be therapeutically targeted by inhibition of the PI 3-kinase/Akt pathway.	Univ Med Ctr Utrecht, Dept Pathol, NL-3508 GA Utrecht, Netherlands; Univ Med Ctr Utrecht, Div Internal Med & Dermatol, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	van Diest, PJ (corresponding author), Univ Med Ctr Utrecht, Dept Pathol, POB 85500, NL-3508 GA Utrecht, Netherlands.	p.j.vandiest@azu.nl						Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alvarez-Tejado M, 2002, J BIOL CHEM, V277, P13508, DOI 10.1074/jbc.M200017200; Arsham AM, 2002, J BIOL CHEM, V277, P15162, DOI 10.1074/jbc.M111162200; Bardos JI, 2004, MOL CELL BIOL, V24, P2905, DOI 10.1128/MCB.24.7.2905-2914.2004; Birner P, 2000, CANCER RES, V60, P4693; Bos R, 2003, CANCER, V97, P1573, DOI 10.1002/cncr.11246; Bos R, 2001, JNCI-J NATL CANCER I, V93, P309, DOI 10.1093/jnci/93.4.309; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Dales JP, 2005, INT J CANCER, V116, P734, DOI 10.1002/ijc.20984; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kirkegaard T, 2005, J PATHOL, V207, P139, DOI 10.1002/path.1829; Kreisberg JI, 2004, CANCER RES, V64, P5232, DOI 10.1158/0008-5472.CAN-04-0272; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mottet D, 2003, J BIOL CHEM, V278, P31277, DOI 10.1074/jbc.M300763200; Schmitz KJ, 2004, MODERN PATHOL, V17, P15, DOI 10.1038/modpathol.3800002; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shibata T, 1998, INT J RADIAT ONCOL, V42, P913, DOI 10.1016/S0360-3016(98)00298-3; Skinner HD, 2004, J BIOL CHEM, V279, P45643, DOI 10.1074/jbc.M404097200; Tang TTL, 2003, J BIOL CHEM, V278, P30125, DOI 10.1074/jbc.M302042200; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; van Diest PJ, 2002, BMJ-BRIT MED J, V325, P648, DOI 10.1136/bmj.325.7365.648; Vaupel P, 2005, TRANSFUS CLIN BIOL, V12, P5, DOI 10.1016/j.tracli.2004.11.005; Vleugel MM, 2005, J CLIN PATHOL, V58, P172, DOI 10.1136/jcp.2004.019885; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Zhong H, 2000, CANCER RES, V60, P1541; Zhou J, 2004, J BIOL CHEM, V279, P13506, DOI 10.1074/jbc.M310164200	39	49	53	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6123	6127		10.1038/sj.onc.1209643	http://dx.doi.org/10.1038/sj.onc.1209643			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16682946				2022-12-28	WOS:000241101200009
J	Hirohashi, Y; Wang, Q; Liu, Q; Li, B; Du, X; Zhang, H; Furuuchi, K; Masuda, K; Sato, N; Greene, MI				Hirohashi, Y.; Wang, Q.; Liu, Q.; Li, B.; Du, X.; Zhang, H.; Furuuchi, K.; Masuda, K.; Sato, N.; Greene, M. I.			Centrosomal proteins Nde1 and Su48 form a complex regulated by phosphorylation	ONCOGENE			English	Article						centrosome; mitosis; cancer; phosphorylation	CYTOPLASMIC DYNEIN; MALIGNANT-TUMORS; MITOTIC SPINDLE; LIVING CELLS; DEFECTS; LIS1; KINETOCHORES; INSTABILITY; PROGRESSION; CARCINOMA	The centrosome modulates spindle formation and plays a critical role in guiding proper segregation of chromosomes during cell division. Centrosome aberrations, frequently seen in human tumors, may cause abnormal chromosome segregation and contribute to malignant transformation. To explore the components of the centrosomes, we previously identified a novel centrosomal protein called Su48. To further characterize the Su48-containing protein ensemble in the centrosome, we performed yeast two-hybrid screens and isolated a number of Su48- interacting molecules, including the centrosomal protein Nde1. Here, we demonstrate that Su48 can associate with Nde1. Moreover, we found that Nde1 is subjected to phosphorylation in vivo. In particular, we identified six putative Cdc2 phosphorylation sites in Nde1 and found that alteration of these sites diminishes phosphorylation by Cdc2 in vitro and affects the stability of Su48- Nde1 interactions and the centrosomal localization of Nde1. Ablation of Nde1 by gene specific small interfering RNA causes mitotic delay and cell death, coupled with a modest decrease in the incidence of the cells that harbor excessive centrosomes. Collectively, our findings indicate that Nde1 can form a protein complex with Su48 in the centrosome and plays an important role for successful mitosis.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Sapporo Med Univ, Sch Med, Dept Pathol, Chuo Ku, Sapporo, Hokkaido, Japan	University of Pennsylvania; Sapporo Medical University	Greene, MI (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 36th Hamilton Walk,252 John Morgan Bldg, Philadelphia, PA 19104 USA.	greene@reo.med.upenn.edu	Hirohashi, Yoshihiko/AFQ-4227-2022; Wang, Qiang/N-7310-2015	Wang, Qiang/0000-0001-9409-0251; Zhang, Hongtao/0000-0001-9173-0049				Doxsey S, 2002, MOL CELL, V10, P439, DOI 10.1016/S1097-2765(02)00654-8; Efimov VP, 2000, J CELL BIOL, V150, P681, DOI 10.1083/jcb.150.3.681; Faulkner NE, 2000, NAT CELL BIOL, V2, P784, DOI 10.1038/35041020; Feng YY, 2004, NEURON, V44, P279, DOI 10.1016/j.neuron.2004.09.023; Feng YY, 2000, NEURON, V28, P665, DOI 10.1016/S0896-6273(00)00145-8; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; Howell BJ, 2004, CURR BIOL, V14, P953, DOI 10.1016/j.cub.2004.05.053; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Lingle WL, 2000, CURR TOP DEV BIOL, V49, P313; Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1; Pihan GA, 2001, CANCER RES, V61, P2212; Pihan GA, 1998, CANCER RES, V58, P3974; Quintyne NJ, 2005, SCIENCE, V307, P127, DOI 10.1126/science.1104905; Sasaki S, 2000, NEURON, V28, P681, DOI 10.1016/S0896-6273(00)00146-X; Sato N, 1999, CLIN CANCER RES, V5, P963; Shono M, 2001, LAB INVEST, V81, P945, DOI 10.1038/labinvest.3780306; Wang Q, 2004, DNA CELL BIOL, V23, P475, DOI 10.1089/1044549041562276; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang Q, 2001, ONCOGENE, V20, P4640, DOI 10.1038/sj.onc.1204625; Yan XM, 2003, MOL CELL BIOL, V23, P1239, DOI 10.1128/MCB.23.4.1239-1250.2003; Young A, 2000, MOL BIOL CELL, V11, P2047, DOI 10.1091/mbc.11.6.2047	22	33	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2006	25	45					6048	6055		10.1038/sj.onc.1209637	http://dx.doi.org/10.1038/sj.onc.1209637			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16682949				2022-12-28	WOS:000241101200002
J	Tremblay, PL; Auger, FA; Huot, J				Tremblay, P-L; Auger, F. A.; Huot, J.			Regulation of transendothelial migration of colon cancer cells by E-selectin-mediated activation of p38 and ERK MAP kinases	ONCOGENE			English	Article						E-selectin; MAP kinases; transendothelial migration; colon cancer	VASCULAR ENDOTHELIAL-CELLS; ACTIN REORGANIZATION; LEUKOCYTE ADHESION; BARRIER DYSFUNCTION; OXIDATIVE STRESS; LIVER METASTASIS; CARCINOMA CELLS; TUMOR-CELLS; PERMEABILITY; PHOSPHORYLATION	The invasive properties of cancer cells depend on their intrinsic motile potential and on their ability to breach the endothelial barrier. In the present work, we investigated the mechanisms by which adhesion of colon cancer cells to E-selectin expressed by endothelial cells regulates the barrier function of these cells and modulates transmigration of cancer cells. We found that the stimulation of E-selectin by activating antibodies or the adhesion of HT-29 cells results in an increase in the activity of extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinases. In turn, the activation of p38 and ERK enhances transendothelial permeability and migration of HT-29 cells. We also obtained evidence suggesting that p38-mediated increase in transendothelial migration of cancer cells depends on a myosin light chain phosphorylation-mediated formation of stress fibres. On the other hand, the activation of ERK by E-selectin modulates the opening of interendothelial spaces by initiating the activation of Src kinase activities and the dissociation of the VE-cadherin/beta-catenin complex. We conclude that activation of E-selectin by adhering cancer cells is an important process that regulates the extravasation of colon cancer cells by initiating p38- and ERK-dependent mechanisms that both contribute to regulate the integrity of the endothelial layer.	Univ Laval, Ctr Rech Cancerol, Quebec City, PQ G1R 2J6, Canada; Univ Quebec, Ctr Hosp, Lab Organogenese Expt, Ste Foy, PQ G1S 4L8, Canada	Laval University; Laval University; University of Quebec	Huot, J (corresponding author), Univ Laval, Ctr Rech Cancerol, 9,Rue McMahon, Quebec City, PQ G1R 2J6, Canada.	Jacques.Huot@phc.ulaval.ca						Baldwin AL, 2001, CRIT REV BIOMED ENG, V29, P247, DOI 10.1615/CritRevBiomedEng.v29.i2.20; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; Bogatcheva NV, 2002, VASC PHARMACOL, V39, P201, DOI 10.1016/S1537-1891(03)00009-0; Borbiev T, 2004, AM J PHYSIOL-LUNG C, V287, pL911, DOI 10.1152/ajplung.00372.2003; Brembeck FH, 2004, GENE DEV, V18, P2225, DOI 10.1101/gad.317604; Brodt P, 1997, INT J CANCER, V71, P612, DOI 10.1002/(SICI)1097-0215(19970516)71:4<612::AID-IJC17>3.0.CO;2-D; Burdick MM, 2003, AM J PHYSIOL-CELL PH, V284, pC977, DOI 10.1152/ajpcell.00423.2002; Criscuoli ML, 2005, BLOOD, V105, P1508, DOI 10.1182/blood-2004-06-2246; DEJANA E, 1992, LAB INVEST, V66, P324; Dejana E, 2001, THROMB HAEMOSTASIS, V86, P308; Dejana E, 1999, EXP CELL RES, V252, P13, DOI 10.1006/excr.1999.4601; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Haier J, 2001, DIS COLON RECTUM, V44, P876, DOI 10.1007/BF02234713; Hale KK, 1999, J IMMUNOL, V162, P4246; Houle FO, 2003, MOL BIOL CELL, V14, P1418, DOI 10.1091/mbc.E02-04-0235; Hu YY, 2001, J BIOL CHEM, V276, P48549, DOI 10.1074/jbc.M105513200; Hu YY, 2000, J IMMUNOL, V165, P2142, DOI 10.4049/jimmunol.165.4.2142; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; Ionescu CV, 2003, MICROCIRCULATION, V10, P205, DOI 10.1038/sj.mn.7800185; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kevil CG, 1998, J BIOL CHEM, V273, P15099, DOI 10.1074/jbc.273.24.15099; Kevil CG, 2001, ENDOTHELIUM-J ENDOTH, V8, P107, DOI 10.3109/10623320109165320; Khatib AM, 2002, CANCER RES, V62, P5393; Khatib AM, 1999, CANCER RES, V59, P1356; Kobayashi K, 2000, CANCER RES, V60, P3978; Krause T, 1999, CLIN EXP METASTAS, V17, P183, DOI 10.1023/A:1006626500852; Laferriere J, 2001, J BIOL CHEM, V276, P33762, DOI 10.1074/jbc.M008564200; Laferriere J, 2002, ANN NY ACAD SCI, V973, P562, DOI 10.1111/j.1749-6632.2002.tb04702.x; Lafferriere J, 2004, CLIN EXP METASTAS, V21, P257, DOI 10.1023/B:CLIN.0000037708.09420.9a; Lamalice L, 2004, ONCOGENE, V23, P434, DOI 10.1038/sj.onc.1207034; Le Boeuf F, 2004, J BIOL CHEM, V279, P39175, DOI 10.1074/jbc.M405493200; Mehta D, 1999, J PHYSIOL-LONDON, V519, P829, DOI 10.1111/j.1469-7793.1999.0829n.x; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; Peng HH, 2005, FRONT BIOSCI-LANDMRK, V10, P1597, DOI 10.2741/1643; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Rousseau S, 2000, TRENDS CARDIOVAS MED, V10, P321, DOI 10.1016/S1050-1738(01)00072-X; Saito H, 1998, J IMMUNOL, V161, P1533; SAWADA R, 1994, J BIOL CHEM, V269, P1425; SCHNITTLER HJ, 1990, J PHYSIOL-LONDON, V431, P379, DOI 10.1113/jphysiol.1990.sp018335; Shaw L, 2003, J VASC RES, V40, P1, DOI 10.1159/000068940; Tinsley JH, 1999, J BIOL CHEM, V274, P24930, DOI 10.1074/jbc.274.35.24930; Verin AD, 2000, AM J PHYSIOL-LUNG C, V279, pL360, DOI 10.1152/ajplung.2000.279.2.L360; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Wang Q, 2001, J IMMUNOL, V166, P6877, DOI 10.4049/jimmunol.166.11.6877; Weis S, 2004, J CELL BIOL, V167, P223, DOI 10.1083/jcb.200408130; Wojciak-Stothard B, 2002, VASC PHARMACOL, V39, P187, DOI 10.1016/S1537-1891(03)00008-9; YAMADA N, 1995, DIGEST DIS SCI, V40, P1005, DOI 10.1007/BF02064189; Yao J, 2001, ONCOGENE, V20, P8066, DOI 10.1038/sj.onc.1204944; Yoshida M, 2003, ARTERIOSCL THROM VAS, V23, P783, DOI 10.1161/01.ATV.0000067427.40133.59; Yoshida M, 1996, J CELL BIOL, V133, P445, DOI 10.1083/jcb.133.2.445; Yuan SY, 2002, VASC PHARMACOL, V39, P213, DOI 10.1016/S1537-1891(03)00010-7; Zhong CL, 1998, J CELL BIOL, V141, P539, DOI 10.1083/jcb.141.2.539	54	115	116	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	50					6563	6573		10.1038/sj.onc.1209664	http://dx.doi.org/10.1038/sj.onc.1209664			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16715142				2022-12-28	WOS:000241569700001
J	Subbarayan, V; Krieg, P; Hsi, LC; Kim, J; Yang, P; Sabichi, AL; Llansa, N; Mendoza, G; Logothetis, CJ; Newman, RA; Lippman, SM; Menter, DG				Subbarayan, V.; Krieg, P.; Hsi, L. C.; Kim, J.; Yang, P.; Sabichi, A. L.; Llansa, N.; Mendoza, G.; Logothetis, C. J.; Newman, R. A.; Lippman, S. M.; Menter, D. G.			15-lipoxygenase-2 gene regulation by its product 15-(S)-hydroxyeicosatetraenoic acid through a negative feedback mechanism that involves peroxisome proliferator-activated receptor gamma	ONCOGENE			English	Article						15-lipoxygenase-2; prostate cancer; gene expression; peroxisome proliferator-activated receptor gamma	PROSTATE-CANCER CELLS; NUCLEAR RECEPTOR; PPAR-GAMMA; ROR-ALPHA; BINDING PROTEIN; FATTY-ACIDS; EXPRESSION; ANDROGEN; LIGANDS; GROWTH	An inverse relationship exists between the expression of 15-lipoxygenase-2 (15-LOX-2) and peroxisome proliferator-activated receptor c (PPARc) in normal prostate epithelial cells (PrECs) compared with their expression in prostate carcinoma cells (PC-3). The reason for this difference, however, is unknown. We hypothesized that this inverse expression partly involves the 15-LOX-2 promoter and 15-S-hydroxyeicosatetraenoic acid (15-(S)HETE), a product of 15- LOX-2 that binds to PPARc. We identified an active steroid nuclear receptor half-site present in the 15-LOX-2 promoter fragment F-5 (-618/+177) that can interact with PPARc. After forced expression of wild-type PPARc, 15-(S)-HETE (1 mu M) decreased F-5 reporter activity in PrECs whereas forced expression of 15-LOX-2 resulted in 15-(S)-HETE production which enhanced F-5 activity in PC-3. In contrast, the expression of dominant-negative PPARc reversed the transcriptional activation of F-5 by enhancing it 202-fold in PrEC or suppressing it in PC-3; the effect in PC-3 was positively increased 150-fold in the presence of 15-(S)-HETE (1 mu M). Peroxisome proliferator-activated receptor c interacted with 15-LOX-2 promoter sequences in pulldown experiments using biotinylated 15-LOX-2 (-560/-596 bp) oligonucleotides. In gelshift analyses PPARc and orphan receptor ROR alpha were shown to interact with the F-5 fragment in PC-3 cells. These data suggest that crosstalk mechanisms exist between the 15-LOX-2 gene and PPARc to counterbalance expression and help explain the inverse relationship of these genes in normal versus cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Unit 1360, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; German Canc Res Ctr, Dept Eicosanoids & Tumor Dev, D-6900 Heidelberg, Germany	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Helmholtz Association; German Cancer Research Center (DKFZ)	Menter, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Unit 1360, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dmenter@mdanderson.org			NATIONAL CANCER INSTITUTE [P01CA091844, P30CA016672, R21CA102145] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA-10241, R21 CA-102145, P01 CA-91844, CA-16672-28] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berhane K, 2001, GENE, V268, P141, DOI 10.1016/S0378-1119(01)00417-6; Bhatia B, 2005, ONCOGENE, V24, P3583, DOI 10.1038/sj.onc.1208406; Bhatia B, 2003, J BIOL CHEM, V278, P25091, DOI 10.1074/jbc.M301920200; Blanquart C, 2003, J STEROID BIOCHEM, V85, P267, DOI 10.1016/S0960-0760(03)00214-0; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Butler R, 2000, CELL GROWTH DIFFER, V11, P49; Cato A.C., 2002, SCI STKE, V2002, pre9, DOI [10.1126/stke.2002.138.re9, DOI 10.1126/STKE.2002.138.RE9]; Elbrecht A, 1996, BIOCHEM BIOPH RES CO, V224, P431, DOI 10.1006/bbrc.1996.1044; Flores AM, 2005, CHEM-BIOL INTERACT, V151, P121, DOI 10.1016/j.cbi.2004.11.001; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; Hsi LC, 2002, J BIOL CHEM, V277, P40549, DOI 10.1074/jbc.M203522200; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Jack GS, 2000, HUM PATHOL, V31, P1146, DOI 10.1053/hupa.2000.16670; Kang LT, 1998, J LIPID RES, V39, P1476; Kilty I, 1999, EUR J BIOCHEM, V266, P83, DOI 10.1046/j.1432-1327.1999.00818.x; Kim J, 2005, CANCER RES, V65, P6189, DOI 10.1158/0008-5472.CAN-04-4439; Koeffler HP, 2003, CLIN CANCER RES, V9, P1; Krieg P, 2001, GENOMICS, V73, P323, DOI 10.1006/geno.2001.6519; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Moretti RM, 2004, INT J CANCER, V112, P87, DOI 10.1002/ijc.20387; Moretti RM, 2002, ONCOL REP, V9, P1139; Moretti RM, 2001, PROSTATE, V46, P327, DOI 10.1002/1097-0045(20010301)46:4<327::AID-PROS1040>3.0.CO;2-6; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Salas TR, 2003, J BIOL CHEM, V278, P41338, DOI 10.1074/jbc.M302972200; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shankaranarayanan P, 2003, J IMMUNOL, V170, P887, DOI 10.4049/jimmunol.170.2.887; Shappell SB, 1999, AM J PATHOL, V155, P235, DOI 10.1016/S0002-9440(10)65117-6; Shappell SB, 2001, CANCER RES, V61, P497; Sharma GD, 2005, J BIOL CHEM, V280, P7917, DOI 10.1074/jbc.M408852200; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; Subbarayan V, 2005, NEOPLASIA, V7, P280, DOI 10.1593/neo.04457; Subbarayan V, 2004, CANCER EPIDEM BIOMAR, V13, P1710; Subbarayan V, 2001, CANCER RES, V61, P2720; Tang SH, 2004, ONCOGENE, V23, P6942, DOI 10.1038/sj.onc.1207913; Tang SH, 2002, J BIOL CHEM, V277, P16189, DOI 10.1074/jbc.M111936200; Warnmark A, 2003, MOL ENDOCRINOL, V17, P1901, DOI 10.1210/me.2002-0384; Wigren J, 2003, J ENDOCRINOL, V177, P207, DOI 10.1677/joe.0.1770207; Xu XC, 2003, NEOPLASIA, V5, P121, DOI 10.1016/S1476-5586(03)80003-9	39	20	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2006	25	44					6015	6025		10.1038/sj.onc.1209617	http://dx.doi.org/10.1038/sj.onc.1209617			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16682954				2022-12-28	WOS:000240826300010
J	Leung, N; Turbide, C; Olson, M; Marcus, V; Jothy, S; Beauchemin, N				Leung, N.; Turbide, C.; Olson, M.; Marcus, V.; Jothy, S.; Beauchemin, N.			Deletion of the carcinoembryonic antigen-related cell adhesion molecule 1 (Ceacam1) gene contributes to colon tumor progression in a murine model of carcinogenesis	ONCOGENE			English	Article						CEACAM1; colon cancer; azoxymethane; knockout; CEA	INDEPENDENT PROGNOSTIC-SIGNIFICANCE; ABERRANT CRYPT FOCI; BILIARY GLYCOPROTEIN; COLORECTAL-CANCER; EPITHELIAL-CELLS; C-CAM; BETA-CATENIN; HEPATOCELLULAR CARCINOMAS; EXPRESSION PROFILES; SIGNAL-TRANSDUCTION	Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is a glycoprotein that is part of the carcinoembryonic antigen and the immunoglobulin superfamilies. We have shown that it functions as a tumor suppressor and that this function depends upon the presence of the longer CEACAM1 cytoplasmic domain. In this report, we describe the generation of a Ceacam1-/- mouse. The Ceacam1-/- colon exhibits increased in vivo proliferation relative to the wild-type counterpart with a corresponding decreased expression of the p21(Cip1) and p27(Kip1) Cyclin D kinase inhibitors. The colonic villi undergo decreased apoptosis. Out of 35 litters of mice, no spontaneous tumors in any tissues normally expressing CEACAM1 were found over the lifespan of the animals, suggesting that CEACAM1 may not be involved in initiation of tumor development. However, when mice are treated with azoxymethane to induce colonic tumors, we find that Ceacam1-/- mice developed a significantly greater number of tumors than their littermate controls. Moreover, the tumor size was greater in the knockout mice relative to that in the wild-type mice. These results indicate that deletion of CEACAM1 favors progression of colon tumorigenesis.	McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Pathol, Montreal, PQ H3G 1Y6, Canada; St Michaels Hosp, Dept Lab Med & Pathobiol, Toronto, ON M5B 1W8, Canada; Univ Toronto, Toronto, ON, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; McGill University; McGill University; McGill University	Beauchemin, N (corresponding author), McGill Univ, McGill Canc Ctr, McIntyre Bldg,Room 711,3655 Promenade Sir William, Montreal, PQ H3G 1Y6, Canada.	Nicole.Beauchemin@mcgill.ca						Bamberger AM, 1998, AM J PATHOL, V152, P1401; Beauchemin N, 1999, EXP CELL RES, V252, P243; Blau DM, 2001, J VIROL, V75, P8173, DOI 10.1128/JVI.75.17.8173-8186.2001; Brabletz T, 2002, VIRCHOWS ARCH, V441, P1, DOI 10.1007/s00428-002-0642-9; Buckhaults P, 2001, CANCER RES, V61, P6996; Busch C, 2002, HUM PATHOL, V33, P290, DOI 10.1053/hupa.2002.32218; Chan CHF, 2004, MOL THER, V9, P775, DOI 10.1016/j.ymthe.2004.03.009; CHEUNG PH, 1993, J BIOL CHEM, V268, P24303; COURNOYER D, 1988, CANCER RES, V48, P3153; Deschenes C, 2001, GASTROENTEROLOGY, V120, P423, DOI 10.1053/gast.2001.21199; Eberhard A, 2000, CANCER RES, V60, P1388; Ergun S, 2000, MOL CELL, V5, P311, DOI 10.1016/S1097-2765(00)80426-8; Estrera VT, 2001, J BIOL CHEM, V276, P15547, DOI 10.1074/jbc.M008156200; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Fournes B, 2001, ONCOGENE, V20, P219, DOI 10.1038/sj.onc.1204058; Frangsmyr L, 1999, TUMOR BIOL, V20, P277, DOI 10.1159/000030075; GOLD P, 1965, J EXP MED, V122, P467, DOI 10.1084/jem.122.3.467; Hemmila E, 2004, J VIROL, V78, P10156, DOI 10.1128/JVI.78.18.10156-10165.2004; HIXSON DC, 1985, CANCER RES, V45, P3742; HORST AK, 2006, IN PRESS J CLIN INVE; HSIEH JT, 1995, CANCER RES, V55, P190; Huang J, 1998, ANTICANCER RES, V18, P3203; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; Ilantzis C, 1997, LAB INVEST, V76, P703; Izzi L, 1999, ONCOGENE, V18, P5563, DOI 10.1038/sj.onc.1202935; Jantscheff P, 2003, J CLIN ONCOL, V21, P3638, DOI 10.1200/JCO.2003.55.135; Kinugasa T, 1998, INT J CANCER, V76, P148, DOI 10.1002/(SICI)1097-0215(19980330)76:1<148::AID-IJC23>3.3.CO;2-J; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kleinerman DI, 1996, CANCER RES, V56, P3431; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; Kunath T, 1995, ONCOGENE, V11, P2375; Laack E, 2002, J CLIN ONCOL, V20, P4279, DOI 10.1200/JCO.2002.08.067; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; Maltzman T, 1997, CARCINOGENESIS, V18, P2435, DOI 10.1093/carcin/18.12.2435; Muenzner P, 2000, INFECT IMMUN, V68, P3601, DOI 10.1128/IAI.68.6.3601-3607.2000; Muller MM, 2005, BLOOD, V105, P3925, DOI 10.1182/blood-2004-09-3618; NEDELLEC P, 1995, EUR J BIOCHEM, V231, P104, DOI 10.1111/j.1432-1033.1995.tb20676.x; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nittka S, 2004, ONCOGENE, V23, P9306, DOI 10.1038/sj.onc.1208259; Nollau P, 1997, AM J PATHOL, V151, P521; Nollau P, 1997, CANCER RES, V57, P2354; Notterman DA, 2001, CANCER RES, V61, P3124; OKAMOTO M, 1995, CARCINOGENESIS, V16, P2659, DOI 10.1093/carcin/16.11.2659; Oliveira-Ferrer L, 2004, CANCER RES, V64, P8932, DOI 10.1158/0008-5472.CAN-04-0505; OLSEN A, 1994, GENOMICS, V23, P659, DOI 10.1006/geno.1994.1555; Papanikolaou A, 1998, CANCER LETT, V130, P29, DOI 10.1016/S0304-3835(98)00101-3; Phan D, 2004, CANCER RES, V64, P3072, DOI 10.1158/0008-5472.CAN-03-3730; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; Quaroni A, 1997, GASTROENTEROLOGY, V113, P1198, DOI 10.1053/gast.1997.v113.pm9322515; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; Robitaille J, 1999, EUR J BIOCHEM, V264, P534, DOI 10.1046/j.1432-1327.1999.00660.x; ROSENBERG M, 1993, CANCER RES, V53, P4938; Scholzel S, 2000, AM J PATHOL, V156, P595, DOI 10.1016/S0002-9440(10)64764-5; Singer BB, 2000, CANCER RES, V60, P1236; Singh J, 1997, INT J ONCOL, V10, P449; Takahashi M, 2000, CARCINOGENESIS, V21, P1117, DOI 10.1093/carcin/21.6.1117; Tanaka K, 1997, INT J CANCER, V74, P15, DOI 10.1002/(SICI)1097-0215(19970220)74:1<15::AID-IJC3>3.0.CO;2-3; Thies A, 2002, J CLIN ONCOL, V20, P2530, DOI 10.1200/JCO.2002.05.033; Turbide C, 1997, CANCER RES, V57, P2781; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; VIVONA AA, 1993, CARCINOGENESIS, V14, P1777, DOI 10.1093/carcin/14.9.1777; Volpert O, 2002, J BIOL CHEM, V277, P35696, DOI 10.1074/jbc.M205319200; Wang QS, 2000, MOL CARCINOGEN, V28, P139, DOI 10.1002/1098-2744(200007)28:3<139::AID-MC2>3.0.CO;2-V; Wang QS, 1998, CARCINOGENESIS, V19, P2001, DOI 10.1093/carcin/19.11.2001; Wong SCC, 2004, CLIN CANCER RES, V10, P1401, DOI 10.1158/1078-0432.CCR-0157-03; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	69	71	76	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2006	25	40					5527	5536		10.1038/sj.onc.1209541	http://dx.doi.org/10.1038/sj.onc.1209541			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16619040				2022-12-28	WOS:000240370400006
J	Pazzaglia, S; Tanori, M; Mancuso, M; Gessi, M; Pasquali, E; Leonardi, S; Oliva, MA; Rebessi, S; Di Majo, V; Covelli, V; Giangaspero, F; Saran, A				Pazzaglia, S.; Tanori, M.; Mancuso, M.; Gessi, M.; Pasquali, E.; Leonardi, S.; Oliva, M. A.; Rebessi, S.; Di Majo, V.; Covelli, V.; Giangaspero, F.; Saran, A.			Two-hit model for progression of medulloblastoma preneoplasia in Patched heterozygous mice	ONCOGENE			English	Article						medulloblastoma; preneoplasia; Patched; hedgehog; ionizing radiation; LOH	IONIZING-RADIATION; KNOCKOUT MICE; LARGE DELETIONS; MOUSE MODEL; CELL-LINES; HPRT LOCUS; TUMORIGENESIS; GROWTH; CEREBELLUM; MUTATION	Inactivation of one Ptc1 allele predisposes humans and mice to spontaneous medulloblastoma development, and irradiation of newborn Ptc1 heterozygous mice results in dramatic increase of medulloblastoma incidence. While a role for loss of wild-type (wt) Ptc1 (LOH) in radiation-induced medulloblastomas from Ptc1(neo67/+) mice is well established, the importance of this event in spontaneous medulloblastomas is still unclear. Here, we demonstrate that biallelic Ptc1 loss plays a crucial role in spontaneous medulloblastomas, as shown by high rate of wt Ptc1 loss in spontaneous tumors. In addition, remarkable differences in chromosomal events involving the Ptc1 locus in spontaneous and radiation-induced medulloblastomas suggest distinct mechanisms for Ptc1 loss. To assess when, during tumorigenesis, Ptc1 loss occurs, we characterized cerebellar abnormalities that precede tumor appearance in Ptc1(neo67/+) mice. We show that inactivation of only one copy of Ptc1 is sufficient to give rise to abnormal cerebellar proliferations with different degree of altered cell morphology, but lacking potential to progress to neoplasia. Furthermore, we identify biallelic Ptc1 loss as the event causally related to the transition from the preneoplastic stage to full blown medulloblastoma. These results underscore the utility of the Ptc1(neo67/+) mouse model for studies on the mechanisms of medulloblastoma and for development of new therapeutic strategies.	ENEA, CR Casaccia, Biotechnol Unit, I-00060 Rome, Italy; Natl Neurol Inst C Besta, Div Neuropathol, Milan, Italy; Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; INM Neuromed, Isernia, Italy; ENEA, CR Casaccia, Radiat Protect Unit, I-00060 Rome, Italy; Univ Roma La Sapienza, Dept Expt Med & Pathol, Rome, Italy	Italian National Agency New Technical Energy & Sustainable Economics Development; IRCCS Istituto Neurologico Besta; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Neuromed; Italian National Agency New Technical Energy & Sustainable Economics Development; Sapienza University Rome	Pazzaglia, S (corresponding author), ENEA, CR Casaccia, Biotechnol Unit, Via Anguillarese 301, I-00060 Rome, Italy.	pazzaglia@casaccia.enea.it	Giangaspero, Felice/AAH-9253-2020; Oliva, Maria Antonietta/AAE-9115-2020; Giangaspero, Felice/Z-4961-2019; Gessi, Marco/K-2572-2018	Giangaspero, Felice/0000-0001-5382-2380; Oliva, Maria Antonietta/0000-0003-3460-696X; Giangaspero, Felice/0000-0001-5382-2380; Saran, Anna/0000-0002-5587-064X				Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Chintagumpala M, 2001, CURR OPIN ONCOL, V13, P154, DOI 10.1097/00001622-200105000-00004; Corcoran RB, 2001, J NEURO-ONCOL, V53, P307, DOI 10.1023/A:1012260318979; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Eberhart CG, 2003, BRAIN PATHOL, V13, P376; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; HUTCHINSON F, 1995, J MOL BIOL, V254, P372, DOI 10.1006/jmbi.1995.0624; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kim JYH, 2003, DEV BIOL, V263, P50, DOI 10.1016/S0012-1606(03)00434-2; Kinzler KW, 1997, NATURE, V386, P763; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Mancuso M, 2004, CANCER RES, V64, P934, DOI 10.1158/0008-5472.CAN-03-2460; NELSON SL, 1995, RADIAT RES, V141, P2, DOI 10.2307/3579083; Oliver TG, 2005, DEVELOPMENT, V132, P2425, DOI 10.1242/dev.01793; Packer R J, 1999, Neuro Oncol, V1, P232, DOI 10.1093/neuonc/1.3.232; Pazzaglia S, 2006, CANCER LETT, V234, P124, DOI 10.1016/j.canlet.2005.03.047; Pazzaglia S, 2006, ONCOGENE, V25, P1165, DOI 10.1038/sj.onc.1209032; Pazzaglia S, 2000, MOL CARCINOGEN, V27, P219, DOI 10.1002/(SICI)1098-2744(200003)27:3<219::AID-MC9>3.0.CO;2-S; Pazzaglia S, 2002, ONCOGENE, V21, P7580, DOI 10.1038/sj.onc.1205973; Ponomareva ON, 2002, CANCER RES, V62, P1518; Shoemaker AR, 1998, P NATL ACAD SCI USA, V95, P10826, DOI 10.1073/pnas.95.18.10826; Turker MS, 1997, MUTAT RES-FUND MOL M, V374, P201, DOI 10.1016/S0027-5107(96)00230-8; Uziel T, 2005, GENE DEV, V19, P2656, DOI 10.1101/gad.1368605; Wallace VA, 1999, CURR BIOL, V9, P445, DOI 10.1016/S0960-9822(99)80195-X; Wetmore C, 2000, CANCER RES, V60, P2239; Yamada Y, 1996, RADIAT RES, V145, P481, DOI 10.2307/3579070; Zurawel RH, 2000, GENE CHROMOSOME CANC, V27, P44, DOI 10.1002/(SICI)1098-2264(200001)27:1<44::AID-GCC6>3.0.CO;2-V	30	51	51	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2006	25	40					5575	5580		10.1038/sj.onc.1209544	http://dx.doi.org/10.1038/sj.onc.1209544			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16636673				2022-12-28	WOS:000240370400011
J	Yamada, A; Fujita, N; Sato, T; Okamoto, R; Ooshio, T; Hirota, T; Morimoto, K; Irie, K; Takai, Y				Yamada, A.; Fujita, N.; Sato, T.; Okamoto, R.; Ooshio, T.; Hirota, T.; Morimoto, K.; Irie, K.; Takai, Y.			Requirement of nectin, but not cadherin, for formation of claudin-based tight junctions in annexin II-knockdown MDCK cells	ONCOGENE			English	Article						adherens junctions; tight junctions; nectin; afadin; annexin II	CANINE KIDNEY-CELLS; ADHESION MOLECULE NECTIN; SMALL G-PROTEINS; ADHERENS JUNCTIONS; EPITHELIAL-CELLS; ALPHA-CATENIN; ACTIN-FILAMENTS; INTERCELLULAR-JUNCTIONS; FUNCTIONAL-ANALYSIS; TRANS-INTERACTIONS	Adherens junctions (AJs) and tight junctions (TJs) comprise a junctional complex which plays key roles not only in cell adhesion and polarization but also in regulation of cell movement and proliferation in epithelial cells. E-Cadherin and nectin are major cell-cell adhesion molecules (CAMs) at AJs, whereas claudin is a major CAM at TJs. We have shown that the cadherin-based cell-cell adhesion is not formed in MDCK cells in which annexin II, a Ca2+- and phospholipid-binding protein, is knocked down. Here, we found that TJs and the nectin-based cell-cell adhesions were formed in annexin II-knockdown cells. The formation of TJs in annexin II-knockdown MDCK cells required the nectin-based cell-cell adhesion and afadin, a nectin- and actin-filament-binding protein. In addition, it required the activation of Cdc42 and Rac small G proteins and subsequent reorganization of the IQGAP1-dependent actin cytoskeleton which were induced by the nectin- based cell-cell adhesion. These results indicate that the nectin-based cell-cell adhesion and afadin, but not the cadherin-based cell-cell adhesion, are necessary for the formation of TJs and that the signaling by nectin and the subsequent reorganization of the actin cytoskeleton are also necessary for the formation of TJs under certain conditions.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; KAN Res Inst Inc, Shimogyo Ku, Kyoto, Japan	Osaka University; KAN Research Institute	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp						ABERCROMBIE M, 1953, EXP CELL RES, V5, P111, DOI 10.1016/0014-4827(53)90098-6; Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Andreeva AY, 2001, J BIOL CHEM, V276, P38480, DOI 10.1074/jbc.M104923200; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; FISHER HW, 1967, SCIENCE, V155, P581, DOI 10.1126/science.155.3762.581; Fukuhara A, 2002, ONCOGENE, V21, P7642, DOI 10.1038/sj.onc.1205875; Fukuhara A, 2002, GENES CELLS, V7, P1059, DOI 10.1046/j.1365-2443.2002.00578.x; Fukuhara T, 2004, J CELL BIOL, V166, P393, DOI 10.1083/jcb.200401093; Fukuyama T, 2005, J BIOL CHEM, V280, P815, DOI 10.1074/jbc.M411099200; Garrod DR, 2002, CURR OPIN CELL BIOL, V14, P537, DOI 10.1016/S0955-0674(02)00366-6; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Getsios S, 2004, NAT REV MOL CELL BIO, V5, P271, DOI 10.1038/nrm1356; GONZALEZMARISCAL L, 1985, J MEMBRANE BIOL, V86, P113, DOI 10.1007/BF01870778; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Harris TJC, 2004, J CELL BIOL, V167, P135, DOI 10.1083/jcb.200406024; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Honda T, 2003, BIOCHEM BIOPH RES CO, V306, P104, DOI 10.1016/S0006-291X(03)00919-7; Honda T, 2003, GENES CELLS, V8, P51, DOI 10.1046/j.1365-2443.2003.00616.x; Hoshino T, 2005, J BIOL CHEM, V280, P24095, DOI 10.1074/jbc.M414447200; Inoue O, 2003, J CELL BIOL, V160, P769, DOI 10.1083/jcb.200208043; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Izumi G, 2004, J CELL BIOL, V166, P237, DOI 10.1083/jcb.200401078; Katata T, 2003, ONCOGENE, V22, P2097, DOI 10.1038/sj.onc.1206255; Kawakatsu T, 2005, J BIOL CHEM, V280, P4940, DOI 10.1074/jbc.M408710200; Kawakatsu T, 2002, J BIOL CHEM, V277, P50749, DOI 10.1074/jbc.M209846200; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Ma TY, 2000, AM J PHYSIOL-GASTR L, V279, pG875, DOI 10.1152/ajpgi.2000.279.5.G875; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Okamoto R, 2005, GENES CELLS, V10, P435, DOI 10.1111/j.1365-2443.2005.00846.x; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Quinlan MP, 1999, CELL GROWTH DIFFER, V10, P839; Roh MH, 2003, AM J PHYSIOL-RENAL, V285, pF377, DOI 10.1152/ajprenal.00086.2003; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Sakisaka T, 2004, CURR OPIN CELL BIOL, V16, P513, DOI 10.1016/j.ceb.2004.07.007; Sato T, 2006, J BIOL CHEM, V281, P5288, DOI 10.1074/jbc.M510070200; Shimizu K, 2003, J BIOCHEM, V134, P631, DOI 10.1093/jb/mvg198; Sonoda N, 1999, J CELL BIOL, V147, P195, DOI 10.1083/jcb.147.1.195; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; STEVENSON BR, 1994, J CELL SCI, V107, P367; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Takekuni K, 2003, J BIOL CHEM, V278, P5497, DOI 10.1074/jbc.C200707200; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; Umeda K, 2004, J BIOL CHEM, V279, P44785, DOI 10.1074/jbc.M406563200; vanHengel J, 1997, J CELL BIOL, V137, P1103, DOI 10.1083/jcb.137.5.1103; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Wittchen ES, 2000, J CELL BIOL, V151, P825, DOI 10.1083/jcb.151.4.825; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Yagi T, 2000, GENE DEV, V14, P1169; Yamada A, 2005, J BIOL CHEM, V280, P6016, DOI 10.1074/jbc.M408215200; Yamada A, 2004, GENES CELLS, V9, P843, DOI 10.1111/j.1365-2443.2004.00768.x; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yokoyama S, 2001, MOL BIOL CELL, V12, P1595, DOI 10.1091/mbc.12.6.1595	65	46	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2006	25	37					5085	5102		10.1038/sj.onc.1209525	http://dx.doi.org/10.1038/sj.onc.1209525			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16607281				2022-12-28	WOS:000240063700002
J	Massard, C; Zermati, Y; Pauleau, AL; Larochette, N; Wetivier, D; Sabatier, L; Kroemer, G; Soria, JC				Massard, C.; Zermati, Y.; Pauleau, A. -L; Larochette, N.; Wetivier, D.; Sabatier, L.; Kroemer, G.; Soria, J. -C			hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway	ONCOGENE			English	Article						apoptosis; Bax; Bcl-2; chemosensitization; p53	TELOMERASE REVERSE-TRANSCRIPTASE; HUMAN CANCER-CELLS; GENE-EXPRESSION; DOWN-REGULATION; APOPTOSIS; P53; GROWTH; BAX; RNA; RESPONSES	hTERT is the catalytic subunit of the telomerase and is hence required for telomerase maintenance activity and cancer cell immortalization. Here, we show that acute hTERT depletion has no adverse effects on the viability or proliferation of cervical and colon carcinoma cell lines, as evaluated within 72h after transfection with hTERT-specific small interfering RNAs (siRNAs). Within the same time frame, hTERT depletion facilitated the induction of apoptotic cell death by cisplatin, etoposide, mitomycin C and reactive oxygen species, yet failed to sensitize cells to death induction via the CD95 death receptor. Experiments performed with p53 knockout cells or chemical p53 inhibitors revealed that p53 was not involved in the chemosensitizing effect of hTERT knockdown. However, the proapoptotic Bcl-2 family protein Bax was involved in cell death induction by hTERT siRNAs. Depletion of hTERT facilitated the conformational activation of Bax induced by genotoxic agents. Moreover, Bax knockout abolished the chemosensitizing effect of hTERT siRNAs. Inhibition of mitochondrial membrane permeabilization by overexpression of Bcl-2 or expression of the cytomegalovirus-encoded protein vMIA (viral mitochondrial inhibitor of apoptosis), which acts as a specific Bax inhibitor, prevented the induction of cell death by the combination of hTERT depletion and chemotherapeutic agents. Altogether, our data indicate that hTERT inhibition may constitute a promising strategy for facilitating the induction of the mitochondrial pathway of apoptosis.	Inst Gustave Roussy, CNRS, UMR 8125, F-94805 Villejuif, France; Inst Gustave Roussy, Div Canc Med, F-94805 Villejuif, France; CEA, DSV, DRR, LRO, Fontenay Aux Roses, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; CEA	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR 8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr; soria@igr.fr	Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013; Soria, Jean-Charles/F-3619-2014; LAROCHETTE, Nathanael/R-4298-2017	KROEMER, Guido/0000-0002-9334-4405; LAROCHETTE, Nathanael/0000-0002-7936-678X; Sabatier, Laure/0000-0003-0552-6549				Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Cao Y, 2002, ONCOGENE, V21, P3130, DOI 10.1038/sj.onc.1205419; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Castedo M, 1996, J IMMUNOL, V157, P512; Castedo M, 2002, EMBO J, V21, P4070, DOI 10.1093/emboj/cdf391; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Del Bufalo D, 2005, CELL DEATH DIFFER, V12, P1429, DOI 10.1038/sj.cdd.4401670; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; Folini M, 2005, EUR J CANCER, V41, P624, DOI 10.1016/j.ejca.2004.12.002; Goldmacher VS, 2005, APOPTOSIS, V10, P251, DOI 10.1007/s10495-005-0800-z; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Gorbunova V, 2003, J BIOL CHEM, V278, P7692, DOI 10.1074/jbc.M212944200; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Haendeler J, 2004, CIRC RES, V94, P768, DOI 10.1161/01.RES.0000121104.05977.F3; Haendeler J, 2003, FEBS LETT, V536, P180, DOI 10.1016/S0014-5793(03)00058-9; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harborth J, 2001, J CELL SCI, V114, P4557; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; Ito H, 2005, HUM GENE THER, V16, P685, DOI 10.1089/hum.2005.16.685; Jacob D, 2005, CANCER GENE THER, V12, P109, DOI 10.1038/sj.cgt.7700773; Jiang F, 2004, J BIOL CHEM, V279, P53213, DOI 10.1074/jbc.M410395200; Kang HJ, 2004, J NEUROSCI, V24, P1280, DOI 10.1523/JNEUROSCI.4082-03.2004; Kawashima T, 2004, CLIN CANCER RES, V10, P285, DOI 10.1158/1078-0432.CCR-1075-3; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Komata T, 2002, ONCOGENE, V21, P656, DOI 10.1038/sj.onc.1205072; Lantuejoul S, 2005, CLIN CANCER RES, V11, P2074, DOI 10.1158/1078-0432.CCR-04-1376; Lewis DL, 2002, NAT GENET, V32, P107, DOI 10.1038/ng944; Li S, 2005, J BIOL CHEM, V280, P23709, DOI 10.1074/jbc.M502782200; Li S, 2004, CANCER RES, V64, P4833, DOI 10.1158/0008-5472.CAN-04-0953; Lin TY, 2002, ONCOGENE, V21, P8020, DOI 10.1038/sj.onc.1205926; Lu CB, 2001, DEV BRAIN RES, V131, P167, DOI 10.1016/S0165-3806(01)00237-1; Luiten RM, 2003, BLOOD, V101, P4512, DOI 10.1182/blood-2002-07-2018; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Perfettini JL, 2004, NAT CELL BIOL, V6, P386, DOI 10.1038/ncb0504-386; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Poncet D, 2004, J BIOL CHEM, V279, P22605, DOI 10.1074/jbc.M308408200; Rahman R, 2005, ONCOGENE, V24, P1320, DOI 10.1038/sj.onc.1208232; Santos JH, 2004, AGING CELL, V3, P399, DOI 10.1111/j.1474-9728.2004.00124.x; Saretzki G, 2001, ANAL CELL PATHOL, V23, P39, DOI 10.1155/2001/630972; Schulze-Bergkamen H, 2004, SEMIN ONCOL, V31, P90, DOI 10.1053/j.seminoncol.2003.11.006; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; Takakura M, 2005, MOL CELL BIOL, V25, P8037, DOI 10.1128/MCB.25.18.8037-8043.2005; Uziel O, 2005, BRIT J CANCER, V92, P1881, DOI 10.1038/sj.bjc.6602592; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wu P, 2005, BIOCHEM BIOPH RES CO, V335, P36, DOI 10.1016/j.bbrc.2005.07.039; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhang PS, 2003, FASEB J, V17, P767, DOI 10.1096/fj.02-0603fje; Zhou CX, 2003, MOL CANCER THER, V2, P789	58	118	133	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2006	25	33					4505	4514		10.1038/sj.onc.1209487	http://dx.doi.org/10.1038/sj.onc.1209487			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16619047				2022-12-28	WOS:000239457500001
J	Darby, S; Sahadevan, K; Khan, MM; Robson, CN; Leung, HY; Gnanapragasam, VJ				Darby, S.; Sahadevan, K.; Khan, M. M.; Robson, C. N.; Leung, H. Y.; Gnanapragasam, V. J.			Loss of Sef (similar expression to FGF) expression is associated with high grade and metastatic prostate cancer	ONCOGENE			English	Article						prostate cancer; similar expression to FGF; fibroblast growth factor; metastasis	ISOFORM-B; OVER-EXPRESSION; TUMOR-GROWTH; RECEPTOR; CELLS; FIBROBLAST-GROWTH-FACTOR-8; ACTIVATION; GENE; GBX2	Fibroblast growth factors (FGF), and in particular FGF8, have been strongly implicated in prostate carcinogenesis. This study investigated the expression of Sef, a key inhibitory regulator of FGF signalling, in prostate cancer. In a panel of cell lines, hSef was detected in both androgen-dependent and independent cells but was significantly reduced in highly metastatic derivative clones. hSef expression was not influenced by androgenic stimulation. Forced downregulation of hSef by siRNA increased FGF8b induced cell migration (P = 0.02) and invasion (P = 0.007). Reduced hSef levels also enhanced FGF8b stimulated expression of MMP9 (P = 0.005). mRNA in situ hybridization revealed hSef expression in 80% (8/10) of benign biopsies but in only 69% (23/33) of Gleason sum 4-7 and 35% (10/28) of Gleason sum 8-10 cancer biopsies (P = 0.004). Quantitative PCR of micro-dissected glands confirmed this trend (P = 0.001). hSef was expressed in 69% (27/39) of non-metastatic tumours but in only 18% (2/11) of metastatic tumours (P = 0.004, n = 50). hSef expression was next correlated with earlier data on FGF8b expression in a subgroup of cancers. In this cohort, 86% (19/22) of high-grade cancers expressed FGF8 but only 31% (7/22) expressed hSef. Positive FGF8 expression but a loss of hSef was observed in 88% (7/8) of metastatic tumours. In contrast, metastasis was evident in only 10% (1/10) of tumours, which co-expressed both FGF8 and hSef (P < 0.001). These results suggest evidence that hSef is downregulated in advanced prostate cancer and might facilitate an enhanced tumorigenic response to FGFs. Further research into the role of hSef in cancer cell signalling and the mechanism of its downregulation may contribute to more effective targeting of growth factors in prostate cancer.	Univ Newcastle Upon Tyne, Urol Res Grp, Canc Res UK, No Inst Canc Res,Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Royal Victoria Infirm, Dept Pathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Cancer Research UK; Newcastle University - UK; Newcastle University - UK	Gnanapragasam, VJ (corresponding author), Univ Newcastle Upon Tyne, Urol Res Grp, Canc Res UK, No Inst Canc Res,Sch Med, Paul O'Gorman Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	V.J.Gnanapragasam@ncl.ac.uk		darby, steven/0000-0002-7226-8634; Leung, Hing Y./0000-0002-3933-3975; Sahadevan, Kanagasabai/0000-0002-3141-3276	Medical Research Council [G0100100] Funding Source: Medline; MRC [G0100100] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Dorkin TJ, 1999, ONCOGENE, V18, P2755, DOI 10.1038/sj.onc.1202624; DORKIN TJ, 2000, BJU INT, V86, P392; Furthauer M, 2002, NAT CELL BIOL, V4, P170, DOI 10.1038/ncb750; Gao AC, 2000, CLIN CANCER RES, V6, P493; Giri D, 1999, CLIN CANCER RES, V5, P1063; Gnanapragasam V, 2003, BRIT J CANCER, V88, P1432, DOI 10.1038/sj.bjc.6600875; Gnanapragasam VJ, 2002, ONCOGENE, V21, P5069, DOI 10.1038/sj.onc.1205663; Gnanapragasam VJ, 2001, BRIT J CANCER, V85, P1928, DOI 10.1054/bjoc.2001.2179; Gowardhan B, 2005, BRIT J CANCER, V92, P320, DOI 10.1038/sj.bjc.6602274; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Johansson JE, 2004, JAMA-J AM MED ASSOC, V291, P2713, DOI 10.1001/jama.291.22.2713; KOSLOWSKI J, 1984, CANCER RES, V44, P3522; Kovalenko D, 2003, J BIOL CHEM, V278, P14087, DOI 10.1074/jbc.C200606200; Kwabi-Addo B, 2004, ENDOCR-RELAT CANCER, V11, P709, DOI 10.1677/erc.1.00535; Leung HY, 1996, ONCOGENE, V12, P1833; Lin W, 2005, GENESIS, V41, P110, DOI 10.1002/gene.20103; Lin W, 2002, MECH DEVELOP, V113, P163, DOI 10.1016/S0925-4773(02)00018-7; Mattila MMT, 2001, ONCOGENE, V20, P2791, DOI 10.1038/sj.onc.1204430; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Ozen M, 2001, J NATL CANCER I, V93, P1783, DOI 10.1093/jnci/93.23.1783; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Rudra-Ganguly N, 1998, ONCOGENE, V16, P1487, DOI 10.1038/sj.onc.1201652; Ruohola JK, 2001, CANCER RES, V61, P4229; Song ZG, 2000, CANCER RES, V60, P6730; Song ZG, 2002, CANCER RES, V62, P5096; Torii S, 2004, DEV CELL, V7, P33, DOI 10.1016/j.devcel.2004.05.019; Tsang M, 2002, NAT CELL BIOL, V4, P165, DOI 10.1038/ncb749; Xiong SQ, 2003, J BIOL CHEM, V278, P50273, DOI 10.1074/jbc.M306936200; YAN G, 1992, MOL CELL BIOL, V13, P4513; Yang RB, 2003, J BIOL CHEM, V278, P33232, DOI 10.1074/jbc.M305022200; Yang XH, 2004, J BIOL CHEM, V279, P38099, DOI 10.1074/jbc.C400318200	31	42	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2006	25	29					4122	4127		10.1038/sj.onc.1209428	http://dx.doi.org/10.1038/sj.onc.1209428			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16474841				2022-12-28	WOS:000238802400013
J	Di Fulvio, M; Lehman, N; Lin, X; Lopez, I; Gomez-Cambronero, J				Di Fulvio, M.; Lehman, N.; Lin, X.; Lopez, I.; Gomez-Cambronero, J.			The elucidation of novel SH2 binding sites on PLD2	ONCOGENE			English	Article						PLD; Grb2; SOS; SH2 domains; cell signalling; cell proliferation; Ras/Erk pathway; site-directed mutagenesis	KINASE SIGNAL-TRANSDUCTION; RECEPTOR TYROSINE KINASES; COLONY-STIMULATING FACTOR; ADP-RIBOSYLATION FACTOR; GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE-D; REGULATORY MECHANISM; CELL-PROLIFERATION; HUMAN NEUTROPHILS; PROTEIN GRB2	Our laboratory has recently reported that the enzyme phospholipase D2 (PLD2) exists as a ternary complex with PTP1b and the growth factor receptor bound protein 2 (Grb2). Here, we establish the mechanistic underpinnings of the PLD2/Grb2 association. We have identified residues Y-169 and Y-179 in the PLD2 protein as being essential for the Grb2 interaction. We present evidence indicating that Y-169 and Y179 are located within two consensus sites in PLD2 that mediate an SH2 interaction with Grb2. This was demonstrated with an SH2-deficient GSTGrb2 R86K mutant that failed to pull-down PLD2 in vitro. In order to elucidate the functions of the two neighboring tyrosines, we created a new class of deletion and point mutants in PLD2. Phenylalanine replacement of Y-169 (PLD2 Y169F)or Y-179 (PLD2 Y179F) reduced Grb2 binding while simultaneous mutation completely abolished it. The role of the two binding sites on PLD2 was found to be functionally nonequivalent: Y-169 serves to modulate the activity of the enzyme, whereas Y-179 regulates total tyrosine phosphorylation of the protein. Interestingly, binding of Grb2 to PLD2 occurs irrespectively of lipase activity, since Grb2 binds to catalytically inactive PLD2 mutants. Finally, PLD2 residues Y-169 and Y-179 are necessary for the recruitment of Sos, but only overexpression of the PLD2 Y179F mutant resulted in increased Ras activity, p44/42(Erk) phosphorylation and enhanced DNA synthesis. Since Y-169 remains able to modulate enzyme activity and is capable of binding to Grb2 in the PLD2 Y179F mutant, we propose that Y-169 is kept under negative regulation by Y-179. When this is released, Y-169 mediates cellular proliferation through the Ras/MAPK pathway.	Wright State Univ, Dept Physiol & Biophys, Sch Med, Dayton, OH 45435 USA; Univ Illinois, Dept Pharmacol, Chicago, IL USA	Wright State University Dayton; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gomez-Cambronero, J (corresponding author), Wright State Univ, Dept Physiol & Biophys, Sch Med, Dayton, OH 45435 USA.	julian.cambronero@wright.edu		Gomez-Cambronero, Julian/0000-0002-7581-9227	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL056653, R01HL056653] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL056653-09, R29 HL056653, HL056653, R01 HL056653] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn BH, 2003, MOL CELL BIOL, V23, P3103, DOI 10.1128/MCB.23.9.3103-3115.2003; Banno Y, 2005, J BIOL CHEM, V280, P16319, DOI 10.1074/jbc.M410903200; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Choi WS, 2004, MOL CELL BIOL, V24, P6980, DOI 10.1128/MCB.24.16.6980-6992.2004; Cockcroft S, 2001, CELL MOL LIFE SCI, V58, P1674, DOI 10.1007/PL00000805; Di Fulvio M, 2000, J ENDOCRINOL, V166, P173, DOI 10.1677/joe.0.1660173; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Exton JH, 1998, BBA-MOL CELL BIOL L, V1436, P105, DOI 10.1016/S0005-2760(98)00124-6; Foster DA, 2003, MOL CANCER RES, V1, P789; Gomez-Cambronero J, 2003, J IMMUNOL, V171, P6846, DOI 10.4049/jimmunol.171.12.6846; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Horn J, 2005, BIOCHEM BIOPH RES CO, V332, P58, DOI 10.1016/j.bbrc.2005.04.093; Horn JM, 2001, BBA-MOL CELL BIOL L, V1530, P97, DOI 10.1016/S1388-1981(00)00172-4; Houle MG, 1999, BBA-MOL CELL BIOL L, V1439, P135, DOI 10.1016/S1388-1981(99)00090-6; Jang IH, 2003, J BIOL CHEM, V278, P18184, DOI 10.1074/jbc.M208438200; Kim JH, 2002, BIOCHEMISTRY-US, V41, P3414, DOI 10.1021/bi015700a; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lehman JA, 2003, J BIOL CHEM, V278, P28130, DOI 10.1074/jbc.M300376200; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Li SG, 2001, EMBO J, V20, P6793, DOI 10.1093/emboj/20.23.6793; Liu MY, 2002, CANCER RES, V62, P6475; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Park JB, 2000, J BIOL CHEM, V275, P21295, DOI 10.1074/jbc.M002463200; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; Powner DJ, 2002, FEBS LETT, V531, P62, DOI 10.1016/S0014-5793(02)03410-5; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Slaaby R, 1998, J BIOL CHEM, V273, P33722, DOI 10.1074/jbc.273.50.33722; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Sung TC, 1999, J BIOL CHEM, V274, P494, DOI 10.1074/jbc.274.1.494; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Xu Y, 2001, BIOCHEM J, V360, P513, DOI 10.1042/0264-6021:3600513; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	35	36	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					3032	3040		10.1038/sj.onc.1209340	http://dx.doi.org/10.1038/sj.onc.1209340			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16407827	Green Accepted			2022-12-28	WOS:000237950800007
J	Han, YH; Cao, X; Lin, B; Lin, F; Kolluri, SK; Stebbins, J; Reed, JC; Dawson, MI; Zhang, XK				Han, Y-H; Cao, X.; Lin, B.; Lin, F.; Kolluri, S. K.; Stebbins, J.; Reed, J. C.; Dawson, M. I.; Zhang, X-k			Regulation of Nur77 nuclear export by c-Jun N-terminal kinase and Akt	ONCOGENE			English	Article						apoptosis; Nur77; JNK; Akt; AHPN; CD437	SYNTHETIC RETINOID CD437; CANCER-CELL-LINES; BREAST-CARCINOMA CELLS; ORPHAN RECEPTOR TR3; NGFI-B; PROSTATE-CANCER; APOPTOSIS INDUCTION; SIGNALING PATHWAY; BINDING DOMAIN; LEUKEMIA-CELLS	Proapoptotic nuclear receptor family member Nur77 translocates from the nucleus to the mitochondria, where it interacts with Bcl-2 to trigger apoptosis. Nur77 translocation is induced by certain apoptotic stimuli, including the synthetic retinoid-related 6-[3-(1-adamantyl)-4hydroxyphenyl]-2- naphthalenecarboxylic acid (AHPN)/CD437 class. In this study, we investigated the molecular mechanism by which AHPN/CD437 analog (E)-4-[3(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3- Cl- AHPC) induces Nur77 nuclear export. Our results demonstrate that 3- Cl- AHPC effectively activated Jun N-terminal kinase (JNK), which phosphorylates Nur77. Inhibition of JNK activation by a JNK inhibitor suppressed 3-Cl-AHPC-induced Nur77 nuclear export and apoptosis. In addition, several JNK upstream activators, including the phorbol ester TPA, anisomycin and MAPK kinase kinase-1 (MEKK1), phosphorylated Nur77 and induced itsnuclear export. However, Nur77 phosphorylation by JNK, although essential, was not sufficient for inducing Nur77 nuclear export. Induction of Nur77 nuclear export by MEKK1 required a prolonged MEKK1 activation and was attenuated by Akt activation. Expression of constitutively active Akt prevented MEKK1-induced Nur77 nuclear export. Conversely, transfection of dominant-negative Akt or treatment with a phosphatidylinositol 3- kinase (PI3-K) inhibitor accelerated MEKK1-induced Nur77 nuclear export. Furthermore, mutation of an Akt phosphorylation residue Ser351 in Nur77 abolished the effect of Akt or the PI3-K inhibitor. Together, our results demonstrate that both activation of JNK and inhibition of Akt play a role in translocation of Nur77 from the nucleus to the cytoplasm.	Burke Med Res Inst, Ctr Canc, La Jolla, CA 92037 USA		Zhang, XK (corresponding author), Burke Med Res Inst, Ctr Canc, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	xzhang@burnham.org			NATIONAL CANCER INSTITUTE [R01CA087000, R01CA109345] Funding Source: NIH RePORTER; NCI NIH HHS [CA109345, CA87000] Funding Source: Medline; NIGMS NIH HHS [GM60544] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi H, 1998, AM J RESP CELL MOL, V18, P323, DOI 10.1165/ajrcmb.18.3.2974; Agadir A, 1999, J BIOL CHEM, V274, P29779, DOI 10.1074/jbc.274.42.29779; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Baker KD, 2003, CELL, V113, P731, DOI 10.1016/S0092-8674(03)00420-3; Boisvieux-Ulrich E, 2005, EXP CELL RES, V307, P76, DOI 10.1016/j.yexcr.2005.02.005; Cao XH, 2004, MOL CELL BIOL, V24, P9705, DOI 10.1128/MCB.24.22.9705-9725.2004; CHANG C, 1989, J STEROID BIOCHEM, V34, P391; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DAVIS IJ, 1993, MOL ENDOCRINOL, V7, P953, DOI 10.1210/me.7.8.953; Dawson MI, 1998, CANCER LETT, V133, P1, DOI 10.1016/S0304-3835(98)00147-5; Dawson MI, 2001, CANCER RES, V61, P4723; FAHRNER TJ, 1990, MOL CELL BIOL, V10, P6454, DOI 10.1128/MCB.10.12.6454; Farhana L, 2004, ONCOGENE, V23, P1874, DOI 10.1038/sj.onc.1207311; Flaig R, 2005, J BIOL CHEM, V280, P19250, DOI 10.1074/jbc.M413175200; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Garattini E, 2004, BLOOD, V103, P194, DOI 10.1182/blood-2003-05-1577; Gianni M, 1999, LEUKEMIA, V13, P739, DOI 10.1038/sj.leu.2401419; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; HIRATA Y, 1993, J BIOL CHEM, V268, P24808; Holmes WF, 2003, J CELL BIOCHEM, V89, P262, DOI 10.1002/jcb.10505; Holmes WF, 2002, J BIOL CHEM, V277, P45408, DOI 10.1074/jbc.M204600200; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; Hsu CKA, 1997, EXP CELL RES, V232, P17, DOI 10.1006/excr.1997.3509; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jacobs CM, 2004, J BIOL CHEM, V279, P50097, DOI 10.1074/jbc.M409145200; Jeong JH, 2003, ANN NY ACAD SCI, V1010, P171, DOI 10.1196/annals.1299.029; Kanda H, 2004, J BIOCHEM, V136, P1, DOI 10.1093/jb/mvh098; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Kolluri SK, 2003, MOL CELL BIOL, V23, P8651, DOI 10.1128/MCB.23.23.8651-8667.2003; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; Labelle Y, 1999, ONCOGENE, V18, P3303, DOI 10.1038/sj.onc.1202675; Langdon SP, 1998, CANCER CHEMOTH PHARM, V42, P429, DOI 10.1007/s002800050841; Lee JM, 2002, P NATL ACAD SCI USA, V99, P11878, DOI 10.1073/pnas.182552499; Lee KW, 2005, J BIOL CHEM, V280, P16942, DOI 10.1074/jbc.M412757200; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li XS, 1996, CANCER RES, V56, P5055; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Liang JY, 1999, PROSTATE, V38, P228; Lin AN, 2002, AGING CELL, V1, P112, DOI 10.1046/j.1474-9728.2002.00014.x; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Liu S, 2002, WORLD J GASTROENTERO, V8, P446, DOI 10.3748/wjg.v8.i3.446; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Masuyama N, 2001, J BIOL CHEM, V276, P32799, DOI 10.1074/jbc.M105431200; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Oridate N, 1997, INT J CANCER, V70, P484, DOI 10.1002/(SICI)1097-0215(19970207)70:4<484::AID-IJC21>3.0.CO;2-E; Pekarsky Y, 2001, P NATL ACAD SCI USA, V98, P3690, DOI 10.1073/pnas.051003198; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Schadendorf D, 1995, Recent Results Cancer Res, V139, P183; SHAO ZM, 1995, ONCOGENE, V11, P493; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Sun SY, 1999, ONCOGENE, V18, P2357, DOI 10.1038/sj.onc.1202543; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Uemura H, 1998, ENDOCRINOLOGY, V139, P2329, DOI 10.1210/en.139.5.2329; Wan XL, 2001, ANTICANCER RES, V21, P2657; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Weih F, 1996, P NATL ACAD SCI USA, V93, P5533, DOI 10.1073/pnas.93.11.5533; Widschwendter M, 1997, INT J CANCER, V71, P497; Wilson AJ, 2003, CANCER RES, V63, P5401; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; WINGATE AD, 2005, BIOCH J         1013; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Wu Q, 2002, CARCINOGENESIS, V23, P1583, DOI 10.1093/carcin/23.10.1583; Wu Q, 1997, EMBO J, V16, P1656, DOI 10.1093/emboj/16.7.1656; Wu Q, 1997, MOL CELL BIOL, V17, P6598, DOI 10.1128/MCB.17.11.6598; Zhang XK, 2002, ENDOCR-RELAT CANCER, V9, DOI 10.1677/erc.0.0090087; Zhang YX, 2003, BLOOD, V102, P3743, DOI 10.1182/blood-2003-01-0108; Zhang YX, 1999, EXP CELL RES, V247, P233, DOI 10.1006/excr.1998.4350; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966	74	110	116	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					2974	2986		10.1038/sj.onc.1209358	http://dx.doi.org/10.1038/sj.onc.1209358			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16434970				2022-12-28	WOS:000237950800002
J	Herman, JF; Mangala, LS; Mehta, K				Herman, J. F.; Mangala, L. S.; Mehta, K.			Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells	ONCOGENE			English	Article						tissue transglutaminase; apoptosis; integrins; chemoresistance	FOCAL ADHESION KINASE; INDUCED APOPTOSIS; BINDING DOMAIN; HUMAN TUMOR; INTEGRIN; FIBRONECTIN; LINE; OVEREXPRESSION; ALPHA-4-BETA-1; ACTIVATION	The development of resistance to chemotherapeutic drugs is a major obstacle to the successful treatment of breast cancer. Ways to block or overcome this resistance are objects of intense research. We have previously shown that cancer cells selected for resistance against chemotherapeutic drugs or isolated from metastatic tumor sites have high levels of a calcium-dependent protein crosslinking enzyme, tissue transglutaminase (TG2) but no direct link between TG2 and resistance was established. As TG2 can associate with the ss members of the integrin family of proteins, we hypothesized that TG2 promotes cell survival signaling pathways by activating integrins on the surface of these cells. To test this hypothesis, we studied the expression of TG2 and its interaction with various integrins in drug-resistant MCF-7 breast cancer cells. TG2 closely associated with ss 1 and ss 5 integrins on the surface of drug-resistant MCF-7 (MCF-7/Dox and MCF-7/RT) cells. The incubation of TG2-expressing drug-resistant MCF-7 cells on fibronectin(Fn)-coated surfaces strongly activated focal adhesion kinase, an event that leads to the activation of several downstream signaling pathways and, in turn, can confer apoptosis-resistant phenotype to cancer cells. The role of TG2 in Fn-mediated cell attachment, cell growth, and cell survival functions was further analysed by small interfering RNA ( siRNA) approach. Inhibition of TG2 by siRNA-inhibited Fn-mediated cell attachment and cell survival functions in drug-resistant MCF-7 cells. We conclude that the expression of TG2 in breast cancer cells contributes to the development of the drug-resistance phenotype by promoting interaction between integrins and Fn.	UT MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Canc Biol Program, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Mehta, K (corresponding author), UT MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 326,Room Y6-5318,1515 Holcombe Blvd, Houston, TX 77030 USA.	kmehta@mdanderson.org						Akimov SS, 2000, J CELL BIOL, V148, P825, DOI 10.1083/jcb.148.4.825; Akimov SS, 2001, J CELL SCI, V114, P2989; ANTONYAK M, 2001, J BIOL CHEM, V279, P8715; Antonyak MA, 2004, J BIOL CHEM, V279, P41461, DOI 10.1074/jbc.M404976200; Aoudjit F, 2001, ONCOGENE, V20, P4995, DOI 10.1038/sj.onc.1204554; Autuori F, 1998, Adv Biochem Eng Biotechnol, V62, P129, DOI 10.1007/BFb0102308; Boehm JE, 2002, J BIOL CHEM, V277, P20127, DOI 10.1074/jbc.C200147200; Cary LA, 1996, J CELL SCI, V109, P1787; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Chen JSK, 2004, J CELL PHYSIOL, V200, P223, DOI 10.1002/jcp.20014; Chen JSK, 2002, BREAST CANCER RES TR, V71, P237, DOI 10.1023/A:1014461832403; Cordes N, 2003, INT J RADIAT BIOL, V79, P709, DOI 10.1080/09553000310001610240; Damiano JS, 2001, LEUKEMIA, V15, P1232, DOI 10.1038/sj.leu.2402179; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; DAVIES PJ, 1994, MOL CELL BIOL, V14, P6584; de la Fuente MT, 2002, J LEUKOCYTE BIOL, V71, P495; De Laurenzi V, 2001, MOL CELL BIOL, V21, P148, DOI 10.1128/MCB.21.1.148-155.2001; Devarajan E, 2002, INT J ONCOL, V20, P913; FESUS L, 1991, EUR J CELL BIOL, V56, P170; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; Hang J, 2005, J BIOL CHEM, V280, P23675, DOI 10.1074/jbc.M503323200; ILLC D, 1995, NATURE, V377, P539; JEONG JM, 1995, J BIOL CHEM, V270, P5654, DOI 10.1074/jbc.270.10.5654; Korah R, 2004, CANCER RES, V64, P4514, DOI 10.1158/0008-5472.CAN-03-3853; Longtin R, 2004, J NATL CANCER I, V96, P6, DOI 10.1093/jnci/96.1.6; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Mangala LS, 2005, PROG EXP TUMOR RES, V38, P125; Mauro L, 1999, EXP CELL RES, V252, P439, DOI 10.1006/excr.1999.4639; Mehta K, 2004, CLIN CANCER RES, V10, P8068, DOI 10.1158/1078-0432.CCR-04-1107; Mehta K, 2002, J NATL CANCER I, V94, P1652; MEHTA K, 1994, INT J CANCER, V58, P400, DOI 10.1002/ijc.2910580316; Milakovic T, 2004, J BIOL CHEM, V279, P8715, DOI 10.1074/jbc.M308479200; Nanda N, 2001, J BIOL CHEM, V276, P20673, DOI 10.1074/jbc.M010846200; Nista A, 1997, INT J CANCER, V72, P133, DOI 10.1002/(SICI)1097-0215(19970703)72:1<133::AID-IJC19>3.0.CO;2-K; Oliverio S, 1997, MOL CELL BIOL, V17, P6040, DOI 10.1128/MCB.17.10.6040; Parise LV, 2000, SEMIN CANCER BIOL, V10, P407, DOI 10.1006/scbi.2000.0337; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; Xu LH, 1998, CELL GROWTH DIFFER, V9, P999; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	44	110	115	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					3049	3058		10.1038/sj.onc.1209324	http://dx.doi.org/10.1038/sj.onc.1209324			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16449978				2022-12-28	WOS:000237950800009
J	Colin, C; Baeza, N; Bartoli, C; Fina, F; Eudes, N; Nanni, I; Martin, PM; Ouafik, L; Figarella-Branger, D				Colin, C; Baeza, N; Bartoli, C; Fina, F; Eudes, N; Nanni, I; Martin, PM; Ouafik, L; Figarella-Branger, D			Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using Suppression Subtractive Hybridization	ONCOGENE			English	Article						human gliomas; SSH (suppression subtractive hybridization); real-time quantitative RT-PCR; SPOCK1; fibronectin	MAMMARY EPITHELIAL-CELLS; MICROARRAY ANALYSIS; LOW-GRADE; MOLECULAR CLASSIFICATION; DNA-MICROARRAY; MESSENGER-RNA; HUMAN GLIOMA; OSTEOPONTIN; PROGRESSION; PROFILES	Glioblastoma (GBM) is a highly malignant glioma, which has the propensity to infiltrate throughout the brain in contrast to pilocytic astrocytoma (PA) of the posterior fossa, which does not spread and can be cured by surgery. We have used Suppression Subtractive Hybridization to de. ne markers that better delineate the molecular basis of brain invasion and distinguish these tumor groups. We have identified 106 genes expressed in PA versus GBM and 80 genes expressed in GBM versus PA. Subsequent analysis identified a subset of 20 transcripts showing a common differential expression pattern for the two groups. GBM differs from PA by the expression of five genes involved in invasion and angiogenesis: fibronectin, osteopontin, chitinase-3-like-1 (YKL-40), keratoepithelin and fibromodulin. PA differs from GBM by the expression of genes related to metabolism ( apolipoprotein D), proteolysis (protease-serine-11), receptor and signal transduction (PLEKHB1 for Pleckstrin-Homology-domain-containing-protein-family-B-member-1), transcription/translation (eukaryotic-translation-elongation-factor-1-alpha 1) processes and cell adhesion ( SPOCK1 for SPARC/Osteonectin-CWCV-kazal-like-domains-proteoglycan). The expression of these genes was confirmed by real-time quantitative RT-PCR and immunohistochemistry. This study highlights the crucial role of brain invasion in GBM and identifies specific molecules involved in this process. In addition, it offers a restricted list of markers that accurately distinguish PA from GBM.	Fac Med Timone, Lab Biopathol Adhes & Signalisat, EA3281, IPHM, F-13005 Marseille, France; Fac Med Nord, APHM, Lab Transfert Oncol Biol, F-13015 Marseille, France; Fac Med Nord, Inst Fed Jean Roche, Lab Cancerol Expt, INSERM,EMI 0359, F-13015 Marseille, France; Hop La Timone, Serv Anat Pathol & Neuropathol, APHM, F-13005 Marseille, France	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Figarella-Branger, D (corresponding author), Fac Med Timone, Lab Biopathol Adhes & Signalisat, EA3281, IPHM, 27 Bd Jean Moulin, F-13005 Marseille, France.	dominique.figarella-branger@medecine.univ-mrs.fr		Ouafik, L'Houcine/0000-0002-4848-1232				Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013; BONNET F, 1992, BIOCHEM J, V288, P565, DOI 10.1042/bj2880565; Caskey LS, 2000, HISTOL HISTOPATHOL, V15, P971, DOI 10.14670/HH-15.971; Castellani P, 2002, AM J PATHOL, V161, P1695, DOI 10.1016/S0002-9440(10)64446-X; Charbonnier F, 1998, GENOMICS, V48, P377, DOI 10.1006/geno.1997.5199; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Coppola D, 2004, CLIN CANCER RES, V10, P184, DOI 10.1158/1078-0432.CCR-1405-2; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Edgell CJS, 2004, INT REV CYTOL, V236, P101, DOI 10.1016/S0074-7696(04)36003-1; Eikmans M, 2003, J AM SOC NEPHROL, V14, P899, DOI 10.1097/01.ASN.0000056611.92730.7B; Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452; Gutmann DH, 2002, CANCER RES, V62, P2085; Hunter S, 2002, J NEUROPATH EXP NEUR, V61, P275, DOI 10.1093/jnen/61.3.275; Khatua S, 2003, CANCER RES, V63, P1865; Kleihues P, 2000, PATHOLOGY GENETICS T; Kumazaki T, 1999, J CELL SCI, V112, P1449; Lal A, 1999, CANCER RES, V59, P5403; Lam P, 2005, MOL THER, V12, P144, DOI 10.1016/j.ymthe.2005.02.028; Markert JM, 2001, PHYSIOL GENOMICS, V5, P21, DOI 10.1152/physiolgenomics.2001.5.1.21; Mischel PS, 2004, NAT REV NEUROSCI, V5, P782, DOI 10.1038/nrn1518; Mittler MA, 1996, J NEUROSURG, V85, P1091, DOI 10.3171/jns.1996.85.6.1091; Nigro JM, 2005, CANCER RES, V65, P1678, DOI 10.1158/0008-5472.CAN-04-2921; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rickman DS, 2001, CANCER RES, V61, P6885; Rittling SR, 2004, BRIT J CANCER, V90, P1877, DOI 10.1038/sj.bjc.6601839; Rocchi P, 2004, ONCOGENE, V23, P9111, DOI 10.1038/sj.onc.1208154; SAITOH Y, 1995, LAB INVEST, V72, P55; Sallinen SL, 2000, CANCER RES, V60, P6617; Shen M, 1997, BIOCHEM BIOPH RES CO, V236, P294, DOI 10.1006/bbrc.1997.6960; Tanwar MK, 2002, CANCER RES, V62, P4364; Tuck AB, 2003, ONCOGENE, V22, P1198, DOI 10.1038/sj.onc.1206209; Tuck AB, 1999, ONCOGENE, V18, P4237, DOI 10.1038/sj.onc.1202799; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; Wai PY, 2004, J SURG RES, V121, P228, DOI 10.1016/j.jss.2004.03.028; Wong KK, 2005, CANCER RES, V65, P76	35	92	95	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2006	25	19					2818	2826		10.1038/sj.onc.1209305	http://dx.doi.org/10.1038/sj.onc.1209305			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16314830				2022-12-28	WOS:000237272900014
J	Hoglund, M; Frigyesi, A; Mitelman, F				Hoglund, M; Frigyesi, A; Mitelman, F			A gene fusion network in human neoplasia	ONCOGENE			English	Article						gene fusion; network; cancer		Cancer is, at the cellular level, a genetic disease and acquired gene fusions play a causal role in the initiation of the neoplastic process either by activating proto-oncogenes or creating hybrid genes. We constructed a network by combining the 5' and 3' parts of all presently known gene fusions in human neoplasia and here we show that the observed network is fragmented and that the organization of the genes demonstrates a scale-free network topology with a power law degree distribution meeting the requirements of P( k) similar to k(-y), that is, conforming to the distributions found in naturally occurring networks such as the Internet and social or ecological networks. The results hence indicate that the complex system of pairwise interacting genes leading to neoplasia is governed by a universal principle.	Univ Lund Hosp, Dept Clin Genet, SE-22185 Lund, Sweden; Lund Univ, Ctr Math Sci Math Stat, Lund, Sweden	Lund University; Skane University Hospital; Lund University	Hoglund, M (corresponding author), Univ Lund Hosp, Dept Clin Genet, SE-22185 Lund, Sweden.	mattias.hoglund@med.lu.se		Hoglund, Mattias/0000-0001-9283-4421; Mitelman, Felix/0000-0002-3757-7212				Albert R, 2002, REV MOD PHYS, V74, P47, DOI 10.1103/RevModPhys.74.47; Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; Apic G, 2001, Bioinformatics, V17 Suppl 1, pS83; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Callaway DS, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.041902; Collins EC, 2002, TRENDS MOL MED, V8, P436, DOI 10.1016/S1471-4914(02)02397-3; Davison AC, 1997, BOOTSTRAP METHODS TH; ERDOS P, 1960, B INT STATIST INST, V38, P343; Holme P, 2003, PHYS REV E, V68, DOI 10.1103/PhysRevE.68.056107; Johnson N.L., 1992, BIOMETRICAL J, V36, P565, DOI [10.1002/bimj.4710360207, DOI 10.1002/BIMJ.4710360207]; Klemm K, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.036123; Liljeros F, 2001, NATURE, V411, P907, DOI 10.1038/35082140; Middendorf M, 2005, P NATL ACAD SCI USA, V102, P3192, DOI 10.1073/pnas.0409515102; Mitelman F, 2004, NAT GENET, V36, P331, DOI 10.1038/ng1335; Vazquez Alexei, 2003, ComPlexUs, V1, P38, DOI 10.1159/000067642; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Wuchty S, 2001, MOL BIOL EVOL, V18, P1694, DOI 10.1093/oxfordjournals.molbev.a003957; Wylie JL, 2001, SEX TRANSM DIS, V28, P14, DOI 10.1097/00007435-200101000-00005	20	21	21	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2674	2678		10.1038/sj.onc.1209290	http://dx.doi.org/10.1038/sj.onc.1209290			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16331252				2022-12-28	WOS:000237099400011
J	Incassati, A; Patel, D; McCance, DJ				Incassati, A; Patel, D; McCance, DJ			Induction of tetraploidy through loss of p53 and upregulation of Plk1 by human papillomavirus type-16 E6	ONCOGENE			English	Article						HPV-16; E6 and E7; tetraploidy; Plk1	POLO-LIKE KINASE-1; HUMAN KERATINOCYTES; SPINDLE CHECKPOINT; GROWTH ARREST; CANCER; CELLS; E7; DEGRADATION; EXPRESSION; ONCOPROTEIN	Cancer cells are insensitive to many signals that inhibit growth of untransformed cells. Here, we show that primary human epithelial cells expressing human papillomavirus (HPV) type-16 E6/E7 bypass arrest caused by the DNA-damaging drug adriamycin and become tetraploid. To determine the contribution of E6 in the context of E7 to the resistance of arrest and induction of tetraploidy, we used an E6 mutant unable to degrade p53 or RNAi targeting p53 for knockdown. The E6 mutant fails to generate tetraploidy; however, the presence of E7 is sufficient to bypass arrest while the p53 RNAi permits both arrest insensitivity and tetraploidy. We published previously that polo-like kinase 1(Plk1) is upregulated in E6/E7-expressing cells. We observe here that abnormal expression of Plk1 protein correlates with tetraploidy. Using the p53 binding-defective mutant of E6 and p53 RNAi, we show that p53 represses Plk1, suggesting that loss of p53 results in tetraploidy through upregulation of Plk1. Consistent with this hypothesis, overexpression of Plk1 in cells generates tetraploidy but does not confer resistance to arrest. These results support a model for transformation caused by HPV-16 where bypass of arrest and tetraploidy are separable consequences of p53 loss with Plk1 required only for the latter effect.	Univ Rochester, Dept Microbiol & Immunol, Rochester, NY 14642 USA; Univ Rochester, Dept Biomed Genet, Rochester, NY USA; Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA	University of Rochester; University of Rochester; University of Rochester	McCance, DJ (corresponding author), Univ Rochester, Dept Microbiol & Immunol, Box 672, Rochester, NY 14642 USA.	dennis_mccance@urmc.rochester.edu			NIDCR NIH HHS [DE13526, T32-DE07165] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007165, R01DE013526] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Burd EM, 2003, CLIN MICROBIOL REV, V16, P1, DOI 10.1128/CMR.16.1.1-17.2003; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Eichten A, 2002, VIROLOGY, V295, P74, DOI 10.1006/viro.2002.1375; Flatt PM, 1998, CELL GROWTH DIFFER, V9, P535; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; Galipeau PC, 1996, P NATL ACAD SCI USA, V93, P7081, DOI 10.1073/pnas.93.14.7081; Guan R, 2005, CANCER RES, V65, P2698, DOI 10.1158/0008-5472.CAN-04-2131; Hanks S, 2004, NAT GENET, V36, P1159, DOI 10.1038/ng1449; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Jackson MW, 2005, J CELL SCI, V118, P1821, DOI 10.1242/jcs.02307; Kho PS, 2004, J BIOL CHEM, V279, P21183, DOI 10.1074/jbc.M311912200; Knecht R, 1999, CANCER RES, V59, P2794; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; McMurray HR, 2004, J VIROL, V78, P5698, DOI 10.1128/JVI.78.11.5698-5706.2004; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Michel L, 2004, P NATL ACAD SCI USA, V101, P4459, DOI 10.1073/pnas.0306069101; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; MUNGER K, 1989, J VIROL, V63, P4417; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Patel D, 2004, CANCER RES, V64, P1299, DOI 10.1158/0008-5472.CAN-03-2917; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Southern SA, 2004, BRIT J CANCER, V90, P1949, DOI 10.1038/sj.bjc.6601827; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Thomas JT, 1998, J VIROL, V72, P1131, DOI 10.1128/JVI.72.2.1131-1137.1998; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; Weichert W, 2005, VIRCHOWS ARCH, V446, P442, DOI 10.1007/s00428-005-1212-8; Weichert W, 2004, BRIT J CANCER, V90, P815, DOI 10.1038/sj.bjc.6601610; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	36	67	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2444	2451		10.1038/sj.onc.1209276	http://dx.doi.org/10.1038/sj.onc.1209276			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16369493				2022-12-28	WOS:000236948000003
J	Suzuki, M; Yamada, T; Kihara-Negishi, F; Sakurai, T; Hara, E; Tenen, DG; Hozumi, N; Oikawa, T				Suzuki, M; Yamada, T; Kihara-Negishi, F; Sakurai, T; Hara, E; Tenen, DG; Hozumi, N; Oikawa, T			Site-specific DNA methylation by a complex of PU.1 and Dnmt3a/b	ONCOGENE			English	Article						PU.1; DNA methyltransferase; epigenetic transcriptional repression; p16(INK4a)	TRANSCRIPTION FACTOR PU.1; ETS FAMILY; EXPRESSION; DNMT1; DIFFERENTIATION; ASSOCIATION; PROTEINS; BINDS; METHYLTRANSFERASES; LOCALIZATION	The Ets transcription factor PU.1 is a hematopoietic master regulator essential for the development of myeloid and B-cell lineages. As we previously reported, PU.1 sometimes represses transcription on forming a complex with mSin3A-histone deacetyl transferase-MeCP2. Here, we show an interaction between PU.1 and DNA methyltransferases, DNA methyltransferase (Dnmt)3a and Dnmt3b (Dnmt3s). Glutathione-S-transferase pulldown assay revealed that PU.1 directly interacted with the ATRX domain of Dnmt3s through the ETS domain. Dnmt3s repressed the transcriptional activity of PU.1 on a reporter construct with trimerized PU.1-binding sites. The repression was recovered by addition of 5-aza-deoxycitidine, a DNA methyltransferase inhibitor, but not trichostatin A, a histone deacetylase inhibitor. Bisulfite sequence analysis revealed that several CpG sites in the promoter region neighboring the PU.1-binding sites were methylated when Dnmt3s were coexpressed with PU.1. We also showed that the CpG sites in the p16(INK4A) promoter were methylated by overexpression of PU.1 in NIH3T3 cells, accompanied by a downregulation of p16(INK4A) gene expression. These results suggest that PU.1 may downregulate its target genes through an epigenetic modi. cation such as DNA methylation.	Sasaki Inst, Dept Cell Genet, Chiyoda Ku, Tokyo 1010062, Japan; Tokyo Univ Sci, Res Inst Biol Sci, Chiba, Japan; Univ Tokushima, Inst Genome Res, Tokushima, Japan; Beth Israel Hosp, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Tokyo University of Science; Tokushima University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Oikawa, T (corresponding author), Sasaki Inst, Dept Cell Genet, Chiyoda Ku, 2-2 Kanda Surugadai, Tokyo 1010062, Japan.	oikawa@sasaki.or.jp		Tenen, Daniel/0000-0002-6423-3888				Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Datta J, 2003, J CELL BIOCHEM, V88, P855, DOI 10.1002/jcb.10457; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Hara E, 1996, MOL CELL BIOL, V16, P859; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hwang CK, 2004, J BIOL CHEM, V279, P19764, DOI 10.1074/jbc.M400755200; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kihara-Negishi F, 2001, ONCOGENE, V20, P6039, DOI 10.1038/sj.onc.1204756; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Konishi Y, 1999, ONCOGENE, V18, P6795, DOI 10.1038/sj.onc.1203118; Linderson Y, 2004, EMBO REP, V5, P291, DOI 10.1038/sj.embor.7400089; Majumder S, 2002, J BIOL CHEM, V277, P16048, DOI 10.1074/jbc.M111662200; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1997, BIOCHIM BIOPHYS ACTA, V1198, P149; Mueller BU, 2002, BLOOD, V100, P998, DOI 10.1182/blood.V100.3.998; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Oikawa T, 1999, CELL DEATH DIFFER, V6, P599, DOI 10.1038/sj.cdd.4400534; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Pongubala JMR, 1997, P NATL ACAD SCI USA, V94, P127, DOI 10.1073/pnas.94.1.127; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059; Suzuki M, 2003, ONCOGENE, V22, P8688, DOI 10.1038/sj.onc.1207182; Tatematsu K, 2000, GENES CELLS, V5, P677, DOI 10.1046/j.1365-2443.2000.00359.x; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	44	95	100	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2477	2488		10.1038/sj.onc.1209272	http://dx.doi.org/10.1038/sj.onc.1209272			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16331260				2022-12-28	WOS:000236948000006
J	Parsons, MJ; Vertino, PM				Parsons, M. J.; Vertino, P. M.			Dual role of TMS1/ASC in death receptor signaling	ONCOGENE			English	Article						TNF alpha; TRAIL; apoptosis; NF-kappa B; epigenetic silencing; caspase-8	NF-KAPPA-B; CASPASE RECRUITMENT DOMAIN; CONTAINING APAF1-LIKE PROTEIN; FACTOR-INDUCED APOPTOSIS; INDUCED-PROXIMITY MODEL; SPECK-LIKE PROTEIN; ABERRANT METHYLATION; HUMAN BREAST; REGULATES ACTIVATION; TERMINAL KINASE	Aberrant DNA methylation of promoter region CpG islands is associated with gene silencing and serves as an alternative to mutations in the inactivation of tumor suppressor genes in human cancers. We identified a gene TMS1 ( for Target of Methylation-mediated Silencing) that is subject to such epigenetic silencing in a significant proportion of human breast and other cancers. Also known as ASC and PYCARD, TMS1 encodes a bipartite intracellular signaling molecule with proposed roles in apoptosis and inflammation. However, the precise role of this protein in the pathogenesis of breast and other cancers has not been clearly defined. In this study, we examined the role of TMS1/ASC in death receptor signaling. We found that TMS1/ASC is upregulated in response to treatment with TNF-related apoptosis-inducing ligand ( TRAIL) and tumor necrosis factor-alpha (TNF alpha) in breast epithelial cells, but not in human fibroblasts. This upregulation was not dependent on the synthesis of a TNF alpha-regulated intermediate or alterations in mRNA stability, suggesting a direct effect on TMS1/ASC transcription. Induction of TMS1/ASC by TNFa was blocked by co-expression of a dominant negative I kappa B alpha, small interfering RNA-mediated knockdown of RelA/p65, or concurrent treatment with SP600125, indicating a requirement for the nuclear factor-kappa B (NF-kappa B) and jun kinase signaling pathways. Although previous work has suggested that TMS1/ASC may be directly regulated by p53, we found that whereas treatment of breast epithelial cells or normal diploid. broblasts with DNA damaging agents resulted in the stabilization of endogenous p53 and a concomitant increase in p21, it had little impact on the expression of TMS1/ASC mRNA or protein. We further show that whereas TMS1/ASC is not required for TNF alpha or TRAIL-induced activation of NF-kappa B or caspase-8, it can promote caspase-8 activation independently of death receptor-ligand interactions. Taken together, these data suggest that upregulation of TMS1/ASC by TNF alpha and subsequent activation of caspase-8 could function to amplify the apoptotic signal induced by death receptors in some cell types, including breast epithelial cells.	Emory Univ, Dept Radiat Oncol, Atlanta, GA 30322 USA; Emory Univ, Grad Program Genet & Mol Biol, Atlanta, GA 30322 USA; Emory Univ, Winship Canc Ctr, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Vertino, PM (corresponding author), Emory Univ, Dept Radiat Oncol, 1365-C Clifton Rd,NE, Atlanta, GA 30322 USA.	pvertin@emory.edu						Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Conway KE, 2000, CANCER RES, V60, P6236; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Furukawa Y, 2005, MOL CANCER RES, V3, P325, DOI 10.1158/1541-7786.MCR-04-0105; Grenier JM, 2002, FEBS LETT, V530, P73, DOI 10.1016/S0014-5793(02)03416-6; Guan X, 2003, INT J CANCER, V107, P202, DOI 10.1002/ijc.11376; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; Hasegawa M, 2005, J BIOL CHEM, V280, P15122, DOI 10.1074/jbc.M412284200; Horak P, 2005, MOL CANCER RES, V3, P335, DOI 10.1158/1541-7786.MCR-04-0136; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, MOL CELL BIOL, V19, P2021; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172; Laird PW, 2005, HUM MOL GENET, V14, pR65, DOI 10.1093/hmg/ddi113; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Levine JJ, 2003, ONCOGENE, V22, P3475, DOI 10.1038/sj.onc.1206430; Li GQ, 2004, J BIOL CHEM, V279, P1123, DOI 10.1074/jbc.M305893200; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Manji GA, 2002, J BIOL CHEM, V277, P11570, DOI 10.1074/jbc.M112208200; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; Masumoto J, 2003, BIOCHEM BIOPH RES CO, V303, P69, DOI 10.1016/S0006-291X(03)00309-7; Masumoto J, 2001, J HISTOCHEM CYTOCHEM, V49, P1269, DOI 10.1177/002215540104901009; Mayo MW, 2003, J BIOL CHEM, V278, P18980, DOI 10.1074/jbc.M211695200; McConnell BB, 2000, CANCER RES, V60, P6243; McConnell BB, 2004, APOPTOSIS, V9, P5, DOI 10.1023/B:APPT.0000012117.32430.0c; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Moriai R, 2002, ANTICANCER RES, V22, P4163; Muppidi JR, 2004, IMMUNITY, V21, P461, DOI 10.1016/j.immuni.2004.10.001; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Ohtsuka T, 2004, NAT CELL BIOL, V6, P121, DOI 10.1038/ncb1087; Richards N, 2001, J BIOL CHEM, V276, P39320, DOI 10.1074/jbc.M104730200; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Sharp DA, 2005, J BIOL CHEM, V280, P19401, DOI 10.1074/jbc.M413962200; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shetty S, 2005, MOL CELL BIOL, V25, P5404, DOI 10.1128/MCB.25.13.5404-5416.2005; Shi YG, 2004, CELL, V117, P855, DOI 10.1016/j.cell.2004.06.007; Shiohara M, 2002, BIOCHEM BIOPH RES CO, V293, P1314, DOI 10.1016/S0006-291X(02)00384-4; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Stehlik C, 2003, J IMMUNOL, V171, P6154, DOI 10.4049/jimmunol.171.11.6154; Stehlik C, 2002, J EXP MED, V196, P1605, DOI 10.1084/jem.20021552; Stone AR, 2004, AM J PATHOL, V165, P1151, DOI 10.1016/S0002-9440(10)63376-7; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Tian B, 2005, J BIOL CHEM, V280, P17435, DOI 10.1074/jbc.M500437200; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; van Noesel MM, 2002, CANCER RES, V62, P2157; Virmani A, 2003, INT J CANCER, V106, P198, DOI 10.1002/ijc.11206; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang L, 2002, J BIOL CHEM, V277, P29874, DOI 10.1074/jbc.M203915200; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Yamamoto M, 2004, GENES CELLS, V9, P1055, DOI 10.1111/j.1365-2443.2004.00789.x; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yokoyama T, 2003, CANCER LETT, V202, P101, DOI 10.1016/j.canlet.2003.08.027; Yu JW, 2006, CELL DEATH DIFFER, V13, P236, DOI 10.1038/sj.cdd.4401734; Zhou A, 2003, ONCOGENE, V22, P2054, DOI 10.1038/sj.onc.1206262	66	22	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	52					6948	6958		10.1038/sj.onc.1209684	http://dx.doi.org/10.1038/sj.onc.1209684			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16715133				2022-12-28	WOS:000241732300005
J	Huang, CL; Ueno, M; Liu, D; Masuya, D; Nakano, J; Yokomise, H; Nakagawa, T; Miyake, M				Huang, C-L; Ueno, M.; Liu, D.; Masuya, D.; Nakano, J.; Yokomise, H.; Nakagawa, T.; Miyake, M.			MRP-1/CD9 gene transduction regulates the actin cytoskeleton through the downregulation of WAVE2	ONCOGENE			English	Article						MRP-1/CD9; WAVE2; actin; motility	ARP2/3 COMPLEX; PHOSPHATIDYLINOSITOL 3-KINASE; CELL-MIGRATION; MAJOR CD9; N-WASP; PROTEIN; MOTILITY; KINASE; ACTIVATION; EXPRESSION	Motility-related protein-1 (MRP-1/CD9) is involved in cell motility. We studied the change in the actin cytoskeleton, and the expression of actin-related protein (Arp) 2 and Arp3 and the Wiskott-Aldrich syndrome protein ( WASP) family according to MRP-1/CD9 gene transduction into HT1080 cells. The frequency of cells with lamellipodia was significantly lower in MRP-1/CD9-transfected HT1080 cells than in control HT1080 cells (P < 0.0001). MRP-1/CD9 gene transduction affected the subcellular localization of Arp2 and Arp3 proteins. Furthermore, MRP-1/CD9 gene transduction induced a downregulation of WAVE2 expression (P < 0.0001). However, no difference was observed in the expression of Arp2, Arp3 or other WASPs. A neutralizing anti-MRP-1/CD9 monoclonal antibody inhibited downregulation of WAVE2 in MRP-1/CD9-transfected HT1080 cells (P < 0.0001 ), and reversed the morphological effects of MRP-1/CD9 gene transduction. Furthermore, downregulation of WAVE2 by transfection of WAVE2-specific small interfering RNA ( siRNA) mimicked the morphological effects of MRP-1/CD9 gene transduction and suppressed cell motility. However, transfection of each siRNA for Wnt1, Wnt2b1 or Wnt5a did not affect WAVE2 expression. Transfection of WAVE2-specific siRNA also did not affect expressions of these Wnts. These results indicate that MRP-1/CD9 regulates the actin cytoskeleton by downregulating of the WAVE2, through the Wnt-independent signal pathway.	Kagawa Univ, Dept Surg 2, Fac Med, Kagawa 7610793, Japan; Kagawa Univ, Fac Med, Dept Pathol & Host Def, Kagawa, Japan; Kagawa Univ, Life Sci Res Ctr, Kagawa, Japan; Kitano Hosp, Dept Oncol 5, Tazuke Kofukai Med Res Inst, Dept Thorac Surg, Osaka, Japan	Kagawa University; Kagawa University; Kagawa University; Kitano Hospital	Huang, CL (corresponding author), Kagawa Univ, Dept Surg 2, Fac Med, 1750-1,Miki Cho, Kagawa 7610793, Japan.	chuang@kms.ac.jp						Bailly M, 1999, J CELL BIOL, V145, P331, DOI 10.1083/jcb.145.2.331; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Charrin S, 2001, J BIOL CHEM, V276, P14329, DOI 10.1074/jbc.M011297200; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Condeelis JS, 2001, SEMIN CANCER BIOL, V11, P119, DOI 10.1006/scbi.2000.0363; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Gutierrez-Lopez MD, 2003, J BIOL CHEM, V278, P208, DOI 10.1074/jbc.M207805200; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002-9440(10)65639-8; Huang CL, 2004, ONCOGENE, V23, P7475, DOI 10.1038/sj.onc.1208063; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kurisu S, 2005, ONCOGENE, V24, P1309, DOI 10.1038/sj.onc.1208177; Le Naour F, 2004, CANCER IMMUNOL IMMUN, V53, P148, DOI 10.1007/s00262-003-0477-5; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miyake M, 2000, ONCOGENE, V19, P5221, DOI 10.1038/sj.onc.1203919; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; Park KR, 2000, MOL HUM REPROD, V6, P719, DOI 10.1093/molehr/6.8.719; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Soderling SH, 2003, P NATL ACAD SCI USA, V100, P1723, DOI 10.1073/pnas.0438033100; Stipp CS, 2001, J BIOL CHEM, V276, P40545, DOI 10.1074/jbc.M107338200; Suetsugu S, 2003, DEV CELL, V5, P595, DOI 10.1016/S1534-5807(03)00297-1; Takenawa T, 2001, J CELL SCI, V114, P1801; Vartiainen MK, 2004, CURR OPIN CELL BIOL, V16, P174, DOI 10.1016/j.ceb.2004.02.004; Yamaguchi H, 2000, P NATL ACAD SCI USA, V97, P12631, DOI 10.1073/pnas.190351397; Yamazaki D, 2003, NATURE, V424, P452, DOI 10.1038/nature01770; Yan C, 2003, EMBO J, V22, P3602, DOI 10.1093/emboj/cdg350; Yauch RL, 2000, BIOCHEM J, V351, P629, DOI 10.1042/0264-6021:3510629; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200; Zhu BM, 2005, GENOMICS, V85, P657, DOI 10.1016/j.ygeno.2005.02.012; Zilber MT, 2005, BLOOD, V106, P3074, DOI 10.1182/blood-2004-10-4094	34	19	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2006	25	49					6480	6488		10.1038/sj.onc.1209654	http://dx.doi.org/10.1038/sj.onc.1209654			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16682943				2022-12-28	WOS:000241395100004
J	Komiya, T; Park, Y; Modi, S; Coxon, AB; Oh, H; Kaye, FJ				Komiya, T.; Park, Y.; Modi, S.; Coxon, A. B.; Oh, H.; Kaye, F. J.			Sustained expression of Mect1-Mam12 is essential for tumor cell growth in salivary gland cancers carrying the t(11 ; 19) translocation	ONCOGENE			English	Article						mucoepidermoid cancer; salivary gland cancer; chromosomal translocation; RNAi	MUCOEPIDERMOID CARCINOMA; GENE FUSION; IDENTIFICATION; FAMILY; COACTIVATORS; ACTIVATION; BENIGN	Mucoepidermoid (MEC) salivary gland tumors arise from a t(11; 19) rearrangement which generates a fusion oncogene, Mect1-Maml2, that functions to activate CREB-responsive target genes. To determine if sustained expression of Mect1-Maml2 is required for tumor cell growth, we first showed that ectopic expression of Mect1-Maml2 in rat epithelial RK3E cells is tumorigenic in vivo in nude mice and that excised xenografts continue to express the fusion oncogene. We then generated a hairpin RNAi vector that selectively suppressed the fusion peptide and showed that ectopic expression in either parotid or pulmonary MEC tumor cell lines containing the t(11; 19) rearrangement resulted in at least 90% colony growth inhibition. In contrast, single nucleotide changes within this RNAi sequence abolished the ability to suppress Mect1-Maml2 protein and abolished all growth inhibition of these MEC tumor lines. In addition, the RNAi-specific vector had no effect on colony growth of non-MEC tumors including a lung tumor or two other salivary gland cell lines that do not express Mect1-Maml2. We also generated a mutant Mect1-Maml2 expression plasmid that carried silent nucleotide changes within the RNAi target sequence and observed that co-transfection of this mutant, but not wild-type Mect1-Maml2, could partially rescue RNAi growth inhibition in the MEC tumor line. The recent detection of acquired fusion oncogenes in epithelial solid tumors has suggested new possibilities for the diagnosis and therapy of these cancers. Our data show that the 'gain-of-function' activity from aberrant Mect1-Maml2 expression is a candidate therapeutic target for this group of malignant salivary gland tumors.	NCI, Canc Res Ctr, Genat Branch, Bethesda, MD 20892 USA; Natl Naval Med Ctr, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Walter Reed National Military Medical Center	Kaye, FJ (corresponding author), Bldg 8,Rm 5101, Bethesda, MD 20889 USA.	fkaye@helix.nih.gov	kaye, frederic/E-2437-2011		Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIASC007256, Z01SC007256] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behboudi A, 2005, GENE CHROMOSOME CANC, V43, P202, DOI 10.1002/gcc.20168; Cho-Chung YS, 2003, ANN NY ACAD SCI, V1002, P124, DOI 10.1196/annals.1281.011; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; Coxon A, 2005, CANCER RES, V65, P7137, DOI 10.1158/0008-5472.CAN-05-1125; ElNaggar AK, 1996, CANCER GENET CYTOGEN, V87, P29, DOI 10.1016/0165-4608(95)00266-9; Enlund F, 2004, EUR J ORAL SCI, V112, P545, DOI 10.1111/j.1600-0722.2004.00174.x; Enlund F, 2004, EXP CELL RES, V292, P21, DOI 10.1016/j.yexcr.2003.09.007; GRENMAN R, 1992, ARCH OTOLARYNGOL, V118, P542; Iourgenko V, 2003, P NATL ACAD SCI USA, V100, P12147, DOI 10.1073/pnas.1932773100; Lin SE, 2002, J BIOL CHEM, V277, P50612, DOI 10.1074/jbc.M209529200; Martins C, 2004, J MOL DIAGN, V6, P205, DOI 10.1016/S1525-1578(10)60511-9; Mitelman F, 2004, NAT GENET, V36, P331, DOI 10.1038/ng1335; Roberts Thomas G Jr, 2003, Clin Adv Hematol Oncol, V1, P486; Speight PM, 2002, ORAL DIS, V8, P229, DOI 10.1034/j.1601-0825.2002.02870.x; Stenman G, 1998, VIRCHOWS ARCH, V433, P579, DOI 10.1007/s004280050293; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tonon G, 2003, NAT GENET, V33, P208, DOI 10.1038/ng1083; Wu L, 2002, MOL CELL BIOL, V22, P7688, DOI 10.1128/MCB.22.21.7688-7700.2002; Wu LZ, 2005, EMBO J, V24, P2391, DOI 10.1038/sj.emboj.7600719	20	61	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2006	25	45					6128	6132		10.1038/sj.onc.1209627	http://dx.doi.org/10.1038/sj.onc.1209627			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16652146				2022-12-28	WOS:000241101200010
J	Jiang, LQ; Feng, X; Zhou, W; Knyazev, PG; Ullrich, A; Chen, Z				Jiang, L. Q.; Feng, X.; Zhou, W.; Knyazev, P. G.; Ullrich, A.; Chen, Z.			Csk-binding protein (Cbp) negatively regulates epidermal growth factor-induced cell transformation by controlling Src activation	ONCOGENE			English	Article						Cbp; EGFR; cell transformation; Src; Csk	GLYCOSPHINGOLIPID-ENRICHED MICRODOMAINS; FAMILY TYROSINE KINASES; C-SRC; FACTOR RECEPTOR; TRANSMEMBRANE ADAPTER; AKT ACTIVATION; BREAST-CANCER; DNA-SYNTHESIS; LIPID RAFTS; PHOSPHORYLATION	Epidermal growth factor receptor (EGFR) and Src tyrosine kinase cooperate in regulating EGFR-mediated cell signaling and promoting cell transformation and tumorigenesis in pathological conditions. Activation of Src is tightly regulated by the C-terminal Src kinase (Csk). The Csk-binding protein (Cbp) is a ubiquitously expressed transmembrane protein. Its functions include suppression of T-cell receptor activation through recruiting Csk and inhibiting Src family kinase (SFK). However, a potential role of Cbp in EGF-induced cell activities has not been investigated. Here, we report that EGF-stimulation-induced Cbp tyrosine phosphorylation followed by Cbp-Csk association, in a SFK-dependent manner. Expression of wild-type (wt) Cbp remarkably suppressed EGF-induced activation of Src, ERK1/2, and Akt-1 enzymes, and NIH3T3 cell transformation, as well as colony formation of a breast cancer cell line (MDAMB468) in soft agar. In contrast, expression of CbpY317F or knockdown endogenous Cbp in NIH3T3 cells by RNA interference significantly enhanced EGF-induced activation of these enzymes and cell transformation. In addition, overexpression of multiple receptor tyrosine kinases (RTKs)-induced Cbp tyrosine phosphorylation. These results demonstrate that Cbp functions as a negative regulator of cell transformation and tumor cell growth through downregulation of Src activation, suggesting that Cbp might be broadly involved in RTKs-activated signaling pathways and tumorigenesis.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Proteom, Shanghai 200031, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, SHARF Lab, Shanghai 200031, Peoples R China; Max Planck Inst Biochem, Chinese Acad Sci, Grad Sch, D-82152 Martinsried, Germany; Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Max Planck Society; Max Planck Society	Chen, Z (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Proteom, Room 210,Bldg 23,320 Yue Yang Rd, Shanghai 200031, Peoples R China.	zjchen@sibs.ac.cn						Baumeister U, 2005, EMBO J, V24, P1686, DOI 10.1038/sj.emboj.7600647; Baumgartner M, 2003, BLOOD, V101, P1874, DOI 10.1182/blood-2002-02-0456; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; CANCE WG, 1995, BREAST CANCER RES TR, V35, P105, DOI 10.1007/BF00694751; Cao HM, 2004, EXP CELL RES, V294, P159, DOI 10.1016/j.yexcr.2003.11.010; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Davidson D, 2003, MOL CELL BIOL, V23, P2017, DOI 10.1128/MCB.23.6.2017-2028.2003; DeMali KA, 1999, EXP CELL RES, V253, P271, DOI 10.1006/excr.1999.4669; DI FP, 1987, CELL, V51, P1063; Dobenecker MW, 2005, MOL CELL BIOL, V25, P10533, DOI 10.1128/MCB.25.23.10533-10542.2005; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Ishizawar RC, 2004, J BIOL CHEM, V279, P23773, DOI 10.1074/jbc.M312368200; Jiang TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kim YN, 2002, EXP CELL RES, V280, P134, DOI 10.1006/excr.2002.5623; Kong M, 2003, J BIOL CHEM, V278, P5837, DOI 10.1074/jbc.M208286200; Lev DC, 2004, BRIT J CANCER, V91, P795, DOI 10.1038/sj.bjc.6602051; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Matsuoka H, 2004, J BIOL CHEM, V279, P5975, DOI 10.1074/jbc.M311278200; Nguyen Dao M, 2004, Semin Thorac Cardiovasc Surg, V16, P3, DOI 10.1053/j.semtcvs.2003.12.002; Ohtake H, 2002, J IMMUNOL, V168, P2087, DOI 10.4049/jimmunol.168.5.2087; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Rae JM, 2004, BREAST CANCER RES TR, V83, P99, DOI 10.1023/B:BREA.0000010702.10130.29; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; Shien Tadahiko, 2004, Breast Cancer, V11, P367, DOI 10.1007/BF02968044; Shima T, 2003, P NATL ACAD SCI USA, V100, P14897, DOI 10.1073/pnas.2432139100; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Tremblay L, 1996, INT J CANCER, V68, P164, DOI 10.1002/(SICI)1097-0215(19961009)68:2<169::AID-IJC4>3.0.CO;2-W; Tsuruda A, 2004, FEBS LETT, V560, P215, DOI 10.1016/S0014-5793(04)00115-2; Van Slyke P, 2005, MOL CELL BIOL, V25, P3831, DOI 10.1128/MCB.25.9.3831-3841.2005; Wang B, 2001, MOL CELL BIOL, V21, P1077, DOI 10.1128/MCB.21.4.1077-1088.2001; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; Xu SL, 2005, MOL CELL BIOL, V25, P8486, DOI 10.1128/MCB.25.19.8486-8495.2005; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4	49	32	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2006	25	40					5495	5506		10.1038/sj.onc.1209554	http://dx.doi.org/10.1038/sj.onc.1209554			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16636672				2022-12-28	WOS:000240370400003
J	Wang, TH; Chan, YH; Chen, CW; Kung, WH; Lee, YS; Wang, ST; Chang, TC; Wang, HS				Wang, T-H; Chan, Y-H; Chen, C-W; Kung, W-H; Lee, Y-S; Wang, S-T; Chang, T-C; Wang, H-S			Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways	ONCOGENE			English	Article						paclitaxel; Taxol; JNK; interleukin 6 (IL-6)	NF-KAPPA-B; GENE-EXPRESSION; PROTEIN-KINASE; NUCLEAR-FACTOR; APOPTOSIS; ACTIVATION; RESISTANCE; INHIBITION; IL-6; LIPOPOLYSACCHARIDE	Paclitaxel (Taxol) is an antineoplastic agent that specifically targets microtubules and arrests cells at the G2/M phase of the cell cycle. In addition to mitotic arrest, the activation of c-Jun N-terminal kinase (JNK) signaling pathway has been demonstrated to be involved in the process leading to apoptosis. In an attempt to explore what genes are transcriptionally regulated by the activated JNK signaling pathway upon paclitaxel treatment, we used cDNA microarrays to analyse the changes of gene expression in human ovarian cancer cells that were treated with paclitaxel and/or the JNK inhibitor SP600125. Among 20 genes that were specifically regulated by the paclitaxel-activated JNK pathway, interleukin (IL)-6 was shown to elicit function through the JAK-STAT signaling pathway in an autocrine and/or paracrine fashion. Subsequently, we identified that 87.5% of eight tested ovarian cancer lines secreted detectable levels of IL-6, which could be further upregulated 2-3.2 fold by 1 mu M paclitaxel. Dissection on regulatory pathways for IL-6 indicated that (i) when ovarian cancer cells were treated with paclitaxel at low but clinically achievable concentrations (exemplified by 1 mu M in this study), the JNK signaling pathway was the major stimulator of IL-6 gene regulation and (ii) at suprapharmacologically high concentrations (exemplified by 50 mu M), paclitaxel exerted lipopolysaccharide-like effects, most likely through the Toll-like receptor 4 signaling pathway. Collectively, these results suggest that paclitaxel upregulates functional IL-6 expression in human ovarian cancer cells through multiple signaling pathways.	Chang Gung Univ, Grad Inst Clin Med Sci, Coll Med, Tao Yuan 333, Taiwan; Chang Gung Mem Hosp, Dept Obstet & Gynecol, Lin Kou Med Ctr, Tao Yuan, Taiwan; Chang Gung Mem Hosp, GMRCL, Tao Yuan, Taiwan; Min Chuan Univ, Dept Biotechnol, Tao Yuan, Taiwan; Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	Chang Gung University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Northwestern University; Feinberg School of Medicine	Wang, HS (corresponding author), Chang Gung Univ, Grad Inst Clin Med Sci, Coll Med, 5 Fuhsing St, Tao Yuan 333, Taiwan.	hswang@cgmh.org.tw						AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BAFFET G, 1991, MOL BIOL MED, V8, P141; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Brichory FM, 2001, P NATL ACAD SCI USA, V98, P9824, DOI 10.1073/pnas.171320598; Churchill GA, 2002, NAT GENET, V32, P490, DOI 10.1038/ng1031; Cui XQ, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-210; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; Dey S, 2003, CLIN CANCER RES, V9, P1557; DING AH, 1990, SCIENCE, V248, P370, DOI 10.1126/science.1970196; Dong QG, 2002, ONCOGENE, V21, P6510, DOI 10.1038/sj.onc.1205848; Du LH, 2004, J BIOL CHEM, V279, P11957, DOI 10.1074/jbc.M304935200; Duan ZF, 1999, CLIN CANCER RES, V5, P3445; Fang XJ, 2004, J BIOL CHEM, V279, P9653, DOI 10.1074/jbc.M306662200; Flynn V, 2003, INT J ONCOL, V23, P317; Gorgoni B, 2001, J BIOL CHEM, V276, P40769, DOI 10.1074/jbc.M106865200; Hefler LA, 2003, CANCER RES, V63, P3066; Huang Y, 2002, MOL PHARMACOL, V61, P105, DOI 10.1124/mol.61.1.105; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kawasaki K, 2003, J IMMUNOL, V170, P413, DOI 10.4049/jimmunol.170.1.413; Kawasaki K, 2000, J BIOL CHEM, V275, P2251, DOI 10.1074/jbc.275.4.2251; Kwok BHB, 2001, CHEM BIOL, V8, P759, DOI 10.1016/S1074-5521(01)00049-7; Lanni JS, 1997, P NATL ACAD SCI USA, V94, P9679, DOI 10.1073/pnas.94.18.9679; Lee LF, 1998, J BIOL CHEM, V273, P28253, DOI 10.1074/jbc.273.43.28253; Lee LF, 1997, MOL CELL BIOL, V17, P5097, DOI 10.1128/MCB.17.9.5097; Lee LF, 1996, CANCER RES, V56, P1303; Lee YS, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-132; LI BY, 1992, CANCER RES, V52, P2248; Lin MT, 2004, J BIOL CHEM, V279, P24015, DOI 10.1074/jbc.M402305200; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; Mingo-Sion AM, 2004, ONCOGENE, V23, P596, DOI 10.1038/sj.onc.1207147; Nakshatri H, 2004, ONCOGENE, V23, P7330, DOI 10.1038/sj.onc.1207995; Penson RT, 2000, INT J GYNECOL CANCER, V10, P33, DOI 10.1046/j.1525-1438.2000.00003.x; Perera PY, 2001, J IMMUNOL, V166, P574, DOI 10.4049/jimmunol.166.1.574; Pusztai L, 2004, CYTOKINE, V25, P94, DOI 10.1016/j.cyto.2003.10.004; ROSETTE C, 1995, J CELL BIOL, V128, P1111, DOI 10.1083/jcb.128.6.1111; Sriuranpong V, 2003, CANCER RES, V63, P2948; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; Taxman DJ, 2003, CANCER RES, V63, P5095; Uematsu S, 2002, J IMMUNOL, V168, P5811, DOI 10.4049/jimmunol.168.11.5811; Uzzo RG, 2002, CLIN CANCER RES, V8, P3579; Villunger A, 1996, INT J CANCER, V65, P498, DOI 10.1002/(SICI)1097-0215(19960208)65:4<498::AID-IJC18>3.0.CO;2-6; Vivat-Hannah V, 2001, CANCER RES, V61, P8703; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Wang XX, 2004, DRUG CHEM TOXICOL, V27, P243, DOI 10.1081/DCT-120037505; WATSON JM, 1990, CANCER RES, V50, P6959; Wei LH, 2003, ONCOGENE, V22, P1517, DOI 10.1038/sj.onc.1206226; Yusuf RZ, 2003, CURR CANCER DRUG TAR, V3, P1, DOI 10.2174/1568009033333754	56	55	63	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2006	25	35					4857	4866		10.1038/sj.onc.1209498	http://dx.doi.org/10.1038/sj.onc.1209498			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16547493				2022-12-28	WOS:000239687100004
J	Yang, DQ; Halaby, MJ; Zhang, Y				Yang, D. -Q; Halaby, M. -J; Zhang, Y.			The identification of an internal ribosomal entry site in the 5 '-untranslated region of p53 mRNA provides a novel mechanism for the regulation of its translation following DNA damage	ONCOGENE			English	Article						p53; translation; 5 '-UTR; IRES; DNA damage	UNTRANSLATED REGION; INDUCED APOPTOSIS; BINDING PROTEIN; PARTICIPATION; REPRESSION; PHOSPHORYLATION; IRRADIATION; INITIATION; SEGMENT; KINASE	The tumor suppressor p53 plays a crucial role in maintaining the genetic integrity of the cell and in suppressing cell transformation. Its cellular levels are usually low and rise substantially in response to DNA damage. Although research on p53 induction following DNA damage has mainly focused on the post-translational modification of p53 by Mdm2, it is known that protein translation also contributes to p53 induction. However, the mechanisms underlying translational regulation of the p53 protein in response to DNA damage are still poorly understood. We show that p53 synthesis increases dramatically in MCF-7 cells treated with etoposide. Interestingly, this increase is accompanied by an increase in the association of the translation initiation factor eIF-4E with its binding protein 4E-BP1, an inhibitor of cap-dependent protein translation. We further identified an internal ribosomal entry site (IRES) located in the 5'-untranslated region of the p53 transcript, that is capable of driving the cap-independent translation of a downstream cistron encoding Firefly luciferase in a dicistronic expression vector. Moreover, we found that the activity of the IRES element increases in response to etoposide-induced DNA damage in MCF-7 cells. These findings provide a novel mechanism for the regulation of p53 translation in response to DNA damage.	Univ S Dakota, Div Basic Biomed Sci, Sanford Sch Med, Vermillion, SD 57069 USA	University of South Dakota	Yang, DQ (corresponding author), Univ S Dakota, Div Basic Biomed Sci, Sanford Sch Med, 414 E Clark St,Lee Med Bldg, Vermillion, SD 57069 USA.	dyang@usd.edu						Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Fu LN, 1999, ONCOGENE, V18, P6419, DOI 10.1038/sj.onc.1203064; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Holcik M, 2004, CURR CANCER DRUG TAR, V4, P299, DOI 10.2174/1568009043333005; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; KASTAN MB, 1991, CANCER RES, V51, P6304; KOMAR AA, 2005, J BIOL CHEM, V4, P4; Kumar V, 2000, J BIOL CHEM, V275, P10779, DOI 10.1074/jbc.275.15.10779; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; Mazan-Mamczarz K, 2003, P NATL ACAD SCI USA, V100, P8354, DOI 10.1073/pnas.1432104100; Miskimins WK, 2001, MOL CELL BIOL, V21, P4960, DOI 10.1128/MCB.21.15.4960-4967.2001; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Mukhopadhyay D, 2003, MOL CELL, V11, P113, DOI 10.1016/S1097-2765(03)00012-1; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Quinn JE, 2003, CANCER RES, V63, P6221; Schumacher B, 2005, CELL, V120, P357, DOI 10.1016/j.cell.2004.12.009; Sherrill KW, 2004, J BIOL CHEM, V279, P29066, DOI 10.1074/jbc.M402727200; Spriggs KA, 2005, CELL DEATH DIFFER, V12, P585, DOI 10.1038/sj.cdd.4401642; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; SULLIVAN NF, 1989, ONCOGENE, V4, P1497; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542	27	101	107	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2006	25	33					4613	4619		10.1038/sj.onc.1209483	http://dx.doi.org/10.1038/sj.onc.1209483			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16607284				2022-12-28	WOS:000239457500011
J	Hayashi, T; Kobayashi, Y; Kohsaka, S; Sano, K				Hayashi, T.; Kobayashi, Y.; Kohsaka, S.; Sano, K.			The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-gamma inducibility of TAP1 and LMP2	ONCOGENE			English	Article						LMP2; JAK1; IFN-gamma; uterus; leiomyosarcoma	MHC CLASS-I; NF-KAPPA-B; IFN-GAMMA; EXPRESSION; GENES; COMPLEX; IMMUNOSURVEILLANCE; PATHWAYS; SUBUNITS; TUMORS	The presentation of human leukocyte antigens (HLA) class I requires the coordinated expression of numerous components involved in antigen presentation. Tumor cells may alter the antigen presentation by HLA class I, allowing them to evade antitumor immunity. In many cases, the lack of antigen presentation can be attributed to the downregulation of genes needed for antigen processing, such as the transporters associated with antigen processing ( TAP) 1, and the proteasomal component, low molecular weight proteins (LMP) 2. The TAP1 and LMP2 genes are transcribed from a shared bidirectional promoter containing an interferon (IFN)-gamma-response factor element; thus, the IFN-gamma-signal strongly induces both TAP1 and LMP2 expression. Low molecular weight proteins2-deficient mice exhibited the development of uterine leiomyosarcomas. Here, the differential responsiveness to IFN-gamma of the SKN human uterine leiomyosarcomas cell line was investigated. We now identify the G871E mutation in the ATP-binding region of Janus kinases 1, suggesting that the loss of TAP1 and LMP2 induction is a defect in the earliest steps of the IFN-gamma-signal pathway, resulting in the inability of SKN cells to upregulate the antigen-processing pathway. Understanding the mechanisms by which these tumors circumvent cytokine signalling, thereby evading antitumor-specific immunity, would greatly aid the efficacy of immunotherapy for treating uterine leiomyosarcomas.	Shinshu Univ, Sch Med, Dept Immunol & Infect Dis, Nagano 3908621, Japan; Shinshu Univ Hosp, Dept Lab Med, Nagano, Japan	Shinshu University; Shinshu University	Hayashi, T (corresponding author), Shinshu Univ, Sch Med, Dept Immunol & Infect Dis, 3-1-1 Asahi, Nagano 3908621, Japan.	takuma-h@sch.md.shinshu-u.ac.jp						Atkins D, 2004, INT J CANCER, V109, P265, DOI 10.1002/ijc.11681; BELICH MP, 1994, CURR BIOL, V4, P769, DOI 10.1016/S0960-9822(00)00174-3; Brucet M, 2004, GENES IMMUN, V5, P26, DOI 10.1038/sj.gene.6364035; Cabrera CM, 2003, TISSUE ANTIGENS, V61, P211, DOI 10.1034/j.1399-0039.2003.00020.x; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Dovhey SE, 2000, CANCER RES, V60, P5789; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; Garrido F, 1997, IMMUNOL TODAY, V18, P89, DOI 10.1016/S0167-5699(96)10075-X; Groettrup M, 1997, P NATL ACAD SCI USA, V94, P8970, DOI 10.1073/pnas.94.17.8970; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; Hayashi T, 2002, CANCER RES, V62, P24; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; LEISER AL, 2005, GYNECOL ONCOL; Leitao MM, 2004, CANCER-AM CANCER SOC, V101, P1455, DOI 10.1002/cncr.20521; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Miyagi T, 2003, J GASTROEN HEPATOL, V18, P32, DOI 10.1046/j.1440-1746.2003.02921.x; MOMBURG F, 1994, CURR OPIN IMMUNOL, V6, P32, DOI 10.1016/0952-7915(94)90030-2; MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Raspollini MR, 2005, GYNECOL ONCOL, V98, P334, DOI 10.1016/j.ygyno.2004.09.035; Seliger B, 2000, IMMUNOL TODAY, V21, P455, DOI 10.1016/S0167-5699(00)01692-3; Sexl V, 2003, BLOOD, V101, P4937, DOI 10.1182/blood-2001-11-0142; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Singal DP, 1996, IMMUNOL LETT, V50, P149, DOI 10.1016/0165-2478(96)02531-X; VAN KL, 1994, IMMUNITY, V1, P533; White LC, 1996, IMMUNITY, V5, P365, DOI 10.1016/S1074-7613(00)80262-9; WRIGHT KL, 1995, J EXP MED, V181, P1459, DOI 10.1084/jem.181.4.1459	34	31	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2006	25	29					4016	4026		10.1038/sj.onc.1209434	http://dx.doi.org/10.1038/sj.onc.1209434			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16474838				2022-12-28	WOS:000238802400002
J	Vogt, M; Butz, K; Dymalla, S; Semzow, J; Hoppe-Seyler, F				Vogt, M.; Butz, K.; Dymalla, S.; Semzow, J.; Hoppe-Seyler, F.			Inhibition of Bax activity is crucial for the antiapoptotic function of the human papillomavirus E6 oncoprotein	ONCOGENE			English	Article						cervical cancer; human papillomavirus; apoptosis	P53-INDEPENDENT APOPTOSIS; HUMAN KERATINOCYTES; DOWN-REGULATION; CANCER-CELLS; E7 PROTEIN; TYPE-18 E6; SENESCENCE; EXPRESSION; GENE; P53	Oncogenic types of human papillomaviruses (HPVs) cause cervical cancer in humans. The antiapoptotic viral E6 gene has been identified as a key factor for maintaining the viability of HPV-positive cancer cells. Although E6 has the potential to modulate many apoptosis regulators, the crucial apoptotic pathway blocked by endogenous E6 in cervical cancer cells remained unknown. Using RNA interference (RNAi), here, we show that targeted inhibition of E6 expression in cervical cancer cells leads to the transcriptional stimulation of the PUMA promoter, in a p53-dependent manner. This is linked to the activation and translocation of Bax to the mitochondrial membrane, cytochrome c release into the cytosol, and activation of caspase-3, in a PUMA-dependent manner. Moreover, inhibition of Bax expression by RNAi efficiently reverts the apoptotic phenotype, which results from inhibition of E6 expression. Thus, interference with the p53/PUMA/Bax cascade is crucial for the antiapoptotic function of the viral E6 oncogene in HPV-positive cancer cells.	Deutsch Krebsforschungszentrum, Arbeitsgrp Mol Therapie Virus Assoz Tumore, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Hoppe-Seyler, F (corresponding author), Deutsch Krebsforschungszentrum, Arbeitsgrp Mol Therapie Virus Assoz Tumore, F065,Neuenheimer Feld 242, D-69120 Heidelberg, Germany.	hoppe-seyler@dkfz.de		Hoppe-Seyler, Felix/0000-0002-1864-300X				Aguilar-Lemarroy A, 2002, ONCOGENE, V21, P165, DOI 10.1038/sj.onc.1204979; Baldus SE, 2005, ONCOGENE, V24, P810, DOI 10.1038/sj.onc.1208235; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; Butz K, 2003, ONCOGENE, V22, P5938, DOI 10.1038/sj.onc.1206894; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DeFilippis RA, 2003, J VIROL, V77, P1551, DOI 10.1128/JVI.77.2.1551-1563.2003; Desaintes C, 1999, ONCOGENE, V18, P4538, DOI 10.1038/sj.onc.1202818; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Filippova M, 2004, J BIOL CHEM, V279, P25729, DOI 10.1074/jbc.M401172200; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P10978, DOI 10.1073/pnas.97.20.10978; Gu J, 2004, ONCOGENE, V23, P1300, DOI 10.1038/sj.onc.1207239; Hall AHS, 2003, J VIROL, V77, P6066, DOI 10.1128/JVI.77.10.6066-6069.2003; Hengstermann A, 2005, J VIROL, V79, P9296, DOI 10.1128/JVI.79.14.9296-9300.2005; Horner SM, 2004, J VIROL, V78, P4063, DOI 10.1128/JVI.78.8.4063-4073.2004; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kelley ML, 2005, J VIROL, V79, P3737, DOI 10.1128/JVI.79.6.3737-3747.2005; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Kong XT, 2001, J BIOL CHEM, V276, P32990, DOI 10.1074/jbc.M103681200; Liu J, 2004, VIROLOGY, V318, P169, DOI 10.1016/j.virol.2003.09.012; Magal SS, 2005, J GEN VIROL, V86, P611, DOI 10.1099/vir.0.80453-0; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Psyrri A, 2004, CANCER RES, V64, P3079, DOI 10.1158/0008-5472.CAN-03-3739; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Wells SI, 2000, EMBO J, V19, P5762, DOI 10.1093/emboj/19.21.5762; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yuan HD, 2005, ONCOGENE, V24, P5069, DOI 10.1038/sj.onc.1208691; Zhang HFM, 2005, MOL CELL BIOL, V25, P6247, DOI 10.1128/MCB.25.14.6247-6258.2005; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	36	48	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2006	25	29					4009	4015		10.1038/sj.onc.1209429	http://dx.doi.org/10.1038/sj.onc.1209429			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16462759				2022-12-28	WOS:000238802400001
J	Horndasch, M; Lienkamp, S; Springer, E; Schmitt, A; Pavenstadt, H; Walz, G; Gloy, J				Horndasch, M.; Lienkamp, S.; Springer, E.; Schmitt, A.; Pavenstaedt, H.; Walz, G.; Gloy, J.			The C/EBP homologous protein CHOP (GADD153) is an inhibitor of Wnt/TCF signals	ONCOGENE			English	Article						C/EBP; CHOP; TCF; tumour cells; Wnt signalling	TRANSCRIPTION FACTORS C/EBP; BINDING-PROTEIN; BETA-CATENIN; UP-REGULATION; GROWTH ARREST; WNT; APOPTOSIS; PATHWAYS; EXPRESSION; KINASE	CHOP (GADD153) is a protein of the C/EBP family of transcriptional regulators, which dimerizes with other C/EBP members and changes their DNA-binding and transactivation properties. It induces growth arrest and apoptosis after endoplasmatic reticulum stress or DNA damage. CHOP is also expressed during early embryogenesis and upregulated in tumour tissues with defective Wnt signals. We report here that CHOP functions as a specific inhibitor of Wnt/T-cell factor (TCF) signalling. CHOP inhibits TCF-dependent transcription in human embryonic and colon cancer cell lines. Injection of CHOP mRNA into early Xenopus laevis embryos suppresses dorsal organizer formation and inhibits secondary axis formation and TCF-dependent transcription in response to Wnt-8, Dishevelled, beta-Catenin and TCF-VP16. In embryos and human cells, this inhibition depends on the N-terminal transactivation domain of CHOP, whereas the C-terminal dimerization domain is dispensable. CHOP binds to TCF factors, thereby preventing the binding of TCF to its DNA recognition site. Our findings demonstrate a novel function of CHOP as a Wnt repressor.	Univ Hosp Freiburg, Div Nephrol, Dept Med, Freiburg, Germany; UKM Munster, Div Nephrol & Hypertens, Dept Med, Munster, Germany	University of Freiburg; University of Munster	Gloy, J (corresponding author), Zentrum Klin Forsch, Breisacher Str 66, D-79106 Freiburg, Germany.	gloy@med1.ukl.uni-freiburg.de	Lienkamp, Soeren/AAH-6296-2020	Lienkamp, Soeren/0000-0003-2963-6865				BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; Clevers H, 2004, CANCER CELL, V5, P5, DOI 10.1016/S1535-6108(03)00339-8; Conn KJ, 2002, J NEUROSCI RES, V68, P755, DOI 10.1002/jnr.10252; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; Fleming JV, 1997, MOL REPROD DEV, V48, P310, DOI 10.1002/(SICI)1098-2795(199711)48:3&lt;310::AID-MRD2&gt;3.0.CO;2-U; Fontanier-Razzaq NC, 1999, MOL REPROD DEV, V54, P326, DOI 10.1002/(SICI)1098-2795(199912)54:4&lt;326::AID-MRD2&gt;3.0.CO;2-3; Friedman AD, 1996, CANCER RES, V56, P3250; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; Houston DW, 2002, DEVELOPMENT, V129, P4015; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Jaiswal AS, 2002, ONCOGENE, V21, P8414, DOI 10.1038/sj.onc.1205947; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; Kim CH, 2000, NATURE, V407, P913, DOI 10.1038/35038097; Kim DG, 2002, J BIOL CHEM, V277, P38930, DOI 10.1074/jbc.M205941200; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Maytin EV, 1998, J INVEST DERMATOL, V110, P238, DOI 10.1046/j.1523-1747.1998.00123.x; Maytin EV, 2001, EXP CELL RES, V267, P193, DOI 10.1006/excr.2001.5248; Meneghini MD, 1999, NATURE, V399, P793, DOI 10.1038/21666; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Oyadomari S, 2001, P NATL ACAD SCI USA, V98, P10845, DOI 10.1073/pnas.191207498; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pereira RC, 2004, ENDOCRINOLOGY, V145, P1952, DOI 10.1210/en.2003-0868; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Rask K, 2000, INT J CANCER, V86, P337, DOI 10.1002/(SICI)1097-0215(20000501)86:3<337::AID-IJC6>3.3.CO;2-V; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Scott DW, 2004, CARCINOGENESIS, V25, P2155, DOI 10.1093/carcin/bgh239; Sokol SY, 1999, CURR OPIN GENET DEV, V9, P405, DOI 10.1016/S0959-437X(99)80061-6; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Talukder AH, 2002, ONCOGENE, V21, P4289, DOI 10.1038/sj.onc.1205529; Tang QQ, 2000, P NATL ACAD SCI USA, V97, P12446, DOI 10.1073/pnas.220425597; Ubeda M, 1999, MOL CELL BIOL, V19, P7589; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; Ubeda M, 2003, J BIOL CHEM, V278, P40514, DOI 10.1074/jbc.M306404200; Vonica A, 2000, DEV BIOL, V217, P230, DOI 10.1006/dbio.1999.9551; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	46	42	46	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3397	3407		10.1038/sj.onc.1209380	http://dx.doi.org/10.1038/sj.onc.1209380			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16434966				2022-12-28	WOS:000238448100005
J	Mantoni, TS; Reid, G; Garrett, MD				Mantoni, T. S.; Reid, G.; Garrett, M. D.			Androgen receptor activity is inhibited in response to genotoxic agents in a p53-independent manner	ONCOGENE			English	Article						androgen receptor; genotoxic agents; p53; chemotherapeutics	PROSTATE-SPECIFIC ANTIGEN; RNA-POLYMERASE-II; TRANSCRIPTIONAL REGULATION; PIFITHRIN-ALPHA; HEAT-SHOCK; IN-VIVO; CANCER; PHOSPHORYLATION; CISPLATIN; CELLS	The androgen receptor (AR) is fundamental to androgen signalling within the prostate gland, and deregulation of its activity is frequently linked to the development of prostate cancer. Advanced prostate cancer is often treated with chemotherapy and most of these drugs exert their function by generating genotoxic stress such as DNA damage. We have investigated here the effects of genotoxic agents used in chemotherapeutic regimens on AR function and expression. We have discovered that endogenous AR activity in LNCaP cells is inhibited in response to the chemotherapeutic agents etoposide and cisplatin. This loss of AR activity is not caused by a change in cell cycle distribution, a change in subcellular localisation of the AR nor by induction of apoptosis. In addition, we found that inhibition of AR activity in response to genotoxic stress is independent of p53 function. Interestingly, our studies revealed that genotoxic stress inhibits the hormone-stimulated recruitment of AR to androgen response elements. Thus, we report for the first time a mechanism by which the AR activity is inhibited in response to different chemotherapeutic agents.	Inst Canc Res, Haddow Labs, Canc Res UK Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England; European Mol Biol Lab, Heidelberg, Germany	Cancer Research UK; University of London; Institute of Cancer Research - UK; European Molecular Biology Laboratory (EMBL)	Garrett, MD (corresponding author), Inst Canc Res, Haddow Labs, Canc Res UK Ctr Canc Therapeut, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	michelle.garrett@icr.ac.uk		Reid, George/0000-0002-0298-693X				Black BE, 2004, MOL ENDOCRINOL, V18, P834, DOI 10.1210/me.2003-0145; BRUCHOVSKY N, 1968, J BIOL CHEM, V243, P2012; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cronauer MV, 2004, ONCOGENE, V23, P3541, DOI 10.1038/sj.onc.1207346; Denmeade SR, 2004, PROSTATE, V58, P211, DOI 10.1002/pros.10360; Edwards J, 2003, BRIT J CANCER, V89, P552, DOI 10.1038/sj.bjc.6601127; Espinosa E, 2003, CANCER TREAT REV, V29, P515, DOI 10.1016/S0305-7372(03)00116-6; Fang YF, 1996, J BIOL CHEM, V271, P28697, DOI 10.1074/jbc.271.45.28697; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Georget V, 2002, BIOCHEMISTRY-US, V41, P11824, DOI 10.1021/bi0259150; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Gregory CW, 2001, CANCER RES, V61, P2892; Gudmundsdottir K, 2004, EMBO REP, V5, P989, DOI 10.1038/sj.embor.7400255; Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959-8049(98)00228-7; Hoshi Senji, 2003, Int J Clin Oncol, V8, P118, DOI 10.1007/s101470300021; Jordan P, 2000, CELL MOL LIFE SCI, V57, P1229, DOI 10.1007/PL00000762; Kang ZG, 2004, MOL ENDOCRINOL, V18, P2633, DOI 10.1210/me.2004-0245; Kang ZG, 2002, J BIOL CHEM, V277, P48366, DOI 10.1074/jbc.M209074200; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Komarova EA, 2003, J BIOL CHEM, V278, P15465, DOI 10.1074/jbc.C300011200; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Linton KD, 2003, CANCER TREAT REV, V29, P151, DOI 10.1016/S0305-7372(03)00096-3; Litvinov IV, 2003, J CLIN ENDOCR METAB, V88, P2972, DOI 10.1210/jc.2002-022038; Louie MC, 2003, P NATL ACAD SCI USA, V100, P2226, DOI 10.1073/pnas.0437824100; Marcelli M, 2000, CANCER RES, V60, P944; Martinez ED, 2002, J BIOL CHEM, V277, P29719, DOI 10.1074/jbc.M112134200; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Parker CC, 2003, CANCER TREAT REV, V29, P161, DOI 10.1016/S0305-7372(03)00070-7; Pilat MJP, 1998, CANCER METAST REV, V17, P373, DOI 10.1023/A:1006166511344; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; Rocha S, 2003, BMC MOL BIOL, V4, DOI 10.1186/1471-2199-4-9; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Rosenhagen MC, 2003, MOL ENDOCRINOL, V17, P1991, DOI 10.1210/me.2003-0141; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; Sciuto R, 2002, J NUCL MED, V43, P79; Shenk JL, 2001, J BIOL CHEM, V276, P38472, DOI 10.1074/jbc.M103652200; Solit DB, 2002, CLIN CANCER RES, V8, P986; Steineck G, 2002, ACTA ONCOL, V41, P668, DOI 10.1080/028418602321028292; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; Vaishampayan U, 2004, AM J CLIN ONCOL-CANC, V27, P550, DOI 10.1097/01.coc.0000135922.12198.e4; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Wong HY, 2004, BIOCHEM J, V383, P267, DOI 10.1042/BJ20040683; Yang J, 2003, CARCINOGENESIS, V24, P1571, DOI 10.1093/carcin/bgg137	49	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3139	3149		10.1038/sj.onc.1209347	http://dx.doi.org/10.1038/sj.onc.1209347			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16434973				2022-12-28	WOS:000237951000005
J	Prieto-Sanchez, RM; Berenjeno, IM; Bustelo, XR				Prieto-Sanchez, R. M.; Berenjeno, I. M.; Bustelo, X. R.			Involvement of the Rho/Rac family member RhoG in caveolar endocytosis	ONCOGENE			English	Article						rhoG; caveolin; endocytosis; cholera toxin; vesicle trafficking	LIPID RAFTS; ACTIVATES RAC1; GOLGI-COMPLEX; CHOLERA-TOXIN; DISTINCT; PATHWAY; CDC42; PHAGOCYTOSIS; INTERNALIZATION; TRANSDUCTION	We show here that the GTPase RhoG is involved in caveolar trafficking. Wild-type RhoG moves sequentially to the plasma membrane, intracellular vesicles, and the Golgi apparatus along markers of this endocytic pathway. Such translocation is associated with changes in RhoG GDP/GTP levels and is highly dependent on lipid raft integrity and on the function of the GTPase dynamin2. In addition, the constitutively active RhoG(Q61L) mutant is preferentially located in endocytic vesicles that can be decorated with markers of the caveola-derived endocytic pathway. RhoG(Q61L,) but not the analogous Rac1 mutant protein, affects caveola internalization and the subsequent delivery of endocytic vesicles to the Golgi apparatus. The expression of RhoG/Rac1 chimeric proteins and RhoG(Q61L) effector mutants in cells induces alterations in the internalization of caveolae and severe changes in vesicle structure, respectively. However, the knockdown of endogenous rhoG transcripts using small interfering RNAs does not affect significantly the trafficking of caveola-derived vesicles, suggesting that RhoG function is dispensable for this endocytic process or, alternatively, that its function is compensated by other molecules. Taken together, these observations assign a novel function to RhoG and suggest that caveolar trafficking, as previously shown for other endocytic routes, is modulated by GTPases of the Ras superfamily.	Univ Salamanca, CSIC, IBMCC, E-37007 Salamanca, Spain; Univ Salamanca, CSIC, Red Temat Cooperat Ctr Canc, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); University of Salamanca	Bustelo, XR (corresponding author), Univ Salamanca, CSIC, IBMCC, Campus Unamuno, E-37007 Salamanca, Spain.	xbustelo@usal.es	Bustelo, Xose R./AAD-2081-2022; Bustelo, Xose R./A-9526-2010	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072	NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER; NCI NIH HHS [5-R01-CA73735-08, R01 CA073735] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Ellis S, 2000, TRENDS CELL BIOL, V10, P85, DOI 10.1016/S0962-8924(99)01710-9; Felberbaum-Corti M, 2003, NAT CELL BIOL, V5, P382, DOI 10.1038/ncb0503-382; Filippi MD, 2004, NAT IMMUNOL, V5, P744, DOI 10.1038/ni1081; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; Gonzallez-Gaitan M, 2003, NAT REV MOL CELL BIO, V4, P213, DOI 10.1038/nrm1053; Greenberg S, 1999, J LEUKOCYTE BIOL, V66, P712, DOI 10.1002/jlb.66.5.712; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Hoppe AD, 2004, MOL BIOL CELL, V15, P3509, DOI 10.1091/mbc.E03-11-0847; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Katoh H, 2003, NATURE, V424, P461, DOI 10.1038/nature01817; Katoh H, 2000, MOL CELL BIOL, V20, P7378, DOI 10.1128/MCB.20.19.7378-7387.2000; LI GP, 1993, J BIOL CHEM, V268, P24475; Massol P, 1998, EMBO J, V17, P6219, DOI 10.1093/emboj/17.21.6219; May V, 2002, J NEUROSCI, V22, P6980; Nichols B, 2003, J CELL SCI, V116, P4707, DOI 10.1242/jcs.00840; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Parton RG, 2003, TRAFFIC, V4, P724, DOI 10.1034/j.1600-0854.2003.00128.x; Pelkmans L, 2005, NATURE, V436, P128, DOI 10.1038/nature03866; Pelkmans L, 2005, NATURE, V436, P78, DOI 10.1038/nature03571; Pelkmans L, 2002, TRAFFIC, V3, P311, DOI 10.1034/j.1600-0854.2002.30501.x; Prieto-Sanchez RM, 2003, J BIOL CHEM, V278, P37916, DOI 10.1074/jbc.M301437200; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Torgersen ML, 2001, J CELL SCI, V114, P3737; Vignal E, 2001, MOL CELL BIOL, V21, P8022, DOI 10.1128/MCB.21.23.8022-8034.2001; Wennerberg K, 2002, J BIOL CHEM, V277, P47810, DOI 10.1074/jbc.M203816200; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	35	32	34	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					2961	2973		10.1038/sj.onc.1209333	http://dx.doi.org/10.1038/sj.onc.1209333			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16568096	Green Accepted, Green Submitted			2022-12-28	WOS:000237950800001
J	Quimby, BB; Yong-Gonzalez, V; Anan, T; Strunnikov, AV; Dasso, M				Quimby, B. B.; Yong-Gonzalez, V.; Anan, T.; Strunnikov, A. V.; Dasso, M.			The promyelocytic leukemia protein stimulates SUMO conjugation in yeast	ONCOGENE			English	Article						promyelocytic leukemia protein (PML); SUMO-1; budding yeast; SUMO ligase; PML : RAR alpha	NUCLEAR-BODY; RAR-ALPHA; PML; ENZYME; PATHOGENESIS; HOMOLOG; LIGASE; GENE; RING	The promyelocytic leukemia gene was first identified through its fusion to the gene encoding the retinoic acid receptor alpha (RAR alpha) in acute promyelocytic leukemia (APL) patients. The promyelocytic leukemia gene product (PML) becomes conjugated in vivo to the small ubiquitin-like protein SUMO-1, altering its behavior and capacity to recruit other proteins to PML nuclear bodies (PML-NBs). In the NB4 cell line, which was derived from an APL patient and expresses PML: RARa, we observed a retinoic acid-dependent change in the modi. cation of specific proteins by SUMO-1. To dissect the interaction of PML with the SUMO-1 modi. cation pathway, we used the budding yeast Saccharomyces cerevisiae as a model system through expression of PML and human SUMO-1 (hSUMO-1). We found that PML stimulated hSUMO-1 modi. cation in yeast, in a manner that was dependent upon PML's RING-finger domain. PML: RARa also stimulated hSUMO-1 conjugation in yeast. Interestingly, however, PML and PML: RARa differentially complemented yeast Smt3p conjugation pathway mutants. These findings point toward a potential function of PML and PML: RARa as SUMO E3 enzymes or E3 regulators, and suggest that fusion of RARa to PML may affect this activity.	NICHD, Lab Gene Regulat & Dev, Sect Cell Cycle Regulat, NIH, Bethesda, MD 20892 USA; NICHD, Unit Chromosome Struct & Funct, Lab Gene Regulat & Dev, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Dasso, M (corresponding author), NICHD, Lab Gene Regulat & Dev, Sect Cell Cycle Regulat, NIH, Bldg 18T,Room 106,18 Lib Dr, Bethesda, MD 20892 USA.	mdasso@helix.nih.gov		Strunnikov, Alexander/0000-0002-9058-2256; Dasso, Mary/0000-0002-5410-1371	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001902, Z01HD001903] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 HD001902-13] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Azuma Y, 2003, J CELL BIOL, V163, P477, DOI 10.1083/jcb.200304088; Azuma Y, 2001, FASEB J, V15, P1825, DOI 10.1096/fj.00-0818fje; Bernardi R, 2003, ONCOGENE, V22, P9048, DOI 10.1038/sj.onc.1207106; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Chen XL, 2005, MOL CELL BIOL, V25, P4311, DOI 10.1128/MCB.25.10.4311-4320.2005; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; Duprez E, 1999, J CELL SCI, V112, P381; GODDARD AD, 1992, LEUKEMIA, V6, pS117; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Quimby BB, 2000, MOL BIOL CELL, V11, P2617, DOI 10.1091/mbc.11.8.2617; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Strudwick S, 2002, LEUKEMIA, V16, P1906, DOI 10.1038/sj.leu.2402724; Strunnikov AV, 2001, GENETICS, V158, P95; Takahashi Y, 1999, BIOCHEM BIOPH RES CO, V259, P582, DOI 10.1006/bbrc.1999.0821; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Zhao XL, 2005, P NATL ACAD SCI USA, V102, P4777, DOI 10.1073/pnas.0500537102; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	31	41	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					2999	3005		10.1038/sj.onc.1209335	http://dx.doi.org/10.1038/sj.onc.1209335			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16501610				2022-12-28	WOS:000237950800004
J	Basrawala, Z; Alimirah, F; Xin, H; Mohideen, N; Campbell, SC; Flanigan, RC; Choubey, D				Basrawala, Z; Alimirah, F; Xin, H; Mohideen, N; Campbell, SC; Flanigan, RC; Choubey, D			Androgen receptor levels are increased by interferons in human prostate stromal and epithelial cells	ONCOGENE			English	Article						prostate; androgen receptor; interferons; stromal cells	CANCER-CELLS; CELLULAR SENESCENCE; IN-VITRO; EXPRESSION; PROGRESSION; MECHANISMS; INDUCTION; DISEASE; IFI-16; GENES	Proliferation of normal and malignant prostate epithelium is regulated by androgen stimulation via both the androgen receptor (AR)-positive stromal and epithelial cells. However, it is not known how AR expression is regulated in human prostate cells. We report that treatment of normal human prostate stromal cells (PrSCs) with type I IFN ( alpha or beta), but not type II IFN ( gamma), resulted in increased levels of AR protein. The maximal increase in AR protein levels was dependent on the dose and the duration of the IFN-alpha treatment. We found that the increase in AR protein levels was independent of de novo transcription and protein synthesis. Interestingly, the IFN-alpha treatment of PrSCs resulted in considerable nuclear accumulation of AR, stimulation of AR-mediated transcription of reporter genes, and retardation of cell proliferation. Furthermore, treatment of normal human prostate epithelial cells with IFNs ( alpha, beta or gamma) also resulted in increased levels of AR protein. Together, our observations identify the androgen receptor as an IFN-regulated protein in normal human prostate stromal and epithelial cells and predict that IFN-induced levels of AR in prostate cells contribute to the regulation of androgen signaling.	Loyola Univ Chicago, Edward Hines Jr VA Hosp, Hines, IL 60141 USA; Loyola Univ Chicago, Dept Radiat Oncol, Hines, IL USA; Loyola Univ Chicago, Dept Urol, Hines, IL USA	Loyola University Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Loyola University Chicago; Loyola University Chicago	Choubey, D (corresponding author), Loyola Univ Chicago, Edward Hines Jr VA Hosp, 5th Ave,Roosevelt Rd,Bldg 1,MC 114B, Hines, IL 60141 USA.	dchoube@lumc.edu	Choubey, Divaker/A-4771-2008					Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Agoulnik IU, 2003, J BIOL CHEM, V278, P31136, DOI 10.1074/jbc.M305153200; Arnold JT, 2002, ENDOCR-RELAT CANCER, V9, P61, DOI 10.1677/erc.0.0090061; Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215; Caraglia M, 2005, J CELL PHYSIOL, V202, P323, DOI 10.1002/jcp.20137; CHANG C, 1989, J STEROID BIOCHEM, V34, P311; Chlenski A, 2001, PROSTATE, V47, P66; Choubey D, 2000, J BIOL REG HOMEOS AG, V14, P187; Condon MS, 1999, IN VIVO, V13, P61; Garraway LA, 2003, PROSTATE, V55, P206, DOI 10.1002/pros.10244; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Henshall SM, 2001, CANCER RES, V61, P423; Janssen M, 2000, PROSTATE, V43, P20, DOI 10.1002/(SICI)1097-0045(20000401)43:1<20::AID-PROS4>3.0.CO;2-6; Kominsky SL, 2000, CANCER RES, V60, P3904; Lee DK, 2003, J CLIN ENDOCR METAB, V88, P4043, DOI 10.1210/jc.2003-030261; Litvinov IV, 2004, PROSTATE, V61, P299, DOI 10.1002/pros.20187; Malmgaard L, 2004, J INTERF CYTOK RES, V24, P439, DOI 10.1089/1079990041689665; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Nelson William G, 2004, J Urol, V172, pS6, DOI 10.1097/01.ju.0000142058.99614.ff; Olapade-Alaopa EO, 1999, CLIN CANCER RES, V5, P569; Ricciardelli C, 2005, PROSTATE, V63, P19, DOI 10.1002/pros.20154; ROY AK, 1995, CRIT REV EUKAR GENE, V5, P157, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.30; Schlaak JF, 2002, J BIOL CHEM, V277, P49428, DOI 10.1074/jbc.M205571200; Shenk JL, 2001, J BIOL CHEM, V276, P38472, DOI 10.1074/jbc.M103652200; Shou JY, 2002, P NATL ACAD SCI USA, V99, P2830, DOI 10.1073/pnas.052705299; SICA G, 1994, UROL RES, V22, P33, DOI 10.1007/BF00431546; Smyth MJ, 2004, IMMUNOL REV, V202, P275, DOI 10.1111/j.0105-2896.2004.00199.x; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Untergasser G, 2002, CANCER RES, V62, P6255; Xin H, 2004, ONCOGENE, V23, P6209, DOI 10.1038/sj.onc.1207836; Xin H, 2003, ONCOGENE, V22, P4831, DOI 10.1038/sj.onc.1206754; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458	32	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2812	2817		10.1038/sj.onc.1209304	http://dx.doi.org/10.1038/sj.onc.1209304			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16331249				2022-12-28	WOS:000237272900013
J	Dang, LH; Chen, F; Ying, C; Chun, S; Knock, SA; Appelman, HD; Dang, DT				Dang, LH; Chen, F; Ying, C; Chun, S; Knock, SA; Appelman, HD; Dang, DT			CDX2 has tumorigenic potential in the human colon cancer cell lines LOVO and SW48	ONCOGENE			English	Article						CDX2; colon cancer; tumorigenesis; LOVO; SW48	HOMEOBOX GENE CDX2; COLORECTAL-CANCER; DOWN-REGULATION; PROTEIN EXPRESSION; RNA EXPRESSION; PROLIFERATION; ADENOCARCINOMA; APOPTOSIS; TUMORS; BCL-2	CDX2 is a Drosophila caudal-related homeo box transcription factor that is important for the establishment and maintenance of intestinal epithelial cells. CDX2 is a marker of colon cancer, with strong staining in up to 90% of colonic adenocarcinomas. CDX2 heterozygous-null mice develop colonic neoplasms, which have suggested that CDX2 is a tumor suppressor. However, CDX2 has not been reported to affect xenograft growth. Furthermore, CDX2 is rarely mutated in colon cancer, which has led to suggestions that it may play only a minor role as a tumor suppressor in colon cancer. To understand the functional contributions of CDX2 to colon cancer, we disrupted CDX2 in LOVO and SW48 human colon cancer cell lines by targeted homologous recombination. Consistent with the literature, disruption of CDX2 enhanced anchorage-dependent cell proliferation. However, homozygous loss of CDX2 led to significant inhibition of anchorage-independent growth in LOVO cells, and cell lethality in SW48 cells. Further analyses revealed that disruption of CDX2 led to anchorage-independent G1 to S growth arrest and anoikis. In vivo xenograft studies confirmed that disruption of CDX2 inhibited LOVO tumor growth. These data demonstrate that CDX2 mediates anchorage-independent growth and survival. Thus, CDX2 has tumorigenic potential in the human colon cancer cell lines LOVO and SW48.	Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Div Anat Pathol, Dept Pathol, Ann Arbor, MI USA; Univ Michigan, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Dang, DT (corresponding author), Univ Michigan, Dept Internal Med, Div Hematol Oncol, 1150 W Med Ctr Dr,MSRB I,Room 6514, Ann Arbor, MI 48109 USA.	dangd@umich.edu						Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265; Bai YQ, 2003, ONCOGENE, V22, P7942, DOI 10.1038/sj.onc.1206634; Beck F, 2002, GUT, V51, P450, DOI 10.1136/gut.51.3.450; Bonhomme C, 2003, GUT, V52, P1465, DOI 10.1136/gut.52.10.1465; Brabletz T, 2004, CANCER RES, V64, P6973, DOI 10.1158/0008-5472.CAN-04-1132; Chan TA, 2002, P NATL ACAD SCI USA, V99, P8265, DOI 10.1073/pnas.082240999; Chawengsaksophak K, 2004, P NATL ACAD SCI USA, V101, P7641, DOI 10.1073/pnas.0401654101; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046; CUMMINS JM, 2004, NATURE, V428, P486, DOI [DOI 10.1038/NATURE02501, 10.1038/nature02501]; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; DANG DT, 2005, CANCER RES, V65, P1; Dang LH, 2001, P NATL ACAD SCI USA, V98, P15155, DOI 10.1073/pnas.251543698; Dang LH, 2004, CANCER BIOL THER, V3, P326, DOI 10.4161/cbt.3.3.704; DANG LH, 2006, IN PRESS ONCOGENE; DONG Z, 2002, SCI STKE, pPL7; DREWINKO B, 1976, CANCER RES, V36, P467; EE HC, 1995, AM J PATHOL, V147, P586; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Freund JN, 1998, BIOCHEM CELL BIOL, V76, P957, DOI 10.1139/bcb-76-6-957; Guo RJ, 2004, CANCER BIOL THER, V3, P593, DOI 10.4161/cbt.3.7.913; Guo RJ, 2004, J BIOL CHEM, V279, P36865, DOI 10.1074/jbc.M405213200; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; Hinoi T, 2001, AM J PATHOL, V159, P2239, DOI 10.1016/S0002-9440(10)63074-X; Hinoi T, 2003, J BIOL CHEM, V278, P44608, DOI 10.1074/jbc.M307435200; Hinoi T, 2005, GASTROENTEROLOGY, V128, P946, DOI 10.1053/j.gastro.2005.01.003; Hinoi T, 2002, GASTROENTEROLOGY, V123, P1565, DOI 10.1053/gast.2002.36598; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JAMES R, 1994, J BIOL CHEM, V269, P15229; KAIMAKTCHIEV V, 2004, MOD PATHOL; Keller MS, 2004, AM J PHYSIOL-GASTR L, V287, pG104, DOI 10.1152/ajpgi.00484.2003; Kohli M, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh009; Koo HM, 1996, CANCER RES, V56, P5211; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Lynch J, 2003, ONCOGENE, V22, P6395, DOI 10.1038/sj.onc.1206770; Lynch J, 2000, J BIOL CHEM, V275, P4499, DOI 10.1074/jbc.275.6.4499; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; McLean GW, 2004, GENE DEV, V18, P2998, DOI 10.1101/gad.316304; Moskaluk CA, 2003, MODERN PATHOL, V16, P913, DOI 10.1097/01.MP.0000086073.92773.55; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rawat VPS, 2004, P NATL ACAD SCI USA, V101, P817, DOI 10.1073/pnas.0305555101; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Rozek LS, 2005, CANCER RES, V65, P5488, DOI 10.1158/0008-5472.CAN-04-3645; Russo P, 2002, INT J CANCER, V100, P266, DOI 10.1002/ijc.10461; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Sugao Y, 1997, HISTOPATHOLOGY, V31, P123, DOI 10.1046/j.1365-2559.1997.2320843.x; Suh E, 1996, MOL CELL BIOL, V16, P619; Tamai Y, 1999, CANCER RES, V59, P2965; Wicking C, 1998, ONCOGENE, V17, P657, DOI 10.1038/sj.onc.1201971; Woodford-Richens KL, 2001, BRIT J CANCER, V84, P1314, DOI 10.1054/bjoc.2001.1800; Yagi OK, 1999, BRIT J CANCER, V79, P440, DOI 10.1038/sj.bjc.6690068	58	43	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2264	2272		10.1038/sj.onc.1209247	http://dx.doi.org/10.1038/sj.onc.1209247			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16314840				2022-12-28	WOS:000236581200013
J	White, PC; Shore, AM; Clement, M; McLaren, J; Soeiro, I; Lam, EWF; Brennan, P				White, PC; Shore, AM; Clement, M; McLaren, J; Soeiro, I; Lam, EWF; Brennan, P			Regulation of cyclin D2 and the cyclin D2 promoter by protein kinase A and CREB in lymphocytes	ONCOGENE			English	Article						cyclin D2; phosphatidylinositol 3-kinase; CREB; interelukin-2; Epstein-Barr virus	ANTIGEN RECEPTOR; B-LYMPHOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; GENE-EXPRESSION; TRANSGENIC MICE; CELL; PROLIFERATION; TRANSCRIPTION; ACTIVATION; COOPERATE	Lymphocyte proliferation is key to the regulation of the immune system. Cyclin D2 is the first cell cycle protein induced following stimulation through the T-cell receptor, the B-cell receptor or cytokines. The promoter of this cyclin integrates a diverse range of signals. Through investigating the regulation of this promoter by interleukin-2 and phosphatidylinositol 3-kinase, we have identified a role for the transcription factor CREB, cAMP response element-binding protein. Mutation of the CREB-binding site reduced cyclin D2 promoter activity 5-10-fold. CREB-1 is phosphorylated at serine 133, a critical site for activity, in both T cells and Epstein Barr virus immortalized B cells. The introduction of an S133A mutant of CREB-1 reduces IL-2 induction of cyclin D2 promoter activity, demonstrating a role for this phosphorylation site in promoter activity. Two inhibitors of protein kinase A reduce lymphocyte proliferation and CREB-1 phosphorylation. This study demonstrates that the cyclin D2 promoter is capable of being regulated by PI3K and CREB and identifies CREB-1 and protein kinase A as potential targets for altering lymphocyte proliferation.	Cardiff Univ, Cardiff CF14 4XX, Wales; Canc Res UK Labs, London, England; Hammersmith Hosp, Imperial Coll Sch Med, Sect Canc Cell Biol, London, England	Cardiff University; Cancer Research UK; Imperial College London	Brennan, P (corresponding author), Cardiff Univ, Henry Wellcome Res Bldg,Heath Pk, Cardiff CF14 4XX, Wales.	brennanp@cf.ac.uk	Brennan, Paul/ABB-9196-2021; Lam, Eric W-F/AAW-8566-2020; Brennan, Paul/B-9210-2009	Brennan, Paul/0000-0001-8792-0499; Lam, Eric W-F/0000-0003-1274-3576; Brennan, Paul/0000-0001-8792-0499; McLaren, James/0000-0002-7021-5934				AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; Appleman LJ, 2000, J IMMUNOL, V164, P144, DOI 10.4049/jimmunol.164.1.144; Banerji L, 2001, ONCOGENE, V20, P7352, DOI 10.1038/sj.onc.1204951; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; Belkowski SM, 1998, J IMMUNOL, V161, P659; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Brennan P, 1996, BIOCHEM SOC T, V24, pS3, DOI 10.1042/bst024003s; Brennan P, 2002, ONCOGENE, V21, P1263, DOI 10.1038/sj.onc.1205182; Breslin EM, 2005, BRIT J PHARMACOL, V144, P791, DOI 10.1038/sj.bjp.0706061; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; DELMER A, 1995, BLOOD, V85, P2870, DOI 10.1182/blood.V85.10.2870.bloodjournal85102870; FEUERSTEIN N, 1995, J BIOL CHEM, V270, P9454, DOI 10.1074/jbc.270.16.9454; FEUERSTEIN N, 1995, J IMMUNOL, V154, P68; Frissora F, 2003, EUR J IMMUNOL, V33, P907, DOI 10.1002/eji.200323657; Fruman DA, 2002, P NATL ACAD SCI USA, V99, P359, DOI 10.1073/pnas.012605099; HORI T, 1987, BLOOD, V70, P1069; Huang YP, 2001, ONCOGENE, V20, P1094, DOI 10.1038/sj.onc.1204198; Lam EWF, 2000, J BIOL CHEM, V275, P3479, DOI 10.1074/jbc.275.5.3479; Martino A, 2001, J IMMUNOL, V166, P1723, DOI 10.4049/jimmunol.166.3.1723; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mehl AM, 2001, J BIOL CHEM, V276, P984, DOI 10.1074/jbc.M003758200; Moriggl R, 1999, IMMUNITY, V11, P225, DOI 10.1016/S1074-7613(00)80097-7; PALMERO I, 1993, ONCOGENE, V8, P1049; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; SAMPLE J, 1990, J VIROL, V64, P1667, DOI 10.1128/JVI.64.4.1667-1674.1990; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; Solvason N, 2000, INT IMMUNOL, V12, P631, DOI 10.1093/intimm/12.5.631; Spender LC, 2001, J VIROL, V75, P3537, DOI 10.1128/JVI.75.8.3537-3546.2001; Takano Y, 1999, J PATHOL, V189, P194; Teramoto N, 1999, INT J CANCER, V81, P543, DOI 10.1002/(SICI)1097-0215(19990517)81:4<543::AID-IJC7>3.3.CO;2-V; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Waltereit R, 2003, MOL NEUROBIOL, V27, P99, DOI 10.1385/MN:27:1:99; XIE HJ, 1995, J IMMUNOL, V154, P1717; Yu CT, 2001, J IMMUNOL, V166, P284, DOI 10.4049/jimmunol.166.1.284; Zhang CY, 2002, J BIOL CHEM, V277, P48359, DOI 10.1074/jbc.M209329200	38	40	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2170	2180		10.1038/sj.onc.1209255	http://dx.doi.org/10.1038/sj.onc.1209255			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16301994				2022-12-28	WOS:000236581200004
J	Bark-Jones, SJ; Webb, HM; West, MJ				Bark-Jones, SJ; Webb, HM; West, MJ			EBV EBNA 2 stimulates CDK9-dependent transcription and RNA polymerase II phosphorylation on serine 5	ONCOGENE			English	Article						CDK9; CTD; EBNA 2; phosphorylation; serine 5; serine 2	EPSTEIN-BARR-VIRUS; CARBOXYL-TERMINAL DOMAIN; DEPENDENT KINASE INHIBITOR; SIGNAL-BINDING-PROTEIN; LYMPHOCYTE GROWTH TRANSFORMATION; NUCLEAR-PROTEIN-2 ACIDIC DOMAIN; LATENT MEMBRANE-PROTEIN; HUMAN LEUKEMIA-CELLS; FACTOR P-TEFB; RBP-J-KAPPA	EBNA 2 is one of only. v e viral genes essential for the infection and immortalization of human B cells by the cancer-associated virus Epstein-Barr virus (EBV). EBNA 2 activates cellular and viral transcription and associates with components of the basal transcription apparatus and a number of coactivators. We provide the first evidence to show that the mechanism of transcriptional activation by EBNA 2 also involves phosphorylation of the C-terminal domain (CTD) of RNA polymerase II (pol II). We found that transcriptional activation by EBNA 2 was inhibited by a dominant-negative mutant of the pol II CTD kinase, CDK9, and by low concentrations of the CDK9 inhibitor 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole. Moreover, using chromatin immunoprecipitation assays we demonstrated that EBNA 2 stimulates both pol II recruitment and pol II phosphorylation on serine 5 of the CTD in vivo. These results identify a new step in the transcription cycle that is subject to regulation by a key EBV-encoded transcription factor and highlight CDK9 inhibitors as potential anti-EBV agents.	Univ Sussex, Sch Life Sci, Dept Biochem, Brighton BN1 9QG, E Sussex, England	University of Sussex	West, MJ (corresponding author), Univ Sussex, Sch Life Sci, Dept Biochem, Brighton BN1 9QG, E Sussex, England.	m.j.west@sussex.ac.uk		West, Michelle/0000-0002-9497-9365	Wellcome Trust [064014] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABBOT SD, 1990, J VIROL, V64, P2126, DOI 10.1128/JVI.64.5.2126-2134.1990; Alazard N, 2003, J VIROL, V77, P8166, DOI 10.1128/JVI.77.14.8166-8172.2003; ALFIERI C, 1991, VIROLOGY, V181, P595, DOI 10.1016/0042-6822(91)90893-G; ALLDAY MJ, 1989, J GEN VIROL, V70, P1755, DOI 10.1099/0022-1317-70-7-1755; Andersson Jan, 2000, Herpes, V7, P76; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; COHEN JI, 1991, J VIROL, V65, P5880, DOI 10.1128/JVI.65.11.5880-5885.1991; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; COHEN JI, 1992, P NATL ACAD SCI USA, V89, P8030, DOI 10.1073/pnas.89.17.8030; Decker RH, 2001, CELL DEATH DIFFER, V8, P715, DOI 10.1038/sj.cdd.4400868; Deng Z, 2003, J VIROL, V77, P11992, DOI 10.1128/JVI.77.22.11992-12001.2003; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; Eberhardy SR, 2002, J BIOL CHEM, V277, P40156, DOI 10.1074/jbc.M207441200; Gold MO, 1998, J VIROL, V72, P4448, DOI 10.1128/JVI.72.5.4448-4453.1998; Gold MO, 1996, NUCLEIC ACIDS RES, V24, P3771, DOI 10.1093/nar/24.19.3771; GROSSMAN SR, 1994, P NATL ACAD SCI USA, V91, P7568, DOI 10.1073/pnas.91.16.7568; HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657; Herrmann CH, 1996, NUCLEIC ACIDS RES, V24, P501, DOI 10.1093/nar/24.3.501; Isel C, 1999, J MOL BIOL, V290, P929, DOI 10.1006/jmbi.1999.2933; JOHANNSEN E, 1995, J VIROL, V69, P253, DOI 10.1128/JVI.69.1.253-262.1995; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; Kim YK, 2002, MOL CELL BIOL, V22, P4622, DOI 10.1128/MCB.22.13.4622-4637.2002; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Lee DK, 2001, J BIOL CHEM, V276, P9978, DOI 10.1074/jbc.M002285200; Lee MA, 1999, J VIROL, V73, P2974, DOI 10.1128/JVI.73.4.2974-2982.1999; LING PD, 1993, P NATL ACAD SCI USA, V90, P9237, DOI 10.1073/pnas.90.20.9237; Litz J, 2003, CLIN CANCER RES, V9, P4586; Ma YH, 2003, MOL CANCER THER, V2, P73; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Nelson PJ, 2003, J ANTIMICROB CHEMOTH, V51, P921, DOI 10.1093/jac/dkg175; Palancade B, 2003, EUR J BIOCHEM, V270, P3859, DOI 10.1046/j.1432-1033.2003.03794.x; Patel V, 1998, J CLIN INVEST, V102, P1674, DOI 10.1172/JCI3661; Ping YH, 1999, J BIOL CHEM, V274, P7399, DOI 10.1074/jbc.274.11.7399; Ramanathan Y, 2001, J BIOL CHEM, V276, P10913, DOI 10.1074/jbc.M010975200; Sadaie AR, 2004, ANTIVIR RES, V61, P1, DOI 10.1016/j.antiviral.2003.09.004; Sedlacek HH, 2001, CRIT REV ONCOL HEMAT, V38, P139, DOI 10.1016/S1040-8428(00)00124-4; SJOBLOM A, 1995, J GEN VIROL, V76, P2679, DOI 10.1099/0022-1317-76-11-2679; SKARE J, 1985, J VIROL, V55, P286, DOI 10.1128/JVI.55.2.286-297.1985; Spilianakis C, 2003, EMBO J, V22, P5125, DOI 10.1093/emboj/cdg496; Swaminathan S, 1996, VIROLOGY, V217, P532, DOI 10.1006/viro.1996.0148; Tian YN, 2003, J BIOL CHEM, V278, P44041, DOI 10.1074/jbc.M306443200; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; TONG X, 1995, J VIROL, V69, P585, DOI 10.1128/JVI.69.1.585-588.1995; TONG X, 1995, MOL CELL BIOL, V15, P4735; TONG X, 1995, P NATL ACAD SCI USA, V92, P3259, DOI 10.1073/pnas.92.8.3259; TSANG SF, 1991, J VIROL, V65, P6765, DOI 10.1128/JVI.65.12.6765-6771.1991; Van Veldhuizen PJ, 2005, CANCER CHEMOTH PHARM, V56, P39, DOI 10.1007/s00280-004-0969-9; WALTZER L, 1994, EMBO J, V13, P5633, DOI 10.1002/j.1460-2075.1994.tb06901.x; WANG F, 1990, J VIROL, V64, P3407, DOI 10.1128/JVI.64.7.3407-3416.1990; Wang L, 2000, P NATL ACAD SCI USA, V97, P430, DOI 10.1073/pnas.97.1.430; Wendtner CM, 2004, SEMIN HEMATOL, V41, P224, DOI 10.1053/j.seminhematol.2004.05.004; West MJ, 2004, J VIROL, V78, P9431, DOI 10.1128/JVI.78.17.9431-9445.2004; West MJ, 1999, EMBO J, V18, P1378, DOI 10.1093/emboj/18.5.1378; WOISETSCHLAEGER M, 1991, P NATL ACAD SCI USA, V88, P3942, DOI 10.1073/pnas.88.9.3942; Wu DY, 1996, J VIROL, V70, P6020, DOI 10.1128/JVI.70.9.6020-6028.1996; Yu CR, 2002, CLIN CANCER RES, V8, P2976; Yue W, 2005, J VIROL, V79, P5880, DOI 10.1128/JVI.79.9.5880-5885.2005; Yue W, 2004, J VIROL, V78, P3542, DOI 10.1128/JVI.78.7.3542-3552.2004; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622; ZIMBERSTROBL U, 1994, EMBO J, V13, P4973, DOI 10.1002/j.1460-2075.1994.tb06824.x	64	48	69	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1775	1785		10.1038/sj.onc.1209205	http://dx.doi.org/10.1038/sj.onc.1209205			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16314842				2022-12-28	WOS:000236013700009
J	Cruz-Munoz, W; Sanchez, OH; Di Grappa, M; English, JL; Hill, RP; Khokha, R				Cruz-Munoz, W.; Sanchez, O. H.; Di Grappa, M.; English, J. L.; Hill, R. P.; Khokha, R.			Enhanced metastatic dissemination to multiple organs by melanoma and lymphoma cells in timp-3(-/-) mice	ONCOGENE			English	Article						TIMP-3; metastasis; melanoma; lymphoma; deficient mice	TISSUE INHIBITOR; MATRIX METALLOPROTEINASE-2; LIVER METASTASIS; TUMOR INVASION; A MMP-2; EXPRESSION; PROGRESSION; CANCER; TIMP; LUNG	Identifying versatile inhibitors of metastasis that operate in multiple sites against distinct cancer cell types is important for designing novel therapeutics for metastasis. We show that multiple tissues of timp-3(-/-) mice are more susceptible to metastatic colonization. Overall, a 5-14-fold increase in liver and kidney colonization occurred by EL-4 lymphoma cells, and a twofold increase upon targeting B16F10 melanoma cells to the bone or lung of timp-3(-/-) mice. There was a general lack of macrophage or neutrophil localization to metastases in the liver, kidney and lung, and of osteoclasts to bone in both genotypes. Analysis of lung showed that proliferation or angiogenesis were unaltered within the metastatic colonies. Lung-trap assays revealed that initial tumor cell trapping was similar in the lung vasculature of timp-3(-/-) and wild-type mice. However, more tumor cells were found in timp-3(-/-) lungs at 48 and 96 h after tumor cell injection indicating more efficient extravasation and initial proliferation. Activation of pro-MMP-2 was greater in timp-3(-/-) lungs at these time points. These data demonstrate TIMP-3 functions to inhibit metastatic dissemination of diverse cancer cells to multiple organs. TIMP-3 regulates MMP-2 activation to limit tumor cell extravasation and subsequent colonization of the lung, without augmenting inflammatory cell response.	Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Ontario, Inst Technol, Oshawa, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Ontario Tech University	Khokha, R (corresponding author), Univ Toronto, Ontario Canc Inst, 610 Univ Ave,Room 10 328, Toronto, ON M5G 2M9, Canada.	rkhokha@uhnres.utoronto.ca		Hill, Richard Peter/0000-0001-5331-8045				Ahonen M, 1998, CANCER RES, V58, P2310; Airola K, 1999, BRIT J CANCER, V80, P733, DOI 10.1038/sj.bjc.6690417; Banerji A, 2004, CANCER LETT, V211, P235, DOI 10.1016/j.canlet.2004.02.007; Cameron MD, 2000, CANCER RES, V60, P2541; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Cruz-Munoz W, 2006, ONCOGENE, V25, P650, DOI 10.1038/sj.onc.1209104; De Larco JE, 2004, CLIN CANCER RES, V10, P4895, DOI 10.1158/1078-0432.CCR-03-0760; Ding L, 2001, BRIT J CANCER, V85, P431, DOI 10.1054/bjoc.2001.1911; English JL, 2006, J BIOL CHEM, V281, P10337, DOI 10.1074/jbc.M512009200; Gill SE, 2003, DEV BIOL, V261, P313, DOI 10.1016/S0012-1606(03)00318-X; Hofmann UB, 2000, J PATHOL, V191, P245; Hofmann UB, 2005, ARCH DERMATOL RES, V297, P154, DOI 10.1007/s00403-005-0588-2; Itoh T, 1998, CANCER RES, V58, P1048; Kassiri Z, 2005, CIRC RES, V97, P380, DOI 10.1161/01.RES.0000178789.16929.cf; Khatib AM, 1999, CANCER RES, V59, P1356; Kitakata H, 2002, CANCER RES, V62, P6682; Leco KJ, 2001, J CLIN INVEST, V108, P817, DOI 10.1172/JCI12067; LECO KJ, 1994, J BIOL CHEM, V269, P9352; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; Miyazaki T, 2004, BRIT J CANCER, V91, P1556, DOI 10.1038/sj.bjc.6602185; Mohammed FF, 2004, NAT GENET, V36, P969, DOI 10.1038/ng1413; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Nuttall RK, 2004, FEBS LETT, V563, P129, DOI 10.1016/S0014-5793(04)00281-9; ORR FW, 1993, BREAST CANCER RES TR, V25, P151, DOI 10.1007/BF00662140; Pastorino U, 1997, J CLIN ONCOL, V15, P2858, DOI 10.1200/JCO.1997.15.8.2858; Perez M, 2001, EUR J CANCER, V37, P629, DOI 10.1016/S0959-8049(00)00436-6; Powe DG, 1997, BRIT J CANCER, V75, P1678, DOI 10.1038/bjc.1997.285; Rustgi A. K., 2003, GASTROINTESTINAL CAN, P69; Salmela MT, 2003, MODERN PATHOL, V16, P108, DOI 10.1097/01.MP.0000051681.43441.82; SanchezSweatman OH, 1997, EUR J CANCER, V33, P918, DOI 10.1016/S0959-8049(97)00513-3; Shamamian P, 2001, J CELL PHYSIOL, V189, P197, DOI 10.1002/jcp.10014; Soloway PD, 1996, ONCOGENE, V13, P2307; Spurbeck WW, 2002, BLOOD, V100, P3361, DOI 10.1182/blood.V100.9.3361; Urban BA, 2000, RADIOGRAPHICS, V20, P197, DOI 10.1148/radiographics.20.1.g00ja09197; Woessner JF, 2001, J CLIN INVEST, V108, P799, DOI 10.1172/JCI13709; Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200; Zhang L, 2004, CANCER RES, V64, P4180, DOI 10.1158/0008-5472.CAN-03-3038	39	34	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2006	25	49					6489	6496		10.1038/sj.onc.1209663	http://dx.doi.org/10.1038/sj.onc.1209663			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16702949				2022-12-28	WOS:000241395100005
J	Zhang, H; OzakiZ, I; Mizuta, T; Hamajima, H; Yasutake, T; Eguchi, Y; Ideguchi, H; Yamamoto, K; Matsuhashi, S				Zhang, H.; Ozaki, I.; Mizuta, T.; Hamajima, H.; Yasutake, T.; Eguchi, Y.; Ideguchi, H.; Yamamoto, K.; Matsuhashi, S.			Involvement of programmed cell death 4 in transforming growth factor-beta 1-induced apoptosis in human hepatocellular carcinoma	ONCOGENE			English	Article						PDCD4 gene; TGF-beta 1; HCC; Smad; tumor suppressor	GROWTH-FACTOR-BETA; PROGRAMMED CELL-DEATH; INITIATION-FACTOR 4A; HUMAN HEPATOMA-CELLS; CHICKEN PDCD4 GENE; NF-KAPPA-B; TGF-BETA; TRANSFORMATION SUPPRESSOR; AP-1 TRANSACTIVATION; BINDING-PROTEIN	The programmed cell death 4 (PDCD4) gene was originally identified as a tumor-related gene in humans and acts as a tumor-suppressor in mouse epidermal carcinoma cells. However, its function and regulatory mechanisms of expression in human cancer remain to be elucidated. We therefore investigated the expression of PDCD4 in human hepatocellular carcinoma (HCC) and the role of PDCD4 in human HCC cells. Downregulation of PDCD4 protein was observed in all HCC tissues tested compared with corresponding noncancerous liver, as revealed by Western blotting or immunohistochemical staining. Human HCC cell line, Huh7, transfected with PDCD4 cDNA showed nuclear fragmentation and DNA laddering characteristic of apoptotic cells associated with mitochondrial changes and caspase activation. Transforming growth factor-beta 1 (TGF-beta 1) treatment of Huh7 cells resulted in increased PDCD4 expression and occurrence of apoptosis, also concomitant with mitochondrial events and caspase activation. Transfection of Smad7, a known antagonist to TGF-beta 1 signaling, protected cells from TGF-beta 1-mediated apoptosis and suppressed TGF-beta 1-induced PDCD4 expression. Moreover, antisense PDCD4 transfectants were resistant to apoptosis induced by TGF-beta 1. In conclusion, these data suggest that PDCD4 is a proapoptotic molecule involved in TGF-beta 1-induced apoptosis in human HCC cells, and a possible tumor suppressor in hepatocarcinogenesis.	Saga Univ, Saga Med Sch, Hlth Adm Ctr, Saga 8498501, Japan; Saga Univ, Saga Med Sch, Dept Internal Med, Div Hepatol & Metab, Saga 840, Japan; China Med Univ, Affiliated Hosp 1, Dept Surg 2, Shenyang, Peoples R China; Saga Univ, Saga Med Sch, Dept Pathol, Saga 840, Japan; Towha Univ, Fac Engn, Fukuoka, Japan	Saga University; Saga University; China Medical University; Saga University	OzakiZ, I (corresponding author), Saga Univ, Saga Med Sch, Hlth Adm Ctr, 5-1-1 Nabeshima, Saga 8498501, Japan.	ozaki@cc.saga-u.ac.jp		Zhang, Hao/0000-0002-9938-8433				Afonja O, 2004, ONCOGENE, V23, P8135, DOI 10.1038/sj.onc.1207983; AKAO Y, 1994, CANCER RES, V54, P2468; Aravind L, 2000, GENOME RES, V10, P1172, DOI 10.1101/gr.10.8.1172; Azzoni L, 1998, J IMMUNOL, V161, P3493; Bissell DM, 2001, HEPATOLOGY, V34, P859, DOI 10.1053/jhep.2001.28457; Bohm M, 2003, ONCOGENE, V22, P4905, DOI 10.1038/sj.onc.1206710; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Horowitz J, 1999, CURR OPIN MOL THER, V1, P500; Huang JZ, 2003, WORLD J GASTROENTERO, V9, P84, DOI 10.3748/wjg.v9.i1.84; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; Jansen AP, 2004, MOL CANCER THER, V3, P103; Jurisicova A, 1998, MOL REPROD DEV, V51, P243, DOI 10.1002/(SICI)1098-2795(199811)51:3&lt;243::AID-MRD3&gt;3.0.CO;2-P; Kang MJ, 2002, BIOCHEM BIOPH RES CO, V293, P617, DOI 10.1016/S0006-291X(02)00264-4; KITAJIMA Y, 1991, J BIOCHEM-TOKYO, V109, P544, DOI 10.1093/oxfordjournals.jbchem.a123417; Kusano N, 1999, HEPATOLOGY, V29, P1858, DOI 10.1002/hep.510290636; Lankat-Buttgereit B, 2003, BIOL CELL, V95, P515, DOI 10.1016/j.biolcel.2003.09.003; Matsuhashi Sachiko, 1997, Research Communications in Biochemistry and Cell and Molecular Biology, V1, P109; Matsuzaki K, 2000, CANCER RES, V60, P1394; Musch A, 2005, DIGESTION, V71, P78, DOI 10.1159/000084523; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Onishi Y, 1998, GENE, V215, P453, DOI 10.1016/S0378-1119(98)00313-8; Ozaki I, 2000, CANCER RES, V60, P6519; Ozturk M, 1999, SEMIN LIVER DIS, V19, P235, DOI 10.1055/s-2007-1007113; Paik SY, 2003, MODERN PATHOL, V16, P86, DOI 10.1097/01.MP.0000047308.03300.9C; Rider MA, 2002, INT J ONCOL, V20, P235; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; Schlichter U, 2001, BBA-GENE STRUCT EXPR, V1520, P99, DOI 10.1016/S0167-4781(01)00252-4; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Shima Y, 1999, HEPATOLOGY, V30, P1215, DOI 10.1002/hep.510300503; Simmons HM, 2005, GENE, V347, P137, DOI 10.1016/j.gene.2004.12.027; Soejima H, 1999, CYTOGENET CELL GENET, V87, P113, DOI 10.1159/000015408; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wong SF, 2001, PATHOLOGY, V33, P85; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Yoshinaga H, 1999, PATHOL INT, V49, P1067, DOI 10.1046/j.1440-1827.1999.00995.x; Yoshinaga Hidetoshi, 1997, Research Communications in Biochemistry and Cell and Molecular Biology, V1, P121; Young MR, 2003, TRENDS MOL MED, V9, P36, DOI 10.1016/S1471-4914(02)00009-6; Zhang H, 2004, CANCER SCI, V95, P878, DOI 10.1111/j.1349-7006.2004.tb02197.x	49	212	237	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2006	25	45					6101	6112		10.1038/sj.onc.1209634	http://dx.doi.org/10.1038/sj.onc.1209634			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16682950				2022-12-28	WOS:000241101200007
J	Babic, I; Cherry, E; Fujita, DJ				Babic, I.; Cherry, E.; Fujita, D. J.			SUMO modification of Sam68 enhances its ability to repress cyclin D1 expression and inhibits its ability to induce apoptosis	ONCOGENE			English	Article						SUMO; Sam68; apoptosis; cyclin D1	NUCLEAR RIBONUCLEOPROTEIN-K; BINDING PROTEIN SAM68; FUNCTIONAL INTERACTION; RNA; PHOSPHORYLATION; PROGRESSION; SUMOYLATION; ACTIVATION; PIAS; SRC	Sam68 (Src associated in mitosis; 68 kDa) is an RNA-binding protein and substrate of Src family kinases. It is thought to play a role in cell cycle progression. Overexpression of Sam68 in fibroblasts was reported to have two separable functions dependent on its ability to bind RNA-cell cycle arrest or the induction of apoptosis. Post-translational modification with SUMO (small ubi-quitinlike modi. er) is common to many transcription factors and can regulate protein localization, stability and function. Here we show Sam68 to be modified by SUMO, and demonstrate that the SUMO E3 ligase (PIAS1) (protein inhibitor of activated STAT1) can enhance Sam68 sumoylation. Lysine 96, the first lysine in the amino-terminal region of Sam68, was found to be the major SUMO acceptor site. Mutation of the SUMO acceptor lysine to arginine enhanced the ability of Sam68 to induce apoptosis but inhibited its ability to act as a transcriptional inhibitor of cyclin D1 expression. A SUMO-1 Sam68 fusion protein, on the other hand, inhibited the ability of Sam68 to induce apoptosis but was a strong repressor of cyclin D1 expression. Thus, SUMO may be an important regulator of Sam68 function in cell cycle progression.	Univ Calgary, So Alberta Canc Res Inst, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary	Fujita, DJ (corresponding author), Univ Calgary, So Alberta Canc Res Inst, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada.	dfujita@ucalgary.ca						Babic I, 2004, ONCOGENE, V23, P3781, DOI 10.1038/sj.onc.1207484; Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; Chen TP, 1999, MOL BIOL CELL, V10, P3015, DOI 10.1091/mbc.10.9.3015; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Gill G, 2003, CURR OPIN GENET DEV, V13, P108, DOI 10.1016/S0959-437X(03)00021-2; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Holmstrom S, 2003, P NATL ACAD SCI USA, V100, P15758, DOI 10.1073/pnas.2136933100; Hong W, 2002, MOL CANCER RES, V1, P48; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kim KI, 2002, J CELL PHYSIOL, V191, P257, DOI 10.1002/jcp.10100; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Lee PSW, 2003, J BIOL CHEM, V278, P27853, DOI 10.1074/jbc.M301755200; Li QH, 2002, FEBS LETT, V525, P145, DOI 10.1016/S0014-5793(02)03103-4; Liu K, 2000, J BIOL CHEM, V275, P40195, DOI 10.1074/jbc.M006194200; Lukong KE, 2005, J BIOL CHEM, V280, P38639, DOI 10.1074/jbc.M505802200; Lukong KE, 2003, BBA-REV CANCER, V1653, P73, DOI 10.1016/j.bbcan.2003.09.001; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; McBride AE, 1996, P NATL ACAD SCI USA, V93, P2296, DOI 10.1073/pnas.93.6.2296; McBride AE, 1998, EXP CELL RES, V241, P84, DOI 10.1006/excr.1998.4047; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Miyauchi Y, 2002, J BIOL CHEM, V277, P50131, DOI 10.1074/jbc.M208319200; Ostareck-Lederer A, 2002, MOL CELL BIOL, V22, P4535, DOI 10.1128/MCB.22.13.4535-4543.2002; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Taylor SJ, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-5; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; Vassileva MT, 2004, MOL CELL BIOL, V24, P3623, DOI 10.1128/MCB.24.9.3623-3632.2004; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; VOGEL LB, 1995, J BIOL CHEM, V270, P2506, DOI 10.1074/jbc.270.6.2506; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; Yamamoto H, 2003, EMBO J, V22, P2047, DOI 10.1093/emboj/cdg204; Yang HP, 2002, ONCOGENE, V21, P7187, DOI 10.1038/sj.onc.1205759; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Zhang H, 2002, MOL CELL BIOL, V22, P6498, DOI 10.1128/MCB.22.18.6498-6508.2002	48	56	62	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					4955	4964		10.1038/sj.onc.1209504	http://dx.doi.org/10.1038/sj.onc.1209504			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568089				2022-12-28	WOS:000239921300001
J	Cotroneo, MS; Merry, GM; Haag, JD; Lan, H; Shepel, LA; Gould, MN				Cotroneo, M. S.; Merry, G. M.; Haag, J. D.; Lan, H.; Shepel, L. A.; Gould, M. N.			The Mcs7 quantitative trait locus is associated with an increased susceptibility to mammary cancer in congenic rats and an allele-specific imbalance	ONCOGENE			English	Article						breast cancer; animal models; loss of heterozygosity (LOH); genotype/phenotype correlation	BREAST-CANCER; TUMOR SUSCEPTIBILITY; MULTIPLE LOCI; GENE; HETEROZYGOSITY; CARCINOMAS; CARCINOGENESIS; CHROMOSOME-10; NEUROBLASTOMA; SCHWANNOMAS	Identification of high-penetrance breast cancer genes such as Brca1 has been accomplished by analysing familial cases. However, these genes occur at low frequency and do not account for the majority of genetic risk. Identification of low-penetrance alleles that occur commonly in populations may benefit from unbiased genome-wide screening. One such approach uses linkage studies in rodent models to identify homologous human candidates. The Wistar Kyoto (WKy) rat is resistant to mammary carcinomas induced with 7,12-dimethybenz[a]anthracene (DMBA), whereas the Wistar Furth (WF) strain is susceptible. Previous genome-wide linkage studies in crosses of these strains identified three WKy resistance quantitative trait loci, Mcs5, Mcs6 and Mcs8, and one predicted to increase susceptibility, Mcs7. The Mcs7 region on rat chromosome 10 (RNO10) is orthologous to human 17q, a common site of genetic aberrations in breast cancer. Here, we establish the independent phenotype conferred by Mcs7 using congenic rats carrying the WKy Mcs7 locus on a WF background. Tumor multiplicity was significantly higher (similar to 50%) in DMBA-treated congenics homozygous and heterozygous for the WKy allele at the Mcs7 locus, compared to controls. We also investigated allelic imbalance (AI) in mammary carcinomas from (WKy x WF)F1 rats and Mcs7 heterozygous congenics. Of the four known WKy Mcs loci tested, only Mcs7 displayed AI. The pattern of AI in carcinomas from both F1 and Mcs7 congenic rats was similar, suggesting a WF allelic loss. Together, these data suggest that one or more breast cancer-related genes are located within the dominantly acting WKy allele at the Mcs7 locus.	Univ Wisconsin, Dept Oncol, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Cotroneo, MS (corresponding author), Univ Wisconsin, Dept Oncol, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	cotroneo@oncology.wisc.edu	Gould, Michael N/C-7414-2014		NATIONAL CANCER INSTITUTE [R01CA077494] Funding Source: NIH RePORTER; NCI NIH HHS [CA77494] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; CALLAHAN R, 1993, J CELL BIOCHEM, P167; Chen KS, 1996, CARCINOGENESIS, V17, P1561, DOI 10.1093/carcin/17.8.1561; Dumitrescu RG, 2005, J CELL MOL MED, V9, P208, DOI 10.1111/j.1582-4934.2005.tb00350.x; Easton D F, 1999, Breast Cancer Res, V1, P14, DOI 10.1186/bcr6; Haag JD, 2003, CANCER RES, V63, P5808; Haag JD, 1996, MOL CARCINOGEN, V17, P134, DOI 10.1002/(SICI)1098-2744(199611)17:3<134::AID-MC5>3.3.CO;2-N; Haag JD, 1999, MOL CARCINOGEN, V24, P47, DOI 10.1002/(SICI)1098-2744(199901)24:1<47::AID-MC7>3.0.CO;2-B; Hino O, 2001, MUTAT RES-FUND MOL M, V477, P155, DOI 10.1016/S0027-5107(01)00116-6; Kindler-Rohrborn A, 1999, CANCER RES, V59, P1109; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Koelsch BU, 2002, CARCINOGENESIS, V23, P1033, DOI 10.1093/carcin/23.6.1033; Lan H, 1999, MAMM GENOME, V10, P687, DOI 10.1007/s003359901071; Lan H, 2001, GENETICS, V157, P331; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; Lastowska M, 2004, GENE CHROMOSOME CANC, V40, P158, DOI 10.1002/gcc.20031; Lastowska M, 2002, GENE CHROMOSOME CANC, V34, P428, DOI 10.1002/gcc.10089; Lesueur F, 2005, HUM MOL GENET, V14, P2349, DOI 10.1093/hmg/ddi237; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Newton MA, 2000, BIOMETRICS, V56, P1088, DOI 10.1111/j.0006-341X.2000.01088.x; NIKITIN AY, 1991, P NATL ACAD SCI USA, V88, P9939, DOI 10.1073/pnas.88.22.9939; NORLANDER C, 2005, CANCER GENET CYTOGEN, V156, P158; Okimoto K, 2004, P NATL ACAD SCI USA, V101, P2023, DOI 10.1073/pnas.0308071100; Peto R, 2000, NEW ENGL J MED, V343, P1495; Phelan CM, 1998, CANCER RES, V58, P1004; Ponder BAJ, 2005, BREAST CANCER RES, V7, pS14, DOI 10.1186/bcr1083; Samuelson DJ, 2005, CANCER RES, V65, P9637, DOI 10.1158/0008-5472.CAN-05-1498; Samuelson DJ, 2003, CARCINOGENESIS, V24, P1455, DOI 10.1093/carcin/bgg112; Shepel LA, 1998, GENETICS, V149, P289; Thompson D, 2004, J MAMMARY GLAND BIOL, V9, P221, DOI 10.1023/B:JOMG.0000048770.90334.3b; Toyota M, 1996, MOL CARCINOGEN, V15, P176, DOI 10.1002/(SICI)1098-2744(199603)15:3<176::AID-MC3>3.0.CO;2-G; Yu MS, 2000, MOL CARCINOGEN, V27, P76, DOI 10.1002/(SICI)1098-2744(200002)27:2<76::AID-MC3>3.0.CO;2-7	32	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					5011	5017		10.1038/sj.onc.1209506	http://dx.doi.org/10.1038/sj.onc.1209506			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568087				2022-12-28	WOS:000239921300006
J	Hagerstrand, D; Hesselager, G; Achterberg, S; Bolin, UW; Kowanetz, M; Kastemar, M; Heldin, CH; Isaksson, A; Nister, M; Ostman, A				Hagerstrand, D.; Hesselager, G.; Achterberg, S.; Bolin, U. Wickenberg; Kowanetz, M.; Kastemar, M.; Heldin, C-H; Isaksson, A.; Nister, M.; Ostman, A.			Characterization of an imatinib-sensitive subset of high-grade human glioma cultures	ONCOGENE			English	Article						PDGF receptor; imatinib; CXCL12; glioblastoma multiforme; microarray	GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE; BRAIN-TUMORS; CELL-GROWTH; PDGF RECEPTORS; MESSENGER-RNA; PHASE-II; B-CHAIN; GLIOBLASTOMA; EXPRESSION	High-grade gliomas, including glioblastomas, are malignant brain tumors for which improved treatment is urgently needed. Genetic studies have demonstrated the existence of biologically distinct subsets. Preliminary studies have indicated that platelet-derived growth factor (PDGF) receptor signaling contributes to the growth of some of these tumors. In this study, human high-grade glioma primary cultures were analysed for sensitivity to treatment with the PDGF receptor inhibitor imatinib/Glivec/Gleevec/STI571. Six out of 15 cultures displayed more than 40% growth inhibition after imatinib treatment, whereas seven cultures showed less than 20% growth inhibition. In the sensitive cultures, apoptosis contributed to growth inhibition. Platelet-derived growth factor receptor status correlated with imatinib sensitivity. Supervised analyses of gene expression profiles and real-time PCR analyses identified expression of the chemokine CXCL12/SDF-1 (stromal cell-derived factor 1) as a predictor of imatinib sensitivity. Exogenous addition of CXCL12 to imatinib-insensitive cultures conferred some imatinib sensitivity. Finally, coregulation of CXCL12 and PDGF alpha-receptor was observed in glioblastoma biopsies. We have thus defined the characteristics of a novel imatinib-sensitive subset of glioma cultures, and provided evidence for a functional relationship between imatinib sensitivity and chemokine signaling. These findings will assist in the design and evaluation of clinical trials exploring therapeutic effects of imatinib on malignant brain tumors.	Canc Ctr Karolinska, Dept Oncol Pathol, Karolinska Inst, S-17176 Stockholm, Sweden; Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, Uppsala, Sweden; Uppsala Univ, Ludwig Inst Canc Res, Uppsala, Sweden	Karolinska Institutet; Uppsala University; Ludwig Institute for Cancer Research; Uppsala University	Ostman, A (corresponding author), Canc Ctr Karolinska, Dept Oncol Pathol, Karolinska Inst, R8-03, S-17176 Stockholm, Sweden.	arne.ostman@ki.se	Hägerstrand, Daniel/AAH-3009-2019; Hägerstrand, Daniel C/D-1584-2014	Hägerstrand, Daniel/0000-0001-7270-0776; Hägerstrand, Daniel C/0000-0001-7270-0776; Isaksson, Anders/0000-0001-6576-7825	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Backlund LM, 2003, CLIN CANCER RES, V9, P4151; Cabioglu N, 2005, CANCER RES, V65, P6493, DOI 10.1158/0008-5472.CAN-04-1303; Capdeville R, 2002, NAT REV DRUG DISCOV, V1, P493, DOI 10.1038/nrd839; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Dresemann G, 2005, ANN ONCOL, V16, P1702, DOI 10.1093/annonc/mdi317; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Haas-Kogan DA, 2005, JNCI-J NATL CANCER I, V97, P880, DOI 10.1093/jnci/dji161; Heimberger AB, 2002, CLIN CANCER RES, V8, P3496; HERMANSON M, 1992, CANCER RES, V52, P3213; HERMANSSON M, 1988, P NATL ACAD SCI USA, V85, P7748, DOI 10.1073/pnas.85.20.7748; Johnson BE, 2005, CANCER RES, V65, P7525, DOI 10.1158/0008-5472.CAN-05-1257; Kilic T, 2000, CANCER RES, V60, P5143; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; KOVALENKO M, 1994, CANCER RES, V54, P6106; Liang Y, 2005, P NATL ACAD SCI USA, V102, P5814, DOI 10.1073/pnas.0402870102; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Mischel PS, 2003, ONCOGENE, V22, P2361, DOI 10.1038/sj.onc.1206344; Nutt CL, 2003, CANCER RES, V63, P1602; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Ostman A, 2004, CYTOKINE GROWTH F R, V15, P275, DOI 10.1016/j.cytogfr.2004.03.002; Pietras K, 2003, CANCER CELL, V3, P439, DOI 10.1016/S1535-6108(03)00089-8; Pietras K, 2001, CANCER RES, V61, P2929; PONTEN J, 1978, MED BIOL, V56, P184; Porcile C, 2005, EXP CELL RES, V308, P241, DOI 10.1016/j.yexcr.2005.04.024; Reardon DA, 2005, J CLIN ONCOL, V23, P9359, DOI 10.1200/JCO.2005.03.2185; Rempel SA, 2000, CLIN CANCER RES, V6, P102; Rich JN, 2004, J CLIN ONCOL, V22, P133, DOI 10.1200/JCO.2004.08.110; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; Sihto H, 2005, J CLIN ONCOL, V23, P49, DOI 10.1200/JCO.2005.02.093; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sjoblom T, 2001, CANCER RES, V61, P5778; STRAWN LM, 1994, J BIOL CHEM, V269, P21215; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Uhrbom L, 1998, CANCER RES, V58, P5275; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; WESTERMARK B, 1995, GLIA, V15, P257, DOI 10.1002/glia.440150307; Yuan XP, 2004, ONCOGENE, V23, P9392, DOI 10.1038/sj.onc.1208311	44	70	70	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2006	25	35					4913	4922		10.1038/sj.onc.1209497	http://dx.doi.org/10.1038/sj.onc.1209497			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16547494	Bronze			2022-12-28	WOS:000239687100009
J	Peduto, L; Reuter, VE; Sehara-Fujisawa, A; Shaffer, DR; Scher, HI; Blobel, CP				Peduto, L.; Reuter, V. E.; Sehara-Fujisawa, A.; Shaffer, D. R.; Scher, H. I.; Blobel, C. P.			ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression	ONCOGENE			English	Article						ADAM12; metalloprotease-disintegrin; prostate cancer; stromal/tumor cell interaction	EPIDERMAL-GROWTH-FACTOR; CELL-PROLIFERATION; CANCER; EGF; RECEPTOR	The interaction between stromal cells and tumor cells is emerging as a critical aspect of tumor progression. Yet there is a paucity of molecular markers for cells participating in such interactions, and only few genes are known to play a critical role in this process. Here, we describe the identification of ADAM12 (a disintegrin and metalloprotease 12) as a novel marker for a subpopulation of stromal cells that are adjacent to epithelial tumor cells in three mouse carcinoma models (models for prostate, breast and colon cancer). Moreover, we show that ADAM12 is essential for tumor development and progression in the W-10 mouse model for prostate cancer. These results suggest that ADAM12 might be a useful marker for stromal cells in mouse tumors that are likely to participate in stromal/tumor cell crosstalk, and that ADAM12 is a potential target for design of drugs that prevent carcinoma growth.	Cornell Univ, Weill Med Coll, Arthritis & Tissue Degenerat Program, Hosp Special Surg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Mol Biol, New York, NY 10021 USA; Kyoto Univ, Inst Frontier Med Sci, Dept Growth Regulat, Kyoto, Japan; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Kyoto University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Blobel, CP (corresponding author), Cornell Univ, Weill Med Coll, Arthritis & Tissue Degenerat Program, Hosp Special Surg, Caspary Res Bldg,Room 426,535 E 70th St, New York, NY 10021 USA.	blobelc@hss.edu		Peduto, Lucie/0000-0003-2414-4407	NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR012538] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064750] Funding Source: NIH RePORTER; NCRR NIH HHS [C06-RR12538-01] Funding Source: Medline; NIGMS NIH HHS [GM64750] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam RM, 2002, ENDOCRINOLOGY, V143, P4599, DOI 10.1210/en.2002-220561; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Cunha GR, 2003, INT J CANCER, V107, P1, DOI 10.1002/ijc.11335; Desmouliere A, 2004, INT J DEV BIOL, V48, P509, DOI 10.1387/ijdb.041802ad; Freeman MR, 1998, J CELL BIOCHEM, V68, P328, DOI 10.1002/(SICI)1097-4644(19980301)68:3<328::AID-JCB4>3.0.CO;2-W; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Iba K, 1999, AM J PATHOL, V154, P1489, DOI 10.1016/S0002-9440(10)65403-X; Kodama T, 2004, AM J PATHOL, V165, P1743, DOI 10.1016/S0002-9440(10)63429-3; Kurisaki T, 1998, MECH DEVELOP, V73, P211, DOI 10.1016/S0925-4773(98)00043-4; Kveiborg M, 2005, CANCER RES, V65, P4754, DOI 10.1158/0008-5472.CAN-05-0262; Le Pabic H, 2003, HEPATOLOGY, V37, P1056, DOI 10.1053/jhep.2003.50205; Loechel F, 2000, BIOCHEM BIOPH RES CO, V278, P511, DOI 10.1006/bbrc.2000.3835; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; MANOVA K, 1992, J NEUROSCI, V12, P4663; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Peduto L, 2005, CANCER RES, V65, P9312, DOI 10.1158/0008-5472.CAN-05-1063; SCHUURMANS ALG, 1988, MOL CELL ENDOCRINOL, V60, P101, DOI 10.1016/0303-7207(88)90124-4; Shaffer DR, 2005, P NATL ACAD SCI USA, V102, P210, DOI 10.1073/pnas.0407362102; Shappell SB, 2004, CANCER RES, V64, P2270, DOI 10.1158/0008-5472.CAN-03-0946; Torring N, 2002, BJU INT, V89, P583, DOI 10.1046/j.1464-410X.2002.02665.x	22	78	84	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2006	25	39					5462	5466		10.1038/sj.onc.1209536	http://dx.doi.org/10.1038/sj.onc.1209536			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16607276				2022-12-28	WOS:000240144900010
J	Wang, L; Tam, JP; Liu, DX				Wang, L.; Tam, J. P.; Liu, D. X.			Biochemical and functional characterization of Epstein-Barr virus-encoded BARF1 protein: interaction with human hTid1 protein facilitates its maturation and secretion	ONCOGENE			English	Article						Epstein-Barr virus; BARF1; human hTid1; interaction; maturation and secretion	HUMAN DNAJ PROTEIN; DROSOPHILA TUMOR-SUPPRESSOR; MALIGNANT-TRANSFORMATION; NASOPHARYNGEAL CARCINOMA; HUMAN HOMOLOG; CELL-LINE; GENE; EXPRESSION; HSP70; ABSENCE	EBV BARF1 gene encodes a secretory protein with transforming and mitogenic activities. In this report, the post-translational modification, folding, maturation and secretion of BARF1 are systematically studied by site-directed mutagenesis and overexpression of the protein in mammalian cells using the vaccinia/T7 system. The protein was shown to be post-translationally modified by N-linked glycosylation on the asparagine 95 residue. This modi. cation was confirmed to be essential for the maturation and secretion of the protein. Analysis of the four cysteine residues by site-directed mutagenesis demonstrated that cysteine 146 and 201 were essential for proper folding and secretion of the protein. To search for human proteins involved in the maturation process of the protein, a yeast two-hybrid screening was carried out using the BARF1 sequence from amino acids 21 - 221 (BARF1 Delta) as bait, leading to the identification of human hTid1 protein as a potential interacting protein. This interaction was subsequently confirmed by coimmunoprecipitation and dual immunofluorescent labeling of cells coexpressing BARF1 and hTid1, and the interaction domain in hTid1 was mapped to amino acids 149 - 320. Interestingly, coexpression of BARF1 with hTid1 demonstrated that hTid1 could promote secretion of BARF1, suggesting that hTid1 may act as a chaperone to facilitate the folding, processing and maturation of BARF1.	Inst Mol & Cell Biol, Singapore 138673, Singapore; Nanyang Technol Univ, Sch Biol Sci, Singapore, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Liu, DX (corresponding author), Inst Mol & Cell Biol, 61 Biopolis Dr, Singapore 138673, Singapore.	dxliu@imcb.a-star.edu.sg	Tam, James P/A-2176-2011; Liu, Ding Xiang/A-2226-2011	Tam, James P/0000-0003-4433-198X; 				BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; Cheng H, 2002, J BIOL CHEM, V277, P20605, DOI 10.1074/jbc.M201204200; Cheng H, 2001, CURR BIOL, V11, P1771, DOI 10.1016/S0960-9822(01)00540-1; Cohen JI, 1999, J VIROL, V73, P7627, DOI 10.1128/JVI.73.9.7627-7632.1999; Danve C, 2001, VIROLOGY, V288, P223, DOI 10.1006/viro.2001.1072; de Turenne-Tessier M, 2005, VIRUS RES, V109, P9, DOI 10.1016/j.virusres.2004.10.003; Decaussin G, 2000, CANCER RES, V60, P5584; Eom CY, 2002, P NATL ACAD SCI USA, V99, P1894, DOI 10.1073/pnas.042689499; KIEFF E, 1996, FIELDS VIROLOGY, V3, P2343; Kim SW, 2004, CANCER RES, V64, P7732, DOI 10.1158/0008-5472.CAN-04-1323; Liu DX, 1997, J VIROL, V71, P1814, DOI 10.1128/JVI.71.3.1814-1820.1997; Mayer MP, 2005, REV PHYSIOL BIOCH P, V153, P1, DOI 10.1007/s10254-004-0025-5; Nishikawa J, 1999, J VIROL, V73, P1286, DOI 10.1128/JVI.73.2.1286-1292.1999; Sall A, 2004, ONCOGENE, V23, P4938, DOI 10.1038/sj.onc.1207607; Sarkar S, 2001, J BIOL CHEM, V276, P49034, DOI 10.1074/jbc.M103683200; Schaaf CP, 2004, FASEB J, V18, P267, DOI 10.1096/fj.04-1558fje; Schilling B, 1998, VIROLOGY, V247, P74, DOI 10.1006/viro.1998.9220; Seto E, 2005, J MED VIROL, V76, P82, DOI 10.1002/jmv.20327; Sheng W, 2003, J VIROL, V77, P3859, DOI 10.1128/JVI.77.6.3859-3865.2003; Sheng W, 2001, ONCOGENE, V20, P1176, DOI 10.1038/sj.onc.1204217; Strockbine LD, 1998, J VIROL, V72, P4015, DOI 10.1128/JVI.72.5.4015-4021.1998; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; Wang CC, 2004, DEV CELL, V7, P359, DOI 10.1016/j.devcel.2004.08.002; WEI MX, 1989, EMBO J, V8, P2897, DOI 10.1002/j.1460-2075.1989.tb08438.x; Wei MX, 1997, ONCOGENE, V14, P3073, DOI 10.1038/sj.onc.1201128; WEI MX, 1994, CANCER RES, V54, P1843; ZHANG CX, 1988, J VIROL, V62, P1862, DOI 10.1128/JVI.62.6.1862-1869.1988	28	16	17	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2006	25	31					4320	4331		10.1038/sj.onc.1209458	http://dx.doi.org/10.1038/sj.onc.1209458			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16518412				2022-12-28	WOS:000239240100007
J	Kanzawa, T; Iwado, E; Aoki, H; Iwamaru, A; Hollingsworth, EF; Sawaya, R; Kondo, S; Kondo, Y				Kanzawa, T.; Iwado, E.; Aoki, H.; Iwamaru, A.; Hollingsworth, E. F.; Sawaya, R.; Kondo, S.; Kondo, Y.			Ionizing radiation induces apoptosis and inhibits neuronal differentiation in rat neural stem cells via the c-Jun NH2-terminal kinase (JNK) pathway	ONCOGENE			English	Article						neural stem cells; ionizing radiation; JNK; apoptosis; neuronal differentiation	BCL-2 FAMILY-MEMBERS; PROGENITOR CELLS; PRECURSOR CELLS; CYTOCHROME-C; EICOSAPENTAENOIC ACID; GAMMA-IRRADIATION; NERVOUS-SYSTEM; GROWTH-FACTOR; MAP KINASES; ADULT-RAT	A substantial number of neural stem cells ( NSCs) continue to proliferate and generate neurons in the central nervous system throughout life. Ionizing radiation, an important adjuvant therapy for glioma patients, may damage NSCs and cause neuronal deficits, such as cognitive dysfunction and memory impairment. However, the precise mechanism of radiation effects on death and differentiation of NSCs remains largely unknown. Here, we found that radiation induced apoptosis in NSCs via the mitochondrial pathway, upregulating the ratio of Bax to Bcl-2 and releasing cytochrome c into the cytoplasm. Radiation also inhibited neuronal differentiation of NSCs by 50%. Of the three stress-associated mitogen-activated protein kinases ( MAPKs), only c-Jun NH2-terminal kinase ( JNK) was activated in NSCs after radiation. Interestingly, JNK inhibition by the specific inhibitor SP600125 rescued NSCs from apoptosis and improved neuronal differentiation. Furthermore, we examined whether radiation directly inhibits neuronal differentiation or not. Radiation did not affect the promoter activity of NeuroD, a basic helix-loop-helix transcription factor that regulates the expression of neuronal differentiation markers. Radiation induced more apoptosis in NeuroD-positive cells than NeuroD-negative cells. We concluded that radiation activates JNK and induces apoptosis, especially in neural progenitor cells, resulting in the inhibition of neurogenesis. Our findings raise the possibility that JNK inhibition has therapeutic potential in protecting NSCs from the adverse effects of radiation.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Kondo, Y (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, BSRB1004, Houston, TX 77030 USA.	yaskondo@mdanderson.org		KANZAWA, TAKAO/0000-0002-8165-5652	NCI NIH HHS [CA088936, CA108558] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088936, R01CA108558] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bieberich E, 2003, J CELL BIOL, V162, P469, DOI 10.1083/jcb.200212067; Bjorkblom B, 2005, J NEUROSCI, V25, P6350, DOI 10.1523/JNEUROSCI.1517-05.2005; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chang LF, 2003, DEV CELL, V4, P521, DOI 10.1016/S1534-5807(03)00094-7; Cheng AW, 2001, J BIOL CHEM, V276, P43320, DOI 10.1074/jbc.M107698200; Cho JH, 2004, MOL NEUROBIOL, V30, P35, DOI 10.1385/MN:30:1:035; Ciccolini F, 1998, J NEUROSCI, V18, P7869; CROSSEN JR, 1994, J CLIN ONCOL, V12, P627, DOI 10.1200/JCO.1994.12.3.627; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Diez del Corral R, 2001, NAT REV NEUROSCI, V2, P835; Eminel S, 2004, J BIOL CHEM, V279, P55385, DOI 10.1074/jbc.M405858200; Erlandsson A, 2001, J NEUROSCI, V21, P3483, DOI 10.1523/JNEUROSCI.21-10-03483.2001; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Harada J, 2004, J NEUROCHEM, V88, P1026, DOI 10.1046/j.1471-4159.2003.02219.x; Harris CA, 2001, J BIOL CHEM, V276, P37754; Huang HP, 2000, MOL CELL BIOL, V20, P3292, DOI 10.1128/MCB.20.9.3292-3307.2000; Jacotot E, 1999, ANN NY ACAD SCI, V887, P18, DOI 10.1111/j.1749-6632.1999.tb07919.x; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; Kondo S, 1996, ONCOGENE, V13, P1773; KONDO S, 1992, NEUROSURGERY, V30, P506; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Limoli CL, 2004, RADIAT RES, V161, P17, DOI 10.1667/RR3112; Lonergan PE, 2002, J BIOL CHEM, V277, P20804, DOI 10.1074/jbc.M202387200; Lynch AM, 2003, J BIOL CHEM, V278, P51075, DOI 10.1074/jbc.M307970200; Madsen TM, 2003, NEUROSCIENCE, V119, P635, DOI 10.1016/S0306-4522(03)00199-4; Monje ML, 2002, NAT MED, V8, P955, DOI 10.1038/nm749; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Peissner W, 1999, MOL BRAIN RES, V71, P61, DOI 10.1016/S0169-328X(99)00170-9; Ross SE, 2003, NEURON, V39, P13, DOI 10.1016/S0896-6273(03)00365-9; Rueda D, 2002, J BIOL CHEM, V277, P46645, DOI 10.1074/jbc.M206590200; Shamblott MJ, 2001, P NATL ACAD SCI USA, V98, P113, DOI 10.1073/pnas.021537998; Surma-aho O, 2001, NEUROLOGY, V56, P1285, DOI 10.1212/WNL.56.10.1285; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Verheij M, 1998, RADIOTHER ONCOL, V47, P225, DOI 10.1016/S0167-8140(98)00007-3; Verheij M, 2000, CELL TISSUE RES, V301, P133, DOI 10.1007/s004410000188; Waetzig V, 2005, TRENDS PHARMACOL SCI, V26, P455, DOI 10.1016/j.tips.2005.07.006; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yu CF, 2004, MOL CELL, V13, P329, DOI 10.1016/S1097-2765(04)00028-0; Zhao WQ, 2003, J NEUROSCI RES, V72, P334, DOI 10.1002/jnr.10591	48	47	51	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3638	3648		10.1038/sj.onc.1209414	http://dx.doi.org/10.1038/sj.onc.1209414			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16491125				2022-12-28	WOS:000238448300003
J	Calvet, L; Geoerger, B; Regairaz, M; Opolon, P; Machet, L; Morizet, J; Joseph, JM; Elie, N; Vassal, G				Calvet, L.; Geoerger, B.; Regairaz, M.; Opolon, P.; Machet, L.; Morizet, J.; Joseph, J-M; Elie, N.; Vassal, G.			Pleiotrophin, a candidate gene for poor tumor vasculature and in vivo neuroblastoma sensitivityto irinotecan	ONCOGENE			English	Article						neuroblastoma; CPT-11; resistance; pleiotrophin; angiogenesis	AFFIN REGULATORY PEPTIDE; DNA-TOPOISOMERASE-I; GROWTH-FACTOR PLEIOTROPHIN; PEDIATRIC-ONCOLOGY-GROUP; PHASE-I; N-MYC; ANTIANGIOGENIC THERAPY; NEURO-BLASTOMA; EXPRESSION; ANGIOGENESIS	In vivo neuroblastoma ( NB) xenograft model, resistant to the DNA-topoisomerase I inhibitor irinotecan (CPT-11), has been established to study resistance mechanisms acquired in a therapeutic setting. Common mechanisms of resistance were not involved in this resistance. Thus, we compared the gene expression profiles of sensitive, resistant, and reverted tumors using cDNA expression arrays. Expression of selected transcripts was confirmed by quantitative real-time PCR. We found that pleiotrophin (PTN), a heparin-binding growth factor, was the only gene significantly affected: PTN gene expression was downregulated in all resistant tumors (8-14-fold) as compared to sensitive tumors, and was increased (2-4-fold) in all reverted tumors as compared to resistant tumors. PTN thus appeared to be a likely candidate gene associated with resistance to CPT-11 in this in vivo model. To investigate the direct implication of PTN in NB, we transfected two NB cell lines with RNA interferences in order to silence PTN. PTN failed to demonstrate implication in resistance to CPT-11 in vitro but could influence sensitivity to CPT-11 exclusively through an in vivo mechanism. Indeed, vasculature was significantly enhanced in resistant NB xenografts compared to sensitive and reverted xenografts, and we suggest that PTN is acting in our resistant in vivo NB model as an angiostatic factor.	Inst Gustave Roussy, UPRES, EA 3535, F-94805 Villejuif, France; Inst Gustave Roussy, UMR 8121, F-94805 Villejuif, France; CHUV, Dept Pediat, Lausanne, Switzerland; Inst Gustave Roussy, LIPA, F-94805 Villejuif, France	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); UNICANCER; Gustave Roussy	Vassal, G (corresponding author), Inst Gustave Roussy, UPRES, EA 3535, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	gvassal@igr.fr	Elie, Nicolas/ABC-4069-2020; Machet, Laurent/A-2976-2010	Elie, Nicolas/0000-0001-5772-8252; Machet, Laurent/0000-0001-5985-878X				Blaney S, 2001, CLIN CANCER RES, V7, P32; BOURHIS J, 1989, J NATL CANCER I, V81, P1401, DOI 10.1093/jnci/81.18.1401; Bowden ET, 2002, J BIOL CHEM, V277, P35862, DOI 10.1074/jbc.M203963200; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Calvet L, 2004, BRIT J CANCER, V91, P1205, DOI 10.1038/sj.bjc.6602079; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; Choudhuri R, 1997, CANCER RES, V57, P1814; Corbley MJ, 1997, J BIOL CHEM, V272, P24696, DOI 10.1074/jbc.272.39.24696; COURTY J, 1991, BIOCHEM BIOPH RES CO, V180, P145, DOI 10.1016/S0006-291X(05)81267-7; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; Deuel TF, 2002, ARCH BIOCHEM BIOPHYS, V397, P162, DOI 10.1006/abbi.2001.2705; Elie N, 2003, CYTOM PART A, V56A, P37, DOI 10.1002/cyto.a.10075; FANG WJ, 1992, J BIOL CHEM, V267, P25889; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; Furman WL, 1999, J CLIN ONCOL, V17, P1815, DOI 10.1200/JCO.1999.17.6.1815; HAYASHI Y, 1989, CANCER, V63, P126, DOI 10.1002/1097-0142(19890101)63:1<126::AID-CNCR2820630120>3.0.CO;2-Z; Herbst RS, 1998, CANCER CHEMOTH PHARM, V41, P497, DOI 10.1007/s002800050773; Heroult M, 2004, ONCOGENE, V23, P1745, DOI 10.1038/sj.onc.1206879; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Kadomatsu KJ, 2004, CANCER LETT, V204, P127, DOI 10.1016/S0304-3835(03)00450-6; Kim YH, 2003, APPL MICROBIOL BIOT, V63, P75, DOI 10.1007/s00253-003-1332-5; KOMURO H, 1994, MED PEDIATR ONCOL, V23, P487, DOI 10.1002/mpo.2950230607; LAAROUBI K, 1994, GROWTH FACTORS, V10, P89, DOI 10.3109/08977199409010982; Li XG, 1996, ANN NY ACAD SCI, V803, P111, DOI 10.1111/j.1749-6632.1996.tb26381.x; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; Liu R, 1999, AM J PATHOL, V155, P1861, DOI 10.1016/S0002-9440(10)65505-8; Lock RB, 1996, CANCER RES, V56, P4006; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; MILNER PG, 1989, BIOCHEM BIOPH RES CO, V165, P1096, DOI 10.1016/0006-291X(89)92715-0; NAKAGAWARA A, 1995, CANCER RES, V55, P1792; Papadimitriou E, 2001, BIOCHEM BIOPH RES CO, V282, P306, DOI 10.1006/bbrc.2001.4574; Polykratis A, 2004, INT J BIOCHEM CELL B, V36, P1954, DOI 10.1016/j.biocel.2004.02.012; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; Ries L.A.G., 1999, CANC INCIDENCE SURVI; Rubin EH, 1996, CANC TREAT RES, V87, P243; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; TEICHER BA, 1995, ONCOL RES, V7, P237; TEICHER BA, 1990, SCIENCE, V247, P1457, DOI 10.1126/science.2108497; Thompson J, 1997, ANTI-CANCER DRUG, V8, P313, DOI 10.1097/00001813-199704000-00002; Thompson J, 1997, CLIN CANCER RES, V3, P423; Vassal G, 1996, BRIT J CANCER, V74, P537, DOI 10.1038/bjc.1996.398; Vassal G, 2003, J CLIN ONCOL, V21, P3844, DOI 10.1200/JCO.2003.08.175; Vassal G, 1997, EUR J CANCER, V33, P2011, DOI 10.1016/S0959-8049(97)00296-7; Vassal G, 2002, MED PEDIATR ONCOL, V39, P257; Wildiers H, 2003, BRIT J CANCER, V88, P1979, DOI 10.1038/sj.bjc.6601005	46	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3150	3159		10.1038/sj.onc.1209348	http://dx.doi.org/10.1038/sj.onc.1209348			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16501609				2022-12-28	WOS:000237951000006
J	Taube, ME; Liu, XW; Fridman, R; Kim, HRC				Taube, M. E.; Liu, X-W; Fridman, R.; Kim, H-RC			TIMP-1 regulation of cell cycle in human breast epithelial cells via stabilization of p27(KIP1) protein	ONCOGENE			English	Article						TIMP-1; cell cycle; p27(KIP1); apoptosis	ERYTHROID-POTENTIATING ACTIVITY; TISSUE INHIBITOR; RETINOBLASTOMA PROTEIN; EXTRACELLULAR-MATRIX; GROWTH-FACTOR; METALLOPROTEINASES-1 TIMP-1; BRANCHING MORPHOGENESIS; SIGNAL-TRANSDUCTION; LIVER FIBROSIS; MAMMARY-GLAND	Increasing evidence suggests that tissue inhibitor of metalloproteinases-1 (TIMP-1) can directly regulate cell growth and apoptosis independent of its matrix metalloproteinases (MMPs)-inhibitory activity. While TIMP-1's antiapoptotic activity has been well demonstrated, con. flicting data has been reported regarding TIMP-1's role in growth regulation. Here we show that TIMP-1 reduces the growth rate of human breast epithelial (MCF10A)cells by inducing cell cycle arrest at G(1). TIMP-1-mediated cell cycle arrest is associated with its downregulation of cyclin D-1 and upregulation of p27(KIP1), resulting in inhibition of cyclin-dependent kinase activity necessary for phosphorylation of the tumor suppressor retinoblastoma protein. We further show that TIMP-1 modulation of cyclin D1 and p27KIP1 is achieved through TIMP-1-mediated differential regulation of protein stability independent of growth factor signaling. We also show that TIMP-1-mediated differential regulation of cyclin D1 and p27KIP1 is independent of cell adhesion signaling. Whereas approximately 50% of MCF10A cells with reduced TIMP-1 expression underwent cell death following loss of cell adhesion (anoikis), TIMP-1 overexpressing cells remained viable with prominent cell cycle arrest without detectable cell death. Taken together, we propose that TIMP-1-mediated cell survival independent of cell adhesion is accompanied with cell cycle arrest in human breast epithelial cells, although cell cycle regulation may not be a prerequisite for TIMP-1 regulation of apoptosis in general.	Wayne State Univ, Sch Med, Dept Pathol, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Kim, HRC (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, Barbara Ann Karmanos Canc Inst, 540 E Canfield Ave, Detroit, MI 48201 USA.	hrckim@med.wayne.edu			NCI NIH HHS [CA89113] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089113] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander CM, 1996, J CELL BIOL, V135, P1669, DOI 10.1083/jcb.135.6.1669; AVALOS BR, 1988, BLOOD, V71, P1720; BARCELLOSHOFF MH, 1989, DEVELOPMENT, V105, P223; BERTAUX B, 1991, J INVEST DERMATOL, V97, P679, DOI 10.1111/1523-1747.ep12483956; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DECLERCK YA, 1992, CANCER RES, V52, P701; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; DULBECCO R, 1986, CANCER RES, V46, P2449; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Fata JE, 1999, DEV BIOL, V211, P238, DOI 10.1006/dbio.1999.9313; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GASSON JC, 1985, NATURE, V315, P768, DOI 10.1038/315768a0; GOLDE DW, 1980, P NATL ACAD SCI-BIOL, V77, P593, DOI 10.1073/pnas.77.1.593; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; Guedez L, 1998, BLOOD, V92, P1342, DOI 10.1182/blood.V92.4.1342.416k22_1342_1349; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; Henriet P, 2000, P NATL ACAD SCI USA, V97, P10026, DOI 10.1073/pnas.170290997; Henriet P, 1999, APMIS, V107, P111, DOI 10.1111/j.1699-0463.1999.tb01533.x; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lee SJ, 2003, BIOCHEM BIOPH RES CO, V312, P1196, DOI 10.1016/j.bbrc.2003.11.050; Lelievre S, 1996, RECENT PROG HORM RES, V51, P417; Li GY, 1999, CANCER RES, V59, P6267; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Liu XW, 2005, CANCER RES, V65, P898; Liu XW, 2003, J BIOL CHEM, V278, P40364, DOI 10.1074/jbc.M302999200; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; McCarthy K, 1999, INT J CANCER, V84, P44, DOI 10.1002/(SICI)1097-0215(19990219)84:1<44::AID-IJC9>3.3.CO;2-G; Mohammed FF, 2005, HEPATOLOGY, V41, P857, DOI 10.1002/hep.20618; MONTGOMERY AMP, 1994, CANCER RES, V54, P5467; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; Murphy FR, 2002, J BIOL CHEM, V277, P11069, DOI 10.1074/jbc.M111490200; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Porter JF, 2004, BRIT J CANCER, V90, P463, DOI 10.1038/sj.bjc.6601533; Ree AH, 1997, CLIN CANCER RES, V3, P1623; ROSKELLEY CD, 1994, P NATL ACAD SCI USA, V91, P12378, DOI 10.1073/pnas.91.26.12378; Schmidt J W, 1993, Semin Cell Biol, V4, P161, DOI 10.1006/scel.1993.1020; Schrohl AS, 2004, CLIN CANCER RES, V10, P2289, DOI 10.1158/1078-0432.CCR-03-0360; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; Wiseman BS, 2003, J CELL BIOL, V162, P1123, DOI 10.1083/jcb.200302090; Yoshiji H, 2002, HEPATOLOGY, V36, P850, DOI 10.1053/jhep.2002.35625; Yoshiji H, 1996, INT J CANCER, V69, P131, DOI 10.1002/(SICI)1097-0215(19960422)69:2<131::AID-IJC11>3.0.CO;2-C	53	46	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					3041	3048		10.1038/sj.onc.1209336	http://dx.doi.org/10.1038/sj.onc.1209336			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16407831				2022-12-28	WOS:000237950800008
J	Togashi, Y; Kobayashi, T; Momose, S; Ueda, M; Okimoto, K; Hino, O				Togashi, Y.; Kobayashi, T.; Momose, S.; Ueda, M.; Okimoto, K.; Hino, O.			Transgenic rescue from embryonic lethality and renal carcinogenesis in the Nihon rat model by introduction of a wild-type Bhd gene	ONCOGENE			English	Article						renal carcinoma; Bhd gene; Nihon rat; transgenic rescue	EKER RAT; PREDISPOSING GENE; CARCINOMA; MUTATIONS; INSERTION; TUMORS; RISE	We recently reported that a germline insertion of a single nucleotide in the rat homologue of the human Birt - Hogg Dube ' gene ( BHD) gives rise to dominantly inherited cancer in the Nihon rat model. In this study, we constructed transgenic Nihon rats with introduction of a wild- type Bhd gene to ascertain whether suppression of the Nihon phenotype is possible. Rescue from embryonic lethality of mutant homozygotes ( Nihon/ Nihon) and suppression of renal carcinogenesis in heterozygotes ( Nihon/ +) were both observed, de. ning the germline Bhd mutation in the Nihon rat as an embryonal lethal and tumor predisposing mutation. This transgenic rescue system will be useful to analyse Bhd gene function, its relation to tumorigenesis in vivo, and genetic - environmental interactions in carcinogenesis.	Juntendo Univ, Sch Med, Dept Pathol, Bunkyo Ku, Tokyo 1138421, Japan; YS Inst Inc, Utsunomiya, Tochigi, Japan; Dainippon Pharmaceut Co Ltd, Toxicol Grp, Safety Res Labs, Suita, Osaka 564, Japan	Juntendo University; Dainippon Sumitomo Pharmaceutical Company	Hino, O (corresponding author), Juntendo Univ, Sch Med, Dept Pathol, Bunkyo Ku, Tokyo 1138421, Japan.	ohino@med.juntendo.ac.jp						BIRT AR, 1977, ARCH DERMATOL, V113, P1674, DOI 10.1001/archderm.113.12.1674; EKER R, 1961, NATURE, V189, P858, DOI 10.1038/189858b0; HINO O, 1993, P NATL ACAD SCI USA, V90, P327, DOI 10.1073/pnas.90.1.327; HINO O, 1994, BIOCHEM BIOPH RES CO, V203, P1302, DOI 10.1006/bbrc.1994.2324; Hino O, 2001, JPN J CANCER RES, V92, P1147, DOI 10.1111/j.1349-7006.2001.tb02133.x; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P3990, DOI 10.1073/pnas.94.8.3990; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; Majima S, 2000, JPN J CANCER RES, V91, P869, DOI 10.1111/j.1349-7006.2000.tb01027.x; Momose S, 2002, HUM MOL GENET, V11, P2997, DOI 10.1093/hmg/11.24.2997; Nickerson ML, 2002, CANCER CELL, V2, P157, DOI 10.1016/S1535-6108(02)00104-6; Okimoto K, 2004, CURR MOL MED, V4, P887, DOI 10.2174/1566524043359737; Okimoto K, 2004, P NATL ACAD SCI USA, V101, P2023, DOI 10.1073/pnas.0308071100; Okimoto K, 2000, JPN J CANCER RES, V91, P1096, DOI 10.1111/j.1349-7006.2000.tb00890.x; Satake N, 1999, CANCER RES, V59, P849; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413	15	10	10	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2885	2889		10.1038/sj.onc.1209317	http://dx.doi.org/10.1038/sj.onc.1209317			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16369488				2022-12-28	WOS:000237448200006
J	Copland, JA; Marlow, LA; Kurakata, S; Fujiwara, K; Wong, AKC; Kreinest, PA; Williams, SF; Haugen, BR; Klopper, JP; Smallridge, RC				Copland, JA; Marlow, LA; Kurakata, S; Fujiwara, K; Wong, AKC; Kreinest, PA; Williams, SF; Haugen, BR; Klopper, JP; Smallridge, RC			Novel high-affinity PPAR gamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21(WAF1/CIP1)	ONCOGENE			English	Article						peroxisome proliferator-activated receptor gamma; paclitaxel; anaplastic thyroid carcinoma; RS5444; p21(WAF1/CIP1); combinatorial therapy; thiazolidinedione	ACTIVATED-RECEPTOR-GAMMA; PANCREATIC-CANCER CELLS; IN-VITRO; DIFFERENTIATION MARKERS; INDEPENDENT GROWTH; PROSTATE-CANCER; GENE-EXPRESSION; CYCLE ARREST; APOPTOSIS; LIGANDS	Peroxisome proliferator-activated receptor gamma (PPARc) agonists demonstrate antitumor activity likely through transactivating genes that regulate cell proliferation, apoptosis, and differentiation. The PAX8/PPARc fusion oncogene, which is common in human follicular thyroid carcinomas appears to act via dominant negative suppression of wild-type PPARc, suggesting that it may be a tumor suppressor gene in thyroid cells. We have identified a novel high-affinity PPARc agonist (RS5444) that is dependent upon PPARc for its biological activity. This is the first report of this molecule and its antitumor activity. In vitro, the IC50 for growth inhibition is similar to 0.8 nM while anaplastic thyroid carcinoma (ATC) tumor growth was inhibited three-to fourfold in nude mice. siRNA against PPARc and a pharmacological antagonist demonstrated that functional PPARc was required for growth inhibitory activity of RS5444. RS5444 upregulated the cell cycle kinase inhibitor, p21(WAF1/CIP1). Silencing p21(WAF1CIP1) rendered cells insensitive to RS5444. RS5444 plus paclitaxel demonstrated additive antiproliferative activity in cell culture and minimal ATC tumor growth in vivo. RS5444 did not induce apoptosis but combined with paclitaxel, doubled the apoptotic index compared to that of paclitaxel. Our data indicate that functional PPARc is a molecular target for therapy in ATC. We demonstrated that RS5444, a thiazolidinedione (Tzd) derivative, alone or in combination with paclitaxel, may provide therapeutic benefit to patients diagnosed with ATC.	Mayo Clin, Coll Med, Dept Canc Biol, Ctr Comprehens Canc, Jacksonville, FL 33224 USA; Sankyo Pharma Res Inst, La Jolla, CA USA; Sankyo Co Ltd, Shinagawa Ku, Tokyo 140, Japan; Sankyo Pharma Res Inst, La Jolla, CA USA; Mayo Clin, Coll Med, Dept Internal Med, Div Endocrinol, Jacksonville, FL 33224 USA; Univ Colorado, Ctr Canc, Dept Med, Div Endocrinol Diabet & Metab, Denver, CO 80262 USA; Hlth Sci Ctr, Aurora, CO USA	Mayo Clinic; Daiichi Sankyo Company Limited; Mayo Clinic; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Copland, JA (corresponding author), Mayo Clin, Coll Med, Dept Canc Biol, Ctr Comprehens Canc, 4500 San Pablo Rd, Jacksonville, FL 33224 USA.	copland.john@mayo.edu		Marlow, Laura/0000-0002-4726-9889	NCI NIH HHS [P30CA15083, CA100560] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA015083, R01CA100560] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ain KB, 1996, J CLIN ENDOCR METAB, V81, P3650, DOI 10.1210/jc.81.10.3650; Ain KB, 2000, THYROID, V10, P587, DOI 10.1089/thy.2000.10.587; Aldred MA, 2003, ONCOGENE, V22, P3412, DOI 10.1038/sj.onc.1206400; Barboule N, 1997, ONCOGENE, V15, P2867, DOI 10.1038/sj.onc.1201469; Bauer AJ, 2002, THYROID, V12, P953, DOI 10.1089/105072502320908286; Belletti B, 1999, ONCOGENE, V18, P4860, DOI 10.1038/sj.onc.1202869; Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1; Castrillo A, 2001, J BIOL CHEM, V276, P34082, DOI 10.1074/jbc.M102472200; Chang TH, 2000, CANCER RES, V60, P1129; Chang TH, 2002, CLIN CANCER RES, V8, P1206; Chen F, 2005, CELL SIGNAL, V17, P809, DOI 10.1016/j.cellsig.2004.11.002; Chung SH, 2002, JPN J CANCER RES, V93, P1358, DOI 10.1111/j.1349-7006.2002.tb01245.x; Davies GF, 2002, J PHARMACOL EXP THER, V300, P72, DOI 10.1124/jpet.300.1.72; de la Lastra CA, 2004, CURR PHARM DESIGN, V10, P3505; Debril MB, 2001, J MOL MED, V79, P30, DOI 10.1007/s001090000145; Dwight T, 2003, J CLIN ENDOCR METAB, V88, P4440, DOI 10.1210/jc.2002-021690; Eibl G, 2001, BIOCHEM BIOPH RES CO, V287, P522, DOI 10.1006/bbrc.2001.5619; Elnemr A, 2000, INT J ONCOL, V17, P1157; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; Fujiwara T, 2000, LIFE SCI, V67, P2405, DOI 10.1016/S0024-3205(00)00829-8; Fujiwara T, 1998, LIFE SCI, V63, P2039, DOI 10.1016/S0024-3205(98)00482-2; Galli A, 2004, GUT, V53, P1688, DOI 10.1136/gut.2003.031997; Girnun GD, 2003, GASTROENTEROLOGY, V124, P564, DOI 10.1053/gast.2003.50070; Guan You-Fei, 1999, Neoplasia (New York), V1, P330, DOI 10.1038/sj.neo.7900050; Han SW, 2004, CLIN CANCER RES, V10, P1911, DOI 10.1158/1078-0432.CCR-03-0985; Hayashi N, 2004, INT J ONCOL, V24, P89; Hong J, 2004, ENDOCRINOLOGY, V145, P5774, DOI 10.1210/en.2004-0686; Huang JW, 2005, MOL PHARMACOL, V67, P1342, DOI 10.1124/mol.104.007732; Itami A, 2001, INT J CANCER, V94, P370, DOI 10.1002/ijc.1488; Kawa S, 2002, PANCREAS, V24, P1, DOI 10.1097/00006676-200201000-00001; Kim S, 2005, MOL CANCER THER, V4, P632, DOI 10.1158/1535-7163.MCT-04-0293; Kitamura S, 1999, JPN J CANCER RES, V90, P75, DOI 10.1111/j.1349-7006.1999.tb00668.x; Klopper JP, 2004, MOL CANCER THER, V3, P1011; Koeffler HP, 2003, CLIN CANCER RES, V9, P1; Koga H, 2001, HEPATOLOGY, V33, P1087, DOI 10.1053/jhep.2001.24024; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Kubota T, 1998, CANCER RES, V58, P3344; Li WW, 1999, MOL PHARMACOL, V55, P1088, DOI 10.1124/mol.55.6.1088; Lovekamp-Swan T, 2005, MOL CELL ENDOCRINOL, V233, P15, DOI 10.1016/j.mce.2005.01.011; Lu ML, 2005, J BIOL CHEM, V280, P6742, DOI 10.1074/jbc.M411519200; Lui WO, 2005, ONCOGENE, V24, P1467, DOI 10.1038/sj.onc.1208135; Margeli A., 2003, Angiogenesis, V6, P165, DOI 10.1023/B:AGEN.0000021377.13669.c0; Martelli ML, 2002, J CLIN ENDOCR METAB, V87, P4728, DOI 10.1210/jc.2001-012054; McIver Bryan, 2004, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V4, P221, DOI 10.2174/1568008043339802; Motomura W, 2000, CANCER RES, V60, P5558; Nakajima A, 2001, GASTROENTEROLOGY, V120, P460, DOI 10.1053/gast.2001.21191; Nakashiro K, 2001, AM J PATHOL, V159, P591, DOI 10.1016/S0002-9440(10)61730-0; Palakurthi SS, 2001, CANCER RES, V61, P6213; Panigrahy D, 2003, EXPERT OPIN INV DRUG, V12, P1925, DOI 10.1517/13543784.12.12.1925; Panigrahy D, 2002, J CLIN INVEST, V110, P923, DOI 10.1172/JCI200215634; Pei XH, 2005, ONCOGENE, V24, P2787, DOI 10.1038/sj.onc.1208611; Perez-Ortiz JM, 2004, J BIOL CHEM, V279, P8976, DOI 10.1074/jbc.M308518200; Place AE, 2003, CLIN CANCER RES, V9, P2798; Powell JG, 2004, ONCOGENE, V23, P3634, DOI 10.1038/sj.onc.1207399; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Rumi MAK, 2004, GENES CELLS, V9, P1113, DOI 10.1111/j.1365-2443.2004.00793.x; Sato K, 2001, ENDOCR J, V48, P635, DOI 10.1507/endocrj.48.635; Schmidt M, 2000, ONCOGENE, V19, P2423, DOI 10.1038/sj.onc.1203546; Sherman SI, 2003, LANCET, V361, P501, DOI 10.1016/S0140-6736(03)12488-9; Shiau CW, 2005, CANCER RES, V65, P1561, DOI 10.1158/0008-5472.CAN-04-1677; Smith WM, 2001, HUM GENET, V109, P146, DOI 10.1007/s004390100563; TAKASHIMA T, 2001, TRENDS MOL MED, V7, P395; Tsubouchi Y, 2000, BIOCHEM BIOPH RES CO, V270, P400, DOI 10.1006/bbrc.2000.2436; Turturro F, 2004, CLIN CANCER RES, V10, P7022, DOI 10.1158/1078-0432.CCR-04-0879; Vogt T, 2003, CANCER, V98, P2251, DOI 10.1002/cncr.11775; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116; Xu GP, 2001, J CLIN ENDOCR METAB, V86, P1769, DOI 10.1210/jc.86.4.1769; Yang HL, 2003, J CLIN ENDOCR METAB, V88, P763, DOI 10.1210/jc.2002-020992; Yang WC, 2005, AM J PATHOL, V166, P1239, DOI 10.1016/S0002-9440(10)62342-5; Yang WL, 2001, CARCINOGENESIS, V22, P1379, DOI 10.1093/carcin/22.9.1379; Yeung SCJ, 2000, CANCER RES, V60, P650; Yin F, 2001, BIOCHEM BIOPH RES CO, V286, P916, DOI 10.1006/bbrc.2001.5491; Yin F, 2004, ONCOGENE, V23, P4614, DOI 10.1038/sj.onc.1207598; Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001; Yuan JY, 2005, UROLOGY, V65, P594, DOI 10.1016/j.urology.2004.10.019	77	120	128	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2304	2317		10.1038/sj.onc.1209267	http://dx.doi.org/10.1038/sj.onc.1209267			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16331265				2022-12-28	WOS:000236764300003
J	Carmagnat, M; Drenou, B; Chahal, H; Lord, JM; Charron, D; Estaquier, J; Mooney, NA				Carmagnat, M; Drenou, B; Chahal, H; Lord, JM; Charron, D; Estaquier, J; Mooney, NA			Dissociation of caspase-mediated events and programmed cell death induced via HLA-DR in follicular lymphoma	ONCOGENE			English	Article						MHC class II; apoptosis; signalling	PROTEIN-KINASE-C; LYMPHOCYTIC-LEUKEMIA CELLS; INDUCED APOPTOSIS; PROTEOLYTIC ACTIVATION; MONOCLONAL-ANTIBODIES; CROSS-LINKING; IN-VITRO; B-CELLS; DELTA; TRANSLOCATION	Human leukocyte antigens (HLA) class II antigen-mediated apoptosis has been documented in antigenpresenting cells and B lymphoproliferations. Characteristics of the apoptosis include rapidity and selectivity for mature cells. Follicular lymphomas are particularly refractory to apoptosis. The B-cell lymphoma Ramos shares characteristics of this subgroup and is insensitive to apoptosis via simple HLA-DR engagement. However, oligomerization of HLA-DR antigens induced caspase activation followed byphosphatidylserine externalization, activation of PKC-delta and cleavage of nuclear lamin B. Mitochondrial injury was also detected. However, inhibition of caspase activation simply delayed the apoptotic phenotype but neither protected against cell death nor prevented mitochondrial injury. The data in this report demonstrate that the requirements for the initiating signal ( oligomerization versus engagement) as well as the molecular pathways varies between different B lymphoproliferations despite their common expression of HLADR. Finally, blockade of caspase activation in parallel with HLA-DR mAb stimulation could provide a potent autovaccination stimulus by leading to necrotic death of B-cell lymphomas.	Inst Univ Hematol, Hop St Louis, INSERM U662, F-75010 Paris, France; Hop St Louis, AP HP, Serv Immunol & Histocompatibil, Paris, France; CHU Rennes, Hop Pontchaillou, Lab Hematol, Rennes, France; Univ Birmingham, Sch Med, Dept Immunol, Birmingham, W Midlands, England; Inst Pasteur, Unite Physiopathol Infect Lentivirales, Paris, France; Univ Paris 06, Fac Med, Inst Hematol, Ctr Hayem, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Rennes; University of Birmingham; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Mooney, NA (corresponding author), Inst Univ Hematol, Hop St Louis, INSERM U662, F-75010 Paris, France.	nuala.mooney@histo.chu-stlouis.fr	, ESTAQUIER/AAR-7799-2020	, ESTAQUIER/0000-0002-9432-8044; Lord, Janet/0000-0003-1030-6786; Mooney, Nuala/0000-0002-3516-6882	Medical Research Council [G9818340B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Besnault L, 2001, J IMMUNOL, V167, P733, DOI 10.4049/jimmunol.167.2.733; BRICKGHANNAM C, 1991, J BIOL CHEM, V266, P24169; BRICKGHANNAM C, 1994, HUM IMMUNOL, V41, P216, DOI 10.1016/0198-8859(94)90039-6; CHAOUCHI N, 1995, J IMMUNOL, V154, P3096; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; Drenou B, 1999, J IMMUNOL, V163, P4115; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Funakoshi S, 1997, BLOOD, V90, P3160, DOI 10.1182/blood.V90.8.3160; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; Huby RDJ, 1999, J BIOL CHEM, V274, P22591, DOI 10.1074/jbc.274.32.22591; Inman GJ, 2000, J IMMUNOL, V165, P2500, DOI 10.4049/jimmunol.165.5.2500; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; Leveille C, 1999, INT IMMUNOL, V11, P719, DOI 10.1093/intimm/11.5.719; Leverkus M, 2003, INT IMMUNOL, V15, P993, DOI 10.1093/intimm/dxg099; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; McLellan AD, 2000, CELL DEATH DIFFER, V7, P933, DOI 10.1038/sj.cdd.4400734; Mecklenbrauker I, 2002, NATURE, V416, P860, DOI 10.1038/416860a; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Mone AP, 2004, BLOOD, V103, P1846, DOI 10.1182/blood-2003-08-2836; Nagy ZA, 2002, NAT MED, V8, P801, DOI 10.1038/nm736; Pedersen IM, 2002, BLOOD, V99, P1314, DOI 10.1182/blood.V99.4.1314; Rich T, 1997, J IMMUNOL, V159, P3792; Scheel-Toellner D, 1999, EUR J IMMUNOL, V29, P2603, DOI 10.1002/(SICI)1521-4141(199908)29:08<2603::AID-IMMU2603>3.0.CO;2-L; Setterblad N, 2004, J LEUKOCYTE BIOL, V75, P1036, DOI 10.1189/jlb.0703356; Truman JP, 1996, EXP HEMATOL, V24, P1409; Webb PR, 2000, APOPTOSIS, V5, P451, DOI 10.1023/A:1009601220552; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378	30	7	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1914	1921		10.1038/sj.onc.1209222	http://dx.doi.org/10.1038/sj.onc.1209222			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16301998				2022-12-28	WOS:000236224800008
J	Mahtouk, K; Cremer, FW; Reme, T; Jourdan, M; Baudard, M; Moreaux, J; Requirand, G; Fiol, G; De Vos, J; Moos, M; Quittet, P; Goldschmidt, H; Rossi, JF; Hose, D; Klein, B				Mahtouk, K.; Cremer, F. W.; Reme, T.; Jourdan, M.; Baudard, M.; Moreaux, J.; Requirand, G.; Fiol, G.; De Vos, J.; Moos, M.; Quittet, P.; Goldschmidt, H.; Rossi, J-F; Hose, D.; Klein, B.			Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma	ONCOGENE			English	Article						myeloma; EGF-family; neuregulin; syndecan-1; heparin	MALIGNANT PLASMA-CELLS; BLOOD B-CELLS; BONE-MARROW; NORMAL COUNTERPART; ERBB RECEPTORS; BINDING; SYNDECAN-1; INTERLEUKIN-6; SURVIVAL; PROLIFERATION	The epidermal growth factor (EGF)/EGF-receptor (ErbB1-4) family is involved in the biology of multiple myeloma (MM). In particular, ErbB-specific inhibitors induce strong apoptosis of myeloma cells (MMC) in vitro. To delineate the contribution of the 10 EGF-family ligands to the pathogenesis of MM, we have assessed their expression and biological activity. Comparing Affymetrix DNA-microarray-expression-profiles of CD138-purified plasma-cells from 65 MM-patients and 7 normal individuals to those of plasmablasts and B-cells, we found 5/10 EGF-family genes to be expressed in MMC. Neuregulin-2 and neuregulin-3 were expressed by MMC only, while neuregulin-1, amphiregulin and transforming growth factor-alpha were expressed by both MMC and normal plasma-cells. Using real-time polymerase chain reaction, we found HB-EGF, amphiregulin, neuregulin1 and epiregulin to be expressed by cells from the bone marrow-environment. Only the EGF-members able to bind heparan-sulphate proteoglycans (HSPGs) neuregulin-1, amphiregulin, HB-EGF -promote the growth of MMC. Those ligands strongly bind MMC through HSPGs. The binding and the MMC growth activity was abrogated by heparitinase, heparin or deletion of the HS-binding domain. The number of HS-binding EGF ligand molecules bound to MMC was higher than 10(5) molecules/cell and paralleled that of syndecan-1. Syndecan-1, the main HSPG present on MM cells, likely concentrates high levels of HS-binding-EGF-ligands at the cell membrane and facilitates ErbB-activation. Altogether, our data further identify EGF-signalling as promising target for MM-therapy.	INSERM U475, F-34197 Montpellier, France; CHU Montpellier, Inst Res Biotherapy, Montpellier, France; Univ Klinikum Heidelberg, Med Klin & Poliklin 5, INF410, Heidelberg, Germany; CHU Montpellier, Dept Clin Hematol, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Ruprecht Karls University Heidelberg; Universite de Montpellier; CHU de Montpellier	Klein, B (corresponding author), INSERM U475, 99 Rue Puech Villa, F-34197 Montpellier, France.	klein@montp.inserm.fr	moreaux, jerome/HGA-5649-2022; De Vos, John/A-5703-2010; J, Moreaux/ABA-2974-2021	De Vos, John/0000-0003-1880-4130; J, Moreaux/0000-0002-5717-3207				Bayer-Garner IB, 2001, MODERN PATHOL, V14, P1052, DOI 10.1038/modpathol.3880435; Belting M, 2003, TRENDS BIOCHEM SCI, V28, P145, DOI 10.1016/S0968-0004(03)00031-8; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Borset M, 2000, BLOOD, V96, P2528; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Citri A, 2003, EXP CELL RES, V284, P54, DOI 10.1016/S0014-4827(02)00101-5; Costes V, 1999, HUM PATHOL, V30, P1405, DOI 10.1016/S0046-8177(99)90160-0; Couchman JR, 2003, NAT REV MOL CELL BIO, V4, P926, DOI 10.1038/nrm1257; De Vos J, 2001, BLOOD, V98, P771, DOI 10.1182/blood.V98.3.771; Derksen PWB, 2002, BLOOD, V99, P1405, DOI 10.1182/blood.V99.4.1405; Dhodapkar MV, 1997, BRIT J HAEMATOL, V99, P368, DOI 10.1046/j.1365-2141.1997.3893203.x; Ferlin M, 2000, BRIT J HAEMATOL, V111, P626, DOI 10.1046/j.1365-2141.2000.02364.x; GeorgiiHemming P, 1996, BLOOD, V88, P2250, DOI 10.1182/blood.V88.6.2250.bloodjournal8862250; Goger B, 2002, BIOCHEMISTRY-US, V41, P1640, DOI 10.1021/bi011944j; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Hendriks J, 2005, CELL DEATH DIFFER, V12, P637, DOI 10.1038/sj.cdd.4401647; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Ingold K, 2005, J EXP MED, V201, P1375, DOI 10.1084/jem.20042309; Jelinek DF, 1997, J IMMUNOL, V159, P487; JOHNSON GR, 1994, J BIOL CHEM, V269, P27149; KAREY KP, 1988, CANCER RES, V48, P4083; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Klein B, 2003, INT J HEMATOL, V78, P106, DOI 10.1007/BF02983377; KLEIN B, 1989, BLOOD, V73, P517; Klein B, 1999, CURR TOP MICROBIOL, V246, P335; Klerk CPW, 2005, J CLIN ONCOL, V23, P2130, DOI 10.1200/JCO.2005.03.134; Kragh M, 2005, INT J ONCOL, V27, P1159; Kumar A, 2003, LANCET ONCOL, V4, P293, DOI 10.1016/S1470-2045(03)01077-5; Liu WM, 2002, BIOINFORMATICS, V18, P1593, DOI 10.1093/bioinformatics/18.12.1593; LOEB JA, 1995, J CELL BIOL, V130, P127, DOI 10.1083/jcb.130.1.127; Mahtouk K, 2005, ONCOGENE, V24, P3512, DOI 10.1038/sj.onc.1208536; Mahtouk K, 2004, BLOOD, V103, P1829, DOI 10.1182/blood-2003-05-1510; Moreaux J, 2004, BLOOD, V103, P3148, DOI 10.1182/blood-2003-06-1984; Mummery RS, 2000, J IMMUNOL, V165, P5671, DOI 10.4049/jimmunol.165.10.5671; Paria BC, 1999, DEVELOPMENT, V126, P1997; Rapraeger AC, 2000, J CELL BIOL, V149, P995, DOI 10.1083/jcb.149.5.995; Rebouissou C, 1998, BLOOD, V91, P4727, DOI 10.1182/blood.V91.12.4727.412k35_4727_4737; Sanderson RD, 2004, MATRIX BIOL, V23, P341, DOI 10.1016/j.matbio.2004.08.004; Seidel C, 2000, BLOOD, V95, P388, DOI 10.1182/blood.V95.2.388; Seidel C, 2000, BLOOD, V96, P3139, DOI 10.1182/blood.V96.9.3139.h8003139_3139_3146; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Sun RX, 1997, J IMMUNOL METHODS, V205, P73, DOI 10.1016/S0022-1759(97)00056-2; Tarte K, 2002, BLOOD, V100, P1113, DOI 10.1182/blood.V100.4.1113.h81602001113_1113_1122; Tarte K, 2000, BLOOD, V96, p514A; Van Driel M, 2002, LEUKEMIA, V16, P135, DOI 10.1038/sj.leu.2402336; Wang YD, 2002, ONCOGENE, V21, P2584, DOI 10.1038/sj.onc.1205355; Wijdenes J, 1996, BRIT J HAEMATOL, V94, P318, DOI 10.1046/j.1365-2141.1996.d01-1811.x; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562; ZHANG XG, 1994, BLOOD, V83, P3654	51	73	75	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	54					7180	7191		10.1038/sj.onc.1209699	http://dx.doi.org/10.1038/sj.onc.1209699			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16732320	Green Accepted, Green Submitted			2022-12-28	WOS:000242046900007
J	Smith, APL; Henze, M; Lee, JA; Osborn, KG; Keck, JM; Tedesco, D; Bortner, DM; Rosenberg, MP; Reed, SI				Smith, A. P. L.; Henze, M.; Lee, J. A.; Osborn, K. G.; Keck, J. M.; Tedesco, D.; Bortner, D. M.; Rosenberg, M. P.; Reed, S. I.			Deregulated cyclin E promotes p53 loss of heterozygosity and tumorigenesis in the mouse mammary gland	ONCOGENE			English	Article						cyclin E; mammary tumorigenesis; genomic instability; p53; loss of heterozygosity	T-CELL LYMPHOMAGENESIS; WILD-TYPE P53; BREAST-CANCER; TRANSGENIC MICE; CHROMOSOMAL INSTABILITY; ENDOMETRIAL CANCER; PHASE-TRANSITION; E OVEREXPRESSION; GENE-EXPRESSION; ACTIVATION	Deregulation of cyclin E expression and/or high levels have been reported in a variety of tumors and have been used as indicators of poor prognosis. Although the role that cyclin E plays in tumorigenesis remains unclear, there is evidence that it confers genomic instability when deregulated in cultured cells. Here we show that deregulated expression of a hyperstable allele of cyclin E in mice heterozygous for p53 synergistically increases mammary tumorigenesis more than that in mice carrying either of these markers individually. Most tumors and tumor-derived cell lines demonstrated loss of p53 heterozygosity. Furthermore, this tumor susceptibility is related to the number of times the transgene is induced indicating that it is directly attributable to the expression of the cyclin E transgene. An indirect assay indicates that loss of p53 function is an early event occurring in the mammary epithelia of midlactation mammary glands in which cyclin E is deregulated long before evidence of malignancy. These data support the hypothesis that deregulated expression of cyclin E stimulates p53 loss of heterozygosity by promoting genomic instability and provides specific evidence for this in vivo. Cyclin E deregulation and p53 loss are characteristics often observed in human breast carcinoma.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Rotherham Gen Hosp, Dept Histopathol, Rotherham, S Yorkshire, England; Scripps Res Inst, Dept Anim Resources, La Jolla, CA 92037 USA; GlaxoSmithKline, Res Triangle Pk, NC USA	Scripps Research Institute; Scripps Research Institute; GlaxoSmithKline	Reed, SI (corresponding author), Scripps Res Inst, Dept Mol Biol, MB7,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	sreed@scripps.edu		Smith, Adrian/0000-0001-9732-1422	NCI NIH HHS [R01-CA78343] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078343] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bieche I, 2002, BRIT J CANCER, V86, P580, DOI 10.1038/sj.bjc.6600109; Blagosklonny MV, 2002, CELL CYCLE, V1, P103, DOI 10.4161/cc.1.2.108; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; Calhoun ES, 2003, AM J PATHOL, V163, P1255, DOI 10.1016/S0002-9440(10)63485-2; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Covini G, 1997, HEPATOLOGY, V25, P75; Cui XS, 2000, ONCOGENE, V19, P5988, DOI 10.1038/sj.onc.1203993; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Geisen C, 2003, ONCOGENE, V22, P1724, DOI 10.1038/sj.onc.1206340; Geisen C, 2002, J BIOL CHEM, V277, P39909, DOI 10.1074/jbc.M205919200; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hamilton AS, 2003, NEW ENGL J MED, V348, P2313, DOI 10.1056/NEJMoa021293; Hosokawa Y, 2001, TRANSGENIC RES, V10, P471, DOI 10.1023/A:1012064911751; Hubalek MM, 2004, ONCOGENE, V23, P4187, DOI 10.1038/sj.onc.1207560; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Karsunky H, 1999, ONCOGENE, V18, P7816, DOI 10.1038/sj.onc.1203205; Kawamura K, 2004, CANCER RES, V64, P4800, DOI 10.1158/0008-5472.CAN-03-3908; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lindahl T, 2004, CARCINOGENESIS, V25, P375, DOI 10.1093/carcin/bgh019; Loeb KR, 2005, CANCER CELL, V8, P35, DOI 10.1016/j.ccr.2005.06.010; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; MOON RC, 1969, INT J CANCER, V4, P312, DOI 10.1002/ijc.2910040308; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Park M, 2000, CANCER RES, V60, P542; Qiu J, 2003, LEUKEMIA, V17, P1891, DOI 10.1038/sj.leu.2403073; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Reed SE, 2004, CANCER RES, V64, P795, DOI 10.1158/0008-5472.CAN-03-3417; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Seghezzi W, 1998, MOL CELL BIOL, V18, P4526, DOI 10.1128/MCB.18.8.4526; Simin K, 2004, PLOS BIOL, V2, P194, DOI 10.1371/journal.pbio.0020022; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Spruck CH, 2002, CANCER RES, V62, P4535; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; SWANSON SM, 1995, CANCER LETT, V90, P171, DOI 10.1016/0304-3835(95)03712-6; THORDARSON G, 1995, CARCINOGENESIS, V16, P2847, DOI 10.1093/carcin/16.11.2847; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wei Y, 2003, MOL CELL BIOL, V23, P3669, DOI 10.1128/MCB.23.10.3669-3680.2003; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Welm BE, 2002, DEV BIOL, V245, P42, DOI 10.1006/dbio.2002.0625; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Yin XY, 2001, CANCER RES, V61, P6487; Yu M, 2002, MOL IMMUNOL, V38, P981, DOI 10.1016/S0161-5890(02)00026-3	56	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	55					7245	7259		10.1038/sj.onc.1209713	http://dx.doi.org/10.1038/sj.onc.1209713			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16751806				2022-12-28	WOS:000242244700003
J	Diry, M; Tomkiewicz, C; Koehle, C; Coumoul, X; Bock, KW; Barouki, R; Transy, C				Diry, M.; Tomkiewicz, C.; Koehle, C.; Coumoul, X.; Bock, K. Walter; Barouki, R.; Transy, C.			Activation of the dioxin/aryl hydrocarbon receptor (AhR) modulates cell plasticity through a JNK-dependent mechanism	ONCOGENE			English	Article						dioxin; Ah receptor; JNK; epithelial plasticity; cell motility; cell scattering	SIGNALING CASCADE; PROTEIN-KINASES; EXPRESSION; MOTILITY; CHEMICALS; ADHESION; ELEGANS; PATHWAY; LACKING; SEVESO	Environmental chemicals such as dioxin adversely affect immune, neurological and reproductive functions and have been implicated in cancer development. However, the mechanisms responsible for dioxin toxicity are still poorly understood. Here, we show that dioxin and related pollutants trigger a marked morphological change in epithelial cells that remodel their cytoskeleton to increase interaction with extra cellular matrix while loosening cell cell contacts. Furthermore, dioxin-treated cells show increased motility. These dioxin-mediated effects are mimicked by constitutive expression and activation of the intracellular dioxin receptor (aryl hydrocarbon receptor (AhR)). They correlate with activation of the Jun NH2-terminal kinase (JNK) and are reverted by treatment with a JNK inhibitor. Dioxin-induced effects occur 48 h post-treatment initiation, a time scale, which argues for a genomic effect of the AhR, linked to induction of target genes. This novel Ahr action on cell plasticity points to a role in cancer progression.	INSERM, U567, CNRS, Dept Malad Infect,Inst Cochin,UMR8104,UFR Biomed, F-75014 Paris, France; Univ Tubingen, Inst Toxicol, D-72074 Tubingen, Germany	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Eberhard Karls University of Tubingen	Transy, C (corresponding author), INSERM, U567, CNRS, Dept Malad Infect,Inst Cochin,UMR8104,UFR Biomed, 27 Rue Faubourg St Jacques,UMR-S 490, F-75014 Paris, France.	transy@cochin.inserm.fr	COUMOUL, Xavier/AAR-3649-2020	COUMOUL, Xavier/0000-0003-2928-9648				Baccarelli A, 2002, ENVIRON HEALTH PERSP, V110, P1169, DOI 10.1289/ehp.021101169; Coumoul X, 2001, CANCER RES, V61, P3942; Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; Fashena SJ, 2002, J CELL SCI, V115, P99; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; Foekens JA, 2000, CANCER RES, V60, P636; Frueh FW, 2001, TOXICOL LETT, V122, P189, DOI 10.1016/S0378-4274(01)00364-2; Gotzmann J, 2004, MUTAT RES-REV MUTAT, V566, P9, DOI 10.1016/S1383-5742(03)00033-4; Huang X, 2004, DEVELOPMENT, V131, P819, DOI 10.1242/dev.00959; Kohle C, 2002, ARCH BIOCHEM BIOPHYS, V402, P172, DOI 10.1016/S0003-9861(02)00076-0; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; Marchand A, 2005, MOL PHARMACOL, V67, P444, DOI 10.1124/mol.104.004010; Mulero-Navarro S, 2005, J BIOL CHEM, V280, P28731, DOI 10.1074/jbc.M504538200; Nesaretnam K, 1998, EUR J CANCER, V34, P389, DOI 10.1016/S0959-8049(97)10026-0; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Pastor-Pareja JC, 2004, DEV CELL, V7, P387, DOI 10.1016/j.devcel.2004.07.022; Pelclova D, 2001, ARCH ENVIRON HEALTH, V56, P493, DOI 10.1080/00039890109602897; Pesatori AC, 2003, IND HEALTH, V41, P127, DOI 10.2486/indhealth.41.127; Poellinger L, 2000, FOOD ADDIT CONTAM A, V17, P261, DOI 10.1080/026520300283333; Puga A, 2000, BIOCHEM PHARMACOL, V60, P1129, DOI 10.1016/S0006-2952(00)00403-2; Qin HT, 2004, DEV BIOL, V270, P64, DOI 10.1016/j.ydbio.2004.02.004; Safe S, 2003, CHEM RES TOXICOL, V16, P807, DOI 10.1021/tx034036r; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sisci D, 2004, ONCOGENE, V23, P8920, DOI 10.1038/sj.onc.1208098; Tan ZQ, 2002, BIOCHEM PHARMACOL, V64, P771, DOI 10.1016/S0006-2952(02)01138-3; Weiss C, 2005, ONCOGENE, V24, P4975, DOI 10.1038/sj.onc.1208679; Xia Y, 2004, TRENDS CELL BIOL, V14, P94, DOI 10.1016/j.tcb.2003.12.005; Yamamoto O, 2003, J DERMATOL SCI, V32, P85, DOI 10.1016/S0923-1811(03)00097-5; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927	31	103	114	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2006	25	40					5570	5574		10.1038/sj.onc.1209553	http://dx.doi.org/10.1038/sj.onc.1209553			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16619036	Green Submitted			2022-12-28	WOS:000240370400010
J	Rodriguez, JA; Lens, SMA; Span, SW; Vader, G; Medema, RH; Kruyt, FAE; Giaccone, G				Rodriguez, J. A.; Lens, S. M. A.; Span, S. W.; Vader, G.; Medema, R. H.; Kruyt, F. A. E.; Giaccone, G.			Subcellular localization and nucleocytoplasmic transport of the chromosomal passenger proteins before nuclear envelope breakdown	ONCOGENE			English	Article						Survivin; Borealin; INCENP; Aurora B; nuclear envelope breakdown; nuclear transport	B KINASE-ACTIVITY; AURORA-B; EXPORT SIGNALS; SURVIVIN; INCENP; SPINDLE; CANCER; EXPRESSION; CENTROMERE; PHOSPHORYLATION	As mitosis progresses, the chromosomal passenger proteins (CPPs) Survivin, Aurora B, INCENP and Borealin dynamically colocalize to mitotic structures. Chromosomal passenger proteins are already expressed during G2, whereas the nuclear envelope is only disassembled at the end of prophase. However, the mechanisms that modulate their nucleocytoplasmic localization before nuclear envelope breakdown (NEB) are poorly characterized. Using epitope-tagged proteins, we show that Aurora B, like Survivin, undergoes CRM1-mediated nucleocytoplasmic shuttling, although both proteins lack identifiable 'classical' nuclear transport signals. On the other hand, INCENP resides more stably in the nucleus and contains multiple nuclear localization signals. Finally, Borealin was detected in the nucleolus and the cytoplasm, but its cytoplasmic localization is not directly regulated by CRM1. Coexpression experiments indicate that the nuclear localization of Aurora B, but not of Survivin, is modulated by INCENP and that Survivin prevents the nucleolar accumulation of Borealin. Our data reveal that, in contrast to their closely related localization during mitosis, the nucleocytoplasmic localization of the CPPs before NEB is largely unrelated. Furthermore, the specific effect of INCENP and Survivin on the localization of Aurora B and Borealin, respectively, suggests that different complexes of CPPs may exist not only during mitosis, as recently reported, but also before NEB.	Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, Amsterdam, Netherlands; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Netherlands Cancer Institute	Rodriguez, JA (corresponding author), Vrije Univ Amsterdam, Dept Med Oncol, Med Ctr, Acad Hosp, KRIGO BR232,Postbus 7057, NL-1007 MB Amsterdam, Netherlands.	ja.rodriguez@vumc.nl	Giaccone, Giuseppe/E-8297-2017; Medema, Rene H/E-2981-2013; Medema, Rene H/G-5415-2011; Rodriguez, Jose Antonio/AAA-1125-2019	Giaccone, Giuseppe/0000-0002-5023-7562; Rodriguez, Jose Antonio/0000-0002-2823-3733; Vader, Gerben/0000-0001-5729-0991; Kruyt, Frank/0000-0002-2445-9380; Medema, Rene/0000-0002-6754-0381				Adams RR, 2001, CHROMOSOMA, V110, P65, DOI 10.1007/s004120100130; Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Altura RA, 2003, BRIT J CANCER, V89, P1743, DOI 10.1038/sj.bjc.6601334; Andersen JS, 2005, NATURE, V433, P77, DOI 10.1038/nature03207; Andrews PD, 2003, CURR OPIN CELL BIOL, V15, P672, DOI 10.1016/j.ceb.2003.10.013; Arnaoutov A, 2005, NAT CELL BIOL, V7, P626, DOI 10.1038/ncb1263; Birbach A, 2002, J BIOL CHEM, V277, P10842, DOI 10.1074/jbc.M112475200; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bishop JD, 2002, J BIOL CHEM, V277, P27577, DOI 10.1074/jbc.C200307200; Bolton MA, 2002, MOL BIOL CELL, V13, P3064, DOI 10.1091/mbc.E02-02-0092; Burke B, 2002, NAT REV MOL CELL BIO, V3, P487, DOI 10.1038/nrm860; Chen J, 2003, J BIOL CHEM, V278, P486, DOI 10.1074/jbc.M211119200; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Gassmann R, 2004, J CELL BIOL, V166, P179, DOI 10.1083/jcb.200404001; Giet R, 2005, TRENDS CELL BIOL, V15, P241, DOI 10.1016/j.tcb.2005.03.004; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kawajiri A, 2003, MOL BIOL CELL, V14, P1489, DOI 10.1091/mbc.E02-09-0612; Krysan K, 2004, FASEB J, V18, P205, DOI 10.1096/fj.03-0369fje; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Mahotka C, 1999, CANCER RES, V59, P6097; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Paraskeva E, 1999, J CELL BIOL, V145, P255, DOI 10.1083/jcb.145.2.255; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Rodriguez JA, 2002, EXP CELL RES, V275, P44, DOI 10.1006/excr.2002.5492; Rodriguez JA, 2004, ONCOGENE, V23, P1809, DOI 10.1038/sj.onc.1207302; Saffery R, 1999, MAMM GENOME, V10, P415, DOI 10.1007/s003359901014; Sampath SC, 2004, CELL, V118, P187, DOI 10.1016/j.cell.2004.06.026; Song JX, 2005, IMMUNITY, V22, P621, DOI 10.1016/j.immuni.2005.03.012; Speliotes EK, 2000, MOL CELL, V6, P211, DOI 10.1016/S1097-2765(00)00023-X; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Tonini G, 2005, BRIT J CANCER, V92, P2225, DOI 10.1038/sj.bjc.6602632; Vader G, 2006, EMBO REP, V7, P85, DOI 10.1038/sj.embor.7400562; Vischioni B, 2004, ANN ONCOL, V15, P1654, DOI 10.1093/annonc/mdh436; Wheatley SP, 2004, J BIOL CHEM, V279, P5655, DOI 10.1074/jbc.M311299200; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X; Yasui Y, 2004, J BIOL CHEM, V279, P12997, DOI 10.1074/jbc.M311128200	43	28	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2006	25	35					4867	4879		10.1038/sj.onc.1209499	http://dx.doi.org/10.1038/sj.onc.1209499			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16547492				2022-12-28	WOS:000239687100005
J	Jin, A; Kurosu, T; Tsuji, K; Mizuchi, D; Arai, A; Fujita, H; Hattori, M; Minato, N; Miura, O				Jin, A.; Kurosu, T.; Tsuji, K.; Mizuchi, D.; Arai, A.; Fujita, H.; Hattori, M.; Minato, N.; Miura, O.			BCR/ABL and IL-3 activate Rap1 to stimulate the B-Raf/MEK/Erk and Akt signaling pathways and to regulate proliferation, apoptosis, and adhesion	ONCOGENE			English	Article						BCR/ABL; IL-3; Rap1; B-Raf; Akt; adhesion	CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; HEMATOPOIETIC-CELL ADHESION; KINASE-ACTIVITY; BCR-ABL; ERYTHROPOIETIN RECEPTOR; PROGENITOR CELLS; EXCHANGE FACTOR; CYCLIC-AMP; PROTEINS	The Ras family small GTPase Rap1 is activated by hematopoietic cytokines, such as interleukin (IL)-3, to induce beta 1 integrin-mediated cell adhesion or by the BCR/ABL fusion tyrosine kinase to stimulate the MEK/Erk signaling pathway. Here, we demonstrate that the abrogation of Rap1 activation by SPA-1, a Rap1-specific GAP, inhibits activation of B-Raf, MEK, Erk, and Akt in a murine hematopoietic cell line, Ton.B210, stimulated with IL-3 or inducibly expressing BCR/ABL. Furthermore, Rap1 inactivation had an inhibitory effects on proliferation and survival of Ton.B210 cells, which were more remarkable when cells were stimulated by BCR/ABL than by IL-3. Induction of BCR/ABL expression increased adhesion of Ton.B210 cells to fibronectin in a manner at least partly dependent on its kinase activity, and Rap1 inhibition by SPA-1 partially inhibited BCR/ABL-induced adhesion of cells. Thus, IL-3- or BCR/ABL-induced activation of Rap1 may play important roles in regulation of cell proliferation and survival through activation of the B-Raf/MEK/Erk and Akt signaling pathways and in induction of integrin-mediated cell adhesion. Furthermore, as compared with IL-3, BCR/ABL is more dependent on Rap1-mediated signaling to induce cell proliferation and survival and, thus, Rap1 may represent an attractive target for novel therapies for leukemias caused by BCR/ABL.	Tokyo Med & Dent Univ, Dept Hematol, Bunkyo Ku, Tokyo 1138519, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Immunol & Cell Biol, Kyoto, Japan	Tokyo Medical & Dental University (TMDU); Kyoto University	Miura, O (corresponding author), Tokyo Med & Dent Univ, Dept Hematol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	miura.hema@tmd.ac.jp		Miura, Osamu/0000-0002-0981-3054; Fujita, Harumi/0000-0003-2133-845X				Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Arai A, 2001, J BIOL CHEM, V276, P10453, DOI 10.1074/jbc.M004627200; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Barnes DJ, 2005, ONCOGENE, V24, P6432, DOI 10.1038/sj.onc.1208796; Bazzoni G, 1996, J CLIN INVEST, V98, P521, DOI 10.1172/JCI118820; Bhatia R, 2001, BRIT J HAEMATOL, V115, P845, DOI 10.1046/j.1365-2141.2001.03192.x; Bondzi C, 2000, ONCOGENE, V19, P5030, DOI 10.1038/sj.onc.1203862; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Brummer T, 2002, EMBO J, V21, P5611, DOI 10.1093/emboj/cdf588; Christian SL, 2003, J BIOL CHEM, V278, P41756, DOI 10.1074/jbc.M303180200; Clarkson B, 2003, LEUKEMIA, V17, P1211, DOI 10.1038/sj.leu.2402912; Downward J, 1997, ADV SEC MESS PHOSPH, V31, P1; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Garcia J, 2001, MOL CELL BIOL, V21, P2659, DOI 10.1128/MCB.21.8.2659-2670.2001; Goldman JM, 2003, NEW ENGL J MED, V349, P1451, DOI 10.1056/NEJMra020777; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; Hattori M, 2003, J BIOCHEM, V134, P479, DOI 10.1093/jb/mvg180; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ishida D, 2003, CANCER CELL, V4, P55, DOI 10.1016/S1535-6108(03)00163-6; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Klein S, 2005, NAT REV CANCER, V5, P573, DOI 10.1038/nrc1651; Klejman A, 2002, ONCOGENE, V21, P5868, DOI 10.1038/sj.onc.1205724; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Kometani K, 2004, TRENDS MOL MED, V10, P401, DOI 10.1016/j.molmed.2004.06.004; Kramer A, 1999, P NATL ACAD SCI USA, V96, P2087, DOI 10.1073/pnas.96.5.2087; Kurachi H, 1997, J BIOL CHEM, V272, P28081, DOI 10.1074/jbc.272.44.28081; Lou LG, 2002, J BIOL CHEM, V277, P32799, DOI 10.1074/jbc.M201491200; Marley SB, 2004, BRIT J HAEMATOL, V125, P500, DOI 10.1111/j.1365-2141.2004.04933.x; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIURA O, 1994, J BIOL CHEM, V269, P614; Mizuchi D, 2005, BIOCHEM BIOPH RES CO, V326, P645, DOI 10.1016/j.bbrc.2004.11.086; Papin C, 1996, ONCOGENE, V12, P2213; PIZON V, 1988, ONCOGENE, V3, P201; Ramaraj P, 2004, CANCER RES, V64, P5322, DOI 10.1158/0008-5472.CAN-03-3656; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Stork PJS, 2005, BLOOD, V106, P2952, DOI 10.1182/blood-2005-03-1062; Stork PJS, 2003, TRENDS BIOCHEM SCI, V28, P267, DOI 10.1016/S0968-0004(03)00087-2; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985; Wang L, 2001, J BIOL CHEM, V276, P37242, DOI 10.1074/jbc.M105089200; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wertheim JA, 2003, BLOOD, V102, P2220, DOI 10.1182/blood-2003-01-0062; Wertheim JA, 2002, BLOOD, V99, P4122, DOI 10.1182/blood.V99.11.4122	47	45	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2006	25	31					4332	4340		10.1038/sj.onc.1209459	http://dx.doi.org/10.1038/sj.onc.1209459			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16518411				2022-12-28	WOS:000239240100008
J	Yeh, HH; Lai, WW; Chen, HHW; Liu, HS; Su, WC				Yeh, H-H; Lai, W-W; Chen, H. H. W.; Liu, H-S; Su, W-C			Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion	ONCOGENE			English	Article						malignant pleural effusion; lung cancer; IL-6; Stat3; VEGF	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; CANCER CELL-LINES; TUMOR ANGIOGENESIS; MOLECULAR TARGETS; CARCINOMA CELLS; FACTOR RECEPTOR; INTERLEUKIN-6; EXPRESSION; CYTOKINES	Malignant pleural effusion (MPE) is a poor prognostic sign for patients with non-small-cell lung cancer (NSCLC). The generation of MPE is largely regulated by vascular endothelial growth factor (VEGF), and upregulation of VEGF by Stat3 has been observed in several types of tumor cells. In this study, we demonstrate constitutively activated Stat3 in several human lung cancer cell lines and in tumor cells infiltrated in the pleurae of patients with adenocarcinoma cell lung cancer (ADCLC) and MPE. The observations suggest that activated Stat3 plays a role in the pathogenesis of ADCLC. In PC14PE6/AS2 cells, a Stat3-positive human ADCLC cell line, autocrine IL-6 activated Stat3 via JAKs, not via Src kinase. PC14PE6/AS2 cells express higher VEGF mRNA and protein than do Stat3-negative PC14PE6/AS2/dnStat3 cells. In an animal model, PC14P6/AS2/dnStat3 cells produced no MPE and less lung metastasis than did PC14P6/AS2 cells. PC14PE6/AS2 cells also expressed higher VEGF protein, microvessel density , and vascular permeability in tumors than did PC14P6/AS2/dnStat3 cells. Therefore, we hypothesize that autocrine IL-6 activation of Stat3 in ADCLC may be involved in the formation of malignant pleural effusion by upregulating VEGF. Higher levels of IL-6 and VEGF were also found in the pleural fluids of patients with ADCLC than in patients with congestive heart failure. The autocrine IL-6/Stat3/VEGF signaling pathway may also be activated in patients with ADCLC and MPE. These findings provide novel targets for the management of MPE.	Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med,Div Hematol Oncol, Tainan 704, Taiwan; Natl Cheng Kung Univ, Coll Med, Inst Basic Med, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Surg, Tainan 704, Taiwan; Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Radiotherapy, Tainan 704, Taiwan	National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital	Su, WC (corresponding author), Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med,Div Hematol Oncol, 138 Sheng Li Rd, Tainan 704, Taiwan.	sunnysu@mail.ncku.edu.tw	, 賴吾為/T-8615-2019	, 賴吾為/0000-0001-9174-8310; Liu, Hsiao-Sheng/0000-0003-0576-7203; Su, Wu-Chou/0000-0003-2953-4105				Alexandrakis MG, 2000, ONCOL REP, V7, P1327; ANDERSON CB, 1974, CANCER-AM CANCER SOC, V33, P916, DOI 10.1002/1097-0142(197404)33:4<916::AID-CNCR2820330405>3.0.CO;2-U; Bihl M, 1998, AM J RESP CELL MOL, V19, P606, DOI 10.1165/ajrcmb.19.4.3247; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buettner R, 2002, CLIN CANCER RES, V8, P945; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Fernandes A, 1999, INT J CANCER, V83, P564, DOI 10.1002/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO;2-Q; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Hoffman PC, 2000, LANCET, V355, P479, DOI 10.1016/S0140-6736(00)82038-3; Hoheisel G, 1998, RESPIRATION, V65, P183, DOI 10.1159/000029256; Hung TL, 2003, CLIN CANCER RES, V9, P2605; HUTCHINS D, 1994, INT J CANCER, V58, P80, DOI 10.1002/ijc.2910580114; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; MEMON A, 1981, Current Problems in Cancer, V5, P1, DOI 10.1016/S0147-0272(81)80012-8; Mesiano S, 1998, AM J PATHOL, V153, P1249, DOI 10.1016/S0002-9440(10)65669-6; Naito T, 1997, ANTICANCER RES, V17, P4743; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Okamoto M, 1997, CANCER RES, V57, P141; Seki Y, 2004, INT J ONCOL, V24, P931; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SIEGSMUND MJ, 1994, J UROLOGY, V151, P1396, DOI 10.1016/S0022-5347(17)35267-9; Song LX, 2003, ONCOGENE, V22, P4150, DOI 10.1038/sj.onc.1206479; Sugiura S, 1997, CLIN CANCER RES, V3, P47; Takayama K, 2000, CANCER RES, V60, P2169; Turkson J, 2004, EXPERT OPIN THER TAR, V8, P409, DOI 10.1517/14728222.8.5.409; Wei LH, 2003, ONCOGENE, V22, P1517, DOI 10.1038/sj.onc.1206226; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Yamaguchi T, 2000, JPN J CLIN ONCOL, V30, P53, DOI 10.1093/jjco/hyd014; Yano S, 2000, AM J PATHOL, V157, P1893, DOI 10.1016/S0002-9440(10)64828-6; Yano S, 2000, CLIN CANCER RES, V6, P957; YOKOYAMA A, 1992, CHEST, V102, P1055, DOI 10.1378/chest.102.4.1055; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zebrowski BK, 1999, CLIN CANCER RES, V5, P3364	36	183	188	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2006	25	31					4300	4309		10.1038/sj.onc.1209464	http://dx.doi.org/10.1038/sj.onc.1209464			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16518408				2022-12-28	WOS:000239240100005
J	Gronholm, M; Muranen, T; Toby, GG; Utermark, T; Hanemann, CO; Golemis, EA; Carpen, O				Gronholm, M.; Muranen, T.; Toby, G. G.; Utermark, T.; Hanemann, C. O.; Golemis, E. A.; Carpen, O.			A functional association between merlin and HEI10, a cell cycle regulator	ONCOGENE			English	Article						NF2; ERM; HEI10	TUMOR-SUPPRESSOR PROTEIN; NEUROFIBROMATOSIS TYPE-2; GENE-PRODUCT; P21-ACTIVATED KINASE; SCHWANN-CELLS; ERM PROTEINS; NF2 GENE; EZRIN; GROWTH; CYTOSKELETON	Merlin and ezrin are homologous proteins with opposite effects on neoplastic growth. Merlin is a tumor suppressor inactivated in the neurofibromatosis 2 disease, whereas upregulated ezrin expression is associated with increased malignancy. Merlin's tumor suppressor mechanism is not known, although participation in cell cycle regulation has been suggested. To characterize merlin's biological activities, we screened for molecules that would interact with merlin but not ezrin. We identified the cyclin B-binding protein and cell cycle regulator HEI10 as a novel merlin-binding partner. The interaction is mediated by the alpha-helical domain in merlin and the coiled-coil domain in HEI10 and requires conformational opening of merlin. The two proteins show partial subcellular colocalization, which depends on cell cycle stage and cell adhesion. Comparison of Schwann cells and schwannoma cultures demonstrated that the distribution of HEI10 depends on merlin expression. In transfected cells, a constitutively open merlin construct affected HEI10 protein integrity. These results link merlin to the cell cycle control machinery and may help to understand its tumor suppressor function.	Univ Helsinki, Program Neurosci, Biomed Helsinki, Dept Pathol, Helsinki 00014, Finland; Helsinki Univ Hosp, Helsinki 00014, Finland; Fox Chase Canc Ctr, Div Basic Sci, Philadelphia, PA USA; Univ Ulm, Dept Neurol, D-7900 Ulm, Germany; Peninsula Med Sch, Clin Neurobiol, Inst Clin & Biomed Sci, Plymouth, Devon, England; Turku Univ, Dept Pathol, Turku, Finland; Turku Univ Hosp, FIN-20520 Turku, Finland	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Fox Chase Cancer Center; Ulm University; University of Plymouth; University of Turku; University of Turku	Gronholm, M (corresponding author), Univ Helsinki, Program Neurosci, Biomed Helsinki, Dept Pathol, Haartmanink 8,PB 63, Helsinki 00014, Finland.	mikaela.gronholm@helsinki.fi	Gronholm, Mikaela/B-4225-2010; Muranen, Taru/AAM-9349-2021; Hanemann, C Oliver/AAV-6257-2020	Hanemann, C Oliver/0000-0002-1951-1025; Muranen, Taru/0000-0003-4158-9002; Golemis, Erica/0000-0003-3618-3673; Gronholm, Mikaela/0000-0002-2378-8924				Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; ARAKAWA H, 1994, HUM MOL GENET, V3, P565, DOI 10.1093/hmg/3.4.565; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Chambers DN, 2005, BIOCHEMISTRY-US, V44, P3926, DOI 10.1021/bi0480382; DENBAKKER MA, 1995, AM J PATHOL, V147, P1339; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Geiger KD, 2000, AM J PATHOL, V157, P1785, DOI 10.1016/S0002-9440(10)64816-X; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; Gronholm M, 2003, J BIOL CHEM, V278, P41167, DOI 10.1074/jbc.M306149200; Gronholm M, 1999, J CELL SCI, V112, P895; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hanemann CO, 1998, GLIA, V23, P89, DOI 10.1002/(SICI)1098-1136(199806)23:2<89::AID-GLIA1>3.0.CO;2-Z; Hirokawa Y, 2004, CANCER J, V10, P20, DOI 10.1097/00130404-200401000-00006; Huynh DP, 1996, ONCOGENE, V13, P73; Ilmonen S, 2005, MODERN PATHOL, V18, DOI 10.1038/modpathol.3800429; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; LOUIS DN, 1995, BRAIN PATHOL, V5, P163, DOI 10.1111/j.1750-3639.1995.tb00590.x; LUTCHMAN M, 1995, CANCER RES, V55, P2270; Makitie T, 2001, INVEST OPHTH VIS SCI, V42, P2442; McClatchey AI, 2003, NAT REV CANCER, V3, P877, DOI 10.1038/nrc1213; Mine N, 2001, JPN J CANCER RES, V92, P135, DOI 10.1111/j.1349-7006.2001.tb01075.x; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Muranen T, 2005, ONCOGENE, V24, P1150, DOI 10.1038/sj.onc.1208283; Pineau P, 2003, INT J CANCER, V106, P216, DOI 10.1002/ijc.11214; Rosenbaum C, 1998, NEUROBIOL DIS, V5, P55, DOI 10.1006/nbdi.1998.0179; Sainio M, 1997, J CELL SCI, V110, P2249; Schulze KMM, 2002, HUM MOL GENET, V11, P69, DOI 10.1093/hmg/11.1.69; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Smith AP, 2004, CANCER BIOL THER, V3, P104, DOI 10.4161/cbt.3.1.661; Toby GG, 2003, MOL CELL BIOL, V23, P2109, DOI 10.1128/MCB.23.6.2109-2122.2003; Tynninen O, 2004, NEUROPATH APPL NEURO, V30, P472, DOI 10.1111/j.1365-2990.2004.00562.x; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200	38	24	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	32					4389	4398		10.1038/sj.onc.1209475	http://dx.doi.org/10.1038/sj.onc.1209475			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16532029				2022-12-28	WOS:000239326000002
J	Oh, J; Diaz, T; Wei, B; Chang, H; Noda, M; Stetler-Stevenson, WG				Oh, J.; Diaz, T.; Wei, B.; Chang, H.; Noda, M.; Stetler-Stevenson, W. G.			TIMP-2 upregulates RECK expression via dephosphorylation of paxillin tyrosine residues 31 and 118	ONCOGENE			English	Article						TIMP-2; RECK; Rac1; paxillin; Src	CYSTEINE-RICH PROTEIN; FOCAL ADHESION KINASE; CELL LUNG-CANCER; NBT-II CELLS; TYROSINE PHOSPHORYLATION; CLINICAL-SIGNIFICANCE; TISSUE INHIBITORS; SIGNALING COMPLEX; KAZAL MOTIFS; SRC	We previously demonstrated that TIMP-2 increases the association of Crk with C3G and via subsequent activation of Rap1 enhances the expression of RECK, a membrane-anchored MMP inhibitor. In the present study, we investigate the mechanism of how the TIMP-2 signal is transduced from the alpha 3 beta 1 integrin receptor to the Crk-C3G-Rap1 molecular complex. TIMP-2 treatment of human microvascular endothelial cells (hMVECs) increased the phosphorylation levels of Src at Tyr-527, the negative regulatory site, through enhanced association of Src with Csk. This results in the reduction of Src kinase activity and dephosphorylation of paxillin at Tyr-31/118, the target sites for Src kinase phosphorylation and also the binding sites for the downstream effector Crk. Such TIMP-2 effects accompany the disassembly of paxillin-Crk-DOCK180 molecular complex and, in turn, Rac1 inactivation. On the contrary, levels of paxillin-Crk-C3G complex formation are not reduced, rather slightly increased, which is consistent with our previous finding. Therefore, TIMP-2-mediated inhibition of Src kinase activity leads to the signaling switch from Rac1 to Rap1, thereby leading to enhanced RECK expression.	Korea Univ, Cellular Oncol Lab, Grad Sch Med, Ansan 425707, Gyeonggi Do, South Korea; NCI, Ctr Canc Res, Cell & Canc Biol Branch, Bethesda, MD 20892 USA; Kyoto Univ, Dept Mol Oncol, Grad Sch Med, Kyoto, Japan	Korea University; Korea University Medicine (KU Medicine); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kyoto University	Oh, J (corresponding author), Korea Univ, Cellular Oncol Lab, Grad Sch Med, Gojan 1 Dong, Ansan 425707, Gyeonggi Do, South Korea.	ohjs@korea.ac.kr	Stetler-Stevenson, William/AAE-3501-2020	Stetler-Stevenson, William/0000-0002-5500-5808; Oh, Junseo/0000-0002-0754-4946	Intramural NIH HHS [Z01 SC009179] Funding Source: Medline; NCI NIH HHS [Z01 SC009179-17] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01SC009179] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn SM, 2004, CANCER LETT, V207, P49, DOI 10.1016/j.canlet.2003.11.025; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Baumeister U, 2005, EMBO J, V24, P1686, DOI 10.1038/sj.emboj.7600647; Bos JL, 2005, CURR OPIN CELL BIOL, V17, P123, DOI 10.1016/j.ceb.2005.02.009; Chen HY, 2004, MOL CELL BIOL, V24, P10558, DOI 10.1128/MCB.24.24.10558-10572.2004; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Furumoto K, 2001, HEPATOLOGY, V33, P189, DOI 10.1053/jhep.2001.21048; Harrison SC, 2003, CELL, V112, P737, DOI 10.1016/S0092-8674(03)00196-X; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291; Masui T, 2003, CLIN CANCER RES, V9, P1779; Nakamura K, 2000, J BIOL CHEM, V275, P27155; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Oh J, 2004, CANCER RES, V64, P9062, DOI 10.1158/0008-5472.CAN-04-1981; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Perez-Martinez L, 2005, J NEUROSCI, V25, P4917, DOI 10.1523/JNEUROSCI.5066-04.2005; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Ren Y, 2004, J BIOL CHEM, V279, P8497, DOI 10.1074/jbc.M312575200; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V331, P1, DOI 10.1016/j.bbrc.2005.03.012; Sasahara RM, 2002, CANCER DETECT PREV, V26, P435, DOI 10.1016/S0361-090X(02)00123-X; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Seo DW, 2003, CELL, V114, P171, DOI 10.1016/S0092-8674(03)00551-8; Span PN, 2003, CANCER, V97, P2710, DOI 10.1002/cncr.11395; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; Takenaka K, 2005, ANN SURG ONCOL, V12, P817, DOI 10.1245/ASO.2005.09.018; Takenaka K, 2004, EUR J CANCER, V40, P1617, DOI 10.1016/j.ejca.2004.02.028; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Valles AM, 2004, J BIOL CHEM, V279, P44490, DOI 10.1074/jbc.M405144200; VANDERJAGT MF, 2005, IN PRESS CANC LETT; Wingfield PT, 1999, J BIOL CHEM, V274, P21362, DOI 10.1074/jbc.274.30.21362; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4	35	36	36	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	30					4230	4234		10.1038/sj.onc.1209444	http://dx.doi.org/10.1038/sj.onc.1209444			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16491114	Green Accepted, Green Submitted			2022-12-28	WOS:000239004800010
J	Simbulan-Rosenthal, CM; Daher, A; Trabosh, V; Chen, WC; Gerstel, D; Soeda, E; Rosenthal, DS				Simbulan-Rosenthal, C. M.; Daher, A.; Trabosh, V.; Chen, W-C; Gerstel, D.; Soeda, E.; Rosenthal, D. S.			Id3 induces a caspase-3- and -9-dependent apoptosis and mediates UVB sensitization of HPV16 E6/7 immortalized human keratinocytes	ONCOGENE			English	Article						Id proteins; apoptosis; immortalization; caspases	LOOP-HELIX PROTEINS; SOLAR KERATOSES; ULTRAVIOLET-B; CELL-GROWTH; PROTEASE; BAX; IDENTIFICATION; TRANSCRIPTION; DIMERIZATION; EXPRESSION	Inhibitor of differentiation/DNA binding ( Id) proteins comprise a class of helix-loop-helix transcription factors involved in proliferation, differentiation, apoptosis, and carcinogenesis. We have shown that while Id2 is induced by UVB in primary keratinocytes, Id3 is upregulated only in immortalized cells. We have now determined that the consequences of ectopic expression of Id3 protein are strikingly different between immortalized and primary keratinocytes. Overexpression of Id3 induces a significant increase in apoptotic cells as revealed by Annexin V positivity as well as proteolytic processing of caspase-3 in immortalized, but not in primary keratinocytes. Id3-green fluorescent protein ( GFP)-positive cells exhibited a fivefold increase in apoptotic nuclear fragmentation compared to Id3-GFP-negative cells. These apoptotic responses were accompanied by activation of caspase-3, as shown by immunocytochemical staining with antibodies to active caspase-3. Immunostaining with antibodies to the active form of caspase-9 as well as to the active form of Bax further revealed that induction of apoptosis in Id3-overexpressing keratinocytes occurred via a mitochondrial-caspase-9-mediated pathway. Coexpression of dominant-negative caspase-9 with Id3 significantly suppressed apoptotic nuclear fragmentation, indicating that caspase-9 activation is essential for Id3-induced cell death. This response was also markedly attenuated by coexpression with the Bax antagonist antiapoptotic protein Bcl-2, confirming a role for Bax activation in this apoptotic response. Id3-induced Bax activation may result from increased expression of Bax protein. Furthermore, reduction of Id3 expression by small interfering RNAs abrogated the UVB-induced proteolytic activation of caspase- 3 in these cells. These data together suggest that UVB-induced apoptosis of immortalized keratinocytes is at least in part due to Id3 upregulation in these cells.	Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20007 USA	Georgetown University	Rosenthal, DS (corresponding author), Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Room 307,3900 Reservoir Rd WV, Washington, DC 20007 USA.	rosenthd@georgetown.edu	Simbulan-Rosenthal, Cynthia M./W-8429-2019; Rosenthal, Dean S/J-2360-2014; Daher, Ahmad/AAL-4605-2020	Rosenthal, Dean/0000-0002-7624-0209; Simbulan-Rosenthal, Ph.D, Cynthia M./0000-0002-5070-0342	NCI NIH HHS [R01 CA100443-05, R01 CA100443, 1R01 CA100443-01A1, R01 CA100443-01A1, R01 CA100443-03, R01 CA100443-02, R01 CA100443-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Atchley WR, 1997, P NATL ACAD SCI USA, V94, P5172, DOI 10.1073/pnas.94.10.5172; Backvall H, 2005, MUTAT RES-FUND MOL M, V571, P65, DOI 10.1016/j.mrfmmm.2004.10.011; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Cleaver JE, 2002, FRONT BIOSCI-LANDMRK, V7, pD1024, DOI 10.2741/cleaver; Daher A, 2006, EXP DERMATOL, V15, P23, DOI 10.1111/j.0906-6705.2005.00384.x; Decraene D, 2004, J INVEST DERMATOL, V123, P207, DOI 10.1111/j.0022-202X.2004.22702.x; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; Frost C, 2000, J INVEST DERMATOL, V115, P273, DOI 10.1046/j.1523-1747.2000.00048.x; Harvey I, 1996, BRIT J CANCER, V74, P1302, DOI 10.1038/bjc.1996.534; Heisler GM, 2004, PHOTOCHEM PHOTOBIOL, V80, P422, DOI 10.1562/0031-8655(2004)080&lt;0422:SURIUE&gt;2.0.CO;2; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Kee BL, 2001, NAT IMMUNOL, V2, P242, DOI 10.1038/85303; Koyama T, 2004, ANTICANCER RES, V24, P1519; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Liu J, 2000, BIOCHEM BIOPH RES CO, V273, P1042, DOI 10.1006/bbrc.2000.3055; MARKS R, 1986, BRIT J DERMATOL, V115, P649, DOI 10.1111/j.1365-2133.1986.tb06644.x; MARKS R, 1988, LANCET, V1, P795, DOI 10.1016/s0140-6736(88)91658-3; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Mitchell KO, 2000, CANCER RES, V60, P6318; MIYASHITA T, 1995, CELL, V80, P293; Mueller C, 2002, CIRCULATION, V105, P2423, DOI 10.1161/01.CIR.0000016047.19488.91; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nickoloff BJ, 2000, J BIOL CHEM, V275, P27501; Norton JD, 2000, J CELL SCI, V113, P3897; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Park HR, 2004, J CUTAN PATHOL, V31, P544, DOI 10.1111/j.0303-6987.2004.00228.x; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Simbulan-Rosenthal CM, 2005, ONCOGENE, V24, P5443, DOI 10.1038/sj.onc.1208709; Simbulan-Rosenthal CM, 2002, J BIOL CHEM, V277, P24709, DOI 10.1074/jbc.M200281200; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Stratton S P, 2001, Curr Oncol Rep, V3, P295, DOI 10.1007/s11912-001-0080-x; Takehara T, 2003, CANCER RES, V63, P3054; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Van Laethem A, 2004, FASEB J, V18, P1946, DOI 10.1096/fj.04-2285fje	40	21	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3649	3660		10.1038/sj.onc.1209407	http://dx.doi.org/10.1038/sj.onc.1209407			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16449966				2022-12-28	WOS:000238448300004
J	Fang, Y; Liu, T; Wang, X; Yang, YM; Deng, H; Kunicki, J; Traganos, F; Darzynkiewicz, Z; Lu, L; Dai, W				Fang, Y.; Liu, T.; Wang, X.; Yang, Y-M; Deng, H.; Kunicki, J.; Traganos, F.; Darzynkiewicz, Z.; Lu, L.; Dai, W.			BubR1 is involved in regulation of DNA damage responses	ONCOGENE			English	Article							POLY(ADP-RIBOSE) POLYMERASE-1; SPINDLE CHECKPOINT; HUMAN CANCERS; APOPTOSIS; P53; ANEUPLOIDY; MUTATIONS; ARREST	Defective mitotic spindles or an impaired spindle-kinetochore interaction activates the spindle checkpoint. We have previously shown that BubR1 haplo-insufficiency results in enhanced genomic instability and tumorigenesis in mice. Here we report that BubR1 deficiency also leads to a compromised response to DNA damage. Following treatment with doxorubicin, BubR1(+/-) murine fibroblast cells (MEF) were defective in undergoing G(2)/M arrest. Thus, whereas in the presence of DNA damage BubR1(+/+) MEF cells remained arrested in mitosis, BubR1(+/-) MEFs rapidly exited from mitosis and divided. The impaired mitotic arrest of BubR1(+/-) MEFs was associated with low levels of phospho-histone H2AX, p53, and p21 after DNA damage caused by treatment with both doxorubicin and ultraviolet light (UV). The impaired expression of p53 and p21 was also confirmed in human cell lines with BubR1 knockdown via RNA interference. Affinity pull-down coupled with mass spectrometry identified Poly(ADPribose) polymerase 1 (PARP-1) as one of the proteins interacting with BubR1. Reciprocal co-immunoprecipitation analysis confirmed the physical interaction between BubR1 and PARP-1. Our further study revealed that the ability of retaining intact PARP-1 or its cleavage product p89 was compromised in BubR1(+/-) MEFs upon treatment with doxorubicin or UV. Given that PARP-1 mediates DNA damage responses and regulates the activity of p53, our studies suggest that there exists a cross-talk between the spindle checkpoint and the DNA damage checkpoint and that BubR1 may play an important role in mediating the cross-talk.	New York Med Coll, Dept Med, Div Mol Carcinogenesis, Valhalla, NY 10595 USA; Rockefeller Univ, Proteom Core Facil, New York, NY 10021 USA; New York Med Coll, Brander Canc Inst, Valhalla, NY 10595 USA; Univ Calif Los Angeles, Harbor UCLA Med Ctr, Div Mol Med, Torrance, CA 90502 USA	New York Medical College; Rockefeller University; New York Medical College; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Dai, W (corresponding author), New York Med Coll, Dept Med, Div Mol Carcinogenesis, Basic Sci Bldg,A22, Valhalla, NY 10595 USA.	wei_dai@nymc.edu	Traganos, Frank/B-8021-2012	Dai, Wei/0000-0003-0169-8327; Darzynkiewicz, Zbigniew/0000-0002-2040-7081	NATIONAL CANCER INSTITUTE [R01CA028704, R01CA090658] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA028704-27, R01-CA90658, R01 CA028704] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Affar EB, 2001, J BIOL CHEM, V276, P2935, DOI 10.1074/jbc.M007269200; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bernal JA, 2002, NAT GENET, V32, P306, DOI 10.1038/ng997; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chang P, 2004, NATURE, V432, P645, DOI 10.1038/nature03061; Dai W, 2004, CANCER RES, V64, P440, DOI 10.1158/0008-5472.CAN-03-3119; de Murcia JMN, 2003, EMBO J, V22, P2255, DOI 10.1093/emboj/cdg206; Hamid T, 2003, HISTOL HISTOPATHOL, V18, P245, DOI 10.14670/HH-18.245; Hanks S, 2004, NAT GENET, V36, P1159, DOI 10.1038/ng1449; Huber A, 2004, DNA REPAIR, V3, P1103, DOI 10.1016/j.dnarep.2004.06.002; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lengauer C, 2003, SCIENCE, V300, P442, DOI 10.1126/science.1084468; Lew DJ, 2003, ANNU REV GENET, V37, P251, DOI 10.1146/annurev.genet.37.042203.120656; Li WQ, 1999, CELL GROWTH DIFFER, V10, P769; Mikhailov A, 2002, CURR BIOL, V12, P1797, DOI 10.1016/S0960-9822(02)01226-5; Nitta M, 2004, ONCOGENE, V23, P6548, DOI 10.1038/sj.onc.1207873; Pirrotta V, 2004, CELL, V119, P735, DOI 10.1016/j.cell.2004.12.002; Rao CV, 2005, P NATL ACAD SCI USA, V102, P4365, DOI 10.1073/pnas.0407822102; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Saxena A, 2002, J BIOL CHEM, V277, P26921, DOI 10.1074/jbc.M200620200; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Wieler S, 2003, J BIOL CHEM, V278, P18914, DOI 10.1074/jbc.M211641200; Xie SQ, 2005, ONCOGENE, V24, P277, DOI 10.1038/sj.onc.1208218; Yang YL, 2004, ONCOGENE, V23, P2096, DOI 10.1038/sj.onc.1207411; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou YL, 2003, J BIOL CHEM, V278, P462, DOI 10.1074/jbc.M203793200	31	58	65	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3598	3605		10.1038/sj.onc.1209392	http://dx.doi.org/10.1038/sj.onc.1209392			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16449973				2022-12-28	WOS:000238448200012
J	Tussie-Luna, MI; Rozo, L; Roy, AL				Tussie-Luna, M. I.; Rozo, L.; Roy, A. L.			Pro-proliferative function of the long isoform of PML-RAR alpha involved in acute promyelocytic leukemia	ONCOGENE			English	Article						APL; PML-RAR alpha; c-fos; transcription; chromatin	RETINOIC ACID RECEPTOR; PML/RAR-ALPHA; FUSION PROTEINS; CELL DIFFERENTIATION; HISTONE DEACETYLASE; GENE; ACTIVATION; PHOSPHORYLATION; TRANSLOCATION; ACETYLATION	The promyelocytic leukemia (PML) gene codes for a tumor suppressor protein that is associated with distinct subnuclear macromolecular structures called the PML bodies. The PML gene is frequently involved in the t(15; 17) chromosomal translocation of acute promyelocytic leukemia (APL). The translocation results in a fusion gene product, PML-RAR alpha, in which the PML gene fuses to the retinoic acid receptor alpha (RAR alpha) gene. PML-RAR alpha has been shown to promote transcriptional repression of genes involved in myeloid terminal differentiation and to disrupt the architecture of PML bodies, a phenotype reversed by treatment with all trans retinoic acid (ATRA). However, there are several alternatively spliced isoforms of PML-RAR alpha. Here, we addressed the differences between the short and the long isoforms of PML-RAR alpha (L and S) since both are associated with APL. We demonstrate that PML-RAR alpha L, but not PML-RAR alpha S, can directly promote cell growth by transcriptionally activating the pro-proliferative gene, c-fos, in response to mitogenic stimulation. The activity of the PML-RAR alpha L is completely sensitive to ATRA. We further show that this activation is not via direct recruitment of the protein to the c-fos promoter but indirectly by altering the chromosomal environment of the c-fos gene, thereby rendering it more accessible to the signal induced transcriptional activators. Our results suggest that in addition to antagonizing the PML-tumor suppressor or the PML-pro-apoptotic activity, PML-RAR alpha proteins can also directly promote cell growth by activating c-fos.	Tufts Univ, Dept Pathol, Sch Med, Boston, MA 02111 USA; Tufts Univ, Program Immunol, Sch Med, Boston, MA 02111 USA; Tufts Univ, Genet Program, Sch Med, Boston, MA 02111 USA	Tufts University; Tufts University; Tufts University	Roy, AL (corresponding author), Tufts Univ, Dept Pathol, Sch Med, 150 Harrison Ave, Boston, MA 02111 USA.	ananda.roy@tufts.edu		Tussie-Luna, Maria Isabel/0000-0002-5033-408X	NIAID NIH HHS [AI056240] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI056240] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Alcalay M, 2003, J CLIN INVEST, V112, P1751, DOI 10.1172/JCI17595; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Casini T, 1999, ONCOGENE, V18, P3235, DOI 10.1038/sj.onc.1202630; Codina A, 2005, P NATL ACAD SCI USA, V102, P6009, DOI 10.1073/pnas.0500299102; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; DOUCAS V, 1993, P NATL ACAD SCI USA, V90, P9345, DOI 10.1073/pnas.90.20.9345; Duprez E, 2004, CELL CYCLE, V3, P389; Duprez E, 2003, EMBO J, V22, P5806, DOI 10.1093/emboj/cdg556; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575; Hartman HB, 2005, EMBO REP, V6, P445, DOI 10.1038/sj.embor.7400391; Hauksdottir H, 2001, CELL GROWTH DIFFER, V12, P85; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Insinga A, 2005, CELL CYCLE, V4, P67, DOI 10.4161/cc.4.1.1400; Insinga A, 2004, EMBO J, V23, P1144, DOI 10.1038/sj.emboj.7600109; Jurcic JG, 2001, BLOOD, V98, P2651, DOI 10.1182/blood.V98.9.2651; Kane JR, 1996, LEUKEMIA, V10, P1296; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Li QJ, 2003, EMBO J, V22, P281, DOI 10.1093/emboj/cdg028; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lunghi P, 2005, LEUKEMIA, V19, P234, DOI 10.1038/sj.leu.2403585; Marmorstein R, 2001, NAT REV MOL CELL BIO, V2, P422, DOI 10.1038/35073047; Meani N, 2005, ONCOGENE, V24, P3358, DOI 10.1038/sj.onc.1208498; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Muller C, 2000, BLOOD, V96, P3894, DOI 10.1182/blood.V96.12.3894.h8003894_3894_3899; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Nissen LJ, 2001, J BIOL CHEM, V276, P5213, DOI 10.1074/jbc.M007824200; Nouzova M, 2004, J PHARMACOL EXP THER, V311, P968, DOI 10.1124/jpet.104.072488; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; Pandolfi PP, 2001, HUM MOL GENET, V10, P769, DOI 10.1093/hmg/10.7.769; Park DJ, 2003, BLOOD, V102, P3727, DOI 10.1182/blood-2003-02-0412; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Segalla S, 2003, MOL CELL BIOL, V23, P8795, DOI 10.1128/MCB.23.23.8795-8808.2003; Soprano DR, 2004, ANNU REV NUTR, V24, P201, DOI 10.1146/annurev.nutr.24.012003.132407; Sucic M, 2002, J HEMATOTH STEM CELL, V11, P941, DOI 10.1089/152581602321080600; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Zelent A, 2001, ONCOGENE, V20, P7186, DOI 10.1038/sj.onc.1204766; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807; Zhu J, 2001, ONCOGENE, V20, P7257, DOI 10.1038/sj.onc.1204852	54	11	12	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3375	3386		10.1038/sj.onc.1209388	http://dx.doi.org/10.1038/sj.onc.1209388			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16434964				2022-12-28	WOS:000238448100003
J	Veeck, J; Niederacher, D; An, H; Klopocki, E; Wiesmann, F; Betz, B; Galm, O; Camara, O; Durst, M; Kristiansen, G; Huszka, C; Knuchel, R; Dahl, E				Veeck, J.; Niederacher, D.; An, H.; Klopocki, E.; Wiesmann, F.; Betz, B.; Galm, O.; Camara, O.; Duerst, M.; Kristiansen, G.; Huszka, C.; Knuechel, R.; Dahl, E.			Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis	ONCOGENE			English	Article						breast cancer; tumour suppressor gene; Wnt pathway; SFRP1; methylation; epigenetics	TUMOR-SUPPRESSOR; BETA-CATENIN; PROMOTER HYPERMETHYLATION; EPIGENETIC INACTIVATION; COLORECTAL-CANCER; BLADDER-CANCER; OVARIAN-CANCER; COMMON EVENT; CYCLIN D1; GENE	The canonical Wnt signalling pathway plays a key role during embryogenesis and defects in this pathway have been implicated in the pathogenesis of various types of tumours, including breast cancer. The gene for secreted frizzled-related protein 1 (SFRP1) encodes a soluble Wnt antagonist and is located in a chromosomal region (8p22-p12) that is often deleted in breast cancer. In colon, lung, bladder and ovarian cancer SFRP1 expression is frequently inactivated by promoter methylation. We have previously shown that loss of SFRP1 protein expression is a common event in breast tumours that is associated with poor overall survival in patients with early breast cancer. To investigate the cause of SFRP1 loss in breast cancer, we performed mutation, methylation and expression analysis in human primary breast tumours and breast cell lines. No SFRP1 gene mutations were detected. However, promoter methylation of SFRP1 was frequently observed in both primary breast cancer (61%, n=130) and cell lines analysed by methylation-specific polymerase chain reaction (MSP). We found a tight correlation (P < 0.001) between methylation and loss of SFRP1 expression in primary breast cancer tissue. SFRP1 expression was restored after treatment of tumour cell lines with the demethylating agent 5-aza-2'-deoxycytidine. Most interestingly, SFRP1 promoter methylation was an independent factor for adverse patient survival in Kaplan-Meier analysis. Our results indicate that promoter hypermethylation is the predominant mechanism of SFRP1 gene silencing in human breast cancer and that SFRP1 gene inactivation in breast cancer is associated with unfavourable prognosis.	Univ Hosp Aachen, Rhein Westfal TH Aachen, Inst Pathol, D-52074 Aachen, Germany; Univ Dusseldorf, Dept Obstet & Gynecol, D-4000 Dusseldorf, Germany; Free Univ Berlin, Inst Med Genet, Berlin, Germany; Univ Hosp Aachen, Rhein Westfal TH Aachen, Med Clin 4, D-52074 Aachen, Germany; Univ Jena, Dept Gynecol, D-6900 Jena, Germany; Free Univ Berlin, Inst Pathol, Berlin, Germany	RWTH Aachen University; RWTH Aachen University Hospital; Heinrich Heine University Dusseldorf; Free University of Berlin; RWTH Aachen University; RWTH Aachen University Hospital; Friedrich Schiller University of Jena; Free University of Berlin	Dahl, E (corresponding author), Univ Hosp Aachen, Rhein Westfal TH Aachen, Inst Pathol, Pauwelsstr 30, D-52074 Aachen, Germany.	edahl@ukaachen.de	Klopocki, Eva/B-6823-2017; Veeck, Jürgen/B-9256-2008	Klopocki, Eva/0000-0003-1438-2081; Veeck, Jürgen/0000-0002-2952-6159; An, Han-Xiang/0000-0002-3453-9149				Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brown AMC, 2001, BREAST CANCER RES, V3, P351, DOI 10.1186/bcr321; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; Costa FF, 2004, ONCOGENE, V23, P1481, DOI 10.1038/sj.onc.1207263; Dahl E, 2005, J PATHOL, V205, P21, DOI 10.1002/path.1687; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2002, J NATL CANCER I, V94, P26; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327; Fukui T, 2005, ONCOGENE, V24, P6323, DOI 10.1038/sj.onc.1208777; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Klopocki E, 2004, INT J ONCOL, V25, P641; Lai J, 2003, BRIT J CANCER, V88, P270, DOI 10.1038/sj.bjc.6600674; Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Marsit CJ, 2005, CANCER RES, V65, P7081, DOI 10.1158/0008-5472.CAN-05-0267; Niederacher D, 1997, GENE CHROMOSOME CANC, V18, P181, DOI 10.1002/(SICI)1098-2264(199703)18:3<181::AID-GCC5>3.0.CO;2-Y; Oshiro MM, 2005, BREAST CANCER RES, V7, pR669, DOI 10.1186/bcr1273; Polakis P, 2000, GENE DEV, V14, P1837; REMMELE W, 1987, PATHOLOGE, V8, P138; Seitz S, 1997, ONCOGENE, V14, P741, DOI 10.1038/sj.onc.1200881; Stoehr R, 2004, LAB INVEST, V84, P465, DOI 10.1038/labinvest.3700068; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Takada T, 2004, CANCER SCI, V95, P741, DOI 10.1111/j.1349-7006.2004.tb03255.x; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; Varga AE, 2005, ONCOGENE, V24, P5043, DOI 10.1038/sj.onc.1208688; Waki T, 2003, ONCOGENE, V22, P4128, DOI 10.1038/sj.onc.1206651; Yokota T, 1999, CANCER-AM CANCER SOC, V85, P447	40	203	217	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3479	3488		10.1038/sj.onc.1209386	http://dx.doi.org/10.1038/sj.onc.1209386			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16449975				2022-12-28	WOS:000238448100013
J	Doane, AS; Danso, M; Lal, P; Donaton, M; Zhang, L; Hudis, C; Gerald, WL				Doane, A. S.; Danso, M.; Lal, P.; Donaton, M.; Zhang, L.; Hudis, C.; Gerald, W. L.			An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen	ONCOGENE			English	Article						breast cancer; estrogen receptor-negative; androgen responsive; gene expression	POSTMENOPAUSAL WOMEN; PROGESTERONE-RECEPTORS; CELL-PROLIFERATION; CYCLIN D1; EXPRESSION; THERAPY; GROWTH; GENES; MICROARRAY; CARCINOMA	Little is known of the underlying biology of estrogen receptor-negative, progesterone receptor-negative (ER(-)/PR(-)) breast cancer (BC), and few targeted therapies are available. Clinical heterogeneity of ER(-)/ PR(-) tumors suggests that molecular subsets exist. We performed genome-wide expression analysis of 99 primary BC samples and eight BC cell lines in an effort to reveal distinct subsets, provide insight into their biology and potentially identify new therapeutic targets. We identified a subset of ER(-)/PR(-) tumors with paradoxical expression of genes known to be either direct targets of ER, responsive to estrogen, or typically expressed in ER(+) BC. Differentially expressed genes included SPDEF, FOXA1, XBP1, CYB5, TFF3, NAT1, APOD, ALCAM and AR (P < 0.001). A classification model based on the expression signature of this tumor class identified molecularly similar BCs in an independent human BC data set and among BC cell lines (MDA-MB453). This cell line demonstrated a proliferative response to androgen in an androgen receptor-dependent and ER-independent manner. In addition, the androgen-induced transcriptional program of MDA-MB-453 significantly overlapped the molecular signature of the unique ER(-)/PR(-) subclass of human tumors. This subset of BCs, characterized by a hormonally regulated transcriptional program and response to androgen, suggests the potential for therapeutic strategies targeting the androgen signaling pathway.	Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Gerald, WL (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA.	geraldw@mskcc.org	Doane, Ashley/R-4263-2016; Doane, Ashley Stephen/A-6442-2015; Hudis, Clifford/AAW-9482-2021; Doane, Ashley Stephen/B-7027-2008	Doane, Ashley/0000-0002-1489-1786; Doane, Ashley Stephen/0000-0002-1489-1786; Hudis, Clifford/0000-0001-7144-8791; Doane, Ashley Stephen/0000-0002-1489-1786				Agoff SN, 2003, AM J CLIN PATHOL, V120, P725, DOI 10.1309/42F00D0DJD0J5EDT; BIRRELL SN, 1995, J STEROID BIOCHEM, V52, P459, DOI 10.1016/0960-0760(95)00005-K; Buchanan G, 2005, CANCER RES, V65, P8487, DOI 10.1158/0008-5472.CAN-04-3077; Carsol JL, 2002, MOL ENDOCRINOL, V16, P1696, DOI 10.1210/me.16.7.1696; Cato A.C., 2002, SCI STKE, V2002, pre9, DOI [10.1126/stke.2002.138.re9, DOI 10.1126/STKE.2002.138.RE9]; Cunliffe HE, 2003, CANCER RES, V63, P7158; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; DeRisi J, 1996, NAT GENET, V14, P457; Dhanasekaran SM, 2004, FASEB J, V18, P243, DOI 10.1096/fj.04-2415fje; Dickson C, 2000, BREAST CANCER RES, V2, P191, DOI 10.1186/bcr53; Farmer P, 2005, ONCOGENE, V24, P4660, DOI 10.1038/sj.onc.1208561; Gatalica Z, 1997, PATHOL RES PRACT, V193, P753, DOI 10.1016/S0344-0338(97)80053-2; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Goss PE, 2003, NEW ENGL J MED, V349, P1793, DOI 10.1056/NEJMoa032312; Greeve MA, 2004, J MOL ENDOCRINOL, V32, P793, DOI 10.1677/jme.0.0320793; Gruber CJ, 2002, NEW ENGL J MED, V346, P340, DOI 10.1056/NEJMra000471; Gruvberger S, 2001, CANCER RES, V61, P5979; Hall RE, 1996, BRIT J CANCER, V74, P1175, DOI 10.1038/bjc.1996.513; HALL RE, 1994, EUR J CANCER, V30A, P484, DOI 10.1016/0959-8049(94)90424-3; Holzbeierlein J, 2004, AM J PATHOL, V164, P217, DOI 10.1016/S0002-9440(10)63112-4; Howell A, 2005, LANCET, V365, P60, DOI 10.1016/s0140-6736(04)17666-6; ISOLA JJ, 1993, J PATHOL, V170, P31, DOI 10.1002/path.1711700106; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Koziczak M, 2004, J BIOL CHEM, V279, P50004, DOI 10.1074/jbc.M404252200; Koziczak M, 2004, ONCOGENE, V23, P3501, DOI 10.1038/sj.onc.1207331; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; Lal P, 2005, AM J CLIN PATHOL, V123, P541, DOI 10.1309/YMJ3A83TB39MRUT9; LIPPMAN M, 1976, CANCER RES, V36, P4610; Losel RM, 2003, PHYSIOL REV, V83, P965, DOI 10.1152/physrev.00003.2003; Matsuo Kaneyuki, 2002, Breast Cancer, V9, P43, DOI 10.1007/BF02967546; Mayfield S, 2001, BREAST CANCER RES TR, V70, P123, DOI 10.1023/A:1012999012192; McKenna NJ, 2002, ENDOCRINOLOGY, V143, P2461, DOI 10.1210/endo.143.7.8892; Mellinghoff IK, 2004, CANCER CELL, V6, P517, DOI 10.1016/j.ccr.2004.09.031; MILLER WR, 1985, BREAST CANCER RES TR, V5, P67, DOI 10.1007/BF01807652; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mouridsen H, 2001, J CLIN ONCOL, V19, P2596, DOI 10.1200/JCO.2001.19.10.2596; Nagahata T, 2004, CANCER SCI, V95, P218, DOI 10.1111/j.1349-7006.2004.tb02206.x; Nantermet PV, 2005, ENDOCRINOLOGY, V146, P564, DOI 10.1210/en.2004-1132; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Osborne CK, 2004, BRIT J CANCER, V90, pS2, DOI 10.1038/sj.bjc.6601629; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pusztai L, 2003, CLIN CANCER RES, V9, P2406; Rossi S, 2003, MOL CANCER RES, V1, P707; Sapp Michelle, 2003, Breast J, V9, P335, DOI 10.1046/j.1524-4741.2003.09422.x; Shao DL, 1999, J CLIN INVEST, V103, P1617, DOI 10.1172/JCI7421; Shurbaji MS, 1996, HUM PATHOL, V27, P917, DOI 10.1016/S0046-8177(96)90218-X; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Smith IE, 2003, NEW ENGL J MED, V348, P2431, DOI 10.1056/NEJMra023246; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Steketee K, 2004, J MOL ENDOCRINOL, V33, P477, DOI 10.1677/jme.1.01478; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tang SH, 2004, NUCLEIC ACIDS RES, V32, pD533, DOI 10.1093/nar/gkh083; Tobias JS, 2004, ANN ONCOL, V15, P1738, DOI 10.1093/annonc/mdh485; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Wilson CA, 2004, BREAST CANCER RES, V6, P192, DOI 10.1186/bcr917; Wong YC, 2001, MARC MALPIG SYMP SER, V7, P111; Yakes FM, 2002, CANCER RES, V62, P4132	60	417	441	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3994	4008		10.1038/sj.onc.1209415	http://dx.doi.org/10.1038/sj.onc.1209415			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16491124	Bronze			2022-12-28	WOS:000238668800013
J	Tan, M; Li, P; Sun, M; Yin, G; Yu, D				Tan, M.; Li, P.; Sun, M.; Yin, G.; Yu, D.			Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKCa and Src inhibitors	ONCOGENE			English	Article						breast cancer; invasion; metastasis; Src; PKC alpha; ErbB2	PROTEIN-KINASE-C; TUMOR PROGRESSION; FAMILY KINASES; EXPRESSION; OVEREXPRESSION; METASTASIS; THERAPY; PHOSPHORYLATION; TRANSFORMATION; INVASIVENESS	Although ErbB2 is known to enhance breast cancer metastasis, the signaling events responsible for this remain elusive. alpha-Isozyme of protein kinase C (PKC alpha), which is involved in cancer development and progression, has been suggested to be activated by ErbB2 without direct evidence. In addition, the roles of PKC alpha in ErbB2-mediated cancer cell malignancy have not been clearly identifed. In this study, we investigated whether ErbB2 can activate PKC alpha and determined what role PKCa plays in ErbB2-mediated breast cancer cell invasion. We expressed wild-type and mutant ErbB2 with altered signaling capacities in MDA-MB-435 breast cancer cells and revealed that overexpression or activation of ErbB2 in MDA-MB-435 cells upregulated and activated PKC alpha and that downregulation of ErbB2by small-interfering RNA decreased the expression and activity of PKC alpha in BT474 breast cancer cells. These in vitro results were supported by data from breast cancer patient samples. In 150 breast cancer tumor samples, ErbB2-overexpressing tumors showed significantly higher positive rates of PKCa membrane immunohistochemistry staining than that of ErbB2-low-expressing tumors. Mechanistically, we found that PKC alpha is co-immunoprecipitated with Src and PKC alpha expression and activity can be decreased by Src inhibitor PP2 and by the expression of a dominantnegative mutant of Src. Moreover, ErbB2-mediated upregulation of urokinase-type plasminogen activator receptor (uPAR) is reduced by either the PKC alpha inhibitor Go6976 or the Src inhibitor PP2, and the combination of Go6976 with PP2 is superior to either agent alone in suppressing uPAR expression and cell invasion. These results demonstrate that PKC alpha is critical for ErbB2-mediated cancer cell invasion and provide valuable insights for current and future PKC alpha and Src inhibitor clinical trials.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Unit 107, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Yu, D (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Unit 107, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dyu@mdanderson.org	Tan, Ming/ABD-5847-2021; Yin, Guosheng/D-3214-2009	Tan, Ming/0000-0003-2007-9898; Yu, Dihua/0000-0001-6231-9381; Yin, Guosheng/0000-0003-3276-1392	NCI NIH HHS [2R01-CA60488, 1R01-CA109570, P30-CA16672, P01-CA099031, R01-CA112567] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA109570, P30CA016672, R01CA112567, P01CA099031, R01CA060488] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Boyd DD, 2004, CLIN CANCER RES, V10, P1545, DOI 10.1158/1078-0432.CCR-1565-02; de Bono JS, 2003, BREAST CANCER RES, V5, P154, DOI 10.1186/bcr597; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; GUM R, 1995, ANTICANCER RES, V15, P1167; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Huigsloot M, 2003, MOL PHARMACOL, V64, P965, DOI 10.1124/mol.64.4.965; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Johnson MD, 1999, EXP CELL RES, V247, P105, DOI 10.1006/excr.1998.4336; Kos KS, 2003, CANCER-AM CANCER SOC, V98, P1377, DOI 10.1002/cncr.11656; Lahn M, 2004, ONCOLOGY-BASEL, V67, P1, DOI 10.1159/000080279; Longo M, 2004, BONE, V34, P100, DOI 10.1016/j.bone.2003.09.007; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Masur K, 2001, MOL BIOL CELL, V12, P1973, DOI 10.1091/mbc.12.7.1973; Michie AM, 2005, IMMUNOL LETT, V96, P155, DOI 10.1016/j.imlet.2004.08.013; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; Morse-Gaudio M, 1998, INT J ONCOL, V12, P1349; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Palka HL, 1997, J CELL SCI, V110, P2359; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Parker PJ, 2004, J CELL SCI, V117, P131, DOI 10.1242/jcs.00982; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; Sidenius N, 2003, CANCER METAST REV, V22, P205, DOI 10.1023/A:1023099415940; Sliva D, 2004, CURR CANCER DRUG TAR, V4, P327, DOI 10.2174/1568009043332961; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Tan M, 1999, CANCER RES, V59, P1620; Tan M, 2005, CANCER RES, V65, P1858, DOI 10.1158/0008-5472.CAN-04-2353; Tan M, 1997, CANCER RES, V57, P1199; VADERGREER P, 1994, ANN REV CELL BIOL, V10, P251; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Yu DH, 1996, ONCOGENE, V13, P1359; Zhou XY, 2004, CLIN CANCER RES, V10, P6779, DOI 10.1158/1078-0432.CCR-04-0112	39	74	75	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3286	3295		10.1038/sj.onc.1209361	http://dx.doi.org/10.1038/sj.onc.1209361			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16407820				2022-12-28	WOS:000237951200007
J	Ehtesham, M; Winston, JA; Kabos, P; Thompson, RC				Ehtesham, M; Winston, JA; Kabos, P; Thompson, RC			CXCR4 expression mediates glioma cell invasiveness	ONCOGENE			English	Article						chemokine; CXCR4; invasion; glioma; brain tumor	BREAST-CANCER METASTASIS; NF-KAPPA-B; TUMOR-GROWTH; CHEMOKINE RECEPTOR; MALIGNANT GLIOMA; INVASION; MIGRATION; BRAIN; METALLOPROTEINASE; ANGIOGENESIS	Glioblastoma multiforme is a highly invasive tumor bearing a dismal prognosis. Experimental strategies that focus on the specific biological cues governing the invasive capacity of these tumors may hold significant therapeutic promise. In this context, we describe the in vitro and in vivo association of the cell surface chemokine receptor, CXCR4, with the development of an invasive phenotype in malignant glioblastoma. We demonstrate that invasive populations of glioma cells overexpress CXCR4 at the message and protein levels, and that this expression ranges from 25- to 89-fold higher than that found in noninvasive tumor cells. Furthermore, neutralization of CXCR4 significantly impairs the in vitro invasive capacity of malignant glial cells. In addition, glioma cells secrete CXCL12 and demonstrate robust invasive capacity toward a CXCL12 gradient in vitro. These findings underscore the importance of CXCR4 as a potential therapeutic target for the treatment of invasive glioblastoma.	Vanderbilt Univ, Med Ctr, Dept Neurol Surg, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Univ So Calif, Dept Med, Los Angeles, CA USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Southern California	Ehtesham, M (corresponding author), Vanderbilt Univ, Med Ctr, Dept Neurol Surg, T-4224 Med Ctr N, Nashville, TN 37232 USA.	moneeb.ehtesham@vanderbilt.edu			NINDS NIH HHS [NS051557] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS051557] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barbero S, 2003, CANCER RES, V63, P1969; Bartolome RA, 2004, CANCER RES, V64, P2534, DOI 10.1158/0008-5472.CAN-03-3398; Belperio JA, 2004, CHEST, V125, p156S, DOI 10.1378/chest.125.5_suppl.156S; COLEMAN MT, 1980, CANCER LETT, V8, P255, DOI 10.1016/0304-3835(80)90011-7; Ehtesham M, 2003, J IMMUNOTHER, V26, P107, DOI 10.1097/00002371-200303000-00003; Ehtesham M, 2002, CANCER GENE THER, V9, P925, DOI 10.1038/sj.cgt.7700516; Fernandis AZ, 2004, ONCOGENE, V23, P157, DOI 10.1038/sj.onc.1206910; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Lakka SS, 2004, ONCOGENE, V23, P4681, DOI 10.1038/sj.onc.1207616; Lakka SS, 2002, ONCOGENE, V21, P8011, DOI 10.1038/sj.onc.1205894; Liang ZX, 2005, CANCER RES, V65, P967; Mori T, 2004, MOL CANCER THER, V3, P29; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Oh JW, 2001, J IMMUNOL, V166, P2695, DOI 10.4049/jimmunol.166.4.2695; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Rubin JB, 2003, P NATL ACAD SCI USA, V100, P13513, DOI 10.1073/pnas.2235846100; Singh S, 2004, LAB INVEST, V84, P1666, DOI 10.1038/labinvest.3700181; Strieter RM, 2001, NAT IMMUNOL, V2, P285, DOI 10.1038/86286; Surawicz TS, 1998, J NEURO-ONCOL, V40, P151, DOI 10.1023/A:1006091608586; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Woo JH, 2003, CANCER RES, V63, P3430; Yu JS, 2001, CANCER RES, V61, P842; Zeelenberg IS, 2003, CANCER RES, V63, P3833; ZHANG J, 2005, CARCINOGENESIS; Zhou Y, 2002, J BIOL CHEM, V277, P49481, DOI 10.1074/jbc.M206222200	26	153	164	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2006	25	19					2801	2806		10.1038/sj.onc.1209302	http://dx.doi.org/10.1038/sj.onc.1209302			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16407848				2022-12-28	WOS:000237272900011
J	Li, N; Li, H; Cherukuri, P; Farzan, S; Harmes, DC; DiRenzo, J				Li, N; Li, H; Cherukuri, P; Farzan, S; Harmes, DC; DiRenzo, J			TA-p63-gamma regulates expression of Delta N-p63 in a manner that is sensitive to p53	ONCOGENE			English	Article						p63; p53; mammary gland; progenitor; self-renewal	EPITHELIAL STEM-CELLS; P63 GENE-MUTATIONS; BREAST-CANCER; DIFFERENTIAL REGULATION; DEVELOPMENTAL SYNDROMES; PROTEIN-DEGRADATION; MAMMARY-GLAND; TARGET GENES; SELF-RENEWAL; EEC-SYNDROME	Geneticanalysis indicates that TP63 is required for establishment and preservation of self-renewing progenitors within the basal layer of several epithelial structures, however, the specific contributions of transactivating ( TAp63) and dominant-negative (DN-p63) isoforms remain largely undemned. Recent studies have suggested a model in which TA-p63 plays an important role in the establishment of progenitor populations in which expression of Delta Np63 contributes to the preservation of self-renewing capacity. Our previous studies indicate that Delta N-p63 is a transcriptional target of p53, however, the absence of overt epithelial deficiencies in p53-/- mice and reports of increased expression of Delta N-p63 in p53-/- mice suggest p53-independent mechanisms also contribute to expression of DN-p63. Here, we present data indicating that, prolonged loss of p53 leads to the activation of a p53-independent mechanism for transcriptional regulation of DN-p63. This p53-independent mechanism is sensitive to ectopic p53 but not to a p53 mutant that lacks the transactivation domain. We further show that in cells in which p53 is expressed TA-p63-gamma protein is destabilized in a manner that is p53 dependent and sensitive to pharmacologic inhibition of the 26S proteosome. Consistent with this observation, we demonstrate that loss of p53 leads to the stabilization of TA-p63-gamma that is reversible by ectopic p53. Finally, we present evidence that disruption of TA-p63-gamma expression leads to decreased expression of Delta N-p63 and that overexpression of TA-p63c was sufficient to enhance the activity of the Delta N-p63 promoter. Taken together, our studies indicate that TAp63 gamma is capable of activating expression of Delta N-p63 and that this mechanism may account for p53-independent expression of DN-p63.	Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA	Dartmouth College	DiRenzo, J (corresponding author), Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.	james.direnzo@dartmouth.edu			NATIONAL CANCER INSTITUTE [R01CA108539] Funding Source: NIH RePORTER; NCI NIH HHS [1R01 CA108539] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Brunner HG, 2002, AM J MED GENET, V112, P284, DOI 10.1002/ajmg.10778; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Chepko G, 1999, J MAMMARY GLAND BIOL, V4, P35, DOI 10.1023/A:1018752519356; Clarke RB, 2003, CELL PROLIFERAT, V36, P1, DOI 10.1046/j.1365-2184.36.s.1.1.x; Di Como CJ, 2002, CLIN CANCER RES, V8, P494; Dick J E, 1996, Semin Immunol, V8, P197, DOI 10.1006/smim.1996.0025; DiRenzo J, 2002, CANCER RES, V62, P89; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Harmes DC, 2003, ONCOGENE, V22, P7607, DOI 10.1038/sj.onc.1207129; Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; Jerry DJ, 1999, J MAMMARY GLAND BIOL, V4, P177, DOI 10.1023/A:1018777224808; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Koster MI, 2002, J INVEST DERM SYMP P, V7, P41, DOI 10.1046/j.1523-1747.2002.19639.x; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Nylander K, 2002, J PATHOL, V198, P417, DOI 10.1002/path.1231; Nylander K, 2000, INT J CANCER, V87, P368, DOI 10.1002/1097-0215(20000801)87:3<368::AID-IJC9>3.3.CO;2-A; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; ROSNER B, 1994, AM J EPIDEMIOL, V139, P819, DOI 10.1093/oxfordjournals.aje.a117079; Smalley M, 2003, NAT REV CANCER, V3, P832, DOI 10.1038/nrc1212; Smith GH, 2001, MICROSC RES TECHNIQ, V52, P190, DOI 10.1002/1097-0029(20010115)52:2<190::AID-JEMT1005>3.0.CO;2-O; Suliman Y, 2001, CANCER RES, V61, P6467; Trosko JE, 2003, ONCOL RES, V13, P353; van Bokhoven H, 2001, AM J HUM GENET, V69, P481, DOI 10.1086/323123; van Bokhoven H, 2002, TRENDS MOL MED, V8, P133, DOI 10.1016/S1471-4914(01)02260-2; Waltermann A, 2003, ONCOGENE, V22, P5686, DOI 10.1038/sj.onc.1206859; Welm AL, 2005, P NATL ACAD SCI USA, V102, P4324, DOI 10.1073/pnas.0500470102; Welm B, 2003, CELL PROLIFERAT, V36, P17, DOI 10.1046/j.1365-2184.36.s.1.3.x; Wu GJ, 2003, CANCER RES, V63, P2351; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Ying HQ, 2005, MOL CELL BIOL, V25, P6154, DOI 10.1128/MCB.25.14.6154-6164.2005	40	22	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2349	2359		10.1038/sj.onc.1209270	http://dx.doi.org/10.1038/sj.onc.1209270			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16331262				2022-12-28	WOS:000236764300007
J	Zhou, YT; Guy, GR; Low, BC				Zhou, YT; Guy, GR; Low, BC			BNIP-S alpha induces cell rounding and apoptosis by displacing p50RhoGAP and facilitating RhoA activation via its unique motifs in the BNIP-2 and Cdc42GAP homology domain	ONCOGENE			English	Article						BNIP-S; RhoA; BCH domain; p50RhoGAP/Cdc42GAP; cell rounding; apoptosis	AKT PHOSPHORYLATION; BCL-2 EXPRESSION; FAMILY PROTEINS; F-ACTIN; GTPASES; KINASE; GROWTH; TRANSLOCATION; BINDING; HOMOLOGY/SEC14P-LIKE	Changes in cell morphology are linked to many cellular events including cytokinesis, differentiation, migration and apoptosis. We recently showed that BNIP-S alpha induced cell rounding that leads to apoptosis via its BNIP-2 and Cdc42GAP Homology (BCH) domain, but the underlying mechanism has not been determined. Here, we have identified a unique region (amino acid 133-177) of the BNIP-S alpha BCH domain that targets RhoA, but not Cdc42 or Rac1 and only the dominant-negative form of RhoA could prevent the resultant cell rounding and apoptotic effect. The RhoA-binding region consists of two parts; one region (residues 133-147) that shows some homology to part of the RhoA switch I region and an adjacent sequence (residues 148-177) that resembles the REM class I RhoA-binding motif. The sequence 133-147 is also necessary for its heterophilic interaction with the BCH domain of the Rho GTPase-activating protein, p50RhoGAP/Cdc42GAP. These overlapping motifs allow tripartite competition such that overexpression of BNIP-S alpha could reduce p50RhoGAP binding to RhoA and restore RhoA activation. Furthermore, BNIP-Sa mutants lacking the RhoA-binding motif completely failed to induce cell rounding and apoptosis. Therefore, via unique binding motifs within its BCH domain, BNIP-S alpha could interact and activate RhoA while preventing its inhibition by p50RhoGAP. This concerted mechanism could allow effective propagation of the RhoA pathway for cell rounding and apoptosis.	Natl Univ Singapore, Dept Biol Sci, Cell Signaling & Dev Biol Lab, Singapore 117548, Singapore; Natl Univ Singapore, Inst Mol & Cell Biol, Signal Transduct Lab, Singapore 117548, Singapore	National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Low, BC (corresponding author), Natl Univ Singapore, Dept Biol Sci, Cell Signaling & Dev Biol Lab, 14 Sci Dr 4, Singapore 117548, Singapore.	dbslowbc@nus.edu.sg	Low, Boon Chuan/H-8049-2012; Low, Boon Chuan/AAU-7685-2021	Low, Boon Chuan/0000-0003-0756-096X; Low, Boon Chuan/0000-0003-0756-096X; Zhou, Yi-Ting/0000-0003-4543-3099				Aspenstrom P, 1999, EXP CELL RES, V246, P20, DOI 10.1006/excr.1998.4300; Aznar S, 2001, CANCER LETT, V165, P1, DOI 10.1016/S0304-3835(01)00412-8; Bando M, 2002, BIOCHEM BIOPH RES CO, V290, P268, DOI 10.1006/bbrc.2001.6199; Bayless KJ, 2004, J BIOL CHEM, V279, P11686, DOI 10.1074/jbc.M308373200; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Chua BT, 2003, NAT CELL BIOL, V5, P1083, DOI 10.1038/ncb1070; Coleman ML, 2002, CELL DEATH DIFFER, V9, P493, DOI 10.1038/sj.cdd.4400987; Collard JG, 2004, NATURE, V428, P705, DOI 10.1038/428705a; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Croft DR, 2005, J CELL BIOL, V168, P245, DOI 10.1083/jcb.200409049; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; Dvorsky R, 2004, EMBO REP, V5, P1130, DOI 10.1038/sj.embor.7400293; Fiorentini C, 1998, EXP CELL RES, V242, P341, DOI 10.1006/excr.1998.4057; Fiorentini C, 1998, INFECT IMMUN, V66, P2660, DOI 10.1128/IAI.66.6.2660-2665.1998; Flusberg DA, 2001, MOL BIOL CELL, V12, P3087, DOI 10.1091/mbc.12.10.3087; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gourlay CW, 2005, J CELL SCI, V118, P2119, DOI 10.1242/jcs.02337; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Jenna S, 2002, J BIOL CHEM, V277, P6366, DOI 10.1074/jbc.M105516200; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; Kim O, 2002, J BIOL CHEM, V277, P30066, DOI 10.1074/jbc.M201713200; Kim SJ, 2003, J BIOL CHEM, V278, P42448, DOI 10.1074/jbc.M304887200; Korichneva I, 1999, J CELL SCI, V112, P2521; Lim J, 2000, J BIOL CHEM, V275, P32837, DOI 10.1074/jbc.M002156200; Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514; Low BC, 1999, J BIOL CHEM, V274, P33123, DOI 10.1074/jbc.274.46.33123; Low BC, 2000, J BIOL CHEM, V275, P14415, DOI 10.1074/jbc.275.19.14415; Low BC, 2000, J BIOL CHEM, V275, P37742, DOI 10.1074/jbc.M004897200; Lua BL, 2004, MOL BIOL CELL, V15, P2873, DOI 10.1091/mbc.E04-02-0141; Melamed I, 1999, CELL IMMUNOL, V194, P136, DOI 10.1006/cimm.1999.1506; Mills JC, 1999, J CELL BIOL, V146, P703, DOI 10.1083/jcb.146.4.703; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Posey SC, 1999, J BIOL CHEM, V274, P4259, DOI 10.1074/jbc.274.7.4259; Qin WX, 2003, BIOCHEM BIOPH RES CO, V308, P379, DOI 10.1016/S0006-291X(03)01387-1; Reuveny M, 2004, FEBS LETT, V569, P129, DOI 10.1016/j.febslet.2004.05.035; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Saeki N, 2005, J BIOL CHEM, V280, P10128, DOI 10.1074/jbc.M413415200; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Shang X, 2003, J BIOL CHEM, V278, P45903, DOI 10.1074/jbc.M304514200; Song YH, 2002, EXP CELL RES, V278, P45, DOI 10.1006/excr.2002.5565; Spector D. L., 1998, CELLS LAB MANUAL; Subauste MC, 2000, J BIOL CHEM, V275, P9725, DOI 10.1074/jbc.275.13.9725; Suria H, 1999, LIFE SCI, V65, P2697, DOI 10.1016/S0024-3205(99)00538-X; Surks HK, 2003, J BIOL CHEM, V278, P51484, DOI 10.1074/jbc.M305622200; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; Tosello-Trampont AC, 2003, J BIOL CHEM, V278, P49911, DOI 10.1074/jbc.M306079200; Ueda H, 2004, EXP CELL RES, V298, P207, DOI 10.1016/j.yexcr.2004.04.015; Wang L, 2006, BLOOD, V107, P98, DOI 10.1182/blood-2005-05-2171; Wang L, 2005, P NATL ACAD SCI USA, V102, P13484, DOI 10.1073/pnas.0504420102; Wennerberg K, 2003, CURR BIOL, V13, P1106, DOI 10.1016/S0960-9822(03)00418-4; White SR, 2001, AM J RESP CELL MOL, V24, P282, DOI 10.1165/ajrcmb.24.3.3995; Yamashita T, 2003, NAT NEUROSCI, V6, P461, DOI 10.1038/nn1045; Zhou XL, 2004, ONCOGENE, V23, P1308, DOI 10.1038/sj.onc.1207246; Zhou Yi Ting, 2005, Experimental Cell Research, V303, P263, DOI 10.1016/j.yexcr.2004.08.044; Zhou YT, 2002, J BIOL CHEM, V277, P7483, DOI 10.1074/jbc.M109459200	58	18	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2393	2408		10.1038/sj.onc.1209274	http://dx.doi.org/10.1038/sj.onc.1209274			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16331259				2022-12-28	WOS:000236764300011
J	Rashi-Elkeles, S; Elkon, R; Weizman, N; Linhart, C; Amariglio, N; Sternberg, G; Rechavi, G; Barzilai, A; Shamir, R; Shiloh, Y				Rashi-Elkeles, S; Elkon, R; Weizman, N; Linhart, C; Amariglio, N; Sternberg, G; Rechavi, G; Barzilai, A; Shamir, R; Shiloh, Y			Parallel induction of ATM-dependent pro- and antiapoptotic signals in response to ionizing radiation in murine lymphoid tissue	ONCOGENE			English	Article						ATM; NF-kappa B; p53; IR response; microarrays	NF-KAPPA-B; CHRONIC LYMPHOCYTIC-LEUKEMIA; PROGRAMMED CELL-DEATH; DNA-DAMAGE; SACCHAROMYCES-CEREVISIAE; ATAXIA-TELANGIECTASIA; P53; ACTIVATION; EXPRESSION; PHOSPHORYLATION	The ATM protein kinase, functionally missing in patients with the human genetic disorder ataxia-telangiectasia, is a master regulator of the cellular network induced by DNA double-strand breaks. The ATM gene is also frequently mutated in sporadic cancers of lymphoid origin. Here, we applied a functional genomics approach that combined gene expression pro. ling and computational promoter analysis to obtain global dissection of the transcriptional response to ionizing radiation in murine lymphoid tissue. Cluster analysis revealed a prominent pattern characterizing dozens of genes whose response to irradiation was Atm-dependent. Computational analysis identified significant enrichment of the binding site signatures of NF-kappa B and p53 among promoters of these genes, pointing to the major role of these two transcription factors in mediating the Atm-dependent transcriptional response in the irradiated lymphoid tissue. Examination of the response showed that pro- and antiapoptotic signals were simultaneously induced, with the proapoptotic pathway mediated by p53 targets, and the prosurvival pathway by NF-kappa B targets. These findings further elucidate the molecular network induced by IR, point to novel putative NF-kappa B targets, and suggest a mechanistic model for cellular balancing between pro- and antiapoptotic signals induced by IR in lymphoid tissues, which has implications for cancer management. The emerging model suggests that restoring the p53-mediated apoptotic arm while blocking the NF-kappa B-mediated prosurvival arm could effectively increase the radiosensitivity of lymphoid tumors.	Sackler Sch Med, David Inez Myers Lab Genet Res, Dept Human Genet, IL-66978 Tel Aviv, Israel; George S Wise Fac Life Sci, Dept Neurobiochem, Tel Aviv, Israel; Sch Comp Sci, Tel Aviv, Israel; Chaim Sheba Med Ctr, Dept Pediat Hematooncol & Funct Genom, Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Shiloh, Y (corresponding author), Sackler Sch Med, David Inez Myers Lab Genet Res, Dept Human Genet, IL-66978 Tel Aviv, Israel.	yossih@post.tau.ac.il	Shamir, Ron/E-6514-2011	Shamir, Ron/0000-0003-1889-9870				ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Chun HH, 2004, DNA REPAIR, V3, P1187, DOI 10.1016/j.dnarep.2004.04.010; Clamp M, 2003, NUCLEIC ACIDS RES, V31, P38, DOI 10.1093/nar/gkg083; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Ding GR, 2003, RADIAT RES, V160, P232, DOI 10.1667/RR3018; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Elkon R, 2003, GENOME RES, V13, P773, DOI 10.1101/gr.947203; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Gasch AP, 2001, MOL BIOL CELL, V12, P2987, DOI 10.1091/mbc.12.10.2987; He KL, 2002, MOL CELL BIOL, V22, P6034, DOI 10.1128/MCB.22.17.6034-6045.2002; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Hur GM, 2003, GENE DEV, V17, P873, DOI 10.1101/gad.1062403; Jelinsky SA, 2000, MOL CELL BIOL, V20, P8157, DOI 10.1128/MCB.20.21.8157-8167.2000; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; MIYASHITA T, 1995, CELL, V80, P293; Pettitt AR, 2001, BLOOD, V98, P814, DOI 10.1182/blood.V98.3.814; Piret B, 1999, ONCOGENE, V18, P2261, DOI 10.1038/sj.onc.1202541; Qin ZH, 1999, J NEUROSCI, V19, P4023; Robles AI, 2001, CANCER RES, V61, P6660; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Sharan R, 2000, Proc Int Conf Intell Syst Mol Biol, V8, P307; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Shishodia S, 2004, BIOCHEM PHARMACOL, V68, P1071, DOI 10.1016/j.bcp.2004.04.026; Stankovic T, 2004, BLOOD, V103, P291, DOI 10.1182/blood-2003-04-1161; Stankovic T, 2002, BLOOD, V99, P300, DOI 10.1182/blood.V99.1.300; Stankovic T, 2002, LEUKEMIA LYMPHOMA, V43, P1563, DOI 10.1080/1042819021000002884; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Weston VJ, 2004, BLOOD, V104, P1465, DOI 10.1182/blood-2003-11-4039; WU HY, 1994, J BIOL CHEM, V269, P20067	41	59	61	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1584	1592		10.1038/sj.onc.1209189	http://dx.doi.org/10.1038/sj.onc.1209189			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16314843				2022-12-28	WOS:000235890400015
J	Humble, MC; Trempus, CS; Spalding, JW; Cannon, RE; Tennant, RW				Humble, MC; Trempus, CS; Spalding, JW; Cannon, RE; Tennant, RW			Biological, cellular, and molecular characteristics of an inducible transgenic skin tumor model: a review	ONCOGENE			English	Review						ras; epidermal; carcinogenesis; Tg.AC; carcinogen assay; transgenic mouse model	V-HA-RAS; TG.AC MOUSE SKIN; CENTER-DOT-AC; VASCULAR-PERMEABILITY FACTOR; LOCUS-CONTROL REGIONS; EPIDERMAL STEM-CELLS; GLOBIN GENE; ORNITHINE-DECARBOXYLASE; PAPILLOMA DEVELOPMENT; CARCINOGENICITY BIOASSAYS	The genetically initiated Tg.AC transgenic mouse carries a transgene consisting of an oncogenic v-Ha-ras coding region flanked 50 by a mouse zeta-globin promoter and 30 by an SV-40 polyadenylation sequence. Located on chromosome 11, the transgene is transcriptionally silent until activated by chemical carcinogens, UV light, or full-thickness wounding. Expression of the transgene is an early event that drives cellular proliferation resulting in clonal expansion and tumor formation, the unique characteristics now associated with the Tg.AC mouse. This ras-dependent phenotype has resulted in the widespread interest and use of the Tg.AC mouse in experimental skin carcinogenesis and as an alternative carcinogenesis assay. This review examines the general biology of the tumorigenic responses observed in Tg.AC mice, the genetic interactions of the ras transgene, and explores the cellular and molecular regulation of zeta-globin promoted transgene expression. As a prototype alternative model to the current long-term rodent bioassays, the Tg.AC has generated a healthy discussion on the future of transgenic bioassays, and opened the doors for subsequent models for toxicity testing. The further exploration and elucidation of the molecular controls of transgene expression will enhance the usefulness of this mouse and enable a better understanding of the Tg.AC's discriminate response to chemical carcinogens.	NIEHS, Natl ctr Toxicogenom, Res Triangle Pk, NC 27709 USA; Univ N Carolina, Curriculum Toxicol, Chapel Hill, NC 27514 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill	Cannon, RE (corresponding author), NIEHS, Natl ctr Toxicogenom, POB 12233,MD FI-05,111 Alexander Dr, Res Triangle Pk, NC 27709 USA.	cannon1@niehs.nih.gov			NIEHS NIH HHS [T32 ES07126] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES021175, T32ES007126, Z01ES021175, Z01ES100610] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARGYRIS TS, 1985, AM J IND MED, V8, P329, DOI 10.1002/ajim.4700080412; Asano S, 1998, TOXICOL PATHOL, V26, P512, DOI 10.1177/019262339802600407; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; Barry G, 1935, PROC R SOC SER B-BIO, V117, P318, DOI 10.1098/rspb.1935.0032; Battalora MS, 2001, CARCINOGENESIS, V22, P651, DOI 10.1093/carcin/22.4.651; Berenblum I, 1941, CANCER RES, V1, P807; Blanchard KT, 1998, TOXICOL PATHOL, V26, P541, DOI 10.1177/019262339802600410; BOS JL, 1989, CANCER RES, V49, P4682; BOUTWELL RK, 1964, PROG EXP TUMOR RES, V4, P207; Cannon RE, 2000, MOL CARCINOGEN, V29, P229, DOI 10.1002/1098-2744(200012)29:4<229::AID-MC1005>3.0.CO;2-9; Cannon RE, 1997, MOL CARCINOGEN, V20, P108, DOI 10.1002/(SICI)1098-2744(199709)20:1<108::AID-MC12>3.0.CO;2-5; Cannon RE, 1998, MOL CARCINOGEN, V21, P244, DOI 10.1002/(SICI)1098-2744(199804)21:4<244::AID-MC3>3.0.CO;2-K; CARDIFF RD, 1993, AM J PATHOL, V142, P1199; Chan EL, 2005, ONCOGENE, V24, P479, DOI 10.1038/sj.onc.1208231; Chignell CF, 2003, PHOTOCHEM PHOTOBIOL, V77, P77, DOI 10.1562/0031-8655(2003)077<0077:PITTAM>2.0.CO;2; Cohen SM, 2001, TOXICOL SCI, V64, P14, DOI 10.1093/toxsci/64.1.14; Collick A, 1996, EMBO J, V15, P1163, DOI 10.1002/j.1460-2075.1996.tb00455.x; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Deelman H T, 1927, Br Med J, V1, P872; Delker DA, 1999, TOXICOL SCI, V50, P90, DOI 10.1093/toxsci/50.1.90; Dodds AP, 2003, ARCH ORAL BIOL, V48, P843, DOI 10.1016/S0003-9969(03)00178-X; El-Abaseri TB, 2005, CANCER RES, V65, P3958, DOI 10.1158/0008-5472.CAN-04-2204; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; Fraser P, 1998, CURR OPIN CELL BIOL, V10, P361, DOI 10.1016/S0955-0674(98)80012-4; FRENCH JE, 1994, MOL CARCINOGEN, V11, P215, DOI 10.1002/mc.2940110407; Germolec DR, 1997, MUTAT RES-REV MUTAT, V386, P209, DOI 10.1016/S1383-5742(97)00006-9; Gilmour SK, 1999, CELL GROWTH DIFFER, V10, P739; Grosveld F, 1999, CURR OPIN GENET DEV, V9, P152, DOI 10.1016/S0959-437X(99)80023-9; Hansen L A, 1995, Prog Clin Biol Res, V391, P223; Hansen LA, 1996, CARCINOGENESIS, V17, P1825, DOI 10.1093/carcin/17.9.1825; HANSEN LA, 1994, MOL CARCINOGEN, V9, P143, DOI 10.1002/mc.2940090306; HANSEN LA, 1994, P NATL ACAD SCI USA, V91, P7822, DOI 10.1073/pnas.91.16.7822; Hansen LA, 1998, CARCINOGENESIS, V19, P1837, DOI 10.1093/carcin/19.10.1837; HENNINGS H, 1970, CANCER RES, V30, P312; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; Humble MC, 1998, TOXICOL PATHOL, V26, P562, DOI 10.1177/019262339802600413; Humble MC, 2000, GENOMICS, V70, P292, DOI 10.1006/geno.2000.6384; HUMBLE MC, UNPUB; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; Kantz DC, 1999, BIOTECHNIQUES, V27, P278, DOI 10.2144/99272bm13; KARLSSON S, 1985, ANNU REV BIOCHEM, V54, P1071; Kaufman CK, 2003, GENE DEV, V17, P2108, DOI 10.1101/gad.1115203; Kouprina N, 1998, P NATL ACAD SCI USA, V95, P4469, DOI 10.1073/pnas.95.8.4469; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; Larcher F, 1996, CANCER RES, V56, P5391; Lavker RM, 2000, P NATL ACAD SCI USA, V97, P13473, DOI 10.1073/pnas.250380097; LEACH DRF, 1994, BIOESSAYS, V16, P893, DOI 10.1002/bies.950161207; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Leder A, 2002, ONCOGENE, V21, P6657, DOI 10.1038/sj.onc.1205795; Lewis S, 1999, ANN NY ACAD SCI, V870, P45, DOI 10.1111/j.1749-6632.1999.tb08864.x; Lozano J, 2003, CANCER RES, V63, P4232; Lyle S, 1998, J CELL SCI, V111, P3179; Mahler JF, 1998, TOXICOL PATHOL, V26, P501, DOI 10.1177/019262339802600406; Mahler JF, 1996, TOXICOL PATHOL, V24, P710, DOI 10.1177/019262339602400606; MARTHINUSS J, 1995, CELL GROWTH DIFFER, V6, P239; MILLS KJ, 1993, CARCINOGENESIS, V14, P2645, DOI 10.1093/carcin/14.12.2645; MOON A, 2001, BIOCHEMISTRY-US, P46; Morris RJ, 2000, J CLIN INVEST, V106, P3, DOI 10.1172/JCI10508; Murphy JE, 2003, J IMMUNOL, V170, P5697, DOI 10.4049/jimmunol.170.11.5697; OBrien TG, 1997, CANCER RES, V57, P2630; Ohara M, 2003, CANCER SCI, V94, P205, DOI 10.1111/j.1349-7006.2003.tb01420.x; ORKIN SH, 1992, BLOOD, V80, P575; OWENS DM, 1995, CANCER RES, V55, P3171; POTTEN CS, 1983, STEM CELLS THEIR IDE, P200; Pritchard JB, 2003, ENVIRON HEALTH PERSP, V111, P444, DOI 10.1289/ehp.5778; PULLINGER BD, 1945, J PATHOL BACTERIOL, V57, P447; Robinson DE, 2001, TOXICOL PATHOL, V29, P13, DOI 10.1080/019262301753178438; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Sistare FD, 2002, INT J TOXICOL, V21, P65, DOI 10.1080/10915810252826028; Smith MK, 1998, CARCINOGENESIS, V19, P1409, DOI 10.1093/carcin/19.8.1409; SPALDING JW, 1993, CARCINOGENESIS, V14, P1335, DOI 10.1093/carcin/14.7.1335; Spalding JW, 1999, TOXICOL SCI, V49, P241, DOI 10.1093/toxsci/49.2.241; Spalding JW, 2000, TOXICOL SCI, V53, P213, DOI 10.1093/toxsci/53.2.213; STENN KS, 1994, J INVEST DERMATOL, V103, P107, DOI 10.1111/1523-1747.ep12391844; Tennant R, 1997, TOXICOL PATHOL, V25, P240, DOI 10.1177/019262339702500219; Tennant RW, 2001, TOXICOL PATHOL, V29, P51, DOI 10.1080/019262301753178474; Tennant RW, 1996, MUTAT RES-REV GENET, V365, P119, DOI 10.1016/S0165-1110(96)90016-0; TENNANT RW, 1995, ENVIRON HEALTH PERSP, V103, P942, DOI 10.2307/3432740; Tennant RW, 1996, ENVIRON HEALTH PERSP, V104, P1095, DOI 10.2307/3433035; Thompson KL, 1998, TOXICOL PATHOL, V26, P548, DOI 10.1177/019262339802600411; Thompson KL, 2001, MOL CARCINOGEN, V32, P176, DOI 10.1002/mc.10009; Tober KL, 1998, BIOCHEM BIOPH RES CO, V247, P644, DOI 10.1006/bbrc.1998.8787; Trempus CS, 2003, J INVEST DERMATOL, V120, P501, DOI 10.1046/j.1523-1747.2003.12088.x; Trempus CS, 1998, J INVEST DERMATOL, V111, P445, DOI 10.1046/j.1523-1747.1998.00237.x; Trempus CS, 1997, MOL CARCINOGEN, V20, P68, DOI 10.1002/(SICI)1098-2744(199709)20:1<68::AID-MC8>3.0.CO;2-E; Trempus CS, 2000, MOL CARCINOGEN, V27, P24, DOI 10.1002/(SICI)1098-2744(200001)27:1<24::AID-MC5>3.0.CO;2-M; Trempus CS, 1998, AM J PATHOL, V153, P247, DOI 10.1016/S0002-9440(10)65565-4; TUAN D, 1984, P NATL ACAD SCI-BIOL, V81, P2718, DOI 10.1073/pnas.81.9.2718; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; Weaver JL, 1998, TOXICOL PATHOL, V26, P532, DOI 10.1177/019262339802600409; Wei SJ, 2003, J BIOL CHEM, V278, P1758, DOI 10.1074/jbc.M206328200; WRIGHT JT, 1995, ARCH ORAL BIOL, V40, P631, DOI 10.1016/0003-9969(95)00017-J; YISRAELI J, 1988, P NATL ACAD SCI USA, V85, P4638, DOI 10.1073/pnas.85.13.4638	94	20	22	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8217	8228		10.1038/sj.onc.1209000	http://dx.doi.org/10.1038/sj.onc.1209000			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16355251				2022-12-28	WOS:000233956500001
J	David, G; Dannenberg, JH; Simpson, N; Finnerty, PM; Miao, L; Turner, GM; Ding, Z; Carrasco, R; DePinho, RA				David, G.; Dannenberg, J. -H.; Simpson, N.; Finnerty, P. M.; Miao, L.; Turner, G. M.; Ding, Z.; Carrasco, R.; DePinho, R. A.			Haploinsufficiency of the mSds3 chromatin regulator promotes chromosomal instability and cancer only upon complete neutralization of p53	ONCOGENE			English	Article						mSin3; chromatin; histone deacetylase; mouse model; aneuploidy; p53	PERICENTRIC HETEROCHROMATIN; DEACETYLASE COMPLEX; COREPRESSOR COMPLEX; INTEGRAL COMPONENT; MAMMALIAN-CELLS; ACETYLATION; SUPPRESSOR; GROWTH; MICE; CARCINOGENESIS	The mSin3 corepressor complex has been linked to diverse cancer signaling pathways through its capacity to regulate target gene expression via chromatin modification. mSds3, a cell essential gene, is a key component of the mSin3 complex serving to maintain its inherent histone deacetylase activity. mSds3 also serves an essential role in the establishment of pericentric heterochromatin, and genetic ablation of mSds3 results in chromosome mis-segregation. In contrast, mSin3A nullizygous cells show normal chromosome dynamics and cytogenetic profiles. The integral role of mSds3 in controlling chromosome segregation and mSin3-regulated transcriptional networks prompted efforts to determine the neoplastic impact of loss of one copy of mSds3 or mSin3A. In particular, we assessed whether loss of one copy of mSds3, alone or in combination with p53 mutation, results in aneuploidy and promotes a cancer-prone condition in the mouse. We observe that, in a p53 null background, loss of one mSds3 allele results in accelerated tumor onset and increased tumor burden. Notably, these mSds3(+/-) p53(-/-) tumors exhibit a more complex cytogenetic profile characterized by marked aneuploidy and centromeric associations. The presence of even one copy of p53 is sufficient to suppress the accelerated tumorigenesis in mSds3(+/-) mice, consistent with a key role for p53 in monitoring mitotic fidelity. These observations with Sds3 mutant mice contrast with mSin3A(+/-) p53(-/-) mice, which do not show an accelerated or increased tumor incidence relative to mSin3A(+/+) p53(-/-) controls, correlating with the absence of aneuploidy detected upon mSin3A genetic inactivation. This genetic study establishes that the capacity of mSds3 to cooperate with p53 deficiency in cancer predisposition relates to its specific role in chromosome segregation, rather than its central role in maintaining a functional mSin3A complex.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; NYU, Sch Med, Dept Pharmacol, New York, NY USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Appl Canc Sci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Belfer Fdn Inst Innovat Canc Sci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med & Genet, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; New York University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	DePinho, RA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St,Mayer 413, Boston, MA 02115 USA.	ron_depinho@dfci.harvard.edu		DePinho, Ronald/0000-0002-5625-577X; , gregory/0000-0002-3371-4558	NCI NIH HHS [R01CA86379] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086379] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 2002, MOL CELL BIOL, V22, P2743, DOI 10.1128/MCB.22.8.2743-2750.2002; Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bunz F, 2002, CANCER RES, V62, P1129; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Cowley SM, 2005, MOL CELL BIOL, V25, P6990, DOI 10.1128/MCB.25.16.6990-7004.2005; Dannenberg JH, 2005, GENE DEV, V19, P1581, DOI 10.1101/gad.1286905; David G, 2003, GENE DEV, V17, P2396, DOI 10.1101/gad.1109403; Dorland S, 2000, GENETICS, V154, P573; Fleischer TC, 2003, MOL CELL BIOL, V23, P3456, DOI 10.1128/MCB.23.10.3456-3467.2003; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Insinga A, 2004, EMBO J, V23, P1144, DOI 10.1038/sj.emboj.7600109; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kalitsis P, 2005, GENE CHROMOSOME CANC, V44, P29, DOI 10.1002/gcc.20215; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Lechner T, 2000, J BIOL CHEM, V275, P40961, DOI 10.1074/jbc.M005730200; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4; Maser RS, 2003, CANCER CELL, V3, P4, DOI 10.1016/S1535-6108(02)00243-X; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Santarosa M, 2004, BBA-REV CANCER, V1654, P105, DOI 10.1016/j.bbcan.2004.01.001; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Xin HW, 2004, J BIOL CHEM, V279, P9539, DOI 10.1074/jbc.M311587200	26	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	56					7354	7360		10.1038/sj.onc.1209734	http://dx.doi.org/10.1038/sj.onc.1209734			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16767157				2022-12-28	WOS:000242419100004
J	James, SR; Link, PA; Karpf, AR				James, S. R.; Link, P. A.; Karpf, A. R.			Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b	ONCOGENE			English	Article						cancer/germline antigens; cancer-testis antigens; DNMT1; DNMT3b; gene expression; DNA methylation; histone modifications	CYTOLYTIC T-LYMPHOCYTES; DE-NOVO METHYLATION; DNA METHYLATION; CANCER-CELLS; CANCER/TESTIS ANTIGENS; CPG METHYLATION; GERM-LINE; METHYLTRANSFERASES; EXPRESSION; TUMOR	We examined the function of two key DNA methyltransferase (DNMT) enzymes in epigenetic regulation of X-linked cancer/germline (CG-X) antigen genes in human cancer cells, using MAGE-A1, NY-ESO-1, and XAGE-1 as models. In HCT116 cells, genetic knockout of DNMT1 caused moderate activation of CG-X genes, DNMT3b knockout had a negligible effect, and double knockout of both enzymes caused robust gene induction. Similarly, dual DNMT knockout caused dramatic hypomethylation of the MAGE-A1 and NY-ESO-1 promoters, DNMT1 knockout showed moderate hypomethylation, and DNMT3b knockout elicited only slight methylation changes. In contrast, both single and double knockout cells showed significant hypomethylation of the XAGE-1 promoter. RNA interference (RNAi) targeting of DNMT1 in HCT116 cells validated the results seen using genetic knockout cells; however, RNAi targeting of DNMT1 in a different colorectal cancer cell line revealed a greater independent role for DNMT1 in mediating CG-X gene repression and promoter methylation in other cell types. Notably, the histone H3 modi. cation pattern at CG-X promoters was altered following DNMT knockout. DNMT1 or DNMT3b knockout reduced dimethylated lysine-9 (diMe-H3K9) levels, but did not significantly affect dimethylated lysine-4 (diMe-H3K4) or acetylated lysine-9 (Ac-H3-K9) levels. In contrast, dual DNMT1/3b knockout reduced the level of diMe-H3K9 and dramatically increased the levels of diMe-H3K4 and Ac-H3K9 at CG-X gene loci. In summary, DNMT1 and DNMT3b were found to perform both redundant and independent functions in epigenetic regulation of CG-X antigen genes in human cancer cells.	New York State Dept Hlth, Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Canc Drug Ctr, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Karpf, AR (corresponding author), New York State Dept Hlth, Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Canc Drug Ctr, Elm & Carlton St, Buffalo, NY 14263 USA.	adam.karpf@roswellpark.org		Karpf, Adam/0000-0002-0866-0666	NATIONAL CANCER INSTITUTE [P30CA016056, R01CA116674] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA116674, R01 CA116674-01A1, CA16056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cheng JC, 2004, CANCER CELL, V6, P151, DOI 10.1016/j.ccr.2004.06.023; Chomez P, 2001, CANCER RES, V61, P5544; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; DE SC, 1996, P NATL ACAD SCI USA, V93, P7149, DOI DOI 10.1073/PNAS.93.14.7149; De Smet C, 2004, MOL CELL BIOL, V24, P4781, DOI 10.1128/MCB.24.11.4781-4790.2004; De Smet C, 1999, MOL CELL BIOL, V19, P7327; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gillespie AM, 1999, CANCER TREAT REV, V25, P219, DOI 10.1053/ctrv.1999.0126; Guo ZS, 2006, CANCER RES, V66, P1105, DOI 10.1158/0008-5472.CAN-05-3020; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jiang GC, 2004, J CELL BIOCHEM, V93, P286, DOI 10.1002/jcb.20146; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; Karpf AR, 2004, MOL PHARMACOL, V65, P18, DOI 10.1124/mol.65.1.18; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; Koslowski M, 2004, CANCER RES, V64, P5988, DOI 10.1158/0008-5472.CAN-04-1187; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Lyko F, 2005, JNCI-J NATL CANCER I, V97, P1498, DOI 10.1093/jnci/dji311; Maio M, 2003, ONCOGENE, V22, P6484, DOI 10.1038/sj.onc.1206956; Odunsi K, 2003, CANCER RES, V63, P6076; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Qian Feng, 2004, Cancer Immun, V4, P12; Reynolds SR, 2003, CLIN CANCER RES, V9, P657; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Rozen S, 2000, Methods Mol Biol, V132, P365; Shi HD, 2003, CANCER RES, V63, P2164; Sigalotti L, 2004, CANCER RES, V64, P9167, DOI 10.1158/0008-5472.CAN-04-1442; Sigalotti L, 2002, J IMMUNOTHER, V25, P16, DOI 10.1097/00002371-200201000-00002; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; Song LG, 2005, ANAL CHEM, V77, P504, DOI 10.1021/ac0489420; Suzuki M, 2004, CANCER RES, V64, P3137, DOI 10.1158/0008-5472.CAN-03-3046; Tachibana M, 2005, GENE DEV, V19, P815, DOI 10.1101/gad.1284005; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Ting AH, 2006, CANCER RES, V66, P729, DOI 10.1158/0008-5472.CAN-05-1537; Ting AH, 2004, NAT GENET, V36, P582, DOI 10.1038/ng1365; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; WEBER J, 1994, CANCER RES, V54, P1766; Weiser TS, 2001, J IMMUNOTHER, V24, P151, DOI 10.1097/00002371-200103000-00010	53	87	92	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	52					6975	6985		10.1038/sj.onc.1209678	http://dx.doi.org/10.1038/sj.onc.1209678			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16715135				2022-12-28	WOS:000241732300008
J	Telang, S; Yalcin, A; Clem, AL; Bucala, R; Lane, AN; Eaton, JW; Chesney, J				Telang, S.; Yalcin, A.; Clem, A. L.; Bucala, R.; Lane, A. N.; Eaton, J. W.; Chesney, J.			Ras transformation requires metabolic control by 6-phosphofructo-2-kinase	ONCOGENE			English	Article						ras; metabolism; phosphofructokinase	6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE GENE PFKFB3; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; FRUCTOSE 2,6-BISPHOSPHATE; ACTIVATED RAS; HUMAN CANCERS; NUCLEIC-ACID; GLYCOLYSIS; EXPRESSION; GLUCOSE; CELLS	Neoplastic cells transport large amounts of glucose in order to produce anabolic precursors and energy within the inhospitable environment of a tumor. The ras signaling pathway is activated in several cancers and has been found to stimulate glycolytic flux to lactate. Glycolysis is regulated by ras via the activity of 6-phosphofructo-2-kinase/fructose- 2,6-bisphosphatases (PFK2/FBPase), which modulate the intracellular concentration of the allosteric glycolytic activator, fructose-2,6-bisphosphate (F2,6BP). We report herein that sequential immortalization and ras-transformation of mouse fibroblasts or human bronchial epithelial cells paradoxically decreases the intracellular concentration of F2,6BP. This marked reduction in the intracellular concentration of F2,6BP sensitizes transformed cells to the antimetabolic effects of PFK2/FBPase inhibition. Moreover, despite co-expression of all four mRNA species (PFKFB1-4), heterozygotic genomic deletion of the inducible PFKFB3 gene in ras-transformed mouse lung fibroblasts suppresses F2,6BP production, glycolytic flux to lactate, and growth as soft agar colonies or tumors in athymic mice. These data indicate that the PFKFB3 protein product may serve as an essential downstream metabolic mediator of oncogenic ras, and we propose that pharmacologic inhibition of this enzyme should selectively suppress the high rate of glycolysis and growth by cancer cells.	Univ Louisville, James Graham Brown Canc Ctr, Mol Targets Program, Louisville, KY 40202 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA	University of Louisville; Yale University	Chesney, J (corresponding author), Univ Louisville, James Graham Brown Canc Ctr, Mol Targets Program, 580 S Preston St, Louisville, KY 40202 USA.	jason.chesney@louisville.edu	Yalcin, Abdullah/ABI-4164-2020; Yalcin, Abdullah/AAA-6938-2022	Yalcin, Abdullah/0000-0001-8519-8375; 	NCI NIH HHS [1 R01 CA11642801] Funding Source: Medline; NCRR NIH HHS [1P20 RR18733] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018733] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Atsumi T, 2002, CANCER RES, V62, P5881; Blum R, 2005, CANCER RES, V65, P999; Boren J, 2001, J BIOL CHEM, V276, P37747; Boros LG, 2001, PANCREAS, V22, P1, DOI 10.1097/00006676-200101000-00001; Boros LG, 2000, CANCER RES, V60, P1183; Chesney J, 2005, BIOCHEM BIOPH RES CO, V331, P139, DOI 10.1016/j.bbrc.2005.02.193; Chesney J, 1999, P NATL ACAD SCI USA, V96, P3047, DOI 10.1073/pnas.96.6.3047; CHESNEY J, 2001, BIOTECHNOL INT, V3, P213; Hamilton JA, 1997, MOL ENDOCRINOL, V11, P490, DOI 10.1210/me.11.4.490; HUE L, 1993, ADV ENZYME REGUL, V33, P97; Kessler R, 2001, MOL BRAIN RES, V87, P190, DOI 10.1016/S0169-328X(01)00014-6; KOLE HK, 1991, ARCH BIOCHEM BIOPHYS, V286, P586, DOI 10.1016/0003-9861(91)90084-V; Mahlknecht U, 2003, INT J ONCOL, V23, P883; Manzano A, 1998, CYTOGENET CELL GENET, V83, P214, DOI 10.1159/000015181; Mazurek S, 2001, ONCOGENE, V20, P6891, DOI 10.1038/sj.onc.1204792; Minchenko A, 2002, J BIOL CHEM, V277, P6183, DOI 10.1074/jbc.M110978200; Minchenko O, 2004, FEBS LETT, V576, P14, DOI 10.1016/j.febslet.2004.08.053; Minchenko O, 2003, FEBS LETT, V554, P264, DOI 10.1016/S0014-5793(03)01179-7; MUELLERKLIESER W, 1986, BRIT J CANCER, V53, P345, DOI 10.1038/bjc.1986.58; Navarro-Sabate A, 2001, GENE, V264, P131, DOI 10.1016/S0378-1119(00)00591-6; Okar DA, 1999, BIOFACTORS, V10, P1, DOI 10.1002/biof.5520100101; RACKER E, 1985, P NATL ACAD SCI USA, V82, P3535, DOI 10.1073/pnas.82.11.3535; Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102; Sakai A, 1996, J BIOCHEM-TOKYO, V119, P506; Sakakibara R, 1997, J BIOCHEM-TOKYO, V122, P122; Sakakibara R, 1999, BIOCHEM BIOPH RES CO, V257, P177, DOI 10.1006/bbrc.1999.0429; Soejima K, 2003, ONCOGENE, V22, P4723, DOI 10.1038/sj.onc.1206510; TAETLE R, 1987, CANCER TREAT REP, V71, P297; VALENZUELA DM, 1986, NUCLEIC ACIDS RES, V14, P843, DOI 10.1093/nar/14.2.843; VANDENBERGHE N, 1994, MOL CELL BIOL, V14, P2372, DOI 10.1128/MCB.14.4.2372; VANSCHAFTINGEN E, 1981, P NATL ACAD SCI-BIOL, V78, P3483; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; Vizan P, 2005, CANCER RES, V65, P5512, DOI 10.1158/0008-5472.CAN-05-0074; Walenta S, 2004, CURR MED CHEM, V11, P2195, DOI 10.2174/0929867043364711; WANG T, 1976, NATURE, V261, P702, DOI 10.1038/261702a0; Warburg O, 1924, BIOCHEM Z, V152, P319; Wechatekar K, 2005, CLIN RADIOL, V60, P1143, DOI 10.1016/j.crad.2005.05.018; Zhong H, 1999, CANCER RES, V59, P5830	38	130	140	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	55					7225	7234		10.1038/sj.onc.1209709	http://dx.doi.org/10.1038/sj.onc.1209709			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16715124				2022-12-28	WOS:000242244700001
J	Cerveira, N; Correia, C; Bizarro, S; Pinto, C; Lisboa, S; Mariz, JM; Marques, M; Teixeira, MR				Cerveira, N.; Correia, C.; Bizarro, S.; Pinto, C.; Lisboa, S.; Mariz, J. M.; Marques, M.; Teixeira, M. R.			SEPT2 is a new fusion partner of MLL in acute myeloid leukemia with t(2 ; 11)(q37 ; q23)	ONCOGENE			English	Article						MLL-SEPT2; fusion oncogenes; t(2;11) (q37; q23); therapy-related AML	ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN INHERITED DISEASE; FUSES MLL; DROSOPHILA-TRITHORAX; FAMILY GENE; 11Q23; TRANSLOCATION; PROTEINS; DELETION; REARRANGEMENTS	We have identified a new mixed lineage leukemia (MLL) gene fusion partner in a patient with treatment-related acute myeloid leukemia (AML) presenting a t(2; 11)(q37; q23) as the only cytogenetic abnormality. Fluorescence in situ hybridization demonstrated a rearrangement of the MLL gene and molecular genetic analyses identified a septin family gene, SEPT2, located on chromosome 2q37, as the fusion partner of MLL. RNA and DNA analyses showed the existence of an in-frame fusion of MLL exon 7 with SEPT2 exon 3, with the genomic breakpoints located in intron 7 and 2 of MLL and SEPT2, respectively. Search for DNA sequence motifs revealed the existence of two sequences with 94.4% homology with the topoisomerase II consensus cleavage site in MLL intron 7 and SEPT2 intron 2. SEPT2 is the fifth septin family gene fused with MLL, making this gene family the most frequently involved in MLL-related AML (about 10% of all known fusion partners). The protein encoded by SEPT2 is highly homologous to septins 1, 4 and 5 and is involved in the coordination of several key steps of mitosis. Further studies are warranted to understand why the septin protein family is particularly involved in the pathogenesis of MLL-associated leukemia.	Portuguese Oncol Inst, Dept Genet, P-4200072 Oporto, Portugal; Portuguese Oncol Inst, Dept Oncohematol, Oporto, Portugal	Portuguese Institute of Oncology; Portuguese Institute of Oncology	Teixeira, MR (corresponding author), Portuguese Oncol Inst, Dept Genet, Rua Dr Antonio Bernardino Almeida, P-4200072 Oporto, Portugal.	mteixeir@ipoporto.min-saude.pt	Teixeira, Manuel AC/AAZ-7251-2020; Teixeira, Manuel António Rodrigues/E-4885-2011	Teixeira, Manuel AC/0000-0002-1959-0624; Teixeira, Manuel António Rodrigues/0000-0002-4896-5982; Correia, Cecilia/0000-0002-4838-7756; Pinto, Carla/0000-0001-8689-3388; Cerveira, Nuno/0000-0001-5098-3840; Lisboa, Susana/0000-0002-9773-331X; de Campos Bizarro, Susana/0000-0002-3495-2080				Abeysinghe SS, 2003, HUM MUTAT, V22, P229, DOI 10.1002/humu.10254; BERGER R, 1987, CANCER GENET CYTOGEN, V29, P9, DOI 10.1016/0165-4608(87)90026-4; Borkhardt A, 2000, P NATL ACAD SCI USA, V97, P9168, DOI 10.1073/pnas.150079597; Chinwalla V, 2003, ONCOGENE, V22, P1400, DOI 10.1038/sj.onc.1206273; Chuzhanova N, 2003, HUM MUTAT, V22, P245, DOI 10.1002/humu.10253; Daser A, 2005, SEMIN CANCER BIOL, V15, P175, DOI 10.1016/j.semcancer.2005.01.007; DELOZIERBLANCHET CD, 1985, CANCER GENET CYTOGEN, V16, P95, DOI 10.1016/0165-4608(85)90001-9; Fischer K, 1997, BLOOD, V89, P2036, DOI 10.1182/blood.V89.6.2036; Fuchs U, 2001, P NATL ACAD SCI USA, V98, P8756, DOI 10.1073/pnas.121433898; Grier DG, 2005, J PATHOL, V205, P154, DOI 10.1002/path.1710; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hall PA, 2004, J PATHOL, V204, P489, DOI 10.1002/path.1654; Harrison CJ, 1998, LEUKEMIA, V12, P811, DOI 10.1038/sj.leu.2401017; Hayette S, 2000, ONCOGENE, V19, P4446, DOI 10.1038/sj.onc.1203789; HURET JL, 2005, ATLAS GENETICS CYTOG; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; Kojima K, 2004, LEUKEMIA, V18, P998, DOI 10.1038/sj.leu.2403334; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; Li ZY, 2005, LEUKEMIA, V19, P183, DOI 10.1038/sj.leu.2403602; MAROSI C, 1992, CANCER GENET CYTOGEN, V61, P14, DOI 10.1016/0165-4608(92)90364-E; Megonigal MD, 1998, P NATL ACAD SCI USA, V95, P6413, DOI 10.1073/pnas.95.11.6413; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Mitelman F., 1995, INT SYSTEM HUMAN CYT; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Ono R, 2005, J CLIN INVEST, V115, P919, DOI 10.1172/JCI200522725; Ono R, 2002, CANCER RES, V62, P333; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; Poirel H, 1996, BLOOD, V87, P2496, DOI 10.1182/blood.V87.6.2496.bloodjournal8762496; Popovic R, 2005, J CELL BIOCHEM, V95, P234, DOI 10.1002/jcb.20430; PRASAD R, 1994, P NATL ACAD SCI USA, V91, P8107, DOI 10.1073/pnas.91.17.8107; Pui CH, 2000, BRIT J HAEMATOL, V109, P13, DOI 10.1046/j.1365-2141.2000.01843.x; RASMUSSEN SW, 2004, SEQ TOOLS VERSION 8; RUDIGER NS, 1995, NUCLEIC ACIDS RES, V23, P256, DOI 10.1093/nar/23.2.256; Russell SEH, 2005, BRIT J CANCER, V93, P499, DOI 10.1038/sj.bjc.6602753; Satake N, 1999, LEUKEMIA, V13, P1013, DOI 10.1038/sj.leu.2401439; SAVAGE PD, 1991, CYTOGENET CELL GENET, V56, P112, DOI 10.1159/000133062; Slany RK, 2005, HEMATOL ONCOL, V23, P1, DOI 10.1002/hon.739; SMIT AFA, 2004, REPEATMASKER OPE 3 0; So CW, 1997, P NATL ACAD SCI USA, V94, P2563, DOI 10.1073/pnas.94.6.2563; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Spiliotis ET, 2005, SCIENCE, V307, P1781, DOI 10.1126/science.1106823; Strehl S, 2003, ONCOGENE, V22, P157, DOI 10.1038/sj.onc.1206042; Surka MC, 2002, MOL BIOL CELL, V13, P3532, DOI 10.1091/mbc.E02-01-0042; Taki T, 1999, P NATL ACAD SCI USA, V96, P14535, DOI 10.1073/pnas.96.25.14535; Taki T, 1999, CANCER RES, V59, P4261; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; von Bergh ARM, 2004, GENE CHROMOSOME CANC, V39, P324, DOI 10.1002/gcc.20004; WINICK NJ, 1993, J CLIN ONCOL, V11, P209, DOI 10.1200/JCO.1993.11.2.209; YAMAMOTO K, 1994, BLOOD, V83, P2912, DOI 10.1182/blood.V83.10.2912.2912	51	34	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6147	6152		10.1038/sj.onc.1209626	http://dx.doi.org/10.1038/sj.onc.1209626			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16682951				2022-12-28	WOS:000241101200013
J	Mise, N; Drosten, M; Racek, T; Tannapfel, A; Putzer, BM				Mise, N.; Drosten, M.; Racek, T.; Tannapfel, A.; Puetzer, B. M.			Evaluation of potential mechanisms underlying genotype-phenotype correlations in multiple endocrine neoplasia type 2	ONCOGENE			English	Article						RET receptor tyrosine kinase; RET protooncogene mutations; multiple endocrine neoplasia type 2 (MEN 2); genotype-phenotype correlation	MEDULLARY-THYROID CARCINOMA; RET TYROSINE KINASE; SIGNALING COMPLEXES; HUMAN CANCER; CYCLIN-E; IN-VIVO; MEN 2A; C-CELL; PROTOONCOGENE; MUTATIONS	Distinct dominant activating mutations in the RET protooncogene are responsible for the development of multiple endocrine neoplasia type 2 (MEN 2). Concise examination of the mutated codons led to the detection of a striking genotype-phenotype correlation between the mutated codon and the MEN 2 phenotype in terms of onset and aggressiveness of the disease, suggesting that manifestation and clinical progression is conditioned by the type of mutation. To gain insight into the molecular basis for this genotype-phenotype correlation, we analysed the impact of common and rare mutations identified in MEN 2A (C609Y, C634R), MEN 2B (A883F, M918T) and familial medullary thyroid carcinoma (Y791F) patients on several aspects of cell transformation, including proliferation, apoptosis, anchorage-independent growth and signaling. We found that tumor cells arising from distinct extracellular or intracellular MEN 2 mutations clearly differ in their proliferation properties owing to the activation of different molecular pathways, but importantly, also in resistance to apoptosis. Whereas MEN 2A mutants resulted in accelerated cell proliferation, MEN 2B-RET mutants significantly enhanced suppression of apoptosis, which may account, at least partially, for some of the clinical differences in MEN 2 patients.	Univ Rostock, Dept Vectorol & Expt Gene Therapy, Biomed Res Ctr, D-18055 Rostock, Germany; Univ Leipzig, Sch Med, Dept Pathol, D-7010 Leipzig, Germany	University of Rostock; Leipzig University	Putzer, BM (corresponding author), Univ Rostock, Dept Vectorol & Expt Gene Therapy, Biomed Res Ctr, Schillingallee 69, D-18055 Rostock, Germany.	brigitte.puetzer@med.uni-rostock.de		Drosten, Matthias/0000-0002-3205-456X				Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Arighi E, 2005, CYTOKINE GROWTH F R, V16, P441, DOI 10.1016/j.cytogfr.2005.05.010; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Bocciardi R, 1997, ONCOGENE, V15, P2257, DOI 10.1038/sj.onc.1201413; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Drosten M, 2004, JNCI-J NATL CANCER I, V96, P1231, DOI 10.1093/jnci/djh226; Durbec PL, 1996, DEVELOPMENT, V122, P349; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; Freche B, 2005, J BIOL CHEM, V280, P36584, DOI 10.1074/jbc.M505707200; Gimm O, 2002, SURGERY, V132, P952, DOI 10.1067/msy.2002.128559; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hansford JR, 2000, J MED GENET, V37, P817, DOI 10.1136/jmg.37.11.817; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Ichihara M, 2004, CANCER LETT, V204, P197, DOI 10.1016/S0304-3835(03)00456-7; IWAMOTO T, 1993, ONCOGENE, V8, P1087; Jijiwa M, 2004, MOL CELL BIOL, V24, P8026, DOI 10.1128/MCB.24.18.8026-8036.2004; Kurokawa K, 2003, J INTERN MED, V253, P627, DOI 10.1046/j.1365-2796.2003.01167.x; Le Hir H, 2000, ONCOLOGY-BASEL, V58, P311, DOI 10.1159/000012118; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Marshall GM, 1997, CANCER RES, V57, P5399; Marx SJ, 2005, NAT REV CANCER, V5, P367, DOI 10.1038/nrc1610; Menacho IP, 2005, CANCER RES, V65, P1729, DOI 10.1158/0008-5472.CAN-04-2363; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Moroy T, 2004, INT J BIOCHEM CELL B, V36, P1424, DOI 10.1016/S1357-2725(03)00432-1; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; Murakami H, 2002, J BIOL CHEM, V277, P32781, DOI 10.1074/jbc.M202336200; Reynolds L, 2001, ONCOGENE, V20, P3986, DOI 10.1038/sj.onc.1204434; Salvatore D, 2001, CANCER RES, V61, P1426; Santoro M, 2004, CELL MOL LIFE SCI, V61, P2954, DOI 10.1007/s00018-004-4276-8; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Smith-Hicks CL, 2000, EMBO J, V19, P612, DOI 10.1093/emboj/19.4.612; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; Takahashi M, 1998, J INTERN MED, V243, P509; Thimmaiah KN, 2005, J BIOL CHEM, V280, P31924, DOI 10.1074/jbc.M507057200; Tsui-Pierchala BA, 2002, J BIOL CHEM, V277, P34618, DOI 10.1074/jbc.M203580200; Vitale G, 2001, CANCER-AM CANCER SOC, V91, P1797, DOI 10.1002/1097-0142(20010501)91:9<1797::AID-CNCR1199>3.0.CO;2-P; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Watanabe T, 2002, AM J PATHOL, V161, P249, DOI 10.1016/S0002-9440(10)64176-4; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Yip L, 2003, ARCH SURG-CHICAGO, V138, P409, DOI 10.1001/archsurg.138.4.409	47	31	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2006	25	50					6637	6647		10.1038/sj.onc.1209669	http://dx.doi.org/10.1038/sj.onc.1209669			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16715139				2022-12-28	WOS:000241569700008
J	Yamanaka, R; Arao, T; Yajima, N; Tsuchiya, N; Homma, J; Tanaka, R; Sano, M; Oide, A; Sekijima, M; Nishio, K				Yamanaka, R.; Arao, T.; Yajima, N.; Tsuchiya, N.; Homma, J.; Tanaka, R.; Sano, M.; Oide, A.; Sekijima, M.; Nishio, K.			Identification of expressed genes characterizing long-term survival in malignant glioma patients	ONCOGENE			English	Article						cDNA array; gene expression profiles; glioma; survival predictor; siRNA	MOLECULAR SUBTYPES; MICROARRAY ANALYSIS; DNA-MICROARRAY; CLASSIFICATION; GLIOBLASTOMA; PROFILES; CANCER; PROGRESSION; PREDICTOR; ADHESION	Better understanding of the underlying biology of malignant gliomas is critical for the development of early detection strategies and new therapeutics. This study aimed to define genes associated with survival. We investigated whether genes coupled with a class prediction model could be used to de. ne subgroups of high-grade gliomas in a more objective manner than standard pathology. RNAs from 29 malignant gliomas were analysed using Agilent microarrays. We identified 21 genes whose expression was most strongly and consistently related to patient survival based on univariate proportional hazards models. In six out of 10 genes, changes in gene expression were validated by quantitative real-time PCR. After adjusting for clinical covariates based on a multivariate analysis, we finally obtained a statistical significance level for DDR1 (discoidin domain receptor family, member 1), DYRK3 (dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 3) and KSP37 (Ksp37 protein). In independent samples, it was confirmed that DDR1 protein expression was also correlated to the prognosis of glioma patients detected by immunohistochemical staining. Furthermore, we analysed the efficacy of the short interfering RNA (siRNA)mediated inhibition of DDR1 mRNA synthesis in glioma cell lines. Cell proliferation and invasion were significantly suppressed by siRNA against DDR1. Thus, DDR1 can be a novel molecular target of therapy as well as an important predictive marker for survival in patients with glioma. Our method was effective at classifying high-grade gliomas objectively, and provided a more accurate predictor of prognosis than histological grading.	Niigata Univ, Brain Res Inst, Dept Neurosurg, Niigata 9518585, Japan; Natl Canc Ctr, Res Inst, Div Pharmacol, Chuo Ku, Tokyo 104, Japan; Mitsubishi Chem Safety Inst, Ibaraki, Japan	Niigata University; National Cancer Center - Japan; Mitsubishi Chemical Holdings Corporation; Mitsubishi Chemical Safety Institute	Yamanaka, R (corresponding author), Niigata Univ, Brain Res Inst, Dept Neurosurg, Asahimachi Dori 1-757, Niigata 9518585, Japan.	ryaman@bri.niigata-u.ac.jp		Yamanaka, Ryuya/0000-0003-2941-7996				Afra D, 2002, LANCET, V359, P1011; Agrawal D, 2002, J NATL CANCER I, V94, P513; Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452; Godard S, 2003, CANCER RES, V63, P6613; Hoelzinger DB, 2005, NEOPLASIA, V7, P7, DOI 10.1593/neo.04535; Hunter SB, 2003, INT J ONCOL, V23, P857; Karpeh M. S., 2001, CANC PRINCIPLES PRAC, P1092; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Kim S, 2002, MOL CANCER THER, V1, P1229; Kleihues P, 2000, PATHOLOGY GENETICS T; Li K, 2002, J BIOL CHEM, V277, P47052, DOI 10.1074/jbc.M205374200; Liang Y, 2005, P NATL ACAD SCI USA, V102, P5814, DOI 10.1073/pnas.0402870102; Mischel PS, 2004, NAT REV NEUROSCI, V5, P782, DOI 10.1038/nrn1518; Mischel PS, 2003, ONCOGENE, V22, P2361, DOI 10.1038/sj.onc.1206344; Nigro JM, 2005, CANCER RES, V65, P1678, DOI 10.1158/0008-5472.CAN-04-2921; Nutt CL, 2003, CANCER RES, V63, P1602; Ogawa K, 2001, J IMMUNOL, V166, P6404, DOI 10.4049/jimmunol.166.10.6404; Ram R, 2006, J NEURO-ONCOL, V76, P239, DOI 10.1007/s11060-005-6874-1; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Rich JN, 2005, CANCER RES, V65, P4051, DOI 10.1158/0008-5472.CAN-04-3936; Rickman DS, 2001, CANCER RES, V61, P6885; Sallinen SL, 2000, CANCER RES, V60, P6617; Shai R, 2003, ONCOGENE, V22, P4918, DOI 10.1038/sj.onc.1206753; Somasundaram K, 2005, ONCOGENE, V24, P7073, DOI 10.1038/sj.onc.1208865; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vogel W, 2000, J BIOL CHEM, V275, P5779, DOI 10.1074/jbc.275.8.5779; Vogel W, 1999, FASEB J, V13, pS77, DOI 10.1096/fasebj.13.9001.s77; Weiner HL, 2000, CANCER INVEST, V18, P544, DOI 10.3109/07357900009012194; Wong KK, 2005, CANCER RES, V65, P76; Yoshimura T, 2005, IMMUNOL RES, V31, P219, DOI 10.1385/IR:31:3:219	34	91	100	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2006	25	44					5994	6002		10.1038/sj.onc.1209585	http://dx.doi.org/10.1038/sj.onc.1209585			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16652150				2022-12-28	WOS:000240826300008
J	Liu, Y; Borchert, GL; Surazynski, A; Hu, CA; Phang, JM				Liu, Y.; Borchert, G. L.; Surazynski, A.; Hu, C. -A; Phang, J. M.			Proline oxidase activates both intrinsic and extrinsic pathways for apoptosis: the role of ROS/superoxides, NFAT and MEK/ERK signaling	ONCOGENE			English	Article						proline oxidase; apoptosis; superoxide radicals; NFAT; ERK; metabolism	COLORECTAL-CANCER CELLS; MITOCHONDRIAL SUPEROXIDE ANIONS; T-CELLS; P53-INDUCED GENE-6; PROTEIN-KINASES; RECEPTOR GENE; EXPRESSION; DEATH; PUMA; FAS	Proline oxidase (POX), often considered a 'housekeeping enzyme' might play an important role in apoptosis. We have shown that POX generated proline-dependent reactive oxygen species (ROS), specifically superoxide radicals, and induced apoptosis through the mitochondrial (intrinsic) pathway. In our current report, we used DLD-1 colorectal cancer cells stably transfected with the POX gene under the control of a tetracycline-inducible promoter and found POX-stimulated expression of tumor necrosis factor-related apoptosis inducing ligand (TRAIL), DR5 and cleavage of caspase-8. Importantly, apoptosis measured by flow cytometry was partially inhibited by Z-IETD-FMK, a specific inhibitor of caspase-8. These findings suggest that the extrinsic (death receptor) pathway also is activated by POX. Furthermore, the mechanism of this effect on the extrinsic pathway, specifically, the induction of TRAIL by POX, may be mediated by NFAT transcription factors. Additionally, POX expression also dramatically decreased phosphorylation of MEK and ERK, and the decrease was partially reversed by expression of manganese superoxide dismutase (MnSOD). Overexpression of constitutively active form of MEK, acMEK, partially blocked POX-induced apoptosis. These findings suggest the involvement of MEK/ERK signaling and further confirm the role of ROS/superoxides in POX-induced apoptosis. Combined with previously published data, we conclude that POX may induce apoptosis through both intrinsic and extrinsic pathways and is involved in nuclear factor of activated T cells (NFAT) signaling and regulation of the MEK/ERK pathway. It is suggested that, as a nutrition factor, POX may modulate apoptosis signals induced by p53 or other anti-cancer agents and enhance apoptosis in stress situations.	Natl Canc Inst, Ctr Canc Res, Comparat Carcinogenesis Lab, Metab & Canc Susceptibil Sect, Frederick, MD 21702 USA; SAIC Federick Inc, Basic Res Program, Frederick, MD USA; Univ New Mexico, Hlth Sci Ctr, Dept Biochem & Mol Biol, Albuquerque, NM 87131 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of New Mexico; University of New Mexico's Health Sciences Center	Liu, Y (corresponding author), Natl Canc Inst, Ctr Canc Res, Comparat Carcinogenesis Lab, Metab & Canc Susceptibil Sect, Frederick, MD 21702 USA.	liuy@ncifcrf.gov; phang@ncifcrf.gov	Surażynski, Arkadiusz/ABG-2795-2020	Surażynski, Arkadiusz/0000-0003-4475-873X	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [N01-CO-12400] Funding Source: Medline; DIVISION OF BASIC SCIENCES - NCI [Z01BC000157] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [Z01BC010743] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams E, 1970, Int Rev Connect Tissue Res, V5, P1; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Delwing D, 2003, BRAIN RES, V991, P180, DOI 10.1016/j.brainres.2003.08.014; Donald SP, 2001, CANCER RES, V61, P1810; Duque J, 2005, J BIOL CHEM, V280, P8686, DOI 10.1074/jbc.M413076200; Dussmann H, 2003, J BIOL CHEM, V278, P12645, DOI 10.1074/jbc.M210826200; HAGEDORN CH, 1983, ARCH BIOCHEM BIOPHYS, V225, P95, DOI 10.1016/0003-9861(83)90010-3; Hamilton G, 2004, J CLIN ONCOL, V22, p235S; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Liu YM, 2005, CARCINOGENESIS, V26, P1335, DOI 10.1093/carcin/bgi083; Loo G, 2003, J NUTR BIOCHEM, V14, P64, DOI 10.1016/S0955-2863(02)00251-6; Lu KP, 2003, CANCER CELL, V4, P175, DOI 10.1016/S1535-6108(03)00218-6; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; Maxwell SA, 2003, J BIOL CHEM, V278, P9784, DOI 10.1074/jbc.M210012200; MCCAFFREY PG, 1994, J BIOL CHEM, V269, P30445; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Pani G, 2004, CURR MED CHEM, V11, P1299, DOI 10.2174/0929867043365297; Phang J. M., 2001, METABOLIC MOL BASES, P1821; PHANG JM, 1982, J CELL PHYSIOL, V110, P255, DOI 10.1002/jcp.1041100306; PHANG JM, 1985, CURR TOP CELL REGUL, V25, P91; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rivera A, 2005, J BIOL CHEM, V280, P29346, DOI 10.1074/jbc.M504852200; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Soderstrom TS, 2002, J IMMUNOL, V169, P2851, DOI 10.4049/jimmunol.169.6.2851; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Wang QD, 2000, BIOCHEM BIOPH RES CO, V276, P466, DOI 10.1006/bbrc.2000.3512; Wenzel U, 2004, CARCINOGENESIS, V25, P703, DOI 10.1093/carcin/bgh079; Wenzel U, 2003, INT J CANCER, V106, P666, DOI 10.1002/ijc.11294; Wilson DJ, 1999, CELL IMMUNOL, V194, P67, DOI 10.1006/cimm.1999.1486; Wu GS, 2000, ADV EXP MED BIOL, V465, P143; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	38	134	137	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2006	25	41					5640	5647		10.1038/sj.onc.1209564	http://dx.doi.org/10.1038/sj.onc.1209564			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16619034				2022-12-28	WOS:000240599100005
J	Sprangers, M; Feldhahn, N; Herzog, S; Hansmann, ML; Reppel, M; Hescheler, J; Jumaa, H; Siebert, R; Muschen, M				Sprangers, M.; Feldhahn, N.; Herzog, S.; Hansmann, M-L; Reppel, M.; Hescheler, J.; Jumaa, H.; Siebert, R.; Mueschen, M.			The SRC family kinase LYN redirects B cell receptor signaling in human SLP65-deficient B cell lymphoma cells	ONCOGENE			English	Article						pre-B cell receptor; SRC kinases; linker molecules; leukemia; tyrosine phosphorylation	ACUTE LYMPHOBLASTIC-LEUKEMIA; BRUTONS TYROSINE KINASE; ANTIGEN-RECEPTOR; LINKER PROTEIN; TUMOR-SUPPRESSOR; ACTIVATION; EXPRESSION; SLP-65; BLNK; REQUIREMENT	SLP65 represents a critical component in (pre-)B cell receptor signal transduction but is compromised in a subset of pre-B cell-derived acute lymphoblastic leukemia. Based on these findings, we investigated (i.) whether SLP65-deficiency also occurs in mature B cell-derived lymphoma and (ii.) whether SLP65-deficient B cell lymphoma cells use an alternative B cell receptor signaling pathway in the absence of SLP65. Indeed, expression of SLP65 protein was also missing in a fraction of B cell lymphoma cases. While SLP65 is essential for B cell receptor-induced Ca2+ mobilization in normal B cells, B cell receptor engagement in SLP65-deficient as compared to SLP65-reconstituted B cell lymphoma cells resulted in an accelerated yet shortlived Ca2+-signal. B cell receptor engagement of SLP65-deficient lymphoma cells involves SRC kinase activation, which is critical for B cell receptor-dependent Ca2+-mobilisation in the absence but not in the presence of SLP65. As shown by RNA interference, the SRC kinase LYN is required for B cell receptor-induced Ca2+ release in SLP65-deficient B cell lymphoma cells but dispensable after SLP65-reconstitution. B cell receptor engagement in SLP65-deficient B cell lymphoma cells also resulted in tyrosine-phosphorylation of the proliferation- and survival-related MAPK1 and STAT5 molecules, which was sensitive to silencing of the SRC kinase LYN. Inhibition of SRC kinase activity resulted in growth arrest and cell death specifically in SLP65-deficient lymphoma cells. These findings indicate that LYN can short-circuit conventional B cell receptor signaling in SLP65-deficient B cell lymphoma cells and thereby promote activation of survival and proliferation-related molecules.	Univ Dusseldorf, Lab Mol Stem Cell Biol, D-40225 Dusseldorf, Germany; Max Planck Inst Immunobiol, D-7800 Freiburg, Germany; Univ Frankfurt, Dept Pathol, D-6000 Frankfurt, Germany; Univ Cologne, Inst Neurophysiol, D-5000 Cologne 41, Germany; Univ Hosp Schleswig Holstein, Inst Human Genet, Kiel, Germany	Heinrich Heine University Dusseldorf; Max Planck Society; Goethe University Frankfurt; University of Cologne; University of Kiel; Schleswig Holstein University Hospital	Muschen, M (corresponding author), Univ Dusseldorf, Lab Mol Stem Cell Biol, Moorenstr 5, D-40225 Dusseldorf, Germany.	markus.mueschen@uni-duesseldorf.de	Siebert, Reiner/A-8049-2010	Herzog, Sebastian/0000-0001-7167-3489				Contri A, 2005, J CLIN INVEST, V115, P369, DOI 10.1172/JC1200522094; Cooperman J, 2004, STEM CELLS, V22, P1111, DOI 10.1634/stemcells.22-6-1111; Feldhahn N, 2005, J EXP MED, V201, P1837, DOI 10.1084/jem.20042101; Flemming A, 2003, NAT IMMUNOL, V4, P38, DOI 10.1038/ni862; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Hayashi K, 2003, IMMUNITY, V18, P825, DOI 10.1016/S1074-7613(03)00142-0; Hayashi K, 2000, P NATL ACAD SCI USA, V97, P2755, DOI 10.1073/pnas.040575697; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Imai C, 2004, LEUKEMIA, V18, P922, DOI 10.1038/sj.leu.2403349; Ishiai M, 1999, J IMMUNOL, V163, P1746; Jumaa H, 2003, NATURE, V423, P452, DOI 10.1038/nature01608; Karras JG, 1996, J IMMUNOL, V157, P39; Kersseboom R, 2003, J EXP MED, V198, P91, DOI 10.1084/jem.20030615; Klein F, 2004, J EXP MED, V199, P673, DOI 10.1084/jem.20031637; Li FJ, 2005, BLOOD, V105, P3295, DOI 10.1182/blood-2004-10-4083; Middendorp S, 2003, J IMMUNOL, V171, P5988, DOI 10.4049/jimmunol.171.11.5988; Minegishi Y, 1999, SCIENCE, V286, P1954, DOI 10.1126/science.286.5446.1954; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; Prakash O, 2005, BLOOD, V105, P3987, DOI 10.1182/blood-2004-07-2781; Ptasznik A, 2004, NAT MED, V10, P1187, DOI 10.1038/nm1127; Reppel M, 2005, J BIOL CHEM, V280, P36019, DOI 10.1074/jbc.M504750200; Richards JD, 2001, J IMMUNOL, V166, P3855, DOI 10.4049/jimmunol.166.6.3855; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791	23	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2006	25	36					5056	5062		10.1038/sj.onc.1209510	http://dx.doi.org/10.1038/sj.onc.1209510			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568084				2022-12-28	WOS:000239921300011
J	Shi, J; Kahle, A; Hershey, JWB; Honchak, BM; Warneke, JA; Leong, SPL; Nelson, MA				Shi, J.; Kahle, A.; Hershey, J. W. B.; Honchak, B. M.; Warneke, J. A.; Leong, S. P. L.; Nelson, M. A.			Decreased expression of eukaryotic initiation factor 3f deregulates translation and apoptosis in tumor cells	ONCOGENE			English	Article						eukaryotic initiation factor 3f; tumorigenesis; translation initiation; apoptosis; melanoma; pancreatic cancer	PREINITIATION COMPLEX; PROTEIN-SYNTHESIS; FACTOR EIF3; SUBUNITS; DEGRADATION; BINDING; DEATH; ACTIVATION; INDUCTION; INTERACTS	The eukaryotic initiation factor 3f (eIF3f) is the p47 subunit of the multi-subunit eIF3 complex. eIF3 plays an important role in translation initiation. In the present study, we investigate the biological function of eIF3f in translation and apoptosis in tumor cells. We demonstrated for the first time that eIF3f is downregulated in most human tumors using a cancer pro. ling array and confirmed by real-time reverse transcription PCR in melanoma and pancreatic cancer. Overexpression of eIF3f inhibits cell proliferation and induces apoptosis in melanoma and pancreatic cancer cells. Silencing of eIF3f protects melanoma cells from apoptosis. We further investigated the biological function of eIF3f. In vitro translation studies indicate that eIF3f is a negative regulator of translation and that the region between amino acids 170 and 248 of eIF3f is required for its translation regulatory function. Ectopic expression of eIF3f inhibits translation and overall cellular protein synthesis. Ribosome pro. le and ribosomal RNA (rRNA) fragmentation assays revealed that eIF3f reduces ribosomes, which may be associated with rRNA degradation. We propose that eIF3f may play a role in ribosome degradation during apoptosis. These data provide critical insights into the cellular function of eIF3f and in linking translation initiation and apoptosis.	Univ Arizona, Dept Pathol, Tucson, AZ 85724 USA; Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA; No Arizona Univ, Flagstaff, AZ 86011 USA; Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA; Univ Calif San Francisco, Dept Surg, Mt Zion Med Ctr, San Francisco, CA 94143 USA	University of Arizona; University of California System; University of California Davis; Northern Arizona University; Arizona Center Cancer Care; University of Arizona; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion	Nelson, MA (corresponding author), Univ Arizona, Dept Pathol, AHSC Rm 5226,1501 N Campbell Ave, Tucson, AZ 85724 USA.	mnelson@azcc.arizona.edu		Shi, Jiaqi/0000-0003-4893-1587	NCI NIH HHS [CA 09213, CA70145, CA95060] Funding Source: Medline; NIEHS NIH HHS [ES066694] Funding Source: Medline; NIGMS NIH HHS [GM22135] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070145, P50CA095060, T32CA009213, R29CA070145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiyoshi Y, 2001, J BIOL CHEM, V276, P10056, DOI 10.1074/jbc.M010188200; Aravind L, 1998, PROTEIN SCI, V7, P1250, DOI 10.1002/pro.5560070521; Ariza ME, 1999, J BIOL CHEM, V274, P28505, DOI 10.1074/jbc.274.40.28505; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Beyaert R, 1997, J BIOL CHEM, V272, P11694, DOI 10.1074/jbc.272.18.11694; Castelli J, 1998, BIOMED PHARMACOTHER, V52, P386, DOI 10.1016/S0753-3322(99)80006-7; Charalampopoulos L, 2004, P NATL ACAD SCI USA, V101, P8209, DOI 10.1073/pnas.0306631101; Clemens MJ, 1998, ONCOGENE, V17, P2921, DOI 10.1038/sj.onc.1202227; Dong JS, 2004, J BIOL CHEM, V279, P42157, DOI 10.1074/jbc.M404502200; Fraser CS, 2004, J BIOL CHEM, V279, P8946, DOI 10.1074/jbc.M312745200; Guo JJ, 2000, EMBO J, V19, P6891, DOI 10.1093/emboj/19.24.6891; Joseph P, 2002, CANCER RES, V62, P703; King KL, 2000, CELL DEATH DIFFER, V7, P994, DOI 10.1038/sj.cdd.4400731; Majumdar R, 2003, J BIOL CHEM, V278, P6580, DOI 10.1074/jbc.M210357200; Martinand C, 1998, EUR J BIOCHEM, V254, P248, DOI 10.1046/j.1432-1327.1998.2540248.x; Mayeur GL, 2003, EUR J BIOCHEM, V270, P4133, DOI 10.1046/j.1432-1033.2003.03807.x; MEYER LJ, 1982, BIOCHEMISTRY-US, V21, P4206, DOI 10.1021/bi00261a003; Mikolajczyk M, 2004, BIOCHEM J, V384, P461, DOI 10.1042/BJ20040848; Miura Y, 2002, BLOOD, V100, P2650, DOI 10.1182/blood-2002-01-0176; Morley SJ, 1998, FEBS LETT, V438, P41, DOI 10.1016/S0014-5793(98)01269-1; Nadano D, 2000, J BIOL CHEM, V275, P13967, DOI 10.1074/jbc.275.18.13967; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Phan L, 1998, MOL CELL BIOL, V18, P4935, DOI 10.1128/MCB.18.8.4935; PHILIP T, 1995, NEW ENGL J MED, V333, P1540, DOI 10.1056/NEJM199512073332305; Sheikh MS, 1999, ONCOGENE, V18, P6121, DOI 10.1038/sj.onc.1203131; Shi JQ, 2003, J BIOL CHEM, V278, P5062, DOI 10.1074/jbc.M206427200; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SONENBERG N, 2000, TRANSLATIONAL CONTRO, P33; Tang DM, 1998, J BIOL CHEM, V273, P16601, DOI 10.1074/jbc.273.26.16601; Thompson FH, 1996, CANCER GENET CYTOGEN, V87, P55, DOI 10.1016/0165-4608(95)00248-0; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3; Watkins SJ, 2002, BRIT J CANCER, V86, P1023, DOI 10.1038/sj/bjc/6600222; Xiang Y, 2003, CANCER RES, V63, P6795	33	87	94	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2006	25	35					4923	4936		10.1038/sj.onc.1209495	http://dx.doi.org/10.1038/sj.onc.1209495			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16532022				2022-12-28	WOS:000239687100010
J	Gianni-Barrera, R; Gariboldi, M; De Cecco, L; Manenti, G; Dragani, TA				Gianni-Barrera, R.; Gariboldi, M.; De Cecco, L.; Manenti, G.; Dragani, T. A.			Specific gene expression profiles distinguish among functional allelic variants of the mouse Pthlh gene in transfected human cancer cells	ONCOGENE			English	Article						parathyroid hormone-like hormone; parathyroid hormone-related protein; PTHrP; NCI-H520; cancer modifiers	HORMONE-RELATED PROTEIN; MODIFIER LOCI; GROWTH-FACTOR; MIGRATION; ADENOCARCINOMA; INFLAMMATION; CARCINOMA; PEPTIDES; PATTERNS	The mouse parathyroid hormone-like hormone (Pthlh) gene encodes three allelic variants characterized by amino acid substitutions that are associated with susceptibility (Pthlh(Pro)) or resistance (Pthlh(Thr) and Pthlh(SerAspTyr)) to two-stage skin carcinogenesis and to modulation of cell migration in vitro in transfected human cancer cells. cDNA microarray hybridization analysis of 8473 transcript clones revealed a similar gene expression profile for the PthlhThr and PthlhSerAspTyr alleles but a distinct pattern for the PthlhPro allele, suggesting an association between a specific gene expression profile and biological function of the Pthlh alleles. Some of the genes modulated by the Pthlh alleles, e.g., ANXA1, CCL2, FN1 and TFF3, play a role in cell migration and may represent candidate targets for this Pthlh function. Our study demonstrates the potential usefulness of gene expression profiling of genetic variants for the functional characterization of candidate cancer modifier genes.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Ist Nazl Tumori, Expt Oncol Lab, Milan, Italy; IFOM Fdn, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of Molecular Oncology	Dragani, TA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.	tommaso.dragani@istitutotumori.mi.it	Gianni-Barrera, Roberto/ACU-4280-2022; Dragani, Tommaso A./K-4493-2016; De Cecco, Loris/K-7036-2016; Manenti, Giacomo/J-3339-2017; Gariboldi, Manuela/K-4744-2016	Gianni-Barrera, Roberto/0000-0001-6303-4513; Dragani, Tommaso A./0000-0001-5915-4598; De Cecco, Loris/0000-0002-7066-473X; Manenti, Giacomo/0000-0002-4887-4482; Gariboldi, Manuela/0000-0001-8406-165X				Benelli R, 2003, ONCOGENE, V22, P7711, DOI 10.1038/sj.onc.1207088; Cambien B, 2001, BLOOD, V97, P359, DOI 10.1182/blood.V97.2.359; De Cecco L, 2004, ONCOGENE, V23, P8171, DOI 10.1038/sj.onc.1207979; Deans C, 2005, CANCER-AM CANCER SOC, V103, P1810, DOI 10.1002/cncr.20972; Dragani TA, 2003, CANCER RES, V63, P3011; Duxbury MS, 2005, ANN SURG, V241, P491, DOI 10.1097/01.sla.0000154455.86404.e9; Dysvik B, 2001, BIOINFORMATICS, V17, P369, DOI 10.1093/bioinformatics/17.4.369; Funk JL, 2001, INT IMMUNOPHARMACOL, V1, P1101, DOI 10.1016/S1567-5769(01)00040-6; Hiraki A, 2002, CANCER, V95, P1706, DOI 10.1002/cncr.10828; Hoffmann W, 2001, HISTOL HISTOPATHOL, V16, P319, DOI 10.14670/HH-16.319; Leeb SN, 2004, AM J GASTROENTEROL, V99, P335, DOI 10.1111/j.1572-0241.2004.04044.x; Manenti G, 2000, ONCOGENE, V19, P5324, DOI 10.1038/sj.onc.1203916; Maus UA, 2003, J IMMUNOL, V170, P3273, DOI 10.4049/jimmunol.170.6.3273; Nagase H, 2001, CANCER RES, V61, P1305; Oertel M, 2001, AM J RESP CELL MOL, V25, P418, DOI 10.1165/ajrcmb.25.4.4429; Parente L, 2004, INFLAMM RES, V53, P125, DOI 10.1007/s00011-003-1235-z; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Strewler GJ, 2000, NEW ENGL J MED, V342, P177, DOI 10.1056/NEJM200001203420306; Yio XY, 2005, CLIN EXP METASTAS, V22, P157, DOI 10.1007/s10585-005-6615-z; Zhang ZW, 2004, CANCER CAUSE CONTROL, V15, P211, DOI 10.1023/B:CACO.0000019510.96285.e9	20	8	8	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	32					4501	4504		10.1038/sj.onc.1209478	http://dx.doi.org/10.1038/sj.onc.1209478			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16547502				2022-12-28	WOS:000239326000014
J	Muerkoster, SS; Lust, J; Arlt, A; Hasler, R; Witt, M; Sebens, T; Schreiber, S; Folsch, UR; Schafer, H				Mueerkoester, S. Sebens; Lust, J.; Arlt, A.; Haesler, R.; Witt, M.; Sebens, T.; Schreiber, S.; Foelsch, U. R.; Schaefer, H.			Acquired chemoresistance in pancreatic carcinoma cells: induced secretion of IL-1 beta and NO lead to inactivation of caspases	ONCOGENE			English	Article						chemoresistance; interleukin-1 beta; pancreatic cancer; nitric oxide	NF-KAPPA-B; NITRIC-OXIDE; APOPTOSIS; CANCER; EXPRESSION; RESISTANCE; CHEMOTHERAPY; PROGRESSION; MECHANISMS; STRATEGIES	Pancreatic cancer exhibits profound chemoresistance resulting either from pre-existing ( intrinsic) mechanisms, or from anticancer drug treatment itself ( acquired chemoresistance). To identify molecular alterations leading to acquired chemoresistance, the chemosensitive pancreatic carcinoma cell line PT45-P1 was exposed to low-dose treatment with etoposide for 6 weeks. Afterwards, these cells (PT45-P1res) were much more resistant to high-dose treatment with anticancer drugs than parental cells. Among several differentially expressed genes in PT45-P1res cells, IL-1 beta was most significantly upregulated, a finding in line with our previous observation that IL-1 beta accounts for intrinsic chemoresistance of pancreatic carcinoma cells. Elevated IL-1 beta expression in PT45-P1res cells was confirmed by real-time PCR and ELISA, and treatment with the IL-1 receptor antagonist restored drug-induced apoptosis. The increased IL-1 beta secretion was accompanied by an elevated formation of nitric oxide ( NO) and a NO-dependent inhibition of the etoposide-induced caspase-3/-7/-8/-9 activity. Caspase activation was restored either by the iNOS inhibitor 1400W, the reducing agent dithiothreitol or the IL-1 receptor antagonist, resulting in greater sensitivity towards anticancer drug treatment. Conversely, IL-1 beta or the NO-donor SNAP decreased caspase activation and apoptosis in etoposide-treated PT45-P1 cells. These data confirm IL-1 beta and NO as determinants of chemoresistance in pancreatic cancer, and indicate that the intrinsic and acquired chemoresistance rely to some extent on common molecular targets beneficial for improved therapeutical strategies.	UKSH, Dept Med 1, Lab Mol Gastroenterol & Hepatol, D-24105 Kiel, Germany; UKSH, Dept Med 1, Mucosal Immunol Res Grp, D-24105 Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital	Schafer, H (corresponding author), UKSH, Dept Med 1, Lab Mol Gastroenterol & Hepatol, Campus Kiel,Schittenhelmstr 12, D-24105 Kiel, Germany.	hschaef@1med.uni-kiel.de	Arlt, Alexander/G-7308-2019; Sebens, Susanne/C-1222-2010; Schäfer, Heiner/C-1055-2011; Häsler, Robert/A-4908-2009	Arlt, Alexander/0000-0002-6160-1059; Häsler, Robert/0000-0003-4174-8229				Arlt A, 2003, ONCOGENE, V22, P3243, DOI 10.1038/sj.onc.1206390; Arlt A, 2002, CANCER RES, V62, P910; Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168; Banerjee D, 2002, BBA-MOL BASIS DIS, V1587, P164, DOI 10.1016/S0925-4439(02)00079-0; BLASZKOWSKY L, 1998, FRONT BIOSCI, V3, P214; BRAMHALL SR, 1995, BRIT J SURG, V82, P111, DOI 10.1002/bjs.1800820137; Brand Randall E., 1998, Current Opinion in Oncology, V10, P362, DOI 10.1097/00001622-199807000-00014; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Erler JT, 2004, MOL CELL BIOL, V24, P2875, DOI 10.1128/MCB.24.7.2875-2889.2004; Friesen C, 1999, LEUKEMIA, V13, P1854, DOI 10.1038/sj.leu.2401333; Jaiswal M, 2001, AM J PHYSIOL-GASTR L, V281, pG626, DOI 10.1152/ajpgi.2001.281.3.G626; KALTHOFF H, 1993, ONCOGENE, V8, P289; Kang HC, 2004, CLIN CANCER RES, V10, P272, DOI 10.1158/1078-0432.CCR-1025-3; Kim KM, 2002, J BIOCHEM MOL BIOL, V35, P127; Kim R, 2004, CANCER-AM CANCER SOC, V101, P2491, DOI 10.1002/cncr.20696; KIM R, 2004, CANCER RES, V59, P3505; Kolb JP, 2000, LEUKEMIA, V14, P1685, DOI 10.1038/sj.leu.2401896; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; Lillemoe K D, 1998, Surg Oncol Clin N Am, V7, P199; Maejima Y, 2005, J MOL CELL CARDIOL, V38, P163, DOI 10.1016/j.yjmcc.2004.10.012; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Morisaki T, 2003, CURR MED CHEM, V10, P2517, DOI 10.2174/0929867033456431; Muerkoster S, 2005, CANCER RES, V65, P1316, DOI 10.1158/0008-5472.CAN-04-1626; Muerkoster S, 2004, CANCER RES, V64, P1331, DOI 10.1158/0008-5472.CAN-03-1860; Muerkoster S, 2003, INT J CANCER, V104, P469, DOI 10.1002/ijc.10963; Neoptolemos JP, 2001, LANCET, V358, P1576, DOI 10.1016/S0140-6736(01)06651-X; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Poppenborg H, 1999, CYTOKINE, V11, P689, DOI 10.1006/cyto.1998.0473; Schafer H, 1999, BIOCHEM BIOPH RES CO, V262, P139, DOI 10.1006/bbrc.1999.1131; Schmid RM, 2000, GASTROENTEROLOGY, V118, P1208, DOI 10.1016/S0016-5085(00)70374-X; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Sreedhar AS, 2004, PHARMACOL THERAPEUT, V101, P227, DOI 10.1016/j.pharmthera.2003.11.004; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Turzanski J, 2004, LEUKEMIA, V18, P1662, DOI 10.1038/sj.leu.2403457; Wang WX, 1999, CLIN CANCER RES, V5, P119; Yan Y, 2004, BRIT J CANCER, V91, P1349, DOI 10.1038/sj.bjc.6602127	36	40	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3973	3981		10.1038/sj.onc.1209423	http://dx.doi.org/10.1038/sj.onc.1209423			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16474845				2022-12-28	WOS:000238668800011
J	Chen, J; Kremer, CS; Bender, TP				Chen, J; Kremer, CS; Bender, TP			The carbonic anhydrase I locus contains a c-Myb target promoter and modulates differentiation of murine erythroleukemia cells	ONCOGENE			English	Article						c-Myb; B-Myb; carbonic anhydrase; erythroleukemia; transcription factor; differentiation	HUMAN HEMATOPOIETIC-CELLS; INDUCED TRANSCRIPTION ACTIVATION; NEUTROPHIL ELASTASE PROMOTER; NEGATIVE REGULATORY DOMAIN; ERYTHROID-DIFFERENTIATION; B-MYB; A-MYB; PHOSPHORYLATION SITE; GENE-EXPRESSION; BINDING-SITES	The Myb proto-oncogene encodes a transcription factor (c-Myb) that is essential for normal hematopoiesis and is thought to regulate hematopoietic cell proliferation and differentiation by regulating expression of specific target genes. We identify the mouse erythroid-specific carbonic anhydrase I promoter (CAIe) as a target of c-Myb activity and demonstrate that Myb activity is critical for carbonic anhydrase I (CAI) expression in C19 MEL cells. CAI expression is downregulated when MEL cells differentiate in response to MEnT or treatment with N, N-hexamethylene bisacetamide (HMBA). Coexpression of GATA-1 with c-Myb results in synergistic activation of transcription from the CAIe promoter and both transcription factors interact with the CAIe promoter in vivo. We identify a novel 20 bp sequence in the CAIe promoter that is sufficient to mediate synergistic activation of the CAIe promoter by c-Myb and GATA-1. c-Myb and GATA-1 interact with this DNA sequence suggesting that c-Myb and GATA-1 may be contained in a complex that interacts with this region of the CAIe promoter. Forced expression of CAI delayed HMBA-induced differentiation of MEL cells and maintained them in a proliferating state. These data strongly suggest that CAI is a c-Myb target and is involved in regulating MEL cell proliferation and differentiation.	Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Mol Physiol & Biol Phys, Charlottesville, VA USA	University of Virginia; University of Virginia	Bender, TP (corresponding author), Univ Virginia Hlth Syst, Dept Microbiol, POB 800734,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	tpb3e@virginia.edu			NATIONAL CANCER INSTITUTE [R01CA085842] Funding Source: NIH RePORTER; NCI NIH HHS [CA85842] Funding Source: Medline; NIGMS NIH HHS [GM55985] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; Bender TP, 2004, NAT IMMUNOL, V5, P721, DOI 10.1038/ni1085; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; Beug H, 1996, BBA-REV CANCER, V1288, pM35, DOI 10.1016/S0304-419X(96)00032-7; BRADY HJM, 1991, BIOCHEM J, V277, P903, DOI 10.1042/bj2770903; BRADY HJM, 1989, FEBS LETT, V257, P451, DOI 10.1016/0014-5793(89)81594-7; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; BUSFIELD SJ, 1995, EUR J BIOCHEM, V230, P475; Cardone RA, 2005, NAT REV CANCER, V5, P786, DOI 10.1038/nrc1713; Chen J, 2002, ONCOGENE, V21, P1859, DOI 10.1038/sj.onc.1205003; Ciana P, 1998, EMBO J, V17, P7382, DOI 10.1093/emboj/17.24.7382; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CUDDIHY AE, 1993, MOL CELL BIOL, V13, P3505, DOI 10.1128/MCB.13.6.3505; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; Emambokus N, 2003, EMBO J, V22, P4478, DOI 10.1093/emboj/cdg434; ENDO T, 1994, LEUKEMIA RES, V18, P49, DOI 10.1016/0145-2126(94)90008-6; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FRASER P, 1989, MOL CELL BIOL, V9, P3308, DOI 10.1128/MCB.9.8.3308; FRASER PJ, 1986, J MOL EVOL, V23, P294, DOI 10.1007/BF02100637; FRASER PJ, 1987, GENE DEV, V1, P855, DOI 10.1101/gad.1.8.855; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; Ganter B, 1997, ONCOGENE, V15, P193, DOI 10.1038/sj.onc.1201173; GOLAY J, 1991, BLOOD, V77, P149; Golay J, 1996, BLOOD, V87, P1900; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; Henry RP, 1996, ANNU REV PHYSIOL, V58, P523, DOI 10.1146/annurev.ph.58.030196.002515; INOUE T, 1994, J BIOL CHEM, V269, P32451; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; Lang G, 2005, ONCOGENE, V24, P1375, DOI 10.1038/sj.onc.1208301; Latchman D. S., 1993, TRANSCRIPTION FACTOR; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Liao SY, 1997, CANCER RES, V57, P2827; Lipsick JS, 1996, ONCOGENE, V13, P223; LOWE N, 1990, GENE, V93, P277, DOI 10.1016/0378-1119(90)90236-K; Marks P A, 1987, Prog Clin Biol Res, V251, P253; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MartinezZaguilan R, 1996, CLIN EXP METASTAS, V14, P176, DOI 10.1007/BF00121214; McAdams TA, 1998, BRIT J HAEMATOL, V103, P317, DOI 10.1046/j.1365-2141.1998.00975.x; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MELOTTI P, 1994, J BIOL CHEM, V269, P25303; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; Miglarese MR, 1996, J BIOL CHEM, V271, P22697, DOI 10.1074/jbc.271.37.22697; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; Ness SA, 1999, ONCOGENE, V18, P3039, DOI 10.1038/sj.onc.1202726; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Nuchprayoon I, 1997, BLOOD, V89, P4546, DOI 10.1182/blood.V89.12.4546; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Parkkila S, 2000, P NATL ACAD SCI USA, V97, P2220, DOI 10.1073/pnas.040554897; Pastorekova S, 2004, J ENZYM INHIB MED CH, V19, P199, DOI 10.1080/14756360410001689540; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; Ratajczak MZ, 1998, BLOOD, V91, P1934, DOI 10.1182/blood.V91.6.1934.1934_1934_1946; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; Rushton JJ, 2003, ONCOGENE, V22, P308, DOI 10.1038/sj.onc.1206131; SCHER W, 1977, CELL DIFFER DEV, V6, P285, DOI 10.1016/0045-6039(77)90003-3; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SOWDEN J, 1993, DIFFERENTIATION, V53, P67, DOI 10.1111/j.1432-0436.1993.tb00647.x; Takahashi T, 2000, ONCOGENE, V19, P134, DOI 10.1038/sj.onc.1203228; TASHIAN RE, 1989, BIOESSAYS, V10, P186, DOI 10.1002/bies.950100603; Tureci O, 1998, P NATL ACAD SCI USA, V95, P7608, DOI 10.1073/pnas.95.13.7608; Webb SD, 1999, J THEOR BIOL, V196, P237, DOI 10.1006/jtbi.1998.0836; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	72	16	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2758	2772		10.1038/sj.onc.1209295	http://dx.doi.org/10.1038/sj.onc.1209295			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16407849				2022-12-28	WOS:000237272900007
J	Qiu, W; Schonleben, F; Thaker, HM; Goggins, M; Su, GH				Qiu, W.; Schoenleben, F.; Thaker, H. M.; Goggins, M.; Su, G. H.			A novel mutation of STK11/LKB1 gene leads to the loss of cell growth inhibition in head and neck squamous cell carcinoma	ONCOGENE			English	Article						HNSCC; PJS; STK11; LKB1; genetic mutation; tumor-suppressor gene	PEUTZ-JEGHERS-SYNDROME; SYNDROME KINASE LKB1; SOMATIC MUTATIONS; LKB1/STK11 GENE; TUMORS; POLYPOSIS; EXPRESSION; CANCER; RISK; LUNG	To investigate whether genetic alteration of the STK11 ( serine/ threonine kinase 11)/ LKB1 tumor- suppressor gene is involved in the carcinogenesis of head and neck squamous cell carcinoma ( HNSCC), the entire encoding exons and flanking intronic sequences of the STK11/ LKB1 gene were analysed with direct genomic sequencing of 15 HNSCC specimens. A novel missense mutation with presumed loss of heterozygosity ( LOH) and 10 polymorphisms were identified in these samples. The novel mutation of STK11/ LKB1 at nucleotide position 613 G -> A, which causes the amino- acid substitution from alanine to threonine at residue 205 within the catalytic kinase domain, was identified in cell line RPMI 2650. To further determine whether this point mutation affects the gene function, constructs of the wild type and A205T mutant of the STK11/ LKB1 gene expression vectors were created and transfected into RPMI 2650 cells. Our results showed that the reintroduction of the wild- type but not the mutant STK11/ LKB1 construct into RPMI 2650 cells induced suppression of the cell growth. The mutation also affected the kinase activity of the Stk11/ Lkb1 protein. This led us to conclude that the A205T point mutation of the STK11/ LKB1 gene produces functionally inactive proteins. This is the first described mutation of the STK11/ LKB1 gene in HNSCC. While the mutation frequency of the STK11/ LKB1 gene in HNSCC remains to be determined in future studies, our data strongly suggests that STK11/ LKB1 is involved in the carcinogenesis of HNSCC.	Columbia Univ Coll Phys & Surg, Dept Otolaryngol Head & Neck Surg, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA	Columbia University; Columbia University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Su, GH (corresponding author), Columbia Univ Coll Phys & Surg, Dept Otolaryngol Head & Neck Surg, 1130 St Nicholas Ave,ICRC 10-04, New York, NY 10032 USA.	gs2157@columbia.edu	Su, Gloria/AAJ-1457-2020	Su, Gloria/0000-0002-5158-6019	NATIONAL CANCER INSTITUTE [R01CA109525, K01CA095434] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA095434, CA95434, R01 CA109525] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avizienyte E, 1998, CANCER RES, V58, P2087; Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Boudeau J, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9112; Chen RW, 1999, J MED GENET, V36, P943; Ghaffar H, 2003, CLIN CANCER RES, V9, P2998; Giardiello FM, 2000, GASTROENTEROLOGY, V119, P1447, DOI 10.1053/gast.2000.20228; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Guldberg P, 1999, ONCOGENE, V18, P1777, DOI 10.1038/sj.onc.1202486; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hemminki A, 1997, NAT GENET, V15, P87, DOI 10.1038/ng0197-87; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Jishage K, 2002, P NATL ACAD SCI USA, V99, P8903, DOI 10.1073/pnas.122254599; Jordanova A, 1997, HUM MUTAT, V10, P65, DOI 10.1002/(SICI)1098-1004(1997)10:1<65::AID-HUMU9>3.3.CO;2-9; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Launonen V, 2005, HUM MUTAT, V26, P291, DOI 10.1002/humu.20222; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Nakau M, 2002, CANCER RES, V62, P4549; Ossipova O, 2003, NAT CELL BIOL, V5, P889, DOI 10.1038/ncb1048; Rossi DJ, 2002, P NATL ACAD SCI USA, V99, P12327, DOI 10.1073/pnas.192301399; Rowan A, 2000, J PATHOL, V192, P203; Rowan A, 1999, J INVEST DERMATOL, V112, P509, DOI 10.1046/j.1523-1747.1999.00551.x; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Smith DP, 2001, HUM MOL GENET, V10, P2869, DOI 10.1093/hmg/10.25.2869; Spicer J, 2003, ONCOGENE, V22, P4752, DOI 10.1038/sj.onc.1206669; Su GH, 1999, AM J PATHOL, V154, P1835, DOI 10.1016/S0002-9440(10)65440-5; Suzuki A, 2004, BIOCHEM BIOPH RES CO, V324, P986, DOI 10.1016/j.bbrc.2004.09.145; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Westerman AM, 1999, HUM MUTAT, V13, P476, DOI 10.1002/(SICI)1098-1004(1999)13:6<476::AID-HUMU7>3.3.CO;2-U; Ylikorkala A, 2001, SCIENCE, V293, P1323, DOI 10.1126/science.1062074	34	30	30	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2937	2942		10.1038/sj.onc.1209325	http://dx.doi.org/10.1038/sj.onc.1209325			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16407837	Green Accepted			2022-12-28	WOS:000237448200012
J	Zhang, DW; Jeang, KT; Lee, CGL				Zhang, DW; Jeang, KT; Lee, CGL			p53 negatively regulates the expression of FAT10, a gene upregulated in various cancers	ONCOGENE			English	Article						FAT10; diubiquitin; promoter; 5 ' UTR; p53	UBIQUITIN-LIKE PROTEIN; WILD-TYPE P53; MHC CLASS-I; CELL-CYCLE; TRANSCRIPTIONAL REPRESSION; HEPATOCELLULAR-CARCINOMA; INTERFERON-GAMMA; TUMOR-SUPPRESSOR; MAMMALIAN-CELLS; CHECKPOINT	FAT10 is a member of the ubiquitin-like modi. er family of proteins and has been implicated to play important roles in antigen presentation, cytokine response, apoptosis and mitosis. We have recently demonstrated the upregulation of FAT10 gene expression in 90% of hepatocellular carcinoma patients. Here, we identified and characterized the promoter of the FAT10 gene to elucidate the mechanism of FAT10 gene expression. Notably, we found that the 50 untranslated region (5'UTR), from the transcription start site to 15 bases before the translational start site, displays significant promoter activity. Regions upstream of the 5'UTR (from +26 to -1997) do not confer any promoter activity. Curiously, FAT10 promoter activity and expression is significantly repressed in KB3-1 and HepG2 cells, which have wild-type p53, than in p53-negative Hep3B cells. The role of p53 in regulating FAT10 expression was evident by the significant down-regulation (P < 0.05) of FAT10 mRNA expression and promoter activity when wild-type p53 was transfected into p53-null Hep3B cells. Conversely, inhibiting p53 expression through siRNA against p53 significantly enhanced FAT10 expression and promoter activity. p53 was found to bind in vivo to the 50 half consensus sequence of p53binding site located at the FAT10 promoter. Hence, we propose that FAT10 is a downstream target of p53 and dysregulation of FAT10 expression in p53-defective cells could contribute to carcinogenesis.	Natl Canc Ctr, Div Med Sci, Singapore 169610, Singapore; Natl Univ Singapore, Dept Biochem, Yong Loo Lin Sch Med, Singapore 117548, Singapore; NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	National Cancer Centre Singapore (NCCS); National University of Singapore; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Lee, CGL (corresponding author), Natl Canc Ctr, Div Med Sci, Level 6,Lab 5,11 Hosp Dr, Singapore 169610, Singapore.	bchleec@nus.edu.sg	Lee, Caroline G/M-8918-2019; Jeang, Kuan-Teh/A-2424-2008	Lee, Caroline G/0000-0002-4323-3635; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001023, Z01AI001023, ZIAAI000547, Z01AI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aguiar J, 1999, BIOCHEM BIOPH RES CO, V254, P315, DOI 10.1006/bbrc.1998.9929; Bates EFM, 1997, EUR J IMMUNOL, V27, P2471, DOI 10.1002/eji.1830271002; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chun ACS, 2003, J BIOL CHEM, V278, P37439, DOI 10.1074/jbc.M307185200; Clark IM, 1997, BIOCHEM J, V324, P611, DOI 10.1042/bj3240611; Dokmanovic M, 2002, CANCER BIOL THER, V1, P24, DOI 10.4161/cbt.1.1.35; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Fan WF, 1996, IMMUNOGENETICS, V44, P97, DOI 10.1007/s002510050095; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Haupt Ygal, 2002, Oncogene, V21, P8223, DOI 10.1038/sj.onc.1206137; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Kumanovics A, 2003, ANNU REV IMMUNOL, V21, P629, DOI 10.1146/annurev.immunol.21.090501.080116; LANE DP, 1992, NATURE, V358, P16; Lee CGL, 2000, FASEB J, V14, P516, DOI 10.1096/fasebj.14.3.516; Lee CGL, 2003, ONCOGENE, V22, P2592, DOI 10.1038/sj.onc.1206337; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li GQ, 2003, WORLD J GASTROENTERO, V9, P1972, DOI 10.3748/wjg.v9.i9.1972; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; Luo XL, 2002, MOL CELL, V9, P59, DOI 10.1016/S1097-2765(01)00435-X; Maeda Y, 2002, MOL ENDOCRINOL, V16, P402, DOI 10.1210/me.16.2.402; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Pagano M, 1997, FASEB J, V11, P1067, DOI 10.1096/fasebj.11.13.9367342; PINES J, 1994, NATURE, V371, P742, DOI 10.1038/371742a0; Raasi S, 1999, EUR J IMMUNOL, V29, P4030, DOI 10.1002/(SICI)1521-4141(199912)29:12<4030::AID-IMMU4030>3.0.CO;2-Y; Stahler F, 1998, ONCOGENE, V17, P3507, DOI 10.1038/sj.onc.1202245; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; van den Elsen PJ, 1998, IMMUNOGENETICS, V48, P208, DOI 10.1007/s002510050425; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang XH, 2002, CANCER RES, V62, P1662; Zhao RB, 2000, GENE DEV, V14, P981	41	63	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 13	2006	25	16					2318	2327		10.1038/sj.onc.1209220	http://dx.doi.org/10.1038/sj.onc.1209220			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16501612				2022-12-28	WOS:000236764300004
J	Chen, E; Lim, MS; Rosic-Kablar, S; Liu, J; Jolicoeur, P; Dube, ID; Hough, MR				Chen, E; Lim, MS; Rosic-Kablar, S; Liu, J; Jolicoeur, P; Dube, ID; Hough, MR			Dysregulated expression of mitotic regulators is associated with B-cell lymphomagenesis in HOX11-transgenic mice	ONCOGENE			English	Article						HOX11; homeobox; aneuploidy; insertional mutagenesis	ACUTE LYMPHOBLASTIC-LEUKEMIA; INSERTIONAL MUTAGENESIS; DISEASE GENES; IDENTIFICATION; HOX11; IMMUNODEFICIENCY; VIRUS; INDUCTION; PATHWAY	Dysregulated expression of the homeobox gene, HOX11 is a frequent etiologic event in T-cell acute lymphoblastic leukemias. HOX11-transgenic mice ( IgH mu-HOX11(Tg))-expressing HOX11 in the B-cell compartment develop B-cell lymphomas with extended latency. The latency suggests that additional genetic events are required prior to the onset of malignant lymphoma. We report the identification of 17 HOX11 collaborating genes, revealed through their propensity to be targeted in a proviral insertional mutagenesis screen. Seven integrations disrupted genes in mitotic spindle checkpoint control, suggesting that cells with elevated HOX11 expression are especially sensitive to dysregulation of chromosome segregation during mitosis. IgH mu-HOX11(Tg) primary B-lymphocyte cultures exposed to the aneugenic agents, colchicine and colcemid, exhibited increased incidences of chromosome missegregation as assessed by cytokinesis-block micronucleus assays. Additionally, IgH mu-HOX11(Tg) cultures were shown to exhibit aberrant bypass of spindle checkpoint arrest, as assessed by the increased presence of cycling cells determined by assessment of DNA content and by BrdU immunolabelling. Western immunoblotting revealed elevated expression of the mitotic effector molecules, cyclin A, cyclin B1 and cdc20 in IgH mu-HOX11(Tg) cultures. Moreover, spontaneously arising lymphoid neoplasms in IgH mu-HOX11(Tg) mice frequently exhibit aberrant expression of mitotic regulators, concomitant with increased development of micronuclei, abnormal mitotic checkpoint control and increased incidences of abnormal karyotypes when expanded in culture. Collectively, these findings indicate that abnormal regulation of spindle checkpoint control as a result of HOX11 overexpression leads to a heightened predisposition for development of aneuploidy, contributing to oncogenesis.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Mol & Cellular Biol, Toronto, ON M4N 3M5, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A1, Canada; Univ Utah, Dept Pathol, Salt Lake City, UT USA; McGill Univ, Clin Res Inst Montreal, Montreal, PQ, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Toronto; Utah System of Higher Education; University of Utah; Institut de Recherche Clinique de Montreal (IRCM); McGill University; Universite de Montreal	Hough, MR (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Mol & Cellular Biol, 2075 Bayview Ave,Room S232, Toronto, ON M4N 3M5, Canada.	margaret.hough@sw.ca	Liu, Ju/Q-6319-2016; Hough, Margaret/AAA-1026-2019	Liu, Ju/0000-0001-9932-2613; Hough, Margaret/0000-0001-8539-6398; Chen, Edwin/0000-0003-0742-9734; Lim, Megan/0000-0002-0415-2867				Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Asnafi V, 2005, BLOOD, V105, P3072, DOI 10.1182/blood-2004-09-3666; Asnafi V, 2004, BLOOD, V104, P4173, DOI 10.1182/blood-2003-11-3944; AZIZ DC, 1989, NATURE, V338, P505, DOI 10.1038/338505a0; BERNS A, 1991, J CELL BIOCHEM, V47, P130, DOI 10.1002/jcb.240470206; Bourner RDP, 1998, MUTAT RES-FUND MOL M, V404, P191, DOI 10.1016/S0027-5107(98)00113-4; Casabianca A, 2003, J VIROL METHODS, V110, P81, DOI 10.1016/S0166-0934(03)00104-6; CHATTOPADHYAY SK, 1989, P NATL ACAD SCI USA, V86, P3862, DOI 10.1073/pnas.86.10.3862; DUBE ID, 1986, BLOOD, V67, P1181; DUBE ID, 1991, BLOOD, V78, P2996; Erkeland SJ, 2004, J VIROL, V78, P1971, DOI 10.1128/JVI.78.4.1971-1980.2004; Ferrando AA, 2004, LANCET, V363, P535, DOI 10.1016/S0140-6736(04)15542-6; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Hough MR, 1998, P NATL ACAD SCI USA, V95, P13853, DOI 10.1073/pnas.95.23.13853; HUANG M, 1995, J VIROL, V69, P4069, DOI 10.1128/JVI.69.7.4069-4078.1995; HUANG M, 1989, SCIENCE, V246, P1614, DOI 10.1126/science.2480643; HUANG M, 1991, J VIROL, V65, P6562, DOI 10.1128/JVI.65.12.6562-6571.1991; HUANG M, 1992, J VIROL, V66, P2398, DOI 10.1128/JVI.66.4.2398-2406.1992; Hwang HC, 2002, P NATL ACAD SCI USA, V99, P11293, DOI 10.1073/pnas.162356099; Iwasaki M, 2005, BLOOD, V105, P784, DOI 10.1182/blood-2004-04-1508; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Kees UR, 2003, LEUKEMIA, V17, P887, DOI 10.1038/sj.leu.2402892; Kim R, 2003, J VIROL, V77, P2056, DOI 10.1128/JVI.77.3.2056-2062.2003; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; LICHTY BD, 1995, LEUKEMIA LYMPHOMA, V16, P209, DOI 10.3109/10428199509049759; Mauvieux L, 2002, LEUKEMIA, V16, P2417, DOI 10.1038/sj.leu.2402709; Morse HC, 2002, BLOOD, V100, P246, DOI 10.1182/blood.V100.1.246; Muehlbauer PA, 2005, MUTAT RES-GEN TOX EN, V585, P156, DOI 10.1016/j.mrgentox.2005.05.002; Rao H, 2001, NATURE, V410, P955, DOI 10.1038/35073627; Riz I, 2005, ONCOGENE, V24, P5561, DOI 10.1038/sj.onc.1208727; Rosic-Kablar S, 2000, P NATL ACAD SCI USA, V97, P13300, DOI 10.1073/pnas.240221297; Shin MS, 2004, CANCER RES, V64, P4419, DOI 10.1158/0008-5472.CAN-03-3885; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142	36	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2575	2587		10.1038/sj.onc.1209285	http://dx.doi.org/10.1038/sj.onc.1209285			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16407851				2022-12-28	WOS:000237099400002
J	Weniger, MA; Melzner, I; Menz, CK; Wegener, S; Bucur, AJ; Dorsch, K; Mattfeldt, T; Barth, TFE; Moller, P				Weniger, MA; Melzner, I; Menz, CK; Wegener, S; Bucur, AJ; Dorsch, K; Mattfeldt, T; Barth, TFE; Moller, P			Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation	ONCOGENE			English	Article						SOCS-1; Hodgkin lymphoma; primary mediastinal B-cell lymphoma; STAT5	B-CELL LYMPHOMA; EPIGENETIC ACTIVATION; SHP1 HYPERMETHYLATION; NEGATIVE REGULATOR; METHYLATION; REL; DEGRADATION; PROTEINS; GAINS; 2P	The suppressors of cytokine signaling ( SOCS) are critically involved in the regulation of cellular proliferation, survival, and apoptosis via cytokine-induced JAK/STAT signaling. SOCS-1 silencing by aberrant DNA methylation contributes to oncogenesis in various B-cell neoplasias and carcinomas. Recently, we showed an alternative loss of SOCS-1 function due to deleterious SOCS-1 mutations in a major subset of primary mediastinal B-cell lymphoma ( PMBL) and in the PMBL line MedB-1, and a biallelic SOCS-1 deletion in PMBL line Karpas1106P. For both cell lines our previous data demonstrated retarded JAK2 degradation and sustained phospho-JAK2 action leading to enhanced DNA binding of phospho-STAT5. Here, we analysed SOCS-1 in laser-microdissected Hodgkin and Reed-Sternberg ( HRS) cells of classical Hodgkin lymphoma ( cHL). We detected SOCS-1 mutations in HRS cells of eight of 19 cHL samples and in three of five Hodgkin lymphoma ( HL)derived cell lines by sequencing analysis. Moreover, we found a significant association between mutated SOCS-1 of isolated HRS cells and nuclear phospho-STAT5 accumulation in HRS cells of cHL tumor tissue ( P < 0.01). Collectively, these findings support the concept that PMBL and cHL share many overlapping features, and that defective tumor suppressor gene SOCS-1 triggers an oncogenic pathway operative in both lymphomas.	Univ Ulm, Dept Pathol, D-89081 Ulm, Germany	Ulm University	Moller, P (corresponding author), Univ Ulm, Dept Pathol, Albert Einstein Allee 11, D-89081 Ulm, Germany.	peter.moeller@medizin.uni-ulm.de						Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; Barth TFE, 2002, LANCET ONCOL, V3, P229, DOI 10.1016/S1470-2045(02)00714-3; Chen CY, 2003, GENE CHROMOSOME CANC, V37, P300, DOI 10.1002/gcc.10222; Chim CS, 2004, BLOOD, V103, P4630, DOI 10.1182/blood-2003-06-2007; Chim CS, 2004, LEUKEMIA, V18, P356, DOI 10.1038/sj.leu.2403216; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Galm O, 2003, BLOOD, V101, P2784, DOI 10.1182/blood-2002-06-1735; Guiter C, 2004, BLOOD, V104, P543, DOI 10.1182/blood-2003-10-3545; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Joos S, 1996, BLOOD, V87, P1571, DOI 10.1182/blood.V87.4.1571.bloodjournal8741571; Joos S, 2003, INT J CANCER, V103, P489, DOI 10.1002/ijc.10845; Komazaki T, 2004, JPN J CLIN ONCOL, V34, P191, DOI 10.1093/jjco/hyh035; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Kube D, 2001, BLOOD, V98, P762, DOI 10.1182/blood.V98.3.762; Melzner I, 2006, INT J CANCER, V118, P1941, DOI 10.1002/ijc.21485; Melzner I, 2005, BLOOD, V105, P2535, DOI 10.1182/blood-2004-09-3701; Ritz O, 2005, J PATHOL, V205, P336, DOI 10.1002/path.1688; Rosenwald A, 2003, J EXP MED, V198, P851, DOI 10.1084/jem.20031074; Rottapel R, 2002, ONCOGENE, V21, P4351, DOI 10.1038/sj.onc.1205537; Savage KJ, 2003, BLOOD, V102, P3871, DOI 10.1182/blood-2003-06-1841; Skinnider BF, 2002, BLOOD, V99, P618, DOI 10.1182/blood.V99.2.618; Sutherland KD, 2004, ONCOGENE, V23, P7726, DOI 10.1038/sj.onc.1207787; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225	25	200	206	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2679	2684		10.1038/sj.onc.1209151	http://dx.doi.org/10.1038/sj.onc.1209151			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16532038				2022-12-28	WOS:000237099400012
J	Deniaud, E; Baguet, J; Mathieu, AL; Pages, G; Marvel, J; Leverrier, Y				Deniaud, E.; Baguet, J.; Mathieu, A-L; Pages, G.; Marvel, J.; Leverrier, Y.			Overexpression of Sp1 transcription factor induces apoptosis	ONCOGENE			English	Article						apoptosis; Sp1; transcription factor	ENDOTHELIAL GROWTH-FACTOR; DNA-BINDING ACTIVITY; CELL-GROWTH; BCL-X; HEMATOPOIETIC-CELLS; GASTRIC-CANCER; S-PHASE; EXPRESSION; INDUCTION; GENE	Transcription factor Sp1 has recently been shown to be overexpressed in a number of human cancers and its overexpression contributes to malignant transformation. Sp1 regulates the expression of a number of genes participating in multiple aspects of tumorigenesis such as angiogenesis, cell growth and apoptosis resistance. To better understand the role of increased Sp1 levels on apoptosis regulation we have used retroviruses to overexpress this protein in haematopoietic Baf-3 cells and in 3T3 fibroblasts. We have also used inducible expression systems to control ectopic Sp1 levels in different cell types. Surprisingly, Sp1 overexpression on its own induces apoptosis in all the cellular models tested. The apoptotic pathways induced by Sp1 overexpression are cell type specific. Finally, using a truncated form of Sp1, we show that Sp1-induced apoptosis requires its DNA-binding domain. Our results highlight that Sp1 levels in untransformed cells must be tightly regulated as Sp1 overexpression leads to the induction of apoptosis. Our results also suggest that cancer cells overexpressing Sp1 can avoid Sp1-induced apoptosis.	Inserm U503, F-69007 Lyon, France; BioSci Lyon Gerland, IFR 128, Lyon, France; Univ Lyon 1, F-69365 Lyon, France; Univ Nice Sophia Antipolis, CNRS, UMR 6543, Ctr Antoine Lacassagne, Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	Marvel, J (corresponding author), Inserm U503, 21 Ave Tony Garnier, F-69007 Lyon, France.	marvel@cervi-lyon.inserm.fr; leverrier@cervi-lyon.inserm.fr	LEVERRIER, Yann/M-3767-2014; marvel, jacqueline/H-8638-2014; Deniaud, Emmanuelle/B-9518-2008; Pages, Gilles/N-7135-2017	LEVERRIER, Yann/0000-0002-4227-5446; marvel, jacqueline/0000-0001-6241-459X; Mathieu, Anne-Laure/0000-0002-2893-7001				Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Chae YM, 2004, BIOCHEM BIOPH RES CO, V319, P550, DOI 10.1016/j.bbrc.2004.05.025; Chen F, 2000, ANTICANCER RES, V20, P661; Chiefari E, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-35; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Demeret C, 2003, ONCOGENE, V22, P168, DOI 10.1038/sj.onc.1206108; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; French SW, 2003, J BIOL CHEM, V278, P948, DOI 10.1074/jbc.M207166200; Gala S, 2001, BLOOD, V97, P227, DOI 10.1182/blood.V97.1.227; Gonin-Giraud S, 2002, CELL DEATH DIFFER, V9, P1147, DOI 10.1038/sj.cdd.4401079; Grillot DAM, 1997, J IMMUNOL, V158, P4750; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Heinrich J, 2000, J MOL MED-JMM, V78, P380, DOI 10.1007/s001090000116; Hofmann A, 1996, P NATL ACAD SCI USA, V93, P5185, DOI 10.1073/pnas.93.11.5185; Im HJ, 2002, J BIOL CHEM, V277, P14612, DOI 10.1074/jbc.M109414200; Ishibashi H, 2000, CANCER RES, V60, P6531; Kavurma MM, 2001, J BIOL CHEM, V276, P4964, DOI 10.1074/jbc.M009251200; Kavurma MM, 2003, J BIOL CHEM, V278, P32537, DOI 10.1074/jbc.M305650200; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Kumar A, 2003, MOL CELL BIOL, V23, P6631, DOI 10.1128/MCB.23.18.6631-6645.2003; Kumar AP, 1999, CANCER LETT, V137, P159, DOI 10.1016/S0304-3835(98)00351-6; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Leverrier Y, 1999, CELL DEATH DIFFER, V6, P290, DOI 10.1038/sj.cdd.4400492; Lietard J, 1997, AM J PATHOL, V151, P1663; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Lomberk G, 2005, BIOCHEM J, V392, P1, DOI 10.1042/BJ20051234; Lou Z, 2005, CANCER RES, V65, P1007; Low W, 2001, ONCOGENE, V20, P4476, DOI 10.1038/sj.onc.1204580; Mangeney M, 1996, ONCOGENE, V13, P1441; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Mathieu AL, 2001, J BIOL CHEM, V276, P10935, DOI 10.1074/jbc.M007147200; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Munoz-Pinedo C, 2001, BIOCHEM J, V353, P101, DOI 10.1042/bj3530101; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Persengiev SP, 2002, GENE DEV, V16, P1806, DOI 10.1101/gad.992202; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Pore N, 2004, MOL BIOL CELL, V15, P4841, DOI 10.1091/mbc.E04-05-0374; Preston GA, 1996, MOL CELL BIOL, V16, P211; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; Ryu H, 2003, J NEUROSCI, V23, P3597; Ryu H, 2003, P NATL ACAD SCI USA, V100, P4281, DOI 10.1073/pnas.0737363100; Santos SCR, 2000, ONCOGENE, V19, P1164, DOI 10.1038/sj.onc.1203418; Shi Q, 2001, CANCER RES, V61, P4143; SHORT ML, 1994, BIOCHEM J, V304, P391, DOI 10.1042/bj3040391; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Takahara T, 2000, J BIOL CHEM, V275, P38067, DOI 10.1074/jbc.M002010200; Thomas J, 1998, ONCOGENE, V16, P1399, DOI 10.1038/sj.onc.1201672; Wang LW, 2003, CLIN CANCER RES, V9, P6371; Yao JC, 2004, CLIN CANCER RES, V10, P4109, DOI 10.1158/1078-0432.CCR-03-0628; Zannetti A, 2000, CANCER RES, V60, P1546	54	73	77	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 9	2006	25	53					7096	7105		10.1038/sj.onc.1209696	http://dx.doi.org/10.1038/sj.onc.1209696			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16715126				2022-12-28	WOS:000241910500009
J	Kiyono, M; Shibuya, M				Kiyono, M.; Shibuya, M.			Inhibitory Smad transcription factors protect arterial endothelial cells from apoptosis induced by BMP4	ONCOGENE			English	Article						apoptosis; BMP4; endothelial cell; I-Smads	BONE MORPHOGENETIC PROTEIN; VENOUS DIFFERENTIATION; MEDIATES APOPTOSIS; ANGIOGENESIS; EXPRESSION; VASCULOGENESIS; RECEPTORS; GENES; FLOW	Arterial endothelial cells (EC) at the adult stage differ from capillary and venous EC in terms of resistance to stress; however, the molecular basis of this resistance is not clear. Here, we found that arterial EC are highly resistant to bone morphogenetic protein (BMP) 4-dependent apoptosis, whereas capillary and venous EC are not. The expression of inhibitory Smads (I-Smads) in arterial EC was well correlated with the resistance to this apoptosis. After the knockdown of I-Smad expression by short interfering RNA, the resistant arterial EC became sensitive to BMP4. In contrast, the ectopic expression of I-Smads in BMP4-sensitive cells suppressed BMP4-induced apoptosis. Furthermore, intravenous administration of BMP4 into mice caused hemorrhage of capillary EC in brain and lung. These results strongly suggest that BMP4/ I-Smads are a novel regulator for the stability of vascular EC.	Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Shibuya, M (corresponding author), Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	shibuya@ims.u-tokyo.ac.jp						Bourdeau A, 2000, TRENDS CARDIOVAS MED, V10, P279, DOI 10.1016/S1050-1738(01)00062-7; Duff SE, 2003, FASEB J, V17, P984, DOI 10.1096/fj.02-0634rev; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; Gu K, 1996, ARCH ORAL BIOL, V41, P919, DOI 10.1016/S0003-9969(96)00052-0; Hanyu A, 2001, J CELL BIOL, V155, P1017, DOI 10.1083/jcb.200106023; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Herzog Y, 2001, MECH DEVELOP, V109, P115, DOI 10.1016/S0925-4773(01)00518-4; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199; Kiyono M, 2003, MOL CELL BIOL, V23, P4627, DOI 10.1128/MCB.23.13.4627-4636.2003; le Noble F, 2004, DEVELOPMENT, V131, P361, DOI 10.1242/dev.00929; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Moyon D, 2001, DEVELOPMENT, V128, P3359; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Patan S, 2004, CANC TREAT, V117, P3; Shawber CJ, 2003, ANN NY ACAD SCI, V995, P162, DOI 10.1111/j.1749-6632.2003.tb03219.x; Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25; Shibuya M, 1999, CURR TOP MICROBIOL, V237, P59; Shin D, 2001, DEV BIOL, V230, P139, DOI 10.1006/dbio.2000.9957; Souchelnytskyi S, 1998, J BIOL CHEM, V273, P25364, DOI 10.1074/jbc.273.39.25364; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738	25	22	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	54					7131	7137		10.1038/sj.onc.1209700	http://dx.doi.org/10.1038/sj.onc.1209700			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16732319				2022-12-28	WOS:000242046900002
J	Trauzold, A; Siegmund, D; Schniewind, B; Sipos, B; Egberts, J; Zorenkov, D; Emme, D; Roder, C; Kalthoff, H; Wajant, H				Trauzold, A.; Siegmund, D.; Schniewind, B.; Sipos, B.; Egberts, J.; Zorenkov, D.; Emme, D.; Roeder, C.; Kalthoff, H.; Wajant, H.			TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma	ONCOGENE			English	Article						pancreatic cancer; metastasis; invasion; TRAIL	INDUCED APOPTOSIS; BCL-X; CANCER; CELLS; ACTIVATION; EXPRESSION; BAX; PROLIFERATION; APO2L/TRAIL; RESISTANCE	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has attracted considerable attention for its potential use in tumor therapy, as some recombinant variants of this ligand induce apoptosis in tumor cells without harming most normal cells. Here, we show that TRAIL strongly induces the expression of the proinflammatory cytokines interleukin-8 and monocyte chemoattractant protein 1 and enhances the invasion of apoptosis-resistant pancreatic ductal adenocarcinoma cells in vitro by upregulation of the urokinase-type plasminogen activator expression. Most importantly, we also demonstrate for the first time that TRAIL treatment results in strongly increased distant metastasis of pancreatic tumors in vivo. We orthotopically transplanted human pancreatic ductal adenocarcinoma cells to the pancreata of severe combined immunodeficiency mice and observed a dramatic increase in metastatic spread including a sixfold increase in the volume and fourfold increase in the number of liver metastases upon TRAIL treatment. Our results point to the necessity to carefully evaluate in vivo side effects of TRAIL and to select therapy conditions that not only enhance apoptosis induction but in addition prevent proinvasive and proinflammatory non-apoptotic TRAIL signaling.	Univ Kiel, Hosp Schleswig Holstein, Clin Gen Surg & Thorac Surg, Sect Mol Oncol, D-24105 Kiel, Germany; Univ Wurzburg, Med Clin & Polyclin 2, Dept Mol Internal Med, D-97070 Wurzburg, Germany; Univ Kiel, Hosp Schleswig Holstein, Inst Gen Pathol, D-24098 Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital; University of Wurzburg; University of Kiel; Schleswig Holstein University Hospital	Kalthoff, H (corresponding author), Clin Gen Surg & Thorac Surg, Sect Mol Oncol, Campus Kiel,Arnold Heller Str 7, D-24105 Kiel, Germany.	hkalthoff@email.uni-kiel.de	Wajant, Harald/A-3020-2017; Trauzold, Anna/P-4398-2014; Egberts, Jan-Hendrik/E-3211-2015; Kalthoff, Holger/B-1618-2010; Roeder, Christian/F-1068-2010	Wajant, Harald/0000-0002-2005-3949; Roeder, Christian/0000-0001-7881-9110				Almasan A, 2003, CYTOKINE GROWTH F R, V14, P337, DOI 10.1016/S1359-6101(03)00029-7; Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Armeanu S, 2003, CANCER RES, V63, P2369; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Baader E, 2005, CANCER RES, V65, P7888, DOI 10.1158/0008-5472.CAN-04-4278; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Evans JD, 2001, PANCREATOLOGY, V1, P254, DOI 10.1159/000055820; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; Ishimura N, 2006, AM J PHYSIOL-GASTR L, V290, pG129, DOI 10.1152/ajpgi.00242.2005; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; MacFarlane M, 2005, CANCER RES, V65, P11265, DOI 10.1158/0008-5472.CAN-05-2801; Miyamoto Y, 1999, ONCOLOGY-BASEL, V56, P73, DOI 10.1159/000011933; Muerkoster S, 2004, CANCER RES, V64, P1331, DOI 10.1158/0008-5472.CAN-03-1860; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Rudner J, 2005, ONCOGENE, V24, P130, DOI 10.1038/sj.onc.1208191; Schniewind B, 2004, INT J CANCER, V109, P182, DOI 10.1002/ijc.11679; Shankar S, 2004, DRUG RESIST UPDATE, V7, P139, DOI 10.1016/j.drup.2004.03.002; Siegmund D, 2005, MOL CELL BIOL, V25, P6363, DOI 10.1128/MCB.25.15.6363-6379.2005; TEPEL J, 2005, INT J COLORECTAL DIS, V16, P1; Trauzold A, 2005, FASEB J, V19, P620, DOI 10.1096/fj.04-2984fje; Trauzold A, 2001, ONCOGENE, V20, P4258, DOI 10.1038/sj.onc.1204559; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; Wajant H, 2002, APOPTOSIS, V7, P449, DOI 10.1023/A:1020039225764; Wajant H, 2005, CYTOKINE GROWTH F R, V16, P55, DOI 10.1016/j.cytogfr.2004.12.001; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517	27	186	193	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	56					7434	7439		10.1038/sj.onc.1209719	http://dx.doi.org/10.1038/sj.onc.1209719			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16751802				2022-12-28	WOS:000242419100012
J	Mulherkar, N; Ramaswamy, M; Mordi, DC; Prabhakar, BS				Mulherkar, N.; Ramaswamy, M.; Mordi, D. C.; Prabhakar, B. S.			MADD/DENN splice variant of the IG20 gene is necessary and sufficient for cancer cell survival	ONCOGENE			English	Article						IG20pa; MADD; DENN-SV; shRNA; alternative-splicing; apoptosis	GDP/GTP EXCHANGE PROTEIN; SMALL INTERFERING RNAS; DEATH DOMAIN PROTEIN; INDUCED APOPTOSIS; NEOPLASTIC-CELLS; MAMMALIAN-CELLS; DENN-SV; MADD; EXPRESSION; RECEPTOR	The IG20 gene is overexpressed in human tumors and cancer cell lines, and encodes at least four splice variants (SVs) namely, IG20pa, MADD, IG20-SV2 and DENNSV. Earlier, gain-of-function studies showed that IG20SVs can exhibit diverse functions and play a critical role in cell proliferation and apoptosis. Expression of exogenous IG20pa or DENN-SV rendered cells either susceptible or resistant to induced apoptosis, respectively, whereas MADD and IG20-SV2 had no apparent effect. In order to understand the contrasting effects of the IG20-SVs in a physiologically more relevant system, we expressed exon-specific small hairpin RNAs (shRNAs) to selectively knockdown specific IG20-SVs. Consistent with an earlier study, knockdown of all IG20-SVs resulted in spontaneous apoptosis of HeLa and PA-1 cells. In addition, we unambiguously demonstrated that knockdown of MADD can render cells susceptible to spontaneous apoptosis but had no discernible effect on cell proliferation, colony size or cell cycle progression. Moreover, expression of MADD alone, and not DENN-SV, in the absence of endogenous IG20-SVs was sufficient to prevent spontaneous apoptosis. Our results show the utility of shRNAs for selective knockdown of particular IG20-SVs and their potential therapeutic value in cancer. Further, they demonstrate that MADD alone is sufficient and necessary for cancer cell survival.	Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA; NIAMSD, NIH, Bethesda, MD 20892 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Prabhakar, BS (corresponding author), Univ Illinois, Coll Med, Dept Microbiol & Immunol, M-C 790,Room E-705,835 S Wolcott Ave, Chicago, IL 60612 USA.	bprabhak@uic.edu		Ramaswamy, Madhu/0000-0001-8870-5328	NATIONAL CANCER INSTITUTE [R01CA107506] Funding Source: NIH RePORTER; NCI NIH HHS [5R01CA107506] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Zoubi AM, 2001, J BIOL CHEM, V276, P47202, DOI 10.1074/jbc.M104835200; ANDREADIS A, 1987, ANNU REV CELL BIOL, V3, P207, DOI 10.1146/annurev.cellbio.3.1.207; Brinkman BMN, 1999, J BIOL CHEM, V274, P30882, DOI 10.1074/jbc.274.43.30882; Brown TL, 1998, CURR BIOL, V8, pR191; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chow VTK, 1998, GENOME, V41, P543, DOI 10.1139/gen-41-4-543; Chow VTK, 1996, DNA SEQUENCE, V6, P263, DOI 10.3109/10425179609020873; Cullen BR, 2004, VIRUS RES, V102, P3, DOI 10.1016/j.virusres.2004.01.009; CULLEN BR, 2005, GENE THER, V6, P503; Cunningham SJ, 1996, THESIS U TEXAS MED B; Del Villar K, 2004, P NATL ACAD SCI USA, V101, P4210, DOI 10.1073/pnas.0307349101; Efimova E, 2003, CANCER RES, V63, P8768; Efimova EV, 2004, ONCOGENE, V23, P1076, DOI 10.1038/sj.onc.1207210; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; GOTO Y, 1992, J BIOL CHEM, V267, P15252; Hall J, 2004, NAT REV GENET, V5, P552, DOI 10.1038/nrg1382; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Iwasaki K, 2000, EMBO J, V19, P4806, DOI 10.1093/emboj/19.17.4806; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Lee MTM, 2003, J VIROL, V77, P11964, DOI 10.1128/JVI.77.22.11964-11972.2003; Levivier E, 2001, BIOCHEM BIOPH RES CO, V287, P688, DOI 10.1006/bbrc.2001.5652; Lim KM, 2004, INT J CANCER, V109, P24, DOI 10.1002/ijc.11660; Lim KM, 2002, MOL CARCINOGEN, V35, P110, DOI 10.1002/mc.10082; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Murakami-Mori K, 1999, J IMMUNOL, V162, P3672; Ramaswamy M, 2004, ONCOGENE, V23, P6083, DOI 10.1038/sj.onc.1207804; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; Tanaka M, 2001, MOL BIOL CELL, V12, P1421, DOI 10.1091/mbc.12.5.1421; Telliez JB, 2000, BBA-PROTEIN STRUCT M, V1478, P280, DOI 10.1016/S0167-4838(00)00029-7; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; Yamaguchi K, 2002, P NATL ACAD SCI USA, V99, P14536, DOI 10.1073/pnas.212511399; Zhang Y, 1998, P NATL ACAD SCI USA, V95, P2586, DOI 10.1073/pnas.95.5.2586	35	27	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2006	25	47					6252	6261		10.1038/sj.onc.1209650	http://dx.doi.org/10.1038/sj.onc.1209650			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	094CY	16682944				2022-12-28	WOS:000241218200003
J	Gonzalez, L; Freije, JMP; Cal, S; Lopez-Otin, C; Serrano, M; Palmero, I				Gonzalez, L.; Freije, J. M. P.; Cal, S.; Lopez-Otin, C.; Serrano, M.; Palmero, I.			A functional link between the tumour suppressors ARF and p33ING1	ONCOGENE			English	Article						ARF; p53; ING1; tumour suppressor	NF-KAPPA-B; ALTERNATIVE TRANSCRIPTS; PHD FINGER; ING FAMILY; P53; P19(ARF); PROTEINS; GENE; MDM2; ACTIVATION	The ARF tumour suppressor protein plays a critical role in the activation of p53 in response to oncogenic stress. ARF can activate p53 through nucleolar sequestration of Mdm2. However, several lines of evidence indicate that this is not the only way of action of ARF, and alternative mechanisms must exist. p33ING1 is a putative tumour suppresor, which induces cell-cycle arrest and apoptosis in a p53-dependent manner. Here, we describe that ARF and p33ING1 can interact in vivo. We also show that the subcellular localization of ING1 can be modulated by ARF protein levels, causing a displacement from nuclear to nucleolar localization. Finally, the ability of p33ING1 to cause cell-cycle arrest and induction of p21CIP1, or Mdm2, is impaired in ARF-deficient primary mouse fibroblasts. Based on these observations, we propose that the interaction with p33ING1 represents a novel mechanism for the tumour suppression function of ARF.	Univ Autonoma Madrid, CSIC, Inst Biomed Res, E-28029 Madrid, Spain; Univ Oviedo, Inst Oncol, Dept Biochem & Mol Biol, Oviedo, Spain; Spanish Natl Canc Ctr, CNIO, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); University of Oviedo; Centro Nacional de Investigaciones Oncologicas (CNIO)	Palmero, I (corresponding author), Univ Autonoma Madrid, CSIC, Inst Biomed Res, Arturo Duperier 4, E-28029 Madrid, Spain.	ipalmero@iib.uam.es	Serrano, Manuel/H-2634-2015; Freije, José M.P./A-6535-2008; López-Otín, Carlos/AAB-2106-2020; Palmero, Ignacio/B-4346-2013	Serrano, Manuel/0000-0001-7177-9312; Freije, José M.P./0000-0002-4688-8266; López-Otín, Carlos/0000-0001-6964-1904; 				Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Calabro V, 2004, MOL CELL BIOL, V24, P8529, DOI 10.1128/MCB.24.19.8529-8540.2004; Campos EI, 2004, CELL MOL LIFE SCI, V61, P2597, DOI 10.1007/s00018-004-4199-4; D'Amico M, 2004, CANCER RES, V64, P4122, DOI 10.1158/0008-5472.CAN-03-2519; Datta A, 2004, J BIOL CHEM, V279, P36698, DOI 10.1074/jbc.M312305200; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Feng XL, 2002, TRENDS CELL BIOL, V12, P532, DOI 10.1016/S0962-8924(02)02391-7; Goeman F, 2005, MOL CELL BIOL, V25, P422, DOI 10.1128/MCB.25.1.422-431.2005; Gong W, 2005, INT J BIOCHEM CELL B, V37, P1054, DOI 10.1016/j.biocel.2004.09.008; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Kuo ML, 2003, CANCER RES, V63, P1046; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Leung KM, 2002, CANCER RES, V62, P4890; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; Nouman GS, 2003, J CLIN PATHOL, V56, P491, DOI 10.1136/jcp.56.7.491; Nourani A, 2001, MOL CELL BIOL, V21, P7629, DOI 10.1128/MCB.21.22.7629-7640.2001; Palmero I, 2002, ONCOGENE, V21, P2939, DOI 10.1038/sj/onc/1205371; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Rocha S, 2005, EMBO J, V24, P1157, DOI 10.1038/sj.emboj.7600608; Scott M, 2001, NUCLEIC ACIDS RES, V29, P2052, DOI 10.1093/nar/29.10.2052; Scott M, 2001, J CELL SCI, V114, P3455; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shimada H, 2002, ONCOGENE, V21, P1208, DOI 10.1038/sj.onc.1205176; Shinoura N, 1999, CANCER RES, V59, P5521; Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Vieyra D, 2002, J BIOL CHEM, V277, P29832, DOI 10.1074/jbc.M200197200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Xin HW, 2004, J BIOL CHEM, V279, P9539, DOI 10.1074/jbc.M311587200; Yarbrough WG, 2002, CANCER RES, V62, P1171; Zeremski M, 1999, J BIOL CHEM, V274, P32172, DOI 10.1074/jbc.274.45.32172	45	34	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2006	25	37					5173	5179		10.1038/sj.onc.1209526	http://dx.doi.org/10.1038/sj.onc.1209526			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16607280				2022-12-28	WOS:000240063700010
J	Glesne, D; Huberman, E				Glesne, D.; Huberman, E.			Smad6 is a protein kinase X phosphorylation substrate and is required for HL-60 cell differentiation	ONCOGENE			English	Article						macrophage differentiation; PrKX; Smad6; HL-60; leukemia	GROWTH-FACTOR-BETA; TUMOR-NECROSIS-FACTOR; MACROPHAGE DIFFERENTIATION; ALPHA(5)BETA(1) INTEGRIN; CATALYTIC SUBUNIT; EXPRESSION; INDUCTION; SEQUENCE; SYSTEM; PRKX	To gain insight into the function of human protein kinase X (PrKX), a signal-transduction protein required for macrophage differentiation, we identified regulatory subunit I alpha of protein kinase A, T54 and Smad6 as partners for this protein using a yeast two-hybrid interaction screen. Interactions between PrKX and these proteins were substantiated by co-immunoprecipitation. Interaction between Smad6 and PrKX was also confirmed in human myeloid HL-60 cells following their phorbol 12-myristate 13-acetate (PMA)-induced differentiation into macrophages. In vitro phosphorylation assays demonstrated that PrKX phosphorylates Smad6 at a serine residue. Mutagenesis of this site resulted in abrogation of PrKX phosphorylation. Both PrKX and Smad6 were shown to be co-localized to the nuclear compartment of HL-60 cells during their macrophage differentiation where PrKX levels are induced and Smad6 protein levels remain relatively constant while levels of serine phosphorylation of Smad6 increase. By using in vitro electrophoretic mobility shift assays and in vivo chromatin immunoprecipitation, we also demonstrate that during macrophage differentiation Smad6 displays an increased binding to the human osteopontin, Id2, and Hex gene promoters, which correlates to an observed increased expression of these genes. Finally, vector-based RNA interference experiments established that both Smad6 and PrKX proteins are required for PMA-induced cell attachment and spreading.	Argonne Natl Lab, Biosci Div, Argonne, IL 60439 USA; Argonne Natl Lab, Gene Express & Funct Grp, Argonne, IL 60439 USA	United States Department of Energy (DOE); Argonne National Laboratory; United States Department of Energy (DOE); Argonne National Laboratory	Huberman, E (corresponding author), Argonne Natl Lab, Biosci Div, 9700 S Cass Ave,Bld 202, Argonne, IL 60439 USA.	elih@anl.gov			NATIONAL CANCER INSTITUTE [R01CA080826] Funding Source: NIH RePORTER; NCI NIH HHS [CA80826] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andersson G, 1996, CONNECT TISSUE RES, V35, P163, DOI 10.3109/03008209609029188; Atkins K, 1998, J CELL PHYSIOL, V175, P229, DOI 10.1002/(SICI)1097-4652(199805)175:2<229::AID-JCP13>3.0.CO;2-3; Bai ST, 2000, J BIOL CHEM, V275, P8267, DOI 10.1074/jbc.275.12.8267; Bai ST, 2002, J BIOL CHEM, V277, P4176, DOI 10.1074/jbc.M105105200; BEDFORD FK, 1993, NUCLEIC ACIDS RES, V21, P1245, DOI 10.1093/nar/21.5.1245; Blaschke RJ, 2000, GENOMICS, V64, P187, DOI 10.1006/geno.2000.6116; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; Chiorini JA, 1998, MOL CELL BIOL, V18, P5921, DOI 10.1128/MCB.18.10.5921; COLLART FR, 1990, BLOOD, V75, P570; Datta PK, 2000, MOL CELL BIOL, V20, P3157, DOI 10.1128/MCB.20.9.3157-3167.2000; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Di Pasquale G, 2003, EMBO J, V22, P1716, DOI 10.1093/emboj/cdg153; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Greenbaum L, 2003, ONCOGENE, V22, P5221, DOI 10.1038/sj.onc.1206723; GUARENTE L, 1993, P NATL ACAD SCI USA, V90, P1639, DOI 10.1073/pnas.90.5.1639; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; HUBERMAN E, 1982, CARCINOGENESIS, V3, P111, DOI 10.1093/carcin/3.1.111; Ishiguro A, 1996, BLOOD, V87, P5225, DOI 10.1182/blood.V87.12.5225.bloodjournal87125225; KAMIJO R, 1990, J IMMUNOL, V144, P1311; KLINK A, 1995, HUM MOL GENET, V4, P869, DOI 10.1093/hmg/4.5.869; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Laouar A, 1999, J IMMUNOL, V162, P407; Li XH, 2002, P NATL ACAD SCI USA, V99, P9260, DOI 10.1073/pnas.132051799; LILJESTROM PL, 1985, NUCLEIC ACIDS RES, V13, P7257, DOI 10.1093/nar/13.20.7257; MELENDEZ A, 1995, GENETICS, V141, P1507; Metcalf D, 1998, BLOOD, V92, P345, DOI 10.1182/blood.V92.2.345b.Con2_345_347; NISHIKAWA M, 1994, CANCER RES, V54, P4879; Nunes I, 1996, CANCER RES, V56, P495; Orkin SH, 1996, CURR OPIN GENET DEV, V6, P597, DOI 10.1016/S0959-437X(96)80089-X; Owens BM, 2002, STEM CELLS, V20, P364, DOI 10.1634/stemcells.20-5-364; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Ribardo DA, 2001, J BIOL CHEM, V276, P5467, DOI 10.1074/jbc.M006690200; ROVERA G, 1982, ANN NY ACAD SCI, V397, P211, DOI 10.1111/j.1749-6632.1982.tb43428.x; Rozovskaia T, 2003, P NATL ACAD SCI USA, V100, P7853, DOI 10.1073/pnas.1132115100; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schindelhauer D, 1996, GENOME RES, V6, P1056, DOI 10.1101/gr.6.11.1056; Semizarov D, 1998, P NATL ACAD SCI USA, V95, P15412, DOI 10.1073/pnas.95.26.15412; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, J BIOL CHEM, V278, P35444, DOI 10.1074/jbc.M301413200; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Strack S, 2002, J BIOL CHEM, V277, P41525, DOI 10.1074/jbc.M203767200; TONETTI DA, 1994, J BIOL CHEM, V269, P23230; Vanegas N, 2003, LEUKEMIA RES, V27, P607, DOI 10.1016/S0145-2126(02)00231-X; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Xie B, 1998, J BIOL CHEM, V273, P11583, DOI 10.1074/jbc.273.19.11583; Zhang WJ, 2002, J BIOL CHEM, V277, P45435, DOI 10.1074/jbc.M208056200; Zhao FP, 2001, J ENDOTOXIN RES, V7, P53, DOI 10.1179/096805101101532549; Zhao Y, 2003, P NATL ACAD SCI USA, V100, P2426, DOI 10.1073/pnas.0536882100; Zimmermann B, 1999, J BIOL CHEM, V274, P5370, DOI 10.1074/jbc.274.9.5370	56	22	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2006	25	29					4086	4098		10.1038/sj.onc.1209436	http://dx.doi.org/10.1038/sj.onc.1209436			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16491121				2022-12-28	WOS:000238802400009
J	Scatton, O; Chiappini, F; Riou, P; Marconi, A; Saffroy, R; Bralet, MP; Azoulay, D; Boucheix, C; Debuire, B; Uzan, G; Lemoine, A				Scatton, O.; Chiappini, F.; Riou, P.; Marconi, A.; Saffroy, R.; Bralet, M. -P.; Azoulay, D.; Boucheix, C.; Debuire, B.; Uzan, G.; Lemoine, A.			Fate and characterization of circulating tumor cells in a NOD/SCID mouse model of human hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; liver cancer; circulating cells; metastasis; mouse model	FETOPROTEIN MESSENGER-RNA; BONE-MARROW-CELLS; BREAST-CANCER; PROGNOSTIC-SIGNIFICANCE; HEMATOGENOUS DISSEMINATION; MOLECULAR SIGNATURE; COLORECTAL-CANCER; LIVER RESECTION; GASTRIC-CANCER; LUNG-CANCER	There is much debate about the way in which epithelial tumors metastasize. It has been proposed that the bone marrow (BM) acts as a tumor cell reservoir. We injected human hepatocellular carcinoma (HCC) cells (Mahlavu cell line) into the livers, circulation or BM of NOD/SCID mice and circulating tumor cells were quantified. When injected under the Glisson capsule, a primary tumor developed and continuously yielded circulating tumor cells. Liver tumor removal led to a very low level of Mahlavu cells both in blood and BM 30 days later. When Mahlavu cells (cultured or from BM of primary mice femurs) were intravenously injected into mice, the number of cells in the bloodstream (BS) steadily decreased, whereas the BM was not significantly colonized. When Mahlavu cells were directly injected into one femur, the controlateral femur was not colonized. Microscopic analysis and a sensitive PCR assay (< 1 Mahlavu cell/nuclear cells) both failed to detect human tumor cells in other organs regardless of injection route. In conclusion, our model strongly supports the hypothesis that HCCs continuously release cells into the BS. However, in sharp contrast with the current hypothesis, the BM is not specifically colonized by tumor cells but could store them at a very low level.	Hop Univ Paul Brousse, INSERM, U602, Serv Biochim & Biol Mol,Assistance Publ Hop Paris, F-94804 Villejuif, France; Hop Univ Paul Brousse, Ctr Hepatobiliaire, EA 35 41, Assistance Publ Hop Paris, F-94804 Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Lemoine, A (corresponding author), Hop Univ Paul Brousse, INSERM, U602, Serv Biochim & Biol Mol,Assistance Publ Hop Paris, 14 Ave Paul Vaillant Couturier, F-94804 Villejuif, France.	antoinette.lemoine@pbr.ap-hop-paris.fr	Uzan, Georges/M-8199-2018; Azoulay, Daniel/Q-7887-2018; Chiappini, Franck/AAB-9894-2021	Uzan, Georges/0000-0002-0178-5386; SAFFROY, RAPHAEL/0000-0002-9878-3669; Boucheix, Claude/0000-0003-4184-7008				Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; BISMUTH H, 1993, ANN SURG, V218, P145, DOI 10.1097/00000658-199308000-00005; Braun S, 2000, NEW ENGL J MED, V342, P525, DOI 10.1056/NEJM200002243420801; Braun S, 2001, J CLIN ONCOL, V19, P368, DOI 10.1200/JCO.2001.19.2.368; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chiappini F, 2004, LAB INVEST, V84, P908, DOI 10.1038/labinvest.3700113; Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766; DIOGUARDI N, 1992, J HEPATOL, V14, P401; Esumi T, 2003, TRANSPLANTATION, V76, P1543, DOI 10.1097/01.TP.0000081945.23698.5D; Fukutomi M, 2001, EUR J GASTROEN HEPAT, V13, P1083, DOI 10.1097/00042737-200109000-00015; Gerber B, 2001, J CLIN ONCOL, V19, P960, DOI 10.1200/JCO.2001.19.4.960; Goodison S, 2003, CLIN CANCER RES, V9, P3808; Greene AK, 2003, J INVEST SURG, V16, P99, DOI 10.1080/08941930390194424; Gross-Goupil M, 2003, ANN SURG, V238, P241, DOI 10.1097/01.sla.0000080959.95226.be; Guller U, 2002, ANN SURG, V236, P768, DOI 10.1097/00000658-200212000-00009; Harris RG, 2004, SCIENCE, V305, P90, DOI 10.1126/science.1098925; Houghton J, 2004, SCIENCE, V306, P1568, DOI 10.1126/science.1099513; Ishikawa H, 2004, GUT, V53, P884, DOI 10.1136/gut.2003.026047; Kienle P, 2000, ARCH SURG-CHICAGO, V135, P213, DOI 10.1001/archsurg.135.2.213; Kushida T, 2001, BLOOD, V97, P3292, DOI 10.1182/blood.V97.10.3292; Lemoine A, 1997, ANN SURG, V226, P43, DOI 10.1097/00000658-199707000-00006; Li QG, 2004, WORLD J GASTROENTERO, V10, P903; LINDEMANN F, 1992, LANCET, V340, P685, DOI 10.1016/0140-6736(92)92230-D; Liu Yang, 2003, Hepatobiliary Pancreat Dis Int, V2, P414; Louha M, 1999, HEPATOLOGY, V29, P879, DOI 10.1002/hep.510290348; Majno PE, 1997, ANN SURG, V226, P688, DOI 10.1097/00000658-199712000-00006; Marx J, 2004, SCIENCE, V306, P1455; MATSUMURA M, 1994, HEPATOLOGY, V20, P1418, DOI 10.1002/hep.1840200607; Minata M, 2001, J GASTROEN HEPATOL, V16, P445, DOI 10.1046/j.1440-1746.2001.02461.x; Osaki T, 2002, J CLIN ONCOL, V20, P2930, DOI 10.1200/JCO.2002.11.011; Pantel K, 1999, JNCI-J NATL CANCER I, V91, P1113, DOI 10.1093/jnci/91.13.1113; Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370; Pantel K, 1996, LANCET, V347, P649, DOI 10.1016/S0140-6736(96)91203-9; Poon RTP, 2002, ANN SURG, V235, P373, DOI 10.1097/00000658-200203000-00009; Qin LX, 2002, WORLD J GASTROENTERO, V8, P193; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Sell S, 2002, SEMIN CELL DEV BIOL, V13, P419, DOI 10.1016/S1084952102001295; Soeth E, 1997, CANCER RES, V57, P3106; Solakoglu O, 2002, P NATL ACAD SCI USA, V99, P2246, DOI 10.1073/pnas.042372199; Tsavellas G, 2001, BRIT J SURG, V88, P1307, DOI 10.1046/j.0007-1323.2001.01863.x; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Weigelt B, 2003, P NATL ACAD SCI USA, V100, P15901, DOI 10.1073/pnas.2634067100; Woelfle U, 2003, CANCER RES, V63, P5679	44	13	14	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2006	25	29					4067	4075		10.1038/sj.onc.1209430	http://dx.doi.org/10.1038/sj.onc.1209430			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16491122				2022-12-28	WOS:000238802400007
J	Verissimo, F; Silva, E; D Morris, J; Pepperkok, R; Jordan, P				Verissimo, F.; Silva, E.; D Morris, J.; Pepperkok, R.; Jordan, P.			Protein kinase WNK3 increases cell survival in a caspase-3-dependent pathway	ONCOGENE			English	Article						apoptosis; Hsp70; procaspase-3; WNK protein kinases	HEAT-SHOCK-PROTEIN-70 INHIBITS APOPTOSIS; HEAT-SHOCK PROTEINS; DEATH; HSP70; CHAPERONES; EXPRESSION; SPAK; COTRANSPORTERS; DOWNSTREAM; PROTECTION	The subfamily of WNK (with no K lysine) protein kinases has four human members and germline mutations in the WNK1 and WNK4 genes were recently found to cause pseudohypoaldosteronism type II, a familial hypertension disease. Here, we describe cloning and functional analysis of a further WNK member, human WNK3. Endogenous WNK3 protein is an active protein kinase when immunoprecipitated from cells and its overexpression increases the survival of HeLa cells by delaying the onset of apoptosis. Suppression of endogenous WNK3 protein by RNA interference accelerates the apoptotic response and promotes the activation of caspase-3. The mechanism of WNK3 action involves interaction with procaspase-3 and heat-shock protein 70. These results demonstrate a role for WNK3 in promoting cell survival and suggest a mechanism at the level of procaspase-3 activation.	Inst Nacl Saude Dr Ricardo Jorge, Ctr Genet Humana, P-1649016 Lisbon, Portugal; Kings Coll London, Sch Med & Dent, Rayne Inst, London SE5 9NU, England; European Mol Biol Lab, Cell Biophys Programme, Heidelberg, Germany	Instituto Nacional de Saude Dr. Ricardo Jorge; University of London; King's College London; European Molecular Biology Laboratory (EMBL)	Jordan, P (corresponding author), Inst Nacl Saude Dr Ricardo Jorge, Ctr Genet Humana, Ave Padre Cruz, P-1649016 Lisbon, Portugal.	peter.jordan@insa.min-saude.pt	Jordan, Peter/G-9335-2012	Jordan, Peter/0000-0002-1425-9211; Pepperkok, Rainer/0000-0002-9762-3583				Bagci EZ, 2006, BIOPHYS J, V90, P1546, DOI 10.1529/biophysj.105.068122; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570; Cosulich SC, 1999, CURR BIOL, V9, P147, DOI 10.1016/S0960-9822(99)80068-2; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Dmitrieva NI, 2005, MUTAT RES-FUND MOL M, V569, P65, DOI 10.1016/j.mrfmmm.2004.06.053; Eischen CM, 2004, ONCOGENE, V23, P8931, DOI 10.1038/sj.onc.1208052; Gagnon KBE, 2006, MOL CELL BIOL, V26, P689, DOI 10.1128/MCB.26.2.689-698.2006; Gamba G, 2005, AM J PHYSIOL-RENAL, V288, pF245, DOI 10.1152/ajprenal.00311.2004; Gotz R, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-85; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Holden S, 2004, GENE, V335, P109, DOI 10.1016/j.gene.2004.03.009; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; JAATTELA M, 1993, J EXP MED, V177, P231, DOI 10.1084/jem.177.1.231; Jiang ZY, 2005, J BIOL CHEM, V280, P21622, DOI 10.1074/jbc.m414464200; Jordan P, 2000, BIOCHEM BIOPH RES CO, V279, P741, DOI 10.1006/bbrc.2000.3901; Kahle KT, 2005, P NATL ACAD SCI USA, V102, P16783, DOI 10.1073/pnas.0508307102; Kahle KT, 2004, CURR OPIN NEPHROL HY, V13, P557, DOI 10.1097/00041552-200409000-00012; Kahle KT, 2004, P NATL ACAD SCI USA, V101, P2064, DOI 10.1073/pnas.0308434100; Kaur J, 2000, INT J CANCER, V85, P1; Kim S, 2002, NAT CELL BIOL, V4, P826, DOI 10.1038/ncb863; Komarova EY, 2004, CELL STRESS CHAPERON, V9, P265, DOI 10.1379/CSC-27R1.1; Kostich M, 2002, GENOME BIOL, V3; Lee BH, 2004, MOL CELL, V15, P741, DOI 10.1016/j.molcel.2004.07.018; Lenertz LY, 2005, J BIOL CHEM, V280, P26653, DOI 10.1074/jbc.M502598200; Li CY, 2000, J BIOL CHEM, V275, P25665, DOI 10.1074/jbc.M906383199; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Mayer MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI 10.1007/s00018-004-4464-6; Moore TM, 2000, J BIOL CHEM, V275, P4311, DOI 10.1074/jbc.275.6.4311; Mori T, 2005, J BIOL CHEM, V280, P9345, DOI 10.1074/jbc.M411122200; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nollen EAA, 2002, J CELL SCI, V115, P2809; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Parcellier A, 2003, BIOCHEM BIOPH RES CO, V304, P505, DOI 10.1016/S0006-291X(03)00623-5; Rinehart J, 2005, P NATL ACAD SCI USA, V102, P16777, DOI 10.1073/pnas.0508303102; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Verissimo F, 2001, ONCOGENE, V20, P5562, DOI 10.1038/sj.onc.1204726; Vitari AC, 2005, BIOCHEM J, V391, P17, DOI 10.1042/BJ20051180; Vitari AC, 2004, BIOCHEM J, V378, P257, DOI 10.1042/BJ20031692; WEI YQ, 1995, CANCER IMMUNOL IMMUN, V40, P73, DOI 10.1007/s002620050146; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; Xu BE, 2005, P NATL ACAD SCI USA, V102, P10315, DOI 10.1073/pnas.0504422102; Xu BE, 2004, J BIOL CHEM, V279, P7826, DOI 10.1074/jbc.M313465200; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795	54	37	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	30					4172	4182		10.1038/sj.onc.1209449	http://dx.doi.org/10.1038/sj.onc.1209449			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16501604				2022-12-28	WOS:000239004800005
J	Yin, W; Rossin, A; Clifford, JL; Gronemeyer, H				Yin, W.; Rossin, A.; Clifford, J. L.; Gronemeyer, H.			Co-resistance to retinoic acid and TRAIL by insertion mutagenesis into RAM	ONCOGENE			English	Article						retinoic acid; rexinoid; apoptosis; TRAIL; insertion mutagenesis; retrovirus	APOPTOSIS-INDUCING LIGAND; NF-KAPPA-B; TUMOR-SELECTIVE APOPTOSIS; INDUCED-PROXIMITY MODEL; ACUTE MYELOID-LEUKEMIA; CYTOCHROME-C; DEATH RECEPTORS; DEFICIENT MICE; CELL-LINES; ACTIVATION	Retinoic acid ( RA), used as first-line therapy for acute promyelocytic leukemia ( APL), exerts its antileukemic activity by inducing blast differentiation and activating tumor-selective TNF-related apoptosis-inducing ligand ( TRAIL) signaling. To identify downstream mediators of RA signaling, we used retrovirus-mediated insertion mutagenesis in PLB985 leukemia cells and established the RA-resistant cell line WY-1. In PLB985, but not WY-1 cells, RA induced TRAIL and its DR4 and DR5 receptors. Knocking down TRAIL expression by RNA interference blocked RA-induced apoptosis. WY-1 cells are defective for RA-induced differentiation, G1 arrest and exhibit coresistance to TRAIL. In WY-1 cells, a single virus copy is integrated into a novel RA-regulated gene termed RAM ( retinoic acid modulator). RAM is expressed in the myelomonocytic lineage and extinguished by RA in PLB985, but not WY-1 cells. Whereas knocking down RAM expression by RNA interference promoted RA-induced differentiation and TRAIL- triggered apoptosis of PLB985 and WY-1 cells, overexpression of the predicted 109 amino-acid RAM open reading frame did not alter RA signaling in PLB985 cells. This indicates that, apart from encoding the putative RAM protein, RAM RNA may exert additional functions that are impaired by the retrovirus insertion. Our study demonstrates that RA induction of the TRAIL pathway is also operative in leukemia cells lacking an RAR alpha oncofusion protein and identifies RAM as a novel RA-dependent modulator of myeloid differentiation and death.	UPL, INSERM, CNRS, IGBMC,Dept Cell Biol & Signal Transduct, Illkirch Graffenstaden, France; CU Strasbourg, Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Gronemeyer, H (corresponding author), LSUHSC, Dept Biochem & Mol Biol, POB 33932,1501 Kings Highway, Shreveport, LA 71130 USA.	hg@igbmc.u-strasbg.fr	Gronemeyer, Hinrich/H-7002-2016; Gronemeyer, Hinrich/G-6240-2011; Gronemeyer, Hinrich/AAH-5575-2019	Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; Rossin, Aurelie/0000-0002-6110-1249				Altucci L, 2005, CANCER RES, V65, P8754, DOI 10.1158/0008-5472.CAN-04-3569; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Altucci L, 2004, VITAM HORM, V67, P319; Baetu TM, 2001, J IMMUNOL, V167, P3164, DOI 10.4049/jimmunol.167.6.3164; Bernard D, 2001, J BIOL CHEM, V276, P27322, DOI 10.1074/jbc.M011183200; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; Clagett-Dame M, 2002, ANNU REV NUTR, V22, P347, DOI 10.1146/annurev.nutr.22.010402.102745E; Clarke N, 2004, EMBO J, V23, P3051, DOI 10.1038/sj.emboj.7600302; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Drexler HG, 2003, LEUKEMIA, V17, P416, DOI 10.1038/sj.leu.2402799; Gavalas A, 2002, TRENDS NEUROSCI, V25, P61, DOI 10.1016/S0166-2236(02)02067-2; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Hansen LA, 2000, CARCINOGENESIS, V21, P1271, DOI 10.1093/carcin/21.7.1271; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Laudet V., 2002, NUCL RECEPTOR FACTS; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Monczak Y, 1997, BLOOD, V90, P3345, DOI 10.1182/blood.V90.9.3345; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; NAGY L, 1995, MOL CELL BIOL, V15, P3540; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Secchiero P, 2003, J LEUKOCYTE BIOL, V74, P223, DOI 10.1189/jlb.0103004; Sedger LM, 2002, EUR J IMMUNOL, V32, P2246, DOI 10.1002/1521-4141(200208)32:8<2246::AID-IMMU2246>3.0.CO;2-6; Shiozaki EN, 2002, P NATL ACAD SCI USA, V99, P4197, DOI 10.1073/pnas.072544399; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; Takeda K, 2004, J EXP MED, V199, P437, DOI 10.1084/jem.20031457; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; TUCKER KA, 1987, BLOOD, V70, P372; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Watabe E, 2001, JPN J CANCER RES, V92, P140, DOI 10.1111/j.1349-7006.2001.tb01076.x; Yin WH, 2005, INT J BIOCHEM CELL B, V37, P1696, DOI 10.1016/j.biocel.2005.03.003; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	51	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3735	3744		10.1038/sj.onc.1209410	http://dx.doi.org/10.1038/sj.onc.1209410			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16449964				2022-12-28	WOS:000238448300012
J	Belloni, L; Moretti, F; Merlo, P; Damalas, A; Costanzo, A; Blandino, G; Levrero, M				Belloni, L.; Moretti, F.; Merlo, P.; Damalas, A.; Costanzo, A.; Blandino, G.; Levrero, M.			DNp73 alpha protects myogenic cells from apoptosis	ONCOGENE			English	Article						p73; DNp73; myogenic differentiation; apoptosis	P73 EXPRESSION; DNA-DAMAGE; DIFFERENTIATION; P53; ACETYLATION; FAMILY; ROLES; GENE	The P73 gene is transcribed from two promoters, P1 and P2, that direct the expression of multiple transactivation competent (TA) and dominant negative (DN) isoforms. TAp73 transcription factors mediate cell cycle arrest and/or apoptosis in response to DNA damage and are involved in developmental processes. P73 mRNA levels increase and the P1p73 promoter is upregulated during myogenic differentiation of C2C12 skeletal muscle satellite cells. The DNp73 proteins act as trans-repressors of p53- and p73-dependent transcription, and possess both antiapoptotic and pro-proliferative potential. Here, we show that DNp73 alpha is expressed in proliferating C2C12 myoblasts, rapidly accumulates in differentiating myocytes and remains elevated in C2C12 myotubes. By combining transactivation assays and chromatin immunoprecipitation analysis, we could show that the upregulation of the P2p73 promoter during myogenic differentiation is mediated by the coordinated recruitment and activity of MyoD and p53/p73. Abrogation of DNp73 expression by specific siRNA led to a strong potentiation of the spontaneous apoptosis of C2C12 myoblasts induced to differentiate. Finally, unlike TAp73 that contributes to DNA damage-induced apoptosis of myotubes, endogenous DNp73 mediates the relative resistance of differentiated myotubes to DNA damage. Altogether, our findings identify DNp73 alpha as an important target in designing strategies aimed at the potentiation of the regenerative potential of skeletal satellite cells.	Univ Roma La Sapienza, Lab Gene Express, Fdn Andrea Cesalpino, Ist Tumori Regina Elena,CRS, I-00158 Rome, Italy; Univ Roma La Sapienza, Dept Internal Med, I-00158 Rome, Italy; Regina Elena Inst Canc Res, Rome Oncogenom Ctr, Rome, Italy; Regina Elena Inst Canc Res, Dept Expt Oncol, Rome, Italy; Univ Roma Tor Vergata, Dept Dermatol, Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Sapienza University Rome; Sapienza University Rome; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Rome Tor Vergata	Levrero, M (corresponding author), Univ Roma La Sapienza, Lab Gene Express, Fdn Andrea Cesalpino, Ist Tumori Regina Elena,CRS, Via Messi Oro 156, I-00158 Rome, Italy.	levmax@tin.it	Costanzo, Antonio/GZG-2433-2022; Blandino, Giovanni/B-1137-2013; Belloni, Laura/S-1432-2019; Merlo, Paola/K-5330-2014; Costanzo, Antonio/D-3896-2012; Levrero, Massimo/G-5680-2016	Costanzo, Antonio/0000-0001-9697-2557; Blandino, Giovanni/0000-0002-6970-2241; Merlo, Paola/0000-0003-0105-7044; Levrero, Massimo/0000-0002-4978-0875	Telethon [E.1325, GGP030358] Funding Source: Medline	Telethon(Fondazione Telethon)		Billon N, 2004, DEVELOPMENT, V131, P1211, DOI 10.1242/dev.01035; Cerone MA, 2000, CELL DEATH DIFFER, V7, P506, DOI 10.1038/sj.cdd.4400676; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; HALEVY O, 1993, BIOCHEM BIOPH RES CO, V192, P714, DOI 10.1006/bbrc.1993.1473; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; Latella L, 2004, MOL CELL BIOL, V24, P6350, DOI 10.1128/MCB.24.14.6350-6361.2004; Levrero M, 2000, J CELL SCI, V113, P1661; Li CY, 2005, J BIOL CHEM, V280, P2159, DOI 10.1074/jbc.M411194200; Liu G, 2004, MOL CELL BIOL, V24, P487, DOI 10.1128/MCB.24.2.487-501.2004; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Porrello A, 2000, J CELL BIOL, V151, P1295, DOI 10.1083/jcb.151.6.1295; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Pozniak CD, 2002, J NEUROSCI, V22, P9800; Puri PL, 2002, NAT GENET, V32, P585, DOI 10.1038/ng1023; Rentzsch F, 2003, GENE, V323, P19, DOI 10.1016/j.gene.2003.10.002; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Tschan MP, 2000, BIOCHEM BIOPH RES CO, V277, P62, DOI 10.1006/bbrc.2000.3627; Vossio S, 2002, ONCOGENE, V21, P3796, DOI 10.1038/sj.onc.1205465; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607	28	25	25	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3606	3612		10.1038/sj.onc.1209321	http://dx.doi.org/10.1038/sj.onc.1209321			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16652159				2022-12-28	WOS:000238448200013
J	Shih, WL; Yu, MW; Chen, PJ; Yeh, SH; Lo, MT; Chang, HC; Liaw, YF; Lin, SM; Liu, CJ; Lee, SD; Lin, CL; Hsiao, CK; Yang, SY; Chen, CJ				Shih, W-L; Yu, M-W; Chen, P-J; Yeh, S-H; Lo, M-T; Chang, H-C; Liaw, Y-F; Lin, S-M; Liu, C-J; Lee, S-D; Lin, C-L; Hsiao, C. K.; Yang, S-Y; Chen, C-J			Localization of a susceptibility locus for hepatocellular carcinoma to chromosome 4q in a hepatitis B hyperendemic area	ONCOGENE			English	Article						chromosome 4q; family-based association analysis; hepatocellular carcinoma; linkage analysis; microsatellite markers; single-nucleotide polymorphism	SEGREGATION ANALYSIS; LINKAGE ANALYSIS; ASSOCIATION; HEPATOCARCINOGENESIS; DISEQUILIBRIUM; ALLELOTYPE; PATHWAYS; VIRUS	Chromosome 4q is one of the most common regions with a high frequency of allelic loss in hepatocellular carcinoma (HCC). To identify the HCC-susceptibility locus on chromosome 4q, we have performed linkage and family-based association analyses on Chinese families with HCC from Taiwan, where hepatitis B is hyperendemic. Using 77 microsatellite markers spanning chromosome 4q on 52 multiplex families, we found suggestive evidence of linkage to 4q22.3 - 28.1 with a maximum two-point heterogeneity LOD (HLOD) score of 2.55 at marker D4S3240 on chromosome 4q25. Multipoint analyses with microsatellite markers in the region 4q22.3 - 28.1 resulted in a maximum HLOD score of 3.12 and a maximum nonparametric linkage (NPL) Z score of 1.98 (pointwise P = 0.0080; region-wide empirical P = 0.021) for D4S3240. The evidence for linkage to D4S3240 was seen mostly in a subset of 28 families lacking affected parents, which showed multipoint HLOD and NPL scores of 3.25 and 2.79 (pointwise P = 0.0028; region-wide empirical P = 0.008), respectively. Family-based association analyses of the 77 microsatellite markers in 191 families ( 53 multiplex plus 138 singleton families) using the pedigree disequilibrium test provide further support for observed linkage. Additional genotyping in the 52 multiplex families informative for linkage analyses was performed for 29 single-nucleotide polymorphisms around D4S3240. A common haplotype (at markers rs7442180 and rs221330) positioned similar to 873 kb away from D4S3240 was associated with HCC, with P = 0.0074.	Natl Taiwan Univ, Coll Publ Hlth, Grad Inst Epidemiol, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Taipei, Taiwan; Shin Kong Wu Ho Su Mem Hosp, Dept Internal Med, Taipei, Taiwan; Chang Gung Univ, Chang Gung Mem Hosp, Liver Res Unit, Taoyuan, Taiwan; Natl Yang Ming Univ, Dept Med, Vet Gen Hosp, Taipei 112, Taiwan; Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan; Taipei Municipal Jen Ai Hosp, Dept Internal Med, Div Gastroenterol, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; Shin Kong Wu Ho Su Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Yu, MW (corresponding author), Natl Taiwan Univ, Coll Publ Hlth, Grad Inst Epidemiol, 1 Jen Ai Rd,Sec 1,Rm 1550, Taipei 100, Taiwan.	mingwhei@ha.mc.ntu.edu.tw	Chen, Chien-Jen/N-4723-2019; Liaw, Yun-Fan/B-4305-2009; Chen, Chien-Jen/C-6976-2008	hsiao, chuhsing kate/0000-0003-4905-8484; LIU, CHUN-JEN/0000-0002-6202-0993; Yu, Ming-Whei/0000-0002-8371-6236; SHIH, WEI-LIANG/0000-0002-4160-7541; /0000-0003-4509-180X; Chen, Pei-Jer/0000-0001-8316-3785				Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786; BEASLEY RP, 1982, HEPATOLOGY, V2, pS21; Befeler AS, 2002, GASTROENTEROLOGY, V122, P1609, DOI 10.1053/gast.2002.33411; BLACKWELDER W C, 1985, Genetic Epidemiology, V2, P85, DOI 10.1002/gepi.1370020109; Bluteau O, 2002, ONCOGENE, V21, P1225, DOI 10.1038/sj.onc.1205197; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Cai RL, 2003, WORLD J GASTROENTERO, V9, P2428; Chen CJ, 2002, HEPATOLOGY, V36, P1046, DOI 10.1053/jhep.2002.37084; Ea CK, 2004, P NATL ACAD SCI USA, V101, P15318, DOI 10.1073/pnas.0404132101; Kong X, 2004, AM J HUM GENET, V75, P1143, DOI 10.1086/426405; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Martin ER, 2000, AM J HUM GENET, V67, P146, DOI 10.1086/302957; MITRA AB, 1994, CANCER RES, V54, P4481; Nyholt DR, 2004, AM J HUM GENET, V74, P765, DOI 10.1086/383251; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; Okabe H, 2000, HEPATOLOGY, V31, P1073, DOI 10.1053/he.2000.6409; OTT J, 1986, GENET EPIDEMIOL, P251; Pershouse MA, 1997, ONCOGENE, V14, P369, DOI 10.1038/sj.onc.1200836; Piao Z, 1998, INT J CANCER, V79, P356, DOI 10.1002/(SICI)1097-0215(19980821)79:4<356::AID-IJC8>3.0.CO;2-U; Roeder K, 2005, GENET EPIDEMIOL, V28, P207, DOI 10.1002/gepi.20050; SHEN FM, 1991, AM J HUM GENET, V49, P88; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Wacholder S, 2004, J NATL CANCER I, V96, P434, DOI 10.1093/jnci/djh075; Wands JR, 2004, NEW ENGL J MED, V351, P1567, DOI 10.1056/NEJMe048237; Wang XL, 1999, ONCOGENE, V18, P823, DOI 10.1038/sj.onc.1202318; Yeh SH, 1996, GASTROENTEROLOGY, V110, P184, DOI 10.1053/gast.1996.v110.pm8536855; Yeh SH, 2001, GASTROENTEROLOGY, V121, P699, DOI 10.1053/gast.2001.27211; YU MW, 1994, CRIT REV ONCOL HEMAT, V17, P71, DOI 10.1016/1040-8428(94)90020-5; Yu MW, 2000, J NATL CANCER I, V92, P1159, DOI 10.1093/jnci/92.14.1159	30	14	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3219	3224		10.1038/sj.onc.1209345	http://dx.doi.org/10.1038/sj.onc.1209345			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16407824	Green Published			2022-12-28	WOS:000237951000013
J	Shank-Calvo, JA; Draheim, K; Bhasin, M; Kelliher, MA				Shank-Calvo, J. A.; Draheim, K.; Bhasin, M.; Kelliher, M. A.			P16Ink4a or p19Arf loss contributes to Tal1-induced leukemogenesis in mice	ONCOGENE			English	Article						T-cell leukemia; Tal1/scl; p16(Ink4a); p19(Arf)	ACUTE LYMPHOBLASTIC-LEUKEMIA; ONCOGENIC TRANSCRIPTION FACTORS; LOOP-HELIX PROTEINS; T-CELL; C-MYC; TUMOR SUPPRESSION; MTS1 P16(INK4A); TRANSGENIC MICE; INK4A LOCUS; EXPRESSION	Analysis of the INK4A/ARF locus in human T-ALL patients revealed frequent deletions in exon 2, the exon common to both p16(INK4A) and p14(ARF). Other studies have described selective deletion of exon 1 ss of p14ARF or methylation of the p16INK4A promoter. Therefore, it is unclear from these studies whether loss of p16INK4A and/or p14ARF contributes to the development of T-ALL. To elucidate the relative contribution of the ink4a/arf locus to T-cell leukemogenesis, we mated our tal1 transgenic mice to ink4a/arf-/-, p16(ink4a)-/-,and p19(arf)-/- mice and generated tal1/ink4a/arf+/-, tal1/p16(ink4a)+/-, and tal1/p19(arf) +/- mice. Each of these mice developed T-cell leukemia rapidly, indicating that loss of either p16(ink4a) or p19(arf) cooperates with Tal1 to induce leukemia in mice. Preleukemic studies reveal that Tal1 expression stimulates entry into the cell cycle and thymocyte apoptosis in vivo. Interestingly, mice expressing a DNA-binding mutant of Tal1 do not exhibit increases in S phase cells. The S phase induction is accompanied by an increase in thymocyte apoptosis in tal1 transgenic mice. Whereas apoptosis is reduced to wild-type levels in tal1/ink4a/arf-/- mice, S phase induction remains unaffected. Thus, Tal1 stimulates cell cycle entry independent of the ink4a/arf locus, but its ability to induce apoptosis is Ink4a/Arf-dependent.	Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01650 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA USA; Dana Faber Canc Inst, Immunobiol Lab, Boston, MA USA; Dana Faber Canc Inst, Dept Med Oncol, Boston, MA USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Kelliher, MA (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, 364 Plantat St, Worcester, MA 01650 USA.	michelle.kelliher@umassmed.edu		Bhasin, Manoj/0000-0001-5172-420X	NATIONAL CANCER INSTITUTE [R01CA096899] Funding Source: NIH RePORTER; NCI NIH HHS [CA096899] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Batova A, 1997, CANCER RES, V57, P832; Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Cayuela JM, 1996, BLOOD, V87, P2180, DOI 10.1182/blood.V87.6.2180.bloodjournal8762180; CAYUELA JM, 1995, BLOOD, V85, P854, DOI 10.1182/blood.V85.3.854a.bloodjournal853854a; Condorelli GL, 1997, MOL CELL BIOL, V17, P2954, DOI 10.1128/MCB.17.5.2954; Condorelli GL, 1996, CANCER RES, V56, P5113; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Ferrando AA, 2004, BLOOD, V103, P1909, DOI 10.1182/blood-2003-07-2577; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Gardie B, 1998, BLOOD, V91, P1016, DOI 10.1182/blood.V91.3.1016.1016_1016_1020; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; Harrison CJ, 2001, BEST PRACT RES CL HA, V14, P593, DOI 10.1053/beha.2001.0156; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; Herblot S, 2000, NAT IMMUNOL, V1, P138, DOI 10.1038/77819; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kees UR, 1997, BLOOD, V89, P4161, DOI 10.1182/blood.V89.11.4161; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; O'Neil J, 2004, CANCER CELL, V5, P587, DOI 10.1016/j.ccr.2004.05.023; O'Neil J, 2001, ONCOGENE, V20, P3897, DOI 10.1038/sj.onc.1204519; O'Neil J, 2005, BLOOD; Pagliuca A, 2000, CANCER RES, V60, P1376; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Staal FJT, 2005, NAT REV IMMUNOL, V5, P21, DOI 10.1038/nri1529; Valtieri M, 1998, CANCER RES, V58, P562; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Zhou MX, 1997, PEDIATR HEMAT ONCOL, V14, P141, DOI 10.3109/08880019709030900; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	39	20	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					3023	3031		10.1038/sj.onc.1209326	http://dx.doi.org/10.1038/sj.onc.1209326			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16407836				2022-12-28	WOS:000237950800006
J	Munoz-Najar, UM; Neurath, KM; Vumbaca, F; Claffey, KP				Munoz-Najar, UM; Neurath, KM; Vumbaca, F; Claffey, KP			Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation	ONCOGENE			English	Article						breast cancer; hypoxia; invasion; MT1-MMP; RhoA	TYPE-1 MATRIX-METALLOPROTEINASE; MESSENGER-RNA EXPRESSION; EXTRACELLULAR-MATRIX; 1-MATRIX METALLOPROTEINASE; TISSUE INHIBITOR; UP-REGULATION; GELATINASE-A; SURFACE; CANCER; TRAFFICKING	The process of cancer cell invasion involves degradation of the extracellular matrix (ECM) by proteases, integrin adhesion and cell motility. The role of ECM degrading proteases on the hypoxia-induced invasion of breast carcinoma cells was investigated. Hypoxia markedly increased the invasion capacity of MDA-MB-231and MDA-MB-435 breast carcinoma cell lines. Matrix metalloproteinase (MMP) inhibitors blocked the hypoxia-induced invasion, whereas other protease inhibitors had no effect. Antibodies or siRNAs blocking either membrane type-1MMP (MT1-MMP) or MMP-2 were effective in reducing the hypoxia-induced invasion. Serum-free reconstitution experiments confirmed the involvement of the MT1-MMP/ MMP-2/tissue inhibitor of metalloproteinase-2 complex in this hypoxia-induced response. Overexpression of MT1-MMP in a poorly invasive breast cancer cell line, T47-D, promoted hypoxia-induced invasion and MMP-2 activation. Cell surface accumulation and activation of MT1-MMP without apparent regulation at the mRNA or protein levels indicated a post-translational adaptive response to hypoxia. Inhibition of the small GTPase RhoA eliminated the hypoxia-induced invasion and blocked the localization of MT1-MMP to the plasma membrane. Zymographic and molecular analysis of human breast tumors showed a strong correlation between hypoxic microenvironments and MMP-2 activation without changes in MT1-MMP expression. Our studies suggest that hypoxic tumor microenvironments promote breast cancer invasion through an MT1-MMP-dependent mechanism.	Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, Farmington, CT 06030 USA	University of Connecticut	Claffey, KP (corresponding author), Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, EM028,263 Farmington Ave, Farmington, CT 06030 USA.	claffey@nso2.uchc.edu			NCI NIH HHS [CA64436] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064436, R29CA064436] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Annabi B, 2003, STEM CELLS, V21, P337, DOI 10.1634/stemcells.21-3-337; AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; Bailly K, 2004, CIRC RES, V94, P1383, DOI 10.1161/01.RES.0000128405.83582.2e; Bartolome RA, 2004, CANCER RES, V64, P2534, DOI 10.1158/0008-5472.CAN-03-3398; Ben-Yosef Y, 2002, CIRC RES, V90, P784, DOI 10.1161/01.RES.0000015588.70132.DC; Brat DJ, 2004, CANCER RES, V64, P920, DOI 10.1158/0008-5472.CAN-03-2073; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Burke B, 2003, AM J PATHOL, V163, P1233, DOI 10.1016/S0002-9440(10)63483-9; Canning MT, 2001, EXP CELL RES, V267, P88, DOI 10.1006/excr.2001.5243; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Claffey KP, 1996, CANCER RES, V56, P172; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; DeClerck YA, 2004, AM J PATHOL, V164, P1131, DOI 10.1016/S0002-9440(10)63200-2; Deschamps AM, 2005, CIRCULATION, V111, P1166, DOI 10.1161/01.CIR.0000157149.71297.3A; Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65; Edwards DR, 1998, NATURE, V394, P527, DOI 10.1038/28961; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fahling M, 2004, COMP BIOCHEM PHYS C, V139, P119, DOI 10.1016/j.cca.2004.09.013; Freije JMP, 2003, ADV EXP MED BIOL, V532, P91; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Giannelli G, 2002, INT J CANCER, V97, P425, DOI 10.1002/ijc.1635; Graham CH, 1999, INT J CANCER, V80, P617, DOI 10.1002/(SICI)1097-0215(19990209)80:4<617::AID-IJC22>3.0.CO;2-C; Hewitt R, 1996, ENZYME PROTEIN, V49, P163, DOI 10.1159/000468623; HOFMANN UB, 2005, ARCH DERMATOL RES, V4, P1; Ishigaki S, 1999, JPN J CANCER RES, V90, P516, DOI 10.1111/j.1349-7006.1999.tb00778.x; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Jones JL, 1999, J PATHOL, V189, P161, DOI 10.1002/(SICI)1096-9896(199910)189:2<161::AID-PATH406>3.0.CO;2-2; Kalman D, 1999, MOL BIOL CELL, V10, P1665, DOI 10.1091/mbc.10.5.1665; Kinoshita T, 1996, CANCER RES, V56, P2535; Krishnamachary B, 2003, CANCER RES, V63, P1138; Lambert E, 2004, CRIT REV ONCOL HEMAT, V49, P187, DOI 10.1016/j.critrevonc.2003.09.008; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Leufgen H, 2005, J CELL PHYSIOL, V204, P146, DOI 10.1002/jcp.20289; Liu WH, 2002, BIOCHEM BIOPH RES CO, V294, P347, DOI 10.1016/S0006-291X(02)00478-3; Lolmede K, 2003, INT J OBESITY, V27, P1187, DOI 10.1038/sj.ijo.0802407; Mimori K, 2001, ONCOL REP, V8, P401; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Ottino P, 2004, MOL VIS, V10, P341; Oxford G, 2003, CANCER LETT, V189, P117, DOI 10.1016/S0304-3835(02)00510-4; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Petrella BL, 2005, ONCOGENE, V24, P1043, DOI 10.1038/sj.onc.1208305; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Ridgway PF, 2005, J SURG RES, V124, P180, DOI 10.1016/j.jss.2004.10.020; Rozanov DV, 2004, EXP CELL RES, V293, P81, DOI 10.1016/j.yexcr.2003.10.006; Saad S, 2002, CANCER RES, V62, P283; Sameshima T, 2000, CANCER LETT, V157, P177, DOI 10.1016/S0304-3835(00)00485-7; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato Y, 2003, ENDOTHELIUM-J ENDOTH, V10, P287, DOI 10.1080/10623320390272334; Seiki M, 2002, CURR OPIN CELL BIOL, V14, P624, DOI 10.1016/S0955-0674(02)00363-0; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; SLOANE JP, 1981, CANCER, V47, P1786, DOI 10.1002/1097-0142(19810401)47:7<1786::AID-CNCR2820470711>3.0.CO;2-8; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; Subarsky P, 2003, CLIN EXP METASTAS, V20, P237, DOI 10.1023/A:1022939318102; Symons M, 2003, CURR BIOL, V13, pR409, DOI 10.1016/S0960-9822(03)00324-5; Takino T, 2003, BIOCHEM BIOPH RES CO, V304, P160, DOI 10.1016/S0006-291X(03)00544-8; Turcotte S, 2003, J CELL SCI, V116, P2247, DOI 10.1242/jcs.00427; Turcotte S, 2004, AM J PHYSIOL-RENAL, V286, pF338, DOI 10.1152/ajprenal.00254.2003; Udayakumar TS, 2003, CANCER RES, V63, P2292; Ueno H, 1997, CANCER RES, V57, P2055; Vaupel P, 2004, ONCOLOGIST, V9, P10, DOI 10.1634/theoncologist.9-90005-10; Wang X, 2004, J BIOL CHEM, V279, P9331, DOI 10.1074/jbc.M312369200; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; Yamanaka M, 2000, J DERMATOL SCI, V24, P99, DOI 10.1016/S0923-1811(00)00086-4; Yoon SO, 2003, J BIOCHEM MOL BIOL, V36, P128; Yoon SO, 2005, CANCER RES, V65, P2761, DOI 10.1158/0008-5472.CAN-04-4122; Yu M, 1997, CANCER RES, V57, P5028; Zhai YL, 2005, CANCER RES, V65, P6543, DOI 10.1158/0008-5472.CAN-05-0231; Zucker S, 2004, EXP CELL RES, V293, P164, DOI 10.1016/j.yexcr.2003.10.007; Zucker S, 2002, LAB INVEST, V82, P1673, DOI 10.1097/01.LAB.0000041713.74852.2A; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	75	149	165	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2379	2392		10.1038/sj.onc.1209273	http://dx.doi.org/10.1038/sj.onc.1209273			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16369494				2022-12-28	WOS:000236764300010
J	Enk, CD; Jacob-Hirsch, J; Gal, H; Verbovetski, I; Amariglio, N; Mevorach, D; Ingber, A; Givol, D; Rechavi, G; Hochberg, M				Enk, CD; Jacob-Hirsch, J; Gal, H; Verbovetski, I; Amariglio, N; Mevorach, D; Ingber, A; Givol, D; Rechavi, G; Hochberg, M			The UVB-induced gene expression profile of human epidermis in vivo is different from that of cultured keratinocytes	ONCOGENE			English	Article						UVB; epidermis; p53; in vivo; in vitro; microarrays	CELL CARCINOMA ANTIGENS; MATRIX METALLOPROTEINASES; FUNCTIONAL GENOMICS; CYCLE CHECKPOINT; DNA MICROARRAYS; MESSENGER-RNA; P53 PROTEIN; ULTRAVIOLET; SKIN; APOPTOSIS	In order to obtain a comprehensive picture of the molecular events regulating cutaneous photodamage of intact human epidermis, suction blister roofs obtained after a single dose of in vivo ultraviolet ( UV) B exposure were used for microarray profiling. We found a changed expression of 619 genes. Half of the UVB-regulated genes had returned to pre-exposure baseline levels at 72 h, underscoring the transient character of the molecular cutaneous UVB response. Of special interest was our finding that several of the central p53 target genes remained unaffected following UVB exposure in spite of p53 protein accumulation. We next compared the in vivo expression profiles of epidermal sheets to that of cultured human epidermal keratinocytes exposed to UVB in vitro. We found 1931 genes that differed in their expression profiles between the two groups. The expression pro. le in intact epidemis was geared mainly towards DNA repair, whereas cultured keratinocytes responded predominantly by activating genes associated with cell-cycle arrest and apoptosis. These differences in expression profiles might reflect differences between mature differentiating keratinocytes in the suprabasal epidermal layers versus exponentially proliferating keratinocytes in cell culture. Our findings show that extreme care should be taken when extrapolating from findings based on keratinocyte cultures to changes in intact epidermis.	Hebrew Univ Jerusalem, Dept Dermatol, Hadassah Med Ctr, IL-91010 Jerusalem, Israel; Safra Childrens Hosp, Chaim Sheba Med Ctr, Dept Pediat Hematooncol & Funct Genom, Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Hebrew Univ Jerusalem, Lab Cellular Mol Immunol, Hadassah Med Ctr, Dept Med, IL-91010 Jerusalem, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Weizmann Institute of Science; Hebrew University of Jerusalem; Hadassah University Medical Center	Enk, CD (corresponding author), Hebrew Univ Jerusalem, Dept Dermatol, Hadassah Med Ctr, POB 12000, IL-91010 Jerusalem, Israel.	enk@md.huji.ac.il						Abts HF, 1999, J MOL BIOL, V293, P29, DOI 10.1006/jmbi.1999.3159; Alowami Salem, 2003, BMC Dermatol, V3, P1, DOI 10.1186/1471-5945-3-1; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; BAADSGAARD O, 1991, ARCH DERMATOL, V127, P99, DOI 10.1001/archderm.127.1.99; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Becker B, 2001, J INVEST DERMATOL, V116, P983, DOI 10.1046/j.1523-1747.2001.01347.x; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Boni R, 1997, J CUTAN PATHOL, V24, P76, DOI 10.1111/j.1600-0560.1997.tb01100.x; Brash DE, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P136; Broome AM, 2003, J HISTOCHEM CYTOCHEM, V51, P675, DOI 10.1177/002215540305100513; BROWN DW, 1993, BIOCHEMISTRY-US, V32, P10527, DOI 10.1021/bi00091a001; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Cataltepe S, 2000, J HISTOCHEM CYTOCHEM, V48, P113, DOI 10.1177/002215540004800112; CELIS JE, 1987, FEBS LETT, V220, P1, DOI 10.1016/0014-5793(87)80865-7; Chaturvedi V, 2004, J INVEST DERMATOL, V123, P1200, DOI 10.1111/j.0022-202X.2004.23514.x; Courtois SJ, 1997, EXP CELL RES, V233, P135, DOI 10.1006/excr.1997.3537; CROMBACH G, 1989, CANCER, V63, P1337, DOI 10.1002/1097-0142(19890401)63:7<1337::AID-CNCR2820630719>3.0.CO;2-J; Dazard JE, 2003, ONCOGENE, V22, P2993, DOI 10.1038/sj.onc.1206537; Decraene D, 2004, J INVEST DERMATOL, V122, pA140; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; DUK JM, 1989, CANCER, V64, P1652, DOI 10.1002/1097-0142(19891015)64:8<1652::AID-CNCR2820640816>3.0.CO;2-M; EL DW, 1993, CELL, V75, P817; Enk CD, 2004, PHOTODERMATOL PHOTO, V20, P129, DOI 10.1111/j.1600-0781.2004.00097.x; ENK CD, 1994, ARCH DERMATOL RES, V287, P72, DOI 10.1007/BF00370722; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Gibbs S, 1998, CELL TISSUE RES, V292, P107, DOI 10.1007/s004410051040; Gniadecki R, 1997, J INVEST DERMATOL, V109, P163, DOI 10.1111/1523-1747.ep12319216; Grimbaldeston MA, 2003, J INVEST DERMATOL, V121, P1168, DOI 10.1046/j.1523-1747.2003.12561.x; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; HALL PA, 1993, ONCOGENE, V8, P203; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Horiuchi Yasuhiro, 1994, Journal of Dermatology (Tokyo), V21, P67; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Joos L, 2003, SWISS MED WKLY, V133, P31; Kahari VM, 1997, EXP DERMATOL, V6, P199, DOI 10.1111/j.1600-0625.1997.tb00164.x; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kato H, 1996, ANTICANCER RES, V16, P2149; Kosmoski JV, 2001, P NATL ACAD SCI USA, V98, P10113, DOI 10.1073/pnas.181073398; Lahmann C, 2001, PHOTOCHEM PHOTOBIOL, V73, P657, DOI 10.1562/0031-8655(2001)073<0657:IOMFMM>2.0.CO;2; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Lee JH, 2002, PHOTODERMATOL PHOTO, V18, P253, DOI 10.1034/j.1600-0781.2002.02755.x; Lee KM, 2005, BRIT J DERMATOL, V152, P52, DOI 10.1111/J.1365-2133.2005.06412.X; Li DL, 2001, FASEB J, V15, P2533, DOI 10.1096/fj.01-0172fje; Li G, 1998, BRIT J DERMATOL, V139, P3; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; Liu XQ, 2000, BIOCHEMISTRY-US, V39, P557, DOI 10.1021/bi991771m; Maelandsmo GM, 1997, INT J CANCER, V74, P464, DOI 10.1002/(SICI)1097-0215(19970822)74:4<464::AID-IJC19>3.0.CO;2-9; Marionnet C, 2003, J INVEST DERMATOL, V121, P1447, DOI 10.1111/j.1523-1747.2003.12629.x; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Murakami T, 2001, J DERMATOL SCI, V27, P121, DOI 10.1016/S0923-1811(01)00124-4; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Park WY, 2002, ONCOGENE, V21, P8521, DOI 10.1038/sj.onc.1205977; Pfundt R, 2000, ARCH DERMATOL RES, V292, P180, DOI 10.1007/s004030050475; Pisarchik A, 2004, GENE, V341, P199, DOI 10.1016/j.gene.2004.06.046; Qin JZ, 2002, ONCOGENE, V21, P2991, DOI 10.1038/sj.onc.1205404; SAGE E, 1993, PHOTOCHEM PHOTOBIOL, V57, P163, DOI 10.1111/j.1751-1097.1993.tb02273.x; SCHARFFETTER K, 1991, ARCH DERMATOL RES, V283, P506, DOI 10.1007/BF00371923; Sellheyer K, 2004, J AM ACAD DERMATOL, V51, P681, DOI 10.1016/j.jaad.2004.03.038; Sesto A, 2002, P NATL ACAD SCI USA, V99, P2965, DOI 10.1073/pnas.052678999; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Sudel KM, 2003, PHOTOCHEM PHOTOBIOL, V78, P355, DOI 10.1562/0031-8655(2003)078<0355:TCOMMA>2.0.CO;2; Suminami Y, 2000, BRIT J CANCER, V82, P981, DOI 10.1054/bjoc.1999.1028; Takao J, 2002, PHOTODERMATOL PHOTO, V18, P5, DOI 10.1034/j.1600-0781.2002.180102.x; Takeda A, 2002, J INVEST DERMATOL, V118, P147, DOI 10.1046/j.0022-202x.2001.01610.x; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tanaka N, 2000, BRIT J DERMATOL, V143, P728, DOI 10.1046/j.1365-2133.2000.03766.x; Thorey IS, 2001, J BIOL CHEM, V276, P35818, DOI 10.1074/jbc.M104871200; Tran SEF, 2004, TRENDS BIOCHEM SCI, V29, P601, DOI 10.1016/j.tibs.2004.09.009; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; Wang XJ, 2004, FEBS LETT, V561, P195, DOI 10.1016/S0014-5793(04)00168-1; Wehrli P, 2000, J INVEST DERMATOL, V115, P141, DOI 10.1046/j.1523-1747.2000.00037.x; Welss T, 2003, BIOCHEMISTRY-US, V42, P7381, DOI 10.1021/bi027307q; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Young AR, 1996, J INVEST DERMATOL, V106, P1307, DOI 10.1111/1523-1747.ep12349031; Zhang T, 2002, J INVEST DERMATOL, V119, P1196, DOI 10.1046/j.1523-1747.2002.19520.x; Zhao RB, 2000, GENE DEV, V14, P981	81	72	74	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2601	2614		10.1038/sj.onc.1209292	http://dx.doi.org/10.1038/sj.onc.1209292			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16434974				2022-12-28	WOS:000237099400004
J	Agirre, X; Roman-Gomez, J; Jimenez-Velasco, A; Garate, L; Montiel-Duarte, C; Navarro, G; Vazquez, I; Zalacain, M; Calasanz, MJ; Heiniger, A; Torres, A; Minna, JD; Prosper, F				Agirre, X; Roman-Gomez, J; Jimenez-Velasco, A; Garate, L; Montiel-Duarte, C; Navarro, G; Vazquez, I; Zalacain, M; Calasanz, MJ; Heiniger, A; Torres, A; Minna, JD; Prosper, F			ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia	ONCOGENE			English	Article						ASPP; TP53; methylation; MSP	P53-INTERACTING PROTEIN 53BP2; MESSENGER-RNA EXPRESSION; GEL-ELECTROPHORESIS; WILD-TYPE; HYPERMETHYLATION; CANCER; CHILDREN; GENES; CHEMOTHERAPY; MUTATIONS	We have analyzed the regulation and expression of ASPP members, genes implicated in the regulation of the apoptotic function of the TP53 tumor-suppressor gene, in acute lymphoblastic leukemia ( ALL). Expression of ASPP1 was significantly reduced in ALL and was dependent on hypermethylation of the ASPP1 gene promoter. Abnormal ASPP1 expression was associated with normal function of the tumor-suppressor gene TP53 in ALL. The analyses of 180 patients with ALL at diagnosis showed that the ASPP1 promoter was hypermethylated in 25% of cases with decreased mRNA expression. Methylation was significantly higher in adult ALL vs childhood ALL ( 32 vs 17%, P = 0.03) and T-ALL vs B-ALL ( 50 vs 9%, P = 0.001). Relapse rate ( 62 vs 44%, P = 0.05) and mortality ( 59 vs 43%, P = 0.05) were significantly higher in patients with methylated ASPP1. DFS and OS were 32.8 and 33.7% for patients with unmethylated ASPP1 and 6.1 and 9.9% for methylated patients ( P < 0.001 y P < 0.02, respectively). On the multivariate analysis, methylation of the ASPP1 gene promoter was an independent poor prognosis factor in ALL patients. Our results demonstrate that decreased expression of ASPP1 in patients with ALL is due to an abnormal methylation of its promoter and is associated with a poor prognosis.	Univ Navarra, Clin Univ, Fdn Appl Med Res, Div Canc & Area Cell Therapy, Navarra 31008, Spain; Univ Navarra, Clin Univ, Serv Hematol, Navarra 31008, Spain; Hosp Reina Sofia, Dept Hematol, Cordoba, Spain; Univ Navarra, Clin Univ, Dept Pediat, Navarra 31008, Spain; Hosp Carlos Haya, Dept Hematol, Malaga, Spain; Univ Navarra, Dept Genet, Sch Sci, Navarra 31008, Spain; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75230 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75230 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75230 USA	University of Navarra; University of Navarra; Hospital Universitario Reina Sofia - Cordoba; University of Navarra; Hospital Carlos Haya; University of Navarra; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Prosper, F (corresponding author), Univ Navarra, Clin Univ, Fdn Appl Med Res, Div Canc & Area Cell Therapy, Avda Pio 12 36, Navarra 31008, Spain.	fprosper@unav.es	Calasanz, MJ/R-5813-2016; Montiel-Duarte, Cristina/AAB-3758-2019; Agirre, Xabier/ABE-4110-2020; Prosper, Felipe/H-6859-2017	Calasanz, MJ/0000-0002-0374-3008; Montiel-Duarte, Cristina/0000-0002-9144-8809; Prosper, Felipe/0000-0001-6115-8790				Agirre X, 2003, ONCOGENE, V22, P1070, DOI 10.1038/sj.onc.1206236; Agirre X, 2002, BIOTECHNIQUES, V32, P1064, DOI 10.2144/02325rr01; Ao Y, 2001, ONCOGENE, V20, P2720, DOI 10.1038/sj.onc.1204352; Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; HAMELIN R, 1993, ONCOGENE, V8, P2213; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; Liu ZJ, 2005, FEBS LETT, V579, P1587, DOI 10.1016/j.febslet.2005.01.069; Liu ZJ, 2004, LEUKEMIA, V18, P880, DOI 10.1038/sj.leu.2403300; Lopez CD, 2000, MOL CELL BIOL, V20, P8018, DOI 10.1128/MCB.20.21.8018-8025.2000; Mori T, 2000, FEBS LETT, V465, P124, DOI 10.1016/S0014-5793(99)01726-3; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; Ortega JJ, 2001, HAEMATOLOGICA, V86, P586; Ribera JM, 2002, HAEMATOLOGICA, V87, P154; Ribera JM, 1998, HAEMATOLOGICA, V83, P222; Roman-Gomez J, 2004, BLOOD, V104, P2492, DOI 10.1182/blood-2004-03-0954; Roman-Gomez J, 2004, BRIT J CANCER, V91, P707, DOI 10.1038/sj.bjc.6602008; Roman-Gomez J, 2004, LEUKEMIA, V18, P362, DOI 10.1038/sj.leu.2403223; Rossi D, 2004, HAEMATOLOGICA, V89, P154; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Slee EA, 2003, TOXICOL LETT, V139, P81, DOI 10.1016/S0378-4274(02)00421-6; Smith M, 1996, J CLIN ONCOL, V14, P18, DOI 10.1200/JCO.1996.14.1.18; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; Zhang XW, 2005, LEUKEMIA RES, V29, P179, DOI 10.1016/j.leukres.2004.07.001	31	56	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1862	1870		10.1038/sj.onc.1209236	http://dx.doi.org/10.1038/sj.onc.1209236			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16314841	Green Published			2022-12-28	WOS:000236224800003
J	Ribas, J; Bettayeb, K; Ferandin, Y; Knockaert, M; Garrofe-Ochoa, X; Totzke, F; Schachtele, C; Mester, J; Polychronopoulos, P; Magiatis, P; Skaltsounis, AL; Boix, J; Meijer, L				Ribas, J.; Bettayeb, K.; Ferandin, Y.; Knockaert, M.; Garrofe-Ochoa, X.; Totzke, F.; Schachtele, C.; Mester, J.; Polychronopoulos, P.; Magiatis, P.; Skaltsounis, A. -L.; Boix, J.; Meijer, L.			7-bromoindirubin-3 '-oxime induces caspase-independent cell death	ONCOGENE			English	Article						indirubin; protein kinase; cell death; autophagy; caspase; cancer	ARYL-HYDROCARBON RECEPTOR; PROTEIN-KINASE INHIBITORS; CYCLIN-DEPENDENT KINASES; INDIRUBIN DERIVATIVES; SELECTIVE INHIBITORS; CRYSTAL-STRUCTURE; TYRIAN PURPLE; AH RECEPTOR; APOPTOSIS; INDUCTION	Indirubin, an isomer of indigo, is a reported inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase-3 (GSK-3) as well as an agonist of the aryl hydrocarbon receptor (AhR). Indirubin is the active ingredient of a traditional Chinese medicinal recipe used against chronic myelocytic leukemia. Numerous indirubin analogs have been synthesized to optimize this promising kinase inhibitor scaffold. We report here on the cellular effects of 7-bromoindirubin-3'-oxime (7BIO). In contrast to its 5-bromo- and 6-bromo-isomers, and to indirubin-3'-oxime, 7BIO has only a marginal inhibitory activity towards CDKs and GSK-3. Unexpectedly, 7BIO triggers a rapid cell death process distinct from apoptosis. 7-Bromoindirubin-3'-oxime induces the appearance of large pycnotic nuclei, without classical features of apoptosis such as chromatin condensation and nuclear fragmentation. 7-Bromoindirubin-3'-oxime-induced cell death is not accompanied by cytochrome c release neither by any measurable effector caspase activation. Furthermore, the death process is not altered either by the presence of Q-VD-OPh, a broad-spectrum caspase inhibitor, or the overexpression of Bcl-2 and Bcl-XL proteins. Neither AhR nor p53 is required during 7BIO-induced cell death. Thus, in contrast to previously described indirubins, 7BIO triggers the activation of non-apoptotic cell death, possibly through necroptosis or autophagy. Although their molecular targets remain to be identified, 7-substituted indirubins may constitute a new class of potential antitumor compounds that would retain their activity in cells refractory to apoptosis.	CNRS, Cell Cycle Grp, F-29682 Roscoff, France; CNRS, Biol Stn, F-29682 Roscoff, France; Univ Lleida, Sch Med, DCMB, Mol Pharmacol Lab, Catalunya, Spain; ProQinase GmbH, Freiburg, Germany; INSERM, U482, Paris, France; Univ Athens, Dept Pharm, Div Pharmacognosy & Nat Prod Chem, Athens, Greece	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universitat de Lleida; ProQinase; Institut National de la Sante et de la Recherche Medicale (Inserm); National & Kapodistrian University of Athens	Meijer, L (corresponding author), CNRS, Cell Cycle Grp, UPS2682,BP 74, F-29682 Roscoff, France.	meijer@sb-roscoff.fr	Magiatis, Prokopios/A-2008-2008; Ribas, Judit/B-3362-2011; skaltsounis, alexios leandros/AAE-9617-2019	Ribas, Judit/0000-0003-0834-2577; Totzke, Frank/0000-0002-7261-8155; , laurent/0000-0003-3511-4916; Magiatis, Prokopios/0000-0002-0399-5344				Adachi J, 2001, J BIOL CHEM, V276, P31475, DOI 10.1074/jbc.C100238200; BACH S, 2006, IN PRESS MONOGRAPHS, V2; Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666; Balfour-Paul Jenny, 1998, INDIGO; Benson C, 2005, BRIT J CANCER, V92, P7, DOI 10.1038/sj.bjc.6602229; Bertrand JA, 2003, J MOL BIOL, V333, P393, DOI 10.1016/j.jmb.2003.08.031; Broker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078-0432.CCR-04-2223; Caserta TM, 2003, APOPTOSIS, V8, P345, DOI 10.1023/A:1024116916932; Chipuk JE, 2005, NAT REV MOL CELL BIO, V6, P268, DOI [10.1038/nrm1573, 10.1038/nrm2239]; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Cooksey CJ, 2001, MOLECULES, V6, P736, DOI 10.3390/60900736; Damiens E, 2001, ONCOGENE, V20, P3786, DOI 10.1038/sj.onc.1204503; Davies TG, 2001, STRUCTURE, V9, P389, DOI 10.1016/S0969-2126(01)00598-6; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828; Elferink Cornelis J, 2003, Prog Cell Cycle Res, V5, P261; Fischer Peter M, 2003, Prog Cell Cycle Res, V5, P235; Fischer PM, 2004, CURR MED CHEM, V11, P1563, DOI 10.2174/0929867043365062; Fischer PM, 2005, EXPERT OPIN INV DRUG, V14, P457, DOI 10.1517/13543784.14.4.457; Guengerich FP, 2004, J MED CHEM, V47, P3236, DOI 10.1021/jm030561b; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; Holton S, 2003, STRUCTURE, V11, P1329, DOI 10.1016/j.str.2003.09.020; Jaattela M, 2004, ONCOGENE, V23, P2746, DOI 10.1038/sj.onc.1207513; Jautelat R, 2005, CHEMBIOCHEM, V6, P531, DOI 10.1002/cbic.200400108; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; Kawanishi M, 2003, MUTAT RES-GEN TOX EN, V540, P99, DOI 10.1016/S1383-5718(03)00174-8; Knockaert M, 2004, ONCOGENE, V23, P4400, DOI 10.1038/sj.onc.1207535; Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Kosmopoulou MN, 2004, EUR J BIOCHEM, V271, P2280, DOI 10.1111/j.1432-1033.2004.04173.x; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Lee JW, 2005, BIOORG MED CHEM LETT, V15, P3948, DOI 10.1016/j.bmcl.2005.05.105; Lu HS, 2005, J MED CHEM, V48, P737, DOI 10.1021/jm049353p; Mapelli M, 2005, J MED CHEM, V48, P671, DOI 10.1021/jm049323m; Marko D, 2001, BRIT J CANCER, V84, P283, DOI 10.1054/bjoc.2000.1546; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010; Merz K H, 2004, Int J Clin Pharmacol Ther, V42, P656; Nam S, 2005, P NATL ACAD SCI USA, V102, P5998, DOI 10.1073/pnas.0409467102; Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920; Polychronopoulos P, 2004, J MED CHEM, V47, P935, DOI 10.1021/jm031016d; Ribas J, 2005, EUR J PHARMACOL, V524, P49, DOI 10.1016/j.ejphar.2005.09.021; Ribas J, 2004, EXP CELL RES, V295, P9, DOI 10.1016/j.yexcr.2003.12.019; Spink BC, 2003, BIOCHEM PHARMACOL, V66, P2313, DOI 10.1016/j.bcp.2003.08.019; Sugihara K, 2004, BIOCHEM BIOPH RES CO, V318, P571, DOI 10.1016/j.bbrc.2004.04.066; Teng X, 2005, BIOORG MED CHEM LETT, V15, P5039, DOI 10.1016/j.bmcl.2005.07.077; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; Weinmann H, 2005, CHEMBIOCHEM, V6, P455, DOI 10.1002/cbic.200500034; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; Wu ZLL, 2005, CHEM BIODIVERS, V2, P51, DOI 10.1002/cbdv.200490166; Xiao ZJ, 2002, LEUKEMIA LYMPHOMA, V43, P1763, DOI 10.1080/1042819021000006295; Yuste VJ, 2002, J NEUROCHEM, V80, P126, DOI 10.1046/j.0022-3042.2001.00695.x	52	87	97	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2006	25	47					6304	6318		10.1038/sj.onc.1209648	http://dx.doi.org/10.1038/sj.onc.1209648			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	094CY	16702956	Green Accepted			2022-12-28	WOS:000241218200007
J	Tamborini, E; Pricl, S; Negri, T; Lagonigro, MS; Miselli, F; Greco, A; Gronchi, A; Casali, PG; Ferrone, M; Fermeglia, M; Carbone, A; Pierotti, MA; Pilotti, S				Tamborini, E.; Pricl, S.; Negri, T.; Lagonigro, M. S.; Miselli, F.; Greco, A.; Gronchi, A.; Casali, P. G.; Ferrone, M.; Fermeglia, M.; Carbone, A.; Pierotti, M. A.; Pilotti, S.			Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients	ONCOGENE			English	Article						imatinib secondary resistance; gastrointestinal stromal tumors (GIST); molecular modeling	GASTROINTESTINAL STROMAL TUMORS; CAVITY-CREATING MUTATIONS; ACQUIRED-RESISTANCE; BCR-ABL; PROTEIN; STABILITY; INSIGHTS; DYNAMICS; INTERIOR; POLAR	Imatinib-acquired resistance related to the presence of secondary point mutations has become a frequent event in gastrointestinal stromal tumors. Here, transient transfection experiments with plasmids carrying two different KIT-acquired point mutations were performed along with immunoprecipitation of total protein extracts, derived from imatinib-treated and untreated cells. The molecular mechanics/Poisson Boltzmann surface area computational techniques were applied to study the interactions of the wild-type and mutated receptors with imatinib at the molecular level. Biochemical analyses showed KIT phosphorylation in cells transfected with vectors carrying the specific mutant genes. Imatinib treatment demonstrated that T670I was insensitive to the drug at all the applied concentrations, whereas V654A was inhibited by 6 mu M of imatinib. The modeling of the mutated receptors revealed that both substitutions affect imatinib-binding site, but to a different extent: T670I substantially modifies the binding pocket, whereas V654A induces only relatively confined structural changes. We demonstrated that T670I and V654A cause indeed imatinib-acquired resistance and that the former is more resistant to imatinib than the latter. The application of molecular simulations allowed us to quantify the interactions between the mutated receptors and imatinib, and to propose a molecular rationale for this type of drug resistance.	Ist Nazl Studio & Cura Tumori, Unit Expt Mol Pathol, Dept Pathol, I-20133 Milan, Italy; Univ Trieste, DICAMP, Mol Simulat Engn Lab, Trieste, Italy; Ist Nazl Studio & Cura Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Ist Nazl Studio & Cura Tumori, Dept Surg, I-20133 Milan, Italy; Ist Nazl Studio & Cura Tumori, Dept Clin Oncol, I-20133 Milan, Italy; FIRC Inst Mol Oncol, IFOM, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Trieste; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of Molecular Oncology	Pilotti, S (corresponding author), Ist Nazl Studio & Cura Tumori, Unit Expt Mol Pathol, Dept Pathol, Via Venezian 1, I-20133 Milan, Italy.	silvana.pilotti@istitutotumori.mi.it	Tamborini, Elena/C-3307-2017; Carbone, Antonino/AAA-2217-2019; casali, Paolo Giovanni/D-1524-2017; Gronchi, Alessandro/O-6589-2016; Pricl, Sabrina/M-7493-2015; Greco, Angela/C-1953-2017; Pierotti, Marco Alessandro/AAC-4728-2022; Fermeglia, Maurizio/O-3973-2018	Tamborini, Elena/0000-0002-3819-8687; Carbone, Antonino/0000-0003-2211-639X; casali, Paolo Giovanni/0000-0003-4056-8023; Gronchi, Alessandro/0000-0002-4703-3534; Pricl, Sabrina/0000-0001-8380-4474; Greco, Angela/0000-0003-2994-0349; Pierotti, Marco Alessandro/0000-0002-7431-8332; Negri, Tiziana/0000-0002-3528-7115; Fermeglia, Maurizio/0000-0001-8810-5082	Telethon [GGP030358] Funding Source: Medline	Telethon(Fondazione Telethon)		Antonescu CR, 2005, CLIN CANCER RES, V11, P4182, DOI 10.1158/1078-0432.CCR-04-2245; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Buckle AM, 1996, BIOCHEMISTRY-US, V35, P4298, DOI 10.1021/bi9524676; CASE DA, 2000, AMBER 7; Chen LL, 2004, CANCER RES, V64, P5913, DOI 10.1158/0008-5472.CAN-04-0085; Corless CL, 2002, AM J PATHOL, V160, P1567, DOI 10.1016/S0002-9440(10)61103-0; Corless CL, 2004, J CLIN ONCOL, V22, P3813, DOI 10.1200/JCO.2004.05.140; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Debiec-Rychter M, 2005, GASTROENTEROLOGY, V128, P270, DOI 10.1053/j.gastro.2004.11.020; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; Dwyer JJ, 2000, BIOPHYS J, V79, P1610, DOI 10.1016/S0006-3495(00)76411-3; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KELLIS JT, 1988, NATURE, V333, P784, DOI 10.1038/333784a0; Lazaridis T, 1995, ADV PROTEIN CHEM, V47, P231, DOI 10.1016/S0065-3233(08)60547-1; LEE B, 1993, PROTEIN SCI, V2, P733, DOI 10.1002/pro.5560020505; Loladze VV, 2002, J MOL BIOL, V320, P343, DOI 10.1016/S0022-2836(02)00465-5; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; Mol CD, 2003, J BIOL CHEM, V278, P31461, DOI 10.1074/jbc.C300186200; Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; O'Hare T, 2005, CANCER RES, V65, P4500, DOI 10.1158/0008-5472.CAN-05-0259; Pace CN, 1996, FASEB J, V10, P75, DOI 10.1096/fasebj.10.1.8566551; Pricl S, 2005, MOL CANCER THER, V4, P1167, DOI 10.1158/1535-7163.MCT-05-0101; Reyes CM, 2000, J MOL BIOL, V295, P1, DOI 10.1006/jmbi.1999.3319; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Srinivasan J, 1998, J AM CHEM SOC, V120, P9401, DOI 10.1021/ja981844+; Takano K, 2001, BIOCHEMISTRY-US, V40, P4853, DOI 10.1021/bi002792f; Tamborini E, 2005, CANCER RES, V65, P1115; Tamborini E, 2004, GASTROENTEROLOGY, V127, P294, DOI 10.1053/j.gastro.2004.02.021; Wardelmann E, 2005, LANCET ONCOL, V6, P249, DOI 10.1016/S1470-2045(05)70097-8; Wilson E.B., 1995, MOL VIBRATIONS	35	90	97	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6140	6146		10.1038/sj.onc.1209639	http://dx.doi.org/10.1038/sj.onc.1209639			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16751810				2022-12-28	WOS:000241101200012
J	Carragher, NO; Walker, SM; Carragher, LSA; Harris, F; Sawyer, TK; Brunton, VG; Ozanne, BW; Frame, MC				Carragher, N. O.; Walker, S. M.; Carragher, L. A. Scott; Harris, F.; Sawyer, T. K.; Brunton, V. G.; Ozanne, B. W.; Frame, M. C.			Calpain 2 and Src dependence distinguishes mesenchymal and amoeboid modes of tumour cell invasion: a link to integrin function	ONCOGENE			English	Article						calpain; Src; invasion; ROCK; mesenchymal; amoeboid	FOCAL ADHESION KINASE; MATRIX METALLOPROTEINASES; EXTRACELLULAR-MATRIX; COLORECTAL-CANCER; CLINICAL-TRIALS; LUNG-CANCER; MIGRATION; DYNAMICS; PROTEOLYSIS; INHIBITOR	Cancer cells can invade three-dimensional matrices by distinct mechanisms, recently defined by their dependence on extracellular proteases, including matrix metalloproteinases. Upon treatment with protease inhibitors, some tumour cells undergo a 'mesenchymal to amoeboid' transition that allows invasion in the absence of pericellular proteolysis and matrix degradation. We show here that in HT1080 cells, this transition is associated with weakened integrin-dependent adhesion, consistently reduced cell surface expression of the alpha 2 beta 1 integrin collagen receptor and impaired signalling downstream, as judged by reduced autophosphorylation of focal adhesion kinase (FAK). On examining cancer cells that use defined invasion strategies, we show that distinct from mesenchymal invasion, amoeboid invasion is independent of intracellular calpain 2 proteolytic activity that is usually needed for turnover of integrin-linked adhesions during two-dimensional planar migration. Moreover, an inhibitor of Rho/ROCK signalling, which specifically impairs amoeboid-like invasion, restores cell surface expression of alpha 2 beta 1 integrin, downstream FAK autophosphorylation and calpain 2 sensitivity - features of mesenchymal invasion. These findings link weakened integrin function to a lack of requirement for calpain 2-mediated integrin adhesion turnover during amoeboid invasion. In keeping with the need for integrin adhesion turnover, mesenchymal invasion is uniquely sensitive to Src inhibitors. Thus, the need for a major pathway that controls integrin adhesion turnover defines and distinguishes cancer cell invasion strategies.	Canc Res UK Beatson Labs, Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA	Beatson Institute; Takeda Pharmaceutical Company Ltd; Takeda Oncology	Frame, MC (corresponding author), Canc Res UK Beatson Labs, Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland.	m.frame@beatson.gla.ac.uk		Frame, Margaret/0000-0001-5882-1942; Carragher, Neil/0000-0001-5541-9747				Adachi Y, 2001, TUMOR BIOL, V22, P247, DOI 10.1159/000050623; Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Brand K, 2000, CANCER RES, V60, P5723; Brunton VG, 2005, CANCER RES, V65, P1335, DOI 10.1158/0008-5472.CAN-04-1949; Carragher NO, 1999, J CELL BIOL, V147, P619, DOI 10.1083/jcb.147.3.619; Carragher NO, 2003, CURR BIOL, V13, P1442, DOI 10.1016/S0960-9822(03)00544-X; Carragher NO, 2001, J BIOL CHEM, V276, P4270, DOI 10.1074/jbc.M008972200; Carragher NO, 2004, TRENDS CELL BIOL, V14, P241, DOI 10.1016/j.tcb.2004.03.011; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Cooke DW, 2005, MOL CELL ENDOCRINOL, V232, P37, DOI 10.1016/j.mce.2004.12.008; Cuevas BD, 2003, EMBO J, V22, P3346, DOI 10.1093/emboj/cdg322; Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955-0674(02)00364-2; Dourdin N, 2001, J BIOL CHEM, V276, P48382, DOI 10.1074/jbc.M108893200; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FALCIONI R, 1994, EXP CELL RES, V210, P113, DOI 10.1006/excr.1994.1017; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Franco SJ, 2004, NAT CELL BIOL, V6, P977, DOI 10.1038/ncb1175; Friedl P, 2004, CURR OPIN CELL BIOL, V16, P14, DOI 10.1016/j.ceb.2003.11.001; Friedl P, 2001, J LEUKOCYTE BIOL, V70, P491; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499-2512.2004; Goss KJH, 1998, INT J CANCER, V78, P629; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jaspars LH, 1996, J PATHOL, V178, P36, DOI 10.1002/(SICI)1096-9896(199601)178:1<36::AID-PATH426>3.0.CO;2-S; Krylyshkina O, 2002, J CELL BIOL, V156, P349, DOI 10.1083/jcb.200105051; Lokuta MA, 2003, P NATL ACAD SCI USA, V100, P4006, DOI 10.1073/pnas.0636533100; Lozonschi L, 1999, CANCER RES, V59, P1252; Malliri A, 2003, CURR OPIN CELL BIOL, V15, P583, DOI 10.1016/S0955-0674(03)00098-X; Mamoune A, 2003, CANCER RES, V63, P4632; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Palecek SP, 1998, J CELL SCI, V111, P929; Pavlaki M, 2003, CANCER METAST REV, V22, P177, DOI 10.1023/A:1023047431869; Petroll WM, 2003, CELL MOTIL CYTOSKEL, V55, P254, DOI 10.1002/cm.10126; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Rintoul RC, 2002, CLIN SCI, V102, P417, DOI 10.1042/CS20010216; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Scott LA, 2004, MOL CELL BIOL, V24, P1540, DOI 10.1128/MCB.24.4.1540-1559.2004; Shepherd FA, 2002, J CLIN ONCOL, V20, P4434, DOI 10.1200/JCO.2002.02.108; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Wagenaar-Miller RA, 2004, CANCER METAST REV, V23, P119, DOI 10.1023/A:1025819214508; Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Yamada KM, 2003, BRAZ J MED BIOL RES, V36, P959, DOI 10.1590/S0100-879X2003000800001; Zamir E, 2001, J CELL SCI, V114, P3583; Zhai JB, 2003, J BIOL CHEM, V278, P24865, DOI 10.1074/jbc.M302381200; Zucker S, 2004, CANCER METAST REV, V23, P101, DOI 10.1023/A:1025867130437	54	121	126	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 21	2006	25	42					5726	5740		10.1038/sj.onc.1209582	http://dx.doi.org/10.1038/sj.onc.1209582			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16652152				2022-12-28	WOS:000240765800004
J	Gupta, SK; Gupta, M; Hoffman, B; Liebermann, DA				Gupta, S. K.; Gupta, M.; Hoffman, B.; Liebermann, D. A.			Hematopoietic cells from gadd45a-deficient and gadd45b-deficient mice exhibit impaired stress responses to acute stimulation with cytokines, myeloablation and inflammation	ONCOGENE			English	Article						hematopoiesis; differentiation; stress; apoptosis	KINASE INHIBITORS; UV-IRRADIATION; GENE MYD118; MAP KINASE; STEM-CELLS; GADD45; EXPRESSION; DIFFERENTIATION; GROWTH; APOPTOSIS	The gadd45 family of gene(s) is rapidly induced by genotoxic stress or by differentiation-inducing cytokines. Using bone marrow ( BM) from gadd45a-/-, gadd45b-/- and wild-type (wt) mice, we investigated their role in stress responses of myeloid cells to acute stimulation with differentiating cytokines, myelotoxic agents and inflammatory substances. Bone marrow cells from gadd45a -/- and gadd45b -/- mice displayed compromised myeloid differentiation and higher apoptosis in vitro, following acute stimulation with a variety of differentiating cytokines. Intriguingly, gadd45a -/- and gadd45b -/- colony forming units granulocyte/macrophage progenitors displayed prolonged proliferation capacity compared to wt controls upon re-plating in methylcellulose supplemented with interleukin-3. The recovery of the BM myeloid compartment following 5-Fluorouracil-induced myeloablation was much slower in gadd45a -/- and gadd45b -/- mice compared to wt controls. Furthermore, the response of myeloid cells to inflammatory stress, inflicted via intraperitoneal administration of sodium caseinate was impaired in gadd45a -/- and gadd45b -/- mice compared to age-matched wt mice, as indicated by lower percentage of Gr-1-positive cells in the BM and lower number of myeloid cells in peritoneal exudates. Overall, these data indicate that both gadd45a and gadd45b play a role in modulating physiological stress responses of myeloid cells to acute stimulation with differentiating cytokines, myelo-ablation and inflammation. These findings should aid in understanding the response of normal and malignant hematopoietic cells to physiological and chemical stressors including anticancer agents.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Dept Biochem, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Liebermann, DA (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Dept Biochem, 3307 N Broad St,Room 331, Philadelphia, PA 19140 USA.	lieberma@temple.edu			NHLBI NIH HHS [R01 HL70530-03] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070530] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; Amanullah A, 2003, NATURE, V424, P741, DOI 10.1038/424741b; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Azam N, 2001, J BIOL CHEM, V276, P2766, DOI 10.1074/jbc.M005626200; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; DAEMS WT, 1978, CELL TISSUE RES, V190, P47; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Gupta M, 2005, ONCOGENE, V24, P7170, DOI 10.1038/sj.onc.1208847; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HESTDAL K, 1991, J IMMUNOL, V147, P22; Hildesheim J, 2002, CANCER RES, V62, P7305; Hoffmeyer A, 2001, MOL CELL BIOL, V21, P3137, DOI 10.1128/MCB.21.9.3137-3143.2001; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Lang R, 2002, J IMMUNOL, V169, P2253, DOI 10.4049/jimmunol.169.5.2253; Liebermann D A, 1994, Curr Opin Hematol, V1, P24; Liebermann DA, 2003, BLOOD CELL MOL DIS, V31, P213, DOI 10.1016/S1079-9796(03)00160-8; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; Lu BF, 2004, NAT IMMUNOL, V5, P38, DOI 10.1038/ni1020; Lu BF, 2001, IMMUNITY, V14, P583, DOI 10.1016/S1074-7613(01)00141-8; Marone M, 2002, LEUKEMIA LYMPHOMA, V43, P51, DOI 10.1080/10428190210195; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; NAKAHATA T, 1982, P NATL ACAD SCI-BIOL, V79, P3843, DOI 10.1073/pnas.79.12.3843; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Randall TD, 1997, BLOOD, V89, P3596, DOI 10.1182/blood.V89.10.3596.3596_3596_3606; RICHMAN CM, 1976, BLOOD, V47, P1031; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1996, ONCOGENE, V13, P2255; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; Taylor PR, 2003, EUR J IMMUNOL, V33, P2090, DOI 10.1002/eji.200324003; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Vairapandi M, 2002, J CELL PHYSIOL, V192, P327, DOI 10.1002/jcp.10140; Vairapandi M, 1996, ONCOGENE, V12, P2579; Vairapandi M, 2000, J BIOL CHEM, V275, P16810, DOI 10.1074/jbc.275.22.16810; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Yang JF, 2001, NAT IMMUNOL, V2, P157, DOI 10.1038/84264; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Zazzeroni F, 2003, BLOOD, V102, P3270, DOI 10.1182/blood-2003-03-0689; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang W, 1999, ONCOGENE, V18, P4899, DOI 10.1038/sj.onc.1202885	47	36	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2006	25	40					5537	5546		10.1038/sj.onc.1209555	http://dx.doi.org/10.1038/sj.onc.1209555			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16732331				2022-12-28	WOS:000240370400007
J	Boisvert-Adamo, K; Aplin, AE				Boisvert-Adamo, K.; Aplin, A. E.			B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis	ONCOGENE			English	Article						adhesion; apoptosis; collagen; ERK1/2; fibronectin; melanoma	GLYCOGEN-SYNTHASE KINASE-3; ONCOGENIC MUTATIONS; BRAF MUTATIONS; NEVUS CELLS; SURVIVAL; PATHWAY; ACTIVATION; APOPTOSIS; AKT; GROWTH	A hallmark feature of cancer is resistance to anoikis, apoptosis induced when cells either lose contact with or encounter an inappropriate extracellular matrix. Melanoma is inherently associated with a high degree of resistance to apoptosis. Mutations in B-RAF are prevalent in melanoma and promote constitutive MEK-ERK1/2 signaling and cell transformation. Acquisition of B-RAF mutations correlates with vertical phase growth when melanoma cells invade into the dermis, a collagen-rich environment that also contains fibronectin matrix. In addition, alterations in phosphoinositide-3 kinase (PI-3 kinase) signaling that lead to activation of AKT are detected in advanced melanomas. Here we show that knockdown of B-RAF expression by siRNA or pharmacological inhibition of MEK rendered melanoma cells susceptible to anoikis. Furthermore, adhesion to fibronectin but not collagen protected melanoma cells from anoikis through a PI-3 kinase-dependent pathway. Therefore, melanoma cells require either B-RAF or PI-3 kinase activation for protection from anoikis. Notably, AKT signaling in melanoma cells is substrate specific. These findings demonstrate that melanoma cells utilize multiple signaling pathways to provide resistance to apoptosis.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA	Albany Medical College	Aplin, AE (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, MC-165,47 New Scotland Ave, Albany, NY 12208 USA.	aplina@mail.amc.edu			NIGMS NIH HHS [GM067893] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067893] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alanko T, 2000, J INVEST DERMATOL, V115, P286, DOI 10.1046/j.1523-1747.2000.00045.x; Alanko T, 1999, J INVEST DERMATOL, V113, P111, DOI 10.1046/j.1523-1747.1999.00636.x; Alonso SR, 2004, AM J PATHOL, V164, P193, DOI 10.1016/S0002-9440(10)63110-0; Bataille V, 2003, EUR J CANCER, V39, P1341, DOI 10.1016/S0959-8049(03)00313-7; Bhatt KV, 2005, ONCOGENE, V24, P3459, DOI 10.1038/sj.onc.1208544; Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; Bouillet P, 2001, DEV CELL, V1, P645, DOI 10.1016/S1534-5807(01)00083-1; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200; Conner SR, 2003, J BIOL CHEM, V278, P34548, DOI 10.1074/jbc.M305797200; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Davies MA, 1998, CANCER RES, V58, P5285; DEL PL, 1997, SCIENCE, V278, P687; Dong JL, 2003, CANCER RES, V63, P3883; Eisenmann KM, 2003, CANCER RES, V63, P8330; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fukazawa H, 2002, MOL CANCER THER, V1, P303; Gaggioli C, 2005, ONCOGENE, V24, P1423, DOI 10.1038/sj.onc.1208318; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gill M, 2005, J AM ACAD DERMATOL, V53, P108, DOI 10.1016/j.jaad.2005.04.013; Guldberg P, 1997, CANCER RES, V57, P3660; Hingorani SR, 2003, CANCER RES, V63, P5198; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Jost M, 2001, MOL BIOL CELL, V12, P1519, DOI 10.1091/mbc.12.5.1519; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KOH HK, 1991, NEW ENGL J MED, V325, P171, DOI 10.1056/NEJM199107183250306; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Marshman E, 2003, J CELL SCI, V116, P675, DOI 10.1242/jcs.00263; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; O'Neill E, 2004, SCIENCE, V306, P2267, DOI 10.1126/science.1103233; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Qi XJ, 2006, J BIOL CHEM, V281, P813, DOI 10.1074/jbc.M505546200; REGINATO MJ, 2003, NAT CELL BIOL, V6, P6; Satyamoorthy K, 2003, CANCER RES, V63, P756; Schulze A, 2004, MOL BIOL CELL, V15, P3450, DOI 10.1091/mbc.E03-11-0807; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Scott G, 1997, J INVEST DERMATOL, V108, P147, DOI 10.1111/1523-1747.ep12332650; She QB, 2005, CANCER CELL, V8, P287, DOI 10.1016/j.ccr.2005.09.006; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Stahl JM, 2003, CANCER RES, V63, P2881; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Tsao HS, 1998, ONCOGENE, V16, P3397, DOI 10.1038/sj.onc.1201881; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433	54	53	54	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2006	25	35					4848	4856		10.1038/sj.onc.1209493	http://dx.doi.org/10.1038/sj.onc.1209493			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16547495				2022-12-28	WOS:000239687100003
J	Yang, H; Zhang, Y; Zhao, R; Wen, YY; Fournier, K; Wu, HB; Yang, HY; Diaz, J; Laronga, C; Lee, MH				Yang, H.; Zhang, Y.; Zhao, R.; Wen, Y. -Y; Fournier, K.; Wu, H. -B; Yang, H. -Y; Diaz, J.; Laronga, C.; Lee, M. -H			Negative cell cycle regulator 14-3-3 sigma stabilizes p27 Kip1 by inhibiting the activity of PKB/Akt	ONCOGENE			English	Article						p27; 14-3-3; Akt; tumor suppression	FORKHEAD TRANSCRIPTION FACTOR; DEPENDENT KINASE INHIBITOR; BREAST-CANCER; CYTOPLASMIC LOCALIZATION; PROTEIN-KINASE; DNA-DAMAGE; PHOSPHORYLATION; P27(KIP1); GROWTH; BRCA1	The 14-3-3 sigma (sigma) protein is a human cancer marker downregulated in various tumors, but its function has not been fully established. 14-3-3 sigma is a negative regulator of cell cycle when overexpressed, but it is not clear whether 14-3-3 sigma regulates cyclin-dependent kinase inhibitor p27(kip1) to negatively affect cell cycle progression. Protein kinase B/Akt is a crucial regulator of oncogenic signal and can phosphorylate p27(Kip1) to enhance p27(kip1)degradation, thereby promoting cell growth. Here, we show that 14-3-3 sigma-mediated cell cycle arrest concurred with p27(kip1) upregulation and Akt inactivation. We show that 14-3-3 sigma blocks Akt-mediated acceleration of P27(kip1) turnover rate. 14-3-3 sigma inhibits Akt-mediated p27(kip1) phosphorylation that targets p27(kip1) for nuclear export and degradation. 14-3-3 sigma inhibits cell survival and tumorigenicity of Akt-activating breast cancer cell. Low expression of 14-3-3 sigma in human primary breast cancers correlates with cytoplasmic location of p27(kip1). These data provide an insight into 14-3-3 sigma activity and rational cancer gene therapy by identifying 14-3-3 sigma as a positive regulator of p27 and as a potential anticancer agent.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, Program Genes & Dev, Grad Sch Biomed Sci, Houston, TX USA; Eastern Virginia Med Sch, Dept Surg, Norfolk, VA 23501 USA; Univ Texas, MD Anderson Canc Ctr, Breast Canc Biol Program, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci Houston, Program Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; Eastern Virginia Medical School; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Lee, MH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Box 79, Houston, TX 77030 USA.	mhlee@mdanderson.org		Lee, Mong-Hong/0000-0001-8675-8215	NCI NIH HHS [R01CA089266, CA16672, R01 CA089266, R56 CA089266] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R56CA089266, R01CA089266] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; ALBERTSEN HM, 1994, NAT GENET, V7, P472, DOI 10.1038/ng0894-472; Aprelikova O, 2001, J BIOL CHEM, V276, P25647, DOI 10.1074/jbc.C100265200; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lee MH, 2001, CELL MOL LIFE SCI, V58, P1907, DOI 10.1007/PL00000826; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Newman L, 2001, MOL CARCINOGEN, V30, P169, DOI 10.1002/mc.1025; PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Sekimoto T, 2004, EMBO J, V23, P1934, DOI 10.1038/sj.emboj.7600198; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; YANG H, 2006, IN PRESS MOL CANC TH; YANG H, 2006, IN PRESS CANC RES; Yang HY, 2003, MOL CELL BIOL, V23, P7096, DOI 10.1128/MCB.23.20.7096-7107.2003; Yang HY, 2001, ONCOGENE, V20, P3695, DOI 10.1038/sj.onc.1204472; YANG HY, 2006, IN PRESS J CELL BIOC; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Zhang YJ, 2004, ONCOGENE, V23, P7132, DOI 10.1038/sj.onc.1207918; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	44	39	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2006	25	33					4585	4594		10.1038/sj.onc.1209481	http://dx.doi.org/10.1038/sj.onc.1209481			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16532026				2022-12-28	WOS:000239457500008
J	Niikura, Y; Ohta, S; Vandenbeldt, KJ; Abdulle, R; McEwen, BF; Kitagawa, K				Niikura, Y.; Ohta, S.; Vandenbeldt, K. J.; Abdulle, R.; McEwen, B. F.; Kitagawa, K.			17-AAG, an Hsp90 inhibitor, causes kinetochore defects: a novel mechanism by which 17-AAG inhibits cell proliferation	ONCOGENE			English	Article						kinetochore; centromere; HSP90; SGT1 (SUGT1); 17-AAG	SACCHAROMYCES-CEREVISIAE KINETOCHORE; BUDDING YEAST KINETOCHORE; BREAST-CANCER CELLS; SPINDLE CHECKPOINT; ATP BINDING; IN-VIVO; CHROMOSOME CONGRESSION; MOLECULAR CHAPERONE; ANAPHASE TRANSITION; CENTROMERE PROTEIN	The Hsp90 inhibitor 17-allylaminogeldanamycin (17-AAG), which is currently in clinical trials, is thought to exert antitumor activity by simultaneously targeting several oncogenic signaling pathways. Here we report a novel mechanism by which 17-AAG inhibits cell proliferation, and we provide the first evidence that HSP90 is required for the assembly of kinetochore protein complexes in humans. 17-AAG caused delocalization of several kinetochore proteins including CENP-I and CENP-H but excluding CENP-B and CENP-C. Consistently, 17-AAG induced a mitotic arrest that depends on the spindle checkpoint and induced misalignment of chromosomes and aneuploidy. We found that HSP90 associates with SGT1 (suppressor of G2 allele of skp1; SUGT1) in human cells and that depletion of SGT1 sensitizes HeLa cells to 17-AAG. Overexpression of SGT1 restored the localization of specific kinetochore proteins and chromosome alignment in cells treated with 17-AAG. Biochemical and genetic results suggest that HSP90, through its interaction with SGT1 (SUGT1), is required for kinetochore assembly. Furthermore, time-course experiments revealed that transient treatment with 17-AAG between late S andG2/M phases causes substantial delocalization of CENP-H and CENP-I, a finding that strongly suggests that HSP90 participates in kinetochore assembly in a cell cycle-dependent manner.	St Jude Childrens Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA; New York State Dept Hlth, Wadsworth Ctr Labs & Res, Div Mol Med, Albany, NY 12201 USA; SUNY Albany, Dept Biomed Sci, Albany, NY USA	St Jude Children's Research Hospital; State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Kitagawa, K (corresponding author), St Jude Childrens Hosp, Dept Mol Pharmacol, 332 N Lauderdale St,Mail Stop 230,Rm D3007C, Memphis, TN 38105 USA.	katsumi.kitagawa@stjude.org			NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066270, R01GM068418] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline; NIGMS NIH HHS [GM68418, GM066270] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andreassen Paul R, 2004, Methods Mol Biol, V281, P213; Arlander SJH, 2003, J BIOL CHEM, V278, P52572, DOI 10.1074/jbc.M309054200; Bansal PK, 2004, MOL CELL BIOL, V24, P8069, DOI 10.1128/MCB.24.18.8069-8079.2004; Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184; Beliakoff J, 2004, ANTI-CANCER DRUG, V15, P651, DOI 10.1097/01.cad.0000136876.11928.be; Biggins S, 2003, CURR BIOL, V13, pR449, DOI 10.1016/S0960-9822(03)00369-5; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; de Carcer G, 2004, CANCER RES, V64, P5106, DOI 10.1158/0008-5472.CAN-03-2214; DeLuca JG, 2005, MOL BIOL CELL, V16, P519, DOI 10.1091/mbc.E04-09-0852; DOHENY KF, 1993, CELL, V73, P761, DOI 10.1016/0092-8674(93)90255-O; DROUIN R, 1988, CYTOBIOS, V56, P107; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fortugno P, 2003, P NATL ACAD SCI USA, V100, P13791, DOI 10.1073/pnas.2434345100; Fukagawa T, 2001, EMBO J, V20, P4603, DOI 10.1093/emboj/20.16.4603; Goetz MP, 2003, ANN ONCOL, V14, P1169, DOI 10.1093/annonc/mdg316; Goetz MP, 2005, J CLIN ONCOL, V23, P1078, DOI 10.1200/JCO.2005.09.119; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Hostein I, 2001, CANCER RES, V61, P4003; JIANG WD, 1993, J CELL BIOL, V121, P513, DOI 10.1083/jcb.121.3.513; Kaplan KB, 1997, CELL, V91, P491, DOI 10.1016/S0092-8674(00)80435-3; Kelland LR, 1999, J NATL CANCER I, V91, P1940, DOI 10.1093/jnci/91.22.1940; Kitagawa K, 2002, BIOTECHNIQUES, V33, P288, DOI 10.2144/02332bm07; Kitagawa K, 1999, MOL CELL, V4, P21, DOI 10.1016/S1097-2765(00)80184-7; Kitagawa K, 2001, NAT REV MOL CELL BIO, V2, P678, DOI 10.1038/35089568; Kranc KR, 2003, MOL CELL BIOL, V23, P7658, DOI 10.1128/MCB.23.21.7658-7666.2003; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; LECHNER J, 1994, EMBO J, V13, P5203, DOI 10.1002/j.1460-2075.1994.tb06851.x; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Lingelbach LB, 2004, MOL CELL BIOL, V24, P8938, DOI 10.1128/MCB.24.20.8938-8950.2004; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; MASUMOTO H, 1989, J CELL BIOL, V109, P1963, DOI 10.1083/jcb.109.5.1963; McEwen BF, 1997, J CELL BIOL, V137, P1567, DOI 10.1083/jcb.137.7.1567; McEwen BF, 2001, MOL BIOL CELL, V12, P2776, DOI 10.1091/mbc.12.9.2776; Meraldi P, 2005, EMBO J, V24, P1621, DOI 10.1038/sj.emboj.7600641; Munster PN, 2001, CANCER RES, V61, P2945; Neckers L, 2002, CLIN CANCER RES, V8, P962; Neckers Len, 2003, Current Opinion in Oncology, V15, P419, DOI 10.1097/00001622-200311000-00003; Nimmanapalli R, 2001, CANCER RES, V61, P1799; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Panaretou B, 2002, MOL CELL, V10, P1307, DOI 10.1016/S1097-2765(02)00785-2; Piper PW, 2003, GENE, V302, P165, DOI 10.1016/S0378-1119(02)01102-2; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Reilly PT, 2002, MOL CELL BIOL, V22, P6767, DOI 10.1128/MCB.22.19.6767-6778.2002; Solit DB, 2002, CLIN CANCER RES, V8, P986; Srethapakdi M, 2000, CANCER RES, V60, P3940; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Steensgaard P, 2004, EMBO REP, V5, P626, DOI 10.1038/sj.embor.7400154; Stemmann O, 1996, EMBO J, V15, P3611, DOI 10.1002/j.1460-2075.1996.tb00730.x; Stemmann O, 2002, P NATL ACAD SCI USA, V99, P8585, DOI 10.1073/pnas.082223899; STRUNNIKOV AV, 1995, J CELL BIOL, V128, P749, DOI 10.1083/jcb.128.5.749; Tatsumi Y, 2003, J BIOL CHEM, V278, P41528, DOI 10.1074/jbc.M307534200; Taylor SS, 2001, J CELL SCI, V114, P4385; TENHAGEN KG, 1990, MOL CELL BIOL, V10, P6348, DOI 10.1128/MCB.10.12.6348; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Workman P, 2003, CURR CANCER DRUG TAR, V3, P297, DOI 10.2174/1568009033481868; Yang ZY, 2005, MOL CELL BIOL, V25, P4062, DOI 10.1128/MCB.25.10.4062-4074.2005; Yoda K, 1996, MOL CELL BIOL, V16, P5169	62	55	58	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	30					4133	4146		10.1038/sj.onc.1209461	http://dx.doi.org/10.1038/sj.onc.1209461			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16501598				2022-12-28	WOS:000239004800001
J	Alabert, C; Rogers, L; Kahn, L; Niellez, S; Fafet, P; Cerulis, S; Blanchard, JM; Hipskind, RA; Vignais, ML				Alabert, C.; Rogers, L.; Kahn, L.; Niellez, S.; Fafet, P.; Cerulis, S.; Blanchard, J. M.; Hipskind, R. A.; Vignais, M. -L.			Cell type-dependent control of NF-Y activity by TGF-beta	ONCOGENE			English	Article						TGF-beta; NF-Y; MAPK	CCAAT-BINDING-FACTOR; CYCLIN-A EXPRESSION; P38 MAP KINASE; TRANSCRIPTION FACTOR; INDEPENDENT PATHWAYS; NUCLEAR-LOCALIZATION; SIGNAL-TRANSDUCTION; GENE-TRANSCRIPTION; B-SUBUNIT; CBF/NF-Y	Transforming growth factor b (TGF-beta) is a pluripotent cytokine that regulates cell growth and differentiation in a cell type-dependent fashion. TGF-beta exerts its effects through the activation of several signaling pathways. One involves membrane proximal events that lead to nuclear translocation of members of the Smad family of transcriptional regulators. TGF-beta can also activate MAPK cascades. Here, we show that TGF-beta induces nuclear translocation of the NF-YA subunit of the transcription factor NF-Y by a process that requires activation of the ERK cascade. This results in increased binding of endogenous NF-Y to chromatin and TGF-beta-dependent transcriptional regulation of the NF-Y target gene cyclin A2. Interestingly, the kinetics of NF-YA relocalization differs between epithelial cells and fibroblasts. NIH3T3 fibroblasts show an elevated basal level of phosphorylated p38 and delayed nuclear accumulation of NF-YA after TGF-beta treatment. In contrast, MDCK cells show low basal p38 activation, higher basal ERK phosphorylation and more rapid localization of NF-YA after induction. Thus, NF-Y activation by TGF-beta 1 involves ERK1/2 and potentially an interplay between MAPK pathways, thereby opening the possibility for finely tuned transcriptional regulation.	CNRS, Inst Mol Genet, UMR5535, IFR122, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Vignais, ML (corresponding author), CNRS, Inst Mol Genet, UMR5535, IFR122, 1919 Route Mende, F-34293 Montpellier 5, France.	vignais@igmm.cnrs.fr	Vignais, Marie Luce/D-5144-2017	Vignais, Marie Luce/0000-0002-0183-5953				Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; BARLAT I, 1995, ONCOGENE, V11, P1309; BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; Bhattacharya A, 2003, CANCER RES, V63, P8167; Bolognese F, 1999, ONCOGENE, V18, P1845, DOI 10.1038/sj.onc.1202494; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Cheung PCF, 2003, EMBO J, V22, P5793, DOI 10.1093/emboj/cdg552; Coustry F, 1996, J BIOL CHEM, V271, P14485, DOI 10.1074/jbc.271.24.14485; de Caestecker M, 2004, CYTOKINE GROWTH F R, V15, P1, DOI 10.1016/j.cytogfr.2003.10.004; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Efimova T, 2003, J BIOL CHEM, V278, P34277, DOI 10.1074/jbc.M302759200; Fajas L, 2001, MOL CELL BIOL, V21, P2956, DOI 10.1128/MCB.21.8.2956-2966.2001; Farina A, 1999, ONCOGENE, V18, P2818, DOI 10.1038/sj.onc.1202472; Frontini M, 2004, CELL CYCLE, V3, P217; Hall JP, 2002, J CELL BIOCHEM, V86, P1, DOI 10.1002/jcb.10187; Hu QH, 2000, J BIOL CHEM, V275, P4435, DOI 10.1074/jbc.275.6.4435; Huang WQ, 2005, J BIOL CHEM, V280, P10047, DOI 10.1074/jbc.M408680200; Huet X, 1996, MOL CELL BIOL, V16, P3789; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kahle J, 2005, MOL CELL BIOL, V25, P5339, DOI 10.1128/MCB.25.13.5339-5354.2005; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Lindahl GE, 2002, J BIOL CHEM, V277, P6153, DOI 10.1074/jbc.M108966200; MAITY SN, 1992, J BIOL CHEM, V267, P16574; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Marziali G, 1999, BLOOD, V93, P519, DOI 10.1182/blood.V93.2.519.402a01_519_526; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nicolas FJ, 2004, J CELL SCI, V117, P4113, DOI 10.1242/jcs.01289; Park SH, 2002, J BIOL CHEM, V277, P5168, DOI 10.1074/jbc.M106451200; Philips A, 1999, ONCOGENE, V18, P6222, DOI 10.1038/sj.onc.1203017; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Plet A, 1997, ONCOGENE, V14, P2575, DOI 10.1038/sj.onc.1201103; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Testa A, 2005, J BIOL CHEM, V280, P13606, DOI 10.1074/jbc.M414039200; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Waite KA, 2003, NAT REV GENET, V4, P763, DOI 10.1038/nrg1178; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Wysocka J, 2001, MOL CELL BIOL, V21, P3820, DOI 10.1128/MCB.21.11.3820-3829.2001; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yingling JM, 2004, NAT REV DRUG DISCOV, V3, P1011, DOI 10.1038/nrd1580; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Yun JH, 2003, J BIOL CHEM, V278, P36966, DOI 10.1074/jbc.M305178200	51	21	21	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3387	3396		10.1038/sj.onc.1209385	http://dx.doi.org/10.1038/sj.onc.1209385			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16434965	Green Published			2022-12-28	WOS:000238448100004
J	McCabe, M; Low, JA; Imperiale, MJ; Day, ML				McCabe, M; Low, JA; Imperiale, MJ; Day, ML			Human polyomavirus BKV transcriptionally activates DNA methyltransferase 1 through the pRb/E2F pathway	ONCOGENE			English	Article						virus; DNA methylation; DNMT1; E2F; kidney	LARGE-T-ANTIGEN; DE-NOVO METHYLATION; ABERRANT METHYLATION; GENE-EXPRESSION; HUMAN-PAPILLOMAVIRUS; TRANSFORMED-CELLS; SIMIAN VIRUS-40; DOWN-REGULATION; TUMOR-ANTIGEN; CADHERIN GENE	Many DNA tumor virus oncogenes are capable of activating and highjacking the host cell's DNA replication machinery for its own reproduction purposes through targeting and inactivation of the retinoblastoma pocket protein family. Pocket proteins function to regulate cell cycle progression and DNA synthesis through inhibitory interactions with the E2F transcription factors. The interaction of viral oncogenes with the pocket proteins is crucial for their transforming activity. We recently demonstrated that the DNA methyltransferase 1 (DNMT1) gene is an E2F target gene that is transcriptionally activated in cells lacking the retinoblastoma gene (Rb-/-). Overexpression of DNMT1 is implicated in tumor suppressor gene hypermethylation which is associated with tumorigenesis. Given that viral oncogenes potently stimulate E2F activity, we hypothesized that viral infection might activate DNMT1 and thereby promote transformation. Herein, we demonstrate that DNMT1 is strongly activated by the human polyomavirus BKV large T antigen (TAg) and adenovirus E1a. Viral oncogene mutants incapable of binding the pocket proteins are ineffective at activating DNMT1 compared to their wildtype counterparts. Additionally, mutation of the E2F sites within the DNMT1 promoters dramatically abrogates transcriptional activation. These data suggest that viral induction of DNMT1 through modulation of the pRB/E2F pathway may be involved in viral transformation.	Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA; Univ Michigan, Mol & Cellular Biol Program, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Day, ML (corresponding author), Univ Michigan, Dept Urol, 6219 CCGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	mday@umich.edu			NATIONAL CANCER INSTITUTE [T32CA009676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061488] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA09676] Funding Source: Medline; NIAID NIH HHS [AI060584] Funding Source: Medline; NIDDK NIH HHS [DK61488] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agoston AT, 2005, J BIOL CHEM, V280, P18302, DOI 10.1074/jbc.M501675200; AZZI A, 1994, BONE MARROW TRANSPL, V14, P235; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bestor TH, 1996, NAT GENET, V12, P363, DOI 10.1038/ng0496-363; Biniszkiewicz D, 2002, MOL CELL BIOL, V22, P2124, DOI 10.1128/MCB.22.7.2124-2135.2002; Boehm JS, 2005, MOL CELL BIOL, V25, P6464, DOI 10.1128/MCB.25.15.6464-6474.2005; BOLLAG B, 1989, J VIROL, V63, P863, DOI 10.1128/JVI.63.2.863-872.1989; BOUCHARD J, 1990, ANTIMICROB AGENTS CH, V34, P206, DOI 10.1128/AAC.34.2.206; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CRAWFORD L, 1982, J VIROL, V41, P709, DOI 10.1128/JVI.41.2.709-709.1982; Das D, 2004, ONCOGENE, V23, P7031, DOI 10.1038/sj.onc.1207920; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; El-Osta A, 2000, GENE EXPRESSION, V9, P63; Etoh T, 2004, AM J PATHOL, V164, P689, DOI 10.1016/S0002-9440(10)63156-2; Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GOORHA R, 1984, VIROLOGY, V138, P94, DOI 10.1016/0042-6822(84)90150-8; GUNTHERT U, 1976, P NATL ACAD SCI USA, V73, P3923, DOI 10.1073/pnas.73.11.3923; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Harris KF, 1998, MOL CELL BIOL, V18, P1746, DOI 10.1128/MCB.18.3.1746; Harris KF, 1996, J VIROL, V70, P2378, DOI 10.1128/JVI.70.4.2378-2386.1996; HELLER H, 1995, P NATL ACAD SCI USA, V92, P5515, DOI 10.1073/pnas.92.12.5515; Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; Hohlweg U, 2003, VIRUS RES, V98, P45, DOI 10.1016/j.virusres.2003.08.012; Humes HD, 2002, AM J KIDNEY DIS, V39, P1078, DOI 10.1053/ajkd.2002.32792; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Jarrard DF, 1997, CLIN CANCER RES, V3, P2121; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOHNSONTHOMPSON M, 1988, IN VITRO CELL DEV B, V24, P1114; KAYE AM, 1967, J MOL BIOL, V24, P475, DOI 10.1016/0022-2836(67)90233-1; Khalili K, 2003, ONCOGENE, V22, P5181, DOI 10.1038/sj.onc.1206559; KOCHANEK S, 1993, EMBO J, V12, P1141, DOI 10.1002/j.1460-2075.1993.tb05755.x; Low J, 2004, VIROLOGY, V323, P182, DOI 10.1016/j.virol.2004.03.027; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; McCabe MT, 2005, CANCER RES, V65, P3624, DOI 10.1158/0008-5472.CAN-04-2158; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; Mikovits JA, 1998, MOL CELL BIOL, V18, P5166, DOI 10.1128/MCB.18.9.5166; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; Munger K, 2002, FRONT BIOSCI-LANDMRK, V7, pD641, DOI 10.2741/munger; NAKSHATRI H, 1988, J VIROL, V62, P4613, DOI 10.1128/JVI.62.12.4613-4621.1988; O'Shea CC, 2005, CURR OPIN GENET DEV, V15, P18, DOI 10.1016/j.gde.2004.12.010; Peterson EJ, 2003, CANCER RES, V63, P6579; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; RAY FA, 1990, J CELL BIOCHEM, V42, P13, DOI 10.1002/jcb.240420103; Remus R, 1999, J VIROL, V73, P1010, DOI 10.1128/JVI.73.2.1010-1022.1999; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rhodes DR, 2005, NAT GENET, V37, P579, DOI 10.1038/ng1578; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Santin AD, 2005, VIROLOGY, V331, P269, DOI 10.1016/j.virol.2004.09.045; Shivapurkar N, 2004, CANCER RES, V64, P3757, DOI 10.1158/0008-5472.CAN-03-3307; SINCLAIR AJ, 1995, J VIROL, V69, P1292, DOI 10.1128/JVI.69.2.1292-1295.1995; Slack A, 1999, J BIOL CHEM, V274, P10105, DOI 10.1074/jbc.274.15.10105; SUTTER D, 1980, P NATL ACAD SCI-BIOL, V77, P253, DOI 10.1073/pnas.77.1.253; Suzuki M, 2005, ONCOGENE, V24, P1302, DOI 10.1038/sj.onc.1208263; Syrjanen SM, 1999, ANN MED, V31, P175, DOI 10.3109/07853899909115976; Tognon M, 2003, ONCOGENE, V22, P5192, DOI 10.1038/sj.onc.1206550; Toyooka KO, 2001, CANCER RES, V61, P4556; Toyooka S, 2001, CANCER RES, V61, P5727; Trabanelli C, 1998, VIROLOGY, V243, P492, DOI 10.1006/viro.1998.9080; Tsai CN, 2002, P NATL ACAD SCI USA, V99, P10084, DOI 10.1073/pnas.152059399; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; Vilchez RA, 2004, CLIN MICROBIOL REV, V17, P495, DOI [10.1128/CMR.17.3.495-508.2004, 10.1128/cmr.17.3.495-508.2004]; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225	71	54	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2727	2735		10.1038/sj.onc.1209266	http://dx.doi.org/10.1038/sj.onc.1209266			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16547506				2022-12-28	WOS:000237272900004
J	Chang, CY; Lin, YM; Lee, WP; Hsu, HH; Chen, EIT				Chang, CY; Lin, YM; Lee, WP; Hsu, HH; Chen, EIT			Involvement of Bcl-X-L deamidation in E1A-mediated cisplatin sensitization of ovarian cancer cells	ONCOGENE			English	Article						E1A; Rb; Bcl-X-L; deamidation; apoptosis	RETINOBLASTOMA GENE-PRODUCT; E1A; APOPTOSIS; PROTEIN; INDUCTION; RB; CHEMOSENSITIVITY; ASSOCIATION; SENSITIVITY; SUPPRESSION	The adenovirus E1A protein has been shown to be involved in the potentiation of apoptosis induced by chemotherapeutic agents, yet the molecular events of E1A-mediated apoptosis are not very clear. A recent report has suggested that deamidation of the Bcl-X-L protein inhibits its antiapoptotic ability and leads to apoptosis induced by alkylating agents in Rb-deficient tumor cells. Since Rb is known to interact with E1A, which interrupts Rb's normal function, we examined Bcl-X-L deamidation and cell death induced by cisplatin in E1A transfectants. We found that the E1A transfectants became sensitive to cisplatin-induced apoptosis compared to the parental cells, SKOV3.ip1. Our data show that cisplatin treatment induced the modi. cation of Bcl-X-L in the E1A transfectants in dosage and time-dependent manner. Furthermore, phosphatase treatment had no effect on the level of Bcl-X-L modi. cation, whereas alkaline lysis buffer appeared to induce the same modi. cation of Bcl-X-L. Ectopic expression of the deamidated forms of Bcl-X-L in SKOV3.ip1 cells revealed that the modi. cation to the Bcl-X-L protein molecules was deamidation. Expression of the E1A mutant ( dl1108) which contains deletion at CR2 domain suppressed Bcl-X-L deamidation and apoptosis induced by cisplatin. We also found that expression of the nondeamidated Bcl-X-L protected E1A transfectants from apoptosis. These findings suggest that Bcl-X-L deamidation contributes to E1A-mediated cisplatin sensitization in SKOV3.ip1 cells.	Natl Yang Ming Univ, Inst Biotechnol Med, Taipei 112, Taiwan; Vet Gen Hosp, Div Internal Med, Taipei, Taiwan; Vet Gen Hosp, Ctr Canc, Taipei, Taiwan	National Yang Ming Chiao Tung University	Chen, EIT (corresponding author), Natl Yang Ming Univ, Inst Biotechnol Med, Lee Lun St,Sect 2, Taipei 112, Taiwan.	chenit@ym.edu.tw						ABRAHAM RT, 1995, BIOL CELL, V83, P105, DOI 10.1016/0248-4900(96)81298-6; Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123; Amundson SA, 2000, CANCER RES, V60, P6101; Brader KR, 1997, CLIN CANCER RES, V3, P2017; Chattopadhyay D, 2001, J VIROL, V75, P9844, DOI 10.1128/JVI.75.20.9844-9856.2001; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN IT, 1995, ONCOGENE, V11, P1931; Deng J, 2002, CANCER RES, V62, P346; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Deverman BE, 2003, CELL, V115, P503, DOI 10.1016/S0092-8674(03)00892-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Duelli DM, 2000, NAT CELL BIOL, V2, P859, DOI 10.1038/35041112; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Lee WP, 2003, CANCER RES, V63, P6229; Lee WP, 2002, ONCOGENE, V21, P329, DOI 10.1038/sj.onc.1205066; NEVINS JR, 1992, SCIENCE, V258, P424; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Robinson NE, 2002, P NATL ACAD SCI USA, V99, P5283, DOI 10.1073/pnas.082102799; Robinson NE, 2001, P NATL ACAD SCI USA, V98, P12409, DOI 10.1073/pnas.221463198; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; Shisler J, 1996, J VIROL, V70, P68, DOI 10.1128/JVI.70.1.68-77.1996; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Takehara T, 2003, CANCER RES, V63, P3054; UNEO NT, 1997, ONCOGENE, V10, P1053; UNEO NT, 2000, CLIN CANCER RES, V6, P250; Viniegra JG, 2002, ONCOGENE, V21, P7131, DOI 10.1038/sj.onc.1205934; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; White E, 2001, ONCOGENE, V20, P7836, DOI 10.1038/sj.onc.1204861; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YU DH, 1993, CANCER RES, V53, P891; Zhao R, 2004, CANCER CELL, V5, P37, DOI 10.1016/S1535-6108(03)00333-7	35	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2656	2665		10.1038/sj.onc.1209294	http://dx.doi.org/10.1038/sj.onc.1209294			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16331250				2022-12-28	WOS:000237099400009
J	Wen, XZ; Akiyama, Y; Baylin, SB; Yuasa, Y				Wen, XZ; Akiyama, Y; Baylin, SB; Yuasa, Y			Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas	ONCOGENE			English	Article						bone morphogenetic protein 2 (BMP-2); DNA methylation; BMP-2 expression; gastrointestinal carcinoma	HISTONE DEACETYLASE INHIBITION; CPG-ISLAND METHYLATION; ABERRANT METHYLATION; CANCER; PROLIFERATION; BMP-2; DIFFERENTIATION; MUTATIONS; GROWTH; CELLS	Recently, it was reported that exogenous bone morphogenetic protein ( BMP)-2 acted as an antiproliferative agent in a variety of cell lines, including normal and cancerous gastric cell lines, indicating that BMP-2 plays an important role during cell growth. However, despite the loss of BMP-2 expression in several cancers, the underlying mechanism remains unknown. Epigenetic silencing through DNA methylation is one of the key steps during carcinogenesis. In this study, we found, through analysis by the methylation- specific polymerase chain reaction technique, CpG island methylation of the BMP-2 promoter region in gastric and colon cancer cell lines. BMP-2 mRNA was found to be activated after 5-aza-2'-deoxycytidine treatment of the methylation- positive cells. Moreover, 24 of the 56 ( 42.9%) gastric cancer tissues exhibited promoter methylation. Immunohistochemical staining revealed that 18 of the 24 ( 75%) gastric cancer tissues without methylation signals exhibited BMP-2 expression, whereas among 20 cancer tissues with strong methylation signals only four ( 20%) expressed BMP-2 ( P = 0.0003). These findings indicate that BMP-2 methylation is strongly associated with the loss of BMP-2 protein expression in the primary gastric carcinomas. BMP-2 methylation was more often observed in diffuse type ( 60.7%) than in intestinal type ( 25%) gastric carcinomas ( P = 0.007). Thus, aberrant BMP-2 methylation and the resultant loss of BMP-2 expression may be related to gastric carcinogenesis, particularly in the diffuse type.	Tokyo Med & Dent Univ, Grad Sch Med & Dent, Dept Mol Oncol, Bunkyo Ku, Tokyo 1138519, Japan; Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA	Tokyo Medical & Dental University (TMDU); Johns Hopkins University; Johns Hopkins Medicine	Yuasa, Y (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med & Dent, Dept Mol Oncol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	yuasa.monc@tmd.ac.jp						Abrams KL, 2004, J BIOL CHEM, V279, P15916, DOI 10.1074/jbc.M313531200; Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; Baylin SB, 1998, ADV CANCER RES, V72, P141; BECKER KF, 1994, CANCER RES, V54, P3845; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Dai ZY, 2004, ONCOGENE, V23, P3521, DOI 10.1038/sj.onc.1207441; Ghosh-Choudhury N, 2001, BIOCHEM BIOPH RES CO, V286, P101, DOI 10.1006/bbrc.2001.5351; Ghosh-Choudhury N, 2000, BBA-MOL CELL RES, V1497, P186, DOI 10.1016/S0167-4889(00)00060-4; Hardwick JCH, 2004, GASTROENTEROLOGY, V126, P111, DOI 10.1053/j.gastro.2003.10.067; Hay E, 2000, J CELL PHYSIOL, V183, P117, DOI 10.1002/(SICI)1097-4652(200004)183:1<117::AID-JCP14>3.0.CO;2-#; Helvering LM, 2000, GENE, V256, P123, DOI 10.1016/S0378-1119(00)00364-4; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Horvath LG, 2004, PROSTATE, V59, P234, DOI 10.1002/pros.10361; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Ide H, 1997, CANCER RES, V57, P5022; Japanese Gastric Cancer Association, 1998, Gastric Cancer, V1, P10; Jeffery TK, 2005, AM J PHYSIOL-LUNG C, V288, pL370, DOI 10.1152/ajplung.00242.2004; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Leung WK, 2001, CANCER-AM CANCER SOC, V91, P2294; Miyazaki H, 2004, ONCOGENE, V23, P9326, DOI 10.1038/sj.onc.1208127; Narita T, 2000, DEVELOPMENT, V127, P981; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; Pouliot F, 2002, J ENDOCRINOL, V172, P187, DOI 10.1677/joe.0.1720187; Pu H, 1999, IN VITRO CELL DEV-AN, V35, P488; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Smiraglia DJ, 2002, ONCOGENE, V21, P5414, DOI 10.1038/sj.onc.1205608; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Toyota M, 1999, CANCER RES, V59, P5438; van den Brink GR, 2001, GASTROENTEROLOGY, V121, P317, DOI 10.1053/gast.2001.26261; von Bubnoff A, 2001, DEV BIOL, V239, P1, DOI 10.1006/dbio.2001.0388; Wen XZ, 2004, BIOCHEM BIOPH RES CO, V316, P100, DOI 10.1016/j.bbrc.2004.02.016; Wong GA, 2003, AM J PHYSIOL-ENDOC M, V284, pE972, DOI 10.1152/ajpendo.00385.2002; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	40	73	78	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2666	2673		10.1038/sj.onc.1209297	http://dx.doi.org/10.1038/sj.onc.1209297			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16314833				2022-12-28	WOS:000237099400010
J	Tahara, H; Shin-ya, K; Seimiya, H; Yamada, H; Tsuruo, T; Ide, T				Tahara, H; Shin-ya, K; Seimiya, H; Yamada, H; Tsuruo, T; Ide, T			G-quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3 ' telomeric overhang in cancer cells	ONCOGENE			English	Article						telomere; telomestatin; G-quadruplex; TRF2; 3 ' telomeric overhang	HYBRIDIZATION PROTECTION ASSAY; G-QUARTET FORMATION; BINDING-PROTEIN; HEPATOCELLULAR CARCINOMAS; HUMAN-CHROMOSOMES; BETA-SUBUNIT; DRUG DESIGN; IN-VITRO; DNA; INHIBITION	Inhibition of telomerase activity by telomerase inhibitors induces a gradual loss of telomeres, and this in turn causes cancer cells to enter to a crisis stage. Here, we report the telomerase inhibitor telomestatin, which is known to stabilize G-quadruplex structures at 30 single-stranded telomeric overhangs ( G-tails), rapidly dissociates TRF2 from telomeres in cancer cells within a week, when given at a concentration that does not cause normal cells to die. The G-tails were dramatically reduced upon short-term treatment with the drug in cancer cell lines, but not in normal. broblasts and epithelial cells. In addition, telomestatin also induced anaphase bridge formation in cancer cell lines. These effects of telomestatin were similar to those of dominant negative TRF2, which also causes a prompt loss of the telomeric G-tails and induces an anaphase bridge. These results indicate that telomestatin exerts its anticancer effect not only through inhibiting telomere elongation, but also by rapidly disrupting the capping function at the very ends of telomeres. Unlike conventional telomerase inhibitors that require long-term treatments, the G-quadruplex stabilizer telomestatin induced prompt cell death, and it was selectively effective in cancer cells. This study also identifies the TRF2 protein as a therapeutic target for treating many types of cancer which have the TRF2 protein at caps of the telomere DNA of each chromosome.	Hiroshima Univ, Sch Biomed Sci, Div Integrated Med Sci, Dept Cellular & Mol Biol, Hiroshima, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 170, Japan	Hiroshima University; University of Tokyo; Japanese Foundation for Cancer Research	Tahara, H (corresponding author), Hiroshima Univ, Sch Biomed Sci, Div Integrated Med Sci, Dept Cellular & Mol Biol, Hiroshima, Japan.	toshi@hiroshima-u.ac.jp; kshinya@jbirc.aist.go.jp		Seimiya, Hiroyuki/0000-0003-3314-9736				Akiyama M, 2003, CANCER RES, V63, P6187; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Carney SA, 2002, LAB INVEST, V82, P719, DOI 10.1097/01.LAB.0000017499.51216.3E; FANG GW, 1993, BIOCHEMISTRY-US, V32, P11646, DOI 10.1021/bi00094a022; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; GIRALDO R, 1994, P NATL ACAD SCI USA, V91, P7658, DOI 10.1073/pnas.91.16.7658; Gomez D, 2004, J BIOL CHEM, V279, P41487, DOI 10.1074/jbc.M406123200; Gowan SM, 2002, MOL PHARMACOL, V61, P1154, DOI 10.1124/mol.61.5.1154; Gowan SM, 2001, MOL PHARMACOL, V60, P981, DOI 10.1124/mol.60.5.981; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Gu J, 2005, CARCINOGENESIS, V26, P1741, DOI 10.1093/carcin/bgi126; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Han HY, 2000, TRENDS PHARMACOL SCI, V21, P136, DOI 10.1016/S0165-6147(00)01457-7; Hanaoka S, 2005, PROTEIN SCI, V14, P119, DOI 10.1110/ps.04983705; Hirose M, 1997, J CANCER RES CLIN, V123, P337, DOI 10.1007/BF01438310; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Kim MY, 2003, CANCER RES, V63, P3247; Kim MY, 2002, J AM CHEM SOC, V124, P2098, DOI 10.1021/ja017308q; Kondo S, 1998, FASEB J, V12, P801, DOI 10.1096/fasebj.12.10.801; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Mergny JL, 1998, NAT MED, V4, P1366, DOI 10.1038/3949; Nakamura Y, 1999, CLIN CHEM, V45, P1718; Nakanishi K, 2003, CLIN CANCER RES, V9, P1105; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Nijjar T, 2005, ONCOGENE, V24, P3369, DOI 10.1038/sj.onc.1208482; Parkinson GN, 2002, NATURE, V417, P876, DOI 10.1038/nature755; Riou JF, 2002, P NATL ACAD SCI USA, V99, P2672, DOI 10.1073/pnas.052698099; Rosu F, 2003, CHEM COMMUN, P2702, DOI 10.1039/b309394h; Seimiya H, 2005, CANCER CELL, V7, P25, DOI 10.1016/j.ccr.2004.11.021; Seimiya H, 2004, MOL CELL BIOL, V24, P1944, DOI 10.1128/MCB.24.5.1944-1955.2004; Seimiya H, 2002, MOL CANCER THER, V1, P657; Shay JW, 2005, CANCER CELL, V7, P1, DOI 10.1016/j.ccr.2004.12.012; Shin-ya K, 2001, J AM CHEM SOC, V123, P1262, DOI 10.1021/ja005780q; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Stansel RM, 2001, EMBO J, V20, P5532; TAHARA H, 1995, CANCER RES, V55, P2734; Tahara H, 2005, NAT METHODS, V2, P829, DOI 10.1038/NMETH797; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tauchi T, 2003, ONCOGENE, V22, P5338, DOI 10.1038/sj.onc.1206833; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	45	192	202	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1955	1966		10.1038/sj.onc.1209217	http://dx.doi.org/10.1038/sj.onc.1209217			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16302000				2022-12-28	WOS:000236224800012
J	Ladiges, WC				Ladiges, WC			Mouse models of XRCC1 DNA repair polymorphisms and cancer	ONCOGENE			English	Review						DNA repair; polymorphisms; XRCC1; cancer; mouse models	STRAND BREAK REPAIR; BASE EXCISION-REPAIR; GENETIC POLYMORPHISMS; PROTEIN; RISK; DOMAIN; DAMAGE; REQUIREMENT; PHENOTYPE	DNA damage plays a major role in mutagenesis, carcinogenesis and aging. A gene that is emerging as an essential element in the repair of both damaged bases and single-strand breaks (SSB) is XRCC1. XRCC1 has been shown to have a large number of single-nucleotide polymorphisms ( SNPs), several of which are being increasingly studied in cancer epidemiology investigations, in part because of their relative high frequency in the population. Although association trends with specific cancer types have occasionally been shown in a variety of ethnic backgrounds, there are often conflicting reports that weaken any substantial conclusions. The functional significance of these SNPs is still largely unknown. XRCC1 is an excellent prototype to provide a forum for determining how epidemiological cancer association studies with DNA repair gene polymorphisms can be validated or refuted. The focus is on the utilization of in silico data and biochemical studies in cell lines and existing mouse models to help provide a framework for the development of new mutant mouse lines that mimic human polymorphisms. These mouse lines will provide the next generation of mammalian tools for carcinogen exposure studies relevant to human cancer and variations in XRCC1, and provide the basis for investigating groups of genes and polymorphisms in an animal model.	Univ Washington, Dept Comparat Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Ladiges, WC (corresponding author), Univ Washington, Dept Comparat Med, Seattle, WA 98195 USA.	wladiges@u.washington.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033, U01ES011045] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES07033, U01 ES11045] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aka P, 2004, MUTAT RES-FUND MOL M, V556, P169, DOI 10.1016/j.mrfmmm.2004.08.002; Au WW, 2003, ENVIRON HEALTH PERSP, V111, P1843, DOI 10.1289/ehp.6632; Beernink PT, 2005, J BIOL CHEM, V280, P30206, DOI 10.1074/jbc.M502155200; Brem R, 2005, NUCLEIC ACIDS RES, V33, P2512, DOI 10.1093/nar/gki543; Caldecott KW, 2003, DNA REPAIR, V2, P955, DOI 10.1016/S1568-7864(03)00118-6; De Bont R, 2004, MUTAGENESIS, V19, P169, DOI 10.1093/mutage/geh025; Dianova II, 2004, NUCLEIC ACIDS RES, V32, P2550, DOI 10.1093/nar/gkh567; El-Khamisy SF, 2003, NUCLEIC ACIDS RES, V31, P5526, DOI 10.1093/nar/gkg761; Fan JS, 2004, NUCLEIC ACIDS RES, V32, P2193, DOI 10.1093/nar/gkh556; Geisler SA, 2005, HEAD NECK-J SCI SPEC, V27, P232, DOI 10.1002/hed.20141; Goode EL, 2002, CANCER EPIDEM BIOMAR, V11, P1513; Hu ZB, 2005, CANCER EPIDEM BIOMAR, V14, P1810, DOI 10.1158/1055-9965.EPI-04-0793; Hung RJ, 2005, JNCI-J NATL CANCER I, V97, P567, DOI 10.1093/jnci/dji101; Kelada SN, 2003, ENVIRON HEALTH PERSP, V111, P1055, DOI 10.1289/ehp.6065; Kirk GD, 2005, CANCER EPIDEM BIOMAR, V14, P373, DOI 10.1158/1055-9965.EPI-04-0161; Loizou JI, 2004, CELL, V117, P17, DOI 10.1016/S0092-8674(04)00206-5; Marintchev A, 1999, NAT STRUCT BIOL, V6, P884; Marsin S, 2003, J BIOL CHEM, V278, P44068, DOI 10.1074/jbc.M306160200; Moullan N, 2003, CANCER EPIDEM BIOMAR, V12, P1168; Ron E, 1998, RADIAT RES, V150, pS30, DOI 10.2307/3579806; Shen NR, 1998, NUCLEIC ACIDS RES, V26, P1032, DOI 10.1093/nar/26.4.1032; Takanami T, 2005, MUTAT RES-GEN TOX EN, V582, P135, DOI 10.1016/j.mrgentox.2005.01.007; Taylor RM, 2002, MOL CELL BIOL, V22, P2556, DOI 10.1128/MCB.22.8.2556-2563.2002; Tebbs RS, 2003, DNA REPAIR, V2, P1405, DOI 10.1016/j.dnarep.2003.08.007; Tebbs RS, 1999, DEV BIOL, V208, P513, DOI 10.1006/dbio.1999.9232; Thomas M C, 2000, BMC Nephrol, V1, P1, DOI 10.1186/1471-2369-1-1; WALLACE SS, 1994, INT J RADIAT BIOL, V66, P579, DOI 10.1080/09553009414551661; Wang YF, 2003, DNA REPAIR, V2, P901, DOI 10.1016/S1568-7864(03)00085-5; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404	29	65	66	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	11					1612	1619		10.1038/sj.onc.1209370	http://dx.doi.org/10.1038/sj.onc.1209370			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020JL	16550161				2022-12-28	WOS:000235904700003
J	Muromoto, R; Nakao, K; Watanabe, T; Sato, N; Sekine, Y; Sugiyama, K; Oritani, K; Shimoda, K; Matsuda, T				Muromoto, R; Nakao, K; Watanabe, T; Sato, N; Sekine, Y; Sugiyama, K; Oritani, K; Shimoda, K; Matsuda, T			Physical and functional interactions between Daxx and STAT3	ONCOGENE			English	Article						IL-6; LIF; STAT3; Daxx; transcriptional regulation	INTERFERON-ALPHA; TRANSCRIPTIONAL ACTIVATION; PML; PROTEIN; EXPRESSION; APOPTOSIS; MELANOMA; GROWTH; CELLS	Signal transducer and activator of transcription 3 (STAT3) play key roles in the intracellular signaling pathways of the interleukin (IL)-6 family of cytokines, which exhibit a diverse set of cellular responses, including cell proliferation and differentiation. Dysregulated IL-6/STAT3 signaling is involved in the pathogenesis of several diseases, for example autoimmune diseases and tumors. Type I interferon (IFN) induces the expression of proapoptotic genes and has been used in the clinical treatment of several tumors. In the present study, we found that type I IFN suppressed IL-6/STAT3-mediated transcription and gene expression. Furthermore, a type I IFN-induced protein, Daxx, also suppressed STAT3-mediated transcriptional activation, while overexpression of Daxx inhibited IL-6/STAT3-mediated gene expression. Importantly, small-interfering RNA-mediated reduction of Daxx expression enhanced IL-6/leukemia inhibitory factor (LIF)-induced STAT3-dependent transcription. Co-immunoprecipitation studies revealed a physical interaction between Daxx and STAT3 in transiently transfected 293T cells. We further found that Daxx and STAT3 were co-localized in the nucleus. These results indicate that Daxx may serve as a transcriptional regulator of type I IFN-mediated suppression of the IL-6/STAT3 signaling pathway.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Nippon Boehringer Ingelheim Co Ltd, Kawanishi Pharma Res Inst, Kawanishi, Hyogo, Japan; Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, Suita, Osaka, Japan; Kyushu Univ, Fac Med, Dept Internal Med 1, Higashi Ku, Fukuoka, Japan	Hokkaido University; Boehringer Ingelheim; Osaka University; Kyushu University	Matsuda, T (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, Kita 12 Nishi 6, Sapporo, Hokkaido 0600812, Japan.	tmatsuda@pharm.hokudai.ac.jp	Muromoto, Ryuta/E-4203-2012; Sekine, Yuichi/S-8813-2019; Matsuda, Tadashi/A-3835-2012	Muromoto, Ryuta/0000-0002-7474-493X; Sekine, Yuichi/0000-0002-2861-603X; Matsuda, Tadashi/0000-0002-3089-3757				Brender C, 2001, EXP CLIN IMMUNOGENET, V18, P80, DOI 10.1159/000049186; Bromberg J, 2000, BREAST CANCER RES, V2, P86, DOI 10.1186/bcr38; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Hollenbach AD, 2002, J CELL SCI, V115, P3319; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jelinek DF, 1997, J CLIN INVEST, V99, P447, DOI 10.1172/JCI119179; Kim EJ, 2003, NUCLEIC ACIDS RES, V31, P5356, DOI 10.1093/nar/gkg741; Kirkwood JM, 1999, MOL MED, V5, P11, DOI 10.1007/BF03402135; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Li Z, 2004, J INVEST DERMATOL, V123, P737, DOI 10.1111/j.0022-202X.2004.23408.x; Muromoto R, 2004, BIOCHEM BIOPH RES CO, V316, P827, DOI 10.1016/j.bbrc.2004.02.126; Muromoto R, 2004, J IMMUNOL, V172, P2985, DOI 10.4049/jimmunol.172.5.2985; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Shimoda K, 2002, J IMMUNOL, V169, P4707, DOI 10.4049/jimmunol.169.9.4707; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631	23	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2131	2136		10.1038/sj.onc.1209235	http://dx.doi.org/10.1038/sj.onc.1209235			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16331268	Green Submitted			2022-12-28	WOS:000236359700017
J	Filomenko, R; Prevotat, L; Rebe, C; Cortier, M; Jeannin, JF; Solary, E; Bettaieb, A				Filomenko, R.; Prevotat, L.; Rebe, C.; Cortier, M.; Jeannin, J-F; Solary, E.; Bettaieb, A.			Caspase-10 involvement in cytotoxic drug-induced apoptosis of tumor cells	ONCOGENE			English	Article						caspase-10; apoptosis; cytotoxic drug; etoposide; acute leukemia	CHEMOTHERAPY-INDUCED APOPTOSIS; ACUTE MYELOID-LEUKEMIA; COLON-CANCER CELLS; CYTOCHROME-C; MITOCHONDRIAL PATHWAYS; INACTIVATING MUTATIONS; SIGNALING PATHWAYS; ARSENIC TRIOXIDE; DEATH RECEPTOR; ACTIVATION	Anticancer drugs can induce tumor cell death by caspase-dependent apoptosis. The observation that procaspase-10 expression decreased in leukemic cells from acute myeloblastic leukemia patients at first relapse led us to explore the role of caspase-10 in cytotoxic drug-induced apoptosis. We show that caspase-10 is activated in etoposide-treated cells in a dose- and time-dependent manner. A caspase-10 peptide inhibitor, a caspase-10 dominant-negative mutant or a small interfering RNA (siRNA)-mediated downregulation of the enzyme negatively interfere with drug-induced cell death and caspase-2, -3, -8 and -9 activation. The extrinsic pathway to apoptosis is not involved in drug-induced caspase-10 activation that occurs downstream of Bax redistribution to mitochondria and cytochrome c release from this organelle. siRNA-mediated downregulation of Apaf-1 prevents etoposide-mediated activation of caspase-10. In a cell-free assay, cytochrome c and dATP treatment of cell extracts after immunodepletion of either caspase-3 or caspase-9 indicates that caspase-10 is activated downstream of caspase-9. Then, caspase-10 is involved in a feedback amplification loop that amplifies caspase-9 and -3 activities. Altogether, these data indicate an active role for caspase-10 in cytotoxic drug-induced tumor cell death, downstream of the mitochondria.	Ecole Prat Hautes Etud, IFR 100, Fac Med, INSERM,U517, F-21079 Dijon, France; CHU Bocage, Clin Hematol Unit, Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; CHU Dijon Bourgogne	Bettaieb, A (corresponding author), Ecole Prat Hautes Etud, IFR 100, Fac Med, INSERM,U517, 7 Blvd Jeanne Arc, F-21079 Dijon, France.	ali.bettaieb@u-bourgogne.fr	REBE, Cédric/AAD-4316-2019	REBE, Cédric/0000-0001-8831-145X; Bettaieb, Ali/0000-0002-6018-9592; Solary, Eric/0000-0002-8629-1341				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Decaudin D, 1998, INT J ONCOL, V12, P141; Del Poeta G, 2003, BLOOD, V101, P2125, DOI 10.1182/blood-2002-06-1714; Delmas D, 2003, J BIOL CHEM, V278, P41482, DOI 10.1074/jbc.M304896200; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Estrov Z, 1998, BLOOD, V92, P3090, DOI 10.1182/blood.V92.9.3090; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Fujita E, 2001, CELL DEATH DIFFER, V8, P335, DOI 10.1038/sj.cdd.4400824; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Harada K, 2002, CANCER RES, V62, P5897; HIDDEMANN W, 1991, ANN HEMATOL, V62, P119, DOI 10.1007/BF01702925; Hill MM, 2004, EMBO J, V23, P2134, DOI 10.1038/sj.emboj.7600210; KAMESAKI S, 1993, CANCER RES, V53, P4251; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lacour S, 2001, CANCER RES, V61, P1645; Laurent G, 2001, BLOOD, V98, P913, DOI 10.1182/blood.V98.4.913; Li J, 2002, J BIOL CHEM, V277, P49504, DOI 10.1074/jbc.M207836200; Marsden VS, 2003, ANNU REV IMMUNOL, V21, P71, DOI 10.1146/annurev.immunol.21.120601.141029; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Millet A, 2002, GASTROENTEROLOGY, V123, P235, DOI 10.1053/gast.2002.34310; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Park SJ, 2004, J BIOL CHEM, V279, P51057, DOI 10.1074/jbc.M406543200; Park WS, 2002, ONCOGENE, V21, P2919, DOI 10.1038/sj.onc.1205394; Perkins C, 1998, CANCER RES, V58, P4561; Reed JC, 1997, SEMIN HEMATOL, V34, P9; Reed JC, 2003, GENOME RES, V13, P1376, DOI 10.1101/gr.1053803; Rikhof B, 2003, CANCER BIOL THER, V2, P707; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmitt E, 1999, DRUG RESIST UPDATE, V2, P21, DOI 10.1054/drup.1999.0065; Shin MS, 2002, BLOOD, V99, P4094, DOI 10.1182/blood.V99.11.4094; Shin MS, 2002, ONCOGENE, V21, P4129, DOI 10.1038/sj.onc.1205527; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sordet O, 2001, BLOOD, V97, P3931, DOI 10.1182/blood.V97.12.3931; Svingen PA, 2000, BLOOD, V96, P3922, DOI 10.1182/blood.V96.12.3922.h8003922_3922_3931; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	51	25	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2006	25	58					7635	7645		10.1038/sj.onc.1209733	http://dx.doi.org/10.1038/sj.onc.1209733			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	16767158				2022-12-28	WOS:000242655500008
J	Schmitz, I; Meyer, C; Schulze-Osthoff, K				Schmitz, I.; Meyer, C.; Schulze-Osthoff, K.			CD95 ligand mediates T-cell receptor-induced apoptosis of a CD4(+) CD8(+) double positive thymic lymphoma	ONCOGENE			English	Article						apoptosis; caspase; CD95; thymic lymphoma; thymus	NEGATIVE SELECTION; THYMOCYTE DEVELOPMENT; CASPASE INHIBITOR; C-FLIPSHORT; IN-VITRO; KAPPA-B; ACTIVATION; DEATH; MICE; GENES	Tumors in the thymus can be of different cellular origin. Among the most common tumors are thymoma and lymphoma, which are derived from transformed thymic epithelial cells and transformed lymphocytes, respectively. Thymic lymphoma and their response to apoptotic stimuli are poorly characterized. Here, we analyse apoptosis events in the thymic lymphoma cell line Thy278, which expresses cell surface antigens characteristic of immature double positive thymocytes. Upon T-cell receptor (TCR)/CD3 stimulation, Thy278 cells die by apoptosis, similar as primary thymocytes during negative selection. Caspases are crucial for deletion of both Thy278cells and normal thymocytes. Moreover, we show that deletion of primary thymocytes and Thy278 cells upon CD3 stimulation is considerably impaired by neutralizing CD95L antibody. Thus, our results not only demonstrate that TCR-induced apoptosis is still functional in transformed thymocytes, but also suggest that Thy278 cells are a helpful model for the molecular analysis of negative selection.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Schmitz, I (corresponding author), Univ Dusseldorf, Inst Mol Med, Univ Str 1,Bldg 23-12, D-40225 Dusseldorf, Germany.	ingo-schmitz@uni-duesseldorf.de	Schulze-Osthoff, Klaus/N-9025-2013; Schmitz, Ingo/G-2093-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Schmitz, Ingo/0000-0002-5360-0419				AISENBERG AC, 1993, J CLIN ONCOL, V11, P2291, DOI 10.1200/JCO.1993.11.12.2291; Alam A, 1997, J EXP MED, V186, P1503, DOI 10.1084/jem.186.9.1503; BERG LJ, 1988, MOL CELL BIOL, V8, P5459, DOI 10.1128/MCB.8.12.5459; BOEHM T, 1989, FASEB J, V3, P2344, DOI 10.1096/fasebj.3.12.2676678; Caserta TM, 2003, APOPTOSIS, V8, P345, DOI 10.1023/A:1024116916932; Castro JE, 1996, IMMUNITY, V5, P617, DOI 10.1016/S1074-7613(00)80275-7; CHAHINIAN AP, 2003, CANC MED, V2, P1467; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Clayton LK, 1997, EMBO J, V16, P2282, DOI 10.1093/emboj/16.9.2282; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; Doerfler P, 2000, J IMMUNOL, V164, P4071, DOI 10.4049/jimmunol.164.8.4071; Fernandez E, 2000, BLOOD, V95, P1356, DOI 10.1182/blood.V95.4.1356.004k23_1356_1361; Fischer U, 2005, PHARMACOL REV, V57, P187, DOI 10.1124/pr.57.2.6; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Geisler C, 2004, CRIT REV IMMUNOL, V24, P67; GROVES T, 1995, J IMMUNOL, V154, P5011; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Izquierdo M, 1999, EMBO J, V18, P156, DOI 10.1093/emboj/18.1.156; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; KAYE J, 1992, CELL, V71, P423, DOI 10.1016/0092-8674(92)90512-B; Kirchhoff S, 2000, EUR J IMMUNOL, V30, P2765, DOI 10.1002/1521-4141(200010)30:10<2765::AID-IMMU2765>3.0.CO;2-W; Kovalik JP, 1996, J IMMUNOL, V157, P5290; Legembre P, 2004, EMBO REP, V5, P1084, DOI 10.1038/sj.embor.7400280; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Maeda T, 1999, J EXP MED, V189, P1063, DOI 10.1084/jem.189.7.1063; Martin DA, 1999, P NATL ACAD SCI USA, V96, P4552, DOI 10.1073/pnas.96.8.4552; Matiba B, 1997, Semin Immunol, V9, P59, DOI 10.1006/smim.1996.0054; Moulian N, 1998, SEMIN IMMUNOL, V10, P449, DOI 10.1006/smim.1998.0155; Muschen M, 2002, TRENDS IMMUNOL, V23, P75, DOI 10.1016/S1471-4906(01)02115-9; NAMBA T, 1978, MEDICINE, V57, P411, DOI 10.1097/00005792-197809000-00002; Nishida T, 2004, J IMMUNOL, V172, P6634, DOI 10.4049/jimmunol.172.11.6634; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; RATHMELL JC, 2002, CELL S, V109, P97; Reichmann E, 2002, SEMIN CANCER BIOL, V12, P309, DOI 10.1016/S1044-579X(02)00017-2; ROSAI J, 1976, ATLAS TUMOR PATHOLOG; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sasada T, 2001, J IMMUNOL, V166, P2394, DOI 10.4049/jimmunol.166.4.2394; Schmitz I, 2004, J IMMUNOL, V172, P2194, DOI 10.4049/jimmunol.172.4.2194; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; SIDMAN CL, 1992, EUR J IMMUNOL, V22, P499, DOI 10.1002/eji.1830220231; Sohn D, 2006, MOL CELL BIOL, V26, P1967, DOI 10.1128/MCB.26.5.1967-1978.2006; Starr TK, 2003, ANNU REV IMMUNOL, V21, P139, DOI 10.1146/annurev.immunol.21.120601.141107; Venanzi ES, 2004, CURR OPIN IMMUNOL, V16, P197, DOI 10.1016/j.coi.2004.01.008; WADSWORTH S, 1990, EUR J IMMUNOL, V20, P723, DOI 10.1002/eji.1830200403; Yefenof E, 1999, ADV IMMUNOL, V73, P511, DOI 10.1016/S0065-2776(08)60792-0	49	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2006	25	58					7587	7596		10.1038/sj.onc.1209741	http://dx.doi.org/10.1038/sj.onc.1209741			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	16767155				2022-12-28	WOS:000242655500004
J	Janda, E; Nevolo, M; Lehmann, K; Downward, J; Beug, H; Grieco, M				Janda, E.; Nevolo, M.; Lehmann, K.; Downward, J.; Beug, H.; Grieco, M.			Raf plus TGF beta-dependent EMT is initiated by endocytosis and lysosomal degradation of E-cadherin	ONCOGENE			English	Article						E-cadherin; Raf; TGFbeta; EMT; endocytosis; monoubiquitination	EPITHELIAL-MESENCHYMAL TRANSITIONS; TRANSCRIPTION FACTOR SNAIL; CELL-ADHESION MOLECULE; TUMOR-CELLS; EXPRESSION; PLASTICITY; MECHANISM; PROTEIN; TRANSFORMATION; PROGRESSION	Oncogenic Ras interferes with adhesive functions of epithelial cells, but requires tumor growth factor beta (TGF beta) signaling to cause epithelial-mesenchymal transition (EMT) and tumor progression in model systems. To investigate the mechanisms by which Ras and TGFb pathways cooperate in EMT induction, we introduced a tamoxifen-inducible version of Raf-1 (RafER) into fully polarized, mammary epithelial cells (EpH4). EMT characterized by loss of E-cadherin expression and upregulation of invasiveness-promoting genes was induced by TGF beta plus 4-hydroxytamoxifen (4HT) activation of RafER. Downregulation of E-cadherin by RafER plus TGF beta was detectable in total cell lysates after 48 h and much earlier in detergent-insoluble fractions of E-cadherin. Both pathways cooperated to strongly enhance endocytosis of E-cadherin, mainly via the clathrin-dependent route. Pulse-chase experiments showed decreased E-cadherin protein stability in cells stimulated with TGF beta and 4HT and increased E-cadherin half-life in the presence of monensin. Monensin and chloroquine prevented E-cadherin degradation to different extent, but only monensin effectively blocked the loss of E-cadherin from the junctional complexes. Both lysosome inhibitors caused accumulation of E-cadherin vesicles, some of which were positive for Cathepsin D and lysosome-associated membrane protein 1 (LAMP-1). In addition, TGF beta and mitogen-activated protein kinase hyperactivation synergistically induced E-cadherin ubiquitination, suggesting that the cooperation of Raf and TGF beta favors lysosomal degradation of E-cadherin instead of its recycling. Our data indicate that early stages of EMT involve cooperative, post-translational downregulation of E-cadherin, whereas loss of E-cadherin via transcriptional repression is a late event in EMT.	Univ Magna Graecia, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; Imperial Canc Res Fund, Signal Transduct Labs, London WC2A 3PX, England; Res Inst Mol Pathol, A-1030 Vienna, Austria	Magna Graecia University of Catanzaro; Cancer Research UK; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Grieco, M (corresponding author), Univ Magna Graecia, Dipartimento Med Sperimentale & Clin, Campus Germaneto Livello 7, I-88100 Catanzaro, Italy.	mgrieco@unicz.it	Downward, Julian/A-3251-2012; Janda, Elzbieta/AFQ-7061-2022; Janda, Elzbieta/AAD-5126-2022	Janda, Elzbieta/0000-0002-6787-7291; Janda, Elzbieta/0000-0002-6787-7291; Downward, Julian/0000-0002-2331-4729; Grieco, Michele/0000-0002-4212-7814				Akhtar N, 2001, MOL BIOL CELL, V12, P847, DOI 10.1091/mbc.12.4.847; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Harbeck N, 1999, BREAST CANCER RES TR, V54, P147, DOI 10.1023/A:1006118828278; Ivanov AI, 2004, MOL BIOL CELL, V15, P176, DOI 10.1091/mbc.E03-05-0319; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Janda E, 2002, ONCOGENE, V21, P5148, DOI 10.1038/sj.onc.1205661; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; Kemler R, 1992, Semin Cell Biol, V3, P149; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; Negroiu G, 2005, BIOCHEM BIOPH RES CO, V328, P914, DOI 10.1016/j.bbrc.2005.01.040; NOSE A, 1986, J CELL BIOL, V103, P2649, DOI 10.1083/jcb.103.6.2649; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Palacios F, 2005, MOL CELL BIOL, V25, P389, DOI 10.1128/MCB.25.1.389-402.2005; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; Rios-Doria J, 2003, J BIOL CHEM, V278, P1372, DOI 10.1074/jbc.M208772200; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Shen L, 2005, MOL BIOL CELL, V16, P3919, DOI 10.1091/mbc.E04-12-1089; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Sun DZ, 2000, DEV BIOL, V228, P337, DOI 10.1006/dbio.2000.9946; Szuts D, 1998, GENE DEV, V12, P2022, DOI 10.1101/gad.12.13.2022; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Viebahn C, 1995, ACTA ANAT, V154, P79; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Wu XF, 2001, J CELL BIOL, V155, P291, DOI 10.1083/jcb.200104085; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhu WJ, 2001, EMBO J, V20, P5999, DOI 10.1093/emboj/20.21.5999	38	118	122	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	54					7117	7130		10.1038/sj.onc.1209701	http://dx.doi.org/10.1038/sj.onc.1209701			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16751808				2022-12-28	WOS:000242046900001
J	Balavenkatraman, KK; Jandt, E; Friedrich, K; Kautenburger, T; Pool-Zobel, B; Ostman, A; Bohmer, FD				Balavenkatraman, K. K.; Jandt, E.; Friedrich, K.; Kautenburger, T.; Pool-Zobel, B. L.; Ostman, A.; Boehmer, F. D.			DEP-1 protein tyrosine phosphatase inhibits proliferation and migration of colon carcinoma cells and is upregulated by protective nutrients	ONCOGENE			English	Article						protein-tyrosine phosphatase; colon cancer; DEP-1; cell migration; cell proliferation	GLUTATHIONE S-TRANSFERASES; GROWTH-FACTOR RECEPTOR; IN-VITRO; ETA SUPPRESSES; CANCER CELLS; EXPRESSION; DEPHOSPHORYLATION; CARCINOGENESIS; ACTIVATION; ADHESION	The transmembrane protein-tyrosine phosphatase (PTP) DEP-1 (density-enhanced phosphatase) is a candidate tumor suppressor in the colon epithelium. We have explored the function of DEP-1 in colon epithelial cells by inducible re-expression in a DEP-1- deficient human colon cancer cell line. Density-enhanced phosphatase-1 re-expression led to profound inhibition of cell proliferation and cell migration, and was associated with cytoskeletal rearrangements. These effects were dependent on the PTP activity of DEP-1 as they were not observed with cells expressing the catalytically inactive DEP-1 C1239S variant. shRNA-mediated suppression of DEP-1 in a colon epithelial cell line with high endogenous DEP-1 levels enhanced proliferation, further supporting the antiproliferative function of DEP-1. Nutrients, which are considered to be chemoprotective with respect to colon cancer development, including butyrate, green tea and apple polyphenols, had the capacity to elevate transcription of endogenous DEP-1 mRNA and expression of DEP-1 protein. Upregulation of DEP-1 expression, and in turn inhibition of cell growth and migration may present a previously unrecognized mechanism of chemoprevention by nutrients.	Univ Jena, Fac Med, Inst Mol Cell Biol, D-07747 Jena, Germany; Univ Jena, Fac Med, Inst Biochem 1, D-6900 Jena, Germany; Univ Jena, Inst Nutr, Dept Nutr Toxicol, D-6900 Jena, Germany; Karolinska Inst, Ctr Canc, Stockholm, Sweden	Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Karolinska Institutet	Bohmer, FD (corresponding author), Univ Jena, Fac Med, Inst Mol Cell Biol, Drackendorfer Str 1, D-07747 Jena, Germany.	i5frbo@rz.uni-jena.de						Barth SW, 2005, CARCINOGENESIS, V26, P1414, DOI 10.1093/carcin/bgi082; Glei M, 2003, TOXICOL IN VITRO, V17, P723, DOI 10.1016/S0887-2333(03)00099-7; Gosse F, 2005, CARCINOGENESIS, V26, P1291, DOI 10.1093/carcin/bgi074; Iuliano R, 2003, CANCER RES, V63, P882; Jandt E, 2003, ONCOGENE, V22, P4175, DOI 10.1038/sj.onc.1206652; KAUTENBURGER T, 2006, IN PRESS INT J CANC; Keane MM, 1996, CANCER RES, V56, P4236; Kellie S, 2004, J CELL SCI, V117, P609, DOI 10.1242/jcs.00879; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; Le Pera I, 2005, ONCOGENE, V24, P3187, DOI 10.1038/sj.onc.1208510; Massa A, 2004, J BIOL CHEM, V279, P29004, DOI 10.1074/jbc.M403573200; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Pool-Zobel B, 2005, MUTAT RES-FUND MOL M, V591, P74, DOI 10.1016/j.mrfmmm.2005.04.020; Pool-Zobel BL, 2005, CARCINOGENESIS, V26, P1064, DOI 10.1093/carcin/bgi059; Richter M, 2002, EUR J CANCER, V38, P1937, DOI 10.1016/S0959-8049(02)00158-2; Ruivenkamp C, 2003, ONCOGENE, V22, P3472, DOI 10.1038/sj.onc.1206246; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; Shimizu M, 2005, CLIN CANCER RES, V11, P2735, DOI 10.1158/1078-0432.CCR-04-2014; Takahashi T, 2003, MOL CELL BIOL, V23, P1817, DOI 10.1128/MCB.23.5.1817-1831.2003; Tenev T, 2000, EUR J CELL BIOL, V79, P261, DOI 10.1078/S0171-9335(04)70029-1; Trapasso F, 2004, CARCINOGENESIS, V25, P2107, DOI 10.1093/carcin/bgh224; Trapasso F, 2000, MOL CELL BIOL, V20, P9236, DOI 10.1128/MCB.20.24.9236-9246.2000	24	65	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2006	25	47					6319	6324		10.1038/sj.onc.1209647	http://dx.doi.org/10.1038/sj.onc.1209647			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	094CY	16682945				2022-12-28	WOS:000241218200008
J	Hill, A; McFarlane, S; Mulligan, K; Gillespie, H; Draffin, JE; Trimble, A; Ouhtit, A; Johnston, PG; Harkin, DP; McCormick, D; Waugh, DJJ				Hill, A.; McFarlane, S.; Mulligan, K.; Gillespie, H.; Draffin, J. E.; Trimble, A.; Ouhtit, A.; Johnston, P. G.; Harkin, D. P.; McCormick, D.; Waugh, D. J. J.			Cortactin underpins CD44-promoted invasion and adhesion of breast cancer cells to bone marrowendothelial cells	ONCOGENE			English	Article						CD44; cortactin; breast cancer; metastasis; invasion	CYTOSKELETON FUNCTION; EXTRACELLULAR-MATRIX; CD44 INTERACTION; PROMOTES; HYALURONAN; KINASE; CARCINOMA; MIGRATION; EMS1; IDENTIFICATION	Using a validated tetracycline (tet)-regulated MCF7-founder (MCF7F) expression system to modulate expression of CD44 standard form (CD44s), we report the functional importance of CD44s and that of a novel transcriptional target of hyaluronan (HA)/CD44s signaling, EMS1/cortactin, in underpinning breast cancer metastasis. In functional experiments, tet-regulated induction of CD44s potentiated the migration and invasion of MCF7F cells through HA-supplemented Matrigel. EMS1/cortactin was identified by expression profiling as a novel transcriptional target of HA/CD44 signaling, an association validated by quantitative PCR and immunoblotting experiments in a range of breast cancer cell lines. The mechanistic basis underpinning CD44-promoted transcription of EMS1/cortactin was shown to be dependent upon a NF kappa B mechanism, since pharmacological inhibition of I kappa Kinase-2 or suppression of p65 Rel A expression attenuated CD44-induced increases in cortactin mRNA transcript levels. Overexpression of a c-myc tagged murine cortactin construct in the weakly invasive, CD44-deficient MCF7F and T47D cells potentiated their invasion. Furthermore, the functional importance of cortactin to CD44s-promoted metastasis was demonstrated by selective suppression of cortactin in CD44-expressing MCF7F-B5 and MDA-MB-231 breast cancer cells using RNAi, which was shown to result in attenuated CD44-promoted invasion and CD44-promoted adhesion to bone marrow endothelial cells (BMECs).	Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast City Hosp, Belfast BT9 7AB, Antrim, North Ireland	Belfast City Hospital; Queens University Belfast	Waugh, DJJ (corresponding author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast City Hosp, Univ Floor,Lisburn Rd, Belfast BT9 7AB, Antrim, North Ireland.	d.waugh@qub.ac.uk		WAUGH, DAVID/0000-0002-4022-3765	MRC [G0200103] Funding Source: UKRI; Medical Research Council [G0200103] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Arderiu G, 2002, BIOCHEM J, V364, P65, DOI 10.1042/bj3640065; Auvinen P, 2000, AM J PATHOL, V156, P529, DOI 10.1016/S0002-9440(10)64757-8; Berner HS, 2001, BREAST CANCER RES TR, V65, P23, DOI 10.1023/A:1006417412046; Bourguignon LYW, 2004, J BIOL CHEM, V279, P29654, DOI 10.1074/jbc.M403608200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Bourguignon LYW, 1999, CELL MOTIL CYTOSKEL, V43, P269, DOI 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Bryce NS, 2005, CURR BIOL, V15, P1276, DOI 10.1016/j.cub.2005.06.043; Draffin JE, 2004, CANCER RES, V64, P5702, DOI 10.1158/0008-5472.CAN-04-0389; Fitzgerald KA, 2000, J IMMUNOL, V164, P2053, DOI 10.4049/jimmunol.164.4.2053; Herrera-Gayol A, 2001, INT J EXP PATHOL, V82, P193, DOI 10.1111/j.1365-2613.2001.iep196.x; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Hui R, 1997, ONCOGENE, V15, P1617, DOI 10.1038/sj.onc.1201311; Isacke CM, 2002, INT J BIOCHEM CELL B, V34, P718, DOI 10.1016/S1357-2725(01)00166-2; Kinoshita J, 1999, BREAST CANCER RES TR, V53, P177, DOI 10.1023/A:1006130601575; Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911-005-5399-8; Lee JY, 2000, CURR OPIN CELL BIOL, V12, P581, DOI 10.1016/S0955-0674(00)00135-6; LESTER BR, 1992, CANCER METAST REV, V11, P31, DOI 10.1007/BF00047601; Li YS, 2001, CANCER RES, V61, P6906; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; Monaghan M, 2000, J PATHOL, V192, P519; Mullins RD, 2000, CURR OPIN CELL BIOL, V12, P91, DOI 10.1016/S0955-0674(99)00061-7; Oliferenko S, 2000, J CELL BIOL, V148, P1159, DOI 10.1083/jcb.148.6.1159; Rodrigo JP, 2000, CLIN CANCER RES, V6, P3177; SAYEGH TY, 2005, MOL BIOL CELL, V12, P5514; SCHUURING E, 1992, ONCOGENE, V7, P355; Tilghman RW, 2002, FASEB J, V16, P1257, DOI 10.1096/fj.01-0969fje; Timpson P, 2005, CANCER RES, V65, P3273, DOI 10.1158/0008-5472.CAN-04-2118; Toole BP, 2002, GLYCOBIOLOGY, V12, p37R, DOI 10.1093/glycob/12.3.37R; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; van Rossum AGSH, 2005, BREAST CANCER RES, V7, P235, DOI 10.1186/bcr1316; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Weber GF, 2002, CANCER RES, V62, P2281; Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002; Zhu D, 1998, CELL MOTIL CYTOSKEL, V39, P209, DOI 10.1002/(SICI)1097-0169(1998)39:3<209::AID-CM4>3.0.CO;2-#	39	96	98	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6079	6091		10.1038/sj.onc.1209628	http://dx.doi.org/10.1038/sj.onc.1209628			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16652145				2022-12-28	WOS:000241101200005
J	Massimi, P; Narayan, N; Cuenda, A; Banks, L				Massimi, P.; Narayan, N.; Cuenda, A.; Banks, L.			Phosphorylation of the discs large tumour suppressor protein controls its membrane localisation and enhances its susceptibility to HPV E6-induced degradation	ONCOGENE			English	Article						Dlg; HPV; JNK; proteasome	PAPILLOMAVIRUS E6 PROTEINS; PROTEASOME-MEDIATED DEGRADATION; HIGH-RISK; HUMAN HOMOLOG; ADENOVIRUS E4-ORF1; CELL POLARITY; ACTIN MOTOR; MYOSIN-VI; ONCOPROTEINS; EXPRESSION	The Discs Large (Dlg) protein is intimately involved in regulating cell polarity and cell proliferation, and is targeted by the high-risk Human Papillomavirus (HPV) E6 proteins for proteasome-mediated degradation. We show here that exposure of cells to osmotic shock induces the hyperphosphorylation of Dlg and its concomitant accumulation within the cell membrane at sites of cell contact, a process that requires an intact actin. lament network. In addition, hyperphosphorylation of Dlg also renders it more susceptible to degradation induced by the HPV-18 E6 oncoprotein. Mutational analysis of Dlg identifies a region within the first 185 amino acids as being important for this, with phosphorylation on residue S158 being responsible for its enhanced targeting by the E6 oncoprotein. Using specific kinase inhibitors, we show that Jun N-terminal kinase (JNK) is in part responsible for this phosphorylation, and for the subsequent Dlg accumulation at sites of cell contact. These results further support the notion of a complex phosphorylation-dependent regulation of Dlg, both with respect to its precise cellular localisation and to its susceptibility to proteasome-mediated degradation.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Univ Dundee, MRC, Prot Phosphorylat Unit, Dundee DD1 4HN, Scotland; Univ Extremadura, Fac Vet, Dipartimento Bioquim & Biol Mol, Caceres, Spain	International Center for Genetic Engineering & Biotechnology (ICGEB); University of Dundee; Universidad de Extremadura	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	banks@icgeb.org						Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Buss F, 2002, TRAFFIC, V3, P851, DOI 10.1034/j.1600-0854.2002.31201.x; Caruana G, 2001, MOL CELL BIOL, V21, P1475, DOI 10.1128/MCB.21.5.1475-1483.2001; Cavatorta AL, 2004, INT J CANCER, V111, P373, DOI 10.1002/ijc.20275; Fuja TJ, 2004, CANCER RES, V64, P942, DOI 10.1158/0008-5472.CAN-03-2100; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 2002, J GEN VIROL, V83, P283, DOI 10.1099/0022-1317-83-2-283; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Guccione E, 2002, VIROLOGY, V293, P20, DOI 10.1006/viro.2001.1290; Hanada T, 2000, J BIOL CHEM, V275, P28774, DOI 10.1074/jbc.M000715200; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Mantovani F, 2001, J CELL SCI, V114, P4285; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Massimi P, 2004, ONCOGENE, V23, P8033, DOI 10.1038/sj.onc.1207977; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Nguyen MM, 2003, MOL CELL BIOL, V23, P8970, DOI 10.1128/MCB.23.24.8970-8981.2003; Sabio G, 2005, EMBO J, V24, P1134, DOI 10.1038/sj.emboj.7600578; Song S, 2000, VIROLOGY, V267, P141, DOI 10.1006/viro.1999.0106; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Watson RA, 2003, J CELL SCI, V116, P4925, DOI 10.1242/jcs.00809; Watson RA, 2002, CARCINOGENESIS, V23, P1791, DOI 10.1093/carcin/23.11.1791; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; Wu HJ, 2002, J BIOL CHEM, V277, P30928, DOI 10.1074/jbc.M203735200; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	32	49	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2006	25	31					4276	4285		10.1038/sj.onc.1209457	http://dx.doi.org/10.1038/sj.onc.1209457			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16532034				2022-12-28	WOS:000239240100003
J	Cao, X; Qin, J; Xie, Y; Khan, O; Dowd, F; Scofield, M; Lin, MF; Tu, Y				Cao, X.; Qin, J.; Xie, Y.; Khan, O.; Dowd, F.; Scofield, M.; Lin, M-F; Tu, Y.			Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells	ONCOGENE			English	Article						RGS2; GPCRs; extracellular signal-regulated; kinases; prostate cancer; androgen receptor; androgen independence	PROTEIN-COUPLED RECEPTOR; LOOP-HELIX PHOSPHOPROTEIN; MESSENGER-RNA; NERVOUS-SYSTEM; ALPHA SUBUNITS; SIGNALING RGS; TARGET GENE; LNCAP CELLS; MAP KINASE; EXPRESSION	Hormones acting through G protein-coupled receptors ( GPCRs) can cause androgen-independent activation of androgen receptor ( AR) in prostate cancer cells. Regulators of G-protein signaling ( RGS) proteins, through their GTPase activating protein ( GAP) activities, inhibit GPCR-mediated signaling by inactivating G proteins. Here, we identified RGS2 as a gene specifically downregulated in androgen-independent prostate cancer cells. Expression of RGS2, but not other RGS proteins, abolished androgen-independent AR activity in androgen-independent LNCaP cells and CWR22Rv1 cells. In LNCaP cells, RGS2 inhibited G(q)-coupled GPCR signaling. Expression of exogenous wild-type RGS2, but not its GAP-deficient mutant, significantly reduced AR activation by constitutively activated G(q)Q209L mutant whereas silencing endogenous RGS2 by siRNA enhanced G(q)Q209L-stimulated AR activity. RGS2 had no effect on RGS-insensitive G(q)Q209L/G188S-induced AR activation. Furthermore, extracellular signal-regulated kinase 1/2 ( ERK1/2) was found to be involved in RGS2-mediated regulation of androgen-independent AR activity. In addition, RGS2 functioned as a growth suppressor for androgen-independent LNCaP cells whereas androgen-sensitive LNCaP cells with RGS2 silencing had a growth advantage under steroid-reduced conditions. Finally, RGS2 expression level was significantly decreased in human prostate tumor specimens. Taken together, our results suggest RGS2 as a novel regulator of AR signaling and its repression may be an important step during prostate tumorigenesis and progression.	Creighton Univ, Sch Med, Dept Pharmacol, Omaha, NE 68178 USA; Univ Nebraska, Ctr Med, Dept Biochem & Mol Biol, Omaha, NE 68198 USA	Creighton University; University of Nebraska System	Tu, Y (corresponding author), Creighton Univ, Sch Med, Dept Pharmacol, 2500 Calif Pl, Omaha, NE 68178 USA.	Yat60399@creighton.edu		Khan, Obaid/0000-0002-5596-2122; Scofield, Margaret/0000-0002-9332-1641	NATIONAL CANCER INSTITUTE [R01CA088184] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018759] Funding Source: NIH RePORTER; NCI NIH HHS [CA88184] Funding Source: Medline; NCRR NIH HHS [P20 RR018759] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Abrahamsson PA, 1999, ENDOCR-RELAT CANCER, V6, P503, DOI 10.1677/erc.0.0060503; Bakin RE, 2003, CANCER RES, V63, P1981; Ben-Josef E, 1999, J UROLOGY, V161, P970, DOI 10.1016/S0022-5347(01)61831-7; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Burchett SA, 1999, J NEUROCHEM, V72, P1529, DOI 10.1046/j.1471-4159.1999.721529.x; Candas B, 2000, PROSTATE, V45, P19; Chay CH, 2002, UROLOGY, V60, P760, DOI 10.1016/S0090-4295(02)01969-6; CHODAK GW, 1992, J UROLOGY, V147, P798, DOI 10.1016/S0022-5347(17)37389-5; Collier LS, 2005, NATURE, V436, P272, DOI 10.1038/nature03681; Cunningham JM, 1996, CANCER RES, V56, P4475; DAAKA Y, 2004, SCI STKE, V216, P2; Dai J, 2002, CLIN CANCER RES, V8, P2399; Denmeade SR, 2003, PROSTATE, V54, P249, DOI 10.1002/pros.10199; DiBello PR, 1998, J BIOL CHEM, V273, P5780, DOI 10.1074/jbc.273.10.5780; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; Gioeli D, 1999, CANCER RES, V59, P279; Gohji K, 2001, J UROLOGY, V165, P1033, DOI 10.1016/S0022-5347(05)66597-4; Grillet N, 2003, J NEUROSCI, V23, P10613; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Guha M, 2001, BLOOD, V98, P1429, DOI 10.1182/blood.V98.5.1429; GUTKIND JS, 2000, SCI STKE, V40, P1; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; Hains MD, 2004, METHOD ENZYMOL, V389, P71; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Heximer SP, 2003, J CLIN INVEST, V111, P445, DOI 10.1172/JC1200315598; Hobisch A, 1996, PROSTATE, V28, P129; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; Ingi T, 1998, J NEUROSCI, V18, P7178; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kammermeier PJ, 1999, NEURON, V22, P819, DOI 10.1016/S0896-6273(00)80740-0; Karan D, 2001, CLIN CANCER RES, V7, P3472; Karan D, 2002, CARCINOGENESIS, V23, P967, DOI 10.1093/carcin/23.6.967; Kasbohm EA, 2005, J BIOL CHEM, V280, P11583, DOI 10.1074/jbc.M414423200; Kehrl JH, 2002, INT J BIOCHEM CELL B, V34, P432, DOI 10.1016/S1357-2725(01)00141-8; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Lee MS, 2003, ONCOGENE, V22, P781, DOI 10.1038/sj.onc.1206066; Lee YF, 2002, CANCER RES, V62, P6039; Lin HK, 2003, J BIOL CHEM, V278, P50902, DOI 10.1074/jbc.M300676200; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; Nelson JB, 1996, CANCER RES, V56, P663; Neubig RR, 2002, NAT REV DRUG DISCOV, V1, P187, DOI 10.1038/nrd747; Oliveira-dos-Santos AJ, 2000, P NATL ACAD SCI USA, V97, P12272, DOI 10.1073/pnas.220414397; Porter AT, 2001, UROL ONCOL, V6, P131, DOI 10.1016/S1078-1439(00)00124-1; Posner BA, 1999, BIOCHEMISTRY-US, V38, P7773, DOI 10.1021/bi9906367; Robinet EA, 2001, NEUROREPORT, V12, P1731, DOI 10.1097/00001756-200106130-00043; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Ross EM, 1999, CRC METH SIG TRANS, P123; Roy AA, 2003, MOL PHARMACOL, V64, P587, DOI 10.1124/mol.64.3.587; SADI MV, 1991, CANCER, V67, P3057, DOI 10.1002/1097-0142(19910615)67:12<3057::AID-CNCR2820671221>3.0.CO;2-S; Salim S, 2003, J BIOL CHEM, V278, P15842, DOI 10.1074/jbc.M210663200; Sato N, 1997, J BIOL CHEM, V272, P17485, DOI 10.1074/jbc.272.28.17485; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Schwable J, 2005, BLOOD, V105, P2107, DOI 10.1182/blood-2004-03-0940; SHAH GV, 1994, ENDOCRINOLOGY, V134, P596, DOI 10.1210/en.134.2.596; SIDEROVSKI DP, 1994, DNA CELL BIOL, V13, P125, DOI 10.1089/dna.1994.13.125; Sinnarajah S, 2001, NATURE, V409, P1051, DOI 10.1038/35059104; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; Tang M, 2003, NAT MED, V9, P1506, DOI 10.1038/nm958; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; Taub JS, 2003, CANCER RES, V63, P2037; Tepper CG, 2002, CANCER RES, V62, P6606; Thebault S, 2003, J CLIN INVEST, V111, P1691, DOI 10.1172/JCI200316293; Tovey SC, 2004, MOL PHARMACOL, V66, P1453, DOI 10.1124/mol.104.005827; Tu YP, 2001, J BIOL CHEM, V276, P20160, DOI 10.1074/jbc.M101599200; Unni E, 2004, CANCER RES, V64, P7156, DOI 10.1158/0008-5472.CAN-04-1121; Weng JS, 2005, INT J CANCER, V113, P811, DOI 10.1002/ijc.20635; Wieland T, 2003, PHARMACOL THERAPEUT, V97, P95, DOI 10.1016/S0163-7258(02)00326-1; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; WU HK, 1995, LEUKEMIA, V9, P1291; Xia CZ, 2001, ONCOGENE, V20, P5903, DOI 10.1038/sj.onc.1204803; Xie YH, 2002, J BIOL CHEM, V277, P32516, DOI 10.1074/jbc.M203864200; Xu LL, 2000, CANCER RES, V60, P6568; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458	78	80	84	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3719	3734		10.1038/sj.onc.1209408	http://dx.doi.org/10.1038/sj.onc.1209408			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16449965				2022-12-28	WOS:000238448300011
J	Chung, J; Roberts, AM; Chow, J; Coady-Osberg, N; Ohh, M				Chung, J.; Roberts, A. M.; Chow, J.; Coady-Osberg, N.; Ohh, M.			Homotypic association between tumour-associated VHL proteins leads to the restoration of HIF pathway	ONCOGENE			English	Article						VHL; ECV; e3; HIF; homotypic association	HIPPEL-LINDAU PROTEIN; SUPPRESSOR PROTEIN; GERMLINE DELETION; COMPLEX; MUTATIONS; HYDROXYLATION; CORRELATE; DISEASE; BINDING; LIGASE	The von Hippel-Lindau (VHL) tumour suppressor gene encodes a substrate-specifying component of an E3 ubiquitin ligase that targets hypoxia-inducible factor (HIF) alpha subunits for degradation under normoxia. The VHL protein is composed of an N-terminal HIF alpha-binding ss domain and a C-terminal alpha domain, which is necessary and sufficient for the formation of the E3 multiprotein enzyme. A large number of disease-causing mutations in either the alpha or ss domain renders HIF alpha stable irrespective of oxygen tension, leading to the upregulation of numerous HIF-target genes, such as GLUT1 and VEGF. Here, we show that VHL forms a self-associated complex in vivo, but not in vitro, and demonstrate that coexpression of two different VHL missense mutants - one in the a domain and the other in the ss domain - restores HIF-mediated gene expression profile. These findings indicate that VHL homotypic complexes can function in vivo in a complementary fashion to target HIF alpha for ubiquitinmediated proteolysis, and potentially explain why VHL-associated tumours witha missense mutation-carrying VHL allele is almost invariably accompanied by a second VHL allele harbouring a gross truncation or deletion.	Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Med Genet, Toronto, ON, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Ohh, M (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, Med Sci Bldg,Room 6303,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	michael.ohh@utoronto.ca						Ang SO, 2002, NAT GENET, V32, P614, DOI 10.1038/ng1019; Bradley JF, 1999, AM J MED GENET, V87, P163, DOI 10.1002/(SICI)1096-8628(19991119)87:2<163::AID-AJMG7>3.0.CO;2-A; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KONDO K, 2002, CANCER CELL, V1, P211; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Maynard MA, 2003, J BIOL CHEM, V278, P11032, DOI 10.1074/jbc.M208681200; Ohh M, 1999, J CLIN INVEST, V104, P1583, DOI 10.1172/JCI8161; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Vortmeyer A, 2002, ONCOGENE, V21, P1167, DOI 10.1038/sj.onc.1205121; Wait SD, 2004, ANN NEUROL, V55, P236, DOI 10.1002/ana.10807	17	13	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					3079	3083		10.1038/sj.onc.1209328	http://dx.doi.org/10.1038/sj.onc.1209328			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16407835	Bronze			2022-12-28	WOS:000237950800013
J	Duensing, A; Liu, Y; Tseng, M; Malumbres, M; Barbacid, M; Duensing, S				Duensing, A.; Liu, Y.; Tseng, M.; Malumbres, M.; Barbacid, M.; Duensing, S.			Cyclin-dependent kinase 2 is dispensable for normal centrosome duplication but required for oncogene-induced centrosome overduplication	ONCOGENE			English	Article						centrosome; CDK2; HPV-16 E7; genomic instability	CELL-DIVISION; PRIMARY CILIA; CDK2; IMMORTALIZATION	Cyclin- dependent kinase 2 ( CDK2) has been proposed to function as a master regulator of centrosome duplication. Using mouse embryonic. broblasts ( MEFs) in which Cdk2 has been genetically deleted, we show here that CDK2 is not required for normal centrosome duplication, maturation and bipolar mitotic spindle formation. In contrast, Cdk2 deficiency completely abrogates aberrant centrosome duplication induced by a viral oncogene. Mechanistically, centrosome overduplication in MEFs wild- type for Cdk2 involves the formation of supernumerary immature centrosomes. These results indicate that normal and abnormal centrosome duplication have significantly different requirements for CDK2 activity and point to a role of CDK2 in licensing centrosomes for aberrant duplication. Furthermore, our findings suggest that CDK2 may be a suitable therapeutic target to inhibit centrosome- mediated chromosomal instability in tumor cells.	Univ Pittsburgh, Inst Canc, Mol Virol Program, Hillman Canc Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Ctr Nacl Invest Oncol, Mol Oncol Program, Madrid, Spain; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Duensing, S (corresponding author), Univ Pittsburgh, Inst Canc, Mol Virol Program, Hillman Canc Ctr, Res Pavil Suite 1-8,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	duensing@pitt.edu	Malumbres, Marcos/E-8834-2011; Holt, Janet E/B-2415-2013	Malumbres, Marcos/0000-0002-0829-6315; Duensing, Anette/0000-0002-0168-4067	NCI NIH HHS [R01 CA112598, R01 CA112598-03, CA112598] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA112598] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRECHTBUEHLER G, 1980, EXP CELL RES, V126, P427, DOI 10.1016/0014-4827(80)90282-7; Aleem E, 2005, NAT CELL BIOL, V7, P831, DOI 10.1038/ncb1284; Alvarez-Salas LM, 1998, P NATL ACAD SCI USA, V95, P1189, DOI 10.1073/pnas.95.3.1189; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Chen ZH, 2002, DEV CELL, V3, P339, DOI 10.1016/S1534-5807(02)00258-7; Delattre M, 2004, J CELL SCI, V117, P1619, DOI 10.1242/jcs.01128; Doxsey S, 2002, MOL CELL, V10, P439, DOI 10.1016/S1097-2765(02)00654-8; DUENSING A, 2004, P AM ASSOC CANC RES, V45, P2596; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2005, CELL BIOL INT, V29, P352, DOI 10.1016/j.cellbi.2005.03.005; Duensing S, 2004, ONCOGENE, V23, P8206, DOI 10.1038/sj.onc.1208012; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Guarguaglini G, 2005, MOL BIOL CELL, V16, P1095, DOI 10.1091/mbc.E04-10-0939; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Mason DX, 2004, ONCOGENE, V23, P9238, DOI 10.1038/sj.onc.1208172; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Matsumoto Y, 2004, SCIENCE, V306, P885, DOI 10.1126/science.1103544; MEIJER L, 1999, PHARM THER, V82; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Wheatley DN, 1996, CELL BIOL INT, V20, P73, DOI 10.1006/cbir.1996.0011; Wong C, 2003, NAT CELL BIOL, V5, P539, DOI 10.1038/ncb993	32	86	88	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2943	2949		10.1038/sj.onc.1209310	http://dx.doi.org/10.1038/sj.onc.1209310			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16331279	Green Accepted			2022-12-28	WOS:000237448200013
J	Lindgren, D; Liedberg, F; Andersson, A; Chebil, G; Gudjonsson, S; Borg, A; Mansson, W; Fioretos, T; Hoglund, M				Lindgren, D; Liedberg, F; Andersson, A; Chebil, G; Gudjonsson, S; Borg, A; Mansson, W; Fioretos, T; Hoglund, M			Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q	ONCOGENE			English	Article						expression profiling; FGFR3; chromosome 9; urothelial carcinoma; bladder cancer	TRANSITIONAL-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR-3; GENE-EXPRESSION; URINARY-BLADDER; MICROARRAY DATA; CANCER; IDENTIFICATION; PAPILLARY; PATHWAYS; PROGRESSION	We used gene expression pro. ling, mutation analyses of FGFR3 and TP53, and LOH analyses of chromosome 9 and the TP53 region on chromosome arm 17p, to molecularly characterize 75 Ta and T1 bladder carcinomas. We identified four major cellular processes related to cell cycle, protein synthesis, immune response, and extra cellular components that contribute to the expressional heterogeneity of early-stage urothelial cell carcinoma ( UCC). Activating FGFR3 mutations were found at the highest frequency in G1 tumors ( 80%), and showed a strong correlation with FGFR3 expression. In contrast, G3 tumors displayed mutations in less than 10% of the cases and a low level of FGFR3 expression. Even though LOH on chromosome 9 was not associated with any specific expression pattern, our data indicate that loss of chromosome 9 is associated with tumor development rather than initiation. The combined analyses suggest the existence of two types of UCC tumors, one which is characterized by FGFR3 mutation or expression, high expression of protein synthesis genes, and low expression of cell cycle genes. Furthermore, the presented data underscore FGFR3 receptor involvement in urothelial cell transformation as the presence of FGFR3 mutations has a major impact on the global gene expression pro. le of bladder carcinomas.	Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Urol, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Oncol, S-22185 Lund, Sweden; Helsingborg Hosp AB, Dept Pathol & Cytol, Helsingborg, Sweden	Lund University; Skane University Hospital; Lund University; Skane University Hospital; Lund University; Skane University Hospital; Helsingborgs Hospital	Lindgren, D (corresponding author), Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden.	david.lindgren@med.lu.se	Gudjonsson, S./K-6878-2015	Gudjonsson, S./0000-0002-5147-595X; Fioretos, Thoas/0000-0002-3235-6154; Hoglund, Mattias/0000-0001-9283-4421; Hagstrom-Andersson, Anna/0000-0002-2904-1311				Bakkar AA, 2003, CANCER RES, V63, P8108; Baud E, 1999, INT J ONCOL, V14, P441; Belkin AM, 2000, MICROSC RES TECHNIQ, V51, P280, DOI 10.1002/1097-0029(20001101)51:3<280::AID-JEMT7>3.0.CO;2-O; Billerey C, 2001, AM J PATHOL, V158, P1955, DOI 10.1016/S0002-9440(10)64665-2; Blaveri E, 2005, CLIN CANCER RES, V11, P4044, DOI 10.1158/1078-0432.CCR-04-2409; Brausi M, 2002, EUR UROL, V41, P523, DOI 10.1016/S0302-2838(02)00068-4; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Cordon-Cardo C, 1998, CANCER SURV, V32, P115; Duggan B, 2004, CURR OPIN UROL, V14, P277, DOI 10.1097/00042307-200409000-00006; Dyrskjot L, 2003, NAT GENET, V33, P90, DOI 10.1038/ng1061; Dyrskjot L, 2005, CLIN CANCER RES, V11, P4029, DOI 10.1158/1078-0432.CCR-04-2095; Dyrskjot L, 2004, CANCER RES, V64, P4040, DOI 10.1158/0008-5472.CAN-03-3620; Hafner C, 2002, INT J CANCER, V101, P1, DOI 10.1002/ijc.10544; Haukaas S, 1999, BJU INT, V83, P957; Herr HW, 2000, J UROLOGY, V163, P60, DOI 10.1016/S0022-5347(05)67972-4; Heyer LJ, 1999, GENOME RES, V9, P1106, DOI 10.1101/gr.9.11.1106; Hoglund M, 2001, CANCER RES, V61, P8241; Kim JH, 2005, LAB INVEST, V85, P532, DOI 10.1038/labinvest.3700250; Knowles MA, 1999, ELECTROPHORESIS, V20, P269, DOI 10.1002/(SICI)1522-2683(19990201)20:2<269::AID-ELPS269>3.3.CO;2-Z; Modlich O, 2004, CLIN CANCER RES, V10, P3410, DOI 10.1158/1078-0432.CCR-03-0134; Mor O, 2003, ONCOGENE, V22, P7702, DOI 10.1038/sj.onc.1207039; Mostofi F, 1999, HISTOLOGICAL TYPING; PROUT GR, 1992, J UROLOGY, V148, P1413, DOI 10.1016/S0022-5347(17)36924-0; Richter J, 1998, AM J PATHOL, V153, P1615, DOI 10.1016/S0002-9440(10)65750-1; Saal LH, 2002, GENOME BIOL, V3; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Sanchez-Carbayo M, 2003, AM J PATHOL, V163, P505, DOI 10.1016/S0002-9440(10)63679-6; Sobin, 2009, UICC TNM CLASSIFICAT; SPRUCK CH, 1994, CANCER RES, V54, P784; Thykjaer T, 2001, CANCER RES, V61, P2492; Trudel S, 2005, BLOOD, V105, P2941, DOI 10.1182/blood-2004-10-3913; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vajo Z, 2000, ENDOCR REV, V21, P23, DOI 10.1210/er.21.1.23; van Rhijn BSW, 2004, CANCER RES, V64, P1911, DOI 10.1158/0008-5472.CAN-03-2421; van Rhijn BWG, 2003, J CLIN ONCOL, V21, P1912, DOI 10.1200/JCO.2003.05.073; van Rhijn BWG, 2002, EUR J HUM GENET, V10, P819, DOI 10.1038/sj.ejhg.5200883; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wild PJ, 2005, CLIN CANCER RES, V11, P4415, DOI 10.1158/1078-0432.CCR-05-0259; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15	39	106	110	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2685	2696		10.1038/sj.onc.1209249	http://dx.doi.org/10.1038/sj.onc.1209249			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16532037				2022-12-28	WOS:000237099400013
J	Liu, YJ; Xu, Y; Yu, Q				Liu, YJ; Xu, Y; Yu, Q			Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively	ONCOGENE			English	Article						ADAMTS-1; tumor metastasis; invasion; proteolytic cleavage; heparin-binding EGF; amphiregulin	NECROSIS-FACTOR-ALPHA; CD44-MEDIATED TUMOR INVASION; GROWTH-FACTOR RECEPTOR; BREAST-CANCER; CELL-SURFACE; METALLOPROTEINASE-DISINTEGRIN; IN-VIVO; EXTRACELLULAR-MATRIX; CONVERTING-ENZYME; TYPE-1 REPEATS	The exact role of a disintegrin and metalloproteinase with thrombospondin motifs-1 (ADAMTS-1) and the underlying mechanism of its involvement in tumor metastasis have not been established. We have now demonstrated that overexpression of ADAMTS-1 promotes pulmonary metastasis of TA3 mammary carcinoma and Lewis lung carcinoma cells and that a proteinase-dead mutant of ADAMTS-1 (ADAMTS-1E/Q) inhibits their metastasis, indicating that the prometastatic activity of ADAMTS-1 requires its metalloproteinase activity. Overexpression of ADAMTS-1 in these cells promoted tumor angiogenesis and invasion, shedding of the transmembrane precursors of heparin-binding epidermal growth factor (EGF) and amphiregulin (AR), and activation of the EGF receptor and ErbB-2, while overexpression of ADAMTS-1E/Q inhibited these events. Furthermore, we found that ADAMTS-1 undergoes auto-proteolytic cleavage to generate the NH2- and COOH-terminal cleavage fragments containing at least one thrombospondin-type-I-like motif and that overexpression of the NH2- terminal ADAMTS-1 fragment and the COOH-terminal ADAMTS-1 fragment can inhibit pulmonary tumor metastasis. These fragments also inhibited Erk1/2 kinase activation induced by soluble heparin-binding EGF and AR. Taken together, our results suggest that the proteolytic status of ADAMTS-1 determines its effect on tumor metastasis, and that the ADAMTS-1E/Q and the ADAMTS-1 fragments likely inhibit tumor metastasis by negatively regulating the availability and activity of soluble heparin-binding EGF and AR.	Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA	University of Pennsylvania	Yu, Q (corresponding author), Univ Penn, Sch Vet Med, Dept Pathobiol, 372E Old Vet,3800 Spruce St, Philadelphia, PA 19104 USA.	qyu@vet.upenn.edu			NCI NIH HHS [R01 CA116510, R01 CA116510-01A1] Funding Source: Medline; NHLBI NIH HHS [R01 HL074117, R01HL074117] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA116510] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074117] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; Billings SD, 2003, AM J PATHOL, V163, P2451, DOI 10.1016/S0002-9440(10)63600-0; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Bostwick DG, 2004, PROSTATE, V58, P164, DOI 10.1002/pros.10322; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Cal S, 2002, GENE, V283, P49, DOI 10.1016/S0378-1119(01)00861-7; Colige A, 2005, J BIOL CHEM, V280, P34397, DOI 10.1074/jbc.M506458200; COOK PW, 1992, CANCER RES, V52, P3224; EBERT M, 1994, CANCER RES, V54, P3959; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; HAMID AS, 2000, CANCER RES, V60, P7094; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Herren B, 2002, NEWS PHYSIOL SCI, V17, P73, DOI 10.1152/nips.01373.2001; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; Iruela-Arispe ML, 2003, ANN NY ACAD SCI, V995, P183, DOI 10.1111/j.1749-6632.2003.tb03221.x; Iwamoto R, 2003, P NATL ACAD SCI USA, V100, P3221, DOI 10.1073/pnas.0537588100; Jackson LF, 2003, EMBO J, V22, P2704, DOI 10.1093/emboj/cdg264; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; KITADAI Y, 1993, JPN J CANCER RES, V84, P879, DOI 10.1111/j.1349-7006.1993.tb02061.x; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kuno K, 1999, J BIOL CHEM, V274, P18821, DOI 10.1074/jbc.274.26.18821; Kuno K, 2004, BIOCHEM BIOPH RES CO, V319, P1327, DOI 10.1016/j.bbrc.2004.05.105; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; Lee DC, 2003, ANN NY ACAD SCI, V995, P22, DOI 10.1111/j.1749-6632.2003.tb03207.x; LEJEUNE S, 1993, CANCER RES, V53, P3597; Luque A, 2003, J BIOL CHEM, V278, P23656, DOI 10.1074/jbc.M212964200; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Masui T, 2001, CLIN CANCER RES, V7, P3437; Merlos-Suarez A, 2001, J BIOL CHEM, V276, P48510, DOI 10.1074/jbc.M103488200; Miao WM, 2001, CANCER RES, V61, P7830; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Miyamoto S, 2004, CANCER RES, V64, P5720, DOI 10.1158/0008-5472.CAN-04-0811; Nokihara H, 2000, CANCER RES, V60, P7002; NORMANNO N, 1995, BREAST CANCER RES TR, V35, P293, DOI 10.1007/BF00665981; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; Panico L, 1996, INT J CANCER, V65, P51, DOI 10.1002/(SICI)1097-0215(19960103)65:1<51::AID-IJC9>3.0.CO;2-0; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Pfeifer A, 2000, P NATL ACAD SCI USA, V97, P12227, DOI 10.1073/pnas.220399597; Porter S, 2004, CLIN CANCER RES, V10, P2429, DOI 10.1158/1078-0432.CCR-0398-3; Porter S, 2005, BIOCHEM J, V386, P15, DOI 10.1042/BJ20040424; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; Russell DL, 2003, J BIOL CHEM, V278, P42330, DOI 10.1074/jbc.M300519200; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; SALOMON DS, 1995, BREAST CANCER RES TR, V33, P103, DOI 10.1007/BF00682718; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; Stern DF, 2000, BREAST CANCER RES, V2, P176, DOI 10.1186/bcr51; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Streit M, 2000, EMBO J, V19, P3272, DOI 10.1093/emboj/19.13.3272; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Tucker RP, 2004, INT J BIOCHEM CELL B, V36, P969, DOI 10.1016/j.biocel.2003.12.011; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; Visscher DW, 1997, BREAST CANCER RES TR, V45, P75, DOI 10.1023/A:1005845512804; Volpert OV, 1998, P NATL ACAD SCI USA, V95, P6343, DOI 10.1073/pnas.95.11.6343; Xu Y, 2004, CANCER RES, V64, P6119, DOI 10.1158/0008-5472.CAN-04-1054; Xu Y, 2004, J BIOL CHEM, V279, P41179, DOI 10.1074/jbc.M400292200; Xu Y, 2003, J BIOL CHEM, V278, P8661, DOI 10.1074/jbc.M208181200; Yamazaki S, 2003, J CELL BIOL, V163, P469, DOI 10.1083/jcb.200307035; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yee KO, 2004, AM J PATHOL, V165, P541, DOI 10.1016/S0002-9440(10)63319-6; Yi M, 2001, P NATL ACAD SCI USA, V98, P620, DOI 10.1073/pnas.98.2.620; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Yu Q, 2000, GENE DEV, V14, P163	69	123	131	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2452	2467		10.1038/sj.onc.1209287	http://dx.doi.org/10.1038/sj.onc.1209287			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16314835	Green Accepted			2022-12-28	WOS:000236948000004
J	Rego, EM; Ruggero, D; Tribioli, C; Cattoretti, G; Kogan, S; Redner, RL; Pandolfi, PP				Rego, EM; Ruggero, D; Tribioli, C; Cattoretti, G; Kogan, S; Redner, RL; Pandolfi, PP			Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha	ONCOGENE			English	Article						acute promyelocytic leukemia; transgenic mouse models; NPM/RAR alpha; PML/RAR alpha; PLZF/RAR alpha	ACUTE PROMYELOCYTIC LEUKEMIA; PML-RAR-ALPHA; ACUTE MYELOGENOUS LEUKEMIA; CYTOPLASMIC NUCLEOPHOSMIN; PROTEINS; GENE; INTERACTS; MODELS; APL	Recurrent chromosomal translocations involving the RAR alpha locus on chromosome 17 are the hallmark of acute promyelocytic leukemia (APL). The RARa gene fuses to variable partners (PML, PLZF, NPM, NuMA and STAT5B: X genes) leading to the expression of APL-specific fusion proteins with identical RARa moieties. To analyse whether the variable X moiety could affect the activity of the fusion protein in vivo, we generated and characterized, on a comparative basis, NPM/RAR alpha transgenic mice ( TM) in which the fusion gene is expressed under the control of a human Cathepsin G ( hCG) minigene. We compared the features of the leukemia observed in these TM with those in hCG-PML/RAR alpha and hCG-PLZF/RAR alpha TM. In all three transgenic models, leukemia developed after a variably long latency, with variable penetrance. However, the three leukemias displayed distinct cytomorphological features. hCG-NPM/RAR alpha leukemic cells resembled monoblasts. This phenotype contrasts with what was observed in the hCG-PML/RAR alpha TM model in which the leukemic phase was characterized by the proliferation of promyelocytic blasts. Similarly, hCG-PLZF/RAR alpha TM displayed a different phenotype where terminally differentiated myeloid cells predominated. Importantly, the NPM/RAR alpha oncoprotein was found to localize in the nucleolus, unlike PML/RAR alpha and PLZF/RAR alpha, thus possibly interfering with the normal function of NPM. Similarly to what was observed in human APL patients, we found that NPM/RAR alpha and PML/RAR alpha, but not PLZF/RAR alpha leukemia, was responsive to all-trans retinoic acid ( ATRA) or As2O3 treatments. Taken together, our results underscore the critical relevance of the X moiety in dictating the biology of the disease and the activity of the APL fusion oncoprotein.	Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, Dept Pathol, Mem Sloan Kettering Inst, New York, NY 10021 USA; Univ Sao Paulo, Div Hematol, Dept Internal Med, Med Sch Ribeirao Preto, Sao Paulo, Brazil; Columbia Univ, Dept Pathol, New York, NY USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Pittsburgh, Med Ctr, Dept Med, Div Hematol Oncol, Pittsburgh, PA USA	Memorial Sloan Kettering Cancer Center; Universidade de Sao Paulo; Columbia University; University of California System; University of California San Francisco; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, Dept Pathol, Mem Sloan Kettering Inst, 1275 York Ave,Box 110, New York, NY 10021 USA.	p-pandolfi@ski.mskcc.org	Rego, Eduardo M/A-1058-2012; Cattoretti, Giorgio/H-2340-2011; Rego, Eduardo/AFS-7973-2022; Rego, Eduardo M./Y-5572-2019	Rego, Eduardo M/0000-0003-1567-4086; Rego, Eduardo/0000-0003-1567-4086; Rego, Eduardo M./0000-0003-1567-4086; Cattoretti, Giorgio/0000-0003-3799-3221; TRIBIOLI, CARLA/0000-0003-2544-476X; Kogan, Scott/0000-0002-2395-8479	NATIONAL CANCER INSTITUTE [R01CA074031] Funding Source: NIH RePORTER; NCI NIH HHS [CA-74031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcalay M, 2005, BLOOD, V106, P899, DOI 10.1182/blood-2005-02-0560; BRUNNING RD, 2001, PATHOLOGY GENETICS T, P75; Cheng GX, 1999, P NATL ACAD SCI USA, V96, P6318, DOI 10.1073/pnas.96.11.6318; Degos L, 2003, BRIT J HAEMATOL, V122, P539, DOI 10.1046/j.1365-2141.2003.04460.x; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Grisendi S, 2005, NEW ENGL J MED, V352, P291, DOI 10.1056/NEJMe048337; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; HEUSEL JW, 1993, BLOOD, V81, P1614; Hummel JL, 2002, CELL GROWTH DIFFER, V13, P173; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783; Okuda M, 2002, ONCOGENE, V21, P6170, DOI 10.1038/sj.onc.1205708; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; Redner RL, 2000, BLOOD, V95, P2683; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073/pnas.180290497; Rego EM, 2001, SEMIN HEMATOL, V38, P54, DOI 10.1053/shem.2001.20865; Rego EM, 2001, J EXP MED, V193, P521, DOI 10.1084/jem.193.4.521; Ruthardt M, 1998, ONCOGENE, V16, P1945, DOI 10.1038/sj.onc.1201722; Sainty D, 2000, BLOOD, V96, P1287; SIRULNIK A, 2003, BEST PRACT RES CLIN, V17, P71; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	26	51	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1974	1979		10.1038/sj.onc.1209216	http://dx.doi.org/10.1038/sj.onc.1209216			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16331271				2022-12-28	WOS:000236224800014
J	Walker, GE; Antoniono, RJ; Ross, HJ; Paisley, TE; Oh, Y				Walker, GE; Antoniono, RJ; Ross, HJ; Paisley, TE; Oh, Y			Neuroendocrine-like differentiation of non-small cell lung carcinoma cells: regulation by cAMP and the interaction of mac25/IGFBP-rP1 and 25.1	ONCOGENE			English	Article						cAMP; mac25/IGFBP-rP1; 25.1; NE differentiation; NSCLC; lung cancer	PROTEIN-RELATED PROTEIN-1; PROSTATE-CANCER CELLS; EPITHELIAL-CELLS; CHROMOGRANIN-A; GROWTH-FACTORS; STAGE-I; INSULIN; MARKERS; CHEMOTHERAPY; IDENTIFICATION	The need to develop more effective therapies for lung cancer has led to investigations in understanding the molecular mechanisms of the differentiation process, in particular neuroendocrine ( NE) differentiation. Recent studies have demonstrated that NE differentiation in nonsmall cell lung carcinoma (NSCLC) is not uncommon. Those NSCLCs with NE differentiation are considered a form of in transition NE carcinoma and show a more aggressive clinical course compared with NSCLC without NE differentiation. 25.1, a novel protein interacting with mac25/insulin-like growth factor-binding protein-related protein 1 (mac25/IGFBP-rP1), induced NE-like differentiation when collectively overexpressed in M12 prostate cancer cells. We have examined mac25/IGFBP-rP1 and 25.1 as potential molecular regulators in vitro of the NE-differentiation process in lung cancer. In a panel of SCLC and NSCLC cell lines, mac25/IGFBP-rP1 and 25.1 were expressed at higher levels in SCLC. An increase and sustained activation of adenosine 3',5'- cyclic monophosphate ( cAMP) levels induced NE-like differentiation in NSCLC cell lines, and a concomitant increase in the expression of mac25/IGFBP-rP1 and 25.1 was observed during the cAMP-regulated differentiation of NCI-H157 cells, suggesting the involvement of these proteins. Furthermore, the collective overexpression of mac25/IGFBP-rP1 and 25.1 in NSCLC cells induced NE-like differentiation as early as 6 h postinfection. The present data suggest that mac25/IGFBP-rP1 and 25.1 may play a functional role in the NE differentiation of NSCLC cell lines and may provide a novel therapeutic target for treating lung cancers, in particular NSCLC with NE differentiation.	Virginia Commonwealth Univ, Dept Pathol, Richmond, VA 23298 USA; Oregon Hlth Sci Univ, Dept Pediat, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Oregon Canc Ctr, Portland, OR 97201 USA; Earle A Chiles Res Inst, Portland, OR USA; Ist Auxol Italiano Piancavallo, Oggebbio, VA, Italy	Virginia Commonwealth University; Oregon Health & Science University; Oregon Health & Science University; IRCCS Istituto Auxologico Italiano	Oh, Y (corresponding author), Virginia Commonwealth Univ, Dept Pathol, Med Coll Virginia Campus,POB 980622,Sanger Hall, Richmond, VA 23298 USA.	yoh@vcu.edu						Ahmed S, 2003, BIOCHEM BIOPH RES CO, V310, P612, DOI 10.1016/j.bbrc.2003.09.058; AKAOGI K, 1994, BIOCHEM BIOPH RES CO, V198, P1046, DOI 10.1006/bbrc.1994.1149; Akaogi K, 1996, CELL GROWTH DIFFER, V7, P1671; BERENDSEN HH, 1989, J CLIN ONCOL, V7, P1614, DOI 10.1200/JCO.1989.7.11.1614; Burger AM, 1998, ONCOGENE, V16, P2459, DOI 10.1038/sj.onc.1201772; Carnaghi C, 2001, ANN ONCOL, V12, pS119, DOI 10.1093/annonc/12.suppl_2.S119; Cersosimo RJ, 2002, AM J HEALTH-SYST PH, V59, P611, DOI 10.1093/ajhp/59.7.611; Chen TS, 1999, CANCER RES, V59, P213; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Deeble PD, 2001, MOL CELL BIOL, V21, P8471, DOI 10.1128/MCB.21.24.8471-8482.2001; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Gajra A, 2002, LUNG CANCER-J IASLC, V36, P159, DOI 10.1016/S0169-5002(01)00463-9; GAZDAR AF, 1988, CANCER RES, V48, P4078; GOSNEY JR, 1995, THORAX, V50, P116, DOI 10.1136/thx.50.2.116; GRAZIANO SL, 1994, CANCER RES, V54, P2908; Graziano SL, 2001, LUNG CANCER, V33, P115, DOI 10.1016/S0169-5002(01)00183-0; Haugk KL, 2000, ENDOCRINOLOGY, V141, P100, DOI 10.1210/en.141.1.100; Heasley LE, 2001, ONCOGENE, V20, P1563, DOI 10.1038/sj.onc.1204183; Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761; Iyoda A, 2001, CANCER, V92, P1108, DOI 10.1002/1097-0142(20010901)92:5<1108::AID-CNCR1427>3.0.CO;2-7; Jiang SX, 1999, MODERN PATHOL, V12, P362; Jiang SX, 1996, AM J PATHOL, V148, P837; Jull BA, 2001, J CANCER RES CLIN, V127, P707; LINNOILA RI, 1994, CHEST S6, V106, P367; Lopez-Bermejo A, 2000, ENDOCRINOLOGY, V141, P4072, DOI 10.1210/en.141.11.4072; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; Pelosi G, 2003, CANCER-AM CANCER SOC, V97, P2487, DOI 10.1002/cncr.11376; Reynolds SD, 2000, AM J PHYSIOL-LUNG C, V278, pL1256, DOI 10.1152/ajplung.2000.278.6.L1256; Schleusener JT, 1996, CANCER-AM CANCER SOC, V77, P1284, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1284::AID-CNCR9>3.0.CO;2-I; SHAW GL, 1993, CANCER RES, V53, P5181; SKOV BG, 1991, ANN ONCOL, V2, P355, DOI 10.1093/oxfordjournals.annonc.a057955; Sprenger CC, 1999, CANCER RES, V59, P2370; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; Tureckova J, 2001, J BIOL CHEM, V276, P39264, DOI 10.1074/jbc.M104991200; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wallace WAH, 2002, EUR J SURG ONCOL, V28, P63, DOI 10.1053/ejso.2001.1170; Wilson EM, 1997, J CLIN ENDOCR METAB, V82, P1301, DOI 10.1210/jc.82.4.1301; Wilson EM, 2001, J CLIN ENDOCR METAB, V86, P4504, DOI 10.1210/jc.86.9.4504; YAMAUCHI T, 1994, BIOCHEM J, V303, P591, DOI 10.1042/bj3030591; Yesner R, 2001, EXP MOL PATHOL, V70, P179, DOI 10.1006/exmp.2001.2373	41	26	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1943	1954		10.1038/sj.onc.1209213	http://dx.doi.org/10.1038/sj.onc.1209213			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16302002				2022-12-28	WOS:000236224800011
J	Freilinger, A; Rosner, M; Krupitza, G; Nishino, M; Lubec, G; Korsmeyer, SJ; Hengstschlager, M				Freilinger, A.; Rosner, M.; Krupitza, G.; Nishino, M.; Lubec, G.; Korsmeyer, S. J.; Hengstschlaeger, M.			Tuberin activates the proapoptotic molecule BAD	ONCOGENE			English	Article						TSC2; tuberin; BAD; apoptosis	TUMOR-SUPPRESSOR GENE; CELL-SURVIVAL; SCLEROSIS COMPLEX; PRODUCT; TSC2; PHOSPHORYLATION; GROWTH; DEATH; AKT; TARGET	TSC1, encoding hamartin, and TSC2, encoding tuberin, are tumor suppressor genes responsible for the autosomal dominantly inherited disease tuberous sclerosis (TSC). TSC affects similar to 1 in 6000 individuals and is characterized by the development of tumors, named hamartomas, in different organs. Hamartin and tuberin form a complex, of which tuberin is assumed to be the functional component. The TSC proteins have been implicated in the control of cell cycle and cell size. In addition to enhanced growth, reduced death rates can lead to tumor development. Therefore, defects in the apoptosis-inducing pathways contribute to neoplastic cell expansion. Here, we show that tuberin triggers apoptosis, accompanied by downregulation of p70S6K activity and of phosphorylation of BAD on residue Ser136, and by upregulation of the interaction of BAD/BCL-2 and BAD/BCL-X-L. AKT phosphorylation negatively regulates tuberin's potential to trigger apoptosis. Experiments with BAD-/- cells demonstrate BAD to be a mediator of tuberin's effects on the regulation of apoptosis. Tuberin interferes with insulin-like growth factor-1-induced BAD Ser136 phosphorylation and cell survival. Our work proposes a model in which tuberin-mediated inhibition of p70S6K activates BAD to heterodimerize with BCL-2 and BCL-XL to promote apoptosis. A mutation of TSC2 - as it occurs in TSC patients - attenuates this proapoptotic potential, underscoring the relevance of our findings for human pathophysiology.	Med Univ Vienna, Gen Hosp, A-1090 Vienna, Austria; Med Univ Vienna, Inst Clin Pathol, Vienna, Austria; Harvard Univ, Sch Med, Howard Hughes Med Inst, Dana Farber Canc Inst,Dept Pathol, Boston, MA USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Dana Farber Canc Inst,Dept Med, Boston, MA USA; Med Univ Vienna, Dept Pediat, Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; Medical University of Vienna	Hengstschlager, M (corresponding author), Med Univ Vienna, Gen Hosp, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	markus.hengstschlaeger@meduniwien.ac.at		Krupitza, Georg/0000-0003-2949-7906; Lubec, Gert/0000-0002-6333-9461				Arrebola F, 2005, APOPTOSIS, V10, P1317, DOI 10.1007/s10495-005-2718-x; Astrinidis A, 2005, ONCOGENE, V24, P7475, DOI 10.1038/sj.onc.1209090; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; Chong-Kopera H, 2006, J BIOL CHEM, V281, P8313, DOI 10.1074/jbc.C500451200; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Grusch M, 2002, CELL DEATH DIFFER, V9, P169, DOI 10.1038/sj.cdd.4400937; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Harrington LS, 2005, TRENDS BIOCHEM SCI, V30, P35, DOI 10.1016/j.tibs.2004.11.003; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; Kolb TM, 2005, TOXICOL SCI, V88, P331, DOI 10.1093/toxsci/kfi310; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Maheshwar MM, 1997, HUM MOL GENET, V6, P1991, DOI 10.1093/hmg/6.11.1991; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; NELLIST M, 1993, CELL, V75, P1305; Pan DJ, 2004, TRENDS CELL BIOL, V14, P78, DOI 10.1016/j.tcb.2003.12.006; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Rosner M, 2004, J BIOL CHEM, V279, P48707, DOI 10.1074/jbc.M405528200; Rosner M, 2003, ONCOGENE, V22, P4786, DOI 10.1038/sj.onc.1206776; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wohlfart S, 2004, AM J PATHOL, V164, P1081, DOI 10.1016/S0002-9440(10)63195-1; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	42	41	41	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2006	25	49					6467	6479		10.1038/sj.onc.1209660	http://dx.doi.org/10.1038/sj.onc.1209660			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16702951				2022-12-28	WOS:000241395100003
J	Rodrigues, S; Rodrigue, CM; Attoub, S; Flejou, JF; Bruyneel, E; Bracke, M; Emami, S; Gespach, C				Rodrigues, S.; Rodrigue, C. M.; Attoub, S.; Flejou, J. F.; Bruyneel, E.; Bracke, M.; Emami, S.; Gespach, C.			Induction of the adenoma-carcinoma progression and Cdc25A-B phosphatases by the trefoil factor TFF1 in human colon epithelial cells	ONCOGENE			English	Article						differential display; anchorage-independent growth; invasion; apoptosis; tumor growth; human colorectal tumors	HUMAN COLORECTAL-CARCINOMA; HUMAN BREAST-CANCER; IN-VIVO; SIGNALING PATHWAYS; CELLULAR INVASION; POOR-PROGNOSIS; EXPRESSION; PEPTIDES; MDM2; P53	TFF1 is overexpressed in inflammatory diseases and human cancers of the digestive and urogenital systems. To examine the transforming potential of TFF1 in human colon epithelial cells, premalignant PC/AA/C1 adenoma cells (PC) derived from a patient with familial adenomatous polyposis (FAP) were transformed by the TFF1 cDNA and used as a model of the adenoma-carcinoma transition. Constitutive expression of TFF1 increased anchorage-independent cell growth in soft agar, and induced or potentiated the growth of colon PC-TFF1 and kidney MDCKts.src-TFF1 tumor xenografts in athymic mice. This resulted in reduction of thapsigargin-induced apoptosis and promotion of collagen type I invasion through several oncogenic pathways. Using the differential display approach to identify TFF1 target genes, we found that the dual specific phosphatases Cdc25A and B implicated in cell cycle transitions are strongly upregulated under active forms in both PC-TFF1 and HCT8/S11-TFF1 colon cancer cells. Accordingly, TFF1 expression is absent in normal human colon crypts but is induced in correlation with Cdc25a and b transcript levels and tumor grade in familial and sporadic colon adenomas and carcinomas. We propose that TFF1 and Cdc25A-B cooperate with other dominant oncogenic pathways to induce the adenoma and adenocarcinoma transitions. Agents that target TFF1/Cdc25 signaling pathways may be useful for treating patients with TFF1-positive solid tumors.	Hop St Antoine, INSERM, U673, F-75571 Paris 12, France; Univ Paris 06, Paris 12, France; Hop St Antoine, Dept Pathol, F-75571 Paris 12, France; Ghent Univ Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital	Gespach, C (corresponding author), Hop St Antoine, INSERM, U673, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.	gespach@st-antoine.inserm.fr	Attoub, Samir/N-6852-2018					Babyatsky MW, 1996, GASTROENTEROLOGY, V110, P489, DOI 10.1053/gast.1996.v110.pm8566596; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bossenmeyer-Pourie C, 2002, J CELL BIOL, V157, P761, DOI 10.1083/jcb200108056; Boutros R, 2006, CURR OPIN CELL BIOL, V18, P185, DOI 10.1016/j.ceb.2006.02.003; BRACKE ME, 2001, METHODS MOL MED; Brezak MC, 2005, MOL CANCER THER, V4, P1378, DOI 10.1158/1535-7163.MCT-05-0168; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; Christine R, 2005, CANCER RES, V65, P195; Daga RR, 1999, J CELL SCI, V112, P3137; Dhar DK, 2005, CLIN CANCER RES, V11, P6472, DOI 10.1158/1078-0432.CCR-05-0671; Emami S, 2004, PEPTIDES, V25, P885, DOI 10.1016/j.peptides.2003.10.019; Emami S, 2001, FASEB J, V15, P351, DOI 10.1096/fj.00-0355com; Empereur S, 1997, BRIT J CANCER, V75, P241, DOI 10.1038/bjc.1997.40; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Hernandez S, 2001, LAB INVEST, V81, P465, DOI 10.1038/labinvest.3780254; Hipfner DR, 2004, NAT REV MOL CELL BIO, V5, P805, DOI 10.1038/nrm1491; Jourdan F, 2003, VIRCHOWS ARCH, V443, P115, DOI 10.1007/s00428-003-0833-z; Kallstrom H, 2005, EXP CELL RES, V303, P89, DOI 10.1016/j.yexcr.2004.09.012; Kang CM, 2004, CARCINOGENESIS, V25, P123, DOI 10.1093/carcin/bgg187; KINDON H, 1995, GASTROENTEROLOGY, V109, P516, DOI 10.1016/0016-5085(95)90340-2; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; Leisser C, 2004, CELL DEATH DIFFER, V11, P80, DOI 10.1038/sj.cdd.4401318; Loffler H, 2003, ONCOGENE, V22, P8063, DOI 10.1038/sj.onc.1206976; Mitra J, 2004, ONCOGENE, V23, P3361, DOI 10.1038/sj.onc.1207446; Moore L, 2003, ONCOGENE, V22, P7831, DOI 10.1038/sj.onc.1206985; Onel K, 2004, MOL CANCER RES, V2, P1; Ozen M, 2005, CLIN CANCER RES, V11, P4701, DOI 10.1158/1078-0432.CCR-04-2551; RIO MC, 1988, SCIENCE, V241, P705, DOI 10.1126/science.3041593; Rodrigue CM, 2005, ONCOGENE, V24, P3274, DOI 10.1038/sj.onc.1208485; Rodrigues S, 2003, FASEB J, V17, P7, DOI 10.1096/fj.02-0201com; Rodrigues S, 2003, ONCOGENE, V22, P4488, DOI 10.1038/sj.onc.1206685; Rodrigues S, 2001, FASEB J, V15, P1517, DOI 10.1096/fj.00-0802com; SHOUSHA S, 1993, MODERN PATHOL, V6, P446; Soufla G, 2005, INT J BIOL MARKER, V20, P18, DOI 10.1177/172460080502000104; Takemasa I, 2000, CANCER RES, V60, P3043; Taupin D, 2003, NAT REV MOL CELL BIO, V4, P721, DOI 10.1038/nrm1203; Taupin DR, 2000, P NATL ACAD SCI USA, V97, P799, DOI 10.1073/pnas.97.2.799; Tomasetto C, 2000, GASTROENTEROLOGY, V118, P70, DOI 10.1016/S0016-5085(00)70415-X; Torres LF, 2002, MOL MED, V8, P273, DOI 10.1007/BF03402153; Van de Bovenkamp JHB, 2005, DIGEST DIS SCI, V50, P1078, DOI 10.1007/s10620-005-2708-4; WILLIAMS AC, 1994, ONCOGENE, V9, P1479; Xu XD, 2003, CLIN CANCER RES, V9, P1764; Yio XY, 2005, CLIN EXP METASTAS, V22, P157, DOI 10.1007/s10585-005-6615-z; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200	44	23	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	50					6628	6636		10.1038/sj.onc.1209665	http://dx.doi.org/10.1038/sj.onc.1209665			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16715141				2022-12-28	WOS:000241569700007
J	Paul, C; Lacroix, M; Iankova, I; Julien, E; Schafer, BW; Labalette, C; Wei, Y; Le Cam, A; Le Cam, L; Sardet, C				Paul, C.; Lacroix, M.; Iankova, I.; Julien, E.; Schaefer, B. W.; Labalette, C.; Wei, Y.; Le Cam, A.; Le Cam, L.; Sardet, C.			The LIM-only protein FHL2 is a negative regulator of E4F1	ONCOGENE			English	Article						FHL2; DRAL; E4F1; p53; proliferation; repression	TRANSCRIPTION FACTOR P120(E4F); DOMAIN PROTEIN; BETA-CATENIN; CELL-CYCLE; COACTIVATOR FHL2; INTERACTS; IDENTIFICATION; ACTIVATION; GENE; BINDING	The E1A-targeted transcription factor E4F1 is a key player in the control of mammalian embryonic and somatic cell proliferation and survival. Mouse embryos lacking E4F die at an early developmental stage, whereas enforced expression of E4F1 in various cell lines inhibits cell cycle progression. E4F1-antiproliferative effects have been shown to depend on its capacity to repress transcription and to interact with pRb and p53. Here we show that full-length E4F1 protein (p120(E4F1)) but not its E1A-activated and truncated form (p50(E4F1)), interacts directly in vitro and in vivo with the LIM-only protein FHL2, the product of the p53-responsive gene FHL2/DRAL (downregulated in rhabdomyosarcoma Lim protein). This E4F1-FHL2 association occurs in the nuclear compartment and inhibits the capacity of E4F1 to block cell proliferation. Consistent with this effect, ectopic expression of FHL2 inhibits E4F1 repressive effects on transcription and correlates with a reduction of nuclear E4F-p53 complexes. Overall, these results suggest that FHL2/DRAL is an inhibitor of E4F1 activity. Finally, we show that endogenous E4F1-FHL2 complexes form in U2OS cells upon UV-light-induced nuclear accumulation of FHL2.	CNRS, Inst Mol Genet, UMR 5535, IFR122, F-34293 Montpellier 5, France; Univ Zurich, Dept Pediat, Div Clin Chem & Biochem, CH-8006 Zurich, Switzerland; Inst Pasteur, Unite Oncogenese & Virol Mol, Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; University of Zurich; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Sardet, C (corresponding author), CNRS, Inst Mol Genet, UMR 5535, IFR122, 1919 Route Mende, F-34293 Montpellier 5, France.	claude.sardet@igmm.cnrs.fr	JULIEN, ERIC/Y-5873-2019; Wei, Yu/A-7289-2016; Lacroix, Matthieu/O-1928-2018; Le Cam, Laurent/O-1408-2016	JULIEN, ERIC/0000-0003-2976-666X; Lacroix, Matthieu/0000-0002-1268-9058; LE CAM, Laurent/0000-0003-0325-878X; Schafer, Beat/0000-0001-5988-2915				Ahmed-Choudhury J, 2005, CANCER RES, V65, P2690, DOI 10.1158/0008-5472.CAN-04-3593; Amaar YG, 2002, J BIOL CHEM, V277, P12053, DOI 10.1074/jbc.M110872200; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chan KK, 1998, GENE, V210, P345, DOI 10.1016/S0378-1119(97)00644-6; Chu PH, 2000, MOL CELL BIOL, V20, P7460, DOI 10.1128/MCB.20.20.7460-7462.2000; CHU PH, 2000, J MECH DEV, V95, P265; Colombo R, 2003, ONCOGENE, V22, P2541, DOI 10.1038/sj.onc.1206379; Dantonel JC, 2000, MOL CELL, V6, P715, DOI 10.1016/S1097-2765(00)00069-1; DU X, 2002, BIOCHIM BIOPHYS ACTA, V577, P93; Fajas L, 2001, MOL CELL BIOL, V21, P2956, DOI 10.1128/MCB.21.8.2956-2966.2001; Fajas L, 2000, P NATL ACAD SCI USA, V97, P7738, DOI 10.1073/pnas.130198397; Fenton SL, 2004, CANCER RES, V64, P102, DOI 10.1158/0008-5472.CAN-03-2622; Fernandes ER, 1999, MOL CELL BIOL, V19, P4739; Fernandes ER, 1997, MOL CELL BIOL, V17, P1890, DOI 10.1128/MCB.17.4.1890; Fernandes ER, 1998, MOL CELL BIOL, V18, P459, DOI 10.1128/MCB.18.1.459; Fimia GM, 2000, MOL CELL BIOL, V20, P8613, DOI 10.1128/MCB.20.22.8613-8622.2000; FOGNANI C, 1993, EMBO J, V12, P4985, DOI 10.1002/j.1460-2075.1993.tb06192.x; Gabriel B, 2004, ANTICANCER RES, V24, P921; Genini M, 1997, DNA CELL BIOL, V16, P433, DOI 10.1089/dna.1997.16.433; Hill AA, 2004, MOL CELL BIOL, V24, P9835, DOI 10.1128/MCB.24.22.9835-9847.2004; Kang CM, 2003, RADIAT RES, V159, P312, DOI 10.1667/0033-7587(2003)159[0312:PBFIRE]2.0.CO;2; Kong YF, 2001, CIRCULATION, V103, P2731; Labalette C, 2004, MOL CELL BIOL, V24, P10689, DOI 10.1128/MCB.24.24.10689-10702.2004; Le Cam L, 2004, MOL CELL BIOL, V24, P6467, DOI 10.1128/MCB.24.14.6467-6475.2004; Li HY, 2001, CELL MOTIL CYTOSKEL, V48, P11, DOI 10.1002/1097-0169(200101)48:1<11::AID-CM2>3.0.CO;2-I; Martin B, 2002, J CELL BIOL, V159, P113, DOI 10.1083/jcb.200202075; McLoughlin P, 2002, J BIOL CHEM, V277, P37045, DOI 10.1074/jbc.M203336200; Morlon A, 2003, P NATL ACAD SCI USA, V100, P3977, DOI 10.1073/pnas.0735923100; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Muller JM, 2002, EMBO J, V21, P736, DOI 10.1093/emboj/21.4.736; Philippar U, 2004, MOL CELL, V16, P867, DOI 10.1016/j.molcel.2004.11.039; Purcell NH, 2004, MOL CELL BIOL, V24, P1081, DOI 10.1128/MCB.24.3.1081-1095.2004; RAYCHAUDHURI P, 1987, EMBO J, V6, P4073, DOI 10.1002/j.1460-2075.1987.tb02753.x; Retaux S, 2002, MOL NEUROBIOL, V26, P269, DOI 10.1385/MN:26:2-3:269; Rizos H, 2003, J BIOL CHEM, V278, P4981, DOI 10.1074/jbc.M210978200; Sandy P, 2000, ONCOGENE, V19, P188, DOI 10.1038/sj.onc.1203250; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Scholl FA, 2000, J CELL BIOL, V151, P495, DOI 10.1083/jcb.151.3.495; Stilo R, 2002, FEBS LETT, V521, P165, DOI 10.1016/S0014-5793(02)02869-7; Tanahashi H, 2000, HUM MOL GENET, V9, P2281, DOI 10.1093/oxfordjournals.hmg.a018919; Tessari MA, 2003, MOL CELL BIOL, V23, P9104, DOI 10.1128/MCB.23.24.9104-9116.2003; Wei Y, 2003, J BIOL CHEM, V278, P5188, DOI 10.1074/jbc.M207216200; Wixler V, 2000, J BIOL CHEM, V275, P33669, DOI 10.1074/jbc.M002519200; Yang YH, 2005, EMBO J, V24, P1021, DOI 10.1038/sj.emboj.7600570	44	36	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2006	25	40					5475	5484		10.1038/sj.onc.1209567	http://dx.doi.org/10.1038/sj.onc.1209567			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16652157				2022-12-28	WOS:000240370400001
J	Bossolasco, M; Veillette, F; Bertrand, R; Mes-Masson, AM				Bossolasco, M.; Veillette, F.; Bertrand, R.; Mes-Masson, A. -M			Human TDE1, a TDE1/TMS family member, inhibits apoptosis in vitro and stimulates in vivo tumorigenesis	ONCOGENE			English	Article						TDE1; apoptosis; transformation; tumorigenesis	ANTIGEN TRANSGENIC MICE; SUBCELLULAR-LOCALIZATION; PROTEIN FAMILY; CELL-LINES; EXPRESSION; IDENTIFICATION; GENE; CULTURE; CANCER; TISSUE	We have previously described hTDE1, the human homologue of the recently described TDE1/TMS family of proteins whose members have been identified in several species. Although a defined biochemical activity has yet to be assigned to TDE1/TMS family members, previous results point to the overexpression of family members in tumor cell lines or tissues. To define whether hTDE1 may directly impact on neoplastic transformation, we derived and characterized stable Rat-1 transfectants that constitutively express hTDE1 at the plasma membrane. Expression of hTDE1 in Rat-1 transfectants had a significant effect on cell contact inhibition in vitro as judged by a focus formation assay. In addition, by monitoring caspase-3 activity and Hoechst staining, we determined that hTDE1 overexpression partially protects cells from serum starvation- and etoposide-induced apoptosis. Finally, hTDE1 Rat-1-expressing clones accelerated the formation of tumors in a nude mouse assay. Our results suggest that hTDE1 contributes directly to oncogenesis in vivo that may in part be explained by its effect on apoptosis in vitro.	CHUM, Ctr Rech, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal	Mes-Masson, AM (corresponding author), CHUM, ICM, Hop Notre Dame de Bon Secours, 1560 Sherbrooke St E, Montreal, PQ H2L 4M1, Canada.	anne-marie.mes-masson@umontreal.ca		Mes-Masson, Anne-Marie/0000-0002-6498-266X				Aoki S, 2002, J NEUROSCI, V22, P10751; Bazzoni G, 2004, PHYSIOL REV, V84, P869, DOI 10.1152/physrev.00035.2003; Bossolasco M, 1999, MOL CARCINOGEN, V26, P189, DOI 10.1002/(SICI)1098-2744(199911)26:3<189::AID-MC8>3.0.CO;2-T; CHALIFOUR LE, 1990, ONCOGENE, V5, P1719; CHALIFOUR LE, 1992, MOL CARCINOGEN, V5, P178, DOI 10.1002/mc.2940050304; Corn PG, 2002, BIOESSAYS, V24, P83, DOI 10.1002/bies.10036; Faust M, 2000, CELL TISSUE RES, V301, P329, DOI 10.1007/s004410000256; Ferrigno P, 1999, METHOD CELL BIOL, V58, P107; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Grossman TR, 2000, J EXP BIOL, V203, P447; Inuzuka M, 2005, J BIOL CHEM, V280, P35776, DOI 10.1074/jbc.M505712200; Krueger WHH, 1997, J NEUROCHEM, V69, P1343; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; LEBEL M, 1994, DNA SEQUENCE, V5, P31, DOI 10.3109/10425179409039702; Nowell PC, 2002, SEMIN CANCER BIOL, V12, P261, DOI 10.1016/S1044-579X(02)00012-3; ORMEROD MG, 1992, J IMMUNOL METHODS, V153, P57, DOI 10.1016/0022-1759(92)90305-D; Pearce DA, 2000, J NEUROSCI RES, V59, P19, DOI 10.1002/(SICI)1097-4547(20000101)59:1<19::AID-JNR3>3.0.CO;2-Y; Player A, 2003, INT J CANCER, V107, P238, DOI 10.1002/ijc.11391; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RENAN MJ, 1993, MOL CARCINOGEN, V7, P139; Rodriguez-Bigas MA, 2003, HOLLAND FREI CANC ME; Ronot X, 2000, CYTOMETRY, V41, P19, DOI 10.1002/1097-0320(20000901)41:1<19::AID-CYTO3>3.0.CO;2-X; Royle SJ, 2003, BIOESSAYS, V25, P39, DOI 10.1002/bies.10200; Shigeta M, 2003, J CELL BIOL, V163, P165, DOI 10.1083/jcb.200301075; Simpson JC, 2000, EMBO REP, V1, P287, DOI 10.1093/embo-reports/kvd058; Stevens FJ, 1999, SEMIN CELL DEV BIOL, V10, P443, DOI 10.1006/scdb.1999.0315; TEMIN HM, 1958, VIROLOGY, V6, P669, DOI 10.1016/0042-6822(58)90114-4; Xu J, 2003, MOL BIOL REP, V30, P47, DOI 10.1023/A:1022250428015	28	20	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2006	25	33					4549	4558		10.1038/sj.onc.1209488	http://dx.doi.org/10.1038/sj.onc.1209488			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16547497				2022-12-28	WOS:000239457500005
J	Ishimura, A; Lee, HS; Bong, YS; Saucier, C; Mood, K; Park, E; Daar, IO				Ishimura, A.; Lee, H-S; Bong, Y-S; Saucier, C.; Mood, K.; Park, E. K.; Daar, I. O.			Oncogenic Met receptor induces ectopic structures in Xenopus embryos	ONCOGENE			English	Article						Met receptor; Xenopus; tyrosine kinase signaling	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; EPITHELIAL-MESENCHYMAL TRANSITIONS; GRB2 BINDING-SITE; TYROSINE KINASE; MESODERM INDUCTION; C-MET; NEURAL CREST; MAP KINASE; CELL-TRANSFORMATION	When aberrantly expressed or activated, the Met receptor tyrosine kinase is involved in tumor invasiveness and metastasis. In this study, we have used the Xenopus embryonic system to de. ne the role of various Met proximal-binding partners and downstream signaling pathways in regulating an induced morphogenetic event. We show that expression of an oncogenic derivative of the Met receptor (Tpr-Met) induces ectopic morphogenetic structures during Xenopus embryogenesis. Using variant forms of Tpr-Met that are engineered to recruit a specific signaling molecule of choice, we demonstrate that the sole recruitment of either the Grb2 or the Shc adaptor protein is sufficient to induce ectopic structures and anterior reduction, while the recruitment of PI-3Kinase (PI-3K) is necessary but not sufficient for this effect. In contrast, the recruitment of PLC gamma can initiate the induction, but fails to maintain or elongate supernumerary structures. Finally, evidence indicates that the Ras/Raf/MAPK pathway is necessary, but not sufficient to induce these structures. This study also emphasizes the importance of examining signaling molecules in the regulatory context that is provided by receptor/effector interactions when assessing a role in cell growth and differentiation.	NCI, Frederick Canc Res & Dev Ctr, Lab Prot Dynam & Signaling, Frederick, MD 21702 USA; McGill Univ, Ctr Hlth, Mol Oncol Grp, Montreal, PQ, Canada	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; McGill University	Daar, IO (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Lab Prot Dynam & Signaling, Bldg 560,Room 22-3, Frederick, MD 21702 USA.	daar@ncifcrf.gov	Saucier, Caroline/Q-9250-2019; Lee, Hyun-Shik/G-3555-2011	Saucier, Caroline/0000-0001-7678-9886; Daar, Ira/0000-0003-2657-526X	NATIONAL CANCER INSTITUTE [Z01BC010006, ZIABC010006] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Aoki S, 1997, BIOCHEM BIOPH RES CO, V234, P8, DOI 10.1006/bbrc.1997.6567; Atabey N, 2001, J BIOL CHEM, V276, P14308, DOI 10.1074/jbc.M010202200; Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BELLUSCI S, 1994, ONCOGENE, V9, P1091; Berthou S, 2004, ONCOGENE, V23, P5387, DOI 10.1038/sj.onc.1207691; Brewster R, 2000, DEVELOPMENT, V127, P4395; Cacace AM, 1999, MOL CELL BIOL, V19, P229; Carballada R, 2001, DEVELOPMENT, V128, P35; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; Chen YL, 1999, MECH DEVELOP, V80, P67, DOI 10.1016/S0925-4773(98)00194-4; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; Chong LD, 2000, MOL CELL BIOL, V20, P724, DOI 10.1128/MCB.20.2.724-734.2000; Christen B, 2003, DEV DYNAM, V226, P349, DOI 10.1002/dvdy.10231; Christensen JG, 2005, CANCER LETT, V225, P1, DOI 10.1016/j.canlet.2004.09.044; Christensen JG, 2003, CANCER RES, V63, P7345; Ciruna BG, 1997, DEVELOPMENT, V124, P2829; Coltella N, 2003, FASEB J, V17, P1162, DOI 10.1096/fj.02-0576fje; Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; DIRENZO MF, 1992, ONCOGENE, V7, P2549; Dupont H, 1999, EUR J BIOCHEM, V265, P530, DOI 10.1046/j.1432-1327.1999.00689.x; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; Gao CF, 2005, CELL RES, V15, P49, DOI 10.1038/sj.cr.7290264; Gupta RW, 1998, ONCOGENE, V17, P2155, DOI 10.1038/sj.onc.1202158; GURDON JB, 1984, CELL, V38, P691, DOI 10.1016/0092-8674(84)90264-2; Hama J, 2001, MECH DEVELOP, V109, P195, DOI 10.1016/S0925-4773(01)00524-X; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; HOMMA Y, 1992, J BIOL CHEM, V267, P21844; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; JACOBSON M, 1986, DEV BIOL, V116, P524, DOI 10.1016/0012-1606(86)90153-3; Jeffers M, 1998, ONCOGENE, V17, P2691, DOI 10.1038/sj.onc.1202209; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, ONCOGENE, V13, P853; Kamikura DM, 1996, BIOCHEMISTRY-US, V35, P1010, DOI 10.1021/bi9514065; Kamikura DM, 2000, MOL CELL BIOL, V20, P3482, DOI 10.1128/MCB.20.10.3482-3496.2000; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kim P, 1997, DEV BIOL, V187, P1, DOI 10.1006/dbio.1997.8572; Koibuchi N, 2004, BLOOD, V103, P3320, DOI 10.1182/blood-2003-02-0352; LABONNE C, 1994, DEVELOPMENT, V120, P463; LABONNE C, 1995, DEVELOPMENT, V121, P1475; Lengyel E, 2005, INT J CANCER, V113, P678, DOI 10.1002/ijc.20598; LIU C, 1992, ONCOGENE, V7, P181; Lock LS, 2003, J BIOL CHEM, V278, P30083, DOI 10.1074/jbc.M302675200; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Lombardo A, 2001, MECH DEVELOP, V106, P191, DOI 10.1016/S0925-4773(01)00438-5; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; Maeda R, 2001, ONCOGENE, V20, P1329, DOI 10.1038/sj.onc.1204250; Maroun CR, 1999, J BIOL CHEM, V274, P31719, DOI 10.1074/jbc.274.44.31719; Maulik G, 2002, CLIN CANCER RES, V8, P620; MAYOR R, 1995, DEVELOPMENT, V121, P767; Mood K, 2006, J CELL PHYSIOL, V207, P271, DOI 10.1002/jcp.20564; Nakata K, 1997, P NATL ACAD SCI USA, V94, P11980, DOI 10.1073/pnas.94.22.11980; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Park EK, 2004, MOL BIOL CELL, V15, P1647, DOI 10.1091/mbc.E03-09-0674; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Pownall ME, 1996, DEVELOPMENT, V122, P3881; Radisky DC, 2005, J CELL SCI, V118, P4325, DOI 10.1242/jcs.02552; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; RONG S, 1994, COLD SPRING HARB SYM, V59, P629, DOI 10.1101/SQB.1994.059.01.072; RONG S, 1993, CANCER RES, V53, P5355; SATO SM, 1991, DEVELOPMENT, V112, P747; Sattler M, 2003, CANCER RES, V63, P5462; Saucier C, 2002, ONCOGENE, V21, P1800, DOI 10.1038/sj.onc.1205261; Schmidt L, 1998, CANCER RES, V58, P1719; Shook D, 2003, MECH DEVELOP, V120, P1351, DOI 10.1016/j.mod.2003.06.005; SIVE HL, 2000, EARLY DEV XENOPUS LA, P143; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; STERN CD, 1990, DEVELOPMENT, V110, P1271; Stewart S, 1999, MOL CELL BIOL, V19, P5523; Tada M, 1997, DEVELOPMENT, V124, P2225; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; To CTT, 1998, ONCOL REP, V5, P1013; TSAO MS, 1993, CELL GROWTH DIFFER, V4, P571; Tsarfaty I, 1999, ANAL QUANT CYTOL, V21, P397; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; Vernon AE, 2004, CURR BIOL, V14, pR719, DOI 10.1016/j.cub.2004.08.048; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Weinstein DC, 1998, NATURE, V394, P904, DOI 10.1038/29808; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yasuo H, 2001, INT J DEV BIOL, V45, P229; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100	93	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2006	25	31					4286	4299		10.1038/sj.onc.1209463	http://dx.doi.org/10.1038/sj.onc.1209463			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16518409				2022-12-28	WOS:000239240100004
J	Ling, X; Wang, Y; Dietrich, MF; Andreeff, M; Arlinghaus, RB				Ling, X.; Wang, Y.; Dietrich, M. F.; Andreeff, M.; Arlinghaus, R. B.			Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice	ONCOGENE			English	Article						vaccination; murine leukemia; membrane-bound GM-CSF; lentivirus	DENDRITIC CELLS; TUMOR-CELLS; BALB/C MICE; GENERATION; CANCER; PROGENITORS; VACCINES; IMMUNITY; EGFP; CML	The fundamental basis for immunotherapy of leukemia is that leukemic cells express specific antigens that are not expressed by normal hematopoietic cells. However, the host immune system appears to be tolerant to leukemia cells. To overcome this tolerance, we vaccinated immuno-competent mice with murine leukemia cells (WEHI-3B and BCR-ABL+ 32D cells) transduced with a specifically constructed transmembrane form of granulocyte macrophage colony-stimulating factor ( tmGM-CSF). The transduced cells expressed tmGM-CSF on the cell-surface. To determine whether tmGM-CSF-expressing WEHI-3B leukemia cells would prevent leukemia formation as a vaccine, immunocompetent mice ( BALB/c and C3H/HEJ) were immunized with lethally irradiated murine leukemia cells expressing cell-surface tmGM-CSF before challenging mice with murine leukemia cells. Two immunocompetent mouse models were investigated, either WEHI-3B cells in BALB/c mice or BCR-ABL+ 32D cells in C3H/HEJ mouse. The results showed that 100% of WEHI-3B/tmGM-CSF-vaccinated BALB/c mice and about 65% of 32D+ BCR-ABL/tmGM-CSF-vaccinated C3H/HEJ mice were protected from leukemia after leukemia cell challenge, whereas all non-vaccinated mice succumbed to leukemia. Spleen and marrow cell suspensions from vaccinated mice challenged with WEHI-3B cells lacked detectable GFP+ WEHI-3B cells at 82 days post-challenge. A significant delay of death was observed in C3H/HEJ mice challenged with the very aggressive DA-1 cell line expressing BCR-ABL. Vaccination of mice with WEHI-3B/CD40L cells protected 80% of the mice from the WEHI-3B challenge. Notably, 60% of the WEHI-3B/BALB/c mice were also protected from leukemia when WEHI-3B/tmGM-CSF vaccination was carried out after the leukemia challenge. In order to determine whether cellular immunity is involved in this vaccine-mediated protection, either CD4+ or CD8+ T cells were depleted from mice after the WEHI-3B/tmGM-CSF vaccination. The results indicate that CD8+ T-cells mediated the protective immune response provided by the irradiated tmGM-CSF-expressing WEHI-3B cells. In addition, vaccination of nude mice did not provide protection from WEHI-3B leukemia induction. Importantly, 80% of non-vaccinated mice were also protected from a WEHI-3B cell challenge after receiving spleen cells from vaccinated mice 1 day before challenge with leukemia cells. These results indicate that overexpression of tmGM-CSF on the leukemia cell-surface can enhance the recognition of leukemic cells by CD8+ T cells, and can either prevent or significantly delay leukemia induction. These findings suggest that injection of irradiated leukemia cells expressing cell-surface-bound GM-CSF has the potential as an immunological approach to treat leukemia.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Bone Marrow Transplant, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Arlinghaus, RB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rarlingh@mdanderson.org			NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [5P30 CA16672-29] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acres B, 2004, CURR OPIN MOL THER, V6, P40; BAHNSON AB, 1995, J VIROL METHODS, V54, P131, DOI 10.1016/0166-0934(95)00035-S; Bitton RJ, 2004, CURR OPIN MOL THER, V6, P17; Bleier JI, 2004, J IMMUNOL, V172, P7408, DOI 10.4049/jimmunol.172.12.7408; Butturini A, 1995, Cancer Treat Res, V76, P299; DALCY GQ, 1990, SCIENCE, V16, P824; de Vos S, 1998, LEUKEMIA, V12, P401, DOI 10.1038/sj.leu.2400940; Denaro M, 2001, GENE THER, V8, P1814, DOI 10.1038/sj.gt.3301601; Dong R, 2003, BLOOD, V101, P3560, DOI 10.1182/blood-2002-06-1841; Fujimura T, 2004, IMMUNOL LETT, V93, P17, DOI 10.1016/j.imlet.2004.01.013; Galea-Lauri J, 2002, IMMUNOLOGY, V107, P20, DOI 10.1046/j.1365-2567.2002.01497.x; Gambotto A, 2000, GENE THER, V7, P2036, DOI 10.1038/sj.gt.3301335; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Hoo WS, 1999, J IMMUNOL, V162, P7343; Larregina A, 1996, IMMUNOLOGY, V87, P317, DOI 10.1046/j.1365-2567.1996.451513.x; Ling XY, 2003, CANCER RES, V63, P298; MATULONIS UA, 1995, BLOOD, V85, P2507, DOI 10.1182/blood.V85.9.2507.bloodjournal8592507; Menetrier-Caux C, 1998, BLOOD, V92, P4778, DOI 10.1182/blood.V92.12.4778; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; O'Keefe Christine L, 2004, Hematology, V9, P189, DOI 10.1080/10245330410001701530; Platzbecker U, 2004, LEUKEMIA LYMPHOMA, V45, P447, DOI 10.1080/10428190310001615684; Pulendran B, 2004, EUR J IMMUNOL, V34, P66, DOI 10.1002/eji.200324567; Rojas R, 2003, LEUKEMIA RES, V27, P351, DOI 10.1016/S0145-2126(02)00180-7; Saudemont A, 2005, BLOOD, V105, P2428, DOI 10.1182/blood-2004-09-3458; Saudemont A, 2002, LEUKEMIA, V16, P1637, DOI 10.1038/sj.leu.2402590; STRIPECKE R, 2001, GENE THER, V6, P1305; Vereecque R, 1999, LEUKEMIA RES, V23, P415; Yei S, 2002, GENE THER, V9, P1302, DOI 10.1038/sj.gt.3301803; Zhao RCH, 1997, BLOOD, V90, P4687, DOI 10.1182/blood.V90.12.4687.4687_4687_4698	30	9	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	32					4483	4490		10.1038/sj.onc.1209477	http://dx.doi.org/10.1038/sj.onc.1209477			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16547503				2022-12-28	WOS:000239326000011
J	Mitra, SK; Lim, ST; Chi, A; Schlaepfer, DD				Mitra, S. K.; Lim, S-T; Chi, A.; Schlaepfer, D. D.			Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model	ONCOGENE			English	Article						FAK; FRNK; shRNA; uPA; invasion; metastasis	CELL MOTILITY; GROWTH-FACTOR; FAK EXPRESSION; CANCER CELLS; MIGRATION; INVASION; SRC; PROMOTES; APOPTOSIS; DEATH	Expression of focal adhesion kinase (FAK) is elevated in malignant breast cancer, yet the role of intrinsic FAK activity in promoting tumor progression remains undefined. Here, we have inhibited FAK activity or expression in murine 4T1 breast carcinoma cells via dominant-negative focal adhesion kinase-related non-kinase (FRNK) or anti-FAK short hairpin RNA (shRNA) expression, respectively. Neither FRNK nor FAK shRNA (similar to 80% reduced FAK levels) affected 4T1 proliferation in culture, whereas reduced FAK activity or expression blocked 4T1 cell invasion through Matrigel and resulted in 2-3-fold lower urokinase plasminogen activator (uPA) expression. Control 4T1 cells implanted into mammary fat pads of BALB/c mice exhibited spontaneous metastasis to the lungs, to the peritoneal cavity, and resulted in 90% lethality within 21 days. Whereas FAK shRNA-expressing 4T1 cells formed tumors in mice with low levels of apoptosis, when mammary-injected, these cells did not exhibit lung metastasis after 21 days and caused only 40% lethality up to 60 days. Transient re-expression of wildtype but not kinase-dead FAK in 4T1 FAK shRNA cells promoted uPA production and mammary to lung metastasis within 7 days. In fact, stable human uPA overexpression in 4T1 FAK shRNA cells promoted Matrigel invasion and lung metastasis equal to 4T1 controls. Conversely, treatment with plasminogen activator inhibitor-1 or neutralizing antibody to uPA blocked Matrigel invasion of 4T1 control cells. These studies provide the first direct proof that FAK catalytic activity can facilitate metastatic breast cancer progression by regulating uPA expression.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Schlaepfer, DD (corresponding author), Scripps Res Inst, Dept Immunol, IMM 21,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	dschlaep@scripps.edu		Lim, Steve/0000-0003-0323-8607	NATIONAL CANCER INSTITUTE [R29CA075240, R01CA075240, R01CA102310, R01CA087038] Funding Source: NIH RePORTER; NCI NIH HHS [CA87038, CA102310, CA75240] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdel-Ghany M, 2002, J BIOL CHEM, V277, P34391, DOI 10.1074/jbc.M205307200; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Benlimame N, 2005, J CELL BIOL, V171, P505, DOI 10.1083/jcb.200504124; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Buccione R, 2004, NAT REV MOL CELL BIO, V5, P647, DOI 10.1038/nrm1436; Duxbury MS, 2003, BIOCHEM BIOPH RES CO, V311, P786, DOI 10.1016/j.bbrc.2003.10.060; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; Ghiso JAA, 2002, ONCOGENE, V21, P2513, DOI 10.1038/sj/onc/1205342; Golubovskaya V, 2002, J BIOL CHEM, V277, P38978, DOI 10.1074/jbc.M205002200; Han EKH, 2004, ANTICANCER RES, V24, P3899; Hanks SK, 2003, FRONT BIOSCI-LANDMRK, V8, pD982, DOI 10.2741/1114; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; Hauck CR, 2002, J BIOL CHEM, V277, P12487, DOI 10.1074/jbc.C100760200; Hauck CR, 2001, CANCER RES, V61, P7079; Heppner GH, 2000, BREAST CANCER RES, V2, P331; Hess AR, 2005, CANCER RES, V65, P9851, DOI 10.1158/0008-5472.CAN-05-2172; Hsia DA, 2005, MOL CELL BIOL, V25, P9700, DOI 10.1128/MCB.25.21.9700-9712.2005; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Itoh S, 2004, CLIN CANCER RES, V10, P2812, DOI 10.1158/1078-0432.CCR-1046-03; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Lightfoot HM, 2004, BREAST CANCER RES TR, V88, P109, DOI 10.1007/s10549-004-1022-8; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Miyazaki T, 2003, BRIT J CANCER, V89, P140, DOI 10.1038/sj.bjc.6601050; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Oktay MH, 2003, HUM PATHOL, V34, P240, DOI 10.1053/hupa.2003.40; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Recher C, 2004, CANCER RES, V64, P3191, DOI 10.1158/0008-5472.CAN-03-3005; Rubio CA, 2003, EUR J CLIN INVEST, V33, P406, DOI 10.1046/j.1365-2362.2003.01151.x; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Sood AK, 2004, AM J PATHOL, V165, P1087, DOI 10.1016/S0002-9440(10)63370-6; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tilghman RW, 2005, J CELL SCI, V118, P2613, DOI 10.1242/jcs.02380; van Nimwegen MJ, 2005, CANCER RES, V65, P4698, DOI 10.1158/0008-5472.CAN-04-4126; Watermann DO, 2005, BRIT J CANCER, V93, P694, DOI 10.1038/sj.bjc.6602744; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Wu XY, 2005, DEV CELL, V9, P185, DOI 10.1016/j.devcel.2005.06.006; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; Xu LH, 1998, CELL GROWTH DIFFER, V9, P999; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; YU H, 1990, CANCER RES, V50, P7623	48	81	88	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	32					4429	4440		10.1038/sj.onc.1209482	http://dx.doi.org/10.1038/sj.onc.1209482			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16547501				2022-12-28	WOS:000239326000006
J	Schiller, M; Bohm, M; Dennler, S; Ehrchen, JM; Mauviel, A				Schiller, M.; Boehm, M.; Dennler, S.; Ehrchen, J. M.; Mauviel, A.			Mitogen- and stress-activated protein kinase 1 is critical for interleukin-1-induced, CREB-mediated, c-fos gene expression in keratinocytes	ONCOGENE			English	Article						cAMP; c-fos; CREB; PKA; MAP kinases; interleukin-1	KINASE SIGNALING CASCADES; SERUM RESPONSE ELEMENT; PROTEIN-KINASE; MAP KINASE; METALLOPROTEINASE EXPRESSION; TRANSGENIC MICE; TRANSCRIPTION; INDUCTION; AP-1; CELLS	c-fos, which encodes a transcription factor of the AP-1 family, is a prototypical immediate-early gene induced by a number of proinflammatory cytokines including interleukin-1 (IL-1), the latter being an important regulator of skin homeostasis. Using the human keratinocyte cell line HaCaT as an in vitro model, we dissected the molecular pathways leading to IL-1-induced c-fos gene induction. Phosphorylation of the transcription factor cAMP response element binding protein (CREB) at Ser133 was found to be essential for IL-1-induced c-fos gene induction and was closely paralleled by protein kinase A (PKA) activation. In contrast to other cell types, the cyclooxy-genase/prostaglandin pathway, known to activate the cAMP/PKA cascade, plays little, if any, role in c-fos expression downstream of the IL-1 receptor in keratinocytes. Simultaneous activation of several of the mitogen-activated protein kinase (MAPK) cascades occurred in response to IL-1, but each differentially contributed to c-fos induction by IL-1, with the p38/MAPK being the most crucial of all, the extracellular signal-regulated kinase pathway contributing in an additive manner and the Jun N-terminal kinase pathway playing little, if any, role. We also demonstrate that p38-dependent activation of mitogen- and stress-activated kinase 1 (MSK1), a CREB kinase, is a key step for c-fos gene activation by IL-1. Finally, we identify MSK1 as playing a positive role in the control of cell proliferation of both HaCaT keratinocytes and the A431 human epidermoid carcinoma line.	Hop St Louis, INSERM, U697, F-75010 Paris, France; Univ Munster, Ludwig Boltzmann Inst Cell Biol & Immunobiol, Dept Dermatol, Munster, Germany	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Munster	Mauviel, A (corresponding author), Hop St Louis, INSERM, U697, Pavillon Bazin,1 Ave Claude Vellefaux, F-75010 Paris, France.	alain.mauviel@stlouis.inserm.fr	MAUVIEL, Alain/F-6251-2013	Mauviel, Alain/0000-0002-0438-2793				Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Andrisani OM, 1999, CRIT REV EUKAR GENE, V9, P19, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.20; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Braddock M, 2004, NAT REV DRUG DISCOV, V3, P1, DOI 10.1038/nrd1342; Caivano M, 2000, J IMMUNOL, V164, P3018, DOI 10.4049/jimmunol.164.6.3018; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; Dayer JM, 2003, RHEUMATOLOGY, V42, P3, DOI 10.1093/rheumatology/keg326; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Dinarello CA, 2002, CLIN EXP RHEUMATOL, V20, pS1; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kumar S, 2001, J CELL PHYSIOL, V187, P294, DOI 10.1002/jcp.1082; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LUGER TA, 1990, J INVEST DERMATOL, V95, pS100, DOI 10.1111/1523-1747.ep12874944; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; Podolsky DK, 1997, J GASTROENTEROL, V32, P122, DOI 10.1007/BF01213309; Price MA, 1996, PHILOS T ROY SOC B, V351, P551, DOI 10.1098/rstb.1996.0054; Ramirez S, 1997, J BIOL CHEM, V272, P31016, DOI 10.1074/jbc.272.49.31016; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; Schuck S, 2003, BMC MOL BIOL, V4, DOI 10.1186/1471-2199-4-6; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Song KS, 2003, J BIOL CHEM, V278, P23243, DOI 10.1074/jbc.M300096200; Strniskova M, 2002, GEN PHYSIOL BIOPHYS, V21, P231; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Vincenti MP, 1996, CRIT REV EUKAR GENE, V6, P391, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.40; WANG ZQ, 1995, CANCER RES, V55, P6244; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; WESTMAYS JA, 1995, P NATL ACAD SCI USA, V92, P6768, DOI 10.1073/pnas.92.15.6768; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378-1119(03)00816-3	38	37	41	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	32					4449	4457		10.1038/sj.onc.1209479	http://dx.doi.org/10.1038/sj.onc.1209479			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16532028				2022-12-28	WOS:000239326000008
J	Chan, IH; Privalsky, ML				Chan, I. H.; Privalsky, M. L.			Thyroid hormone receptors mutated in liver cancer function as distorted antimorphs	ONCOGENE			English	Article						nuclear hormone receptors; dominant-negatives; hepatocellular carcinoma; DNA recognition; c-Jun; AP-1	DOMINANT-NEGATIVE ACTIVITY; RETINOIC ACID RECEPTORS; HUMAN HEPATOCELLULAR-CARCINOMA; NUCLEAR RECEPTORS; V-ERBA; TRANSCRIPTIONAL ACTIVATION; RESISTANCE; COREPRESSOR; GENE; EXPRESSION	Aberrant thyroid hormone receptors (TRs) are found in over 70% of the human hepatocellular carcinomas (HCCs) analysed. To better understand the role(s) of these TR mutants in this neoplasia, we analysed a panel of HCC mutant receptors for their molecular properties. Virtually all HCC-associated TR mutants tested retained the ability to repress target genes in the absence of T3, yet were impaired in T3-driven gene activation and functioned as dominant-negative inhibitors of wild-type TR activity. Intriguingly, the HCC TRa1 mutants exerted dominant-negative interference at all T3 concentrations tested, whereas the HCC TR beta 1 mutants were dominant-negatives only at low and intermediate T3 concentrations, reverting to transcriptional activators at higher hormone levels. The relative affinity for the SMRT versus N-CoR corepressors was detectably altered for several of the HCC mutant TRs, suggesting changes in corepressor preference and recruitment compared to wild type. Several of the TR alpha HCC mutations also altered the DNA recognition properties of the encoded receptors, indicating that these HCC TR mutants may regulate a distinct set of target genes from those regulated by wild-type TRs. Finally, whereas wild-type TRs interfere with c-Jun/AP-1 function in a T3-dependent fashion and suppress anchorage-independent growth when ectopically expressed in HepG2 cells, at least certain of the HCC mutants did not exert these inhibitory properties. These alterations in transcriptional regulation and DNA recognition appear likely to contribute to oncogenesis by reprogramming the differentiation and proliferative properties of the hepatocytes in which the mutant TRs are expressed.	Univ Calif Davis, Microbiol Sect, Div Biol Sci, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Privalsky, ML (corresponding author), Univ Calif Davis, Microbiol Sect, Div Biol Sci, 1 Shields Ave, Davis, CA 95616 USA.	mlprivalsky@ucdavis.edu	Chan, Ivan/B-7922-2010	Chan, Ivan/0000-0003-2834-2574	NATIONAL CANCER INSTITUTE [R37CA053394] Funding Source: NIH RePORTER; NCI NIH HHS [R37-CA53394, R37 CA053394, R37 CA053394-13] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ando S, 2001, J CLIN ENDOCR METAB, V86, P5572, DOI 10.1210/jc.86.11.5572; Apriletti JW, 1998, CLIN EXP PHARMACOL P, V25, pS2, DOI 10.1111/j.1440-1681.1998.tb02293.x; BARLOW C, 1994, EMBO J, V13, P4241, DOI 10.1002/j.1460-2075.1994.tb06744.x; Beato M, 2000, HUM REPROD UPDATE, V6, P225, DOI 10.1093/humupd/6.3.225; Chatterjee VKK, 1997, HORM RES, V48, P43, DOI 10.1159/000191312; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; Cheng SY, 2003, MOL CELL ENDOCRINOL, V213, P23, DOI 10.1016/j.mce.2003.10.051; DeGroot LJ, 1996, ANN INTERN MED, V125, P623, DOI 10.7326/0003-4819-125-7-199610010-00022; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Farboud B, 2004, MOL ENDOCRINOL, V18, P2839, DOI 10.1210/me.2004-0236; Furumoto H, 2005, MOL CELL BIOL, V25, P124, DOI 10.1128/MCB.25.1.124-135.2005; Garcia-Silva S, 2004, MOL CELL BIOL, V24, P7514, DOI 10.1128/MCB.24.17.7514-7523.2004; Glass CK, 1996, J ENDOCRINOL, V150, P349, DOI 10.1677/joe.0.1500349; Glass CK, 2000, GENE DEV, V14, P121; Gonzalez-Sancho JM, 2003, CANCER LETT, V192, P121, DOI 10.1016/S0304-3835(02)00614-6; Goodson ML, 2005, J BIOL CHEM, V280, P7493, DOI 10.1074/jbc.M411514200; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HuberGieseke T, 1997, ONCOLOGY, V54, P214; Ikeda M, 1996, J BIOL CHEM, V271, P23096, DOI 10.1074/jbc.271.38.23096; Jonas BA, 2004, J BIOL CHEM, V279, P54676, DOI 10.1074/jbc.M410128200; Judelson C, 1996, J BIOL CHEM, V271, P10800, DOI 10.1074/jbc.271.18.10800; Kamiya Y, 2003, ENDOCRINOLOGY, V144, P4144, DOI 10.1210/en.2003-0239; Kamiya Y, 2002, CARCINOGENESIS, V23, P25, DOI 10.1093/carcin/23.1.25; Kato Y, 2004, ENDOCRINOLOGY, V145, P4430, DOI 10.1210/en.2004-0612; Koenig RJ, 1998, THYROID, V8, P703, DOI 10.1089/thy.1998.8.703; Kopp P, 1996, P SOC EXP BIOL MED, V211, P49; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; Lee JW, 2002, CANCER LETT, V184, P149, DOI 10.1016/S0304-3835(02)00206-9; Lee MO, 2002, BIOL PHARM BULL, V25, P1298, DOI 10.1248/bpb.25.1298; Lee S, 2005, MOL ENDOCRINOL, V19, P863, DOI 10.1210/me.2004-0210; LENG XH, 1993, J STEROID BIOCHEM, V46, P643, DOI 10.1016/0960-0760(93)90306-H; Lin BC, 1997, MOL CELL BIOL, V17, P6131, DOI 10.1128/MCB.17.10.6131; Lin KH, 1997, ENDOCRINOLOGY, V138, P5308, DOI 10.1210/en.138.12.5308; Lin KH, 2001, ENDOCRINOLOGY, V142, P653, DOI 10.1210/en.142.2.653; Lin KH, 1999, MOL CARCINOGEN, V26, P53, DOI 10.1002/(SICI)1098-2744(199909)26:1<53::AID-MC7>3.0.CO;2-Z; Liu Y, 1998, ENDOCRINOLOGY, V139, P4197, DOI 10.1210/en.139.10.4197; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Matsushita A, 2000, J ENDOCRINOL, V167, P493, DOI 10.1677/joe.0.1670493; Moehren U, 2004, ESSAYS BIOCHEM, V40, P89, DOI 10.1042/bse0400089; Murata Y, 1998, Nagoya J Med Sci, V61, P103; Nagaya T, 1998, BIOCHEM BIOPH RES CO, V247, P620, DOI 10.1006/bbrc.1998.8854; Nagaya T, 1998, ENDOCR J, V45, P709, DOI 10.1507/endocrj.45.709; Ordentlich P, 2001, CURR TOP MICROBIOL, V254, P101; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556; Privalsky ML, 2000, MOL CELL ENDOCRINOL, V159, P109, DOI 10.1016/S0303-7207(99)00201-4; Puzianowska-Kuznicka M, 2002, J CLIN ENDOCR METAB, V87, P1120, DOI 10.1210/jc.87.3.1120; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; REFETOFF S, 1993, CLIN LAB MED, V13, P563, DOI 10.1016/S0272-2712(18)30426-8; Ribeiro RCJ, 1998, RECENT PROG HORM RES, V53, P351; Safer JD, 1998, J BIOL CHEM, V273, P30175, DOI 10.1074/jbc.273.46.30175; SANDE S, 1993, J VIROL, V67, P1067, DOI 10.1128/JVI.67.2.1067-1074.1993; SCHMIDT EDL, 1993, BIOCHEM BIOPH RES CO, V192, P151, DOI 10.1006/bbrc.1993.1394; SHARIF M, 1992, ONCOGENE, V7, P953; SISLEY K, 1993, MELANOMA RES, V3, P457, DOI 10.1097/00008390-199311000-00009; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; Suriawinata A, 2004, SEMIN LIVER DIS, V24, P77; Tagami T, 1998, ENDOCRINOLOGY, V139, P640, DOI 10.1210/en.139.2.640; Tenbaum S, 1997, INT J BIOCHEM CELL B, V29, P1325, DOI 10.1016/S1357-2725(97)00087-3; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Wang CS, 2002, CANCER LETT, V175, P121, DOI 10.1016/S0304-3835(01)00722-4; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; Winter WE, 2001, ANN CLIN LAB SCI, V31, P221; Wong CW, 1998, MOL CELL BIOL, V18, P5724, DOI 10.1128/MCB.18.10.5724; Yen PM, 2003, J ENDOCRINOL INVEST, V26, P780, DOI 10.1007/BF03347365; Yoh SM, 1997, MOL ENDOCRINOL, V11, P470, DOI 10.1210/me.11.4.470; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	72	49	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3576	3588		10.1038/sj.onc.1209389	http://dx.doi.org/10.1038/sj.onc.1209389			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16434963	Green Accepted			2022-12-28	WOS:000238448200010
J	Sheth, SS; Bodnar, JS; Ghazalpour, A; Thipphavong, CK; Tsutsumi, S; Tward, AD; Demant, P; Kodama, T; Aburatani, H; Lusis, AJ				Sheth, S. S.; Bodnar, J. S.; Ghazalpour, A.; Thipphavong, C. K.; Tsutsumi, S.; Tward, A. D.; Demant, P.; Kodama, T.; Aburatani, H.; Lusis, A. J.			Hepatocellular carcinoma in Txnip-deficient mice	ONCOGENE			English	Article						hepatocellular carcinoma; mouse model; Txnip; thioredoxin	THIOREDOXIN-INTERACTING PROTEIN; DIFFERENTIALLY EXPRESSED GENES; MESSENGER-RNA; 1,25-DIHYDROXYVITAMIN D-3; COMBINED HYPERLIPIDEMIA; PLASMINOGEN-ACTIVATOR; LIVER-REGENERATION; UP-REGULATION; E-CADHERIN; IN-VITRO	The molecular pathogenesis and the genetic aberrations that lead to the progression of hepato cellular carcinoma (HCC) are largely unknown. Here, we demonstrate that the thioredoxin interacting protein (Txnip) gene is a candidate tumor suppressor gene in vivo. We previously showed that the recombinant inbred congenic strain HcB-19 has a spontaneous mutation of the Txnip gene, and we now show that the strain has dramatically increased incidence of HCC, and that the HCC cosegregates with the Txnip mutation. Approximately 40% of the Txnip deficient mice developed hepatic tumors with an increased prevalence in male mice. Visible tumors develop as early as 8 months of age. Histological analysis confirmed the morphology of HCC in the Txnip-deficient mice. Molecular markers of HCC, alpha-fetoprotein and p53, were increased in tumors of Txnip-deficient mice. The upregulation of p53 preceded tumor development; however, bromodeoxyuridine (BrdU) labeling of normal hepatic tissue of Txnip-deficient mice did not reveal increased cell proliferation. Finally, microarray analyses of tumor, non-tumor adjacent, and normal tissue of Txnip-deficient mice highlighted the genetic differences leading to the predisposition and onset of HCC. Our findings suggest that Txnip de. ciency is sufficient to initiate HCC and suggest novel mechanisms in hepatocarcinogenesis.	Univ Calif Los Angeles, David Geffen Sch Med, Ctr Hlth Sci 47 123, Dept Human Genet,Mol Biol Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; Beckman Coulter Inc, Biomed Res Div, Fullerton, CA USA; Univ Tokyo, Adv Sci & Technol Res Ctr, Genome Sci Div, Meguro Ku, Tokyo, Japan; Univ Calif San Francisco, Dept Microbiol & Immunol, George Williams Hooper Fdn, San Francisco, CA 94143 USA; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Univ Tokyo, Adv Sci & Technol Res Ctr, Lab Syst Biol & Med, Meguro Ku, Tokyo, Japan; Univ Calif Los Angeles, Johnson Comprehens Canc Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Beckman Coulter Inc.; University of Tokyo; University of California System; University of California San Francisco; Roswell Park Cancer Institute; University of Tokyo; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Lusis, AJ (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Ctr Hlth Sci 47 123, Dept Human Genet,Mol Biol Inst, Los Angeles, CA 90095 USA.	jlusis@mednet.ucla.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028481] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28481] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bechard D, 2001, J BIOL CHEM, V276, P48341, DOI 10.1074/jbc.M108395200; Bodnar JS, 2002, NAT GENET, V30, P110, DOI 10.1038/ng811; Buendia MA, 2002, MED PEDIATR ONCOL, V39, P530, DOI 10.1002/mpo.10180; Capiati DA, 2004, J CELL BIOCHEM, V93, P384, DOI 10.1002/jcb.20165; Castellani LW, 1998, NAT GENET, V18, P374, DOI 10.1038/ng0498-374; Chen F, 2004, CANCER RES, V64, P5425, DOI 10.1158/0008-5472.CAN-04-0806; CHEN KS, 1994, BBA-GENE STRUCT EXPR, V1219, P26, DOI 10.1016/0167-4781(94)90242-9; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; DEMANT P, 1986, IMMUNOGENETICS, V24, P416, DOI 10.1007/BF00377961; DRAGANI TA, 1989, MOL CARCINOGEN, V2, P355, DOI 10.1002/mc.2940020610; Dudoit S, 2002, GENOME BIOL, V3; Elchuri S, 2005, ONCOGENE, V24, P367, DOI 10.1038/sj.onc.1208207; Escrich E, 2004, MOL CARCINOGEN, V40, P73, DOI 10.1002/mc.20028; Faith DA, 2004, PROSTATE, V61, P215, DOI 10.1002/pros.20095; Feitelson MA, 1997, AM J PATHOL, V150, P1141; Feng SLY, 2000, AM J PATHOL, V156, P1253, DOI 10.1016/S0002-9440(10)64996-6; Furutani M, 1996, HEPATOLOGY, V24, P1441, DOI 10.1053/jhep.1996.v24.pm0008938178; Goldberg SF, 2003, CANCER RES, V63, P432; GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513; Han SH, 2003, ONCOGENE, V22, P4035, DOI 10.1038/sj.onc.1206610; Heinzelmann-Schwarz VA, 2004, CLIN CANCER RES, V10, P4427, DOI 10.1158/1078-0432.CCR-04-0073; HSU HC, 1993, CANCER RES, V53, P4691; Ikarashi M, 2002, ANTICANCER RES, V22, P4045; Jeon JH, 2005, CANCER RES, V65, P4485, DOI 10.1158/0008-5472.CAN-04-2271; Jiang F, 2004, J BIOL CHEM, V279, P53213, DOI 10.1074/jbc.M410395200; Jiao W, 2002, BRIT J CANCER, V86, P98, DOI 10.1038/sj.bjc.6600017; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Koteish A, 2002, ALCOHOL CLIN EXP RES, V26, P1710, DOI 10.1097/01.ALC.0000036923.77613.59; Lee KN, 2005, IMMUNITY, V22, P195, DOI 10.1016/j.immuni.2004.12.012; Lee YI, 2004, J BIOL CHEM, V279, P15460, DOI 10.1074/jbc.M309280200; MARONPOT RR, 1995, TOXICOLOGY, V101, P125, DOI 10.1016/0300-483X(95)03112-S; Minn AH, 2005, ENDOCRINOLOGY, V146, P2397, DOI 10.1210/en.2004-1378; Miyaguchi S, 2000, HEPATO-GASTROENTEROL, V47, P468; Pajukanta P, 2001, MAMM GENOME, V12, P238, DOI 10.1007/s003350010265; Pourgholami MH, 2000, CANCER LETT, V151, P97, DOI 10.1016/S0304-3835(99)00416-4; Powis G, 2001, ANNU REV PHARMACOL, V41, P261, DOI 10.1146/annurev.pharmtox.41.1.261; Saitoh T, 2001, J NEUROCHEM, V78, P1267, DOI 10.1046/j.1471-4159.2001.00505.x; Scherpereel A, 2003, CANCER RES, V63, P6084; Sergeev IN, 2004, J STEROID BIOCHEM, V89-90, P419, DOI 10.1016/j.jsbmb.2004.03.010; Sheth SS, 2005, J LIPID RES, V46, P123, DOI 10.1194/jlr.M400341-JLR200; Shih DM, 2000, J BIOL CHEM, V275, P17527, DOI 10.1074/jbc.M910376199; Solmi R, 2004, INT J ONCOL, V25, P1049; Tackels-Horne D, 2001, CANCER-AM CANCER SOC, V92, P395, DOI 10.1002/1097-0142(20010715)92:2<395::AID-CNCR1335>3.0.CO;2-U; Takahashi Y, 2002, ONCOL REP, V9, P75; Trowbridge JM, 2002, GLYCOBIOLOGY, V12, p117R, DOI 10.1093/glycob/cwf066; Wei Y, 2002, HEPATOLOGY, V36, P692, DOI 10.1053/jhep.2002.35342; Yamada Y, 1999, LAB INVEST, V79, P1059; Yang XQ, 1998, BREAST CANCER RES TR, V48, P33, DOI 10.1023/A:1005929714900; Zhou L, 2000, PATHOL INT, V50, P392, DOI 10.1046/j.1440-1827.2000.01059.x	50	113	117	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3528	3536		10.1038/sj.onc.1209394	http://dx.doi.org/10.1038/sj.onc.1209394			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16607285				2022-12-28	WOS:000238448200005
J	To, MD; Gokgoz, N; Doyle, TG; Donoviel, DB; Knight, JA; Hyslop, PS; Bernstein, A; Andrulis, IL				To, M. D.; Gokgoz, N.; Doyle, T. G.; Donoviel, D. B.; Knight, J. A.; Hyslop, P. S.; Bernstein, A.; Andrulis, I. L.			Functional characterization of novel presenilin-2 variants identified in human breast cancers	ONCOGENE			English	Article						presenilins; PS-2; breast cancer; Alzheimer's disease; susceptibility	FAMILIAL ALZHEIMERS-DISEASE; AMYLOID PRECURSOR PROTEIN; BETA-CATENIN; SUBCELLULAR-LOCALIZATION; CAENORHABDITIS-ELEGANS; MISSENSE MUTATIONS; CELL-CYCLE; IN-VIVO; GENE; MUTANT	We identified in breast cancer cases two germline alterations, R62H and R71W, in presenilin-2 (PS-2), a gene involved in familial Alzheimer's disease (FAD). The role of these alleles in FAD is unclear, but neither allele affected A beta(42)/A beta(40) ratio. However, both R62H and R71W alterations compromised PS-2 function in Notch signaling in Caenorhabditis elegans and cell growth inhibition in mouse embryonic fibroblasts, and these effects were dependent on gene dosage. We found that both alterations enhanced the degradation of the PS-2 full-length protein, indicating that they may have a loss-of function effect. The effect of the R71W alteration was noticeably stronger, and we observed an almost threefold higher frequency of this allele in breast cancer cases versus controls, but this difference did not reach statistical significance. Nonetheless, these results collectively suggest that the novel PS-2 alleles described here, especially R71W, affect PS-2 function and may potentially confer a moderate risk of susceptibility to breast cancer.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Fred A Litwin Ctr Canc Genet, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Columbia Univ, Integrated Program Cellular Mol & Biophys Studies, New York, NY USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Prosserman Ctr Hlth Res, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; Univ Toronto, Ctr Res Neurodegenerat, Toronto, ON, Canada; Univ Toronto, Dept Med Neurol, Toronto, ON, Canada; Canadian Inst Hth Res, Ottawa, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Columbia University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto	Andrulis, IL (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Fred A Litwin Ctr Canc Genet, 600 Univ Ave,Room 984, Toronto, ON M5G 1X5, Canada.	andrulis@mshri.on.ca	Knight, Julia/R-5617-2019; Knight, Julia/A-6843-2012; Andrulis, Irene L./E-7267-2013	Knight, Julia/0000-0002-7610-7635; St George-Hyslop, Peter/0000-0003-0796-7209	NATIONAL CANCER INSTITUTE [U01CA069467] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA69467] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; Baumeister R, 1997, Genes Funct, V1, P149; Bird TD, 1996, ANN NEUROL, V40, P932, DOI 10.1002/ana.410400619; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Cruts M, 1998, HUM MOL GENET, V7, P43, DOI 10.1093/hmg/7.1.43; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; Deng GM, 1996, FEBS LETT, V397, P50, DOI 10.1016/S0014-5793(96)01142-8; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Gokgoz N, 2001, CANCER, V92, P2181, DOI 10.1002/1097-0142(20011015)92:8<2181::AID-CNCR1561>3.0.CO;2-3; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Hutton M, 1997, HUM MOL GENET, V6, P1639, DOI 10.1093/hmg/6.10.1639; Jacobsen H, 1999, J BIOL CHEM, V274, P35233, DOI 10.1074/jbc.274.49.35233; Janicki SM, 1999, AM J PATHOL, V155, P135, DOI 10.1016/S0002-9440(10)65108-5; Janicki SM, 2000, NEUROBIOL AGING, V21, P829, DOI 10.1016/S0197-4580(00)00222-0; Jeong SJ, 2000, FASEB J, V14, P2171, DOI 10.1096/fj.99-1068com; Joutel A, 1998, SEMIN CELL DEV BIOL, V9, P619, DOI 10.1006/scdb.1998.0261; Kang DE, 2002, CELL, V110, P751, DOI 10.1016/S0092-8674(02)00970-4; Knight JA, 2002, ANN EPIDEMIOL, V12, P27, DOI 10.1016/S1047-2797(01)00253-8; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li JH, 1997, CELL, V90, P917, DOI 10.1016/S0092-8674(00)80356-6; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Saura CA, 1999, J BIOL CHEM, V274, P13818, DOI 10.1074/jbc.274.20.13818; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sherrington R, 1996, HUM MOL GENET, V5, P985, DOI 10.1093/hmg/5.7.985; Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Takano T, 1997, NEUROSCI LETT, V221, P205, DOI 10.1016/S0304-3940(96)13290-0; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Walker ES, 2005, J NEUROCHEM, V92, P294, DOI 10.1111/j.1471-4159.2004.02858.x; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Xia XF, 2001, P NATL ACAD SCI USA, V98, P10863, DOI 10.1073/pnas.191284198; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 2000, J BIOL CHEM, V275, P27348; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	43	29	29	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 15	2006	25	25					3557	3564		10.1038/sj.onc.1209397	http://dx.doi.org/10.1038/sj.onc.1209397			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16474849				2022-12-28	WOS:000238448200008
J	Falvella, FS; Manenti, G; Spinola, M; Pignatiello, C; Conti, B; Pastorino, U; Dragani, TA				Falvella, F. S.; Manenti, G.; Spinola, M.; Pignatiello, C.; Conti, B.; Pastorino, U.; Dragani, T. A.			Identification of RASSF8 as a candidate lung tumor suppressor gene	ONCOGENE			English	Article						lung cancer; KRAS; RAS genes; cancer progression	ANCHORAGE-INDEPENDENT GROWTH; K-RAS; METASTASIS; CANCER; ONCOGENE; MUTATIONS; PROTEIN; PATHWAY	The RASSF8 gene, which maps close to the KRAS2 gene, contains a RAS-associated domain and encodes a protein that is evolutionarily conserved from fish to humans. Analysis of the RASSF8 transcript revealed a complex expression pattern of 5'-UTR mRNA isoforms in normal lung and in lung adenocarcinomas (ADCAs), with no apparent differences. However, RASSF8 gene transcript levels were similar to seven-fold-lower in lung ADCAs as compared to normal lung tissue. Expression of RASSF8 protein by transfected lung cancer cells led to inhibition of anchorage-independent growth in soft agar in A549 cells and reduction of clonogenic activity in NCI-H520 cells. These results raise the possibility protein encoded by RASSF8 is a novel tumor suppressor for lung cancer.	Ist Nazl Tumori, Dept Expt Oncol & Labs, I-20133 Milan, Italy; Ist Nazl Tumori, Unit Thorac Surg, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Dragani, TA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol & Labs, Via Venezian 1, I-20133 Milan, Italy.	tommaso.dragani@istitutotumori.mi.it	Manenti, Giacomo/J-3339-2017; Dragani, Tommaso A./K-4493-2016; Pastorino, Ugo/C-2712-2017	Manenti, Giacomo/0000-0002-4887-4482; Dragani, Tommaso A./0000-0001-5915-4598; Pastorino, Ugo/0000-0001-9974-7902				Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Clezardin P, 1998, CELL MOL LIFE SCI, V54, P541, DOI 10.1007/s000180050182; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; De Gregorio L, 1998, INT J CANCER, V79, P269, DOI 10.1002/(SICI)1097-0215(19980619)79:3<269::AID-IJC10>3.3.CO;2-J; Debeer P, 2002, J MED GENET, V39, P98, DOI 10.1136/jmg.39.2.98; Ellis CA, 2000, CELL SIGNAL, V12, P425, DOI 10.1016/S0898-6568(00)00084-X; Guerois R, 2002, J MOL BIOL, V320, P369, DOI 10.1016/S0022-2836(02)00442-4; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Huncharek M, 1999, CARCINOGENESIS, V20, P1507, DOI 10.1093/carcin/20.8.1507; Jiang YX, 2001, ONCOGENE, V20, P2254, DOI 10.1038/sj.onc.1204293; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kiel C, 2005, J MOL BIOL, V348, P759, DOI 10.1016/j.jmb.2005.02.046; Malaney S, 2001, J MAMMARY GLAND BIOL, V6, P101, DOI 10.1023/A:1009572700317; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Mascaux C, 2005, BRIT J CANCER, V92, P131, DOI 10.1038/sj.bjc.6602258; Nakanishi K, 2002, CANCER RES, V62, P2971; Nikiforov MA, 1996, ONCOGENE, V13, P1709; Wall JD, 2003, NAT REV GENET, V4, P587, DOI 10.1038/nrg1123; Wohlgemuth S, 2005, J MOL BIOL, V348, P741, DOI 10.1016/j.jmb.2005.02.048	19	41	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3934	3938		10.1038/sj.onc.1209422	http://dx.doi.org/10.1038/sj.onc.1209422			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16462760				2022-12-28	WOS:000238668800006
J	Vasilcanu, D; Weng, WH; Girnita, A; Lui, WO; Vasilcanu, R; Axelson, M; Larsson, O; Larsson, C; Girnita, L				Vasilcanu, D.; Weng, W-H; Girnita, A.; Lui, W-O; Vasilcanu, R.; Axelson, M.; Larsson, O.; Larsson, C.; Girnita, L.			The insulin-like growth factor-1 receptor inhibitor PPP produces only very limitedresistance in tumor cells exposed to long-term selection	ONCOGENE			English	Article						IGF-1 receptor; drug resistance; PPP	TYROSINE KINASE-ACTIVITY; SINGLE-CHAIN ANTIBODY; BREAST-CANCER CELLS; INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR; IGF-I; ANTITUMOR-ACTIVITY; CYCLOLIGNAN PPP; MULTIDRUG-RESISTANCE; MOLECULAR-MECHANISMS; MULTIPLE-MYELOMA	The cyclolignan PPP was recently demonstrated to inhibit the activity of insulin-like growth factor-1 receptor (IGF-1R), without affecting the highly homologous insulin receptor. In addition, PPP caused complete regression of xenografts derived from various types of cancer. These data highlight the use of this compound in cancer treatment. However, a general concern with antitumor agents is development of resistance. In light of this problem, we aimed to investigate whether malignant cells may develop serious resistance to PPP. After trying to select 10 malignant cell lines, with documented IGF-1R expression and apoptotic responsiveness to PPP treatment (IC(50)s less than 0.1 mu M), only two survived an 80-week selection but could only tolerate maximal PPP doses of 0.2 and 0.5 mu M, respectively. Any further increase in the PPP dose resulted in massive cell death. These two cell lines were demonstrated not to acquire any essential alteration in responsiveness to PPP regarding IGF-1-induced IGF-1R phosphorylation. Neither did they exhibit any increase in expression of the multidrug resistance proteins MDR1 or MRP1. Consistently, they did not exhibit decreased sensitivity to conventional cytostatic drugs. Rather, the sensitivity was increased. During the first half of the selection period, both cell lines responded with a temporary and moderate increase in IGF-1R expression, which appeared to be because of an increased transcription of the IGF-1R gene. This increase in IGF-1R might be necessary to make cells competent for further selection but only up to a PPP concentration of 0.2 and 0.5 mu M. In conclusion, malignant cells develop no or remarkably weak resistance to the IGF-1R inhibitor PPP.	Karolinska Univ Hosp, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden; Karolinska Univ Hosp, Dept Mol Med, SE-17176 Stockholm, Sweden; Karolinska Univ Hosp, Dept Clin Chem, SE-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Larsson, O (corresponding author), Karolinska Univ Hosp, Dept Pathol & Oncol, CCK R8-04, SE-17176 Stockholm, Sweden.	olllar@ki.se	Girnita, Leonard/A-4168-2008; Weng, Wen Hui/AAV-7260-2021; Lui, Weng-Onn/X-5957-2019; Girnita, Ada/AAC-4518-2020; Lui, Weng-Onn/G-6703-2013	Girnita, Leonard/0000-0003-0280-9500; Lui, Weng-Onn/0000-0003-4717-4473; Lui, Weng-Onn/0000-0003-4717-4473				Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; Ahlen J, 2005, CLIN CANCER RES, V11, P206; Alexia C, 2004, BIOCHEM PHARMACOL, V68, P1003, DOI 10.1016/j.bcp.2004.05.029; All-Ericsson C, 2002, INVEST OPHTH VIS SCI, V43, P1; BASERGA R, 1995, CANCER RES, V55, P249; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Baserga R, 2000, ONCOGENE, V19, P5574, DOI 10.1038/sj.onc.1203854; Blum G, 2003, J BIOL CHEM, V278, P40442, DOI 10.1074/jbc.M305490200; Blum G, 2000, BIOCHEMISTRY-US, V39, P15705, DOI 10.1021/bi001516y; Bohula EA, 2003, J BIOL CHEM, V278, P15991, DOI 10.1074/jbc.M300714200; Brodt P, 2000, BIOCHEM PHARMACOL, V60, P1101, DOI 10.1016/S0006-2952(00)00422-6; BUCHARDT O, 1986, J PHARM SCI, V75, P1076, DOI 10.1002/jps.2600751111; Catrina SB, 2005, BRIT J CANCER, V92, P1467, DOI 10.1038/sj.bjc.6602408; Chen LL, 2004, CANCER RES, V64, P5913, DOI 10.1158/0008-5472.CAN-04-0085; DAmbrosio C, 1996, CANCER RES, V56, P4013; De Meyts P, 2002, NAT REV DRUG DISCOV, V1, P769, DOI 10.1038/nrd917; Favelyukis S, 2001, NAT STRUCT BIOL, V8, P1058, DOI 10.1038/nsb721; Garcia-Echeverria C, 2004, CANCER CELL, V5, P231, DOI 10.1016/S1535-6108(04)00051-0; Girnita A, 2004, CANCER RES, V64, P236, DOI 10.1158/0008-5472.CAN-03-2522; GIRNITA A, 2005, IN PRESS CLIN CANC R; Girnita L, 2000, CANCER RES, V60, P5278; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Girnita L, 2000, ANTI-CANCER DRUG DES, V15, P67; Girnita L, 2005, J BIOL CHEM, V280, P24412, DOI 10.1074/jbc.M501129200; Goetsch L, 2005, INT J CANCER, V113, P316, DOI 10.1002/ijc.20543; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Guo YS, 1998, J CELL PHYSIOL, V175, P141, DOI 10.1002/(SICI)1097-4652(199805)175:2<141::AID-JCP3>3.0.CO;2-O; HernandezSanchez C, 1997, J BIOL CHEM, V272, P4663, DOI 10.1074/jbc.272.8.4663; HIRSCHERNST KI, 1995, BIOCHEM BIOPH RES CO, V215, P179, DOI 10.1006/bbrc.1995.2450; Jerome L, 2003, ENDOCR-RELAT CANCER, V10, P561, DOI 10.1677/erc.0.0100561; Jones HE, 2004, ENDOCR-RELAT CANCER, V11, P793, DOI 10.1677/erc.1.00799; Kanter-Lewensohn L, 2000, MOL CELL ENDOCRINOL, V165, P131, DOI 10.1016/S0303-7207(00)00253-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsson O, 2005, BRIT J CANCER, V92, P2097, DOI 10.1038/sj.bjc.6602627; Le Roith D, 1999, ISR MED ASSOC J, V1, P25; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706; Lu YH, 2004, INT J CANCER, V108, P334, DOI 10.1002/ijc.11445; Menu E, 2006, BLOOD, V107, P655, DOI 10.1182/blood-2005-01-0293; Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nair PN, 2001, ONCOGENE, V20, P8203, DOI 10.1038/sj.onc.1205044; Navab R, 2001, J BIOL CHEM, V276, P13644, DOI 10.1074/jbc.M100019200; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; Pautsch A, 2001, STRUCTURE, V9, P955, DOI 10.1016/S0969-2126(01)00655-4; Peggs K, 2004, CLIN EXP MED, V4, P1, DOI 10.1007/s10238-004-0032-5; Reinmuth N, 2002, CLIN CANCER RES, V8, P3259; RESNICOFF M, 1994, CANCER RES, V54, P4848; ROHLIK QT, 1987, BIOCHEM BIOPH RES CO, V149, P276, DOI 10.1016/0006-291X(87)91635-4; Sachdev D, 2003, CANCER RES, V63, P627; Scotlandi K, 2005, CANCER RES, V65, P3868, DOI 10.1158/0008-5472.CAN-04-3192; Stromberg T, 2006, BLOOD, V107, P669, DOI 10.1182/blood-2005-01-0306; Ulfarsson E, 2005, CLIN CANCER RES, V11, P4674, DOI 10.1158/1078-0432.CCR-05-0129; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; VANWYK JJ, 1985, J CLIN ENDOCR METAB, V61, P639; Vasilcanu D, 2004, ONCOGENE, V23, P7854, DOI 10.1038/sj.onc.1208065; Yang K, 2002, ONCOGENE, V21, P4181, DOI 10.1038/sj.onc.1205569; Ye JJ, 2003, HORM METAB RES, V35, P836; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472	59	37	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3186	3195		10.1038/sj.onc.1209339	http://dx.doi.org/10.1038/sj.onc.1209339			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16407828				2022-12-28	WOS:000237951000009
J	Soria, G; Podhajcer, O; Prives, C; Gottifredi, V				Soria, G.; Podhajcer, O.; Prives, C.; Gottifredi, V.			P21(Cip1/WAF1) downregulation is required for efficient PCNA ubiquitination after UV irradiation	ONCOGENE			English	Article						p21; PCNA; ubiquitination; proteolysis; DNA repair	CELL NUCLEAR ANTIGEN; NUCLEOTIDE EXCISION-REPAIR; KINASE INHIBITOR P21; DOUBLE-STRAND BREAK; DNA-DAMAGE; REPLICATION ARREST; POLYMERASE SWITCH; IN-VITRO; S-PHASE; DEGRADATION	p21(Cip1/WAF1) is a known inhibitor of the short- gap. filling activity of proliferating cell nuclear antigen ( PCNA) during DNA repair. In agreement, p21 degradation after UV irradiation promotes PCNA- dependent repair. Recent reports have identified ubiquitination of PCNA as a relevant feature for PCNA- dependent DNA repair. Here, we show that PCNA ubiquitination in human cells is notably augmented after UV irradiation and other genotoxic treatments such as hydroxyurea, aphidicolin and methylmethane sulfonate. Intriguingly, those DNA damaging agents also promoted downregulation of p21. While ubiquitination of PCNA was not affected by deficient nucleotide excision repair ( NER) and was observed in both proliferating and arrested cells, stable p21 expression caused a significant reduction in UV-induced ubiquitinated PCNA. Surprisingly, the negative regulation of PCNA ubiquitination by p21 does not depend on the direct interaction with PCNA but requires the cyclin dependent kinase binding domain of p21. Taken together, our data suggest that p21 downregulation plays a role in efficient PCNA ubiquitination after UV irradiation.	Fdn Inst Leloir, RA-1405 Buenos Aires, DF, Argentina; Consejo Nacl Invest Cient & Tecn, RA-1033 Buenos Aires, DF, Argentina; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Leloir Institute; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Columbia University	Gottifredi, V (corresponding author), Fdn Inst Leloir, RA-1405 Buenos Aires, DF, Argentina.	vgottifredi@leloir.org.ar	Gottifredi, Vanesa/AAI-1788-2019	Gottifredi, Vanesa/0000-0001-9656-5951; podhajcer, osvaldo/0000-0002-6512-8553	NCI NIH HHS [CA058316] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058316, R37CA058316] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Binz SK, 2004, DNA REPAIR, V3, P1015, DOI 10.1016/j.dnarep.2004.03.028; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Carr AM, 2003, SCIENCE, V300, P1512, DOI 10.1126/science.1085689; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; Chuang LC, 2005, J BIOL CHEM, V280, P35299, DOI 10.1074/jbc.M506429200; Cooper MP, 1999, MOL BIOL CELL, V10, P2119, DOI 10.1091/mbc.10.7.2119; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; Frouin I, 2005, NUCLEIC ACIDS RES, V33, P5354, DOI 10.1093/nar/gki845; Furstenthal L, 2001, NAT CELL BIOL, V3, P715, DOI 10.1038/35087026; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Gottifredi V, 2004, J BIOL CHEM, V279, P5802, DOI 10.1074/jbc.M310373200; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hammond EM, 2004, DNA REPAIR, V3, P1117, DOI 10.1016/j.dnarep.2004.03.035; Hammond EM, 2003, MUTAT RES-FUND MOL M, V532, P205, DOI 10.1016/j.mrfmmm.2003.08.017; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Kannouche PL, 2004, CELL CYCLE, V3, P1011; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kuhne C, 2003, NUCLEIC ACIDS RES, V31, P7227, DOI 10.1093/nar/gkg937; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; McDonald E, 1996, CANCER RES, V56, P2250; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P8917, DOI 10.1128/MCB.24.20.8917-8928.2004; Nikiforov A, 2004, BIOCHEM BIOPH RES CO, V323, P831, DOI 10.1016/j.bbrc.2004.08.165; Oku T, 1998, GENES CELLS, V3, P357, DOI 10.1046/j.1365-2443.1998.00199.x; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; Pickart CM, 2002, NATURE, V419, P120, DOI 10.1038/419120a; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; Shivji MKK, 1998, ONCOGENE, V17, P2827, DOI 10.1038/sj.onc.1202352; Shroff R, 2004, CURR BIOL, V14, P1703, DOI 10.1016/j.cub.2004.09.047; SOBELL HM, 1985, P NATL ACAD SCI USA, V82, P5328, DOI 10.1073/pnas.82.16.5328; Solomon DA, 2004, J CELL BIOL, V166, P455, DOI 10.1083/jcb.200312048; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Thyberg J, 1999, EXP CELL RES, V246, P263, DOI 10.1006/excr.1998.4326; TIMSON J, 1975, MUTAT RES, V32, P115, DOI 10.1016/0165-1110(75)90002-0; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Waga S, 1998, MOL CELL BIOL, V18, P4177, DOI 10.1128/MCB.18.7.4177; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Watanabe K, 2004, EMBO J, V23, P3886, DOI 10.1038/sj.emboj.7600383	51	87	90	12	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2829	2838		10.1038/sj.onc.1209315	http://dx.doi.org/10.1038/sj.onc.1209315			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16407842				2022-12-28	WOS:000237448200001
J	Yin, MB; Li, ZR; Toth, K; Cao, S; Durrani, FA; Hapke, G; Bhattacharya, A; Azrak, RG; Frank, C; Rustum, YM				Yin, MB; Li, ZR; Toth, K; Cao, S; Durrani, FA; Hapke, G; Bhattacharya, A; Azrak, RG; Frank, C; Rustum, YM			Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1 alpha expression, resulting in reduced angiogenesis	ONCOGENE			English	Article						MSC; irinotecan; COX-2; iNOS; HIF-1 alpha; angiogenesis	NF-KAPPA-B; SQUAMOUS-CELL CARCINOMA; COLON-CANCER CELLS; GENE-EXPRESSION; COLORECTAL-CANCER; ENDOTHELIAL-CELLS; MAMMARY-CANCER; NECK-CANCER; MOUSE SKIN; HUMAN HEAD	Until recently, the use of Se-methylselenocysteine ( MSC) as selective modulator of the antitumor activity and selectivity of anticancer drugs including irinotecan, a topoisomerase I poison, had not been evaluated. Therapeutic synergy between MSC and irinotecan was demonstrated by our laboratory in mice bearing human squamous cell carcinoma of the head and neck tumors. In FaDu xenografts, a poorly differentiated tumor-expressing mutant p53, the cure rate was increased from 30% with irinotecan alone to 100% with the combination of irinotecan and MSC. Cellular exposure to cytotoxic concentration of SN-38, the active metabolite of irinotecan (0.1 mu M) alone and in combination with noncytotoxic concentration of MSC (10 mu M) did not result in additional enhancement of chk2 phosphorylation and downregulation of specific DNA replication-associated proteins, cdc6, MCM2, cdc25A, nor increase in PARP cleavage, caspase activation and the 30-300 kb DNA fragmentation induced by SN-38 treatment. MSC did not alter significantly markers associated with apoptosis, nor potentiate irinotecan-induced apoptosis. These results indicate that apoptosis is unlikely to be one of the main mechanism associated with the observed in vivo therapeutic synergy. In contrast, significant downregulation of cyclooxygenase-2 (COX-2) expression and activity was observed in the cells exposed to SN-38 in combination with MSC compared to SN-38 alone. Moreover, the inhibition of PGE(2) production was also observed in the cells treated with the combination as compared with SN-38 alone. Analysis of tumor tissues at 24 h after treatment with synergistic modality of irinotecan and MSC revealed significant downregulation of COX-2, inducible nitric oxide synthase (iNOS) and hypoxia-induced factor-1 alpha expression (HIF 1 alpha). Moreover, decreased micro-vessel density was observed after irinotecan treatment with the addition of MSC. These results suggest that observed therapeutic synergy correlates with the inhibition of neoangiogenesis through the downregulation of COX-2, iNOS and HIF-1 alpha expression.	Roswell Pk Canc Inst, Dept Canc Biol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Rustum, YM (corresponding author), Roswell Pk Canc Inst, Dept Canc Biol, Elm & Carlton St, Buffalo, NY 14263 USA.	youcef.rustum@roswellpark.org			NCI NIH HHS [CA16056, CA65761] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056, R01CA065761] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn KS, 2005, LIFE SCI, V76, P2315, DOI 10.1016/j.lfs.2004.10.042; Apostolou S, 2004, ONCOGENE, V23, P5032, DOI 10.1038/sj.onc.1207683; Azrak RG, 2004, CLIN CANCER RES, V10, P1121, DOI 10.1158/1078-0432.CCR-0913-3; Bhattacharya A, 2004, CLIN CANCER RES, V10, P8005, DOI 10.1158/1078-0432.CCR-04-1306; Bing RJ, 2001, CLIN CANCER RES, V7, P3385; Bussolati B, 2003, FASEB J, V17, P1159, DOI 10.1096/fj.02-0557fje; Cao SS, 2004, CLIN CANCER RES, V10, P2561, DOI 10.1158/1078-0432.CCR-03-0268; Chang SH, 2004, P NATL ACAD SCI USA, V101, P591, DOI 10.1073/pnas.2535911100; Chapple KS, 2002, J PATHOL, V198, P435, DOI 10.1002/path.1223; Chen YC, 2000, BIOCHEM PHARMACOL, V59, P1445, DOI 10.1016/S0006-2952(00)00255-0; Cherukuri DR, 2005, CANCER BIOL THER, V4, P175; Chun KS, 2004, CARCINOGENESIS, V25, P445, DOI 10.1093/carcin/bgh021; Cianchi F, 2004, CLIN CANCER RES, V10, P2694, DOI 10.1158/1078-0432.CCR-03-0192; Cianchi F, 2001, GASTROENTEROLOGY, V121, P1339, DOI 10.1053/gast.2001.29691; Cianchi F, 2003, AM J PATHOL, V162, P793, DOI 10.1016/S0002-9440(10)63876-X; Collins JA, 1997, J HISTOCHEM CYTOCHEM, V45, P923, DOI 10.1177/002215549704500702; Deregibus MC, 2003, J BIOL CHEM, V278, P18008, DOI 10.1074/jbc.M300711200; Dimmeler S, 2000, CIRC RES, V86, P4, DOI 10.1161/01.RES.86.1.4; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Gallo O, 2002, BIOCHEM BIOPH RES CO, V299, P517, DOI 10.1016/S0006-291X(02)02683-9; Gallo O, 1998, J NATL CANCER I, V90, P587, DOI 10.1093/jnci/90.8.587; Ganther HE, 1999, CARCINOGENESIS, V20, P1657, DOI 10.1093/carcin/20.9.1657; GIACCIA AJ, 1991, MUTAT RES, V263, P69, DOI 10.1016/0165-7992(91)90062-9; Guo B, 2000, CLIN CANCER RES, V6, P718; Hussain SP, 2004, CANCER RES, V64, P6849, DOI 10.1158/0008-5472.CAN-04-2201; Iniguez MA, 2003, TRENDS MOL MED, V9, P73, DOI 10.1016/S1471-4914(02)00011-4; Ip C, 1999, ANTICANCER RES, V19, P2875; Jiang BB, 2004, J BIOL CHEM, V279, P1323, DOI 10.1074/jbc.M307521200; Jiang C, 1999, MOL CARCINOGEN, V26, P213, DOI 10.1002/(SICI)1098-2744(199912)26:4<213::AID-MC1>3.0.CO;2-Z; Jones MK, 1999, NAT MED, V5, P1418; Jung YJ, 2003, FASEB J, V17, P2115, DOI 10.1096/fj.03-0329fje; Kisley LR, 2002, CANCER RES, V62, P6850; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Lu JX, 2001, NUTR CANCER, V40, P64, DOI 10.1207/S15327914NC401_12; Lu JX, 2001, ADV EXP MED BIOL, V492, P131; Masferrer JL, 2000, CANCER RES, V60, P1306; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; MEDINA D, 1988, PATHOL IMMUNOPATH R, V7, P187, DOI 10.1159/000157115; Merchan JR, 2005, INT J CANCER, V113, P490, DOI 10.1002/ijc.20595; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Murakami M, 2003, J BIOL CHEM, V278, P37937, DOI 10.1074/jbc.M305108200; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Park SW, 2003, INT J CANCER, V107, P729, DOI 10.1002/ijc.11498; Pichiule P, 2004, J BIOL CHEM, V279, P12171, DOI 10.1074/jbc.M305146200; Rajnakova A, 2001, CANCER LETT, V172, P177, DOI 10.1016/S0304-3835(01)00645-0; Rapisarda A, 2004, CANCER RES, V64, P6845, DOI 10.1158/0008-5472.CAN-04-2116; Reid ME, 2002, CANCER EPIDEM BIOMAR, V11, P1285; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; Surh YJ, 2001, MUTAT RES-FUND MOL M, V480, P243, DOI 10.1016/S0027-5107(01)00183-X; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Wei DY, 2004, CANCER RES, V64, P2030, DOI 10.1158/0008-5472.CAN-03-1945; Wink DA, 1998, CARCINOGENESIS, V19, P711, DOI 10.1093/carcin/19.5.711; Yin MB, 2004, MOL PHARMACOL, V66, P153, DOI 10.1124/mol.66.1.153; Zhou N, 2003, J BIOL CHEM, V278, P29532, DOI 10.1074/jbc.M301877200; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451; ZICHE M, 1993, BIOCHEM BIOPH RES CO, V192, P1198, DOI 10.1006/bbrc.1993.1543	57	32	35	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2509	2519		10.1038/sj.onc.1209073	http://dx.doi.org/10.1038/sj.onc.1209073			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16518418				2022-12-28	WOS:000236948000009
J	Bigelow, RLH; Cardelli, JA				Bigelow, RLH; Cardelli, JA			The green tea catechins, (-)-epigallocatechin-3-gallate (EGCG) and (-)-epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells	ONCOGENE			English	Article						green tea; EGCG; HGF; Met; breast cancer	COLON-CARCINOMA CELLS; MET EXPRESSION; SCATTER-FACTOR; IN-VIVO; GROWTH; CANCER; POLYPHENOLS; PHOSPHORYLATION; RECEPTOR; ACTIVATION	The hepatocyte growth factor (HGF) receptor, Met, is a strong prognostic indicator of breast cancer patient outcome and survival, suggesting that therapies targeting Met may have beneficial outcomes in the clinic. (-)Epigallocatechin- 3-gallate ( EGCG), a catechin found in green tea, has been recognized as a potential therapeutic agent. We assessed the ability of EGCG to inhibit HGF signaling in the immortalized, nontumorigenic breast cell line, MCF10A, and the invasive breast carcinoma cell line, MDA-MB-231. HGF treatment in both cell lines induced rapid, sustained activation of Met, ERK and AKT. Pretreatment of cells with concentrations of EGCG as low as 0.3 mu M inhibited HGF-induced Met phosphorylation and downstream activation of AKT and ERK. Treatment with 5.0 mu M EGCG blocked the ability of HGF to induce cell motility and invasion. We assessed the ability of alternative green tea catechins to inhibit HGF induced signaling and motility. (-)-Epicatechin-3-gallate ( ECG) functioned similar to EGCG by completely blocking HGF-induced signaling as low as 0.6 mu M and motility at 5 mu M in MCF10A cells; whereas, (-)- epicatechin (EC) was unable to inhibit HGF-induced events at any concentration tested. (-)- Epigallocatechin ( EGC), however, completely repressed HGF-induced AKT and ERK phosphorylation at concentrations of 10 and 20 mu M, but was incapable of blocking Met activation. Despite these observations, EGC did inhibit HGF-induced motility in MCF10A cells at 10 mu M. These observations suggest that the R1 galloyl and the R2 hydroxyl groups are important in mediating the green tea catechins' inhibitory effect towards HGF/Met signaling. These combined in vitro studies reveal the possible benefits of green tea polyphenols as cancer therapeutic agents to inhibit Met signaling and potentially block invasive cancer growth.	Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol & Immunol, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Cardelli, JA (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol & Immunol, Feist Weiller Canc Ctr, 1501 Kings Highway, Shreveport, LA 71130 USA.	jcarde@lsuhsc.edu			NATIONAL CANCER INSTITUTE [R01CA104242] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA104242-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adhami VM, 2004, CANCER RES, V64, P8715, DOI 10.1158/0008-5472.CAN-04-2840; Berger SJ, 2001, BIOCHEM BIOPH RES CO, V288, P101, DOI 10.1006/bbrc.2001.5736; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Camp RL, 1999, CANCER, V86, P2259, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2259::AID-CNCR13>3.0.CO;2-2; Cao YH, 1999, NATURE, V398, P381, DOI 10.1038/18793; Crespy V, 2004, J NUTR, V134, p3431S, DOI 10.1093/jn/134.12.3431S; Edakuni G, 2001, PATHOL INT, V51, P172, DOI 10.1046/j.1440-1827.2001.01182.x; Fang MZ, 2003, CANCER RES, V63, P7563; Fujimura Y, 2004, FEBS LETT, V556, P204, DOI 10.1016/S0014-5793(03)01432-7; Ghoussoub RAD, 1998, CANCER, V82, P1513, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7; Jung YD, 2001, BRIT J CANCER, V84, P844, DOI 10.1054/bjoc.2000.1691; Katiyar SK, 2001, TOXICOL APPL PHARM, V176, P110, DOI 10.1006/taap.2001.9276; Kavanagh KT, 2001, J CELL BIOCHEM, V82, P387, DOI 10.1002/jcb.1164; Lambert JD, 2003, J NUTR, V133, p3262S, DOI 10.1093/jn/133.10.3262S; Liang TJ, 1996, J CLIN INVEST, V97, P2872, DOI 10.1172/JCI118744; Liang YC, 1997, J CELL BIOCHEM, V67, P55, DOI 10.1002/(SICI)1097-4644(19971001)67:1<55::AID-JCB6>3.0.CO;2-V; Masuda M, 2003, CLIN CANCER RES, V9, P3486; Nakachi K, 1998, JPN J CANCER RES, V89, P254, DOI 10.1111/j.1349-7006.1998.tb00556.x; Nam S, 2001, J BIOL CHEM, V276, P13322, DOI 10.1074/jbc.M004209200; Ocal IT, 2003, CANCER-AM CANCER SOC, V97, P1841, DOI 10.1002/cncr.11335; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sachinidis A, 2000, FEBS LETT, V471, P51, DOI 10.1016/S0014-5793(00)01360-0; Sah JF, 2004, J BIOL CHEM, V279, P12755, DOI 10.1074/jbc.M312333200; Su LJ, 2002, PUBLIC HEALTH NUTR, V5, P419, DOI 10.1079/PHN2001314; Sun CL, 2002, CARCINOGENESIS, V23, P1497, DOI 10.1093/carcin/23.9.1497; Tachibana H, 2004, NAT STRUCT MOL BIOL, V11, P380, DOI 10.1038/nsmb743; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Yang GY, 1998, CARCINOGENESIS, V19, P611, DOI 10.1093/carcin/19.4.611; Yang GY, 2000, CARCINOGENESIS, V21, P2035, DOI 10.1093/carcin/21.11.2035	31	111	117	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1922	1930		10.1038/sj.onc.1209227	http://dx.doi.org/10.1038/sj.onc.1209227			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16449979				2022-12-28	WOS:000236224800009
J	Leon, A; Omri, B; Gely, A; Klein, C; Crisanti, P				Leon, A; Omri, B; Gely, A; Klein, C; Crisanti, P			QN1/KIAA1009: a new essential protein for chromosome segregation and mitotic spindle assembly	ONCOGENE			English	Article						QN1/KIAA1009; ATPase; mitosis; microtubule-associated motor	NERVE GROWTH-FACTOR; PROLIFERATION ARREST; TRANSCRIPTION FACTOR; CELL-PROLIFERATION; CHECKPOINT; MECHANISMS; EXPRESSION; APOPTOSIS; ANAPHASE; BINDING	We previously reported the involvement of QN1 ( quail neuroretina 1) protein in cell cycle control during retinal development. We show here that QN1 is an ATPase conserved through evolution, from fugu to humans. We show that chicken/quail QN1 protein is orthologous to the KIAA1009 protein in humans, the function of which was not known. We demonstrate here for the first time that QN1/KIAA1009 protein is located at the spindle poles of the mitotic apparatus and at centrosomes during mitosis. The siRNA-mediated depletion of KIAA1009 led to abnormal mitosis with chromosome segregation defects and abnormal centrosome separation leading to the death of PC12 and MCF7 cells. Thus, QN1/KIAA1009 is a new microtubule-associated ATPase involved in cell division.	Univ Paris 06, Inst Biomed Cordeliers, INSERM U598, F-75006 Paris, France; Univ Paris 06, Paris, France; Ctr Cordeliers, IFR 58, Ctr Imagerie, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Crisanti, P (corresponding author), Univ Paris 06, Inst Biomed Cordeliers, INSERM U598, 15 Rue Ecole Med, F-75006 Paris, France.	plassiaz@infobiogen.fr		klein, christophe/0000-0001-8015-287X				BIDOU L, 1993, MECH DEVELOP, V43, P159, DOI 10.1016/0925-4773(93)90033-T; Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; Cai ZZ, 1997, J BIOL CHEM, V272, P96; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Crisanti P, 2001, ONCOGENE, V20, P5475, DOI 10.1038/sj.onc.1204711; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Gollapudi L, 1997, J NEUROSCI RES, V49, P461, DOI 10.1002/(SICI)1097-4547(19970815)49:4<461::AID-JNR7>3.3.CO;2-6; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hsu HL, 1996, J CELL SCI, V109, P277; LOMBILLO VA, 1995, NATURE, V373, P161, DOI 10.1038/373161a0; Munnia A, 2001, ONCOGENE, V20, P4853, DOI 10.1038/sj.onc.1204650; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Neron B, 2001, MECH DEVELOP, V102, P107, DOI 10.1016/S0925-4773(01)00297-0; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Nugoli M, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-13; Oberdoerster J, 1998, J PHARMACOL EXP THER, V287, P359; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Weaver BAA, 2003, J CELL BIOL, V162, P551, DOI 10.1083/jcb.200303167	22	12	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1887	1895		10.1038/sj.onc.1209215	http://dx.doi.org/10.1038/sj.onc.1209215			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16302001				2022-12-28	WOS:000236224800005
J	Embry, MR; Billiard, SM; Di Giulio, RT				Embry, MR; Billiard, SM; Di Giulio, RT			Lack of p53 induction in fish cells by model chemotherapeutics	ONCOGENE			English	Article						PLHC-1; rainbow trout; p53; chemotherapeutics; protein induction; apoptosis	FLOUNDER PLATICHTHYS-FLESUS; TUMOR-SUPPRESSOR PROTEIN; EUROPEAN FLOUNDER; DNA-DAMAGE; WILD-TYPE; MUTATION ANALYSIS; EPITHELIAL-CELLS; PRIMARY CULTURES; GENE; APOPTOSIS	Although p53 has been extensively studied in mammalian models, relatively little is known about its specific function in lower vertebrates. It has long been assumed that p53 pathways characterized in mammals apply to other vertebrates as well. Fish provide a useful model for the study of environmental carcinogenesis, and populations of fish inhabiting highly polluted environments provide information on the etiology of pollutant-mediated cancer. In this study, we investigated p53 protein and apoptosis induction in PLHC-1 ( desert topminnow hepatocellular carcinoma), RTL-W1 ( rainbow trout normal liver), and primary rainbow trout hepatocytes exposed to model chemotherapeutics. All of the chemicals used in these studies have been demonstrated to increase p53 protein levels and induce apoptosis in mammalian cell lines. In contrast, PLHC-1 p53 protein was not induced in response to any model mammalian p53 inducers following 24 h exposures. Additionally, both trout cell types demonstrated this same lack of p53 induction upon exposure to model chemotherapeutic drugs. PLHC-1 cells demonstrated an induction of apoptosis as measured by caspase-3 activation following exposure to all of the chemotherapeutics tested. Our results suggest that fish p53 may be activated differently from that of their mammalian counterparts, and that important differences may exist between phyla in the function and regulation of p53 as well as other mechanisms involved in environmental carcinogenesis.	Duke Univ, Ecotoxicol Lab, Nicholas Sch Environm & Earth Sci, Integrated Toxicol Program, Durham, NC USA	Duke University	Embry, MR (corresponding author), US EPA, Off Pollut Prevent & Tox Subst, Off Pesticide Programs, 1200 Penn Ave,NW,NW Mail Code 7507C, Washington, DC 20460 USA.	embry.michelle@epa.gov			NIEHS NIH HHS [ES07031, ES10356] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007031, P42ES010356] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Benjamin CW, 1998, MOL PHARMACOL, V53, P446, DOI 10.1124/mol.53.3.446; Bensaad K, 2001, ONCOGENE, V20, P3766, DOI 10.1038/sj.onc.1204492; Blagosklonny MV, 2002, INT J CANCER, V98, P161, DOI 10.1002/ijc.10158; Cachot J, 2004, GENE, V324, P97, DOI 10.1016/j.gene.2003.09.052; Cachot J, 2000, MUTAT RES-GEN TOX EN, V464, P279, DOI 10.1016/S1383-5718(99)00205-3; Cachot J, 1998, COMP BIOCHEM PHYS C, V120, P351, DOI 10.1016/S0742-8413(98)00039-5; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Colman MS, 2000, MUTAT RES-REV MUTAT, V462, P179, DOI 10.1016/S1383-5742(00)00035-1; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Franklin TM, 2000, MAR ENVIRON RES, V50, P251, DOI 10.1016/S0141-1136(00)00091-X; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; FRITSCHE M, 1993, ONCOGENE, V8, P307; HIGHTOWER LE, 1988, J EXP ZOOL, V248, P290, DOI 10.1002/jez.1402480307; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Houser S, 2001, BIOCHEM BIOPH RES CO, V289, P998, DOI 10.1006/bbrc.2001.6073; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; Kazianis S, 1998, GENE, V212, P31, DOI 10.1016/S0378-1119(98)00144-9; Krause MK, 1997, GENE, V189, P101, DOI 10.1016/S0378-1119(96)00841-4; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lee JH, 2003, FEBS LETT, V550, P5, DOI 10.1016/S0014-5793(03)00771-3; LEE LEJ, 1993, CELL BIOL TOXICOL, V9, P279, DOI 10.1007/BF00755606; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marechal V, 1997, PATHOL BIOL, V45, P824; Matsubara H, 1999, INT J ONCOL, V14, P1081; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Okamura M, 2004, ANTICANCER RES, V24, P655; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; PART P, 1993, J EXP BIOL, V175, P219; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; Qian H, 2002, ONCOGENE, V21, P7901, DOI 10.1038/sj.onc.1205974; Sandbacka M, 2000, COMP BIOCHEM PHYS C, V127, P307, DOI 10.1016/S0742-8413(00)00156-0; Schlenk D, 1998, AQUAT TOXICOL, V43, P121, DOI 10.1016/S0166-445X(98)00050-2; Sekelsky JJ, 2000, J CELL BIOL, V150, pF31, DOI 10.1083/jcb.150.2.F31; Sueiro RA, 2000, MUTAT RES-GEN TOX EN, V468, P63, DOI 10.1016/S1383-5718(00)00040-1; Thisse C, 2000, DIFFERENTIATION, V66, P61, DOI 10.1046/j.1432-0436.2000.660201.x; Wallingford JB, 1997, CURR BIOL, V7, P747, DOI 10.1016/S0960-9822(06)00333-2; Wang YX, 1999, FEBS LETT, V445, P269, DOI 10.1016/S0014-5793(99)00136-2; Xu Y, 2003, CELL DEATH DIFFER, V10, P1213, DOI 10.1038/sj.cdd.4401292; Yang YL, 2004, ONCOGENE, V23, P2096, DOI 10.1038/sj.onc.1207411; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	44	28	29	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2004	2010		10.1038/sj.onc.1209238	http://dx.doi.org/10.1038/sj.onc.1209238			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16434976				2022-12-28	WOS:000236359700003
J	Kamiyama, M; Pozzi, A; Yang, L; DeBusk, LM; Breyer, RM; Lin, PC				Kamiyama, M.; Pozzi, A.; Yang, L.; DeBusk, L. M.; Breyer, R. M.; Lin, P. C.			EP2, a receptor for PGE(2), regulates tumor angiogenesis through direct effects on endothelial cell motility and survival	ONCOGENE			English	Article						PGE2; EP2; endothelial cell; angiogenesis	PROSTANOID RECEPTORS; PROSTAGLANDIN; CYCLOOXYGENASE; EXPRESSION; CANCER; INHIBITION; SUBTYPE; PROTEIN; INFLAMMATION; MIGRATION	Prostaglandin E2 (PGE(2)), a major cyclooxygenase (COX) metabolite, plays important roles in tumor biology. We studied the role of EP2, a receptor for PGE2, in tumor angiogenesis using EP2 knockout mice. We found that deletion of the EP2 receptor impaired tumor angiogenesis and this finding was confirmed by an in vivo corneal angiogenesis model and an ex vivo aortic ring assay. To further characterize the cellular mechanisms of the EP2 receptor in angiogenesis, we isolated primary pulmonary endothelial cells (ECs) from wild-type (wt) and EP2(-/)-mice and observed that EP2(-/)-ECs exhibited defects in vascular branch formation when compared to wt ECs. In addition, EP2(-/)-ECs showed impaired cell motility on collagen-coated surface and they responded poorly to PGE(2)-induced cell migration compared to control cells. However, no difference in cell proliferation was observed between the EP2(-/)-and wt Ecs. In addition, EP2(-/)-ECs were more susceptible to apoptosis than wt cells under growth factor depletion conditions. Collectively, our data demonstrate that EP2 signaling in endothelium directly regulates tumor angiogenesis by contributing to cell survival and endothelial cell motility. Moreover, our finding suggests that EP2 is a major receptor in PGE(2)-mediated cell motility in ECs.	Vanderbilt Univ, Med Ctr, Dept Radiat Oncol, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Canc Biol, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Lin, PC (corresponding author), Vanderbilt Univ, Med Ctr, Dept Radiat Oncol, Vanderbilt Ingram Canc Ctr, 338 PRB,2220 Pierce Ave, Nashville, TN 37232 USA.	charles.lin@vanderbilt.edu			NATIONAL CANCER INSTITUTE [P30CA068485, T32CA009592, R01CA108856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045888] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA009592, CA108856, CA68485] Funding Source: Medline; NINDS NIH HHS [NS45888] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amano H, 2003, J EXP MED, V197, P221, DOI 10.1084/jem.20021408; Bradbury D, 2005, J BIOL CHEM, V280, P29993, DOI 10.1074/jbc.M414530200; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; Chang SH, 2004, P NATL ACAD SCI USA, V101, P591, DOI 10.1073/pnas.2535911100; Chang SH, 2005, PROSTAG OTH LIPID M, V76, P48, DOI 10.1016/j.prostaglandins.2004.12.001; Dormond O, 2002, J BIOL CHEM, V277, P45838, DOI 10.1074/jbc.M209213200; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Elder DJE, 2002, INT J CANCER, V99, P323, DOI 10.1002/ijc.10330; Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607; Hida T, 1998, CANCER RES, V58, P3761; Huang LW, 1999, J BIOL CHEM, V274, P38183, DOI 10.1074/jbc.274.53.38183; Husain SS, 2001, LIFE SCI, V69, P3045, DOI 10.1016/S0024-3205(01)01411-4; Jiang HM, 2004, J BIOL CHEM, V279, P55905, DOI 10.1074/jbc.M406094200; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kennedy CRJ, 1999, NAT MED, V5, P217, DOI 10.1038/5583; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Klagsbrun M, 1999, CHEM BIOL, V6, pR217, DOI 10.1016/S1074-5521(99)80081-7; Kuwano T, 2004, FASEB J, V18, P300, DOI 10.1096/fj.03-0473com; Lin PN, 1997, J CLIN INVEST, V100, P2072, DOI 10.1172/JCI119740; Mutoh M, 2002, CANCER RES, V62, P28; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; Rozic JG, 2001, INT J CANCER, V93, P497, DOI 10.1002/ijc.1376; SANO H, 1995, CANCER RES, V55, P3785; Seno H, 2002, CANCER RES, V62, P506; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Tilley SL, 2001, J CLIN INVEST, V108, P15, DOI 10.1172/JCI200113416; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Watanabe K, 1999, CANCER RES, V59, P5093; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yang L, 2003, J CLIN INVEST, V111, P727, DOI 10.1172/JCI200316492	34	97	100	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2006	25	53					7019	7028		10.1038/sj.onc.1209694	http://dx.doi.org/10.1038/sj.onc.1209694			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16732324				2022-12-28	WOS:000241910500002
J	Chen, H; Li, M; Campbell, RA; Burkhardt, K; Zhu, D; Li, SG; Lee, HJ; Wang, C; Zeng, Z; Gordon, MS; Bonavida, B; Berenson, JR				Chen, H.; Li, M.; Campbell, R. A.; Burkhardt, K.; Zhu, D.; Li, S. G.; Lee, H. J.; Wang, C.; Zeng, Z.; Gordon, M. S.; Bonavida, B.; Berenson, J. R.			Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis	ONCOGENE			English	Article						TRAF6; multiple myeloma; NF-kappa B; JNK; proliferation; apoptosis	TUMOR-NECROSIS-FACTOR; HUMAN MULTIPLE-MYELOMA; MARROW STROMAL CELLS; BONE-MARROW; DEFECTIVE INTERLEUKIN-1; INDUCE APOPTOSIS; ACTIVATION; MECHANISM; PATHWAYS; RECEPTOR	The tumor necrosis factor receptor (TNFR)-associated factor ( TRAF) family of six adaptor proteins (TRAF1-6) links the TNFR superfamily to the nuclear factor kappa B (NF-kappa B) and activator protein-1 (AP-1) transcriptional activators. Unlike other TRAFs, TRAF6 is also involved in Toll-like/interleukin (IL)-1 receptor (TIR) signal transduction. Thus, inhibition of TRAF6 function could interrupt both CD40 ( TNFR family) and IL-1 growth signals, pathways critical to myeloma proliferation. To block TRAF6-mediated IL-1 signaling, we constructed small interfering RNA ( siRNA) against TRAF6. We found that siRNA targeting the TRAF6 C-terminal (siTRAF6C) receptor interaction domain specifically reduced only TRAF6 protein expression, without affecting TRAF2 or 5 levels, and substantially interfered with IL-1-induced NF-kappa B and c-Jun/AP-1 activation. Inhibition by siTRAF6C was concentration-dependent. SiTRAF6C also significantly reduced myeloma proliferation and enhanced apoptosis in a similar dose-dependent fashion in vitro. More importantly, marked siTRAF6C growth inhibition was detected in vivo when these cells were implanted into the bone marrow of irradiated normal mice. In contrast, introduction of siRNA derived from the TRAF6 Zn-finger domain or an irrelevant siRNA construct failed to alter cell growth or cell death. These studies suggest that TRAF6 may be a new molecular target to block cell signal transduction important for the survival and proliferation of multiple myeloma cells.	Inst Myeloma & Bone Canc Res, W Hollywood, CA 90069 USA; Amgen Inc, Thousand Oaks, CA 91320 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA; Univ Calif Los Angeles, Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA USA; Cedars Sinai Med Ctr, Dept Neurosurg, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA USA	Amgen; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Berenson, JR (corresponding author), Inst Myeloma & Bone Canc Res, 9201 W Sunset Blvd,Ste 300, W Hollywood, CA 90069 USA.	jberenson@imbcr.org						Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200; Berenson JR, 2002, BLOOD, V99, P3163, DOI 10.1182/blood.V99.9.3163; Berenson JR, 2001, SEMIN ONCOL, V28, P626, DOI 10.1053/sonc.2001.29542; Bharti AC, 2004, J BIOL CHEM, V279, P6065, DOI 10.1074/jbc.M308062200; Callander NS, 2001, SEMIN HEMATOL, V38, P276, DOI 10.1053/shem.2001.26007; Cao Z, 1999, COLD SPRING HARB SYM, V64, P473, DOI 10.1101/sqb.1999.64.473; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chatterjee M, 2004, BLOOD, V104, P3712, DOI 10.1182/blood-2004-04-1670; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Chung JY, 2002, J CELL SCI, V115, P679; Corso A, 2005, CANCER, V104, P118, DOI 10.1002/cncr.21104; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Ma MH, 2003, CLIN CANCER RES, V9, P1136; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588; Pagnucco G, 2004, ANN NY ACAD SCI, V1028, P390, DOI 10.1196/annals.1322.047; Sanda T, 2005, CLIN CANCER RES, V11, P1974, DOI 10.1158/1078-0432.CCR-04-1936; Sinha SK, 2002, J BIOL CHEM, V277, P44953, DOI 10.1074/jbc.M207923200; Tai YT, 2005, CANCER RES, V65, P5898, DOI 10.1158/0008-5472.CAN-04-4125; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Teoh G, 2000, BLOOD, V95, P1039, DOI 10.1182/blood.V95.3.1039.003k02_1039_1046; Vincent T, 2005, LEUKEMIA LYMPHOMA, V46, P803, DOI 10.1080/10428190500051448; Yaccoby S, 2004, CANCER RES, V64, P2016, DOI 10.1158/0008-5472.CAN-03-1131; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888	29	31	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2006	25	49					6520	6527		10.1038/sj.onc.1209653	http://dx.doi.org/10.1038/sj.onc.1209653			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16702955				2022-12-28	WOS:000241395100008
J	Benzeno, S; Lu, F; Guo, M; Barbash, O; Zhang, F; Herman, JG; Klein, PS; Rustgi, A; Diehl, JA				Benzeno, S.; Lu, F.; Guo, M.; Barbash, O.; Zhang, F.; Herman, J. G.; Klein, P. S.; Rustgi, A.; Diehl, J. A.			Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1	ONCOGENE			English	Article						cyclin D1; GSK-3 beta; CDK4; nuclear export; cancer	GLYCOGEN-SYNTHASE KINASE-3; CDK INHIBITORS; CELL-CYCLE; ESTROGEN-RECEPTOR; SUBSTRATE-SPECIFICITY; BARRETTS-ESOPHAGUS; HUMAN CANCER; PROTEIN; GENE; RAS	Although cyclin D1 is overexpressed in a significant number of human cancers, overexpression alone is insufficient to promote tumorigenesis. In vitro studies have revealed that inhibition of cyclin D1 nuclear export unmasks its neoplastic potential. Cyclin D1 nuclear export depends upon phosphorylation of a C-terminal residue, threonine 286, (Thr-286) which in turn promotes association with the nuclear exportin, CRM1. Mutation of Thr-286 to a non-phosphorylatable residue results in a constitutively nuclear cyclin D1 protein with significantly increased oncogenic potential. To determine whether cyclin D1 is subject to mutations that inhibit its nuclear export in human cancer, we have sequenced exon 5 of cyclin D1 in primary esophageal carcinoma samples and in cell lines derived from esophageal cancer. Our work reveals that cyclin D1 is subject to mutations in primary human cancer. The mutations identified specifically disrupt phosphorylation of cyclin D1 at Thr-286, thereby enforcing nuclear accumulation of cyclin D1. Through characterization of these mutants, we also de. ne an acidic residue within the C-terminus of cyclin D1 that is necessary for recognition and phosphorylation of cyclin D1 by glycogen synthase kinase-3 beta. Finally, through construction of compound mutants, we demonstrate that cell transformation by the cancer-derived cyclin D1 alleles correlates with their ability to associate with and activate CDK4. Our data reveal that cyclin D1 is subject to mutations in primary human cancer that specifically disrupt phosphorylation-dependent nuclear export of cyclin D1 and suggest that such mutations contribute to the genesis and progression of neoplastic growth.	Univ Penn, Leonard & Madlyn Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA; Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Dept Hematol Oncol, Baltimore, MD 21205 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Johns Hopkins University; Johns Hopkins Medicine; University of Pennsylvania	Diehl, JA (corresponding author), Univ Penn, Leonard & Madlyn Abramson Family Canc Res Inst, Dept Canc Biol, 454 BRB II-III,421 Curie Blvd, Philadelphia, PA 19104 USA.	adiehl@mail.med.upenn.edu			NCI NIH HHS [R01 CA093237, CA111360, CA93237] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093237, R01CA111360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADELAIDE J, 1995, BRIT J CANCER, V71, P64, DOI 10.1038/bjc.1995.13; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Alt JR, 2002, J BIOL CHEM, V277, P8517, DOI 10.1074/jbc.M108867200; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Arber N, 1996, CANCER EPIDEM BIOMAR, V5, P457; Bani-Hani K, 2000, J NATL CANCER I, V92, P1316, DOI 10.1093/jnci/92.16.1316; Bax B, 2001, STRUCTURE, V9, P1143, DOI 10.1016/S0969-2126(01)00679-7; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Benzeno S, 2004, J BIOL CHEM, V279, P56061, DOI 10.1074/jbc.M411910200; Benzeno S, 2004, CANCER RES, V64, P3885, DOI 10.1158/0008-5472.CAN-03-2818; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Calbo J, 2002, J BIOL CHEM, V277, P50263, DOI 10.1074/jbc.M209181200; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Collecchi P, 2000, CYTOMETRY, V42, P254; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Farkas T, 2002, J BIOL CHEM, V277, P26741, DOI 10.1074/jbc.M200381200; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Fraser E, 2002, J BIOL CHEM, V277, P2176, DOI 10.1074/jbc.M109462200; Fry DW, 2004, MOL CANCER THER, V3, P1427; Fry DW, 2001, J BIOL CHEM, V276, P16617, DOI 10.1074/jbc.M008867200; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; GLADDEN AB, 2005, ONCOGENE, V25, P1620; Hagen T, 2002, J BIOL CHEM, V277, P23330, DOI 10.1074/jbc.M201364200; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; Hedgepeth CM, 1999, MOL CELL BIOL, V19, P7147; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; Hirai H, 1996, MOL CELL BIOL, V16, P6457; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lamb J, 2000, MOL CELL BIOL, V20, P8667, DOI 10.1128/MCB.20.23.8667-8675.2000; Landis MW, 2006, CANCER CELL, V9, P13, DOI 10.1016/j.ccr.2005.12.019; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Leng XH, 2002, MOL CELL BIOL, V22, P2242, DOI 10.1128/MCB.22.7.2242-2254.2002; Lin J, 2004, SEMIN ONCOL, V31, P476, DOI 10.1053/j.seminoncol.2004.04.019; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; Lu FM, 2003, CANCER RES, V63, P7056; LUKAS J, 1994, ONCOGENE, V9, P2159; Moreno-Bueno G, 2003, ONCOGENE, V22, P6115, DOI 10.1038/sj.onc.1206868; Muraoka RS, 2002, MOL CELL BIOL, V22, P2204, DOI 10.1128/MCB.22.7.2204-2219.2002; Muraoka RS, 2001, J CELL BIOL, V153, P917, DOI 10.1083/jcb.153.5.917; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; PARK IK, 1994, J BIOL CHEM, V269, P944; Petre CE, 2002, J BIOL CHEM, V277, P2207, DOI 10.1074/jbc.M106399200; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Rimerman RA, 2000, J BIOL CHEM, V275, P14736, DOI 10.1074/jbc.M910241199; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Winston JT, 1996, ONCOGENE, V12, P127; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Yu QY, 2006, CANCER CELL, V9, P23, DOI 10.1016/j.ccr.2005.12.012; Zhang F, 2003, J BIOL CHEM, V278, P33067, DOI 10.1074/jbc.M212635200; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	75	99	100	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2006	25	47					6291	6303		10.1038/sj.onc.1209644	http://dx.doi.org/10.1038/sj.onc.1209644			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	094CY	16732330				2022-12-28	WOS:000241218200006
J	Strozyk, E; Poppelmann, B; Schwarz, T; Kulms, D				Strozyk, E.; Poeppelmann, B.; Schwarz, T.; Kulms, D.			Differential effects of NF-kappa B on apoptosis induced by DNA-damaging agents: the type of DNA damage determines the final outcome	ONCOGENE			English	Article						apoptosis; DNA damage; NF-kappa B; TNF-alpha	PROTECTS TRANSFORMED KERATINOCYTES; RADIATION-INDUCED APOPTOSIS; GENE-EXPRESSION; HUMAN-CELLS; ACTIVATION; ALPHA; RECEPTOR; NUCLEAR; PHOSPHORYLATION; RECOGNITION	The transcription factor nuclear factor kappa-B ( NF-kB) is generally regarded as an antiapoptotic factor. Accordingly, NF-kB activation inhibits death ligand-induced apoptosis. In contrast, ultraviolet light B (UVB)-induced apoptosis is not inhibited but even enhanced upon NF-kappa B activation by interleukin-1 (IL-1). This study was performed to identify the molecular mechanisms underlying this switch of NF-kappa B. Enhancement of UVB-induced apoptosis was always associated with increased release of tumour necrosis factor-alpha (TNF-alpha), which was dependent on NF-kappa B activation. The same was observed when UVA and cisplatin were used, which like UVB induce base modi. cations. In contrast, apoptosis caused by DNA strand breaks was not enhanced by IL-1, indicating that the type of DNA damage is critical for switching the effect of NF-kappa B on apoptosis. Surprisingly, activated NF-kappa B induced TNF-alpha mRNA expression in the presence of all DNA damage-inducing agents. However, in the presence of DNA strand breaks, there was no release of the TNF-alpha protein, which is so crucial for enhancing apoptosis. Together, this indicates that induction of DNA damage may have a significant impact on biological effects but it is the type of DNA damage that determines the final outcome. This may have implications for the role of NF-kappa B in carcinogenesis and for the application of NF-kappa B inhibitors in anticancer therapy.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; Univ Kiel, Dept Dermatol, D-2300 Kiel, Germany; Univ Munster, Dept Dermatol, D-4400 Munster, Germany	University of Stuttgart; University of Kiel; University of Munster	Kulms, D (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.	Dagmar.Kulms@izi.uni-stuttgart.de	Schwarz, Thomas/A-9148-2010; Kulms, Dagmar/H-1653-2014					Abdel-Raheem IT, 2005, BRIT J PHARMACOL, V145, P415, DOI 10.1038/sj.bjp.0706207; Armstrong BK, 2001, J PHOTOCH PHOTOBIO B, V63, P8, DOI 10.1016/S1011-1344(01)00198-1; Beissert S, 1999, J INVEST DERM SYMP P, V4, P61, DOI 10.1038/sj.jidsp.5640183; Besaratinia A, 2005, P NATL ACAD SCI USA, V102, P10058, DOI 10.1073/pnas.0502311102; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cornelis S, 2005, ONCOGENE, V24, P1552, DOI 10.1038/sj.onc.1208401; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Hailer MK, 2005, DNA REPAIR, V4, P41, DOI 10.1016/j.dnarep.2004.07.006; Ho WC, 2005, CANCER RES, V65, P4273, DOI 10.1158/0008-5472.CAN-04-3494; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hur GM, 2003, GENE DEV, V17, P873, DOI 10.1101/gad.1062403; Konemann S, 2005, APOPTOSIS, V10, P177, DOI 10.1007/s10495-005-6072-9; Kothny-Wilkes G, 1999, J BIOL CHEM, V274, P28916, DOI 10.1074/jbc.274.41.28916; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; Kulms D, 2002, ONCOGENE, V21, P5844, DOI 10.1038/sj.onc.1205743; Kulms D, 2002, BIOCHEM PHARMACOL, V64, P837, DOI 10.1016/S0006-2952(02)01146-2; Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974; Kulms D, 2000, J BIOL CHEM, V275, P15060, DOI 10.1074/jbc.M910113199; Lee JY, 2000, J BIOL CHEM, V275, P29290, DOI 10.1074/jbc.M000170200; Mezyk R, 2003, ACTA BIOCHIM POL, V50, P625; Nakajima S, 2004, J BIOL CHEM, V279, P46674, DOI 10.1074/jbc.M406070200; Panta GR, 2004, MOL CELL BIOL, V24, P1823, DOI 10.1128/MCB.24.5.1823-1835.2004; Poppelmann B, 2005, J BIOL CHEM, V280, P15635, DOI 10.1074/jbc.M413006200; Rosell Rafael, 2003, Cancer Control, V10, P297; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Sclabas GM, 2005, CANCER-AM CANCER SOC, V103, P2485, DOI 10.1002/cncr.21075; Sordet Olivier, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P271, DOI 10.2174/1568011033482378; Sun NK, 1996, BIOCHEM J, V313, P441, DOI 10.1042/bj3130441; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; Thyss R, 2005, EMBO J, V24, P128, DOI 10.1038/sj.emboj.7600501; Wajant H, 2005, CYTOKINE GROWTH F R, V16, P55, DOI 10.1016/j.cytogfr.2004.12.001; Xu CJ, 2005, ONCOGENE, V24, P4486, DOI 10.1038/sj.onc.1208656; Zavrski I, 2005, ANTI-CANCER DRUG, V16, P475, DOI 10.1097/00001813-200506000-00002	38	46	47	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2006	25	47					6239	6251		10.1038/sj.onc.1209655	http://dx.doi.org/10.1038/sj.onc.1209655			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	094CY	16702954				2022-12-28	WOS:000241218200002
J	Poulikakos, PI; Xiao, GH; Gallagher, R; Jablonski, S; Jhanwar, SC; Testa, JR				Poulikakos, P. I.; Xiao, G-H; Gallagher, R.; Jablonski, S.; Jhanwar, S. C.; Testa, J. R.			Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK	ONCOGENE			English	Article						NF2; merlin; invasion; FAK; mesothelioma	FOCAL-ADHESION KINASE; MEDIATES CONTACT INHIBITION; NEUROFIBROMATOSIS TYPE-2; MALIGNANT MESOTHELIOMA; GENE-PRODUCT; MERLIN PHOSPHORYLATION; MEMBRANE ORGANIZATION; PLASMA-MEMBRANE; UNITED-STATES; ERM PROTEINS	The neuro. bromatosis type 2 NF2 gene product, merlin, is a tumor suppressor frequently inactivated in malignant mesothelioma (MM). To investigate a possible correlation between merlin inactivation and MM invasiveness, we restored merlin expression in NF2-deficient MM cells. Re-expression of merlin markedly inhibited cell motility, spreading and invasiveness, properties connected with the malignant phenotype of MM cells. To test directly whether merlin inactivation promotes invasion in a nonmalignant system, we used small interfering RNA to silence Nf2 in mouse embryonic fibroblasts (MEFs) and found that downregulation of merlin resulted in enhanced cell spreading and invasion. To delineate signaling events connected with this phenotype, we investigated the effect of merlin expression on focal adhesion kinase (FAK), a key component of cellular pathways affecting migration and invasion. Expression of merlin attenuated FAK phosphorylation at the critical phosphorylation site Tyr397 and disrupted the interaction of FAK with its binding partners Src and p85, the regulatory subunit of phosphatidylinositol-3-kinase. In addition, NF2-null MM cells stably overexpressing FAK showed increased invasiveness, which decreased significantly when merlin expression was restored. Collectively, these findings suggest that merlin inactivation is a critical step in MM pathogenesis and is related, at least in part, with upregulation of FAK activity.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Fox Chase Canc Ctr, Cell Imaging Facil, Philadelphia, PA 19111 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA	Fox Chase Cancer Center; Fox Chase Cancer Center; Memorial Sloan Kettering Cancer Center	Testa, JR (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Joseph.Testa@fccc.edu			NCI NIH HHS [CA-06927, CA-114047, CA-45745] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA114047, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altomare DA, 2005, CANCER RES, V65, P8090, DOI 10.1158/0008-5472.CAN-05-2312; Baser ME, 2003, CURR OPIN NEUROL, V16, P27, DOI 10.1097/00019052-200302000-00004; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Brown MC, 2005, MOL BIOL CELL, V16, P4316, DOI 10.1091/mbc.E05-02-0131; Carbone M, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.30227; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Cheng JQ, 1999, GENE CHROMOSOME CANC, V24, P238, DOI 10.1002/(SICI)1098-2264(199903)24:3<238::AID-GCC9>3.0.CO;2-M; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; Fleury-Feith J, 2003, ONCOGENE, V22, P3799, DOI 10.1038/sj.onc.1206593; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; GUSELLA JF, 1999, BIOCHIM BIOPHYS ACTA, V1423, P29; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; Hirokawa Y, 2004, CANCER J, V10, P20, DOI 10.1097/00130404-200401000-00006; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; James MF, 2004, J CELL SCI, V117, P2951, DOI 10.1242/jcs.01156; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Lallemand D, 2003, GENE DEV, V17, P1090, DOI 10.1101/gad.1054603; Lee WC, 1999, INT J ONCOL, V14, P181; Manchanda N, 2005, J BIOL CHEM, V280, P12517, DOI 10.1074/jbc.C400583200; Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002; Martin TA, 2003, CRIT REV ONCOL HEMAT, V46, P165, DOI 10.1016/S1040-8428(02)00172-5; McClatchey AI, 2005, GENE DEV, V19, P2265, DOI 10.1101/gad.1335605; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Muranen T, 2005, ONCOGENE, V24, P1150, DOI 10.1038/sj.onc.1208283; Okada T, 2005, J CELL BIOL, V171, P361, DOI 10.1083/jcb.200503165; OWENS LV, 1995, CANCER RES, V55, P2752; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Poullet P, 2001, J BIOL CHEM, V276, P37686, DOI 10.1074/jbc.M106175200; Price B, 2004, AM J EPIDEMIOL, V159, P107, DOI 10.1093/aje/kwh025; Price B, 1997, AM J EPIDEMIOL, V145, P211, DOI 10.1093/oxfordjournals.aje.a009093; Robinson BWS, 2005, NEW ENGL J MED, V353, P1591, DOI 10.1056/NEJMra050152; Rong R, 2004, ONCOGENE, V23, P8447, DOI 10.1038/sj.onc.1207794; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; SEKIDO Y, 1995, CANCER RES, V55, P1227; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Srivastava J, 2005, MOL BIOL CELL, V16, P1481, DOI 10.1091/mbc.e04-08-0721; Surace EI, 2004, ONCOGENE, V23, P580, DOI 10.1038/sj.onc.1207142; Watermann DO, 2005, BRIT J CANCER, V93, P694, DOI 10.1038/sj.bjc.6602744; Wells A, 2000, ADV CANCER RES, V78, P31; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200	51	130	132	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2006	25	44					5960	5968		10.1038/sj.onc.1209587	http://dx.doi.org/10.1038/sj.onc.1209587			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16652148				2022-12-28	WOS:000240826300005
J	Remacle, AG; Rozanov, DV; Fugere, M; Day, R; Strongin, AY				Remacle, A. G.; Rozanov, D. V.; Fugere, M.; Day, R.; Strongin, A. Y.			Furin regulates the intracellular activation and the uptake rate of cell surface-associated MT1-MMP	ONCOGENE			English	Article						MT1-MMP; furin; internalization; proprotein convertase; PA83; anthrax	TYPE-1 MATRIX-METALLOPROTEINASE; 3-DIMENSIONAL EXTRACELLULAR-MATRIX; TRANS-GOLGI NETWORK; 1-MATRIX METALLOPROTEINASE; ANTHRAX TOXIN; TISSUE INHIBITOR; PROPROTEIN CONVERTASES; CRYSTAL-STRUCTURE; CANCER-CELLS; MEMBRANE	Invasion-promoting membrane type-1 matrix metallo-proteinase (MT1-MMP) functions in cancer cells as an oncogene and as a mediator of proteolytic events on the cell surface. To exert its functional activity, MT1-MMP requires proteolytic removal of the prodomain sequence. There are two potential furin cleavage motifs, R-89-R-P-R-C-93 and R-108-R-K-R-Y-112, in the prodomain sequence of MT1-MMP. Our data suggest an important role of furin and related proprotein convertases (PCs) in mediating both the activation of MT1-MMP and the levels of functionally active MT1-MMP at the surface of cancer cells. We have determined that the peptide sequence that spans the first cleavage site is susceptible to furin and PC5/6, whereas the second sequence is susceptible to furin and also to PC5/6, PC7 and PACE4. In the structure of the MT1-MMP proenzyme, the R-89-R-P-R-C-93 site, however, is inaccessible to PCs. Our studies also demonstrated a direct functional link between the activation and the uptake rate of the proenzyme and the enzyme of MT1-MMP. Thus, the uptake rate of the latent MT1-MMP proenzyme noticeably exceeded that of the active enzyme. We conclude that furin and related PCs are the essential components of the specialized cellular machinery that controls the levels of the functionally active, mature, MT1-MMP enzyme on the cell surface to continually support the potency of pericellular proteolysis.	Burnham Inst Med Rs, La Jolla, CA 92037 USA; Univ Sherbrooke, Fac Med, Inst Pharmacol, Dept Pharmacol, Sherbrooke, PQ J1K 2R1, Canada	Sanford Burnham Prebys Medical Discovery Institute; University of Sherbrooke	Strongin, AY (corresponding author), Burnham Inst Med Rs, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	strongin@burnham.org	Strongin, Alex/R-6609-2019	Strongin, Alex/0000-0003-3765-3016	NATIONAL CANCER INSTITUTE [R01CA077470, R01CA083017] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR020843] Funding Source: NIH RePORTER; NCI NIH HHS [CA77470, CA83017] Funding Source: Medline; NCRR NIH HHS [RR020843] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bassi DE, 2001, P NATL ACAD SCI USA, V98, P10326, DOI 10.1073/pnas.191199198; Bradley KA, 2003, BIOCHEM PHARMACOL, V65, P309, DOI 10.1016/S0006-2952(02)01455-7; Cao J, 2005, J BIOL CHEM, V280, P10974, DOI 10.1074/jbc.M412370200; Cheng M, 1997, INT J CANCER, V71, P966, DOI 10.1002/(SICI)1097-0215(19970611)71:6<966::AID-IJC10>3.3.CO;2-A; Chun TH, 2004, J CELL BIOL, V167, P757, DOI 10.1083/jcb.200405001; Deryugina EI, 2004, TRAFFIC, V5, P627, DOI 10.1111/j.1600-0854.2004.00206.x; Deryugina EI, 1997, J CELL SCI, V110, P2473; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Fugere M, 2005, TRENDS PHARMACOL SCI, V26, P294, DOI 10.1016/j.tips.2005.04.006; Fugere M, 2002, J BIOL CHEM, V277, P7648, DOI 10.1074/jbc.M107467200; Gomis-Ruth FX, 2003, MOL BIOTECHNOL, V24, P157, DOI 10.1385/MB:24:2:157; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hernandez-Barrantes S, 2002, SEMIN CANCER BIOL, V12, P131, DOI 10.1006/scbi.2001.0421; Holmbeck K, 2004, J CELL PHYSIOL, V200, P11, DOI 10.1002/jcp.20065; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Itoh Y, 2006, J CELL PHYSIOL, V206, P1, DOI 10.1002/jcp.20431; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kridel SJ, 2002, J BIOL CHEM, V277, P23788, DOI 10.1074/jbc.M111574200; KUAN SF, 1989, J BIOL CHEM, V264, P19271; Liu SH, 2003, EXPERT OPIN BIOL TH, V3, P843, DOI 10.1517/14712598.3.5.843; Mazzone M, 2004, J CELL SCI, V117, P6275, DOI 10.1242/jcs.01563; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; Morgunova E, 2002, P NATL ACAD SCI USA, V99, P7414, DOI 10.1073/pnas.102185399; Murphy G, 1999, APMIS, V107, P38, DOI 10.1111/j.1699-0463.1999.tb01524.x; Okumura Y, 1997, FEBS LETT, V402, P181, DOI 10.1016/S0014-5793(96)01523-2; Osenkowski P, 2004, J CELL PHYSIOL, V200, P2, DOI 10.1002/jcp.20064; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Ratnikov B, 2000, ANAL BIOCHEM, V286, P149, DOI 10.1006/abio.2000.4798; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Rozanov DV, 2004, EXP CELL RES, V293, P81, DOI 10.1016/j.yexcr.2003.10.006; Rozanov DV, 2003, J BIOL CHEM, V278, P8257, DOI 10.1074/jbc.M213246200; Rozanov DV, 2002, J BIOL CHEM, V277, P9318, DOI 10.1074/jbc.M110711200; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Santelli E, 2004, NATURE, V430, P905, DOI 10.1038/nature02763; Sato T, 1999, J BIOL CHEM, V274, P37280, DOI 10.1074/jbc.274.52.37280; Scobie HM, 2005, CURR OPIN MICROBIOL, V8, P106, DOI 10.1016/j.mib.2004.12.005; Seidah NG, 2002, ESSAYS BIOCHEM, V38, P79, DOI 10.1042/bse0380079; SITRIN RG, 1990, CANCER RES, V50, P4957; Stawowy P, 2005, CIRCULATION, V111, P2820, DOI 10.1161/CIRCULATIONAHA.104.502617; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Toth M, 2005, BIOCHEM J, V387, P497, DOI 10.1042/BJ20041324; Wang P, 2004, J BIOL CHEM, V279, P20461, DOI 10.1074/jbc.M400264200; Wang X, 2004, J BIOL CHEM, V279, P9331, DOI 10.1074/jbc.M312369200; Wu YI, 2004, J BIOL CHEM, V279, P8278, DOI 10.1074/jbc.M311870200; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387	50	56	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2006	25	41					5648	5655		10.1038/sj.onc.1209572	http://dx.doi.org/10.1038/sj.onc.1209572			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16636666				2022-12-28	WOS:000240599100006
J	Archangelo, LF; Glaser, J; Krause, A; Bohlander, SK				Archangelo, L. Froehlich; Glaeser, J.; Krause, A.; Bohlander, S. K.			The novel CALM interactor CATS influences the subcellular localization of the leukemogenic fusion protein CALM/AF10	ONCOGENE			English	Article						CALM/AF10; PICALM; leukemia; nucleolus	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CALM-AF10 FUSION; LEUCINE-ZIPPER; MOLECULAR CHARACTERIZATION; COATED PITS; CLATHRIN; AF10; GENE; MLL	The Clathrin Assembly Lymphoid Myeloid leukemia gene (CALM or PICALM) was first identified as the fusion partner of AF10 in the t(10;11)(p13;q14) translocation, which is observed in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and malignant lymphoma. The CALM/AF10 fusion protein plays a crucial role in t(10;11)(p13;q14) associated leukemogenesis. Using the N-terminal half of CALM as a bait in a yeast two-hybrid screen, a novel protein named CATS (CALM interacting protein expressed in thymus and spleen) was identified. Multiple tissue Northern blot analysis showed predominant expression of CATS in thymus, spleen and colon. CATS codes for two protein isoforms of 238 and 248 amino acids (aa). The interaction between CALM and CATS could be confirmed using pull down assays, co-immunoprecipitation and colocalization experiments. The CATS interaction domain of CALM was mapped to aa 221-335 of CALM. This domain is contained in the CALM/AF10 fusion protein. CATS localizes to the nucleus and shows a preference for nucleoli. Expression of CATS was able to markedly increase the nuclear localization of CALM and of the leukemogenic fusion protein CALM/AF10. The possible implications of these findings for CALM/AF10-mediated leukemogenesis are discussed.	Univ Munich, Dept Med 3, Grosshadern Hosp, D-81377 Munich, Germany; GSF Munich, Clin Cooperat Grp Leukemia, Munich, Germany; Univ Gottingen, Inst Human Genet, D-3400 Gottingen, Germany	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Gottingen	Bohlander, SK (corresponding author), Univ Munich, Dept Med 3, Grosshadern Hosp, Marchioninistr 15, D-81377 Munich, Germany.	sbohlan@gwdg.de	Archangelo, Leticia Fröhlich/P-7048-2015; Krause, Alexandre/K-7221-2013	Archangelo, Leticia Fröhlich/0000-0003-2264-4504; Bohlander, Stefan/0000-0002-2202-9088				Abdou SMH, 2002, LEUKEMIA LYMPHOMA, V43, P89, DOI 10.1080/10428190290000437; Asnafi V, 2003, BLOOD, V102, P1000, DOI 10.1182/blood-2002-09-2913; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Bohlander SK, 2000, LEUKEMIA, V14, P93, DOI 10.1038/sj.leu.2401614; Carlson KM, 2000, LEUKEMIA, V14, P100, DOI 10.1038/sj.leu.2401629; Chao MM, 2004, BLOOD, V104, p922A, DOI 10.1182/blood.V104.11.3380.3380; CHAPLIN T, 1995, BLOOD, V85, P1435, DOI 10.1182/blood.V85.6.1435.bloodjournal8561435; De Camilli P, 2002, FEBS LETT, V513, P11, DOI 10.1016/S0014-5793(01)03306-3; Delabesse E, 2004, BLOOD, V104, p315A; Deshpande A, 2003, BLOOD, V102, p216A; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; DiMartino JF, 2002, BLOOD, V99, P3780, DOI 10.1182/blood.V99.10.3780; Dreyling MH, 1996, P NATL ACAD SCI USA, V93, P4804, DOI 10.1073/pnas.93.10.4804; Dreyling MH, 1998, BLOOD, V91, P4662; Evans PR, 2002, CURR OPIN STRUC BIOL, V12, P814, DOI 10.1016/S0959-440X(02)00395-0; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Huang FT, 2004, J BIOL CHEM, V279, P16657, DOI 10.1074/jbc.C400046200; Jones LK, 2001, LEUKEMIA, V15, P910, DOI 10.1038/sj.leu.2402140; Kalthoff C, 2002, J BIOL CHEM, V277, P8209, DOI 10.1074/jbc.M111587200; Klebig ML, 2003, P NATL ACAD SCI USA, V100, P8360, DOI 10.1073/pnas.1432634100; Kobayashi H, 1997, GENE CHROMOSOME CANC, V20, P253, DOI 10.1002/(SICI)1098-2264(199711)20:3<253::AID-GCC5>3.0.CO;2-1; Krause A, 2004, BLOOD, V104, p791A, DOI 10.1182/blood.V104.11.2895.2895; Kumon K, 1999, GENE CHROMOSOME CANC, V25, P33, DOI 10.1002/(SICI)1098-2264(199905)25:1<33::AID-GCC5>3.0.CO;2-3; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; Nakamura F, 2003, AM J HEMATOL, V72, P138, DOI 10.1002/ajh.10265; Narita M, 1999, BRIT J HAEMATOL, V105, P928, DOI 10.1046/j.1365-2141.1999.01433.x; Netzer C, 2001, HUM MOL GENET, V10, P3017, DOI 10.1093/hmg/10.26.3017; Nonet ML, 1999, MOL BIOL CELL, V10, P2343, DOI 10.1091/mbc.10.7.2343; Perrin L, 2003, MOL CELL BIOL, V23, P119, DOI 10.1128/MCB.23.1.119-130.2003; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; Salmon-Nguyen F, 2000, CANCER GENET CYTOGEN, V122, P137, DOI 10.1016/S0165-4608(00)00277-6; Schlosser I, 2003, NUCLEIC ACIDS RES, V31, P6148, DOI 10.1093/nar/gkg794; Silliman CC, 1998, LEUKEMIA, V12, P1404, DOI 10.1038/sj.leu.2401109; Stahelin RV, 2003, J BIOL CHEM, V278, P28993, DOI 10.1074/jbc.M302865200; Tebar F, 1999, MOL BIOL CELL, V10, P2687, DOI 10.1091/mbc.10.8.2687; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; Vecchi M, 2001, J CELL BIOL, V153, P1511, DOI 10.1083/jcb.153.7.1511; Zhang B, 1998, NEURON, V21, P1465, DOI 10.1016/S0896-6273(00)80664-9	39	39	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2006	25	29					4099	4109		10.1038/sj.onc.1209438	http://dx.doi.org/10.1038/sj.onc.1209438			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16491119				2022-12-28	WOS:000238802400010
J	Chini, C; Wood, J; Chen, J				Chini, C. C. S.; Wood, J.; Chen, J.			Chk1 is required to maintain Claspin stability	ONCOGENE			English	Article						claspin; Chk1; protein stability; cell cycle	DNA-REPLICATION; CHECKPOINT; BRCA1; PROTEIN; ATR; PHOSPHORYLATION; UBIQUITINATION; LOCALIZATION; ACTIVATION; EXPRESSION	Claspin is a Chk1-interacting protein that participates in the DNA replication checkpoint. Expression of Claspin fluctuates in a cell cycle-dependent manner, but the mechanisms involved in the regulation of Claspin protein levels have not been explored. In this study, we show that Claspin expression is downregulated by the proteasome-mediated degradation pathway and that Chk1 is required to maintain Claspin stability. Downregulation of Chk1 expression by siRNA or inhibition of Chk1 activity by UCN01 decreases Claspin levels in cells. Conversely, overexpression of Chk1 increases Claspin levels. These data indicate a role of Chk1 in regulating Claspin stability in the cell. Since Claspin has also been shown to participate in Chk1 activation following DNA damage, we further explored the exact role of Claspin during Chk1 activation following replication stress. We observed that while Rad17 is required for early Chk1 activation after hydroxyurea treatment, Claspin is only required to sustain Chk1 activation. Based on these findings, we propose that Claspin functions at late stages of Chk1 activation following DNA damage. Once Chk1 is activated, it stabilizes Claspin, which in turn helps to maintain Chk1 activation during replication stress. In summary, these data indicate that the interaction between Claspin and Chk1 is complex. These proteins regulate each other and thus ensure the proper cell cycle progression and replication checkpoint control.	Mayo Clin & Mayo Fdn, Coll Med, Dept Oncol Res, Rochester, MN 55905 USA	Mayo Clinic	Chen, J (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Dept Oncol Res, 200 1st St SW, Rochester, MN 55905 USA.	Chen.Junjie@mayo.edu			NATIONAL CANCER INSTITUTE [R01CA092312, R01CA089239, R01CA100109] Funding Source: NIH RePORTER; NCI NIH HHS [CA100109, CA89239, CA92312] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal R, 2003, J BIOL CHEM, V278, P45027, DOI 10.1074/jbc.M306783200; Busby EC, 2000, CANCER RES, V60, P2108; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Chini CCS, 2004, DNA REPAIR, V3, P1033, DOI 10.1016/j.dnarep.2004.03.001; Choudhury AD, 2004, J BIOL CHEM, V279, P33909, DOI 10.1074/jbc.M403646200; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Clarke CAL, 2005, BIOCHEM J, V388, P705, DOI 10.1042/BJ20041966; Hackbarth JS, 2004, BIOTECHNIQUES, V37, P835; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; Kim JE, 2005, MOL CELL BIOL, V25, P10907, DOI 10.1128/MCB.25.24.10907-10915.2005; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; Kumagai A, 2004, J BIOL CHEM, V279, P49599, DOI 10.1074/jbc.M408353200; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Lou ZK, 2003, J BIOL CHEM, V278, P13599, DOI 10.1074/jbc.C300060200; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Shechter D, 2004, DNA REPAIR, V3, P901, DOI 10.1016/j.dnarep.2004.03.020; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Sorensen CS, 2004, CELL CYCLE, V3, P941; Tomlinson GE, 1998, CANCER RES, V58, P3237; Wang X, 2003, GENE DEV, V17, P965, DOI 10.1101/gad.1065103; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299	26	46	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	30					4165	4171		10.1038/sj.onc.1209447	http://dx.doi.org/10.1038/sj.onc.1209447			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16501606				2022-12-28	WOS:000239004800004
J	Ito, K; Oji, Y; Tatsumi, N; Shimizu, S; Kanai, Y; Nakazawa, T; Asada, M; Jomgeow, T; Aoyagi, S; Nakano, Y; Tamaki, H; Sakaguchi, N; T Shirakata,; Nishida, S; Kawakami, M; Tsuboi, A; Oka, Y; Tsujimoto, Y; Sugiyama, H				Ito, K.; Oji, Y.; Tatsumi, N.; Shimizu, S.; Kanai, Y.; Nakazawa, T.; Asada, M.; Jomgeow, T.; Aoyagi, S.; Nakano, Y.; Tamaki, H.; Sakaguchi, N.; T Shirakata; Nishida, S.; Kawakami, M.; Tsuboi, A.; Oka, Y.; Tsujimoto, Y.; Sugiyama, H.			Antiapoptotic function of 17AA(+) WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway	ONCOGENE			English	Article						Wilms' tumor gene; WT1; anti-apoptosis; 17AA(+) WT1 isoform	PROMOTER ACTIVITY; EXPRESSION; SUPPRESSOR; OVEREXPRESSION; DIFFERENTIATION; PROLIFERATION; INVOLVEMENT; INHIBITION; REPRESSION; PRODUCT	The WT1 gene is overexpressed in human primary leukemia and a wide variety of solid cancers. The WT1 gene is alternatively spliced at two sites, yielding four isoforms: 17AA(+) KTS(+), 17AA(+) KTS(-), 17AA(-) KTS(+), and 17AA(-) KTS(-). Here, we showed that 17AA(+) WT1-specific siRNA induced apoptosis in three WT1-expressing leukemia cell lines (K562, HL-60, and Kasumi-1), but not in WT1-nonexpressing lymphoma cell line (Daudi). 17AA(+) WT1-specific siRNA activated caspase- 3 and - 9 in the intrinsic apoptosis pathway but not caspase- 8 in the extrinsic one. On the other hand, 17AA(-) WT1-specific siRNA did not induce apoptosis in the three WT1-expressing cell lines. The apoptosis was associated with activation of proapoptotic Bax, which was activated upstream of the mitochondria. Constitutive expression of 17AA(+) WT1 isoforms inhibited apoptosis of K562 leukemia cells induced by apoptosis-inducing agents, etoposide and doxorubicin, through the protection of mitochondrial membrane damages, and DNA-binding zinc-finger region of 17AA(+) WT1 isoform was essential for the antiapoptotic functions. We further studied the gene(s) whose expression was altered by the expression of 17AA(+) WT1 isoforms and showed that the expression of proapoptotic Bak was decreased by the expression of 17AA(+) KTS(-) WT1 isoform. Taken together, these results indicated that 17AA(+) WT1 isoforms played antiapoptotic roles at some points upstream of the mitochondria in the intrinsic apoptosis pathway.	Osaka Univ, Dept Funct Diagnost Sci, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Biomed Informat, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Med Genet, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Mol Med, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Canc Immunotherapy, Grad Sch Med, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University; Osaka University; Osaka University	Sugiyama, H (corresponding author), Osaka Univ, Dept Funct Diagnost Sci, Grad Sch Med, 1-7 Yamada Oka, Suita, Osaka 5650871, Japan.	sugiyama@sahs.med.osaka-u.ac.jp	Nakazawa, Tsutomu/ABF-2907-2020	Nakazawa, Tsutomu/0000-0003-4286-9356				Algar EM, 1996, ONCOGENE, V12, P1005; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Davies JA, 2004, HUM MOL GENET, V13, P235, DOI 10.1093/hmg/ddh015; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; Englert C, 1997, CANCER RES, V57, P1429; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GOODYER P, 1995, ONCOGENE, V10, P1125; Harada Y, 1999, MOL UROL, V3, P357; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; Herzer U, 1999, CURR BIOL, V9, P837, DOI 10.1016/S0960-9822(99)80369-8; Hubinger G, 2001, EXP HEMATOL, V29, P1226, DOI 10.1016/S0301-472X(01)00719-6; Inoue K, 1998, BLOOD, V91, P2969, DOI 10.1182/blood.V91.8.2969.2969_2969_2976; INOUE K, 1994, BLOOD, V84, P3071, DOI 10.1182/blood.V84.9.3071.3071; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Li H, 2003, INT J HEMATOL, V77, P463, DOI 10.1007/BF02986614; Loeb DM, 2001, CANCER RES, V61, P921; Loeb DM, 2003, LEUKEMIA, V17, P965, DOI 10.1038/sj.leu.2402906; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Miyoshi Y, 2002, CLIN CANCER RES, V8, P1167; Niksic M, 2004, HUM MOL GENET, V13, P463, DOI 10.1093/hmg/ddh040; Oji Y, 1999, JPN J CANCER RES, V90, P194, DOI 10.1111/j.1349-7006.1999.tb00733.x; Oji Y, 2002, INT J CANCER, V100, P297, DOI 10.1002/ijc.10476; Oji Y, 2004, CANCER SCI, V95, P822, DOI 10.1111/j.1349-7006.2004.tb02188.x; Oji Y, 2004, ANTICANCER RES, V24, P3103; Oji Y, 2004, CANCER SCI, V95, P583, DOI 10.1111/j.1349-7006.2004.tb02490.x; Oji Y, 2003, CANCER SCI, V94, P712, DOI 10.1111/j.1349-7006.2003.tb01507.x; Oji Y, 2003, CANCER SCI, V94, P606, DOI 10.1111/j.1349-7006.2003.tb01490.x; Oji Y, 2003, CANCER SCI, V94, P523, DOI 10.1111/j.1349-7006.2003.tb01477.x; Osaka M, 1997, INT J CANCER, V72, P696, DOI 10.1002/(SICI)1097-0215(19970807)72:4<696::AID-IJC23>3.0.CO;2-8; Reynolds PA, 2003, GENE DEV, V17, P2094, DOI 10.1101/gad.1110703; Shimizu S, 1996, ONCOGENE, V12, P2251; Siehl JM, 2004, ANN HEMATOL, V83, P745, DOI 10.1007/s00277-004-0941-0; Sugiyama H, 2001, INT J HEMATOL, V73, P177, DOI 10.1007/BF02981935; Tsuboi A, 1999, LEUKEMIA RES, V23, P499, DOI 10.1016/S0145-2126(99)00037-5; Tuna M, 2005, ONCOGENE, V24, P1648, DOI 10.1038/sj.onc.1208345; Ueda T, 2003, CANCER SCI, V94, P271, DOI 10.1111/j.1349-7006.2003.tb01432.x; Wagner KD, 2002, EMBO J, V21, P1398, DOI 10.1093/emboj/21.6.1398; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; Yamagami T, 1998, LEUKEMIA RES, V22, P383, DOI 10.1016/S0145-2126(97)00176-8; Yamagami T, 1996, BLOOD, V87, P2878, DOI 10.1182/blood.V87.7.2878.bloodjournal8772878	42	83	89	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	30					4217	4229		10.1038/sj.onc.1209455	http://dx.doi.org/10.1038/sj.onc.1209455			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16518414				2022-12-28	WOS:000239004800009
J	Siddique, M; Sabapathy, K				Siddique, M.; Sabapathy, K.			Trp53-dependent DNA-repair is affected by the codon 72 polymorphism	ONCOGENE			English	Article						Trp53; codon 72; polymorphism; DNA-repair; target genes	STRAND BREAK REPAIR; TEMPERATURE-SENSITIVE MUTANT; CELL-CYCLE CHECKPOINT; WILD-TYPE; IN-VITRO; P53 POLYMORPHISM; LACKING P53; EXPRESSION; RADIATION; CANCER	Trp53 is arguably the most critical tumour suppressor gene product that inhibits malignant transformation. Besides mutations that inactivate Trp53 functions, genetic polymorphisms have been suggested to be risk factors for cancer. A polymorphic site at codon 72 in exon 4 encodes either an arginine amino acid (Trp53(72R)) or a proline residue (Trp53(72P)). Previous studies have shown that the Trp53(72R) form is more efficient in apoptosis induction, whereas the Trp53(72P) form was suggested to induce G1 arrest better. Here we report that Trp53(72P) is more efficient than Trp53(72P) in specifically activating several Trp53-dependent DNA-repair target genes in several cellular systems. Moreover, using isogenic cell lines and several DNA-repair assays, we show that Trp53(72P) cells have a significantly higher DNA-repair capacity than the Trp53(72R) cells. Furthermore, Trp53(72P)-expressing cells exhibit reduced micronuclei formation compared to Trp53(72R)-expressing cells, suggesting that genomic instability is reduced in these cells. Together, the data highlight the functional differences between the Trp53 polymorphic variants, and suggest that their expression status may influence cancer risk.	Natl Canc Ctr, Lab Mol Carcinogenesis, Singapore 169610, Singapore; Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore	National Cancer Centre Singapore (NCCS); National University of Singapore	Sabapathy, K (corresponding author), Natl Canc Ctr, Lab Mol Carcinogenesis, 11 Hosp Dr, Singapore 169610, Singapore.	cmrksb@nccs.com.sg						Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; Chipuk JE, 2003, J CLIN IMMUNOL, V23, P355, DOI 10.1023/A:1025365432325; Cho HJ, 2002, J BIOL CHEM, V277, P19358, DOI 10.1074/jbc.M200933200; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Dahm-Daphi J, 2005, ONCOGENE, V24, P1663, DOI 10.1038/sj.onc.1208396; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Evans SC, 1997, MOL MED TODAY, V3, P390, DOI 10.1016/S1357-4310(97)01105-2; Fenech M, 2002, MUTAT RES-FUND MOL M, V504, P131, DOI 10.1016/S0027-5107(02)00086-6; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; Ghebranious N, 1998, ONCOGENE, V17, P3385, DOI 10.1038/sj.onc.1202573; Hanawalt PC, 2003, MUTAT RES-REV MUTAT, V544, P107, DOI 10.1016/j.mrrev.2003.06.002; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; Haupt S, 2003, J CELL SCI, V116, P4077, DOI 10.1242/jcs.00739; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Lahav G, 2004, SCI STKE, V264, P55; Langerod A, 2002, CANCER EPIDEM BIOMAR, V11, P1684; Lee MK, 2005, J CELL SCI, V118, P819, DOI 10.1242/jcs.01673; Lin YF, 2003, DNA REPAIR, V2, P1, DOI 10.1016/S1568-7864(02)00183-0; Mallya SM, 1998, INT J RADIAT BIOL, V74, P231, DOI 10.1080/095530098141618; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MATSUOKA A, 1992, MUTAT RES, V272, P223, DOI 10.1016/0165-1161(92)91535-Y; McGregor JM, 2002, J INVEST DERMATOL, V119, P84, DOI 10.1046/j.1523-1747.2002.01655.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Okorokov AL, 2002, CARCINOGENESIS, V23, P549, DOI 10.1093/carcin/23.4.549; Olivier Magali, 2004, IARC Sci Publ, P247; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Papadakis E. N., 2000, Molecular Cell Biology Research Communications, V3, P389, DOI 10.1006/mcbr.2000.0241; PATRICK MH, 1977, PHOTOCHEM PHOTOBIOL, V25, P357, DOI 10.1111/j.1751-1097.1977.tb07355.x; Pim D, 2004, INT J CANCER, V108, P196, DOI 10.1002/ijc.11548; RAUTH S, 1994, ANTICANCER RES, V14, P2457; Risinger MA, 2004, CANCER CELL, V6, P539, DOI 10.1016/j.ccr.2004.12.001; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Schwarz A, 2002, NAT CELL BIOL, V4, P26, DOI 10.1038/ncb717; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; Siddique MM, 2005, CANCER EPIDEM BIOMAR, V14, P2245, DOI 10.1158/1055-9965.EPI-05-0153; Sjalander A, 1996, CARCINOGENESIS, V17, P1313, DOI 10.1093/carcin/17.6.1313; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Stopper H, 1997, Recent Results Cancer Res, V143, P183; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Sullivan A, 2004, ONCOGENE, V23, P3328, DOI 10.1038/sj.onc.1207428; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tang W, 1999, CANCER RES, V59, P2562; THODAY JM, 1951, BRIT J RADIOL, V24, P572, DOI 10.1259/0007-1285-24-286-572; Thomas M, 1999, MOL CELL BIOL, V19, P1092; Toh WH, 2005, J BIOL CHEM, V280, P17329, DOI 10.1074/jbc.M500044200; Vikhanskaya F, 2005, CLIN CANCER RES, V11, P4348, DOI 10.1158/1078-0432.CCR-04-1547; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wani MA, 2002, CARCINOGENESIS, V23, P403, DOI 10.1093/carcin/23.3.403; Weston A, 1997, ENVIRON HEALTH PERSP, V105, P919, DOI 10.2307/3433304; Yang TT, 1997, ONCOGENE, V14, P1511, DOI 10.1038/sj.onc.1200979; Yang WL, 1998, BIOCHEM BIOPH RES CO, V250, P593, DOI 10.1006/bbrc.1998.9366; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	61	113	117	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3489	3500		10.1038/sj.onc.1209405	http://dx.doi.org/10.1038/sj.onc.1209405			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16462765				2022-12-28	WOS:000238448200001
J	Moniaux, N; Nemos, C; Schmied, BM; Chauhan, SC; Deb, S; Morikane, K; Choudhury, A; VanLith, M; Sutherlin, M; Sikela, JM; Hollingsworth, MA; Batra, SK				Moniaux, N.; Nemos, C.; Schmied, B. M.; Chauhan, S. C.; Deb, S.; Morikane, K.; Choudhury, A.; VanLith, M.; Sutherlin, M.; Sikela, J. M.; Hollingsworth, M. A.; Batra, S. K.			The human homologue of the RNA polymerase II-associated factor 1 (hPaf1), localized on the 19q13 amplicon, is associated with tumorigenesis	ONCOGENE			English	Article						hPaf1; hPAF1 complex; amplicon; pancreatic cancer	COMPARATIVE GENOMIC HYBRIDIZATION; CELL-CYCLE REGULATION; PROTEIN-KINASE; AKT2 ONCOGENE; BREAST-CANCER; PANCREATIC ADENOCARCINOMA; MOLECULAR-CLONING; PAF1 COMPLEX; DNA GAINS; EXPRESSION	The 19q13 amplicon in pancreatic cancer cells contains a novel pancreatic differentiation 2 (PD2) gene (accession number AJ401156), which was identified by differential screening analysis. PD2 is the human homologue of the RNA polymerase II-associated factor 1 (hPaf1). In yeast, Paf1 is part of the transcription machinery, acting as a docking protein in between the complexes Rad6-Bre1, COMPASS-Dot1p, and the phosphorylated carboxyl terminal domain of the RNA polymerase II. As such, Paf1 is directly involved in transcription elongation via histone H2B ubiquitination and histone H3 methylation. The PD2 sequence is highly conserved from Drosophila to humans with up to 98% identity between rodent and human, suggesting the functional importance of PD2/hPaf1 to maintain cellular homeostasis. PD2 is a modular protein composed of RNA recognition motif, DEAD-boxes, an aspartic/serine (DS)-domain, a regulator of the chromosome condensation domain and myc-type helix-loop-helix domains. Our results further showed that PD2 is a nuclear 80kDa protein, which interacts with RNA polymerase II. In addition, we have demonstrated that the overexpression of PD2 in the NIH 3T3 cells result in enhanced growth rates in vitro and tumor formation in vivo. Altogether, this paper presents strong evidence that the overexpression of PD2/hPaf1 is involved in cancer development.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Inst, Omaha, NE 68198 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Batra, SK (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 985870 Nebraska Med Ctr, Omaha, NE 68198 USA.	sbatra@unmc.edu	Moniaux, Nicolas/Y-3243-2018	Moniaux, Nicolas/0000-0001-9718-1386; Morikane, Keita/0000-0002-4215-7829; Schmied, Bruno/0000-0003-4552-7386	NATIONAL CANCER INSTITUTE [R01CA078590, P50CA072712] Funding Source: NIH RePORTER; NCI NIH HHS [CA72712, CA78590] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altomare DA, 2003, J CELL BIOCHEM, V88, P470, DOI 10.1002/jcb.10287; Arboleda MJ, 2003, CANCER RES, V63, P196; BATRA SK, 1991, CELL GROWTH DIFFER, V2, P385; BATRA SK, 1991, J BIOL CHEM, V266, P6830; Bauer B, 2002, MOL IMMUNOL, V38, P1087, DOI 10.1016/S0161-5890(02)00011-1; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BELLANNECHANTELOT C, 1992, CELL, V70, P1059, DOI 10.1016/0092-8674(92)90254-A; BERRY R, 1995, NAT GENET, V10, P415, DOI 10.1038/ng0895-415; Betz JL, 2002, MOL GENET GENOMICS, V268, P272, DOI 10.1007/s00438-002-0752-8; Bjorkqvist AM, 1998, GENE CHROMOSOME CANC, V22, P79; Blain SW, 2002, NAT MED, V8, P1076, DOI 10.1038/nm1002-1076; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Grande MA, 1997, J CELL SCI, V110, P1781; GRIFFIN CA, 1994, GENE CHROMOSOME CANC, V9, P93, DOI 10.1002/gcc.2870090204; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Heselmeyer K, 1997, GENE CHROMOSOME CANC, V19, P233, DOI 10.1002/(SICI)1098-2264(199708)19:4<233::AID-GCC5>3.0.CO;2-Y; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; KHATIB ZA, 1993, CANCER RES, V53, P5535; KIM YW, 1989, PANCREAS, V4, P353, DOI 10.1097/00006676-198906000-00013; LAN MS, 1990, J BIOL CHEM, V265, P15294; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LIEBER M, 1975, INT J CANCER, V15, P741, DOI 10.1002/ijc.2910150505; Meyer T, 2002, EMBO J, V21, P344, DOI 10.1093/emboj/21.3.344; Mueller CL, 2004, MOL CELL, V14, P447, DOI 10.1016/S1097-2765(04)00257-6; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; RIED T, 1994, CANCER RES, V54, P1801; Ruggeri BA, 1998, MOL CARCINOGEN, V21, P81, DOI 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Squazzo SL, 2002, EMBO J, V21, P1764, DOI 10.1093/emboj/21.7.1764; Werner CA, 1997, AM J PATHOL, V151, P335; WILCOX AS, 1991, NUCLEIC ACIDS RES, V19, P1837, DOI 10.1093/nar/19.8.1837; Woodard GE, 2005, ONCOGENE, V24, P1272, DOI 10.1038/sj.onc.1208274	43	61	67	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3247	3257		10.1038/sj.onc.1209353	http://dx.doi.org/10.1038/sj.onc.1209353			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16491129				2022-12-28	WOS:000237951200003
J	Giles, RH; Lolkema, MP; Snijckers, CM; Belderbos, M; van der Groep, P; Mans, DA; van Beest, M; van Noort, M; Goldschmeding, R; van Diest, PJ; Clevers, H; Voest, EE				Giles, R. H.; Lolkema, M. P.; Snijckers, C. M.; Belderbos, M.; van der Groep, P.; Mans, D. A.; van Beest, M.; van Noort, M.; Goldschmeding, R.; van Diest, P. J.; Clevers, H.; Voest, E. E.			Interplay between VHL/HIF1 alpha and Wnt/beta-catenin pathways during colorectal tumorigenesis	ONCOGENE			English	Article						von Hippel-Lindau; Wnt signaling; hypoxiainducible factor; colorectal cancer	HYPOXIA-INDUCIBLE FACTOR; ENDOTHELIAL GROWTH-FACTOR; HIPPEL-LINDAU-DISEASE; TUMOR-SUPPRESSOR PROTEIN; BETA-CATENIN; COLON-CARCINOMA; CANCER CELLS; HIF-ALPHA; FACTOR-I; EXPRESSION	Activation of the Wnt signaling pathway initiates the transformation of colorectal epithelial cells, although the transition to metastatic cancer requires angiogenesis. We have investigated the expression of the von Hippel-Lindau (VHL) tumor suppressor in the intestines from humans and mice. Here, we show that VHL expression is regulated by TCF4 and is restricted to the proliferative compartment at the bottom of intestinal crypts. Accordingly, VHL is completely absent from the proliferative intestinal pockets of Tcf4(-/-) perinatal mice. We observed complementary staining of the hypoxia-inducible factor (HIF) 1 alpha to VHL in normal intestinal epithelium as well as in all stages of colorectal cancer (CRC). To the best of our knowledge, this is the first report demonstrating the presence of nuclear HIF1 alpha in normoxic healthy adult tissue. Although we observed upregulated levels of VHL in very early CRC lesions from sporadic and familial adenomatous polyposis patients-presumably due to activated Wnt signaling - a clear reduction of VHL expression is observed in later stages of CRC progression, coinciding with stabilization of HIF1 alpha. As loss of VHL in later stages of CRC progression results in stabilization of HIF, these data provide evidence that selection for VHL downregulation provides a proangiogenic impulse for CRC progression.	Univ Utrecht, Med Ctr, Dept Med Oncol, Expt Oncol Lab, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Pathol, Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Urol, Utrecht, Netherlands; NIOB, Hubrecht Lab, Utrecht, Netherlands	Utrecht University; Utrecht University; Utrecht University; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Voest, EE (corresponding author), Univ Utrecht, Med Ctr, Dept Med Oncol, Expt Oncol Lab, Heidelberglaan 100,Rm F02-126, NL-3584 CX Utrecht, Netherlands.	e.e.voest@umcutrecht.nl	Lolkema, M.P./AAE-2906-2019; Goldschmeding, Roel/I-1723-2014	Lolkema, M.P./0000-0003-0466-2928; Belderbos, Mirjam/0000-0002-6164-2918; Giles, Rachel/0000-0001-9133-2008				Aotake T, 1999, CLIN CANCER RES, V5, P135; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Bluyssen HAR, 2004, FEBS LETT, V556, P137, DOI 10.1016/S0014-5793(03)01392-9; Bos R, 2001, JNCI-J NATL CANCER I, V93, P309, DOI 10.1093/jnci/93.4.309; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Easwaran V, 2003, CANCER RES, V63, P3145; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Fujii H, 2002, J PATHOL, V197, P298, DOI 10.1002/path.1122; Fukuda R, 2003, CANCER RES, V63, P2330; Furuta GT, 2001, J EXP MED, V193, P1027, DOI 10.1084/jem.193.9.1027; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Goel A, 2003, CANCER RES, V63, P1608; Iniesta P, 2000, CANCER-AM CANCER SOC, V89, P1220, DOI 10.1002/1097-0142(20000915)89:6<1220::AID-CNCR5>3.0.CO;2-Z; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Karhausen J, 2004, J CLIN INVEST, V114, P1098, DOI 10.1172/JCI200421086; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Krishnamachary B, 2003, CANCER RES, V63, P1138; Kuwai T, 2004, CANCER SCI, V95, P149, DOI 10.1111/j.1349-7006.2004.tb03196.x; Kuwai T, 2003, INT J CANCER, V105, P176, DOI 10.1002/ijc.11068; Los M, 1997, ANN ONCOL, V8, P1015, DOI 10.1023/A:1008213320642; Los M, 1996, LAB INVEST, V75, P231; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Mayer RJ, 2004, NEW ENGL J MED, V350, P2406, DOI 10.1056/NEJMe048098; Maynard MA, 2004, AM J NEPHROL, V24, P1, DOI 10.1159/000075346; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; OOSTERWEGEL MA, 1991, INT IMMUNOL, V3, P1189, DOI 10.1093/intimm/3.11.1189; Shibamoto S, 1998, GENES CELLS, V3, P659; Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo-reports/kvf002; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; Vleugel MM, 2005, J CLIN PATHOL, V58, P172, DOI 10.1136/jcp.2004.019885; WANG GL, 1993, J BIOL CHEM, V268, P21513; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8; WIZIGMANNVOOS S, 1995, CANCER RES, V55, P1358; Zhong H, 1999, BIOCHEM BIOPH RES CO, V259, P523, DOI 10.1006/bbrc.1999.0815; Zhong H, 1999, CANCER RES, V59, P5830; Zhuang ZP, 1996, HUM PATHOL, V27, P152, DOI 10.1016/S0046-8177(96)90368-8	41	89	94	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					3065	3070		10.1038/sj.onc.1209330	http://dx.doi.org/10.1038/sj.onc.1209330			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16407833				2022-12-28	WOS:000237950800011
J	Watanabe, S; Umehara, H; Murayama, K; Okabe, M; Kimura, T; Nakano, T				Watanabe, S; Umehara, H; Murayama, K; Okabe, M; Kimura, T; Nakano, T			Activation of Akt signaling is sufficient to maintain pluripotency in mouse and primate embryonic stem cells	ONCOGENE			English	Article						Akt; ES cells; pluripotency; stem cell system	SELF-RENEWAL; ES CELLS; PROTEIN; MAINTENANCE; STAT3; DIFFERENTIATION; EXPRESSION; PATHWAY; PROLIFERATION; SUPPRESSION	Embryonic stem (ES) cells can self-renew indefinitely without losing their differentiation ability to any cell types. Phosphoinositide-3 kinase (PI3K)/Akt signaling plays a pivotal role in various stem cell systems, including the formation of embryonic germ (EG) cells from primordial germ cells and self-renewal of neural stem cells. Here, we show that myristoylated, active form of Akt (myr-Akt) maintained the undifferentiated phenotypes in mouse ES cells without the addition of leukemia inhibitory factor (LIF). The effects of myr-Akt were reversible, because LIF dependence and pluripotent differentiation activity were restored by the deletion of myr-Akt. In addition, myr-Akt-Mer fusion protein, whose enzymatic activity is controlled by 4-hydroxy-tamoxifen, also maintained the pluripotency of not only mouse but also cynomolgus monkey ES cells. These results clearly demonstrate that Akt signaling sufficiently maintains pluripotency in mouse and primate ES cells, and support the notion that PI3K/Akt signaling axis regulates 'stemness' in a broad spectrum of stem cell systems.	Osaka Univ, Grad Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka, Japan; Osaka Univ, Genome Informat Res Ctr, Suita, Osaka, Japan	Osaka University; Osaka University; Osaka University	Kimura, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Pathol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	tkimura@patho.med.osaka-u.ac.jp; tnakano@patho.med.osaka-u.ac.jp	; Okabe, Masaru/B-6917-2015	Kimura, Tohru/0000-0001-9227-0996; Okabe, Masaru/0000-0002-0803-9044				Ben-Shushan E, 1998, MOL CELL BIOL, V18, P1866, DOI 10.1128/MCB.18.4.1866; Boeuf H, 1997, J CELL BIOL, V138, P1207, DOI 10.1083/jcb.138.6.1207; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Daheron L, 2004, STEM CELLS, V22, P770, DOI 10.1634/stemcells.22-5-770; Furuya M, 2003, GENESIS, V37, P180, DOI 10.1002/gene.10246; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Humphrey RK, 2004, STEM CELLS, V22, P522, DOI 10.1634/stemcells.22-4-522; Jirmanova L, 2002, ONCOGENE, V21, P5515, DOI 10.1038/sj.onc.1205728; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Kim SJ, 2005, FEBS LETT, V579, P534, DOI 10.1016/j.febslet.2004.12.024; Kimura T, 2003, DEVELOPMENT, V130, P1691, DOI 10.1242/dev.00392; Kimura T, 2003, MOL CELL BIOL, V23, P1304, DOI 10.1128/MCB.23.4.1304-1315.2003; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Masuyama N, 2001, J BIOL CHEM, V276, P32799, DOI 10.1074/jbc.M105431200; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Nagata M, 2003, J GENE MED, V5, P921, DOI 10.1002/jgm.431; Nakano T, 1996, SCIENCE, V272, P722, DOI 10.1126/science.272.5262.722; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Paling NRD, 2004, J BIOL CHEM, V279, P48063, DOI 10.1074/jbc.M406467200; Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271; Qi XX, 2004, P NATL ACAD SCI USA, V101, P6027, DOI 10.1073/pnas.0401367101; Saitou M, 2002, NATURE, V418, P293, DOI 10.1038/nature00927; Sato M, 2002, MECH DEVELOP, V113, P91, DOI 10.1016/S0925-4773(02)00002-3; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Stiles B, 2004, DEV BIOL, V273, P175, DOI 10.1016/j.ydbio.2004.06.008; Stiles B, 2002, MOL CELL BIOL, V22, P3842, DOI 10.1128/MCB.22.11.3842-3851.2002; Suemori H, 2003, METHOD ENZYMOL, V365, P419; Sumi T, 2004, STEM CELLS, V22, P861, DOI 10.1634/stemcells.22-5-861; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Takahashi K, 2003, NATURE, V423, P541, DOI 10.1038/nature01646; Xu RH, 2005, NAT METHODS, V2, P185, DOI 10.1038/NMETH744; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X	42	252	268	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2697	2707		10.1038/sj.onc.1209307	http://dx.doi.org/10.1038/sj.onc.1209307			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16407845	Bronze			2022-12-28	WOS:000237272900001
J	Baldwin, RM; Garratt-Lalonde, M; Parolin, DAE; Krzyzanowski, PM; Andrade, MA; Lorimer, IAJ				Baldwin, R. M.; Garratt-Lalonde, M.; Parolin, D. A. E.; Krzyzanowski, P. M.; Andrade, M. A.; Lorimer, I. A. J.			Protection of glioblastoma cells from cisplatin cytotoxicity via protein kinase C iota-mediated attenuation of p38 MAP kinase signaling	ONCOGENE			English	Article						glioblastoma; protein kinase C iota; glia maturation factor beta; p38 MAP kinase; cisplatin	GLIA MATURATION FACTOR; NF-KAPPA-B; GROWTH-FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; INDUCED APOPTOSIS; ACTIVATION; ISOFORMS; SURVIVAL; PATHWAY; TARGET	Glioblastoma multiforme is an aggressive form of brain cancer that responds poorly to chemotherapy and is generally incurable. The basis for the poor response of this cancer to chemotherapy is not well understood. The atypical protein kinases C ( PKC iota andPKC zeta) have previously been implicated in leukaemia cell chemoresistance. To assess the role of atypical PKC in glioblastoma cell chemoresistance, RNA interference was used to deplete human glioblastoma cells of PKC iota. Transfection of cells with either of two different RNA duplexes specific for PKC iota causeda partial sensitisation to cell death induced by the chemotherapy agent cisplatin. To screen for possible mechanisms for PKC iota- mediated chemoresistance, microarray analysis of gene expression was performed on RNA from glioblastoma cells that were either untreated or depleted of PKC iota. This identified sets of genes that were regulated either positively or negatively by PKC iota. Within the set of genes that were negatively regulated by PKC iota, the function of the gene coding for GMF beta, an enhancer of p38 mitogen- activated-protein kinase ( MAP kinase) signaling, was investigated further, as the p38 MAP kinase pathway has been previously identified as a key mediator of cisplatin cytotoxicity. The expression of both GMFb mRNA and protein increased upon PKC iota depletion, and this was accompanied by an increase in cisplatin- activated p38 MAP kinase signaling. Transient overexpression of GMFb increased cisplatin-activated p38 MAP kinase signaling and also sensitised cells to cisplatin cytotoxicity. The increase in cisplatin cytotoxicity seen with PKCi depletion was blocked by the p38 MAP kinase inhibitor SKF86002. These data show that PKCi can confer partial resistance to cisplatin in glioblastoma cells by suppressing GMF beta- mediated enhancement of p38 MAP kinase signaling.	Ottawa Hosp Reg Canc Ctr, Ctr Canc Therapeut, Ottawa Hlth Res Inst, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada; Ontario Genom Innovat Ctr, Ottawa, ON, Canada; Univ Ottawa, Dept Med, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa	Lorimer, IAJ (corresponding author), Ottawa Hosp Reg Canc Ctr, Ctr Canc Therapeut, Ottawa Hlth Res Inst, 3rd Floor,501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.	ilorimer@ohri.ca		Krzyzanowski, Paul/0000-0001-6430-5995				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169; Choi BK, 2004, NEUROTOXICOLOGY, V25, P915, DOI 10.1016/j.neuro.2004.06.002; Diaz-Meco MT, 2001, MOL CELL BIOL, V21, P1218, DOI 10.1128/MCB.21.4.1218-1227.2001; Filomenko R, 2002, CANCER RES, V62, P1815; Garcia-Cao I, 2003, EMBO REP, V4, P307, DOI 10.1038/sj.embor.embor769; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hanigan MH, 2005, AM J PHYSIOL-RENAL, V288, pF125, DOI 10.1152/ajprenal.00041.2003; Holland EC, 2001, NAT REV GENET, V2, P120, DOI 10.1038/35052535; Inagaki M, 2004, BBA-GEN SUBJECTS, V1670, P208, DOI 10.1016/j.bbagen.2003.12.006; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Jin ZJ, 2005, J BIOL CHEM, V280, P16045, DOI 10.1074/jbc.M413488200; Kaimori J, 2003, J BIOL CHEM, V278, P33519, DOI 10.1074/jbc.M301552200; Kanzaki M, 2004, J CELL BIOL, V164, P279, DOI 10.1083/jcb.200306152; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Lim R, 2004, BRAIN RES, V1024, P225, DOI 10.1016/j.brainres.2004.08.003; Lim R, 1996, J BIOL CHEM, V271, P22953, DOI 10.1074/jbc.271.38.22953; Lorimer IAJ, 2002, CURR CANCER DRUG TAR, V2, P91, DOI 10.2174/1568009023333926; Lorimer IAJ, 2000, J IMMUNOL METHODS, V237, P147, DOI 10.1016/S0022-1759(99)00219-7; Losa JH, 2003, ONCOGENE, V22, P3998, DOI 10.1038/sj.onc.1206608; Lu WG, 2004, CELL, V119, P97, DOI 10.1016/j.cell.2004.09.019; Lu Y, 2001, ONCOGENE, V20, P4777, DOI 10.1038/sj.onc.1204607; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Semizarov D, 2003, P NATL ACAD SCI USA, V100, P6347, DOI 10.1073/pnas.1131959100; Soloff RS, 2004, J IMMUNOL, V173, P3250, DOI 10.4049/jimmunol.173.5.3250; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Zaheer A, 2004, NEUROCHEM RES, V29, P1473, DOI 10.1023/B:NERE.0000029558.82943.00; Zhan Y, 2004, CANCER RES, V64, P8292, DOI 10.1158/0008-5472.CAN-03-3143	37	57	61	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2006	25	20					2909	2919		10.1038/sj.onc.1209312	http://dx.doi.org/10.1038/sj.onc.1209312			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16331246				2022-12-28	WOS:000237448200009
J	Dang, LH; Chen, F; Knock, SA; Huang, EH; Feng, J; Appelman, HD; Dang, DT				Dang, LH; Chen, F; Knock, SA; Huang, EH; Feng, J; Appelman, HD; Dang, DT			CDX2 does not suppress tumorigenicity in the human gastric cancer cell line MKN45	ONCOGENE			English	Article						CDX2; gastric cancer; tumorigenicity; MKN45	HOMEODOMAIN PROTEIN CDX2; HOMEOBOX GENE CDX2; INTESTINAL METAPLASIA; COLON-CANCER; ECTOPIC EXPRESSION; BETA-CATENIN; TRANSCRIPTION FACTORS; ABERRANT EXPRESSION; MESSENGER-RNA; GUT	CDX2 is a Drosophila caudal-related homeobox transcription factor that is expressed specifically in the intestine. In mice, ectopic expression of CDX2 in the gastric mucosa gives rise to intestinal metaplasia and in one model, gastric carcinoma. In humans, increased CDX2 expression is associated with gastric intestinal metaplasia and tubular adenocarcinomas. These patterns of expression have shown that CDX2 is important for the initiation of intestinal metaplasia in the gastric mucosa, but the role of CDX2 in established gastric cancer remains unclear. We sought to determine whether CDX2 contributes to tumorigenic potential in established gastric cancer. The CDX2 gene in MKN45 gastric carcinoma cells was disrupted using targeted homologous recombination. The resulting CDX2(-/-) cells are essentially identical to their parental cells, with the exception of CDX2 ablation. We found no significant differences in the proliferation of CDX2(-/-) cells compared to CDX2(-/-) cells, in vitro or in vivo. Molecular analyses show that loss of CDX2 predominantly altered the expression of genes involved in intestinal glandular differentiation and adhesion. However, there were no microscopic differences in tumor differentiation. We conclude that disruption of CDX2 in MKN45 cells does not significantly affect their tumorigenic potential.	Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI USA; Univ Michigan, Dept Surg, Div Colorectal Surg, Ann Arbor, MI USA; Johns Hopkins Univ, Div Gastroenterol, Baltimore, MD USA; Univ Michigan, Dept Pathol, Div Anat Pathol, Ann Arbor, MI USA; Univ Michigan, Div Gastroenterol, Dept Internal Med, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Johns Hopkins University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Dang, DT (corresponding author), Univ Michigan, Dept Internal Med, Div Hematol Oncol, 1150 W Med Ctr Dr,MSRB 1,Room 6514, Ann Arbor, MI 48109 USA.	dangd@umich.edu		Huang, Emina/0000-0003-2495-4370	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK059970] Funding Source: NIH RePORTER; NIDDK NIH HHS [K08DK59970] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Almeida R, 2003, J PATHOL, V199, P36, DOI 10.1002/path.1246; Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265; Bai YQ, 2000, MOL CARCINOGEN, V28, P184, DOI 10.1002/1098-2744(200007)28:3<184::AID-MC7>3.0.CO;2-6; Bai YQ, 2003, ONCOGENE, V22, P7942, DOI 10.1038/sj.onc.1206634; Bai YQ, 2002, CANCER LETT, V176, P47, DOI 10.1016/S0304-3835(01)00753-4; Bjerknes M, 1999, GASTROENTEROLOGY, V116, P7, DOI 10.1016/S0016-5085(99)70222-2; BOLLER K, 1988, DIFFERENTIATION, V39, P51, DOI 10.1111/j.1432-0436.1988.tb00080.x; Bonhomme C, 2003, GUT, V52, P1465, DOI 10.1136/gut.52.10.1465; Boudreau F, 2002, J BIOL CHEM, V277, P31909, DOI 10.1074/jbc.M204622200; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bunz F, 2002, CURR OPIN ONCOL, V14, P73, DOI 10.1097/00001622-200201000-00013; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chan TA, 2002, P NATL ACAD SCI USA, V99, P8265, DOI 10.1073/pnas.082240999; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CORREA P, 1994, CANCER RES, V54, pS1941; CORREA P, 1992, CANCER RES, V52, P6735; Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046; CUMMINS JM, 2004, NATURE, V428, P486, DOI [DOI 10.1038/NATURE02501, 10.1038/nature02501]; Dang DT, 2005, CANCER RES, V65, P9485, DOI 10.1158/0008-5472.CAN-05-1930; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; Dang LH, 2004, CANCER BIOL THER, V3, P326, DOI 10.4161/cbt.3.3.704; DANG LH, 2003, IN PRESS ONCOGENE; DONG Z, 2002, SCI STKE, pPL7; Ebert MPA, 2002, ALIMENT PHARM THER, V16, P1059, DOI 10.1046/j.1365-2036.2002.01288.x; Ebert MPA, 2003, J CLIN ONCOL, V21, P1708, DOI 10.1200/JCO.2003.10.017; Ebert MPA, 2002, CARCINOGENESIS, V23, P87, DOI 10.1093/carcin/23.1.87; Eda A, 2002, J GASTROENTEROL, V37, P94, DOI 10.1007/s005350200002; Fang RX, 2000, GASTROENTEROLOGY, V118, P115, DOI 10.1016/S0016-5085(00)70420-3; FENOGLIOPREISER CM, 2000, PATHOLOGY GENETICS T; Freund JN, 1998, BIOCHEM CELL BIOL, V76, P957, DOI 10.1139/bcb-76-6-957; FRIEDERICH E, 1990, BIOESSAYS, V12, P403, DOI 10.1002/bies.950120902; Gao XP, 1998, MOL CELL BIOL, V18, P2901, DOI 10.1128/MCB.18.5.2901; Grotzinger C, 2001, GUT, V49, P73, DOI 10.1136/gut.49.1.73; Guo RJ, 2004, CANCER BIOL THER, V3, P593, DOI 10.4161/cbt.3.7.913; Guo RJ, 2004, J BIOL CHEM, V279, P36865, DOI 10.1074/jbc.M405213200; Hinoi T, 2003, J BIOL CHEM, V278, P44608, DOI 10.1074/jbc.M307435200; Hinoi T, 2002, GASTROENTEROLOGY, V123, P1565, DOI 10.1053/gast.2002.36598; Ishikawa A, 2004, LAB INVEST, V84, P629, DOI 10.1038/labinvest.3700087; Ji JF, 2002, ONCOGENE, V21, P6549, DOI 10.1038/sj.onc.1205829; Kaimaktchiev V, 2004, MODERN PATHOL, V17, P1392, DOI 10.1038/modpathol.3800205; Katz JP, 2002, DEVELOPMENT, V129, P2619; Keller MS, 2004, AM J PHYSIOL-GASTR L, V287, pG104, DOI 10.1152/ajpgi.00484.2003; Kim JS, 2004, CANCER RES, V64, P1932, DOI 10.1158/0008-5472.CAN-03-3862; Kim JS, 2002, CANCER RES, V62, P2744; Kobayashi M, 1999, P NATL ACAD SCI USA, V96, P4874, DOI 10.1073/pnas.96.9.4874; Kohli M, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh009; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Leung WK, 2002, J PATHOL, V197, P582, DOI 10.1002/path.1147; Mahatan CS, 1999, NUCLEIC ACIDS RES, V27, P4562, DOI 10.1093/nar/27.23.4562; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; McKenna BJ, 2002, J CLIN GASTROENTEROL, V34, P111, DOI 10.1097/00004836-200202000-00002; Mesquita P, 2003, J BIOL CHEM, V278, P51549, DOI 10.1074/jbc.M309019200; Mizoshita T, 2004, PATHOL INT, V54, P392, DOI 10.1111/j.1440-1827.2004.01647.x; Mizoshita T, 2004, J CANCER RES CLIN, V130, P29, DOI 10.1007/s00432-003-0503-1; Mizoshita T, 2003, J CANCER RES CLIN, V129, P727, DOI 10.1007/s00432-003-0499-6; MOTOYAMA T, 1986, ACTA PATHOL JAPON, V36, P65; Mutoh H, 2004, CANCER RES, V64, P7740, DOI 10.1158/0008-5472.CAN-04-1617; Mutoh H, 2002, BIOCHEM BIOPH RES CO, V294, P470, DOI 10.1016/S0006-291X(02)00480-1; Nakajima T, 2002, DIGEST DIS SCI, V47, P2729, DOI 10.1023/A:1021005221934; Niwa T, 2005, J HISTOCHEM CYTOCHEM, V53, P75, DOI 10.1369/jhc.4A6443.2005; OSBORN M, 1988, VIRCHOWS ARCH A, V413, P303, DOI 10.1007/BF00783022; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pinto D, 1999, J BIOL CHEM, V274, P6476, DOI 10.1074/jbc.274.10.6476; Piso P, 2003, EUR SURG RES, V35, P470, DOI 10.1159/000073385; Rawat VPS, 2004, P NATL ACAD SCI USA, V101, P817, DOI 10.1073/pnas.0305555101; Sakate Y, 2004, J SURG RES, V122, P89, DOI 10.1016/j.jss.2004.06.011; Satoh K, 2002, HELICOBACTER, V7, P192, DOI 10.1046/j.1523-5378.2002.00080.x; SEDIVY JM, 1999, SCIENCE, V283, P9, DOI DOI 10.1126/SCIENCE.283.5398.9A); Seno H, 2002, INT J ONCOL, V21, P769; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Sikorski R, 1997, SCIENCE, V277, P1848, DOI 10.1126/science.277.5333.1848; Silberg DG, 2002, GASTROENTEROLOGY, V122, P689, DOI 10.1053/gast.2002.31902; Sipponen P, 2000, GASTROENTEROL CLIN N, V29, P579, DOI 10.1016/S0889-8553(05)70131-X; Sonoda H, 2004, J SURG ONCOL, V88, P63, DOI 10.1002/jso.20143; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Taylor JK, 1997, DNA CELL BIOL, V16, P1419, DOI 10.1089/dna.1997.16.1419; Tsukamoto T, 2004, J CANCER RES CLIN, V130, P135, DOI 10.1007/s00432-003-0519-6; Tsukashita S, 2001, INT J CANCER, V94, P166, DOI 10.1002/ijc.1460; Ullman-Cullere MH, 1999, LAB ANIM SCI, V49, P319; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; WALDMAN T, 1995, CANCER RES, V55, P5187; WALDMAN TA, 2003, METH MOL B, V241, P163; Yamamoto H, 2003, BIOCHEM BIOPH RES CO, V300, P813, DOI 10.1016/S0006-291X(02)02935-2; Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Yuasa Y, 2005, CARCINOGENESIS, V26, P193, DOI 10.1093/carcin/bgh304; Yuasa Y, 2003, NAT REV CANCER, V3, P592, DOI 10.1038/nrc1141; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zheng Leizhen, 2004, Gastric Cancer, V7, P61	95	11	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2048	2059		10.1038/sj.onc.1209243	http://dx.doi.org/10.1038/sj.onc.1209243			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16331267				2022-12-28	WOS:000236359700008
J	Hein, DW				Hein, DW			N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk	ONCOGENE			English	Review						N-acetyltransferase 2; urinary bladder cancer; aromatic amines; NAT2 acetylator genotype; singlenucleotide polymorphisms; NAT2 haplotypes	ARYLAMINE N-ACETYLTRANSFERASE; GLUTATHIONE-S-TRANSFERASE; SLOW ACETYLATOR PHENOTYPE; METABOLIC-ACTIVATION; AROMATIC-AMINES; FUNCTIONAL-CHARACTERIZATION; MOLECULAR-GENETICS; HUMAN LIVER; CHROMOSOMAL LOCALIZATION; KINETIC CHARACTERIZATION	A role for the N-acetyltransferase 2 (NAT2) genetic polymorphism in cancer risk has been the subject of numerous studies. Although comprehensive reviews of the NAT2 acetylation polymorphism have been published elsewhere, the objective of this paper is to briefly highlight some important features of the NAT2 acetylation polymorphism that are not universally accepted to better understand the role of NAT2 polymorphism in carcinogenic risk assessment. NAT2 slow acetylator phenotype(s) infer a consistent and robust increase in urinary bladder cancer risk following exposures to aromatic amine carcinogens. However, identification of specific carcinogens is important as the effect of NAT2 polymorphism on urinary bladder cancer differs dramatically between monoarylamines and diarylamines. Misclassifications of carcinogen exposure and NAT2 genotype/phenotype confound evidence for a real biological effect. Functional understanding of the effects of NAT2 genetic polymorphisms on metabolism and genotoxicity, tissue-specific expression and the elucidation of the molecular mechanisms responsible are critical for the interpretation of previous and future human molecular epidemiology investigations into the role of NAT2 polymorphism on cancer risk. Although associations have been reported for various cancers, this paper focuses on urinary bladder cancer, a cancer in which a role for NAT2 polymorphism was first proposed and for which evidence is accumulating that the effect is biologically significant with important public health implications.	Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA; Univ Louisville, Sch Med, James Graham Brown Canc Ctr, Louisville, KY 40292 USA	University of Louisville; University of Louisville	Hein, DW (corresponding author), Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA.	d.hein@louisville.edu	Garcia-Closas, Montserrat/AAZ-6930-2021; Hein, David W/A-9707-2008	Garcia-Closas, Montserrat/0000-0003-1033-2650; Hein, David/0000-0003-3261-9775	NATIONAL CANCER INSTITUTE [R01CA034627] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA34627, R01 CA034627] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE M, 1993, BIOCHEM BIOPH RES CO, V191, P811, DOI 10.1006/bbrc.1993.1289; Agundez JAG, 1996, PHARMACOGENETICS, V6, P465; Airoldi L, 2002, CARCINOGENESIS, V23, P861, DOI 10.1093/carcin/23.5.861; Anitha A, 2003, INT J MOL MED, V11, P125; BADAWI AF, 1995, CANCER RES, V55, P5230; BLUM M, 1991, P NATL ACAD SCI USA, V88, P5237, DOI 10.1073/pnas.88.12.5237; BLUM M, 1990, DNA CELL BIOL, V9, P193, DOI 10.1089/dna.1990.9.193; BLUM M, 1989, P NATL ACAD SCI USA, V86, P9554, DOI 10.1073/pnas.86.23.9554; Bolt HM, 2005, ARCH TOXICOL, V79, P196, DOI 10.1007/s00204-004-0622-8; Boukouvala S, 2005, BASIC CLIN PHARMACOL, V96, P343, DOI 10.1111/j.1742-7843.2005.pto_02.x; Brockmoller J, 1996, CANCER RES, V56, P3915; Carreon T, 2006, INT J CANCER, V118, P161, DOI 10.1002/ijc.21308; CARTWRIGHT RA, 1982, LANCET, V2, P842; Cascorbi I, 1999, PHARMACOGENETICS, V9, P123, DOI 10.1097/00008571-199902000-00016; Cascorbi I, 1999, DRUG METAB REV, V31, P489, DOI 10.1081/DMR-100101932; CASCORBI I, 1995, AM J HUM GENET, V57, P581; Cascorbi I, 1996, PHARMACOGENETICS, V6, P257, DOI 10.1097/00008571-199606000-00009; CHAPRON DJ, 1980, CLIN PHARMACOL THER, V27, P104, DOI 10.1038/clpt.1980.16; CHUNG JG, 1993, DRUG METAB DISPOS, V21, P1057; CRIBB AE, 1994, PHARMACOGENETICS, V4, P166, DOI 10.1097/00008571-199406000-00009; DEGUCHI T, 1990, J BIOL CHEM, V265, P12757; DEGUCHI T, 1992, J BIOL CHEM, V267, P18140; Deitz AC, 2004, CANCER EPIDEM BIOMAR, V13, P1543; Deitz AC, 2000, CANCER EPIDEM BIOMAR, V9, P905; Delomenie C, 1996, PHARMACOGENETICS, V6, P177, DOI 10.1097/00008571-199604000-00004; Dewan A., 1995, Indian Journal of Cancer, V32, P15; DOLL MA, 1995, PHARMACOGENETICS, V5, P247, DOI 10.1097/00008571-199508000-00009; DUPRET JM, 1992, J BIOL CHEM, V267, P7381; Dupret JM, 2005, CURR MED CHEM, V12, P311, DOI 10.2174/0929867053363289; EBISAWA T, 1991, BIOCHEM BIOPH RES CO, V177, P1252, DOI 10.1016/0006-291X(91)90676-X; El Desoky ES, 2005, THER DRUG MONIT, V27, P297, DOI 10.1097/01.ftd.0000164197.95494.aa; FERGUSON RJ, 1994, DRUG METAB DISPOS, V22, P371; Ferguson RJ, 1996, PHARMACOGENETICS, V6, P55, DOI 10.1097/00008571-199602000-00004; Filiadis IF, 1999, J UROLOGY, V161, P1672, DOI 10.1016/S0022-5347(05)69002-7; FREDERICKSON SM, 1992, CARCINOGENESIS, V13, P955, DOI 10.1093/carcin/13.6.955; FREDERICKSON SM, 1994, CANCER EPIDEM BIOMAR, V3, P25; Fretland AJ, 2001, PHARMACOGENETICS, V11, P511, DOI 10.1097/00008571-200108000-00006; Gago-Dominguez M, 2003, CARCINOGENESIS, V24, P483, DOI 10.1093/carcin/24.3.483; Garcia-Closas M, 2005, LANCET, V366, P649, DOI 10.1016/S0140-6736(05)67137-1; Giannakopoulos X, 2002, ANTICANCER RES, V22, P3801; Golka K, 2002, TOXICOL LETT, V128, P229, DOI 10.1016/S0378-4274(01)00544-6; GRANT DM, 1990, J CLIN INVEST, V85, P968, DOI 10.1172/JCI114527; Grant DM, 2004, BRIT J CLIN PHARMACO, V58, pS788, DOI 10.1111/j.1365-2125.2004.02297.x; Grant DM, 1997, MUTAT RES-FUND MOL M, V376, P61, DOI 10.1016/S0027-5107(97)00026-2; Green J, 2000, BRIT J CANCER, V83, P412, DOI 10.1054/bjoc.2000.1265; Gross M, 1999, CANCER EPIDEM BIOMAR, V8, P683; Gu J, 2005, MUTAT RES-GEN TOX EN, V581, P97, DOI 10.1016/j.mrgentox.2004.11.012; HANSSEN HP, 1985, EUR UROL, V11, P263; Hao Gang-yue, 2004, Zhonghua Zhongliu Zazhi, V26, P283; HAYES RB, 1993, CARCINOGENESIS, V14, P675, DOI 10.1093/carcin/14.4.675; HEARSE DJ, 1973, BIOCHEM J, V132, P519, DOI 10.1042/bj1320519; Hein DW, 2002, MUTAT RES-FUND MOL M, V506, P65, DOI 10.1016/S0027-5107(02)00153-7; HEIN DW, 1994, HUM MOL GENET, V3, P729; HEIN DW, 1995, CANCER RES, V55, P3531; HEIN DW, 1993, CARCINOGENESIS, V14, P1633, DOI 10.1093/carcin/14.8.1633; Hein DW, 2000, CANCER EPIDEM BIOMAR, V9, P29; HEIN DW, 1991, J PHARMACOL EXP THER, V259, P699; HEIN DW, 1991, DRUG METAB DISPOS, V19, P933; Hein DW, 1997, MUTAT RES-FUND MOL M, V376, P101, DOI 10.1016/S0027-5107(97)00031-6; HEIN DW, 1993, CANCER RES, V53, P509; Hein DW, 2003, PHARMACOGENETICS, V13, P159, DOI 10.1097/00008571-200303000-00005; HEIN DW, 1988, DRUG METAB DISPOS, V16, P341; HEIN DW, 1988, BIOCHIM BIOPHYS ACTA, V948, P37, DOI 10.1016/0304-419X(88)90004-2; HEIN DW, 1985, J PHARMACOL EXP THER, V234, P358; HEIN DW, 1994, TOXICOL APPL PHARM, V124, P16, DOI 10.1006/taap.1994.1003; HEIN DW, 2006, IN PRESS MOL CARCINO; HICKMAN D, 1995, BIOCHEM PHARMACOL, V50, P697, DOI 10.1016/0006-2952(95)00182-Y; HICKMAN D, 1994, BIOCHEM J, V297, P441, DOI 10.1042/bj2970441; Hickman D, 1998, GUT, V42, P402, DOI 10.1136/gut.42.3.402; HORAI Y, 1989, EUR J CLIN PHARMACOL, V37, P581; Hsieh FI, 1999, BRIT J CANCER, V81, P537, DOI 10.1038/sj.bjc.6690727; HUGHES HB, 1954, AM REV TUBERC PULM, V70, P266; Hung RJ, 2004, INT J CANCER, V110, P598, DOI 10.1002/ijc.20157; ILETT KF, 1991, CARCINOGENESIS, V12, P1465, DOI 10.1093/carcin/12.8.1465; ILETT KF, 1994, BIOCHEM PHARMACOL, V47, P914, DOI 10.1016/0006-2952(94)90493-6; Ishizu S, 1995, JPN J CANCER RES, V86, P1179, DOI 10.1111/j.1349-7006.1995.tb03312.x; Jaskula-Sztul Renata, 2001, Journal of Applied Genetics, V42, P223; JENNE JW, 1965, J CLIN INVEST, V44, P1992, DOI 10.1172/JCI105306; KAISARY A, 1987, CANCER RES, V47, P5488; KARAKAYA AE, 1986, HUM TOXICOL, V5, P333, DOI 10.1177/096032718600500507; Kim WJ, 2000, J UROLOGY, V164, P209, DOI 10.1016/S0022-5347(05)67496-4; KIRLIN WG, 1991, CANCER RES, V51, P549; KIRLIN WG, 1989, CANCER RES, V49, P2448; LADERO JM, 1985, ANN CLIN RES, V17, P96; Lan Q, 2003, CANCER EPIDEM BIOMAR, V12, P384; LEE EJD, 1982, BRIT J CLIN PHARMACO, V13, P375, DOI 10.1111/j.1365-2125.1982.tb01388.x; Lee SY, 2002, CLIN CHEM, V48, P775; Leff MA, 1999, J BIOL CHEM, V274, P34519, DOI 10.1074/jbc.274.49.34519; Loktionov A, 2002, CANCER DETECT PREV, V26, P15, DOI 10.1016/S0361-090X(02)00010-7; LORENZO B, 1989, BRIT J CLIN PHARMACO, V28, P207, DOI 10.1111/j.1365-2125.1989.tb05420.x; LOWER GM, 1979, ENVIRON HEALTH PERSP, V29, P71, DOI 10.2307/3429048; LUCERI F, 1993, TOXICOL IND HEALTH, V9, P405, DOI 10.1177/074823379300900302; Ma QW, 2004, BIOMED ENVIRON SCI, V17, P291; MARTELL KJ, 1991, MOL PHARMACOL, V40, P218; Matas N, 1997, CYTOGENET CELL GENET, V77, P290, DOI 10.1159/000134601; MILLER ME, 1983, J UROLOGY, V130, P65, DOI 10.1016/S0022-5347(17)50956-8; MINCHIN RF, 1992, BIOCHEM BIOPH RES CO, V185, P839, DOI 10.1016/0006-291X(92)91703-S; Mittal Rama D., 2004, Int. braz j urol., V30, P279, DOI 10.1590/S1677-55382004000400003; MITTAL RD, 2004, INT BRAZ J UROL, V30, P285, DOI DOI 10.1590/S1677-55382004000400003; MOMMSEN S, 1985, SCAND J UROL NEPHROL, V19, P203, DOI 10.3109/00365598509180254; NAGATA K, 1994, PHARMACOGENETICS, V4, P91, DOI 10.1097/00008571-199404000-00006; O'Neil WM, 2000, PHARMACOGENETICS, V10, P171, DOI 10.1097/00008571-200003000-00009; Okkels H, 1997, CANCER EPIDEM BIOMAR, V6, P225; OZAWA S, 1990, CARCINOGENESIS, V11, P2137, DOI 10.1093/carcin/11.12.2137; PACIFICI GM, 1986, PHARMACOLOGY, V32, P283; Palmiotto G, 2001, CHEMOSPHERE, V43, P355, DOI 10.1016/S0045-6535(00)00109-0; Parkin DP, 1997, AM J RESP CRIT CARE, V155, P1717, DOI 10.1164/ajrccm.155.5.9154882; Peluso M, 1998, CANCER EPIDEM BIOMAR, V7, P341; PINK JC, 1992, DRUG METAB DISPOS, V20, P559; Probst-Hensch NM, 2000, CANCER EPIDEM BIOMAR, V9, P619; Reilly TP, 2000, J INVEST DERMATOL, V114, P1164, DOI 10.1046/j.1523-1747.2000.00985.x; RISCH A, 1995, HUM MOL GENET, V4, P231, DOI 10.1093/hmg/4.2.231; Rodrigues-Lima F, 2002, BIOCHEM BIOPH RES CO, V291, P116, DOI 10.1006/bbrc.2002.6414; Rodrigues-Lima F, 2001, BIOCHEM J, V356, P327, DOI 10.1042/0264-6021:3560327; ROTHMAN N, 1993, CANCER EPIDEM BIOMAR, V2, P299; Rothman N, 1996, P NATL ACAD SCI USA, V93, P5084, DOI 10.1073/pnas.93.10.5084; Sandy J, 2002, J MOL BIOL, V318, P1071, DOI 10.1016/S0022-2836(02)00141-9; Sinclair JC, 2000, NAT STRUCT BIOL, V7, P560; Smith CAD, 1997, J MED GENET, V34, P758, DOI 10.1136/jmg.34.9.758; SMITH TJ, 1986, CARCINOGENESIS, V7, P697, DOI 10.1093/carcin/7.5.697; Stabbert R, 2003, RAPID COMMUN MASS SP, V17, P2125, DOI 10.1002/rcm.1161; Stanley LA, 1997, PHARMACOGENETICS, V7, P121, DOI 10.1097/00008571-199704000-00005; Su HJ, 1998, PHARMACOGENETICS, V8, P187, DOI 10.1097/00008571-199804000-00011; Sugamori KS, 2003, MOL PHARMACOL, V64, P170, DOI 10.1124/mol.64.1.170; Svensson CK, 2005, METHOD PHARMACOL TOX, P173; Taylor JA, 1998, CANCER RES, V58, P3603; TRINIDAD A, 1989, DRUG METAB DISPOS, V17, P238; Tsukino H, 2004, EUR J CANCER PREV, V13, P509, DOI 10.1097/00008469-200412000-00008; TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839; van der Hel OL, 2003, PHARMACOGENETICS, V13, P399, DOI 10.1097/00008571-200307000-00005; VATSIS KP, 1991, P NATL ACAD SCI USA, V88, P6333, DOI 10.1073/pnas.88.14.6333; VATSIS KP, 1995, PHARMACOGENETICS, V5, P1, DOI 10.1097/00008571-199502000-00001; Vineis P, 2004, INT J CANCER, V108, P2, DOI 10.1002/ijc.11467; Vineis P, 2001, CANCER EPIDEM BIOMAR, V10, P1249; VINEIS P, 1994, NATURE, V369, P154, DOI 10.1038/369154a0; WEBER WW, 1985, PHARMACOL REV, V37, P25; Windmill KF, 2000, TOXICOL SCI, V54, P19, DOI 10.1093/toxsci/54.1.19; WOODHOUSE KW, 1982, HUM TOXICOL, V1, P443, DOI 10.1177/096032718200100411; YEROKUN T, 1989, DRUG METAB DISPOS, V17, P231; YU MC, 1994, J NATL CANCER I, V86, P712, DOI 10.1093/jnci/86.9.712; Zang Y, 2004, PHARMACOGENETICS, V14, P717, DOI 10.1097/00008571-200411000-00002; ZANG Y, 2005, P AM ASS CANC RES, V46; ZHANG X, 2006, IN PRESS J PHARM EXP, V316	143	144	148	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	11					1649	1658		10.1038/sj.onc.1209374	http://dx.doi.org/10.1038/sj.onc.1209374			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020JL	16550165	Green Accepted			2022-12-28	WOS:000235904700007
J	Martinelli, S; Kostylina, G; Niggli, V; Baumann, C; Fey, MF; Wendel, HG; Lowe, SW; Yousefi, S; Simon, HU				Martinelli, S.; Kostylina, G.; Niggli, V.; Baumann, C.; Fey, M. F.; Wendel, H-G; Lowe, S. W.; Yousefi, S.; Simon, H-U			Targeting survivin via PI3K but not c-akt/PKB by anticancer drugs in immature neutrophils	ONCOGENE			English	Article						apoptosis; cancer; chemotherapy; myelosuppression; neutrophils; survivin	CANCER-CELLS; INDUCED APOPTOSIS; ACTIVATION; PATHWAY; GENE; AKT; TRANSCRIPTION; INHIBITION; CYCLE; DEATH	Myelosuppression is the most common unwanted side effect associated with the administration of anticancer drugs, and infections remain a common cause of death in chemotherapy-treated patients. Several mechanisms of the cytotoxicity of these drugs have been proposed and may synergistically operate in a given cell. Survivin expression has been associated with cancer, but recent reports suggest that this molecule is also expressed in several immature and mature hematopoietic cells. Here, we provide evidence that treatment of immature neutrophils with anticancer drugs reduced endogenous survivin levels causing apoptosis. The anticancer drugs did not directly target survivin, instead they blocked the activity of phosphatidylinositol-3-OH kinase, which regulated survivin expression and apoptosis in these cells. Strikingly, and in contrast to other cells, this pathway did not involve the serine/threonine kinase c-akt/PKB. Moreover, in combination with anticancer drug therapy, rapamycin did not induce increased myelosuppression in an experimental lymphoma mouse model. These data suggest that drugs that block either c-akt/PKB or signaling molecules located distal to c-akt/PKB may preferentially induce apoptosis of cancer cells as they exhibit no cytotoxicity for immature neutrophils.	Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland; Univ Bern, Dept Pathol, CH-3010 Bern, Switzerland; Univ Bern, Inselspital, Inst Med Oncol, CH-3010 Bern, Switzerland; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	University of Bern; University of Bern; University of Bern; University Hospital of Bern; Cold Spring Harbor Laboratory	Simon, HU (corresponding author), Univ Bern, Dept Pharmacol, Friedbuhlstr 49, CH-3010 Bern, Switzerland.	hus@pki.unibe.ch	Yousefi, Shida/L-9689-2016; Yousefi, Shida/AAU-7986-2020; Simon, Hans-Uwe/AAU-5079-2020; Simon, Hans-Uwe/AAU-7410-2020	Yousefi, Shida/0000-0002-9855-4305; Yousefi, Shida/0000-0002-9855-4305; Simon, Hans-Uwe/0000-0002-9404-7736				Altznauer F, 2004, J EXP MED, V199, P1343, DOI 10.1084/jem.20032033; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Baumann R, 2003, FASEB J, V17, P2221, DOI 10.1096/fj.03-0110com; Belyanskaya LL, 2005, INT J CANCER, V117, P755, DOI 10.1002/ijc.21242; Beuvink I, 2005, CELL, V120, P747, DOI 10.1016/j.cell.2004.12.040; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Bruno A, 2005, J IMMUNOL, V174, P8090, DOI 10.4049/jimmunol.174.12.8090; BURERING BM, 1995, NATURE, V376, P599; Carter BZ, 2001, BLOOD, V97, P2784, DOI 10.1182/blood.V97.9.2784; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Conus S, 2005, J ALLERGY CLIN IMMUN, V116, P1228, DOI 10.1016/j.jaci.2005.09.003; Cowburn AS, 2002, BLOOD, V100, P2607, DOI 10.1182/blood-2001-11-0122; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Dale D, 2003, SEMIN ONCOL, V30, P3, DOI 10.1016/S0093-7754(03)00326-9; Daly C, 2004, GENE DEV, V18, P1060, DOI 10.1101/gad.1189704; Debatin KM, 2004, CANCER IMMUNOL IMMUN, V53, P153, DOI 10.1007/s00262-003-0474-8; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Fornaro M, 2003, J BIOL CHEM, V278, P50402, DOI 10.1074/jbc.M307627200; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Fukuda S, 2004, BLOOD, V103, P120, DOI 10.1182/blood-2003-05-1756; Fukuda S, 2002, BLOOD, V100, P2463, DOI 10.1182/blood.V100.7.2463; Gardai SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200; Herr I, 2000, ONCOGENE, V19, P4255, DOI 10.1038/sj.onc.1203776; Hersey P, 2003, J CELL PHYSIOL, V196, P9, DOI 10.1002/jcp.10256; Kozikowski AP, 2003, J AM CHEM SOC, V125, P1144, DOI 10.1021/ja0285159; Martinelli S, 2004, J BIOL CHEM, V279, P44123, DOI 10.1074/jbc.M405883200; McCormick F, 2004, NATURE, V428, P267, DOI 10.1038/428267a; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Murphy BM, 2003, J EXP MED, V197, P625, DOI 10.1084/jem.20021862; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Sakai A, 1998, BLOOD, V92, P3410, DOI 10.1182/blood.V92.9.3410.421a06_3410_3415; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Scheel-Toellner D, 2002, EUR J IMMUNOL, V32, P486, DOI 10.1002/1521-4141(200202)32:2<486::AID-IMMU486>3.0.CO;2-U; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Scheid MP, 2002, MOL CELL BIOL, V22, P6247, DOI 10.1128/MCB.22.17.6247-6260.2002; Straka C, 2004, BLOOD, V104, P1989, DOI 10.1182/blood-2004-02-0628; Suzuki J, 1997, ONCOGENE, V15, P1689, DOI 10.1038/sj.onc.1201333; Uruno A, 2005, CIRCULATION, V112, P727, DOI 10.1161/CIRCULATIONAHA.104.500959; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vong QP, 2005, SCIENCE, V310, P1499, DOI 10.1126/science.1120160; Wang Shulin, 2004, Cancer Treat Res, V119, P175; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Zangemeister-Wittke U, 2004, CELL CYCLE, V3, P1121	48	13	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	52					6915	6923		10.1038/sj.onc.1209692	http://dx.doi.org/10.1038/sj.onc.1209692			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16715127				2022-12-28	WOS:000241732300002
J	Wang, X; Zhou, YX; Qiao, W; Tominaga, Y; Ouchi, M; Ouchi, T; Deng, CX				Wang, X.; Zhou, Y-X; Qiao, W.; Tominaga, Y.; Ouchi, M.; Ouchi, T.; Deng, C-X			Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation	ONCOGENE			English	Article						cyclin D1; mTOR; centrosome; chromosome tetraploidization; premature sister chromatid segregation	SPINDLE ASSEMBLY CHECKPOINT; BREAST-CANCER; CENTROSOME AMPLIFICATION; MITOTIC SPINDLE; CHROMOSOME SEGREGATION; CELL-CYCLE; COLORECTAL CANCERS; AMPLIFIED KINASE; MAMMALIAN-CELLS; PROTEIN-KINASE	Aurora-A/ STK15/ BTAK, which encodes a centrosome-associated kinase, is amplified and overexpressed in multiple types of human tumors, including breast cancer. However, the causal relationship between overexpression of Aurora-A and tumorigenesis has not been fully established due to contradictory data obtained from different experimental systems. To investigate this, we generated a mouse strain that carries an MMTV-Aurora-A transgene. We showed that all the MMTV-Aurora-A mice displayed enhanced branch morphogenesis in the mammary gland and about 40% developed mammary tumors at 20 months of age. The tumor incidence was significantly increased in a p53(+/-) mutation background with about 70% MMTV-Aurora-A; p53(+/-) animals developed tumors at 18 months of age. Of note, overexpression of Aurora-A led to genetic instability, characterized by centrosome amplification, chromosome tetraploidization and premature sister chromatid segregation, at stages prior to tumor formation. Most notably, the severe chromosomal abnormality did not cause cell death owing to the activation of AKT pathway, including elevated levels of phosphorylated AKT and mammalian target of rapamycin, and nuclear accumulation of cyclin D1, which enabled continuous proliferation of the tetraploid cells. These data establish Aurora-A as an oncogene that causes malignant transformation through inducing genetic instability and activating oncogenic pathways such as AKT and its downstream signaling.	NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; NYU, Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Icahn School of Medicine at Mount Sinai; New York University	Deng, CX (corresponding author), NIDDK, Genet Dev & Dis Branch, NIH, 10-9N105,10 Ctr Dr, Bethesda, MD 20892 USA.	chuxiad@bdg10.niddk.nih.gov	deng, chuxia/N-6713-2016		Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK056001, Z01DK056001, ZIADK056011, Z01DK056011, Z01DK056007] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Andreassen PR, 2003, MUTAT RES-FUND MOL M, V532, P245, DOI 10.1016/j.mrfmmm.2003.08.020; Aust DE, 2004, SCAND J GASTROENTERO, V39, P766, DOI 10.1080/00365520410003191; Berdnik D, 2002, CURR BIOL, V12, P640, DOI 10.1016/S0960-9822(02)00766-2; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Chiba S, 2000, EXP CELL RES, V258, P310, DOI 10.1006/excr.2000.4916; Colditz GA, 1998, JNCI-J NATL CANCER I, V90, P814, DOI 10.1093/jnci/90.11.814; Crane R, 2004, BIOL CELL, V96, P215, DOI 10.1016/j.biolcel.2003.09.008; Deng Chu-Xia, 2004, Methods Mol Biol, V280, P185; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Ducat D, 2004, EXP CELL RES, V301, P60, DOI 10.1016/j.yexcr.2004.08.016; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Gadducci A, 2005, GYNECOL ENDOCRINOL, V20, P343, DOI 10.1080/09513590500128492; Giet R, 2005, TRENDS CELL BIOL, V15, P241, DOI 10.1016/j.tcb.2005.03.004; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Gotoh J, 2003, CARCINOGENESIS, V24, P435, DOI 10.1093/carcin/24.3.435; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Hu W, 2005, ONCOL RES, V15, P49, DOI 10.3727/096504005775082101; Kamada K, 2004, ONCOL REP, V12, P593; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Katayama Hiroshi, 2003, Cancer and Metastasis Reviews, V22, P451, DOI 10.1023/A:1023789416385; Kufer TA, 2003, CHROMOSOMA, V112, P159, DOI 10.1007/s00412-003-0265-1; Liu Q, 2004, J BIOL CHEM, V279, P18210, DOI 10.1074/jbc.M400678200; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Meraldi P, 2004, CURR OPIN GENET DEV, V14, P29, DOI 10.1016/j.gde.2003.11.006; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Mita Monica M, 2003, Clin Breast Cancer, V4, P126, DOI 10.3816/CBC.2003.n.018; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Oikawa T, 2005, MOL CELL BIOL, V25, P4046, DOI 10.1128/MCB.25.10.4046-4061.2005; Ouchi M, 2004, J BIOL CHEM, V279, P19643, DOI 10.1074/jbc.M311780200; Prall OWJ, 1998, J STEROID BIOCHEM, V65, P169, DOI 10.1016/S0960-0760(98)00021-1; Satyamoorthy K, 2001, CANCER RES, V61, P7318; Sen S, 2002, JNCI-J NATL CANCER I, V94, P1320; Shah A, 2005, CLIN CANCER RES, V11, P2930, DOI 10.1158/1078-0432.CCR-04-1385; Stenoien DL, 2003, CELL MOTIL CYTOSKEL, V55, P134, DOI 10.1002/cm.10120; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Tanaka E, 2005, CLIN CANCER RES, V11, P1827, DOI 10.1158/1078-0432.CCR-04-1627; Tanaka T, 1999, CANCER RES, V59, P2041; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Wang RH, 2004, P NATL ACAD SCI USA, V101, P17108, DOI 10.1073/pnas.0407585101; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yoon DS, 2002, AM J PATHOL, V161, P391, DOI 10.1016/S0002-9440(10)64194-6; Zhang DW, 2004, ONCOGENE, V23, P8720, DOI 10.1038/sj.onc.1208153; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	51	192	197	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	54					7148	7158		10.1038/sj.onc.1209707	http://dx.doi.org/10.1038/sj.onc.1209707			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16715125				2022-12-28	WOS:000242046900004
J	Macip, S; Kosoy, A; Lee, SW; O'Connell, MJ; Aaronson, SA				Macip, S.; Kosoy, A.; Lee, S. W.; O'Connell, M. J.; Aaronson, S. A.			Oxidative stress induces a prolonged but reversible arrest in p53-null cancer cells, involving a Chk1-dependent G(2) checkpoint	ONCOGENE			English	Article						senescence; p53; ROS; Chk1; checkpoints	DNA-DAMAGE CHECKPOINT; LACKING FUNCTIONAL P53; STRAND BREAK REPAIR; HUMAN FIBROBLASTS; TUMOR-CELLS; REPLICATIVE SENESCENCE; GROWTH ARREST; IN-VIVO; PREMATURE SENESCENCE; CELLULAR SENESCENCE	Reactive oxygen species (ROS), the principal mediators of oxidative stress, induce responses suchas apoptosis or permanent growth arrest/senescence in normal cells. Moreover, p53 activation itself contributes to ROS accumulation. Here we show that treatment of p53-null cancer cells with sublethal concentrations of ROS triggered an arrest with some morphological similarities to cellular senescence. Different from a classical senescent arrest in G(1), the ROS-induced arrest was predominantly in the G(2) phase of the cell cycle, and its establishment depended at least in part on an intact Chk1-dependent checkpoint. Chk1 remained phosphorylated only during the repair of double strand DNA breaks, after which Chk1 was inactivated, the G2 arrest was suppressed, and some cells recovered their ability to proliferate. Inhibition of Chk1 by an RNAi approach resulted in an increase in cell death in p53-null cells, showing that the Chk1-dependent G2 checkpoint protected cells that lacked a functional p53 pathway from oxidative stress. It has been proposed that the induction of a senescent-like phenotype by antineoplastic agents can contribute therapeutic efficacy. Our results indicate that oxidative stress-induced growth arrest of p53-null tumor cells cannot be equated with effective therapy owing to its reversibility and supports the concept that targeting Chk1 may enhance the effects of DNA-damaging agents on cancer progression in such tumors.	Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Harvard Cutaneous Biol Res Ctr, Charlestown, MA USA	Icahn School of Medicine at Mount Sinai; Harvard University; Massachusetts General Hospital	Aaronson, SA (corresponding author), Mt Sinai Sch Med, Dept Oncol Sci, 1 Gustave L Levy Pl,Box 1130, New York, NY 10029 USA.	stuart.aaronson@mssm.edu	Macip, Salvador/K-5985-2014; Macip, Salvador/P-4233-2019; Macip, Salvador/S-6358-2019	Macip, Salvador/0000-0003-1963-8840; 	NCI NIH HHS [CA80058, CA78356, CA100076, CA82211, CA85214] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082211, R01CA078356, R01CA100076, R56CA100076, R01CA085214] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Aubry JP, 1999, CYTOMETRY, V37, P197, DOI 10.1002/(SICI)1097-0320(19991101)37:3<197::AID-CYTO6>3.0.CO;2-L; Bai JX, 2003, J BIOL CHEM, V278, P4660, DOI 10.1074/jbc.M206273200; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Bakondi E, 2003, J INVEST DERMATOL, V121, P88, DOI 10.1046/j.1523-1747.2003.12329.x; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkowiak D, 1999, CYTOMETRY, V37, P191, DOI 10.1002/(SICI)1097-0320(19991101)37:3<191::AID-CYTO5>3.0.CO;2-U; Barzilai A, 2004, DNA REPAIR, V3, P1109, DOI 10.1016/j.dnarep.2004.03.002; Caldini R, 1998, MECH AGEING DEV, V105, P137, DOI 10.1016/S0047-6374(98)00085-2; Campisi J, 2001, EXP GERONTOL, V36, P1619, DOI 10.1016/S0531-5565(01)00160-7; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chang BD, 1999, CANCER RES, V59, P3761; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Chiu CC, 2005, CANCER LETT, V223, P249, DOI 10.1016/j.canlet.2004.10.049; CLOPTON DA, 1995, BIOCHEM BIOPH RES CO, V210, P189, DOI 10.1006/bbrc.1995.1645; Curman D, 2001, J BIOL CHEM, V276, P17914, DOI 10.1074/jbc.M100728200; Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404; de Magalhaes JP, 2004, EXP GERONTOL, V39, P1379, DOI 10.1016/j.exger.2004.06.004; de Vries HI, 2005, J CELL SCI, V118, P1833, DOI 10.1242/jcs.02309; Dean RT, 1997, BIOCHEM J, V324, P1; den Elzen N, 2004, CELL CYCLE, V3, P529; den Elzen NR, 2004, EMBO J, V23, P908, DOI 10.1038/sj.emboj.7600105; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dumont P, 2000, FREE RADICAL BIO MED, V28, P361, DOI 10.1016/S0891-5849(99)00249-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fang L, 1999, ONCOGENE, V18, P2789, DOI 10.1038/sj.onc.1202615; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Foster ER, 2005, FEBS J, V272, P3231, DOI 10.1111/j.1742-4658.2005.04741.x; Garber K, 2005, J NATL CANCER I, V97, P1026, DOI 10.1093/jnci/dji224; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hammond EM, 2003, J BIOL CHEM, V278, P12207, DOI 10.1074/jbc.M212360200; Hampton MB, 1998, TOXICOL LETT, V103, P355, DOI 10.1016/S0378-4274(98)00333-6; Hara E, 1996, MOL CELL BIOL, V16, P859; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Ho CC, 2005, EXP CELL RES, V304, P1, DOI 10.1016/j.yexcr.2004.10.016; Hwang ES, 2002, MECH AGEING DEV, V123, P1681, DOI 10.1016/S0047-6374(02)00102-1; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jackson JR, 2000, CANCER RES, V60, P566; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN WK, 1995, CANCER RES, V55, P7; Koniaras K, 2001, ONCOGENE, V20, P7453, DOI 10.1038/sj.onc.1204942; Latif C, 2004, J CELL SCI, V117, P3489, DOI 10.1242/jcs.01204; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu QH, 2000, GENE DEV, V14, P1448; Long H, 2003, CELL PHYSIOL BIOCHEM, V13, P401, DOI 10.1159/000075128; Macip S, 2003, MOL CELL BIOL, V23, P8576, DOI 10.1128/MCB.23.23.8576-8585.2003; Mason DX, 2004, ONCOGENE, V23, P9238, DOI 10.1038/sj.onc.1208172; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; O'Connell MJ, 2005, J CELL SCI, V118, P1, DOI 10.1242/jcs.01626; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Renschler MF, 2004, EUR J CANCER, V40, P1934, DOI 10.1016/j.ejca.2004.02.031; RILEY PA, 1994, INT J RADIAT BIOL, V65, P27, DOI 10.1080/09553009414550041; Roberson RS, 2005, CANCER RES, V65, P2795, DOI 10.1158/0008-5472.CAN-04-1270; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Roninson IB, 2003, CANCER RES, V63, P2705; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shackelford RE, 2001, J BIOL CHEM, V276, P21951, DOI 10.1074/jbc.M011303200; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; te Poele RH, 2002, CANCER RES, V62, P1876; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Zamzami N, 1998, ONCOGENE, V16, P1055, DOI 10.1038/sj.onc.1201864; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	81	32	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6037	6047		10.1038/sj.onc.1209629	http://dx.doi.org/10.1038/sj.onc.1209629			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16652144				2022-12-28	WOS:000241101200001
J	Peter, M; Rosty, C; Couturier, J; Radvanyi, F; Teshima, H; Sastre-Garau, X				Peter, M.; Rosty, C.; Couturier, J.; Radvanyi, F.; Teshima, H.; Sastre-Garau, X.			MYC activation associated with the integration of HPV DNA at the MYC locus in genital tumors	ONCOGENE			English	Article						MYC; HPV; integration; insertional mutagenesis; cervix	HUMAN-PAPILLOMAVIRUS TYPE-16; C-MYC; CERVICAL CARCINOMAS; HUMAN GENOME; PHYSICAL STATE; RAS GENE; SITES; AMPLIFICATION; SEQUENCES; ONCOGENES	To determine whether integration of human papillomavirus (HPV) DNA sequences could lead to the deregulation of genes implied in oncogenesis, we analysed the HPV integration sites in a series of nine cell lines derived from invasive genital carcinomas. Using in situ hybridization, HPV16 or 18 sequences were found at chromosome band 8q24, the localization of MYC, in IC1, IC2, IC3, IC6 and CAC-1 cells and at other sites in IC4, IC5, IC7 and IC8 cells. We then localized viral sequences at the molecular level and searched for alterations of MYC structure and expression in these cells. MYC genomic status and viral integration sites were also analysed in primary tumors from which IC1, IC2, IC3 and IC6 cells were derived. In IC1, IC2 and CAC-1 cells, HPV DNA was located within 58 kb of MYC, downstream, upstream, or within MYC. In IC3 and IC6 cells, HPV DNA was located 400-500 kb upstream of MYC. Amplification studies showed that, in IC1, IC2 and IC3, viral and MYC sequences were coamplified in an amplicon between less than 50 and 800 kb in size. MYC amplification was also observed in primary tumors, indicating that this genetic alteration, together with viral insertion at the MYC locus, had already taken place in vivo. MYC was not amplified in the other cell lines. MYC mRNA and protein overexpression was observed in the five cell lines in which the HPV DNA was inserted close to the MYC locus, but in none of the lines where the insertion had occurred at other sites. MYC activation, triggered by the insertion of HPV DNA sequences, can be an important genetic event in cervical oncogenesis.	Inst Curie, Serv Pathol, Dept Biol Tumeurs, F-75248 Paris 05, France; Inst Curie, UMR 144, CNRS, F-75248 Paris 05, France; Oita Prefectural Hosp, Dept Obstet & Gynaecol, Oita, Japan	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Sastre-Garau, X (corresponding author), Inst Curie, Serv Pathol, Dept Biol Tumeurs, 26 Rue Ulm, F-75248 Paris 05, France.	xavier.sastre@curie.net	Rosty, Christophe/F-1796-2010	Radvanyi, Francois/0000-0002-5696-6424; Rosty, Christophe/0000-0001-7671-2651; Sastre-Garau, Xavier/0000-0001-5992-2083				Alonso L, 2003, P NATL ACAD SCI USA, V100, P11830, DOI 10.1073/pnas.1734203100; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Bouallaga I, 2000, EMBO REP, V1, P422, DOI 10.1093/embo-reports/kvd091; Brink AATP, 2002, CANCER GENET CYTOGEN, V134, P145, DOI 10.1016/S0165-4608(01)00620-3; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; COUTURIER J, 1991, J VIROL, V65, P4534, DOI 10.1128/JVI.65.8.4534-4538.1991; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; Dang CV, 1999, MOL CELL BIOL, V19, P1; Daniel R, 1999, SCIENCE, V284, P644, DOI 10.1126/science.284.5414.644; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; Ferber MJ, 2003, ONCOGENE, V22, P7233, DOI 10.1038/sj.onc.1207006; Ferber MJ, 2003, ONCOGENE, V22, P3813, DOI 10.1038/sj.onc.1206528; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; Frye M, 2003, DEVELOPMENT, V130, P2793, DOI 10.1242/dev.00462; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HAYAKAWA O, 1988, Sapporo Medical Journal, V57, P603; HENGLEIN B, 1989, MOL CELL BIOL, V9, P2105, DOI 10.1128/MCB.9.5.2105; Herrick J, 2005, CANCER RES, V65, P1174, DOI 10.1158/0008-5472.CAN-04-2802; HORI T, 1991, JPN J CANCER RES, V82, P371, DOI 10.1111/j.1349-7006.1991.tb01857.x; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; JIKO K, 1994, INT J CANCER, V59, P601, DOI 10.1002/ijc.2910590505; JOOS S, 1992, CANCER RES, V52, P6547; Kalantari M, 2001, DIAGN MOL PATHOL, V10, P46, DOI 10.1097/00019606-200103000-00008; Klaes R, 1999, CANCER RES, V59, P6132; Klimov E, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-24; KRAUS I, 2005, 22 INT PAP C CLIN WO, V23, P157; LAZO PA, 1989, CANCER RES, V49, P4305; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lombard I, 1998, J CLIN ONCOL, V16, P2613, DOI 10.1200/JCO.1998.16.8.2613; Luft F, 2001, INT J CANCER, V92, P9, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1144>3.0.CO;2-L; Munger K, 2004, J VIROL, V78, P11451, DOI 10.1128/JVI.78.21.11451-11460.2004; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; NURNBERG W, 1995, CANCER RES, V55, P4432; PEI XF, 1993, VIROLOGY, V196, P855, DOI 10.1006/viro.1993.1546; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; POPESCU NC, 1987, CYTOGENET CELL GENET, V44, P58, DOI 10.1159/000132342; Reuter S, 1998, EMBO J, V17, P215, DOI 10.1093/emboj/17.1.215; RIOU G, 1987, LANCET, V1, P761; RIOU G, 1988, ONCOGENE, V3, P329; Roix JJ, 2003, NAT GENET, V34, P287, DOI 10.1038/ng1177; ROSTY C, 2005, ONCOGENE; Rosty C, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-15; Sastre-Garau X, 2000, J GEN VIROL, V81, P1983, DOI 10.1099/0022-1317-81-8-1983; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Thorland EC, 2003, ONCOGENE, V22, P1225, DOI 10.1038/sj.onc.1206170; Thorland EC, 2000, CANCER RES, V60, P5916; Veldman T, 2003, P NATL ACAD SCI USA, V100, P8211, DOI 10.1073/pnas.1435900100; Waikel RL, 2001, NAT GENET, V28, P165, DOI 10.1038/88889; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wentzensen N, 2004, CANCER RES, V64, P3878, DOI 10.1158/0008-5472.CAN-04-0009; Wentzensen N, 2002, ONCOGENE, V21, P419, DOI 10.1038/sj.onc.1205104; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; ZEIDLER R, 1994, GENE CHROMOSOME CANC, V9, P282, DOI 10.1002/gcc.2870090408; Zhang A, 2002, INT J CANCER, V101, P427, DOI 10.1002/ijc.10627; Ziegert C, 2003, ONCOGENE, V22, P3977, DOI 10.1038/sj.onc.1206629	63	97	110	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2006	25	44					5985	5993		10.1038/sj.onc.1209625	http://dx.doi.org/10.1038/sj.onc.1209625			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16682952				2022-12-28	WOS:000240826300007
J	Shimura, T; Toyoshima, M; Adiga, SK; Kunoh, T; Nagai, H; Shimizu, N; Inoue, M; Niwa, O				Shimura, T.; Toyoshima, M.; Adiga, S. K.; Kunoh, T.; Nagai, H.; Shimizu, N.; Inoue, M.; Niwa, O.			Suppression of replication fork progression in low-dose-specic p53-dependent S-phase DNA damage checkpoint	ONCOGENE			English	Article						p53; PCNA; ATM; S-phase DNA damage checkpoint; replication fork progression	CELL NUCLEAR ANTIGEN; ATM GENE-PRODUCT; REPLICON INITIATION; IONIZING-RADIATION; BLM HELICASE; P53; PROTEIN; REPAIR; ACTIVATION; DYNAMICS	The S-phase DNA damage checkpoint is activated by DNA damage to delay DNA synthesis allowing time to resolve the replication block. We previously discovered the p53-dependent S-phase DNA damage checkpoint in mouse zygotes fertilized with irradiated sperm. Here, we report that the same p53 dependency holds in mouse embryonic fibroblasts (MEFs) at low doses of irradiation. DNA synthesis in p53 wild-type (WT) MEFs was suppressed in a biphasic manner in which a sharp decrease below 2.5 Gy was followed by a more moderate decrease up to 10 Gy. In contrast, p53-/- MEFs exhibited radioresistant DNA synthesis below 2.5 Gy whereas the cells retained the moderate suppression above 5 Gy. DNA fiber analysis revealed that 1 Gy irradiation suppressed replication fork progression in p53 WT MEFs, but not in p53-/- MEFs. Proliferating cell nuclear antigen (PCNA), clamp loader of DNA polymerase, was phosphorylated in WT MEFs after 1 Gy irradiation and redistributed to form foci in the nuclei. In contrast, PCNA was not phosphorylated and dissociated from chromatin in 1 Gy-irradiated p53-/- MEFs. These results demonstrate that the novel low-dosespecific p53-dependent S-phase DNA damage checkpoint is likely to regulate the replication fork movement through phosphorylation of PCNA.	Kyoto Univ, Dept Late Effect Studies, Radiat Biol Ctr, Sakyo Ku, Kyoto, Japan; Kyoto Univ, Dept Radiat Syst Biol, Radiat Biol Ctr, Sakyo Ku, Kyoto, Japan; Hiroshima Univ, Grad Sch Biosphere Sci, Hiroshima, Japan; Kanazawa Med Univ, Med Res Inst, Uchinada, Ishikawa 92002, Japan	Kyoto University; Kyoto University; Hiroshima University; Kanazawa Medical University	Shimura, T (corresponding author), NCI, Mol Pharmacol Lab, Canc Res Ctr, NIH Bldg 37,Rm 5056 37 Convent Dr, Bethesda, MD 20892 USA.	shimurat@mail.nih.gov	Kunoh, Tatsuki/AAQ-7881-2021; Kunoh, Tatsuki/K-7824-2019; Adiga, Satish Kumar/AAU-4386-2020	Kunoh, Tatsuki/0000-0002-8423-2903; Adiga, Satish Kumar/0000-0002-2897-4697				Agarwal ML, 1998, P NATL ACAD SCI USA, V95, P14775, DOI 10.1073/pnas.95.25.14775; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Balajee AS, 2001, NUCLEIC ACIDS RES, V29, P1341, DOI 10.1093/nar/29.6.1341; Boddy MN, 2001, CURR BIOL, V11, pR953, DOI 10.1016/S0960-9822(01)00572-3; Bohnke A, 2004, INT J RADIAT BIOL, V80, P53, DOI 10.1080/09553000310001642902; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; Brown KD, 2003, NAT GENET, V33, P80, DOI 10.1038/ng1052; Buscemi G, 2004, ONCOGENE, V23, P7691, DOI 10.1038/sj.onc.1207986; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; Dimitrova DS, 1999, MOL CELL, V4, P983, DOI 10.1016/S1097-2765(00)80227-0; ELKIND MM, 1959, NATURE, V184, P1293, DOI 10.1038/1841293a0; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Henry-Mowatt J, 2003, MOL CELL, V11, P1109, DOI 10.1016/S1097-2765(03)00132-1; Hu T, 1999, MUTAT RES-FUND MOL M, V426, P51, DOI 10.1016/S0027-5107(99)00077-9; Jackson DA, 1998, J CELL BIOL, V140, P1285, DOI 10.1083/jcb.140.6.1285; Janz C, 2002, ONCOGENE, V21, P5929, DOI 10.1038/sj.onc.1205757; Karmakar P, 2001, MUTAGENESIS, V16, P225, DOI 10.1093/mutage/16.3.225; KEARSEY JM, 1995, SCIENCE, V270, P1004; Kim JM, 2002, EMBO J, V21, P2168, DOI 10.1093/emboj/21.9.2168; Laderoute MP, 1996, ANTICANCER RES, V16, P2825; Larner JM, 1999, NUCLEIC ACIDS RES, V27, P803, DOI 10.1093/nar/27.3.803; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ma H, 1998, J CELL BIOL, V143, P1415, DOI 10.1083/jcb.143.6.1415; MAKINO F, 1975, RADIAT RES, V62, P37, DOI 10.2307/3574182; Merrick CJ, 2004, J BIOL CHEM, V279, P20067, DOI 10.1074/jbc.M400022200; Miura M, 1996, RADIAT RES, V145, P75, DOI 10.2307/3579198; Nayak BK, 2002, ONCOGENE, V21, P7226, DOI 10.1038/sj.onc.1205889; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAINTER RB, 1975, RADIAT RES, V64, P648, DOI 10.2307/3574254; PAINTER RB, 1976, BIOCHIM BIOPHYS ACTA, V418, P146, DOI 10.1016/0005-2787(76)90063-0; Pilch DR, 2003, BIOCHEM CELL BIOL, V81, P123, DOI 10.1139/o03-042; PROSPERI E, 1993, EXP CELL RES, V205, P320, DOI 10.1006/excr.1993.1092; Rowley R, 1999, INT J RADIAT BIOL, V75, P267, DOI 10.1080/095530099140456; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Savio M, 1998, CARCINOGENESIS, V19, P591, DOI 10.1093/carcin/19.4.591; Sedelnikova OA, 2003, CANCER BIOL THER, V2, P233; Sengupta S, 2004, J CELL BIOL, V166, P801, DOI 10.1083/jcb.200405128; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Shimada K, 2002, GENE DEV, V16, P3236, DOI 10.1101/gad.239802; Shimura T, 2002, MOL CELL BIOL, V22, P2220, DOI 10.1128/MCB.22.7.2220-2228.2002; Shimura T, 2002, RADIAT RES, V158, P735, DOI 10.1667/0033-7587(2002)158[0735:TNSMOT]2.0.CO;2; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Solomon DA, 2004, J CELL BIOL, V166, P455, DOI 10.1083/jcb.200312048; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Storer RD, 1997, MUTAT RES-FUND MOL M, V373, P157, DOI 10.1016/S0027-5107(96)00227-8; Toyoshima M, 2005, ONCOGENE, V24, P3229, DOI 10.1038/sj.onc.1208514; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WATANABE I, 1974, RADIAT RES, V58, P541, DOI 10.2307/3573922; Xie GF, 1998, ONCOGENE, V16, P721, DOI 10.1038/sj.onc.1201793	57	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2006	25	44					5921	5932		10.1038/sj.onc.1209624	http://dx.doi.org/10.1038/sj.onc.1209624			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16682953				2022-12-28	WOS:000240826300001
J	Artus, C; Maquarre, E; Moubarak, RS; Delettre, C; Jasmin, C; Susin, SA; Robert-Lezenes, J				Artus, C.; Maquarre, E.; Moubarak, R. S.; Delettre, C.; Jasmin, C.; Susin, S. A.; Robert-Lezenes, J.			CD44 ligation induces caspase-independent cell death via a novel calpain/AIF pathwayin human erythroleukemia cells	ONCOGENE			English	Article						CD44; apoptosis; calpain; AIF; erythroleukemia	ACUTE MYELOID-LEUKEMIA; CYTOCHROME-C RELEASE; ANTI-CD44 MONOCLONAL-ANTIBODIES; CANCER-CELLS; FACTOR AIF; POLY(ADP-RIBOSE) POLYMERASE-1; ERYTHROID-DIFFERENTIATION; NUCLEAR TRANSLOCATION; APOPTOSIS; MITOCHONDRIA	Ligation of the cell surface molecule CD44 by anti-CD44 monoclonal antibodies (mAbs) has been shown to induce cell differentiation, cell growth inhibition and in some cases, apoptosis in myeloid leukemic cells. We report, herein, that exposure of human erythroleukemic HEL cells to the anti-CD44 mAb A3D8 resulted in cell growth inhibition followed by caspase-independent apoptosis-like cell death. This process was associated with the disruption of mitochondrial membrane potential (Delta Psi m), the mitochondrial release of apoptosis-inducing factor (AIF), but not of cytochrome c, and the nuclear translocation of AIF. All these effects including cell death, loss of mitochondrial Delta Psi m and AIF release were blocked by pretreatment with the poly(ADP-ribose) polymerase inhibitor isoquinoline. A significant protection against cell death was also observed by using small interfering RNA for AIF. Moreover, we show that calpain protease was activated before the appearance of apoptosis, and that calpain inhibitors or transfection of calpain-siRNA decrease A3D8-induced cell death, and block AIF release. These data suggest that CD44 ligation triggers a novel caspase-independent cell death pathway via calpain-dependent AIF release in erythroleukemic HEL cells.	Hop Paul Brousse, INSERM, U602, F-94807 Villejuif, France; Inst Pasteur, Apoptose & Syst Immunitaire Grp, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Robert-Lezenes, J (corresponding author), Hop Paul Brousse, INSERM, U602, 14 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.	lezenes@vjf.inserm.fr	Delettre, Cécile/AAC-3096-2020; Susin, Santos A/Q-6754-2017	Delettre, Cécile/0000-0003-3269-2155; Susin, Santos A/0000-0002-3366-1628; Moubarak, Rana/0000-0003-2096-1258				Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Altznauer F, 2004, J BIOL CHEM, V279, P5947, DOI 10.1074/jbc.M308576200; Benito A, 1996, BLOOD, V87, P3837, DOI 10.1182/blood.V87.9.3837.bloodjournal8793837; Bras M, 2005, BIOCHEMISTRY-MOSCOW+, V70, P231, DOI 10.1007/s10541-005-0105-4; Broker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078-0432.CCR-04-2223; BROWN LR, 1977, BIOCHIM BIOPHYS ACTA, V468, P389, DOI 10.1016/0005-2736(77)90290-5; Cande C, 2004, CELL DEATH DIFFER, V11, P591, DOI 10.1038/sj.cdd.4401400; Cerisano V, 2004, ONCOGENE, V23, P5664, DOI 10.1038/sj.onc.1207741; Charrad RS, 2002, BLOOD, V99, P290, DOI 10.1182/blood.V99.1.290; Charrad RS, 1999, NAT MED, V5, P669, DOI 10.1038/9518; Chen M, 2004, CARDIOVASC RES, V63, P682, DOI 10.1016/j.cardiores.2004.04.018; Cheung ECC, 2005, J NEUROSCI, V25, P1324, DOI 10.1523/JNEUROSCI.4261-04.2005; Corbiere C, 2004, CELL RES, V14, P188, DOI 10.1038/sj.cr.7290219; Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517; Dejean LM, 2005, MOL BIOL CELL, V16, P2424, DOI 10.1091/mbc.E04-12-1111; Donovan M, 2004, BBA-MOL CELL RES, V1644, P133, DOI 10.1016/j.bbamcr.2003.08.011; Gadhoum Z, 2004, LEUKEMIA LYMPHOMA, V45, P1501, DOI 10.1080/1042819042000206687; Gadhoum Z, 2004, BLOOD, V103, P1059, DOI 10.1182/blood-2003-04-1218; Gao G, 2000, J CELL BIOCHEM, V80, P53; Ghaffari S, 1999, EXP HEMATOL, V27, P978, DOI 10.1016/S0301-472X(99)00023-5; Hafid-Medheb K, 2003, BLOOD, V101, P2575, DOI 10.1182/blood-2002-02-0478; Henry-Mowatt J, 2004, ONCOGENE, V23, P2850, DOI 10.1038/sj.onc.1207534; Hong SJ, 2004, TRENDS PHARMACOL SCI, V25, P259, DOI 10.1016/j.tips.2004.03.005; Ishitsuka K, 2005, ONCOGENE, V24, P5888, DOI 10.1038/sj.onc.1208739; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kang YH, 2004, CANCER RES, V64, P8960, DOI 10.1158/0008-5472.CAN-04-1830; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Lipton SA, 2002, CELL, V111, P147, DOI 10.1016/S0092-8674(02)01046-2; Liu T, 2004, ONCOGENE, V23, P39, DOI 10.1038/sj.onc.1206978; Liu XL, 2004, ANNU REV PHARMACOL, V44, P349, DOI 10.1146/annurev.pharmtox.44.101802.121804; Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514; Lu T, 2002, BBA-MOL CELL RES, V1590, P16, DOI 10.1016/S0167-4889(02)00193-3; Maquarre E, 2005, LEUKEMIA, V19, P2296, DOI 10.1038/sj.leu.2403944; Mateo W, 2002, BLOOD, V100, P2882, DOI 10.1182/blood-2001-12-0217; Mathiasen IS, 2002, J BIOL CHEM, V277, P30738, DOI 10.1074/jbc.M201558200; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Otera H, 2005, EMBO J, V24, P1375, DOI 10.1038/sj.emboj.7600614; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Park YC, 2005, LIFE SCI, V77, P2059, DOI 10.1016/j.lfs.2005.04.021; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Poindessous-Jazat V, 2002, LEUKEMIA, V16, P233, DOI 10.1038/sj.leu.2402350; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Roue G, 2003, BIOCHIMIE, V85, P741, DOI 10.1016/S0300-9084(03)00129-9; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Schotte P, 1999, FEBS LETT, V442, P117, DOI 10.1016/S0014-5793(98)01640-8; Song GL, 2004, LEUKEMIA RES, V28, P1089, DOI 10.1016/j.leukres.2004.02.005; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Wang HM, 2004, J NEUROSCI, V24, P10963, DOI 10.1523/JNEUROSCI.3461-04.2004; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Yu SW, 2003, NEUROBIOL DIS, V14, P303, DOI 10.1016/j.nbd.2003.08.008; Yuste VJ, 2005, CELL DEATH DIFFER, V12, P1445, DOI 10.1038/sj.cdd.4401687; Zada AAP, 2003, ONCOGENE, V22, P2296, DOI 10.1038/sj.onc.1206330; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904	61	40	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2006	25	42					5741	5751		10.1038/sj.onc.1209581	http://dx.doi.org/10.1038/sj.onc.1209581			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16636662				2022-12-28	WOS:000240765800005
J	Tauchi, T; Shin-ya, K; Sashida, G; Sumi, M; Okabe, S; Ohyashiki, JH; Ohyashiki, K				Tauchi, T.; Shin-ya, K.; Sashida, G.; Sumi, M.; Okabe, S.; Ohyashiki, J. H.; Ohyashiki, K.			Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia	ONCOGENE			English	Article						telomerase inhibition; p38 MAP kinase; MKK3/6; apoptosis; in vivo study	TYROSINE KINASE INHIBITOR; DNA; SENESCENCE; TARGET; CELLS; INVOLVEMENT; ARREST; PARP-2	The telomerase complex is responsible for telomere maintenance and represents a promising neoplasia therapeutic target. Recently, we have demonstrated that treatment with a G-quadruplex-interactive agent, telomestatin reproducibly inhibited telomerase activity in the BCR-ABL-positive leukemic cell lines. In the present study, we investigated the mechanisms of apoptosis induced by telomerase inhibition in acute leukemia. We have found the activation of caspase-3 and poly-(ADPribose) polymerase in telomestatin-treated U937 cells (PD20) and dominant-negative DN-hTERT-expressing U937 cells (PD25). Activation of p38 mitogen-activated protein (MAP) kinase and MKK3/6 was also found in telomestatin-treated U937 cells (PD20) and dominant-negative DN-hTERT-expressing U937 cells (PD25); however, activation of JNK and ASK1 was not detected in these cells. To examine the effect of p38 MAP kinase inhibition on growth properties and apoptosis in telomer-ase-inhibited cells, we cultured DN-hTERT-expressing U937 cells with or without SB203580. Dominant-negative-hTERT-expressing U937 cells stopped proliferation on PD25; however, a significant increase in growth rate was observed in the presence of SB203580. Treatment of SB203580 also reduced the induction of apoptosis in DN-hTERT-expressing U937 cells (PD25). These results suggest that p38 MAP kinase has a critical role for the induction of apoptosis in telomerase-inhibited leukemia cells. Further, we evaluated the effect of telomestatin on the growth of U937 cells in xenograft mouse model. Systemic intraperitoneal administration of telomestatin in U937 xenografts decreased tumor telomerase levels and reduced tumor volumes. Tumor tissue from telomestatin-treated animals exhibited marked apoptosis. None of the mice treated with telomestatin displayed any signs of toxicity. Taken together, these results lay the foundations for a program of drug development to achieve the dual aims of efficacy and selectivity in vivo.	Tokyo Med Univ, Dept Internal Med 1, Shinjuku Ku, Tokyo 1600023, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo, Japan; Tokyo Med Univ, Intractable Dis Res Ctr, Shinjuku Ku, Tokyo 1600023, Japan	Tokyo Medical University; University of Tokyo; Tokyo Medical University	Tauchi, T (corresponding author), Tokyo Med Univ, Dept Internal Med 1, Shinjuku Ku, 6-7-1 Nishishinjuku, Tokyo 1600023, Japan.	tauchi@tokyo-med.ac.jp; kshin@iam.u-tokyo.ac.jp	Sashida, Goro/N-5259-2014	Sashida, Goro/0000-0003-2318-5987				Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Bearss DJ, 2000, ONCOGENE, V19, P6632, DOI 10.1038/sj.onc.1204092; Blackburn EH, 1995, TELOMERES; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Gomez D, 2004, J BIOL CHEM, V279, P41487, DOI 10.1074/jbc.M406123200; Gomez D, 2003, CANCER RES, V63, P6149; Gowan SM, 2002, MOL PHARMACOL, V61, P1154, DOI 10.1124/mol.61.5.1154; Gowan SM, 2001, MOL PHARMACOL, V60, P981, DOI 10.1124/mol.60.5.981; Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x; IZBICKA E, 1999, CANCER RES, V59, P369; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kim MY, 2003, CANCER RES, V63, P3247; Kim MY, 2002, J AM CHEM SOC, V124, P2098, DOI 10.1021/ja017308q; Mergny JL, 1998, NAT MED, V4, P1366, DOI 10.1038/3949; Nakajima A, 2003, LEUKEMIA, V17, P560, DOI 10.1038/sj.leu.2402825; Nakajima A, 2001, LEUKEMIA, V15, P989, DOI 10.1038/sj.leu.2402137; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Ohyashiki JH, 2002, ONCOGENE, V21, P680, DOI 10.1038/sj.onc.1205075; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Riou JF, 2002, P NATL ACAD SCI USA, V99, P2672, DOI 10.1073/pnas.052698099; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Shammas MA, 2004, CLIN CANCER RES, V10, P770, DOI 10.1158/1078-0432.CCR-0793-03; Shin-ya K, 2001, J AM CHEM SOC, V123, P1262, DOI 10.1021/ja005780q; Sun DY, 1997, J MED CHEM, V40, P2113, DOI 10.1021/jm970199z; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; Tauchi T, 2003, ONCOGENE, V22, P5338, DOI 10.1038/sj.onc.1206833; Tauchi T, 2002, CLIN CANCER RES, V8, P3341; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Wheelhouse RT, 1998, J AM CHEM SOC, V120, P3261, DOI 10.1021/ja973792e; White LK, 2001, TRENDS BIOTECHNOL, V19, P114, DOI 10.1016/S0167-7799(00)01541-9; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0	32	182	189	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2006	25	42					5719	5725		10.1038/sj.onc.1209577	http://dx.doi.org/10.1038/sj.onc.1209577			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16652154				2022-12-28	WOS:000240765800003
J	Wu, Y; Fan, Y; Xue, B; Luo, L; Shen, J; Zhang, S; Jiang, Y; Yin, Z				Wu, Y.; Fan, Y.; Xue, B.; Luo, L.; Shen, J.; Zhang, S.; Jiang, Y.; Yin, Z.			Human glutathione S-transferase P1-1 interacts with TRAF2 and regulates TRAF2-ASK1 signals	ONCOGENE			English	Article						glutathione S-transferase P1-1; TNF-alpha; TRAF2; ASK1; apoptosis	NF-KAPPA-B; INDUCED CELL-DEATH; TNF RECEPTOR 1; PROTEIN-KINASE; TERMINAL KINASE; INDUCED ACTIVATION; STRUCTURAL BASIS; HEAT-SHOCK; APOPTOSIS; ASK1	Human glutathione S-transferase P1-1 (GSTP1-1) is an ubiquitously expressed protein that plays an important role in the detoxification and xenobiotics metabolism. It has been shown that GSTP1-1 interacts with c-Jun NH2-terminal kinase (JNK) and suppresses its activity. Here, we report a novel function of GSTP1-1 in regulating tumor necrosis factor-alpha (TNF-alpha)-triggered signaling. The present experiments showed that GSTP1-1 physically associated with tumor necrosis factor receptor-associated factor 2(TRAF2) in vivo and in vitro. Overexpression of GSTP1-1 inhibited TRAF2-induced activation of both JNK and p38 but not of nuclear factor-KB (NF-KB). Glutathione S-transferase P1-1 also attenuated TRAF2-enhanced apoptosis signal-regulating kinase 1 (ASK1) autophosphorylation and inhibited TRAF2-ASK1-induced cell apoptosis by suppressing the interaction of TRAF2 and ASK1. Conversely, silencing of GSTP1-1 expression through RNA interference (RNAi) resulted in increase of TNF-alpha-dependent TRAF2-ASK1 association followed by hyper-activation of ASK1 and JNK. A mutant GSTP1-1 lacking TRAF domain-binding motif exhibited a significant decline of capacity to bind TRAF2 and block TRAF2-ASK1 signaling compared with the wild type of GSTP1-1. Moreover, the glutathione-conjugating activity of GSTP1-1 was not involved in the regulation of TRAF2 signaling. These findings indicate that GSTP1-1 plays an important regulatory role in TNF-alpha-induced signaling by forming ligand-binding interactions with TRAF2, which provides a new insight for analysing the protective effects of GSTP1-1 in tumor cells.	Nanjing Normal Univ, Coll Life Sci, Jiangsu Prov Key Lab Mol & Med Biotechnol, Nanjing 210097, JiangSu, Peoples R China; Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing 210008, Peoples R China; So Med Univ, Dept Pathophysiol, Key Lab Funct Proteom Guangdong Prov, Guangzhou, Peoples R China	Nanjing Normal University; Nanjing University; Southern Medical University - China	Yin, Z (corresponding author), Nanjing Normal Univ, Coll Life Sci, Jiangsu Prov Key Lab Mol & Med Biotechnol, 122 Ninghai Rd, Nanjing 210097, JiangSu, Peoples R China.	yinzhimin@njnu.edu.cn		Xue, Bin/0000-0002-5472-1300				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Arch RH, 1999, ANNU REV CELL DEV BI, V15, P113, DOI 10.1146/annurev.cellbio.15.1.113; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200; Chung JY, 2002, J CELL SCI, V115, P679; Cumming RC, 2001, NAT MED, V7, P814, DOI 10.1038/89937; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dorion S, 2002, J BIOL CHEM, V277, P30792, DOI 10.1074/jbc.M203642200; Fan YM, 2005, CELL BIOL INT, V29, P695, DOI 10.1016/j.cellbi.2005.04.006; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; Fessler MB, 2002, J BIOL CHEM, V277, P31291, DOI 10.1074/jbc.M200755200; Gate Laurent, 2001, Expert Opin Ther Targets, V5, P477; Gilot D, 2002, J BIOL CHEM, V277, P49220, DOI 10.1074/jbc.M207325200; Gotoh Y, 2004, BIOCHEM BIOPH RES CO, V314, P688, DOI 10.1016/j.bbrc.2003.12.148; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Hoeflich KP, 1999, ONCOGENE, V18, P5814, DOI 10.1038/sj.onc.1202975; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; KONG KH, 1992, BIOCHEM BIOPH RES CO, V182, P1122, DOI 10.1016/0006-291X(92)91848-K; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Lo HW, 2004, CANCER RES, V64, P9131, DOI 10.1158/0008-5472.CAN-04-0283; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lu M, 2004, ONCOGENE, V23, P3945, DOI 10.1038/sj.onc.1207500; Matsuzawa A, 2005, NAT IMMUNOL, V6, P587, DOI 10.1038/ni1200; MOSCOW JA, 1989, CANCER RES, V49, P1422; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Noguchi T, 2005, J BIOL CHEM, V280, P37033, DOI 10.1074/jbc.M506771200; Park HS, 2002, MOL CELL BIOL, V22, P7721, DOI 10.1128/MCB.22.22.7721-7730.2002; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; PINKUS R, 1995, BIOCHEMISTRY-US, V34, P81, DOI 10.1021/bi00001a010; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Ryoo K, 2004, J BIOL CHEM, V279, P43589, DOI 10.1074/jbc.M404359200; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SHEA TC, 1988, CANCER RES, V48, P527; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TEW KD, 1994, CANCER RES, V54, P4313; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Townsend Danyelle, 2003, Am J Pharmacogenomics, V3, P157, DOI 10.2165/00129785-200303030-00002; Townsend DM, 2003, ONCOGENE, V22, P7369, DOI 10.1038/sj.onc.1206940; Townsend DM, 2002, MOL CANCER THER, V1, P1089; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; XIA ZP, 2005, SCI STKE, V272, pPE7; Xu LG, 2004, J BIOL CHEM, V279, P17278, DOI 10.1074/jbc.C400063200; Xue B, 2005, FEBS LETT, V579, P4081, DOI 10.1016/j.febslet.2005.06.034; Ye H, 2000, P NATL ACAD SCI USA, V97, P8961, DOI 10.1073/pnas.160241997; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yin ZM, 2000, CANCER RES, V60, P4053; Yin ZM, 2001, ACTA BIOCH BIOPH SIN, V33, P185; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zhang R, 2005, ONCOGENE, V24, P3954, DOI 10.1038/sj.onc.1208548; Zhou L, 2005, BLOOD, V105, P1198, DOI 10.1182/blood-2003-12-4299	71	168	174	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2006	25	42					5787	5800		10.1038/sj.onc.1209576	http://dx.doi.org/10.1038/sj.onc.1209576			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16636664				2022-12-28	WOS:000240765800009
J	Bell, LA; O'Prey, J; Ryan, KM				Bell, L. A.; O'Prey, J.; Ryan, K. M.			DNA-binding independent cell death from a minimal proapoptotic region of E2F-1	ONCOGENE			English	Article						E2F; apoptosis; DNA binding	S-PHASE ENTRY; TRANSCRIPTION FACTORS E2F-1; RETINOBLASTOMA PROTEIN; E2F-DEPENDENT APOPTOSIS; E2F-1-INDUCED APOPTOSIS; P53-MEDIATED APOPTOSIS; MAMMALIAN-CELLS; MOUSE EMBRYOS; CYCLE ARREST; P53	The ability to induce cell cycle progression while evading cell death is a de. ning characteristic of cancer. Deregulation of E2F is a common event in most human cancers. Paradoxically, this can lead to both cell cycle progression and apoptosis. Although the way in which E2F causes cell cycle progression is well characterized, the pathways by which E2F induces cell death are less well defined. Many of the known mechanisms through which E2F induces apoptosis occur through regulation of E2F target genes. However, mutants of E2F-1 that lack the transactivation domain are still able to induce cell death. To further investigate this activity, we refined a transactivation independent mutant to identify a minimal apoptotic domain. This revealed that only 75 amino acids from within the DNA-binding domain of E2F-1 is sufficient for cell death and that this activity is also present in the DNA-binding domains of E2F-2 and E2F-3. However, analysis of this domain from E2F-1 revealed it does not bind DNA and is consequently unable to transactivate, repress or derepress E2F target genes. This provocative observation therefore defines a potential new mechanism of death from E2F and opens up new opportunities for inducing cell death in tumours for therapeutic gain.	Canc Res UK Beatson Labs, Tumour Cell Death Lab, Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Ryan, KM (corresponding author), Canc Res UK Beatson Labs, Tumour Cell Death Lab, Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	k.ryan@beatson.gla.ac.uk		Ryan, Kevin M./0000-0002-1059-9681				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Bandara LR, 1997, NAT BIOTECHNOL, V15, P896, DOI 10.1038/nbt0997-896; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bell LA, 2004, CELL DEATH DIFFER, V11, P137, DOI 10.1038/sj.cdd.4401324; Berkovich E, 2003, ONCOGENE, V22, P161, DOI 10.1038/sj.onc.1206144; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Brooks LA, 2002, BRIT J CANCER, V86, P263, DOI 10.1038/sj.bjc.6600033; Chen D, 2005, CELL DEATH DIFFER, V12, P358, DOI 10.1038/sj.cdd.4401536; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; Croxton R, 2002, ONCOGENE, V21, P1359, DOI 10.1038/sj.onc.1205157; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Denchi EL, 2005, EMBO REP, V6, P661, DOI 10.1038/sj.embor.7400452; Ding Y, 1999, DNA Res, V6, P347, DOI 10.1093/dnares/6.5.347; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Fogal V, 2005, CELL DEATH DIFFER, V12, P369, DOI 10.1038/sj.cdd.4401562; Furukawa Y, 2002, J BIOL CHEM, V277, P39760, DOI 10.1074/jbc.M200805200; Hallstrom TC, 2003, P NATL ACAD SCI USA, V100, P10848, DOI 10.1073/pnas.1831408100; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1994, J VIROL, V68, P5027, DOI 10.1128/JVI.68.8.5027-5035.1994; Hershko T, 2005, CELL DEATH DIFFER, V12, P377, DOI 10.1038/sj.cdd.4401575; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; La Thangue NB, 2003, NAT CELL BIOL, V5, P587, DOI 10.1038/ncb0703-587; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Liu DX, 2001, NEURON, V32, P425, DOI 10.1016/S0896-6273(01)00495-0; Liu NS, 1998, ONCOGENE, V16, P2957, DOI 10.1038/sj.onc.1201838; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUELLE DE, 1995, CELL, V83, P993; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Ryan KM, 2004, CANCER RES, V64, P4415, DOI 10.1158/0008-5472.CAN-04-1474; Ryan KM, 1997, BIOCHEM J, V325, P79, DOI 10.1042/bj3250079; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Tsai KY, 2002, CURR BIOL, V12, P159, DOI 10.1016/S0960-9822(01)00659-5; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	64	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2006	25	41					5656	5663		10.1038/sj.onc.1209580	http://dx.doi.org/10.1038/sj.onc.1209580			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16652153				2022-12-28	WOS:000240599100007
J	Niizuma, H; Nakamura, Y; Ozaki, T; Nakanishi, H; Ohira, M; Isogai, E; Kageyama, H; Imaizumi, M; Nakagawara, A				Niizuma, H.; Nakamura, Y.; Ozaki, T.; Nakanishi, H.; Ohira, M.; Isogai, E.; Kageyama, H.; Imaizumi, M.; Nakagawara, A.			Bcl-2 is a key regulator for the retinoic acid-induced apoptotic cell death in neuroblastoma	ONCOGENE			English	Article						apoptosis; Bcl-2; neuroblastoma; retinoic acid	NEURONAL DIFFERENTIATION; NEURAL DIFFERENTIATION; SIGNALING PATHWAY; EXPRESSION; PROTEIN; CHEMOTHERAPY; ACTIVATION; FAMILY; LINE; BAX	Retinoic acid (RA) has been shown to induce neuronal differentiation and/or apoptosis, and is widely used as a chemotherapeutic agent for treating the patients with neuroblastoma. However, the therapeutic effect of RA is still limited. To unveil the molecular mechanism(s) inducing differentiation and apoptosis in neuroblastoma cells, we compared CHP134 and NB-39-nu cell lines, in which all-trans-RA (ATRA) induces apoptosis, with LAN-5 and RTBM1 cell lines, in which it induces neuronal differentiation. Here, we found that Bcl-2 was strongly downregulated in CHP134 and NB-39-nu cells, whereas it was abundantly expressed in LA-N-5 and RTBM1 cells. ATRA-mediated apoptosis in CHP134 and NB-39-nu cells was associated with a significant activation of caspase-9 and caspase-3 as well as cytoplasmic release of cytochrome c from mitochondria in a p53-independent manner. Enforced expression of Bcl-2 significantly inhibited ATRA-mediated apoptosis in CHP134 cells. In addition, treatment of RTBM1 cells with a Bcl-2 inhibitor, HA14-1, enhanced apoptotic response induced by ATRA. Of note, two out of 10 sporadic neuroblastomas expressed bcl-2 at undetectable levels and underwent cell death in response to ATRA in primary cultures. Thus, our present results suggest that overexpression of Bcl-2 is one of the key mechanisms to give neuroblastoma cells the resistance against ATRA-mediated apoptosis. This may provide a new therapeutic strategy against the ATRA-resistant and aggressive neuroblastomas by combining treatment with ATRA and a Bcl-2 inhibitor.	Chiba Canc Ctr, Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; Tohoku Univ, Sch Med, Dept Pediat, Aoba Ku, Sendai, Miyagi 980, Japan; Miyagi Childrens Hosp, Dept Hematol & Oncol, Aoba Ku, Sendai, Miyagi, Japan	Chiba Cancer Center; Tohoku University	Nakagawara, A (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp	Niizuma, Hidetaka/L-9023-2019					Abel F, 2005, EUR J CANCER, V41, P635, DOI 10.1016/j.ejca.2004.12.021; Antonsson B, 2001, CELL TISSUE RES, V306, P347, DOI 10.1007/s00441-001-0472-0; Balmer JE, 2002, J LIPID RES, V43, P1773, DOI 10.1194/jlr.R100015-JLR200; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Culmsee C, 2005, BIOCHEM BIOPH RES CO, V331, P761, DOI 10.1016/j.bbrc.2005.03.149; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; DOLE M, 1994, CANCER RES, V54, P3253; Encinas M, 1999, J NEUROCHEM, V73, P1409, DOI 10.1046/j.1471-4159.1999.0731409.x; Freemantle SJ, 2003, ONCOGENE, V22, P7305, DOI 10.1038/sj.onc.1206936; Gallo G, 2003, ANTICANCER RES, V23, P777; Kim R, 2004, CANCER-AM CANCER SOC, V101, P2491, DOI 10.1002/cncr.20696; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; Lippman SC, 2000, J NUTR, V130, p479S, DOI 10.1093/jn/130.2.479S; Lombet A, 2001, EUR J BIOCHEM, V268, P1352, DOI 10.1046/j.1432-1327.2001.02002.x; Lopez-Carballo G, 2002, J BIOL CHEM, V277, P25297, DOI 10.1074/jbc.M201869200; Maden M, 2001, INT REV CYTOL, V209, P1; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; McCaffery PJ, 2003, EUR J NEUROSCI, V18, P457, DOI 10.1046/j.1460-9568.2003.02765.x; Melino G, 1997, J NEURO-ONCOL, V31, P65, DOI 10.1023/A:1005733430435; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nagai J, 2004, CANCER RES, V64, P7910, DOI 10.1158/0008-5472.CAN-04-1178; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; Nakagawara A, 1997, CANCER RES, V57, P4578; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Nakagawara A, 1998, Hum Cell, V11, P115; Nakamura Y, 2003, BIOCHEM BIOPH RES CO, V307, P206, DOI 10.1016/S0006-291X(03)01138-0; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Okuno S, 2004, J NEUROSCI, V24, P7879, DOI 10.1523/JNEUROSCI.1745-04.2004; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; PIACENTINI M, 1992, INT J CANCER, V52, P271, DOI 10.1002/ijc.2910520220; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; RAMANI P, 1994, J PATHOL, V172, P273, DOI 10.1002/path.1711720308; Reynolds CP, 2001, HEMATOL ONCOL CLIN N, V15, P867, DOI 10.1016/S0889-8588(05)70256-2; Schor NF, 1999, J NEURO-ONCOL, V41, P159, DOI 10.1023/A:1006171406740; Shi LY, 2005, NEUROSCI LETT, V375, P7, DOI 10.1016/j.neulet.2004.10.082; Takada N, 2001, MED PEDIATR ONCOL, V36, P122, DOI 10.1002/1096-911X(20010101)36:1<122::AID-MPO1029>3.0.CO;2-R; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; van Noesel MM, 2004, GENE, V325, P1, DOI 10.1016/j.gene.2003.09.042; van Noesel MM, 2003, GENE CHROMOSOME CANC, V38, P226, DOI 10.1002/gcc.10278; VILLABLANCA JG, 1995, J CLIN ONCOL, V13, P894, DOI 10.1200/JCO.1995.13.4.894; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124	46	59	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					5046	5055		10.1038/sj.onc.1209515	http://dx.doi.org/10.1038/sj.onc.1209515			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568081				2022-12-28	WOS:000239921300010
J	Chiaradonna, F; Sacco, E; Manzoni, R; Giorgio, M; Vanoni, M; Alberghina, L				Chiaradonna, F.; Sacco, E.; Manzoni, R.; Giorgio, M.; Vanoni, M.; Alberghina, L.			Ras-dependent carbon metabolism and transformation in mouse broblasts	ONCOGENE			English	Article						transformed cells; Ras; glucose metabolism; apoptosis; cell cycle	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; DEPRIVATION-INDUCED CYTOTOXICITY; HUMAN CANCER-CELLS; HUMAN TUMOR-CELLS; GLUCOSE DEPRIVATION; OXIDATIVE STRESS; PANCREATIC-CANCER; ANTISENSE OLIGONUCLEOTIDES; MALIGNANT-TRANSFORMATION; SIGNAL-TRANSDUCTION	Mutational activation of ras genes is required for the onset and maintenance of different malignancies. Here we show, using a combination of molecular physiology, nutritional perturbations and transcriptional pro. ling, that full penetrance of phenotypes related to oncogenic Ras activation, including the shift of carbon metabolism towards fermentation and upregulation of key cell cycle regulators, is dependent upon glucose availability. These responses are induced by Ras activation, being specifically reverted by downregulation of the Ras pathway obtained through the expression of a dominant-negative Ras-specific guanine nucleotide exchange protein. Our data allow to link directly to ras activation the alteration in energy metabolism of cancer cells, their fragility towards glucose shortage and ensuing apoptotic death.	Univ Milano Bicocca, Dept Biotechnol & Biosci, I-20126 Milan, Italy; European Inst Oncol, Dept Expt Oncol, Milan, Italy	University of Milano-Bicocca; IRCCS European Institute of Oncology (IEO)	Alberghina, L (corresponding author), Univ Milano Bicocca, Dept Biotechnol & Biosci, Piazza Sci 2, I-20126 Milan, Italy.	lilia.alberghina@unimib.it	CHIARADONNA, Ferdinando/K-4959-2016; Sacco, Elena/T-3274-2018; Vanoni, Marco/AAA-3699-2021; Giorgio, Marco/I-9425-2012	CHIARADONNA, Ferdinando/0000-0001-8529-2732; Sacco, Elena/0000-0002-3190-7671; Vanoni, Marco/0000-0002-8690-2587; Giorgio, Marco/0000-0002-5842-6042; Alberghina, Lilia/0000-0003-1694-931X				Ahmad IM, 2005, J BIOL CHEM, V280, P4254, DOI 10.1074/jbc.M411662200; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Alberghina L, 2004, CHEMBIOCHEM, V5, P1322, DOI 10.1002/cbic.200400170; Arellano M, 1997, INT J BIOCHEM CELL B, V29, P559, DOI 10.1016/S1357-2725(96)00178-1; BAGGETTO LG, 1992, BIOCHIMIE, V74, P959, DOI 10.1016/0300-9084(92)90016-8; Blackburn RV, 1999, FREE RADICAL BIO MED, V26, P419, DOI 10.1016/S0891-5849(98)00217-2; Blum R, 2005, CANCER RES, V65, P999; BOARD M, 1990, BIOCHEM J, V265, P503, DOI 10.1042/bj2650503; BOS JL, 1995, EUR J CANCER, V31A, P1051, DOI 10.1016/0959-8049(95)00168-I; Bossu P, 2000, ONCOGENE, V19, P2147, DOI 10.1038/sj.onc.1203539; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chang FM, 2001, ONCOGENE, V20, P4354, DOI 10.1038/sj.onc.1204564; Chen CM, 1997, J BIOL CHEM, V272, P26803, DOI 10.1074/jbc.272.43.26803; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chiaradonna F, 2005, BIOCHEM SOC T, V33, P297, DOI 10.1042/BST0330297; Cochet O, 1999, CANCER DETECT PREV, V23, P506, DOI 10.1046/j.1525-1500.1999.99058.x; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; deVries JE, 1996, PATHOL RES PRACT, V192, P658, DOI 10.1016/S0344-0338(96)80087-2; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; GRUNICKE HH, 1993, CRIT REV ONCOGENESIS, V4, P389; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hellerstein MK, 2004, CURR OPIN MOL THER, V6, P249; Hlavata L, 2003, EMBO J, V22, P3337, DOI 10.1093/emboj/cdg314; Jinno S, 1999, P NATL ACAD SCI USA, V96, P13197, DOI 10.1073/pnas.96.23.13197; KAHN S, 1987, ANTICANCER RES, V7, P639; Kato-Stankiewicz J, 2002, P NATL ACAD SCI USA, V99, P14398, DOI 10.1073/pnas.222222699; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; Kijima H, 2004, INT J ONCOL, V24, P559; Kita K, 1999, INT J CANCER, V80, P553, DOI 10.1002/(SICI)1097-0215(19990209)80:4<553::AID-IJC12>3.0.CO;2-6; Kitano H, 2004, NAT REV CANCER, V4, P227, DOI 10.1038/nrc1300; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Kocher HM, 2005, NEPHROL DIAL TRANSPL, V20, P886, DOI 10.1093/ndt/gfh744; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee Ji-Won, 2004, Experimental & Molecular Medicine, V36, P1; Lee YJ, 1998, J BIOL CHEM, V273, P5294, DOI 10.1074/jbc.273.9.5294; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Mabuchi T, 2000, J BIOL CHEM, V275, P10492, DOI 10.1074/jbc.275.14.10492; Mathupala SP, 1997, J BIOENERG BIOMEMBR, V29, P339, DOI 10.1023/A:1022494613613; Mazurek S, 2003, ANTICANCER RES, V23, P1149; Mazurek S, 1999, J CELL PHYSIOL, V181, P136; Messer JI, 2004, AM J PHYSIOL-CELL PH, V286, pC565, DOI 10.1152/ajpcell.00146.2003; MONIA BP, 1992, J BIOL CHEM, V267, P19954; Nheu T, 2004, CELL CYCLE, V3, P71; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; Rajendran JG, 2004, CLIN CANCER RES, V10, P2245, DOI 10.1158/1078-0432.CCR-0688-3; Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102; Rebollo A, 1999, ONCOGENE, V18, P4930, DOI 10.1038/sj.onc.1202875; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Robey IF, 2005, NEOPLASIA, V7, P324, DOI 10.1593/neo.04430; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; Rolland F, 2002, FEMS YEAST RES, V2, P183, DOI 10.1111/j.1567-1364.2002.tb00084.x; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Russell JS, 1999, CANCER RES, V59, P5239; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shoshan-Barmatz V, 2003, CELL BIOCHEM BIOPHYS, V39, P279, DOI 10.1385/CBB:39:3:279; Spitz DR, 2000, ANN NY ACAD SCI, V899, P349, DOI 10.1111/j.1749-6632.2000.tb06199.x; Takeuchi M, 2000, GENE THER, V7, P518, DOI 10.1038/sj.gt.3301125; Takuwa N, 2001, MOL CELL ENDOCRINOL, V177, P25, DOI 10.1016/S0303-7207(01)00439-7; Thomas S, 1998, EUR J BIOCHEM, V258, P956, DOI 10.1046/j.1432-1327.1998.2580956.x; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Vanoni M, 1999, J BIOL CHEM, V274, P36656, DOI 10.1074/jbc.274.51.36656; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; YAMAMOTO F, 1984, NUCLEIC ACIDS RES, V12, P8873, DOI 10.1093/nar/12.23.8873	75	87	87	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	39					5391	5404		10.1038/sj.onc.1209528	http://dx.doi.org/10.1038/sj.onc.1209528			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16607279				2022-12-28	WOS:000240144900004
J	Li, H; Watts, GS; Oshiro, MM; Futscher, BW; Domann, FE				Li, H.; Watts, G. S.; Oshiro, M. M.; Futscher, B. W.; Domann, F. E.			AP-2 alpha and AP-2 gamma are transcriptional targets of p53 in human breast carcinoma cells	ONCOGENE			English	Article						activator protein-2; p53; tumor suppressor gene; breast carcinoma	FACTOR AP-2; DOWN-REGULATION; EPIDERMAL MORPHOGENESIS; GENE-EXPRESSION; HUMAN-MELANOMA; DNA-BINDING; CANCER; DIFFERENTIATION; METASTASIS; APOPTOSIS	Activating enhancer-binding protein 2 alpha (AP-2 alpha) and activating enhancer-binding protein 2 gamma (AP-2 gamma) are transcription factors that bind GC-rich consensus sequences and regulate the expression of many downstream genes. AP-2 alpha and AP-2 gamma interact with p53 both physically and functionally. Expression microarray results in human breast carcinoma cells with forced p53 expression revealed AP-2 gamma as a putative transcriptional target of p53. To command extend these findings we measured the effects of forced p53 expression in human breast carcinoma cells by real-time reverse transcription-PCR, Western blotting, electrophoretic gel mobility shift assays, promoter reporter, chromatin immunoprecipitation and chromatin accessibility assays. Wild-type p53 expression rapidly induced not only AP-2 gamma but also AP-2 alpha mRNA. The subsequent increase in these proteins led to increased AP-2 DNA-binding and transactivating activity. Candidate p53-binding sites were identified in the AP-2 alpha and AP-2 gamma promoters. p53 binding to these cis-elements in vivo was also observed, together with a relaxation of chromatin structure in these regions. Finally, expression of either AP-2 alpha or gamma inhibited growth of human breast carcinoma cells in vitro. Taken together, our findings indicate that these AP-2 genes are targets for transcriptional activation by p53 and suggest that AP-2 proteins may mediate some of the downstream effects of p53 expression such as inhibition of proliferation.	Univ Iowa, Free Rad & Radiat Biol Program, Dept Radiat Oncol, Iowa City, IA 52242 USA; Univ Arizona, Bone Marrow Transplant Program, Arizona Canc Ctr, Tucson, AZ 85721 USA; Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA	University of Iowa; Arizona Center Cancer Care; University of Arizona; University of Arizona	Domann, FE (corresponding author), Univ Iowa, Free Rad & Radiat Biol Program, Dept Radiat Oncol, Med Lab B180, Iowa City, IA 52242 USA.	Frederick-domann@uiowa.edu		Domann, Frederick/0000-0002-0489-2179	NCI NIH HHS [CA66081, CA65662, CA73612, P30 CA023074] Funding Source: Medline; NIEHS NIH HHS [P30 ES006694] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065662, R56CA073612, P01CA066081, P30CA023074, R29CA065662, R29CA073612, R01CA073612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; CHEN PH, 1993, CLIN CHEM, V39, P2186; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Douglas DB, 2004, CANCER RES, V64, P1611, DOI 10.1158/0008-5472.CAN-0318-2; Gee JMW, 1999, J PATHOL, V189, P514, DOI 10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang Y, 1998, BIOCHEM BIOPH RES CO, V249, P307, DOI 10.1006/bbrc.1998.9139; HURSTING SD, 1994, P NATL ACAD SCI USA, V91, P7036, DOI 10.1073/pnas.91.15.7036; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; Karjalainen JM, 2000, BRIT J CANCER, V82, P2015; Koster MI, 2006, DEV BIOL, V289, P253, DOI 10.1016/j.ydbio.2005.10.041; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Marreiros A, 2003, GENE, V302, P155, DOI 10.1016/S0378-1119(02)01101-0; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; McPherson LA, 2002, J BIOL CHEM, V277, P45028, DOI 10.1074/jbc.M208924200; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Modugno M, 2002, ONCOGENE, V21, P7478, DOI 10.1038/sj.onc.1205957; Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545; Paggi MG, 2001, ONCOGENE, V20, P2570, DOI 10.1038/sj.onc.1204356; Pellikainen J, 2002, CLIN CANCER RES, V8, P3487; PETSKO G, 2002, CURRENT PROTOCOLS BI; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Ruiz M, 2001, CLIN CANCER RES, V7, P4086; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; STABACH PR, 2005, ONCOGENE; Tellez C, 2003, J BIOL CHEM, V278, P46632, DOI 10.1074/jbc.M309159200; Tummala R, 2003, GENE, V321, P93, DOI 10.1016/S0378-1119(03)00840-0; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wajapeyee N, 2003, J BIOL CHEM, V278, P52093, DOI 10.1074/jbc.M305624200; Watts GS, 2004, NEOPLASIA, V6, P187, DOI 10.1593/neo.03292; West-Mays JA, 2003, DIFFERENTIATION, V71, P206, DOI 10.1046/j.1432-0436.2003.710302.x; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200; Zhu CH, 2001, J BIOL CHEM, V276, P14407, DOI 10.1074/jbc.M009708200	40	23	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2006	25	39					5405	5415		10.1038/sj.onc.1209534	http://dx.doi.org/10.1038/sj.onc.1209534			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16636674				2022-12-28	WOS:000240144900005
J	Mariano, AR; Colombo, E; Luzi, L; Martinelli, P; Volorio, S; Bernard, L; Meani, N; Bergomas, R; Alcalay, M; Pelicci, PG				Mariano, A. R.; Colombo, E.; Luzi, L.; Martinelli, P.; Volorio, S.; Bernard, L.; Meani, N.; Bergomas, R.; Alcalay, M.; Pelicci, P. G.			Cytoplasmic localization of NPM in myeloid leukemias is dictated by gain-of-function mutations that create a functional nuclear export signal	ONCOGENE			English	Article						NPM; AML; nucleus-cytoplasmic shuttling; NES; CRM1	ACUTE MYELOGENOUS LEUKEMIA; NORMAL KARYOTYPE; NUCLEOPHOSMIN; PROTEIN; ARF	Nucleophosmin (NPM) is a nucleus-cytoplasmic shuttling protein that is implicated in centrosome duplication, cell cycle progression and stress response. At the steady state, NPM localizes mainly in the nucleolus, where it forms a complex with different cellular proteins. One-third of acute myeloid leukemias (AML) are characterized by aberrant cytoplasmic localization of NPM, due to mutations within its last coding exon (exon 12) that cause a frameshift and the formation of novel C-termini. We report here our investigations on the molecular basis for the aberrant localization of mutated NPM. Alignment of the C-terminus of the various NPM mutants revealed the obligatory presence of four amino-acid residues that match a CRM1-dependent nuclear export signal (NES). Single alanine-substitutions at these sites provoked nuclear re-localization, while fusion of the mutated C-terminus to a heterologous nuclear protein induced CRM1-dependent cytoplasmic localization. Molecular characterization of one exceptional AML carrying cytoplasmic NPM and germ line exon 12 revealed a somatic mutation in the splicing donor site of exon 9 that caused the formation of a functional NES. It appears, therefore, that AMLs are frequently characterized by gain-of-function mutations of NPM that create functional NES, suggesting that alterations of nuclear export might represent a general mechanism of leukemogenesis and a novel target for therapeutic intervention.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; IFOM Inst, Milan, Italy; Univ Milan, Dept Med Surg & Dent, Milan, Italy	IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology; University of Milan	Pelicci, PG (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.	piergiuseppe.pelicci@ifom-ieo-campus.it	Luzi, Lucilla/K-4350-2018; Pelicci, Pier Giuseppe/AAL-6572-2020; Colombo, Emanuela/AAO-8113-2020; Alcalay, Myriam/AAB-4300-2019; Alcalay, Myriam/B-3182-2016	Luzi, Lucilla/0000-0002-8746-4179; Colombo, Emanuela/0000-0003-2079-7398; Alcalay, Myriam/0000-0002-5558-4272; Alcalay, Myriam/0000-0002-5558-4272; Martinelli, Paola/0000-0002-1643-8731				BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Cazzaniga G, 2005, BLOOD, V106, P1419, DOI 10.1182/blood-2005-03-0899; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; COLOMBO E, 2006, IN PRESS CANC RES; den Besten W, 2005, CELL CYCLE, V4, P1593; Dohner K, 2005, BLOOD, V106, P3740, DOI 10.1182/blood-2005-05-2164; Engelsma D, 2004, EMBO J, V23, P3643, DOI 10.1038/sj.emboj.7600370; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Nakagawa M, 2005, NEW ENGL J MED, V352, P1819; Slape C, 2004, LEUKEMIA LYMPHOMA, V45, P1341, DOI 10.1080/10428190310001659325; Suzuki T, 2005, BLOOD, V106, P2854, DOI 10.1182/blood-2005-04-1733; Wang W, 2005, NAT CELL BIOL, V7, P823, DOI 10.1038/ncb1282; Zirwes RF, 1997, MOL BIOL CELL, V8, P231, DOI 10.1091/mbc.8.2.231	14	56	57	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2006	25	31					4376	4380		10.1038/sj.onc.1209453	http://dx.doi.org/10.1038/sj.onc.1209453			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16501600				2022-12-28	WOS:000239240100013
J	Shulewitz, M; Soloviev, I; Wu, T; Koeppen, H; Polakis, P; Sakanaka, C				Shulewitz, M.; Soloviev, I.; Wu, T.; Koeppen, H.; Polakis, P.; Sakanaka, C.			Repressor roles for TCF-4 and Sfrp1 in Wnt signaling in breast cancer	ONCOGENE			English	Article						Wnt; TCF-4; Sfrp1; breast cancer	BETA-CATENIN; COLORECTAL-CANCER; PROGNOSTIC MARKER; CYCLIN D1; EXPRESSION; TRANSCRIPTION; GENE; CELLS; PROTEIN; APC	Mutations in Wnt pathway genes are rare in human breast cancer, yet activation of the pathway is evident from the misolocalization of beta-catenin. We searched for relationships in the expression of Wnt pathway genes and found that both secreted frizzled related protein 1 (Sfrp1) and TCF-4 transcripts were all highly downregulated in a common subset of breast cancers relative to normal breast tissue. Sfrp1 has been previously characterized as a Wnt inhibitor, and we found that interfering with its expression in the human mammary epithelial cell line MCF10A activated Wnt signaling. Reduction of TCF-4 levels in breast cancer was surprising as it is a transcription factor that is responsive to Wnt signaling. Therefore, we investigated a possible inhibitory role for TCF-4 in human breast cells as well as further characterizing Sfrp1. We identified CD24 as a Wnt target in MCF10A cells and used its expression a marker of Wnt signaling. Interfering with either Sfrp1 or TCF-4 in this cell line enhanced CD24 expression. Furthermore, removal of TCF/LEF binding sites in a CD24-luciferase reporter resulted in elevated reporter gene expression. Our results indicate that both Sfrp1 and TCF-4 repress Wnt signaling in breast tissue and their downregulation contributes to the activation of Wnt signaling.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Bioinformat, San Francisco, CA 94080 USA; Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Sakanaka, C (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way,MS40, San Francisco, CA 94080 USA.	chies@gene.com						Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Brannon M, 1999, DEVELOPMENT, V126, P3159; Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; Bukholm IK, 2000, J PATHOL, V190, P15; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chung GG, 2004, CANCER, V100, P2084, DOI 10.1002/cncr.20232; Cowin P, 2005, CURR OPIN CELL BIOL, V17, P499, DOI 10.1016/j.ceb.2005.08.014; Dorsky RI, 2003, DEVELOPMENT, V130, P1937, DOI 10.1242/dev.00402; Duval A, 2000, CANCER RES, V60, P3872; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Hatsell S, 2003, J MAMMARY GLAND BIOL, V8, P145, DOI 10.1023/A:1025944723047; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Kim CH, 2000, NATURE, V407, P913, DOI 10.1038/35038097; Kouzmenko AP, 2004, J BIOL CHEM, V279, P40255, DOI 10.1074/jbc.C400331200; Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092-8674(02)00679-7; Kristiansen G, 2003, CLIN CANCER RES, V9, P4906; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Lo MC, 2004, CELL, V117, P95, DOI 10.1016/S0092-8674(04)00203-X; Merrill BJ, 2004, DEVELOPMENT, V131, P263, DOI 10.1242/dev.00935; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PIRRUCCELLO SJ, 1986, J IMMUNOL, V136, P3779; Polakis P, 2000, GENE DEV, V14, P1837; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Sinner D, 2004, DEVELOPMENT, V131, P3069, DOI 10.1242/dev.01176; SOULE HD, 1990, CANCER RES, V50, P6075; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Thorpe CJ, 2004, DEVELOPMENT, V131, P2899, DOI 10.1242/dev.01171; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Wong SCC, 2002, J PATHOL, V196, P145, DOI 10.1002/path.1035	48	81	87	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2006	25	31					4361	4369		10.1038/sj.onc.1209470	http://dx.doi.org/10.1038/sj.onc.1209470			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16532032				2022-12-28	WOS:000239240100011
J	Burnworth, B; Popp, S; Stark, HJ; Steinkraus, V; Broecker, EB; Hartschuh, W; Birek, C; Boukamp, P				Burnworth, B.; Popp, S.; Stark, H-J; Steinkraus, V.; Broecker, E. B.; Hartschuh, W.; Birek, C.; Boukamp, P.			Gain of 11q/cyclin D1 overexpression is an essential early step in skin cancer development and causes abnormal tissue organization and differentiation	ONCOGENE			English	Article						keratoacanthoma; cdk4; p21; aberrant differentiation; tumorigenicity	COMPARATIVE GENOMIC HYBRIDIZATION; SQUAMOUS-CELL CARCINOMA; CYCLIN D1; P53 MUTATIONS; CHROMOSOMAL-ABERRATIONS; ORGANOTYPIC COCULTURE; KERATINOCYTES HACAT; GENE; PROGRESSION; EXPRESSION	Non-melanoma skin cancers, in particular keratoacanthomas (KAs) and squamous cell carcinomas (SCCs), have become highly frequent tumor types especially in immune-suppressed transplant patients. Nevertheless, little is known about essential genetic changes. As a paradigm of 'early' changes, that is, changes still compatible with tumor regression, we studied KAs by comparative genomic hybridization and show that gain of chromosome 11q is not only one of the most frequent aberration (8/18), but in four tumors also the only aberration. Furthermore, 11q gain correlated with amplification of the cyclin D1 locus (10/14), as determined by fluorescence in situ hybridization, and overexpression of cyclin D1 protein (25/31), as detected by immunohistochemistry. For unraveling the functional consequence, we overexpressed cyclin D1 in HaCaT skin keratinocytes. These cells only gained little growth advantage in conventional and in organotypic cocultures. However, although the control vector-transfected cells formed a well-stratified and orderly differentiated epidermis-like epithelium, they showed deregulation of tissue architecture with an altered localization of proliferation and impaired differentiation. The most severe phenotype was seen in a clone that additionally upregulated cdk4 and p21. These cells lacked terminal differentiation, exhibited a more autonomous growth in vitro and in vivo and even formed tumors in two injection sites with a growth pattern resembling that of human KAs. Thus, our results identify 11q13 gain/cyclin D1 overexpression as an important step in KA formation and point to a function that exceeds its known role in proliferation by disrupting tissue organization and thereby allowing abnormal growth.	DKFZ, German Canc Res Ctr, Genet Skin Carcinogenesis, D-69120 Heidelberg, Germany; Dermatologicum Hamburg, Hamburg, Germany; Univ Wurzburg, Wurzburg, Germany; Heidelberg Univ, Heidelberg, Germany; Univ Manitoba, Fac Dent, Winnipeg, MB, Canada	Helmholtz Association; German Cancer Research Center (DKFZ); Dermatologikum Hamburg; University of Wurzburg; Ruprecht Karls University Heidelberg; University of Manitoba	Boukamp, P (corresponding author), DKFZ, German Canc Res Ctr, Genet Skin Carcinogenesis, Neuenheimer Feld 280,Postfach 101949, D-69120 Heidelberg, Germany.	p.boukamp@dkfz-heidelberg.de						Arnold A, 2005, J CLIN ONCOL, V23, P4215, DOI 10.1200/JCO.2005.05.064; Ashton KJ, 2003, ARCH DERMATOL, V139, P876, DOI 10.1001/archderm.139.7.876; Billingsley E M, 1999, J Cutan Med Surg, V3, P193; Boukamp P, 1997, GENE CHROMOSOME CANC, V19, P201, DOI 10.1002/(SICI)1098-2264(199708)19:4<201::AID-GCC1>3.0.CO;2-0; BOUKAMP P, 1990, CANCER RES, V50, P2840; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Boukamp P, 1999, ONCOGENE, V18, P5638, DOI 10.1038/sj.onc.1202934; Boukamp Petra, 2005, J Dtsch Dermatol Ges, V3, P493, DOI 10.1111/j.1610-0387.2005.05037.x; Cerezo A, 2003, J INVEST DERMATOL, V121, P110, DOI 10.1046/j.1523-1747.2003.12304.x; Clausen OPF, 2002, J INVEST DERMATOL, V119, P1367, DOI 10.1046/j.1523-1747.2002.19613.x; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Euvrard S, 2003, NEW ENGL J MED, V348, P1681, DOI 10.1056/NEJMra022137; Ewen ME, 2004, TRENDS MOL MED, V10, P158, DOI 10.1016/j.molmed.2004.02.005; Freedberg IM EA, 1999, FITZPATRICKS DERMATO; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; Hosokawa Y, 1998, GENE CHROMOSOME CANC, V22, P66, DOI 10.1002/(SICI)1098-2264(199805)22:1<66::AID-GCC9>3.0.CO;2-5; Jin YS, 1999, GENE CHROMOSOME CANC, V26, P295, DOI 10.1002/(SICI)1098-2264(199912)26:4<295::AID-GCC3>3.0.CO;2-W; Jin YS, 2002, CANCER GENET CYTOGEN, V136, P48, DOI 10.1016/S0165-4608(01)00517-9; JOHNSON TM, 1992, J AM ACAD DERMATOL, V26, P467, DOI 10.1016/0190-9622(92)70074-P; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Lesage D, 2005, INT J CANCER, V115, P171, DOI 10.1002/ijc.20907; Ling G, 2001, AM J PATHOL, V159, P1247, DOI 10.1016/S0002-9440(10)62511-4; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; Oyama T, 1998, CANCER RES, V58, P2876; Parangi S, 1996, P NATL ACAD SCI USA, V93, P2002, DOI 10.1073/pnas.93.5.2002; Popp S, 2002, INT J CANCER, V99, P352, DOI 10.1002/ijc.10321; Popp S, 2000, J INVEST DERMATOL, V115, P1095, DOI 10.1046/j.1523-1747.2000.00173.x; QUINN AG, 1994, GENE CHROMOSOME CANC, V11, P222, DOI 10.1002/gcc.2870110404; Rehman I, 1996, ONCOGENE, V12, P2483; Ren ZP, 1996, ONCOGENE, V12, P765; ROTZER D, 2006, IN PRESS ONCOGENE; Schoop VM, 1999, J INVEST DERMATOL, V112, P343, DOI 10.1046/j.1523-1747.1999.00524.x; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shoker BS, 2001, BRIT J CANCER, V84, P1064, DOI 10.1054/bjoc.2001.1705; Stark HJ, 2004, EUR J CELL BIOL, V83, P631, DOI 10.1078/0171-9335-00435; Utikal J, 2005, CANCER LETT, V219, P197, DOI 10.1016/j.canlet.2004.07.011; Utikal J, 2005, INT J ONCOL, V26, P597; Waring AJ, 1996, BRIT J CANCER, V73, P649, DOI 10.1038/bjc.1996.113; Zahnow CA, 2002, BREAST CANCER RES, V4, P109, DOI 10.1186/bcr428	44	47	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	32					4399	4412		10.1038/sj.onc.1209474	http://dx.doi.org/10.1038/sj.onc.1209474			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16547504				2022-12-28	WOS:000239326000003
J	Kommagani, R; Caserta, TM; Kadakia, MP				Kommagani, R.; Caserta, T. M.; Kadakia, M. P.			Identification of vitamin D receptor as a target of p63	ONCOGENE			English	Article						p63 gamma; VDR; p14(ARF); differentiation	FAMILY-MEMBER GENES; P53 HOMOLOG P63; TUMOR-SUPPRESSOR; EPIDERMAL DIFFERENTIATION; PROSTATE-CANCER; DEVELOPMENTAL SYNDROMES; EEC-SYNDROME; EXPRESSION; MUTATIONS; CELLS	p63, a p53 homolog has been shown to play a role in development and cancer. p63 is essential for both commitment of ectoderm to stratified epithelia and for the proliferative potential of epithelial stem cells. p63 knockout mice are born with severe development defects and lack organs of epithelial origin. In addition, p63 has also been shown to play a role in cancer development through the differential regulation of genes with tumor suppressor function and genes involved in metastasis. In order to understand the role of p63 in cancer and development, genes that are specifically regulated by p63 but not p53 were identified. In this study, we provide evidence that p63 gamma specifically upregulates vitamin D Receptor ( VDR). In contrast, p53 does not appear to be involved in upregulation of VDR expression. Additionally, we demonstrate that a naturally occurring p63 missense mutant, p63c ( R279H) and p14(ARF), both act in a dominant negative manner to inhibit p63 gamma-mediated upregulation of VDR. Furthermore, using chromatin immunoprecipitation assays, we demonstrated that p63 directly binds to the VDR promoter in vivo. Our findings clearly demonstrate that VDR is a direct target of p63 and suggests that p63 may play a role in cancer and differentiation through modulation of the VDR pathway.	Wright State Univ, Dept Biohchem & Mol Biol, Dayton, OH 45435 USA; Wright State Univ, Ctr Genom Res, Dayton, OH USA	University System of Ohio; Wright State University Dayton; University System of Ohio; Wright State University Dayton	Kadakia, MP (corresponding author), Wright State Univ, Dept Biohchem & Mol Biol, 3640 Col Glenn Highway,142 Biol Sci, Dayton, OH 45435 USA.	madhavi.kadakia@wright.edu		Kommagani, Ramakrishna/0000-0003-0403-0971				Banerjee P, 2003, MOL CELL BIOCHEM, V253, P247, DOI 10.1023/A:1026072118217; Barbieri CE, 2005, CANCER RES, V65, P2314, DOI 10.1158/0008-5472.CAN-04-3449; Barrow LL, 2002, J MED GENET, V39, P559, DOI 10.1136/jmg.39.8.559; Bikle DD, 2004, J NUTR, V134, p3472S, DOI 10.1093/jn/134.12.3472S; Bikle DD, 2004, J STEROID BIOCHEM, V89-90, P355, DOI 10.1016/j.jsbmb.2004.03.020; BIKLE DD, 1992, ENDOCR REV, V13, P765, DOI 10.1210/er.13.4.765; Bikle DD, 2003, J CELL BIOCHEM, V88, P290, DOI 10.1002/jcb.10339; Blutt SE, 1999, P SOC EXP BIOL MED, V221, P89, DOI 10.1046/j.1525-1373.1999.d01-60.x; Brunner HG, 2002, J MED GENET, V39, P377, DOI 10.1136/jmg.39.6.377; Brunner HG, 2002, AM J MED GENET, V112, P284, DOI 10.1002/ajmg.10778; Calabro V, 2004, MOL CELL BIOL, V24, P8529, DOI 10.1128/MCB.24.19.8529-8540.2004; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Christakos S, 2003, J CELL BIOCHEM, V88, P238, DOI 10.1002/jcb.10349; Feldman D, 2000, ENDOCRINOLOGY, V141, P5, DOI 10.1210/en.141.1.5; Gressner O, 2005, EMBO J, V24, P2458, DOI 10.1038/sj.emboj.7600708; Guzey M, 2004, J CELL BIOCHEM, V93, P271, DOI 10.1002/jcb.20182; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hudson DL, 2004, PROSTATE CANCER P D, V7, P188, DOI 10.1038/sj.pcan.4500745; Kim S, 2004, CANCER RES, V64, P6900, DOI 10.1158/0008-5472.CAN-04-1657; Konety B R, 1999, Semin Urol Oncol, V17, P77; Koszewski NJ, 1996, J STEROID BIOCHEM, V59, P377, DOI 10.1016/S0960-0760(96)00127-6; Lian J. B., 2003, Current Pharmaceutical Design, V9, P2677, DOI 10.2174/1381612033453659; Lu JF, 2005, J INVEST DERMATOL, V124, P778, DOI 10.1111/j.0022-202X.2005.23641.x; Miller GJ, 1998, CANCER METAST REV, V17, P353, DOI 10.1023/A:1006102124548; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Miyamoto K, 1997, MOL ENDOCRINOL, V11, P1165, DOI 10.1210/me.11.8.1165; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; Osada M, 2005, MOL CELL BIOL, V25, P6077, DOI 10.1128/MCB.25.14.6077-6089.2005; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Petitjean A, 2005, ONCOGENE, V24, P512, DOI 10.1038/sj.onc.1208215; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Sasaki Y, 2005, ONCOGENE, V24, P5131, DOI 10.1038/sj.onc.1208695; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; Senoo M, 2002, ONCOGENE, V21, P2455, DOI 10.1038/sj.onc.1205330; Shimada A, 1999, CANCER RES, V59, P2781; South AP, 2002, BRIT J DERMATOL, V146, P216, DOI 10.1046/j.1365-2133.2002.04638.x; Spiesbach K, 2005, INT J CANCER, V114, P555, DOI 10.1002/ijc.20766; van Bokhoven H, 2002, TRENDS MOL MED, V8, P133, DOI 10.1016/S1471-4914(01)02260-2; Wagner EF, 2001, CURR OPIN GENET DEV, V11, P527, DOI 10.1016/S0959-437X(00)00228-8; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Wu GJ, 2003, CANCER RES, V63, P2351; Xie ZJ, 2002, J INVEST DERMATOL, V118, P11, DOI 10.1046/j.1523-1747.2002.01644.x; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	47	42	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3745	3751		10.1038/sj.onc.1209412	http://dx.doi.org/10.1038/sj.onc.1209412			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16462763				2022-12-28	WOS:000238448300013
J	Lapi, E; Iovino, A; Fontemaggi, G; Soliera, AR; Iacovelli, S; Sacchi, A; Rechavi, G; Givol, D; Blandino, G; Strano, S				Lapi, E.; Iovino, A.; Fontemaggi, G.; Soliera, A. R.; Iacovelli, S.; Sacchi, A.; Rechavi, G.; Givol, D.; Blandino, G.; Strano, S.			S100A2 gene is a direct transcriptional target of p53 homologues during keratinocyte differentiation	ONCOGENE			English	Article						p73; p63; differentiation; transcription; keratinocytes; S100A2	DNA-DAMAGE; P73 GENE; EXPRESSION; P63; PROTEINS; IDENTIFICATION; FAMILY; CELLS; PROLIFERATION; NEUROBLASTOMA	The p53 paralogues p73, p63 and their respective truncated isoforms have been shown to be critical regulators of developmental and differentiation processes. Indeed, both p73- and p63-deficient mice exhibit severe developmental defects. Here, we show that S100A2 gene, whose transcript and protein are induced during keratinocyte differentiation of HaCaT cells, is a direct transcriptional target of p73 beta and Delta Np63 alpha and is required for proper keratinocyte differentiation. Transactivation assays reveal that p73b and DNp63a exert opposite transcriptional effects on S100A2 gene. While DNp63a is found in vivo onto S100A2 regulatory regions predominantly in proliferating cells, p73b is recruited in differentiating cells. Silencing of p73 impairs the induction of S100A2 during the differentiation of HaCaT cells. Moreover, silencing of p73 or S100A2 impairs the proper expression of keratinocyte differentiation markers. Of note, p53 family members do not trigger S100A2 gene expression in response to apoptotic doses of cisplatin and doxorubicin.	Regina Elena Inst Canc Res, Dept Expt Onocl, Mol Oncogenesis Lab, Rome, Italy; Chaim Sheba Med Ctr, Dept Pediat Hematol Oncol, Tel Hashomer, Israel; Rome Oncogenom Ctr, Rome, Italy; Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Chaim Sheba Medical Center; Weizmann Institute of Science	Blandino, G (corresponding author), Regina Elena Inst Canc Res, Dept Expt Onocl, Mol Oncogenesis Lab, Via Messi Oro,156, Rome, Italy.	blandino@ifo.it	strano, sabrina/B-6743-2013; Fontemaggi, Giulia/K-9702-2016; Strano, Sabrina/K-9654-2016; Lapi, Eleonora/ABF-9748-2021; Blandino, Giovanni/B-1137-2013	strano, sabrina/0000-0002-6341-4230; Fontemaggi, Giulia/0000-0001-8332-8842; Lapi, Eleonora/0000-0003-4052-0361; Blandino, Giovanni/0000-0002-6970-2241; iacovelli, stefano/0000-0003-0806-6365	Telethon [GGP030358] Funding Source: Medline	Telethon(Fondazione Telethon)		Attardi LD, 2000, GENE DEV, V14, P704; Bamberger C, 2002, J INVEST DERMATOL, V118, P133, DOI 10.1046/j.0022-202x.2001.01649.x; Blandino G, 2004, CELL CYCLE, V3, P886; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Dale BA, 1997, J INVEST DERMATOL, V108, P179, DOI 10.1111/1523-1747.ep12334205; Dazard JE, 2003, ONCOGENE, V22, P2993, DOI 10.1038/sj.onc.1206537; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Eckert RL, 2004, J INVEST DERMATOL, V123, P23, DOI 10.1111/j.0022-202X.2004.22719.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fernandez-Fernandez MR, 2005, P NATL ACAD SCI USA, V102, P4735, DOI 10.1073/pnas.0501459102; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; Gupta S, 2003, J CLIN ONCOL, V21, P106, DOI 10.1200/JCO.2003.03.024; Heierhorst J, 1996, NATURE, V380, P636, DOI 10.1038/380636a0; Hibi K, 2003, CLIN CANCER RES, V9, P4282; Ihrie RA, 2005, CELL, V120, P843, DOI 10.1016/j.cell.2005.01.008; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Maelandsmo GM, 1997, INT J CANCER, V74, P464, DOI 10.1002/(SICI)1097-0215(19970822)74:4<464::AID-IJC19>3.0.CO;2-9; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Tan MJ, 1999, FEBS LETT, V445, P265, DOI 10.1016/S0014-5793(99)00135-0; Vellucci VF, 1995, GENE, V166, P213, DOI 10.1016/0378-1119(95)00543-9; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zaika AI, 1999, CANCER RES, V59, P3257	40	28	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3628	3637		10.1038/sj.onc.1209401	http://dx.doi.org/10.1038/sj.onc.1209401			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16449968				2022-12-28	WOS:000238448300002
J	Qiu, J; Wong, J; Tweardy, DJ; Dong, S				Qiu, J.; Wong, J.; Tweardy, D. J.; Dong, S.			Decreased intranuclear mobility of acute myeloid leukemia 1-containing fusion proteins is accompanied by reduced mobility and compartmentalization of core binding factor beta	ONCOGENE			English	Article						AML1; AML1-X; FRAP	ESTROGEN-RECEPTOR-ALPHA; TRANSCRIPTION FACTORS; GENE; AML1; ETO; ACTIVATION; REPRESSION; OLIGOMERIZATION; TRANSLOCATION; DIMERIZATION	Acute myeloid leukemia 1 (AML1) gene on chromosome 21 is involved in several chromosomal translocations, including t(8; 21) and t(16; 21), that produce chimeric fusion proteins AML1-eight twenty-one (ETO) and AML- myeloid transforming gene chromosome 16 (MTG16), which contribute to leukemogenesis. The molecular basis for the leukemogenic effects of these fusion proteins is incompletely understood. Using gel-shift assay, we showed that AML1-ETO and AML1-MTG16 bound to a series of AML1 consensus DNA-binding sites with different affinities. Using fluorescence recovery after photobleaching (FRAP), we demonstrated that a fusion of AML1 with ETO or MTG16 exhibits reduced intranuclear mobility compared with wild-type AML1 or either fusion partner. The dimerization domain (nervy homology region 2) of ETO is responsible for the reduced mobility of AML1-ETO. Dual FRAP studies revealed that CBF beta colocalized with AML1-ETO within the nucleus, resulting in reduced mobility of CBF beta. Therefore, AML1 fusion proteins may interfere with normal AML1 function due to aberrant nuclear dynamics, which leads to spatial and temporal sequestration of CBF beta and perhaps other coregulators critical for myeloid differentiation.	Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX USA	Baylor College of Medicine; Baylor College of Medicine	Dong, S (corresponding author), Baylor Coll Med, Dept Med, Infect Dis Sect, 1 Baylor Plaza,BCM 286,Room N1319, Houston, TX 77030 USA.	sdong@bcm.tmc.edu	Tweardy, David/L-3929-2019	Wong, Jiemin/0000-0002-5311-842X	NATIONAL CANCER INSTITUTE [R21CA119080] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA119080] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adya N, 1998, MOL CELL BIOL, V18, P7432, DOI 10.1128/MCB.18.12.7432; Bangsow C, 2001, GENE, V279, P221, DOI 10.1016/S0378-1119(01)00760-0; Barseguian K, 2002, P NATL ACAD SCI USA, V99, P15434, DOI 10.1073/pnas.242588499; Davis JN, 2003, GENE, V303, P1, DOI 10.1016/S0378-1119(02)01172-1; Dong S, 2004, MOL CELL BIOL, V24, P4465, DOI 10.1128/MCB.24.10.4465-4475.2004; Dong S, 2003, ONCOGENE, V22, P858, DOI 10.1038/sj.onc.1206182; Dong S, 2002, BLOOD, V99, P2637, DOI 10.1182/blood.V99.8.2637; Francastel C, 2001, P NATL ACAD SCI USA, V98, P12120, DOI 10.1073/pnas.211444898; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Harrington KS, 2002, J CELL SCI, V115, P4167, DOI 10.1242/jcs.00095; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; Hinojos CAD, 2005, TRENDS ENDOCRIN MET, V16, P12, DOI 10.1016/j.tem.2004.11.006; Hug BA, 2002, CANCER RES, V62, P2906; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Licht JD, 2001, ONCOGENE, V20, P5660, DOI 10.1038/sj.onc.1204593; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; McNeil S, 1999, P NATL ACAD SCI USA, V96, P14882, DOI 10.1073/pnas.96.26.14882; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Peterson LF, 2004, ONCOGENE, V23, P4255, DOI 10.1038/sj.onc.1207727; So CW, 2004, BLOOD, V104, P919, DOI 10.1182/blood-2004-03-0992; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Stewart MD, 2005, MOL CELL BIOL, V25, P2525, DOI 10.1128/MCB.25.7.2525-2538.2005; Tanaka K, 1998, BLOOD, V91, P1688, DOI 10.1182/blood.V91.5.1688.1688_1688_1699; Westendorf JJ, 1999, J CELL BIOCHEM, P51; Yoon HG, 2003, MOL CELL, V12, P723, DOI 10.1016/j.molcel.2003.08.008; Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001	30	12	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3982	3993		10.1038/sj.onc.1209431	http://dx.doi.org/10.1038/sj.onc.1209431			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16474840				2022-12-28	WOS:000238668800012
J	Cerda, SR; Mustafi, R; Little, H; Cohen, G; Khare, S; Moore, C; Majumder, P; Bissonnette, M				Cerda, S. R.; Mustafi, R.; Little, H.; Cohen, G.; Khare, S.; Moore, C.; Majumder, P.; Bissonnette, M.			Protein kinase C delta inhibits Caco-2 cell proliferation by selective changes in cell cycle and cell death regulators	ONCOGENE			English	Review						pKC; cyclins; p21(Waf1); Bcl-2; Bax; colon cancer cells	COLON-CANCER CELLS; PKC-DELTA; INDUCED APOPTOSIS; BREAST-CANCER; UP-REGULATION; 1,25-DIHYDROXYVITAMIN D-3; P21(WAF1/CIP1) EXPRESSION; RETINOBLASTOMA PROTEIN; TRANSFORMED PHENOTYPE; ACTIVATION MECHANISMS	PKC-delta is a serine/threonine kinase that mediates diverse signal transduction pathways. We previously demonstrated that overexpression of PKC-delta slowed the G1 progression of Caco-2 colon cancer cells, accelerated apoptosis, and induced cellular differentiation. In this study, we further characterized the PKC-delta dependent signaling pathways involved in these tumor suppressor actions in Caco-2 cells overexpressing PKC-delta using a Zn2+ inducible expression vector. Consistent with a G1 arrest, increased expression of PKC-delta caused rapid and significant downregulation of cyclin D1 and cyclin E proteins (50% decreases, P < 0.05), while mRNA levels remained unchanged. The PKC agonist, phorbol 12-myristate 13-acetate (TPA, 100 nM, 4 h), induced two-fold higher protein and mRNA levels of p21(Waf1), a cyclin-dependent kinase (cdk) inhibitor in PKC-delta transfectants compared with empty vector (EV) transfected cells, whereas the PKC-delta specific inhibitor rottlerin (3 mu M) or knockdown of this isoenzyme with specific siRNA oligonucleotides blocked p21(Waf1) expression. Concomitantly, compared to EV control cells, PKC-delta upregulation decreased cyclin D1 and cyclin E proteins co-immunoprecipitating with cdk6 and cdk2, respectively. In addition, overexpression of PKC-delta increased binding of cdk inhibitor p27(Kip1) to cdk4. These alterations in cyclin-cdks and their inhibitors are predicted to decrease G1 cyclin kinase activity. As an independent confirmation of the direct role PKC-delta plays in cell growth and cell cycle regulation, we knocked down PKC-delta using specific siRNA oligonucleotides. PKC-delta specific siRNA oligonucleotides, but not irrelevant control oligonucleotides, inhibited PKC-delta protein by more than 80% in Caco-2 cells. Moreover, PKC-delta knockdown enhanced cell proliferation (similar to 1.4-2-fold, P < 0.05) and concomitantly increased cyclin D1 and cyclin E expression (similar to 1.7-fold, P < 0.05). This was a specific effect, as nontargeted PKC-zeta was not changed by PKC-delta siRNA oligonucleotides. Consistent with accelerated apoptosis in PKC-delta transfectants, compared to EV cells, PKC-delta upregulation increased proapoptotic regulator Bax two-fold at mRNA and protein levels, while antiapoptotic Bcl-2 protein was decreased by 50% at a post-transcriptional level. PKC-delta specific siRNA oligonucleotides inhibited Bax protein expression by more than 50%, indicating that PKC-delta regulates apoptosis through Bax. Taken together, these results elucidate two critical mechanisms regulated by PKC-delta that inhibit cell cycle progression and enhance apoptosis in colon cancer cells. We postulate these antiproliferative pathways mediate an important tumor suppressor function for PKC-delta in colonic carcinogenesis.	Univ Chicago, Dept Med, Div Gastroenterol, Chicago, IL 60637 USA; Loyola Univ, Med Ctr, Dept Med, Div Gastroenterol, Maywood, IL 60153 USA	University of Chicago; Loyola University Chicago	Cerda, SR (corresponding author), Univ Chicago, Dept Med, Div Gastroenterol, MC 4076,5841 S Maryland Ave, Chicago, IL 60637 USA.	scerda@medicine.bsd.uchicago.edu		Cerda, Sandra/0000-0002-7779-6110	NCI NIH HHS [2R01CA36745] Funding Source: Medline; NIDDK NIH HHS [P30DK42086] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036745] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham C, 1998, GASTROENTEROLOGY, V114, P503, DOI 10.1016/S0016-5085(98)70533-5; Acevedo-Duncan M, 2002, CELL PROLIFERAT, V35, P23, DOI 10.1046/j.1365-2184.2002.00220.x; AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; Andre F, 1999, GASTROENTEROLOGY, V116, P64, DOI 10.1016/S0016-5085(99)70230-1; Arber N, 1997, CANCER RES, V57, P1569; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; Arita Y, 1998, EXP CELL RES, V242, P381, DOI 10.1006/excr.1997.3911; Ashton AW, 1999, J BIOL CHEM, V274, P20805, DOI 10.1074/jbc.274.30.20805; Assert R, 1999, INT J CANCER, V80, P47, DOI 10.1002/(SICI)1097-0215(19990105)80:1<47::AID-IJC10>3.3.CO;2-A; Atten MJ, 2005, INVEST NEW DRUG, V23, P111, DOI 10.1007/s10637-005-5855-8; Avazeri N, 2004, J CELL SCI, V117, P4969, DOI 10.1242/jcs.01375; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Banan A, 2002, J PHARMACOL EXP THER, V303, P17, DOI 10.1124/jpet.102.037218; Barrett CM, 2002, MOL CANCER THER, V1, P469; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; BARTKOVA J, 1994, INT J CANCER, V58, P568, DOI 10.1002/ijc.2910580420; Besson A, 2000, MOL CELL BIOL, V20, P4580, DOI 10.1128/MCB.20.13.4580-4590.2000; Black JD, 2001, GASTROENTEROLOGY, V120, P1868, DOI 10.1053/gast.2001.25287; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; BOSARI S, 1995, HUM PATHOL, V26, P534, DOI 10.1016/0046-8177(95)90250-3; Brasitus TA, 1998, GASTROENTEROLOGY, V115, P225, DOI 10.1016/S0016-5085(98)70387-7; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; BRONNER MP, 1995, AM J PATHOL, V146, P20; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Cerda SR, 2001, GASTROENTEROLOGY, V120, P1700, DOI 10.1053/gast.2001.24843; Chen AP, 1999, J BIOL CHEM, V274, P35505, DOI 10.1074/jbc.274.50.35505; Clark JA, 2004, J BIOL CHEM, V279, P9233, DOI 10.1074/jbc.M312268200; CRAVEN PA, 1992, CANCER RES, V52, P2216; CRAVEN PA, 1994, DIGEST DIS SCI, V39, P481, DOI 10.1007/BF02088331; DARZYNKIEWICZ Z, 1994, CELL BIOL LAB HDB, P261; DAVIDSON LA, 1994, ARCH BIOCHEM BIOPHYS, V312, P547, DOI 10.1006/abbi.1994.1344; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Di Mari JF, 2005, GASTROENTEROLOGY, V128, P2131, DOI 10.1053/j.gastro.2004.09.078; Ding QM, 1998, AM J PHYSIOL-CELL PH, V275, pC1193, DOI 10.1152/ajpcell.1998.275.5.C1193; Djelloul S, 1997, FEBS LETT, V406, P234, DOI 10.1016/S0014-5793(97)00208-1; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evers BM, 1996, AM J PHYSIOL-GASTR L, V271, pG722, DOI 10.1152/ajpgi.1996.271.4.G722; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fikaris AJ, 2005, J BIOL CHEM, V280, P32107, DOI 10.1074/jbc.M504432200; Fima E, 2001, ONCOGENE, V20, P6794, DOI 10.1038/sj.onc.1204885; Fishman DD, 1998, INT J ONCOL, V12, P181; Frey MR, 2000, J CELL BIOL, V151, P763, DOI 10.1083/jcb.151.4.763; Frey MR, 1997, J BIOL CHEM, V272, P9424; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; Gartel AL, 2000, ONCOGENE, V19, P961, DOI 10.1038/sj.onc.1203411; Gartel AL, 2000, ONCOGENE, V19, P5182, DOI 10.1038/sj.onc.1203900; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; Gavrielides MV, 2004, CURR DRUG TARGETS, V5, P431, DOI 10.2174/1389450043345380; GEIGES D, 1995, EXP CELL RES, V219, P299, DOI 10.1006/excr.1995.1231; Goerke A, 2002, J BIOL CHEM, V277, P32054, DOI 10.1074/jbc.M203734200; GOLDSTEIN DR, 1995, CARCINOGENESIS, V16, P1121, DOI 10.1093/carcin/16.5.1121; Graham MA, 2000, INVEST OPHTH VIS SCI, V41, P4124; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Hosokawa Y, 1998, GENE CHROMOSOME CANC, V22, P66, DOI 10.1002/(SICI)1098-2264(199805)22:1<66::AID-GCC9>3.0.CO;2-5; Irie N, 2002, BIOCHEM BIOPH RES CO, V298, P738, DOI 10.1016/S0006-291X(02)02531-7; Jackson DN, 2004, FASEB J, V18, P627, DOI 10.1096/fj.03-0979rev; Jang SJ, 1999, EUR J SURG ONCOL, V25, P157, DOI 10.1053/ejso.1998.0619; Jones SM, 2001, FEBS LETT, V490, P110, DOI 10.1016/S0014-5793(01)02113-5; KAHLRAINER P, 1994, CARCINOGENESIS, V15, P779, DOI 10.1093/carcin/15.4.779; KahlRainer P, 1996, GASTROENTEROLOGY, V110, P1753, DOI 10.1053/gast.1996.v110.pm8964400; Khare S, 1999, AM J PHYSIOL-GASTR L, V276, pG993, DOI 10.1152/ajpgi.1999.276.4.G993; Kikkawa U, 2002, J BIOCHEM, V132, P831, DOI 10.1093/oxfordjournals.jbchem.a003294; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kitamura K, 2003, GENES CELLS, V8, P311, DOI 10.1046/j.1365-2443.2003.00635.x; Klein IK, 2000, CANCER RES, V60, P2077; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; La Porta CAM, 2002, MELANOMA RES, V12, P297, DOI 10.1097/00008390-200208000-00001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee YJ, 2002, CELL GROWTH DIFFER, V13, P237; Leontieva OV, 2004, J BIOL CHEM, V279, P5788, DOI 10.1074/jbc.M308375200; Lewis AE, 2005, CELL SIGNAL, V17, P253, DOI 10.1016/j.cellsig.2004.07.005; Li WQ, 1996, ONCOGENE, V13, P731; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; Li WQ, 1997, J BIOL CHEM, V272, P24550, DOI 10.1074/jbc.272.39.24550; Lin SY, 2002, MOL CARCINOGEN, V35, P21, DOI 10.1002/mc.10070; LIPKIN M, 1971, CANCER-AM CANCER SOC, V28, P38, DOI 10.1002/1097-0142(197107)28:1<38::AID-CNCR2820280108>3.0.CO;2-W; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; Mandal M, 2001, GASTROENTEROLOGY, V120, P71, DOI 10.1053/gast.2001.20897; McCracken MA, 2003, MOL CANCER THER, V2, P273; MCGARRITY TJ, 1994, DIGEST DIS SCI, V39, P458, DOI 10.1007/BF02088328; McMillan L, 2003, BRIT J CANCER, V88, P748, DOI 10.1038/sj.bjc.6600793; Meyer E, 2005, CANCER RES, V65, P4261, DOI 10.1158/0008-5472.CAN-04-2908; Milde-Langosch K, 2000, INT J CANCER, V87, P468, DOI 10.1002/1097-0215(20000815)87:4<468::AID-IJC2>3.0.CO;2-R; Moss SF, 1996, GASTROENTEROLOGY, V111, P1425, DOI 10.1016/S0016-5085(96)70003-3; Nabha SM, 2005, ONCOGENE, V24, P3166, DOI 10.1038/sj.onc.1208502; Nakagawa M, 2005, J BIOL CHEM, V280, P33926, DOI 10.1074/jbc.M505748200; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Ogura E, 1999, ONCOL REP, V6, P365; Page K, 2002, AM J RESP CELL MOL, V27, P204, DOI 10.1165/ajrcmb.27.2.20010016oc; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Perletti G, 2004, J CELL MOL MED, V8, P563, DOI 10.1111/j.1582-4934.2004.tb00481.x; Perletti G, 2005, INT J CANCER, V113, P42, DOI 10.1002/ijc.20535; Perletti GP, 1999, ONCOGENE, V18, P1251, DOI 10.1038/sj.onc.1202408; Perletti GP, 1998, ONCOGENE, V16, P3345, DOI 10.1038/sj.onc.1201871; PINTO M, 1983, BIOL CELL, V47, P323; Polyak K, 1996, AM J PATHOL, V149, P381; Pongracz J, 1999, J BIOL CHEM, V274, P37329, DOI 10.1074/jbc.274.52.37329; Potten CS, 1997, STEM CELLS, V15, P82, DOI 10.1002/stem.150082; Qiao L, 1996, CANCER LETT, V107, P83, DOI 10.1016/0304-3835(96)04346-7; Ruemmele FM, 1999, CELL DEATH DIFFER, V6, P729, DOI 10.1038/sj.cdd.4400545; Rybin VO, 2003, J BIOL CHEM, V278, P14555, DOI 10.1074/jbc.M212644200; RYVES WJ, 1991, FEBS LETT, V288, P5, DOI 10.1016/0014-5793(91)80989-G; Sauma S, 1996, CELL GROWTH DIFFER, V7, P587; Savickiene J, 1999, CELL DEATH DIFFER, V6, P698, DOI 10.1038/sj.cdd.4400541; SAXON ML, 1994, J CELL BIOL, V126, P747, DOI 10.1083/jcb.126.3.747; Scaglione-Sewell B, 1998, CANCER RES, V58, P1074; Scaglione-Sewell BA, 2000, ENDOCRINOLOGY, V141, P3931, DOI 10.1210/en.141.11.3931; Schmittgen TD, 2000, ANAL BIOCHEM, V285, P194, DOI 10.1006/abio.2000.4753; Seki T, 2005, GENES CELLS, V10, P225, DOI 10.1111/j.1365-2443.2005.00830.x; Shanmugam M, 2001, CANCER LETT, V172, P43, DOI 10.1016/S0304-3835(01)00602-4; Shanmugathasan M, 2000, PATHOL INT, V50, P273, DOI 10.1046/j.1440-1827.2000.01047.x; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sitailo LA, 2004, J INVEST DERMATOL, V123, P434, DOI 10.1111/j.0022-202X.2004.23403.x; Soh JW, 2003, J BIOL CHEM, V278, P34709, DOI 10.1074/jbc.M302016200; Srivastava J, 2002, BIOCHEM J, V368, P349, DOI 10.1042/BJ20020737; Steinberg SF, 2004, BIOCHEM J, V384, P449, DOI 10.1042/BJ20040704; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tillman DM, 2003, CANCER RES, V63, P5118; Toyoda M, 1998, BIOCHEM BIOPH RES CO, V250, P430, DOI 10.1006/bbrc.1998.9332; Umar S, 2000, AM J PHYSIOL-GASTR L, V278, pG765, DOI 10.1152/ajpgi.2000.278.5.G765; Verstovsek G, 1998, GASTROENTEROLOGY, V115, P75, DOI 10.1016/S0016-5085(98)70367-1; Villalba M, 1998, NEUROREPORT, V9, P2381, DOI 10.1097/00001756-199807130-00042; Wakino S, 2001, J BIOL CHEM, V276, P47650, DOI 10.1074/jbc.M108719200; WALI RK, 1995, CANCER RES, V55, P5257; Wang QD, 2006, INT J CANCER, V118, P326, DOI 10.1002/ijc.21373; Wang QD, 2003, J BIOL CHEM, V278, P51091, DOI 10.1074/jbc.M306541200; Wang XF, 2004, ONCOGENE, V23, P1885, DOI 10.1038/sj.onc.1207312; Watters D, 1998, BIOCHEM PHARMACOL, V55, P1691, DOI 10.1016/S0006-2952(97)00680-1; Weinstein I B, 1991, Princess Takamatsu Symp, V22, P277; Weller SG, 1999, GASTROENTEROLOGY, V117, P848, DOI 10.1016/S0016-5085(99)70343-4; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; Yin LH, 2005, J BIOL CHEM, V280, P5533, DOI 10.1074/jbc.M405266200; Yokoyama G, 2005, BIOCHEM BIOPH RES CO, V327, P720, DOI 10.1016/j.bbrc.2004.12.070; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275; Zeng YX, 1996, ONCOGENE, V12, P1557; Zezula J, 1997, J BIOL CHEM, V272, P29967, DOI 10.1074/jbc.272.47.29967; Zhu GH, 2000, GASTROENTEROLOGY, V118, P507, DOI 10.1016/S0016-5085(00)70256-3	152	45	48	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3123	3138		10.1038/sj.onc.1209360	http://dx.doi.org/10.1038/sj.onc.1209360			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16434969				2022-12-28	WOS:000237951000004
J	Tanaka, Y; Kanai, F; Tada, M; Asaoka, Y; Guleng, B; Jazag, A; Ohta, M; Ikenoue, T; Tateishi, K; Obi, S; Kawabe, T; Yokosuka, O; Omata, M				Tanaka, Y.; Kanai, F.; Tada, M.; Asaoka, Y.; Guleng, B.; Jazag, A.; Ohta, M.; Ikenoue, T.; Tateishi, K.; Obi, S.; Kawabe, T.; Yokosuka, O.; Omata, M.			Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients	ONCOGENE			English	Article						PIK3CA; mutation; HCC; pseudogene; PI3K	HUMAN CANCER; GENE; OVARIAN; PATHWAY	A recent study revealed that the p110 alpha ( PIK3CA), catalytic subunit of phosphatidylinositol 3- kinase ( PI3K), is somatically mutated in many types of cancer. For example, PIK3CA is mutated in an estimated 35.6% of hepatocellular carcinoma ( HCC) cases. To measure the frequency of PIK3CA hotspot mutations in Japanese HCC patients, exons 9 and 20 of the PIK3CA gene were sequenced in 47 clinical HCC samples. Contrary to expectations, no hotspot mutations were found any of the HCC samples. In addition, we found abnormally migrating waves near the end of exon 9 in the PCR chromatograms from 13 of the 47 samples. PCR amplification and subsequent cloning and sequencing revealed that these chromatograms contained two distinct sequences, the wild- type p110 alpha sequence and a different sequence found on human chromosome 22q11.2, the Cat Eye Syndrome region, which contains a putative pseudogene of PIK3CA. These abnormally migrating waves were also found in noncancerous liver tissue, indicating that this was not a result of HCC- associated mutations. Therefore, it is likely that the percentage of hotspot mutations in the PIK3CA gene of Japanese HCC patients is lower than was previously reported.	Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan; Chiba Univ, Grad Sch Med, Dept Med & Clin Oncol, Chiba, Japan	University of Tokyo; Chiba University	Kanai, F (corresponding author), Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kanaif-int@h.u-tokyo.ac.jp	Asaoka, Yoshinari/ABC-5412-2021	Asaoka, Yoshinari/0000-0002-2805-8226; Tanaka, Yasuo/0000-0002-2917-3365				Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Ikenoue T, 2005, CANCER RES, V65, P4562, DOI 10.1158/0008-5472.CAN-04-4114; Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102; Lee JW, 2005, ONCOGENE, V24, P1477, DOI 10.1038/sj.onc.1208304; Levine DA, 2005, CLIN CANCER RES, V11, P2875, DOI 10.1158/1078-0432.CCR-04-2142; Li VSW, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-29; McDermid HE, 2002, AM J HUM GENET, V70, P1077, DOI 10.1086/340363; OR YY, 2005, INT J CANC      0819; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Sahin F, 2004, CLIN CANCER RES, V10, P8421, DOI 10.1158/1078-0432.CCR-04-0941; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Velho S, 2005, EUR J CANCER, V41, P1649, DOI 10.1016/j.ejca.2005.04.022; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839	16	57	61	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2950	2952		10.1038/sj.onc.1209311	http://dx.doi.org/10.1038/sj.onc.1209311			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16331247				2022-12-28	WOS:000237448200014
J	Zhu, Y; McAvoy, S; Kuhn, R; Smith, DI				Zhu, Y.; McAvoy, S.; Kuhn, R.; Smith, D. I.			RORA, a large common fragile site gene, is involved in cellular stress response	ONCOGENE			English	Article						RORA; breast cancer; common fragile site; stress response	ORPHAN RECEPTOR-ALPHA; N-MYC GENE; CANCER-CELLS; DNA-DAMAGE; FHIT GENE; NUCLEAR RECEPTORS; HUMAN-CHROMOSOMES; STAGGERER MICE; EXPRESSION; FRA16D	Common fragile sites ( CFSs) are large genomic regions present in all individuals that are highly unstable and prone to breakage and rearrangement, especially in cancer cells with genomic instability. Eight of the 90 known CFSs have been precisely defined and five of these span genes that extend from 700 kb to over 1.5Mb of genomic sequence. Although these genes reside within some of the most unstable chromosomal regions in the human genome, they are highly conserved evolutionarily. These genes are targets for large chromosomal deletions and rearrangements in cancer and are frequently inactivated in multiple tumor types. There is also an association between these genes and cellular responses to stress. Based upon the association between large genes and CFSs, we began to systematically test other large genes derived from chromosomal regions that were known to contain a CFS. In this study, we demonstrate that the 730 kb retinoic acid receptor- related orphan receptor alpha ( RORA) gene is derived from the middle of the FRA15A ( 15q22.2) CFS. Although this gene is expressed in normal breast, prostate and ovarian epithelium, it is frequently inactivated in cancers that arise from these organs. RORA was previously shown to be involved in the cellular response to hypoxia and here we demonstrate changes in the amount of RORA message produced in cells exposed to a variety of different cellular stresses. Our results demonstrate that RORA is another very large CFS gene that is inactivated in multiple tumors. In addition, RORA appears to play a critical role in responses to cellular stress, lending further support to the idea that the large CFS genes function as part of a highly conserved stress response network that is uniquely susceptible to genomic instability in cancer cells.	Mayo Clin & Mayo Fdn, Coll Med, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA; Univ Calif Santa Cruz, Dept Biomol Sci & Engn, Santa Cruz, CA 95064 USA	Mayo Clinic; University of California System; University of California Santa Cruz	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Dept Lab Med & Pathol, Div Expt Pathol, 200 1st St SW, Rochester, MN 55905 USA.	smith.david@mayo.edu						Arlt MF, 2003, CYTOGENET GENOME RES, V100, P92, DOI 10.1159/000072843; Becker NA, 2002, ONCOGENE, V21, P8713, DOI 10.1038/sj.onc.1205950; BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; Bednarek AK, 2001, CANCER RES, V61, P8068; Broussard DR, 2004, J VIROL, V78, P4943, DOI 10.1128/JVI.78.9.4943-4946.2004; Buttel I, 2004, ANN NY ACAD SCI, V1028, P14, DOI 10.1196/annals.1322.002; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Chang NS, 2003, BIOCHEM PHARMACOL, V66, P1347, DOI 10.1016/S0006-2952(03)00484-2; Chauvet C, 2004, BIOCHEM J, V384, P79, DOI 10.1042/BJ20040709; Chauvet C, 2002, BIOCHEM J, V364, P449, DOI 10.1042/BJ20011558; Druck T, 1997, CANCER RES, V57, P504; Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098; Dussault I, 1997, MOL CELL BIOL, V17, P1860, DOI 10.1128/MCB.17.4.1860; Finnis M, 2005, HUM MOL GENET, V14, P1341, DOI 10.1093/hmg/ddi144; Gemma A, 1997, CANCER RES, V57, P1435; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; Gopalakrishnan VK, 2003, PANCREATOLOGY, V3, P293, DOI 10.1159/000071767; Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0; He YW, 1998, IMMUNITY, V9, P797, DOI 10.1016/S1074-7613(00)80645-7; HIROSE T, 1994, BIOCHEM BIOPH RES CO, V205, P1976, DOI 10.1006/bbrc.1994.2902; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; HUEBNER K, 1997, BIOCHIM BIOPHYS ACTA, V1332, P65; Ishii H, 2005, MOL CANCER RES, V3, P130, DOI 10.1158/1541-7786.MCR-04-0209; Jetten AM, 2002, CELL DEATH DIFFER, V9, P1167, DOI 10.1038/sj.cdd.4401085; Jetten Anton M., 2004, Current Drug Targets - Inflammation and Allergy, V3, P395, DOI 10.2174/1568010042634497; Jiang HB, 2004, HUM MOL GENET, V13, P1745, DOI 10.1093/hmg/ddh180; Krummel KA, 2002, GENE CHROMOSOME CANC, V34, P154, DOI 10.1002/gcc.10047; Laiho M, 2003, ANN MED, V35, P391, DOI 10.1080/07853890310014605; Lau P, 1999, NUCLEIC ACIDS RES, V27, P411, DOI 10.1093/nar/27.2.411; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; Littman DR, 1999, COLD SPRING HARB SYM, V64, P373, DOI 10.1101/sqb.1999.64.373; Ludes-Meyers JH, 2003, CYTOGENET GENOME RES, V100, P101, DOI 10.1159/000072844; Matsuyama A, 2003, P NATL ACAD SCI USA, V100, P14988, DOI 10.1073/pnas.2336256100; MatysiakScholze U, 1997, GENOMICS, V43, P78, DOI 10.1006/geno.1997.4757; Migita H, 2004, FEBS LETT, V557, P269, DOI 10.1016/S0014-5793(03)01502-3; Missbach M, 1996, J BIOL CHEM, V271, P13515, DOI 10.1074/jbc.271.23.13515; Moretti RM, 2001, PROSTATE, V46, P327, DOI 10.1002/1097-0045(20010301)46:4<327::AID-PROS1040>3.0.CO;2-6; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Pawlikowski M, 1999, ADV EXP MED BIOL, V460, P369; Schrader M, 1996, J BIOL CHEM, V271, P19732, DOI 10.1074/jbc.271.33.19732; Smith DI, 1998, INT J ONCOL, V12, P187; Sutherland GR, 1998, TRENDS GENET, V14, P501, DOI 10.1016/S0168-9525(98)01628-X; SUTHERLAND GR, 1995, CURR OPIN GENET DEV, V5, P323, DOI 10.1016/0959-437X(95)80046-8; Wang F, 2004, GENE CHROMOSOME CANC, V40, P85, DOI 10.1002/gcc.20020	48	101	104	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2901	2908		10.1038/sj.onc.1209314	http://dx.doi.org/10.1038/sj.onc.1209314			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16462772				2022-12-28	WOS:000237448200008
J	Nagaraja, GM; Othman, M; Fox, BP; Alsaber, R; Pellegrino, CM; Zeng, Y; Khanna, R; Tamburini, P; Swaroop, A; Kandpal, RP				Nagaraja, GM; Othman, M; Fox, BP; Alsaber, R; Pellegrino, CM; Zeng, Y; Khanna, R; Tamburini, P; Swaroop, A; Kandpal, RP			Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics	ONCOGENE			English	Article						representational difference analysis; microarrays; proteomics; breast carcinoma; biomarkers; copper homeostasis	CARCINOMA CELLS; LYSYL OXIDASE; PROTEINS; DISEASE; IDENTIFICATION; ADHESION; TUMORS; FAMILY; GROWTH; PROGRESSION	We have characterized comprehensive transcript and proteomic profiles of cell lines corresponding to normal breast (MCF10A), noninvasive breast cancer (MCF7) and invasive breast cancer (MDA-MB-231). The transcript profiles were first analysed by a modified protocol for representational difference analysis (RDA) of cDNAs between MCF7 and MDA-MB-231 cells. The majority of genes identified by RDA showed nearly complete concordance with microarray results, and also led to the identification of some differentially expressed genes such as lysyl oxidase, copper transporter ATP7A, EphB6, RUNX2 and a variant of RUNX2. The altered transcripts identified by microarray analysis were involved in cell-cell or cell-matrix interaction, Rho signaling, calcium homeostasis and copper-binding/sensitive activities. A set of nine genes that included GPCR11, cadherin 11, annexin A1, vimentin, lactate dehydrogenase B (upregulated in MDA-MB-231) and GREB1, S100A8, amyloid beta precursor protein, claudin 3 and cadherin 1 (downregulated in MDA-MB-231) were sufficient to distinguish MDA-MB-231 from MCF7 cells. The downregulation of a set of transcripts for proteins involved in cell-cell interaction indicated these transcripts as potential markers for invasiveness that can be detected by methylation-specific PCR. The proteomic profiles indicated altered abundance of fewer proteins as compared to transcript profiles. Antisense knockdown of selected transcripts led to inhibition of cell proliferation that was accompanied by altered proteomic profiles. The proteomic profiles of antisense transfectants suggest the involvement of peptidylprolyl isomerase, Raf kinase inhibitor and 80 kDa protein kinase C substrate in mediating the inhibition of cell proliferation.	Fordham Univ, Dept Biol Sci, Bronx, NY 10458 USA; Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA; Bayer Corp, West Haven, CT USA	Fordham University; University of Michigan System; University of Michigan; Bayer AG	Kandpal, RP (corresponding author), Fordham Univ, Dept Biol Sci, Larkin Hall,Room 250,441 E Fordham Rd, Bronx, NY 10458 USA.	kandpal@fordham.edu		Swaroop, Anand/0000-0002-1975-1141				Akiri G, 2003, CANCER RES, V63, P1657; Alpan RS, 1996, MOL MED, V2, P469, DOI 10.1007/BF03401906; Arnuthan G, 2002, ONCOGENE, V21, P7839, DOI 10.1038/sj.onc.1205983; Baskaran N, 1996, GENOME RES, V6, P633, DOI 10.1101/gr.6.7.633; Becker M, 2005, MOL CANCER THER, V4, P151; Berger M, 2005, MOL CELL BIOL, V25, P5380, DOI 10.1128/MCB.25.13.5380-5388.2005; BIECHE I, 1995, CLIN CANCER RES, V1, P123; CAMPBELL FC, 1983, BRIT J SURG, V70, P202, DOI 10.1002/bjs.1800700405; CEROSALETTI KM, 1995, GENOMICS, V25, P226, DOI 10.1016/0888-7543(95)80130-E; Costa FF, 2004, ONCOGENE, V23, P1481, DOI 10.1038/sj.onc.1207263; Dan S, 2002, CANCER RES, V62, P1139; Fletcher GC, 2003, BRIT J CANCER, V88, P579, DOI 10.1038/sj.bjc.6600740; Fox BP, 2004, BIOCHEM BIOPH RES CO, V318, P882, DOI 10.1016/j.bbrc.2004.04.102; Hall J, 2005, CANCER LETT, V227, P105, DOI 10.1016/j.canlet.2004.12.001; Jacob ANK, 1997, SOMAT CELL MOLEC GEN, V23, P83, DOI 10.1007/BF02679968; JOHNSON JP, 1991, CANCER METAST REV, V10, P11, DOI 10.1007/BF00046840; Jones CE, 2004, J BIOL CHEM, V279, P32018, DOI 10.1074/jbc.M403467200; Katoh M, 2003, INT J MOL MED, V12, P3; Keller ET, 2004, CANCER LETT, V207, P131, DOI 10.1016/j.canlet.2004.02.006; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Kousidou OC, 2004, ANTICANCER RES, V24, P4025; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; Malliri A, 2003, CURR OPIN CELL BIOL, V15, P583, DOI 10.1016/S0955-0674(03)00098-X; Mantovani F, 2004, CELL CYCLE, V3, P905; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V322, P1111, DOI 10.1016/j.bbrc.2004.07.096; Missiaen L, 2000, CELL CALCIUM, V28, P1, DOI 10.1054/ceca.2000.0131; Moller LB, 2005, HUM MUTAT, V26, P84, DOI 10.1002/humu.20190; Nagaraja GM, 2004, BIOCHEM BIOPH RES CO, V313, P654, DOI 10.1016/j.bbrc.2003.12.001; Pase L, 2004, BIOCHEM J, V378, P1031, DOI 10.1042/BJ20031181; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pratap J, 2003, CANCER RES, V63, P5357; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Ridley AJ, 2004, BREAST CANCER RES TR, V84, P13, DOI 10.1023/B:BREA.0000018423.47497.c6; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Shao Q, 2005, CANCER RES, V65, P2705, DOI 10.1158/0008-5472.CAN-04-2367; SIEGEL RC, 1976, J BIOL CHEM, V251, P5786; Takayama Y, 2003, GENE DEV, V17, P1153, DOI 10.1101/gad.1065903; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Warner SL, 2003, MOL CANCER THER, V2, P589; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Wiseman A, 2005, MED HYPOTHESES, V65, P32, DOI 10.1016/j.mehy.2005.01.041; Yoshida S, 2004, HUM MOL GENET, V13, P1487, DOI 10.1093/hmg/ddh160; Yu YX, 2001, INT J ONCOL, V18, P905	45	150	199	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2328	2338		10.1038/sj.onc.1209265	http://dx.doi.org/10.1038/sj.onc.1209265			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16314837				2022-12-28	WOS:000236764300005
J	Beaujouin, M; Baghdiguian, S; Glondu-Lassis, M; Berchem, G; Liaudet-Coopman, E				Beaujouin, M; Baghdiguian, S; Glondu-Lassis, M; Berchem, G; Liaudet-Coopman, E			Overexpression of both catalytically active and -inactive cathepsin D by cancer cells enhances apoptosis-dependent chemo-sensitivity	ONCOGENE			English	Article						protease; cathepsin D; chemo-cytotoxicity; apoptosis; etoposide; catalytic activity	CYTOCHROME-C RELEASE; BREAST-CANCER; CASPASE ACTIVATION; RAT CARDIOMYOCYTES; TNF-ALPHA; DEATH; INVOLVEMENT; DEFICIENT; GROWTH; FIBROBLASTS	The aspartic protease cathepsin D (cath-D) is a key mediator of induced-apoptosis and its proteolytic activity has been generally involved in this event. During apoptosis, cath-D is translocated to the cytosol. Because cath-D is one of the lysosomal enzymes that requires a more acidic pH to be proteolytically active relative to the cysteine lysosomal enzymes such as cath-B and -L, it is therefore open to question whether cytosolic cath-D might be able to cleave substrate(s) implicated in the apoptotic cascade. Here, we have investigated the role of wild-type cath-D and its proteolytically inactive counterpart overexpressed by 3Y1-Ad12 cancer cells during chemotherapeutic-induced cytotoxicity and apoptosis, as well as the relevance of cath-D catalytic function. We demonstrate that wild-type or mutated catalytically inactive cath-D strongly enhances chemo- sensitivity and apoptotic response to etoposide. Both wild-type and mutated inactive cath-D are translocated to the cytosol, increasing the release of cytochrome c, the activation of caspases-9 and -3 and the induction of a caspase-dependent apoptosis. In addition, pretreatment of cells with the aspartic protease inhibitor, pepstatin A, does not prevent apoptosis. Interestingly therefore, the stimulatory effect of cath- D on cell death is independent of its catalytic activity. Overall, our results imply that cytosolic cath- D stimulates apoptotic pathways by interacting with a member of the apoptotic machinery rather than by cleaving specific substrate( s).	Univ Montpellier I, INSERM U540, F-34090 Montpellier, France; Univ Montpellier 2, CNRS, UMR 5554, Montpellier, France; Ctr Hosp Luxembourg, CRP Sante, Lab Hematocancerol Expt, Luxembourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Institut de Recherche pour le Developpement (IRD); Universite de Montpellier	Liaudet-Coopman, E (corresponding author), Univ Montpellier I, INSERM U540, 60 Rue Navacelles, F-34090 Montpellier, France.	liaudet@montp.inserm.fr	Liaudet-Coopman, Emmanuelle/N-4744-2017; Berchem, Guy/C-9364-2014	Liaudet-Coopman, Emmanuelle/0000-0001-9313-9690; Berchem, Guy/0000-0003-0157-2257; Baghdiguian, Stephen/0000-0002-2992-9708				Berchem G, 2002, ONCOGENE, V21, P5951, DOI 10.1038/sj.onc.1205745; Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; CAPONY F, 1987, J CELL BIOL, V104, P253, DOI 10.1083/jcb.104.2.253; Cirman T, 2004, J BIOL CHEM, V279, P3578, DOI 10.1074/jbc.M308347200; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Demoz M, 2002, BIOL CHEM, V383, P1237, DOI 10.1515/BC.2002.137; Emert-Sedlak L, 2005, MOL CANCER THER, V4, P733, DOI 10.1158/1535-7163.MCT-04-0301; Ferrandina G, 1997, BRIT J CANCER, V76, P661, DOI 10.1038/bjc.1997.442; Foekens JA, 1999, BRIT J CANCER, V79, P300, DOI 10.1038/sj.bjc.6990048; GARCIA M, 1990, ONCOGENE, V5, P1809; Glondu M, 2001, ONCOGENE, V20, P6920, DOI 10.1038/sj.onc.1204843; Glondu M, 2002, ONCOGENE, V21, P5127, DOI 10.1038/sj.onc.1205657; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; Heinrich M, 2004, CELL DEATH DIFFER, V11, P550, DOI 10.1038/sj.cdd.4401382; Johansson AC, 2003, CELL DEATH DIFFER, V10, P1253, DOI 10.1038/sj.cdd.4401290; Kagedal K, 2001, FASEB J, V15, P1592, DOI 10.1096/fj.00-0708fje; Koike M, 2003, MOL CELL NEUROSCI, V22, P146, DOI 10.1016/S1044-7431(03)00035-6; Koike M, 2000, J NEUROSCI, V20, P6898, DOI 10.1523/JNEUROSCI.20-18-06898.2000; Laurent-Matha V, 2005, J CELL BIOL, V168, P489, DOI 10.1083/jcb.200403078; LIAUDET E, 1994, ONCOGENE, V9, P1145; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; Nakanishi H, 2001, J NEUROSCI, V21, P7526, DOI 10.1523/JNEUROSCI.21-19-07526.2001; Ollinger K, 2000, ARCH BIOCHEM BIOPHYS, V373, P346, DOI 10.1006/abbi.1999.1567; Reiners JJ, 2002, CELL DEATH DIFFER, V9, P934, DOI 10.1038/sj.cdd.4401048; Roberg K, 1998, AM J PATHOL, V152, P1151; Roberg K, 2002, AM J PATHOL, V161, P89, DOI 10.1016/S0002-9440(10)64160-0; Roberg K, 2001, LAB INVEST, V81, P149, DOI 10.1038/labinvest.3780222; Rochefort H, 1996, EUR J CANCER, V32A, P7, DOI 10.1016/0959-8049(95)00637-0; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; Sawada N, 2000, CELL DEATH DIFFER, V7, P761, DOI 10.1038/sj.cdd.4400711; Shibata M, 1998, BIOCHEM BIOPH RES CO, V251, P199, DOI 10.1006/bbrc.1998.9422; Takuma K, 2003, NEUROCHEM INT, V42, P153, DOI 10.1016/S0197-0186(02)00077-3; Tardy C, 2003, CELL DEATH DIFFER, V10, P1090, DOI 10.1038/sj.cdd.4401272; Terman A, 2002, EXP CELL RES, V274, P9, DOI 10.1006/excr.2001.5441; Werneburg NW, 2002, AM J PHYSIOL-GASTR L, V283, pG947, DOI 10.1152/ajpgi.00151.2002; Westley BR, 1996, EUR J CANCER, V32A, P15, DOI 10.1016/0959-8049(95)00530-7; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755	37	58	65	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1967	1973		10.1038/sj.onc.1209221	http://dx.doi.org/10.1038/sj.onc.1209221			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16331270	Green Accepted, Green Submitted			2022-12-28	WOS:000236224800013
J	Pazzaglia, S; Tanori, M; Mancuso, M; Rebessi, S; Leonardi, S; Di Majo, V; Covelli, V; Atkinson, MJ; Hahn, H; Saran, A				Pazzaglia, S; Tanori, M; Mancuso, M; Rebessi, S; Leonardi, S; Di Majo, V; Covelli, V; Atkinson, MJ; Hahn, H; Saran, A			Linking DNA damage to medulloblastoma tumorigenesis in patched heterozygous knockout mice	ONCOGENE			English	Article						ionizing radiation; apoptosis; LOH; p53; PI3K-Akt/Pkb pathway	MODULATES HOMOLOGOUS RECOMBINATION; CENTRAL-NERVOUS-SYSTEM; BASAL-CELL CARCINOMA; SONIC HEDGEHOG; MOLECULAR-GENETICS; P53; GROWTH; CEREBELLUM; APOPTOSIS; PROTEIN	Hemizygous Ptc1 mice have many features of Gorlin syndrome, including predisposition to medulloblastoma development. Ionizing radiation synergize with Ptc1 mutation to induce medulloblastoma only in neonatally exposed mice. To explore the mechanisms underlying age-dependent susceptibility, we irradiated Ptc(neo67/+) mice at postnatal day 1 (P1) or 10 (P10). We observed a dramatic difference in medulloblastoma incidence, which ranged from 81% in the cerebellum irradiated at P1 to 3% in the cerebellum irradiated at P10. A stricking difference was also detected in the frequency of cerebellar preneoplastic lesions (100 versus 14%). Our data also show significantly lower induction of apoptosis in the cerebellum of medulloblastoma-susceptible (P1) compared to resistant (P10) mice, strongly suggesting that medulloblastoma formation in Ptc1 mutants may be associated with resistance to radiation-induced cell killing. Furthermore, in marked contrast with P10 mice, cerebellum at P1 displays substantially increased activation of the cell survival-promoting Akt/Pkb protein, and markedly decreased p53 levels in response to radiation-induced genotoxic stress. Overall, these results show that developing cerebellar granule neuron precursors' (CGNPs) radiosensitivity to radiation-induced cell death increases with progressing development and inversely correlates with their ability to neoplastically transform.	ENEA, Biotechnol Unit, I-00060 Rome, Italy; Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; ENEA, CR Casaccia, Radiat Protect Unit, Rome, Italy; Univ Goettingen, Inst Human Genet, Gottingen, Germany	Italian National Agency New Technical Energy & Sustainable Economics Development; Fondazione IRCCS Istituto Nazionale Tumori Milan; Italian National Agency New Technical Energy & Sustainable Economics Development; University of Gottingen	Pazzaglia, S (corresponding author), ENEA, Biotechnol Unit, Via Anguillarese 301, I-00060 Rome, Italy.	pazzaglia@casaccia.enea.it	Atkinson, Michael J/E-5537-2011; Atkinson, Michael/AAU-5127-2020	Atkinson, Michael J/0000-0003-3358-2089; Atkinson, Michael/0000-0003-3358-2089; Saran, Anna/0000-0002-5587-064X				ANDERSON WJ, 1977, J COMP NEUROL, V171, P17, DOI 10.1002/cne.901710103; BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Blackburn AC, 2004, CANCER RES, V64, P5140, DOI 10.1158/0008-5472.CAN-03-3435; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Calzada-Wack J, 2002, CARCINOGENESIS, V23, P727, DOI 10.1093/carcin/23.5.727; CERDA H, 1983, INT J RADIAT BIOL, V44, P113, DOI 10.1080/09553008314550911; Chrysis D, 2001, J NEUROSCI, V21, P1481, DOI 10.1523/JNEUROSCI.21-05-01481.2001; Dahmane N, 1999, DEVELOPMENT, V126, P3089; DErcole AJ, 1996, MOL NEUROBIOL, V13, P227, DOI 10.1007/BF02740625; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Enokido Y, 1996, EUR J NEUROSCI, V8, P1812, DOI 10.1111/j.1460-9568.1996.tb01325.x; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Johnson MD, 1998, J NEUROSCI RES, V54, P721, DOI 10.1002/(SICI)1097-4547(19981215)54:6<721::AID-JNR1>3.0.CO;2-1; Lee Y, 2002, CANCER RES, V62, P6395; Linke SP, 2003, CANCER RES, V63, P2596; MacDonald TJ, 2003, ONCOLOGIST, V8, P174, DOI 10.1634/theoncologist.8-2-174; Mancuso M, 2004, CANCER RES, V64, P934, DOI 10.1158/0008-5472.CAN-03-2460; Marino S, 2000, GENE DEV, V14, P994; Pazzaglia S, 2002, ONCOGENE, V21, P7580, DOI 10.1038/sj.onc.1205973; Raffel C, 1997, CANCER RES, V57, P842; Raffel C, 2004, NEOPLASIA, V6, P310, DOI 10.1593/neo.03454; Rao G, 2004, ONCOGENE, V23, P6156, DOI 10.1038/sj.onc.1207818; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Singh B, 2002, GENE DEV, V16, P984, DOI 10.1101/gad.973602; Stark JM, 2003, MOL CELL BIOL, V23, P733, DOI 10.1128/MCB.23.2.733-743.2003; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Tong WM, 2003, AM J PATHOL, V162, P343, DOI 10.1016/S0002-9440(10)63825-4; Wallace VA, 1999, CURR BIOL, V9, P445, DOI 10.1016/S0960-9822(99)80195-X; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Wetmore C, 2000, CANCER RES, V60, P2239; Wetmore C, 2001, CANCER RES, V61, P513; WOOD KA, 1995, J NEUROSCI, V15, P5851; Ye P, 1996, DEV BRAIN RES, V95, P44; Zindy F, 2003, CANCER RES, V63, P5420; Zurawel RH, 2000, GENE CHROMOSOME CANC, V27, P44, DOI 10.1002/(SICI)1098-2264(200001)27:1<44::AID-GCC6>3.0.CO;2-V; Zurawel RH, 2000, GENE CHROMOSOME CANC, V28, P77, DOI 10.1002/(SICI)1098-2264(200005)28:1<77::AID-GCC9>3.0.CO;2-Y	42	53	53	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 23	2006	25	8					1165	1173		10.1038/sj.onc.1209032	http://dx.doi.org/10.1038/sj.onc.1209032			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16407852				2022-12-28	WOS:000235537500004
J	Huang, L; Watanabe, M; Chikamori, M; Kido, Y; Yamamoto, T; Shibuya, M; Gotoh, N; Tsuchida, N				Huang, L.; Watanabe, M.; Chikamori, M.; Kido, Y.; Yamamoto, T.; Shibuya, M.; Gotoh, N.; Tsuchida, N.			Unique role of SNT-2/FRS2 beta/FRS3 docking/adaptor protein for negative regulation in EGF receptor tyrosine kinase signaling pathways	ONCOGENE			English	Article						SNT-2; FRS2 beta; FRS3; EGF; transformation; ERK2	GROWTH-FACTOR-RECEPTOR; MAP KINASE; PHOSPHORYLATION SITES; TRANSDUCTION PATHWAYS; DOCKING PROTEINS; PC12 CELLS; ACTIVATION; FRS2-ALPHA; FRS2; SHC	The membrane-linked docking protein SNT-2/FRS2b/FRS3 becomes tyrosine phosphorylated in response to fibroblast growth factors (FGFs) and neurotrophins and serves as a platform for recruitment of multiple signaling proteins, including Grb2 and Shp2, to FGF receptors or neurotrophin receptors. We previously reported that SNT-2 is not tyrosine phosphorylated significantly in response to epidermal growth factor (EGF) but that it inhibits ERK activation via EGF stimulation by forming a complex with ERK2. In the present report, we show that expression of SNT-2 suppressed EGF-induced cell transformation and proliferation, and expression level of SNT-2 is down-regulated in cancer. The activities of the major signaling molecules in EGF receptor ( EGFR) signal transduction pathways, including autophosphorylation of EGFR, were attenuated in cells expressing SNT-2 but not in cells expressing SNT-2 mutants lacking the ERK2-binding domain. Furthermore, SNT-2 constitutively bound to EGFR through the phosphotyrosine binding (PTB) domain both with and without EGF stimulation. Treatment of cells with MEK inhibitor U0126 partially restored the phosphorylation levels of MEK and EGFR in cells expressing SNT-2. On the basis of these findings, we propose a novel mechanism of negative control of EGFR tyrosine kinase activity with SNT-2 by recruiting ERK2, which is the site of negative-feedback loop from ERK, ultimately leading to inhibition of EGF-induced cell transformation and proliferation.	Univ Tokyo, Inst Med Sci, Div Genet, Minato Ku, Tokyo 1088639, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Mol Cellular Oncol & Microbiol, Bunkyo Ku, Tokyo, Japan; Univ Tokyo, Inst Med Sci, Div Oncol, Minato Ku, Tokyo, Japan; Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet & Digest & Kidney Dis,Chuo Ku, Kobe, Hyogo, Japan	University of Tokyo; Tokyo Medical & Dental University (TMDU); University of Tokyo; Kobe University	Gotoh, N (corresponding author), Univ Tokyo, Inst Med Sci, Div Genet, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	ngotoh@ims.u-tokyo.ac.jp; tsuchida.mcom@tmd.ac.jp	Huang, Lin/AAI-5740-2020; GOTOH, Noriko/D-8430-2015					BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Dhalluin C, 2000, MOL CELL, V6, P921, DOI 10.1016/S1097-2765(00)00089-7; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; Gotoh N, 2005, MOL CELL BIOL, V25, P4105, DOI 10.1128/MCB.25.10.4105-4116.2005; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; Gotoh N, 2004, P NATL ACAD SCI USA, V101, P17144, DOI 10.1073/pnas.0407577101; Gotoh N, 2004, FEBS LETT, V564, P14, DOI 10.1016/S0014-5793(04)00287-X; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Gotoh N, 1995, ONCOGENE, V11, P2525; Habib AA, 2003, MOL CANCER RES, V1, P219; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Harada A, 2005, J BIOL CHEM, V280, P18418, DOI 10.1074/jbc.M411356200; Hirata A, 2005, CANCER RES, V65, P4253, DOI 10.1158/0008-5472.CAN-04-2748; Ho R, 2005, CANCER RES, V65, P9868, DOI 10.1158/0008-5472.CAN-04-2426; Huang L, 2004, BIOCHEM BIOPH RES CO, V324, P1011, DOI 10.1016/j.bbrc.2004.09.152; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Lax I, 2002, MOL CELL, V10, P709, DOI 10.1016/S1097-2765(02)00689-5; LEE M, 1992, JNCI-J NATL CANCER I, V13, P117; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Rubenstein M, 1999, METHOD FIND EXP CLIN, V21, P391, DOI 10.1358/mf.1999.21.6.541918; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Wu YJ, 2003, BIOL CHEM, V384, P1215, DOI 10.1515/BC.2003.134; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	36	24	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2006	25	49					6457	6466		10.1038/sj.onc.1209656	http://dx.doi.org/10.1038/sj.onc.1209656			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16702953				2022-12-28	WOS:000241395100002
J	Dunne, J; Cullmann, C; Ritter, M; Soria, NM; Drescher, B; Debernardi, S; Skoulakis, S; Hartmann, O; Krause, M; Krauter, J; Neubauer, A; Young, BD; Heidenreich, O				Dunne, J.; Cullmann, C.; Ritter, M.; Soria, N. Martinez; Drescher, B.; Debernardi, S.; Skoulakis, S.; Hartmann, O.; Krause, M.; Krauter, J.; Neubauer, A.; Young, B. D.; Heidenreich, O.			siRNA-mediated AML1/MTG8 depletion affects differentiation and proliferation-associated gene expression in t(8 ; 21)-positive cell lines and primary AML blasts	ONCOGENE			English	Article						RNA interference; siRNA; gene expression profiling; acute myeloid leukaemia; AML1/MTG8	ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; T(8/21) FUSION PROTEIN; EPITHELIAL-CELLS; MESSENGER-RNA; GROWTH ARREST; TARGET GENE; C/EBP-ALPHA; AML1-ETO; BINDING	The chromosomal translocation t(8; 21) is associated with 10 - 15% of all cases of acute myeloid leukaemia (AML). The resultant fusion protein AML1/MTG8 interferes with haematopoietic gene expression and is an important regulator of leukaemogenesis. We studied the effects of small interfering RNA (siRNA)-mediated AML1/MTG8 depletion on global gene expression in t(8; 21)- positive leukaemic cell lines and in primary AML blasts using cDNA arrays, oligonucleotide arrays and real-time reverse transcription-polymerase chain reaction (RT-PCR). Suppression of AML1/MTG8 results in the increased expression of genes associated with myeloid differentiation, such as AZU1, BPI, CTSG, LYZ and RNASE2 as well as of antiproliferative genes such as IGFBP7, MS4A3 and SLA both in blasts and in cell lines. Furthermore, expression levels of several genes affiliated with drug resistance or indicative of poor prognosis AML (BAALC, CD34, PRG2, TSPAN7) are affected by AML1/MTG8 depletion. In conclusion, siRNA-mediated suppression of AML1/MTG8 cause very similar changes in gene expression pattern in t(8; 21)- positive cell lines and in primary AML blasts. Furthermore, the results suggest that the specific targeting of AML1/MTG8 function may be a promising approach for complementing existing treatment strategies.	Univ Tubingen, Dept Mol Biol, Interfac Inst Cell Biol, Fac Biol, D-72076 Tubingen, Germany; Barts & London Queen Marys Sch Med & Dent, Canc Res UK Med Oncol Lab, London, England; Univ Hosp Marburg, Dept Haematol Oncol & Immunol, Marburg, Germany; Hannover Med Sch, Dept Haematol Haemostaseol & Oncol, D-3000 Hannover, Germany; Univ Marburg, Inst Med Biometry & Epidemiol, Marburg, Germany; Univ Marburg, Inst Mol Biol & Tumour Res, Marburg, Germany	Eberhard Karls University of Tubingen; Cancer Research UK; University of London; Queen Mary University London; University Hospital of Giessen & Marburg; Hannover Medical School; Philipps University Marburg; Philipps University Marburg	Heidenreich, O (corresponding author), Univ Tubingen, Dept Mol Biol, Interfac Inst Cell Biol, Fac Biol, Morgenstelle 15, D-72076 Tubingen, Germany.	olaf.heidenreich@uni-tuebingen.de	Heidenreich, Olaf/AAP-5045-2021	Heidenreich, Olaf/0000-0001-5404-6483	Cancer Research UK [A6438, A6789] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Alcalay M, 2003, J CLIN INVEST, V112, P1751, DOI 10.1172/JCI17595; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; ASOU H, 1991, BLOOD, V77, P2031; Baldus CD, 2003, EXP HEMATOL, V31, P1051, DOI 10.1016/j.exphem.2003.08.004; Baldus CD, 2003, BLOOD, V102, P1613, DOI 10.1182/blood-2003-02-0359; Banker DE, 1998, CLIN CANCER RES, V4, P3051; Barrett T, 2005, NUCLEIC ACIDS RES, V33, pD562; Basecke J, 2005, LEUKEMIA LYMPHOMA, V46, P265, DOI 10.1080/10428190400010767; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Debernardi S, 2003, GENE CHROMOSOME CANC, V37, P149, DOI 10.1002/gcc.10198; Donato JL, 2002, J CLIN INVEST, V109, P51, DOI 10.1172/JCI200214025; ERICKSON P, 1992, BLOOD, V80, P1825; Fliegauf M, 2004, ONCOGENE, V23, P9070, DOI 10.1038/sj.onc.1208042; Follows GA, 2003, EMBO J, V22, P2798, DOI 10.1093/emboj/cdg250; Frank R, 1995, ONCOGENE, V11, P2667; Garwicz D, 2005, HAEMATOLOGICA, V90, P38; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Guenther MG, 2005, P NATL ACAD SCI USA, V102, P8603, DOI 10.1073/pnas.0503072102; Heidenreich O, 2003, BLOOD, V101, P3157, DOI 10.1182/blood-2002-05-1589; Heuser M, 2005, HAEMATOLOGICA, V90, P1484; Hiebert SW, 1996, CURR TOP MICROBIOL, V211, P253; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; KUSEC R, 1994, LEUKEMIA, V8, P735; Landberg G, 2001, ONCOGENE, V20, P3497, DOI 10.1038/sj.onc.1204471; LAUSENJ, 2006, ONCOGENE, V25, P1349; Lebigot I, 2003, BLOOD, V102, P4555, DOI 10.1182/blood-2003-06-2077; Lennartsson A, 2003, BIOCHEM BIOPH RES CO, V311, P853, DOI 10.1016/j.bbrc.2003.10.067; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Lopez-Bermejo A, 2000, ENDOCRINOLOGY, V141, P4072, DOI 10.1210/en.141.11.4072; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Martinez N, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-44; MATOZAKI S, 1995, BRIT J HAEMATOL, V89, P805; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Mori H, 2002, P NATL ACAD SCI USA, V99, P8242, DOI 10.1073/pnas.112218799; Morohoshi F, 2000, GENE, V241, P287, DOI 10.1016/S0378-1119(99)00481-3; Mulloy JC, 2005, P NATL ACAD SCI USA, V102, P4016, DOI 10.1073/pnas.0404701102; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; Mutaguchi K, 2003, CANCER RES, V63, P7717; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Philippar U, 2004, MOL CELL, V16, P867, DOI 10.1016/j.molcel.2004.11.039; Puccetti E, 2002, CANCER RES, V62, P7050; Rhoades KL, 2000, BLOOD, V96, P2108; Roche S, 1998, CURR BIOL, V8, P975, DOI 10.1016/S0960-9822(98)70400-2; Ross ME, 2004, BLOOD, V104, P3679, DOI 10.1182/blood-2004-03-1154; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; Tonks A, 2003, BLOOD, V101, P624, DOI 10.1182/blood-2002-06-1732; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WEISS J, 1987, BLOOD, V69, P652; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Yagi T, 2003, BLOOD, V102, P1849, DOI 10.1182/blood-2003-02-0578; Yamanaka Y, 1997, J BIOL CHEM, V272, P30729, DOI 10.1074/jbc.272.49.30729; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Zhang JS, 2004, SCIENCE, V305, P1286, DOI 10.1126/science.1097937; ZIMMER M, 1992, P NATL ACAD SCI USA, V89, P8215, DOI 10.1073/pnas.89.17.8215	68	55	56	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6067	6078		10.1038/sj.onc.1209638	http://dx.doi.org/10.1038/sj.onc.1209638			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16652140				2022-12-28	WOS:000241101200004
J	Piltti, K; Kerosuo, L; Hakanen, J; Eriksson, M; Angers-Loustau, A; Leppa, S; Salminen, M; Sariola, H; Wartiovaara, K				Piltti, K.; Kerosuo, L.; Hakanen, J.; Eriksson, M.; Angers-Loustau, A.; Leppa, S.; Salminen, M.; Sariola, H.; Wartiovaara, K.			E6/E7 oncogenes increase and tumor suppressors decrease the proportion of self-renewing neural progenitor cells	ONCOGENE			English	Article						oncogene; tumor suppressor; progenitor; self-renewal	HUMAN-PAPILLOMAVIRUS TYPE-16; STEM-CELL; E7 GENE; RETINOBLASTOMA PROTEIN; SIGNALING PATHWAY; EPITHELIAL-CELLS; PRECURSOR CELLS; LARGE-T; PROMOTES; KINASE	Many if not most tissues need a controlled number of stem cells to maintain normal function. Cancer can be seen as a process of disturbed tissue homeostasis, in which too many cells have or acquire too primitive identity. Here we measured how oncogenes and tumour suppressors affect the differentiation capacity, proportion and characteristics of progenitor cells in a model tissue. Neural progenitor cells (NPCs) were exposed to human papilloma virus E6, E7 or E6/E7 oncogenes, which degrade tumour suppressors p53 and pRb family members, respectively. E6/E7-expressing or p53(-/-) NPCs were able to differentiate, but simultaneously retained high capacity for self-renewal, proliferation, ability to remain multi-potent in conditions promoting differentiation and showed delayed cell cycle exit. These functions were mediated through p53 and pRb family, and involved MEK-ERK signalling. Decreased amount of p53 increased self-renewal and proliferation, whereas pRb affected only proliferation. Our results suggest that the oncogenes increase whereas p53 and pRb family tumour suppressors decrease the number and proportion of progenitor cells. These findings provide one explanation how oncogenes and tumour suppressors control tissue homeostasis and highlight their importance in stem cell self-renewal, linked both to cancer and life-long tissue turnover.	Univ Helsinki, Dept Biol, Inst Biomed, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, HUCH Lab Diagnost, Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Wartiovaara, K (corresponding author), Univ Helsinki, Dept Biol, Inst Biomed, POB 63, FIN-00014 Helsinki, Finland.	kirmo.wartiovaara@helsinki.fi	Hakanen, Janne/O-2166-2016	Hakanen, Janne/0000-0002-7501-2917; Salminen, Marjo/0000-0003-0696-6845; Piltti, Katja/0000-0002-9773-0442; Leppa, Sirpa/0000-0002-8265-511X; Angers-Loustau, Alexandre/0000-0003-1425-4143				Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; Bach S, 2005, J BIOL CHEM, V280, P31208, DOI 10.1074/jbc.M500806200; Boyer SN, 1996, CANCER RES, V56, P4620; Bruggeman SWM, 2005, GENE DEV, V19, P1438, DOI 10.1101/gad.1299305; Callaghan DA, 1999, DEV BIOL, V207, P257, DOI 10.1006/dbio.1998.9162; Chakrabarti O, 2004, J VIROL, V78, P5934, DOI 10.1128/JVI.78.11.5934-5945.2004; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; Choi J, 1999, CELL MOL LIFE SCI, V55, P38, DOI 10.1007/s000180050268; Coursen JD, 1997, EXP CELL RES, V235, P245, DOI 10.1006/excr.1997.3670; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; Dazy S, 2003, ONCOGENE, V22, P9205, DOI 10.1038/sj.onc.1207049; DeCaprio JA, 1999, BIOLOGICALS, V27, P23, DOI 10.1006/biol.1998.0173; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; Farah MH, 2000, DEVELOPMENT, V127, P693; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fehrmann F, 2003, ONCOGENE, V22, P5201, DOI 10.1038/sj.onc.1206554; Ferguson KL, 2000, J BIOL CHEM, V275, P33593, DOI 10.1074/jbc.M004879200; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Harris KF, 1998, MOL CELL BIOL, V18, P1746, DOI 10.1128/MCB.18.3.1746; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Liu HP, 2004, CURR OPIN GENET DEV, V14, P55, DOI 10.1016/j.gde.2003.11.005; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Miller MW, 2003, BRAIN RES, V965, P57, DOI 10.1016/S0006-8993(02)04119-7; Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Munger K, 2004, J VIROL, V78, P11451, DOI 10.1128/JVI.78.21.11451-11460.2004; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Popsueva A, 2003, J CELL BIOL, V161, P119, DOI 10.1083/jcb.200212174; Ross SE, 2003, NEURON, V39, P13, DOI 10.1016/S0896-6273(03)00365-9; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Singh SK, 2003, CANCER RES, V63, P5821; SLACK RS, 1993, ONCOGENE, V8, P1585; Slack RS, 1998, J CELL BIOL, V140, P1497, DOI 10.1083/jcb.140.6.1497; TeKippe M, 2003, EXP HEMATOL, V31, P521, DOI 10.1016/S0301-472X(03)00072-9; Toma JG, 2001, NAT CELL BIOL, V3, P778, DOI 10.1038/ncb0901-778; Toma JG, 2000, J NEUROSCI, V20, P7648; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; van Houten VMM, 2001, INT J CANCER, V93, P232, DOI 10.1002/ijc.1313; Vanderluit JL, 2004, J CELL BIOL, V166, P853, DOI 10.1083/jcb.200403156; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	45	16	17	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2006	25	35					4880	4889		10.1038/sj.onc.1209492	http://dx.doi.org/10.1038/sj.onc.1209492			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16532024				2022-12-28	WOS:000239687100006
J	Cohen, Z; Bacharach, E; Lavi, S				Cohen, Z.; Bacharach, E.; Lavi, S.			Mouse major satellite DNA is prone to eccDNA formation via DNA Ligase IV-dependent pathway	ONCOGENE			English	Article						eccDNA; spcDNA; genomic instability; major satellite DNA; DNA Ligase IV	EXTRACHROMOSOMAL CIRCULAR DNAS; MAMMALIAN-CELLS; GENOMIC INSTABILITY; RECOMBINATION; CIRCLES; MOLECULES; SPCDNA; DROSOPHILA; TELOMERES; SEQUENCES	Elevated levels of extrachromosomal circular DNA (eccDNA or spcDNA) are closely associated with genomic instability and aging. Despite extensive studies, the mechanism of its generation in mammalian cells is unknown. We report here that mouse major satellite DNA (MSD) is prone to eccDNA formation and that the resulting molecules are multimeres of the basic repeat. Extrachromosomal circular major satellite (ECMS) DNA constitutes the majority of eccDNA in B16 mouse melanoma cells and is highly abundant in other mouse cells. Production of these molecules is enhanced in proliferating cells, suggesting that processes associated with DNA replication are involved in their appearance. Using siRNA technique we show that DNA Ligase IV is engaged in ECMS synthesis. Based on our findings we propose a novel two-step model for eccDNA formation in mammalian cells.	Tel Aviv Univ, Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel	Tel Aviv University	Lavi, S (corresponding author), Tel Aviv Univ, Fac Life Sci, Dept Cell Res & Immunol, POB 39040, IL-69978 Tel Aviv, Israel.	lavisara@post.tau.ac.il		Bacharach, Eran/0000-0001-8341-2833; Cohen, Zoya/0000-0002-1284-3035				ASSUM G, 1993, HUM GENET, V91, P489; Autiero M, 2002, INT J CANCER, V99, P370, DOI 10.1002/ijc.10368; BERTELSEN AH, 1982, BIOCHEMISTRY-US, V21, P2076, DOI 10.1021/bi00538a015; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cesare AJ, 2004, MOL CELL BIOL, V24, P9948, DOI 10.1128/MCB.24.22.9948-9957.2004; CHATTERJEE B, 1989, J MOL BIOL, V210, P303, DOI 10.1016/0022-2836(89)90332-X; Cohen S, 1997, ONCOGENE, V14, P977, DOI 10.1038/sj.onc.1200917; Cohen S, 2003, GENOME RES, V13, P1133, DOI 10.1101/gr.907603; Cohen S, 1996, MOL CELL BIOL, V16, P2002; Cohen S, 1999, MOL CELL BIOL, V19, P6682; Cohen S, 2001, NUCLEIC ACIDS RES, V29, P2542, DOI 10.1093/nar/29.12.2542; DEGROOTE F, 1989, CHROMOSOMA, V89, P201; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; GAUBATZ JW, 1990, MUTAT RES, V237, P29, DOI 10.1016/0921-8734(90)90029-Q; GAUBATZ JW, 1990, MUTAT RES, V237, P271, DOI 10.1016/0921-8734(90)90009-G; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KIYAMA R, 1987, J MOL BIOL, V193, P591, DOI 10.1016/0022-2836(87)90342-1; KUNISADA T, 1985, MECH AGEING DEV, V29, P89, DOI 10.1016/0047-6374(85)90050-8; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; MOTEJLEK K, 1993, MUTAT RES, V293, P205, DOI 10.1016/0921-8777(93)90071-N; NEHLS M, 1995, TRENDS GENET, V11, P39, DOI 10.1016/S0168-9525(00)88990-8; Ohki R, 1995, NUCLEIC ACIDS RES, V23, P4971, DOI 10.1093/nar/23.24.4971; Park PU, 1999, MOL CELL BIOL, V19, P3848; PONT G, 1988, NUCLEIC ACIDS RES, V16, P8817, DOI 10.1093/nar/16.18.8817; Regev A, 1998, ONCOGENE, V17, P3455, DOI 10.1038/sj.onc.1202250; Sambrook J., 2002, MOL CLONING LAB MANU; SELIG S, 1988, EMBO J, V7, P419, DOI 10.1002/j.1460-2075.1988.tb02829.x; Silver L.M., 1995, MOUSE GENETICS CONCE; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Takeuchi Y, 2003, GENE DEV, V17, P1497, DOI 10.1101/gad.1085403; VANLOON N, 1994, NUCLEIC ACIDS RES, V13, P2447; Wang RC, 2004, CELL, V119, P355, DOI 10.1016/j.cell.2004.10.011; Zhong Q, 2002, CANCER RES, V62, P3966	34	36	37	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2006	25	33					4515	4524		10.1038/sj.onc.1209485	http://dx.doi.org/10.1038/sj.onc.1209485			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16547499				2022-12-28	WOS:000239457500002
J	Ridgeway, AG; McMenamin, J; Leder, P				Ridgeway, A. G.; McMenamin, J.; Leder, P.			P53 levels determine outcome during beta-catenin tumor initiation and metastasis in the mammary gland and male germ cells	ONCOGENE			English	Article						oncogene; tumor suppressor; teratomas; metastasis; breast cancer	WNT SIGNALING PATHWAY; ADENOMATOUS POLYPOSIS-COLI; FUNCTIONAL INTERACTION; NEGATIVE REGULATOR; P53-DEFICIENT MICE; PROGENITOR CELLS; DOWN-REGULATION; CYCLIN D1; TUMORIGENESIS; CANCER	beta-catenin, an oncogene, and P53, a tumor suppressor, are common targets of mutation in human cancers. It has been observed that P53 is often inactivated in tumors involving b-catenin activation. In an attempt to model this situation in vivo, we crossed the previously characterized MMTV-Delta N-beta- catenin mouse with the P53 knockout mouse. Female multiparous mice that carry the MMTV-Delta N-beta-catenin transgene and that are heterozygous for P53 (Tg(Delta N-beta Cat)/+, P53 +/-) display an increased tumor burden (2.05 vs 1.31 tumors/animal), with a generally more advanced pathology, and increased metastatic rate (39 vs 0%) relative to transgenic female mice that are wild type for P53 (Tg(Delta N-beta Cat)/ +, P53 +/+). These differences were not due to complete loss of P53 as only one of 21 tumors demonstrated loss of heterozygosity at the P53 locus. Furthermore, no mutations were present in tumors retaining a single wild-type allele. Tg(Delta N-beta Cat)/ +, P53 -/- male mice developed testicular teratomas and survived an average of 65 days, whereas non-Tg(Delta N-beta Cat), P53 -/- males survived an average of 84 days. Sixty-two percent of Tg(Delta N-beta Cat), P53 -/- mice developed testicular teratomas, whereas only 10% of the non-Tg(Delta N-beta Cat), P53 -/- mice developed these tumors. These results indicate that the level of P53 and the tissue of origin are important factors in determining outcome of cancer caused by oncogene activation.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Leder, P (corresponding author), Harvard Univ, Sch Med, Dept Genet, NRB 356B,77 Ave Louis Pasteur, Boston, MA 02115 USA.	leder@genetics.med.harvard.edu						Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brennan KR, 2004, J MAMMARY GLAND BIOL, V9, P119, DOI 10.1023/B:JOMG.0000037157.94207.33; Brodie SG, 2001, ONCOGENE, V20, P1445, DOI 10.1038/sj.onc.1204222; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Chung GG, 2004, CANCER, V100, P2084, DOI 10.1002/cncr.20232; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Gunther EJ, 2003, GENE DEV, V17, P488, DOI 10.1101/gad.1051603; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Hatsell S, 2003, J MAMMARY GLAND BIOL, V8, P145, DOI 10.1023/A:1025944723047; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HENRARD D, 1988, J VIROL, V62, P3046, DOI 10.1128/JVI.62.8.3046-3049.1988; Honecker F, 2004, J PATHOL, V204, P167, DOI 10.1002/path.1614; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; KOZMA S, 1980, J GEN VIROL, V51, P327, DOI 10.1099/0022-1317-51-2-327; Levina E, 2004, ONCOGENE, V23, P4444, DOI 10.1038/sj.onc.1207587; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Martin SS, 2004, ONCOGENE, V23, P4641, DOI 10.1038/sj.onc.1207595; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Polakis P, 2000, GENE DEV, V14, P1837; Rodriguez I, 1997, EMBO J, V16, P2262, DOI 10.1093/emboj/16.9.2262; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Sadot E, 2001, MOL CELL BIOL, V21, P6768, DOI 10.1128/MCB.21.20.6768-6781.2001; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Smalley MJ, 2001, J MAMMARY GLAND BIOL, V6, P37, DOI 10.1023/A:1009564431268; STEVENS LC, 1967, J NATL CANCER I, V38, P549; STEVENS LC, 1961, J NATL CANCER I, V27, P443; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Yin YZ, 1998, DEV BIOL, V204, P165, DOI 10.1006/dbio.1998.9074	51	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3518	3527		10.1038/sj.onc.1209391	http://dx.doi.org/10.1038/sj.onc.1209391			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16434961				2022-12-28	WOS:000238448200004
J	Kim, HJ; Chakravarti, N; Oridate, N; Choe, C; Claret, FX; Lotan, R				Kim, HJ; Chakravarti, N; Oridate, N; Choe, C; Claret, FX; Lotan, R			N-(4-hydroxyphenyl)retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cells	ONCOGENE			English	Article						4HPR; apoptosis; ROS; MAPK; HNSCC	N-TERMINAL KINASE; MITOCHONDRIAL-MEMBRANE DEPOLARIZATION; FENRETINIDE-INDUCED APOPTOSIS; SIGNAL-REGULATED KINASES; PROSTATE-CANCER CELLS; MEK-ERK PATHWAY; PROTEIN-KINASE; C-JUN; OXIDATIVE STRESS; CYTOCHROME-C	N-(4-hydroxyphenyl) retinamide (4HPR), a synthetic retinoid effective in cancer chemoprevention and therapy, is thought to act via apoptosis induction resulting from increased reactive oxygen species (ROS) generation. As ROS can activate MAP kinases and protein kinase C (PKC), we examined the role of such enzymes in 4HPR-induced apoptosis in HNSCC UMSCC22B cells. 4HPR increased ROS level within 1 h and induced activation of caspase 3 and PARP cleavage within 24 h. Activation of MKK3/6 and MKK4, JNK, p38 and ERK was detected between 6 and 12 h, increased up to 24 h and preceded apoptosis. 4HPR-induced activation of these kinases was abrogated by the antioxidants BHA and vitamin C. SP600125, a JNK inhibitor, suppressed 4HPR-induced c-Jun phosphorylation, cytochrome c release from mitochondria and apoptosis. Suppression of JNK1 and JNK2 using siRNA decreased, whereas overexpression of wild type-JNK1 enhanced 4HPR-induced apoptosis. PD169316, a p38, inhibitor suppressed phosphorylation of Hsp27 and apoptosis. PD98059, an MEK1/2 inhibitor, also suppressed ERK1/2 activation and apoptosis induced by 4HPR. Likewise, PKC inhibitor GF109203X suppressed ERK and p38 phosphorylation and PARP cleavage. These data indicate that 4HPR-induced apoptosis is triggered by ROS increase, leading to the activation of the mitogen-activated protein serine/threonine kinases JNK, p38, PKC and ERK, and subsequent apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Unit 432, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Lotan, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Unit 432, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rlotan@mdanderson.org	Claret, Francois X/R-2104-2016; Oridate, Nobuhiko/G-5365-2012; Oridate, Nobuhiko/ABC-4116-2020; Chakravarti, Nitin/F-7964-2011	Claret, Francois X/0000-0003-4629-6495; Oridate, Nobuhiko/0000-0002-6968-3028; Chakravarti, Nitin/0000-0002-6619-953X	NCI NIH HHS [P30 CA16672-30, P50 CA97007, R01 CA090853, P50 CA097007, P30 CA016672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA090853, P50CA097007] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Asumendi A, 2002, BRIT J CANCER, V86, P1951, DOI 10.1038/sj.bjc.6600356; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bhatt NY, 2002, J IMMUNOL, V169, P6427, DOI 10.4049/jimmunol.169.11.6427; Boya P, 2003, ONCOGENE, V22, P6220, DOI 10.1038/sj.onc.1206827; Carvalho H, 2004, J CELL BIOCHEM, V92, P502, DOI 10.1002/jcb.20070; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen YR, 1999, MOL PHARMACOL, V56, P1271, DOI 10.1124/mol.56.6.1271; Chen YR, 2000, INT J ONCOL, V16, P651; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Delia D, 1997, CARCINOGENESIS, V18, P943, DOI 10.1093/carcin/18.5.943; Donovan N, 2002, J BIOL CHEM, V277, P40944, DOI 10.1074/jbc.M206113200; Formelli F, 1996, FASEB J, V10, P1014, DOI 10.1096/fasebj.10.9.8801162; Freemantle SJ, 2003, ONCOGENE, V22, P7305, DOI 10.1038/sj.onc.1206936; Garaventa A, 2003, CLIN CANCER RES, V9, P2032; Guise S, 2001, J NEUROSCI RES, V63, P257, DOI 10.1002/1097-4547(20010201)63:3<257::AID-JNR1019>3.0.CO;2-T; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hail N, 2001, J BIOL CHEM, V276, P45614, DOI 10.1074/jbc.M106559200; Hail N, 2000, CANCER EPIDEM BIOMAR, V9, P1293; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kim DG, 2002, J BIOL CHEM, V277, P38930, DOI 10.1074/jbc.M205941200; Kim HJ, 2004, CANCER RES, V64, P2439, DOI 10.1158/0008-5472.CAN-03-2643; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lee YJ, 2003, EXP CELL RES, V291, P251, DOI 10.1016/S0014-4827(03)00391-4; Liao YF, 2005, LIFE SCI, V77, P707, DOI 10.1016/j.lfs.2005.01.010; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; Lovat PE, 2000, EXP CELL RES, V260, P50, DOI 10.1006/excr.2000.4988; Lovat PE, 2002, CANCER RES, V62, P5158; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; Malone W, 2003, EXPERT OPIN INV DRUG, V12, P1829, DOI 10.1517/eoid.12.11.1829.21882; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Maurer BJ, 1999, JNCI-J NATL CANCER I, V91, P1138, DOI 10.1093/jnci/91.13.1138; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Nguyen TTT, 2004, CARCINOGENESIS, V25, P647, DOI 10.1093/carcin/bgh052; Osone S, 2004, INT J CANCER, V112, P219, DOI 10.1002/ijc.20412; Poot M, 2002, EXP CELL RES, V279, P128, DOI 10.1006/excr.2002.5582; Reed JC, 1999, J NATL CANCER I, V91, P1099, DOI 10.1093/jnci/91.13.1099; Reynolds CP, 2004, PEDIATR TRANSPLANT, V8, P56, DOI 10.1111/j.1398-2265.2004.00216.x; Robertson JD, 2002, TOXICOLOGY, V181, P491, DOI 10.1016/S0300-483X(02)00464-X; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Seidman R, 2001, EXP CELL RES, V268, P84, DOI 10.1006/excr.2001.5262; Shimada K, 2003, MOL CARCINOGEN, V36, P115, DOI 10.1002/mc.10107; Shimada K, 2002, MOL CARCINOGEN, V35, P127, DOI 10.1002/mc.10084; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Sun SY, 1999, CANCER RES, V59, P2493; Sun SY, 2004, JNCI-J NATL CANCER I, V96, P662, DOI 10.1093/jnci/djh123; Suzuki S, 1999, ONCOGENE, V18, P6380, DOI 10.1038/sj.onc.1203024; Tamura Y, 2004, FEBS LETT, V569, P249, DOI 10.1016/j.febslet.2004.06.003; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Traore K, 2005, LEUKEMIA RES, V29, P863, DOI 10.1016/j.leukres.2004.12.011; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Ulukaya E, 2003, CELL DEATH DIFFER, V10, P856, DOI 10.1038/sj.cdd.4401242; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Won YK, 2005, CARCINOGENESIS, V26, P2149, DOI 10.1093/carcin/bgi194; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiao D, 2004, ONCOGENE, V23, P5594, DOI 10.1038/sj.onc.1207747; Xiao D, 2002, CANCER RES, V62, P3615; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yu CR, 2004, EXP CELL RES, V295, P555, DOI 10.1016/j.yexcr.2004.02.001; Yu WP, 2003, CANCER RES, V63, P2483; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1; Zhang XC, 2003, AM J RESP CELL MOL, V28, P305, DOI 10.1165/rcmb.2002-0156OC	67	66	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2785	2794		10.1038/sj.onc.1209303	http://dx.doi.org/10.1038/sj.onc.1209303			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16407847	Green Accepted			2022-12-28	WOS:000237272900009
J	Smeets, SJ; Braakhuis, BJM; Abbas, S; Snijders, PJF; Ylstra, B; van de Wiel, MA; Meijer, GA; Leemans, CR; Brakenhoff, RH				Smeets, SJ; Braakhuis, BJM; Abbas, S; Snijders, PJF; Ylstra, B; van de Wiel, MA; Meijer, GA; Leemans, CR; Brakenhoff, RH			Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus	ONCOGENE			English	Article						cancer genetics; head and neck cancer; human papillomavirus; array CGH; multi-step carcinogenesis	GENETICALLY ALTERED FIELDS; TUMOR-SUPPRESSOR GENE; PROGRESSION MODEL; ALLELIC LOSS; ORAL-CANCER; RISK; IDENTIFICATION; IMBALANCES; IMPACT; DPC4	Oncogene-expressing human papillomavirus type 16 (HPV16) is found in a subset of head and neck squamous cell carcinomas (HNSCC). HPV16 drives carcinogenesis by inactivating p53 and pRb with the viral oncoproteins E6 and E7, paralleled by a low level of mutations in TP53 and allelic loss at 3p, 9p, and 17p, genetic changes frequently found in HNSCCs of nonviral etiology. We hypothesize that two pathways to HNSCC exist: one determined by HPV16 and the other by environmental carcinogens. To de. ne the critical genetic events in these two pathways, we now present a detailed genome analysis of HNSCC with and without HPV16 involvement by employing high-resolution microarray comparative genomic hybridization. Four regions showed alterations in HPV-negative tumors that were absent in HPV-positive tumors: losses at 3p11.2-26.3, 5q11.2-35.2, and 9p21.1-24, and gains/amplifications at 11q12.1-13.4. Also, HPV16-negative tumors demonstrated loss at 18q12.1-23, in contrast to gain in HPV16-positive tumors. Seven regions were altered at high frequency (> 33%) in both groups: gains at 3q22.2-qter, 5p15.2-pter, 8p11.2-qter, 9q22-34.1, and 20p-20q, and losses at 11q14.1-qter and 13q11-33. These data show that HNSCC arising-by environmental carcinogens are characterized by genetic alterations that differ from those observed in HPV16-induced HNSCC, and most likely occur early in carcinogenesis. A number of genetic changes are shared in both tumor groups and can be considered crucial in the later stages of HNSCC progression.	Vrije Univ Amsterdam Med Ctr, Dept Otolaryngol Head & Neck Surg, Sect Tumor Biol, NL-1007 MB Amsterdam, Netherlands; Vrije Univ Amsterdam Med Ctr, Dept Pathol, Amsterdam, Netherlands; Vrije Univ Amsterdam Med Ctr, Microarray Core Facil, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Brakenhoff, RH (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Otolaryngol Head & Neck Surg, Sect Tumor Biol, POB 7057, NL-1007 MB Amsterdam, Netherlands.	rh.brakenhoff@vumc.nl	Brakenhoff, Ruud/D-3960-2009; Braakhuis, Boudewijn JM/B-4383-2008; Abbas, Saman/L-1981-2013; Ylstra, Bauke/D-2906-2012; van de Wiel, Mark/F-6759-2013	Ylstra, Bauke/0000-0001-9479-3010; Leemans, C. Rene/0000-0001-7887-083X; van de Wiel, Mark/0000-0003-4780-8472; Meijer, Gerrit/0000-0003-0330-3130				AHOMADEGBE JC, 1995, ONCOGENE, V10, P1217; Beder LB, 2003, LAB INVEST, V83, P99, DOI 10.1097/01.LAB.0000047489.26246.E1; Bockmuhl U, 2000, AM J PATHOL, V157, P369, DOI 10.1016/S0002-9440(10)64549-X; Braakhuis BJM, 2004, JNCI-J NATL CANCER I, V96, P998, DOI 10.1093/jnci/djh183; Braakhuis BJM, 2004, J ORAL PATHOL MED, V33, P317; Califano J, 1996, CANCER RES, V56, P2488; Dahlgren L, 2003, INT J CANCER, V107, P244, DOI 10.1002/ijc.11371; Erber R, 1998, ONCOGENE, V16, P1671, DOI 10.1038/sj.onc.1201690; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Gollin SM, 2001, HEAD NECK-J SCI SPEC, V23, P238, DOI 10.1002/1097-0347(200103)23:3<238::AID-HED1025>3.0.CO;2-H; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Herrero R, 2003, JNCI-J NATL CANCER I, V95, P1772, DOI [10.1093/jnci/djg/107, 10.1093/jnci/djg107]; Jong K, 2004, BIOINFORMATICS, V20, P3636, DOI 10.1093/bioinformatics/bth355; Kim SK, 1996, CANCER RES, V56, P2519; Mao L, 2004, J NATL CANCER I, V96, P978, DOI 10.1093/jnci/djh209; Mao L, 1996, NAT MED, V2, P682, DOI 10.1038/nm0696-682; Partridge M, 2000, CANCER RES, V60, P3893; Pisani P, 2002, INT J CANCER, V97, P72, DOI 10.1002/ijc.1571; Rosin MP, 2000, CLIN CANCER RES, V6, P357; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Tabor MP, 2004, CLIN CANCER RES, V10, P3607, DOI 10.1158/1078-0432.CCR-03-0632; Tabor MP, 2003, J PATHOL, V199, P354, DOI 10.1002/path.1285; Tabor MP, 2001, CLIN CANCER RES, V7, P1523; Tsao AS, 2004, CA-CANCER J CLIN, V54, P150, DOI 10.3322/canjclin.54.3.150; van de Wiel MA, 2005, BIOINFORMATICS, V21, P3193, DOI 10.1093/bioinformatics/bti489; van Houten VMM, 2001, INT J CANCER, V93, P232, DOI 10.1002/ijc.1313; VANDERRIET P, 1994, CANCER RES, V54, P1156; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wreesmann VB, 2004, J CLIN ONCOL, V22, P3965, DOI 10.1200/JCO.2004.01.094; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	30	188	189	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2558	2564		10.1038/sj.onc.1209275	http://dx.doi.org/10.1038/sj.onc.1209275			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16314836				2022-12-28	WOS:000236948000014
